{"pair_type": "slc_pathway", "key1": "SLCO1B1", "key2": "oxidative stress", "summary": "Modification of CYPs, PPAR-α, and SLCO1B1 by palm oil might increase the risk of fatty acid accumulation with associated oxidative stress.\nTreatment with tauroursodeoxycholic acid (TUDCA) increased the expression levels of the bile acid transporters and Nrf2, decreased the expression levels of glucose-regulated protein 78 (GRP78), PKR-like ER kinase (PERK), activating transcription factor 4 (ATF4), and C/EBP-homologous protein (CHOP), and inhibited RFP-induced oxidative stress.\nBoth of the reused oils-induced profiles of all CYP and SLCO1B1, but the new oil upregulated CYP2E1, CYP3A4, and CYP4A11.\nExpression of CYP1A2, CYP2C19, CYP2E1, CYP3A4, CYP4A11, and SLCO1B1 was induced by reused oils.\nThese findings revealed the impacts of reused palm oil on metabolism via CYPs which related to oxidative stress for further study.\nThis study evaluated effects of reused palm oil (from frying pork or potato) on expression of cytochrome P450s (CYPs), the transporter (SLCO1B1), and lipid metabolism regulators;\nBilirubin is an endogenous antioxidant that protects cells against oxidative stress.\nBioactive fatty acid-derived oxylipin molecules play key roles mediating inflammation and oxidative stress.\nBioactive fatty acid-derived oxylipin molecules play key roles in mediating inflammation and oxidative stress, which underlie many chronic diseases.\n2-Ethyl-6-methyl-3-hydroxypyridine succinate (EMHPS, Mexidol) is an original antioxidant and an anti-ischemic drug with the possibility of wide applications in the complex therapy of diseases, accompanied by the development of oxidative stress and ischemia;\nThe anticancer effect of the combined treatment of SN38 and EP is related to changes in the redox-homeostasis of cancer cells, leading to", "dois": ["10.1155/2021/6978450", "10.1016/j.xhgg.2024.100390", "10.1101/2024.05.21.24307719", "10.3390/ph16111529", "10.21873/anticanres.14519", "10.1111/jfbc.13178", "10.4178/epih.e2019034", "10.1016/j.freeradbiomed.2017.07.003"]}
{"pair_type": "slc_pathway", "key1": "SLC9A1", "key2": "apoptosis", "summary": "Most importantly, NHE1 inhibition prevented prosurvival extracellular signal-regulated kinase activation and accelerated TMZ-induced apoptosis.\nThese results demonstrate that CT could ameliorate DOX-induced cardiotoxicity by inhibiting the NHE1-mediated oxidative stress, apoptosis in rats.\nInhibition of RSK1 or siRNA-mediated silencing of RSK1 attenuates H/R-induced apoptosis, demonstrating the role of RSK1 in cardiomyocyte apoptosis.\nLJE inhibited doxorubicin-induced apoptosis and upregulated Na/H exchanger isoform 1 (NHE1) expression in NRK-52E cells, which were blocked by the NHE1 inhibitor cariporide.\nOverall, our findings demonstrate that H/R-mediated decrease in PKARIα protein levels leads to activation of RSK1, which via phosphorylation of NHE1 induces cardiomyocyte apoptosis.\nUsing adult rat ventricular myocytes and mouse-derived cardiac HL-1 cardiomyocytes, we demonstrate that hypoxia/reoxygenation (H/R)-induced apoptosis is accompanied by a decrease in the type I PKA regulatory subunit (PKARIα) and activation of RSK1.\nWe found that the knockdown of NHE1 in ESCC cells inhibited apoptosis and promoted cell proliferation, migration, and invasion and showed increases in Snail, β-catenin, and activation of PI3K-AKT signaling, which was consistent with the results obtained from microarrays.\nInhibitors of NHE-1 are able to decrease intracellular pH and induce apoptosis.\nKnockout, knockdown, or chemical inhibition of SLC9A1 blocked necroptosis induced by osmotic stresses.\nCombining TMZ therapy with NHE1 inhibition suppresses GC migration and invasion, and also augments TMZ-induced apoptosis.\nMoreover, cariporide decreased MDR1 expression and activated cleaved caspase-3 and casp", "dois": ["10.1126/scisignal.abn5881", "10.1158/1541-7786.MCR-14-0011", "10.1530/JOE-24-0099", "10.1016/j.jhazmat.2024.135038", "10.2147/CMAR.S270200", "10.1152/ajplung.00083.2024", "10.3390/ijms241713289", "10.1002/jbt.22971", "10.3390/ijms22115437", "10.1002/ddr.21799", "10.1016/j.lfs.2020.118276", "10.1097/SHK.0000000000001573", "10.1161/HYPERTENSIONAHA.119.14485", "10.1038/s41598-020-62430-z", "10.1016/j.pdpdt.2019.05.007", "10.1038/s41419-019-1602-5", "10.1186/s12885-019-5397-7", "10.1016/j.niox.2019.02.011", "10.1016/j.yexmp.2018.12.004", "PMID:30377691", "10.1016/j.gastrohep.2018.05.026", "10.1016/j.jep.2018.06.023", "10.1016/j.archoralbio.2018.02.018", "10.1186/s12885-017-3532-x", "10.1159/000458427", "10.3892/or.2017.5386", "10.18632/oncotarget.13645", "10.3349/ymj.2016.57.5.1252", "10.5507/bp.2015.060", "PMID:26521941", "10.3892/ijmm.2015.2366", "10.1159/000368521", "10.1074/jbc.M114.626960", "10.1002/jcp.24958", "PMID:25620102", "10.1093/carcin/bgu089", "10.1161/JAHA.113.000434", "10.1182/blood-2013-07-512194", "10.1371/journal.pone.0090273", "10.1172/JCI71863", "10.1124/mol.113.090613", "10.1016/j.cbi.2013.11.002", "10.1186/1479-5876-11-282", "10.1371/journal.pone.0067582", "PMID:23800993", "PMID:23461016", "10.1038/aps.2012.155", "10.1016/j.bbrc.2012.09.023", "PMID:22360552", "10.1074/jbc.M110.212845", "10.3389/fimmu.2025.1623511"]}
{"pair_type": "slc_pathway", "key1": "SLC7A5", "key2": "oxidative stress", "summary": "In vivo experiments showed that SLC7A5 promoted the activation of mammalian target of rapamycin complex 1 (mTORC1) signaling pathway, enhanced serine synthesis and maintained oxidative stress balance in fibroblasts.\nMoreover, siRNA-mediated CTH knockdown induced oxidative stress in response to JPH203 leading to decreased cell viability in MDA-MB-231 cells.\n1,25(OH)D significantly upregulated LAT1 expression in placental trophoblasts, and also prevented the decrease of mTOR activity under CoCl-induced oxidative stress.\nJPH203, a specific inhibitor of SLC7A5, effectively reversed the above phenomena, inhibited mTORC1 signaling activation, and reduced the proliferation of fibroblasts.\nInhibition of Gln metabolism or knockdown of Gln transporters SLC1A5, SLC7A5, or SLC38A1 induces expression of NUPR1, a stress response transcriptional regulator, but simultaneously uncouples the NUPR1-driven metabolic stress-adaptation program.\nIn vitro: Mg deficiency reduced BeWo nutrient uptake (P < 0.01) and cell proliferation (P < 0.01), and increased oxidative stress (P < 0.01).\nl-Tryptophan at 0.4, 0.8, and 1.6 mM remarkably decreased the percentage of apoptosis and enhanced antioxidative capacity in HO-mediated BIEC.\nl-Tryptophan increased catalase and superoxide dismutase activities in HO-mediated BIEC, although not with a present mTOR inhibitor.\nSimilarly to the effect from NUPR1 knockdown, depletion of these Gln transporters led to reduced cell viability, accumulation of mitochondrial ROS, and increased PCa radiosensitivity.\nl-Tryptophan increased the protein expression of large neutral amino acid transporter 1 and alanine-serine-cysteine transporter 2 in HO-mediated BIEC with or without the presence of an mTOR inhibitor.", "dois": ["10.1186/s12964-025-02344-3", "10.7717/peerj.17213", "10.3390/ijms22041707", "PMID:17498859", "10.1016/j.yexcr.2025.114732", "10.1016/j.cbd.2025.101601", "10.1186/s13048-025-01700-8", "10.1093/toxres/tfaf035", "10.1016/j.psj.2024.103716", "10.1016/j.jbc.2023.105409", "10.1155/2022/3818216", "10.3390/nu14183856", "10.3390/cancers13010125", "10.3389/fphys.2020.609335", "10.1097/JOM.0000000000001669", "10.1016/j.placenta.2016.01.009", "10.1021/acs.molpharmaceut.2c00328", "10.1038/s41598-022-08641-y", "10.1155/2019/3528148", "10.3168/jds.2022-21869", "10.1007/s12035-020-02045-7", "10.3390/ijms20102435", "10.1158/1078-0432.CCR-18-2951", "10.1038/s41598-018-33861-6", "10.2217/bmm-2017-0086", "10.18632/oncotarget.11526", "10.1016/j.parint.2015.11.011", "10.1089/ars.2013.5664", "10.1038/s41598-022-04987-5", "10.1038/s41467-025-64160-0"]}
{"pair_type": "slc_pathway", "key1": "SLC7A5", "key2": "ferroptosis", "summary": "SLC7A5 overexpression weakened the protective effect of YTHDF1 knockdown, resulting in decreased cell viability, deterioration of mitochondrial function, and increased ferroptosis.\nThis subpopulation suppresses ferroptosis in malignant cells through the transcriptional upregulation of SLC7A5 mediated by high TP63 expression, thereby promoting tumor growth and resistance to immunotherapy.\nOur research elucidates the TME in HNSCC before and after immunotherapy, revealing a novel mechanism by which TP63 SLC7A5 HNSCC inhibits ferroptosis and enhances tumor resistance via TP63-induced SLC7A5 upregulation.\nPLB ameliorates DHT-induced mitochondrial dysfunction and ferroptosis in KGN cells by inhibiting YTHDF1 expression, and its action is dependent on the mechanism by which YTHDF1 regulates SLC7A5 translation through m6A modification.\nFurthermore, the application of sublethal doses of ferroptosis-inducers such as erastin and sorafenib, low cystine growth conditions, or genetic knockdown of SLC7A11 and GPX4 all similarly protect cells from Golgi stress and lead to modulation of ACSL4, SLC7A5, SLC7A11 or GPX4 levels.\nSLC7A5, SLC7A11, and CHAC1 may affect the development of psoriasis by regulating ferroptosis.\nInterestingly, SSPH I elevated the expression levels of SLC7A5, which is the negative regulator of ferroptosis.\nThe experimental results demonstrated that the overexpression of TP63 upregulated the expression of SLC7A5 and suppressed the concentrations of Fe and ROS in HNSCC cells.\nBy integrating bulk transcriptome data, we developed a clinical scoring model based on TP63 and SLC7A5, which are closely associated with tumor stage, revealing the significant prognostic efficacy of the TP63 SLC7A5 HNSCC-mediated ferroptosis mechanism in HNSCC patients.", "dois": ["10.1371/journal.pone.0327990", "10.1186/s12931-025-03323-5", "10.1186/s13048-025-01700-8", "10.1097/MD.0000000000038322", "10.3389/fimmu.2024.1445472", "10.3233/CBM-230325", "10.1016/j.compbiomed.2023.107370", "10.1007/s12032-023-02000-1", "10.1002/cam4.4706", "10.1016/j.cbd.2025.101601", "10.3892/etm.2024.12722", "10.1038/s41467-024-51860-2", "10.1016/j.radonc.2024.110259", "10.3389/fonc.2023.1251100", "10.3389/fgene.2023.1170737", "10.3389/fonc.2022.1033044", "10.1155/2022/3818216", "10.3389/fonc.2022.833814", "10.1007/s00204-020-02826-y", "10.1038/s42003-018-0212-6", "10.3390/ijms262110736"]}
{"pair_type": "slc_pathway", "key1": "SLC7A5", "key2": "oxidative phosphorylation", "summary": "Targeting the BCAA transporter SLC7A5 with JPH203 inhibited oxidative phosphorylation and elicited strong antileukemia effects, specifically in mouse and patient AML samples while sparing healthy bone marrow cells.\nExperiments where TGF-β function was activated with extracellular TGF-β1 or inhibited through TGF-β receptor I silencing showed that TGF-β induces a switch from oxidative metabolism, coincident with a decrease in OCR and the upregulation of glutamine transporter Solute Carrier Family 7 Member 5 (SLC7A5) and GLS1.\nA diminished metabolic reprogramming, including a decrease in oxidative phosphorylation that regulates Hif-1α expression and subsequent control of glycolysis enzymes, was involved in the downregulation of Th17 differentiation by LAT1 inhibition.\nMechanistically, valine restriction reduced translation rates of mRNAs that encode subunits of mitochondrial complex I, leading to defective assembly of complex I and impaired oxidative phosphorylation.\nFinally, a genome-wide CRISPR-Cas9 loss-of-function screen in differential valine conditions identified several genes, including SLC7A5 and BCL2, whose genetic ablation or pharmacological inhibition synergized with valine restriction to reduce T-ALL growth.\nFurthermore, CD46 activation simultaneously drove expression of LAMTOR5, which mediated assembly of the AA-sensing Ragulator-Rag-mTORC1 complex and increased glycolysis and oxidative phosphorylation (OXPHOS), required for cytokine production.\nCytokine activation of NK cell glycolysis and oxidative phosphorylation (OXPHOS) are essential for robust NK cell responses.\nNK cell receptor ligation and IL2 collaborate to induce mTORC1/cMyc signalling leading to high rates of glycolysis and oxidative phosphorylation (OXPHOS) and prolonged NK cell survival.\nHere we found that in activated human T cells, autocrine stimulation of the complement receptor CD46, and specifically its intracellular domain CYT-1,", "dois": ["10.1038/s41586-021-04244-1", "10.1038/s41467-018-04719-2", "10.1038/s41598-017-12837-y", "10.1007/s40200-025-01691-9", "10.1016/j.jbc.2023.105409", "10.1182/bloodadvances.2023010460", "10.1016/j.intimp.2022.108817", "10.20900/immunometab20190014", "10.1016/j.immuni.2015.05.024", "PMID:25597310"]}
{"pair_type": "slc_pathway", "key1": "SLC7A5", "key2": "glycolysis", "summary": "E2F2 deficiency upregulates the expression of SLC7A5 to mediate amino acids flux, resulting in enhanced glycolysis, impaired mitochondrial function, and increased macrophages proinflammatory response in a Leu-mTORC1-dependent manner.\nWe demonstrated that the elevated SLC7A5 expression activated the amino acid pathway and promoted cell proliferation, tumor growth, and therapeutic resistance by inducing the switch from PKM1 to PKM2 expression, thereby mediating the crosstalk between amino acid metabolism and glycolysis.\nKnockdown of SLC7A5 inhibits malignant progression and attenuates oxaliplatin resistance in GC by suppressing glycolysis.\nIn addition, the miR-152/SLC7A5 axis mediated the expression of PTBP1, which maintains the balance between PKM1 and PKM2, linking amino acid signaling with the glycolysis pathway.\nFurthermore, knockdown of SLC7A5 downregulated the expression of HK2, LDHA, Glut1, and PDK1 both in vivo and in vitro, leading to increased extracellular glucose levels and decreased lactate levels.\nDeletion of SLC7A5 in T cells compromises mTORC1, glycolysis and mitochondrial oxidation.\nWe provide evidence that SLC7A5-mediated leucine influx contributes to pro-inflammatory cytokine production mTOR complex 1 (mTORC1)-induced glycolytic reprograming in activated human monocytes/macrophages.\nInhibition of SLC7A5-mediated leucine influx was linked to downregulation of glycolytic metabolism as evidenced by the decreased extracellular acidification rate, suggesting a regulatory role for this molecule in glycolytic reprograming.\nOn the contrary, L-Leu removal reduced mTORC1 and completely blocked glycolysis but preserved mitochondrial function, favoring the generation of central memory responses and expression of stemness marker TCF1.\nMechanistically, E2F2 can inhibit the SLC7A5 transcription directly.\nIn this study, we found that MAIT cells significantly", "dois": ["10.1186/s13018-025-06072-9", "10.1186/s10020-025-01175-9", "10.1016/j.canlet.2025.217612", "10.1126/scisignal.abo2709", "10.4049/jimmunol.1801600", "10.1038/s41467-018-04719-2", "10.3389/fimmu.2018.00053", "10.1038/s41598-017-12837-y", "10.1186/s13046-025-03446-z", "10.1038/s44321-025-00250-2", "10.1002/advs.202410880", "10.3389/fimmu.2022.955614", "10.1016/j.intimp.2022.108817", "10.1016/j.apsb.2021.09.019", "10.1038/s41467-021-25715-z", "10.20900/immunometab20190014", "10.3168/jds.2017-13707", "10.1016/j.smim.2016.09.001", "10.18632/oncotarget.10131", "10.1007/s00109-013-1064-7", "10.1016/j.immuni.2015.05.024", "PMID:25597310"]}
{"pair_type": "slc_pathway", "key1": "SLC7A11", "key2": "oxidative phosphorylation", "summary": "tropicalis, which was attributed to augmented mitochondrial oxidative phosphorylation (OXPHOS) caused by reduced SLC7A11 expression.\nKetotic cows exhibited lower ferroportin (FPN), solute carrier family 7 member 11 (SLC7A11), glutathione peroxidase 4 (GPX4), mitochondrial oxidative phosphorylation complexes I-V (CO I-V), peroxisome proliferator-activated receptor gamma coactivator 1-α (PGC-1α), mitofusin-2 (MFN2), nuclear respiratory factor 1 (NRF-1), and mitochondrial transcription factor A (Tfam) protein expression levels, along with lower ATP content compared with control cows.\nConversely, hnRNPK overexpression was correlated with enhanced ferroptosis pathway and improved ECM organization, but was also associated with reduced oxidative phosphorylation and protein synthesis.\nAmong them, we show that LUC7L2 represses OXPHOS and promotes glycolysis by multiple mechanisms, including (1) splicing of the glycolytic enzyme PFKM to suppress glycogen synthesis, (2) splicing of the cystine/glutamate antiporter SLC7A11 (xCT) to suppress glutamate oxidation, and (3) secondary repression of mitochondrial respiratory supercomplex formation.\nThe expression of EPAS1 and SLC7A11 was significantly correlated with oxidative phosphorylation and immune cell infiltration levels.\nWe further explore the effects of GLUD1 inhibition in endocrine therapy-resistant ILC cells using the small-molecule inhibitor R162, which reduces ER protein levels, increases reactive oxygen species, and inhibits oxidative phosphorylation.\nDHA and Sora significantly inhibited the cell energy metabolism by decreasing the ATP synthesis rate of oxidative phosphorylation and glycolysis rate, and induced ferroptosis by increasing the level of lipid reactive oxygen species (L-ROS), labile iron pool (LIP) as well as malondialdehyde (MDA) and decreasing the level of glutathione (GSH) in", "dois": ["10.1073/pnas.2411241122", "10.1038/s41418-024-01427-x", "10.1016/j.molcel.2021.02.033", "10.3390/toxins10110464", "10.1016/j.redox.2025.103839", "10.21037/tp-2024-596", "10.1186/s13395-025-00393-3", "10.1186/s12951-025-03545-1", "10.1016/j.jconrel.2025.113887", "10.1038/s41531-025-00995-0", "10.3168/jds.2025-26265", "10.1038/s41531-024-00858-0", "10.1002/alz.14375", "10.1101/2024.09.29.615681", "10.1016/j.redox.2024.103213", "10.1186/s12964-024-01581-2", "10.18632/oncotarget.28540", "10.1016/j.jbc.2023.105409", "10.1080/15548627.2022.2084862", "10.1016/j.jphs.2021.09.008", "10.1016/j.freeradbiomed.2020.06.023", "PMID:27658422", "10.1038/ncomms15074"]}
{"pair_type": "slc_pathway", "key1": "SLC7A5", "key2": "apoptosis", "summary": "Further study on the function of SLC7A5 gene in SKM-1 cell line showed that downregulation of SLC7A5 inhibited SKM-1 cells proliferation, increased apoptosis and caused cell cycle arrest in the G0/G1 stage.\nYAP/TAZ protects cells from KRAS inhibitor-induced apoptosis by downregulating the expression of proapoptotic genes such as BMF, BCL2L11, and PUMA\nSLC7A5 knockdown in LUSC cells reduces colony formation and induces apoptosis.\nSlc7a5 deletion in chondrocytes led to general disorganization of chondrocytes in the vertebral growth plate, along with an increase in apoptosis and a decrease in cell proliferation.\nThese findings indicate that SLC7A5 mediates the effect of Dex on cell viability, thus providing a novel molecular target for the prevention and treatment of Dex-induced cell cycle arrest and apoptosis in placental cells.\nCirc-SLC7A5 depletion impaired cell growth, migration, invasiveness, and promoted apoptosis.\nTransfection of microRNA-194 mimics increased apoptosis of H9c2 cells, which was rescued by overexpression of pcDNA3/Slc7a5.\nMoreover, laboratory experiments confirm that SLC7A5 promotes the proliferation of NSCLC cells, and the knockout of SLC7A5 significantly increases tumor cell apoptosis.\nWe identified how miR-626 causes apoptosis and macula degeneration in RPE cells by targeting SLC7A5 through the mTOR signaling pathway.\nThe impaired amino acids uptake leads to inhibition of mTOR signaling which in turn causes inhibited proliferation and enhanced autophagy and apoptosis in BeWo cells.\nWe show here that a potent and LAT1 selective inhibitor (JPH203) decreased leukemic cell viability and proliferation, and induced transient autophagy followed by apoptosis.\nNext, loss-of-function experiments demonstrated that LINC00857 knockdown suppressed CRC cell viability, proliferation and migration, as", "dois": ["10.1186/s12931-025-03323-5", "10.1186/s10020-025-01175-9", "10.1002/advs.202406220", "10.1172/jci.insight.178535", "10.1007/s13402-024-01025-6", "10.1111/crj.13799", "10.1097/CJI.0000000000000523", "10.1016/j.radonc.2024.110259", "10.1016/j.compbiomed.2023.107370", "10.1016/j.exer.2021.108650", "10.3390/ijms22041707", "10.1002/smll.202003757", "10.3390/ijms21020612", "10.1016/j.bbrc.2018.11.162", "10.1186/s13046-018-0907-z", "10.26355/eurrev_201804_14739", "10.1074/jbc.RA117.001103", "10.18632/oncotarget.6512", "10.1158/1078-0432.CCR-15-0489", "10.18632/oncotarget.5957", "10.1002/jcp.25076", "10.1038/leu.2014.338", "10.1038/s41389-025-00568-z", "10.3389/fimmu.2025.1607770", "10.1038/s44321-025-00250-2", "10.1002/jgm.70012", "10.14715/cmb/2023.69.10.3", "10.1007/s12013-023-01183-8", "10.22074/cellj.2023.2004011.1319", "10.1007/s12032-023-02000-1", "10.1073/pnas.2208886119", "10.1002/jcp.30883", "10.3389/fonc.2022.833814", "10.14670/HH-18-494", "10.3390/brainsci12060690", "10.5187/jast.2021.e128", "10.1016/j.bioactmat.2021.07.009", "10.3892/ol.2021.12839", "10.1016/j.taap.2020.115030", "10.3389/fonc.2019.01163", "10.15252/embr.201948469", "10.1038/s42003-018-0212-6", "10.1038/s41419-018-0761-0", "10.1007/s11010-016-2862-3", "10.3969/j.issn.1672-7347.2013.08.009", "10.1016/j.ygyno.2010.01.041", "10.1007/s00726-025-03456-3", "10.1038/s41467-023-37593-8", "10.1111/ced.15038", "10.1158/0008-5472.CAN-20-3694", "10.1007/s10495-020-01603-7", "10.1161/ATVBAHA.119.313800", "10.1038/s41598-019-40013-x", "10.3390/ijms252011266", "10.3168/jds.2022-21869", "10.1016/j.cbi.2021.109560", "10.1667/RADE-20-00214.1", "10.1016/j.ijpharm.2020.119585", "10.1016/j.mce.2020.110868", "10.21873/anticanres.13092", "10.1021/acs.molpharmaceut.7b00569", "10.1186/s12987-017-0068-z", "10.1177/1010428317694545", "10.1128/MCB.00427-16", "10.18632/oncotarget.11526", "10.1016/j.jphs.2016.04.021", "10.1021/cb500120x", "PMID:24492461", "10.1007/s00726-011-1122-9", "PMID:19597571", "PMID:18520037", "10.1227/01.neu.0000316018.51292.19", "PMID:17889654", "10.1007/s12035-020-02045-7", "PMID:17896864", "PMID:14977877", "10.31083/FBL45811", "10.1007/s12672-025-03903-3", "10.1620/tjem.2025.J113"]}
{"pair_type": "slc_pathway", "key1": "SLC7A11", "key2": "glycolysis", "summary": "Among them, we show that LUC7L2 represses OXPHOS and promotes glycolysis by multiple mechanisms, including (1) splicing of the glycolytic enzyme PFKM to suppress glycogen synthesis, (2) splicing of the cystine/glutamate antiporter SLC7A11 (xCT) to suppress glutamate oxidation, and (3) secondary repression of mitochondrial respiratory supercomplex formation.\nCirc_0072088 elicited oncogenic role in malignant cell progression and glycolysis of PDAC cells through circ_0072088/miR-545-3p/SLC7A11 pathway.\nBlocking circ_0072088 suppressed cell proliferation, migration, invasion, and glycolysis in PDAC cells.\nSND1 bound with and promoted the expression of SLC7A11, an aerobic glycolysis regulator.\nFurther research indicated that ISL promoted DC efferocytosis by regulating SLC7A11-mediated glycolysis.\nAltogether, SNHG1 contributes to sorafenib resistance of liver cancer cells by promoting SND1-m6A-SLC7A11-mediated aerobic glycolysis.\nMoreover, SLC7A11 downregulation could be mediated by both circ_0072008 siRNA and miR-545-3p mimic, and participating in suppressive role in cell progression and glycolysis of SW1990 and PANC-1 cells.\nSLC7A11-deficient dendritic cells were dependent on aerobic glycolysis using glucose derived from glycogen stores for increased efferocytosis;\nFurthermore, either silencing SLC7A11 or blocking aerobic glycolysis with 2-deoxy-d-glucose (2-DG) was able to reverse the promotion of Snhg1 overexpression on malignancy, sorafenib resistance, and aerobic glycolysis of HepG2 cells.\nTranscriptomic analyses across cancers demonstrate strong correlations between GSH, SLC7A11, PKM2, glycolysis, and ferroptosis pathways.", "dois": ["10.1016/j.ejphar.2025.177839", "10.1089/ars.2024.0585", "10.1016/j.biopha.2024.117578", "10.1002/tox.24329", "10.1080/01635581.2023.2203353", "10.4149/neo_2022_220626N665", "10.1038/s41586-022-04754-6", "10.1080/08916934.2022.2027919", "10.1016/j.molcel.2021.02.033", "10.7554/eLife.55994", "10.3390/toxins10110464", "10.1016/j.ejmech.2018.09.037", "10.1186/s41065-025-00530-4", "10.1016/j.redox.2025.103839", "10.1016/j.bbamcr.2025.120047", "10.1186/s12951-025-03545-1", "10.1016/j.intimp.2025.115056", "10.1016/j.bioactmat.2025.05.009", "10.1016/j.intimp.2025.114914", "10.1158/1541-7786.MCR-24-0194", "10.14744/AnatolJCardiol.2025.5042", "10.3389/fphar.2025.1518481", "10.1038/s41531-024-00858-0", "10.1038/s41418-024-01427-x", "10.3892/mmr.2024.13341", "10.1016/j.redox.2024.103213", "10.22088/IJMCM.BUMS.13.4.374", "10.1016/j.jgr.2023.06.006", "10.1002/tox.24014", "10.20517/cdr.2023.49", "10.1242/jcs.259090", "10.1016/j.redox.2022.102257", "10.1016/j.jphs.2021.09.008", "10.1016/j.jbior.2017.12.002", "10.1016/j.celrep.2025.115774", "10.1016/j.mcpro.2021.100159", "10.1158/1078-0432.CCR-11-0687", "10.1002/kjm2.70123", "10.1002/advs.202519368", "10.1038/s41418-025-01585-6"]}
{"pair_type": "slc_pathway", "key1": "SLC43A3", "key2": "apoptosis", "summary": "In vitro cell apoptosis and viability analysis were employed to verify the specific tumor inhibition effects of AZD5153.\nAZD5153, a novel bivalent BET bromodomain inhibitor which could inhibit the transcription of MYC and E2F exhibited specific antitumor function for cells with high-risk score.", "dois": ["PMID:27807008", "10.1186/s10020-024-00988-4"]}
{"pair_type": "slc_pathway", "key1": "SLC4A7", "key2": "apoptosis", "summary": "The electroneutral sodium bicarbonate co-transporter SLC4A7 localizes in mitochondria and suppresses the ischaemia-induced activation of the mitochondrial pathway of apoptosis in coronary EC.\nIn Affymetrix primeview human GeneChip array, we found six upregulated genes (STAT1, ATF2, TNFRSF10B, TGFBR2, BAX, and SQSTM1) and two downregulated genes (SLC4A7 and CD274) related to apoptosis and proliferation of colorectal cancer cells after hsa_circ_0064559 knockdown.\nThe initial characterization of the participating mechanisms of SLC4A7-dependent apoptosis revealed an activation of the mitochondrial pathway of apoptosis, i.e.\nTUNEL staining uncovered the extensive apoptosis of retinal cells induced by slc4a7 knockdown.\nKnockdown of SLC4A7 in EC by transfecting appropriate siRNA similarly increased apoptosis of EC under simulated ischaemia.\nTreatment with S0859 significantly increased caspase-3 activity and elevated the number of apoptotic EC.\ncleavage of caspase-9 and binding of Bax to mitochondria.\nBy examining the expression of bicarbonate transporters (BT) in EC by reverse transcriptase polymerase chain reaction and western blotting, a marked expression of the electroneutral sodium bicarbonate co-transporter (SLC4A7) was defined.\nFinally, a mitochondrial localization of SLC4A7 was demonstrated.\nBicarbonate transport has been shown to participate in apoptosis under ischaemic stress.\nTo analyse the potential role of this transporter during apoptosis, a selective inhibitor (S0859, Sanofi-Aventis) was applied.\nHowever, the precise transporting mechanisms involved in ischaemic apoptosis are unknown and were thus the aim of the present study.\nIn contrast, no activation of the endoplasmic reticulum-dependent pathway (caspase-12 cleavage) or the extrinsic apoptotic pathway (caspase", "dois": ["10.3390/ijms25179613", "10.1038/s41416-024-02591-0", "10.1002/jgm.3469", "10.1158/1541-7786.MCR-14-0011", "10.1093/cvr/cvq330", "PMID:16181686", "10.1016/j.bbrc.2025.152757", "10.1186/s12957-023-03050-5", "10.1038/s41467-020-17312-3", "10.1186/s12920-018-0467-2", "10.1371/journal.pone.0090273"]}
{"pair_type": "slc_pathway", "key1": "SLC5A8", "key2": "oxidative stress", "summary": "Oxidative stress was induced in ARPE-19 cells and primary RPE cells isolated from wild type and Slc5a8(-/-) mouse retinas using H(2)O(2), and the effects of OTC on cell death and intracellular glutathione concentration were examined.\nTo evaluate the role of SLC5A8 in the transport of 2-oxothiazolidine-4-carboxylate (OTC) and to determine whether OTC augments glutathione production in RPE cells, thereby providing protection against oxidative stress.\nRats fed with ethanol-containing Lieber-DeCarli liquid diet showed decreased expression of TJ proteins, and increased intestinal barrier injury resulting in pro-inflammatory response and oxidative stress in the colon.\nTransport via SLC5A8 is obligatory for this process.\nOTC increased glutathione levels and protected ARPE-19 and primary RPE cells isolated from wild type mouse retinas from H(2)O(2)-induced cell death.\nThese effects were abolished in primary RPE isolated from Slc5a8(-/-) mouse retinas.\nOTC augments glutathione production in RPE cells, thereby protecting them from oxidative damage.\nthe concentration necessary for half-maximal inhibition was 17 ± 1 μM.\nThe transport of OTC via SLC5A8 was saturable, with a K(t) of 104 ± 3 μM.\nOTC is a transportable substrate for SLC5A8.\nOxidative stress is a common pathological factor in degenerative retinal diseases;\nGiven the important role played by butyrate in the intestine, this mechanism may contribute to the procarcinogenic and proinflammatory effect of oxidative stress at this level.\nThe effect of tBOOH upon uptake of [(14)C]butyrate ([(14)C]BT) (10μM) can be summarized as follows: (a) it caused a reduction in the intracellular accumulation of [(14)C]BT over time, (b) it strongly reduced total [(14)C]BT uptake but did not affect Na(+)-independent uptake of [(14)C]BT", "dois": ["10.1155/2021/5245197", "10.1186/s13104-015-1500-6", "PMID:24426777", "10.1167/iovs.10-6825", "10.3389/fnut.2024.1505357", "10.1167/iovs.12-11289", "10.1016/j.ejphar.2012.11.029", "10.1016/j.pharmthera.2008.09.005"]}
{"pair_type": "slc_pathway", "key1": "SLC3A2", "key2": "apoptosis", "summary": "HCMV-miR-US33-5p suppressed proliferation, key factors of integrin signal pathway, and EPAS1/SLC3A2 expression, but promoted HA-VSMC apoptosis.\nUpregulation of SLC3A2 significantly decreased cell viability in response to cisplatin, increased cisplatin-induced apoptosis, and decreased migration and invasion in the presence of cisplatin.\nNUP210 and SLC3A2 were significantly upregulated in clinical CRPC tissues, and their knockdown resulted in significant suppression of cellular growth of LNCaP95 through apoptosis and growth arrest.\nNotably, flow cytometry further showed that SLC3A2 inhibition also enhanced the apoptosis of rat cardiomyocytes.\nCell experiments confirmed that melanocyte proliferation decreased, whereas apoptosis increased, after SLC3A2 knockdown.\nIn vitro experiments showed that knocking down of SLC3A2 was associated with reduced migration, invasion, and proliferation, but increased apoptosis of OSCC cells.\nMechanistic study showed that HCMV-miR-US33-5p bound to the 3'-untranslated region of EPAS1 to suppress its expression, leading to suppression of SLC3A2 expression, which ultimately promoted cell apoptosis and inhibited cell proliferation.\nTNFSF9 regulated by SP1 aggravated CIRI via boosting ferroptosis, apoptosis, and release of inflammatory mediators of BMECs under OGD/R situation by suppressing SLC3A2 expression in vitro and in vivo.\nEx vivo and in vitro, loss of CD98hc suppressed proliferation and induced apoptosis in VSMCs.\nCD98 depletion decreased cell proliferation, clonogenic survival, and migration and induced apoptosis in HCC cells.\nSLC3A2 exerted a harmful effect on OSCC patients by increasing migration, invasion and proliferation, and decreasing apoptosis.\nCD98hc KO cells showed reduced endoreplication capacity and lower sensitivity towards PRZ induced apoptosis than wild type cells.", "dois": ["10.1371/journal.pone.0318016", "10.1007/s12031-025-02310-1", "10.1038/s41598-025-85569-z", "10.1002/advs.202406220", "10.1186/s10020-024-01024-1", "10.3390/biom14111456", "10.1007/s00262-024-03827-x", "10.5152/tjg.2024.23454", "10.3390/molecules29112623", "10.1186/s11658-022-00340-w", "10.1186/s13046-019-1177-0", "10.1371/journal.pone.0208993", "10.1159/000493864", "10.18632/oncotarget.5957", "10.1186/1476-4598-12-169", "10.1016/j.tox.2008.12.004", "PMID:15625115", "10.1016/j.tice.2025.103181", "10.1016/j.tranon.2025.102534", "10.1038/s41598-025-14572-1", "10.3389/fnagi.2025.1506276", "10.3791/68019", "10.3892/ol.2025.15015", "10.7150/jca.102618", "10.1186/s12935-024-03560-6", "10.24976/Discov.Med.202436190.208", "10.1515/med-2024-0941", "10.1016/j.tranon.2024.101981", "10.1186/s12864-024-10147-y", "10.3390/ijms242015195", "10.22074/cellj.2023.2004011.1319", "10.1016/j.phymed.2023.154756", "10.1016/j.phymed.2022.154617", "10.7717/peerj.13757", "10.3389/fphar.2022.851680", "10.3389/fphar.2022.851540", "10.1186/s12920-022-01194-z", "10.1038/s41388-021-02097-6", "10.1002/JLB.3MA1220-815RRR", "10.1158/1078-0432.CCR-20-3605", "10.1097/HP.0000000000001385", "10.1016/j.freeradbiomed.2021.02.010", "10.26355/eurrev_202102_24876", "10.1111/jop.13132", "10.1016/j.tranon.2020.100915", "10.1038/s41586-019-1170-y", "10.1038/s41419-019-1564-7", "10.1016/j.bbamcr.2018.06.006", "10.18632/oncotarget.25101", "10.1084/jem.20082845"]}
{"pair_type": "slc_pathway", "key1": "SLC48A1", "key2": "oxidative stress", "summary": "Abstract: Heme is critical for a variety of cellular processes, but excess intracellular heme may result in oxidative stress and membrane injury.\nUsing the dietary isothiocyanate sulforaphane (SFN) to activate NRF2, chromatin immunoprecipitation sequencing (ChIP-seq) identified several hundred novel NRF2-mediated targets beyond its role in oxidative stress.\nUnder oxidative stress, NRF2 heterodimerizes with small Maf proteins and binds cis-acting enhancer sequences found near oxidative stress response genes.\nActivated NRF2 bound the antioxidant response element (ARE) in promoters of several known and novel target genes involved in iron homeostasis and heme metabolism, including known targets FTL and FTH1, as well as novel binding in the globin locus control region.\nFive novel NRF2 target genes were chosen for followup: AMBP, ABCB6, FECH, HRG-1 (SLC48A1), and TBXAS1.\nSLC48A1 (heme responsive gene-1, HRG-1), the sole member of the SLC48 family, is associated with the endosome and appears to transport heme from the endosome into the cytosol.\nAbstract: Nuclear factor- (erythroid-derived 2) like 2 (NFE2L2, NRF2) is a key transcriptional activator of the antioxidant response pathway and is closely related to erythroid transcription factor NFE2.", "dois": ["10.1158/0008-5472.CAN-18-2156", "10.1074/jbc.M111.220178", "10.1155/2013/120305", "10.1016/j.mam.2012.07.013"]}
{"pair_type": "slc_pathway", "key1": "SLC5A1", "key2": "glycolysis", "summary": "Metformin increased expression of Slc2a1 (GLUT1), decreased expression of Slc2a2 (GLUT2) and Slc5a1 (SGLT1) whilst increasing GLUT-dependent glucose uptake and glycolytic rate as observed by live cell imaging of genetically encoded metabolite sensors and measurement of oxygen consumption and extracellular acidification rates.\nSGLT1 and SGLT2 are expressed in various tumors where they supply the tumor cells with glucose for euglycemic glycolysis.\nBoth glycolysis and glycogen formation require cellular glucose uptake which could be accomplished by the Na+ coupled glucose transporter-1 (SGLT1; SLC5A1).\nGlucose can be utilized not only for glycolysis but also for glycogen formation.\nWe conclude that metformin affects glucose uptake, glycolysis and GDF-15 secretion, likely downstream of the observed mitochondrial dysfunction.\nBulk RNA-sequencing analysis identified changes in hexose metabolism pathways, particularly glycolytic genes.\nLEFTY2 down-regulates Na+/H+ exchanger activity with subsequent inhibition of glycolytic flux and lactate production in endometrial cancer cells.\nA glycometabolism-related prognostic model consisting of four genes (PLOD2, CHSY3, SLC2A3 and SLC5A1) was developed and validated, effectively stratifying GC patients into high- and low-risk subgroups with distinct survival outcomes.\nAs a result, a 48-hour treatment with LEFTY2 significantly increased SGLT1 and GYS1 transcript levels as well as SGLT1 and GYS1 protein abundance in both Ishikawa and HEC1a cells.\nWe further show the treatment with LEFTY2 fosters cellular glucose uptake and glycogen formation and TGF-β can negate this effect in endometrial cancer cells.\nIn conclusion, LEFTY2 up-regulates expression and activity of the Na+ coupled glucose transporter SGLT1 and glycogen synthase GYS1 in a cell line specific manner.\nFunctional analyses revealed that PLOD2 promotes glycolysis and tumor", "dois": ["10.1186/s12876-025-03878-z", "10.1038/s41598-021-81349-7", "10.1016/j.foodres.2018.07.032", "10.1371/journal.pone.0230044", "10.1016/j.pharmthera.2016.10.017"]}
{"pair_type": "slc_pathway", "key1": "SLC5A8", "key2": "apoptosis", "summary": "Besides, decreased proliferation activity and increased apoptosis were also observed in CC cells overexpressing SLC5A8 plasmid.\nThe changes in gene expression in SLC5A8/butyrate-induced apoptosis include upregulation of pro-apoptotic genes and downregulation of anti-apoptotic genes.\nMoreover, the impaired proliferation activity and increased apoptosis proportion of CC cells induced by SLC5A8 over-expression could be counteracted by the Wnt signaling pathway activator LiCl.\nHowever, when transfected with SLC5A8 or treated with inhibitors of DNA methylation, these cells underwent apoptosis in the presence of 3-bromopyruvate.\nReexpression of SLC5A8 in colon cancer cells leads to apoptosis but only in the presence of butyrate.\nEctopic expression of the transporter in MCF7 cells led to apoptosis, and the mechanism involved the inhibition of HDAC1/HDAC3.\nButyrate treatment-induced apoptosis of wild-type T cells but not Fas-deficient (Fas(lpr)) or FasL-deficient (Fas(gld)) T cells, revealing a potential role of Fas-mediated apoptosis of T cells as a mechanism of butyrate function.\nOur data thus suggest that butyrate delivers a double-hit: induction of T cell apoptosis to eliminate the source of inflammation and suppression of IFN-γ-mediated inflammation in colonic epithelial cells, to suppress colonic inflammation.\nPossible cell death pathways included expression of caspase 8 and activated caspase 3, autophagy, Slc5a8-mediated inactivation of survivin (Birc5), and pStat3-mediated lysosomal lysis, the latter of which is the principal death route in involuting wild type cells.\nAcetate was shown to induce apoptosis in CRC cells.\nMoreover, an apoptosis assay, demonstrated that the TTFM extracts significantly increased the proportion of apoptotic cells.\nThese studies show that SLC5A8 mediates the tumor-suppressive effects", "dois": ["PMID:27465549", "10.1042/BJ20121248", "10.1152/ajpgi.00543.2011", "10.1167/iovs.10-6825", "10.1038/onc.2011.113", "10.1158/0008-5472.CAN-09-3073", "10.1002/cncr.24532", "10.1042/BJ20081132", "PMID:17178845", "10.3892/br.2023.1652", "10.1096/fba.2021-00059", "10.3389/fphys.2020.00561", "10.26355/eurrev_202005_21155", "PMID:24934552", "10.1007/s11605-008-0573-0", "PMID:15667316", "PMID:15090606", "10.1007/s12275-022-1533-1", "10.18632/oncotarget.12156", "10.1167/iovs.12-10312", "10.1016/j.pharmthera.2008.09.005", "PMID:16858683"]}
{"pair_type": "slc_pathway", "key1": "SLC5A2", "key2": "oxidative stress", "summary": "Dapagliflozin decreased oxidative stress, as evidenced by reduced levels of malondialdehyde (MDA), reactive oxygen species (ROS), increased superoxide dismutase (SOD) and Glutathione (GSH) activity.\nIncreased SGLT1 and SGLT2 protein levels were observed in the rat aortic arch, and Ang II- and eNOS inhibitor-treated thoracic aorta segments, and were associated with enhanced levels of oxidative stress and prevented by VAS-2780, losartan, Sota and Empa.\nAmong these, SGLT2Is inhibit fibrosis, hypertrophy, apoptosis, inflammation, and oxidative stress.\nIn addition, EMPA prevented increases in oxidative stress, sodium calcium exchanger expression and calcium/calmodulin-dependent protein kinase II activation to an equal degree in WT and SGLT2 KO animals.\nCompared with plaques from patients with diabetes, SGLT2i-treated patients with type 2 diabetes presented increased SIRT6 expression and collagen content and lowered inflammation and ion and oxidative stress, thus indicating a more stable plaque phenotype.\nUnexpectedly, mechanistic studies revealed that antagonism of AMPK aggravated oxidative stress and ferroptosis, reduced GPX4 (glutathione peroxidase 4) level, and partially abolished the anti-hypertrophic and anti-ferroptosis effects of SGLT2i in H9C2 cells.\nGene expression and protein levels of main biomarkers of cardiac fibrosis (galectin-3, sST2, serpin-4, procollagen type I amino-terminal peptide, procollagen type I carboxy-terminal propeptide, collagen, transforming growth factor [TGF]-β), inflammation (growth differentiation factor-15, interleukin-6, nuclear factor-κB [NF-κB]), oxidative stress (superoxide dismutase 1 [SOD1] and 2 [SOD2]), and cardiac metabolism (sodium-hydrogen exch", "dois": ["10.1016/j.intimp.2025.114117", "10.1080/15548627.2024.2435238", "10.1016/j.csbj.2022.10.030", "10.3389/fphar.2022.901340", "10.1007/s11010-025-05294-z", "10.1038/s41598-025-98997-8", "10.1152/ajprenal.00246.2024", "10.1093/cvr/cvae257", "10.1186/s12933-024-02539-x", "10.1172/JCI176708", "10.1038/s41598-024-71416-0", "10.1007/s11010-024-05084-z", "10.1007/s00395-024-01067-9", "10.1093/cvr/cvae047", "10.1002/ejhf.3145", "10.1016/j.jtha.2023.09.022", "10.3390/ijms24076039", "10.1016/j.vph.2022.107095", "10.1161/HYPERTENSIONAHA.122.19586", "10.1007/s11033-022-07183-w", "10.1016/j.molmet.2021.101337", "10.1038/s41598-021-91546-z", "10.3390/ijms22115863", "10.1139/cjpp-2020-0278", "10.1186/s12933-021-01252-3"]}
{"pair_type": "slc_pathway", "key1": "SLC39A4", "key2": "apoptosis", "summary": "RNAi knockdown of Zip4 in mouse Hepa cells significantly increased apoptosis and modestly slowed progression from G(0)/G(1) to S phase when cells were released from hydroxyurea block into zinc-deficient medium.\nZIP4 may play a role in the acquisition of zinc by hepatocellular carcinomas, and potentially many different cancerous cell-types, leading to repressed apoptosis, enhanced growth rate and enhanced invasive behavior.\nUKLF promoted cell proliferation, migration and invasion, and inhibited cell apoptosis.\nCell migration assays revealed that RNAi knockdown of Zip4 in Hepa cells depressed in vitro migration whereas forced over-expression in Hepa cells and MCF-7 cells enhanced in vitro migration.\nIn addition, CP induced apoptosis modestly and modulated antimicrobial gene expression.\nHowever, in the Znhigh group, we found a prevention of villus atrophy and decreased caspase-3-mediated apoptosis of jejunal epithelium.\nMoreover, UKLF modulated the expression of solute carrier family 39 member 4 (SLC39A4) at the transcriptional level.\nTaken together, these findings elucidated the regulatory mechanism of UKLF and uncovered the importance of the PCBP2/UKLF/SLC39A4 pathway.\nCP had antiproliferative effects and reduced the expression of proliferative and stemness genes in jejunal organoids, effects that were largely independent of Zn chelation.\nCP addition upregulated the expression of the Zn absorptive transporter Slc39a4 and of methallothionein Mt1 in a Zn-sensitive manner, while downregulating the expression of the Zn exporter Slc30a2 and of methallothionein 2 (Mt2).\nThe promotion effect of UKLF on tumor growth was further confirmed in vivo.", "dois": ["10.1016/j.bbamcr.2024.119755", "10.1371/journal.pone.0013158", "10.1016/j.biopha.2024.116555", "10.2147/CMAR.S282269", "PMID:26722421", "10.1186/1746-6148-10-75", "PMID:12699353"]}
{"pair_type": "slc_pathway", "key1": "SLC39A8", "key2": "oxidative phosphorylation", "summary": "The expression of wild-type hSLC39A8, but not the disease-associated mutants, promoted mitochondrial functions.\nInterestingly, expression of hSLC39A8 mutants of both CDG type II and Leigh syndrome reduced mitochondrial Mn levels and activity of Mn-dependent mitochondrial superoxide dismutase MnSOD, and in turn increased oxidative stress.\nMoreover, loss of function analyses further corroborate hSLC39A8's critical role in mediating Mn uptake and mitochondrial function.\nWhile expression of wild-type hSLC39A8 increased Mn uptake activity, disease-associated mutations abrogated the ability of the transporter to mediate Mn uptake into the cells, thereby providing a causal link to severe Mn deficiency.", "dois": ["10.1038/s41598-018-21464-0"]}
{"pair_type": "slc_pathway", "key1": "SLC3A2", "key2": "oxidative stress", "summary": "RY-A induced neuroprotective effects by increasing the production of key proteins involved in ferroptosis inhibition, such as SLC7A11, SLC3A2, GSS, and GPX4, while increasing antioxidant enzyme activities and alleviating oxidative stress.\nIn this study, we showed that HCV upregulated both mRNA and protein expression levels of SLC3A2 and this upregulation occurred through NS3/4A-mediated oxidative stress.\nInterestingly, SLC7A11 and SLC3A2 mRNA were also both deregulated in JEV-infected SH-SY5Y cells and encode the two constituent subunits of the plasma membrane xCT amino acid antiporter that relieves oxidative stress by export of glutamate and import of cystine.\nTaken together, our data suggested that acupuncture was effective in treating asthma by attenuation of AHR, mucus secretion and airway inflammation, and the mechanism was associated with regulation of ferroptosis, SLC3A2 and ATP1A3 protein expression as well as oxidative stress.\nAdditionally, iron overload inhibited Xc system (SLC7A11 and SLC3A2), decreasing GSH synthesis, ultimately further induced ferroptosis.\nAfter adjustment for differences in the background characteristics of the two groups, we finally identified seven Cd-responsive genes (CASP9, TNFRSF1B, GPX3, SLC3A2, ITGAL, BCL2A1, and COX7B), all of which constituted a network that controls oxidative stress response by IPA.\nCancer cells overexpress CD98hc-transporters in order to meet their increased nutritional and antioxidant demands, since they provide branched-chain AA (BCAA) and aromatic AA (AAA) availability while protecting cells from oxidative stress.\nFurthermore, system xc (SLC7A11 and SLC3A2) were found to be suppressed and a decreased GSH/GSSG ratio was observed at the same time when treated with FZKA.\nCatalpol treatment inhibited changes to several ferroptosis-related proteins, including p-PI3K", "dois": ["10.7150/ijbs.103971", "10.24976/Discov.Med.202436190.208", "10.1016/j.jep.2024.118874", "10.1016/j.aquatox.2024.107078", "10.1002/kjm2.12851", "10.1016/j.envpol.2024.124280", "10.1038/s41598-019-50547-9", "10.1158/1078-0432.CCR-18-2951", "10.1038/s41598-018-33861-6", "10.1074/jbc.M115.704254", "PMID:25415224", "10.1016/j.tox.2008.12.004", "10.1152/physiolgenomics.00263.2007", "10.4103/ejpi.EJPI-D-24-00104", "10.1002/advs.202417330", "10.4103/NRR.NRR-D-25-00024", "10.3390/ph18091382", "10.3389/fphar.2025.1564783", "10.1111/febs.70101", "10.3389/fphar.2025.1552228", "10.3389/fimmu.2024.1456649", "10.1007/s10620-025-08843-0", "10.3390/foods13213358", "10.1016/j.ejphar.2024.176406", "10.1016/j.envpol.2024.123332", "10.1016/j.expneurol.2023.114641", "10.1016/j.tox.2023.153689", "10.1016/j.jbc.2023.105409", "10.1016/j.envpol.2023.122207", "10.1016/j.actbio.2023.01.053", "10.1039/d2fo02994d", "10.3390/nu14183856", "10.4103/1673-5374.350203", "10.3389/fphar.2022.851680", "10.1016/j.freeradbiomed.2021.02.010", "10.3390/antiox10020317", "10.1016/j.biopha.2020.111001", "10.1002/pro.3966", "10.1007/s11262-019-01683-x"]}
{"pair_type": "slc_pathway", "key1": "SLC2A4", "key2": "ferroptosis", "summary": "ADPN inhibited oxidation/peroxide imbalance-induced ferroptosis in placental tissues of GDM mice.\nAdditionally, eight common genes of Tibetan plateau key and ferroptosis-related differentially expressed mRNAs (DEmRNAs) (CBS, SLC2A4, STAT3, ALOX15B, ATF3, IDO1, NOX4, and SOCS1) were identified in CAG.\nADPN ameliorated placental injury in GDM by correcting fatty acid oxidation/peroxide imbalance-induced ferroptosis via restoration of CPT-1 activity.\nIn addition to apoptosis pathways, Cd toxicity through ROS generation, ferroptosis and pyroptosis were summarized.\nThe common genes of Tibetan plateau key and ferroptosis-related DEmRNAs can play a role in the JAK-STAT signaling pathway.\nADPN inhibited the expression of CPT-1 and GLUT4 in placental tissues of GDM mice.", "dois": ["10.1038/s41598-024-59836-4", "10.3390/ijms26157515", "10.1007/s12020-021-02933-5"]}
{"pair_type": "slc_pathway", "key1": "SLC7A11", "key2": "ferroptosis", "summary": "GLEXG and quercetin alleviate GTW-induced SGD by inhibiting ferroptosis via HIF-1α/SLC7A11.\nMechanistically, ACSL1 elevated ROS, activated p53, downregulated SLC7A11/GPX4, and triggered ferroptosis.\nHOXA13 promotes prostate cancer metastasis by inhibiting ferroptosis via upregulating SLC7A11 and SLC3A2.\nOur findings indicate that RBMS2 inhibits CRC progression by promoting ferroptosis and regulating SLC7A11 mRNA stability.\nBECN1 activator peptide Tat-beclin 1 promotes ferroptosis via the BECN1-SLC7A11 axis to inhibit NSCLC progression.\nPteris wallichiana bioactives induce ferroptosis via the SLC7A11-GSH-GPX4 axis to directly suppress colorectal cancer.\nIn summary, ALA inhibits ferroptosis in macrophages by activating the Nrf2/SLC7A11/GPX4 pathway and attenuates HS-induced ALI.\nSesamin promotes the survival of skin flaps in rats by inhibiting ferroptosis through the Nrf2/SLC7A11/GPX4 signaling pathway.\nFindings demonstrate that HnRNPU promotes proliferation and inhibits ferroptosis by regulating the mRNA stability of SLC7A11 and SLC3A2.\nTat-beclin 1 promotes ferroptosis and tumor suppression in NSCLC by activating BECN1 and inhibiting SLC7A11-mediated system Xc⁻ activity.\nExpression of COX2 was downregulated, whereas key ferroptosis suppressors, SLC7A11, GPX4, and FTH1, were upregulated following hUC-MSC treatment.\nIGF2BP2 plays a critical role in NSCLC by stabilizing SLC7A11 mRNA via m6A modification, promoting cell proliferation and suppressing ferroptosis.", "dois": ["10.1016/j.biomaterials.2025.123675", "10.1016/j.jep.2025.120938", "10.1016/j.jep.2025.120743", "10.1016/j.cellsig.2025.112257", "10.1016/j.tice.2025.103225", "10.1016/j.cellsig.2025.112212", "10.1016/j.expneurol.2025.115537", "10.1016/j.tice.2025.103199", "10.1016/j.tice.2025.103181", "10.1016/j.jep.2025.120037", "10.1016/j.jep.2025.120472", "10.1016/j.prp.2025.156297", "10.1016/j.intimp.2025.115876", "10.1016/j.yexcr.2025.114825", "10.1016/j.taap.2025.117622", "10.2478/aite-2026-0002", "10.1016/j.freeradbiomed.2025.11.001", "10.1016/j.intimp.2025.115767", "10.1016/j.abb.2025.110669", "10.1016/j.bcp.2025.117519", "10.1016/j.reprotox.2025.109099", "10.1016/j.freeradbiomed.2025.10.297", "10.1016/j.bcp.2025.117481", "10.1016/j.freeradbiomed.2025.10.291", "10.1016/j.tox.2025.154324", "10.1016/j.freeradbiomed.2025.10.266", "10.1016/j.bbalip.2025.159692", "10.1016/j.jes.2025.04.059", "10.1016/j.jnutbio.2025.110098", "10.1016/j.theriogenology.2025.117658", "10.1016/j.theriogenology.2025.117628", "10.1016/j.avsg.2025.05.056", "10.1080/15384047.2025.2567815", "10.1016/j.foodchem.2025.146690", "10.1016/j.freeradbiomed.2025.10.003", "10.1016/j.ejmech.2025.118181", "10.1038/s41598-025-26647-0", "10.1007/s10555-025-10306-x", "10.1007/s11033-025-11273-w", "10.1021/acsami.5c19528", "10.1016/j.intimp.2025.115703", "10.1016/j.intimp.2025.115672", "10.1016/j.ejphar.2025.178376", "10.1371/journal.pone.0337060", "10.1016/j.intimp.2025.115573", "10.1016/j.intimp.2025.115507", "10.1021/acs.est.5c11674", "10.1016/j.ecoenv.2025.119489", "10.1016/j.brainresbull.2025.111659", "10.1016/j.peptides.2025.171454", "10.1016/j.jphotobiol.2025.113309", "10.1016/j.brainresbull.2025.111638", "10.1016/j.bioorg.2025.109192", "10.1016/j.ijbiomac.2025.148831", "10.1080/13510002.2025.2583802", "10.1016/j.etap.2025.104856", "10.1016/j.jtemb.2025.127792", "10.1016/j.ijbiomac.2025.148554", "10.1016/j.atherosclerosis.2025.120548", "10.1016/j.cellsig.2025.112168", "10.1016/j.abb.2025.110632", "10.1080/01652176.2025.2569558", "10.1002/advs.202507718", "10.1016/j.biocel.2025.106866", "10.1016/j.archoralbio.2025.106398", "10.1016/j.canlet.2025.218058", "10.1016/j.jtemb.2025.127755", "10.1007/s12035-025-05272-y", "10.1016/j.cellsig.2025.112111", "10.1016/j.bmc.2025.118374", "10.1080/0886022X.2025.2548613", "10.1158/0008-5472.CAN-24-4949", "10.1016/j.freeradbiomed.2025.08.051", "10.1016/j.bios.2025.117881", "10.1016/j.bbamcr.2025.120047", "10.1080/13510002.2025.2544412", "10.1007/s10534-025-00732-3", "10.1080/13510002.2025.2538294", "10.1080/21505594.2025.2530164", "10.1111/febs.70191", "10.1007/s00210-025-04404-4", "10.1007/s00210-025-04324-3", "10.1080/0886022X.2025.2523573", "10.1016/j.biomaterials.2025.123407", "10.1080/13510002.2025.2503130", "10.1080/16078454.2025.2497041", "10.1080/16078454.2025.2451446", "10.1080/0886022X.2024.2438857", "10.1007/s10528-024-10959-3", "10.1096/fj.202501348RRR", "10.1096/fj.202502018R", "10.1007/s10142-025-01757-0", "10.1021/acs.jmedchem.5c02567", "10.3390/ijms262311439", "10.1007/s12032-025-03144-y", "10.1016/j.phymed.2025.157463", "10.1016/j.phymed.2025.157470", "10.1016/j.phymed.2025.157422", "10.1016/j.phymed.2025.157413", "10.1016/j.phymed.2025.157321", "10.1016/j.phymed.2025.157306", "10.1016/j.phymed.2025.157269", "10.1016/j.phymed.2025.157319", "10.1007/s12035-025-05458-4", "10.3389/fimmu.2025.1674321", "10.1007/s10238-025-01933-3", "10.1038/s41598-025-26588-8", "10.1016/j.ecoenv.2025.119459", "10.1007/s12035-025-05358-7", "10.1016/j.ejphar.2025.178175", "10.1590/1414-431X2025e14679", "10.1016/j.intimp.2025.115485", "10.1007/s12026-025-09720-8", "10.3389/fimmu.2025.1619944", "10.1038/s41598-025-22984-2", "10.1038/s41419-025-08146-2", "10.1186/s13018-025-06417-4", "10.1186/s12967-025-07047-4", "10.1016/j.gene.2025.149819", "10.1186/s41065-025-00591-5", "10.1038/s41419-025-08143-5", "10.1007/s11011-025-01729-0", "10.3390/ijms262110679", "10.1038/s12276-025-01569-z", "10.1002/brb3.70930", "10.1016/j.brainresbull.2025.111619", "10.1016/j.ecoenv.2025.119301", "10.1016/j.bbrc.2025.152788", "10.1177/15230864251386447", "10.1002/ptr.70111", "10.1111/1440-1681.70072", "10.1016/j.neuint.2025.106065", "10.1002/ddr.70174", "10.1016/j.biopha.2025.118584", "10.1016/j.neulet.2025.138368", "10.1038/s41388-025-03562-2", "10.1016/j.taap.2025.117540", "10.1016/j.lfs.2025.123941", "10.1016/j.taap.2025.117538", "10.1016/j.jstrokecerebrovasdis.2025.108440", "10.1016/j.taap.2025.117531", "10.1016/j.taap.2025.117512", "10.1016/j.freeradbiomed.2025.08.003", "10.1016/j.cellsig.2025.112040", "10.1016/j.canlet.2025.217942", "10.1016/j.freeradbiomed.2025.07.029", "10.1016/j.freeradbiomed.2025.07.031", "10.1016/j.freeradbiomed.2025.07.021", "10.1016/j.cellsig.2025.112010", "10.1016/j.cellsig.2025.112007", "10.1002/2211-5463.70090", "10.1016/j.cellsig.2025.111998", "10.1016/j.jnutbio.2025.110019", "10.1016/j.colsurfb.2025.114908", "10.1016/j.jad.2025.119690", "10.1080/15548627.2025.2503564", "10.17219/acem/200588", "10.1096/fj.202502289R", "10.3389/fimmu.2025.1675373", "10.1186/s41065-025-00587-1", "10.3390/cells14211685", "10.1186/s12903-025-07048-1", "10.12122/j.issn.1673-4254.2025.10.03", "PMID:41131763", "10.1016/j.brainresbull.2025.111543", "10.1007/s13577-025-01274-z"]}
{"pair_type": "slc_pathway", "key1": "SLC40A1", "key2": "ferroptosis", "summary": "Mechanistically, CAP downregulated transferrin (Trf) and upregulated solute carrier family 40 member 1 (SLC40A1), which helped maintain iron levels in the cells and prevent ferroptosis.\nThe PI3K/AKT signaling pathway mediates TBMS1-induced ferroptosis, which was accompanied by altered expression of NRF2, SLC40A1, and GPX4, ultimately suppressing cell proliferation and collagen synthesis.\nThe natural IGF1R inhibitor PPP induced ferroptosis through blockage of PI3K/AKT/NRF2 signaling pathway and subsequent inhibition of downstream gene expression of SLC7A11 and SLC40A1 in hepatocellular carcinoma.\nMechanistically, iCoDMSNs upregulate heme oxygenase 1 (HMOX1), which increases transferrin receptors and reduces solute carrier family 40 member 1 (SLC40A1), resulting in Fe accumulation and ferroptosis initiation.\nValidation of transcriptome data showed that 1,25(OH)D inhibits ferroptosis in zebrafish larvae and ZFL caused by excessive FAC via promoting the expression of slc40a1 and hmox1a genes and increasing SLC40A1 protein levels.\nMechanistically, JIB04 suppressed nuclear-factor-E2-related factor 2 (Nrf2) and reduced chromatin accessibility at distal regulatory regions of its downstream target solute carrier family 40 member 1 (Slc40a1), impairing iron efflux and promoting ferroptosis in tumor cells.\nNRF2 attenuated PQ-induced ferroptosis in A549 cells, mainly through the upregulation of SLC40A1 to encourage the movement of iron to the extracellular side to alleviate iron overload, and the upregulation of SLC7A11 to promote the expression of GPX4 to inhibit lipid peroxidation.\nSubsequently, the contributions of abnormal GSK-3β expression to NaIO3-induced mice and HLE-B3 cell model were further evaluated, inhibition of", "dois": ["10.7150/ijbs.114930", "10.7150/ijbs.114545", "10.1016/j.bbrc.2025.152417", "10.1016/j.cbpc.2025.110285", "10.1016/j.phymed.2025.156840", "10.1136/jitc-2025-013269", "10.1186/s12967-025-07018-9", "10.1097/MD.0000000000044384", "10.1016/j.ecoenv.2025.118999", "10.1177/15230864251363577", "10.1038/s41598-025-93834-4", "10.1038/s41418-025-01510-x", "10.1111/febs.70101", "10.1155/cdr/9106621", "10.12182/20250160502", "10.1007/s12012-025-09982-6", "10.1186/s12974-025-03373-y", "10.1016/j.bcp.2025.116790", "10.1016/j.ijbiomac.2024.138841", "10.1016/j.redox.2024.103419", "10.1038/s41419-024-06902-4", "10.1016/j.freeradbiomed.2024.05.007", "10.1016/j.jep.2024.118162", "10.1002/wsbm.1644", "10.1590/1414-431X2023e13218", "10.1016/j.envpol.2024.123626", "10.1038/s41598-024-54278-4", "10.1016/j.ecoenv.2024.115960", "10.1016/j.envpol.2024.123332", "10.1016/j.toxicon.2023.107529", "10.1038/s41419-023-06282-1", "10.1007/s00432-023-05423-5", "10.1016/j.envpol.2023.122278", "10.1016/j.tiv.2023.105655", "10.1111/1440-1681.13801", "10.1016/j.gene.2023.147597", "10.1242/dev.201690", "10.1016/j.freeradbiomed.2023.04.022", "10.1093/jb/mvad036", "10.1089/ars.2022.0202", "10.1016/j.neuro.2023.01.005", "10.1002/smll.202206415", "10.1080/15548627.2023.2165323", "10.1002/jmv.28386", "10.1155/2022/9735555", "10.1155/2022/2843990", "10.1155/2022/4213401", "10.1080/15548627.2022.2059170", "10.1111/febs.16272", "10.1016/j.wneu.2021.05.098", "10.1016/j.neuroscience.2021.03.009", "10.1016/j.freeradbiomed.2021.02.010", "10.1080/15548627.2021.1872241", "10.1016/j.yjmcc.2020.10.010", "10.7150/thno.44705", "10.1074/jbc.RA119.009548", "10.1016/j.redox.2019.101297", "10.1016/j.ibneur.2025.10.017", "10.3390/genes16101166", "10.3390/ijms26199662", "10.3389/fphar.2025.1654108", "10.1016/j.bioactmat.2025.09.019", "10.3389/fnagi.2025.1506276", "10.3389/fphar.2025.1567942", "10.1186/s40164-025-00657-0", "10.1038/s41420-025-02421-z", "10.1002/mco2.70049", "10.3389/fimmu.2024.1480492", "10.21203/rs.3.rs-5153598/v1", "10.1016/j.psj.2024.104599", "10.1080/13510002.2024.2428147", "10.20517/cdr.2024.123", "10.1016/j.ijbiomac.2024.136962", "10.1080/00207454.2024.2401661", "10.1016/j.heliyon.2024.e33675", "10.2174/0115665232279426240217174738", "10.3892/etm.2024.12509", "10.1007/s12031-023-02187-y", "10.3390/ijms25020763", "10.1016/j.expneurol.2023.114659", "10.1186/s40246-023-00562-9", "10.1016/j.freeradbiomed.2023.11.042", "10.1177/11779322231214445", "10.3389/fimmu.2023.1249379", "10.18632/aging.205138", "10.18632/aging.204945", "10.3390/metabo13091005", "10.1016/j.biopha.2023.115567", "10.1016/j.biopha.2023.115465", "10.1007/s10142-023-01100-5", "10.3389/fsurg.2022.1060036", "10.1016/j.ecoenv.2022.113373", "10.1080/21655979.2021.2001913", "10.3389/fmolb.2021.650264", "10.1016/j.bbrc.2016.10.068"]}
{"pair_type": "slc_pathway", "key1": "SLC39A6", "key2": "apoptosis", "summary": "Experimentally, the suppression of SLC39A6 expression promoted ESCC cell apoptosis but abrogated proliferation and invasion, and induced an EMT phenotype that included enhanced expression of E-cadherin, loss of vimentin, and morphological changes in ESCC cells in vitro.\nAnd the zip6 deficiency increases caspase-related cell apoptosis in both zebrafish cells and human T cells.\nAmong them, FADD, FIBP, FIBP, GNE, IGF1R, MKL1, PIGP, and SLC39A6 were identified in the Reactome pathway database as involved in signal transduction, transcription, protein metabolism, immune system, cell cycle, and apoptosis.\nThe biological effects of SLC39A6 (LIV-1) and GrpE-like 1 (GRPEL1) on mitotic exit and apoptosis were evaluated both in vitro and in vivo using flow cytometry, western blotting, xenografts and time-lapse imaging.\nAnd the effects of SLC39A6 silencing by siRNA on cell proliferation, apoptosis, and invasiveness, as well as the proteins involved in epithelial-to-mesenchymal transition (EMT) of esophageal cancer cells, were studied.\nLIV-1-GRPEL1 axis depletion works to reduce the mitotic arrest by inducing PP2A-B55α phosphates activity, while inhibit apoptosis by banding AIF and preventing the latter's release into the nucleus.\nThese data demonstrate that LIV-1-GRPEL1 axis dually regulates mitotic exit as well as apoptosis by interacting with PP2A B55α and AIF.\nOverexpression of LIV-1 led to direct apoptosis.\nMost Zn-dependent genes that were expressed differently between early and late passages were correlated with changes in the expression of anti-apoptotic genes.", "dois": ["10.1186/s12885-024-12830-5", "10.1016/j.ebiom.2019.09.054", "10.1016/j.bbrc.2019.02.148", "10.1016/j.exger.2017.09.006", "10.18632/oncotarget.6603", "10.1186/s12967-015-0681-z", "10.1074/jbc.M115.640524", "10.3389/fonc.2023.1198992", "10.1016/j.tripleo.2011.05.009"]}
{"pair_type": "slc_pathway", "key1": "SLC34A2", "key2": "oxidative phosphorylation", "summary": "Moreover, we uncovered the regulatory networks of PHF5A-TOMM22-oxidative phosphorylation, TLR3-CTSO inflammation-related pathway, SECISBP2L-targeted RNA (ADGRF5, TGFBR2, CD302, AC096921.2, AHCYL2, RPS6KA2, SLC34A2, and SFTPB) angiogenesis, and SECISBP2L-AKAP13 signaling (DNA repair, MTORC1 signaling, and MYC targets).\nThese biomarkers were enriched in oxidative phosphorylation and mitogen-activated protein kinase signaling pathways, which are relevant to DM.\nFour genes [ATP binding cassette subfamily C member 8 (), retinol binding protein 4 (), Ras protein-specific guanine nucleotide-releasing factor 1 (), and solute carrier family 34 member 2 ()] were identified as ubiquitin-pyroptosis-related biomarkers in T2DM, based on consistent expression trends and significant differences in GSE76894 and GSE41762.", "dois": ["10.1089/dna.2021.0145", "10.4239/wjd.v16.i8.104879"]}
{"pair_type": "slc_pathway", "key1": "SLC2A13", "key2": "oxidative phosphorylation", "summary": "Oxygen consumption rates also decreased upon BPTES treatment, indicating a glutamine dependency for oxidative phosphorylation.\nThe current study suggests that BCR-ABL-positive cancer cells make use of enhanced glutamine metabolism to maintain TCA cell cycle activity in glycolytic cells.\nLactate and pyruvate levels were increased in BCR-ABL-expressing cells even under normoxia, coinciding with enhanced glutaminolysis which occurred in an HIF1/2-dependent manner.\nExpression of the glutamine importer SLC1A5 was increased in BCR-ABL+ cells, coinciding with an increased susceptibility to the glutaminase inhibitor BPTES.", "dois": ["10.1371/journal.pone.0153226", "10.3390/ijerph17165866"]}
{"pair_type": "slc_pathway", "key1": "SLC2A2", "key2": "oxidative phosphorylation", "summary": "Metformin increased expression of Slc2a1 (GLUT1), decreased expression of Slc2a2 (GLUT2) and Slc5a1 (SGLT1) whilst increasing GLUT-dependent glucose uptake and glycolytic rate as observed by live cell imaging of genetically encoded metabolite sensors and measurement of oxygen consumption and extracellular acidification rates.\nMetformin caused mitochondrial dysfunction and metformin's effects on 2D-cultures were phenocopied by treatment with rotenone and antimycin-A, including upregulation of GDF15 expression, previously linked to metformin dependent weight loss.\nWe conclude that metformin affects glucose uptake, glycolysis and GDF-15 secretion, likely downstream of the observed mitochondrial dysfunction.", "dois": ["10.1038/s41598-021-81349-7"]}
{"pair_type": "slc_pathway", "key1": "SLC7A11", "key2": "oxidative stress", "summary": "Mechanistically, AA activated the Nrf2/Keap1 pathway, upregulating antioxidant proteins GPX4 and SLC7A11, thereby inhibiting oxidative stress and ferroptosis.\nVNS protects against myocardial injury from hepatic ischemia-reperfusion, likely by inhibiting oxidative stress and ferroptosis through activation of the SLC7A11/GPX4 axis.\nOXA suppressed oxidative stress, upregulated OX1R and HO-1 protein expression, elevated ferroptosis-related markers (SLC7A11 and GPX4), and promoted the nuclear translocation of Nrf2.\nATF3 was found to be highly expressed in VaD rat hippocampus, while its silencing improved cognitive dysfunction and resulted in repressed ferroptosis in the hippocampus, reduced iron content and COX2, and upregulated SLC7A11/GPX4, thus alleviating inflammatory reaction and oxidative stress in VaD rat hippocampus.\nTunicamycin insult prompted cardiac remodeling (interstitial fibrosis), deranged echocardiographic (higher LVESD, dropped ejection fraction and fractional shortening), cardiomyocyte mechanical and intracellular Ca features alongside mitochondrial injury (collapsed mitochondrial membrane potential and ultrastructural change), oxidative stress, compromised Akt-GSK3β signaling, ER stress (upregulated GRP78 and Gadd153), carbonyl formation, apoptosis and ferroptosis (decreased GPX4, SLC7A11).\nSimultaneously, the Fe²⁺ levels increased and SLC7A11 and GPX4 protein expressions decreased, causing oxidative stress.\nIn vitro, BAP1 promoted ferroptosis by increasing oxidative stress and iron accumulation while inhibiting SLC7A11 expression.\nAt the gene level, TCDD exposure induced the expression of ferroptosis-related genes (tf, tfr, tfr1b, and fpn), inflammatory factor-related genes (NF-kB, ptgs2a, and ptgs2b), and lipid degeneration and autophagy", "dois": ["10.1080/01902148.2025.2536484", "10.1111/1440-1681.70068", "10.7150/ijbs.107402", "10.1002/jbt.70418", "10.12116/j.issn.1004-5619.2024.440411", "10.2147/DDDT.S528831", "10.1016/j.freeradbiomed.2025.08.003", "10.1016/j.cellsig.2025.112040", "10.1016/j.fitote.2025.106779", "10.3390/ijms26146669", "10.1111/jcmm.70693", "10.1016/j.freeradbiomed.2025.07.021", "10.1016/j.ejphar.2025.177969", "10.1016/j.redox.2025.103763", "10.1016/j.redox.2025.103761", "10.1016/j.celrep.2025.115939", "10.3390/ijms26136045", "10.1038/s41598-025-08968-2", "10.1007/s10238-025-01766-0", "10.1007/s11418-025-01930-6", "10.1038/s41598-025-08235-4", "10.1016/j.lfs.2025.123820", "10.1167/iovs.66.6.72", "10.1002/ddr.70110", "10.1016/j.ejphar.2025.177870", "10.1016/j.jep.2025.120165", "10.1016/j.jep.2025.120157", "10.1016/j.ecoenv.2025.118523", "10.3390/ijms26115231", "10.1016/j.pestbp.2025.106450", "10.1172/JCI184653", "10.1016/j.lfs.2025.123787", "10.1016/j.ecoenv.2025.118427", "10.1016/j.intimp.2025.114957", "10.1016/j.cbpc.2025.110234", "10.1007/s00408-025-00818-2", "10.12122/j.issn.1673-4254.2025.05.03", "10.1016/j.brainresbull.2025.111396", "10.1007/s12035-025-04922-5", "10.7150/ijbs.103971", "10.1016/j.drup.2025.101250", "10.1016/j.intimp.2025.114866", "10.1007/s12010-025-05261-w", "10.1038/s41598-025-99182-7", "10.1016/j.bbalip.2025.159628", "10.1016/j.bbamcr.2025.119987", "10.3168/jds.2025-26265", "10.1016/j.intimp.2025.114730", "10.1016/j.phymed.2025.156806", "10.3390/ijms26083632", "10.3389/fphar.2025.1685567", "10.1007/s00432-025-06300-z", "10.1177/15593258251377710", "10.1016/j.jnutbio.2025.110098", "10.4103/ejpi.EJPI-D-24-00104", "10.4103/jcrt.jcrt_28_25", "10.1016/j.taap.2025.117540", "10.1016/j.aninu.2025.03.018", "10.1016/j.lfs.2025.123941", "10.1016/j.theriogenology.2025.117658", "10.1016/j.biopha.2025.118499", "10.21873/invivo.14068", "10.3390/antiox14080930", "10.3390/antiox14080914", "10.1158/0008-5472.CAN-24-4949", "10.1038/s41420-025-02668-6", "10.1002/tox.24565", "10.1007/s10266-025-01176-4", "10.3389/fphar.2025.1600489", "10.1016/j.reprotox.2025.109036", "10.2174/0113895575408729250811073556", "10.1016/j.ejphar.2025.178085", "10.1038/s41598-025-13324-5", "10.3389/fphar.2025.1590797", "10.3389/fphar.2025.1564783", "10.1016/j.gendis.2025.101678", "10.1016/j.phrs.2025.107915", "10.1016/j.jep.2025.120421", "10.3390/ijms26157204", "10.3390/cancers17152486", "10.1007/s11064-025-04508-6", "10.1007/s00109-025-02588-z", "10.1016/j.redox.2025.103816", "10.1111/ejn.70209", "10.3389/fphar.2025.1644436", "10.1016/j.redox.2025.103811", "10.1007/s10534-025-00732-3", "10.1016/j.jep.2025.120357", "10.1016/j.jep.2025.120343", "10.1016/j.redox.2025.103798", "10.3389/fphar.2025.1586578", "10.1021/acsomega.5c02063", "10.1007/s12035-025-05358-7", "10.1126/sciimmunol.adz5181", "10.1038/s41598-025-22984-2", "10.31083/FBL43761", "10.1186/s10020-025-01375-3", "10.1038/s41598-025-19092-6", "10.1080/01652176.2025.2569558", "10.14814/phy2.70580", "10.7150/thno.116013", "10.13702/j.1000-0607.20240287", "10.1177/07482337251376455", "10.1002/ptr.70048", "10.1016/j.intimp.2025.115111", "10.7150/ijms.108518", "10.1016/j.cbpc.2025.110213", "10.1002/smll.202500880", "10.1016/j.jhazmat.2025.138359", "10.1016/j.freeradbiomed.2025.04.025", "10.1002/adhm.202405259", "10.1016/j.jenvman.2025.125360", "10.1016/j.jep.2025.119800", "10.3390/nu17071262", "10.1016/j.ijbiomac.2025.143030", "10.1073/pnas.2411241122", "10.1016/j.cellimm.2025.104948", "10.1016/j.lfs.2025.123591", "10.3389/fimmu.2025.1529991", "10.1007/s11011-025-01588-9", "10.1007/s12035-025-04841-5", "10.1186/s12917-025-04587-1", "10.1016/j.tice.2025.102848", "10.1016/j.redox.2025.103550", "10.1186/s40001-025-02416-7"]}
{"pair_type": "slc_pathway", "key1": "SLC2A4", "key2": "oxidative stress", "summary": "RT-PCR validation of the pathways confirmed a significant decrease in SLC2A4 mRNA levels and a significant increase in PDK4, TXNIP, ANGPTL4 mRNA levels, suggesting that insulin sensitivity of the biceps femoris muscle may be reduced in cortisol offspring.\nAdditionally, TNFα treatments decreased insulin receptor substrate 1 (Irs1), insulin receptor substrate 2 (Irs2), solute carrier family 2, facilitated glucose transporter member 4 (Slc2a4), and phosphoinositide 3 kinase regulatory subunit 1 (Pik3r1) mRNA expression.\nHowever, silencing of Arf reduced mRNAs of Adipoq and Slc2a4 and enhanced release of Il6.\nHO release and dihydroethidium (DHE) staining was increased, while superoxide dismutase (SOD) activity was reduced in long-term cultured adipocytes, which is suggestive of enhanced oxidative stress in this group.\nMoreover, qRT-PCR revealed increased mRNAs of Nox4 (a subunit of NADPH oxidase complex), Ccl2 (a proinflammatory chemokine) and Il6 [a marker of senescence-associated secretory phenotype (SASP)] along with decreased levels of Pparγ, Adipoq and Slc2a4 (genes related to glucose metabolism).\nCBS gene KD in ASC52telo cells led to increased cellular inflammation (IL6, CXCL8, TNF) and oxidative stress markers (increased intracellular reactive oxygen species and decreased reduced glutathione levels) in parallel to decreased HS production and rejuvenation (LC3 and SIRT1)-related gene expression.\nIn this context, shCBS-ASC52telo cells displayed enhanced adipogenic (FABP4, ADIPOQ, SLC2A4, CEBPA, PPARG)-, lipogenic (FASN, DGAT1)- and adipocyte (LEP, LBP)-related gene expression markers, decreased expression of proinflammatory cytokines, and increased int", "dois": ["10.1016/j.ejphar.2025.177526", "10.1177/09603271211021476", "10.1016/j.redox.2020.101668", "10.1152/physiolgenomics.00096.2019", "10.3390/metabo15010041", "10.1007/s12013-024-01522-3", "10.3168/jds.2022-23187", "10.3390/cells12091250", "10.3390/antiox12030592", "10.3168/jds.2021-21379", "10.3390/biology11060839", "10.3390/cells11091443", "10.3168/jds.2021-20541", "10.3390/antiox9010057", "10.3389/fphar.2017.00787", "10.1007/s10522-016-9661-9", "10.1016/j.theriogenology.2012.09.019", "PMID:17616136"]}
{"pair_type": "slc_pathway", "key1": "SLC25A4", "key2": "oxidative stress", "summary": "Loci and pathway data in muscle suggest HS induced oxidative stress and that the stress response was moderated by ZH.\nIn addition, sh myoblasts displayed greater endoplasmic reticulum (e.g., increased CAPN activity and HSPA) and mitochondrial (e.g., mPTP formation, reduced mitochondrial membrane potential, elevated mitochondrial 4-HNE) stress.\nThe activation of HIF-1α in inflammatory macrophages may also drive proinflammatory cytokine production and complement activation and oxidative stress in infected lungs.\nHere, we show that the hypoxia-inducible factor (HIF-1α) transcriptional pathway is activated, perhaps due to a lack of oxygen or an accumulation of mitochondrial reactive oxygen species (ROS) in the lungs of adult Syrian hamsters infected with SARS-CoV-2.\nErythroid and B-cell development may be particularly vulnerable to Ant2 depletion-mediated mitochondrial dysfunction and oxidative stress.\nsh and myoblasts also displayed altered mitochondria-associated signaling (e.g., PPARGC1A, DNM1L, OPA1) and protein content (e.g., SLC25A4, VDAC1, CYCS).\nOmega-3 supplementation also increased the capacity for mitochondrial reactive oxygen species emission without altering the content of oxidative products, suggesting the absence of oxidative damage.\nTogether, these data demonstrate an essential role for autophagy in protecting myoblasts from mitochondrial oxidative stress and apoptotic signaling during differentiation, as well as in the regulation of mitochondrial network remodelling and myogenesis.\nSenescence, oxidative stress, and mitochondrial dysfunction are known contributory factors.\nProteomic analysis further revealed specific deficits in the mitochondrial ATP synthase (Atp5a1) within complex V and in the ATP/ADP translocase (Slc25a4).\nIn adipose, 4 loci (MISP3, APOL6, SLC25A4, and S100A12) were DE due to ZH on day 3, and 2 (RRAD, AL", "dois": ["10.3390/ijms24010558", "10.1093/jas/skac019", "10.1080/15548627.2019.1591672", "10.1038/cdd.2014.230", "10.1016/j.clineuro.2020.106197", "10.1113/jphysiol.2013.267336", "10.1111/acel.70264"]}
{"pair_type": "slc_pathway", "key1": "SLC2A1", "key2": "oxidative phosphorylation", "summary": "We assessed the functional relevance of these SLCs in efferocytic phagocytes and observed a robust induction of an aerobic glycolysis program, initiated by SLC2A1-mediated glucose uptake, with concurrent suppression of the oxidative phosphorylation program.\nCEBPD promoted glucose uptake and lactate production by upregulating SLC2A1 and HK2, leading to mitochondrial fission, increased extracellular acidification rate and decreased oxygen consumption rate to fuel cell growth.\nMetformin increased expression of Slc2a1 (GLUT1), decreased expression of Slc2a2 (GLUT2) and Slc5a1 (SGLT1) whilst increasing GLUT-dependent glucose uptake and glycolytic rate as observed by live cell imaging of genetically encoded metabolite sensors and measurement of oxygen consumption and extracellular acidification rates.\nOxygen consumption rates also decreased upon BPTES treatment, indicating a glutamine dependency for oxidative phosphorylation.\nOn the contrary, metabolic shifts from oxidative phosphorylation to glucose metabolism promote cardiomyocyte (CM) proliferation after heart injury.\nWe report that genetic or pharmacological inhibition of GLUT1 with BAY-876 impairs the growth of a subset of TNBC cells displaying high glycolytic and lower oxidative phosphorylation (OXPHOS) rates.\nExposure of mesothelial cells to TGF-β1 increased production of lactate (P < .05), increased HIF1A mRNA (P < .05), and protein, and increased concentrations of mRNAs encoded by glycolysis-associated genes (LDHA, PDK1, SLC2A1;\nRecognizing the elevated expression of glucose transporter 1 (GLUT1, encoded by SLC2A1) and associated metabolic dependencies in TNBC, we investigated the vulnerability of TNBC cell lines and patient-derived samples to GLUT1 inhibition.\nThis coincided with an upregulation of glucose importers SLC2A1/3, hexokinases and HIF1 and 2.", "dois": ["10.1016/j.jnutbio.2021.108922", "10.1038/s41598-021-81349-7", "10.1038/s41467-020-18020-8", "PMID:27793977", "10.1371/journal.pone.0153226", "10.1158/1078-0432.CCR-14-1209", "10.1210/jc.2014-1026", "10.3389/fmolb.2025.1492729", "10.1016/j.heliyon.2023.e18292", "10.3390/jcdd10060246", "10.3389/fcvm.2023.1136252", "10.1186/s12885-022-10128-y", "10.1002/ctm2.674", "10.3390/jcdd8110134", "10.1530/EO-21-0014", "10.1038/s41586-018-0735-5"]}
{"pair_type": "slc_pathway", "key1": "SLC27A2", "key2": "oxidative stress", "summary": "This is associated with a number of adverse effects, including lipid deposition in cardiomyocytes, elevated levels of inflammation and oxidative stress, impaired cardiac function, decreased cardiomyocyte viability, and increased apoptosis.\nAn excessively high-fat diet has been demonstrated to result in an increased expression of solute carrier family 27 member 2 (Slc27a2/FATP2) on cardiomyocyte membranes.\nThe reduction of Slc27a2 expression downstream of this receptor has been demonstrated to enhance lipid metabolism and mitigate lipid overdeposition in cardiomyocytes, thereby conferring cardioprotection.\nThe administration of semaglutide was observed to partially reverse the cardiac dysfunction induced by an excessive high-fat diet, to protect cardiomyocytes, and to significantly reduce the expression of Slc27a2.\nMeanwhile, RT-qPCR and Western Blotting demonstrated that the mechanism of the antioxidant effect of EEP reversed the mRNA expression of EHHADH, HMGCR and SLC27A2 and the protein expression of FABP and HMGCR in AMPK and PPAR signaling pathways.\nThis study was designed to evaluate the antioxidative effect of ethanolic (EEP) on hyperthyroidism-induced oxidative stress mice using an integrated strategy combining transcriptomics with network pharmacology analysis.\nThe results showed that EEP significantly changed the thyroid-stimulating hormones and oxidative stress markers.\nHowever, the effects of EP on oxidative stress induced by hyperthyroidism have not yet been studied.", "dois": ["10.1016/j.cbi.2025.111583", "10.3390/ijms24010187", "10.1186/s13104-015-1500-6"]}
{"pair_type": "slc_pathway", "key1": "SLC2A2", "key2": "apoptosis", "summary": "Abrogation of glut2 led to defective brain organogenesis, reduced glucose uptake and increased programmed cell death in the brain.\nIn conclusion, we describe EDEM2 as a likely/potential novel diabetes gene, in which inhibition in vitro reduces the expression of β-cell genes involved in the glucose-stimulated insulin secretion (GSIS) pathway, leading to an overall suppression of insulin secretion but not apoptosis.\nModerate hypoxia also induced apoptosis in MIN6 cells.\nAblating Isl-1 in postnatal β-cells reduced glucose tolerance without significantly reducing β-cell mass or increasing β-cell apoptosis.\ncell apoptosis examination showed that high concentration of oligosaccharide increased cell death, while at low concentration protected cells from streptozotocin-induced apoptosis.\nEsculentin-2CHa(1-30) peptides markedly reduced high fat diet-induced increase in beta cell proliferation and apoptosis.\nFurther analysis revealed an increase in BiP and the PDI family member PDIA4, but without any concomitant apoptosis and cell death.\n[D-Ser]palmitoyl-paddlefish glucagon stimulated proliferation of BRIN-BD11 cells and protected against cytokine-mediated apoptosis as effectively as GLP-1.\nPFKFB4 was overexpressed in LR cells, and its knockdown significantly enhances the antiproliferative and pro-apoptotic effects of lenvatinib on resistant cells.\nOverall, the current study suggests that miR-143 is ubiquitously expressed among tissues and is likely to be involved in the regulation of cell proliferation and apoptosis.\nAlthough no developmental phenotype was detected during embryogenesis, mutant mice displayed reduced insulin-expressing β-cells at P14 and P21 without any changes in the rate of cell death and proliferation.\nEnrichment analysis of Gene Ontology (GO) biological processes showed that the regulation of insulin secretion, glucose homeostasis, apoptosis, nitric oxide biosynthesis, and cell signaling are significantly enriched for hypoglycemia.\nWe then measured the level of four selected circular RNAs in the islets", "dois": ["10.1186/s12882-021-02447-2", "10.1016/j.ejphar.2020.173101", "10.1016/j.molmet.2018.01.010", "10.1016/j.bbrc.2015.10.038", "10.1371/journal.pone.0114868", "10.1038/jcbfm.2014.171", "10.2337/db14-0096", "10.1530/ERC-13-0164", "PMID:10700186", "10.1186/s12876-025-03861-8", "10.3390/ijms222212419", "10.1016/j.molmet.2021.101334", "10.1007/s00438-020-01695-5", "10.4103/1735-5362.278713", "10.1007/s00726-017-2469-3", "10.1111/j.1365-2052.2009.02015.x", "10.1186/1746-6148-5-29", "PMID:11923875"]}
{"pair_type": "slc_pathway", "key1": "SLC22A5", "key2": "oxidative stress", "summary": "We hypothesized that carnitine deficiency results in increased myocardial oxidative stress.\nThese findings suggest that increased oxidant stress may contribute to myocardial dysfunction and arrhythmogenesis in this disorder.\nImmunohistochemistry demonstrated accumulation of the reactive aldehyde 4-hydroxy-2-nonenal, indicative of increased lipid peroxidation, and sulfonylation of sarcoendoplasmic reticulum calcium ATPase 2 at cysteine 674.\nIntegration with IPF GWAS, eQTL, and mQTL data identified key genes and regulatory elements involved in IPF pathogenesis, highlighting the role of specific genes such as KCNMA1 and SLC22A5 in modulating IPF risk through epigenetic mechanisms.\nOxidative stress (OS) is crucial in idiopathic pulmonary fibrosis (IPF) pathogenesis, with its genes potentially acting as both causes and consequences of the disease.\nPrimary carnitine deficiency is an autosomal recessive disorder caused by mutations in the SLC22A5 gene which results in impaired carnitine transport, cytosolic fatty acid accumulation and impaired beta oxidation.\nMitochondrial dysfunction, oxidative stress and energy production have been implicated in the etiology of Parkinson's disease (PD).", "dois": ["10.1038/s41435-024-00292-5", "10.3724/zdxbyxb-2021-0259", "10.1159/000333127", "10.1016/j.neulet.2018.03.064", "10.1074/jbc.RA120.015175"]}
{"pair_type": "slc_pathway", "key1": "SLC31A1", "key2": "oxidative stress", "summary": "Moreover, Cu supplementation intensified cisplatin-induced cell death, mitochondrial dysfunction, and oxidative stress in HK-2 cells, indicating the involvement of cuproptosis in cisplatin-induced AKI, whereas these changes were partially counteracted by SLC31A1 knockdown.\nThe expressions of the four markers were significantly positively correlated with the abnormal activation phenotypes of oxidative stress, the ROS and glucometabolic pathways, and suppressive immune infiltration.\nCluster and pseudotime analyses showed that macrophages with high SLC31A1 expression are often in advanced stages of cell growth, accompanied by notable changes in oxidative stress.\nThese data confirmed that PTBP1 plays a pivotal role in promoting the oxidative response and cuproptosis in Alzheimer's disease models via the SLC31A1 pathway.\nELF3 transcriptionally activated SLC31A1 to trigger cuproptosis that drove cisplatin-induced AKI through mitochondrial dysfunction, indicating that SLC31A1 might be a promising therapeutic target to mitigate AKI during cisplatin chemotherapy.\nICT consequently inhibited the FDX1-mediated cuproptosis pathway, reducing dihydrolipoamide S-acetyltransferase (DLAT) oligomerization, modulating cuproptosis sensitivity proteins, restoring copper homeostasis by increasing ATPase copper transporting beta (ATP7B) and decreasing solute carrier family 31 member 1 (SLC31A1), and suppressing the lipoylation pathway.\nE74 like ETS transcription factor 3 (ELF3) could directly bind to SLC31A1 promoter and promote its transcription.\nAccording to cross-sectional research, up to 50% of patients with micronutrient imbalances have been linked to oxidative stress, mitochondrial dysfunction, reduced ATP production, and the prognosis of various diseases.\nDOX administration induced significant cardiac dysfunction, oxidative stress, and upregulation of cuproptosis markers.\nThe enrichment score of the oxidative stress, ROS, metabolism, and inflammatory pathways was calculated, and we found that these pathways were significantly activated in IA", "dois": ["10.1080/0886022X.2025.2518227", "10.1016/j.sleep.2025.01.025", "10.31083/j.fbl2908294", "10.1007/s11356-021-14853-y", "10.1021/acs.est.5b03988", "10.1007/s00432-025-06191-0", "10.3389/fneur.2025.1525416", "10.3390/biom15091320", "10.1016/j.toxlet.2025.08.006", "10.1016/j.freeradbiomed.2025.09.044", "10.1016/j.cbi.2024.110943", "10.1016/j.mito.2023.05.003", "10.3390/biology12010100", "10.1152/ajpcell.00106.2018"]}
{"pair_type": "slc_pathway", "key1": "SLC22A8", "key2": "oxidative stress", "summary": "The principal mechanisms are as follows: inhibition of XOD activity in the serum to reduce uric acid production, regulation of renal reabsorption and secretion of uric acid to increase uric acid excretion, and alleviation of oxidative stress reaction to decrease systemic damage and, eventually, treatment of HUA.\nConsistent with the Remote Sensing and Signaling Theory, this indicates an important in vivo role in the oxidative stress response for multiple SLC22 transporters within the fly renal system, perhaps through interaction with SLC22 counterparts in non-renal tissues.\nIn vitro/vivo studies on OTA and CIT effects showed they elevate oxidative stress parameters.\nHere, we show that the multispecific organic anion transporters of drugs, OAT1 (SLC22A6 or NKT) and OAT3 (SLC22A8), play a role in organ sensing.\nExpression in the Malpighian tubule and likely other tissues as well (e.g., gut, fat body, nervous system) appear critical for managing oxidative stress.\nOur work not only indicates the importance of SLC22 transporters in the fly renal system but also sets the stage for in vivo studies by examining their role in mammalian oxidative stress and organ crosstalk.\nUbiquitous knockdowns of related SLC22s-including transporters homologous to those previously identified by us in mammals such as the \"Fly-Like Putative Transporters\" FLIPT1 (SLC22A15) and FLIPT2 (SLC22A16)-have shown modest protection against oxidative stress.\nUsing two tissue-selective knockdown strategies, we were able to demonstrate much greater and longer protection from oxidative stress compared to previous whole fly knockdowns as well as both parent and WT strains (CG6126: < 0.001, CG4630: < 0.01, CG16727: < 0.0001 and CG6006: < 0.01).\nAbstract: Several SLC22 transporters in the human kidney and other tissues are thought to regulate endogenous small antioxidant molecules such as uric acid, ergothioneine, carnitine, and carnitine", "dois": ["10.3390/ijms222413407", "10.1016/j.jbc.2021.100575", "10.1007/s12550-020-00399-4", "10.3390/ijms25169082", "10.1016/j.jep.2023.116814"]}
{"pair_type": "slc_pathway", "key1": "SLC25A4", "key2": "oxidative phosphorylation", "summary": "At the same time, more ATP was produced by coupling with mitochondrial small G protein ARF-like 2 (ARL2) GTPase, which triggered the phosphorylation of ANT1 (SLC25A4) to affect the opening degree of mitochondrial permeability transition pore (mPTP), and significantly promoted the aerobic oxidation and oxidative phosphorylation of glucose.\nThe mitochondrial ADP/ATP carrier (SLC25A4), also called the adenine nucleotide translocase, imports ADP into the mitochondrial matrix and exports ATP, which are key steps in oxidative phosphorylation.\nOur results show that SLC25A46 interacts with a large number of proteins and protein complexes involved in the mitochondria architecture, energy production, and flux and also in inter-organellar contacts.\nA total of 79 co-immunoprecipitated proteins were common in two or more tissues, mainly participating in mitochondrial activities such as oxidative phosphorylation (OXPHOS) and ATP production, active transport of ions or molecules, and the metabolism.\nOur proteomic approach confirmed known mitochondrial interactors of SLC25A46 including MICOS complex subunits and also OPA1 and VDACs, while we identified novel interactors including the ADP/ATP translocases SLC25A4 and SLC25A5, subunits of the OXPHOS complexes and FF-ATP synthase, and components of the mitochondria-ER contact sites.\nIn aerobic eukaryotic cells, the high energy metabolite ATP is generated mainly within the mitochondria following the process of oxidative phosphorylation.\nMitochondrial DNA (mtDNA) maintenance is critical for oxidative phosphorylation (OXPHOS) since some subunits of the respiratory chain complexes are mitochondrially encoded.\nThe mitochondrial ATP is exported to the cytoplasm using a specialized transport protein, the ADP/ATP carrier, to provide energy to the cell.\nTherefore, acetylation of ANT1 could have dramatic physiological effects on ADP-ATP exchange.\nInsertion of these derived binding affinities as parameters into a complete mathematical description of ANT1 kinetics predicte", "dois": ["10.3390/cells11223594", "10.1016/j.bbrc.2025.152198", "10.3389/fimmu.2024.1453587", "10.15252/embr.202357127", "10.1021/acs.jproteome.1c00728", "10.3390/genes12121866", "10.1016/j.mam.2012.05.006", "PMID:27658776", "10.1021/bi401651e"]}
{"pair_type": "slc_pathway", "key1": "SLC25A5", "key2": "apoptosis", "summary": "Moreover, SLC25A5-AS1 could inhibit GC cell proliferation, induce G1/G1 cell cycle arrest and cell apoptosis in vitro, as well as GC growth in vivo.\nAts-1 targeted translocation to the mitochondria where it up-regulated the expression of NDUFB5, NDUFB3, NDUFS7, COX6C, and SLC25A5, thereby enhancing energy production and inhibiting HEK293T cells apoptosis while enhancing HEK293T cells proliferation, and ultimately facilitating Anaplasma phagocytophilum replication in HEK293T cells.\nExperimental validation demonstrated that SLC25A5 enhanced the proliferative, migratory, invasive, and osteolytic properties of drug-resistant osteosarcoma cells while reducing apoptosis, intensifying cisplatin resistance.\nDual-luciferase reporter assay confirmed the direct interaction between SLC25A5-AS1 and miR-19a-3p, rescue experiment showed that co-transfection miR-19a-3p mimics and pcDNA-SLC25A5-AS1 could partially restore the ability of GC cell proliferation and the inhibition of cell apoptosis.\nSLC25A5 attenuated cell proliferation, upregulated the expression of programmed cell death-related signatures, and exerted its biological function by inhibiting the MAPK signaling pathway.\nPhyllanthin inhibited the malignant phenotype of cisplatin-resistant osteosarcoma cells and enhanced their sensitivity to cisplatin by suppressing SLC25A5 expression.\nTaken together, this study indicated that SLC25A5-AS1 was down-regulated in GC and functioned as a suppressor in the progression of GC.\nAfter intracellular expression of Ats-1, adenosine triphosphate levels and the proliferation of HEK293T cells were both up-regulated, while HEK293T cells apoptosis was inhibited.\nThis study demonstrated that Anaplasma phagocytophilum Ats-1 induces anti-apopt", "dois": ["10.3389/fimmu.2024.1453633", "10.1016/j.phymed.2024.156291", "10.1038/s41598-024-65745-3", "10.1002/ijc.34349", "10.1111/jcmm.14200", "10.1016/j.mam.2012.05.006", "10.1007/s10142-025-01573-6", "10.1111/jcmm.17830", "10.3390/ijms232113618", "10.1186/s12866-022-02668-x", "10.1186/s12957-022-02802-z", "10.1007/s10571-022-01277-6", "10.1186/s12876-022-02423-6", "10.1038/s41419-022-04692-1", "10.1186/s12014-021-09320-2", "10.1371/journal.pone.0244098"]}
{"pair_type": "slc_pathway", "key1": "SLC38A1", "key2": "oxidative stress", "summary": "RIPK1 inhibition in Mecp2-deficient microglia reduced oxidative stress, cytokines production and induction of SLC7A11, SLC38A1, and GLS, which mediate the release of glutamate.\nSLC38A1 was identified as a significantly downregulated marker for aging skeletal muscle.\nMoreover, increased expression of GLS and SLC38A1 was observed exclusively at the 2.5 concentration group, suggesting a shift in glutamate synthesis mechanisms depending on PQ exposure levels.\nGlutamate emerged as a pivotal metabolite, with its upregulation being accompanied by a significant increase in SLC7A11 expression increasing with PQ concentration, indicating an enhanced cellular response to oxidative stress via glutathione synthesis.\nand upregulated the ferroptosis-associated genes, including Ptgs2 (prostaglandin-endoperoxide synthase 2), GLS2 (glutaminase 2), solute carrier family 1 member 5 (SLC1A5), and solute carrier family 38 member 1 (SLC38A1) in HT22 cells, indicating the inductive role of FA in the ferroptosis of HT22 cells.\nIn contrast, SLC38A1 overexpression markedly reduced the accumulation of ROS, mtROS, iron concentration, and lipid peroxidation associated with D-gal treatment in these cells.\nIn both D-gal treated and sh-SLC38A1 C2C12 cells, increased ROS levels, elevated mtROS, higher intracellular iron concentrations, and intensified lipid peroxidation were observed.\nOverexpression of SLC38A1 mitigated cellular aging in D-gal treated C2C12 cells.\nIn conclusion, through screening analyses and validation experiments, we identified SLC38A1 as a ferroptosis-related regulator for skeletal muscle aging.\nOur work underscores the role of Gln transporters and the NUPR1-mediated stress response in PCa cell survival, oxidative stress, mitochondrial functions, and radioresistance.\nAnalysis of the hippocampus performed 6 months after the exposure", "dois": ["10.1186/s12964-025-02344-3", "10.1016/j.cbpc.2025.110234", "PMID:24316858", "10.1016/j.neuint.2011.01.007", "10.1016/j.exger.2025.112880", "10.1016/j.bcp.2025.117100", "10.1073/pnas.2320383121", "10.3390/ijms241310872", "10.3389/fgene.2023.1118391", "10.3389/fgene.2022.1090467", "10.3389/fgene.2022.919188", "10.3390/ani11072114", "10.1016/j.tox.2020.152650", "10.3389/fnmol.2017.00182"]}
{"pair_type": "slc_pathway", "key1": "SLC27A4", "key2": "oxidative stress", "summary": "OSO remarkably upregulates levels of Fatp1 and Glut1 and decreases expression of Snat2 and Glut3.\nOSO decreased the level of IL-10 but increased expression of IL-1β in placenta and plasma.\nThe expression of Bax showed a linear increase, and Bcl-2 decreased as the oxidative degree increased.\nOn day 20 of gestation, OSO decreased placental and embryonic weights as the oxidative degree increased linearly and quadratically.\nThese results suggest that GLP-1 inhibits hepatic steatosis and inflammation through the inhibition of hepatic FFA influx and oxidative stress in a non-obese NASH model.\nAdditionally, it further decreased the hepatic SREBP-1c level and alleviated the MCD-mediated inhibition of the ACOX1 mRNA level.\nThe levels of hepatic sterol regulatory element-binding protein-1c (SREBP-1c) mRNA (lipogenesis-related gene) and acyl-coenzyme A oxidase 1 (ACOX1) mRNA (β-oxidation-related gene) had decreased at 4 wk and further decreased at 8 wk.\nFour weeks of MCD feeding induced hepatic steatosis and inflammation and increased the hepatic TG and FFA content.\nThe administration of exendin-4 significantly attenuated the MCD-induced increase in hepatic steatosis, hepatic TG and FFA content, and FATP4 expression as well as the MCD-induced augmentation of hepatic inflammation, macrophage recruitment, and MDA levels.\nand the level of malondialdehyde (MDA), an oxidative stress marker, were significantly augmented by a 4-wk MCD.\nThe expression of fatty acid transport protein 4 (FATP4), a hepatic FFA influx-related gene;\nOSO aggravates placental injury by modulating nutrient transporters and apoptosis-related genes, impedes placental growth and development, and ultimately leads to the decrease of fetal weight.", "dois": ["10.1507/endocrj.EJ24-0008", "10.1074/jbc.M117.817692", "10.1002/mnfr.202100301", "10.3748/wjg.v22.i8.2512"]}
{"pair_type": "slc_pathway", "key1": "SLC2A1", "key2": "apoptosis", "summary": "Downregulation of SLC2A1 could not only inhibit cell proliferation, migration and cell cycle, but also promote cell apoptosis.\nKnockdown of SLC2A1 resulted in reduced cell viability, decreased migration, and increased apoptosis in Caco-2 and SW480 cells.\nTherefore, the present study demonstrated that exosomes derived from patients with sepsis may inhibit glycolysis and promote the apoptosis of human myocardial cells through exosomal hsa‑miR‑1262 via its target SLC2A1.\nOur results showed that simvastatin increased the expression of miR-140-5p in a dose dependent manner via activating transcription factor NRF1, reduced cell proliferation and induced apoptosis, and we also found that SLC2A1 was a new target of miR-140-5p.\nIn vitro functional experiments have shown that knocking down SFXN1 inhibits the proliferation and migration of LUAD cells, promotes cell apoptosis, and may inhibit tumor activity by regulating the expression of glycolytic related genes SLC2A1, HK2, GPI, ALDOA, GAPDH, ENO1, PKM, and LDHA.\nThe silencing of SLC2A1 promoted apoptosis and suppressed glycolysis in AC16 cells, whereas SLC2A1 overexpression resulted in the opposite effects.\nSLC2A1-AS1 promoted cell growth in vitro and in vivo, migration and invasion, and suppressed apoptosis, leading to EMT progression and increased glycolysis in ESCC cells.\nMiR-378a-3p inhibited cell proliferation and invasion as well as induced apoptosis, resulting in reduced glycolysis, which was partly reversed by SLC2A1-AS1 or Glut1 overexpression in ESCC cells.\nMechanistic investigations revealed that elevated SM enhances SLC2A1-dependent glucose uptake and glycolysis, leading to increased lactate production and subsequent CASP3 lactylation on lysine residue 14, which inhibits CASP3 activation and apoptosis.", "dois": ["10.1186/s12964-024-01951-w", "10.1038/s41598-024-78911-4", "10.18632/aging.205873", "10.1016/j.intimp.2024.113282", "10.3389/ti.2024.13212", "10.1186/s12885-024-12830-5", "10.1155/2024/8217215", "10.3390/molecules29174275", "10.1186/s13062-024-00528-4", "10.1007/s10534-024-00631-z", "10.1016/j.intimp.2024.112834", "10.1016/j.biopha.2024.117048", "10.1038/s41598-025-21123-1", "10.1016/j.yexcr.2024.114037", "10.18632/aging.205521", "10.3390/ijms242216188", "10.18632/aging.205126", "10.1007/s10495-023-01900-x", "10.1002/jgm.3566", "10.1186/s40478-023-01604-y", "10.1002/jgm.3534", "10.3390/medicina59020297", "10.3892/mmr.2022.12635", "10.3892/or.2021.8218", "10.1016/j.jep.2021.114771", "10.18632/aging.203331", "10.1515/hsz-2020-0290", "10.1080/15548627.2021.1872227", "10.1038/s41467-020-18020-8", "10.1038/s41598-020-66913-x", "10.1186/s12943-020-01190-w", "10.1016/j.foodres.2019.108563", "10.1186/s13046-019-1390-x", "10.1016/j.celrep.2019.07.027", "10.1016/j.bbrc.2019.01.113", "10.1016/j.theriogenology.2019.01.002", "10.1038/s41586-018-0735-5", "10.1088/1748-605X/aaca5b", "10.1093/biolre/ioy086", "10.1071/RD16441", "10.3892/or.2017.5414", "10.1371/journal.pone.0161163", "10.1371/journal.pone.0153226", "10.18632/oncotarget.4977", "10.1371/journal.pone.0023183", "10.1530/REP-08-0220", "10.1093/biolre/ioaf238", "10.1016/j.bbadis.2025.168050", "10.22037/ghfbb.v18i2.3002", "10.1186/s12943-025-02392-w", "10.1016/j.biocel.2025.106831", "10.1186/s13008-025-00148-y", "10.3389/fphar.2025.1524736", "10.3390/ani14182751", "10.1038/s41420-024-02106-z", "10.1007/s11010-023-04915-9", "10.1016/j.lungcan.2023.107449", "10.1016/j.bbalip.2023.159429", "10.1186/s12935-023-03082-7", "10.1186/s12967-023-04454-3", "10.1128/iai.00085-23", "10.1016/j.heliyon.2023.e18292", "10.1101/2023.03.06.531456", "10.1111/acel.13807", "10.3390/genes13091501", "10.3389/fcvm.2022.875434", "10.7150/jca.67990", "10.3389/fphar.2022.851540", "10.3389/fnins.2022.823741", "10.1155/2021/3060375", "10.1186/s13046-021-02081-8", "10.3390/life11060462", "10.1016/j.jaut.2021.102644", "10.1097/SHK.0000000000001785", "10.1101/2021.02.21.432171", "10.1016/j.ejphar.2020.173103", "10.1002/jpen.1763", "10.1016/j.yexcr.2019.111713", "10.1186/s12964-019-0447-y", "10.18632/aging.101974", "10.3389/fonc.2018.00217", "10.1038/s41598-018-25736-7", "10.3168/jds.2017-12783", "10.3389/fcimb.2017.00092", "10.1016/j.theriogenology.2016.09.035", "10.1038/onc.2016.187", "10.1007/s11259-015-9647-0", "10.1017/S2040174413000068", "10.1074/jbc.M111.240812", "10.1016/j.theriogenology.2011.05.036", "10.1530/REP-10-0512", "PMID:20981268", "PMID:19700929"]}
{"pair_type": "slc_pathway", "key1": "SLC22A5", "key2": "oxidative phosphorylation", "summary": "Rats of the O+N group had a higher percentage of oxidative type I fibers and higher mRNA levels of genes encoding regulators of muscle fiber composition (Ppard, Ppargc1a, Ppargc1b), angiogenic factors (Vegfa, Vegfb), and genes involved in fatty acid utilization (Cpt1b, Slc25a20, Slc22a4, Slc22a5, Slc27a1) and oxidative phosphorylation (Cox4i1, Cox6a2) and a higher activity of the mitochondrial oxidative enzyme succinate dehydrogenase in muscle than rats of the O and L groups (P < 0.05).\nThese niacin-induced changes in muscle metabolic phenotype are indicative of an increased capacity of muscle for oxidative utilization of fatty acids and are likely mediated by the upregulation of Ppard, Ppargc1a, and Ppargc1b, which are key regulators of muscle fiber composition, mitochondrial biogenesis, angiogenesis, and genes involved in fatty acid catabolism and oxidative phosphorylation.\nfasting downregulated numerous metabolic pathways in human adipose tissue, including triglyceride and fatty acid synthesis, glycolysis and glycogen synthesis, TCA cycle, oxidative phosphorylation, mitochondrial translation, and insulin signaling", "dois": ["10.1152/physiolgenomics.00083.2020", "10.3945/jn.112.164038"]}
{"pair_type": "slc_pathway", "key1": "SLC3A2", "key2": "ferroptosis", "summary": "SLC3A2 and SLC7A11 are two subunits of the system x, which is one key inhibitory regulator of ferroptosis.\nHOXA13 drives PCa progression by transcriptionally activating SLC7A11 and SLC3A2, which suppress ferroptosis and enhance proliferation and metastasis.\nMechanistically, ERα transcriptionally upregulated the expression of SLC7A11 and SLC3A2, two subunits of the system x, which is one key inhibitory regulator of ferroptosis.\nOverexpression of the exogenous SLC7A11 and SLC3A2 was able to mitigate ferroptosis induced by ERα inhibition.\nKnockdown of SLC3A2 promoted ferroptosis, inflammation, and fibrosis, while BMSCs reversed these effects, likely through the inhibition of the MAPK signaling pathway.\nFurthermore, HOXA11-AS was found to enhance SLC3A2 expression, a key regulator of ferroptosis, by interacting with the transcriptional repressor POU2F2.\nIFN-γ activated STAT1 phosphorylation and downregulated system Xc components solute carrier family 3 member 2 (SLC3A2), glutathione, and GPX4 thereby triggering ferroptosis in SGEC.\nTaken together, knockdown of hsa_circ_0050900 inhibited SLC3A2 expression via sponging hsa-miR-605-3p to promote ICC cell ferroptosis, and finally suppressed proliferation and migration.\nMechanically, SLC3A2 deficiency facilitated ferroptosis through upregulating the expression of mTOR and P70S6K, whereas inhibited p-mTOR and p-P70S6K expression in laryngeal carcinoma cells.\nMoreover, Mo and/or Cd exposure could downregulate the expression levels of xCT (SLC7A11 and SLC3A2), GPX4 and FTH-1 and upregulate the expression levels of PTGS2 and NCOA4, which led to iron over", "dois": ["10.1038/s41419-025-07872-x", "10.1016/j.ecoenv.2025.118600", "10.7150/ijbs.103971", "10.1134/S0006297925602266", "10.1016/j.cellsig.2025.112168", "10.1016/j.bbrc.2025.152788", "10.1038/s41388-025-03585-9", "10.4103/ejpi.EJPI-D-24-00104", "10.3760/cma.j.cn112144-20250420-00145", "10.1016/j.jep.2025.120456", "10.1038/s41375-025-02718-z", "10.1016/j.placenta.2025.04.016", "10.1111/febs.70101", "10.1016/j.wneu.2025.123908", "10.1002/jbt.70183", "10.1186/s13048-025-01637-y", "10.1186/s12967-025-06241-8", "10.1007/s10753-025-02261-0", "10.1038/s44318-025-00369-5", "10.1007/s12031-025-02310-1", "10.1038/s41419-025-07354-0", "10.1007/s10620-025-08843-0", "10.1038/s41590-024-02047-w", "10.1038/s41598-024-84135-3", "10.1172/JCI173994", "10.13702/j.1000-0607.20230949", "10.1002/mc.23861", "10.24976/Discov.Med.202436190.208", "10.3390/biom14111456", "10.1016/j.exer.2024.110182", "10.1016/j.prostaglandins.2024.106909", "10.1016/j.cellsig.2024.111399", "10.1016/j.aquatox.2024.107078", "10.1002/mnfr.202400199", "10.1021/acsnano.4c05084", "10.1007/s00018-024-05348-3", "10.1016/j.freeradbiomed.2024.06.023", "10.1007/s10863-024-10022-1", "10.1002/kjm2.12851", "10.1016/j.asjsur.2024.05.064", "10.1016/j.colsurfb.2024.113911", "10.1177/15330338241246649", "10.1016/j.archoralbio.2024.105965", "10.1186/s12864-024-10147-y", "10.1016/j.neuint.2024.105705", "10.1016/j.canlet.2024.216732", "10.1016/j.ejphar.2024.176406", "10.1016/j.scitotenv.2024.170724", "10.1016/j.envpol.2024.123332", "10.1186/s13048-023-01328-6", "10.1016/j.expneurol.2023.114641", "10.1016/j.tox.2023.153689", "10.7150/thno.87968", "10.1016/j.virs.2023.09.001", "10.1007/s43032-023-01310-z", "10.7150/ijms.84872", "10.1038/s41418-023-01188-z", "10.1111/jre.13165", "10.1016/j.envpol.2023.122207", "10.1016/j.envpol.2023.122211", "10.3390/nu15112461", "10.1016/j.freeradbiomed.2023.05.027", "10.1016/j.ecoenv.2023.114753", "10.1016/j.actbio.2023.01.053", "10.1007/s10620-023-07824-5", "10.3390/ijms24010449", "10.1002/jmv.28386", "10.18632/aging.204385", "10.3390/cells11213430", "10.1039/d2fo02994d", "10.7717/peerj.13757", "10.1186/s10020-022-00481-w", "10.2174/1566524022666220509124608", "10.1186/s12920-022-01194-z", "10.1186/s41065-022-00225-0", "10.1002/JLB.3MA1220-815RRR", "10.1016/j.freeradbiomed.2021.03.023", "10.1097/HP.0000000000001385", "10.1016/j.freeradbiomed.2021.02.010", "10.1158/0008-5472.CAN-20-3477", "10.1016/j.ymthe.2020.08.021", "10.1038/s41598-019-52513-x", "10.1038/s41419-019-1897-2", "10.1038/s41586-019-1170-y", "10.1038/s41419-019-1564-7", "10.1002/advs.202417330", "10.1016/j.tice.2025.103181", "10.1007/s12672-025-03719-1", "10.34133/bmr.0258", "10.1002/advs.202507718", "10.3390/ph18091382", "10.1002/1878-0261.70129", "10.1016/j.tranon.2025.102534", "10.3389/fphar.2025.1564783", "10.1016/j.isci.2025.113196", "10.1155/ije/1186113", "10.1111/febs.70191", "10.1007/s10616-025-00795-7", "10.3389/fnagi.2025.1506276", "10.1016/j.apsb.2025.03.002", "10.1038/s41420-025-02401-3", "10.3892/ol.2025.15015", "10.4143/crt.2024.933", "10.3389/fphar.2025.1552228", "10.3389/fgene.2024.1504114", "10.3389/fonc.2024.1492498", "10.7150/jca.102618", "10.3389/fcvm.2024.1469805", "10.3390/foods13213358", "10.1016/j.jep.2024.118874", "10.1016/j.gendis.2024.101212", "10.1002/ctm2.1782", "10.3390/molecules29112623", "10.1016/j.envpol.2024.124280", "10.1515/med-2024-0941", "10.7150/jca.90574", "10.21037/tp-23-189", "10.3892/ol.2023.14135", "10.1111/jcmm.18010", "10.3390/ijms242015195", "10.3389/fonc.2023.1251100", "10.1186/s13020-023-00820-x", "10.1111/bjh.18884", "10.1016/j.phymed.2023.154756", "10.3389/fgene.2023.1099272", "10.7150/ijms.79162", "10.3389/fncel.2022.1023947", "10.1016/j.mtbio.2022.100503", "10.1016/j.gendis.2022.04.011", "10.1002/cam4.5243", "10.4103/1673-5374.350203", "10.3389/fmolb.2022.961410", "10.1155/2022/7410865", "10.1186/s40537-022-00641-z", "10.21037/tcr-22-96", "10.21037/jgo-21-916", "10.3389/fphar.2022.851680", "10.7150/jca.68568", "10.3389/fphar.2022.851540", "10.15698/cst2022.02.264", "10.3389/fgene.2021.672904", "10.3390/antiox10020317", "10.26355/eurrev_202102_24876", "10.1016/j.biopha.2020.111001", "10.1155/2020/1675613", "10.1074/jbc.M115.704254"]}
{"pair_type": "slc_pathway", "key1": "SLC22A1", "key2": "oxidative stress", "summary": "Ubiquitous knockdowns of related SLC22s-including transporters homologous to those previously identified by us in mammals such as the \"Fly-Like Putative Transporters\" FLIPT1 (SLC22A15) and FLIPT2 (SLC22A16)-have shown modest protection against oxidative stress.\nConsistent with the Remote Sensing and Signaling Theory, this indicates an important in vivo role in the oxidative stress response for multiple SLC22 transporters within the fly renal system, perhaps through interaction with SLC22 counterparts in non-renal tissues.\nExpression in the Malpighian tubule and likely other tissues as well (e.g., gut, fat body, nervous system) appear critical for managing oxidative stress.\nOur work not only indicates the importance of SLC22 transporters in the fly renal system but also sets the stage for in vivo studies by examining their role in mammalian oxidative stress and organ crosstalk.\nUsing two tissue-selective knockdown strategies, we were able to demonstrate much greater and longer protection from oxidative stress compared to previous whole fly knockdowns as well as both parent and WT strains (CG6126: < 0.001, CG4630: < 0.01, CG16727: < 0.0001 and CG6006: < 0.01).\nSeveral SLC22 transporters in the human kidney and other tissues are thought to regulate endogenous small antioxidant molecules such as uric acid, ergothioneine, carnitine, and carnitine derivatives.\nSince the antioxidant resveratrol (RSV) has shown measurable protective effects against OTA- and CIT-related oxidative stress toxicity in vitro, we investigated the effects of an OTA + CIT + RSV combination on rOct1/2 localization/expression in the same model.", "dois": ["10.3390/ijms222413407", "10.1007/s12550-022-00450-6", "PMID:21677353", "PMID:12101027"]}
{"pair_type": "slc_pathway", "key1": "SLC29A1", "key2": "apoptosis", "summary": "ENT1 inhibition attenuates apoptosis by activation of cAMP/pCREB/Bcl2 pathway after MCAO in rats.\nThe BM stroma secretes a soluble factor that significantly protects leukemia cells from cytarabine-induced apoptosis and blocks ENT1 activity.\nApoptosis of hENT1 silenced SKM-1 cells induced by DAC was decreased, and the susceptibility of these cells to demethylation treatment was also decreased.\nMoreover, NBTI significantly increased the level of CREB phosphorylation and extracellular adenosine concentration, and decreased the neuronal apoptosis 24 h after MCAO.\nIn an orthotopic pancreatic cancer mouse model, both low and high dose verapamil was shown to substantially reduce L3.6plGres-SP cell tumor growth and metastasis, enhance tumor apoptosis, and reduce microvascular density.\nFunctional analyses in iCC cell lines revealed that hENT-1 silencing inhibited cell proliferation and induced apoptosis in HUH-28 cells expressing hENT-1 on the cell membrane, but not in SNU-1079 cells expressing the transporter only in the cytoplasm.\nWestern blot analysis revealed decreased levels of cleaved caspase-3 and cleaved poly(ADP-ribose) polymerase in T24-GR and T24-CD cells following gemcitabine exposure, whereas these markers were upregulated in parental T24 and T24-CDKO cells.\nENT1 inhibition prevented neuronal apoptosis and improves neurological deficits through cAMP/PKA/CREB/Bcl-2 signaling pathway after MCAO in rats.\nIn vitro, the BM stromal cells secreted a soluble factor that mediated significant chemoprotection to leukemia cells from cytarabine induced apoptosis.\nBy suppressing apoptosis and altering drug metabolism pathways, highlighting CDCP1 as a potential therapeutic target for overcoming gemcitabine resistance in UC.\nCRISPR/Cas9-mediated knockout of CYR61 increased expression of", "dois": ["10.1186/s12920-023-01552-5", "10.1002/adbi.202200277", "10.1007/s11064-021-03377-z", "10.18632/oncotarget.10448", "10.1186/s12864-024-10975-y", "10.1038/s41586-022-05041-0", "10.22038/IJBMS.2022.61118.13528", "10.1016/j.drup.2020.100728", "10.3892/mmr.2017.8319", "10.1371/journal.pone.0331289", "10.1097/WNR.0000000000001733", "10.1016/j.cell.2021.07.020", "10.1186/s12951-021-00931-3", "10.1073/pnas.2100939118", "10.1016/j.canlet.2021.01.015", "10.1016/j.expneurol.2020.113362", "10.1007/s11010-020-03731-9", "10.1038/s41375-019-0497-6", "10.1016/j.ejca.2018.11.005", "10.2147/IJN.S166769", "10.3892/or.2017.5856", "10.3892/mmr.2017.6182", "10.1016/j.ijpharm.2016.09.063", "10.1093/carcin/bgw093", "10.3892/ijo.2016.3512", "10.1038/cddis.2015.172", "10.2217/pgs.15.44", "10.3760/cma.j.issn.0253-2727.2015.05.012", "10.1074/jbc.M114.620294", "10.1016/j.leukres.2014.08.016", "10.1016/j.jneuroim.2014.10.006", "10.1371/journal.pone.0050176", "10.1371/journal.pone.0037203", "10.2217/pgs.11.148", "10.1002/cmdc.201100126", "10.1007/s00280-008-0829-0", "PMID:18078872", "PMID:17637678", "PMID:17296311", "PMID:16965766"]}
{"pair_type": "slc_pathway", "key1": "SLC2A1", "key2": "ferroptosis", "summary": "SLC2A1 knockdown caused obvious activation of cell ferroptosis, reduced GPX4 and xCT expressions, and increased intracellular levels of ROS and Fe.\nHigh SLC2A1 expression is correlated with poor prognosis of patients with LUAD, and inhibiting SLC2A1 can induce ferroptosis and autophagy of LUAD cells, suggesting the potential of SLC2A1 as a target for LUAD diagnosis and treatment.\nWe discovered that during the induction of environmental factors, the transcription and methylation levels of SLC2A1 were greatly increased, autophagy and ferroptosis were inhibited, and the immune system was defective, resulting in a poor prognosis for patients.\nOur findings indicated that CAT inhibited HIF-1a expression and reduced ferroptosis-relative osteoarthritis progression by activating SLC2A1.\nValidation experiments revealed that SLC2A1 functions by regulating ferroptosis.\nSTAT3, MAPK14, HSPA5, MTOR and SLC2A1 may influence CKD onset by regulating ferroptosis.\nDownregulation of SLC2A1 expression promoted ferroptosis and suppressed tumor cell growth in breast cancer cells ( < 0.01), while overexpression of TXNIP or ATF3 had the same effect ( < 0.01).\nHowever, the protective effect of CAT against ferroptosis-dependent osteoarthritis could be eliminated by silencing SLC2A1.\nSLC2A1 knockdown also resulted in increased cell autophagy shown by increased LC3B expression, which could be reversed by treatement with 3-MA.\nMechanistically, SLC2A1-mediated glucose uptake promotes glycolysis and, thus, facilitates pyruvate oxidation, fuels the tricyclic acid cycle, and stimulates fatty acid synthesis, which finally facilitates lipid peroxidation-dependent ferroptotic death.\nAdditionally, FA inhibited ferroptosis and apoptosis by suppressing the HIF-1 signaling pathway, up-regulating the expression of GPX4 and Bcl2, and down-regulating the expression of HIF-1", "dois": ["10.3390/ijms26062779", "10.1097/MD.0000000000041525", "10.1016/j.compbiolchem.2025.108343", "10.12122/j.issn.1673-4254.2024.12.17", "10.1002/iid3.70059", "10.1002/cam4.70415", "10.18632/aging.206110", "10.1097/MD.0000000000038322", "10.1016/j.ijbiomac.2024.133323", "10.1016/j.gene.2024.148701", "10.18632/aging.205669", "10.3389/fendo.2024.1346842", "10.18632/aging.205459", "10.1002/2211-5463.13764", "10.1007/s10495-023-01900-x", "10.1016/j.exer.2023.109513", "10.1016/j.lfs.2025.123882", "10.14336/AD.2024.1560", "10.1016/j.cellsig.2023.110698", "10.1186/s12890-023-02410-x", "10.1111/acel.13807", "10.3390/medicina59020297", "10.1016/j.clim.2021.108872", "10.1007/s10637-021-01114-5", "10.1016/j.celrep.2021.108767", "10.1038/s41598-025-21123-1", "10.3389/fphar.2025.1524736", "10.3390/bioengineering11111070", "10.1038/s41598-024-78911-4", "10.21037/tcr-23-2402", "10.1016/j.intimp.2023.110906", "10.3389/fgene.2022.1058062", "10.3892/etm.2022.11759", "10.1038/s41598-022-17622-0", "10.1155/2022/9077424", "10.3389/fcvm.2022.875434", "10.3389/fcell.2022.853596", "10.3389/fphar.2022.851540", "10.3389/fnins.2022.823741", "10.3389/fnins.2021.661663"]}
{"pair_type": "slc_pathway", "key1": "SLC22A2", "key2": "oxidative stress", "summary": "The results of this study suggest that CA attenuates CP-induced kidney injury through suppression of oxidative stress, inflammation, apoptosis and autophagy, with the improvement in kidney regeneration.\nRenal oxidative stress, evidenced by increased 4-hydroxynonenal (4-HNE) expression, was significantly reduced with CA.\nIt also activates apoptotic pathways and inflicts cellular damage via oxidative stress and inflammation.\nNotably, glutamine reduced the cisplatin-induced expression of organic cation transporter 2 (OCT2) and cisplatin accumulation.\nDOX significantly reduced the expression of OCT2, lipid peroxidation marker (MDA), and inflammatory cytokines, including TNF-α, IL-6, IL-1, IL-2, and IL-1β, and increased the activity of antioxidant enzymes.\nDOX exerts a nephroprotective impact against CP-mediated nephrotoxicity via the inhibition of OCT2, suppression of inflammation, oxidative stress, and apoptotic markers, and modulation of PI3K/Akt signaling cascade.\nThe expression of multidrug resistance-associated proteins (Mrp1 and Mrp2) increased and organic cation transporter 2 (Oct2) decreased by CP, protecting the kidneys from nephrotoxicity by reducing the burden of tubular cells.\nCisplatin increased cell death, caspase-3 cleavage, activation of MAPKs and p53, oxidative stress, and mRNA expression of TNF-α and TNFR1 in HK-2 cells.\nThis study suggests the promising nephroprotective impact of Clon as an OCT2 inhibitor against CP nephrotoxicity and its proficient role in attenuating oxidative stress, inflammatory status and apoptotic status.\nConsistent with the Remote Sensing and Signaling Theory, this indicates an important in vivo role in the oxidative stress response for multiple SLC22 transporters within the fly renal system, perhaps through interaction with SLC22 counterparts in non-renal tissues.\nExpression in the Malpighian tubule and likely other tissues as well (e.g., gut, fat body, nervous", "dois": ["10.3390/ijms222413407", "10.1007/s12550-022-00450-6", "PMID:23774469", "PMID:21677353", "10.1007/s00210-024-03473-1", "10.1093/jpp/rgac039", "10.1016/j.toxlet.2018.06.1220", "10.1007/s40620-017-0392-z", "10.1016/j.jphs.2014.11.009", "10.1016/j.tox.2014.07.004"]}
{"pair_type": "slc_pathway", "key1": "SLC25A5", "key2": "oxidative phosphorylation", "summary": "Moreover, the knockdown of Slc25a5 resulted in significant reduction of oxidative phosphorylation (OXPHOS) protein expression (ATP5A1, CQCRC2, and MTCO1) and ATP production.\nTranscriptional signature revealed that Favourable- and intermediate-risk patients presented enriched molecular programs related to mature myeloid progenitors, cell cycle progression, and oxidative phosphorylation, indicating that this cells differs in their origin, metabolic state, and cell cycle regulation, in comparison to the adverse-risk.\nIn aerobic eukaryotic cells, the high energy metabolite ATP is generated mainly within the mitochondria following the process of oxidative phosphorylation.\nA total of 79 co-immunoprecipitated proteins were common in two or more tissues, mainly participating in mitochondrial activities such as oxidative phosphorylation (OXPHOS) and ATP production, active transport of ions or molecules, and the metabolism.\nOur proteomic approach confirmed known mitochondrial interactors of SLC25A46 including MICOS complex subunits and also OPA1 and VDACs, while we identified novel interactors including the ADP/ATP translocases SLC25A4 and SLC25A5, subunits of the OXPHOS complexes and FF-ATP synthase, and components of the mitochondria-ER contact sites.\nIn this study, based on a bioinformatics analysis to identify the genes and pathways that display significant differences between tumour tissues of NFPA patients and normal pituitary tissues, we selected lncRNAs related to cAMP and oxidative phosphorylation pathways, namely DNAH17-AS1, LINC00706 and SLC25A5-AS1.\nThe mitochondrial ATP is exported to the cytoplasm using a specialized transport protein, the ADP/ATP carrier, to provide energy to the cell.\nAny deficiency or dysfunction of this membrane protein leads to serious consequences on cell metabolism and can cause various diseases such as muscular dystrophy.\nOur results show that SLC25A46 interacts with a large number of proteins and protein complexes involved in the mitochondria architecture, energy production, and flux and also in inter-organ", "dois": ["10.1111/jcmm.18011", "10.1186/s11658-022-00314-y", "10.1021/acs.jproteome.1c00728", "10.1038/s41598-020-80918-6", "10.1016/j.mam.2012.05.006"]}
{"pair_type": "slc_pathway", "key1": "SLC2A1", "key2": "oxidative stress", "summary": "Finally, we identified 21 upregulated and 9 downregulated FRDEGs, among which 10 key target genes (P53, TXN, PTEN, SLC2A1, HMOX1, PRKAA1, ATG7, HIF1A, TGFBR1, and IL1B) were recognized with enriched functions, mainly relating to responses to oxidative stress and hypoxia in biological processes of PDR.\nEmbryos cultured with 10 or 50 μM DGAT1 inhibitor had greater mitochondrial activity (P < 0.01), and increased number of cells (P < 0.05), while the cytoplasmic lipid content was reduced (P < 0.01), the latter associated with altered expression profiles of selected genes regulating lipid metabolism or genes related with oxidative stress (transcript abundance increased for SLC2A1 and SLC2A5 and decreased for DGAT1 and GPX1).\nIn cultured astrocytes, PIF promotes BDNF-myelin synthesis promoter and SLC2A1 (glucose transport) while reducing deleterious E2F5, and HSP90ab1 (oxidative stress) genes expression.\nFurthermore, both Slc2a1 overexpression in C8-D1A cells and lactate treatment rescued oAβ-induced mitochondrial oxidative stress and membrane potential alterations in energy-deficient HT22 neurons, thereby enhancing lactate secretion from astrocytes and promoting the lactate shuttle to neuron for energy supply.\nBioinformatics results suggested that SLC2A1, Metastasis-Associated Lung Adenocarcinoma Transcript 1 (MALAT1), and HIF-1α (Hypoxia Inducible Factor 1 Alpha)-related oxidative stress signaling pathways play an important role in iron homeostasis and OA.\nOxidative stress gene SLC2A1 (also named GLUT1) is related to cuproptosis gene in age-related hearing loss.\nThe interaction network analysis indicated that 10 hub genes, including MT1H, MT1G, MT1X, MT1M", "dois": ["10.1016/j.cellsig.2025.111776", "10.1186/s10020-025-01106-8", "10.14336/AD.2024.1560", "10.1016/j.biopha.2024.117048", "10.3390/ijms242216188", "10.1038/s41598-023-40560-4", "10.1038/s41598-020-66913-x", "10.18632/aging.101974", "10.1002/hep.26052", "10.1016/j.heares.2011.03.011", "10.1016/j.expneurol.2025.115493", "10.1002/epd2.70107", "10.3831/KPI.2025.28.3.191", "10.3390/antiox14091097", "10.1016/j.jse.2025.07.012", "10.1007/s12672-025-03173-z", "10.1021/acsami.5c02721", "10.3390/ijms25010529", "10.1016/j.exer.2023.109513", "10.3390/antiox12030592", "10.1111/acel.13807", "10.3389/fnut.2022.1001031", "10.3389/fcvm.2022.875434", "10.3390/antiox11071295", "10.1093/bib/bbac090", "10.3389/fnins.2022.823741", "10.3389/fnins.2021.661663", "10.1007/s10067-020-05539-w", "10.1016/j.theriogenology.2020.09.014", "10.1186/s12964-019-0447-y", "10.1016/j.celrep.2019.07.027", "10.1017/S0007114519000047", "10.4049/jimmunol.1800002", "10.1071/RD18178", "10.18632/oncotarget.15662", "10.1016/j.theriogenology.2016.09.035", "PMID:27863474", "10.1007/s11064-014-1388-x", "10.1074/jbc.M113.522037", "PMID:22509097", "10.1016/j.theriogenology.2011.05.036", "PMID:20981268", "PMID:17616136"]}
{"pair_type": "slc_pathway", "key1": "SLC16A1", "key2": "oxidative phosphorylation", "summary": "Our results unveil a new gene regulatory program by which E2F1-induced lncRNA-SLC16A1-AS1 forms a complex with its transcription factor that promotes cancer metabolic reprogramming towards the acquisition of a hybrid oxidative phosphorylation/glycolysis cell phenotype favoring BC invasiveness.\nWe assessed the functional relevance of these SLCs in efferocytic phagocytes and observed a robust induction of an aerobic glycolysis program, initiated by SLC2A1-mediated glucose uptake, with concurrent suppression of the oxidative phosphorylation program.\nMoreover, SLC16A1-AS1 increases aerobic glycolysis and mitochondrial respiration and fuels ATP production by fatty acid β-oxidation.\nThe absence of MCT1 impaired CD8 T cell proliferation with a shift of ATP production to mitochondrial oxidative phosphorylation.\nSLC16A1 was upregulated after corpse uptake, increasing the release of lactate, a natural by-product of aerobic glycolysis.\nWhereas glycolysis within phagocytes contributed to actin polymerization and the continued uptake of corpses, lactate released via SLC16A1 promoted the establishment of an anti-inflammatory tissue environment.\nMechanistically, upon E2F1-mediated co-transactivation of the gene pair, SLC16A1-AS1 associates with E2F1 in a structure-dependent manner and forms an RNA-protein complex that enhances SLC16A1/MCT1 expression through binding to a composite SLC16A1-AS1:E2F1-responsive promoter element.\nThese metabolic changes are accompanied by alterations in the expression of the SLC16A1-AS1:E2F1-responsive gene PPARA, a key mediator of fatty acid β-oxidation.\nFunctional pathway analysis revealed TIC-specific activation of oxidative phosphorylation, PI3K-Akt signaling, and ribosome-related processes.\nTICs exhibited distinct transcriptomic signatures, including enrichment of non-coding RNAs (e.g., MIR4737 and SNORD19) and selective upregulation of metabolic transport", "dois": ["10.1158/0008-5472.CAN-13-2034", "10.3390/cells14161255", "10.1158/0008-5472.CAN-24-0019", "10.3390/biom13020258", "10.1016/j.isci.2022.104435", "10.7150/thno.44176", "10.1038/s41586-018-0735-5", "10.1158/1535-7163.MCT-17-1253"]}
{"pair_type": "slc_pathway", "key1": "SLC1A5", "key2": "oxidative phosphorylation", "summary": "These results suggest that activated ISR-induced increased expression of SLC1A5var may regulate mitochondrial oxidative phosphorylation and glycolytic metabolic characteristics to enhance glucose depletion-induced cell death.\nMechanistically, upregulation of glutamine transporter solute carrier family 1 member 5 (SLC1A5) transcription compensates for the increased glutamine requirement upon OXPHOS inhibition.\nThe activity of C1 in glutamine metabolism and transport is significantly enhanced, while its oxidative phosphorylation activity is reduced.\nWe show that genetic inhibition of MYC or SLC1A5 acts to phenocopy the impairment of OXPHOS observed with STAT3 inhibition, thereby establishing this axis as a regulatory mechanism linking STAT3 to energy metabolism.\nOxygen consumption rates also decreased upon BPTES treatment, indicating a glutamine dependency for oxidative phosphorylation.\nMechanistically, iMQT_020 reduces glutamine anaplerosis and oxidative phosphorylation, resulting in a broad disruption of cancer metabolism.\nMoreover, the knockdown of SLC1A5var reduces the oxygen consumption rate (OCR) and extracellular acidification rate (ECAR) while increasing the maximal OCR and ECAR under glucose depletion.\nInhibition of SLC1A5 reduces intracellular levels of glutamine, glutathione, and multiple tricarboxylic acid (TCA) cycle metabolites, leading to reduced TCA cycle activity and inhibition of OXPHOS.\nDYRK1A directly phosphorylates SMAD3 Thr132, thereby suppressing the negative impact of TGF-β signaling on transcription of SLC1A5, leading to intrinsic resistance of liver cancer cells to OXPHOS inhibition.\nSTAT3 regulates AML-specific expression of MYC, which in turn controls transcription of the neutral amino acid transporter gene SLC1A5.\nOur findings establish that TRAP-1 contributes to enhanced glutamine utilization through the HIF2α-SLC1A5-GLS axis.\nWe show that STAT3 inhibition selectively leads to cell death in AML stem", "dois": ["10.1016/j.devcel.2024.12.035", "10.1182/blood.2021013201", "10.1371/journal.pone.0153226", "10.3324/haematol.2024.287265", "10.1186/s12885-025-14123-x", "10.1016/j.biocel.2024.106688", "10.1016/j.imbio.2024.152841", "10.1016/j.mito.2023.02.011", "10.3389/fonc.2022.841054", "10.1293/tox.2019-0048", "10.1038/s41419-020-2242-5", "10.1172/jci.insight.131106", "10.1038/s41467-025-64730-2"]}
{"pair_type": "slc_pathway", "key1": "SLC16A1", "key2": "apoptosis", "summary": "Remarkably, PDIA6 and SLC16A1 were observed to inhibit the proliferation of pancreatic β cells and promote apoptosis in vitro, while downregulation of PDIA6 and SLC16A1 expression led to enhanced insulin secretion.\nThese findings indicated that HS-induced autophagy regulates lactate secretion by inhibiting apoptosis and increasing mRNA transcript and protein levels of SLC2A3, LDHA, and SLC16A1, which suggests that HS-induced autophagy may enhance lactate secretion by SCs.\nFunctionally, SLC16A1-AS1 overexpression could inhibit the viability and proliferation of lung cancer cell, block the cell cycle and promote cell apoptosis in vitro which may result from reduced phosphorylation of rat sarcoma (RAS)/ proto-oncogene serine/threonine-protein kinase (RAF)/ mitogen-activated protein kinase kinase (MEK)/ extracellular regulated protein kinases (ERK) pathway caused by elevated expression of SLC16A1-AS1.\nIn vitro experiments showed that overexpression of SLC16A1-AS1 promoted cell proliferation and invasion but suppressed cell apoptosis.\nOverexpression of SLC16A1-AS1 inhibited HCC cell proliferation, invasion, and epithelial-mesenchymal transition (EMT) process as well as promoted cell apoptosis.\nSLC16A1-AS1 suppressed miR-1269 maturation and promoted cell proliferation, migration, and invasion, and inhibited cell apoptosis, while miR-1269 displayed the opposite trend.\nAlso, silencing of circ-SLC16A1 promoted apoptosis of NSCLC cells.\nMechanistically, lactate retention due to Slc16a1 deletion initiates adipocyte apoptosis and cytokine release.\nIt also resulted in significantly less lactate secretion and increased apoptosis but showed no effect on B-cell lymphoma-2 expression in heat-treated immature SCs.", "dois": ["10.1016/j.cell.2024.10.021", "10.1111/jcmm.18141", "10.1186/s12885-024-12327-1", "10.1111/jcmm.18091", "10.1002/mc.23415", "10.1186/s12885-022-09282-0", "10.1038/s41586-018-0735-5", "10.1016/j.theriogenology.2016.09.016", "10.18632/oncotarget.7373", "PMID:26038943", "10.3389/fonc.2025.1519473", "10.62347/ABOI7514", "10.1158/0008-5472.CAN-24-0019", "10.1186/s11658-024-00549-x", "10.1016/j.heliyon.2024.e27727", "10.1186/s12885-023-10636-5", "10.1002/jbt.23247", "10.1021/acs.jmedchem.2c01612", "10.1016/j.anireprosci.2022.107033", "10.1080/21655979.2022.2070581", "10.2337/db21-0535", "10.1007/s11356-020-09998-1", "10.1136/jim-2019-001080", "10.1136/gutjnl-2012-303333", "10.1080/08923973.2022.2056482"]}
{"pair_type": "slc_pathway", "key1": "SLC7A11", "key2": "apoptosis", "summary": "Restoring the expression of SLC7A11/GPX4 can enhance cell viability, alleviate neuronal apoptosis, and reduce Fe overload.\nGas (25µM) increased cell viability, decreased LDH, Fe, MDA and ACSL4 levels, up-regulated SLC7A11 and GPX4 and ameliorated OGD/R-induced apoptosis (P < 0.01).\nMoreover, Icariside II suppressed SKOV3 cell proliferation, inhibited cells migration and invasion, and promoted apoptosis by downregulating SLC7A11 expression.\nPDT promotes apoptosis and ferroptosis of cholangiocarcinoma cells by activating the P53/SLC7A11/GPX4 signaling pathway and inhibits the growth of cholangiocarcinoma.\nVB promoted the proliferation and inhibited apoptosis, inflammation and ferroptosis in OGD/R-treated SK-N-SH cells by regulating METTL14/CHAC1/NRF2/SLC7A11/GPX4 pathway.\nOverexpression of miR-490-3p downregulated the expression of SLC7A11, inhibiting the proliferation, invasion, and metastasis of HCC cells while promoting apoptosis and erastin-induced ferroptosis.\nCordycepin suppressed HG-induced apoptosis, inflammation, and ferroptosis in podocytes in vitro, and ameliorated renal injury and inflammation in STZ-induced diabetic mice by activating the SLC7A11/GPX4 pathway.\nIn summary, CBR-470-1 prevented I/R-mediated cardiac injury possibly through inhibiting cardiomyocyte apoptosis, ferroptosis and pyroptosis via Nrf2-mediated inhibition of p53 and Nlrp3 and activation of the SLC7A11/GPX4 pathway.\nMoreover, AKR1C1 upregulation repressed cell apoptosis and ferroptosis induced by ICH through downregulating the expression of pro-apoptotic factors, inhibiting iron accumulation and lipid peroxidation,", "dois": ["10.1016/j.biomaterials.2025.123592", "10.1016/j.jep.2025.120607", "10.7150/thno.122956", "10.1016/j.prp.2025.156297", "10.1016/j.bcp.2025.117519", "10.1016/j.freeradbiomed.2025.10.266", "10.1016/j.theriogenology.2025.117628", "10.1371/journal.pone.0337060", "10.1016/j.peptides.2025.171454", "10.1007/s12035-025-05272-y", "10.1016/j.cellsig.2025.112111", "10.1016/j.bmc.2025.118374", "10.1016/j.freeradbiomed.2025.08.051", "10.1016/j.biomaterials.2025.123407", "10.1186/s43556-025-00355-7", "10.1016/j.brainresbull.2025.111543", "10.1016/j.ejphar.2025.178085", "10.1016/j.jconrel.2025.114127", "10.1002/jcp.70100", "10.1002/ptr.70010", "10.1016/j.lfs.2025.123820", "10.3390/biom15101353", "10.1016/j.cancergen.2025.07.009", "10.1016/j.redox.2025.103761", "10.1016/j.acthis.2025.152274", "10.1186/s41065-025-00530-4", "10.3389/fimmu.2025.1595900", "10.1080/10715762.2025.2565686", "10.1007/s12010-025-05261-w", "10.1016/j.biomaterials.2025.123168", "10.1007/s12011-024-04473-1", "10.1021/jacs.5c10005", "10.1016/j.jep.2025.120057", "10.3760/cma.j.cn112152-20240219-00078", "10.1007/s00011-025-02070-z", "10.1016/j.yexcr.2025.114659", "10.1126/sciadv.adw1720", "10.1016/j.ultsonch.2025.107368", "10.1007/s12035-025-04798-5", "10.1007/s00210-025-03849-x", "10.3390/ijms26125559", "10.1167/iovs.66.6.72", "10.1186/s11658-025-00743-5", "10.3390/cells14110823", "10.1111/jcmm.70580", "10.1038/s41556-025-01673-2", "10.1002/smll.202500880", "10.1111/jdi.14407", "10.1038/s41598-025-03404-x", "10.12122/j.issn.1673-4254.2025.05.03", "10.1002/cbf.70079", "10.1002/jbt.70267", "10.1016/j.jenvman.2025.125360", "10.1016/j.cellimm.2025.104948", "10.1007/s12033-024-01166-x", "10.1186/s12885-025-14173-1", "10.3390/ijms26083496", "10.1186/s13048-025-01650-1", "10.1002/adhm.202500272", "10.1038/s41418-024-01440-0", "10.3390/md23030123", "10.1007/s11481-025-10184-8", "10.1111/cbdd.70071", "10.1080/10715762.2025.2475390", "10.1016/j.brainresbull.2025.111254", "10.1016/j.neo.2025.101136", "10.1002/ptr.8457", "10.1002/advs.202411131", "10.1371/journal.pone.0317080", "10.1038/s41598-025-87982-w", "10.1016/j.jep.2024.119126", "10.1016/j.intimp.2025.114019", "10.1002/advs.202408789", "10.1016/j.clbc.2024.10.001", "10.1002/jat.4697", "10.1038/s41598-025-85329-z", "10.3760/cma.j.cn121094-20240117-00024", "10.1016/j.gene.2024.148944", "10.1007/s10238-024-01550-6", "PMID:40089274", "10.1186/s12964-024-01916-z", "10.1111/cbdd.70010", "10.1002/lsm.23857", "10.1016/j.biochi.2024.08.001", "10.1080/01443615.2023.2301324", "10.1186/s10020-024-01002-7", "10.3389/fendo.2024.1422787", "10.1016/j.freeradbiomed.2024.09.039", "10.3390/biom14111456", "10.1007/s12032-024-02483-6", "10.1080/10715762.2024.2417279", "10.1016/j.taap.2024.117113", "10.1093/toxsci/kfae099", "10.1002/biof.2083", "10.1038/s41467-024-53135-2", "10.1523/ENEURO.0174-24.2024", "10.1002/advs.202402795", "10.1080/01616412.2024.2370205", "10.1002/mc.23778", "10.1007/s10495-024-01989-8", "10.3390/medicina60101581", "10.1186/s13062-024-00528-4", "10.5152/tjg.2024.24159", "10.1016/j.bbrc.2024.150200", "10.1016/j.bbrc.2024.150178", "10.1016/j.cellsig.2024.111278", "10.1097/CAD.0000000000001620", "PMID:39264079", "10.1007/s11033-024-09867-x", "10.3390/cells13171421", "10.1016/j.jep.2024.118264", "10.1038/s41419-024-06939-5", "10.1016/j.xphs.2024.05.015", "10.12122/j.issn.1673-4254.2024.07.19", "10.1038/s41598-024-66533-9", "10.18632/aging.206009", "10.12122/j.issn.1673-4254.2024.06.07", "10.3760/cma.j.cn121090-20231218-00323", "10.1186/s11658-024-00605-6", "10.18632/aging.205916", "10.1016/j.pdpdt.2024.104104", "10.1097/SHK.0000000000002339", "10.1016/j.redox.2024.103145", "10.1016/j.psj.2024.103674", "10.1016/j.phymed.2024.155533", "10.3779/j.issn.1009-3419.2024.101.12", "10.2147/IJN.S455427", "10.1016/j.intimp.2024.111959", "10.14336/AD.2024.0083", "10.1186/s12864-024-10307-0", "10.3390/molecules29081838", "10.1038/s41598-024-58499-5", "10.1111/jcmm.18207", "10.1016/j.bcp.2024.116068", "10.1016/j.jinorgbio.2024.112502", "10.1016/j.redox.2024.103035", "10.1007/s10495-023-01909-2", "10.1038/s41598-024-57594-x", "10.1002/tox.24051", "10.17219/acem/168242", "10.7150/thno.92663", "10.1038/s41598-024-52128-x", "10.3390/ijms25042315", "10.1038/s41598-024-54075-z", "10.1186/s12885-024-11951-1", "10.1007/s10495-023-01900-x", "10.1007/s10495-023-01894-6", "10.12122/j.issn.1673-4254.2024.01.19", "10.18632/aging.205371", "10.2174/0115672026286243240105115419", "10.1111/cbdd.14417", "10.1016/j.ijbiomac.2023.127976", "10.4103/jcrt.jcrt_608_23", "10.1007/s00432-023-05378-7", "10.1002/cbf.3848", "10.1016/j.cancergen.2023.10.001", "10.1038/s41598-023-45295-w", "10.1016/j.aquatox.2023.106659", "10.1016/j.redox.2023.102825", "10.1016/j.bbcan.2023.188955", "10.1016/j.yexcr.2023.113697", "10.1007/s10495-023-01856-y", "10.1007/s10495-023-01850-4", "10.1016/j.freeradbiomed.2023.04.008", "10.1080/15548627.2023.2200554", "10.1007/s10571-023-01343-7", "10.1186/s13018-023-04010-1", "10.1016/j.jep.2023.116409", "10.1016/j.bcp.2023.115592", "10.1155/2023/2061071", "10.1016/j.lfs.2023.121649", "10.1016/j.tice.2023.102051", "10.1016/j.canlet.2023.216147", "10.1016/j.biopha.2023.114458", "10.1007/s00438-023-02001-9", "10.1002/tox.23670", "10.1080/15384101.2023.2178102", "10.3724/abbs.2023068", "10.1002/kjm2.12650", "10.1007/s10495-023-01814-8", "10.1007/s10495-022-01808-y", "10.1016/j.ecoenv.2023.114708", "10.3390/ijms24065144", "10.1038/s41556-023-01091-2", "10.1002/tox.23740", "10.1016/j.biopha.2023.114241", "10.3390/molecules28052078", "10.4149/neo_2022_220418N423", "10.1016/j.freeradbiomed.2023.01.002", "10.1177/09603271231180864", "10.1080/01635581.2023.2203353", "10.1177/09603271231167585", "10.3390/molecules27238564", "10.1016/j.freeradbiomed.2022.10.268", "10.1186/s11658-022-00395-9", "10.3389/fimmu.2022.967151", "10.1016/j.biopha.2022.113572", "10.1016/j.lfs.2022.120859", "10.3390/ijms231911092", "10.1007/s12192-022-01284-y", "10.1016/j.phrs.2022.106306", "10.1002/ddr.21941", "10.1016/j.phymed.2022.154102", "10.1155/2022/1112987", "10.1139/bcb-2021-0399", "10.3892/mmr.2022.12645", "10.1016/j.freeradbiomed.2022.01.013", "10.2174/1574892817666220629105543", "10.1021/acs.jafc.1c05393", "10.1080/21655979.2021.2010369", "10.1016/j.fct.2021.112672", "10.1158/0008-5472.CAN-21-0567", "10.1158/1535-7163.MCT-21-0067", "10.1016/j.lfs.2021.119529", "10.3389/fendo.2021.670031", "10.1158/0008-5472.CAN-20-2496", "10.1186/s13046-021-01995-7", "10.3390/ijms22115547", "10.1016/j.phrs.2020.105305", "10.1016/j.ymthe.2020.09.024", "10.1016/j.phymed.2020.153370", "10.1016/j.biopha.2020.110092", "10.1172/JCI124049", "10.1158/0008-5472.CAN-19-1577", "10.3390/ijms20194968", "10.1080/17435390.2019.1576238", "10.3390/ijms20102493", "10.1158/0008-5472.CAN-19-0487", "10.1158/0008-5472.CAN-18-3037", "10.1016/j.ccell.2018.12.009", "10.1021/acs.chemrestox.8b00209", "10.3892/or.2018.6585", "10.1016/j.cub.2018.05.094", "10.1016/j.cell.2018.04.012", "10.1080/15548627.2018.1513758", "10.3892/or.2017.5976", "10.1002/mnfr.201600754", "10.1016/j.celrep.2017.07.055", "10.1002/hep.29117", "10.1691/ph.2017.7449", "10.1002/cam4.1110", "10.3390/ijms18040852", "10.1038/ncomms14844", "10.18632/oncotarget.11858", "10.1016/j.celrep.2016.09.022", "10.18632/oncotarget.7864", "10.1186/s12864-015-1783-y", "10.1038/cddis.2014.566", "10.7554/eLife.02523", "10.1016/j.fitote.2012.07.006", "10.1016/j.febslet.2011.04.018", "10.3892/ijo.2011.971", "10.1124/jpet.109.162248", "10.1016/j.tice.2025.103181", "10.2478/aite-2026-0002", "10.1016/j.abb.2025.110669"]}
{"pair_type": "slc_pathway", "key1": "SLC25A6", "key2": "oxidative stress", "summary": "Transcript levels of NFE2L2 (NRF2) and NF-κB1 were elevated, coinciding with reduced expression of the mitochondrial transporter gene SLC25A6, suggesting a compensatory response to oxidative stress.\nFurthermore, carvacrol has been shown to reduce VDAC1 protein expression, improve mitochondrial function and energy metabolism by regulating MMP, mPTP opening, ROS levels, and ATP production, and increase SLC25A6 protein expression.\napoptosis was reduced, enzymatic activity of cytochrome C oxidase (COX) and superoxide dismutase and expression of uncoupling protein 2, voltage-dependent anion channel 1, and Bcl 2 were upregulated and SLC25A6, MDA levels were downregulated.\nIt also decreased oxidative stress levels, inhibited excessive tube formation capacity, and promoted cytoskeletal remodeling.\nThe results of this study demonstrate that carvacrol exerts a protective effect on human microvascular endothelial cells by improving mitochondrial function and alleviating oxidative stress through the inhibition of VDAC1.\nIn the mechanism of inflammatory injury, SLC25A6 may act as a downstream effector of VDAC1.\nA significant 10-fold reduction in hemoglobin subunit alpha (HbA1) RNA was observed in disease groups compared to controls, indicating compromised oxygen transport and cellular stress.", "dois": ["10.1186/s40001-020-00431-4", "10.3389/fnins.2025.1589857", "10.1021/acsomega.4c10795"]}
{"pair_type": "slc_pathway", "key1": "SLC25A6", "key2": "oxidative phosphorylation", "summary": "In conclusion, our study elucidates the mechanism by which the MRPL13-SLC25A6 axis enhances mitochondrial function and promotes tumor progression in OC by inhibiting mPTP opening, suggesting that MRPL13 holds significant potential for prognostic evaluation and targeted therapy in OC.\nMoreover, MRPL13 knockdown impairs mitochondrial function in OC cells, leading to decreased OXPHOS and ATP levels, increased reactive oxygen species (ROS) generation, mitochondrial depolarization, aberrant opening of the mitochondrial permeability transition pore (mPTP), and mitochondrial structural damage.\nMRPL13 inhibits mPTP opening by accelerating the degradation of SLC25A6, thereby preventing cytochrome c release into the cytoplasm, inhibiting cell death, and enhancing mitochondrial function.\nMitochondrial ribosomal protein L13 (MRPL13), involved in the translation of oxidative phosphorylation (OXPHOS) complex subunits, plays a critical role in regulating mitochondrial function.\nMechanistically, MRPL13 specifically interacts with SLC25A6 and facilitates its degradation via lysine (K)48-linked ubiquitination.\nBoth in vitro and in vivo experiments confirmed that MRPL13 overexpression significantly promotes the malignant biological behavior of OC, while MRPL13 knockdown induces the opposite phenotype.\nThe mitochondrial ATP is exported to the cytoplasm using a specialized transport protein, the ADP/ATP carrier, to provide energy to the cell.\nIn aerobic eukaryotic cells, the high energy metabolite ATP is generated mainly within the mitochondria following the process of oxidative phosphorylation.\nAny deficiency or dysfunction of this membrane protein leads to serious consequences on cell metabolism and can cause various diseases such as muscular dystrophy.", "dois": ["10.1038/s41419-025-07953-x", "10.1186/s12864-017-4148-x", "10.1016/j.mam.2012.05.006"]}
{"pair_type": "slc_pathway", "key1": "SLC16A1", "key2": "glycolysis", "summary": "It was found for the first time that EMB promoted lactic acid accumulation and further induced redox dyshomeostasis and glycolysis disorder by simultaneously inhibiting SLC16A1/3.\nSLC16A1 was upregulated after corpse uptake, increasing the release of lactate, a natural by-product of aerobic glycolysis.\nIn turn, the reciprocal SLC16A1-AS1/IL-6 signaling between HCC cells and M2 macrophages promoted the proliferation, invasion and glycolysis of HCC cells.\nWhereas glycolysis within phagocytes contributed to actin polymerization and the continued uptake of corpses, lactate released via SLC16A1 promoted the establishment of an anti-inflammatory tissue environment.\nOur results unveil a new gene regulatory program by which E2F1-induced lncRNA-SLC16A1-AS1 forms a complex with its transcription factor that promotes cancer metabolic reprogramming towards the acquisition of a hybrid oxidative phosphorylation/glycolysis cell phenotype favoring BC invasiveness.\nMoreover, SLC16A1-AS1 increases aerobic glycolysis and mitochondrial respiration and fuels ATP production by fatty acid β-oxidation.\nSLC16A1/3 is the critical hub for regulating the internal and external environment, glycolysis, and redox homeostasis in cervical cancer cells.\nGA-Fe@EMB can target cervical cancer marker SLC16A1/3 to regulate glycolysis and redox pathways, synergistically with photothermal therapy, which provides a new avenue for the synergistic treatment of malignant cervical cancer.\nWe further show both in vitro and in vivo that the sodium lactate-mediated inhibition of CD4+ T cell motility is due to an interference with glycolysis activated upon engagement of the chemokine receptor CXCR3 with the chemokine CXCL10.\nSLC16A1 functions to efflux lactic acid during aerobic glycolysis.\nIn HepG2 cells with the highest NaCT expression, extracellular citrate treatment upon hypoxia induced HIF1α degradation, which led to reduce", "dois": ["10.1186/s12943-024-02037-4", "10.1021/acs.molpharmaceut.3c00294", "10.18632/oncotarget.28351", "10.7150/thno.44176", "10.1038/s41586-018-0735-5", "10.1371/journal.ppat.1006020", "10.1371/journal.pbio.1002202", "10.1158/0008-5472.CAN-13-2034", "10.1038/ng.2471", "10.1016/j.repbio.2025.101008", "10.7150/ijbs.94440", "10.3748/wjg.v30.i19.2575", "10.2174/0113895575284780240327103039", "10.1158/0008-5472.CAN-24-0019", "10.1016/j.trsl.2023.09.006", "10.3389/fimmu.2023.1183825", "10.3390/ijms24065141", "10.1097/MD.0000000000033242", "10.3390/biom13020258", "10.3390/cancers14143355", "10.1002/sctm.19-0392", "PMID:27729975", "PMID:25859558", "PMID:22497081", "10.1371/journal.pone.0028789", "10.1074/jbc.M110.168666", "10.1016/j.humpath.2009.02.003"]}
{"pair_type": "slc_pathway", "key1": "SLC6A14", "key2": "apoptosis", "summary": "Reducing SLC6A14 increased cell proliferation and suppressed apoptosis.\nWhile SLC6A14 genetic deficiency does not have a major impact on cell proliferation, combined depletion of AMPK and SLC6A14 leads to an increase in apoptosis upon methionine starvation, suggesting that combined targeting of SLC6A14 and AMPK can be exploited as a therapeutic approach to starve tumor cells.\nIn PDAC cell line, knockdown inhibited cells proliferation, migration and promoted cells apoptosis.\nAdministration of α-MT to mice showed evidence of IDO1 inhibition and rectification of metabolic dysfunctions with concurrent suppression of mTOR signaling and apoptosis.\nThese studies show that blockade of amino acid entry amplifies the anticancer effect of lapatinib via interference with mTOR signaling, promotion of apoptosis, and suppression of cell proliferation and metastasis.\nReducing SLC6A14 decreased pyroptosis-associated proteins (ASC, IL-1β, IL-18, NLRP3).\nNLRP3 overexpression counteracted the effects of sh-SLC6A14 on LPS-induced FHC and NCM460 cell pyroptosis.\nFurther knockdown SLC6A14 with siRNA or treatment with α-MT in CRC cell lines reduced cell proliferation and migration in vitro and inhibited xenograft tumor growth in vivo.\nSLC6A14 promotes UC pyroptosis by regulating NLRP3, suggesting the therapeutic potential of modulating the SLC6A14/NLRP3 axis.\nMechanistically, SLC6A14 was demonstrated to regulate the expression and phosphorylation of Akt-mTOR, which mediates the promoting tumor growth function of SLC6A14.\nSLC6A14 was upregulated in CRC and could promote tumor progression by activating the Akt-mTOR signaling pathway, which may serve as an effective molecular target for the treatment of CRC.\nThese disturbances are chiefly characterized by alterations in amino acid metabolism, energy production pathways, membrane biochemical features, and nicotinamide metabolism, all of which", "dois": ["10.1097/SHK.0000000000002587", "10.3748/wjg.v30.i3.252", "10.1042/BCJ20200275", "10.1042/BCJ20200099", "10.3389/fphar.2024.1463673", "10.1016/j.heliyon.2022.e11321", "10.1186/s12885-022-09935-0", "10.1016/j.bioactmat.2021.07.009", "10.2147/OTT.S288709", "10.18632/oncotarget.27758", "10.1074/jbc.M111.229518", "10.1167/iovs.12-10312"]}
{"pair_type": "slc_pathway", "key1": "SLC38A1", "key2": "apoptosis", "summary": "Knockdown of SLC38A1 inhibited cell viability and cell cycle progression, induced apoptosis, and suppressed tumor growth in vivo.\nMoreover, METTL3 silencing inhibited cell viability, cell cycle progression, intracellular glutamine content, and induced apoptosis, but these effects were reversed by SLC38A1 overexpression.\nCircRUNX1 promoted CRC cell growth, metastasis and glutamine metabolism and repressed apoptosis by elevating SLC38A1 through sponging miR-485-5p, which might provide a novel target for CRC treatment.\nCircRUNX1 deficiency restrained CRC cell colony formation, migration, invasion and glutaminolysis and induced apoptosis in vitro as well as blocked tumour growth in vivo.\nWe suggest that hsFLT1 exerts an inhibitory influence on placental vascularization by reducing Vegf signaling, which leads to apoptosis in fetal vessels, impairing placental differentiation, and the nutrient exchange function of the labyrinth.\nWe describe how Slc38a2 senses amino acid availability and passes this onto intracellular signaling pathways and how it regulates protein synthesis, cellular proliferation and apoptosis through the mechanistic (mammalian) target of rapamycin (mTOR) and general control nonderepressible 2 (GCN2) pathways.\nMoreover, miR-485-5p overexpression repressed the malignant behaviours of CRC cells, with SLC38A1 elevation overturned the impacts.\nActivation of PPARs may in turn affect nutrient transport, PG synthesis, angiogenesis, apoptosis, or cell proliferation in this tissue.\nThe effects of circRUNX1 knockdown on CRC cell colony formation, migration, invasion, apoptosis and glutaminolysis were reversed by miR-485-5p inhibition.\nSuppression of endogenous SNAT1 leads to cell growth inhibition, cell cycle arrest, and apoptosis of 4T1 cells and lowered the phosphorylation level of Akt.", "dois": ["10.1016/j.bbrc.2024.150039", "10.1016/j.theriogenology.2019.01.002", "10.1371/journal.pone.0157453", "10.2147/JHC.S500394", "10.5009/gnl210542", "10.1038/s41401-021-00717-1", "10.1111/eci.13540", "10.1016/j.fct.2020.111698", "10.1089/cbr.2020.3608", "10.1016/j.neuropharm.2019.107789", "10.3389/fendo.2019.00165", "10.3892/or.2015.3868", "10.1186/1471-2407-13-343", "10.1038/mp.2010.23", "PMID:15687482", "10.1002/mnfr.202100301"]}
{"pair_type": "slc_pathway", "key1": "SLC1A1", "key2": "migration", "summary": "R-2-HG hijacks SLC1A1 to promote mitochondrial Na/Ca exchange, which activates the mitochondrial respiratory chain and fuels vascular endothelial cell migration in tumor angiogenesis.\nmiR-96a-5p was identified as the putative target for CircRNA ZFR and its inhibition promoted HCC through modulating the expression of SLC1A1 gene.\nTogether, we identify a new role of SLC1A1 as a gatekeeper of R-2-HG-mediated crosstalk between IDH1-mutant tumor cells and vascular endothelial cells, and demonstrate the therapeutic potential of mIDH1 inhibitors in treating IDH1-mutant solid tumors via disrupting R-2-HG-promoted tumor angiogenesis.\nCircRNA ZFR overexpression promoted HCC cell proliferation, migration and invasion while its knockdown inhibited HCC progression.\nSLC1A1 deficiency in mice abolishes mIDH1-promoted tumor angiogenesis as well as the therapeutic benefit of mIDH1 inhibitor in solid tumors.\nMechanistically, SLC1A1, a Na-dependent glutamate transporter that is preferentially expressed in endothelial cells, facilitates the influx of R-2-HG from the tumor microenvironment into the endothelial cells as well as the intracellular trafficking of R-2-HG from cytoplasm to mitochondria.\nIn this study, we discover that R-2-HG produced by IDH1-mutant tumor cells is preferentially imported into vascular endothelial cells and remodels mitochondrial respiration to promote tumor angiogenesis, conferring a therapeutic vulnerability in IDH1-mutant solid tumors.\nCollectively, circRNA ZFR knockdown retarded HCC progression by sponging miR-96a-5p and modulating SLC1A1 expression, suggesting that the circZFR/miR-96a-5p/SLC1A1 axis may serve as potential therapeutic targets for HCC.", "dois": ["10.1038/s41598-025-07974-8", "10.3389/fimmu.2024.1483498", "10.1038/s41422-022-00650-w", "PMID:30416854", "PMID:25326682", "PMID:22738901"]}
{"pair_type": "slc_pathway", "key1": "SLC12A2", "key2": "apoptosis", "summary": "For instance, SLC12A2 was found to enhance invasion, proliferation, and migration of colorectal cancer cells while inhibiting apoptosis.\nTherefore, blocking NKCC1 function augments TMZ-induced apoptosis in glioma cells.\nInhibition of NKCC1 activity with bumetanide accelerated AVD, early apoptosis, as well as activation of caspase-3 and caspase-8.\nInterfering with SLC12A2 expression or function resulted in a significant increase in apoptotic corpse uptake per phagocyte, whereas the loss of SLC12A4 inhibited corpse uptake.\nACVR1 overexpression can promote the proliferation of sweat gland cells and inhibit apoptosis by promoting the expression of AQP5 and NKCC1.\nPharmacological inhibitor bumetanide (Bume) or NKCC1 RNA interference significantly attenuated TBI-induced intracellular Na(+) increase, inhibited neuronal apoptosis, and improved brain edema and neurological function.\nThis study demonstrates the role of NKCC1 in TBI-induced brain cortex injury, establishing that NKCC1 may play a neurotoxic role in TBI and that the inhibition of NKCC1 may protect neurons from TBI via the regulation of Erk signaling.\nIn addition, silencing of WNK3 reduced neuronal apoptosis, and inflammatory responses in rats that underwent ICH.\nAfter inhibiting p‑SPAK, the expression level of p‑NKCC1, neuronal apoptosis and BBB permeability were significantly reduced in SBI model rats.\nChoroid plexuses with increased AQP1 and NKCC1 after 6 hr of hyponatremia showed caspase 3-dependent apoptosis and disruption of the blood-CSF barrier.\nWe introduce a preclinical mouse model for small-interfering RNA (siRNA)-based gene silencing to provide protection of SG from radiation-induced apoptosis.", "dois": ["10.1016/j.bbrc.2020.05.052", "10.1158/1535-7163.MCT-19-0910", "10.1038/s41556-019-0431-1", "10.3389/fonc.2025.1532602", "10.1177/1559325819852444", "10.1158/1541-7786.MCR-17-0413", "10.12182/20250160204", "10.1089/neu.2023.0580", "10.1111/jcmm.18589", "10.1053/j.gastro.2021.11.022", "10.3892/mmr.2021.12356", "10.1111/epi.16912", "10.1152/ajpgi.00282.2020", "10.1016/j.expneurol.2020.113386", "10.1007/s12031-018-1043-0", "PMID:27113187", "10.1016/j.neuint.2016.02.002", "10.1016/j.brainres.2015.04.006", "PMID:25620102", "10.1038/mt.2013.42", "10.1159/000339047", "10.1002/jnr.23017", "10.1159/000149782", "PMID:17320059", "PMID:15155267"]}
{"pair_type": "slc_pathway", "key1": "SLC1A5", "key2": "glycolysis", "summary": "We also found CDDO-Me could inhibit N-linked glycosylation of SLC1A5, which promotes protease-mediated degradation.\nIn summary, the ATF4/SLC1A5 axis plays a significant role in the progression of colorectal cancer by regulating glutamine metabolism and glycolysis.\nOur results demonstrate a novel adaptive mechanism of glycolytic inhibition in which Trx-1 increases GSH levels by regulating SLC1A5 to rescue cytotoxicity induced by 2DG in CRC cells.\nWe also found that the SLC1A5 expression was upregulated in CRC tissues, and inhibition of SLC1A5 significantly enhanced the inhibitory effect of 2DG on the growth of CRC cells in vitro and in vivo.\nThis includes the upregulation of glutamine transporter SLC1A5 and glutamine uptake, with concomitant build-up of essential amino acids, and mTORC1 activation, to ameliorate the effects of LDHA inhibition.\npromoter enrichment is increased by anti-ATF4 antibody immunoprecipitation in -overexpressing colorectal cells, indicating that ATF4 targets SLC1A5 to promote glutamine and glucose metabolism in these cells.\nIn addition, Trx-1 promoted SLC1A5 expression by increasing the promoter activity of the SLC1A5 gene by binding to SP1.\nOverexpression of SLC1A5 reduced the cytotoxicity of 2DG in combination with PX-12 treatment in CRC cells.\nInhibition of glycolysis in combination with inhibition of Trx-1 or SLC1A5 may be a promising strategy for the treatment of CRC.\nThe role of activating transcription factor 4 (ATF4) in solute carrier family 1 member 5 (SLC1A5)-mediated glutaminolysis and glycolysis remains to be elucidated.\nMoreover, we confirmed that SLC1A5 depletion reduced the ratio of glutathione/oxidized glutathione.\nWe also verified CDDO-Me downregulated glutamine transporter", "dois": ["10.3390/cells14050388", "10.3724/abbs.2024226", "10.1007/s13402-023-00887-6", "10.1016/j.mito.2023.02.011", "10.1016/j.tox.2020.152650", "10.1186/s12964-020-00678-8", "10.15252/embj.201899735", "10.17219/acem/68979", "10.1016/j.cmet.2017.12.007", "10.1002/jbmr.1976", "10.1016/j.phymed.2024.156223", "10.1165/rcmb.2022-0339OC", "10.3389/fnut.2023.1124678", "10.3390/cancers15041050", "10.1002/jbt.23192", "10.1016/j.apsb.2021.09.019", "10.3390/metabo11010001", "10.1293/tox.2019-0048", "10.1111/1759-7714.13226", "10.1126/scisignal.aan4667", "10.18632/oncotarget.10131", "10.1371/journal.ppat.1005052", "10.1007/s00109-013-1064-7", "10.1007/s13402-020-00575-9", "10.1172/jci.insight.131106", "10.18632/oncotarget.4544", "10.1309/AJCPXAYH10WENLTC", "10.1016/j.stem.2014.06.002", "10.1016/j.prp.2025.156248"]}
{"pair_type": "slc_pathway", "key1": "SLC16A1", "key2": "oxidative stress", "summary": "However, feeding OVE upregulated the acute-phase protein SAA3 by 3.5-fold and downregulated a volatile fatty acid transporter (SLC16A1) and a Fe and Cu transporter (SLC11A2).\nGene expression analysis revealed significant tissue-specific alterations including changes in the expression of SDHA in the liver, an upregulated SLC16A1 in cardiac tissue (in-silico and in-vivo), a downregulated SLC5A3 in cardiac tissue (in-vivo), an upregulated SLC25A10 in cardiac tissue (in-vivo) and differential in-silico expression of SLC25A10 across liver and kidney tissues.\nTo address the potential mechanisms, transcripts related to oxidative stress, cell fate, and cell metabolism (Pdk1, Pdk2, Pdk4, Spr, Slc16a1, Slc16a3, Ppargc1a, Cs, Lgr5, Casp3, Tnfr2, Bax, Bcl2, Sod1, Sod2, and Cat) were measured, and untargeted liquid chromatography-tandem mass spectrometry (LC-MS/MS) was employed to profile the metabolic responses of colonocytes following exposure to butyrate and TNFα.\nIt was found for the first time that EMB promoted lactic acid accumulation and further induced redox dyshomeostasis and glycolysis disorder by simultaneously inhibiting SLC16A1/3.\nAfter SMPs treatment, the serum levels of ALT, AST, liver LPO, ROS, and IL-6 were significantly reduced (P < 0.0 5 or P < 0.01), and the contents of T-AOC, GSH-PX, IL-4, and IL-10 in the liver were significantly increased (P < 0.0 5 or P < 0.01).\nCompared with the GP1 group, the serum levels of ALT, AST, liver LPO, ROS, and IL-6 in the GP2 group were significantly increased (P < 0.0 5 or P", "dois": ["10.1111/dom.12029", "10.1007/s11306-025-02318-z", "10.1016/j.trsl.2023.09.006", "10.1021/acs.molpharmaceut.3c00294", "10.3390/biom13020258", "10.1038/s41467-021-27329-x", "10.1007/s11356-021-15687-4", "10.3168/jds.2017-12866", "10.1210/me.2014-1281"]}
{"pair_type": "slc_pathway", "key1": "SLC1A3", "key2": "apoptosis", "summary": "In vivo and in vitro experiments showed that silencing FN1 inhibits the activation of the YAP1/Hippo pathway by enhancing YAP1 phosphorylation, down-regulates SLC1A3-mediated aspartate uptake and utilization by tumor cells, inhibits BC cell proliferation, invasion and migration, and promotes apoptosis.\nInactivation of Trp53 and Rb1, whose pathways are commonly altered in HGSC, leads to elimination of targeted Slc1a3+ cells by apoptosis, thereby preventing their malignant transformation.\nIn combination with ASNase, SLC1A3 inhibition caused cell cycle arrest or apoptosis, and myriads of metabolic vulnerabilities in tricarboxylic acid (TCA) cycle, urea cycle, nucleotides biosynthesis, energy production, redox homeostasis, and lipid biosynthesis.\nThe results indicated that suppression of miR-342-3p improves expression of Glu transporter and promotes dopaminergic neuron proliferation while suppressing apoptosis through the Wnt signaling pathway by targeting PAK1 in mice with PD.\nKnockdown of Rhotekin 2 expression suppresses proliferation and induces apoptosis in colon cancer cells.\nexperiments demonstrated that knockdown of restrained the proliferation activity of ovarian cancer cells, enhanced cell apoptosis, and inhibited cell migration.\nTreatment with FA resulted in a significant decrease in both glial activation and the rate of apoptosis in GCL in comparison with diabetic mice treated with vehicle.\nLastly, in vivo experiments indicated that SLC1A3 expression promoted tumor development and metastasis while negating the suppressive effects of ASNase by fueling aspartate, glutamate, and glutamine metabolisms despite of asparagine shortage.\nAfter 8 weeks of intraocular pressure (IOP) elevation, staining with terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling (TUNEL) revealed an increase in the ganglion cell layer, and the number of TUNEL-positive cells was reduced by brimonidine treatment (P<0.05).", "dois": ["10.1007/s10549-023-07032-9", "10.1111/jcmm.16060", "10.15252/embj.2019102147", "PMID:15312324", "10.21037/tcr-24-1909", "10.1038/s41467-024-52984-1", "10.1111/jcmm.18568", "PMID:30285010", "PMID:25326682", "10.1002/glia.24307", "10.1007/s13105-021-00799-9", "10.1016/j.toxlet.2019.10.005", "10.1002/ijc.31985", "10.1002/jcp.27577", "10.1159/000460514", "10.1111/imm.12674", "10.1016/j.brainres.2016.06.015", "10.1016/j.ejphar.2015.08.035", "10.1007/s12035-015-9161-y", "10.1007/s00592-014-0610-2", "10.1111/cns.12150", "10.1038/cdd.2013.91", "10.1242/jcs.088120", "10.1177/1933719111410710", "10.1002/jcp.22762", "10.1038/cdd.2010.62", "10.1016/j.expneurol.2009.01.022", "10.1007/s10571-009-9346-x", "PMID:17239606", "PMID:16465529", "PMID:15578657", "PMID:11744117"]}
{"pair_type": "slc_pathway", "key1": "SLC1A2", "key2": "apoptosis", "summary": "Enrichment analysis showed that it was related to MAPK cascade, negative/positive regulation of apoptotic process and other biological functions as well as PI3K/AKT, neurotrophin and other signal pathways.\nMusk, gardenia and borneol compatibility can play a bidirectional regulation of apoptosis;\nThe results indicated that SLC6A1,SLC1A2,BDNF,GAP43,NRXN1,GAD1,OLIG2, PLP1,S100B and GRIA3 were the key genes in the signaling pathway of the interacting protein network.\nSLC6A1, SLC1A2, BDNF, GAP43, NRXN1, GAD1, OLIG2, PLP1, S100B and GRIA3 are key genes for glioma development and are related to the prognosis of patients.", "dois": ["10.3760/cma.j.issn.0376-2491.2019.29.013", "10.19540/j.cnki.cjcmm.20180115.011", "10.1016/j.gene.2013.11.029"]}
{"pair_type": "slc_pathway", "key1": "SLC1A1", "key2": "apoptosis", "summary": "Additionally, ATP inhibited the migration of BC cells and promoted their apoptosis.\nSpermine supplementation may regulate cell cycle during the G1/S phase, suppress apoptosis and modulate amino acid transport.\nGene ontology (GO) enrichment analysis of upregulated genes in the induced samples showed that the biological processes related to neuronal differentiation and development, such as neuronal differentiation, projection, and apoptosis, were significantly upregulated with a longer induction time during cell cluster differentiation.\nIn addition, extended spermine administration also markedly promoted cell proliferation, depressed apoptosis and modulated amino acid transport (p&lt;\nIrrespective of the treatment period, the reduced Bax and caspase-3 gene expressions and improved Bcl-2 mRNA level were observed in the thymus and spleen of spermine-administrated piglets (p&lt;0.05).\nSTXBP5-AS1 and RFX3-AS1 exhibited anti- and pro-proliferation effects, respectively, in the cancer cells, and the effects of Rg3 and KRG extract on apoptosis and cell proliferation were weakened after deregulating the lncRNAs.\nFinally, maternal Ezh1/2 deletion led to cell apoptosis in blastocyst embryos in mice.\nCentral among the fetotoxic responses to in utero ethanol (E) exposure is redox-shift related glutathione (GSH) loss and apoptosis.\nAll of these cell lines express the vitamin D receptor (VDR) and exhibit anti-cancer responses to 1,25D such as changes in proliferation, apoptosis, metabolism, or invasion.\nThe induction of cell death by ATP appears to play a protective role in BC progression.\nThis study employed genomic methodologies to investigate the correlation between drug sensitivity and types of AICD in BC.\nThe effect of the lncRNAs on the apoptosis and proliferation of MCF-7 cells was monitored in the presence of Rg3 or Korean Red Ginseng (KRG) extract after deregulating the lncRNAs.\nRegardless of administration time, spermine supplementation significantly up-regulated cyclin A", "dois": ["10.3389/fimmu.2024.1483498", "10.1002/jcp.31244", "10.1371/journal.pone.0183854", "10.1016/j.heliyon.2024.e33079", "10.1016/j.jgr.2019.02.004", "10.5713/ajas.17.0799", "10.3390/ijms18122596", "PMID:25326682", "10.1016/j.jsbmb.2014.09.014"]}
{"pair_type": "slc_pathway", "key1": "SLC15A1", "key2": "apoptosis", "summary": "In conclusion, JBP485 alleviated indomethacin-induced intestinal injury through restoring the redox balance, suppressing inflammation, reducing apoptosis, which was further enhanced by Res via upregulation of Pept1 and improvement of bioavailability of JBP485, at least in part.\nMoreover, Met-Met increased tight junction protein and decreased apoptosis-related proteins expression in the jejunum and ileum.\nSpermine supplementation may regulate cell cycle during the G1/S phase, suppress apoptosis and modulate amino acid transport.\nUnlike single decitabine treatment, the combined decitabine/PBA treatment caused > 95% inhibition of cell proliferation, prevented cell cycle progression especially in the S and G2-phase and induced programmed cell death.\nJBP485 treatment ameliorated indomethacin-induced enteropathy characterized by severe histopathological changes and a large number of TUNEL-positive cells in rat intestinal epithelium, elevated levels of MDA, MPO, TNF-α, IL-6, IL-1β and increased expression of COX-2, and reduced levels of SOD, GSH, CAT, HDL-c, PGE2, expression of COX-1 and Bcl-2/Bax ratio in rat intestinal tissues.\nIn addition, extended spermine administration also markedly promoted cell proliferation, depressed apoptosis and modulated amino acid transport (p&lt;\nIL-6 and TNF-α expression and apoptosis were increased, and mitochondrial damage was severe, as indicated by increased mtDNA in the MDP group compared with controls.\nRegardless of supplementation time, spermine intake significantly enhanced the expressions of amino acid transporter-related genes (SLC1A1, SLC1A5, SLC7A1, SLC7A7, and SLC15A1) in both thymus and spleen, as well as SLC7A9 in the spleen of piglets (p&lt;0.05).\nFurthermore, Res increased the plasma concentration of JBP485 in both indomethacin-treated and healthy rats, as well as the intracellular accumulation of JB", "dois": ["10.1186/s12864-015-1783-y", "10.1186/s13148-023-01500-1", "10.3390/ani12182324", "10.5713/ajas.17.0799", "10.1007/s11033-024-09759-0", "10.1111/jpn.13126", "10.1016/j.biopha.2018.12.084", "10.2147/IJN.S97207", "10.1016/j.pdpdt.2011.12.004", "10.1152/ajpgi.90657.2008", "PMID:17638014", "PMID:17081567", "PMID:12669956"]}
{"pair_type": "slc_pathway", "key1": "SLC25A12", "key2": "oxidative phosphorylation", "summary": "In response to physiological glutamate signals, cytosolic Ca(2+) activates respiration by stimulation of the NADH malate-aspartate shuttle through Ca(2+)-binding to the mitochondrial aspartate/glutamate carrier (Aralar/AGC1/Slc25a12), and by stimulation of adenine nucleotide uptake through Ca(2+) binding to the mitochondrial ATP-Mg/Pi carrier (SCaMC-3/Slc25a23).\nAGC1 is an important component of the malate/aspartate shuttle, a crucial system supporting oxidative phosphorylation and adenosine triphosphate production.\nAGC1 is an important component of the malate/aspartate shuttle, a crucial system supporting oxidative phosphorylation and adenosine triphosphate (ATP) production.\nAralar/slc25a12/AGC1 is the neuronal isoform of the aspartate-glutamate mitochondrial carrier, a component of the malate-aspartate shuttle (MAS) which plays an important role in redox balance, which is essential to maintain glycolytic pyruvate supply to neuronal mitochondria.\nThe concomitant down-regulation of all participating proteins (SLC25A11, SLC25A12, GOT2 and MDH2) of malate-aspartate shuttle might be responsible for the metabolic in-coordination between the cytosol and mitochondria resulting in the failure of energy metabolism.\nBioinformatics data mining and immunochemical validation of pivotal perturbed proteins revealed a global failure of the cellular energy metabolism in the infarcted tissues as seen by the parallel down-regulation of proteins related to glycolysis, pyruvate dehydrogenase complex, TCA cycle and oxidative phosphorylation.\nOxidative phosphorylation is required in order to respond to the metabolic challenge caused by glutamate.\nWe found that the ATP synthase inhibitor oligomycin caused a smaller inhibition of mitochondrial movement in Aralar-KO than control neurons, whereas the glycolysis inhibitor iodoacetate had similar effects in neurons from both genotypes.", "dois": ["10.1186/s12957-024-03581-5", "10.1523/JNEUROSCI.1463-21.2022", "10.1016/j.neuint.2019.104541", "10.1016/j.bbabio.2016.04.003", "PMID:15983191", "10.1016/j.ymgmr.2023.100967", "10.1016/j.jprot.2013.08.017", "10.1007/s12035-011-8192-2", "10.1016/j.biopsych.2009.08.042"]}
{"pair_type": "slc_pathway", "key1": "SLC1A2", "key2": "proliferation", "summary": "When we specifically silenced CD44-SLC1A2, cellular proliferation, invasion, and anchorage-independent growth were significantly reduced.\nConversely, CD44-SLC1A2 overexpression in gastric cells stimulated these pro-oncogenic traits.\nCD44-SLC1A2 may represent a class of gene fusions in cancers that establish a pro-oncogenic metabolic milieu favoring tumor growth and survival.\nTo infer functional relationships between SLCs and metabolites, we developed a strategy to identify SLCs able to sustain cell viability and proliferation under growth-limiting concentrations of essential nutrients.\nOne-by-one depletion of 13 amino acids required for cell proliferation enabled gain-of-function genetic screens using a SLC-focused CRISPR/Cas9-based transcriptional activation approach to uncover transporters relieving cells from growth-limiting metabolic bottlenecks.\nTheir induction by ovarian steroids indicates a complex upregulation of multiple components in the glutamate cycle and antioxidation, in addition to spine proliferation.\nDendritic spines are the elementary structural units of neuronal plasticity and their proliferation and stabilization involve components of glutamate neurotransmission.\nWe conclude that fusion of the SLC1A2 gene coding region to CD44 regulatory elements likely causes SLC1A2 transcriptional dysregulation, because tumors expressing high SLC1A2 levels also tended to be CD44-SLC1A2-positive.\nAnalysis of a breakpoint-positive SNU16 cell line revealed expression of a CD44-SLC1A2 fusion transcript caused by a paracentric chromosomal inversion, which was predicted to produce a truncated but functional SLC1A2 protein.\nCD44-SLC1A2 silencing caused significant reductions in intracellular glutamate concentrations and sensitized SNU16 cells to cisplatin, a commonly used chemotherapeutic agent in gastric cancer.\nMoreover, we identified metabolic compensation mediated by the glutamate/aspartate transporters SLC1A2 and SLC1A3 under glutamine-limiting conditions.", "dois": ["10.26508/lsa.202201404", "10.3760/cma.j.issn.0376-2491.2019.29.013", "10.1016/j.mcn.2011.11.005", "10.1126/scitranslmed.3001423"]}
{"pair_type": "slc_pathway", "key1": "SLC6A14", "key2": "oxidative stress", "summary": "Metabolic syndrome (MetS) is characterized by chronic inflammation, oxidative stress, and mitochondrial dysfunction.\nThirty-six male Slc6a14 mice were divided into four groups: low-fat diet (LFD), high-fat diet (HFD), HFD + 200 mg PSE/kg BW (PSE, p.o.), and HFD + 100 mg LUT/kg BW (LUT, p.o.) for 4 months.\nOutcome measures included glucose homeostasis, intestinal permeability, gut microbiome composition, and mRNA gene expression of mitochondrial homeostasis and inflammation/oxidative stress in the kidneys, colon, and ileum.\nRelative to the LFD group, the HFD group (1) upregulated mitochondrial fusion (MFN1, MFN2, OPA1), mitophagy (TLR4, PINK1, LC3B), and inflammation (NFκB, TNFα, IL6), and (2) downregulated mitochondrial fission (FIS1, DRP1), biosynthesis (PGC1α, NRF1, NRF2, TFAM), electron transport chain (complex I), and antioxidant enzyme (SOD1) in the kidneys, colon, and ileum.\nHFD resulted in glucose dysregulation with hyperglycemia and insulin resistance.\nPSE and LUT improved insulin tolerance and beta-cell function.\nPSE and LUT reversed such HFD-induced changes in the aforementioned gene expression levels.\nMetS is associated with increased intestinal permeability and dysbiosis.\nPSE and LUT mitigated HFD-increased serum lipopolysaccharide-binding protein concentration.\nPerturbations in the gut microbiome were associated with HFD, and PSE or LUT reversed some of these changes.", "dois": ["10.3390/nu17142290"]}
{"pair_type": "slc_pathway", "key1": "SLC1A3", "key2": "chemotherapy", "summary": "Inhibiting SLC1A3 significantly enhanced the efficacy of chemotherapy plus anti-PD-1, underscoring its potential as a therapeutic target.\nImportantly, the non-selective glutamate transporter inhibitor DL-TBOA reduces chemotherapy-induced p53 induction and augments CRC cell death induced by SN38, while attenuating that induced by oxaliplatin.\nDL-TBOA did not significantly alter cellular levels of p21, cleaved PARP-1, or phospho-Retinoblastoma protein, yet altered SLC1A1 subcellular localization, and reduced chemotherapy-induced p53 induction.\nWe sought to investigate the mechanisms by which chemotherapy augments the responses to immune checkpoint blockade and elucidate the factors contributing to persistent resistance in non-responding patients.\nIn non-responders, we identified a subset of tumour cells with high SLC1A3 expression, which localised at the tumour boundary and interacted with COL1A1 myofibroblastic cancer-associated fibroblasts, inducing an extracellular matrix-enriched TME that hindered the infiltration of CD8 T cells.\nDL-TBOA co-treatment concentration-dependently augmented loss of cell viability induced by SN38, while strongly counteracting that induced by oxaliplatin, in both HCT116 and LoVo cells.\nThe changes in SLC1A1 expression were accompanied by parallel changes in DL-Threo-β-Benzyloxyaspartic acid (TBOA)-sensitive, UCPH101-insensitive [(3)H]-D-Aspartate uptake, consistent with increased activity of SLC1A1 (or other family members), yet not of SLC1A3.\nWe demonstrated that combination therapy exerted superior antitumour efficacy by mitigating immune checkpoint engagements (TIGIT-NECTIN2 and NECTIN1-CD96) between epithelial-stress tumour cells and CD8 T cells, thereby preventing T cells from exhaustion and boosting vitality.\nIn SN38-resistant HCT116 and LoVo cells, SLC1A", "dois": ["10.1136/gutjnl-2025-335642", "10.1186/s12885-015-1405-8", "10.1002/iub.1372"]}
{"pair_type": "slc_pathway", "key1": "SLC1A1", "key2": "ferroptosis", "summary": "In addition, HIF-1α also enhances transcription of SLC1A1, an important glutamate transporter, and promotes cystine uptake to promote ferroptosis resistance.\nIn support of the role of hypoxia in ferroptosis resistance, silencing HIF-1α sensitizes mouse solid tumors to ferroptosis inducers.\nIn combination with HIF-2α, which promotes tumor ferroptosis under hypoxia, HIF-1α is the main driver of hypoxia-induced ferroptosis resistance.\nMechanistically, HIF-1α-induced lactate contributes to ferroptosis resistance in a pH-dependent manner that is parallel to the classical SLC7A11 and FSP1 systems.\nHere, we report that the hypoxic tumor microenvironment potently promotes ferroptosis resistance in solid tumors in a hypoxia-inducible factor 1α (HIF-1α)-dependent manner.\nIn conclusion, our results reveal a mechanism by which hypoxia drives ferroptosis resistance and identify the combination of hypoxia alleviation and ferroptosis induction as a promising therapeutic strategy for solid tumors.\nSolid tumors have developed robust ferroptosis resistance.", "dois": ["10.1016/j.celrep.2023.112945", "10.21037/jtd-2025-854"]}
{"pair_type": "slc_pathway", "key1": "SLC25A11", "key2": "ferroptosis", "summary": "Specifically, knockdown of SLC25A11 in FUNDC2-knockout (KO) cells reduced mitoGSH and augmented erasin-induced ferroptosis.\nThe regulatory effect of SLC25A11, a mitochondrial glutathione transporter, on mitoGSH and NET-induced ferroptosis of SMCs was investigated using in vitro and in vivo experiments.\nDuring AAA formation, NETs regulate the stability of the mitochondrial carrier protein SLC25A11, leading to the depletion of mitoGSH and subsequent activation of NET-induced ferroptosis of SMCs.\nFUNDC2 also affected the stability of both SLC25A11 and glutathione peroxidase 4 (GPX4), key regulators for ferroptosis.\nInhibition of DIC and OGC aggravated ferroptosis and increased mitochondrial ROS, membrane depolarization, and GSH depletion.\nSpecifically, NETs promoted AAA formation by inducing ferroptosis of SMCs.\nThis depletion induced the ferroptosis of SMCs and promoted AAA formation.\nFurthermore, NETs decreased the stability and dimerization of SLC25A11, leading to the depletion of mitoGSH.\nMechanistic studies reveal that FUNDC2 interacts with SLC25A11, the mitochondrial glutathione transporter, to regulate mitoGSH levels.\nMitochondria regulate the progression of ferroptosis, which is characterized by the depletion of mitochondrial glutathione (mitoGSH) levels.\nOur results demonstrate that FUNDC2 modulates ferroptotic stress via regulating mitoGSH and further support a therapeutic strategy of cardioprotection by preventing mitoGSH depletion and ferroptosis.\nPreventing mitoGSH depletion and ferroptosis in SMCs is a potential strategy for treating AAA.\nHere, we elucidated the role of DIC and OGC as well as mitochondrial bioenergetics in ferroptosis in H9c2 cardioblasts.\nSubsequently, SLC25A11 was identified as a potential biomarker for evaluating the clinical prognosis of", "dois": ["10.1016/j.freeradbiomed.2024.05.036", "10.1073/pnas.2117396119", "10.1016/j.redox.2021.102021"]}
{"pair_type": "slc_pathway", "key1": "SLC1A1", "key2": "proliferation", "summary": "Both in vitro and in vivo, ectopic expression of SLC1A1 increased cellular glutamine uptake, enhanced glutathione metabolic flux, and induced glutamine addiction, leading to acceleration of cell proliferation and tumor growth.\nCircRNA ZFR overexpression promoted HCC cell proliferation, migration and invasion while its knockdown inhibited HCC progression.\nOur results demonstrate for the first time that EAAT3 facilitates anionic amino acid transport and activates the mTOR pathway, promoting Cys transport and IPEC-J2 cell proliferation.\nSLC1A1 functioned as an extracellular glutamine transporter, promoted tumor growth through reprogramming glutamine metabolism of NKTCL, while rendered tumor cells sensitive to asparaginase treatment.\nMTT and cell counting assays suggested that IPEC-J2 cell proliferation increased (P<0.05) with EAAT3 overexpression.\nCDX2 overexpression in IPEC-1 cells increased cell proliferation, the percentage of cells in S/G2 phase, and the abundance of transcripts of the cell cycle-related genes Cyclin A2\nIn addition, extended spermine administration also markedly promoted cell proliferation, depressed apoptosis and modulated amino acid transport\nRegardless of supplementation time, spermine intake significantly enhanced the expressions of amino acid transporter-related genes (SLC1A1, SLC1A5, SLC7A1, SLC7A7, and SLC15A1) in both thymus and spleen, as well as SLC7A9 in the spleen of piglets\nCollectively, circRNA ZFR knockdown retarded HCC progression by sponging miR-96a-5p and modulating SLC1A1 expression, suggesting that the circZFR/miR-96a-5p/SLC1A1 axis may serve as potential therapeutic targets for HCC.\nAnionic amino acid and cystine (Cys) transport were increased (P<0.05) by EAAT3 overexpression and decreased (P<0.05) by EAAT3 knockdown rather than other amino acids.", "dois": ["10.1038/s41598-025-07974-8", "10.3389/fgene.2022.1092678", "10.1016/j.ebiom.2021.103614", "10.1016/j.jgr.2019.02.004", "10.5713/ajas.17.0799", "PMID:27807832", "10.18632/oncotarget.9583", "10.18632/oncotarget.8894", "PMID:25326682", "10.1016/j.jsbmb.2014.09.014", "10.1016/j.gene.2013.09.049", "PMID:22738901"]}
{"pair_type": "slc_pathway", "key1": "SLC11A1", "key2": "apoptosis", "summary": "Furthermore, higher concentrations of IL-33 were associated with a decrease in myocyte enhancer factor 2C (MEF2C) expression, a transcription factor that regulates synaptic function, and an increase in apoptosis, NOD2, and SLC11A1 in clade B infection.\nMoreover, the impact of SLC11A1 on apoptosis and intracellular ROS level confirmed the potential association between SLC11A1 and COAD cell apoptosis.\nSLC11A1 induced CCL2 and PD-L1 expression, thereby activating the JAK/STAT3 pathway.\nIn vitro experiments confirmed that modulation of a key LDCD regulator, SLC11A1, affected the proliferation and invasiveness of COAD cells.\nSLC11A1 deficiency constrained KIRC cell malignant phenotypes and immune response via regulating CCL2 and PD-L1-mediated JAK/STAT3 pathway, providing a promising therapeutic target for KIRC treatment.\nEffects of KIRC cells on macrophage polarization and the proliferation and apoptosis of CD8 T cells were analyzed using flow cytometry assays.\nThe GSVA suggested that DNA repair, oxidative phosphorylation, peroxisome, IL-6-JAK-STAT3 signaling, and apoptosis were crucial in the development of IDD.\nThis led to neuroinflammation which dysregulates synaptic function and apoptosis.\nFine mapping supports SIVA1 as a candidate gene controlling SAL1-mediated resistance and indicates that the proposed cell-death mechanism associated with extracellular trap production, ETosis, likely functions through the CD27/Siva-1-mediated apoptotic pathway.\nThe causative agent, , produces mycolactone, a macrolide toxin, which causes apoptosis of mammalian cells.\nbovis (P<0.01), produced more nitric oxide (P<0.05) and were slightly more prone to undergo apoptosis than susceptible cells.\nbovis field strain induced more apoptosis than BCG, although the difference was not significant.", "dois": ["10.1186/s12872-024-04343-7", "10.1016/j.taap.2024.116975", "10.1021/acschemneuro.5b00156", "10.1371/journal.pone.0063464", "10.1007/s00251-011-0523-y", "PMID:11903051", "10.1038/s41598-025-02123-7", "10.1007/s11250-024-04236-z", "10.1186/s13578-024-01276-8", "10.7150/jca.95515", "10.3389/fgene.2022.864100", "10.1186/s13287-020-01846-w", "10.3389/fmicb.2017.01903", "PMID:24040438", "PMID:14510669", "10.1038/s41598-025-18267-5"]}
{"pair_type": "slc_pathway", "key1": "SLC1A1", "key2": "chemotherapy", "summary": "DL-TBOA did not significantly alter cellular levels of p21, cleaved PARP-1, or phospho-Retinoblastoma protein, yet altered SLC1A1 subcellular localization, and reduced chemotherapy-induced p53 induction.\nImportantly, the non-selective glutamate transporter inhibitor DL-TBOA reduces chemotherapy-induced p53 induction and augments CRC cell death induced by SN38, while attenuating that induced by oxaliplatin.\nIn SN38-resistant HCT116 and LoVo cells, SLC1A1 expression was down-regulated ~60 % and up-regulated ~4-fold, respectively, at both mRNA and protein level, whereas SLC1A3 protein was undetectable.\nSLC1A1 expression and glutamate transporter activity are altered in SN38-resistant CRC cells.\nDL-TBOA co-treatment concentration-dependently augmented loss of cell viability induced by SN38, while strongly counteracting that induced by oxaliplatin, in both HCT116 and LoVo cells.\nThe changes in SLC1A1 expression were accompanied by parallel changes in DL-Threo-β-Benzyloxyaspartic acid (TBOA)-sensitive, UCPH101-insensitive [(3)H]-D-Aspartate uptake, consistent with increased activity of SLC1A1 (or other family members), yet not of SLC1A3.", "dois": ["10.1186/s12885-015-1405-8"]}
{"pair_type": "slc_pathway", "key1": "SLC1A4", "key2": "glycolysis", "summary": "GSEA revealed that NOS2 failed to affect the enrichments of glycolysis, fatty acid metabolism, and cholesterol biosynthesis in HB.", "dois": ["10.3389/fonc.2023.1228199"]}
{"pair_type": "slc_pathway", "key1": "SLC1A2", "key2": "chemotherapy", "summary": "The possible downregulated mechanisms of glutamate uptake would facilitate persistence of glutamate in the extracellular environment, rather than intracellular uptake.\nCompounds like riluzole used in the treatment of amyotrophic lateral sclerosis and the antibiotic ceftriaxone have the potential to facilitate glutamate uptake.\nThe present study provides preliminary evidence of the downregulation of membrane expression of excitatory amino acid transporters solute carrier family 1 member 3 (SLC1A3) and its palmitoylated form in gliosomes, as well as SLC1A2 in the glio-synaptosomes.\nThese medications may be examined as adjunct chemotherapy in the massively aggressive tumor glioblastoma multiforme.\nIt has been reported that glutamate acts as an extracellular signaling molecule for facilitating local spread of advanced grades of glioblastoma.", "dois": ["10.1002/iub.1372"]}
{"pair_type": "slc_pathway", "key1": "SLC1A3", "key2": "migration", "summary": "In vivo and in vitro experiments showed that silencing FN1 inhibits the activation of the YAP1/Hippo pathway by enhancing YAP1 phosphorylation, down-regulates SLC1A3-mediated aspartate uptake and utilization by tumor cells, inhibits BC cell proliferation, invasion and migration, and promotes apoptosis.\nWe also found a reduction in neuronal arborization, spine size, growth rate, and migration, but increased astrocyte size and a reduced growth rate in autism.\nexperiments demonstrated that knockdown of restrained the proliferation activity of ovarian cancer cells, enhanced cell apoptosis, and inhibited cell migration.\nFurthermore, miR-3099 overexpression between E15.5 and E18.5 mouse embryonic brains led to disorganised neuronal migration potentially due to significantly decreased Gfap+ cells.\nIn addition, inhibition of FN1 combined with the YAP1 inhibitor or SLC1A3 inhibitor can effectively inhibit tumor growth, of which inhibition of FN1 combined with the YAP1 inhibitor is more effective.\nMCF7 and MDA-MB-231 cells were used to explore the effects of FN1-regulated aspartic acid metabolism on cell survival, invasion, migration and tumor growth.\nAfter the knockdown of , proliferation was evaluated with Cell Counting Kit 8 (CCK8) assay, apoptosis was measured by flow cytometry, and migration was evaluated via wound-healing assay.\nThe purpose of this study was to investigate the role of the gene in the proliferation, apoptosis, migration, and outcomes of ovarian cancer.\nactivity impedes apoptosis while enhancing the proliferation and migration of ovarian cancer cells, suggesting its potential as a therapeutic target for drug development.\nHigh expression of was associated with poor prognosis in ovarian cancer patients, and the expression of in ovarian cancer cells was higher than that in ovarian epithelial cells.\nStudies have found that solute carrier family 1 member 3 () is highly expressed in various cancers and is associated with the poor prognosis of these cancers.", "dois": ["10.31083/FBL27047", "10.21037/tcr-24-1909", "10.3390/cells13131095", "10.1007/s10549-023-07032-9", "10.1016/j.gene.2019.02.014", "PMID:25326682", "PMID:15055445"]}
{"pair_type": "slc_pathway", "key1": "SLC1A6", "key2": "migration", "summary": "MiR-374c-5p expression was downregulated, and transfection of miR-374c-5p mimics significantly decreased BC cell proliferation, migration and invasion induced by 10 μM Cd.\nTogether, these findings demonstrated that m6A modification of pri-miRNA-374c blocks miRNA-374c-5p maturation and then activates GRM3 expression, which drives BC cell metastasis after Cd exposure.\nOf note, we verified that suppression of N6-methyladenosine (m6A) modification led to miR-374c-5p downregulation by decreasing its RNA transcript stability.\nThe glutamatergic synapse pathway was enriched by DEGs such as GRM4, SLC1A6, GRIN2C, GRM2, GRM5, GRIN3A, and GRIN2B.\nhowever, luciferase reporter assays indicated that miR-374c-5p only repressed GRM3 by directly binding to its 3'-untranslated region (UTR).\nBesides glutamatergic synapse, altered expression of other genes such as GABRB1 (synapse formation), SLIT2 (axonal growth), and PROKR2 (neuron migration) could be linked to epileptogenesis in ECTs.\nImportantly, we used the Cytoscape software plugin cytoHubba to analyse the intersected genes between our RNA-Seq results and the mirDIP database, and six hub genes (CNR1, CXCR4, GRM3, RTN1, SLC1A6 and ZEB1) were identified as potential direct targets of miR-374c-5p in our model;\nEmerging evidence has indicated that the progression of Cd-exposed BC is related to the dysregulation of microRNAs (miRNAs).", "dois": ["10.1007/s10142-022-00869-1", "10.1016/j.ecoenv.2021.113085"]}
{"pair_type": "slc_pathway", "key1": "SLC1A2", "key2": "ferroptosis", "summary": "In addition, KBA-Z-GS synergistically regulated inflammatory reactions in microglia and cellular metabolism and ferroptosis in astrocytes.\nPseudo-time trajectory indicated that Slc1a2 and Timp1 were core fate transition genes regulated by KBA-Z-GS.", "dois": ["10.1016/j.phrs.2023.106803"]}
{"pair_type": "slc_pathway", "key1": "SLC1A6", "key2": "ferroptosis", "summary": "Two molecular subtypes (C1 and C2) of MIBC were identified according to the expression of ferroptosis-related genes.\nNonnegative matrix factorization (NMF) analysis was performed to identify two molecular subtypes based on 41 ferroptosis-related prognostic genes.\nA novel MIBC classification approach based on ferroptosis-related gene expression profiles was established to provide guidance for patients who are more sensitive to immunotherapy.\nThe purpose of this study was to identify the ferroptosis-related molecular subtypes in muscle invasive bladder cancer (MIBC) associated with the tumor microenvironment (TME) and immunotherapy.\nThe C2 subtype manifested poor prognosis, high enrichment in the cytokine-cytokine receptor interaction pathway, high abundance of immune cell infiltration, immune/stromal scores and low tumor purity.\nThe risk prediction model based on five pivotal genes (, , , and ) effectively predicted the prognosis of MIBC patients.", "dois": ["10.21037/tcr-22-1653"]}
{"pair_type": "slc_pathway", "key1": "SLC2A1", "key2": "glycolysis", "summary": "The expression of glycolysis-related gene SLC2A1 (also known as GLUT1) was found to be upregulated, while notably WNT5A was downregulated.\nThen, miR-30d inhibited aerobic glycolysis through regulating SLC2A1 and HK1 expression by directly targeting the transcription factor RUNX1, which bound to the promoters of the SLC2A1 and HK1 genes.\nTherefore, the present study demonstrated that exosomes derived from patients with sepsis may inhibit glycolysis and promote the apoptosis of human myocardial cells through exosomal hsa‑miR‑1262 via its target SLC2A1.\nThe silencing of SLC2A1 promoted apoptosis and suppressed glycolysis in AC16 cells, whereas SLC2A1 overexpression resulted in the opposite effects.\nSLC2A1-AS1 promoted cell growth in vitro and in vivo, migration and invasion, and suppressed apoptosis, leading to EMT progression and increased glycolysis in ESCC cells.\nMiR-378a-3p inhibited cell proliferation and invasion as well as induced apoptosis, resulting in reduced glycolysis, which was partly reversed by SLC2A1-AS1 or Glut1 overexpression in ESCC cells.\nMechanistic investigations revealed that elevated SM enhances SLC2A1-dependent glucose uptake and glycolysis, leading to increased lactate production and subsequent CASP3 lactylation on lysine residue 14, which inhibits CASP3 activation and apoptosis.\nMechanically, SLC2A1 promoted the formation of CD90 and EpCAM CSCs via activating glycolysis.\nAn upregulation of HK1, PFKP and SLC2A1 was observed, while components of the respiratory chain were downregulated, confirming a metabolic shift towards aerobic glycolysis.\nIn conclusion, Dex has been demonstrated to attenuate renal IRI by inhibiting SLC2A1-mediated glycolysis, which was regulated by SLC2A1 expression, internalization,", "dois": ["10.1016/j.biocel.2025.106831", "10.1038/s41598-025-94843-z", "10.1002/jcp.31523", "10.1016/j.bbadis.2025.168050", "10.1016/j.bcp.2025.117166", "10.1186/s12967-024-06014-9", "10.1186/s12964-024-01951-w", "10.1002/biot.202400163", "10.1136/gutjnl-2024-332412", "10.1152/ajpgi.00032.2024", "10.1007/s00125-024-06185-6", "10.1016/j.asjsur.2024.05.092", "10.7150/ijbs.86658", "10.1016/j.micinf.2024.105305", "10.1016/j.jcmgh.2023.10.001", "10.1186/s12967-023-04454-3", "10.1186/s40478-023-01604-y", "10.3389/fimmu.2023.1188745", "10.1007/s00018-023-04741-8", "10.1186/s12885-023-10622-x", "10.1038/s41419-022-05213-w", "10.1002/1878-0261.13263", "10.1155/2022/9273559", "10.1186/s13046-022-02285-6", "10.3892/mmr.2022.12635", "10.1002/ctm2.674", "10.18632/aging.203331", "10.1186/s13046-021-02081-8", "10.3389/fimmu.2021.724741", "10.1038/s41418-021-00804-0", "10.1186/s13046-021-01927-5", "10.1038/s41598-021-81349-7", "10.1111/bph.15358", "10.1186/s12964-020-00678-8", "10.1161/CIRCRESAHA.120.316653", "10.1210/endocr/bqaa098", "10.1007/s00432-020-03278-8", "10.1161/CIRCRESAHA.119.316463", "10.1186/s12943-020-01190-w", "10.1186/s13045-020-00857-7", "10.1002/1878-0261.12666", "10.1016/j.yexcr.2019.111713", "10.1186/s12964-019-0447-y", "10.1016/j.foodres.2019.108563", "10.1186/s13046-019-1390-x", "10.1002/jcp.28974", "10.2217/epi-2019-0072", "10.1007/s13238-019-0637-9", "10.1053/j.gastro.2019.05.004", "10.1096/fj.201900201RR", "10.1111/exd.13850", "10.1038/s41586-018-0735-5", "10.1038/s41467-018-07132-x", "10.1016/j.jid.2018.10.019", "10.1016/j.exer.2018.03.021", "10.1071/RD16441", "10.1016/j.molcel.2017.05.020", "10.1002/cam4.1008", "10.3892/or.2016.4646", "10.1371/journal.pone.0122373", "10.1158/1078-0432.CCR-14-1209", "10.1038/ni.2985", "10.1210/jc.2014-1026", "10.1038/ncomms4608", "10.1038/labinvest.2014.48", "10.1186/1476-4598-12-78", "10.1093/toxsci/kfs325", "10.1074/jbc.M111.240812", "10.1093/biolre/ioaf238", "10.1186/s12943-025-02392-w", "10.1155/mi/8828435", "10.5114/aoms/191153", "10.1002/advs.202500369", "10.1016/j.neo.2025.101146", "10.1038/s42003-025-07622-x", "10.1186/s40635-025-00715-1", "10.1186/s12885-024-13418-9", "10.1186/s12967-024-05854-9", "10.3390/biomedicines12102250", "10.1016/j.heliyon.2024.e35603", "10.1016/j.tranon.2024.102082", "10.1038/s41420-024-02106-z", "10.1186/s12935-024-03432-z", "10.1016/j.heliyon.2024.e29655", "10.1038/s41467-024-46971-9", "10.1016/j.compbiomed.2024.108183", "10.1016/j.lungcan.2023.107449", "10.1021/acs.biomac.3c01169", "10.1002/biof.2031", "10.1101/2023.07.23.550235", "10.3389/fgene.2023.1217952", "10.1186/s40170-023-00310-6", "10.3390/cimb45060309", "10.3389/fcvm.2023.1136252", "10.1186/s13046-023-02632-1", "10.3390/cancers15030586", "10.3390/cancers14215344", "10.3389/fvets.2022.984703", "10.1111/jnc.15684", "10.3390/cancers14143355", "10.3389/fgene.2022.828543", "10.3389/fcell.2022.853596", "10.1016/j.celrep.2022.110489", "10.3390/jcdd8110134", "10.3892/or.2021.8218", "10.1186/s13046-021-02123-1", "10.7150/jca.57926", "10.1530/EO-21-0014", "10.1155/2021/6645220", "10.1016/j.bbrc.2021.04.059", "10.1016/j.celrep.2021.108767", "10.7717/peerj.10604", "10.2147/CMAR.S258497", "10.3390/biomedicines8090310", "10.3390/biomedicines8020020", "10.1093/intimm/dxz059", "10.1038/s41598-019-44661-x", "10.1093/jnen/nly124", "10.4049/jimmunol.1800002", "10.1071/RD18178", "10.1007/s12094-018-1836-1", "10.1080/15548627.2017.1371397", "10.1016/j.neo.2017.02.009", "PMID:27884183", "10.7717/peerj.2379", "10.18632/oncotarget.12004", "10.1021/acschembio.6b00304", "10.18632/oncotarget.4977", "10.1007/s13277-014-2838-4", "10.1530/ERC-14-0107", "10.1152/ajpendo.00484.2013", "10.1074/jbc.M113.522037", "10.1093/neuonc/not243", "10.1007/s12253-012-9500-5"]}
{"pair_type": "slc_pathway", "key1": "SLC1A7", "key2": "apoptosis", "summary": "Functional assays demonstrated that CDO1 expression is associated with increased apoptosis and reduced cell viability, suggesting a protective role against tumor progression.\nCorrelation analysis in clinical BC samples revealed significant associations between CDO1 and other key genes, including SLC1A7 and KITLG, underscoring its relevance in tumor biology.", "dois": ["10.1245/s10434-025-17944-z"]}
{"pair_type": "slc_pathway", "key1": "SLC1A4", "key2": "oxidative phosphorylation", "summary": "Intriguingly, the evolution of modern birds (Neoaves) has entailed the purging of genes including SLC3A2, SLC7A5, -7, -8, -10, and SLC1A4, -5, largely removing BCAA exchangers and their interacting Na/Gln symporters in pursuit of improved energetics.\nThe expression profile revealed enriched gene sets associated with treatment resistance, including oxidative phosphorylation and ATP-binding cassette transporters.\nMaintenance of the proteasome requires oxidative phosphorylation (ATP) and mitigation of oxidative damage, in an increasingly dysfunctional relationship with aging.\nEndurance in mammalian muscle depends in part on oxidation of BCAA;\nAdditional gene purging included mitochondrial BCAA aminotransferase (BCAT2), pointing to reduced oxidation of BCAA and increased hepatic conversion to triglycerides and glucose.\nDuplications of the bidirectional α-ketoacid transporters SLC16A3, SLC16A7, the cystine transporters SLC7A9, SLC7A11, and N-glycan branching enzymes MGAT4B, MGAT4C in Neoaves suggests a shift to the transport of deaminated essential amino acid, and stronger mitigation of oxidative stress supported by the galectin lattice.\nSLC3A2 plays a role on both sides of this dichotomy as an adaptor to SLC7A5, a transporter of branched-chain amino acids (BCAA: Leu, Ile, Val), and to SLC7A11, a cystine importer supplying cysteine to the synthesis of the antioxidant glutathione.", "dois": ["10.1016/j.jbc.2023.105409", "10.18632/oncotarget.13239"]}
{"pair_type": "slc_pathway", "key1": "SLC38A5", "key2": "apoptosis", "summary": "Both conditions also lower reproductive hormone levels, increase oxidative stress, and promote germ cell apoptosis.\nSeven differentially expressed genes (Slc38a5, Adgrg2, Gpc1, Arx, Egr2, Ebp, Il2rb) were identified in CoQ10-treated rats with either condition.\nChanges in alternative splicing of the Slc38a5 and Uspl1 genes were detectable in prephenotypic-stage embryos and neonates but became more pronounced with the severity of the phenotype.", "dois": ["10.1002/jnr.22189", "PMID:23358152", "10.1111/andr.70130"]}
{"pair_type": "slc_pathway", "key1": "SLC1A3", "key2": "oxidative stress", "summary": "Simultaneously, a significant decrease in glutamate uptake was observed in LRRK2-I1371V astrocytes, with lower gene expression of glutamate transporters SLC1A2 and SLC1A3.\nhowever, the astrocytic capability to mitigate oxidative stress in terms of glutathione content was significantly reduced in the mutant astrocytes, along with a reduction in the gene expression of the enzymes involved in glutathione machinery and nuclear factor erythroid 2-related factor 2 (Nrf2) expression.\nThe study elucidates the molecular mechanisms of BaP-induced COPD, specifically highlighting the role of oxidative stress and inflammation pathways in promoting immune cell infiltration.\nFunctional enrichment analysis highlighted pathways related to oxidative stress and inflammation.\nCorrelation analysis showed strong links between oxidative stress, inflammation pathway scores, and the infiltration of immune cells, including aDC, macrophages, T cells, Th1 cells, and Th2 cells.\nThese responses coupled with the upregulation of transporters for Lys, Arg, and His (SLC7A1) and glutamate/aspartate (SLC1A3) over time were suggestive of dynamic adaptations in cellular functions.\nOur data demonstrate for the first time that the mutation in the LRRK2-I1371V allele causes significant astrocytic dysfunction with respect to Nrf2-mediated antioxidant machinery, AT -generation, and glutamate metabolism, even with comparable astrocyte yields.\nEnzymes catalyzing the generation of γ glutamyl cysteine (precursor of glutathione) from glutamate and the metabolism of glutamate to enter the Krebs cycle (α-ketoglutaric acid) were impaired, with significantly lower ATP generation in LRRK2-I1371V astrocytes.\nExcessive inflammatory reactions and oxidative stress are well-recognized molecular findings in autism and these processes can affect or be affected by the epigenetic landscape.\nThen, immune and oxidative stress-related hub genes were screened by combined WGCNA, machine learning, and protein-protein interaction (PPI) networks and validated by external validation sets.", "dois": ["10.1186/s40360-025-00842-1", "10.3389/fimmu.2023.1084531", "10.3390/cells13131095", "10.3390/cells12121592", "10.3168/jds.2022-23187"]}
{"pair_type": "slc_pathway", "key1": "SLC1A4", "key2": "apoptosis", "summary": "More importantly, the knockdown of SLC1A4 or simple supplementation of serine suppressed CTX-induced apoptosis of GCs.\nFurthermore, the functional analysis revealed that silenced SLC1A4 inhibited cell proliferation, migration, cell cycle, and promoted cell apoptosis in HCC.\nIn addition, we observed that miR-27b-3p was highly expressed in hUSC-Exo and markedly suppressed CTX-induced GC apoptosis by specifically inhibiting the expression of SLC1A4, a serine transporter, in ovarian GCs, which, in turn, elevated the concentration of the intracellular serine by inhibiting the outflux of cellular serine.\nFinally, we demonstrated that CTX-induced apoptosis of ovarian GCs was essential for POF by reducing the intracellular serine concentration via elevating the expression of SLC1A4, whereas hUSCs protected against CTX-induced POF via miR-27b-3p/SLC1A4/serine axis-mediated activation of the PI3K/AKT/mTOR signaling pathway.\nhUSCs remarkably inhibited CTX-induced apoptosis and promoted the proliferation of GCs, respectively.\nThis metabolic disruption causes mitochondrial damage, impaired energy production, and increased apoptosis in GC cells.\nGSEA and REACTOME analyses identified altered signaling in cells exposed to amino acid deprivation, such as pathways related to stress responses, the cell cycle and apoptosis.\nPlacentitis was associated with the upregulation of matrix metalloproteinase (MMP1, MMP2, and MMP9) and apoptosis-related genes such as caspases (CASP3, CASP4, and CASP7) in CA.\nFunctional enrichment highlighted DEG involvement in cell death/apoptosis and the Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways like apoptosis, tumor necrosis factor (TNF), and NF-κB signaling.\nKey PCD types included apoptosis, immunogenic cell death, necrosis, necroptosis, and ferroptosis.", "dois": ["10.1186/s11658-025-00701-1", "10.1016/j.compbiomed.2023.107370", "10.21037/jtd-2024-2173", "10.1002/advs.202417225", "10.22074/cellj.2023.2004011.1319", "10.3389/fonc.2021.650355", "10.1093/biolre/ioaa209", "PMID:22906261"]}
{"pair_type": "slc_pathway", "key1": "SLC1A4", "key2": "oxidative stress", "summary": "SkII-induced disruption of serine metabolism resulted in an imbalance in GSSG/GSH, leading to increased accumulation of intracellular ROS and oxidative stress.\nFunctional enrichment analysis revealed that these DE-FRGs are significantly involved in oxidative stress, immune regulation, and vitiligo-associated signaling pathways.\nThese results may lend genetic support to the hypothesis that oxidative stress is associated with the pathogenesis of MSA.\nAlthough the etiology of MSA remains obscure, recent studies suggest that oxidative stress is associated with the pathogenesis of MSA.\nThe aim of this study was to evaluate genetic associations between the candidate genes involved in oxidative stress and MSA in a case-control study.\nDuplications of the bidirectional α-ketoacid transporters SLC16A3, SLC16A7, the cystine transporters SLC7A9, SLC7A11, and N-glycan branching enzymes MGAT4B, MGAT4C in Neoaves suggests a shift to the transport of deaminated essential amino acid, and stronger mitigation of oxidative stress supported by the galectin lattice.\nA consequence of sulfur amino acid restriction appears to be the upregulation of the cellular capacity to cope with oxidative and chemical stresses via the integrated stress response.\nAlthough GCLC, GCLM, SLC7A11, HMOX, and TXNRD1 were upregulated, most genes known to be upregulated via oxidative stress were not affected by cysteine deprivation.\nincreased expression of several enzymes that favor glutathione synthesis and maintenance of protein thiol groups (GCLC, GCLM, SLC7A11, and TXNRD1).\nincreased expression of genes for amino acid transporters (SLC7A11, SLC1A4, and SLC3A2), aminoacyl-tRNA synthetases (CARS), and, to a limited extent, amino acid metabolism (ASNS and CTH);", "dois": ["10.1002/mds.22046", "10.1152/physiolgenomics.00263.2007", "10.1002/advs.202417225", "10.1038/s41598-025-86061-4", "10.1016/j.jbc.2023.105409"]}
{"pair_type": "slc_pathway", "key1": "SLC1A5", "key2": "stemness", "summary": "Transcription factor YY1 binds to SLC1A5 promoter region to induce SLC1A5 expression, and the inhibition effect of YY1 knockdown on GBM cell growth, invasion, stemness, and glutamine metabolism can be reversed by SLC1A5 overexpression.\nSilibinin inhibits GBM cell proliferation, invasion, stemness, and glutamine metabolism, while promotes apoptosis.\nIn addition, Silibinin reduces GBM tumor growth by regulating YY1/SLC1A5 pathway.\nSilibinin plays an anti-tumor role in GBM process, which may be achieved via inhibiting YY1/SLC1A5 pathway.\nSLC1A5 overexpression abolishes the anti-tumor effect of Silibinin in GBM cells.\nIGF2BP3 presented a negative correlation with the ferroptosis molecule NFE2L2, and a positive correlation with the ferroptosis molecule SLC1A5 as well as the immune checkpoint HAVCR2.\nThe data showed that IGF2BP3 may enhance the proliferation, colony formation and invasion capacities of HCC cells, and IGF2BP3 is mainly positively correlated with the expression level of stemness marker SOX2.\nFurthermore, we also provide evidence for the increased abundance of pSTAT3 and the stemness marker ALDH1A1 upon EV-induced resistance.", "dois": ["10.7150/thno.100374", "10.7150/jca.92768", "10.3892/ol.2024.14320", "10.1515/tnsci-2022-0333"]}
{"pair_type": "slc_pathway", "key1": "SLC1A6", "key2": "proliferation", "summary": "MiR-374c-5p expression was downregulated, and transfection of miR-374c-5p mimics significantly decreased BC cell proliferation, migration and invasion induced by 10 μM Cd.\nTogether, these findings demonstrated that m6A modification of pri-miRNA-374c blocks miRNA-374c-5p maturation and then activates GRM3 expression, which drives BC cell metastasis after Cd exposure.\nImportantly, we used the Cytoscape software plugin cytoHubba to analyse the intersected genes between our RNA-Seq results and the mirDIP database, and six hub genes (CNR1, CXCR4, GRM3, RTN1, SLC1A6 and ZEB1) were identified as potential direct targets of miR-374c-5p in our model;", "dois": ["10.1016/j.ecoenv.2021.113085"]}
{"pair_type": "slc_pathway", "key1": "SLC1A7", "key2": "proliferation", "summary": "In contrast to GLS, the glutamate transporter SLC1A7 was significantly reduced in HA cells compared to HA cells and its expression was enhanced by 1,25D.\nSome upregulated genes, such as Slc38a5 and Slc1a7 encoding glutamine transporters, may be parts of the total body adaptation to alleviate negative nitrogen balance.\nHA populations exhibited elevated HA production, smaller size, increased proliferation and higher motility than HA populations.\nGene ontology analysis suggested effects of CMA on cellular processes, such as cell adhesion, proliferation, fuel metabolism, and biotransformation.", "dois": ["10.1016/j.jsbmb.2020.105688", "10.1007/s11010-008-9931-1"]}
{"pair_type": "slc_pathway", "key1": "SLC1A3", "key2": "oxidative phosphorylation", "summary": "Key pathways predicted to be modulated in astrocytes from EC-KO mice include oxidative phosphorylation and FOXO signaling, mitochondrial dysfunction and ephrin B signaling.\nGene set enrichment analysis revealed that 11 pathways were positively correlated to ITP, such as type I diabetes mellitus, intestinal immune network for IgA production, and oxidative phosphorylation.\nThe messenger RNA expression levels of the indicated genes, including HLA-DRB5, IGHV3-66, IFI27, FAM212A, PLD5, tumor necrosis factor (TNF)-α, interferon-γ, interleukin (IL)-1β, and IL-4, were significantly increased in patients with ITP compared with healthy humans, while MMP8, SLC1A3, CRISP3, THBS1, FMN1, and IL-10 were decreased.", "dois": ["10.1016/j.mcn.2025.104003", "10.1177/1087057116664029"]}
{"pair_type": "slc_pathway", "key1": "SLC1A1", "key2": "oxidative stress", "summary": "The results suggest that genes involved in glutamate (SLC1A1), glutathione neurotransmission (GSTZ1), and oxidative stress (CALCRL), in association with harsh punitive parenting, may contribute to social anxiety in adolescence.\nMoreover, the brains of Slc1a1+/- mice displayed elevated levels of oxidized glutathione, a trend for increased oxidative DNA damage, and significantly increased levels of cytokines.\nTaken together, our results suggest that partial loss of the Slc1a1 gene in mice causes haploinsufficiency associated with behavioral, histological and biochemical changes that reflect an altered redox state and may promote the expression of behavioral features and inflammatory states consistent with those observed in schizophrenia.\nIn addition to transporting glutamate, EAAC1 plays other roles in regulating GABA synthesis, reducing oxidative stress in neurons, and is important in supporting neuron viability.\nMoreover, because it can also transport cysteine, EAAT3/EAAC1 is believed to be important for the synthesis of intracellular glutathione and subsequent protection from oxidative stress.\nIn PCNs, EAAC1 knockdown significantly decreased GSH but not oxidized glutathione (GSSG) illustrating that while not the sole provider of Cys, EAAC1 plays an important role in neuron GSH homeostasis.\nThese studies strongly support the concept that in both E exposed intact fetal brain and cultured PCNs a mechanism underlying E impairment of GSH homeostasis is reduction of import of external Cys which is mediated by perturbations of EAAC1 expression/function.\nThese findings indicate that Glu plays an important role in mucosal barrier function by enhancing cell growth and maintaining membrane integrity in response to oxidative stress.\nIn a cell model of oxidative stress induced by 1 mmol/L diquat, 0.5 mmol/L Glu enhanced cell viability, TEER, and membrane integrity (as indicated by the reduced release of LDH) in IPEC-1 cells by increasing the abundance of the tight junction proteins occludin, claudin-3, zonula occludens (Z", "dois": ["10.1002/jcp.31244", "10.1158/0008-5472.CAN-20-0617", "10.3390/ijms18122596", "10.1371/journal.pone.0183854", "10.3945/jn.115.217661", "10.1007/s00018-013-1484-0", "PMID:16311588", "10.21037/jtd-2025-854", "10.1016/j.pneurobio.2021.102070", "10.1192/j.eurpsy.2020.62", "10.1523/JNEUROSCI.6577-10.2011", "10.1111/j.1750-3639.2008.00186.x"]}
{"pair_type": "slc_pathway", "key1": "SLC1A5", "key2": "migration", "summary": "Knockdown SLC1A5 in gastric cancer cells suppressed cell proliferation, caused G0/G1 arrest and inhibited cell invasion as well as migration partly by inactivated mTOR/p-70S6K1 signaling pathway.\nMoreover, ABHD11-AS1 enhanced the abilities of cell proliferation, migration, and invasion, inhibited apoptosis in vitro, promoted tumorigenesis in vivo via sponging miR-199a-5p and then induced SLC1A5 activation.\nKnockdown of SLC1A5 decreased proliferation, colony formation, and migration, but increased apoptosis and increased sensitivity to chemotherapy drugs.\nSLC1A5var knockdown reduced cancer cell proliferation, colony formation, and migration, whereas SLC1A5var overexpression increased cell proliferation and migration.\nOverexpression of β-catenin in SLC1A5-knockdown HCC cell lines could augment Vimentin and N-cadherin expression, suppress E-cadherin expression, and increase the migration and drug resistance.\nCirc_0062558 promoted TNBC progression by enhancing proliferation, survival, migration, invasion, and glutamine metabolism via miR-876-3p/SLC1A5 axis, which was helpful for understanding the carcinogenic roles of circ_0062558.\nFinally, the overexpression of SLC1A5 markedly promoted proliferation, migration, and invasion of pancreatic cancer cells.\nThe inhibitory effects of miR-622 enrichment on EC cell proliferation, migration, EMT and glutamine metabolism were recovered by SLC1A5 overexpression.\nUpon further investigation, we found that SLC1A5 is a suppressor of ferroptosis in glioma, and SLC1A5 knockdown inhibited the proliferation and migration of glioma cells.\nFurthermore, loss-of-function assays using small interfering RNAs or an SLC1A5 inhibitor (V9302) in human ccRCC cell lines (A498 and Caki1) showed that inhibition of SLC1A5 significantly suppressed tumor growth, invasion, and migration.", "dois": ["10.1016/j.prp.2025.156248", "10.1080/15548627.2025.2535765", "10.3724/abbs.2024226", "10.1111/jcmm.70245", "10.1016/j.biocel.2024.106688", "10.1186/s12967-024-05298-1", "10.1016/j.gene.2024.148498", "10.1016/j.advms.2024.02.007", "10.1093/carcin/bgae010", "10.3389/fimmu.2023.1187108", "10.18632/aging.204911", "10.1165/rcmb.2022-0339OC", "10.3390/cancers15041050", "10.1002/mc.23497", "10.1016/j.trim.2022.101764", "10.1097/CAD.0000000000001400", "10.1186/s12957-022-02777-x", "10.1183/13993003.00062-2022", "10.1111/1759-7714.14458", "PMID:35530270", "10.1016/j.bbrc.2022.04.068", "10.1080/15384101.2022.2071565", "10.3389/fcell.2022.800925", "10.1007/s00404-022-06481-9", "10.1002/jcla.24116", "10.1038/s41388-021-02023-w", "10.2147/OTT.S319300", "10.1007/s10528-021-10092-5", "10.1038/s41419-019-1850-4", "10.1074/jbc.RA118.006378", "10.18632/oncotarget.19479", "10.3390/ijms18081632", "10.1095/biolreprod.112.100487"]}
{"pair_type": "slc_pathway", "key1": "SLC1A5", "key2": "chemotherapy", "summary": "Knockdown of SLC1A5 decreased proliferation, colony formation, and migration, but increased apoptosis and increased sensitivity to chemotherapy drugs.\nThis is the first time to report that Que was a SLC1A5 inhibitor, which could be served as a template compound to potentially develop novel P-gp-mediated MDR reversal modulators in cancer chemotherapy.\nThe results showed that three FRGs, SLC1A5, CD44 and NQO1, have significant potential in targeted therapies for SCC chemotherapy resistance.\nOverexpression of β-catenin in SLC1A5-knockdown HCC cell lines could augment Vimentin and N-cadherin expression, suppress E-cadherin expression, and increase the migration and drug resistance.\nPreclinical studies of At-labeled transporter ligands, particularly LAT1-targeted conjugates, demonstrate potent tumor suppression and synergy with targeted therapy, chemotherapy, radiotherapy, immunotherapy, and ferroptosis inducers.\nMechanistically, GDH1 knockdown inhibited glutamine uptake by downregulating SLC1A5.\nWe demonstrate that trabectedin downregulates both the glutamine transporter SLC1A5 and glutamine synthetase, thereby interfering with glutamine metabolism.\nThese targets are experimentally validated where treating drug-resistant cancer cells with small-molecule inhibitors results in increased sensitivity of drug-resistant cells to doxorubicin or paclitaxel.\nThe metabolomics studies based on UPLC-MS/MS analysis revealed that Que could reverse the MDR by significantly blocking D-glutamine and D-glutamate metabolism, and the underlying mechanism is that Que down-regulated the expression of the glutamine transporter solute sarrier family 1, member 5 (SLC1A5) in SW620/Ad300 cells.\nFurthermore, silencing IGF2BP2 can enhance the sensitivity of pancreatic cancer to radiotherapy and chemotherapy.\nFurthermore, increasing evidence has shown that ferroptosis inhibition or induction can improve drug sensitivity or overcome chemotherapy drug resistance.\nCollectively, triggering ferroptosis in AML cells in a GSH depletion manner, GDH1 inhibition was", "dois": ["10.3390/ijms262110736", "10.1073/pnas.2425384122", "10.1186/s12935-025-03736-8", "10.1101/2024.06.24.600340", "10.1186/s12967-024-05298-1", "10.3892/ol.2024.14320", "10.1111/bjh.18884", "10.1155/2023/2664370", "10.3389/fonc.2023.1132559", "10.3389/fimmu.2022.997265", "10.1016/j.bcp.2022.115159", "10.1002/cam4.4812", "10.18632/aging.204057", "10.1016/j.apsb.2021.09.019", "10.1016/j.ejphar.2020.173185", "10.1007/s10549-018-5060-z", "10.1074/jbc.M115.700534", "10.1021/pr2012335"]}
{"pair_type": "slc_pathway", "key1": "SLC2A1", "key2": "chemotherapy", "summary": "Everolimus ± 5 Gy suppressed endothelin 1 and lactate dehydrogenase expression and increased VEGFA, p21, hypoxia-inducible factor-1α and SLC2A1 (facilitated glucose transporter 1).\nWe assessed the response to conventional chemotherapy drugs, including fluorouracil, a compound of fluoropyrimidine S-1, oxaliplatin, and all-trans-retinoic acid (ATRA), in gastric cancer cell lines with high SLC2A1 expression.\nExisting evidence suggests that regulation of ferroptosis can induce PAAD cell death, inhibit tumor growth, and may synergistically improve the sensitivity of other antitumor drugs.\nNotably, FOSL1 promotes tumor growth in TNBC in a glycolysis-dependent manner, as inhibiting glycolysis with 2-Deoxy-D-glucose markedly diminishes the oncogenic effects of FOSL1 in TNBC.\nClinically, everolimus has also been evaluated in patients with advanced non-small cell lung cancer (NSCLC) that were refractory to chemotherapy and epidermal growth factor receptor tyrosine kinase inhibitors.\nHigh SLC2A1 expression was associated with poor prognosis, cancer cell proliferation, decreased immune cells, including CD8 T cells and B cells, and a low prognostic nutrition index, representing body nutrition-related status.\nmTOR inhibition can restore sensitivity to DNA damaging agents such as cisplatin.\nMCT4 inhibition suppressed the in vitro malignant characteristics of pancreatic cancer cells and showed a synergistic effect with gemcitabine treatment.\nWe report that genetic or pharmacological inhibition of GLUT1 with BAY-876 impairs the growth of a subset of TNBC cells displaying high glycolytic and lower oxidative phosphorylation (OXPHOS) rates.\nIn the high-risk group, patients treated with chemotherapy had a better prognosis.\nMoreover, the signature may help to select stage I-IIA patients who might benefit from adjuvant chemotherapy.\nIn addition, we found that the high-risk group had a poor pr", "dois": ["10.1007/s12672-025-03763-x", "10.1186/s12967-024-06014-9", "10.3389/fimmu.2024.1497300", "10.1002/biot.202400163", "10.1038/s41420-024-02106-z", "10.1186/s12935-023-03097-0", "10.1007/s10495-023-01900-x", "10.7717/peerj.15621", "10.1016/j.taap.2023.116630", "10.1016/j.csbj.2023.03.037", "10.3389/fgene.2022.1058062", "10.1038/s41598-022-17622-0", "10.2147/PGPM.S375284", "10.21037/atm-22-1430", "10.18632/aging.204169", "10.1002/cam4.4812", "10.1007/s13402-021-00643-8", "10.1093/jnen/nlab044", "10.1007/s10637-021-01114-5", "10.1371/journal.pone.0245075", "10.1038/s41467-020-18020-8", "10.1002/path.5096", "10.1038/s41598-017-05246-8", "10.3390/ph10010005", "10.1007/s13277-015-4048-0", "10.1245/s10434-015-4730-x", "10.1021/pr4010822", "10.3892/or.2012.1666", "PMID:21226991"]}
{"pair_type": "slc_pathway", "key1": "SLC1A2", "key2": "migration", "summary": "We also found a reduction in neuronal arborization, spine size, growth rate, and migration, but increased astrocyte size and a reduced growth rate in autism.", "dois": ["10.3390/cells13131095"]}
{"pair_type": "slc_pathway", "key1": "SLC1A4", "key2": "proliferation", "summary": "Furthermore, the functional analysis revealed that silenced SLC1A4 inhibited cell proliferation, migration, cell cycle, and promoted cell apoptosis in HCC.\nAs a result, silencing SLC1A4 inhibited the proliferation, migration, and stemness of hepatic cancer cells, which was successfully reversed by the introduction of exogenous AKT.\nhUSCs remarkably inhibited CTX-induced apoptosis and promoted the proliferation of GCs, respectively.\nAdditionally, FOXA1 knockout inhibited cell proliferation and further increased the dependence of THBEc1 cells on Glu.\nMore importantly, the knockdown of SLC1A4 or simple supplementation of serine suppressed CTX-induced apoptosis of GCs.\nMechanically, silencing SLC1A4 inhibited the phosphorylation activation of AKT by suppressing the ubiquitin modification of AKT at lysine 63 and amino acid influx represented by D-serine, decreasing the protein level of -catenin in the cell nucleus and suppressing the transcriptional activity of c-Myc and EpCAM promoters.\nIn addition, we observed that miR-27b-3p was highly expressed in hUSC-Exo and markedly suppressed CTX-induced GC apoptosis by specifically inhibiting the expression of SLC1A4, a serine transporter, in ovarian GCs, which, in turn, elevated the concentration of the intracellular serine by inhibiting the outflux of cellular serine.\nIn conclusion, SLC1A4 promotes the malignant transformation of HCC through activating signal transduction mediated by AKT.\nMoreover, epithelial-mesenchymal transition (EMT) in vitro and metastasis potential in vivo of hepatic cancer cells was suppressed by the downregulated SLC1A4 level.\nFinally, we demonstrated that CTX-induced apoptosis of ovarian GCs was essential for POF by reducing the intracellular serine concentration via elevating the expression of SLC1A4, whereas hUSCs protected against CTX-induced POF via miR-27b-3p/SLC1A4/se", "dois": ["10.1002/advs.202417225", "10.1186/s11658-025-00701-1", "10.1155/ancp/1115184", "10.3389/fonc.2023.1228199", "10.1016/j.taap.2023.116402", "10.3389/fonc.2021.650355", "10.1186/s40104-021-00554-6", "10.1158/2159-8290.CD-19-0959", "10.1371/journal.pone.0175954", "10.1371/journal.pone.0132099", "PMID:22906261", "PMID:22738901"]}
{"pair_type": "slc_pathway", "key1": "SLC1A4", "key2": "migration", "summary": "Furthermore, the functional analysis revealed that silenced SLC1A4 inhibited cell proliferation, migration, cell cycle, and promoted cell apoptosis in HCC.\nAs a result, silencing SLC1A4 inhibited the proliferation, migration, and stemness of hepatic cancer cells, which was successfully reversed by the introduction of exogenous AKT.\nMechanically, silencing SLC1A4 inhibited the phosphorylation activation of AKT by suppressing the ubiquitin modification of AKT at lysine 63 and amino acid influx represented by D-serine, decreasing the protein level of -catenin in the cell nucleus and suppressing the transcriptional activity of c-Myc and EpCAM promoters.\nSLC1A4 Promotes Malignant Transformation of Hepatocellular Carcinoma by Activating the AKT Signaling.\nIn conclusion, SLC1A4 promotes the malignant transformation of HCC through activating signal transduction mediated by AKT.\nMoreover, epithelial-mesenchymal transition (EMT) in vitro and metastasis potential in vivo of hepatic cancer cells was suppressed by the downregulated SLC1A4 level.\nNOS2 overexpression promoted the proliferation, migration and invasion of HepG2 and HuH-6 cells.", "dois": ["10.1155/ancp/1115184", "10.3389/fonc.2023.1228199", "10.3389/fonc.2021.650355", "PMID:22738901"]}
{"pair_type": "slc_pathway", "key1": "SLC1A5", "key2": "oxidative stress", "summary": "SLC1A5 knockdown also suppressed glutamine uptake, enhanced oxidative stress, and increased sensitivity to cisplatin.\nOur results suggest that chronic use of standard immunosuppressive regimens increases the risk of oxidative stress in the rat intestine, as manifested by increased expression of glutathione or the SLC1A5 transporter.\nUSP48 overexpression deubiquitinated SLC1A5 to elevate cell proliferation and suppress cell apoptosis, inflammation, ferroptosis and oxidative stress in HG-triggered ARPE-19 cells, thereby inhibiting the progression of diabetic retinopathy.\nTopotecan-induced hepatocytes death is dependent on ASCT2 down-regulation, which causes oxidative stress via inhibiting GSH production.\nTPT inhibits glutamine uptake via down-regulation of ASCT2 which causes oxidative stress and induces apoptosis through the mitochondrial pathway.\nstudies had shown that the knockdown of SLC1A5 resulted in a significant decrease in cell viability and promoted lipid peroxidation and oxidative damage introduced by irradiation (10 Gy).\nAg120 blocked glutamine uptake and metabolism, leading to reduced cell proliferation, elevated autophagy, and increased oxidative stress in CRC cells and , potentially the ERK and mTOR signaling pathways.\nCombination of ASCT2 inhibitor V9302 and proteasome inhibitor carfilzomib upregulates the intracellular levels of ROS and oxidative stress markers and triggers catastrophic UPR as shown by upregulated spliced Xbp1 mRNA, ATF3 and CHOP levels.\nER-localized HSP90B1 accelerates the clearance of radiotherapy-induced misfolded proteins and upregulates the PERK-EIF2α-ATF4 pathway, which further transcriptionally upregulates antioxidant factors, such as SLC1A5, GCLC, and CTNS, to inhibit radiotherapy-induced ROS accumulation, ultimately leading to radiotherapy resistance, and poor clinical outcomes.\nDisruptions in immune modulation, metabolism, and oxidative stress components were associated with", "dois": ["10.1186/s12964-025-02344-3", "10.1021/acs.est.4c07053", "10.1016/j.jbc.2024.107299", "10.1007/s10863-024-10008-z", "10.1016/j.ajpath.2024.02.009", "10.1155/2022/3403009", "10.1177/09603271211021476", "10.1038/s41416-019-0637-9", "10.1016/j.canlet.2016.07.020", "10.1021/pr2012335", "10.1016/j.redox.2025.103712", "10.31083/FBL36781", "10.3724/SP.J.1123.2024.04003", "10.3390/antiox13091111", "10.1038/s41420-024-02158-1", "10.3389/fphar.2022.871392", "10.1007/s10735-022-10070-0", "10.1016/j.apsb.2021.07.008", "10.3390/cancers13010125", "10.1016/j.tox.2020.152650", "10.3168/jds.2018-15219", "PMID:30210919", "10.1186/s12940-017-0288-3", "10.3389/fimmu.2017.00549", "10.1158/0008-5472.CAN-16-2458", "10.1002/ijc.29535", "10.1016/j.xcrm.2024.101706", "10.1016/j.canlet.2021.02.020", "10.1007/s00280-020-04218-6", "10.1016/j.gastrohep.2020.05.017", "10.3390/cells9040995", "10.1111/cas.14182", "10.1016/j.phymed.2018.12.011", "10.1038/nm.4464", "10.1371/journal.pone.0133506", "10.1007/s00726-010-0664-6", "10.1007/s00280-010-1316-y", "PMID:17468184", "PMID:15516806", "10.3390/ijms26178330", "10.1038/s41416-025-03191-2"]}
{"pair_type": "slc_pathway", "key1": "SLC1A5", "key2": "ferroptosis", "summary": "Thus, inhibiting SLC1A5 or GLS1 activity could alleviate the antagonistic effect of YAP1 on the ferroptosis of RSL3-induced CRPC cells.\nDownregulation of SLC1A5 could inhibit TAM-induced hepatocyte ferroptosis, thereby alleviating HSCs activation and the increased expression of ECM proteins.\nCollectively, data in the present study indicated that targeting the miR-338-3p/SLC1A5 axis could block high glucose-induced ferroptosis in RPE cells.\nInhibitors against apoptosis, autophagy, or ferroptosis rescued the cell viability repressed by SLC1A5 knockdown.\nCRISPR/dCas9-mediated SLC1A5 induction conferred cisplatin resistance and reduced apoptosis, autophagy, and ferroptosis.\nOur study suggests that TAM induces hepatocyte ferroptosis through SLC1A5, leading to HSC activation and liver fibrosis.\nFurthermore, the mechanism of how APOC1 inhibits ferroptosis in prostate cancer through PI3K/AKT/SREBP2/SLC1A5 was detected.\nNotably, the overexpression of SLC1A5 could activate the mTORC1 signaling pathway and may increase the cellular sensitivity to ferroptosis.\nCollectively, our findings indicated that SLC1A5 may act as a suppressor gene against ferroptosis and can be a potential target for ionizing radiation mediated effects.\nIn addition, SLC1A5 knockdown could significantly inhibit glioma cell proliferation and invasion, and reduce the sensitivity of ferroptosis via the GPX4-dependent pathway.\nCollectively, the results demonstrated that curcumin exhibited antitumorigenic activity in BC by promoting SLC1A5-mediated ferroptosis, which suggests its use as a potential therapeutic agent for the treatment of BC.\nNotably, the anti-ferroptosis function of APOC1 was mediated through SREBP2-dependent transcriptional regulation, with Cut&Tag (Cleavage Under Targets and Tagmentation) confirming SREBP-2's direct binding to", "dois": ["10.7717/peerj.19899", "10.1016/j.bcp.2025.117047", "10.31083/FBL36781", "10.1016/j.cbi.2025.111586", "10.1016/j.freeradbiomed.2025.04.029", "10.1186/s40246-024-00693-7", "10.1186/s12903-024-04342-2", "10.1016/j.gene.2024.148498", "10.1016/j.canlet.2024.216727", "10.1007/s10863-024-10008-z", "10.1016/j.ajpath.2024.02.009", "10.26355/eurrev_202401_35045", "10.1016/j.freeradbiomed.2024.01.002", "10.1002/cbf.3889", "10.1097/MD.0000000000035917", "10.1007/s11010-023-04847-4", "10.3390/ijms241612880", "10.18632/aging.204911", "10.1002/jcla.24930", "10.1158/1535-7163.MCT-23-0041", "10.1080/16078454.2023.2198862", "10.1155/2023/9808100", "10.1038/s41419-022-05526-w", "10.3389/fimmu.2022.962000", "10.1155/2022/3403009", "10.1002/jcla.24632", "10.1371/journal.pone.0271202", "10.1002/cam4.5032", "10.1159/000524900", "10.18632/aging.204057", "10.1007/s10735-022-10070-0", "10.1371/journal.pone.0261370", "10.1155/2021/6014202", "10.1186/s12885-021-08559-0", "10.1016/j.tox.2020.152650", "10.12659/MSM.921947", "10.1097/SCS.0000000000011563", "10.1038/s41420-024-02158-1", "10.1101/2024.06.24.600340", "10.18332/tid/189490", "10.7150/jca.92768", "10.3892/ol.2024.14320", "PMID:37693126", "10.1007/s12094-023-03269-4", "10.1111/bjh.18884", "10.3390/jcm12051715", "10.21037/tcr-22-2203", "10.3389/fcell.2022.843297", "10.3389/fcell.2022.800925", "10.1186/s12935-022-02544-8", "10.3389/fcvm.2022.824756", "10.21037/jgo-21-237", "10.3389/fonc.2021.738477", "10.3748/wjg.v31.i32.108654", "10.1038/s41416-024-02670-2", "10.1186/s12967-025-07092-z", "10.3390/ijms262110736", "10.1007/s12672-025-03629-2", "10.1155/2021/7391560", "10.1155/2021/6687391", "10.1038/s41418-017-0053-8"]}
{"pair_type": "slc_pathway", "key1": "SLC1A5", "key2": "apoptosis", "summary": "Moreover, ABHD11-AS1 enhanced the abilities of cell proliferation, migration, and invasion, inhibited apoptosis in vitro, promoted tumorigenesis in vivo via sponging miR-199a-5p and then induced SLC1A5 activation.\nKnockdown of circSEPT9 or SLC1A5 inhibited glutamine uptake and cell proliferation, but induced cell apoptosis in BC cells.\nKnockdown of SLC1A5 decreased proliferation, colony formation, and migration, but increased apoptosis and increased sensitivity to chemotherapy drugs.\nThe knockdown of the SLC1A5 high-affinity transporter for glutamine induces apoptosis and inhibits tumor formation in a mouse AML xenotransplantation model.\nInactivation of SLC1A5 genetically or pharmacologically decreased Gln consumption, inhibited cell growth, induced autophagy and apoptosis in a subgroup of NSCLC cell lines that overexpress SLC1A5.\nInhibitors against apoptosis, autophagy, or ferroptosis rescued the cell viability repressed by SLC1A5 knockdown.\nCRISPR/dCas9-mediated SLC1A5 induction conferred cisplatin resistance and reduced apoptosis, autophagy, and ferroptosis.\nFurthermore, the effects of downregulated circ-LDLRAD3 on cell proliferation, apoptosis and mobility were all reversed by knocking down miR-137 and overexpressing SLC1A5.\nRemarkably, silencing SLC1A5 expression partially counteracted the promotion of CRC cell proliferation by LINC01134 overexpression and alleviated its inhibition of apoptosis.\nDeprivation of Gln or blockade of Gln transporter solute carrier family 1 member 5 (SLC1A5) inhibits bone resorption by enhancing apoptosis of monocytes.\nIn vitro findings showed that SLC1A5 knockdown reduced THCA cell activity and accelerated apoptosis, and the results were consistent with the effect of SLC1A5 inhibitor GPNA", "dois": ["10.1186/s12885-025-14123-x", "10.1002/advs.202406220", "10.1039/d4nr00426d", "10.2147/DDDT.S458613", "10.1186/s12967-024-05298-1", "10.3390/ijms241612880", "10.1038/s41419-022-05526-w", "10.1002/jbt.23192", "10.1183/13993003.00062-2022", "10.1007/s10735-022-10070-0", "10.1042/BSR20212171", "10.1002/jcla.24116", "10.1080/21655979.2021.2000731", "10.1016/j.canlet.2021.07.027", "10.1177/09603271211021476", "10.1080/15476286.2020.1789819", "10.1016/j.ejphar.2020.173185", "10.1038/s41416-019-0637-9", "10.1016/j.bbrc.2019.10.200", "10.1016/j.yexcr.2019.03.032", "10.1159/000491769", "10.1002/mc.22849", "10.1002/ijc.31274", "10.1038/s41418-017-0053-8", "10.3390/ijms18081632", "10.1002/hep.29183", "10.1016/j.canlet.2016.07.020", "10.1371/journal.pone.0153226", "10.1016/j.ccell.2015.02.006", "PMID:25337245", "10.1182/blood-2013-03-493163", "10.1021/pr2012335", "10.1002/advs.202500585", "10.7150/jca.100147", "10.1038/s41420-024-02158-1", "10.1007/s10863-024-10008-z", "10.1016/j.ajpath.2024.02.009", "10.1515/tnsci-2022-0333", "10.1016/j.biopha.2023.115438", "10.22074/cellj.2023.2004011.1319", "10.1016/j.heliyon.2023.e17598", "10.3390/cancers15041050", "10.1016/j.trim.2022.101764", "10.1186/s11658-022-00364-2", "10.1097/CAD.0000000000001400", "10.1186/s12957-022-02777-x", "10.1371/journal.pone.0271202", "10.1111/1759-7714.14458", "PMID:35530270", "10.1080/15384101.2022.2071565", "10.1007/s00404-022-06481-9", "10.1155/2022/7985468", "10.14670/HH-18-401", "10.1177/15347354211045349", "10.1186/s12935-021-02156-8", "10.2147/OTT.S319300", "10.1038/s41401-021-00717-1", "10.1007/s10528-021-10092-5", "10.3389/fphar.2021.671328", "10.1158/1535-7163.MCT-20-0354", "10.1016/j.fct.2020.111698", "10.1038/s42255-019-0039-6", "10.1038/s41419-019-1850-4", "10.3390/metabo9030050", "10.3168/jds.2018-15219", "PMID:30210919", "10.3748/wjg.v31.i32.108654", "10.1016/j.intimp.2025.114226", "10.1111/1759-7714.15257", "10.1021/acs.jmedchem.3c01093", "10.21873/anticanres.16634", "10.1016/j.lfs.2021.120054", "10.1016/j.canlet.2021.02.020", "10.1016/j.prp.2025.156248", "10.3390/ijms26178330", "10.1007/s12672-025-03629-2", "10.1038/s41419-018-0761-0", "10.1007/s00125-018-4614-2", "10.5713/ajas.17.0799", "10.1371/journal.pone.0179363", "10.1002/ijc.29535"]}
{"pair_type": "slc_pathway", "key1": "SLC1A3", "key2": "proliferation", "summary": "In vivo and in vitro experiments showed that silencing FN1 inhibits the activation of the YAP1/Hippo pathway by enhancing YAP1 phosphorylation, down-regulates SLC1A3-mediated aspartate uptake and utilization by tumor cells, inhibits BC cell proliferation, invasion and migration, and promotes apoptosis.\nThe PI3K/AKT inhibitor LY294002 prevented SLC1A3-induced glucose metabolism and cell proliferation.\nHere, we demonstrate that ASNase stimulates aspartate and glutamate consumptions, and their refilling through SLC1A3 promotes cancer cell proliferation.\nLastly, in vivo experiments indicated that SLC1A3 expression promoted tumor development and metastasis while negating the suppressive effects of ASNase by fueling aspartate, glutamate, and glutamine metabolisms despite of asparagine shortage.\nWe show that the glutamate-aspartate transporter EAAT1 (SLC1A3), which is normally expressed in the central nervous system, is crucial for glutamine conversion to aspartate and nucleotides and that T-ALL cell proliferation depends on EAAT1 function.\nSLC1A3 Promotes Gastric Cancer Progression via the PI3K/AKT Signalling Pathway.\nSLC1A3 overexpression activated the PI3K/AKT pathway and up-regulated GLUT1, HK II and LDHA expression.\nOur findings indicate that SLC1A3 promotes gastric cancer progression via the PI3K/AKT signalling pathway.\nCell lines least sensitive to ETC inhibition maintain aspartate levels by importing it through an aspartate/glutamate transporter, SLC1A3.\nImportantly, inhibition of the IGF1R-MTOR pathway decreases cell proliferation and reactivity of mutant SOD1 astrocytes, and attenuates their toxicity to motor neurons.\nInhibition of GID8 attenuated CRC proliferation and metastasis both in vitro and in vivo.\nIn vitro and in vivo assays showed that SLC1A3 affected glucose metabolism and promote", "dois": ["10.31083/FBL27047", "10.21037/tcr-24-1909", "10.1016/j.canlet.2024.217186", "10.1111/jcmm.18568", "10.1016/j.bbadis.2024.167451", "10.3324/haematol.2023.283471", "10.1089/omi.2023.0092", "10.1007/s10549-023-07032-9", "10.3389/fimmu.2023.1038651", "10.1016/j.taap.2023.116402", "10.3168/jds.2022-21923", "10.15252/embr.202255478", "10.26508/lsa.202201404", "10.3389/fvets.2021.756375", "10.1080/15548627.2021.1899682", "10.1111/jcmm.16060", "10.15252/embj.2019102147", "10.1038/s41556-018-0118-z", "10.15252/embj.201899393", "10.18632/oncotarget.24498", "10.1038/ncb3359", "PMID:25326682", "10.1016/j.mcn.2011.11.005"]}
{"pair_type": "slc_pathway", "key1": "SLC1A2", "key2": "oxidative stress", "summary": "Besides cytoskeletal remodelling (e.g., GFAP), bioinformatics analyses revealed a wide range of functional alterations including neuroinflammation (e.g., IL6, MAPK1/3/8 and TNF), oxidative stress and antioxidant defence (e.g., MT1A/2A, NFE2L2, NOS1/2/3, PRDX6 and SOD1/2), lipid metabolism (e.g., APOE, CLU and LRP1), proteostasis (e.g., cathepsins, CRYAB and HSPB1/2/6/8), extracellular matrix organisation (e.g., CD44, MMP1/3 and SERPINA3), and neurotransmission (e.g., CHRNA7, GABA, GLUL, GRM5, MAOB and SLC1A2), among others.\nSimultaneously, a significant decrease in glutamate uptake was observed in LRRK2-I1371V astrocytes, with lower gene expression of glutamate transporters SLC1A2 and SLC1A3.\nAdditionally, several lines of experimental evidence indicate that inflammation and inflammation-induced oxidative stress, as well as many insidious/latent infectious elements including the gut microbiome, alter the expression status and the epigenetic landscapes of brain non-neuronal cells.\nhowever, the astrocytic capability to mitigate oxidative stress in terms of glutathione content was significantly reduced in the mutant astrocytes, along with a reduction in the gene expression of the enzymes involved in glutathione machinery and nuclear factor erythroid 2-related factor 2 (Nrf2) expression.\nThe reduction in the protein expression of SLC1A2 was also directly confirmed.\nExcessive inflammatory reactions and oxidative stress are well-recognized molecular findings in autism and these processes can affect or be affected by the epigenetic landscape.\nOur data demonstrate for the first time that the mutation in the LRRK2-I1371V allele causes significant astrocytic dysfunction with respect to Nrf2-mediated antioxidant machinery, AT -generation, and glutamate metabolism, even", "dois": ["10.3390/cells13131095", "10.3390/cells12121592", "10.3390/genes14040896", "10.1111/nan.12753", "10.1097/MD.0000000000017267"]}
{"pair_type": "slc_pathway", "key1": "SLC1A4", "key2": "stemness", "summary": "As a result, silencing SLC1A4 inhibited the proliferation, migration, and stemness of hepatic cancer cells, which was successfully reversed by the introduction of exogenous AKT.\nSLC1A4 Promotes Malignant Transformation of Hepatocellular Carcinoma by Activating the AKT Signaling.\nIn conclusion, SLC1A4 promotes the malignant transformation of HCC through activating signal transduction mediated by AKT.\nMechanically, silencing SLC1A4 inhibited the phosphorylation activation of AKT by suppressing the ubiquitin modification of AKT at lysine 63 and amino acid influx represented by D-serine, decreasing the protein level of -catenin in the cell nucleus and suppressing the transcriptional activity of c-Myc and EpCAM promoters.\nHere, we report that ac4C and its catalytic enzyme NAT10 drive leukaemogenesis and sustain self-renewal of leukaemic stem cells/leukaemia-initiating cells through reprogramming serine metabolism.\nMechanistically, NAT10 facilitates exogenous serine uptake and de novo biosynthesis through ac4C-mediated translation enhancement of the serine transporter SLC1A4 and the transcription regulators HOXA9 and MENIN that activate transcription of serine synthesis pathway genes.\nMoreover, epithelial-mesenchymal transition (EMT) in vitro and metastasis potential in vivo of hepatic cancer cells was suppressed by the downregulated SLC1A4 level.", "dois": ["10.1155/ancp/1115184", "10.1038/s41556-024-01548-y"]}
{"pair_type": "slc_pathway", "key1": "SLC1A5", "key2": "proliferation", "summary": "Knockdown SLC1A5 in gastric cancer cells suppressed cell proliferation, caused G0/G1 arrest and inhibited cell invasion as well as migration partly by inactivated mTOR/p-70S6K1 signaling pathway.\nMoreover, ABHD11-AS1 enhanced the abilities of cell proliferation, migration, and invasion, inhibited apoptosis in vitro, promoted tumorigenesis in vivo via sponging miR-199a-5p and then induced SLC1A5 activation.\nKnockdown of circSEPT9 or SLC1A5 inhibited glutamine uptake and cell proliferation, but induced cell apoptosis in BC cells.\nMoreover, inhibition of SLC1A5 significantly enhanced the inhibitory efficacy of cetuximab on CRC proliferation both in vitro and in vivo.\nKnockdown of SLC1A5 decreased proliferation, colony formation, and migration, but increased apoptosis and increased sensitivity to chemotherapy drugs.\nSLC1A5var knockdown reduced cancer cell proliferation, colony formation, and migration, whereas SLC1A5var overexpression increased cell proliferation and migration.\nImportantly, inhibiting SLC1A5 blocked cell proliferation by downregulating mTORC1 in long-term arsenite-treated cells.\nStudies have also shown that downregulation of SLC1A5 can inhibit wound healing, invasion, and proliferation of HCC cells.\nFurthermore, the effects of downregulated circ-LDLRAD3 on cell proliferation, apoptosis and mobility were all reversed by knocking down miR-137 and overexpressing SLC1A5.\nIn addition, SLC1A5 knockdown could significantly inhibit glioma cell proliferation and invasion, and reduce the sensitivity of ferroptosis via the GPX4-dependent pathway.\nRemarkably, silencing SLC1A5 expression partially counteracted the promotion of CRC cell proliferation by LINC01134 overexpression and alleviated its inhibition of apoptosis.\nThe uptake of macrophage-derived glutamine by satellite cells through the glutamine transporter SLC1A5 activates mTOR an", "dois": ["10.3390/ijms262110736", "10.1016/j.prp.2025.156248", "10.1007/s00535-025-02305-0", "10.1186/s12967-025-07092-z", "10.1080/15548627.2025.2535765", "10.1097/HC9.0000000000000742", "10.12122/j.issn.1673-4254.2025.02.08", "10.1186/s12885-025-13560-y", "10.1038/s41598-025-87292-1", "10.1002/advs.202406220", "10.3389/fgene.2024.1499915", "10.1111/jcmm.70245", "10.1186/s12885-024-13275-6", "10.1016/j.biocel.2024.106688", "10.7150/jca.100147", "10.7150/ijbs.96210", "10.1038/s41418-024-01323-4", "10.1186/s12967-024-05298-1", "10.1111/jop.13561", "10.1111/bjh.19516", "10.1016/j.molmet.2024.101952", "10.1016/j.gene.2024.148498", "10.1152/ajpcell.00523.2023", "10.1016/j.bbamcr.2024.119721", "10.7150/jca.92768", "10.3892/ol.2024.14320", "10.1007/s10863-024-10008-z", "10.1515/tnsci-2022-0333", "10.1093/carcin/bgae010", "10.1101/2024.01.18.576263", "10.1016/j.jbc.2023.105602", "10.3389/fimmu.2023.1187108", "10.18632/aging.204911", "10.1016/j.heliyon.2023.e17598", "10.1016/j.ecoenv.2023.115204", "10.3389/fnut.2023.1124678", "10.1111/bjh.18884", "10.1186/s12864-023-09361-x", "10.3390/cells12060943", "10.21037/tcr-22-2203", "10.1016/j.taap.2023.116402", "10.1038/s41419-022-05526-w", "10.1002/mc.23497", "10.3389/fcell.2022.1007924", "10.1016/j.trim.2022.101764", "10.1186/s11658-022-00364-2", "10.1097/CAD.0000000000001400", "10.1186/s12957-022-02777-x", "10.1002/jcla.24632", "10.1155/2022/4996980", "10.1007/s10637-022-01284-w", "10.1016/j.bcp.2022.115159", "10.1183/13993003.00062-2022", "10.1111/1759-7714.14458", "PMID:35530270", "10.1080/15384101.2022.2071565", "10.3389/fcell.2022.800925", "10.3389/fphar.2022.871392", "10.1007/s10735-022-10070-0", "10.1007/s00404-022-06481-9", "10.3390/cancers14051163", "10.1042/BSR20212171", "10.3892/ijo.2022.5327", "10.1007/s13402-022-00659-8", "10.3390/cancers14010245", "10.14670/HH-18-401", "10.1002/jcla.24116", "10.1080/21655979.2021.2000731", "10.7554/eLife.71595", "10.1177/15347354211045349", "10.1186/s12935-021-02156-8", "10.2147/OTT.S319300", "10.1073/pnas.2104093118", "10.18632/aging.203495", "10.1016/j.jbc.2021.100954", "10.1016/j.prp.2021.153525", "10.1007/s10528-021-10092-5", "10.1177/09603271211021476", "10.3389/fphar.2021.671328", "10.1002/1878-0261.12999", "10.3389/fimmu.2021.624324", "10.1016/j.toxlet.2021.03.007", "10.1038/s41586-020-2857-9", "10.1080/15476286.2020.1789819", "10.1016/j.ejphar.2020.173185", "10.21037/atm.2020.03.31", "10.2147/OTT.S235667", "10.15698/cst2020.01.210", "10.1038/s41416-019-0637-9", "10.1038/s41416-019-0626-z", "10.1293/tox.2019-0048", "10.1101/gad.327056.119", "10.1038/s41419-019-1850-4", "10.3390/metabo9030050", "10.1161/CIRCRESAHA.118.314187", "10.1007/s10549-018-05111-w", "10.3168/jds.2018-15219", "10.1007/s10549-018-5060-z", "10.3892/ijo.2018.4596", "10.3892/or.2018.6729", "PMID:30210919", "10.15252/embj.201899735", "10.3390/ijms19072093", "10.1007/s00125-018-4614-2", "10.1016/j.celrep.2018.03.099", "10.1074/jbc.RA117.000735", "10.5713/ajas.17.0799", "10.1002/ijc.31274", "10.1074/jbc.RA117.001342", "10.1126/scisignal.aan4667", "10.18632/oncotarget.19479", "10.1089/rej.2017.1948", "10.3389/fimmu.2017.00549", "10.1038/onc.2015.381", "10.1371/journal.pcbi.1004477", "10.1371/journal.pone.0132099", "10.1158/0008-5472.CAN-14-3745", "10.1016/j.ccell.2015.02.006", "10.1016/j.jsbmb.2015.02.004", "PMID:25337245", "10.1002/path.4429", "10.2967/jnumed.111.101279", "10.1016/j.cell.2008.11.044"]}
{"pair_type": "slc_pathway", "key1": "SLC2A3", "key2": "chemotherapy", "summary": "To study the molecular mechanism of cisplatin chemotherapy resistance in colorectal cancer cells and to explore the effect of miRNA in regulating the expression of glucose transporter 3 (SLC2A3) and the proliferation and migration of colon cancer cells.\nFerroptosis, an iron-dependent form of programmed cell death, plays a crucial role in tumor suppression and chemotherapy resistance in cancer.\nNotably, an SLC2A3-neutralizing antibody enhances the ferroptosis-inducing and anticancer effects of sorafenib on ovarian cancer patient-derived xenograft tumors.\nOverall, miR-103a can inhibit the proliferation of human colon cancer cells by targeting SLC2A3, and this result will provide a potential target for the treatment of colon cancer.\nOur results demonstrated that loss of the OSGIN1 gene promoted ovarian cancer growth and conferred resistance to drug-induced ferroptosis.\nMechanistically, the loss of OSGIN1 activates AMPK signaling through ATM, leading to the upregulation of SLC2A3, which protects cells from ferroptosis and renders them insensitive to ferroptosis inducers.\nOverall, anti-SLC2A3 therapy is a promising method to improve ovarian cancer treatment by targeting ferroptosis.\nIn addition, resistance to Erlotinib, Rapamycin, MG-132, Cyclopamine, AZ628, and Sorafenib was reduced in patients with low IAS.\nBesides, the signature was found to be remarkably correlated with sensitivity of common chemotherapy drugs for HNSCC patients and the expression levels of signature genes were also significantly associated with drug sensitivity to cancer cells.\nIAS was a reliable prognostic indicator.\nFor GC patients, IAS showed excellent robustness in predicting GC prognosis, immune activity status, immunotherapy response, and chemotherapeutic drug resistance.\nIAS demonstrated excellent robustness in predicting immunotherapy outcome and GC prognosis, with low-IAS patients having better prognosis and immunotherapy.\nWe also evaluated the value of IAS in estimating immunotherapy and chemotherapy response based on immunotherapy cohort.\nFunctional recovery experiments showed that increasing the expression of miR-", "dois": ["10.1038/s41698-024-00791-8", "10.7717/peerj.16317", "10.18502/ijph.v50i12.7941", "10.3389/fmolb.2022.792482", "10.3389/fgene.2021.755486"]}
{"pair_type": "slc_pathway", "key1": "SLC2A3", "key2": "oxidative phosphorylation", "summary": "Mechanistically, TRPM7 transcriptionally regulated the solute carrier family 2 member 3 (SLC2A3, also known as GLUT3) via Ca influx-induced calcineurin activation.\nCancer or endothelial cells preferably catabolize glucose through aerobic glycolysis rather than oxidative phosphorylation.\nDifferential flux analysis revealed that metabolic changes such as enhanced aerobic glycolysis, impaired oxidative phosphorylation, fluctuating biogenesis of lipids, vitamins (folate and retinol), and nucleotides played important roles in the inflammation adaptation of PBMCs.\nFurthermore, CREB-regulated transcription coactivator 2 (CRTC2) and CREB act downstream of calcineurin to relay Ca signal to SLC2A3 transcription.\nRNA-seq, metabolomics and genetic assay revealed that the TRPM7 channel regulated cellular glycolysis.\nThe TRPM7 channel represents a novel regulator of glycolytic reprogramming.\nMoreover, the main metabolic enzymes such as the solute carrier (SLC) family 2 member 3 (SLC2A3) and fatty acid synthase (FASN), responsible for the reactions with large differential fluxes, were identified as potential therapeutic targets.\nDeletion of TRPM7 suppressed cancer cell glycolysis and reduced the xenograft tumor burden.\nInhibition of the TRPM7-dependent glycolysis could be harnessed for cancer therapy.\nExpression of the constitutively active CRTC2 or CREB in TRPM7 knockout cell normalized glycolytic metabolism and cell growth.", "dois": ["10.1038/s41419-023-05701-7", "10.3390/ijms232012400"]}
{"pair_type": "slc_pathway", "key1": "SLC2A2", "key2": "glycolysis", "summary": "Moreover, SIRT6 could inhibit the Warburg effect by regulating glycolysis-related genes of SLC2A2, SLC2A4 and PKM2.\nTucum-do-cerrado consumption (Tuc) increased hepatic Slc2a2, Prkaa1α, Prkaa2α and intestinal Slc5a1 mRNA levels, also decreased hepatic G6Pase activity, muscle Slc2a4 and Prkaa2α in relation to CT group.\nThe association of tucum-do-cerrado with iron-enriched diet increased hepatic Prkaa1 and Pck1 compared to the CT and + Fe groups, intestinal Slc2a2 mRNA levels compared to the +Fe group, while decreased hepatic G6Pase activity in relation to the CT, +Fe and Tuc + Fe groups and muscle Slc2a4 and Prkaa2α compared to CT group.\nMetformin increased expression of Slc2a1 (GLUT1), decreased expression of Slc2a2 (GLUT2) and Slc5a1 (SGLT1) whilst increasing GLUT-dependent glucose uptake and glycolytic rate as observed by live cell imaging of genetically encoded metabolite sensors and measurement of oxygen consumption and extracellular acidification rates.\nThese results suggest that tucum-do-cerrado consumption might induce Prkaa1α and Prkaa2α expression, which may inhibit gluconeogenic rate limiting enzyme, G6Pase, and upregulates GLUT2 hepatic glucose uptake.\nIron supplementation increased muscle lipid and protein oxidation, hepatic glucokinase (GK) and phosphofrutokinase 1 (PFK1) activities and decreased hepatic glucose-6-phosphatase (G6Pase), intestinal Scl2a2 and muscle Slc2a4 and Prkaa2α mRNA levels compared to CT group.\nTo satisfy the improved energy demands, glycolysis flux is increased in cancers compared with healthy tissues.", "dois": ["10.1111/jcmm.70053", "10.1038/s41598-021-81349-7", "10.1016/j.ceca.2020.102339", "10.1210/endocr/bqaa098", "10.1016/j.foodres.2018.07.032", "10.1074/jbc.M109.026708", "10.1016/j.heliyon.2024.e29655", "10.1038/s41419-022-04517-1", "10.1016/j.bbrc.2021.04.059"]}
{"pair_type": "slc_pathway", "key1": "SLC2A3", "key2": "stemness", "summary": "Finally, the hub gene SLC2A3 was found exclusively upregulated in extracellular matrix-related CSCs, predicting prognosis, and shaping an immunosuppressive tumor microenvironment.\nBesides, SLC2A3 may serve as a promising stemness target facilitating cancer effective management.\nFinally, we identified TMZ-upregulated activating transcription factor 4 (ATF4) as an upstream regulator of DDIT4-mediated GLUT3/stemness signaling and autophagy.\nMesenchymal stem cells (MSCs) and cancer stem cells (CSCs) maintain bladder cancer (BCa) stemness and facilitate the progression, metastasis, drug resistance, and prognosis.\nAmong these 5 genes, only GLUT3 was upregulated in both TMZ-treated and DDIT4-overexpressing cells.\nDDIT4-mediated GLUT3 expression was also identified, and its expression decreased TMZ's cytotoxicity.\nHowever, GLUT3 only participated in the exhibition of DDIT4-mediated stemness, resulting from glycolytic regulation, but not in DDIT4-mediated autophagic signaling.\nConsequently, ATF4/DDIT4 signaling was connected to both autophagy and GLUT3-regulated stemness, which are involved in TMZ drug resistance and the poor prognoses of GBM patients.\nEPI was formulated, incorporating six genes (CYTL1, FAM43A, GSN, HSPG2, RBP7, and SLC2A3).\nFunctional assays uncovered the stem traits of SLC2A3 in BCa by tumorsphere formation and western blotting.\nCDMs are positively correlated with the tumor-cell stemness, immune-related score and T cells are infiltrated.\nWe determined that higher levels of 5 DDIT4-associated downstream genes, including SLC2A3 (also known as glucose transporter 3 (GLUT3)), can be used to predict a poor prognosis.\nA loss-of-function study showed that knockdown of SLC12A2 expression restrained proliferation an", "dois": ["10.3389/fimmu.2024.1487966", "10.1007/s12672-024-00992-4", "10.1038/s41598-024-55048-y", "10.3390/ijms24054760", "10.1007/s13311-019-00826-0"]}
{"pair_type": "slc_pathway", "key1": "SLC2A4", "key2": "oxidative phosphorylation", "summary": "RNA-Sequencing data suggest that diabetic skeletal muscle is characterized by decreased expression of genes that are related to insulin resistance (IRS2, MTOR, SLC2A4, and PPARA), carbohydrate, energy, and amino acid metabolism pathways (NDUFS1, NDUFA10, NDUFB4, NDUFB5, NDUFA5, NDUFB10, SDHB, SDHC, ATP5H, ATP5A, and ATP5J).\nPeroxisome proliferator-activated receptor-γ coactivator 1α (PGC-1α) has emerged as a critical control factor in skeletal muscle adaptation to exercise, acting via transcriptional control of genes responsible for angiogenesis, fatty acid oxidation, oxidative phosphorylation, mitochondrial biogenesis and muscle fibre type composition.\ninfantum failed to activate AMPK and up-regulate its targets such as Slc2a4 and Ppargc1a, which are essential for parasite growth.\nThese results confirm the essential regulation of impaired insulin signaling and oxidative phosphorylation in the muscle of T2DM patients, and provide novel molecular insights into the pathophysiological mechanisms of T2DM.\nDespite transcriptome studies in limited T2DM human subjects suggesting an association of T2DM with impaired oxidative phosphorylation in muscle, its molecular pathogenesis remains largely unknown.\nOur data support adult tumors relying more on fatty acid oxidation, as they have an abundance of acyl carnitines compared to pediatric tumors and have significant enrichment of transcripts needed for oxidative phosphorylation.\nGene expression associations were identified between PPARGC1A and genes involved in angiogenesis, mitochondrial respiration, glucose transport, insulin signalling and transcriptional regulation.\ninsulin signalling (FOXO1, PPPARGC1A and SLC2A4);\nDifferential gene expression in PCOS cells at these time points involved triacylglycerol synthesis, lipid oxidation, free fatty acid beta-oxidation, and oxidative phosphorylation of the TCA cycle, with TGFB1 as a significant upstream regulator", "dois": ["10.1371/journal.ppat.1004684", "10.1186/s40478-025-01961-w", "10.1016/j.heliyon.2024.e40414", "10.1186/s13148-020-00970-x", "10.1016/j.bbrc.2016.11.055", "10.1111/j.1365-2052.2011.02238.x"]}
{"pair_type": "slc_pathway", "key1": "SLC2A4", "key2": "stemness", "summary": "Three metabolism-associated clusters with significantly different characteristics in disease-free survival (DFS), clinical stage, stemness index, tumor microenvironment including stromal and immune cells, DNA mutation ( and ), copy number variation, and microsatellite instability were identified in PCa.", "dois": ["10.3389/fonc.2020.598801"]}
{"pair_type": "slc_pathway", "key1": "SLC2A5", "key2": "chemotherapy", "summary": "Compensating for this, fructose was flexibly utilized by tumor cells as an alternative energy source to maintain proliferation and exert chemotherapy resistance in vitro by upregulating GLUT5, a major fructose transporter encoded by SLC2A5.\nIn addition, reducing dietary fructose or pharmacological blockade of fructose utilization significantly reduced CRC growth and sensitized CRC cells to chemotherapy in vivo.\nMechanistically, in glucose-deprived but fructose-rich environments, GLUT5 could interact with ketohexokinase and inhibit its autophagy-dependent degradation, thus trapping fructose into glycolysis and tricarboxylic acid cycle for the malignant growth of CRC cells.", "dois": ["10.1016/j.canlet.2022.215617"]}
{"pair_type": "slc_pathway", "key1": "SLC16A3", "key2": "glycolysis", "summary": "Mechanistically, sorafenib itself upregulates SLC16A3 protein expression by enhancing glycolysis, increasing lactate secretion which fosters an immunosuppressive TIME.\nOur findings suggest that nodakenetin inhibits the viability, promotes apoptosis, and represses glycolysis in breast cancer cells through decreasing SLC16A3 expression, proving the anti-cancer potential of nodakenetin in breast cancer.\nThe upregulated genes in SLC16A3-positive epithelial cells were enriched in the glycolysis process pathway and monocarboxylic acid metabolic process pathway.\nThe study reveals that LINC00035 promotes OC progression by regulating glycolysis and cell apoptosis through CEBPB-mediated transcriptional promotion of SLC16A3.\nMonocarboxylate transporter 4 (MCT4), encoded by SLC16A3 gene, is responsible for exporting lactic acid into the extracellular microenvironment, and an acidic microenvironment promotes cytokine production and remodels chronic inflammation, providing a link from glycolysis to inflammatory bowel disease (IBD).\nSLC16A3 upregulation reversed the effects of nodakenetin on the viability, apoptosis, and glycolysis in breast cancer cells.\nStatistically significant associations between SLC16A3 and m6A modification (ALKBH5) gene (p<0.001), key genes in aerobic glycolysis, M2 macrophage infiltration (p=0.0058), and immune checkpoint regulation were observed.\nMutant TP53-related (mTP53) pathways and genes including PKM, SLC16A3, HK2, PFKP, PHGDH, and CTSC were obtained from enrichment analysis and interestingly, top pathways were associated with metabolism including glycolysis and mTORC1 pathway.\nWe found that HIF1α-responsive genes, including many essential for glycolysis (SLC2A1, PDK1, LDHA, SLC16A3), were underexpressed in IDH(mt) gliomas and/or derived BTSCs.", "dois": ["10.1172/JCI176207", "10.1021/acs.molpharmaceut.3c00294", "10.1007/s00262-023-03382-x", "10.1038/s41388-021-02157-x", "10.1002/cam4.3945", "10.1186/s12967-019-02173-2", "10.1002/path.4006", "10.1016/j.bbrep.2025.102034", "10.1007/s00210-025-04585-y", "10.1002/glia.70066", "10.1158/0008-5472.CAN-24-2097", "10.1002/ags3.12793", "10.2174/0113862073278304240614064748", "10.1016/j.canlet.2024.216824", "10.1101/2023.10.03.560700", "10.1155/2023/9783125", "10.3389/fimmu.2023.1183825", "10.1016/j.heliyon.2023.e14896", "10.3390/biom13020258", "10.3390/ijms24031992", "10.1016/j.lfs.2022.120650", "10.2147/IJGM.S353592", "10.1155/2021/5802082", "10.3389/fonc.2021.704857", "10.2147/OTT.S304298", "10.3390/biomedicines8090310", "10.1016/j.bbagrm.2019.06.004", "10.1155/2018/2649491", "10.1016/j.bbacli.2015.11.001", "10.1158/1541-7786.MCR-14-0423", "10.1152/ajpendo.00484.2013", "10.1093/neuonc/not243", "10.1016/j.lfs.2021.119230", "10.1038/s41467-018-03525-0", "10.1371/journal.pone.0105038", "10.1007/s00394-013-0640-5", "10.1111/bph.12522", "10.1007/s00441-013-1722-7", "PMID:16514190", "PMID:15743406", "PMID:11052969", "PMID:10926847", "10.1016/j.ijbiomac.2025.148223"]}
{"pair_type": "slc_pathway", "key1": "SLC2A4", "key2": "apoptosis", "summary": "SLC2A4RG could attenuate cell proliferation via G2/M phase arrest and induce glioma cell apoptosis by direct transactivation of caspase-3 and caspase-6.\nSLC2A4 overexpression significantly enhanced proliferation but inhibited apoptosis in glucose-treated pancreatic cells.\nThe data indicated that miR-335-5p targeting of SLC2A4 could hamper the growth of T2D cell model by inhibiting their proliferation and elevating apoptosis.\nThe miR-335-5p mimic markedly suppressed proliferation and elevated apoptosis in glucose-treated pancreatic cells.\nMoreover, miR-335-5p inhibited the expression of SLC2A4 in the pancreatic cells and suppressed the growth of these cells.\nKnockdown of SNHG16 reduced PC cell proliferation, migration and invasion.\nShuttling SLC2A4RG is regulated by 14-3-3θ to modulate cell survival via caspase-3 and caspase-6 in human glioma.\nWe identify a new pro-oncogenic mechanism whereby 14-3-3θ negatively regulates the nuclear function of the tumor suppressor SLC2A4RG, with significant therapeutic implications for the intervention of human glioma.\nMoreover, its function displaying showed to depend on the nuclear transportation of SLC2A4RG, however, bound with 14-3-3θ, it would be sequestered in the cytoplasm followed by reversal effect.\nSNHG16 promoted the progression of PC via the miR-302b-3p/SLC2A4 axis and was expected to be a potential target for the early diagnosis and treatment of PC.\nUp-regulated genes in T2DM are mainly enriched in apoptosis pathways (TP53, GADD45A, TNFRSF10B, TP53AIP1, and PMAIP1), and notably include immune-related pathways suggestive of a response to various infectious diseases (C2, CFB, C4A, C4B, C1S, C1R, C3, HLA-DRA", "dois": ["10.3390/ijms26157515", "10.1016/j.phymed.2025.156866", "10.1016/j.ejphar.2025.177526", "10.1177/09603271211021476", "10.1016/j.bbrc.2021.04.011", "10.1016/j.ebiom.2019.01.030", "10.1093/biolre/ioy086", "10.1016/j.bbrc.2016.11.055", "10.3390/molecules20058409", "10.1016/j.repbio.2013.01.173", "10.3390/biology11060839", "10.3390/cells11091443", "10.3390/genes13040668", "10.1186/s12935-020-01715-9", "10.3389/fendo.2017.00233", "10.1007/s00726-017-2469-3", "10.1016/j.theriogenology.2012.09.019"]}
{"pair_type": "slc_pathway", "key1": "SLC2A4", "key2": "migration", "summary": "SNHG16 promoted the progression of PC via the miR-302b-3p/SLC2A4 axis and was expected to be a potential target for the early diagnosis and treatment of PC.\nKnockdown of SNHG16 reduced PC cell proliferation, migration and invasion.\nHypoxia facilitates the progression of the tumor from different aspects, including proliferation, metabolism, angiogenesis, and migration, and improves resistance to ICI.\nSevere hypoxia conditions promoted activation of some cancer-related signaling pathways, including Wnt, Notch, ECM-related pathways, and remodeled the tumor microenvironment of COAD, tending to present as an immune-excluded phenotype.\nIn addition, miR-302b-3p targeted SLC2A4 directly.\nSNHG16 acted as a sponge to regulate miR-302b-3p expression in PC cells.\nSNHG16 expression was significantly elevated in PC tissues and cell lines and was associated with poor prognosis of PC patients.", "dois": ["10.1530/JME-23-0050", "10.3389/fimmu.2022.853352", "10.3390/genes13040668", "10.1186/s12935-020-01715-9", "10.1016/j.theriogenology.2012.09.019"]}
{"pair_type": "slc_pathway", "key1": "SLC2A5", "key2": "ferroptosis", "summary": "Notably, α-DIPA robustly suppressed LPS-induced mRNA expression of abundant genes participating in the ferroptosis pathway, including Acsl4, Slc7a11, Me1, and Hmox1.\nInterestingly, the expressions of multiple ferroptosis-related genes were regulated specifically by α-DIPA but not LPS, such as Acsl5, Acsl6, Alox5, Cars, Dpp3, Dpp10, Slc2a5, and Slc7a1.\nα-DIPA inhibits microglial inflammation likely through regulating the pathways of the ferroptosis and NF-κB signaling.", "dois": ["10.1186/s12967-025-06296-7"]}
{"pair_type": "slc_pathway", "key1": "SLC2A4", "key2": "proliferation", "summary": "The potential tumor suppressor role of SLC2A4RG was further validated by in vitro and in vivo experiments that SLC2A4RG could attenuate cell proliferation via G2/M phase arrest and induce glioma cell apoptosis by direct transactivation of caspase-3 and caspase-6.\nSLC2A4 overexpression significantly enhanced proliferation but inhibited apoptosis in glucose-treated pancreatic cells.\nThe data indicated that miR-335-5p targeting of SLC2A4 could hamper the growth of T2D cell model by inhibiting their proliferation and elevating apoptosis.\nMoreover, miR-335-5p inhibited the expression of SLC2A4 in the pancreatic cells and suppressed the growth of these cells.\nWe show that our lead compound (compound 20) decreases glucose uptake and cell proliferation as well as inhibits the expression of pro-survival MCL-1 in MM similar to the effect observed via knockdown of GLUT4 expression.\nKnockdown of SNHG16 reduced PC cell proliferation, migration and invasion.\nThe miR-335-5p mimic markedly suppressed proliferation and elevated apoptosis in glucose-treated pancreatic cells.\nThe results showed that lobetyolin inhibited the proliferation of both MDA-MB-231 and MDA-MB-468 breast cancer cells.\nThe plasma cell malignancy multiple myeloma (MM) exhibits increased constitutive expression of GLUT4 on the PM, co-opting use of GLUT4 for survival and proliferation.\nHypoxia facilitates the progression of the tumor from different aspects, including proliferation, metabolism, angiogenesis, and migration, and improves resistance to ICI.\nIn comparison with control cells, rapamycin-treated cells exhibited reduced proliferation, similar to serum-starved cells.\nGranulosa cells exhibited transient proliferation senescence, oxidative stress, an increased rate of apoptosis, and a decline in steroidogenic activity.\nSNHG16 promoted the progression of PC via the miR-302b-3p/SLC2A4 axis and was expected to be a", "dois": ["10.1038/s41598-024-78357-8", "10.1038/s41586-024-07972-2", "10.1016/j.tjnut.2023.01.024", "10.1186/s12967-022-03846-1", "10.3390/biology11060839", "10.3389/fimmu.2022.853352", "10.3390/cells11091443", "10.1177/09603271211021476", "10.1016/j.bbrc.2021.04.011", "10.1186/s12935-020-01715-9", "10.1016/j.redox.2020.101668", "10.1016/j.ebiom.2019.01.030", "10.2174/1570163815666180801152110", "10.1016/j.ejmech.2017.08.029", "10.1007/s00726-017-2469-3", "10.1016/j.neo.2017.02.009", "10.1089/cell.2015.0090", "10.1371/journal.ppat.1004684", "10.4161/auto.26563", "10.1016/j.theriogenology.2012.09.019", "10.1530/REP-10-0146"]}
{"pair_type": "slc_pathway", "key1": "SLC2A5", "key2": "glycolysis", "summary": "Given that TKIs could inhibit SLC2A5 expression, repression of fructose utility after TKI treatment contributes to TKI-induced Ph+ALL cytotoxicity.\nMoreover, lung cancer cell migration and AKT activation were restrained by glycolysis inhibitor 2-deoxy-D-glucose (2-DG) or GLUT5-specific inhibitor 2,5-anhydro-D-mannitol (2,5-AM).\nSLC2A5, encoding the fructose transporter, GLUT5, was specifically upregulated in these cells.\nOur study unveils glycolysis/lactate/AKT pathway is responsible for lung cancer cell migration induced by GLUT5-mediated fructose metabolism, providing a potential therapeutic avenue for lung cancer metastasis.\nTo satisfy the improved energy demands, glycolysis flux is increased in cancers compared with healthy tissues.\nThe tyrosine kinase inhibitors (TKIs) imatinib and dasatinib repressed SLC2A5 expression and the cell uptake of fructose.\nOverexpression of SLC2A5 promoted migration of lung cancer cells both in vitro and in vivo, and shortened the overall survival of mice.\nMechanistically, in glucose-deprived but fructose-rich environments, GLUT5 could interact with ketohexokinase and inhibit its autophagy-dependent degradation, thus trapping fructose into glycolysis and tricarboxylic acid cycle for the malignant growth of CRC cells.\nEnhanced fructose metabolism mediated by GLUT5 directly contributes to cancer metastasis.\nGLUT5-mediated fructose utilization upregulated phosphorylated AKT, which was responsible for enhanced migration of lung cancer cells.\nGLUT5 permitted fructose to flux through glycolysis using hexokinase (HK) and not ketohexokinase (KHK).\nAdditionally, GLUT5-mediated fructose utilization boosted glycolysis with overproduction of lactate, resulting in upregulation of phosphorylated AKT.\nCompensating for this, fructose was flexibly", "dois": ["10.1007/s12094-022-03015-2", "10.2217/epi-2019-0072", "10.3390/nu9020181", "10.1186/s12974-025-03401-x", "10.1016/j.ijbiomac.2024.131892", "10.1016/j.heliyon.2024.e29655", "10.1165/rcmb.2022-0443OC", "10.1002/gcc.23147", "10.1016/j.canlet.2022.215617", "10.1186/s40170-021-00246-9", "10.1111/bjh.15580", "10.1530/JME-13-0194"]}
{"pair_type": "slc_pathway", "key1": "SLC2A3", "key2": "oxidative stress", "summary": "Mechanistically, the loss of OSGIN1 activates AMPK signaling through ATM, leading to the upregulation of SLC2A3, which protects cells from ferroptosis and renders them insensitive to ferroptosis inducers.\nGenes affected by insufficient sleep were associated with circadian rhythms (PER1, PER2, PER3, CRY2, CLOCK, NR1D1, NR1D2, RORA, DEC1, CSNK1E), sleep homeostasis (IL6, STAT3, KCNV2, CAMK2D), oxidative stress (PRDX2, PRDX5), and metabolism (SLC2A3, SLC2A5, GHRL, ABCA1).\nexpression of genes related to oxidative stress (HSPA5), cell metabolism (SLC2A3), cell repair (MSH6), placentation (KRT8 and PLAC8), and implantation (FOSL1) were assessed in the blastocysts.\nWe demonstrate that MAPK14 is phosphoactivated during nutrient deprivation and affects glucose metabolism at 2 different levels: on the one hand, it increases SLC2A3 mRNA and protein levels, resulting in a higher incorporation of glucose within the cell.\nThe MAPK14-driven metabolic reprogramming sustains the production of NADPH, an important cofactor for many reduction reactions and for the maintenance of the proper intracellular redox environment, resulting in reduced levels of ROS.\nHere, we provide evidence for a dual role of MAPK14 in driving a rearrangement of glucose metabolism that contributes to limiting reactive oxygen species (ROS) production and autophagy activation in condition of nutrient deprivation.\nThese modifications were associated with the redirection of glucose metabolism to appropriate defensive pathways under chronic stress conditions, and an increased ability to maintain mitochondrial function as potential adaptive responses.\nAlthough previous studies have demonstrated that chronic stress is associated with the overproduction of reactive oxygen species (ROS), which leads to oxidative stress and the disruption of glucose metabolism, the molecular mechanisms and cerebral gluconeogenesis in depression have not yet been completely elucidated.", "dois": ["10.3892/mmr.2019.9865", "10.4161/auto.29456", "10.1159/000547896", "10.1080/23723556.2025.2518773", "10.1038/s41698-024-00791-8", "10.3168/jds.2022-22390", "10.3389/fnut.2022.1001031", "10.1016/j.theriogenology.2020.10.028", "10.1017/S0007114519000047", "10.1071/RD18178", "10.1073/pnas.1217154110", "PMID:17616136"]}
{"pair_type": "slc_pathway", "key1": "SLC2A4", "key2": "glycolysis", "summary": "Moreover, SIRT6 could inhibit the Warburg effect by regulating glycolysis-related genes of SLC2A2, SLC2A4 and PKM2.\nWe conclude that adiponectin influences the glucose metabolism of rabbit blastocysts via the phosphorylation of PRKAA1/2, which in turn results in a decrease of gluconeogenesis and an increase in glycolysis.\nGenes related to glucose uptake, glycolysis, glycogen synthesis, fatty acid synthesis () are more activated in Luchuan, while genes related to fatty acid oxidation, cholesterol synthesis () are more suppressed.\nThese results suggest that tucum-do-cerrado consumption might induce Prkaa1α and Prkaa2α expression, which may inhibit gluconeogenic rate limiting enzyme, G6Pase, and upregulates GLUT2 hepatic glucose uptake.\nButyrate enhances insulin sensitivity and induces glycolysis, without the requirement of upregulated long-chain fatty acid oxidation.\nHCAR1 expressed in BAT can promote glucose entry and reduce lipolysis, resulting in body weight loss and increased insulin sensitivity.\nTaken together, our results support the interpretation that HCAR1 expressed in BAT promotes glucose entry and reduces lipolysis in BAT of male DIO mice.\nIncreased glucose entry and glycolysis in BAT result in lactate production and release.\nGlucose transport across glioblastoma membranes plays a crucial role in maintaining the enhanced glycolysis typical of high-grade gliomas and glioblastoma.\nAdiponectin enhanced embryonic glucose uptake and led to a translocation of solute carrier family 2 (facilitated glucose transporter), member 4 (SLC2A4), previously known as GLUT4.\nBy knocking down the gene encoding medium-chain 3-ketoacyl-CoA thiolase (MCKAT, Acaa2), butyrate oxidation was inhibited, which amplified the effects of the SCFA on insulin sensitivity and glycolysis.\nThe effect of HIF1α excessive activation is to increase the expression of genes encoding proteins directly involved in the glycolysis which may lead to pathological changes in glucose metabolism observe", "dois": ["10.1111/jcmm.70053", "10.1210/endocr/bqaa098", "10.1016/j.foodres.2018.07.032", "PMID:16736133", "10.1016/j.heliyon.2024.e40414", "10.3389/fgene.2023.1128033", "10.1152/ajpendo.00084.2022", "10.1016/j.bbadis.2022.166476", "10.7717/peerj.10604", "10.1016/j.neo.2017.02.009", "10.1530/JME-13-0194", "10.1095/biolreprod.110.084665"]}
{"pair_type": "slc_pathway", "key1": "SLC2A3", "key2": "proliferation", "summary": "Further results showed that NETs promoted LLC cell proliferation and migration and inhibited ferroptosis by promoting YTHDF2-mediated SLC2A3 mRNA degradation.\nThe proliferation rate of CRC cells was significantly reduced and apoptosis of CRC cells was increased after SLC2A3 was knocked down.\nIn HNSC cell lines, SLC2A3 knockdown inhibited cell proliferation and migration.\nInhibition of SLC2A3 by miR-106a attenuated cell proliferation and inhibited glucose uptake.\nKnockdown of SLC2A3 led to a significant increase in the proliferation of CD8 T cells compared to those without knockdown.\nInterestingly, exogenous lactic acid restored the EMT, proliferation, migration, and invasion abilities of oral cancer cells inhibited by knocking down SLC2A3.\nWe also found that oral squamous cell carcinoma cells had increased proliferation, migration, invasion, EMT phenotype, and glycolysis due to SLC2A3 overexpression.\nAlso, CTGF induced Glut3 (also known as SLC2A3) expression, leading to increased glycolysis, which enhanced cell proliferation and migration in tamoxifen-resistant cells.\nOverall, miR-103a can inhibit the proliferation of human colon cancer cells by targeting SLC2A3, and this result will provide a potential target for the treatment of colon cancer.\nCellular states which lead to increased energetic demand, such as organ development, proliferation, and cellular degeneration, appear particularly susceptible to alterations in SLC2A3 copy number.\nThen, through clone formation analysis, SLC2A3 was closely related to the proliferation of human colon cancer cells.\nWe also observed that high SLC2A3 expression led to EMT and the activation of the TGF-β signaling pathway, while knockdown inhibited it.\nThe upregulated expression of SLC2A3 is predominantly enriched in immune-related biological processes and linked to the suppression of CD8 T cells, which are crucial for the survival of HNSC patients.", "dois": ["10.1002/ijc.70180", "10.1080/23723556.2025.2518773", "10.1186/s12876-025-03878-z", "10.21037/tcr-24-1177", "10.1002/ctm2.70192", "10.1038/s41598-024-79417-9", "10.1038/s41598-024-78357-8", "10.4251/wjgo.v16.i5.2018", "10.1371/journal.pone.0301724", "10.1038/s41598-024-55048-y", "10.3389/fphar.2023.1253169", "10.1186/s12935-023-03159-3", "10.1242/jcs.260964", "10.3168/jds.2022-22390", "10.1080/19336950.2023.2208928", "10.3389/fphar.2023.1131610", "10.1186/s12894-023-01217-6", "10.1159/000528084", "10.18502/ijph.v50i12.7941", "10.1155/2022/2371057", "10.1016/j.csbj.2022.07.021", "10.1002/mrd.23570", "10.1016/j.tranon.2022.101389", "10.3389/fgene.2022.829384", "10.1007/s10620-021-07145-5", "10.1242/jcs.256503", "10.1002/jcp.29753", "10.1074/jbc.RA119.009827", "10.3389/fphar.2018.00502", "10.1016/j.gene.2018.04.086", "10.1371/journal.pone.0172430", "10.1186/2049-3002-2-11", "10.1186/1471-2407-13-478", "10.1186/1476-4598-12-78", "10.1016/j.theriogenology.2012.02.034", "10.1210/me.2009-0427", "PMID:18046015"]}
{"pair_type": "slc_pathway", "key1": "SLC2A5", "key2": "apoptosis", "summary": "On the other hand, deletion of the GLUT5-encoding gene SLC2A5 dramatically attenuated cellular malignancy via activating the apoptotic pathway.\nIn addition, hsa-mir-503 knockdown promoted 22RV1 cell apoptosis.\nDepletion of undermined cell proliferation and invasion meanwhile increased cell apoptosis.\nIn both sexes of yellow catfish, the cell cycle was arrested and apoptosis was inhibited under chronic hypoxia.\nThese findings suggest that maternal FA supplementation could improve the offspring's small intestinal phenotype and the expression of development-, apoptosis- and digestion-related genes, so it could promote the small intestinal development of newborn lambs.\nThe NF-kB pathway was also promoted to some extent in individuals in the HT group relative to the HS group to resist apoptosis.\nAlso genes associated with either cytotoxic responses or induction of apoptosis (BCL2L11, FOS, HMOX1, TIMP3, and AHR) were commonly upregulated and might represent future molecular biomarkers for hepatotoxicity.\nIn addition, the relative downregulation of apoptosis and autophagy-related genes, such as , , and , was also detected in the HT group.\nMeanwhile, the expression levels of insulin-like growth factor I (), B-cell lymphoma-2 ( and sodium/glucose co-transporter-1 () in the small intestines of the newborn lambs were increased, while the opposite was true for Bcl2-associated × ( in response to FA supplementation ( < 0.05).\nFlow cytometry was used to detect the effect of hsa-mir-503/hsa-mir-1247 knockdown on 22RV1 apoptosis rate.\nAbstract: The purpose of this study was to investigate the effect of maternal dietary folic acid (FA) supplementation during gestation on small intestinal development of newborn lambs of different litter sizes, focusing on the intestinal morphology and development-, apoptosis- and digestion-related genes expression.", "dois": ["10.1007/s10565-019-09478-4", "10.1089/scd.2013.0157", "10.1530/REP-08-0220", "10.1016/j.ijbiomac.2024.131892", "10.18632/aging.205213", "10.3390/ani13172717", "10.3390/ani10112183", "10.1038/s41420-018-0038-5", "PMID:19700929", "PMID:18466468"]}
{"pair_type": "slc_pathway", "key1": "SLC2A5", "key2": "migration", "summary": "We discovered that CRISPR/Cas9-mediated inactivation of the SLC2A5 gene inhibited cancer cell proliferation and migration as well as metastases in several animal models.\nWhile, SLC2A5 deletion blocked the migration of lung cancer cells.\nIts knockdown suppressed GC cell growth, invasion, and migration in vitro and in vivo, attenuated EMT, and reduced SLC2A5 expression.\nOverexpression of SLC2A5 promoted migration of lung cancer cells both in vitro and in vivo, and shortened the overall survival of mice.\nMoreover, lung cancer cell migration and AKT activation were restrained by glycolysis inhibitor 2-deoxy-D-glucose (2-DG) or GLUT5-specific inhibitor 2,5-anhydro-D-mannitol (2,5-AM).\nThe direct association of increased abundance of SLC2A5 in cancer cells with metastatic risk in several types of cancers identifies SLC2A5 as an important therapeutic target to reduce or prevent cancer metastasis.\nMoreover, SLC2A5-attenuated cancer cells exhibited dramatic alterations in mitochondrial architecture and localization, uncovering the importance of SLC2A5 in directing mitochondrial function for cancer cell motility and migration.\nCrucially, overexpression of SLC2A5 rescued the inhibitory effects of KLC3 knockdown on the MAPK pathway and EMT.\nGLUT5-mediated fructose utilization upregulated phosphorylated AKT, which was responsible for enhanced migration of lung cancer cells.\nThis study identifies KLC3 as a key oncoprotein that promotes GC progression by modulating the MAPK signaling pathway through a novel interaction with the fructose transporter SLC2A5.\nOur study unveils glycolysis/lactate/AKT pathway is responsible for lung cancer cell migration induced by GLUT5-mediated fructose metabolism, providing a potential therapeutic avenue for lung cancer metastasis.\nOverexpression of enhances cell proliferation, migration, invasion, and tumorigenic.\nEnhanced fructose metabolism mediated by GLUT5 directly contributes to", "dois": ["10.1186/s12885-025-15084-x", "10.18632/aging.205213", "10.1158/0008-5472.CAN-22-1844", "10.1007/s12094-022-03015-2", "10.3389/fcell.2022.896297", "10.3389/fonc.2020.01344", "10.1038/s41420-018-0038-5", "10.1095/biolreprod.112.100487"]}
{"pair_type": "slc_pathway", "key1": "SLC2A6", "key2": "ferroptosis", "summary": "Knockdown of SLC2A6 markedly suppressed the proliferation, migration, and invasion of HCC cells, with this inhibition being closely tied to the ferroptosis pathway.\nIn LIHC, SLC2A6 was associated with key biological processes, including the cell cycle, P53 signaling, and ferroptosis.\nEight core ferroptosis-related genes (ATF3, BNIP3, DDIT4, LPIN1, NOS2, NQO1, SLC2A1 and SLC2A6) were further selected in random forest model, which showed high diagnostic performance for PCOS.\nSLC2A6 plays a pivotal role in the regulation of pan-cancer processes, particularly in tumor prognosis and immune-related mechanisms.\nIn LIHC, it emerges as a potential prognostic biomarker and therapeutic target for the regulation of ferroptosis, offering new insights for targeted cancer therapies.\nSubsequently, further KEGG and GO analyses were performed, and it was found that it was enriched in the ferroptosis pathway, and then the ferroptosis-related differential genes were obtained.\nFurthermore, in vitro and in vivo experiments were performed to assess the impact of SLC2A6 knockout on the proliferation, migration, invasion, and underlying mechanisms in hepatocellular carcinoma (LIHC) cells.\nLasso cox regression analysis screened GCH1, IL6, and SLC2A6.\nIt was found that six of these genes, SRC, NCF2, SLC2A8, FTL, SLC2A6, SLC3A2, were present in all three datasets.\nSLC2A6 expression was significantly correlated with tumor prognosis, clinical stage, and methylation levels, and was found to influence immune cell infiltration and immune checkpoint gene expression.\nOur experimental results showed that the expression of GCH1 and IL6 in the LPS group was higher than that in the control group, but there was no difference in the expression of SLC2A6.\nImmunofluorescence staining, western blot and quantitative real-time PCR were performed to detect the expression of iNOS, CD206, GCH1,", "dois": ["10.1186/s13048-025-01637-y", "10.1038/s41598-025-85504-2", "10.3389/fendo.2024.1346842", "10.1007/s00011-023-01785-1"]}
{"pair_type": "slc_pathway", "key1": "SLC2A5", "key2": "stemness", "summary": "Moreover, the SLC2A family gene expression is significantly correlated with the pan-cancer stromal and immune scores, and the RNA and DNA stemness scores.\nA three-gene prognostic signature based on the stemness-hypoxia genes (, , and ) was constructed.\nThe stemness of cancer cells and hypoxic microenvironment in HCC influence tumor progression and resistance to anti-tumor therapies.\nThe prognostic stemness-hypoxia genes were identified using Cox regression analysis and a stemness-hypoxia prognostic model was constructed.\nWe then examined the association among SLC2As expression and TME, Stemness score, clinical characteristics, immune subtypes, and drug sensitivity.\nOur established stemness-hypoxia gene signature showed favorable prognosis performance for HCC and was related to TIME.\nHerein, we aimed to combine tumoral stemness and hypoxia features to evaluate the prognosis and tumor immune microenvironment (TIME) in HCC.\nFor instance, SLC2A2 and SLC2A5 were associated with the overall survival (OS) of hepatocellular carcinoma.", "dois": ["10.21037/tcr-24-2030", "10.1016/j.heliyon.2024.e29655"]}
{"pair_type": "slc_pathway", "key1": "SLC2A6", "key2": "apoptosis", "summary": "Overexpression of SLC2A6 could inhibit proliferation, promote mitochondrial damage, and result in apoptosis of tumor cells.\nThe differential analysis demonstrated that 32 transcription factors and 135 target genes were mainly modulated (FDR set at 0.1) including the upregulation of lipid and carbohydrates metabolism (HMGSC2, LDHA, GLUT3), fibrin metabolism (FGG, FGB), apoptosis (CASP7).\nIn summary, the risk signature provides a reference for BC risk assessment, and the signature gene SLC2A6 could act as a tumor suppressor in BC.\nAll these changes were associated with unaffected glucose-stimulated insulin secretion (GSIS), suggesting that they precede the defect of insulin secretion and death induced by PA.\nDevelopmental neurotoxicity was characterized by brain apoptosis, damage to the central nervous system (P < 0.01) and peripheral motor neurons (P < 0.0001), and reduced autonomous motor distance (P < 0.01).\nThis list contained previously identified changes and was enriched for genes involved in many cancer-related processes such as tissue remodelling, inflammation, differentiation and apoptosis.\nNeurodevelopmental toxicity has been studied in particular in terms of central nervous system apoptosis, peripheral motor abnormalities, and abnormal autonomic motor behavior.\nThe HSP70 family member protein HSPA6 could bind with SLC2A6 and increase with the increased expression of SLC2A6.\nThe signature gene SLC2A6 was found to have an abnormally low expression in tumor tissues.", "dois": ["10.1016/j.ecoenv.2025.118111", "10.1007/s10495-024-01964-3", "10.1016/j.gene.2024.148441", "10.1371/journal.pone.0035276"]}
{"pair_type": "slc_pathway", "key1": "SLC2A5", "key2": "oxidative stress", "summary": "transcript abundance increased for SLC2A1 and SLC2A5 and decreased for DGAT1 and GPX1.\nGenes affected by insufficient sleep were associated with circadian rhythms (PER1, PER2, PER3, CRY2, CLOCK, NR1D1, NR1D2, RORA, DEC1, CSNK1E), sleep homeostasis (IL6, STAT3, KCNV2, CAMK2D), oxidative stress (PRDX2, PRDX5), and metabolism (SLC2A3, SLC2A5, GHRL, ABCA1).\nEmbryos cultured with 10 or 50 μM DGAT1 inhibitor had greater mitochondrial activity (P < 0.01), and increased number of cells (P < 0.05), while the cytoplasmic lipid content was reduced (P < 0.01), the latter associated with altered expression profiles of selected genes regulating lipid metabolism or genes related with oxidative stress (transcript abundance increased for SLC2A1 and SLC2A5 and decreased for DGAT1 and GPX1).\ninhibition of DGAT1 synthesis in bovine embryos produced in vitro abrogates the negative effect of FCS by decreasing their lipid content, increasing mitochondria activity and improving embryo cryotolerance, as well as favoring the expression of lipid metabolism regulating and oxidative stress-related transcripts.", "dois": ["10.1016/j.theriogenology.2020.09.014", "10.1073/pnas.1217154110"]}
{"pair_type": "slc_pathway", "key1": "SLC2A5", "key2": "proliferation", "summary": "We discovered that CRISPR/Cas9-mediated inactivation of the SLC2A5 gene inhibited cancer cell proliferation and migration as well as metastases in several animal models.\nCompensating for this, fructose was flexibly utilized by tumor cells as an alternative energy source to maintain proliferation and exert chemotherapy resistance in vitro by upregulating GLUT5, a major fructose transporter encoded by SLC2A5.\nCrucially, overexpression of SLC2A5 rescued the inhibitory effects of KLC3 knockdown on the MAPK pathway and EMT.\nOverexpression of enhances cell proliferation, migration, invasion, and tumorigenic.\nDepletion of undermined cell proliferation and invasion meanwhile increased cell apoptosis.\nIts knockdown suppressed GC cell growth, invasion, and migration in vitro and in vivo, attenuated EMT, and reduced SLC2A5 expression.\nThis indicates that fructose uptake is the limiting factor for fructose-mediated cell proliferation.\nOn the other hand, deletion of the GLUT5-encoding gene SLC2A5 dramatically attenuated cellular malignancy via activating the apoptotic pathway.\nMechanistically, KLC3 interacts with SLC2A5, potentially regulating its membrane localization and stability, and thus activating the MAPK pathway.\nMoreover, administration of 2,5-anhydro-D-mannitol (2,5-AM), a competitive inhibitor of fructose uptake, could markedly suppress ccRCC cell growth.\nIn addition, reducing dietary fructose or pharmacological blockade of fructose utilization significantly reduced CRC growth and sensitized CRC cells to chemotherapy in vivo.\nHigh GLUT5 expression exacerbated the neoplastic phenotypes of ccRCC cells, including cell proliferation and colony formation.\nWe show that GLUT5 is a robust and generalizable driver of fructose-dependent cell proliferation.\nA positive selection approach was used to \"train\" non-fructolytic PC3 cells to utilize fructose for proliferation.\nThe expression of determined fructose uptake and utilization efficacy in", "dois": ["10.1186/s12885-025-15084-x", "10.1186/s12967-025-06296-7", "10.1158/0008-5472.CAN-22-1844", "10.3389/fcell.2022.896297", "10.1016/j.canlet.2022.215617", "10.3389/fgene.2021.778487", "10.1038/s41598-021-92525-0", "10.1186/s40170-021-00246-9", "10.2217/epi-2019-0072", "10.1007/s10565-019-09478-4", "10.1038/s41420-018-0038-5", "10.1089/scd.2013.0157", "10.1530/REP-10-0146"]}
{"pair_type": "slc_pathway", "key1": "SLC2A7", "key2": "migration", "summary": "In vitro and in vivo experiments showcased that SLC2A1 inhibition significantly hampered LUAD A549 cell proliferation, migration, and invasion capabilities, as well as tumor growth in nude mice.\nSLC2A1 and SLC2A7 emerged as prognostic biomarkers for LUAD.", "dois": ["10.1371/journal.pone.0324043"]}
{"pair_type": "slc_pathway", "key1": "SLC2A6", "key2": "proliferation", "summary": "Overexpression of SLC2A6 could inhibit proliferation, promote mitochondrial damage, and result in apoptosis of tumor cells.\nKnockdown of SLC2A6 markedly suppressed the proliferation, migration, and invasion of HCC cells, with this inhibition being closely tied to the ferroptosis pathway.\nFurthermore, in vitro and in vivo experiments were performed to assess the impact of SLC2A6 knockout on the proliferation, migration, invasion, and underlying mechanisms in hepatocellular carcinoma (LIHC) cells.\nMoreover, senescent CAFs significantly promoted ESCC cell proliferation and migration as shown by CCK-8 and scratch assays.\nIn summary, the risk signature provides a reference for BC risk assessment, and the signature gene SLC2A6 could act as a tumor suppressor in BC.\nIn LIHC, SLC2A6 was associated with key biological processes, including the cell cycle, P53 signaling, and ferroptosis.\nSLC2A6 plays a pivotal role in the regulation of pan-cancer processes, particularly in tumor prognosis and immune-related mechanisms.\nSLC2A6 expression was significantly correlated with tumor prognosis, clinical stage, and methylation levels, and was found to influence immune cell infiltration and immune checkpoint gene expression.\nSoluble vector family member 6 (SLC2A6) has been implicated in the aggressiveness and poor prognosis of various cancers, yet its specific role in hepatocellular carcinoma (HCC) remains to be fully elucidated.\nIn LIHC, it emerges as a potential prognostic biomarker and therapeutic target for the regulation of ferroptosis, offering new insights for targeted cancer therapies.\nThe HSP70 family member protein HSPA6 could bind with SLC2A6 and increase with the increased expression of SLC2A6.", "dois": ["10.1038/s41598-025-85504-2", "10.7150/jca.100430", "10.1007/s10495-024-01964-3"]}
{"pair_type": "slc_pathway", "key1": "SLC2A8", "key2": "apoptosis", "summary": "Subsequently, relative transcript abundance (RA) of IGF-related genes (IGFR1, IGFBP2, and IGFBP3), glucose transporter genes (SLC2A4 and SLC2A8), and apoptosis-related genes (BAX and BCL-XL) was analyzed.\nHowever, RA of BAX and BCL-XL genes decreased in response to all IGF-I concentrations, whereas the BCL-XL/BAX RA ratio was enhanced when embryos were cultured in medium containing 150ng/ml of IGF-I.\nIGF-I treatment did not affect RA of IGFR1, IGFBP3, and SLC2A4 genes, but decreased RA of IGFBP2 and SLC2A8 genes.\nHowever, IGF-I at the highest dose was able to increase the BCL-XL/BAX transcript expression ratio.\nThis may indicate that the primary role of IGF-I during the first days of embryo development in the pig is associated with anti-apoptotic actions rather than with growth stimulation.", "dois": ["10.1016/j.repbio.2013.01.173"]}
{"pair_type": "slc_pathway", "key1": "SLC2A5", "key2": "oxidative phosphorylation", "summary": "In gene expression analyses, oxidative phosphorylation, glycolysis, and protein secretion were upregulated in patients with TP53 and/or RB1 alterations.\nIn the brain, microglia predominantly express the fructose transporter SLC2A5 (GLUT5), and enzymes involved in fructolysis and endogenous fructose production, with their expression being upregulated in aging and disease.\nWhile homeostatic microglia are driven by oxidative phosphorylation (OXPHOS) and glycolysis, in aging and AD, microglia shift further towards glycolysis.\nOther pathways, including the TCA cycle, oxidative phosphorylation, and Parkinson's and Huntington's disease, were highly enriched by hypoxia in male fish, suggesting that mitochondrial function was dysregulated.\nMulti-omics suggested that SLC2A5, CD209, LGMN, and NEDD8 served as sex-specific markers in these fish under chronic hypoxia.", "dois": ["10.1186/s12974-025-03401-x", "10.1016/j.ijbiomac.2024.131892", "10.1165/rcmb.2022-0443OC", "10.1002/gcc.23147"]}
{"pair_type": "slc_pathway", "key1": "SLC2A6", "key2": "glycolysis", "summary": "Furthermore, we show that Slc2a6 regulates the myogenic differentiation of C2C12 myoblasts partly through the glycolysis pathway by targeting LDHB, which affects lactic acid accumulation.\nBoth metabolomics and RNA-seq analyses showed that the significantly differentially expressed genes (e.g., LDHB) and metabolites (e.g., Lactate) during the myogenic differentiation of C2C12 myoblasts post-Slc2a6-RNAi were enriched in the glycolysis pathway.\nA mechanistic study further validated that YBX1 was upregulated in TNBC cell lines, and knockdown of YBX1 suppressed expression of those glycolytic genes.\nMetabolic reprogramming is one of the hallmarks of cancer, and aberrant glycolysis was reported to be upregulated in TNBC.\nAfter gene ontology analysis along with the Kyoto Encyclopedia of Genes and Genomes, 16 genes associated with glycolysis, fatty acid metabolism, protein metabolism, and heme content were identified as candidate genes that regulate the color of chicken breast meat, especially (redness), (yellowness), (lightness), and (lightness).\nOur data revealed an YBX1-glycolysis-EMT network as an attractive diagnostic marker and metabolic target in TNBC patients.\nMeat color, an important index of chicken quality, is highly related to heme pigment, glycolysis, and intramuscular fat metabolisms.\nNotably, we found a transcription factor named Y-box-binding protein 1 (YBX1) to be strongly associated with this glycolysis gene signature, and it was overexpressed in TNBC.\nOur study broadens the understanding of myogenic differentiation and offers the Slc2a6-LDHB axis as a potential therapeutic target for the treatment of diabetes-associated muscle atrophy.\nThus, identifying metabolic biomarkers for diagnoses and investigating cross-talk between glycolysis and invasiveness could potentially enable the development of therapeutics for patients with TNBC.\nIn order to determine novel and reliable metabolic biomarkers for predicting clinical outcomes of TNBC, we analyzed transcriptome levels", "dois": ["10.3390/cells10081890", "10.1186/s12964-022-00915-2", "10.3390/genes13020307"]}
{"pair_type": "slc_pathway", "key1": "SLC2A8", "key2": "migration", "summary": "However, porcine conceptuses develop rapidly through extensive cellular proliferation and migration as they elongate and attach to the uterine wall resulting in increased metabolic demands.\nOxidative metabolism primarily occurs through the tricarboxylic acid (TCA) cycle and the electron transport chain, but proliferating and migrating cells, like the trophectoderm of pigs, enhance aerobic glycolysis.\nGlucose and fructose enter cells via their transporters, SLC2A, SLC2A3, and SLC2A8, and amino acids enter the cells via specific transporters that are expressed by the conceptus trophectoderm.\nThe synthesis of ATP, nucleotides, amino acids, and fatty acids through these biosynthetic pathways is essential to support elongation, migration, hormone synthesis, implantation, and early placental development of conceptuses.\nConceptus elongation and early placentation involve growth and remodeling that requires proliferation and migration of cells.", "dois": ["10.1002/mrd.23570"]}
{"pair_type": "slc_pathway", "key1": "SLC2A9", "key2": "migration", "summary": "Compared to that in HCV-associated cirrhosis, the expression levels of PABPC1 and UHRF1 are higher while the expression level of SLC2A9 is lower in clinical HCV-associated HCC samples.\nUHRF1 enhances the proliferation and migration ability of HCC cells.\nUHRF1 serves as an oncogene that promotes the proliferation and migration of HCC cells.", "dois": ["10.21037/tcr-22-989"]}
{"pair_type": "slc_pathway", "key1": "SLC2A7", "key2": "proliferation", "summary": "In vitro and in vivo experiments showcased that SLC2A1 inhibition significantly hampered LUAD A549 cell proliferation, migration, and invasion capabilities, as well as tumor growth in nude mice.\nSLC2A1 and SLC2A7 emerged as prognostic biomarkers for LUAD.\nA significant negative correlation was observed between SLC2A1 expression and DNA methylation levels in LUAD, and the gene was closely linked to cellular processes such as cell nuclear division, DNA replication, and metabolism.", "dois": ["10.1371/journal.pone.0324043"]}
{"pair_type": "slc_pathway", "key1": "SLC2A8", "key2": "proliferation", "summary": "Slc2a8 knockout mice were viable, developed normally, and showed mild alterations in brain (increased proliferation of neuronal cells in dentate gyrus of the hippocampus, hyperactivity), heart (impaired transmission of electrical wave through the atrium), and sperm cells (reduced number of motile sperm cells associated with reduced mitochondrial membrane potential and ATP levels in sperm).\nHowever, porcine conceptuses develop rapidly through extensive cellular proliferation and migration as they elongate and attach to the uterine wall resulting in increased metabolic demands.\nMechanistically, si-SLC7A6-RI isoform exerted oncogenic effects by activating the PI3K-Akt-mTOR signaling pathway and promoting cell proliferation, evidenced by increased expression of key regulators Phosphorylated Mammalian Target of Rapamycin (p-mTOR) and a cell proliferation marker Proliferating Cell Nuclear Antigen (PCNA) using western blotting.\nKnockdown of the intronic region of SLC7A6-RI isoform enhanced colon cancer cell proliferation.\nResults show that even a short in vivo exposure of oocytes to a supraphysiological IGF-1 microenvironment can increase ICM cell proliferation in vitro during the morula to blastocyst transition.\nOxidative metabolism primarily occurs through the tricarboxylic acid (TCA) cycle and the electron transport chain, but proliferating and migrating cells, like the trophectoderm of pigs, enhance aerobic glycolysis.\nThe mRNA expression of SLC2A8 was higher in morulae collected from cows treated with IGF-1.\nConceptus elongation and early placentation involve growth and remodeling that requires proliferation and migration of cells.\nCompacted morulae were non-surgically collected and frozen for subsequent mRNA expression analysis (IGF1R, IGBP3, TP53, AKT1, SLC2A1, SLC2A3, and SLC2A8), or underwent confocal microscopy analysis for protein localization (IGF1R and TP53), or were cultured in vitro for 24 h.", "dois": ["10.1111/cas.16351", "10.1002/mrd.23570", "10.1016/j.theriogenology.2012.02.034", "10.1530/REP-10-0146", "10.1152/ajpendo.91019.2008"]}
{"pair_type": "slc_pathway", "key1": "SLC2A6", "key2": "migration", "summary": "Knockdown of SLC2A6 markedly suppressed the proliferation, migration, and invasion of HCC cells, with this inhibition being closely tied to the ferroptosis pathway.\nFurthermore, in vitro and in vivo experiments were performed to assess the impact of SLC2A6 knockout on the proliferation, migration, invasion, and underlying mechanisms in hepatocellular carcinoma (LIHC) cells.\nMoreover, senescent CAFs significantly promoted ESCC cell proliferation and migration as shown by CCK-8 and scratch assays.\nMoreover, YBX1 expression was positively associated with epithelial-to-mesenchymal transition (EMT) genes in breast cancer patients, and suppression of YBX1 downregulated expressions of EMT-related genes and tumor migration and invasion in MDA-MB-231 and BT549 TNBC cells.\nA mechanistic study further validated that YBX1 was upregulated in TNBC cell lines, and knockdown of YBX1 suppressed expression of those glycolytic genes.\nSLC2A6 expression was significantly correlated with tumor prognosis, clinical stage, and methylation levels, and was found to influence immune cell infiltration and immune checkpoint gene expression.\nIn LIHC, SLC2A6 was associated with key biological processes, including the cell cycle, P53 signaling, and ferroptosis.\nSLC2A6 plays a pivotal role in the regulation of pan-cancer processes, particularly in tumor prognosis and immune-related mechanisms.\nIn LIHC, it emerges as a potential prognostic biomarker and therapeutic target for the regulation of ferroptosis, offering new insights for targeted cancer therapies.\nSoluble vector family member 6 (SLC2A6) has been implicated in the aggressiveness and poor prognosis of various cancers, yet its specific role in hepatocellular carcinoma (HCC) remains to be fully elucidated.\nTriple-negative breast cancer (TNBC) is the most malignant subtype of breast cancer as it shows a high capacity for metastasis and poor prognoses.\nMetabolic reprogramming is one of the hallmarks of cancer, an", "dois": ["10.1038/s41598-025-85504-2", "10.7150/jca.100430", "10.3390/cells10081890"]}
{"pair_type": "slc_pathway", "key1": "SLC2A8", "key2": "glycolysis", "summary": "Glucose and fructose enter cells via their transporters, SLC2A, SLC2A3, and SLC2A8, and amino acids enter the cells via specific transporters that are expressed by the conceptus trophectoderm.\nOxidative metabolism primarily occurs through the tricarboxylic acid (TCA) cycle and the electron transport chain, but proliferating and migrating cells, like the trophectoderm of pigs, enhance aerobic glycolysis.\nA result of aerobic glycolysis is limited availability of pyruvate for maintaining the TCA cycle, and trophectoderm cells likely replenish TCA cycle metabolites primarily through glutaminolysis to convert glutamine into TCA cycle intermediates.\nThe glycolytic intermediates from glucose can then be shunted into the pentose phosphate pathway and one-carbon metabolism for the de novo synthesis of nucleotides.", "dois": ["10.3390/ijms242316992", "10.1002/mrd.23570", "10.1113/JP272301"]}
{"pair_type": "slc_pathway", "key1": "SLC2A9", "key2": "chemotherapy", "summary": "Five genes were significantly upregulated: SLC2A9, SLC16A3, SLC16A14, SLC38A4 and SLC39A8.\nPossible drug resistance genes like Atg14, Abcb1b, Tbx2, Slc2a9, Slc10a3 and Slc22a18 were up-regulated while Foxm1, Bcl2, Brca1, Chek1, Hiatl1 and Abcb9 were down regulated.\nIn results of MDR development during chemotherapy cancer cells become resistant to further treatment.\nOvercoming chemoresistance will prevent cancer relapse and contribute to clinical chemotherapy.\nABCG2 is a semi-transport protein that plays a key role in human diseases, including bladder cancer and lung cancer, and maybe resistant to chemotherapy drugs.\nThe present study investigated whether single nucleotide polymorphisms (SNPs) in genes encoding these proteins were predictive or prognostic factors in patients with metastatic gastric cancer (MGC) undergoing chemotherapy.\nTaken together, these results will contribute to revealing the mechanism of chemoresistance and discovering potential prognostic factors for cancer medication.\nIn order to explore the underlying mechanism of chemoresistance, we firstly incubated cancer cells with a combination of cisplatin + paclitaxel (C + P) or cisplatin + paclitaxel + docetaxel (C + P + D) to mimic the treatment of cancer therapy in the laboratory.\nABC and SLC transporters are most important proteins responsible for this phenomenon.\nA retrospective study of 108 MGC patients who received epirubicin, oxaliplatin, and 5-fluorouracil (EOF) as first-line treatment was performed.\nIn this study changes of ABC and SLC genes expression pattern in drugs resistant sublines of the A2780 ovarian cancer cell line were demonstrated.\nExpression profiles of these genes give strong arguments for assumption of correlation between expression of ABC and SLC genes and drug resistance phenomenon.\nCytochrome-P450 enzymes, ATP-binding cassette transporters, and solute carriers mediate drug metabolism as metabolic enzymes and membrane transporters, respectively.", "dois": ["10.2174/1574892816666210218220531", "10.3892/ol.2018.9147", "10.1039/c7mb00334j", "10.1016/j.biopha.2014.02.002"]}
{"pair_type": "slc_pathway", "key1": "SLC2A8", "key2": "oxidative phosphorylation", "summary": "Functional analyses revealed differentially expressed genes involved in various metabolic pathways associated with cellular respiration, oxidative phosphorylation, and ATP synthesis.\nCollectively, these data indicate that deficiency may impact placental uptake of glucose, but that its likely primary function in trophoblast cells is to support cellular respiration.\nSince the placenta oxidizes the majority of the glucose it takes up to support its own metabolic needs, impairment of SLC2A8 function could set the stage for functional placental insufficiency.", "dois": ["10.3390/cells13050391"]}
{"pair_type": "slc_pathway", "key1": "SLC2A8", "key2": "ferroptosis", "summary": "It was found that six of these genes, SRC, NCF2, SLC2A8, FTL, SLC2A6, SLC3A2, were present in all three datasets.\nFour genes, including DUSP1, GPX4, HSD17B11, and SLC2A8, were technically selected and determined to be potential biomarkers for iNOA.\nDifferentially spliced SLCs were enriched in biological processes, including transmembrane transporter activity, transporter activity, ferroptosis, and choline metabolism.\nWe developed a prognostic risk model based on the screened 6-SLC-AS (SLC7A6_RI_37208 (SLC7A6-RI), SLC11A2_AP_21724, SLC2A8_ES_87631, SLC35B1_AA_42317, SLC39A11_AD_43204, and SLC7A8_AP_26712).\nSubsequently, further KEGG and GO analyses were performed, and it was found that it was enriched in the ferroptosis pathway, and then the ferroptosis-related differential genes were obtained.\nOur findings demonstrated that these ferroptosis genes could be involved in the underlying pathogenesis mechanisms of iNOA by regulating ferroptosis and serve as potential diagnostic biomarkers.\nSRC involves in lysosomal function and regulates ferroptosis in polycystic ovary syndrome.\nSRC, as an important gene involved in lysosomal function and regulating ferroptosis, is expected to be a potential target for PCOS.\nThe ferroptotic features, like shrunken mitochondria with electron-dense membranes and a reduction in cristae were observed across various cell types within iNOA patients, accompanied by the overload of ferrous ions and increased lipid peroxidation production.\nDifferentially expressed ferroptotic genes were identified from iNOA mRNA microarray datasets by bioinformatic analyses, and these ferroptotic genes were subsequently filtered by various algorithms.\nGenerally, 11 differentially expressed ferroptotic genes were downregulated, and five genes were upregulated in iNOA samples.", "dois": ["10.1186/s13048-025-01637-y", "10.1111/cas.16351", "10.1080/19396368.2023.2257352"]}
{"pair_type": "slc_pathway", "key1": "SLC39A3", "key2": "apoptosis", "summary": "Zip3-null mice also had altered mammary tissue architecture, increased number of apoptotic cells, and reduced mammary gland weight implicating subtle changes in Zip3-mediated intracellular Zn pools in apoptosis regulation.", "dois": ["10.1152/ajpregu.00162.2009"]}
{"pair_type": "slc_pathway", "key1": "SLC2A9", "key2": "apoptosis", "summary": "With Bonferroni correction, SLC2A9 (solute carrier family 2 member 9), LRRC20 (leucine rick repeat containing 20), PLK1 (polo like kinase 1), and AATK (apoptosis-associated tyrosine kinase) were all 2-fold changed genes.\nThe analysis of differentially expressed genes using the gene ontology (GO) classification indicated that the following were enriched: downregulated genes such as cell cycle, extracellular matrix, glycosylphosphatidylinositol-anchor biosynthesis and upregulated genes such as calcium signaling, neurotrophin signaling, apoptosis, arginine and proline metabolism, gap junction, transforming growth factor-β signaling, tight junction, vascular smooth muscle contraction, and vascular endothelial growth factor (VEGF) signaling.\nGenes involved in the pathways of p53 signaling, lysosomes and apoptosis were up-regulated, and in contrast, genes in the cell cycle, DNA replication, and mismatch repair pathways were down-regulated.\nPossible drug resistance genes like Atg14, Abcb1b, Tbx2, Slc2a9, Slc10a3 and Slc22a18 were up-regulated while Foxm1, Bcl2, Brca1, Chek1, Hiatl1 and Abcb9 were down regulated.", "dois": ["10.3727/096504018X15199489058224", "10.1039/c7mb00334j", "10.5213/inj.2346074.037", "10.1080/08820139.2023.2168554"]}
{"pair_type": "slc_pathway", "key1": "SLC2A9", "key2": "glycolysis", "summary": "Two important pathways determining hyperuricemia have been confirmed (renal and gut excretion of uric acid with glycolysis now firmly implicated).\nExcess circulating uric acid, a product of hepatic glycolysis and purine metabolism, often accompanies metabolic syndrome.\nThe largest genetic effects are seen in genes involved in the renal excretion of uric acid, with others being involved in glycolysis.\nHere we present a genetic model of spontaneous, early-onset metabolic syndrome in mice lacking the enterocyte urate transporter Glut9 (encoded by the SLC2A9 gene).\nRecent studies show that SLC2A9 is involved in renal and gut excretion of uric acid and is implicated in antioxidant defense.\nGlut9-deficient mice develop impaired enterocyte uric acid transport kinetics, hyperuricaemia, hyperuricosuria, spontaneous hypertension, dyslipidaemia and elevated body fat.\nThese data provide evidence that hyperuricaemia per se could have deleterious metabolic sequelae.\nMoreover, these findings suggest that enterocytes may regulate whole-body metabolism, and that enterocyte urate metabolism could potentially be targeted to modulate or prevent metabolic syndrome.\nThe positions of implicated genetic variants within or near chromatin regions involved in transcriptional control suggest that this mechanism (rather than structural changes in SLC2A9) is important in regulating the activity of SLC2A9.", "dois": ["10.1016/j.rdc.2014.01.009", "10.1186/s13075-015-0609-2", "10.1038/ncomms5642"]}
{"pair_type": "slc_pathway", "key1": "SLC2A9", "key2": "proliferation", "summary": "Inhibition of ENSR00000165816 significantly reduced transcript level of SLC2A9 and impaired cell proliferation and invasion.\nUHRF1 enhances the proliferation and migration ability of HCC cells.\nUHRF1 serves as an oncogene that promotes the proliferation and migration of HCC cells.\nHCC cell lines with UHRF1 knockdown or overexpression were assayed for cell proliferation and migration.", "dois": ["10.1002/hed.27316", "10.21037/tcr-22-989", "10.3727/096504018X15199489058224"]}
{"pair_type": "slc_pathway", "key1": "SLC39A4", "key2": "oxidative stress", "summary": "ZIP4 upregulation aggravates nucleus pulposus cell degradation by promoting inflammation and oxidative stress by mediating the HDAC4-FoxO3a axis.\nZIP4 upregulation aggravates the extracellular matrix (ECM) degradation of NP cells by mediating inflammation and oxidative stress through the HDAC4-FoxO3a axis.\nZIP4 upregulation bolstered inflammation and oxidative stress in NP cells undergoing IL-1β treatment and exacerbated their extracellular matrix degradation, whereas ZIP4 knockdown produced the opposite outcome.\nMechanistically, ZIP4 upregulated HDAC4 and enhanced NF-κB phosphorylation while repressing Sirt1 and FoxO3a phosphorylation levels.\nHDAC4 knockdown or Sirt1 promotion attenuated the effects mediated by ZIP4 overexpression in NP cells.\nThe ZIP4 profile increased in the NP tissues of IDD patients and IL-1β- or HO-treated NP cells.\nWe found that CBD upregulates the expression of the mRNAs for metallothionein 2 (Mt2), N-myc-downstream regulated gene 1 and matrix metalloproteinase 23 as well as of the zinc transporters ZnT1/Slc30a1 and Zip4/Slc39a4 but downregulates the expression of the mRNA for the zinc transporter Zip10/Slc39a10 as well as for the zinc finger protein 472.\nGene expression signature showed dysregulation in mediators associated with autophagy, ubiquitination, ER stress, oxidative stress, carbohydrate metabolism, solute transport, and T cell regulation in the colonic mucosa from patients with UC, suggesting that these genes could be involved in the pathogenesis of UC.\nThe gene expressions of FOXO4, ALDOB, SOD2, TOD2, SLC26A3, and SLC39A4 were associated with the clinical course and histological activity and are of relevance since these provide the utility of new prognostic markers in IBD.", "dois": ["10.1155/2020/9238970", "10.1016/j.neuint.2011.12.002", "10.18632/aging.205412"]}
{"pair_type": "slc_pathway", "key1": "SLC16A3", "key2": "oxidative stress", "summary": "4-NQO/EtOH treatment also caused increases in markers of oxidative stress, including 4-HNE, MCT4/SLC16a3, and TOM20, as measured by immunohistochemistry.\nDuplications of the bidirectional α-ketoacid transporters SLC16A3, SLC16A7, the cystine transporters SLC7A9, SLC7A11, and N-glycan branching enzymes MGAT4B, MGAT4C in Neoaves suggests a shift to the transport of deaminated essential amino acid, and stronger mitigation of oxidative stress supported by the galectin lattice.\nIt was found for the first time that EMB promoted lactic acid accumulation and further induced redox dyshomeostasis and glycolysis disorder by simultaneously inhibiting SLC16A1/3.\nThe background working of the AMPK pathway through upregulation of AKT1, AMPK, SIRT1, PYGM, SLC2A4 and SERBP1 genes, and downregulation of PPARGICIA, IGF2, PPARA, SLC27A3, SLC16A3, TSC1/2, KCNJ2, KCNJ16, etc., evidence the repression of cellular transcriptional activity and energetic homeostasis modifications in response to heat stress.\nHigh inflammatory response was found to be responsible for oxidative-stress-mediated apoptosis of GCs and nodes towards the involvement of the NF-κB pathway and repression of the Nrf2 pathway.\nSubsequently, EMB was released and mediated the lactic acid accumulation and the GA-Fe nanoparticle synergistic Fenton reaction to promote ROS accumulation, thereby increasing the lethality of the nanoparticles on cervical cancer cells.\nAnalysis of the drug response profiles reveals that 77 drugs affect cell viability, with the top effective compounds targeting nucleic acid synthesis, oxidative stress, and the PI3K/mTOR pathway.\nSLC16A1/3 is the critical hub for regulating the internal and external environment, glycolysis, and redox homeostasis in cervical cancer cells.", "dois": ["10.1155/2020/5821428", "10.1111/acer.12772", "10.1016/j.jbc.2023.105409", "10.1021/acs.molpharmaceut.3c00294", "10.3390/biom13020258", "10.3390/biology11060839", "10.3390/cells11091443", "10.1038/s41467-021-27329-x"]}
{"pair_type": "slc_pathway", "key1": "SLC2A1", "key2": "migration", "summary": "Loss of tumor-suppressive miR-1291 enhanced RCC cell proliferation, migration and invasion through targeting SLC2A1/GLUT1.\nDownregulation of SLC2A1 could not only inhibit cell proliferation, migration and cell cycle, but also promote cell apoptosis.\nKnockdown of SLC2A1 resulted in reduced cell viability, decreased migration, and increased apoptosis in Caco-2 and SW480 cells.\nIn vitro functional experiments have shown that knocking down SFXN1 inhibits the proliferation and migration of LUAD cells, promotes cell apoptosis, and may inhibit tumor activity by regulating the expression of glycolytic related genes SLC2A1, HK2, GPI, ALDOA, GAPDH, ENO1, PKM, and LDHA.\nknockdown of these genes in LUAD cells by transfection with small interfering RNAs significantly inhibited LUAD cell proliferation and migration, and promoted anoikis.\nIn PC9 cells, SLC2A1 overexpression significantly promoted cell proliferation, invasion and migration, and SLC2A1 knockdown significanty increased cell death and inhibited cell invasion and proliferation.\nIn vitro cell experiments have shown that interfering with DARS2 expression can inhibit the proliferation and migration of LUAD cells, promote cell apoptosis, and inhibit the glycolytic activity of tumor cells by inhibiting the expression of glycolytic related genes SLC2A1, GPI, ALDOA, and PGAM1.\nTogether, silencing PVT1 downregulated SLC2A1 expression via targeting miR-378c, and then repressed lung ADC cells growth, migration, and invasion.\nCC-DG inhibited the proliferation, migration, invasion of SGC7901/MFC gastric cells, and in turn, suppressed tumorigenesis by regulating glucose metabolism through regulation of LDHA and SLC2A1 genes.\nTargeted inhibition of glycolysis via SLC2A1 siRNA attenuated metabolic stress, evidenced by reduced extracellular acidification rate (Seahorse) and tricarboxylic", "dois": ["10.7150/ijms.119651", "10.1096/fj.202502391R", "10.3389/fimmu.2025.1638445", "10.1016/j.bbadis.2025.168050", "10.1371/journal.pone.0324043", "10.1007/s12672-025-03173-z", "10.1155/mi/8828435", "10.1002/advs.202500369", "10.1186/s13008-025-00148-y", "10.3390/biom15030432", "10.7150/jca.105351", "10.3390/biom15010036", "10.12122/j.issn.1673-4254.2024.12.17", "10.3390/bioengineering11111070", "10.1016/j.intimp.2024.113282", "10.3390/ani14182751", "10.1186/s13062-024-00528-4", "10.1038/s41598-024-71317-2", "10.1016/j.tranon.2024.102082", "10.1016/j.gene.2024.148701", "10.1016/j.yexcr.2024.114037", "10.18632/aging.205521", "10.1016/j.lungcan.2023.107449", "10.1021/acs.biomac.3c01169", "10.1186/s12935-023-03097-0", "10.1186/s12935-023-03082-7", "10.1186/s12967-023-04454-3", "10.3390/molecules27238457", "10.1080/15548627.2022.2119353", "10.18632/aging.204169", "10.7150/jca.67990", "10.3389/fcell.2022.853596", "10.1002/jcp.30686", "10.1016/j.jep.2021.114771", "10.18632/aging.203331", "10.1093/abbs/gmab076", "10.3389/fonc.2021.666391", "10.1097/SHK.0000000000001785", "10.7150/thno.53176", "10.1007/s13577-020-00434-7", "10.1161/CIRCRESAHA.119.316463", "10.1186/s13046-019-1390-x", "10.1080/15548627.2019.1603547", "10.1097/MD.0000000000015083", "10.1371/journal.pone.0161163", "10.1038/onc.2016.187", "10.3168/jds.2014-8811", "10.1111/cas.12240", "PMID:22738901", "10.1095/biolreprod.112.100487", "PMID:17658597"]}
{"pair_type": "slc_pathway", "key1": "SLC12A2", "key2": "oxidative stress", "summary": "These include genes with a potential role in protection against oxidative stress (Dhcr24, Cdo1, Akr1b7, Prdx6), inflammation (Ltb4dh, Wdr1), ion transport (Pdzk1ip1, Slc12a2, Slc25a17) and transcription (Zfp36l3, Pdzk1ip1).\nAbstract: The cation cotransporters Na(+)-K(+)-2Cl(-) cotransporter 1 and 2 (NKCC1 and NKCC2) and Na(+)-Cl cotransporter (NCC) are phosphorylated and activated by the kinases Ste20-related proline alanine-rich kinase (SPAK) and oxidative stress-responsive kinase (OSR1), and their targeted disruption in mice causes phenotypes resembling the human disorders Bartter syndrome and Gitelman syndrome, reflecting reduced NKCC2 and NCC activity, respectively.\nIn the CLP + NAC group, oxidative stress was significantly lower and survival rates were significantly higher than in the CLP group.\nIn SLC12A2-deficient phagocytes, the canonical anti-inflammatory program was replaced by pro-inflammatory and oxidative-stress-associated gene programs.\nThe protective effects of NAC (against kidney and lung injury) are likely attributable to the decrease in oxidative stress, suggesting that NAC can be useful in the treatment of sepsis.\nWe therefore address that enhanced physical force-sensitive cytokine and oxidative stress by the gravitational force mediate activation of the cotransporter involved in possibilities of edema and calcium loading in cardiac tissue.\nAbstract: Physical trauma, psychosocial stress, and oxidative stress increase the neuronal transcription ratio of genes encoding the sodium-potassium chloride cotransporter () and the potassium chloride cotransporter (), which leads to neuronal depolarization and excitability.\nAbstract: We analyzed the mechanisms underlying the ion transport induced by tert-butyl hydroperoxide (t-BOOH), a membrane-permeant oxidant that has been widely used as a model of oxidative stress, in human airway epithelial cells (", "dois": ["10.1038/s41556-019-0431-1", "10.1152/ajpheart.00462.2025", "10.1016/j.mbplus.2021.100082", "10.1016/j.exer.2008.06.001", "10.12182/20250160204", "10.1007/s00441-020-03299-2", "10.1016/j.jpain.2019.05.005", "10.1074/jbc.RA118.006393", "10.1096/fj.201801023R", "10.1002/cbic.201800272", "10.1016/j.neuropharm.2018.03.035", "10.1177/0271678X16675368", "10.1152/ajpcell.00193.2015", "10.1152/ajpcell.00080.2016", "10.1074/jbc.M113.540518", "10.1152/ajprenal.00211.2013", "10.1016/j.tiv.2013.07.006", "10.1042/BJ20121903", "10.1152/ajpcell.00284.2012", "10.1074/jbc.M112.398750", "10.1152/ajplung.00097.2011", "10.1523/JNEUROSCI.5415-11.2012", "10.1159/000335854", "10.1042/BJ20111879", "10.1073/pnas.1107452108", "10.1152/ajpcell.00203.2011", "10.1007/s11011-010-9180-3", "10.1074/jbc.M900142200", "10.1074/jbc.M804016200", "10.1124/jpet.108.141580", "10.1111/j.1471-4159.2008.05501.x", "10.1097/MNH.0b013e3282f5244e", "PMID:17229812", "PMID:16669787", "PMID:12740379", "PMID:12386165"]}
{"pair_type": "slc_pathway", "key1": "SLC2A1", "key2": "proliferation", "summary": "The inhibition of miR-378b or the enhancement of SLC2A1 reversed ZNF609 depletion-regulated glioma cell proliferation.\nLoss of tumor-suppressive miR-1291 enhanced RCC cell proliferation, migration and invasion through targeting SLC2A1/GLUT1.\nDownregulation of SLC2A1 could not only inhibit cell proliferation, migration and cell cycle, but also promote cell apoptosis.\nKnocking down SFXN1 inhibits the proliferation and migration of LUAD cells, promotes cell apoptosis, and may inhibit tumor activity by regulating the expression of glycolytic related genes SLC2A1, HK2, GPI, ALDOA, GAPDH, ENO1, PKM, and LDHA.\nKnockdown of these genes in LUAD cells by transfection with small interfering RNAs significantly inhibited LUAD cell proliferation and migration, and promoted anoikis.\nMiR-378a-3p inhibited cell proliferation and invasion as well as induced apoptosis, resulting in reduced glycolysis, which was partly reversed by SLC2A1-AS1 or Glut1 overexpression in ESCC cells.\nIn PC9 cells, SLC2A1 overexpression significantly promoted cell proliferation, invasion and migration, and SLC2A1 knockdown significanty increased cell death and inhibited cell invasion and proliferation.\nInterfering with DARS2 expression can inhibit the proliferation and migration of LUAD cells, promote cell apoptosis, and inhibit the glycolytic activity of tumor cells by inhibiting the expression of glycolytic related genes SLC2A1, GPI, ALDOA, and PGAM1.\nCC-DG inhibited the proliferation, migration, invasion of SGC7901/MFC gastric cells, and in turn, suppressed tumorigenesis by regulating glucose metabolism through regulation of LDHA and SLC2A1 genes.\nIn vitro Cell Counting Kit-8, colony formation, transwell assays as well as in vivo tumorigenesis and metastasis assays showed that SLC2A1-AS", "dois": ["10.1096/fj.202502391R", "10.3389/fimmu.2025.1638445", "10.1186/s12967-025-06889-2", "10.1016/j.bbadis.2025.168050", "10.1371/journal.pone.0324043", "10.1038/s41594-025-01614-5", "10.1186/s12943-025-02392-w", "10.1007/s12672-025-02733-7", "10.5114/aoms/191153", "10.1002/advs.202500369", "10.3389/fphar.2025.1579126", "10.3390/biom15030432", "10.3390/ijms26062779", "10.7150/jca.105351", "10.1186/s12885-024-13409-w", "10.12122/j.issn.1673-4254.2024.12.17", "10.3389/fimmu.2024.1497300", "10.3390/bioengineering11111070", "10.1002/ddr.70020", "10.1016/j.jormas.2024.102146", "10.3390/biomedicines12102250", "10.1016/j.intimp.2024.113282", "10.3390/ani14182751", "10.3389/ti.2024.13212", "10.3390/molecules29174275", "10.1016/j.cmet.2024.08.008", "10.1038/s41598-024-71317-2", "10.1016/j.tranon.2024.102082", "10.1186/s12935-024-03432-z", "10.1016/j.ejmech.2024.116645", "10.1186/s12864-024-10537-2", "10.1007/s11010-023-04915-9", "10.18632/aging.205521", "10.1016/j.lungcan.2023.107449", "10.1002/biof.2031", "10.1016/j.bbalip.2023.159429", "10.1097/MD.0000000000036108", "10.1186/s12935-023-03082-7", "10.1186/s12967-023-04454-3", "10.1172/jci.insight.169736", "10.7717/peerj.15621", "10.1016/j.heliyon.2023.e18292", "10.1002/jgm.3566", "10.3390/jcdd10060246", "10.1007/s00018-023-04741-8", "10.1101/2023.02.11.528093", "10.1002/cac2.12403", "10.3390/molecules27238457", "10.1002/cbin.11917", "10.1038/s41419-022-05213-w", "10.1080/15548627.2022.2119353", "10.3390/cancers14143355", "10.7150/jca.67990", "10.3389/fcell.2022.853596", "10.3389/fphar.2022.851540", "10.1016/j.anireprosci.2022.106968", "10.1186/s13046-022-02285-6", "10.21037/tcr-21-741", "10.1002/jcp.30686", "10.1016/j.devcel.2021.12.006", "10.1186/s12935-021-02380-2", "10.1016/j.jep.2021.114771", "10.18632/aging.203331", "10.1186/s13046-021-02081-8", "10.1177/14791641211041225", "10.3389/fimmu.2021.724741", "10.1530/EO-21-0014", "10.1093/jnen/nlab044", "10.1093/abbs/gmab076", "10.3389/fonc.2021.665388", "10.1155/2021/6645220", "10.3389/fonc.2021.666391", "10.1097/SHK.0000000000001785", "10.1530/JOE-20-0446", "10.1371/journal.pone.0245075", "10.7150/thno.53176", "10.1515/hsz-2020-0290", "10.2147/CMAR.S258497", "10.1007/s13577-020-00434-7", "10.1007/s00432-020-03278-8", "10.1161/CIRCRESAHA.119.316463", "10.1016/j.biochi.2020.04.001", "10.1002/1878-0261.12666", "10.1016/j.apsb.2019.11.001", "10.1002/jpen.1763", "10.1016/j.yexcr.2019.111713", "10.3390/cells8091093", "10.1186/s13046-019-1390-x", "10.2217/epi-2019-0072", "10.18632/aging.101974", "10.1093/jnen/nly124", "10.1016/j.theriogenology.2019.01.002", "10.1111/exd.13850", "10.1038/s41467-018-07316-5", "10.1038/s41467-018-07132-x", "10.1038/s41598-018-26782-x", "PMID:31966419", "10.1097/CAD.0000000000000571", "10.1210/en.2017-00187", "10.3168/jds.2017-12783", "10.1016/j.theriogenology.2017.06.013", "10.1016/j.humpath.2017.03.008", "10.3389/fcimb.2017.00092", "10.1016/j.neo.2017.02.009", "10.3892/or.2017.5414", "10.1186/s13058-016-0795-0", "PMID:27884183", "PMID:27540529", "10.1371/journal.pone.0161163", "10.3892/or.2016.4646", "10.1007/s11259-015-9647-0", "10.18632/oncotarget.4977", "10.3390/ijms160716144", "10.2217/bmm.15.36", "10.7150/jca.11404", "PMID:25714027", "10.1530/ERC-14-0107", "10.1093/neuonc/not243", "10.1016/j.ijrobp.2013.07.023", "10.1111/cas.12240", "10.1186/1476-4598-12-78", "10.1095/biolreprod.112.100222", "10.1186/1750-9378-7-21", "PMID:22738901", "10.1016/j.theriogenology.2012.02.034", "PMID:21226991", "PMID:20981268", "10.1530/REP-10-0146", "10.1016/j.critrevonc.2010.05.003", "10.1007/s11010-008-9931-1", "PMID:17221210", "PMID:16261612", "PMID:14675165"]}
{"pair_type": "slc_pathway", "key1": "SLC2A1", "key2": "stemness", "summary": "We provided evidence suggesting that SLC2A1 could influence the migration, invasion, and stemness of ESCA cells, and it was associated with sensitivity to Foretinib.\nFinally, our results revealed that SLC2A1 had the highest correlation with B cells in single-cell data analysis, and we validated its correlation with B cells and its expression with FA-related genes, tumor invasiveness, stemness, and drug sensitivity.\nWe found that stem cell-like GBM tumor subpopulations possessed higher basal levels of glycolytic activity and increased expression of several glycolysis-related enzymes including, GLUT1/SLC2A1, PFKP, ALDOA, GAPDH, ENO1, PKM2, and LDH, compared to their non-stem-like counterparts.\nAlso, we found that hypoxia strongly expressed anti-senescence related genes such as HDAC1 (histone deacetylase 1), DNMT1 (DNA (cytosine-5)-methyltransferase 1), Bcl-2 (inhibitor of apoptosis), TERT (telomerase reverse transcriptase), LDHA (lactate dehydrogenase A), SLC2A1 (glucose transporter), and DKC1 (telomere holoenzyme complex) and differentiation potential of cAD-MSCs into chondrocytes, than seen under the normoxic culture conditions.\nCombinatorial treatment of stem cell-like GBM tumor subpopulations with autophagy and glycolysis inhibitors blocked the induction of senescence while drastically impairing their stemness capacity which drove cells towards apoptotic cell death.\nWhile treatment with glycolysis inhibitors induced senescence in stem cell-like GBM tumor subpopulations, as evidenced by increased β-galactosidase staining and upregulation of the cell cycle regulators p21/CDKN1A and p16/CDKN2A, these cells maintained their aggressive stemness features and failed to undergo apoptotic cell death.\nSimilarly, blocking autophagy in stem cell-like GBM tumor subpopulations induced senescence-associated growth arrest without hampering stemness capacity or indu", "dois": ["10.1002/ddr.70020", "10.1016/j.gene.2024.148701", "10.1016/j.heliyon.2024.e29655", "10.3390/ijms242216188", "10.1186/s40478-023-01604-y", "10.3389/fgene.2022.954840", "10.1186/s13058-021-01401-2", "10.1007/s11259-015-9647-0"]}
{"pair_type": "slc_pathway", "key1": "SLC1A1", "key2": "glycolysis", "summary": "HS elevated the concentrations of serum amino acids and mRNA levels of ubiquitination-related genes (MuRF1 and MAFbx) in the skeletal muscle and amino acid transporter-related genes (SLC1A1 and SLC7A1) and gluconeogenesis-related genes (PCK1 and PCase) in the liver compared to the PF group.\nSerum metabolomics results revealed that heat-stressed ducks showed enhanced glycolysis and pentose phosphate pathways, as demonstrated by higher glucose 6-phosphate and 6-phogluconic acid levels in the PF vs.\nThese results suggest that chronic HS induces protein degradation in the skeletal muscle to provide amino acids for hepatic gluconeogenesis to provide sufficient energy, as Pekin ducks under HS conditions failed to efficiently oxidise fatty acids and ketones in the mitochondria, leading to poor growth performance and slaughter characteristics.", "dois": ["10.1016/j.scitotenv.2023.169382"]}
{"pair_type": "slc_pathway", "key1": "SLC38A7", "key2": "oxidative phosphorylation", "summary": "SLC38A7 silencing suppressed cell viability, migration, invasion, oxidative phosphorylation, and mitochondrial function in cancer cells.\nOur results suggest that SLC38A7, stabilized by METTL3 and IGF2BP2-mediated mA methylation, enhances cell viability, migration, invasion, oxidative phosphorylation, and mitochondrial function in GC, highlighting its role as a potential therapeutic target for GC.", "dois": ["10.1016/j.jbc.2024.107843"]}
{"pair_type": "slc_pathway", "key1": "SLC2A2", "key2": "chemotherapy", "summary": "M2 macrophages play a crucial role in promoting tumor angiogenesis and proliferation, as well as contributing to chemotherapy resistance and metastasis.\nThe risk score was identified as a promising prognostic marker for TACE response, and the high-risk subgroup showed higher sensitivity to chemotherapeutic drugs (e.g., sorafenib, doxorubicin, cisplatin, and mitomycin) and immune checkpoint inhibitor (ICI) treatments.", "dois": ["10.3389/fonc.2023.1170775"]}
{"pair_type": "slc_pathway", "key1": "SLC2A2", "key2": "migration", "summary": "experiments showed that may enhance the migration ability of HepG2 cells by activating the Wnt signaling pathway.\nIn addition, CCK8 and wound healing assays demonstrated that the overexpression of human GYS2 and UPP2 proteins inhibited the proliferation and migration of HepG2 cells, accompanied by elevated expression of p53, a tumor suppressor protein.\nM2 macrophages play a crucial role in promoting tumor angiogenesis and proliferation, as well as contributing to chemotherapy resistance and metastasis.\nThe high-risk group exhibited higher proliferation and invasion capacity, MSI, and degree of stemness.\nEight BRGs (Nr1d1, Cry1, Gys2, Homer2, Serpina6, Slc2a2, Nmrk1, and Upp2) were selected to validate their expression patterns in both control and L-Bmal1 mice livers over 24 h.\nThese genes were significantly enriched in glycolipid metabolism, immune response, and tumorigenesis pathways.\nTwo circadian genes, Gys2 and Upp2, have been proposed and validated as potential candidates for advancing the prevention and treatment of HCC.\nFinally, the role of in HepG2 cells was investigated using various techniques, including Western blotting, RT-PCR and Transwell and wound healing assays.", "dois": ["10.1016/j.bbrc.2023.149422", "10.3389/fonc.2023.1170775", "PMID:22738901"]}
{"pair_type": "slc_pathway", "key1": "SLC2A10", "key2": "apoptosis", "summary": "Silencing PDK4 expression induced glucose utilization by upregulating glucose transporters (SLC2A1, SLC2A10) and glycolytic enzymes (GAPDH, ENO1, LDHA).\nTranscriptome analysis revealed differential expression of 176 genes, with downregulation of steroidogenesis and fatty acid synthesis pathways, and upregulation of apoptosis, fatty acid oxidation, and innate immune responses in NEFA treated cells.\nIn transcriptional regulation, intra-breed bioinformatics analysis identified 3331 genes whose expression levels were opposite to the trend of pectoral muscle hypertrophy both in LD and SW geese, and the 3331 genes were mainly enriched into abundant KEGG pathways related to lipid metabolism, proliferation/apoptosis, and immune response.\nMoreover, 23 genes (including SLC2A10, TNFRSF1A, PRKAA1, SLC27A4, ITGB2, THY1, RHOA, MYL10, ACTB, PRKCB, PIK3R2, RAC2, DMD, LATS2, YAP1, WWTR1, SMAD7, CTGF, FGF1, AXIN2, GLI2, ID2, and CCND2) who were enriched in 6 crosstalk pathways named viral myocarditis, insulin resistance, sphingolipid signaling pathway, hippo signaling pathway, chemokine signaling pathway, and leukocyte transendothelial migration were identified as the key candidate genes regulating the hypertrophy of goose pectoral muscles.\nIn inter-breed bioinformatics analysis, abundant different expression genes (DEGs) related to lipid metabolism, immune response, and proliferation/apoptosis were identified between LD and SW geese too, and compared with SW geese, the expression level of MYL10 in LD geese was lower, while the expression levels of GLI2/CTGF/SMAD7 in LD geese were higher.", "dois": ["10.1093/biolre/ioaf238", "10.1016/j.psj.2024.104498"]}
{"pair_type": "slc_pathway", "key1": "SLC2A9", "key2": "oxidative stress", "summary": "Oxidative stress induced SLC2A9 expression in a p53-dependent manner, and inhibition of SLC2A9 by small interfering RNA (siRNA) or anti-gout drugs such as probenecid significantly increased ROS levels in an uric acid-dependent manner and greatly sensitized cancer cells to chemotherapeutic drugs.\nThis review comprehensively summarizes the molecular and clinical interplay between T2DM and HUA, with a focus on oxidative stress signaling, RAAS activation, microbiota-derived metabolites, and gene-environment interactions (e.g., SLC2A9 variants).\nEmerging mechanistic studies reveal a bidirectional relationship: elevated uric acid impairs insulin sensitivity and β-cell function via activation of oxidative stress, inflammation, and urate transporter dysregulation, while insulin resistance reduces renal urate excretion, forming a vicious metabolic cycle.\nIn vitro, 1,4-GL was observed to reduce lipopolysaccharide-induced ROS levels in NCTC-1469 cells with enhanced mRNA and protein expression of SLC2A9 and decreased mRNA level of XDH.\nIn vitro experiments determined that UA significantly suppressed hydrogen peroxide (HO)-induced oxidative stress in female donor-derived primary human bronchial epithelial (NHBE) cells in the absence of estrogen, implying that the benefit of UA is limited to the female airway in postmenopausal conditions.\nIn this work, pharmacological and genetic inhibition of UA metabolism in experimental mouse models of acute and chronic obstructive pulmonary disease (COPD) revealed that increased plasma UA levels improved emphysematous phenotype and lung dysfunction in accordance with reduced oxidative stress specifically in female but not in male mice, despite no impact of plasma UA induction on the pulmonary phenotypes in nondiseased mice.\nThe protective effects of 1,4-GL against DEN-induced HCC by reducing uric acid and ROS levels due to down-regulation of uric acid production and up-regulation of SLC2A9 expressions.\nFurther investigation into its mechanism revealed that the extract prevents and treats hyperuricemia by decreasing uric acid production, enhancing uric acid excretion, and mitigating the", "dois": ["10.1111/joor.13663", "10.1038/onc.2014.119", "10.1016/j.bbadis.2025.168102", "10.1111/1756-185x.70421", "10.1016/j.jep.2024.118569", "10.3390/nu16020184", "10.3390/antiox9050387", "10.1152/ajprenal.00083.2013"]}
{"pair_type": "slc_pathway", "key1": "SLC2A10", "key2": "ferroptosis", "summary": "The micropeptide encoded by LINC02381 regulates ferroptosis through the glucose transporter SLC2A10 in GBM.\nWe screened out that Solute Carrier Family 2 Member 10 (SLC2A10) is significantly highly expressed in GBM with a poor prognosis, which is also enriched in the NF-E2 p45-related factor 2 (NRF2) signalling pathway.\nThe NRF2 signalling pathway is an important defence mechanism against ferroptosis.", "dois": ["10.1186/s12885-022-09972-9"]}
{"pair_type": "slc_pathway", "key1": "SLC2A2", "key2": "proliferation", "summary": "Compared with CC, pre- and postnatal LP (RR) decreased β-cell fraction, mass, proliferation, aggregate size, and number and increased Hnf1a, Hnf4a, Pdx1, Isl1, Rfx6, and Slc2a2 mRNA levels.\nPostnatal LP offspring (CR) showed decreased β-cell mass but increased β-cell fraction, aggregate number, and Hnf1a, Hnf4a, Rfx6, and Slc2a2 mRNA levels.\nLP only in pregnancy (RC) also decreased β-cell fraction, mass, proliferation, aggregate size, and number and increased Hnf1a, Hnf4a, Pdx1, Rfx6, and Ins mRNA levels.\nEsculentin-2CHa(1-30) peptides markedly reduced high fat diet-induced increase in beta cell proliferation and apoptosis.\nMale Seipin mice showed obvious, but rosiglitazone-sensitive, increases in islet insulin concentration, islet number and beta cell mass and proliferation, with a notable decline in GSIS.\nIn addition, empagliflozin treatment enhanced β-cell proliferation assessed by Ki-67 immunostaining.\nMimicking this decrease in the islets of wild type animals resulted in impaired insulin secretion, reduced β-cell proliferation, and survival.\nAlthough no developmental phenotype was detected during embryogenesis, mutant mice displayed reduced insulin-expressing β-cells at P14 and P21 without any changes in the rate of cell death and proliferation.\nPKSZ-EO upregulated mRNA expression of SLC2A2, SLC2A3, and SLC2A4, leading to increased glucose uptake in SH-SY5Y cells.\nMoreover, compared to the pretreatment levels, Mafa and insulin 1 expression increased in empagliflozin-treated mice, and Slc2a2 increased in combination-treated mice.\nTargeting glutamine pathway selectively suppressed the proliferation of HLE cells.\nAbstract: M2 macrophages play a crucial role in promoting tumor angiogen", "dois": ["10.1186/s12876-025-03861-8", "10.1038/s41598-024-78357-8", "10.1101/2024.05.17.594179", "10.1016/j.bbrc.2023.149422", "10.3389/fonc.2023.1170775", "10.3390/ijms222212419", "10.1016/j.molmet.2021.101334", "10.1016/j.ejphar.2020.173101", "10.4103/1735-5362.278713", "10.1007/s00125-019-05038-x", "10.1186/s13046-018-0872-6", "10.1016/j.molmet.2018.01.010", "10.1007/s00726-017-2469-3", "10.1016/j.vetimm.2017.06.004", "10.1038/srep28452", "10.1089/cell.2015.0090", "10.1016/j.bbrc.2015.10.038", "10.1530/ERC-13-0164", "PMID:22738901", "10.1152/ajpendo.00619.2011", "10.1038/ng.520", "10.1111/j.1365-2052.2009.02015.x", "10.1186/1746-6148-5-29"]}
{"pair_type": "slc_pathway", "key1": "SLC2A10", "key2": "glycolysis", "summary": "Silencing PDK4 expression induced glucose utilization by upregulating glucose transporters (SLC2A1, SLC2A10) and glycolytic enzymes (GAPDH, ENO1, LDHA).\nIn SW480 cells, RNAi-mediated depletion of EIF2S2 inhibited lactic acid production (P <0.05) and SLC2A1, SLC2A3, SLC2A10, HK2, PKM2, LDHA mRNA level (P <0.01).\nPrimary CRC FDG uptake is strongly associated with the overexpression of EIF2S2, and EIF2S2 may promote glycolysis in CRC by mediating GLUT1.", "dois": ["10.1093/biolre/ioaf238", "10.7150/jca.57926"]}
{"pair_type": "slc_pathway", "key1": "SLC2A2", "key2": "stemness", "summary": "Analysis of GEO datasets (GSE132606, GSE25417, GSE67848) and TCGA HCC data revealed that while SLC2A2 expression decreases with HCC progression, stemness-associated genes, including SOX2 and POU5F1, are upregulated.\nIn HepG2 cells, SLC2A2 knockdown increased stemness and IGF1R pathway markers, indicating a shift toward less differentiated states.\nThese findings suggest that SLC2A2 supports liver differentiation by regulating glucose metabolism and suppressing pathways associated with stemness and malignancy.\nWe further show that inhibition of RAC1 activation attenuated pluripotency marker expression and self-renewal ability, while depletion of RAC1b dramatically enhanced stemness features and clonogenic potential.\nEctopic expression in PANC-1 cells of dominant negative or constitutively active mutants of RAC1 activation blocked or enhanced, respectively, the cytokine-induced activation of a ductal-to-endocrine transdifferentiation transcriptional program (deTDtP) as revealed by induction of the NEUROG3, INS, SLC2A2, and MAFA genes.\nThese results indicated that VA may increase the stemness of intestinal stem cell in vitro.\nZebrafish embryos injected with SLC2A2-targeting morpholino exhibited reduced expression of the liver differentiation marker fabp10a without significantly altering the hepatoblast marker hhex.\nThe high-risk group exhibited higher proliferation and invasion capacity, MSI, and degree of stemness.\nThe risk score was significantly associated with immune cell infiltration, immune checkpoint expression, angiogenesis, and tumor stemness.\nBeyond its metabolic role, SLC2A2 contributes to cell differentiation and metabolic adaptation during embryogenesis and tissue regeneration.\nMoreover, the SLC2A family gene expression is significantly correlated with the pan-cancer stromal and immune scores, and the RNA and DNA stemness scores.\nTargeting SLC2A2 may serve as a promising therapeutic strategy for liver-related diseases, particularly HCC, by addressing its dual role in differentiation and tumor progression.", "dois": ["10.1371/journal.pone.0321020", "10.1186/s12876-025-03861-8", "10.1016/j.heliyon.2024.e29655", "10.3389/fonc.2023.1170775", "10.3390/cancers13215541", "10.1093/jas/skaa020"]}
{"pair_type": "slc_pathway", "key1": "SLC2A10", "key2": "migration", "summary": "Moreover, 23 genes (including SLC2A10, TNFRSF1A, PRKAA1, SLC27A4, ITGB2, THY1, RHOA, MYL10, ACTB, PRKCB, PIK3R2, RAC2, DMD, LATS2, YAP1, WWTR1, SMAD7, CTGF, FGF1, AXIN2, GLI2, ID2, and CCND2) who were enriched in 6 crosstalk pathways named viral myocarditis, insulin resistance, sphingolipid signaling pathway, hippo signaling pathway, chemokine signaling pathway, and leukocyte transendothelial migration were identified as the key candidate genes regulating the hypertrophy of goose pectoral muscles.", "dois": ["10.1016/j.psj.2024.104498"]}
{"pair_type": "slc_pathway", "key1": "SLC2A10", "key2": "proliferation", "summary": "The genes identified include eight that are essential for cell proliferation (FGD5, METTL6, CPT1A, DTX3, MRPS23, EIF2S2, EIF6 and SLC2A10) and are uniquely amplified in patients with highly proliferative luminal breast tumors, a clinical subset of patients for which few therapeutic options are effective.\nThe current model of ATS holds that loss of GLUT10 at the nuclear periphery induces a glucose-dependent increase in Transforming Growth Factor-beta (TGFbeta) that stimulates vessel wall cell proliferation.\nThese results suggested that the hypertrophy of goose pectoral muscles might be achieved through more lipid deposition and less leukocyte infiltration to promote the proliferation of cells within the muscles, and the low expression of MYL10 and high expressions of GLI2/CTGF/SMAD7 might the keys to induce the pectoral muscle hypertrophy of LD geese from 6 to 30 weeks of age over that of SW geese.\nHistopathology revealed thickening and irregular vessel wall shape of large and medium size arteries characterized by markedly increased elastic fibres, both in number and size.\nAbnormal elastogenesis with early elastic fibre proliferation provides a clue to the pathogenesis of arterial tortuosity in human ATS.\nIn transcriptional regulation, intra-breed bioinformatics analysis identified 3331 genes whose expression levels were opposite to the trend of pectoral muscle hypertrophy both in LD and SW geese, and the 3331 genes were mainly enriched into abundant KEGG pathways related to lipid metabolism, proliferation/apoptosis, and immune response.\nIn inter-breed bioinformatics analysis, abundant different expression genes (DEGs) related to lipid metabolism, immune response, and proliferation/apoptosis were identified between LD and SW geese too, and compared with SW geese, the expression level of MYL10 in LD geese was lower, while the expression levels of GLI2/CTGF/SMAD7 in LD geese were higher.", "dois": ["10.1016/j.psj.2024.104498", "10.1038/ng.3073", "10.1016/j.febslet.2010.06.011", "10.1093/cvr/cvn319"]}
{"pair_type": "slc_pathway", "key1": "SLC2A2", "key2": "oxidative stress", "summary": "Administration of 0.5 mg/kg OXR reduced blood glucose while promoting insulin, mainly through upregulation of messenger RNA expression of GLUD1, GLUT2, and GCK in the pancreas.\nFollowing 5 weeks of treatment, OXR significantly increased the level of total antioxidant power, decreased reactive oxygen species, and lipid peroxidation in the DRGs of diabetic rats.\nOur results indicate that increased levels of oxidative damage ROS content and production and susceptibility to oxidative damage, parallel increased fasting plasma level of glucose and insulin, reduced activation of Akt and increased activation of JNK.\nHigh glucose induced oxidative stress in FVB ESC but not in B6 ESC.\nSince hyperthyroidism-linked increase in ROS results in tissue oxidative stress that is considered a hallmark of conditions leading to IR, it is conceivable a role of ROS in the onset of IR in hyperthyroidism.\nThese results indicate that FVB embryos are more dependent on exogenous GlcN for glycosylation, but also for stimulation of the PPP and NADPH production, than are B6 embryos, thereby rendering FVB embryos more susceptible to high glucose to induce oxidative stress.\n4 weeks' administration of 70 % ethanol FD extract (125, 250 and 500 mg/kg/d) to streptozotocin-nicotinamide-induced type 2 diabetic rats reversed the abnormal changes of blood glucose, insulin, total Hb, GLUT2, lipid profile, and oxidative stress in liver and pancreas.\nThe factors involved in oxidative damage, namely the total content of ROS, the mitochondrial production of ROS, the activity of antioxidant enzymes, the in vitro susceptibility to oxidative stress, have been correlated to insulin resistance indices, such as insulin activation of hepatic Akt and plasma level of glucose, insulin and HOMA index.\nIn conclusion, OXR has neuroprotective effects in diabetic rats by lowering oxidative stress, lowering blood glucose, and stimulating insulin secretion.\nThe high K glucose transporter, GLUT2 (SLC2A2),", "dois": ["10.1186/s10020-025-01106-8", "10.1002/jbt.23125", "10.1017/jns.2019.40", "10.3168/jds.2016-11018", "10.3390/antiox11071295", "10.3390/antiox10081156", "10.1074/jbc.M114.595579", "PMID:17616136"]}
{"pair_type": "slc_pathway", "key1": "SLC2A10", "key2": "oxidative stress", "summary": "GLUT10 deficiency leads to oxidative stress and non-canonical αvβ3 integrin-mediated TGFβ signalling associated with extracellular matrix disarray in arterial tortuosity syndrome skin fibroblasts.\nBiochemical and functional studies showed a marked increase in ROS-induced lipid peroxidation sustained by altered PPARγ function, which contributes to the redox imbalance and the compensatory antioxidant activity of ALDH1A1.\nTranscriptome analyses revealed the dysregulation of several genes involved in TGFβ signalling and extracellular matrix (ECM) homeostasis as well as the perturbation of specific pathways that control both the cell energy balance and the oxidative stress response.\nStable GLUT10 expression in patients' fibroblasts normalized redox homeostasis and PPARγ activity, rescued canonical TGFβ signalling and induced partial ECM re-organization.", "dois": ["10.1093/hmg/ddv382"]}
{"pair_type": "slc_pathway", "key1": "SLC2A11", "key2": "apoptosis", "summary": "In vitro cell apoptosis and viability analysis were employed to verify the specific tumor inhibition effects of AZD5153.\nConversely, the LB group placentae excel in regulating critical biological processes, including cell migration, proliferation, differentiation, apoptosis, and signal transduction;\nAZD5153, a novel bivalent BET bromodomain inhibitor which could inhibit the transcription of MYC and E2F exhibited specific antitumor function for cells with high-risk score.\nNineteen survival related lipid metabolism genes TMEM176B, LAYN, RAB6B, MMP9, ATAD3B, SLC2A11, CD3E, SLIT2, SLC2A13, SLC43A3, CD6, SIRPG, NEK6, LCP2, CTTN, CXCL2, SNX22, BCL6 and FABP4 were identified and subjected to build the prognostic model which was further verified in four external microarray cohorts and one RNA seq cohorts.\nLipids are crucial components of biological membranes and signal transduction while accumulating evidence has supported the vital roles of abnormal lipid metabolism in tumorigenesis.\nFurthermore, by determining novel subtypes with our lipid metabolism prognostic model we illustrated that drugs that compromising MYC target genes rather than immune checkpoint inhibitors may be beneficial to DLBCL patients with certain lipid metabolism profiles.\nTumor immune microenvironment analysis and GSEA results showed that the activation of MYC targets genes rather than immunosuppression contribute to the poor survival outcome of patients in the high-risk group.", "dois": ["10.1186/s10020-024-00988-4", "10.3390/ani14182751"]}
{"pair_type": "slc_pathway", "key1": "SLC2A11", "key2": "migration", "summary": "Here we identify a novel fusion transcript of solute carrier family 2-member 11 () and macrophage migration inhibitory factor ().\nSubsequently, functional investigations demonstrated that enhanced the proliferation, antiapoptotic effects, and metastasis of bladder cancer cells in vitro and in vivo.\nConversely, the LB group placentae excel in regulating critical biological processes, including cell migration, proliferation, differentiation, apoptosis, and signal transduction;\nMechanistically, the fusion protein encoded by interacted with polypyrimidine tract binding protein 1 () and regulated the mRNA half-lives of Polo Like Kinase 1, Roundabout guidance receptor 1, and phosphoinositide-3-kinase regulatory subunit 3 in BCa cells.\nIn contrast, the placenta of the low-birth-weight (LB) group prioritizes cell proliferation ( and ) and angiogenesis.", "dois": ["10.3390/ani14182751", "10.1002/mco2.685"]}
{"pair_type": "slc_pathway", "key1": "SLC2A11", "key2": "oxidative phosphorylation", "summary": "At least ten entities were concomitantly upregulated on the two analysis platforms: GOT1, ALDH4A1, PDHB, BDH1, SLC2A11, HSP90AA1, HSP90AB1, H2AFV, HSPA5 and NDUFV1.\nGene ontology analyses of DEGs and DEPs revealed significant overlap with enrichment of genes/proteins related to metabolic process, biosynthetic process, cellular component organization, oxidative phosphorylation, alterations in glycolysis and ATP synthesis, Alzheimer's disease, chemokine-mediated inflammation and cytokine signalling pathways.", "dois": ["10.1371/journal.pone.0162669"]}
{"pair_type": "slc_pathway", "key1": "SLC2A11", "key2": "glycolysis", "summary": "Gene ontology analyses of DEGs and DEPs revealed significant overlap with enrichment of genes/proteins related to metabolic process, biosynthetic process, cellular component organization, oxidative phosphorylation, alterations in glycolysis and ATP synthesis, Alzheimer's disease, chemokine-mediated inflammation and cytokine signalling pathways.\nAt least ten entities were concomitantly upregulated on the two analysis platforms: GOT1, ALDH4A1, PDHB, BDH1, SLC2A11, HSP90AA1, HSP90AB1, H2AFV, HSPA5 and NDUFV1.", "dois": ["10.1371/journal.pone.0162669"]}
{"pair_type": "slc_pathway", "key1": "SLC2A12", "key2": "apoptosis", "summary": "HBO upregulated the expression of BAK1, PPIF, DDIT3, TP53I11 and FAS, whereas downregulated the expression of MDM4 and SIVA1, thus promoting apoptosis.\nHBO not only inhibited hypoxia-inducing genes including CA9, FGF11, PPFIA4, TCAF2 and SLC2A12, but also regulated vascularization by downregulating the expression of COL1A1, COL8A1, COL12A1, RHOJ and FILIP1L, ultimately attenuated hypoxic microenvironment of glioblastoma.\nEight bona fide SRA downstream target genes were identified (SLC2A3, SLC2A12, CCL20, TGFB2, DIO2, TMEM65, TBL1X, and TMPRSS2), representing entirely novel SRA targets, except for TMPRSS2.\nThat SRA RNA levels might affect some biological functions, such as proliferation, apoptosis, steroidogenesis, and myogenesis, has been reported.", "dois": ["10.1007/s11596-024-2934-7", "10.1074/jbc.M111.240812", "10.1210/me.2009-0427"]}
{"pair_type": "slc_pathway", "key1": "SLC2A11", "key2": "proliferation", "summary": "Silencing of another recurrent chimera, SLC2A11-MIF, resulted in cell cycle arrest and reduced cellular proliferation.\nSubsequently, functional investigations demonstrated that enhanced the proliferation, antiapoptotic effects, and metastasis of bladder cancer cells in vitro and in vivo.\nConversely, the LB group placentae excel in regulating critical biological processes, including cell migration, proliferation, differentiation, apoptosis, and signal transduction;\nIn contrast, the placenta of the low-birth-weight (LB) group prioritizes cell proliferation ( and ) and angiogenesis.\nMechanistically, the fusion protein encoded by interacted with polypyrimidine tract binding protein 1 () and regulated the mRNA half-lives of Polo Like Kinase 1, Roundabout guidance receptor 1, and phosphoinositide-3-kinase regulatory subunit 3 in BCa cells.\nMoreover, knockdown abolished the enhanced impact of on biological function and mRNA stability.\nHere we identify a novel fusion transcript of solute carrier family 2-member 11 () and macrophage migration inhibitory factor ().\nOverall, our findings revealed a significant fusion protein orchestrated by the axis that governs mRNA stability during the multistep progression of bladder cancer.\nFurthermore, the expression of mRNA is regulated by CCCTC-binding factor and stabilized through RNA N4-acetylcytidine modification facilitated by N-acetyltransferase 10.", "dois": ["10.3390/ani14182751", "10.1002/mco2.685", "10.1016/j.ebiom.2018.10.059"]}
{"pair_type": "slc_pathway", "key1": "SLC2A12", "key2": "ferroptosis", "summary": "Hypoxia promoted ovarian cancer progression by upregulating SLC2A12 and then regulating glutathione metabolism to inhibit ferroptosis.\nHypoxia suppressed ferroptosis by SLC2A12 because silencing SLC2A12 declined the cell viability of HO-8910 and A2780 cells under hypoxia conditions, while the ferroptosis inhibitor ferrostatin-1 (Fer-1) breached that result and upregulated the expression of glutathione peroxidase 4 (GPX4).\nSubsequently, SLC2A12 regulated glutathione metabolism and in turn inhibited ferroptosis.\nThe animal experiments indicated that silencing SLC2A12 could significantly inhibit tumor growth and metastasis in vivo.\nMoreover, hypoxia increased the expression of hypoxia inducible factor 1 A (HIF-1A), and the accumulated HIF-1A binds to hypoxia inducible factor 1 B (HIF1B) to form HIF-1 complex, then promoted the binding of hypoxic response elements (HRE) to SLC2A12 promoter by HIF-1/HRE signal.\nRNA-seq and enrichment analysis showed that SLC2A12 was hyper-expressed under hypoxia condition and it may be related to glutathione and lipid metabolism.\nBesides, the expression of SLC2A12 was negatively correlated with overall survival.", "dois": ["10.1016/j.yexcr.2023.113851", "10.18632/aging.204385"]}
{"pair_type": "slc_pathway", "key1": "SLC2A3", "key2": "apoptosis", "summary": "These findings indicated that HS-induced autophagy regulates lactate secretion by inhibiting apoptosis and increasing mRNA transcript and protein levels of SLC2A3, LDHA, and SLC16A1, which suggests that HS-induced autophagy may enhance lactate secretion by SCs.\nThe proliferation rate of CRC cells was significantly reduced and apoptosis of CRC cells was increased after SLC2A3 was knocked down.\nIt also resulted in significantly less lactate secretion and increased apoptosis but showed no effect on B-cell lymphoma-2 expression in heat-treated immature SCs.\nMechanistically, the loss of OSGIN1 activates AMPK signaling through ATM, leading to the upregulation of SLC2A3, which protects cells from ferroptosis and renders them insensitive to ferroptosis inducers.\nNotably, an SLC2A3-neutralizing antibody enhances the ferroptosis-inducing and anticancer effects of sorafenib on ovarian cancer patient-derived xenograft tumors.\nGene overlapping analysis revealed that IL-1B is related to necroptosis and pyroptosis, TREM1 and FPR2 are related to pyroptosis, and SLC2A3 is related to ferroptosis.\nGene Ontology (GO) enrichment analysis and functional classification of Kyoto Encyclopedia of Genes and Genomes (KEGG) signaling pathways showed that these genes were mainly involved in signaling pathways or biological functions related to inflammation and apoptosis.\nMoreover, functional studies showed miR-29c could inhibit cell growth, induce apoptosis and deceased the rate of glucose metabolism.\nSLC2A3, a regulator of glycolysis, was validated as a direct target of miR-29c.\nFunctional assays indicated that silencing MMP14 in COLO205 cells enhanced apoptosis and upregulated the expression of the immune-related cytokine IL-1β.\nNotably, inhibition of SAP30 expression can reduce the apoptosis of HMC3 cells and inhibit the production of ROS and MDA.\nSubsequently, rescue experiments confirmed that knocking out SLC2A3", "dois": ["10.1002/mnfr.70167", "10.2174/0115672026286243240105115419", "10.1038/s41598-023-49336-2", "10.18632/aging.205339", "10.1186/s12920-023-01619-3", "10.1186/s40001-023-01137-z", "10.1071/RD16441", "10.1016/j.theriogenology.2016.09.016", "10.1155/2016/1648030", "10.4161/auto.29456", "PMID:18046015", "PMID:16221986", "10.1097/JS9.0000000000003848", "10.1159/000547896", "10.3389/fonc.2025.1564375", "10.21037/tcr-24-1177", "10.1038/s41698-024-00791-8", "10.1016/j.micpath.2024.107243", "10.1016/j.micpath.2024.107199", "10.3389/fphar.2023.1253169", "10.3389/fphar.2022.1098851", "10.3389/fimmu.2022.893301", "10.1007/s10620-021-07145-5", "10.1016/j.theriogenology.2020.10.028", "10.1071/RD18447", "10.1016/j.gene.2018.04.086", "10.1017/S2040174413000068", "10.1210/me.2009-0427", "10.1677/JOE-08-0262"]}
{"pair_type": "slc_pathway", "key1": "SLC2A12", "key2": "migration", "summary": "Expression levels of endometrial GRP, IGFBP1, and LGALS15, whose products stimulate trophectoderm cell migration and attachment, were increased by PGE2, PGI2, and IFNT.\nFor glucose transporters, IFNT and all PGs increased SLC2A1 expression, but only PGs increased SLC2A5 expression, whereas endometrial SLC2A12 and SLC5A1 expression levels were increased by IFNT, PGE2, and PGF2alpha.", "dois": ["10.1095/biolreprod.112.100487"]}
{"pair_type": "slc_pathway", "key1": "SLC2A12", "key2": "oxidative stress", "summary": "The identified loci implicated genes involved in glucose transport (SLC2A12), iron homeostasis (HFE, TMPRSS6), tissue repair (ADAMTSL1, VEGFC), oxidative stress (SOD2), cardiac hypertrophy (MYH7B) and calcium signaling (CAMK2D).", "dois": ["10.1038/s41588-023-01371-5"]}
{"pair_type": "slc_pathway", "key1": "SLC2A13", "key2": "glycolysis", "summary": "We investigated the DEGs associated with the starch and sucrose metabolism pathways, citrate cycle pathway, glycolysis pathway, and a handful of sugar transporter proteins, which were considered to be important regulators of sugar and acid accumulation.", "dois": ["10.3390/ijms242316992"]}
{"pair_type": "slc_pathway", "key1": "SLC2A13", "key2": "apoptosis", "summary": "Nineteen survival related lipid metabolism genes TMEM176B, LAYN, RAB6B, MMP9, ATAD3B, SLC2A11, CD3E, SLIT2, SLC2A13, SLC43A3, CD6, SIRPG, NEK6, LCP2, CTTN, CXCL2, SNX22, BCL6 and FABP4 were identified and subjected to build the prognostic model which was further verified in four external microarray cohorts and one RNA seq cohorts.\nIn vitro cell apoptosis and viability analysis were employed to verify the specific tumor inhibition effects of AZD5153.\nThere are no excerpts that connect SLC2A13 directly to apoptosis mechanisms, nor are there any statements describing how one entity affects the other.", "dois": ["10.1371/journal.pone.0153226", "10.1186/s10020-024-00988-4", "10.3390/ijerph17165866"]}
{"pair_type": "slc_pathway", "key1": "SLC2A13", "key2": "proliferation", "summary": "In summary, this study found that chicken circSLC2A13 can bind to miR-34a-3p and weaken its inhibitory effect on the SMAD family member 3 gene (), thereby promoting the proliferation and differentiation of myoblasts.\nCurrently, our results show that circSLC2A13 promoted the proliferation and differentiation of chicken myoblasts.\nThe double luciferase reporter system revealed that circSLC2A13 regulated the proliferation and differentiation of myoblasts by competitive binding with miR-34a-3p.\nIn addition, results indicated that circSLC2A13 acts as a miR-34a-3p sponge to relieve its inhibitory effect on the target gene.\nThe proliferation and differentiation of myoblasts are important factors determining chicken muscle development.", "dois": ["10.1021/acs.jafc.4c01550", "PMID:21861841"]}
{"pair_type": "slc_pathway", "key1": "SLC2A3", "key2": "ferroptosis", "summary": "Further results showed that NETs promoted LLC cell proliferation and migration and inhibited ferroptosis by promoting YTHDF2-mediated SLC2A3 mRNA degradation.\nOur results suggested that NETs promoted the growth of LUAD through inhibiting ferroptosis and CD8(+) T cell activity by promoting YTHDF2-mediated SLC2A3 mRNA degradation.\nIn our experiment, we treated synovial fibroblast-like cells of RA (RA-FLS) with RSL3 (Ferroptosis inducers) and found that RSL3 can downregulate SLC2A3 expression and induce ferroptosis in RA-FLS.\nIt was also found that RSL3 can induce ferroptosis in RA-FLS via lead to the downregulation of SLC2A3.\nMechanistically, the loss of OSGIN1 activates AMPK signaling through ATM, leading to the upregulation of SLC2A3, which protects cells from ferroptosis and renders them insensitive to ferroptosis inducers.\nNotably, an SLC2A3-neutralizing antibody enhances the ferroptosis-inducing and anticancer effects of sorafenib on ovarian cancer patient-derived xenograft tumors.\nMoreover, high SLC2A3 expression in CD8 T cells may drive cell death through ferroptosis, fostering tumor progression.\nFurthermore, SLC2A3 exhibits specific overexpression in CD8 T cells and may potentially trigger ferroptosis.\nSh-YTHDF2 partially reversed the effect of NETs on LLC cells, whereas si-SLC2A3 partially reversed sh-YTHDF2 effects on LLC cells.\nKnockdown of SLC2A3 led to a significant increase in the proliferation of CD8 T cells compared to those without knockdown.\nOur results demonstrated that loss of the OSGIN1 gene promoted ovarian cancer growth and conferred resistance to drug-induced ferroptosis.\nOverall, anti-SLC2A3 therapy is a promising method to improve ovarian cancer treatment by targeting ferroptosis.", "dois": ["10.1371/journal.pone.0332769", "10.1002/ctm2.70192", "10.1111/1756-185X.70009", "10.1177/10815589241288518", "10.1186/s12920-024-01872-0", "10.1038/s41598-023-49336-2", "10.1186/s12920-023-01619-3", "10.1038/s41598-023-41028-1", "10.1186/s40001-023-01137-z", "10.1016/j.ejphar.2023.175568", "10.18632/aging.204385", "10.1177/00368504211050275", "10.1007/s12672-025-03719-1", "10.1038/s41698-025-00839-3", "10.21037/tcr-24-1177", "10.1038/s41698-024-00791-8", "10.1016/j.micpath.2024.107243", "10.3892/br.2024.1894", "10.1038/s41598-024-79417-9", "10.4251/wjgo.v16.i5.2018", "10.2174/0115672026286243240105115419", "10.2147/JIR.S438308", "10.3389/fimmu.2023.1164742", "10.3389/fonc.2023.1201616", "10.3389/fphar.2022.1098851", "10.3389/fgene.2022.1062293", "10.3389/fncel.2022.1016682", "10.3389/fgene.2022.919313", "10.3389/fgene.2022.829384", "10.3389/fcell.2022.800650", "10.3389/fgene.2021.755486", "10.3389/fonc.2021.686044"]}
{"pair_type": "slc_pathway", "key1": "SLC2A12", "key2": "proliferation", "summary": "Hypoxia promoted ovarian cancer progression by upregulating SLC2A12 and then regulating glutathione metabolism to inhibit ferroptosis.\nHypoxia suppressed ferroptosis by SLC2A12 because silencing SLC2A12 declined the cell viability of HO-8910 and A2780 cells under hypoxia conditions, while the ferroptosis inhibitor ferrostatin-1 (Fer-1) breached that result and upregulated the expression of glutathione peroxidase 4 (GPX4).\nwe identified five five recently characterized lncRNAs-Lnc-SLC2A12-10:1, LncRNA BCRT1, lncRNA IGFBP4-1, LncRNA PCNAP1, and LncRNA CDC6-that have been linked to the promotion of cancer cell proliferation, invasion, and metastasis.\nSubsequently, SLC2A12 regulated glutathione metabolism and in turn inhibited ferroptosis.\nThe animal experiments indicated that silencing SLC2A12 could significantly inhibit tumor growth and metastasis in vivo.\nHypoxia treatment promoted the cell proliferation, mobility, and colony growth abilities of the two ovarian cancer cell lines HO-8910 and A2780.\nMoreover, hypoxia increased the expression of hypoxia inducible factor 1 A (HIF-1A), and the accumulated HIF-1A binds to hypoxia inducible factor 1 B (HIF1B) to form HIF-1 complex, then promoted the binding of hypoxic response elements (HRE) to SLC2A12 promoter by HIF-1/HRE signal.\nHypoxia promotes the growth and metastasis of ovarian cancer cells by suppressing ferroptosis via upregulating SLC2A12.\nRNA-seq and enrichment analysis showed that SLC2A12 was hyper-expressed under hypoxia condition and it may be related to glutathione and lipid metabolism.", "dois": ["10.1007/s12094-024-03619-w", "10.1016/j.yexcr.2023.113851", "10.1210/me.2009-0427"]}
{"pair_type": "slc_pathway", "key1": "SLC2A14", "key2": "apoptosis", "summary": "Correlation analysis revealed the negative correlation between SLC7A11 (driving gene of disulfidptosis) and the glucose transporter GLUTs (SLC2A1-4) family genes (suppressing genes of disulfidptosis) in the IVDD group.\nThese analyses converged on four hub genes of DRGs (SLC2A3, SLC2A14, SLC7A11, NCKAP1) associated with stroke.\nAssociations between hub genes and apoptosis, necroptosis, ferroptosis, and cuproptosis, were also identified.\nStroke-Induced Immunodepression (SIID) is characterized by apoptosis in blood immune populations, such as T cells, B cells, NK cells, and monocytes, leading to the clinical presentation of lymphopenia.\nGene Set Enrichment Analysis (GSEA) demonstrated enrichment of apoptosis-related pathways, neurotrophin signaling, and actin cytoskeleton regulation.\nThese results suggest that the DRG hub genes are interconnected with various cell death pathways and immune processes, potentially contributing to stroke pathological development.", "dois": ["10.1186/s13062-024-00528-4", "10.2174/0115672026286243240105115419"]}
{"pair_type": "slc_pathway", "key1": "SLC2A14", "key2": "chemotherapy", "summary": "Four additional genes were significantly downregulated: SLC2A14, SLC6A15, SLC8A1 and SLC27A2.\nIn multivariate analysis including International Union Against Cancer (UICC) stages, R category, Lauren classification, surgery alone versus neoadjuvant/perioperative chemotherapy, and marker expression as covariates, GLUT-1 (p = 0.011) and GLUT-14 (p = 0.025) kept their prognostic independence.\nIn results of MDR development during chemotherapy cancer cells become resistant to further treatment.\nThe role of glucose transporter 14 (GLUT-14/SLC2A14) in tumor biology is entirely unknown, and the significance of hypoxia inducible factor 1-alpha (HIF1-α) for gastric adenocarcinoma is controversial.\nThe study findings suggest that detection of GLUT-1 and GLUT-14 is of high prognostic value.\nIt gives additional information to UICC stages and identifies patients with inferior prognosis.\nAn inferior prognosis also was seen for GLUT-14-positive cases compared with GLUT-14-negative cases (p = 0.004).\nExpression of GLUT-14 was correlated with pT category (p = 0.043), whereas HIF1-α did not show any correlation with histopathology or survival.\nThus, worst survival was seen with both GLUT-1- and GLUT-14-positive expression followed by single-positive and then double-negative cases (p = 0.004).\nABC and SLC transporters are most important proteins responsible for this phenomenon.\nExpression profiles of these genes give strong arguments for assumption of correlation between expression of ABC and SLC genes and drug resistance phenomenon.\nIdentifying correlations between specific drug transporters and cytostatic drug resistance will require further investigation.", "dois": ["10.1245/s10434-015-4730-x", "10.1016/j.biopha.2014.02.002"]}
{"pair_type": "slc_pathway", "key1": "SLC2A14", "key2": "ferroptosis", "summary": "The ferroptosis-related genes identified in this study, including SLC1A5, SLC2A14, LURAP1L, and HERPUD1, may serve as novel diagnostic and therapeutic targets for periodontitis.\nThey are likely involved in the occurrence and development of periodontitis through mechanisms such as immune infiltration, cellular metabolism, and inflammatory chemotaxis, potentially linking the ferroptosis pathway to the progression of periodontitis.\nThese analyses converged on four hub genes of DRGs (SLC2A3, SLC2A14, SLC7A11, NCKAP1) associated with stroke.\nAssociations between hub genes and apoptosis, necroptosis, ferroptosis, and cuproptosis, were also identified.\nSubsequent machine learning algorithm screening highlighted 4 key genes: SLC1A5(Solute Carrier Family 1 Member 5), SLC2A14(Solute Carrier Family 1 Member 14), LURAP1L(Leucine Rich Adaptor Protein 1 Like), and HERPUD1(Homocysteine Inducible ER Protein With Ubiquitin Like Domain 1).\nTargeted drugs such as flurofamide, L-733060, memantine, tetrabenazine, and WAY-213613 hold promise for potential therapeutic interventions in periodontitis associated with these ferroptosis-related genes.\nA total of 36 ferroptosis-related genes (30 upregulated, 6 downregulated) were identified from 829 differentially expressed genes between 9 periodontitis samples and the control group.\nUtilizing the periodontitis-related microarray dataset GSE16134 from the Gene Expression Omnibus (GEO) and a set of 528 ferroptosis-related genes identified in prior studies, this research unveils differentially expressed ferroptosis-related genes in periodontitis.\nTwo algorithms, randomForest and SVM(Support Vector Machine), were employed to reveal potential ferroptosis diagnostic markers for periodontitis.\nFinally, potential targeted drugs for differentially expressed ferroptosis markers in periodontitis were predicted.\nExploration of these 4 key genes, supported by time-correlated ROC analysis,", "dois": ["10.1186/s12903-024-04342-2", "10.2174/0115672026286243240105115419"]}
{"pair_type": "slc_pathway", "key1": "SLC2A14", "key2": "proliferation", "summary": "Among the co-expressed genes with the highest correlation, ITGA5, SLC2A3, SLC2A14, SHC1, CEBPB, and ADA were overexpressed and associated with shorter overall survival (OS) in ccRCC.\nCell experiments showed that knockdown SERPINE1 expression could inhibit the proliferation, migration and invasion of ccRCC cells.", "dois": ["10.1186/s12894-023-01217-6"]}
{"pair_type": "slc_pathway", "key1": "SLC3A1", "key2": "apoptosis", "summary": "Integration analysis of DEGs with DElncRNA profiles identified genes involved in apoptosis signal pathway are regulated by and .\nIntegration analysis of DEmiRNA and DEG profiles revealed two microRNAs ( and ) and five genes (, and ) participating in the apoptosis signal, of which and were mainly linked to the p53 pathway.\nSome studies reported that apoptosis of placental cells and pig endometrial epithelial cells (PECs) is an obvious sign linked to reproductive failure in pregnant sows, but the mechanism is still unknown.\nPathway enrichment revealed that the phagosome and p53 pathways are the two main signals causing apoptosis of PECs, and functional analysis revealed a role of in regulating apoptosis of PECs after PRRSV inoculation.\nThe greatest number of DEGs enriched in signal transduction, some of which (Wnt, Hippo, TGF-beta, mTOR, PI3K-Akt, and MAPK signaling pathways) were closely related to the differentiation, proliferation, maturation and apoptosis of intestinal epithelial cells.\nSubsequently, the whole transcriptome was compared between mock- and PRRSV-infected PECs and 54 differentially expressed microRNAs (DEmiRNAs), 104 differentially expressed genes (DEGs), 22 differentially expressed lncRNAs (DElncRNAs), and 109 isoforms were obtained, which were mainly enriched in apoptosis, necroptosis, and p53 signal pathways.\nFunctional analyses indicated that some DEGs were involved in the transcriptional regulation of nutrient transportation (SLC15A1, SLC5A1, and SLC3A1), cell differentiation (LGR5, HOXA5 and KLF4), cell proliferation (PLK2 and TGFB3), transcriptional regulation (JUN, FOS and ATF3), and signaling transduction (WNT10B and BMP1), suggesting that these genes were related to intestinal epithelial cell maturation and cell renewal.\nPRRSV-infected PECs exhibited apoptosis, indicative of their susceptibility to PRRSV.", "dois": ["10.3389/fimmu.2019.01221", "10.3390/ani12182324"]}
{"pair_type": "slc_pathway", "key1": "SLC3A1", "key2": "ferroptosis", "summary": "Cancer cells often uptake more cystines to increase glutathione (GSH) biosynthesis and reduce reactive oxygen species (ROS), thereby preventing ROS-induced ferroptosis and leading to therapeutic resistance.\nMolecularly, SLC7A13 silencing reduced cystine uptake and GSH biosynthesis, leading to increased lipid ROS levels.\nFunctionally, SLC7A13 overexpression promoted, while its silencing attenuated, cell survival or proliferation.\nHere, we report that the gene for SLC7A13, a member of the SLC7A13-SLC3A1 cystine transporter, was amplified and overexpressed in 19.7% and 49.7% of breast cancers, respectively.\nThese findings suggest that the SLC7A13-SLC3A1 cystine transporter is a therapeutic target for treating luminal breast cancer.\nSLC7A13 amplification and overexpression were associated with worse overall survival and disease-free survival in patients with luminal breast cancer.", "dois": ["10.1093/procel/pwaf076"]}
{"pair_type": "slc_pathway", "key1": "SLC2A14", "key2": "migration", "summary": "Among the co-expressed genes with the highest correlation, ITGA5, SLC2A3, SLC2A14, SHC1, CEBPB, and ADA were overexpressed and associated with shorter overall survival (OS) in ccRCC.\nCell experiments showed that knockdown SERPINE1 expression could inhibit the proliferation, migration and invasion of ccRCC cells.\nMoreover, the accumulation of disulfide bonds in cytoskeletal proteins was indicated by slowed migration in non-reducible protein blotting experiments.", "dois": ["10.1186/s13062-024-00528-4", "10.1186/s12894-023-01217-6"]}
{"pair_type": "slc_pathway", "key1": "SLC3A1", "key2": "oxidative stress", "summary": "High doses of diquat but not acetaminophen induced Slc3a1, suggesting Slc3a1 may respond to oxidative stress but not necessarily to GSH depletion.\nAdditionally, reduced glutathione may predispose those with cystinuria to injury caused by oxidative stress.\nOxidative stress-responsive long non-coding RNAs (lncRNAs) are deregulated in preeclamptic placenta;\nWe found significantly lowered levels of both reduced and total glutathione in the knockout animals.\nCystine is a precursor for the antioxidant molecule glutathione, so we evaluated glutathione levels in the livers of Slc3a1 mice.\nSlc7a11 (xCT) and Slc3a1 (rBAT) are cystine uptake transporters that maintain intracellular concentrations of cysteine, the rate-limiting amino acid in glutathione synthesis.\nWe investigated serum redox-sensitive lncRNAs TUG1, H19, and NEAT1, and their target miR-29b/cystine/neutral/dibasic amino acids transporter solute carrier family 3, member 1 (SLC3A1) as potential non-invasive biomarkers of PE risk, onset, and severity.", "dois": ["10.1080/10715762.2020.1812597", "10.1016/j.ncrna.2024.06.007", "10.1186/s12882-019-1417-8"]}
{"pair_type": "slc_pathway", "key1": "SLC2A14", "key2": "oxidative stress", "summary": "Enrichment analyses revealed shared pathways linked to immune modulation, oxidative stress, and metabolic dysfunction.\nThree hub genes-DNAJA1, NDUFA5, and SLC2A14-were identified with robust discriminatory capabilities (AUC ≥ 0.7).", "dois": ["10.1007/s11239-025-03072-8"]}
{"pair_type": "slc_pathway", "key1": "SLC3A2", "key2": "chemotherapy", "summary": "ZEB1/SLC3A2 may be promising therapeutic targets for enhancement of the sensitivity of ovarian cancer cells to cisplatin-mediated chemotherapy.\nFurthermore, in the presence of TSA, cisplatin downregulated TFAM and SLC3A2 to enhance cisplatin-induced ferroptosis, also contributing to the promotion of cisplatin cytotoxicity.\nUpregulation of SLC3A2 significantly decreased cell viability in response to cisplatin, increased cisplatin-induced apoptosis, and decreased migration and invasion in the presence of cisplatin.\nDownregulation of ZEB1 resulted in a significant increase of SLC3A2 expression.\nMoreover, upregulation of SLC3A2 decreased the volume and weight of implanted tumors.\nMoreover, downregulation of SLC3A2 significantly inhibited ZEB1 knockdown-mediated inhibition of cisplatin-resistance.\nSLC3A2 was decreased in cisplatin-resistant SKOV3/DPP cells.\nZEB1-mediated regulation of SLC3A2 was involved in the chemoresistance to cisplatin in ovarian cancer cells.\nOur findings suggest that combining AMXT 1501 and DFMO with standard chemotherapy might be an effective strategy for treating neuroblastoma.\nThe rs351855 AA genotype was a risk factor for partial chemotherapy response, and the GA + AA genotype for age ≥ 50 years at diagnosis and rectal cancer was associated with a partial response to chemotherapy ( < 0.05).\nPatients with high risk scores generally experienced worse prognoses and exhibited greater resistant to classical chemotherapy drugs.\nRNA sequencing and subsequent pathway analysis revealed that the ferroptosis pathway was likely implicated, and key ferroptosis-related genes (i.e., GPX4, NRF2, and SLC3A2) were downregulated following vorinostat treatment.\nMoreover, the expression of ferroptosis-associated genes glutathione peroxidase 4 (GPX4), solute carrier family 7 member 11 (SLC7A11) and solute carrier family 3 member 2 (SLC3A2) was", "dois": ["10.1002/1878-0261.70129", "10.1111/febs.70191", "10.3390/molecules29112623", "10.3390/biomedicines12030602", "10.1186/s12935-024-03294-5", "10.1615/CritRevEukaryotGeneExpr.2023048536", "10.1111/bjh.18884", "10.1002/cam4.5243", "10.1038/s41388-021-02097-6", "10.1126/scitranslmed.aau1099", "10.1159/000493864", "10.3892/ijmm.2018.3781", "10.1111/j.1365-2362.2009.02096.x", "PMID:17367118"]}
{"pair_type": "slc_pathway", "key1": "SLC3A2", "key2": "stemness", "summary": "Silencing ATF4 or CCT3 inhibited the selection and growth of TRCs whereas reduction of SLC3A2 or hsa-miR-199a-5p promoted TRCs growth.\nFurther studies showed that CCT3 promoted cell proliferation and stemness in vitro, while its suppression inhibited TRCs-induced tumor formation.\nBesides, these genes were critical regulators modulating drug resistance, tumor microenvironment infiltration, and cancer stemness.\nBy integrating networks for membrane proteins, the WNT pathway and cancer-related genes, we identified key molecules in the selection of TRCs, such as ATF4, SLC3A2, CCT3, and hsa-miR-199a-5p.\nIn this mini-review, we discuss the physiological functions of CD98hc, its role in regulating tumor stemness, metastases, and therapy resistance, and the clinical significance of CD98hc as a tumor marker and therapeutic target.\nWe also contemplated CCT3 as a stemness-related gene.\nOur results suggest that the microbiome is heavily associated with castration resistance and stemness in prostate cancer.\nAdditionally, we observed positive correlations between these DRGs and tumor stemness (DNAss DNA stemness score and RNAss RNA stemness score) as well as RNA modifications, particularly m6A modification, in several cancer types.\nHere we evaluated the transcriptome alteration during TRCs generation in 3D culture and revealed that a variety of molecules related with integrin/membrane and stemness were continuously altered by mechanical environment.\nThis multifaceted role makes CD98hc one of the critical regulators of tumor growth, therapy resistance, and metastases.\nIn this way, CD98hc connects the signaling pathways sustaining cell proliferation and migration, biosynthesis and antioxidant defense, energy production, and stem cell properties.\nThey regulated membrane genes and the downstream mechanotransduction pathways such as Hippo/WNT/TGF-β/PI3K-AKT pathways, thus further affecting the expression of downstream cancer-related genes.\nAbstract: Tumor-repopulating cells (TRCs) are cancer stem cell (CSC)-like cells with highly tumorig", "dois": ["10.1007/s12672-024-01612-x", "10.3390/ijms25063291", "10.3389/fonc.2023.1251100", "10.3389/fgene.2021.672904", "10.1038/s41388-019-0925-0"]}
{"pair_type": "slc_pathway", "key1": "SLC2A3", "key2": "glycolysis", "summary": "Additionally, METTL14 restrains aerobic glycolysis in p53-WT CRC, by repressing SLC2A3 and PGAM1 expression via selectively promoting m A-YTHDF2-dependent pri-miR-6769b/pri-miR-499a processing.\nDNMT1-driven methylation of RORA promotes ESCC progression largely through affecting SLC2A3 transcription and glycolysis.\nWe then investigated the consequences of SLC2A3 upregulation or inhibition on aerobic glycolysis, also explored the underlying mechanism.\nSLC2A3 activates the TGF-β signaling pathway through lactic acid generated from glycolysis, thus regulating the biological behavior of OSCC.\nFurthermore, rescue experiments revealed that RORA-mediated suppressive effects on ESCC cell migration and invasion were largely based on its negative regulation of SLC2A3 and glycolysis.\nSLC2A3 is frequently upregulated in various tumors, playing a pivotal role in aerobic glycolysis and thereby furnishing vital energy for tumor sustenance and malignant advancement, particularly in adverse conditions.\nHere we found that the transcription factor Bcl-6 directly repressed genes encoding molecules involved in the glycolysis pathway, including Slc2a1, Slc2a3, Pkm and Hk2, in type 1 helper T cells (TH1 cells) exposed to low concentrations of interleukin 2 (IL-2).\nWe hypothesize that during regeneration, cells use leptin, slc2a3, proinsulin, g6pd, hif1α expression, receptor tyrosine kinase (RTK) signaling, and the production of reactive oxygen species (ROS) to promote glucose entry into glycolysis and the pentose phosphate pathway (PPP), thus stimulating macromolecular biosynthesis.\nHere, we show that SLC2A3 acts as a tumor promoter and accelerates aerobic glycolysis in GC cells.\nWe also found that oral squamous cell carcinoma cells had increased proliferation, migration, invasion, EMT phenotype, and glycolysis due to SLC", "dois": ["10.1016/j.toxlet.2025.06.014", "10.1186/s12876-025-03878-z", "10.3389/fimmu.2025.1514061", "10.1186/s12967-024-05960-8", "10.1038/s41419-023-05701-7", "10.15252/embr.202256325", "10.1155/2022/9273559", "10.1038/s42255-021-00390-y", "10.1210/endocr/bqaa098", "10.1016/j.gene.2018.04.086", "10.1071/RD16441", "10.1038/ni.2985", "10.1002/bies.201300110", "10.1186/1471-2407-13-478", "10.1186/1476-4598-12-78", "10.4161/auto.21487", "10.1002/ijc.70180", "10.2147/OARRR.S541568", "10.7150/ijbs.104484", "10.1371/journal.pone.0301724", "10.1186/s12935-023-03159-3", "10.1242/jcs.260964", "10.3390/ijms232012400", "10.1155/2022/2371057", "10.1002/mrd.23570", "10.7150/jca.57926", "10.1242/jcs.256503", "10.1016/j.bbrc.2021.04.059", "10.1186/s12935-020-01599-9", "10.3390/genes11070720", "10.3390/biomedicines8020020", "10.1016/j.ymgmr.2019.100470", "10.1136/gutjnl-2017-315690", "10.1071/RD18178", "10.3389/fphar.2018.00502", "PMID:25859558", "10.1007/s13277-014-2838-4", "10.4161/auto.29456", "10.1152/ajpendo.00484.2013", "10.1530/JME-13-0194", "10.1128/MCB.06643-11"]}
{"pair_type": "slc_pathway", "key1": "SLC3A2", "key2": "glycolysis", "summary": "Furthermore, our data indicate that CD98hc sustains glucose uptake and glycolysis, and, as a consequence, the pentose phosphate pathway (PPP).\nMetabolism-related pathways nucleotide synthesis and glycolysis pathways were significantly upregulated, while amino acid synthesis and fatty acid oxidation pathways were significantly downregulated in HSCC tissues compared to adjacent normal tissues.\nOverall survival analysis showed that upregulated genes CD276, LDHB, SLC3A2, EGFR, SLC7A5, and HPRT1 are potential unfavorable prognostic markers in HNSCC, while downregulated genes EEA1, IDO1, NCOA2, REST, CCL19, and ALDH2 are potential favorable prognostic markers in HNSCC.\nMoreover, metabolism-related genes IDO1, ALDH2, NCOA2, SLC7A5, SLC3A2, LDHB, and HPRT1 are correlated with immune infiltrates in HNSCC.\nCancer cells overexpress CD98hc-transporters in order to meet their increased nutritional and antioxidant demands, since they provide branched-chain AA (BCAA) and aromatic AA (AAA) availability while protecting cells from oxidative stress.\nOn the basis of our findings, we conclude that CD98hc plays a central role in AA and glucose cellular nutrition, redox homeostasis and nucleotide availability, all key for cell proliferation.\nβ-Zfp148KO islets also exhibited elevated sensitivity to amino acid-induced Ca2+ influx under low glucose conditions, suggesting enhanced mitochondrial phosphoenolpyruvate-dependent (PEP-dependent), ATP-sensitive K+ channel closure, independent of glycolysis.\nRNA-Seq and proteomics of β-Zfp148KO islets revealed altered levels of enzymes involved in amino acid metabolism (specifically, SLC3A2, SLC7A8, GLS, GLS2, PSPH, PHGDH, and PSAT1) and intermediary metabolism (namely, GOT1 and PCK2), consistent with altered PEP cycling.", "dois": ["10.3389/fimmu.2022.955614", "10.1172/jci.insight.154198", "10.1038/s41598-019-50547-9"]}
{"pair_type": "slc_pathway", "key1": "SLC2A3", "key2": "migration", "summary": "Further results showed that NETs promoted LLC cell proliferation and migration and inhibited ferroptosis by promoting YTHDF2-mediated SLC2A3 mRNA degradation.\nSilencing LINC01094, up-regulating miR-184, or reducing SLC2A3 inhibited the growth, migration, and invasion of ccRCC cells.\nFurthermore, rescue experiments revealed that RORA-mediated suppressive effects on ESCC cell migration and invasion were largely based on its negative regulation of SLC2A3 and glycolysis.\nIn HNSC cell lines, SLC2A3 knockdown inhibited cell proliferation and migration.\nSLC2A3 knockdown suppressed migration and inhibited the expression of Vimentin and MMP9 in CRC cell line SW480 and RKO.\nInterestingly, exogenous lactic acid restored the EMT, proliferation, migration, and invasion abilities of oral cancer cells inhibited by knocking down SLC2A3.\nWe also found that oral squamous cell carcinoma cells had increased proliferation, migration, invasion, EMT phenotype, and glycolysis due to SLC2A3 overexpression.\nAlso, CTGF induced Glut3 (also known as SLC2A3) expression, leading to increased glycolysis, which enhanced cell proliferation and migration in tamoxifen-resistant cells.\nWe also observed that high SLC2A3 expression led to EMT and the activation of the TGF-β signaling pathway, while knockdown inhibited it.\nOur in vivo experiments confirmed that SLC2A3 overexpression promoted tumor growth and metastasis while knockdown inhibited it.\nDNMT1-driven methylation of RORA promotes ESCC progression largely through affecting SLC2A3 transcription and glycolysis.\nTaken together, silencing LINC01094 inhibited SLC2A3 expression by up-regulating miR-184, thereby inhibiting the development of ccRCC.\nIn this work, we found that LINC00667 expression was up-regulated in EC cell lines, and LINC00667 knockdown inhibited cell proliferation, migration, and invasion in EC", "dois": ["10.1002/ijc.70180", "10.1002/mnfr.70167", "10.21037/tcr-24-1177", "10.1002/ctm2.70192", "10.7150/ijbs.104484", "10.1186/s12967-024-05960-8", "10.4251/wjgo.v16.i7.3169", "10.1186/s12885-024-12549-3", "10.1371/journal.pone.0301724", "10.1186/s12935-023-03159-3", "10.1242/jcs.260964", "10.1080/19336950.2023.2208928", "10.1186/s12894-023-01217-6", "10.18502/ijph.v50i12.7941", "10.1016/j.csbj.2022.07.021", "10.1002/mrd.23570", "10.1016/j.tranon.2022.101389", "10.1007/s10620-021-07145-5", "10.3389/fonc.2021.638099", "10.1242/jcs.256503", "10.1038/s42255-021-00390-y", "10.3389/fgene.2020.562967", "10.1164/rccm.200803-456OC"]}
{"pair_type": "slc_pathway", "key1": "SLC3A2", "key2": "oxidative phosphorylation", "summary": "We further explore the effects of GLUD1 inhibition in endocrine therapy-resistant ILC cells using the small-molecule inhibitor R162, which reduces ER protein levels, increases reactive oxygen species, and inhibits oxidative phosphorylation.\nThis work identifies structure-specific recognition protein 1 (SSRP1), which upregulates SLC3A2, as a co-transcription factor with JUNB.\nHigh SLC3A2 expression predicts poor outcomes in PTCL, as SLC3A2-mediated arginine uptake promotes the malignant behaviors of tumor cells and induces tumor immune escape, thereby fueling tumor progression.\nMechanistically, high arginine levels induce global metabolic changes, including enhanced oxidative phosphorylation by promoting nascent RNA synthesis.\nAll four proteins are associated with increased tumor size in ILC, but not IDC/NST, with SLC3A2 also specifically linked to shorter overall survival and the presence of comorbidities in ILC.\nMechanistically, YBX3 stabilizes the mRNA of Slc3a2 and Pparg, which facilitates branched-chain amino acid (BCAA) influx and catabolism and fuels brown adipocyte differentiation and thermogenesis.\nQuinacrine disrupts SLC3A2-mediated arginine transport by targeting SSRP1.\nSingle-cell transcriptomic analyses reveal aberrant arginine metabolism in patients with PTCL, characterized by excessive solute carrier family 3 member 2 (SLC3A2) mediated arginine uptake preferentially in tumor cells.\nTranscriptome analysis and mitochondrial stress test indicate that Ybx3 deficiency compromises the mitochondrial oxidative phosphorylation, leading to thermogenic failure.\nSLC3A2 plays a role on both sides of this dichotomy as an adaptor to SLC7A5, a transporter of branched-chain amino acids (BCAA: Leu, Ile, Val), and to SLC7A11, a cystine importer supplying cysteine to the synthesis of the antioxidant glutathione.\nIntriguingly, the evolution of modern birds (", "dois": ["10.1002/advs.202415698", "10.1016/j.molmet.2024.102053", "10.1101/2024.09.29.615681", "10.1016/j.jbc.2023.105409"]}
{"pair_type": "slc_pathway", "key1": "SLC3A2", "key2": "migration", "summary": "Overexpression of hsa-miR-605-3p regulated SLC3A2 to promote ICC cell ferroptosis and inhibit proliferation and migration.\nTaken together, knockdown of hsa_circ_0050900 inhibited SLC3A2 expression via sponging hsa-miR-605-3p to promote ICC cell ferroptosis, and finally suppressed proliferation and migration.\nUpregulation of SLC3A2 significantly decreased cell viability in response to cisplatin, increased cisplatin-induced apoptosis, and decreased migration and invasion in the presence of cisplatin.\nOur results suggest that circBTBD7-420aa may inhibit the abnormal proliferation and migration of human coronary artery smooth muscle cells by promoting SLC3A2 degradation through the ubiquitin-proteasome pathway.\nIn vitro experiments showed that knocking down of SLC3A2 was associated with reduced migration, invasion, and proliferation, but increased apoptosis of OSCC cells.\nKnockout of SLC3A2 suppressed the migration and invasion of BGC-823 cells and , whereas overexpression of SLC3A2 in NCI-N87 cells promoted the migration and invasion and .\nUpregulated SLC3A2 influenced the tumor microenvironment by altering immune cell infiltration, particularly of macrophages, and tumor migration and invasion.\nKnockdown of SLC3A2 suppressed melanoma cell proliferation and migration in vitro.\nThe proliferation, invasion, and migration of BLCA cells were reduced after interfering with SLC3A2.\nIn vitro experiments showed that reduced SLC3A2 expression decreased cell proliferation, migration, and invasion.\nKnockdown HOXA13 inhibited PCa cell proliferation, migration, and invasion, partially rescued by SLC7A11/SLC3A2 overexpression.\nInhibition of MIF or SLC3A2 expression prevented cell proliferation, migration, epithelial-mesenchymal transition (EMT) and invasion.\nInhibition of miR-142-3p or overexpression of SLC3A2 reversed ferroptosis and inhibited the prolif", "dois": ["10.1016/j.cellsig.2025.112168", "10.3390/ph18091382", "10.1016/j.tranon.2025.102534", "10.1016/j.jep.2025.120456", "10.1016/j.isci.2025.113196", "10.1007/s12672-025-03125-7", "10.1038/s41420-025-02401-3", "10.1016/j.placenta.2025.04.016", "10.1016/j.jacbts.2024.09.003", "10.1186/s12967-025-06241-8", "10.3389/fonc.2025.1451034", "10.3389/fimmu.2024.1456649", "10.1016/j.exer.2024.110182", "10.1016/j.prostaglandins.2024.106909", "10.1007/s00262-024-03827-x", "10.1038/s41598-024-66484-1", "10.3390/molecules29112623", "10.1177/15330338241246649", "10.1016/j.heliyon.2023.e23502", "10.1186/s12014-023-09445-6", "10.3892/ol.2023.14135", "10.3389/fonc.2023.1251100", "10.1016/j.phymed.2023.154741", "10.1007/s10620-023-07824-5", "10.1016/j.gendis.2022.04.011", "10.1111/jcmm.17352", "10.21037/jgo-21-916", "10.1186/s12920-022-01194-z", "10.1158/0008-5472.CAN-20-3477", "10.1111/jop.13132", "10.1159/000493864", "10.18632/oncotarget.25101", "10.1371/journal.pone.0190179", "10.18632/oncotarget.19529", "10.18632/oncotarget.11913", "10.1186/1476-4598-12-169", "PMID:17623099", "PMID:17597067", "PMID:15625115"]}
{"pair_type": "slc_pathway", "key1": "SLC4A1", "key2": "chemotherapy", "summary": "We identified upregulated proteins in the HGSOC relapse tissues, including COL12A1, FUBP1, PLEC, SLC4A1, and TKT.\nIHC showed COL12A1, FUBP1, PLEC, SLC4A1, and TKT protein abundance were significantly elevated in HGSOC relapse tissues compared to matching tissues at diagnosis.\nFurthermore, both COL12A1 and PLEC mRNA and protein levels were significantly associated with chemotherapy resistance.\nIn summary, using MALDI-MSI, we have identified proteins, including COL12A1 and PLEC, associated with chemotherapy resistance to be further evaluated as HGSOC biomarkers and/or therapeutic targets.", "dois": ["10.3390/ijms26125893"]}
{"pair_type": "slc_pathway", "key1": "SLC3A1", "key2": "proliferation", "summary": "Functional analyses indicated that some DEGs were involved in the transcriptional regulation of nutrient transportation (SLC15A1, SLC5A1, and SLC3A1), cell differentiation (LGR5, HOXA5 and KLF4), cell proliferation (PLK2 and TGFB3), transcriptional regulation (JUN, FOS and ATF3), and signaling transduction (WNT10B and BMP1), suggesting that these genes were related to intestinal epithelial cell maturation and cell renewal.\nFunctionally, SLC7A13 overexpression promoted, while its silencing attenuated, cell survival or proliferation.\nThese effects of L-Trp were associated with mTOR activation and increased (P < 0.05) mRNA abundance for L-Trp transporters (SLC6A19, SLC6A14, and SLC3A1) by 1.5-2.7 fold and ATP1A1 by 3 fold.\nFurthermore, both compounds promoted the proliferation of intestinal Lactobacillus species, a tryptophan-metabolizing bacterium, stimulated short-chain fatty acid production, and lowered intestinal pH.\nThey regulated tryptophan metabolism by increasing the diversity and content of indole tryptophan metabolites, activating the aryl hydrocarbon receptor (AhR) pathway, and elevating the mRNA levels of CYP1A1, CYP1B1, SLC3A1, IDO2 and TPH1.\nThe greatest number of DEGs enriched in signal transduction, some of which (Wnt, Hippo, TGF-beta, mTOR, PI3K-Akt, and MAPK signaling pathways) were closely related to the differentiation, proliferation, maturation and apoptosis of intestinal epithelial cells.\nCompared with basal medium containing 0.04 mmol/L L-Trp, 0.4 and 0.8 mmol/L L-Trp enhanced (P < 0.05) protein synthesis by 45-52% and cell growth by 17% and 25% on day", "dois": ["10.1093/procel/pwaf076", "10.1007/s43032-025-01914-7", "10.1186/s40104-025-01220-x", "10.3390/ani12182324", "10.3945/jn.114.209817"]}
{"pair_type": "slc_pathway", "key1": "SLC3A1", "key2": "migration", "summary": "Silencing of S100A4 significantly inhibited the migration and invasion ability of endometrial stromal cells, whereas overexpression of S100A4 reversed this inhibitory effect.\nAmong these key lactate metabolism-related genes, S100A4 was found to be significantly upregulated in the lesions of endometriosis and plays a pivotal role in regulating cellular invasion and metabolic reprogramming in endometriosis.\nFive key genes (MRPS2, YARS2, SLC3A1, CALD1, and S100A4) were validated as highly accurate diagnostic markers.", "dois": ["10.1007/s43032-025-01914-7", "PMID:14730569", "PMID:10620184"]}
{"pair_type": "slc_pathway", "key1": "SLC4A1", "key2": "apoptosis", "summary": "In BC cells, lnc-SLC4A1-1 knockdown promoted cell apoptosis and suppressed cell proliferation, migration and invasion.\nGain-of-function experiments indicated that lnc-SLC4A1-1 facilitated trophoblast cell migration and apoptosis.\nMeanwhile, CXCL8 overexpression partly reversed the effects of lnc-SLC4A1-1 knockdown on cell viability, apoptosis, migration and invasion in BC cells.\nActivation of CXCL8 exacerbated inflammatory reactions in trophoblast cells by inducing TNF-α and IL-1β, which could be blocked by an antagonist of lnc-SLC4A1-1.\nLnc-SLC4A1-1 could promote the development of BC by regulating NF-κB/CXCL8.\nThese findings indicate that an eRNA, lnc-SLC4A1-1, alters trophoblast function via activation of immune responses and by regulating the NF-κB/CXCL8 axis.\nFurthermore, lnc-SLC4A1-1 is transcriptionally activated by H3K27 acetylation, and lnc-SLC4A1-1 interacted with transcription factor (NF)-κB p65, thereby regulating CXCL8 expression.\nPG treatment resulted in dramatical depression of cell viability, remarkable promotion of cell apoptosis and dramatic suppression of migration and invasion in Ishikawa cells in a dose-dependent way.\nLnc-SLC4A1-1 could promote the development of BC.\nLnc-SLC4A1-1 interacted with NF-κB to promote CXCL8 expression.\nMechanistically, as an eRNA, lnc-SLC4A1-1 was retained in the nuclei and recruited transcription factor NF-κB to bind to CXCL8, resulting in increased H3K27ac in the CXCL8 promoter and subsequent elevation of CXCL8 expression.", "dois": ["10.1016/j.freeradbiomed.2024.07.017", "10.1691/ph.2020.9608", "10.1080/21691401.2019.1664559", "10.1186/s12974-019-1433-4", "10.1016/j.ebiom.2018.11.015", "10.1111/1756-185X.12745", "10.1074/jbc.M114.548651", "PMID:12669066"]}
{"pair_type": "slc_pathway", "key1": "SLC4A1", "key2": "ferroptosis", "summary": "In addition, specific biological processes and molecular functions during progressive periodontitis were revealed and a set of hub proteins, including SNCA, CA1, HBB, SLC4A1, and ANK1 was strongly associated with the clinical progression status of periodontitis.\nMoreover, we found specific proteins - drivers or suppressors - associated with ferroptosis (SNCA, FTH1, HSPB1, CD44, and GCLC), revealing the co-occurrence of this specific type of regulated cell death during the clinical progression of periodontitis.\nAdditionally, the integration of quantitative proteomic data with scRNA-seq analysis suggested the susceptibility of fibroblasts to ferroptosis.\nTo investigate the involvement and significance of ferroptosis in periodontitis progression, we assessed sixteen periodontitis-diagnosed patients.\nFerroptosis is implicated in the pathogenesis of numerous chronic-inflammatory diseases, yet its association with progressive periodontitis remains unexplored.\nClinical metrics, proteomic data, in silico methods, and bioinformatics tools were combined to identify protein profiles linked to periodontitis progression and to explore their potential connection with ferroptosis.\nOur analyses reveal proteins and processes linked to ferroptosis for the first time in periodontal patients, which offer new insights into the molecular mechanisms of progressive periodontal disease.", "dois": ["10.1038/s41368-024-00306-y"]}
{"pair_type": "slc_pathway", "key1": "SLC1A4", "key2": "ferroptosis", "summary": "Our data suggest SLC1A4, TXNIP, and PLIN4 are involved in ferroptosis mediated cisplatin resistance in BLCA, findings which merit further study.\nFive ferroptosis-related genes (SCP2, MUC1, DPP4, SLC1A4, and TF) were identified as promising diagnostic biomarkers for NAFLD.\nour analysis revealed that a combination of six ferroptosis-related genes, including TBK1, SLC1A4, PIK3CA, ENO3, EGR1, and ATG5, could serve as optimal markers for the diagnosis of pSS.\nSLC1A4 was markedly upregulated in tumors.\nNQO1, SLC1A4, and NOS2 were identified as potential genes in HB and found to be significantly upregulated in tumor samples.\nThe emergence of ferroptosis as a novel form of cell death has gained increased attention in various human cancers.\nFerroptosis is a novel mechanism of programmed cell death that depends on iron accumulation and lipid peroxidation.\nVarious studies have confirmed the role of ferroptosis in tumor regulation and ferroptosis is now considered to play an important role in breast cancer development.\nThe correlations between the expression of ferroptosis-related genes and immune cell infiltration might shed light on the study of the molecular mechanism underlying NAFLD development.\nCNOT6-miR-145-5p-SLC1A4 are likely to be the potential RNA regulatory pathways that affect NAFLD development.\nFive prognostic genes were found by machine learning: TRIB3, CHAC1, NNMT, EGFR, and SLC1A4.\nFerroptosis has recently been identified to play a significant role in autoimmune diseases.\nMoreover, growing evidence implicates ferroptosis in the development of this resistance.\nThis study identified five ferroptosis-related genes as potential biomarkers for diagnosing NAFLD.\nFerroptosis is an iron-dependent cell death mode that is characterized by intracellular accumulation of reactive oxygen species (ROS).\nFerroptosis plays a key role in the death of cells including cardiomyocytes,", "dois": ["10.1038/s41598-025-86061-4", "10.1002/cbin.12146", "10.1186/s40001-023-01457-0", "10.4317/medoral.26190", "10.1016/j.compbiomed.2023.107370", "10.1111/jcmm.17239", "10.1080/10255842.2025.2585143", "10.21037/jtd-2024-2173", "10.3389/fonc.2023.1228199", "10.3389/fgene.2022.1062212", "PMID:35693077", "10.1038/s41420-021-00473-5"]}
{"pair_type": "slc_pathway", "key1": "SLC4A1", "key2": "oxidative phosphorylation", "summary": "Ingenuity pathway analysis revealed increased cell proliferation and RNA processing in SCA and borderline tumors compared to benign tumors, with SCA showing greater oxidative phosphorylation than borderline tumors.\nOur comparative analysis indicates that upregulated (ASS1 - argininosuccinate synthase 1, CAPS, PPA1, BCAT1, MCM4) and downregulated proteins (MUC5B, SLC4A1, tenascin-XB - TNXB, carbonic anhydrase 1, hemoglobin β) may offer a robust panel for distinguishing SCA from benign and borderline ovarian tumors, potentially aiding in early diagnosis and disease monitoring.", "dois": ["10.5114/wo.2025.149180"]}
{"pair_type": "slc_pathway", "key1": "SLC4A1", "key2": "migration", "summary": "In BC cells, lnc-SLC4A1-1 knockdown promoted cell apoptosis and suppressed cell proliferation, migration and invasion.\nGain-of-function experiments indicated that lnc-SLC4A1-1 facilitated trophoblast cell migration and apoptosis.\nMeanwhile, CXCL8 overexpression partly reversed the effects of lnc-SLC4A1-1 knockdown on cell viability, apoptosis, migration and invasion in BC cells.\nLnc-SLC4A1-1 could promote the development of BC by regulating NF-κB/CXCL8.\nPG treatment resulted in dramatical depression of cell viability, remarkable promotion of cell apoptosis and dramatic suppression of migration and invasion in Ishikawa cells in a dose-dependent way.\nMoreover, PG decreased the level of lnc-SLC4A1-1, and high levels of lnc-SLC4A1-1 reversed the effects of PG on Ishikawa cells.", "dois": ["10.1691/ph.2020.9608", "10.1080/21691401.2019.1664559", "10.1016/j.ebiom.2018.11.015", "PMID:16392641"]}
{"pair_type": "slc_pathway", "key1": "SLC3A2", "key2": "proliferation", "summary": "Overexpression of hsa-miR-605-3p regulated SLC3A2 to promote ICC cell ferroptosis and inhibit proliferation and migration.\nTaken together, knockdown of hsa_circ_0050900 inhibited SLC3A2 expression via sponging hsa-miR-605-3p to promote ICC cell ferroptosis, and finally suppressed proliferation and migration.\nOur results suggest that circBTBD7-420aa may inhibit the abnormal proliferation and migration of human coronary artery smooth muscle cells by promoting SLC3A2 degradation through the ubiquitin-proteasome pathway.\nCell experiments confirmed that melanocyte proliferation decreased, whereas apoptosis increased, after SLC3A2 knockdown.\nHOXA13 drives PCa progression by transcriptionally activating SLC7A11 and SLC3A2, which suppress ferroptosis and enhance proliferation and metastasis.\nIn vitro experiments showed that knocking down of SLC3A2 was associated with reduced migration, invasion, and proliferation, but increased apoptosis of OSCC cells.\nMechanistic study showed that HCMV-miR-US33-5p bound to the 3'-untranslated region of EPAS1 to suppress its expression, leading to suppression of SLC3A2 expression, which ultimately promoted cell apoptosis and inhibited cell proliferation.\nReduced expression of SLC3A2 inhibited OS cell proliferation through G2/M phase arrest.\nIn vitro, CLDND1 knockdown reduced viability and proliferation, accompanied by morphological degeneration and decreased SRC, GPX4, SLC3A2, COL1, and KI67\nThis was confirmed by the findings that silencing EPAS1 significantly reduced the SLC3A2 expression and inhibited proliferation and key factors of integrin signal pathway.\nThese findings highlight that macrophage-derived l-glutamine promoted CRC cell proliferation and adhesion by regulating FOXA2 activity through SLC3A2-mediated metabolic sensing.\nIn addition, MYCN directly increased polyamine synthesis and promoted neuroblastoma cell proliferation by", "dois": ["10.1002/advs.202417330", "10.1016/j.cellsig.2025.112168", "10.1016/j.bbrc.2025.152788", "10.1016/j.tice.2025.103181", "10.3390/ph18091382", "10.1038/s41388-025-03585-9", "10.1016/j.tranon.2025.102534", "10.1016/j.jep.2025.120456", "10.1016/j.isci.2025.113196", "10.1038/s41375-025-02718-z", "10.1007/s12672-025-03125-7", "10.1126/sciadv.adg3481", "10.1016/j.intimp.2025.115115", "10.1038/s41420-025-02401-3", "10.1016/j.placenta.2025.04.016", "10.1016/j.jacbts.2024.09.003", "10.1158/0008-5472.CAN-24-3180", "10.4143/crt.2024.933", "10.1186/s12967-025-06241-8", "10.3389/fonc.2025.1451034", "10.3389/fimmu.2024.1456649", "10.1007/s10620-025-08843-0", "10.1002/advs.202406220", "10.24976/Discov.Med.202436190.208", "10.1016/j.exer.2024.110182", "10.1016/j.prostaglandins.2024.106909", "10.3389/fonc.2024.1407538", "10.1007/s00262-024-03827-x", "10.1038/s41598-024-66484-1", "10.1515/med-2024-0941", "10.1177/15330338241246649", "10.1101/2024.04.03.587917", "10.1101/2024.03.08.584072", "10.1186/s12864-024-10147-y", "10.1055/s-0044-1781457", "10.1016/j.heliyon.2023.e23502", "10.1016/j.jbc.2023.105602", "10.3892/ol.2023.14135", "10.1111/jcmm.18010", "10.3389/fonc.2023.1251100", "10.3389/fvets.2023.1202369", "10.7150/ijms.84872", "10.1111/bjh.18884", "10.1101/2023.04.13.536765", "10.1016/j.phymed.2023.154741", "10.1080/01443615.2023.2188085", "10.1007/s10620-023-07824-5", "10.3390/cancers14215191", "10.1016/j.gendis.2022.04.011", "10.1007/s12010-022-04119-9", "10.3389/fmolb.2022.961410", "10.1186/s11658-022-00340-w", "10.1111/jcmm.17352", "10.21037/jgo-21-916", "10.1038/s42003-022-03363-3", "10.3389/fphar.2022.851680", "10.3389/fphar.2022.851540", "10.1186/s12920-022-01194-z", "10.1186/s41065-022-00225-0", "10.3390/cancers14010229", "10.1038/s41388-021-02097-6", "10.1016/j.jaci.2021.07.014", "10.1002/JLB.3MA1220-815RRR", "10.18632/oncotarget.27981", "10.3389/fimmu.2021.624324", "10.1038/s41467-021-20896-z", "10.1111/jop.13132", "10.1016/j.tranon.2020.100915", "10.3390/ijms21041407", "10.3389/fonc.2019.01470", "10.1038/s41416-019-0626-z", "10.1038/s41598-019-50547-9", "10.1038/s41388-019-0925-0", "10.1016/j.celrep.2019.05.039", "10.1016/j.celrep.2019.04.034", "10.1186/s13046-019-1177-0", "10.1126/scitranslmed.aau1099", "10.1007/s10549-018-05111-w", "10.1158/1535-7163.MCT-17-1178", "10.1016/j.bbamcr.2018.06.006", "10.1016/j.jid.2018.05.026", "10.18632/oncotarget.25101", "10.1038/s41416-018-0038-5", "10.1371/journal.pone.0190179", "10.1242/jcs.211755", "10.3892/or.2017.5530", "10.15252/embr.201744000", "10.18632/oncotarget.11913", "10.1074/jbc.M115.704254", "10.1242/jcs.178129", "10.1371/journal.pone.0139692", "10.1158/0008-5472.CAN-14-0579", "10.1186/1476-4598-12-169", "10.1084/jem.20121651", "10.1186/2045-3701-1-7", "10.4049/jimmunol.1100002", "10.1172/JCI44631", "10.1084/jem.20082845", "10.1016/j.cell.2008.11.044", "PMID:17623099", "PMID:17597067", "PMID:17192196"]}
{"pair_type": "slc_pathway", "key1": "SLC4A1", "key2": "proliferation", "summary": "In BC cells, lnc-SLC4A1-1 knockdown promoted cell apoptosis and suppressed cell proliferation, migration and invasion.\nLnc-SLC4A1-1 could promote the development of BC by regulating NF-κB/CXCL8.\nInhibiting Bloodlinc or Hnrnpu compromises the terminal erythropoiesis gene program, blocking red cell production, whereas expressing Bloodlinc ectopically stimulates this program and can promote erythroblast proliferation and enucleation in the absence of differentiation stimuli.\nLnc-SLC4A1-1 could promote the development of BC.\nFurthermore, lnc-SLC4A1-1 is transcriptionally activated by H3K27 acetylation, and lnc-SLC4A1-1 interacted with transcription factor (NF)-κB p65, thereby regulating CXCL8 expression.\nLnc-SLC4A1-1 interacted with NF-κB to promote CXCL8 expression.\nMeanwhile, CXCL8 overexpression partly reversed the effects of lnc-SLC4A1-1 knockdown on cell viability, apoptosis, migration and invasion in BC cells.\nIngenuity pathway analysis revealed increased cell proliferation and RNA processing in SCA and borderline tumors compared to benign tumors, with SCA showing greater oxidative phosphorylation than borderline tumors.\nThus, Bloodlinc is a trans-acting super-enhancer RNA that potentiates red blood cell development.\nBloodlinc localizes to trans-chromosomal loci encoding critical regulators and effectors of terminal erythropoiesis and directly binds chromatin-organizing and transcription factors, including the chromatin attachment factor HNRNPU.\nHere, we show that one such RNA, alncRNA-EC7/Bloodlinc, is transcribed from a super-enhancer of the erythroid membrane transporter SLC4A1/BAND3 but diffuses beyond this site.", "dois": ["10.1111/xen.70081", "10.5114/wo.2025.149180", "10.1093/cei/uxad135", "10.1080/21691401.2019.1664559", "10.1016/j.celrep.2017.05.082", "10.4238/2012.April.3.6"]}
{"pair_type": "slc_pathway", "key1": "SLC4A2", "key2": "apoptosis", "summary": "Overexpression of TMPRSS3 increased cell viability, whereas suppression of TMPRSS3 increased the percentage of apoptotic cells and decreased cell viability, compared to the control group.\nAt early ages (1-9 months), knockout mice had reduced numbers of intrahepatic T cells, which exhibited increased activation, programmed-cell-death (PD)-1 expression, and apoptosis.\nOlder (≥ 10 months) knockouts, however, showed intrahepatic accumulation of cytotoxic CD8(+) T cells with downregulated PD-1 and diminished apoptosis.\nPeptide p17AE2 exhibited optimal interaction ability and indeed promoted apoptosis in mouse and human Treg cells, while activating effector T-cell function.\nLoss of SLC4A2 function appears to induce premature cell death, and likely results in cytoplasmic alkalinization of osteoclasts which, in turn, may disrupt acidification of resorption lacunae.\nInterestingly, this linear peptide also induced apoptosis in different types of human leukemia, lymphoma and multiple myeloma cell lines and primary malignant samples, while it showed only moderate effects on normal B lymphocytes.\nEarly in life, AE2 deficiency results in intrahepatic T-cell activation and PD-1/PD-L1 mediated deletion.\nMoreover, young knockouts had upregulated PD-1 ligand (PD-L1) on bile-duct cells, and administration of neutralizing anti-PD-L1 antibodies prevented their intrahepatic T-cell deletion.\nTMPRSS3 is an important molecule in the regulation of cell viability and cell apoptosis of HEI-OC1 cells.\nHistological examination of affected tissues revealed scarce, morphologically abnormal osteoclasts displaying evidence of apoptosis.\nThough these cells express the osteoclast markers CD68, cathepsin K, and NFATc1, compared with their wild-type (WT) counterparts they are larger, fail to express tartrate-resistant acid phosphatase (TRAP) activity, and display a propensity to undergo", "dois": ["10.1002/jgm.3118", "10.3324/haematol.2017.175687", "10.18632/oncotarget.5665", "10.1073/pnas.0808763105", "PMID:16816370", "10.1186/1471-2164-11-337"]}
{"pair_type": "slc_pathway", "key1": "SLC4A2", "key2": "chemotherapy", "summary": "Western blot analysis results further confirmed that the EPHX1 PLIN2 RAB27B SLC4A2 are upregulated in Bel/5Fu cells in accordance with the proteomics data.\nThe extensive drug resistance of hepatocellular carcinoma (HCC) has become a major cause of chemotherapy failure.\nPlasma membrane protein EPHX1 is closely related to the chemotherapy resistance of Bel/5Fu cells and can be used as a new drug target to improve the clinical prognosis of patients with HCC.\nMoreover, cell viability assay and clonogenic survival assay results demonstrated that EPHX1 is closely related to the chemoresistance of Bel/5Fu to 5-Fu.\nIn total, 25 plasma membrane proteins are shown differentially expressed in Bel/5Fu compared with Bel7402.", "dois": ["10.1002/prca.201900080"]}
{"pair_type": "slc_pathway", "key1": "SLC4A1", "key2": "oxidative stress", "summary": "This investigation aimed to explore the cellular and molecular mechanisms related to oxidative stress underlying anion exchanger 1 activity (band 3, SLC4A1/AE1) in human RBCs.\nIn the present study, we investigated whether the anion exchange capability mediated by AE1 (SLC4A1), which is sensitive to oxidative stress, was altered in human red blood cells (RBCs) obtained from prediabetic volunteers.\nExpected, oxidative stress was also associated with a decreased band 3 ion transport activity and an increase of oxidized haemoglobin, which led to abnormal clustering of band 3.\nExposure to AAPH caused oxidative stress, exhaustion of reduced glutathione, and over-activation of the endogenous antioxidant machinery, resulting in morphological alterations of RBCs, specifically the formation of acanthocytes, increased lipid peroxidation and oxidation of proteins, as well as abnormal distribution and hyper-phosphorylation of band 3.\nParticularly well studied is the impact of oxidative stress on the red blood cell SLC4A1/AE1 (Band 3 protein), of which the function seems to be directly affected by oxidative stress and possibly involves oxidation of the transporter itself or its interacting proteins, with detrimental consequences in oxidative stress-related diseases including inflammation, metabolic dysfunctions and ageing.\nOxidative stress mediated by hyperglycemia-induced production of reactive species could play a crucial role in this context.\nOxidative stress was also associated with an altered band 3 ion transport activity and increased oxidized haemoglobin, which led to abnormal clustering of band 3 on the plasma membrane.\nHydrogen peroxide significantly increased oxidative stress parameters, modulus elasticity values and clustered EB3 levels and induced conjugation of membrane proteins to form high-molecular-weight complexes (p < 0.05).\nDuring their lifespan in the bloodstream, red blood cells (RBCs) are exposed to multiple stressors, including increased oxidative stress, which can affect their morphology and function, thereby contributing to disease.\nThese data suggest that the RBC dysfunction observed during exercise-induced oxidative stress could be associated with alterations in the structure an", "dois": ["10.1002/cbf.4105", "10.1016/j.freeradbiomed.2024.07.017", "10.1111/apha.13796", "10.1172/JCI146077", "10.1016/j.jbiomech.2019.07.045", "10.1139/cjpp-2013-0145", "10.3389/fvets.2025.1583291", "10.1016/j.intimp.2025.114197", "10.3389/fphys.2023.1303815", "10.3389/fimmu.2021.709173", "10.3389/fphys.2020.00357", "10.1016/j.jagp.2019.06.007", "10.1074/jbc.RA118.006393"]}
{"pair_type": "slc_pathway", "key1": "SLC4A2", "key2": "migration", "summary": "siRNA-mediated SLC4A2 knockdown significantly suppressed BPS-induced cell migration and reversed EMT phenotypes.\nThis study first demonstrates that BPS promotes CRC cell migration by activating the EMT signaling pathway via SLC4A2 upregulation.\nBPS exposure within the concentration range of 10⁻¹ ⁰ to 10⁻⁶ M did not significantly inhibit HCT8 cell viability but markedly enhanced migration and invasion capabilities, accompanied by EMT progression.\nWe further demonstrate a previously unrecognized consequence of SLC4A2 loss of function in the osteoclast: dysregulation of calpain-dependent podosome disassembly, leading to abnormal actin belt formation, cell spreading, and migration.\nNotably, BPS exposure specifically induced SLC4A2 upregulation, while siRNA-mediated SLC4A2 knockdown significantly suppressed BPS-induced cell migration and reversed EMT phenotypes.\nSLC4A2, being a key player in BPS-induced tumorigenesis, could function as a promising biomarker and therapeutic target for CRC.\nRescue of SLC4A2-deficient osteoclasts with functionally defined mutants of SLC4A2 indicates regulation of actin cytoskeletal reorganization by anion-exchange activity and intracellular pH, independent of SLC4A2's long N-terminal cytoplasmic domain.\nThe impact of BPS on HCT8 cell proliferation, migratory ability, and EMT progression were systematically evaluated through Western blot, CCK-8 proliferation assays, scratch wound healing experiments, and Transwell assays for migration and invasion.", "dois": ["10.1016/j.tox.2025.154236", "10.1073/pnas.1206392110"]}
{"pair_type": "slc_pathway", "key1": "SLC4A3", "key2": "apoptosis", "summary": "Our result showed that CAMK1 transport subnetwork upstream KCNQ3, LCN2, NKX2_5, NUP62, SORT1, STX1A activated CAMK1, and downstream CAMK1-activated AFP, ENAH, KPNA2, SLC4A3;\nWe proposed that CAMK1 activated network enhanced endosome to lysosome transport, endosome transport via multivesicular body sorting pathway, Golgi to endosome transport, intracellular protein transmembrane transport, intracellular protein transport, ion transport, mRNA transport, plasma membrane to endosome transport, potassium ion transport, protein transport, vesicle-mediated transport, anion transport, intracellular transport, androgen receptor signaling pathway, cell surface receptor-linked signal transduction, hormone-mediated signaling, induction of apoptosis by extracellular signals, signal transduction by p53 class mediator resulting in transcription of p21 class mediator, signal transduction resulting in induction of apoptosis, phosphoinositide-mediated signaling, Wnt receptor signaling pathway, as a result of inducing phosphoinositide signal-mediated protein sorting, and transport in HCC.\nalso by CAMK1 negative functional regulation subnetwork including negative regulation of apoptosis, cell proliferation, centriole replication, fatty acid biosynthesis, lipoprotein lipase activity, MAPK activity, progression through cell cycle, transcription, transcription from RNA polymerase II promoter, cell growth, phosphorylation, and ubiquitin ligase activity during mitotic cell cycle in HCC.\nOur hypothesis was verified by CAMK1 functional regulation subnetwork containing positive regulation of calcium ion transport via voltage gated calcium channel, cell proliferation, DNA repair, exocytosis, I-kappaB kinase/NF-kappaB cascade, immunoglobulin-mediated immune response, mast cell activation, natural killer cell-mediated cytotoxicity directed against tumor cell target, protein ubiquitination, sodium ion transport, survival gene product activity, T cell-mediated cytotoxicity, transcription, transcription from RNA polymerase II", "dois": ["10.1007/s12013-014-0011-8"]}
{"pair_type": "slc_pathway", "key1": "SLC4A3", "key2": "migration", "summary": "Our result showed that CAMK1 transport subnetwork upstream KCNQ3, LCN2, NKX2_5, NUP62, SORT1, STX1A activated CAMK1, and downstream CAMK1-activated AFP, ENAH, KPNA2, SLC4A3;\nalso by CAMK1 negative functional regulation subnetwork including negative regulation of apoptosis, cell proliferation, centriole replication, fatty acid biosynthesis, lipoprotein lipase activity, MAPK activity, progression through cell cycle, transcription, transcription from RNA polymerase II promoter, cell growth, phosphorylation, and ubiquitin ligase activity during mitotic cell cycle in HCC.\nOur hypothesis was verified by CAMK1 functional regulation subnetwork containing positive regulation of calcium ion transport via voltage gated calcium channel, cell proliferation, DNA repair, exocytosis, I-kappaB kinase/NF-kappaB cascade, immunoglobulin-mediated immune response, mast cell activation, natural killer cell-mediated cytotoxicity directed against tumor cell target, protein ubiquitination, sodium ion transport, survival gene product activity, T cell-mediated cytotoxicity, transcription, transcription from RNA polymerase II promoter, transcription initiation from RNA polymerase II promoter, transcription via serum response element binding, exit from mitosis, ubiquitin ligase activity during mitotic cell cycle, regulation of angiogenesis, apoptosis, cell growth, cell proliferation, cyclin-dependent protein kinase activity, gene expression, insulin secretion, steroid biosynthesis, transcription from RNA polymerase II promoter, transcription from RNA polymerase III promoter, cell cycle, cell migration, DNA recombination, and protein metabolism;", "dois": ["10.1007/s12013-014-0011-8"]}
{"pair_type": "slc_pathway", "key1": "SLC4A2", "key2": "oxidative stress", "summary": "On the other hand, reduced AE2 in cholangiocytes could cause cholestasis and oxidative stress of bile duct cells.\nCholangiocytes isolated from Ae2(a,b)(-/-) mice showed gene expression changes compatible with oxidative stress and increased antigen presentation.", "dois": ["10.1159/000324144", "10.1016/j.jhep.2008.12.006"]}
{"pair_type": "slc_pathway", "key1": "SLC4A2", "key2": "proliferation", "summary": "Notably, BPS exposure specifically induced SLC4A2 upregulation, while siRNA-mediated SLC4A2 knockdown significantly suppressed BPS-induced cell migration and reversed EMT phenotypes.\nThis study first demonstrates that BPS promotes CRC cell migration by activating the EMT signaling pathway via SLC4A2 upregulation.\nSLC4A2, being a key player in BPS-induced tumorigenesis, could function as a promising biomarker and therapeutic target for CRC.\nThese findings demonstrate that CD8(+) T cells are critically dependent on Ae2 for pHi homeostasis and tuning of cell proliferation and activation.\nMoreover, stimulated Ae2-deficient CD8(+) T cells show enhanced intracellular production of IL-2 and membrane expression of its receptor IL-2Rα, together with increased cell proliferation and activation.\nAcid uptake into CCD-112-CoN and NHDF-Ad cells was slower and comparable to levels in CRC cells, but increased alongside SLC4A2 expression under stimulation with transforming growth factor β1 (TGFβ1), a cytokine involved in cancer-stroma interplay.\nBPS exposure within the concentration range of 10⁻¹ ⁰ to 10⁻⁶ M did not significantly inhibit HCT8 cell viability but markedly enhanced migration and invasion capabilities, accompanied by EMT progression.\nThe impact of BPS on HCT8 cell proliferation, migratory ability, and EMT progression were systematically evaluated through Western blot, CCK-8 proliferation assays, scratch wound healing experiments, and Transwell assays for migration and invasion.", "dois": ["10.1016/j.tox.2025.154236", "10.1073/pnas.1610954113", "10.1002/eji.201344218", "10.4238/2012.April.3.6"]}
{"pair_type": "slc_pathway", "key1": "SLC4A3", "key2": "glycolysis", "summary": "Among these, somatic mutations in SLC4A3 had features consistent with meaningful consequences on cellular fitness.\nThe orchestrated activity of acid-base transporters of the solute-linked carrier (SLC) family is critical for removing the end-products of fermentative metabolism (lactate/H) and maintaining a favourably alkaline cytoplasm.\nSomatic mutation patterns of monocarboxylate transporters (MCTs) were consistent with their proposed essentiality in facilitating lactate/H efflux.", "dois": ["10.1007/s00424-023-02876-y"]}
{"pair_type": "slc_pathway", "key1": "SLC4A3", "key2": "oxidative stress", "summary": "We hypothesized that increases in the ratio of gene transcription in these injuries would be countered with downregulation of the gene encoding the cardiac and neuronal isoform of the chloride/bicarbonate exchanger ().\nAbstract: Physical trauma, psychosocial stress, and oxidative stress increase the neuronal transcription ratio of genes encoding the sodium-potassium chloride cotransporter () and the potassium chloride cotransporter (), which leads to neuronal depolarization and excitability.\nApigenin and sodium butyrate have been reported to help alleviate oxidative stress.\nThis study evaluated the jejunal transcriptomic responses in ducks receiving apigenin and sodium butyrate supplementation under oxidative stress.\nCollectively, our findings provide molecular evidence for the beneficial effects of apigenin and sodium butyrate against oxidative stress in the jejunum of ducks.\nCompared to the DIQ group, sodium butyrate supplementation during oxidative stress elevated jejunal villus height and villus height/crypt depth ratio in ducks ( < 0.05).\nAnalysis revealed that the dietary supplementation of apigenin and sodium butyrate reduced malondialdehyde (MDA) levels and increased total antioxidant capacity (T-AOC) ( < 0.05).", "dois": ["10.1152/ajpheart.00462.2025", "10.3390/vetsci12070655"]}
{"pair_type": "slc_pathway", "key1": "SLC4A3", "key2": "proliferation", "summary": "Our result showed that CAMK1 transport subnetwork upstream KCNQ3, LCN2, NKX2_5, NUP62, SORT1, STX1A activated CAMK1, and downstream CAMK1-activated AFP, ENAH, KPNA2, SLC4A3;\nResults of the survival analysis, conducted on the validation cohort and commonly deregulated genes, indicated that overexpression of HOXC4 ( < 0.001), LLGL1 ( = 0.0015), and SLC4A3 ( = 0.0034) is associated with worse OS in early-stage SqCLC patients.\nAs a result, we developed a prognostic risk model based on the screened 6-SLC genes (SLC39A8, SLC2A3, SLC39A13, SLC35B1, SLC4A3, SLC12A2).\nA loss-of-function study showed that knockdown of SLC12A2 expression restrained proliferation and stemness of CRC cells while a gain-of-function study showed the contrary results.\nAt the same time, we identified that SLC12A2 could promote tumor progression in CRC, which may serve as a potential therapeutic target.\nalso by CAMK1 negative functional regulation subnetwork including negative regulation of apoptosis, cell proliferation, centriole replication, fatty acid biosynthesis, lipoprotein lipase activity, MAPK activity, progression through cell cycle, transcription, transcription from RNA polymerase II promoter, cell growth, phosphorylation, and ubiquitin ligase activity during mitotic cell cycle in HCC.\nOur hypothesis was verified by CAMK1 functional regulation subnetwork containing positive regulation of calcium ion transport via voltage gated calcium channel, cell proliferation, DNA repair, exocytosis, I-kappaB kinase/NF-kappaB cascade, immunoglobulin-mediated immune response, mast cell activation, natural killer cell-mediated cytotoxicity directed against tumor cell target, protein ubiquitination, sodium ion transport, survival gene product activity, T cell-mediated cytotoxicity, transcription, transcription", "dois": ["10.3390/cancers16040720", "10.1038/s41598-024-55048-y", "10.1007/s12013-014-0011-8", "10.4238/2012.April.3.6"]}
{"pair_type": "slc_pathway", "key1": "SLC4A4", "key2": "glycolysis", "summary": "Functionally, SLC4A4 inhibition in PDAC cancer cells mitigates the acidosis of the TME due to bicarbonate accumulation in the extracellular space and a decrease in lactate production by cancer cells as the result of reduced glycolysis.\nThe genes involved in both glycolysis pathway (LDHA) and tricarboxylic acid cycle (IDH2 and OGDH) were up-regulated in gills and heart of hypoxic large yellow croakers, possibly because gill and heart tissues need enough energy to accelerate gas exchange and blood circulation.\nHypoxia also affected the ion transport in gills of large yellow croaker, through down-regulating the expression levels of numerous classical ion transporters, including HVCN1, SLC20A2, SLC4A4, RHBG, RHCG, and SCN4A, suggesting an energy conservation strategy to hypoxia stress.\nAll these results indicate that the immune processes, glycolytic pathways, and ion transport were significantly altered in gills and/or heart of large yellow croaker under hypoxia, possibly contributing to maintain cellular energy balance during hypoxia.", "dois": ["10.1523/JNEUROSCI.2310-11.2011", "10.1038/s43018-022-00470-2", "10.1016/j.fsi.2020.06.028", "10.1096/fj.201902352R"]}
{"pair_type": "slc_pathway", "key1": "SLC4A3", "key2": "stemness", "summary": "A loss-of-function study showed that knockdown of SLC12A2 expression restrained proliferation and stemness of CRC cells while a gain-of-function study showed the contrary results.\nAs a result, we developed a prognostic risk model based on the screened 6-SLC genes (SLC39A8, SLC2A3, SLC39A13, SLC35B1, SLC4A3, SLC12A2).\nAt the same time, we identified that SLC12A2 could promote tumor progression in CRC, which may serve as a potential therapeutic target.", "dois": ["10.1038/s41598-024-55048-y"]}
{"pair_type": "slc_pathway", "key1": "SLC4A4", "key2": "oxidative phosphorylation", "summary": "Higher succinylation scores correlated with mitochondrial oxidative phosphorylation, while lower succinylation scores were linked to immune cell differentiation.\nA prognostic model consisting of 11 succinylation-related genes (ATP6V1C2, CAPS, DAPK1, P4HA1, PCED1A, RASL10B, AGT, EREG, HYAL1, SARAF, and SLC4A4) was developed.", "dois": ["10.3389/fimmu.2025.1571446"]}
{"pair_type": "slc_pathway", "key1": "SLC4A4", "key2": "migration", "summary": "Upregulation of SLC4A4 promoted apoptosis in the LUAD cell line and significantly inhibited the migration and invasive ability of cancer cells (P<0.01).\nSLC4A4 knockdown inhibited cell proliferation, migration and invasion, while facilitated apoptosis, which was also confirmed in vivo.\nTherefore, hsa_circRNA_001587 inhibits PC cell migration, invasion, angiogenesis and tumorigenesis by impairing miR-223-mediated SLC4A4 inhibition.\nOverexpression of miR-223 downregulates the expression of SLC4A4 and promotes PC cell growth.\nOur functional analysis revealed that SLC4A4 knockdown retards tumor growth and lowers invasion and migration potential.\nIn MDA-MB-231 breast cancer cells expressing high levels of SLC4A4 compared to LS174 cells, SLC4A4 knockdown had a strong impact on cell proliferation, migration, and invasion.\nOverexpressing miR-224-5p increased the proliferative, migratory and invasive abilities of CRC cells and inhibit CRC cell apoptosis, while overexpressing SLC4A4 caused the opposite result.\nMoreover, SLC4A4 promoted PCa progression through the AKT-mediated signalling pathway.\nSLC4A4 knockdown suppressed PCa development in vitro and in vivo.\nNDBT inhibition (S0859) and shRNA knockdown suppressed migration (40% reduction) and invasion (70% reduction) in vitro.\nImportantly, SLC9A2 overexpression in SW480 cells led to a notable inhibition of cell proliferation, migration, and invasion.\nDelivery of circ_0086375 by nanoparticles suppresses the tumorigenicity of pancreatic cancer by miR-646/SLC4A4 axis, suggesting a new potential target for future pancreatic cancer treatment.\nTumour xenograft metastasis in vivo was significantly reduced by NDBT knockdown.\nFirstly, we reported the SLC4A4/GSK-3β/β-catenin signaling axis, which reg", "dois": ["10.36721/PJPS.2025.38.4.REG.13101.1", "10.3389/fimmu.2025.1571446", "10.1038/s41598-024-72408-w", "10.1007/s12672-024-01488-x", "10.1016/j.intimp.2024.112756", "10.1007/s11596-024-2871-5", "10.1021/acsomega.4c00901", "10.1007/s10585-022-10197-0", "10.1186/s12935-022-02546-6", "10.1016/j.neo.2022.01.003", "10.1186/s12864-021-08182-0", "10.14670/HH-18-387", "10.1093/carcin/bgab055", "10.1152/ajpgi.00118.2020", "10.1002/jcp.24930"]}
{"pair_type": "slc_pathway", "key1": "SLC4A4", "key2": "apoptosis", "summary": "Upregulation of SLC4A4 promoted apoptosis in the LUAD cell line and significantly inhibited the migration and invasive ability of cancer cells (P<0.01).\nSLC4A4 knockdown inhibited cell proliferation, migration and invasion, while facilitated apoptosis, which was also confirmed in vivo.\nOverexpressing miR-224-5p increased the proliferative, migratory and invasive abilities of CRC cells and inhibit CRC cell apoptosis, while overexpressing SLC4A4 caused the opposite result.\nOverall, 14% of the top candidate biomarkers also had evidence for involvement in psychological stress response, and 19% for involvement in programmed cell death/cellular suicide (apoptosis).\nMoreover, SLC4A4 promoted PCa progression through the AKT-mediated signalling pathway.\nSLC4A4 knockdown suppressed PCa development in vitro and in vivo.\nmiR-224-5p in CAFs-derived EVs facilitated the proliferation, migration, invasion and anti-apoptosis of CRC cells.\nRescue assay also demonstrated that overexpressing miR-224-5p reversed the inhibitory effect of overexpressed SLC4A4 on cancer cell growth.\nImportantly, we demonstrated that high expression of SLC4A4 was able to increase the proliferation level and cytokine secretion of CD8+ T cells for the purpose of promoting the immune system response to LUAD.\nIt has been demonstrated that lipopolysaccharide (LPS)-induced vascular occlusion is associated with the apoptosis, activating calpain and increased [Ca(2+)]i that are related to NHE1 activity in endothelia cells.\nIt may be that in the face of adversity (stress), death mechanisms are turned on at a cellular (apoptosis) and organismal level.\nSLC4A4 acts as a tumor promotor in PCa by regulating key components of the AKT pathway and may therefore act as a potential therapeutic target for PCa treatment.\nThe results of this study indicated that SLC4A4 overexpression was closely associated with the progression of PCa.\nAltered expression and activity of solute carrier", "dois": ["10.1016/j.exer.2025.110614", "10.36721/PJPS.2025.38.4.REG.13101.1", "10.1016/j.intimp.2024.112756", "10.1158/0008-5472.CAN-15-1862", "10.1016/j.exer.2012.04.013", "PMID:20383337", "10.1016/j.cbpb.2025.111173", "10.1016/j.cbd.2025.101572", "10.1186/s12935-022-02546-6", "10.1093/carcin/bgab055", "10.4330/wjc.v10.i9.97", "10.1038/mp.2015.112", "10.1371/journal.pone.0090273", "10.1371/journal.pone.0084201"]}
{"pair_type": "slc_pathway", "key1": "SLC4A4", "key2": "oxidative stress", "summary": "A decrease in the activity of superoxide dismutase and catalase, and reduced glutathione content with increased malondialdehyde concentration were also measured in the arsenic-exposed fish.\nArsenic exposure also decreased gene expression of intestinal transporters (solute carrier family (slc) 26a6, slc4a4, ATPase Na/K transporting subunit alpha 3, and slc15a1a) and the tight junction protein zonula occludens-1.\nIon regulation was also disrupted by CdCl₂, as evidenced by reduced gill Ca⁺-ATPase (↓81%) and Na⁺/K⁺-ATPase (↓75%) activities, along with significant downregulation of ion transporter genes (pc, nka-α3, atp6v1a, and slc4a4;\nThis study investigated the protective role of purslane (Portulaca oleracea, PUR), a medicinal plant rich in antioxidant bioactives, against Cd-induced oxidative stress and ion transporter dysfunction in Nile tilapia (Oreochromis niloticus).\nAntioxidant enzyme activities in the gills were markedly suppressed (GPx (↓67%), CAT (↓67%), and SOD (↓61%)), with a depletion of GSH (↓58%) and an elevation of MDA (↑55%).\nFeeding the arsenic-exposed fish on a GE diet improved their growth and intestinal microenvironment and mitigated the changes in oxidative stress, inflammatory, and apoptotic cascades.\nAdditionally, PLP corrected altered expressions of tight junction proteins (zo-1, zo-2, and claudin-4) and nutrient transporters (glut-1, slc15a2, slc26a6, and slc4a4) in Cd-exposed fish.\nPLP mitigated pathological alterations, replenished antioxidants (SOD, CAT, and GSH), and reduced lipid peroxidation in the intestinal tissues.\nIts antioxidant activity and regulation of intestinal tight junction proteins and nutrient transporters contribute to its effectiveness.", "dois": ["10.1007/s10695-024-01415-5", "10.1167/iovs.11-7592", "10.1016/j.cbpb.2025.111173", "10.1007/s12011-025-04761-4"]}
{"pair_type": "slc_pathway", "key1": "SLC4A5", "key2": "apoptosis", "summary": "Identification of SLC4A5, SLC5A10 and LDOC1 indicated that sodium/bicarbonate transport, sodium/glucose transport and cell-proliferation regulation may play important upstream roles and identification of BNIP1, APOBEC3F and LDOC1 suggested that apoptosis, innate immune response and cell-proliferation regulation may play important downstream roles in hypertension.\nIt has been demonstrated that lipopolysaccharide (LPS)-induced vascular occlusion is associated with the apoptosis, activating calpain and increased [Ca(2+)]i that are related to NHE1 activity in endothelia cells.", "dois": ["10.1371/journal.pone.0090273", "10.1093/bioinformatics/btp106"]}
{"pair_type": "slc_pathway", "key1": "SLC4A4", "key2": "proliferation", "summary": "Knockdown of SLC4A4 via shRNA reduced cell proliferation and increased mortality during external acidosis and spheroid growth.\nSLC4A4 knockdown inhibited cell proliferation, migration and invasion, while facilitated apoptosis, which was also confirmed in vivo.\nSLC4A4 overexpression restrained cell proliferation and metastasis by suppressing Kirsten rat sarcoma viral oncogene (KRAS) expression in renal cancer cells.\nImportantly, we demonstrated that high expression of SLC4A4 was able to increase the proliferation level and cytokine secretion of CD8+ T cells for the purpose of promoting the immune system response to LUAD.\nOverexpression of miR-223 downregulates the expression of SLC4A4 and promotes PC cell growth.\nUpregulation of SLC4A4 promoted apoptosis in the LUAD cell line and significantly inhibited the migration and invasive ability of cancer cells (P<0.01).\nSecondly, we investigated the SLC4A4/RB axis, which acts to drive cell proliferation.\nThe target gene SLC4A4 we had selected using bioinformatics had a strong effect on the proliferation of prostate cells;\nThe role of SLC4A4 in the proliferation and migration of colon cancer cells was verified by CCK8, EdU and wound healing assays.\nIn renal cancer cells, overexpression of miR-223-3p enhanced cell proliferation and metastasis, while inhibition of miR-223-3p reduced the malignant capacity of the cells.\nIn MDA-MB-231 breast cancer cells expressing high levels of SLC4A4 compared to LS174 cells, SLC4A4 knockdown had a strong impact on cell proliferation, migration, and invasion.\nOverexpressing miR-224-5p increased the proliferative, migratory and invasive abilities of CRC cells and inhibit CRC cell apoptosis, while overexpressing SLC4A4 caused the opposite result.\nMoreover, SLC4A4 promoted PCa progression through the AKT-mediated signalling pathway.", "dois": ["10.36721/PJPS.2025.38.4.REG.13101.1", "10.3389/fimmu.2025.1571446", "10.1038/s41598-024-72408-w", "10.1007/s12672-024-01488-x", "10.1016/j.intimp.2024.112756", "10.1007/s11596-024-2871-5", "10.1021/acsomega.4c00901", "10.1007/s10585-022-10197-0", "10.1155/2022/3290479", "10.1186/s12935-022-02546-6", "10.1002/art.42077", "10.14670/HH-18-387", "10.1093/carcin/bgab055", "10.1177/0885328220975249", "10.1152/ajpgi.00118.2020", "10.1089/dna.2019.5088", "10.1097/WNR.0000000000001372", "10.7717/peerj.7968", "10.3934/mbe.2019145", "10.1016/j.bbamem.2019.03.007", "10.18632/aging.101763", "10.1186/s13287-017-0737-5", "10.1002/jcp.24930", "PMID:23651669", "10.1167/iovs.11-7592", "PMID:20383337"]}
{"pair_type": "slc_pathway", "key1": "SLC4A5", "key2": "proliferation", "summary": "Identification of SLC4A5, SLC5A10 and LDOC1 indicated that sodium/bicarbonate transport, sodium/glucose transport and cell-proliferation regulation may play important upstream roles and identification of BNIP1, APOBEC3F and LDOC1 suggested that apoptosis, innate immune response and cell-proliferation regulation may play important downstream roles in hypertension.", "dois": ["10.1093/bioinformatics/btp106"]}
{"pair_type": "slc_pathway", "key1": "SLC4A5", "key2": "migration", "summary": "Hypoxia induced the expression of NDBTs in TNBC, most frequently SLC4A4 and SLC4A5.\nNDBT inhibition (S0859) and shRNA knockdown suppressed migration (40% reduction) and invasion (70% reduction) in vitro.\nThese results demonstrate that targeting hypoxia-induced NDBT can be used as an approach to modulate phospho-signalling, EMT, and metabolic activity and reduce tumour migration, invasion, and metastasis in vivo.\nTumour xenograft metastasis in vivo was significantly reduced by NDBT knockdown.\nWe showed that NDBT knockdown inhibited EMT, modulating the expression of key EMT transcription factors and ablating the expression of vimentin whilst increasing the expression of E-cadherin.\nNDBT knockdown resulted in an attenuation in hypoxic phospho-signalling activation; most notably LYN (Y397) reduced by 75%, and LCK (Y394) by 72%.\nNDBT knockdown also altered metabolic activity reducing overall ATP and extracellular lactate levels.\nWe and others have previously identified increased hypoxic expression of Na driven bicarbonate transporters (NDBTs) as a major mechanism of tumour pH regulation.\nTo investigate the mechanism by which NDBTs support metastasis, we investigated their role in regulation of phospho-signalling, epithelial-to-mesenchymal transition (EMT) and metabolism.\nIn line with this the metastatic process is dependent on pH regulatory mechanisms.\nRegions of tumour hypoxia tend to be more acidic and both hypoxia and acidosis increase tumour metastasis.", "dois": ["10.1016/j.neo.2022.01.003"]}
{"pair_type": "slc_pathway", "key1": "SLC4A7", "key2": "chemotherapy", "summary": "RNA-seq, KEGG pathway enrichment analysis and Western blot further revealed that downregulation of SLC4A7 in HNSCC cells inhibited the PI3K/AKT pathway.\nOur findings suggest that SLC4A7 promotes EMT and metastasis of HNSCC through the PI3K/AKT/mTOR signaling pathway, which may be a valuable predictive biomarker and potential therapeutic target in HNSCC.\nMeanwhile, SLC4A7 could promote epithelial-mesenchymal transition (EMT) in HNSCC.\nIn vitro and in vivo experiments showed that dysregulation of SLC4A7 had minor influence on the proliferation of HNSCC but impacted HNSCC's migration and invasion.\nIn this study, we identified the Na -coupled bicarbonate transporter, SLC4A7, play essential roles in the metastasis of HNSCC.\nCurrently, therapeutic modalities such as surgery, chemotherapy, radiotherapy, and immunotherapy are being used to treat HNSCC.", "dois": ["10.1002/mc.23511", "10.1158/1541-7786.MCR-14-0011"]}
{"pair_type": "slc_pathway", "key1": "SLC4A7", "key2": "glycolysis", "summary": "NBCn1 protein expression increased 2.5-fold during breast carcinogenesis and was responsible for the increased net acid extrusion and alkaline intracellular pH of breast cancer compared with normal breast tissue.\nWe conclude that NBCn1 facilitates acid extrusion from breast cancer tissue, maintains the alkaline intracellular environment and promotes aggressive cancer development and growth.\nThe extracellular tumor microenvironment in NBCn1 KO mice contained higher concentrations of glucose and lower concentrations of lactate than that in WT mice.\nGenetic disruption of NBCn1 delayed breast cancer development: tumor latency was ~50% increased while tumor growth rate was ~65% reduced in NBCn1 KO compared with wild-type (WT) mice.", "dois": ["10.1038/onc.2015.273"]}
{"pair_type": "slc_pathway", "key1": "SLC4A7", "key2": "migration", "summary": "Overexpression of miR-888-5p or knockdown of SLC4A7 reduced the proliferation and migration of gastric cancer cells.\nIn addition, rescue experiments confirmed that the inhibitory effects of the knockdown of PSMB8-AS1 or the knockdown of SLC4A7 on the proliferation and migration of gastric cancer cells could be reversed by miR-888-5p inhibitor treatment.\nIn vitro and in vivo experiments showed that dysregulation of SLC4A7 had minor influence on the proliferation of HNSCC but impacted HNSCC's migration and invasion.\nRNA-seq, KEGG pathway enrichment analysis and Western blot further revealed that downregulation of SLC4A7 in HNSCC cells inhibited the PI3K/AKT pathway.\nOur findings suggest that SLC4A7 promotes EMT and metastasis of HNSCC through the PI3K/AKT/mTOR signaling pathway, which may be a valuable predictive biomarker and potential therapeutic target in HNSCC.\nMeanwhile, SLC4A7 could promote epithelial-mesenchymal transition (EMT) in HNSCC.\nIn this study, we identified the Na -coupled bicarbonate transporter, SLC4A7, play essential roles in the metastasis of HNSCC.\nWe propose that axial pHi gradients enhance VSMC migration whereas global acidification inhibits VSMC proliferation and media hypertrophy after carotid artery ligation.\nwith [Formula: see text] present), NBCn1-mediated [Formula: see text] uptake raises VSMC pHi and promotes filopodia, VSMC migration, and hypertrophic inward remodelling.\nKnock-out or pharmacological inhibition of NBCn1 also reduces filopodia and lowers initial rates of VSMC migration after scratch-wound infliction.\nInterventions to reduce H(+)-buffer mobility (omission of [Formula: see text] or inhibition of carbonic anhydrases) re-establish axial pHi gradients, filopodia, and migration rates in explants from NBCn1", "dois": ["10.1016/j.bbrc.2025.152757", "10.1016/j.bbadis.2024.167450", "10.1152/ajpcell.00079.2024", "10.1002/mc.23511", "10.18632/oncotarget.28224", "10.1186/s12920-018-0467-2", "10.1093/cvr/cvw079", "10.1007/s00424-014-1524-0", "10.1002/ijc.27782"]}
{"pair_type": "slc_pathway", "key1": "SLC4A7", "key2": "stemness", "summary": "Moreover, the inhibitory role of SLC4A7 in regulating tumor stemness was verified.\nCollectively, the present results uncovered the inhibitory effect exerted by SLC4A7 on tumor progression via its regulation of lactate transport, protein lactylation and stemness properties.\nAdditionally, low expression levels of SLC4A7 in LUAD cancer stem cells were validated using tumor tissue samples from patients with LUAD.\nAnalyzing the lactylome revealed that SLC4A7 suppressed lysine lactylation of numerous genes like HSP90AA1 and pathways such as focal adhesion associated with carcinogenesis.\nSLC4A7 inhibited tumor progression, including metastasis, invasion and proliferation.\nMechanistically, SLC4A7 decreased both intracellular and extracellular lactate accumulation and inhibited overall protein lactylation, as confirmed by lactylome analysis.", "dois": ["10.3892/ijo.2025.5739"]}
{"pair_type": "slc_pathway", "key1": "SLC4A7", "key2": "proliferation", "summary": "SLC4A7 inhibited tumor progression, including metastasis, invasion and proliferation.\nOverexpression of miR-888-5p or knockdown of SLC4A7 reduced the proliferation and migration of gastric cancer cells.\nIn addition, rescue experiments confirmed that the inhibitory effects of the knockdown of PSMB8-AS1 or the knockdown of SLC4A7 on the proliferation and migration of gastric cancer cells could be reversed by miR-888-5p inhibitor treatment.\n(2022) show that bicarbonate uptake by SLC4A7 fuels de novo nucleotide synthesis and cell proliferation and is regulated by mTORC1.\nIn vitro and in vivo experiments showed that dysregulation of SLC4A7 had minor influence on the proliferation of HNSCC but impacted HNSCC's migration and invasion.\nDisrupting NBCn1 expression delays ErbB2-induced breast cancer development, inhibits cancer cell proliferation, and decelerates tumor growth.\nWe propose that axial pHi gradients enhance VSMC migration whereas global acidification inhibits VSMC proliferation and media hypertrophy after carotid artery ligation.\nDisruption of NBCn1 expression inhibited cell proliferation-evaluated by staining for the proliferative marker Ki67-particularly in central tumor areas with predicted increase in acid loading from glycolytic metabolism.\nExtrusion of the acid load from the cancer cells raises intracellular pH, while it decreases extracellular pH creating an inverted pH gradient across the plasma membrane compared to normal cells and promoting cancer cell metabolism, proliferation, migration, and invasion.\nMoreover, the inhibitory role of SLC4A7 in regulating tumor stemness was verified.\nThese results suggest that SFN inhibits gastric cancer growth through the YY1/PSMB8-AS1/miR-888-5p/SLC4A7 axis.\nProliferation was increased in Panc-1 cells and decreased in BxPC-3 cells, upon TGFβ-1 treatment, and this, as well as EMT , was unaffected by NHE1- or NBC", "dois": ["10.1016/j.bbrc.2025.152757", "10.3892/ijo.2025.5739", "10.1016/j.bbadis.2024.167450", "10.1152/ajpcell.00079.2024", "10.1038/s41416-024-02591-0", "10.1186/s12957-023-03050-5", "10.1002/mc.23511", "10.1002/jgm.3469", "10.1016/j.molcel.2022.08.010", "10.18632/oncotarget.28224", "10.7554/eLife.68447", "10.3389/fonc.2020.00687", "10.1016/j.bbamem.2019.03.007", "10.1186/s12920-018-0467-2", "10.1038/s41388-018-0353-6", "10.1080/15384101.2018.1464850", "10.1093/cvr/cvw079", "10.1038/onc.2015.273", "10.1007/s00424-014-1524-0", "10.1002/ijc.27782"]}
{"pair_type": "slc_pathway", "key1": "SLC4A9", "key2": "oxidative stress", "summary": "Some of these were likely beneficial for cetaceans, for example, by reducing the risk of thrombus formation during diving ( and ), erroneous DNA damage repair (), and oxidative stress-induced lung inflammation ().", "dois": ["10.1126/sciadv.aaw6671"]}
{"pair_type": "slc_pathway", "key1": "SLC4A10", "key2": "apoptosis", "summary": "SLC4A10 CD8 T cells were significantly enriched in unstable human carotid plaques and were correlated with the apoptosis of vascular smooth muscle cells (VSMCs).\nThe extent of atherosclerotic plaques was mitigated, the amount of collagen fibers were diminished, and the apoptosis of VSMCs were alleviated.\nSLC4A10 decreased the levels of IFN-γ and GZMB in CD8T cells.\nThe CCK8 demonstrated that IFN-γ and GZMB lead to the decrease in MOVAS cell viability.\nThese data demonstrate that SLC4A10 mitigates cytotoxicity by decreasing the levels of IFN-γ/GZMB of SLC4A10 CD8 T cells via the MAPK pathway, which impedes plaque progression and aids stabilization.", "dois": ["10.3389/fimmu.2025.1568999"]}
{"pair_type": "slc_pathway", "key1": "SLC4A10", "key2": "proliferation", "summary": "Further investigation demonstrated that PI stimulation increased the expression of PITPNM1, POU1F1, C2orf15 and LDHA as well as the phosphorylation of AKT and ERK, and promoted the proliferation, migration and invasion of GH3 cells, which were blocked by PITPNM1knockdown.\nThese results suggested that elevated serum PI might contribute to the proliferation and invasion of pituitary adenoma by regulating the expression of PITPNM1/AKT/ERK/POU1F1 axis.\nProteomic data showed that the top five up-regulated proteins were AD021, C2orf15, PLCXD3, HIST3H2BB and POU1F1, and the top five down-regulated proteins were AIPL1, CALB2, GLUD2, SLC4A10 and GTF2I.", "dois": ["10.1186/s40170-024-00372-0"]}
{"pair_type": "slc_pathway", "key1": "SLC4A10", "key2": "migration", "summary": "Proteomic data showed that the top five up-regulated proteins were AD021, C2orf15, PLCXD3, HIST3H2BB and POU1F1, and the top five down-regulated proteins were AIPL1, CALB2, GLUD2, SLC4A10 and GTF2I.\nPI stimulation increased the expression of PITPNM1, POU1F1, C2orf15 and LDHA as well as the phosphorylation of AKT and ERK, and promoted the proliferation, migration and invasion of GH3 cells, which were blocked by PITPNM1knockdown.\nIn addition, PI propelled the metastasis of GH3 cells in vivo, and elevated the expression of PITPNM1, POU1F1, C2orf15 and LDHA.\nThese results suggested that elevated serum PI might contribute to the proliferation and invasion of pituitary adenoma by regulating the expression of PITPNM1/AKT/ERK/POU1F1 axis.", "dois": ["10.2147/JHC.S493907", "10.1186/s40170-024-00372-0"]}
{"pair_type": "slc_pathway", "key1": "SLC4A11", "key2": "chemotherapy", "summary": "Functional in vitro assays, including colony formation, migration, and CCK-8 experiments, demonstrated that SLC4A11 overexpression enhanced OV cell proliferation and migration, while its knockdown inhibited these processes.\nIn vivo studies using a subcutaneous xenograft mouse model further validated the role of SLC4A11 in promoting tumor growth.\nMechanistically, SLC4A11 was found to directly interact with the Epidermal growth factor receptor (EGFR), activating the PI3K/AKT signaling pathway, a critical driver of cancer progression.\nThese findings highlight SLC4A11 as a key regulator of OV development and a potential therapeutic target, offering new insights for improving treatment strategies and patient outcomes in ovarian cancer.\nAnalysis of public datasets (TCGA and GEO) revealed that SLC4A11 expression was significantly elevated in OV tissues compared to normal tissues and was associated with poorer overall survival and advanced clinical stages.\nDespite standard treatments, including tumor reduction surgery and platinum-based chemotherapy, the majority of patients face high risks of recurrence and metastasis, underscoring the need for a deeper understanding of the molecular mechanisms driving OV progression.\nCancer stem cells (CSCs) are accountable for tumor initiation and exhibit resistance to chemotherapy and radiotherapy.\nPatients in the high stemness risk group presented a poorer prognosis ( < 0.0001), and patients with lower stemness scores were more likely to benefit from chemotherapy.\nThe stemness-relevant prognostic gene signature has the potential to serve as a clinically helpful biomarker for guiding the management of OC patients.\nOvarian cancer (OC) stands as the leading cause of cancer-related deaths among women, globally, owing to metastasis and acquired chemoresistance.\nAssociations between signature score, tumor immune phenotype, and response to chemotherapy were analyzed via TIMER 2.0 and oncoPredict R package, respectively.\nA cohort of Shanghai Cancer Center was employed to verify the predictive robustness of the signature with respect to chemotherapy response.\nIdentifying stemness-related biomarkers that can aid in the stratification of risk and the response to chemotherapy for OC is feasible and critical.", "dois": ["10.1038/s41598-025-10255-z", "10.1155/sci/2505812", "10.1245/s10434-023-13594-1"]}
{"pair_type": "slc_pathway", "key1": "SLC4A11", "key2": "glycolysis", "summary": "We conclude that Slc4a11 KO induces a coordinated decrease in glycolysis, glutaminolysis, lactate transport and Na-K-ATPase activity.\nSeveral tumorigenesis pathways, such as mitotic spindle and glycolysis, were enriched in the high stemness risk group.\nFunctional testing revealed decreases in endothelial lactate production, Extracellular Acidification Rate (ECAR), glutaminolysis, and Oxygen Consumption Rate (OCR) of KO CEDM in the presence of Glutamine (Gln) that was not compensated by fatty acid oxidation.\nQPCR and Western analysis validated downregulation of Glycolytic enzymes, Mitochondrial complex components and Ion transporters.", "dois": ["10.1016/j.exer.2021.108884", "10.1155/sci/2505812"]}
{"pair_type": "slc_pathway", "key1": "SLC4A11", "key2": "oxidative phosphorylation", "summary": "Here we demonstrate that SLC4A11 is localized to the inner mitochondrial membrane of CE and SLC4A11 transfected PS120 fibroblasts, where it acts as an NH-sensitive mitochondrial uncoupler that enhances glutamine-dependent oxygen consumption, electron transport chain activity, and ATP levels by suppressing damaging Reactive Oxygen Species (ROS) production.\nOverall, our studies reveal a unique metabolic mechanism that reduces mitochondrial oxidative stress while promoting glutamine catabolism.\nLoss of SLC4A11 activity induces oxidative stress and cell death, resulting in Congenital Hereditary Endothelial Dystrophy (CHED) with corneal edema and vision loss.\nSLC4A11 is a NH sensitive membrane transporter with H channel-like properties that facilitates Glutamine catabolism in Human and Mouse corneal endothelium (CE).\nHowever, the mechanism by which SLC4A11 prevents ROS production and protects CE is unknown.\nIn the presence of glutamine, Slc4a11 (KO) mouse CE generate significantly greater mitochondrial superoxide, a greater proportion of damaged depolarized mitochondria, and more apoptotic cells than WT.\nMoreover, we demonstrate that this role for SLC4A11 is not specific to CE cells, as SLC4A11 knockdown in glutamine-addicted colon carcinoma cells reduced glutamine catabolism, increased ROS production, and inhibited cell proliferation.", "dois": ["10.1016/j.redox.2019.101260"]}
{"pair_type": "slc_pathway", "key1": "SLC4A11", "key2": "migration", "summary": "We demonstrate SLC4A11-/- and SLC4A11MU hCEnC lines exhibited increased migration rates, altered proliferation and decreased cell viability compared to SLC4A11WT hCEnC.\nFunctional in vitro assays, including colony formation, migration, and CCK-8 experiments, demonstrated that SLC4A11 overexpression enhanced OV cell proliferation and migration, while its knockdown inhibited these processes.\nThe overexpressed SLC4A11 promoted OC cell proliferation, migration, and invasion.\nOverall, our findings suggest CHED-associated SLC4A11 mutations likely lead to hCEnC dysfunction, and ultimately CHED, by interfering with cell migration, proliferation, viability, membrane conductance, barrier function, and/or cell surface localization of the SLC4A11 protein in hCEnC.\nIn vivo studies using a subcutaneous xenograft mouse model further validated the role of SLC4A11 in promoting tumor growth.\nThe in vivo study with a xenographic model revealed that the knockdown of SLC4A11 suppressed tumor growth.\nMechanistically, SLC4A11 was found to directly interact with the Epidermal growth factor receptor (EGFR), activating the PI3K/AKT signaling pathway, a critical driver of cancer progression.\nThese findings highlight SLC4A11 as a key regulator of OV development and a potential therapeutic target, offering new insights for improving treatment strategies and patient outcomes in ovarian cancer.\nThese findings have illustrated the oncogenic role of SLC4A11 in OC.\nSLC4A11 is overexpressed and is correlated with poor prognosis in OC.\nSLC4A11 was found to be highly expressed in OC tissues/cells and had a relationship with an unfavorable prognosis in patients with OC.\nAnalysis of public datasets (TCGA and GEO) revealed that SLC4A11 expression was significantly elevated in OV tissues compared to normal tissues and was associated with poorer overall survival and advanced clinical stages.\nAdditionally, SLC4A11-/- hCEnC demonstrated decreased cell-substrate adhesion and membrane capacitances compared to SLC4A", "dois": ["10.1186/s13048-025-01758-4", "10.1038/s41598-025-10255-z", "10.1371/journal.pone.0296928", "10.1002/humu.21655"]}
{"pair_type": "slc_pathway", "key1": "SLC4A11", "key2": "apoptosis", "summary": "Alterations in apoptotic gene expression following SLC4A11 silencing were determined using the RT(2)Profiler PCR array for human apoptosis while activation of the apoptotic pathway was ascertained by western analysis.\nIn vitro, SLC4A11 (K263R) variant increased ROS level and apoptosis rate.\nThis reduction in cell growth is associated with increased apoptosis in SLC4A11-silenced cells.\nThe missense variant SLC4A11 (K263R) caused mitochondrial dysfunction and increased apoptosis in mutant transfected cells.\nOur data suggest that the reduction of cell number with time in SLC4A11-depleted HCECs is due to an increase in cell death by apoptosis.\nCongenital hereditary endothelial dystrophy (CHED) is a rare condition that manifests at an early age showing corneal edema, increased oxidative stress, mitochondrial dysfunction, and eventually apoptosis of the endothelium due to loss of function of the membrane transport protein SLC4A11.\nReducing SLC4A11 caused the cell cycle arrest at the G0/G1 phase and triggered apoptosis.\nSLC4A11 knockdown suppressed HCEC growth and reduced HCEC viability compared to the control.\nCaspase activation and cell vitality assays revealed that expression of SLC4A11 mutants in HEK293 cells does not induce cell death.\nThis suggests that SLC4A11 is necessary for cell survival and may explain the pathologic corneal endothelial cell loss in endotheliopathies due to SLC4A11 mutations.\nDysregulation of pathways involving oxidative stress and apoptosis, epithelial-to-mesenchymal transition, microRNA, mitochondrial genes, and unfolded protein response has been implicated in FCD pathogenesis.\nThe molecular mechanisms associated with Fuchs endothelial corneal dystrophy, such as endoplasmic reticulum stress and unfolded protein response pathway, oxidative stress, mitochondrial dysregulation pathway, apoptosis pathway, mitophagy, epithelial-mesenchymal", "dois": ["10.1186/s13048-025-01758-4", "10.1097/ICO.0000000000000421", "10.1002/humu.22601", "10.1167/iovs.11-8724", "10.1167/tvst.12.10.1", "10.1016/j.xops.2021.100084", "10.3389/fgene.2021.697883", "10.1186/s40662-021-00246-2", "10.1016/bs.pmbts.2015.04.005"]}
{"pair_type": "slc_pathway", "key1": "SLC4A11", "key2": "stemness", "summary": "SLC4A11 mediates ammonia import and promotes cancer stemness in hepatocellular carcinoma.\nEnhancing ammonia clearance reduced HCC stemness and tumor growth.\nElevated ammonia promoted cancer stem cell properties in vitro and tumor initiation in vivo.\nUsing preclinical models, we discovered that ammonia entered the cell through the transporter SLC4A11 and served as a nitrogen source for amino acid and nucleotide biosynthesis.", "dois": ["10.1172/jci.insight.184826"]}
{"pair_type": "slc_pathway", "key1": "SLC4A11", "key2": "proliferation", "summary": "We demonstrate SLC4A11-/- and SLC4A11MU hCEnC lines exhibited increased migration rates, altered proliferation and decreased cell viability compared to SLC4A11WT hCEnC.\nFunctional in vitro assays, including colony formation, migration, and CCK-8 experiments, demonstrated that SLC4A11 overexpression enhanced OV cell proliferation and migration, while its knockdown inhibited these processes.\nMoreover, we demonstrate that this role for SLC4A11 is not specific to CE cells, as SLC4A11 knockdown in glutamine-addicted colon carcinoma cells reduced glutamine catabolism, increased ROS production, and inhibited cell proliferation.\nThe overexpressed SLC4A11 promoted OC cell proliferation, migration, and invasion.\nAmong cellular responses towards this stress is the inhibition of proliferation through the activation of p38 MAPK and p53.\nOverall, our findings suggest CHED-associated SLC4A11 mutations likely lead to hCEnC dysfunction, and ultimately CHED, by interfering with cell migration, proliferation, viability, membrane conductance, barrier function, and/or cell surface localization of the SLC4A11 protein in hCEnC.\nSlc4a11-/- MCECs exhibited decreased proliferative capacity, reduced NH3:H+ transport, altered expression of glutaminolysis enzymes similar to the Slc4a11-/- mouse, and reduced proportion of TCA cycle intermediates derived from glutamine with compensatory increases in glucose flux compared with Slc4a11+/+ MCECs.\nHere we demonstrate that SLC4A11 is localized to the inner mitochondrial membrane of CE and SLC4A11 transfected PS120 fibroblasts, where it acts as an NH-sensitive mitochondrial uncoupler that enhances glutamine-dependent oxygen consumption, electron transport chain activity, and ATP levels by suppressing damaging Reactive Oxygen Species (ROS) production.\nOverall, our studies reveal a unique metabolic mechanism that reduces mitochondrial oxidative stress while promoting glutamine catabolism.\nThe inhibition of ATP1A1 had the most prominent effect on the transcription of", "dois": ["10.1186/s13048-025-01758-4", "10.1038/s41598-025-10255-z", "10.3389/fimmu.2025.1537483", "10.1016/j.exer.2024.109815", "10.1371/journal.pone.0296928", "10.1186/s13287-021-02611-3", "10.1016/j.redox.2019.101260", "10.1371/journal.pone.0184906", "10.1167/iovs.17-21781", "10.1002/jcp.25040"]}
{"pair_type": "slc_pathway", "key1": "SLC5A1", "key2": "chemotherapy", "summary": "PNLDC1, SLC5A1, and SYNM are the hub genes that may serve as potential biomarkers in OC treatment.\nPNLDC1, SLC5A1, and SYNM were then identified as hub genes that were associated with both platinum response status and prognosis, which was further validated by the Fudan University Shanghai cancer center (FUSCC) cohort.\nAnd increased resistance to platinum-based chemotherapy represents the major obstacle in the treatment of OC currently.", "dois": ["10.1186/s13048-022-00969-3"]}
{"pair_type": "slc_pathway", "key1": "SLC5A1", "key2": "apoptosis", "summary": "Furthermore, we found that overexpression of circ_0003028 could increase the proliferation and glycolytic capacity and restrain the apoptosis of NSCLC cells, and circ_0003028 silencing played the opposite role to circ_0003028 overexpression.\nMoreover, circ_0003028 might regulate miR-1305 and miR-1322, which might further regulate solute carrier family 5 member 1 (SLC5A1).\nCirc_0003028 could accelerate the malignant behaviors and glycolytic capacity of NSCLC cells via a mechanism that may be related to miR-1305 or the miR-1322/SLC5A1 axis.\nalleviated inflammation caused by LPS via the downregulation of the target genes and in association with apoptosis;\nFunctional analyses indicated that some DEGs were involved in the transcriptional regulation of nutrient transportation (SLC15A1, SLC5A1, and SLC3A1), cell differentiation (LGR5, HOXA5 and KLF4), cell proliferation (PLK2 and TGFB3), transcriptional regulation (JUN, FOS and ATF3), and signaling transduction (WNT10B and BMP1), suggesting that these genes were related to intestinal epithelial cell maturation and cell renewal.\nIt is well known that the small intestinal epithelial cells of mammals rapidly undergo differentiation, maturation, and apoptosis.\nAnimals with elevated preovulatory estradiol had greater endometrial abundance of SLC2A1 (P = 0.05) and SLC5A1 (P = 0.04) in both INCAR and CAR tissue.\nFunctionally, the proliferation, apoptosis, and glycolytic capacity were examined using cell counting kit-8 (CCK-8), 5-ethynyl-2'-deoxyuridine (EdU) staining, a flow cytometer, commercial kits [glucose, lactate, and adenosine triphosphate (ATP)], and a Seahorse XF extracellular flux analyzer.", "dois": ["10.1093/biolre/ioy086", "10.3390/antiox13060682", "10.21037/atm-23-178", "10.21037/atm-22-6406", "10.3390/ani12182324"]}
{"pair_type": "slc_pathway", "key1": "SLC5A1", "key2": "migration", "summary": "Here, we explore the role of glucose (SLC5A1) and inositol transporters (SLC5A3) in GBM cell migration.\nWhile GBM cell migration was significantly increased by extracellular inositol and glucose, it was strongly impaired by SLC transporter inhibition.\nWe provide several lines of evidence for the involvement of SLC5A1 and SLC5A3 in GBM cell migration, thereby complementing the migration-associated transportome.\nThis flavonoid dose-dependently reduced cancer cell proliferation, migration, and invasion.\nOverexpressing SLC5A1 significantly reduced the inhibitory effects of Hesperidin, highlighting its crucial role in this context.\nWe also employed wound-healing assays to examine the effect of SLC inhibition on GBM cell migration and examined the chemotactic potential of inositol.\nOur findings were significantly restored following SLC5A1 overexpression in colon cancer cells, highlighting its pivotal role in Hesperidin-induced responses.\nExpression levels of endometrial GRP, IGFBP1, and LGALS15, whose products stimulate trophectoderm cell migration and attachment, were increased by PGE2, PGI2, and IFNT.\nInvasive cell migration has been linked to the aberrant expression of transmembrane solute-linked carriers (SLC).\nWe employed clone formation, EdU incorporation, Transwell, and wound healing assays to clarify Hesperidin efficacy on cancer cell proliferation, invasion, and migration.\nInterestingly, in GBM cells migrating via blebbing, SLC5A1 and SLC5A3 were predominantly detected in nascent and mature blebs, respectively.\nIn single GBM cells, both transporters were primarily localized at the leading edge of the lamellipodium.\nIn the GBM cell monolayers, both SLCs were exclusively detected in the migrating cells at the monolayer edge.\nHesperidin exerts its anticancer effects on colon cancer by inhibiting SLC5A1 expression and consequently downregulating EGFR phosphorylation.", "dois": ["10.7150/jca.104867", "10.3390/cancers15215139", "10.3390/cancers14235794", "PMID:22738901", "10.1095/biolreprod.112.100487"]}
{"pair_type": "slc_pathway", "key1": "SLC4A11", "key2": "oxidative stress", "summary": "Depletion of SLC4A11 using targeted siRNA, caused an increase in reactive oxygen species, cytochrome c, lowered mitochondrial membrane potential, and reduced cell viability during oxidative stress.\nSLC4A11 expression is induced by oxidative stress through the transcription factor NRF2, the master regulator of antioxidant genes.\nWe found increased expression of SLC4A11 in presence of oxidative stress.\nThe loss of Slc4a11 NH-activated mitochondrial uncoupling leads to mitochondrial membrane potential hyperpolarization-induced oxidative stress.\nSlc4a11 KO-induced CE oxidative stress triggered increased Src kinase activity that resulted in perturbation of the pump components and barrier function of the CE.\nLoss of SLC4A11 activity induces oxidative stress and cell death, resulting in Congenital Hereditary Endothelial Dystrophy (CHED) with corneal edema and vision loss.\nGln promotes SLC4A11 import to the mitochondria, and the continuous oxidative stress derived from Gln catabolism induced HSP70 and HSP90, protecting cells against oxidative stress.\nCongenital hereditary endothelial dystrophy (CHED) is a rare condition that manifests at an early age showing corneal edema, increased oxidative stress, mitochondrial dysfunction, and eventually apoptosis of the endothelium due to loss of function of the membrane transport protein SLC4A11.\nOn the other hand, over expression of SLC4A11 reduces reactive oxygen species levels and increases cell viability.\nOverall, our studies reveal a unique metabolic mechanism that reduces mitochondrial oxidative stress while promoting glutamine catabolism.\nIn conclusion, our data suggests a possible role of SLC4A11 in regulating oxidative stress, and might be responsible for both the etiology and treatment of corneal endothelial dystrophy.\nSLC4A11 expression is also responsive to oxidative stress.\nMitochondrial oxidative stress in SLC4A11 KO also triggers dysfunctional autophagy and lysosomes, as well as ER stress.", "dois": ["10.1080/13816810.2025.2450455", "10.3390/cells11020197", "10.1016/j.exer.2021.108884", "10.1016/j.freeradbiomed.2021.07.029", "10.1167/iovs.62.7.28", "10.1016/j.freeradbiomed.2021.03.006", "10.1016/j.redox.2019.101260", "10.1038/s41598-017-03654-4", "10.1097/ICO.0000000000000421", "PMID:25548511", "10.1167/iovs.65.4.18", "10.4103/tjo.TJO-D-23-00135", "10.3390/cells12111528", "10.1016/j.xops.2022.100212", "10.1016/j.xops.2021.100084", "10.3389/fcell.2022.878395", "10.1167/iovs.62.12.4", "10.1186/s40662-021-00246-2", "10.1016/bs.pmbts.2015.04.005", "PMID:23585771"]}
{"pair_type": "slc_pathway", "key1": "SLC5A2", "key2": "apoptosis", "summary": "After the overexpression of SGLT-2 in HUVECs, the proliferation, migration and tubule formation ability of HUVECs were inhibited, and autophagy and apoptosis were increased, which were reversed by 3-MA (P < 0.05).\nMoreover, the increased protein expression levels of autophagy and apoptosis in HG/PA induced HUVECs were also decreased by the treatment of Dapagliflozin (P < 0.05).\nAfter the addition of Sodium-glucose co-transporters 2 inhibitor, Dapagliflozin, the proliferation of HUVECs, the tubule formation, autophagy, apoptosis and migration ability of cells inhibited by HG/PA were significantly improved (P < 0.05).\nDapagliflozin can improve the dysfunction of high glucose/high fat-induced human umbilical vein endothelial cells by downregulate autophagy through inhibiting SGLT-2.\nFurthermore, the human islet grafts showed no effects of DAPA treatment on hormone content, endocrine cell proliferation or apoptosis, or amyloid deposition.\nThere are numerous ways of treating T2DM with empagliflozin, including by regulating apoptosis, cell aging, as well as the , , , , , , and pathways.\nThe top 10 pathways were endocrine resistance, the signaling pathway, the signaling pathway, apoptosis, cell senescence, the Ras signaling pathway, the signaling pathway, the signaling pathway, the signaling pathway, and the p53 signaling pathway.", "dois": ["10.1016/j.jdiacomp.2024.108907", "10.21037/atm-22-6406", "10.1210/endocr/bqaa080"]}
{"pair_type": "slc_pathway", "key1": "SLC5A1", "key2": "oxidative stress", "summary": "In vivo hyperinsulinemia and in vitro exposure of cardiomyocytes to high glucose or insulin led to an increase in SGLT1 expression by increasing binding of the transcription factors HNF-1 and Sp1 to the SGLT1 gene (Slc5a1), and the transcript stabilizer HuR to SGLT1 mRNA.\nNevertheless, TG mice exhibited attenuation of cardiomyopathy, manifested by less hypertrophy, systolic and diastolic dysfunction, fibrosis, nicotinamide adenine dinucleotide phosphate oxidase 2 (Nox2) activation, and reactive oxygen species (ROS) production.\nSGLT1 may contribute to cardiac injury in obesity and insulin resistance by stimulating ROS through its interaction with EGFR.", "dois": ["10.1007/s00395-025-01136-7"]}
{"pair_type": "slc_pathway", "key1": "SLC5A2", "key2": "glycolysis", "summary": "Although these inhibitors can influence tumor glycolysis, the underlying mechanism requires further exploration.\nRTV treatment but not IDV treatment induced AMP-activated protein kinase (AMPKα) phosphorylation that paralleled the decrease in glycolytic activity and cell growth.\nIn addition to activation of glycolysis, we observed activation of the pentose phosphate pathway (PPP) and an increase in the total amount of amino acids in miR-210-transfected cells.\nGlucose transport across glioblastoma membranes plays a crucial role in maintaining the enhanced glycolysis typical of high-grade gliomas and glioblastoma.\nOn the basis of these findings, we propose that miR-210 may induce a shift of energy metabolism from OxPhos to glycolysis by acting on the mitochondrial inner membrane.\nFurthermore, metabolome analysis revealed activation of anaerobic glycolysis in miR-210-transfected cells, and consistent with this the secretion of lactate, the final metabolite of anaerobic glycolysis, was significantly increased.\nWe tested the ability of two inhibitors of the glucose transporters GLUT/SLC2A superfamily, indinavir (IDV) and ritonavir (RTV), and of one inhibitor of the Na/glucose antiporter type 2 (SGLT2/SLC5A2) superfamily, phlorizin (PHZ), in decreasing glucose consumption and cell proliferation of human and murine glioblastoma cells.\nWe found in vitro that RTV, active on at least three different GLUT/SLC2A transporters, was more effective than IDV, a specific inhibitor of GLUT4/SLC2A4, both in decreasing glucose consumption and lactate production and in inhibiting growth of U87MG and Hu197 human glioblastoma cell lines and primary cultures of human glioblastoma.\nSGLT1 and SGLT2 are expressed in various tumors where they supply the tumor cells with glucose for euglycemic glycolysis.\nLactate concentration was higher in the kidney cortex of transgenic mice relative to wild-type mice, although the difference was not significant (p = 0.070).", "dois": ["10.1096/fj.202501018R", "10.3389/fphar.2024.1443045", "10.1002/path.5394", "10.1016/j.neo.2017.02.009", "10.1016/j.pharmthera.2016.10.017"]}
{"pair_type": "slc_pathway", "key1": "SLC5A1", "key2": "oxidative phosphorylation", "summary": "Metformin increased expression of Slc2a1 (GLUT1), decreased expression of Slc2a2 (GLUT2) and Slc5a1 (SGLT1) whilst increasing GLUT-dependent glucose uptake and glycolytic rate as observed by live cell imaging of genetically encoded metabolite sensors and measurement of oxygen consumption and extracellular acidification rates.\nMetformin caused mitochondrial dysfunction and metformin's effects on 2D-cultures were phenocopied by treatment with rotenone and antimycin-A, including upregulation of GDF15 expression, previously linked to metformin dependent weight loss.\nWe conclude that metformin affects glucose uptake, glycolysis and GDF-15 secretion, likely downstream of the observed mitochondrial dysfunction.", "dois": ["10.1038/s41598-021-81349-7"]}
{"pair_type": "slc_pathway", "key1": "SLC5A2", "key2": "migration", "summary": "After the overexpression of SGLT-2 in HUVECs, the proliferation, migration and tubule formation ability of HUVECs were inhibited, and autophagy and apoptosis were increased, which were reversed by 3-MA (P < 0.05).\nAfter the addition of Sodium-glucose co-transporters 2 inhibitor, Dapagliflozin, the proliferation of HUVECs, the tubule formation, autophagy, apoptosis and migration ability of cells inhibited by HG/PA were significantly improved (P < 0.05).\nDapagliflozin can improve the dysfunction of high glucose/high fat-induced human umbilical vein endothelial cells by downregulate autophagy through inhibiting SGLT-2.", "dois": ["10.1096/fj.202501018R", "10.1016/j.jdiacomp.2024.108907"]}
{"pair_type": "slc_pathway", "key1": "SLC5A1", "key2": "proliferation", "summary": "Circ_0003028 enhances the proliferation and glycolytic capacity and suppresses apoptosis in non-small cell lung cancer cells via the miR-1305/miR-1322-SLC5A1 axis.\nFunctional analyses indicated that some DEGs were involved in the transcriptional regulation of nutrient transportation (SLC15A1, SLC5A1, and SLC3A1), cell differentiation (LGR5, HOXA5 and KLF4), cell proliferation (PLK2 and TGFB3), transcriptional regulation (JUN, FOS and ATF3), and signaling transduction (WNT10B and BMP1), suggesting that these genes were related to intestinal epithelial cell maturation and cell renewal.\nHesperidin exerts its anticancer effects on colon cancer by inhibiting SLC5A1 expression and consequently downregulating EGFR phosphorylation.\nIt significantly suppressed SLC5A1 and phosphorylated EGFR expression.\nThis flavonoid dose-dependently reduced cancer cell proliferation, migration, and invasion.\nCDX2 increases SLC7A7 expression and proliferation of pig intestinal epithelial cells.\nOverexpressing SLC5A1 significantly reduced the inhibitory effects of Hesperidin, highlighting its crucial role in this context.\nOur findings show that nutrient transporters are activated during CDX2-induced proliferation of normal intestinal epithelial cells.\nOur findings were significantly restored following SLC5A1 overexpression in colon cancer cells, highlighting its pivotal role in Hesperidin-induced responses.\nCDX2 overexpression in IPEC-1 cells increased cell proliferation, the percentage of cells in S/G2 phase, and the abundance of transcripts of the cell cycle-related genes Cyclin A2.\nFurthermore, we found that overexpression of circ_0003028 could increase the proliferation and glycolytic capacity and restrain the apoptosis of NSCLC cells, and circ_0003028 silencing played the opposite role to circ_0003028 overexpression.", "dois": ["10.1530/EO-25-0030", "10.1186/s12876-025-03878-z", "10.7150/jca.104867", "10.3390/antiox13060682", "10.21037/atm-23-178", "10.3390/ani12182324", "10.1039/d0fo03097j", "10.1371/journal.pone.0230044", "10.3892/ol.2019.11004", "10.2147/CMAR.S195424", "10.1093/jas/sky349", "10.18632/oncotarget.8894", "PMID:22738901"]}
{"pair_type": "slc_pathway", "key1": "SLC5A2", "key2": "oxidative phosphorylation", "summary": "Along with mitochondrial biogenesis, Cana also increased mitochondrial oxidative phosphorylation, fatty acid oxidation and thermogenesis.\nOur results show that Cana treatment directly increased cellular energy expenditure of adipocytes by inducing mitochondrial biogenesis independently of SGLT2 inhibition.\nMechanistically, Cana promoted mitochondrial biogenesis and function via an Adenosine monophosphate-activated protein kinase (AMPK) - silent information regulator 1 (Sirt1) - peroxisome proliferator-activated receptor γ coactivator-1α (Pgc-1α) signalling pathway.\nIn the present study, to investigate the biological impact of miR-210 in ccRCC tumorigenesis, we developed a transgenic mouse line expressing miR-210 in proximal tubule cells under control of the mouse SGLT2/Slc5a2 promoter.\nElectron microscopy revealed alterations to the mitochondria in proximal tubule cells, with marked reduction of the mitochondrial inner membrane, which is the main site of ATP production via oxidative phosphorylation (OxPhos).\nOn the basis of these findings, we propose that miR-210 may induce a shift of energy metabolism from OxPhos to glycolysis by acting on the mitochondrial inner membrane.\nAn additional in vitro study revealed that this loss of the inner membrane was associated with downregulation of Iscu and Ndufa4, the target genes of miR-210, suggesting that the miR-210-ISCU/NDUFA4 axis may affect mitochondrial energy metabolism.\nConsistently, study demonstrated that Cana increased AMPK phosphorylation and the expression of Sirt1 and Pgc-1α.", "dois": ["10.1080/21623945.2020.1807850", "10.1002/path.5394"]}
{"pair_type": "slc_pathway", "key1": "SLC5A2", "key2": "proliferation", "summary": "After the overexpression of SGLT-2 in HUVECs, the proliferation, migration and tubule formation ability of HUVECs were inhibited, and autophagy and apoptosis were increased, which were reversed by 3-MA (P < 0.05).\nFurthermore, our data reveal that the knockdown of SGLT2 using siRNA inhibits cell proliferation and impedes cell cycle progression.\nSodium-glucose co-transporter-2 [SGLT2, also known as solute carrier family 5 member 2 (SLC5A2)] is an oncogene that promotes tumorigenesis.\nAfter the addition of Sodium-glucose co-transporters 2 inhibitor, Dapagliflozin, the proliferation of HUVECs, the tubule formation, autophagy, apoptosis and migration ability of cells inhibited by HG/PA were significantly improved (P < 0.05).\nCollectively, data suggest that miR‑296‑5p not only inhibits NSCLC by downregulating SGLT2 expression, but also acts as a novel regulator of aberrant lung cancer cells to limit lung cancer progression.\nWe tested the ability of two inhibitors of the glucose transporters GLUT/SLC2A superfamily, indinavir (IDV) and ritonavir (RTV), and of one inhibitor of the Na/glucose antiporter type 2 (SGLT2/SLC5A2) superfamily, phlorizin (PHZ), in decreasing glucose consumption and cell proliferation of human and murine glioblastoma cells.\nRTV treatment but not IDV treatment induced AMP-activated protein kinase (AMPKα) phosphorylation that paralleled the decrease in glycolytic activity and cell growth.\nWe found in vitro that RTV, active on at least three different GLUT/SLC2A transporters, was more effective than IDV, a specific inhibitor of GLUT4/SLC2A4, both in decreasing glucose consumption and lactate production and in inhibiting growth of U87MG and Hu197 human glioblastoma cell lines and primary cultures of human glioblastoma.", "dois": ["10.1096/fj.202501018R", "10.1016/j.jdiacomp.2024.108907", "10.1210/endocr/bqaa080", "10.3892/ijo.2018.4599", "10.1016/j.neo.2017.02.009"]}
{"pair_type": "slc_pathway", "key1": "SLC5A3", "key2": "oxidative phosphorylation", "summary": "Mitochondrial analysis showed that SLC5A3 inhibition disrupted the mitochondrial dynamics, leading to increased reactive oxygen species production, mitochondrial fission, and impaired oxidative phosphorylation.\nSLC5A3 levels were significantly upregulated in gemcitabine-resistant PDAC cells, enhancing their cell survival by stabilizing the mitochondrial functions and inhibiting apoptosis.\nMoreover, SLC5A3 inhibition activated the PTEN-induced kinase 1/Parkin-mediated mitophagy pathway, resulting in the excessive removal of damaged and healthy mitochondria, thereby depleting the mitochondrial reserves and sensitizing the cells to apoptosis.", "dois": ["10.1038/s41419-025-07476-5"]}
{"pair_type": "slc_pathway", "key1": "SLC5A4", "key2": "apoptosis", "summary": "There are numerous ways of treating T2DM with empagliflozin, including by regulating apoptosis, cell aging, as well as the , , , , , , and pathways.\nEnrichment analysis of Gene Ontology (GO) biological processes showed that the regulation of insulin secretion, glucose homeostasis, apoptosis, nitric oxide biosynthesis, and cell signaling are significantly enriched for hypoglycemia.\nThe top 10 pathways were endocrine resistance, the signaling pathway, the signaling pathway, apoptosis, cell senescence, the Ras signaling pathway, the signaling pathway, the signaling pathway, the signaling pathway, and the p53 signaling pathway.", "dois": ["10.21037/atm-22-6406", "10.3390/ijms222212419"]}
{"pair_type": "slc_pathway", "key1": "SLC5A3", "key2": "migration", "summary": "Lentiviral SLC5A3 overexpression construct transduction upregulated the cellular myo-inositol level and promoted Akt-mTOR activation, enhancing cervical cancer cell proliferation and migration.\nIn addition, suppressing the expression of the signature gene, SLC5A3, in a SKCM cell line through the utilization of small interfering RNAs (siRNAs) could inhibit the proliferation and migration of cells, as evidenced by the implementation of colony formation assay, CCK8, and cell transfection techniques.\nConversely, ectopic overexpression of SLC5A3 further enhanced proliferation and migration in primary NSCLC cells.\nWhile GBM cell migration was significantly increased by extracellular inositol and glucose, it was strongly impaired by SLC transporter inhibition.\nWe provide several lines of evidence for the involvement of SLC5A1 and SLC5A3 in GBM cell migration, thereby complementing the migration-associated transportome.\nIn primary NSCLC cells and immortalized lines, SLC5A3 depletion, using small hairpin RNA (shRNA) and CRSIRP/Cas9 methods, robustly impeded cell proliferation and migration, simultaneously provoking cell cycle arrest and apoptosis.\nTogether, elevated SLC5A3 promotes NSCLC cell growth possibly by maintaining myo-inositol contents and promoting Akt-mTOR activation.\nWe also employed wound-healing assays to examine the effect of SLC inhibition on GBM cell migration and examined the chemotactic potential of inositol.\nInvasive cell migration has been linked to the aberrant expression of transmembrane solute-linked carriers (SLC).\nIn single GBM cells, both transporters were primarily localized at the leading edge of the lamellipodium.\nIn the GBM cell monolayers, both SLCs were exclusively detected in the migrating cells at the monolayer edge.\nInterestingly, in GBM cells migrating via blebbing, SLC5A1 and SLC5A3 were predominantly detected in nascent and mature blebs, respectively.", "dois": ["10.1007/s12672-025-03186-8", "10.1111/cbdd.14571", "10.3390/cancers15215139", "10.7150/ijbs.84570", "10.3390/cancers14235794", "10.1038/s41419-022-05017-y", "10.1097/SHK.0000000000001785"]}
{"pair_type": "slc_pathway", "key1": "SLC5A5", "key2": "chemotherapy", "summary": "scRNA-seq analysis revealed heterogeneous epithelial populations, with Epi1 cells exhibiting SLC5A5 and SPTBN4 as risk factors for advanced progression of seminomas.\nConversely, the SPTBN4-high group exhibited increased sensitivity to multiple chemotherapeutic agents, including thapsigargin and sorafenib, indicating its potential as a predictive marker for chemotherapy.", "dois": ["10.1155/ijog/3530098", "10.1097/JCMA.0000000000000389", "10.1016/S2213-8587(14)70051-8"]}
{"pair_type": "slc_pathway", "key1": "SLC5A5", "key2": "migration", "summary": "KI treatment reduced SGC cell proliferation and viability without impacting migration.\nGene ontology analysis revealed biological processes like thyroid hormone generation, cell migration regulation, and hormone biosynthesis as key targets.\ncostus root extract to hypothyroid rats upregulated genes like SLC5A5, TPO, and Dio1, enhancing T4-to-T3 conversion and restoring normal T3 levels.\nAdministration of S. costus root extract to hypothyroid rats upregulated genes like SLC5A5, TPO, and Dio1, enhancing T4-to-T3 conversion and restoring normal T3 levels.\nThe component-target network identified 67 nodes with 51 target genes, such as SLC26A4, SLC5A5, Dio1, Dio2, TPO, CTSB, and THR-β.\nIon transporters, particularly the sodium/iodide symporter (SLC5A5), which transport iodine in the form of iodide anion (I) into cells, have emerged as potential therapeutic targets in tumors of glandular origin.\nOur research indicates that SLC5A5 is expressed predominantly in ductal cells of human and murine SGC cells.", "dois": ["10.1093/jpp/rgaf068", "10.3390/ijms26115199", "10.1158/0008-5472.CAN-12-0516"]}
{"pair_type": "slc_pathway", "key1": "SLC5A5", "key2": "oxidative phosphorylation", "summary": "We found genes MUC17, CDA, TRIM15, TBX3, FLVCR2, ONECUT2, ACY3, NMUR2, and MAL2 were highly expressed in GIM cells, while GLDN, SLC5A5, MAL, and MALAT1 showed down-regulated, which can be used as potential biomarkers for GIM cells.\nIn parallel, these genes that highly expressed in GIM samples were mainly involved in cancer-related pathways, such as the MAPK signal pathway and oxidative phosphorylation signal pathway.", "dois": ["10.1186/s12967-024-05276-7"]}
{"pair_type": "slc_pathway", "key1": "SLC5A6", "key2": "migration", "summary": "In vitro functional experiments conducted in HeLa and SiHa cell lines demonstrated that overexpression of SLC5A6 enhanced cell proliferation, colony formation, and migration abilities, while inhibiting cell apoptosis;\nOverexpression of SLC5A6 enhanced cell proliferation and migration, while knockout of SLC5A6 impaired these processes and induced apoptosis by disrupting mitochondrial function.\nconversely, knockdown of SLC5A6 suppressed these oncogenic phenotypes.\nImportantly, knockdown of FASN could reverse the promotional effect of SLC5A6 overexpression on the growth of cervical cancer cells, indicating that SLC5A6 promotes cervical cancer progression through FASN-mediated reprogramming of lipid metabolism.\nIn vivo experiments demonstrated that SLC5A6 knockout effectively inhibited tumor growth.\nFurther in vivo experiments confirmed that knockdown of SLC5A6 could inhibit the growth of xenograft tumors.\nIt was found that the expression of SLC5A6 was significantly upregulated in cervical cancer tissues, and its high expression was associated with poorer overall survival of patients.\nWe found that SLC5A6 is significantly upregulated in LUAD tissues and is associated with poor prognosis.\nReduced expression of SLC5A6 leads to a decrease in the expression of biotin-dependent acetyl-CoA carboxylase (ACC), which in turn downregulates its downstream target gene FASN.\nAdditionally, we identified Foxd3 as a key transcription factor regulating SLC5A6 expression.\nThrough transcriptomic analysis and pathway enrichment analysis, this study identified lipid metabolism as a key downstream pathway of SLC5A6, in which fatty acid synthase (FASN) serves as a crucial effector molecule.\nMechanistically, SLC5A6 is responsible for the transmembrane transport of biotin.\nIn conclusion, this study identified SLC5A6 as a novel oncogenic factor in cervical cancer and reveals its mechanism of regulating lipid metabolism via FASN, suggesting that targeting the SLC5A6-FASN axis may serve as a potential therapeutic strategy for cervical cancer.", "dois": ["10.1002/mc.70052", "10.1016/j.cellsig.2024.111473", "10.1016/j.heliyon.2023.e18242"]}
{"pair_type": "slc_pathway", "key1": "SLC5A5", "key2": "apoptosis", "summary": "These findings indicated that SLC5A5 deficiency led to the inhibition of proliferation, steroid hormone synthesis and secretion, and promotion of apoptosis in chicken GCs.\nSubsequent cellular function studies with knockdown of SLC5A5 in chicken ovarian follicle granulosa cells (GCs) led to the down-regulation of genes associated with cell proliferation and steroid hormone synthesis, and concurrent promotion of gene expression linked to apoptosis.\nSilencing NIS expression reduced doxorubicin-induced apoptosis in HCC cells, pointing to a possible role of a p53-family-dependent expression of NIS in apoptotic cell death.\nKI increased ROS levels and triggered caspase-dependent apoptosis, as indicated by the upregulation of the pro-apoptotic protein BAX, downregulation of the anti-apoptotic protein Bcl-2, and induction of SGC cell shrinkage.\nTop KEGG pathways related to these targets included cancer, TNF signalling, apoptosis, NF-kappa B, and cAMP signalling pathways.\nOur study demonstrated a pivotal role for SLC5A5 in the development and function of chicken GCs, shedding light on its potential significance in the broader context of chicken ovarian follicle development, and providing a prospective target to improve the egg-laying performance of chickens via molecular marker-assisted breeding technology.", "dois": ["10.3390/ijms26115199", "10.1016/j.psj.2023.103241", "10.1089/thy.2019.0196", "10.1186/s13046-018-0907-z", "10.1038/cddis.2013.302", "10.1093/jpp/rgaf068", "10.1530/JOE-23-0373", "10.1631/jzus.B2000043", "10.2147/BCTT.S84648"]}
{"pair_type": "slc_pathway", "key1": "SLC5A4", "key2": "proliferation", "summary": "Eleven GO biological processes (glucose homeostasis, nitric oxide biosynthesis, smooth muscle cell proliferation, ERK1 and ERK2 cascade, etc.) were overrepresented in all reconstructed networks.", "dois": ["10.3390/ijms222212419"]}
{"pair_type": "slc_pathway", "key1": "SLC5A6", "key2": "proliferation", "summary": "In vitro functional experiments conducted in HeLa and SiHa cell lines demonstrated that overexpression of SLC5A6 enhanced cell proliferation, colony formation, and migration abilities, while inhibiting cell apoptosis;\nOverexpression of SLC5A6 enhanced cell proliferation and migration, while knockout of SLC5A6 impaired these processes and induced apoptosis by disrupting mitochondrial function.\nconversely, knockdown of SLC5A6 suppressed these oncogenic phenotypes.\nIn vivo experiments demonstrated that SLC5A6 knockout effectively inhibited tumor growth.\nFurther in vivo experiments confirmed that knockdown of SLC5A6 could inhibit the growth of xenograft tumors.\nImportantly, knockdown of FASN could reverse the promotional effect of SLC5A6 overexpression on the growth of cervical cancer cells, indicating that SLC5A6 promotes cervical cancer progression through FASN-mediated reprogramming of lipid metabolism.\nKnockdown of TASK-1 by siRNA significantly enhanced apoptosis and reduced proliferation in A549 cells, but not in weakly TASK-1 expressing NCI-H358 cells.\nIn summary, we show for the first time that the TASK-1 channel regulates apoptosis and proliferation in a subset of NSCLC.", "dois": ["10.1002/mc.70052", "10.1016/j.cellsig.2024.111473", "10.1371/journal.pone.0157453"]}
{"pair_type": "slc_pathway", "key1": "SLC5A3", "key2": "apoptosis", "summary": "Knockdown of HTR2B and SLC5A3 restrained apoptosis and increased TGF-β and IL-4 expression as well as reduced TNF-α and IL-1β expression in OA synovial cells.\nSLC5A3 levels were significantly upregulated in gemcitabine-resistant PDAC cells, enhancing their cell survival by stabilizing the mitochondrial functions and inhibiting apoptosis.\nMoreover, SLC5A3 inhibition activated the PTEN-induced kinase 1/Parkin-mediated mitophagy pathway, resulting in the excessive removal of damaged and healthy mitochondria, thereby depleting the mitochondrial reserves and sensitizing the cells to apoptosis.\nSLC5A3 silencing, myo-inositol depletion, Akt-mTOR inactivation and apoptosis induction were detected in SLC5A3 shRNA virus-injected NSCLC xenograft tissues.\nCollectively, this study identified two OA-specific markers HTR2B and SLC5A3 and their knockdown ameliorated apoptosis and inflammation of OA synovial cells.\nIn primary/established cervical cancer cells, shRNA/knockout (KO) exerted growth-inhibitory effects and promoted cell death/apoptosis.\nConversely, MRPS6 overexpression reduces UPR, mitigates high glucose-induced ROS levels and apoptosis, and enhances GSIS in an ATF5-dependent manner.\nKnockdown of TASK-1 by siRNA significantly enhanced apoptosis and reduced proliferation in A549 cells, but not in weakly TASK-1 expressing NCI-H358 cells.\nIn primary NSCLC cells and immortalized lines, SLC5A3 depletion, using small hairpin RNA (shRNA) and CRSIRP/Cas9 methods, robustly impeded cell proliferation and migration, simultaneously provoking cell cycle arrest and apoptosis.\nDisruption of such feedback by MRPS6 knockdown causes UPR hyperactivation in high glucose conditions, hence elevated ROS levels, increased apoptosis, and impaired GSIS", "dois": ["10.1038/s41419-025-07476-5", "10.1002/iub.2344", "10.1371/journal.pone.0157453", "10.1016/j.fsi.2024.109850", "10.1038/s41598-023-43438-7", "10.7150/ijbs.84570", "10.1038/s41419-022-05017-y", "10.1158/2159-8290.CD-20-1851", "10.3389/fmolb.2021.691602", "10.1097/SHK.0000000000001785"]}
{"pair_type": "slc_pathway", "key1": "SLC5A6", "key2": "glycolysis", "summary": "Since both glucose and fatty acids inhibit coenzyme A synthesis from pantothenate, it was concluded that these data were consistent with downregulated fatty acid β-oxidation, glutaminolysis, glycolysis, and TCA cycle activity, due to impaired anaplerosis.\nPantothenate levels were 3-fold elevated accompanied by a modest increased gene expression of Scl5a6 that encodes the pantothenate transporter SLC5A6.\nBy incorporating cofactor dependency and subcellular localization, PM identified a coordinated suppression of multivitamin transporters (e.g., -4.5% in SLC5A6, -3.5% in SLC19A2), potentially limiting cofactor availability and compounding energy deficits in ASD brains.\nwherein the subtle suppression of cofactor-dependent pathways may impair energy metabolism and neurodevelopment.\nWe propose that chronic microbial lipopolysaccharide (LPS) exposure in ASD suppresses vitamin transporter function, initiating mitochondrial dysfunction and transcriptomic reprogramming.\nUsing unsupervised machine learning (Isolation Forest) to detect outlier expression patterns, Euclidean distance, and percent expression difference metrics, PM revealed a consistent downregulation of glycolysis (e.g., -5.4% in PFKM) and mitochondrial enzymes (e.g., -12% in SUCLA2).\nHFD-fed mice serum displayed statistically significantly reduced concentrations of pyruvate, citrate, succinate, fumarate, and 2-oxoglutarate, with an elevated concentration of pantothenic acid.\nIn liver tissue, HFD-fed mice exhibited depressed levels of glycolysis end-products pyruvate and lactate, glutamate, and the TCA cycle intermediates citrate, succinate, fumarate, malate, and oxaloacetate.", "dois": ["10.3390/metabo15060399", "10.1371/journal.pone.0177953"]}
{"pair_type": "slc_pathway", "key1": "SLC5A6", "key2": "apoptosis", "summary": "In vitro functional experiments conducted in HeLa and SiHa cell lines demonstrated that overexpression of SLC5A6 enhanced cell proliferation, colony formation, and migration abilities, while inhibiting cell apoptosis;\nOverexpression of SLC5A6 enhanced cell proliferation and migration, while knockout of SLC5A6 impaired these processes and induced apoptosis by disrupting mitochondrial function.\nconversely, knockdown of SLC5A6 suppressed these oncogenic phenotypes.\nIn vivo experiments demonstrated that SLC5A6 knockout effectively inhibited tumor growth.\nFurther in vivo experiments confirmed that knockdown of SLC5A6 could inhibit the growth of xenograft tumors.\nImportantly, knockdown of FASN could reverse the promotional effect of SLC5A6 overexpression on the growth of cervical cancer cells, indicating that SLC5A6 promotes cervical cancer progression through FASN-mediated reprogramming of lipid metabolism.\nMechanistically, SLC5A6 is responsible for the transmembrane transport of biotin.\nReduced expression of SLC5A6 leads to a decrease in the expression of biotin-dependent acetyl-CoA carboxylase (ACC), which in turn downregulates its downstream target gene FASN.\nThis study explores the role of the SLC5A6 gene, which encodes a sodium-dependent multivitamin transporter critical for mitochondrial function, in LUAD progression.\nWe found that SLC5A6 is significantly upregulated in LUAD tissues and is associated with poor prognosis.\nIt was found that the expression of SLC5A6 was significantly upregulated in cervical cancer tissues, and its high expression was associated with poorer overall survival of patients.\nAdditionally, we identified Foxd3 as a key transcription factor regulating SLC5A6 expression.\nThrough transcriptomic analysis and pathway enrichment analysis, this study identified lipid metabolism as a key downstream pathway of SLC5A6, in which fatty acid synthase (FASN) serves as a crucial effector molecule.\nThese findings suggest that SLC5A6 is a potential therapeutic target for LUAD, offering a new avenue for treatment strategies", "dois": ["10.1016/j.cellsig.2024.111473", "10.1371/journal.pone.0157453", "10.1002/mc.70052", "10.1016/j.heliyon.2022.e11343", "10.1016/j.celrep.2022.110505"]}
{"pair_type": "slc_pathway", "key1": "SLC5A3", "key2": "oxidative stress", "summary": "Gene expression analysis revealed significant tissue-specific alterations including changes in the expression of SDHA in the liver, an upregulated SLC16A1 in cardiac tissue (in-silico and in-vivo), a downregulated SLC5A3 in cardiac tissue (in-vivo), an upregulated SLC25A10 in cardiac tissue (in-vivo) and differential in-silico expression of SLC25A10 across liver and kidney tissues.\nFirst, we found that NORAD was obviously reduced in MPP -treated neuroblastoma cells and lightened the MPP -induced cytotoxicity, oxidative stress, and inflammatory response.\nSLC5A3 knockdown assuaged the anti-miR-204-5p-induced protection for neuroblastoma cells from MPP .\nAltogether, NORAD played a neuroprotective role against the progression of MPP -induced PD model in neuroblastoma cells relying on the miR-204-5p/SLC5A3 axis.\nThen, NORAD was shown to be a miR-204-5p sponge and avoided the injury induced by MPP in neuroblastoma cells via targeting miR-204-5p.\nSLC5A3 was a miR-204-5p target and could be regulated by NORAD/miR-204-5p axis.\nThe dysregulated microRNAs affect downstream targets such as SNCA, PARK2, LRRK2, TNFSF13B, LTA, SLC5A3, PSMB2, GSR, GBA, LAMP-2A, HSC.\nSeveral studies have demonstrated that microRNAs can regulate oxidative stress and prevent ROS-mediated damage to dopaminergic neurons, suggesting that specific microRNAs may be putative targets for novel therapeutic strategies in PD.\nOxidative stress and inflammation were measured by the standard indicators.\nPotential biomarkers were associated with inflammatory, oxidative stress responses, and abnormal lipid metabolism.\nNORAD, microRNA-204-5p (miR-204-5p), and solute carrier family 5 member 3 (SLC5A3) levels were quantified using", "dois": ["10.1002/iub.2344", "10.1007/s11306-025-02318-z", "10.4103/1673-5374.221147"]}
{"pair_type": "slc_pathway", "key1": "SLC5A3", "key2": "proliferation", "summary": "Lentiviral SLC5A3 overexpression construct transduction upregulated the cellular myo-inositol level and promoted Akt-mTOR activation, enhancing cervical cancer cell proliferation and migration.\nIn addition, suppressing the expression of the signature gene, SLC5A3, in a SKCM cell line through the utilization of small interfering RNAs (siRNAs) could inhibit the proliferation and migration of cells, as evidenced by the implementation of colony formation assay, CCK8, and cell transfection techniques.\nConversely, ectopic overexpression of SLC5A3 further enhanced proliferation and migration in primary NSCLC cells.\nAmong cellular responses towards this stress is the inhibition of proliferation through the activation of p38 MAPK and p53.\nKnockdown of TASK-1 by siRNA significantly enhanced apoptosis and reduced proliferation in A549 cells, but not in weakly TASK-1 expressing NCI-H358 cells.\nThe interference of significantly inhibited fat deposition during preadipocyte differentiation and promoted cell proliferation by increasing S-phase cell numbers.\nIn primary NSCLC cells and immortalized lines, SLC5A3 depletion, using small hairpin RNA (shRNA) and CRSIRP/Cas9 methods, robustly impeded cell proliferation and migration, simultaneously provoking cell cycle arrest and apoptosis.\nThe inhibition of ATP1A1 had the most prominent effect on the transcription of the rest of the transporters and was found to enhance the anti-proliferative effect of hyperosmotic conditions through an increased G2/M cell cycle block, ascribing to this pump a central role in the osmoregulatory response of nucleus pulposus cells.\nTransduction of sh-TonEBP AAV construct downregulated SLC5A3 expression and inhibited pCCa-1 cervical cancer xenograft growth.\nIn primary/established cervical cancer cells, shRNA/knockout (KO) exerted growth-inhibitory effects and promoted cell death/apoptosis.\nSLC5A3 KO also inhibited pCCa-1 cervical", "dois": ["10.1007/s12672-025-03186-8", "10.1016/j.fsi.2024.109850", "10.1111/cbdd.14571", "10.3390/ijms241411281", "10.7150/ijbs.84570", "10.1038/s41419-022-05017-y", "10.1097/SHK.0000000000001785", "10.1371/journal.pone.0157453", "10.1002/jcp.25040"]}
{"pair_type": "slc_pathway", "key1": "SLC5A5", "key2": "oxidative stress", "summary": "Adding the antioxidant N-acetylcysteine reversed KI-induced growth inhibition, underscoring ROS-induced oxidative stress's crucial role in growth inhibition.\nAdditionally, the biofortified diet improved the liver function markers (ALAT, ASAT) and reduced oxidative stress markers (TBARS).\nKI increased ROS levels and triggered caspase-dependent apoptosis, as indicated by the upregulation of the pro-apoptotic protein BAX, downregulation of the anti-apoptotic protein Bcl-2, and induction of SGC cell shrinkage.\nThese hypothyroid mice displayed oxidative stress in the thyroid, but not in the brown adipose tissue or liver.\nBiofortified curly kale supports thyroid function and improves liver and kidney health by reducing oxidative stress and modulating key biochemical and genetic markers.\nThe sodium/iodide symporter (NIS) mediates active iodide (I) accumulation in the thyroid, the first step in thyroid hormone (TH) biosynthesis.\nMutations in the SLC5A5 gene encoding NIS that result in a non-functional protein lead to congenital hypothyroidism due to I transport defect (ITD).\nNIS KO mice showed undetectable serum T and very low serum T levels when fed a diet supplying the minimum I requirement for rodents.\nIn NIS KO mice, in the thyroid, stomach, and salivary gland, NIS is absent, and hence there is no active accumulation of the NIS substrate pertechnetate (TcO).", "dois": ["10.3390/ijms26115199", "10.3390/ijms26020822", "10.1530/EC-17-0106", "10.1038/s41598-017-04326-z", "PMID:27599561"]}
{"pair_type": "slc_pathway", "key1": "SLC5A5", "key2": "proliferation", "summary": "Iodide also inhibits endogenous TRPM7-like currents as assessed in MCF-7 breast cancer cells, where upregulation of SLC5A5 sodium-iodide symporter enhances iodide uptake and inhibits cell proliferation.\nThese findings indicated that SLC5A5 deficiency led to the inhibition of proliferation, steroid hormone synthesis and secretion, and promotion of apoptosis in chicken GCs.\nSubsequent cellular function studies with knockdown of SLC5A5 in chicken ovarian follicle granulosa cells (GCs) led to the down-regulation of genes associated with cell proliferation and steroid hormone synthesis, and concurrent promotion of gene expression linked to apoptosis.\nKI treatment reduced SGC cell proliferation and viability without impacting migration.\nAdding the antioxidant N-acetylcysteine reversed KI-induced growth inhibition, underscoring ROS-induced oxidative stress's crucial role in growth inhibition.\nCell proliferation inhibitory effects of the pan-deacetylase inhibitors panobinostat, SAHA and Trichostatin A (TSA), the modulation of the sodium iodide symporter (NIS;\nmorphants exhibited a reduced expression of the early transcription factors and at the thyroid primordium level, which is not caused by changes in proliferation or apoptosis of the pharyngeal endoderm.\nAnalysis of thyroid-specific knockout (-Pax8Cre) mice fed either a normal or low-iodine diet (ND or LID) revealed that, in contrast to ubiquitous mice, thyroid follicular cell proliferation and the expression of cell cycle genes were not repressed suggesting that the inhibition of thyroid follicular cell proliferation in ubiquitous KO mice is related to loss of GLIS3 function in other cell types.\nCell viability decreased after treatment in all five cell lines.\nKI increased ROS levels and triggered caspase-dependent apoptosis, as indicated by the upregulation of the pro-apoptotic protein BAX, downregulation of the anti-apoptotic protein Bcl-2, and induction of SGC cell shrinkage.", "dois": ["10.3390/ijms26115199", "10.1530/JOE-23-0373", "10.1007/s00018-024-05113-6", "10.1016/j.psj.2023.103241", "10.3389/fcvm.2023.1261330", "10.21203/rs.3.rs-3044388/v1", "10.1089/thy.2019.0196", "10.3390/jcm7040061", "10.1007/s00018-013-1284-6"]}
{"pair_type": "slc_pathway", "key1": "SLC5A7", "key2": "ferroptosis", "summary": "HBO treatment decreased the expression of Hspb1 (heat shock protein beta 1), Hmox1 (heme oxygenase 1), Ftl1 (ferritin light polypeptide 1), Tnc (tenascin C) and Igfbp3 (insulin-like growth factor binding protein 3) and increased the expression of Slc5a7 (solute carrier family 5 choline transporter member 7) after SCI.\nWe also found enriched functional pathways including ferroptosis, calcium signaling pathway, serotonergic synapse, hypoxia-inducible factor-1 signaling pathway, cholinergic synapse, and neuroactive ligand-receptor interaction.", "dois": ["10.4103/1673-5374.339498"]}
{"pair_type": "slc_pathway", "key1": "SLC5A7", "key2": "apoptosis", "summary": "Specifically, the significant up-regulation of Axud1, Cdc37, and Ube2v1 caused severe apoptosis, and great suppression of Adcy8, Fos, and Slc5a7 expression led to impairment of mouse cognitive ability.\nTherefore, Axud1, Cdc37, Ube2v1, Adcy8, Fos, and Slc5a7 may be potential biomarkers of hippocampal toxicity caused by CeCl3 exposure.\nOur findings suggested that exposure to CeCl(3) led to hippocampal lesions, apoptosis, oxidative stress and impairment of spatial recognition memory.\nFurthermore, microarray data showed marked alterations in the expression of 154 genes involved in learning and memory, immunity and inflammation, signal transduction, apoptosis and response to stress in the 2 mg/kg CeCl(3) exposed hippocampi.", "dois": ["10.1158/0008-5472.CAN-12-3190", "10.3389/fncel.2024.1288991", "10.1016/j.gene.2013.11.029", "10.1371/journal.pone.0060092"]}
{"pair_type": "slc_pathway", "key1": "SLC5A7", "key2": "migration", "summary": "We found that choline inhibited the proliferation, migration, and invasion of HCC cells by downregulating autophagy and .\nFunctionally, ectopic expression of circFBXW4 strikingly impairs the proliferation, migration, and invasion capacities of CRC cells in vitro and in vivo, whereas circFBXW4 knockdown has the opposite effects.\nMechanistically, circFBXW4 competitively binds to miR-338-5p and prevents it from interacting with and repressing its target SLC5A7, thus suppressing the progression of CRC.\nWe further discovered that choline could promote SLC5A7 expression, upregulate cytoplasm p53 expression to impair the AMPK/mTOR pathway, and attenuate autophagy.", "dois": ["10.21037/hbsn-22-476", "10.1002/advs.202300129"]}
{"pair_type": "slc_pathway", "key1": "SLC5A8", "key2": "chemotherapy", "summary": "VPA-NaDCA and TMZ reduced the invasion of U87 and T98G tumors, as well as the expression of PCNA and EZH2 in the tumor.\nTMZ reduced p53 expression in tumors from both cell lines, whereas VPA-NaDCA did not affect the expression of this marker.\nThe data suggest that VPA-NaDCA has a more effective impact than TMZ.\nThis study demonstrated that VPA-NaDCA exhibits a more effective anticancer effect than NaDCA.\nThe study of the efficacy of drugs used to treat tumors on the CAM and cells demonstrates that it is essential to assess the effectiveness of treatment, which should be personalized, before administering chemotherapy.", "dois": ["10.3390/ijms26146784"]}
{"pair_type": "slc_pathway", "key1": "SLC5A7", "key2": "oxidative stress", "summary": "great suppression of Adcy8, Fos, and Slc5a7 expression led to impairment of mouse cognitive ability.\nthe DP189&GOS interventions effectively mitigated the MPs-induced cognitive dysfunction and intestinal microbiota alteration, improved intestinal and BBB integrity, attenuated the oxidative stress and inflammatory response, and also saw a rebound in the release of acetylcholine.\nThese results indicated that LDPE-MPs and Ox-LDPE-MPs exert neurotoxic effects on mice by inducing oxidative stress, inflammatory responses, and dysregulation of cholinergic signaling pathways in the mouse brain.\nReal-time quantitative polymerase chain reaction and Western Blotting results further demonstrated that the critical genes (Slc5a7, Chat and Slc18a3) and proteins (Chat and Slc18a3) in the cholinergic synaptic signaling pathway were significantly down-regulated after exposure to LDPE-MPs or Ox-LDPE-MPs.\nTherefore, Axud1, Cdc37, Ube2v1, Adcy8, Fos, and Slc5a7 may be potential biomarkers of hippocampal toxicity caused by CeCl3 exposure.\nOur findings suggested that exposure to CeCl(3) led to hippocampal lesions, apoptosis, oxidative stress and impairment of spatial recognition memory.\nThe experimental results indicated that LDPE-MPs or Ox-LDPE-MPs caused several adverse effects in mice, mainly manifested by behavioral changes, disruption of the intestinal and blood-brain barrier (BBB), and simultaneous oxidative stress, inflammatory reactions, and pathological damage in the brain and intestines.\nBrain transcriptomic analysis revealed that the cholinergic synaptic signaling pathways, which affect cognitive function, were significantly disrupted after exposure to LDPE-MPs or Ox-LDPE-MPs.", "dois": ["10.1371/journal.pone.0060092", "10.1016/j.envint.2024.108523"]}
{"pair_type": "slc_pathway", "key1": "SLC5A8", "key2": "migration", "summary": "Overexpression of SLC5A8 in the HeLa cell line decreased its proliferation by arresting cancer cells in the G1 phase and inhibiting cellular migration.\nFurthermore, we observed that pyruvate increased the SLC5A8 effect, inducing S-phase arrest and inhibiting the entry into mitosis.\nThese variants significantly increased the proliferation, migration, and invasion abilities of CRC cells.\nSLC5A8 decreased tumor growth in xenograft transplants, significantly reducing the volume and tumor weight at 35 days of analysis.\nDecreased SLC5A8 expression caused by missense variants appeared to significant impair the tumor-suppressive function of the transporter.\nSLC5A8 can suppress colorectal cancer (CRC), and its tumor-suppressive function is mainly associated with butyrate, propionate, and pyruvate, which inhibit histone deacetylase.\nFinally, using colony-formation, wound-healing, and invasion assays, we investigated whether the decrease in SLC5A8 expression resulting from its variants could affect the tumor-suppressive function of the transporter.\nRPE cells from iron-overloaded mice exhibit several features of tumor cells: decreased senescence, enhanced migration, increased glucose uptake, and elevated levels of HDACs and DNMTs.\nVal193Ile and H2 significantly decreased SLC5A8 expression.\nThe expression of Slc5a8 was decreased in Hfe(-/-) RPE cells, but treatment with a DNA methylation inhibitor restored the transporter expression, indicating involvement of DNA methylation in the silencing of Slc5a8 in Hfe(-/-) cells.", "dois": ["10.3346/jkms.2025.40.e146", "10.31083/j.fbl2901016", "PMID:27465549", "10.1371/journal.pone.0139342", "10.1167/iovs.12-10312"]}
{"pair_type": "slc_pathway", "key1": "SLC5A9", "key2": "glycolysis", "summary": "Low-salinity stress obviously increased SLC39A6, SLC5A9, NKAα1, CYP1A1, CYP1B1, and GSTA expression.\nAfter q-value correction, 7 pathways (Glycolysis/Gluconeogenesis; Pentose phosphate pathway; Biosynthesis of amino acids; Fructose and mannose metabolism; Metabolism of xenobiotics by cytochrome P450; and Glycine, serine and threonine metabolism) remained significant.\nIn contrast, the genes encoding Aldoaa, GPI, FBP2 and GAPDH exhibited downregulation.", "dois": ["10.1016/j.cbpb.2020.110437"]}
{"pair_type": "slc_pathway", "key1": "SLC5A8", "key2": "glycolysis", "summary": "3-Bromopyruvate was transported into cells actively through the tumor suppressor SLC5A8, and the process was energized by an electrochemical Na+ gradient.\nIt is currently believed that blockade of adenosine triphosphate production from glycolysis and mitochondria is the primary mechanism responsible for this antitumor effect.\nThe transport of 3-bromopyruvate by sodium-coupled monocarboxylate transporter SMCT1 (SLC5A8), a tumor suppressor and a sodium (Na+)-coupled, electrogenic transporter for short-chain monocarboxylates, was studied using a mammalian cell expression and the Xenopus laevis oocyte expression systems.\n3-Bromopyruvate is a transportable substrate for SLC5A8, and that transport process is Na+-coupled and electrogenic.\nLactic acid was previously considered a waste product of glycolysis, and has now become a key metabolite for cancer development, maintenance and metastasis.\nthermophilus in the GIT, where its activity led to 49 mM of intra-luminal L-lactate that was related to the induction of mono-carboxylic transporter mRNAs (SLC16A1 and SLC5A8) and p27(Kip1) cell cycle arrest protein in epithelial cells.\nWe selected lactic acid metabolism and transporter related twenty-one genes for LASSO cox regression analysis in the E-MTAB-1980 cohort, and finally screened three genes (PNKD, SLC16A8, SLC5A8) to construct a clinical prognostic model for patients with clear cell renal cell carcinoma.", "dois": ["10.3390/genes13040620", "10.1371/journal.pone.0028789", "10.1074/jbc.M110.168666", "10.1002/cncr.24532", "PMID:17178845"]}
{"pair_type": "slc_pathway", "key1": "SLC5A10", "key2": "apoptosis", "summary": "Identification of SLC4A5, SLC5A10 and LDOC1 indicated that sodium/bicarbonate transport, sodium/glucose transport and cell-proliferation regulation may play important upstream roles and identification of BNIP1, APOBEC3F and LDOC1 suggested that apoptosis, innate immune response and cell-proliferation regulation may play important downstream roles in hypertension.", "dois": ["10.1093/bioinformatics/btp106"]}
{"pair_type": "slc_pathway", "key1": "SLC5A10", "key2": "proliferation", "summary": "Identification of SLC4A5, SLC5A10 and LDOC1 indicated that sodium/bicarbonate transport, sodium/glucose transport and cell-proliferation regulation may play important upstream roles and identification of BNIP1, APOBEC3F and LDOC1 suggested that apoptosis, innate immune response and cell-proliferation regulation may play important downstream roles in hypertension.", "dois": ["10.1093/bioinformatics/btp106"]}
{"pair_type": "slc_pathway", "key1": "SLC6A1", "key2": "migration", "summary": "MiR-200c-3p inhibited the proliferation, migration and invasion in 786-O cells by down-regulating SLC6A1 expression.\nIn addition, enforced expression of SLC6A1 effectively promoted cell proliferation, migration and invasion of PCa cells in vitro.\nThe proliferation, migration, and invasion of SK-OV-3 cells were significantly reduced following the silencing of CDX2 or SLC6A1 (P<0.05).\nThe results showed both SLC6A7 and SLC6A17 from amino acid transporters AA1 and AA2 sub-families, respectively, significantly suppressed the cell proliferation and migration.\nWhile SLC6A1 and SLC6A4, which were classified into GABA and monoamine transporters, respectively, did not affect the cell proliferation and migration in HEK293T, HeLa, and MCF7 cells.\nThe results suggested that the miR-200c-3p served as a suppressor for CCRCC via down-regulating SLC6A1.\nFinally, the cell viability revealed that the overexpression of SLC6A1 obviously promoted the PCa cell resistant to docetaxel (DTX), and the transplanted tumor in the overexpression group had no significant reduction compared with the untreated group.\nMoreover, the inhibition of SLC6A1 suppressed the tumor growth in vivo.\nCDX2 may therefore be inferred to promote the proliferation, migration and invasion in SK-OV-3 OC cells, acting as a competing endogenous RNA.", "dois": ["10.3390/brainsci15040393", "10.1186/s13062-024-00569-9", "10.1002/epi4.12993", "10.1186/s12885-020-06776-7", "10.1016/j.gene.2019.04.056", "10.3892/ol.2018.9273", "10.1080/15384047.2017.1394551"]}
{"pair_type": "slc_pathway", "key1": "SLC6A1", "key2": "chemotherapy", "summary": "Finally, the cell viability revealed that the overexpression of SLC6A1 obviously promoted the PCa cell resistant to docetaxel (DTX), and the transplanted tumor in the overexpression group had no significant reduction compared with the untreated group.\nMoreover, the inhibition of SLC6A1 suppressed the tumor growth in vivo.\nIn addition, enforced expression of SLC6A1 effectively promoted cell proliferation, migration and invasion of PCa cells in vitro.\nSolute Carrier Family 6 Member 1 (SLC6A1) has been identified as a cancer-promoting gene in various human cancers, such as clear cell renal cell carcinoma and ovarian cancer.\nOur data suggest that SLC6A1 overexpression may be associated with aggressive progression and short biochemical recurrence-free survival of PCa, and may be related to the resistance to docetaxel therapy.\nBoth unvariate and multivariate analyses demonstrated that SLC6A1 expression was significantly associated with biochemical recurrence-free survival in PCa patients.", "dois": ["10.1016/j.jprot.2025.105547", "10.1186/s12885-020-06776-7"]}
{"pair_type": "slc_pathway", "key1": "SLC5A10", "key2": "stemness", "summary": "The assessments of tumor stemness and heterogeneity and tumor microenvironment (TME) were conducted to reveal potential mechanisms.\nAmong subtype 1 and subtype 2, the top ten mutation genes were MUC5B, DNAH9, SLC5A10, ZNF462, USP31, SIPA1L3, PLEC, HRAS, MYOM1, and ITGB6.", "dois": ["10.1186/s12885-024-12492-3"]}
{"pair_type": "slc_pathway", "key1": "SLC5A12", "key2": "proliferation", "summary": "Functional experiments confirmed SLC5A12's role in promoting gastric cancer cell proliferation, invasion, and migration both in vitro and in vivo.\nWe found that the tumor microenvironment underwent metabolic reprograming driven by mutations accumulate to satisfy tumor proliferation and invasion.\nFurther, the co-expression network identifies three mutant long non-coding RNAs as potential therapeutic targets, which can promote tumor progression by participating in specific carcinogenic mechanisms.\nWhile lactate metabolism is recognized as a significant factor in tumor progression, its potential as a predictive tool for treatment response remains unexplored.\nRandom forest analysis identified SLC5A12 as the most significant gene differentiating gastric cancer from normal tissues.\nThe impact of Solute Carrier Family 5 Member 12 (SLC5A12), a gene of particular interest, on gastric cancer cell functions was evaluated using in vitro assays and an in vivo zebrafish model.\nMacrophages were found to be significantly associated with patient risk scores, and high levels of macrophages accelerated patient mortality.\nBy characterizing the immune landscape of LIHC, loss of immunogenicity was revealed as a key factor of immune checkpoint suppression.", "dois": ["10.1016/j.bbagen.2024.130739", "10.3389/fgene.2021.737965"]}
{"pair_type": "slc_pathway", "key1": "SLC6A1", "key2": "apoptosis", "summary": "Reducing SLC6A14 increased cell proliferation and suppressed apoptosis.\nFunctional studies elucidated that interference with CCNA2 significantly inhibited proliferation and migration, while simultaneously promoting apoptosis in hepatoma cells and resulting in the downregulation of epithelial-mesenchymal transition (EMT)-related protein markers.\nReducing SLC6A14 decreased pyroptosis-associated proteins (ASC, IL-1β, IL-18, NLRP3).\nNLRP3 overexpression counteracted the effects of sh-SLC6A14 on LPS-induced FHC and NCM460 cell pyroptosis.\nSLC6A14 promotes UC pyroptosis by regulating NLRP3, suggesting the therapeutic potential of modulating the SLC6A14/NLRP3 axis.\nCuproptosis is a novel type of cell death, which differs from previously reported types of cell death such as apoptosis, autophagy, proptosis, ferroptosis, necroptosis, etc.\nCuproptosis represents an innovative type of cell death, distinct from apoptosis, driven by copper dependency, yet the involvement of copper apoptosis-associated long non-coding RNAs (CRLncRNAs) in hepatocellular carcinoma (HCC) remains unclear.\nDisulfidptosis, identified as an innovative form of cellular death subsequent to cuproptosis, is currently under investigation for its mechanisms in oncological contexts.\nPyroptosis markers were quantified using enzyme-linked immunosorbent assay, Western blotting, and qRT-PCR, and EdU incubation, CCK-8 assays and flow cytometry were used to examine proliferation and apoptosis.", "dois": ["10.1186/s13062-024-00569-9", "10.1186/s12876-024-03219-6", "10.3748/wjg.v30.i3.252", "10.1016/j.heliyon.2023.e19352", "10.3760/cma.j.issn.0376-2491.2019.29.013"]}
{"pair_type": "slc_pathway", "key1": "SLC6A1", "key2": "oxidative stress", "summary": "GAT2-expressing cells pretreated with hypotaurine showed resistance to HO-induced oxidative stress.\nThese results suggest that under physiological conditions, TAUT and GAT2 would be major contributors to hypotaurine transfer across the plasma membrane, and that uptake of hypotaurine via GAT2 contributes to the cellular resistance to oxidative stress.\nFinally, a pathway enrichment analysis of both XBP1s and RIDD targets in the PD samples uncovered associations with processes such as immune response, oxidative stress, signal transduction, and cell-cell communication that have previously been linked to PD.", "dois": ["10.1248/bpb.b18-00168", "10.3390/ijms26146711"]}
{"pair_type": "slc_pathway", "key1": "SLC6A1", "key2": "ferroptosis", "summary": "Cuproptosis is a novel type of cell death, which differs from previously reported types of cell death such as apoptosis, autophagy, proptosis, ferroptosis, necroptosis, etc.", "dois": ["10.1016/j.heliyon.2023.e19352"]}
{"pair_type": "slc_pathway", "key1": "SLC6A2", "key2": "chemotherapy", "summary": "With further analysis, five primary genes including HTR2C, TRH, AGTR2, MCHR2, and SLC6A2 as well as three miRNAs (hsa-miR-4445, hsa-miR-466, and hsa-miR-2114) have been suggested as the potential targets for sorafenib.\nCompared with HCC patients without any chemotherapy drugs, the sorafenib-treated patients develop 66 differentially expressed genes (DEGs), including 12 upregulated genes and 54 downregulated genes.\nThe RNA sequencing data and miRNA sequencing data of 114 HCC patients treated with sorafenib only and 326 HCC control patients treated without any chemotherapeutic drugs were studied using differential expression, functional enrichment, and protein-protein interaction analysis.", "dois": ["10.1097/MD.0000000000031281", "10.3389/fgene.2020.577000"]}
{"pair_type": "slc_pathway", "key1": "SLC5A11", "key2": "apoptosis", "summary": "There are numerous ways of treating T2DM with empagliflozin, including by regulating apoptosis, cell aging, as well as the , , , , , , and pathways.\nThe top 10 pathways were endocrine resistance, the signaling pathway, the signaling pathway, apoptosis, cell senescence, the Ras signaling pathway, the signaling pathway, the signaling pathway, the signaling pathway, and the p53 signaling pathway.", "dois": ["10.21037/atm-22-6406", "PMID:18069935"]}
{"pair_type": "slc_pathway", "key1": "SLC6A2", "key2": "apoptosis", "summary": "Eight autism-linked genes were differentially expressed in P1 (upregulated: NLGN3, SLC6A2; downregulated: GRIN2D, GRIN2B, CHRNA4).\nMany other genes involved in neurodevelopment, apoptosis, neurotransmission, and cognitive function were differentially expressed at P7 in MAO A KO mice.", "dois": ["PMID:24604048", "10.1016/j.brainres.2017.05.017"]}
{"pair_type": "slc_pathway", "key1": "SLC6A2", "key2": "proliferation", "summary": "High ADRB2/SLC6A2 expression stimulated HNSCC proliferation, adhesion, invasion, and angiogenesis.\nOur findings revealed for the first time that, in addition to its primary function as a transporter, NET also promotes NE-enhanced colon cancer cell proliferation, tumor angiogenesis, and tumor growth.\nExperimental validation confirmed that β-caryophyllene, a major constituent, dose-dependently inhibited the proliferation of HT29 and MCF-7 cells (0-320 μM).\nThis study demonstrates that a widely used antidepressant venlafaxine (VEN) antagonizes NE-promoted colon cancer in vivo and in vitro.\nThe NET-protein phosphatase 2 scaffold subunit alpha/phosphorylated Akt/vascular endothelial growth factor pathway partially mediates the antagonizing effect of VEN on NE's actions in colon cancer cells.\nIn addition, the knockdown of NET antagonized the effect of NE.\nGenes over-expressed in cells treated with DMIOA+20(S) compared with those treated with DMIOA include those involved in cellular growth and proliferation (CD44, CDK6, IL1B), cellular development (ADORA2B, ATP6VOD2, TNFAIP3), and cell-to-cell signaling and interaction (VCAM1, SPON2, VLDLR).\nMonoamines (serotonin, dopamine, norepinephrine) are crucial neuromodulators for proper placenta functions and fetal development, including cell proliferation, differentiation, and neuronal migration.\nWe demonstrated that 20(S) is capable of suppressing DMIOA-induced adipogenesis.", "dois": ["10.3390/cimb47070541", "10.1038/s41420-023-01447-5", "10.1038/s41598-022-15790-7", "10.1016/j.tranon.2021.101117", "10.1186/s12864-015-1231-z"]}
{"pair_type": "slc_pathway", "key1": "SLC6A2", "key2": "stemness", "summary": "On the other hand, genes related to cell stemness were downregulated in patients with activation of the beta- adrenergic pathway.", "dois": ["10.1016/j.tranon.2021.101117"]}
{"pair_type": "slc_pathway", "key1": "SLC6A2", "key2": "migration", "summary": "We show that the placental uptake of dopamine and norepinephrine across the mother-facing MVM is mediated via the high-affinity and low-capacity serotonin (SERT/SLC6A4) and norepinephrine (NET/SLC6A2) transporters.\nMonoamines (serotonin, dopamine, norepinephrine) are crucial neuromodulators for proper placenta functions and fetal development, including cell proliferation, differentiation, and neuronal migration.\nAlthough these latter studies could be improved and need to be replicated they are starting to implicate processes like neuronal migration and cell adhesion and cell division as potentially important in the aetiology of ADHD and have suggested several new directions for future ADHD genetics studies.\nAccumulating evidence suggests that even a transient disruption of monoamine balance during gestation may lead to permanent changes in the fetal brain structures and functions, projecting into adulthood.", "dois": ["10.1038/s41598-022-15790-7", "10.1007/s00787-010-0090-z"]}
{"pair_type": "slc_pathway", "key1": "SLC5A11", "key2": "ferroptosis", "summary": "The clusters showed different FRG expression and m6A methylation profiles and immune features, and prognostic models showed that the model integrating 5 MRP genes (MRPS15, MRPL3, MRPL9, MRPL36, and MRPL37) and 2 FRGs (SLC1A5 and SLC5A11) attained a greater clinical net benefit than three other prognostic models.\nWe investigated FRG and m6A modification-related gene expression profiles and immune features in patients with HCC, and developed and validated a model incorporating MRP and FRG expression that accurately and reliably predicts HCC prognosis and may predict disease progression and treatment response.\nHowever, further research is necessary to establish a link between mitochondrial ribosomal protein (MRP) family expression and HCC diagnosis, prognosis, ferroptosis-related gene (FRG) expression, m6A modification-related gene expression, tumor immunity, and drug sensitivity.", "dois": ["10.1007/s12094-023-03269-4"]}
{"pair_type": "slc_pathway", "key1": "SLC6A3", "key2": "apoptosis", "summary": "In conclusion, our findings suggest that scoulerine may induce apoptosis in RCC by targeting SLC6A3 and inhibiting the activation of the MAPK signaling pathway, thereby positioning it as a promising natural compound for potential future RCC treatment.\nUnexpectedly, RSB protected PC12 cells from oxidative stress induced by H2O2 via inhibiting autophagy and apoptosis.\nIn addition, scoulerine inhibited the viability of 769-P and 786-O cell lines in a time-dependent and dose-dependent manner, and promoted the level of apoptosis associated with B-cell lymphoma-2 associated X protein (Bax).\nThe results showed that EUMF significantly rescued the dyskinesia of zebrafish and inhibited Aβ deposition, Ache activity, and occurrence of cell apoptosis in the head of zebrafish induced by AlCl.\nMoreover, the administration of scoulerine resulted in a significant suppression of the mitogen activated protein kinase (MAPK) signaling pathway.\nMechanistically, quercetin activated the Nrf2/STAT3 signaling pathway, promoting nuclear translocation of Nrf2 and transcriptional upregulation of the dopamine transporter gene SLC6A3.\nThe results of our study indicate a significant affinity between scoulerine and SLC6A3, with competitive inhibition of this interaction leading to a reduction in the inhibitory impact of scoulerine on RCC cell viability.\nFurthermore, DA at a high concentration induced apoptosis in PCOS-derived GCs.\nDA, in the concentration range found in follicular fluid, did not induce apoptosis of cultured GCs.\nAn increase in apoptosis-related genes expression (casp8, casp9 and casp3) was observed in the MPs exposed group.\nQuercetin significantly reduced cerebral edema, improved neurological function, and inhibited neuronal apoptosis following MCAO.\nMatrine treatment in this model resulted in significant improvements in neurological function, reductions in brain damage, and marked decreases in oxidative stress and apoptosis.\nThe GDGSHJ formulation reduced Lactate Dehydrogenase (L", "dois": ["10.1016/j.phymed.2025.157061", "10.1016/j.intimp.2025.115213", "10.1038/s41598-025-10076-0", "10.1016/j.biopha.2024.117524", "10.18632/aging.205391", "10.1016/j.ecoenv.2022.113926", "10.1093/humrep/det422", "10.1016/j.phymed.2024.155999", "10.2174/0109298673291838240311075415", "10.3389/fnmol.2022.901953", "10.19852/j.cnki.jtcm.2021.06.003"]}
{"pair_type": "slc_pathway", "key1": "SLC6A1", "key2": "proliferation", "summary": "MiR-200c-3p inhibited the proliferation, migration and invasion in 786-O cells by down-regulating SLC6A1 expression.\nIn addition, enforced expression of SLC6A1 effectively promoted cell proliferation, migration and invasion of PCa cells in vitro.\nThe proliferation, migration, and invasion of SK-OV-3 cells were significantly reduced following the silencing of CDX2 or SLC6A1 (P<0.05).\nThe results showed both SLC6A7 and SLC6A17 from amino acid transporters AA1 and AA2 sub-families, respectively, significantly suppressed the cell proliferation and migration.\nConsequently, malfunctioning GABA signaling may cause altered neurodevelopment and neurotransmission, such as enhanced tonic inhibition and altered cell proliferation in vivo.\nWhile SLC6A1 and SLC6A4, which were classified into GABA and monoamine transporters, respectively, did not affect the cell proliferation and migration in HEK293T, HeLa, and MCF7 cells.\nOur experimental data demonstrated that Ciona amino acid transporters, such as SLC6A7 and SLC6A17, were essential for cell physiology and behaviors, indicating their crucially potential roles in the control of cell proliferation and migration during ascidian embryogenesis.\nThese findings suggest that MAOB-driven GABA synthesis, LRRC8D-regulated chloride and GABA transport, and GAT-1-facilitated GABA reuptake can regulate neural circuit activation and influence NSC proliferation dynamics in the LV.\nRecent studies have demonstrated that circuit activation in vivo can regulate proliferation of lateral ventricular neural stem cells (LV NSCs), although the underlying molecular and cellular mechanisms are not yet fully understood.\nFinally, the cell viability revealed that the overexpression of SLC6A1 obviously promoted the PCa cell resistant to docetaxel (DTX), and the transplanted tumor in the overexpression group had no significant reduction compared with the untreated group.\nMoreover, the inhibition of SLC6A1 suppressed the tumor growth in vivo.", "dois": ["10.3390/brainsci15040393", "10.3390/cells14060426", "10.1186/s13062-024-00569-9", "10.3748/wjg.v30.i3.252", "10.3233/JAD-230300", "10.1186/s13041-020-00612-6", "10.1186/s12885-020-06776-7", "10.3760/cma.j.issn.0376-2491.2019.29.013", "10.1016/j.gene.2019.04.056", "10.3892/ol.2018.9273", "10.1080/15384047.2017.1394551", "10.1371/journal.pone.0173178"]}
{"pair_type": "slc_pathway", "key1": "SLC6A3", "key2": "proliferation", "summary": "We identify LRP5, SLC6A3, and SOX10 as potentially important genes related to cell proliferation and invasion in the pathogenesis of ameloblastomas, along with both parthenolide and vorinostat as inhibitory drugs that could be further investigated for the development of novel therapeutic approaches against ameloblastoma.\nAmong the nine prognostic genes, MMP1, identified as the most promising candidate, demonstrated the capacity to enhance tumor cell proliferation and invasion.\nThe objective of this study was the identification of key genes and inhibitory drugs related to the cell proliferation and invasion of ameloblastoma using bioinformatic analysis.\nGene ontology enrichment analysis identified four pathways related to cell proliferation and cell invasion.\nThe inhibitory drugs bioinformatically obtained for the above three genes were parthenolide and vorinostat.\nWhen considering neurogenesis genes, a downregulation of proliferating cell nuclear antigen (pcna) was noticed in zebrafish exposed to the mixture treatment, while for dopaminergic system-related genes (th and slc6a3) an upregulation was observed in MPs, Cu25 and Cu25 +MPs groups.\nCell proliferation, apoptosis, and invasion assays were conducted to investigate the functional role of the target gene.\nThe cell proliferation assay and wound-healing assay results showed that RSB does not affect PC12 cell proliferation and chemotaxis.\nhowever, only SLC6A3, SOX10, and LRP5 were negatively associated with overall survival (HR = 1.49 ( = 0.0072), HR = 1.55 ( = 0.0018), and HR = 1.38 ( = 0.025), respectively).\nCell proliferation and invasion are characteristic of many tumors, including ameloblastoma, and are important features to target in possible future", "dois": ["10.25259/Cytojournal_35_2025", "10.1038/s41598-025-10076-0", "10.2147/DDDT.S508709", "10.3390/genes14081524", "10.1016/j.ecoenv.2022.113926", "10.19852/j.cnki.jtcm.2021.06.003", "10.3810/pgm.2010.11.2236", "PMID:17175058"]}
{"pair_type": "slc_pathway", "key1": "SLC6A3", "key2": "migration", "summary": "K674 methylation significantly decreased HIF-1-dependent migration of U251MG cells under hypoxia.\nK674 methylation suppressed HIF-1 transcriptional activity and expression of its downstream target genes PTGS1, NDNF, SLC6A3, and Linc01132 in human glioblastoma U251MG cells.\nHere we present evidence for a novel epigenetic mechanism that regulates HIF-1 transcriptional activity and HIF-1-dependent migration of glioblastoma cells.\nAdhesion G protein-coupled receptor L3 (ADGRL3, LPHN3) has putative roles in neuronal migration and synapse function.\nHypoxia-inducible factor 1 (HIF-1) is a master transcriptional regulator in response to hypoxia and its transcriptional activity is crucial for cancer cell mobility.", "dois": ["10.1016/j.neuropharm.2019.02.039", "10.1093/nar/gky449", "10.1093/ntr/ntv213", "10.1007/s00787-010-0090-z"]}
{"pair_type": "slc_pathway", "key1": "SLC6A4", "key2": "glycolysis", "summary": "Using global inverse gene expression profiling, drug affinity responsive target stability assays, and in silico molecular docking, we demonstrate that citalopram targets glucose transporter 1 (GLUT1), resulting in reduced glycolytic flux.\nA mutant GLUT1 variant at the citalopram binding site (E380) diminishes the drug's inhibitory effects on the Warburg effect and tumor growth.\nIn preclinical models, citalopram dampens the growth of GLUT1 liver tumors and displays a synergistic effect with anti-PD-1 therapy.\nA combined transcriptomics and metabolomics analysis suggested that WJHXD may be involved in eight metabolism-related pathways, with the most reliable ones being mucin-type O-glycan biosynthesis and glycolysis or gluconeogenesis.", "dois": ["10.1016/j.celrep.2024.114818", "10.2174/0113816128295774240523062258"]}
{"pair_type": "slc_pathway", "key1": "SLC5A11", "key2": "oxidative stress", "summary": "Additionally, dapagliflozin seems to also have a stronger impact on brain tissue through the regulation of SGLT3 and SLC5A11.\nWe analyzed it in the context of the so-called key terms ( autophagy, oxidative stress, aging, senescence, inflammation, AMPK pathways, and mTOR pathways) which seem to be crucial to elucidating the SGLT2 role in a variety of clinical manifestations.", "dois": ["10.3389/fphar.2022.901340"]}
{"pair_type": "slc_pathway", "key1": "SLC6A5", "key2": "migration", "summary": "The developmental delay in hyperekplexia, and speech acquisition in particular, may represent failure of developmental neural networks or subtle neurogenic migration defects in the absence of presynaptic glycine release.", "dois": ["10.1093/brain/awt207"]}
{"pair_type": "slc_pathway", "key1": "SLC6A5", "key2": "oxidative stress", "summary": "Pathway perturbation analysis showed that the overall dysregulation of these genes results in a significant increase in redox pathway activity (adjusted -value 1.11 × 10) and a significant inhibition of the necroptosis pathway (adjusted -value 4.64 × 10).\nThese findings suggest RS-GRA's potential as an adjuvant in neurodegenerative disease treatment, as both increased redox activity and necroptosis inhibition may be beneficial in this context.", "dois": ["10.3390/antiox13091111"]}
{"pair_type": "slc_pathway", "key1": "SLC6A6", "key2": "migration", "summary": "Collectively, overexpression of SLC6A6 suppresses neointimal formation by inhibiting VSMC proliferation and migration via Wnt/β-catenin signaling and maintaining the VSMC contractile phenotype.\nSLC6A6 suppressed VSMC proliferation and migration, while increasing contractile VSMC proteins.\nCCK8, flow cytometry, transwell analysis, tube formation assays, and Western blotting of the CC cell lines with miR-3156-3p over/under-expression in vitro showed that miR-3156-3p was involved in cell proliferation, apoptosis, migration, neovascularization, and SLC6A6 regulation.\nMechanistically, SLC6A6 overexpression reduced ROS production and inhibited the Wnt/β-catenin pathway.\nSLC6A6 was downregulated in dedifferentiated VSMCs, atherosclerotic vascular tissues, and injured vascular tissues.\nFurthermore, SLC6A6 overexpression suppressed neointimal formation in vivo.\nWe previously demonstrated that taurine action regulates the cation-chloride cotransporter activity and the differentiation and radial migration of pyramidal neuron progenitors in the developing neocortex of rodent fetuses.\nReactive oxygen species (ROS), proliferation, migration, and phenotype-related proteins of VSMCs were measured.\nVascular stenosis rate and related genes were assessed in a rat vascular balloon injury model overexpressing SLC6A6.\nSolute carrier family 6 member 6 (SLC6A6) is a transmembrane transporter that maintains a variety of physiological functions and is highly expressed in VSMCs.", "dois": ["10.3390/ijms24033018", "10.3389/fnmol.2022.806798", "10.1186/s12985-017-0695-7"]}
{"pair_type": "slc_pathway", "key1": "SLC5A12", "key2": "glycolysis", "summary": "We further show both in vitro and in vivo that the sodium lactate-mediated inhibition of CD4+ T cell motility is due to an interference with glycolysis activated upon engagement of the chemokine receptor CXCR3 with the chemokine CXCL10.\nIt also leads to CD4 T cell retention in the inflamed tissue as a consequence of reduced glycolysis and enhanced fatty acid synthesis.\nSLC5A12-mediated lactate uptake into CD4 T cells induces a reshaping of their effector phenotype, resulting in increased IL17 production via nuclear PKM2/STAT3 and enhanced fatty acid synthesis.\nFinally, we propose that lactate/SLC5A12-induced metabolic reprogramming is a distinctive feature of lymphoid synovitis in rheumatoid arthritis patients and a potential therapeutic target in chronic inflammatory disorders.\nWe report that lactate accumulation in the inflamed tissue contributes to the upregulation of the lactate transporter SLC5A12 by human CD4 T cells.\nThis selective control of T cell motility is mediated via subtype-specific transporters (Slc5a12 and Slc16a1) that we find selectively expressed by CD4+ and CD8+ subsets, respectively.\nIn contrast, we find the lactic acid effect on CD8+ T cell motility to be independent of glycolysis control.\nAccording to our analysis, the prognostic risk markers composed of HPRT1, STC2, PLCB3, GPR87, PYGL, and SLC5A12 may be an independent risk factor for the prognosis of HNSCC.\nWe further show that the expression of lactate transporters correlates with the clinical T cell score in the synovia of rheumatoid arthritis patients.\nFurthermore, antibody-mediated blockade of SLC5A12 ameliorates the disease severity in a murine model of arthritis.\nFinally, pharmacological or antibody-mediated blockade of subtype-specific lactate transporters on T cells results in their release from the inflammatory site in an in vivo model of peritonitis.", "dois": ["10.1155/2021/8824195", "10.1016/j.cmet.2019.10.004", "10.1371/journal.pbio.1002202"]}
{"pair_type": "slc_pathway", "key1": "SLC6A3", "key2": "oxidative stress", "summary": "Such behavioral change was related, at molecular level, to an enhanced expression of sod1, cat, and gpxa, suggesting an overproduction of pro-oxidant molecules.\nOxidative stress and dopaminergic dysfunction are key contributors to neuronal injury following cerebral ischemia.\nMechanistically, quercetin activated the Nrf2/STAT3 signaling pathway, promoting nuclear translocation of Nrf2 and transcriptional upregulation of the dopamine transporter gene SLC6A3.\nNetwork pharmacology and molecular docking identified Nrf2, STAT3, and SLC6A3 as core targets of quercetin.\nOur findings identify the Nrf2/STAT3/SLC6A3 axis as a key mediator of quercetin's neuroprotective effects in ischemic stroke.\nTo our knowledge, this is the first study to identify the Nrf2/STAT3/SLC6A3 axis as a key regulatory pathway underlying the neuroprotective action of quercetin.\nThis regulatory axis was critical for mitigating oxidative DNA damage and preserving neuronal integrity.\nQuercetin significantly reduced cerebral edema, improved neurological function, and inhibited neuronal apoptosis following MCAO.\nInhibition of Nrf2 or STAT3 abrogated the protective effects of quercetin in both in vitro and in vivo models.\nAccumulation of dopamine in the neuronal cytosol can trigger oxidative stress and neurotoxicity, suggesting that the proper compartmentalization of dopamine is critical for neuron function and risk of disease.\nthere is evidence that they may involve neurotransmitter imbalance, mitochondrial impairment, oxidative stress, and neuroinflammation, as well as the dysregulation of neurotrophic factors and their downstream signaling pathways.\nIn common among cADHD and aADHD, the most significant findings are for oxidative stress proteins (MAD, SOD, PON1, ARES, TOS, TAS and OSI), and, in the second level, DISC1, DBH, DDC, microRNA and adiponectin.", "dois": ["10.1016/j.phymed.2025.157061", "10.1016/j.intimp.2025.115213", "10.1038/s41598-025-10076-0", "10.1007/s00128-025-04073-2", "10.1007/s11356-019-06619-4", "10.1007/s40203-025-00398-2", "10.3390/medicina59061138", "10.19852/j.cnki.jtcm.2021.06.003", "10.1016/j.phymed.2019.152982", "10.1080/15622975.2017.1282175", "10.1111/ejn.13357", "PMID:27333929", "PMID:17239488"]}
{"pair_type": "slc_pathway", "key1": "SLC6A6", "key2": "chemotherapy", "summary": "The study found that taurine exerts its anti-cancer effects by modulating CD8 T cells rather than directly inhibiting tumor cells, revealing the SP1-SLC6A6 axis as a key mechanism behind chemotherapy-induced immune evasion.\nIn gastric cancer, we identify a chemotherapy-induced SP1-SLC6A6 regulatory axis.\nSLC6A6-mediated taurine uptake promotes the malignant behaviors of tumor cells but also increases the survival and effector function of CD8 T cells.\nOur findings suggest that tumoral-SLC6A6-mediated taurine deficiency promotes immune evasion and that taurine supplementation reinvigorates exhausted CD8 T cells and increases the efficacy of cancer therapies.\nTumor cells outcompete CD8 T cells for taurine by overexpressing SLC6A6, which induces T cell death and malfunction, thereby fueling tumor progression.\nMechanistically, taurine deficiency in CD8 T cells increases ER stress, promoting ATF4 transcription in a PERK-JAK1-STAT3 signaling-dependent manner.\nIncreased ATF4 transactivates multiple immune checkpoint genes and induces T cell exhaustion.\nHere, we report that cancer-related taurine consumption causes T cell exhaustion and tumor progression.", "dois": ["10.1038/s41598-024-81335-9", "10.1016/j.biocel.2024.106661", "10.1016/j.cell.2024.03.011"]}
{"pair_type": "slc_pathway", "key1": "SLC6A4", "key2": "apoptosis", "summary": "In vitro, AAEO (5-20 μg/mL) protected PC12 cells against CORT-induced apoptosis and mitochondrial dysfunction, concurrently upregulating GABRB3 and SLC6A4 expression.\nCritically, siRNA-mediated knockdown of GABRB3 or SLC6A4 significantly abolished AAEO's cytoprotective effects.\nGene expression related to serotonin receptors (HTR2A, HTR2B, HTR3A), Serotonin transporter (SLC6A4), apoptosis (Bcl-2, Bax), and proliferation (PCNA) was evaluated via real-time PCR.\nThese treatments significantly reduced anti-apoptotic Bcl-2 and PCNA, proliferation marker, expression, while pro-apoptotic Bax expression was markedly elevated (p < 0.05).\nThe main signaling pathways in which the target genes were enriched are cell cycle, EMT, PI3K/AKT, and apoptosis.\nStudies focused on serotonin pathway targets, cell viability, apoptosis, differentiation, and the osteoblast/osteoclast feedback loop.\nIn vitro, corticosterone (CORT)-injured PC12 cells evaluated AAEO's cytoprotection (viability, LDH, apoptosis, mitochondrial potential).\nCell apoptosis was analyzed using flow cytometry, and the expression of apoptosis-related proteins was determined through Western blotting.\nThese target genes were further found to be associated with pathways involved in neuronal apoptosis, such as pathways in cancer, Toll-like receptor signaling pathway, and TNF signaling.\nMoreover, the pathways that serve as major contributors are the PI3K-Akt signaling pathway, the HIF-1 signaling pathway, the STAT3 signaling pathway, the MAPK signaling pathway, the NF-κB signaling pathway, and the apoptosis-related pathway.\nThe top biological pathways were related to apoptosis.\nUnexpectedly, RSB protected PC12 cells from oxidative stress induced by H2", "dois": ["10.1007/s11033-025-10474-7", "10.1007/s00439-020-02200-z", "10.1016/j.lfs.2020.117827", "10.1111/j.1601-183X.2009.00522.x", "PMID:15870169", "10.1093/eep/dvaf025", "10.1016/j.jep.2025.120308", "10.1007/s12672-025-02939-9", "10.2174/0109298673299665240924090617", "10.1038/s41398-024-03071-y", "10.1016/j.phymed.2024.155999", "10.3390/genes15081025", "10.1016/j.aquatox.2024.106841", "10.19540/j.cnki.cjcmm.20230510.701", "10.1007/s12640-022-00586-4", "10.1007/s00432-022-04353-y", "10.12122/j.issn.1673-4254.2022.08.15", "10.26355/eurrev_202207_29196", "10.19852/j.cnki.jtcm.2021.06.003", "10.33425/2639-9342.1140", "10.1016/j.neubiorev.2020.12.016", "10.1016/j.brainres.2016.08.031"]}
{"pair_type": "slc_pathway", "key1": "SLC6A6", "key2": "apoptosis", "summary": "CCK8, flow cytometry, transwell analysis, tube formation assays, and Western blotting of the CC cell lines with miR-3156-3p over/under-expression in vitro showed that miR-3156-3p was involved in cell proliferation, apoptosis, migration, neovascularization, and SLC6A6 regulation.\nThis effect was accompanied by reduced caspase-3 activation, indicating impaired apoptosis.\nCD8 T cells cultured with exogenous taurine exhibited decreased apoptosis, enhanced proliferation, and increased secretion of cytotoxic cytokines.\nHG promotes cisplatin chemoresistance by preventing apoptosis.\nCancer cells are characterized by uncontrolled growth, proliferation, and impaired apoptosis.\nSLC6A6 knockdown limited the function and proliferation of CD8 T cells.\nFurthermore, taurine enhanced T cell proliferation and function in vitro by stimulation of PLCγ1-mediated calcium and MAPK signaling.\nRNA sequencing revealed that SLC6A6 knockdown altered the calcium signaling pathway, oxidative phosphorylation, and T cell receptor signaling in CD8 T cells.\nTaurine plus immune checkpoint blockade antibody significantly attenuated tumor growth and markedly improved the function and proliferation of CD8 T cells in a mouse tumor model.\nHigh SLC6A6 expression in CD8 T cells was positively associated with an effector T cell signature.\nHerein, we present the potential role of taurine (SLC6A6) and creatine (SLC6A8) transporters in cancer development as well as therapeutic potential of their inhibitors.\nThese proteins were noticed to play important physiological roles through transferring nutrient amino acids, osmolytes, neurotransmitters, and ions, and many of them are necessary for survival of the cells.\nThus, our findings indicate that taurine is an important driver for improving CD8 T cell immune responses and could serve as a potential therapeutic agent for cancer patients.\nCisplatin cytotoxicity was assessed by the MTT assay and was attenuated by HG.", "dois": ["10.3892/br.2025.2064", "10.1096/fj.202300272R", "10.3390/ijms24043788", "10.1007/s00262-022-03308-z", "10.2106/JBJS.21.00750", "10.1186/s12985-017-0695-7"]}
{"pair_type": "slc_pathway", "key1": "SLC6A6", "key2": "glycolysis", "summary": "Our results indicate that the taurine transporter TauT/SlC6A6 is upregulated at the transcriptional level during M1 macrophage polarization.\nMechanistically, taurine inhibits SAM-dependent PP2Ac methylation to block PINK1-mediated mitophagy flux, thereby maintaining a high mitochondrial density, which ultimately hinders the conversion of energy metabolism to glycolysis required for M1.\nThe nutrient uptake signal on the membrane supports the high abundance of taurine in macrophages after taurine supplementation, which weakens the status of methionine metabolism, resulting in insufficient S-adenosylmethionine (SAM).", "dois": ["10.3389/fimmu.2021.648913", "10.1016/j.meatsci.2017.07.019"]}
{"pair_type": "slc_pathway", "key1": "SLC5A12", "key2": "chemotherapy", "summary": "Functional experiments confirmed SLC5A12's role in promoting gastric cancer cell proliferation, invasion, and migration both in vitro and in vivo.\nA key finding was LRGS's ability to predict patient responses to both adjuvant chemotherapy and immunotherapy.\nThe LRGS is a dependable and efficient prognostic tool for assessing the survival outcomes in individuals with gastric cancer, as well as a predictor of patient response to adjuvant chemotherapy and immunotherapy.", "dois": ["10.1016/j.bbagen.2024.130739"]}
{"pair_type": "slc_pathway", "key1": "SLC6A4", "key2": "chemotherapy", "summary": "The inclusion criteria for the study were advanced ovarian cancer or endometrial cancer, as well as treatment in the form of cytoreductive therapy and chemotherapy.\nBC survivors recruited from Moffitt Cancer Center and the University of South Florida's Breast Health Program, who had completed adjuvant radiation and/or chemotherapy treatment, were randomized to either the 6-week MBSR(BC) program (n = 37) or usual care (UC; n = 35) group.\nResults showed that SNPs in four genes (ankyrin repeat and kinase domain containing 1 [ANKK1], apolipoprotein E [APOE], methylenetetrahydrofolate reductase [MTHFR], and solute carrier family 6 member 4 [SLC6A4]) were associated with cognitive impairment.", "dois": ["10.3389/fpubh.2025.1543696", "10.1097/MD.0000000000031281", "10.1177/1099800415577633", "10.1188/14.ONF.195-202", "PMID:16443263"]}
{"pair_type": "slc_pathway", "key1": "SLC6A4", "key2": "migration", "summary": "While SLC6A1 and SLC6A4, which were classified into GABA and monoamine transporters, respectively, did not affect the cell proliferation and migration in HEK293T, HeLa, and MCF7 cells.\nWe next found that 5-HT6 receptors were expressed in cortical interneurons and that 5-HT6 receptor activation decreased interneuron migration, whereas 5-HT6 receptor blockade prevented the migratory effects induced by 5-HT.\nUsing time-lapse videometry to monitor the migration of interneurons in embryonic mouse cortical slices, we discovered that the application of 5-HT decreased interneuron migration in a reversible and dose-dependent manner.\nThe discovery that a common polymorphism (5-HTTLPR, short variant) in the human serotonin transporter gene (SLC6A4) can influence personality traits and increase the risk for depression in adulthood has led to the hypothesis that a relative increase in the extracellular levels of serotonin (5-HT) during development could be critical for the establishment of brain circuits.\nIn this study we hypothesized that an excess of 5-HT could affect embryonic cortical interneuron migration.\nIn humans, serotonergic fibers appear in the developing cortex as early as the 10th gestational week, a period of intense neuronal migration.\nFinally, we observed that interneurons were abnormally distributed in the cerebral cortex of serotonin transporter gene (Slc6a4) knockout mice that have high levels of extracellular 5-HT.\nMonoamines (serotonin, dopamine, norepinephrine) are crucial neuromodulators for proper placenta functions and fetal development, including cell proliferation, differentiation, and neuronal migration.\nOur experimental data demonstrated that Ciona amino acid transporters, such as SLC6A7 and SLC6A17, were essential for cell physiology and behaviors, indicating their crucially potential roles in the control of cell proliferation and migration during ascidian embryogenesis.\nThe results showed both SLC6A7 and SLC6A17 from amino aci", "dois": ["10.3892/mmr.2023.13036", "10.1111/mec.16916", "PMID:36247281", "10.1007/s00432-022-04353-y", "10.1038/s41598-022-15790-7", "10.3389/fonc.2021.630235", "10.1016/j.gene.2019.04.056", "10.7554/eLife.32640", "10.1007/s00787-010-0090-z", "10.1038/mp.2008.89", "PMID:17510734", "PMID:11206084"]}
{"pair_type": "slc_pathway", "key1": "SLC6A4", "key2": "proliferation", "summary": "Gene expression related to serotonin receptors (HTR2A, HTR2B, HTR3A), Serotonin transporter (SLC6A4), apoptosis (Bcl-2, Bax), and proliferation (PCNA) was evaluated via real-time PCR.\nWhile SLC6A1 and SLC6A4, which were classified into GABA and monoamine transporters, respectively, did not affect the cell proliferation and migration in HEK293T, HeLa, and MCF7 cells.\nThe results showed both SLC6A7 and SLC6A17 from amino acid transporters AA1 and AA2 sub-families, respectively, significantly suppressed the cell proliferation and migration.\nConsistent with the central role played by Rac1 in ADM formation, inhibition of the 5-HT transporter Sert (Slc6a4) with fluoxetine reduced ADM formation both in vitro and in vivo in a cell-autonomous manner.\nPreviously, we have shown decreased cardiomyocyte proliferation, left ventricle size, and cardiac expression of the serotonin receptor 5-HT in the offspring of mice exposed to the SSRI sertraline relative to the offspring of saline-exposed mice.\nThese treatments significantly reduced anti-apoptotic Bcl-2 and PCNA, proliferation marker, expression, while pro-apoptotic Bax expression was markedly elevated (p < 0.05).\nWe observed decreases in proliferation and increases in alkaline phosphatase activity after citalopram exposure.\nThe downregulated genes were involved with cell proliferation, morphogenesis, motility, and growth, whereas genes that were upregulated controlled cell survival and protection pathways.\n5-HT uptake promoted activation of the small GTPase Ras-related C3 botulinum toxin substrate 1 (Rac1), which is required for transdifferentiation of acinar cells into acinar-to-ductal metaplasia (ADM), a key determinant in PDAC development.\nSerotonin is a key contributing factor in pulmonary arterial hypertension (PAH", "dois": ["10.1210/endocr/bqaf124", "10.1007/s12672-025-02939-9", "10.1007/s11033-025-10474-7", "10.1152/ajpheart.00692.2023", "PMID:36247281", "10.1007/s00432-022-04353-y", "10.1038/s41598-022-15790-7", "10.19852/j.cnki.jtcm.2021.06.003", "10.33425/2639-9342.1140", "10.1007/s00439-020-02200-z", "10.1016/j.gene.2019.04.056", "10.1002/path.5147", "10.1172/JCI84877", "10.1002/bdra.23323", "10.3389/fpsyt.2012.00032", "10.3810/pgm.2010.11.2236", "10.3899/jrheum.091156", "PMID:17510734", "PMID:17242179", "PMID:12081984"]}
{"pair_type": "slc_pathway", "key1": "SLC5A12", "key2": "migration", "summary": "Functional experiments confirmed SLC5A12's role in promoting gastric cancer cell proliferation, invasion, and migration both in vitro and in vivo.\nThis selective control of T cell motility is mediated via subtype-specific transporters (Slc5a12 and Slc16a1) that we find selectively expressed by CD4+ and CD8+ subsets, respectively.\nExtracellular sodium lactate and lactic acid inhibit the motility of CD4+ and CD8+ T cells, respectively.\nWe further show both in vitro and in vivo that the sodium lactate-mediated inhibition of CD4+ T cell motility is due to an interference with glycolysis activated upon engagement of the chemokine receptor CXCR3 with the chemokine CXCL10.\nFinally, pharmacological or antibody-mediated blockade of subtype-specific lactate transporters on T cells results in their release from the inflammatory site in an in vivo model of peritonitis.\nIn CD4+ T helper cells, sodium lactate also induces a switch towards the Th17 subset that produces large amounts of the proinflammatory cytokine IL-17, whereas in CD8+ T cells, lactic acid causes the loss of their cytolytic function.\nBy establishing a novel role of lactate in control of proinflammatory T cell motility and effector functions, our findings provide a potential molecular mechanism for T cell entrapment and functional changes in inflammatory sites that drive chronic inflammation and offer targeted therapeutic interventions for the treatment of chronic inflammatory disorders.", "dois": ["10.1016/j.bbagen.2024.130739", "10.1371/journal.pbio.1002202"]}
{"pair_type": "slc_pathway", "key1": "SLC6A4", "key2": "oxidative stress", "summary": "These polymorphisms were in genes related to neurotransmission (COMT, ADRB2, DRD2, ANKK1, SLC6A4 and HTR2A), inflammatory mediators (TNFα, IL10 and MMP1), sex hormones (ESR1and ESRRB), oxidative stress (GSTM1) and bone metabolism (VDR).\nIn vivo, was induced during aging and hypertension but the expression of the corresponding serotonin uptake receptor () was reduced and enzymes that reduce either oxidative stress () or accumulation of 5-hydroxyindolacetaldehyde () were induced.\nParental and postnatal FR autoantibodies tend to block folate passage to the brain affecting folate-dependent pathways restored by folinic acid treatment, while an abnormal redox status tends to induce reduced serotonin turnover, corrected by antioxidant therapy.\nMeasurements in the whole brain homogenates from newborn and adult offspring indicated decreased melatonin and serotonin levels and increased reactive oxygen species level in PCLE offspring.\nOur results point to adverse behavioral effects of PCLE on adult offspring, involving serotonin and melatonin signaling dysregulation, increased chronic oxidative stress, and altered gene expression.\nThe serotonin reuptaker Slc6a4 displayed a decreased expression in the prefrontal cortex of PCLE group.\nOxidative stress was found to be present in autistic children where these reactive oxygen derivatives can cause damage to DNA, which changes DNA function and regulation of gene expression.\nIt is possible that migraine is a multifactorial disease with polygenic influence.Recent studies have shown that the pathomechanisms of migraine involves both factors responsible for immune response and oxidative stress such as: cytokines, tyrosine metabolism, homocysteine;\nthe specific mechanisms underlying the potential role of genetic diversity in PD depression are still under investigation, however, there is evidence that they may involve neurotransmitter imbalance, mitochondrial impairment, oxidative stress, and neuroinflammation, as well as the dysregulation of neurot", "dois": ["10.1016/j.bbrc.2024.150968", "10.1016/j.mehy.2019.109406", "10.1016/j.brainres.2016.08.031", "10.18632/oncotarget.9367", "10.19852/j.cnki.jtcm.2025.05.013", "10.1016/j.archoralbio.2025.106235", "10.3390/medicina59061138", "10.3390/biom13061013", "10.1007/s12640-022-00586-4", "10.26355/eurrev_202207_29196", "10.19852/j.cnki.jtcm.2021.06.003", "10.1155/2020/9095284", "PMID:24694231", "PMID:17239488"]}
{"pair_type": "slc_pathway", "key1": "SLC6A6", "key2": "oxidative phosphorylation", "summary": "Mechanically, SLC6A6-mediated taurine uptake enhanced oxidative phosphorylation by upregulating mitochondrial cytochrome oxidase II (MT-CO2), supporting the energy requirements of the arsenic-induced transformation.\nRNA sequencing revealed that SLC6A6 knockdown altered the calcium signaling pathway, oxidative phosphorylation, and T cell receptor signaling in CD8 T cells.\nUpregulated taurine transporter SLC6A6 facilitated taurine uptake, promoting the arsenic-induced transformation.\nThe KEGG pathway GSEA results indicated that the DEGs were enriched for oxidative phosphorylation, whereas the downregulated DEGs were negatively enriched for the p53 signaling pathway.\nIn conclusion, our results suggest that taurine uptake, mediated by mA-methylated SLC6A6, promotes arsenite-induced malignant transformation while enhancing sensitivity to cuproptosis in arsenite-transformed keratinocytes.\nNotably, this taurine uptake also enhanced MT-CO2-dependent copper utilization, thereby sensitizing arsenite-transformed keratinocytes to copper-dependent and oxidative-phosphorylation-driven metabolic cell death, known as cuproptosis.\nSLC6A6 knockdown limited the function and proliferation of CD8 T cells.\nFurthermore, -methyladenosine (mA) methyltransferase METTL3 catalyzed mA modifications at multiple sites on SLC6A6 mRNA, promoting the stability and translation of SLC6A6 mRNA by recruiting mA binding protein YTHDF1 during arsenite-induced transformation.\nImportantly, shRNA-based knockdown of SLC6A6 expression in primary human MSCs reduces osteogenic differentiation, indicating a key role of taurine uptake in human MSC function.\nHigh SLC6A6 expression in CD8 T cells was positively associated with an effector T cell signature.\nThese cells also show reduced oxidative phosphorylation, and increased ROS levels, indicating that impaired Wnt signaling and elevated oxidative stress may contribute to the observed defects in osteogenic differentiation capacity.", "dois": ["10.1021/acs.est.5c01604", "10.1101/2025.06.24.661367", "10.1016/j.heliyon.2024.e24356", "10.1007/s00262-022-03308-z"]}
{"pair_type": "slc_pathway", "key1": "SLC6A4", "key2": "oxidative phosphorylation", "summary": "We describe a method that estimates the collaborative contribution to the disease between a certain well-studied pathway and the other candidate pathway using Gene Set Enrichment Analysis (GSEA).\nWe describe a modified GSEA (improved derivation) to identify genes that are significantly and differentially expressed between disease and non-disease states and that are consistently co-expressed with a target pathway which is deeply related to disease etiology.\nWe believe that this approach could reveal hidden relations between a certain well-studied pathway and the other candidate pathway known in literature.\nThe modified GSEA uses available gene expression data to identify molecular mechanism (ubiquitin-proteasome and inflammatory response) associated with the disease.\nBipolar disorder (BD) is a psychiatric disease considered to polygenic with multiple factors in genetics, each of which is not dominant but collaborative during pathogenic progression.", "dois": ["10.6026/97320630011207"]}
{"pair_type": "slc_pathway", "key1": "SLC6A7", "key2": "proliferation", "summary": "The results showed both SLC6A7 and SLC6A17 from amino acid transporters AA1 and AA2 sub-families, respectively, significantly suppressed the cell proliferation and migration.\nOur experimental data demonstrated that Ciona amino acid transporters, such as SLC6A7 and SLC6A17, were essential for cell physiology and behaviors, indicating their crucially potential roles in the control of cell proliferation and migration during ascidian embryogenesis.", "dois": ["10.1016/j.gene.2019.04.056"]}
{"pair_type": "slc_pathway", "key1": "SLC6A7", "key2": "migration", "summary": "The results showed both SLC6A7 and SLC6A17 from amino acid transporters AA1 and AA2 sub-families, respectively, significantly suppressed the cell proliferation and migration.\nOur experimental data demonstrated that Ciona amino acid transporters, such as SLC6A7 and SLC6A17, were essential for cell physiology and behaviors, indicating their crucially potential roles in the control of cell proliferation and migration during ascidian embryogenesis.", "dois": ["10.1016/j.gene.2019.04.056"]}
{"pair_type": "slc_pathway", "key1": "SLC5A8", "key2": "proliferation", "summary": "Besides, decreased proliferation activity and increased apoptosis were also observed in CC cells overexpressing SLC5A8 plasmid.\nConsistent with this, in cells expressing functional SLC5A8, 2,4,6-THBA induced CDK inhibitory proteins p21 and p27 and inhibited cell proliferation.\nMoreover, the impaired proliferation activity and increased apoptosis proportion of CC cells induced by SLC5A8 over-expression could be counteracted by the Wnt signaling pathway activator LiCl.\nOverexpression of SLC5A8 in the HeLa cell line decreased its proliferation by arresting cancer cells in the G1 phase and inhibiting cellular migration.\nFurthermore, we observed that pyruvate increased the SLC5A8 effect, inducing S-phase arrest and inhibiting the entry into mitosis.\nectopic expression of SLC5A8 in SLC5A8-deficient colon cancer cell lines leads to suppression of the colony-forming ability of these cells.\nThese variants significantly increased the proliferation, migration, and invasion abilities of CRC cells.\nSLC5A8 decreased tumor growth in xenograft transplants, significantly reducing the volume and tumor weight at 35 days of analysis.\nDecreased SLC5A8 expression caused by missense variants appeared to significant impair the tumor-suppressive function of the transporter.\nActivin A, a member of the transforming growth factor-β (TGF-β) superfamily, has been shown to inhibit the proliferation of a variety of tumor (and normal) human cell types.\nSLC5A8 can suppress colorectal cancer (CRC), and its tumor-suppressive function is mainly associated with butyrate, propionate, and pyruvate, which inhibit histone deacetylase.\nIn this study, we investigated the ability of one metabolite, 2,4,6-trihydroxybenzoic acid (2,4,6-THBA) to inhibit Cyclin Dependent Kinase (CDK) activity and cancer cell proliferation.\nSLC5A8 alleviates the progression of CC by regulating the Wnt signaling pathway.", "dois": ["10.3346/jkms.2025.40.e146", "10.31083/j.fbl2901016", "10.3390/nu14183706", "10.26355/eurrev_202005_21155", "10.3389/fmicb.2020.00090", "10.3390/cancers11030427", "10.1016/j.urolonc.2017.04.017", "10.1371/journal.pone.0139342", "PMID:24934552", "10.1016/j.biocel.2010.08.007", "10.1158/0008-5472.CAN-09-3073", "PMID:16295698"]}
{"pair_type": "slc_pathway", "key1": "SLC6A6", "key2": "proliferation", "summary": "Collectively, overexpression of SLC6A6 suppresses neointimal formation by inhibiting VSMC proliferation and migration via Wnt/β-catenin signaling and maintaining the VSMC contractile phenotype.\nSLC6A6 suppressed VSMC proliferation and migration, while increasing contractile VSMC proteins.\nSLC6A6 knockdown limited the function and proliferation of CD8 T cells.\nCD8 T cells cultured with exogenous taurine exhibited decreased apoptosis, enhanced proliferation, and increased secretion of cytotoxic cytokines.\nMechanistically, SLC6A6 overexpression reduced ROS production and inhibited the Wnt/β-catenin pathway.\nFurthermore, taurine enhanced T cell proliferation and function in vitro by stimulation of PLCγ1-mediated calcium and MAPK signaling.\nFurthermore, SLC6A6 overexpression suppressed neointimal formation in vivo.\nTaurine plus immune checkpoint blockade antibody significantly attenuated tumor growth and markedly improved the function and proliferation of CD8 T cells in a mouse tumor model.\nProliferating chondrocytes cultured under hyperosmolar conditions showed low proliferation, spheroidal morphology, a significant reduction of de-differentiation markers [collagen type I (Col1) and RUNX2] and an increase of differentiation markers [collagen type II (Col2) and aggrecan].\nHigh SLC6A6 expression in CD8 T cells was positively associated with an effector T cell signature.\nReactive oxygen species (ROS), proliferation, migration, and phenotype-related proteins of VSMCs were measured.\nSolute carrier family 6 member 6 (SLC6A6) is a transmembrane transporter that maintains a variety of physiological functions and is highly expressed in VSMCs.\nCancer cells are characterized by uncontrolled growth, proliferation, and impaired apoptosis.\nCCK8, flow cytometry, transwell analysis, tube formation assays, and Western blotting of the CC cell lines with miR-3156-3p over/under-expression in vitro showed that miR-3", "dois": ["10.1007/s10014-025-00508-0", "10.1007/s11259-023-10140-y", "10.3390/ijms24043788", "10.3390/ijms24033018", "10.1007/s00262-022-03308-z", "10.1186/s12985-017-0695-7"]}
{"pair_type": "slc_pathway", "key1": "SLC6A8", "key2": "ferroptosis", "summary": "SLC6A8-mediated creatine uptake suppresses ERK2-FSP1 signaling and induces ferroptosis in colorectal cancer.\nInhibiting the creatine transporter SLC6A8 reduces creatine uptake and activates ERK2.\nActivated ERK2 then binds, phosphorylates ferroptosis suppressor protein 1 (FSP1) at Thr109, and stabilizes it to inhibit ferroptosis.\nHere, using untargeted metabolomics, we demonstrate that creatine potently induces ferroptosis in colorectal cancer (CRC).\nMechanistically, creatine binds extracellular signal-regulated kinase 2 (ERK2), impairing its activation by mitogen-activated protein kinase kinase 1 (MEK1).\nOur study identifies ERK2 as a creatine sensor regulating FSP1 stability and ferroptosis resistance, highlighting the therapeutic potential of creatine supplementation in combination cancer immunotherapy.", "dois": ["10.1016/j.celrep.2025.116139"]}
{"pair_type": "slc_pathway", "key1": "SLC6A6", "key2": "stemness", "summary": "SLC6A6 inhibition delayed corneal wound healing, triggered senescence pathway activation and pluripotency suppression, and downregulated stemness markers (BCAM, p63, KRT14, Wnt4) and proliferative markers (Ki67), which recapitulated key features of corneal aging.\nSLC6A6-driven taurine uptake critically regulates LSPC homeostasis, presenting a therapeutic strategy for age-related corneal disorders.\nMoreover, VPA effectively reversed the inhibitory effect of GES, whereas DAPT attenuated the effect of taurine, indicating involvement of the Notch1 signaling pathway in taurine-induced LSPC maintenance.\nThe cornea exhibited high taurine concentrations, with its transporter SLC6A6 predominantly localized in LSPCs (limbal stem cells, transient amplifying cells, and basal cells) and displaying age-dependent expression patterns.\nThis functional decline was reversed through topical taurine supplementation.", "dois": ["10.1167/iovs.66.6.25"]}
{"pair_type": "slc_pathway", "key1": "SLC6A8", "key2": "apoptosis", "summary": "SLC6A8-mediated accumulation of creatine promoted survival and suppressed apoptosis via maintaining redox homeostasis in hypoxic TNBC cells.\nIn this study, we revealed that SLC6A8 knockdown significantly induced apoptosis and suppressed the migration and invasion of Hep3B and Huh-7 cells.\nWe report that RGX-202, an oral small-molecule SLC6A8 transporter inhibitor, robustly inhibits creatine import in vitro and in vivo, reduces intracellular phosphocreatine and ATP levels, and induces tumor apoptosis.\nMechanistically, intracellular creatine bolstered cell antioxidant defense by reducing mitochondrial activity and oxygen consumption rates to reduce accumulation of intracellular reactive oxygen species, ultimately activating AKT-ERK signaling, the activation of which protected the viability of hypoxic TNBC cells via mediating the upregulation of Ki-67 and Bcl-2, and the downregulation of Bax and cleaved Caspase-3.\nSLC6A8 was aberrantly upregulated in TNBC cells in hypoxia.\nWe found that SLC6A8 was transcriptionally upregulated by p65/NF-κB and mediated accumulation of intracellular creatine in hypoxia.\nOur study indicates that SLC6A8-mediated creatine accumulation plays an important role in promoting TNBC progression, and may provide a potential therapeutic strategy option for treatment of SLC6A8 high expressed TNBC.\nAfter TUNEL and KI67 immunofluorescence analyses of the intestine and detection of the expression of relevant genes at the protein and transcript levels, the results showed that dietary addition of creatine significantly alleviated intestinal apoptosis and cellular inflammatory responses due to DSS-induced enteritis.\nOxidative stress contributed toward the severe form of CDS, with increases seen in the intracellular ROS content and the percentage of apoptotic cells.\np38MAPK activation only correlated with oxidative stress in the CRTR cells.\nTogether, these findings suggest that the", "dois": ["10.1177/1533033820983029", "10.1002/humu.21421", "10.1016/j.fsi.2025.110164", "10.3390/ijms24043788", "10.1126/sciadv.abi7511", "10.1186/s13046-021-01933-7", "10.1016/j.bbagen.2019.129507", "10.3748/wjg.v19.i21.3249"]}
{"pair_type": "slc_pathway", "key1": "SLC6A6", "key2": "oxidative stress", "summary": "These cells also show reduced oxidative phosphorylation, and increased ROS levels, indicating that impaired Wnt signaling and elevated oxidative stress may contribute to the observed defects in osteogenic differentiation capacity.\nPretreatment with taurine inhibited naturally aging, chemically induced senescent and inflammatory program, oxidative stress, and defective insulin secretion in pancreatic β-cells.\nGAT2-expressing cells pretreated with hypotaurine showed resistance to HO-induced oxidative stress.\nSLC6A6 transporter was required to mediate exogenous taurine uptake, and inhibition of SLC6A6 abolished the anti-senescent effects of taurine.\nTaurine was found to promote the total superoxide dismutase (SOD) activity in the testis.\nThese results suggest that under physiological conditions, TAUT and GAT2 would be major contributors to hypotaurine transfer across the plasma membrane, and that uptake of hypotaurine via GAT2 contributes to the cellular resistance to oxidative stress.\nOverall, our present data suggest that taurine may modulate Cu/Zn SOD at the translational level and thereby may play an important role in the protection of germ cells from oxidative stress.\nMoreover, our results indicate that taurine does not affect the mRNA levels of copper-zinc (Cu/Zn) SOD or manganese SOD, but promotes the translation of Cu/Zn SOD.\nTaurine, a non-proteinogenic amino acid derived from cysteine, has demonstrated anti-aging effects in multiple cell types and tissues.\nUsing young TauT genetic loss-of-function murine models we find that TauT loss impacts MSC populations and impairs MSC osteogenic differentiation.\nImportantly, shRNA-based knockdown of SLC6A6 expression in primary human MSCs reduces osteogenic differentiation, indicating a key role of taurine uptake in human MSC function.\nTaurine has been shown to have positive effects on bone mass, which are thought to be due in part to its cytoprotective effects on osteoblasts and here we show that taurine also protects osteocytes against cell death due to reactive oxygen", "dois": ["10.1111/1753-0407.70100", "10.1016/j.bone.2020.115374", "10.1096/fj.201900914RR", "10.1248/bpb.b18-00168", "10.1007/s00726-012-1316-9", "10.1101/2025.06.24.661367"]}
{"pair_type": "slc_pathway", "key1": "SLC6A8", "key2": "glycolysis", "summary": "Importantly, we discovered that inhibiting Slc6a8 can counter these detrimental effects, offering a new strategy for treating AML by targeting metabolic pathways.\nThe upregulation of creatine synthetases Gatm and Gamt, as well as the creatine transporter Slc6a8, resulted in a marked accumulation of creatine within tumor foci.\nThis process further enhances oxidative phosphorylation and glycolysis of leukemia cells, thereby boosting ATP production to foster proliferation and infiltration.\nIn the absence of adequate creatine, IECs transition toward a stressed, glycolysis-predominant form of metabolism;\nCorrespondingly, RNA-sequencing datasets showed altered gene expression of key metabolic enzymes involved in NAD, creatine, glucose and glutamine metabolism (e.g NAMPT, SLC6A8, HK2) in Mtb-infected M2 macrophages.\nWe studied the functions of the creatine transporter solute carrier family 6 member 8 (SLC6A8, also called CRT) in intestinal epithelial cells (IECs) and mice, and we measured levels in mucosal biopsies from patients with IBD.\nIn analyses of IECs with CRT knockdown or overexpression, we found that CRT regulates intracellular creatine, barrier formation, and wound healing.\nIn an analysis of IEC cell lines and colonoids derived from CRT-knockout mice, we found that CRT regulates energy balance in IECs and thereby epithelial integrity and barrier function.\nStimulation of macrophages with Mtb lysate or lipopolysaccharide (LPS) induced a relative increase in glycolysis versus oxidative phosphorylation.", "dois": ["10.1016/j.apsb.2024.07.004", "10.1053/j.gastro.2020.05.033", "10.1038/s41598-020-62911-1"]}
{"pair_type": "slc_pathway", "key1": "SLC6A8", "key2": "migration", "summary": "In this study, we revealed that SLC6A8 knockdown significantly induced apoptosis and suppressed the migration and invasion of Hep3B and Huh-7 cells.\nMoreover, SLC6A8 overexpression promotes the proliferation, migration and invasion in NSCLC, accompanied by the activation of notch signaling pathway and the up-regulation of MMP9 and E-cadherin proteins.\nSLC6A8 promotes the malignant progression of NSCLC and activates the Notch signaling pathway.\nKnocking down SLC6A8 can inhibit the above effects on cells.\nUsing overexpression and knockdown of the gene, we analyzed the effects of SLC6A8 on the proliferation, invasion, and epithelial-mesenchymal transition (EMT) of NSCLC and also the possible molecular mechanism with Notch signaling pathway.\nThese findings depicted the vital role of SLC6A8 in the initiation and progression of human hepatocellular carcinoma.\nBoth periods involve proliferation, migration, and changes in morphology of cells that require adenosine triphosphate (ATP).\nSolute carrier family 6 member 8 (SLC6A8) is known to be involved in the development of human tumors\nBioinformatic analysis demonstrated that SLC6A8 is highly expressed in NSCLC and is related to poor prognosis.\nWe found that the expression of the SLC6A8 protein in human lung cancer tissues was significantly higher than that in adjacent tissues.\nTherefore, SLC6A8 is expected to become a molecular target for NSCLC treatment.", "dois": ["10.1093/biolre/ioae088", "10.21037/atm-20-5984", "10.1177/1533033820983029", "10.3748/wjg.v19.i21.3249"]}
{"pair_type": "slc_pathway", "key1": "SLC6A9", "key2": "apoptosis", "summary": "ALX-5407 suppressed Th1 differentiation, reducing IFN-γCD4T cells proportions (p < 0.05) and activation markers (CD25, CD69), while inducing apoptosis via caspase-3 activation and BCL-2 downregulation.\nAddition of 10 mM glycine to the culture medium (currently containing 0.1 mM) reduced the abundance of SLC6A9 transcript and increased total cell number, primarily in the trophectoderm lineage (P = 0.003);\nTransfection of myeloma cell lines with miR-7 suppressed cell proliferation, induced apoptosis, and enhanced the effects of the HDAC inhibitor panobinostat.\nGlyT1 serves as a metabolic checkpoint in Th1 differentiation, and its inhibition by ALX-5407 attenuates allograft rejection through dual suppression of Th1 function and apoptosis induction.\nKnockdown and overexpression experiments of in granulosa cells demonstrated that the number of EdU-positive cells significantly decreased in the knockdown group ( < 0.05), while the expression levels of ( < 0.05), / ( < 0.01), and ( < 0.05) were significantly upregulated, indicating that knockdown of markedly inhibited granulosa cell proliferation.\nPathway over-representation analysis suggests G-protein signaling/visual transduction, and synaptic transmission for miR-1, and transmembrane transport, cell-adhesion, signal transduction and apoptosis for miR-183/96/182 as regulated functions in retina.\nthis was likely by decreasing the percentage of apoptotic nuclei.\nPSME3 knockdown increases myeloma cell death and panobinostat sensitivity.\nComprehensive examination of miR-7 targets revealed four candidates: SLC6A9, LR", "dois": ["10.3389/fimmu.2025.1644529", "10.1007/s12185-024-03812-1", "10.3390/ani15162354", "10.1038/srep31431", "10.1002/mrd.22618"]}
{"pair_type": "slc_pathway", "key1": "SLC6A9", "key2": "chemotherapy", "summary": "RNA-sequencing analysis identified five potential vortioxetine-responsive targets in GBM cells: SCN5A, HTR1D, SLC6A9, KIF11, and ADRB2.\nGlioblastoma (GBM), the most aggressive primary brain tumor, presents significant therapeutic challenges owing to limited treatment options beyond the cornerstone chemotherapy temozolomide (TMZ) and its intrinsic chemoresistance.\nCrucially, HTR1D knockdown enhanced TMZ sensitivity in GBM cells.\nIn vivo, the TMZ-vortioxetine combination more effectively suppressed GBM proliferation than either agent alone.\nMoreover, the TMZ-vortioxetine combination demonstrated marked synergistic anti-tumor effects concomitant with HTR1D suppression.\nThis study provides convincing preclinical evidence for TMZ-vortioxetine combination therapy, proposing both a new therapeutic target and a viable strategy to circumvent TMZ resistance in GBM.\nLinkedOmics database analysis revealed the HTR1D regulation on PI3K/Akt axis, a dominant signaling pathway showing significant positive correlation with TMZ resistance.\nCollectively, these findings identify HTR1D as a novel vortioxetine target in GBM that modulates proliferation, metastasis, and TMZ resistance via PI3K/Akt signaling.\nHTR1D-overexpressing GBM cells exhibited enhanced proliferative and migratory capacities.\nVortioxetine-mediated HTR1D suppression suggests its potential role as an HTR1D inhibitor in GBM progression.\nNotably, only HTR1D overexpression correlated with poor disease-free survival in GBM patients.", "dois": ["10.1016/j.cbi.2025.111748"]}
{"pair_type": "slc_pathway", "key1": "SLC6A8", "key2": "oxidative phosphorylation", "summary": "By combining drug profiling with transcriptomics and through a whole-genome CRISPR/Cas9 screen, we demonstrate that HSPD1-targeted anti-cancer effects are dependent on oxidative phosphorylation and validated molecular determinants of KHS101 sensitivity, in particular, the creatine-transporter SLC6A8 and the subunit of the cytochrome c oxidase complex COX5B.\nHSPD1 knockdown or its chemical disruption by the small molecule KHS101 induces a drastic breakdown of oxidative phosphorylation, and suppresses cell proliferation both in vitro and in vivo.\nStimulation of macrophages with Mtb lysate or lipopolysaccharide (LPS) induced a relative increase in glycolysis versus oxidative phosphorylation.\nThis process further enhances oxidative phosphorylation and glycolysis of leukemia cells, thereby boosting ATP production to foster proliferation and infiltration.\nOur investigation revealed impaired mitochondrial oxidative phosphorylation, reduced spare respiratory capacity, elevated oxidative stress, and significant alterations in amino acid transporter activity.\nCreatine transporter deficiency (CTD) caused by mutations in SLC6A8 encoding the creatine transporter (CRT), leads to cerebral creatine deficiency syndromes\nDespite the diminished role of creatine and phosphocreatine in oxidative phosphorylation in CTD, we found no elevation of lactate or lowered pH, indicating that the brain energy supply still largely relied on oxidative metabolism.\nWe observed severe intracellular creatine deficiency (> 90% reduction), leading to impaired energy metabolism (low ATP and high ADP/ATP).", "dois": ["10.1038/s41598-025-11386-z", "10.1002/nbm.4419", "10.1016/j.apsb.2024.07.004", "10.1186/s13046-021-02049-8", "10.1038/s41598-020-62911-1", "PMID:16601897"]}
{"pair_type": "slc_pathway", "key1": "SLC6A8", "key2": "oxidative stress", "summary": "SLC6A8-mediated accumulation of creatine promoted survival and suppressed apoptosis via maintaining redox homeostasis in hypoxic TNBC cells.\nMechanistically, intracellular creatine bolstered cell antioxidant defense by reducing mitochondrial activity and oxygen consumption rates to reduce accumulation of intracellular reactive oxygen species, ultimately activating AKT-ERK signaling, the activation of which protected the viability of hypoxic TNBC cells via mediating the upregulation of Ki-67 and Bcl-2, and the downregulation of Bax and cleaved Caspase-3.\nSLC6A8-mediated intracellular creatine accumulation enhances hypoxic breast cancer cell survival via ameliorating oxidative stress.\nOur study indicates that SLC6A8-mediated creatine accumulation plays an important role in promoting TNBC progression, and may provide a potential therapeutic strategy option for treatment of SLC6A8 high expressed TNBC.\nOxidative stress contributed toward the severe form of CDS, with increases seen in the intracellular ROS content and the percentage of apoptotic cells.\nOur investigation revealed impaired mitochondrial oxidative phosphorylation, reduced spare respiratory capacity, elevated oxidative stress, and significant alterations in amino acid transporter activity.\nCr supplementation has been shown to have a beneficial effect in numerous in vitro and in vivo models, particularly in cases of oxidative stress, and is also widely used by athletes as a performance enhancement nutraceutical.\np38MAPK activation only correlated with oxidative stress in the CRTR cells.\nThey also suggest that reducing oxidative stress could be helpful in treating CDS.\nIn conclusion, dietary nitrate may have therapeutic utility against obesity and associated metabolic complications possibly by increasing adipocyte mitochondrial respiration and by dampening inflammation and oxidative stress.\nThese findings elucidate the key pathological mechanisms induced by the CRT-G561R mutation-including energy metabolic reprogramming, mitochondrial dysfunction, and cellular stress-which significantly contribute to our understanding of the pathogenesis of creatine transporter deficiency and suggest potential therapeutic targets.", "dois": ["10.1038/s41598-025-11386-z", "10.1186/s13046-021-01933-7", "10.1007/s00726-016-2206-3", "10.1177/0883073809352109", "10.1016/j.redox.2019.101387", "10.1159/000368465", "10.1002/humu.21421"]}
{"pair_type": "slc_pathway", "key1": "SLC6A8", "key2": "proliferation", "summary": "Moreover, SLC6A8 overexpression promotes the proliferation, migration and invasion in NSCLC, accompanied by the activation of notch signaling pathway and the up-regulation of MMP9 and E-cadherin proteins.\nUsing overexpression and knockdown of the gene, we analyzed the effects of SLC6A8 on the proliferation, invasion, and epithelial-mesenchymal transition (EMT) of NSCLC and also the possible molecular mechanism with Notch signaling pathway.\nIn this study, we revealed that SLC6A8 knockdown significantly induced apoptosis and suppressed the migration and invasion of Hep3B and Huh-7 cells.\nHSPD1 knockdown or its chemical disruption by the small molecule KHS101 induces a drastic breakdown of oxidative phosphorylation, and suppresses cell proliferation both in vitro and in vivo.\nSLC6A8 promotes the malignant progression of NSCLC and activates the Notch signaling pathway.\nCreatine supplementation suppresses tumor growth, enhances CD8 T cell infiltration, and sensitizes tumors to anti-programmed cell death protein 1 (PD-1) immunotherapy.\nMechanistically, VTN upregulates SLC6A8 expression in CRC cells and macrophages by enhancing FAK phosphorylation, which increases creatine and ATP uptake, promoting cancer progression and macrophage polarization.\nKnocking down SLC6A8 can inhibit the above effects on cells.\nTumor metabolic reprogramming is critical for providing energy to support proliferation and resistance to stress-induced cell death.\nThis process further enhances oxidative phosphorylation and glycolysis of leukemia cells, thereby boosting ATP production to foster proliferation and infiltration.\nComprehensive analyses, including cytometry by time -of- flight (CyTOF), in vitro co-culture assays, transgenic mouse models, and azoxymethane (AOM)/dextran sodium sulfate (DSS)-induced CRC models, demonstrate that VTN enhances CRC proliferation, metastasis, and resistance to therapy.", "dois": ["10.1016/j.celrep.2025.116139", "10.1002/advs.202505769", "10.1016/j.apsb.2024.07.004", "10.1093/biolre/ioae088", "10.3390/ijms24043788", "10.3389/fcell.2022.1007924", "10.1101/2022.06.30.498338", "10.1158/0008-5472.CAN-21-1301", "10.1186/s13046-021-02049-8", "10.21037/atm-20-5984", "10.1177/1533033820983029", "10.1002/humu.21421"]}
{"pair_type": "slc_pathway", "key1": "SLC6A13", "key2": "proliferation", "summary": "ASCL1 upregulated SLC6A13 and inhibited proliferation, migration, and invasion of HCC cells.", "dois": ["10.17305/bb.2024.10328"]}
{"pair_type": "slc_pathway", "key1": "SLC6A12", "key2": "proliferation", "summary": "Inhibiting SLC6A12 expression in PD models enhanced neuronal growth and proliferation activity while reducing cell apoptosis.\nMorusin Suppresses Pancreatic Cancer Cell Proliferation and Migration by Targeting SLC6A12 to Inhibit NF-κB and β-catenin Signaling Pathways.\nMechanistically, Morusin was found to regulate the expression of SLC6A12 and inhibit NF-κB and β- catenin signaling pathways, which may represent the underlying mechanisms of its antitumor activity.\nOur findings suggest that Morusin holds potential as an anti-pancreatic cancer agent by targeting SLC6A12 and modulating its associated signaling pathways.\nOur results demonstrated that Morusin administration significantly impaired cell proliferation, migration and invasive activity of pancreatic cancer cells.\nWe evaluated the anticancer effect of Morusin in pancreatic cancer cells, including its impact on pancreatic cancer cell proliferation, colony formation potential, migration, invasion, cell cycle and apoptosis.\nAdditionally, Morusin induced apoptosis and disrupted cell cycle progression.\nFurthermore, SLC6A12 was found to be involved in neuronal development, synaptic function, and neural protein transport processes in PD, potentially regulating the MAPK signaling pathway through the Ras/Raf/MEK/ERK axis, contributing to the pathological process of PD.\nThis study documented the pathogenicity of SLC6A12 in PD for the first time, expanding the understanding of its molecular function and providing a potential target for precise treatment of PD.", "dois": ["10.2174/0115748928376279250613051117", "10.1016/j.exger.2024.112484"]}
{"pair_type": "slc_pathway", "key1": "SLC6A9", "key2": "migration", "summary": "Interestingly, the chemical inhibition of the glycine transporter SLC6A9/Glyt1 triggers senescence features.\nMoreover, UVB-induced senescent keratinocytes secrete senescence-associated secretory phenotype factors that influence cutaneous squamous cell carcinoma cell migration.", "dois": ["10.1016/j.jid.2022.11.017"]}
{"pair_type": "slc_pathway", "key1": "SLC6A14", "key2": "chemotherapy", "summary": "Inhibition of SLC6A14 reduces stemness, impairs tumor growth, and sensitizes tumors to chemotherapy.\nHere, we developed an amino acid transporter-targeted nanoplatform (F/C@Trp-NPs) co-loaded with 5-FU and Cpt to target the SLC6A14 (ATB) transporter, which is abnormally upregulated in gastric cancer cells, and evaluated its anticancer effects.\nHerein, in this study, we designed oxaliplatin/berbamine-coloaded, ATB-targeted nanoparticles ((O + B)@Trp-NPs) to therapeutically target SLC6A14 (ATB) and inhibit cancer proliferation.\nThe (O + B)@Trp-NPs utilize the surface-modified tryptophan to achieve SLC6A14-targeted delivery of Berbamine (BBM), a compound that is found in a number of plants used in traditional Chinese medicine, which could suppress autolysosome formation though impairing autophagosome-lysosome fusion.\nImportantly, cancer cells-especially drug-resistant cells-often upregulate amino acid transporters to import indispensable nutrients that support rapid proliferation, and therefore these transporters could guide the target delivery of chemotherapeutics for enhanced delivery efficiency.\nSLC6A14 (ATB) is an essential amino acid transporter, that is often abnormally up-regulated in most cancer cells.\nThe F/C@Trp-NPs significantly inhibited gastric cancer cell proliferation in vitro, consistent with the in vivo results.\nIn vivo, (O + B)@Trp-NPs greatly suppressed the tumor growth in tumor-bearing mice, which is consistent with the in vitro data.\nThe (O + B)@Trp-NPs significantly inhibited the proliferation and decreased the drug resistance of resistant colorectal cancer cells.\nAs a self-protection mechanism, autophagy may contribute to tumor drug resistance, therefore autophagy suppression could be regarded as a possible treatment option in chemotherapy.\nOxaliplatin (OXA) resistance remains the major obstacle to the successful chemotherapy of colorectal cancer (CRC).", "dois": ["10.1002/advs.202510811", "10.1016/j.colsurfb.2025.114918", "10.1016/j.ijpharm.2023.123082", "10.1042/BCJ20200275", "10.1042/BJ20080622"]}
{"pair_type": "slc_pathway", "key1": "SLC6A9", "key2": "proliferation", "summary": "Inhibiting glycine utilization via SLC6A9 knockdown or the treatment with betaine suppresses MM cell proliferation and enhances the effects of bortezomib on MM cells.\nKnockdown and overexpression experiments of in granulosa cells demonstrated that the number of EdU-positive cells significantly decreased in the knockdown group ( < 0.05), while the expression levels of ( < 0.05), / ( < 0.01), and ( < 0.05) were significantly upregulated, indicating that knockdown of markedly inhibited granulosa cell proliferation.\nIn contrast, overexpression of significantly promoted cell proliferation.\nMM cells utilize the channel protein solute carrier family 6 member 9 (SLC6A9) to absorb extrinsic glycine subsequently involved in the synthesis of glutathione (GSH) and purines.\nHere, we show that the glycine concentration in the BM microenvironment is elevated due to bone collagen degradation mediated by MM cell-secreted matrix metallopeptidase 13 (MMP13), while the elevated glycine level is linked to MM progression.\nTogether, we identify glycine as a key metabolic regulator of MM, unveil molecular mechanisms governing MM progression, and provide a promising therapeutic strategy for MM treatment.\nKEGG enrichment analysis showed that was significantly enriched in the glycine, serine and threonine metabolism and vitamin B6 metabolism pathways.\nNormal proliferation of ovarian granulosa cells is essential for follicular development.", "dois": ["10.1016/j.cbi.2025.111748", "10.3390/ani15162354", "10.1007/s12185-024-03812-1", "10.1038/s41467-022-31248-w"]}
{"pair_type": "slc_pathway", "key1": "SLC6A15", "key2": "apoptosis", "summary": "Further validation demonstrated that SLC6A15 was lowly expressed in keloid tissues and fibroblasts, and SLC6A15 overexpression inhibited proliferation and facilitated apoptosis in keloid fibroblasts.\nWe show that cysteine limitation and deprivation cause apoptotic cell death (cytotoxic effect) in both normal and K-ras-transformed fibroblasts, due to accumulation of reactive oxygen species and a decrease in reduced glutathione.\nAnti-oxidants glutathione and MitoTEMPO inhibit apoptosis, but only cysteine-containing glutathione partially rescues the cell growth defect induced by limiting cysteine.\nThe results demonstrated that downregulation of ROBO2 or PRKG2 significantly increased the expression levels of FSHR mRNA and protein with the boosted expression of CCND1, STAR, and BCL-2, whereas remarkably inhibited the expression of Caspase-3, consequently, brought about the decrease of GC apoptosis in the ovarian follicles, but increase of GC proliferation and differentiation serving as the hallmarks for follicle selection.\nThis fragility correlates with decreased expression of the Slc6a15 gene-encoding the nutrient transporter SBAT1, known to exhibit a strong preference for methionine-and decreased methionine uptake.\nMethionine limitation and deprivation has a cytostatic effect on mouse fibroblasts, unaffected by glutathione.\nK-ras-transformed cells-but not their parental NIH3T3-are extremely sensitive to methionine limitation.", "dois": ["10.1007/s10528-025-11215-y", "10.1093/jas/skad241", "10.1371/journal.pone.0163790"]}
{"pair_type": "slc_pathway", "key1": "SLC6A15", "key2": "migration", "summary": "SLC6A15 acts as a tumor suppressor to inhibit migration and invasion in human papillary thyroid cancer.\nEctopic overexpression of SLC6A15 impaired migratory and invasive abilities of PTC cell in vitro.\nThese results indicate that SLC6A15 acts as a tumor suppressor and might be a potential therapeutic target in the treatment of PTC.\nDGUOK-AS1 promotes malignant behaviors of LUSC cells by upregulating SLC6A15 level through interaction with miR-653-5p.\nDGUOK-AS1 knockdown suppressed LUSC cell proliferation, migration, and invasion.\nOverexpression of SLC6A15 reversed the suppressive effects of DGUOK-AS1 knockdown on LUSC cell processes.", "dois": ["10.1007/s12033-024-01088-8", "10.1002/jcb.29914"]}
{"pair_type": "slc_pathway", "key1": "SLC6A9", "key2": "oxidative phosphorylation", "summary": "DEGs were significantly enriched in pathways involving E2F targets, cholesterol homeostasis, and oxidative phosphorylation.", "dois": ["10.1101/2024.11.12.24317218"]}
{"pair_type": "slc_pathway", "key1": "SLC6A15", "key2": "proliferation", "summary": "SLC6A15 was lowly expressed in keloid tissues and fibroblasts, and SLC6A15 overexpression inhibited proliferation and facilitated apoptosis in keloid fibroblasts.\nDGUOK-AS1 promotes malignant behaviors of LUSC cells by upregulating SLC6A15 level through interaction with miR-653-5p.\nDGUOK-AS1 knockdown suppressed LUSC cell proliferation, migration, and invasion.\nOverexpression of SLC6A15 reversed the suppressive effects of DGUOK-AS1 knockdown on LUSC cell processes.\nCancer cells have an increased demand for amino acids and require transport even of non-essential amino acids to support their increased proliferation rate.\nThe selected follicles with a higher expression level of follicle-stimulating hormone receptor (FSHR) mRNA that facilitates response to FSH, and rapidly develops into preovulatory follicles with distinctive characteristics of granulosa cells (GCs) proliferation and differentiation.\ndownregulation of ROBO2 or PRKG2 significantly increased the expression levels of FSHR mRNA and protein with the boosted expression of CCND1, STAR, and BCL-2, whereas remarkably inhibited the expression of Caspase-3, consequently, brought about the decrease of GC apoptosis in the ovarian follicles, but increase of GC proliferation and differentiation serving as the hallmarks for follicle selection.\ncysteine limitation and deprivation cause apoptotic cell death (cytotoxic effect) in both normal and K-ras-transformed fibroblasts, due to accumulation of reactive oxygen species and a decrease in reduced glutathione.\nAnti-oxidants glutathione and MitoTEMPO inhibit apoptosis, but only cysteine-containing glutathione partially rescues the cell growth defect induced by limiting cysteine.\nK-ras-transformed cells-but not their parental NIH3T3-are extremely sensitive to methionine limitation.\nMethionine limitation and deprivation has a cytostatic effect on mouse fibroblasts, unaffected by glutathione.", "dois": ["10.1007/s10528-025-11215-y", "10.1007/s12033-024-01088-8", "10.1093/jas/skad241", "10.1371/journal.pone.0163790"]}
{"pair_type": "slc_pathway", "key1": "SLC6A17", "key2": "migration", "summary": "The results showed both SLC6A7 and SLC6A17 from amino acid transporters AA1 and AA2 sub-families, respectively, significantly suppressed the cell proliferation and migration.\nOur experimental data demonstrated that Ciona amino acid transporters, such as SLC6A7 and SLC6A17, were essential for cell physiology and behaviors, indicating their crucially potential roles in the control of cell proliferation and migration during ascidian embryogenesis.", "dois": ["10.3390/ani13050902", "10.1016/j.gene.2019.04.056"]}
{"pair_type": "slc_pathway", "key1": "SLC6A17", "key2": "proliferation", "summary": "The results showed both SLC6A7 and SLC6A17 from amino acid transporters AA1 and AA2 sub-families, respectively, significantly suppressed the cell proliferation and migration.\nOur experimental data demonstrated that Ciona amino acid transporters, such as SLC6A7 and SLC6A17, were essential for cell physiology and behaviors, indicating their crucially potential roles in the control of cell proliferation and migration during ascidian embryogenesis.", "dois": ["10.1016/j.gene.2019.04.056"]}
{"pair_type": "slc_pathway", "key1": "SLC6A14", "key2": "oxidative phosphorylation", "summary": "DEHP upregulates the glutamine transporter SLC6A14 to enhance glutamine uptake, while suppressing mitochondrial fission factor (MFF), which exacerbates mitochondrial fusion.\nMechanistically, DEHP exposure promotes tumor initiation by enhancing cancer stemness through mitochondrial fusion and glutamine-driven oxidative phosphorylation.\nInhibition of SLC6A14 reduces stemness, impairs tumor growth, and sensitizes tumors to chemotherapy.\nHigh SLC6A14 expression correlates with cancer stemness signatures and earlier onset in patient cohorts.", "dois": ["10.1002/advs.202510811"]}
{"pair_type": "slc_pathway", "key1": "SLC6A15", "key2": "oxidative stress", "summary": "This fragility correlates with decreased expression of the Slc6a15 gene-encoding the nutrient transporter SBAT1, known to exhibit a strong preference for methionine-and decreased methionine uptake.\nIndividuals with the TXNRD2 rs5748469 AA genotype had higher blood and plasma Hg concentrations, while SLC6A15 rs11116642 CT carriers had lower Hg levels and increased glutathione peroxidase (GPX) activity.\nWe show that cysteine limitation and deprivation cause apoptotic cell death (cytotoxic effect) in both normal and K-ras-transformed fibroblasts, due to accumulation of reactive oxygen species and a decrease in reduced glutathione.\nChronic exposure to environmental-like stress leads to dysregulation of hypothalamic-pituitary-adrenal (HPA) axis and to appearance of oxidative stress, which is implicated in the development of depression-like behaviour.\nGrowth defects induced by cysteine limitation in mouse fibroblasts are largely-though not exclusively-due to cysteine utilization in the synthesis of glutathione, mouse fibroblasts requiring an exogenous cysteine source for protein synthesis.\nthe specific mechanisms underlying the potential role of genetic diversity in PD depression are still under investigation, however, there is evidence that they may involve neurotransmitter imbalance, mitochondrial impairment, oxidative stress, and neuroinflammation, as well as the dysregulation of neurotrophic factors and their downstream signaling pathways.\nStatistical analyses revealed significant genetic associations with Hg levels and oxidative stress markers.\nA possible role in Fkbp5, Comt, Adora1 and Slc6a15 genes' expression in mediating this effect is postulated.\nThe heat shock response and the oxidative stress response were also identified as transcriptome responses that showed significant changes upon 3D growth.\nThis study examined the impact of genetic polymorphisms on Hg exposure levels and oxidative stress biomarkers in 329 individuals from riverside communities in the Brazilian Amazon.\nCysteine is a precursor for the biosynthesis of glutathione, the major scavenger for reactive oxygen species.", "dois": ["10.1016/j.chemosphere.2025.144646", "10.3390/medicina59061138", "10.1016/j.taap.2019.114689", "10.1371/journal.pone.0182930", "10.1371/journal.pone.0163790"]}
{"pair_type": "slc_pathway", "key1": "SLC6A14", "key2": "glycolysis", "summary": "Hypoxia-induced PYCR1 enhances glycolysis, leading to increased lactate production and elevated H3K18la levels, which upregulates SLC6A14 transcription and glutamine catabolism, thereby promoting BC growth and metastasis.\nUpregulated SLC6A14 expression promoted glutamine catabolism and enhanced BC cell proliferation, migration, and invasion.\nPYCR1 knockdown inhibited H3K18la levels, SLC6A14 expression, and BC cell aggressiveness\nHypoxia induced PYCR1 expression in BC cells, enhancing glycolysis and lactate production, which increased H3K18la levels.\nexperiments confirmed that the PYCR1/H3K18la/SLC6A14 axis is critical for hypoxia-driven BC growth and metastasis.\nThis study investigated how PYCR1 promotes BC progression through glycolysis, histone H3 Lysine 18 Lactylation (H3K18la), and Solute Carrier Family 6 Member 14 (SLC6A14)-driven glutamine catabolism.", "dois": ["10.1080/15384047.2025.2546219"]}
{"pair_type": "slc_pathway", "key1": "SLC6A11", "key2": "oxidative stress", "summary": "GAT2-expressing cells pretreated with hypotaurine showed resistance to HO-induced oxidative stress.\nSuch behavioral change was related, at molecular level, to an enhanced expression of sod1, cat, and gpxa, suggesting an overproduction of pro-oxidant molecules.\nThese results suggest that under physiological conditions, TAUT and GAT2 would be major contributors to hypotaurine transfer across the plasma membrane, and that uptake of hypotaurine via GAT2 contributes to the cellular resistance to oxidative stress.\nIn addition, FLX modulated the expression of oxtl, slc6a4a, slc6a4b, and slc6a11, suggesting its capability to affect anxiety- and neurotransmitter-related genes.", "dois": ["10.1007/s11356-019-06619-4", "10.1248/bpb.b18-00168"]}
{"pair_type": "slc_pathway", "key1": "SLC6A14", "key2": "ferroptosis", "summary": "Collectively, these findings indicate that SLC6A14 facilitates ferroptosis in UC by promoting C/EBPβ expression and binding activity to inhibit PAK6 expression, suggesting that targeting SLC6A14-C/EBPβ-PAK6 axis-mediated ferroptosis may be a promising therapeutic alternative for UC.\nRNA sequencing revealed that SLC6A14 inhibited the expression of P21 (RAC1)-activated kinase 6 (PAK6) and that PAK6 knockdown abolished the effects of SLC6A14 on RAS-selective lethal 3 (RSL3)-induced ferroptosis in Caco-2 cells.\nMoreover, a series of in vitro and in vivo experiments showed that SLC6A14 knockdown markedly suppressed ferroptosis.\nIn this study, we aimed to explore the roles of solute carrier (SLC) family 6 member 14 (SLC6A14) in regulating ferroptosis in UC.\nFurthermore, chromatin immunoprecipitation (ChIP) and Western blot analysis demonstrated that SLC6A14 negatively regulated PAK6 expression in a CCAAT enhancer binding protein beta (C/EBPβ)-dependent manner.\nThe expression of SLC6A14 was significantly increased and positively associated with that of prostaglandin-endoperoxide synthase 2 (PTGS2) in tissue samples from patients with UC.\nSubsequently, intracellular high concentration of GSH and extracellular spatio-temporal controlled US irradiation programmatically triggered the release of α-MT, which enabled the synergistically amplified SDT by inducing amino acid starvation, inhibiting mTOR, and mediating ferroptosis.\nFerroptosis is a unique mode of regulated cell death characterized by iron accumulation and lipid peroxidation, and its induction by aberrant STAT3 signaling may contribute to chemotherapy resistance.\nEmerging evidence suggests that ferroptosis is involved in the pathogenesis of ulcerative colitis (UC).", "dois": ["10.1016/j.colsurfb.2025.114918", "10.1097/SHK.0000000000002587", "10.1007/s00018-022-04594-7", "10.1016/j.bioactmat.2022.11.020"]}
{"pair_type": "slc_pathway", "key1": "SLC6A15", "key2": "chemotherapy", "summary": "Four additional genes were significantly downregulated: SLC2A14, SLC6A15, SLC8A1 and SLC27A2.\nIn results of MDR development during chemotherapy cancer cells become resistant to further treatment.\nABC and SLC transporters are most important proteins responsible for this phenomenon.\nIn this study changes of ABC and SLC genes expression pattern in drugs resistant sublines of the A2780 ovarian cancer cell line were demonstrated.\nExpression profiles of these genes give strong arguments for assumption of correlation between expression of ABC and SLC genes and drug resistance phenomenon.", "dois": ["10.1016/j.biopha.2014.02.002"]}
{"pair_type": "slc_pathway", "key1": "SLC6A12", "key2": "oxidative stress", "summary": "GAT2-expressing cells pretreated with hypotaurine showed resistance to HO-induced oxidative stress.\nThese results suggest that under physiological conditions, TAUT and GAT2 would be major contributors to hypotaurine transfer across the plasma membrane, and that uptake of hypotaurine via GAT2 contributes to the cellular resistance to oxidative stress.\nOur in vitro model functionally recapitulated mitochondrial dysfunction and oxidative stress.\nCrucially, a cross-model analysis revealed a core signature of seven genes (including APOE, CDKN1A, and CLOCK) consistently dysregulated in both the cognitively impaired mouse brain and in neuronal cells subjected to direct oxidative insult.\nSubsequent validation was performed using a two-tiered approach: an in vivo AD mouse model to establish phenotypic relevance and an in vitro HO-induced oxidative stress model in HT22 cells to provide direct mechanistic validation.\nOur computational analyses identified key biomarkers such as hsa-miR-129-5p and SLC6A12 as pivotal regulators and highlighted the importance of the tricarboxylic acid (TCA) cycle.", "dois": ["10.1111/cns.70634", "10.1248/bpb.b18-00168"]}
{"pair_type": "slc_pathway", "key1": "SLC6A20", "key2": "proliferation", "summary": "Finally, the proliferation and invasion of PRCC cell line were decreased in the reduced group, and the differential expression was identified.\nis a risk factor, and co-expression factors were enriched in cell proliferation and cancer-related pathways.\nis a potential risk biomarker which involved in cell proliferation in PRCC.\nGene expression of luminal imino and amino acid transporter SIT1 (SLC6A20) was approximately threefold lower in newborns versus adults.\nSubsequently, using the PRCC cell line, the role of TPX2 was determined by Cell proliferation assay, 5-Ethynyl-20-deoxyuridine assay and Transwell assay.\nThe co-expression genes of factors were enriched and displayed the biological process.", "dois": ["10.18632/aging.104001", "10.1152/ajpgi.00318.2017"]}
{"pair_type": "slc_pathway", "key1": "SLC6A12", "key2": "apoptosis", "summary": "Inhibiting SLC6A12 expression in PD models enhanced neuronal growth and proliferation activity while reducing cell apoptosis.\nSimilarly, in primary hepatocytes, BGT-1 deficiency or treatment with a BGT-1 inhibitor, NNC 05-2090, attenuated TNF-α mediated apoptosis.\nAdditionally, Morusin induced apoptosis and disrupted cell cycle progression.\nFurthermore, mice deficient in BGT-1 showed significant resistance to ALF compared with wild type (WT) mice, manifesting as improved survival rate, reduced alanine transaminase/aspartate aminotransferase levels, better histopathological symptoms and fewer apoptotic cells in the liver.\nOur findings suggest BGT-1 is a promising candidate drug target to prevent and treat hepatocyte apoptosis related diseases, such as ALF.\nIn addition, BGT-1 deficiency or dosing with NNC 05-2090 stimulated the expression of the anti-apoptotic gene, c-Met in the liver, suggesting the involvement of c-Met in the function on hepatocytes of BGT-1 apoptosis.\nWe evaluated the anticancer effect of Morusin in pancreatic cancer cells, including its impact on pancreatic cancer cell proliferation, colony formation potential, migration, invasion, cell cycle and apoptosis.\nSubsequent experiments reveal that Slc6a12 inhibitors and SGK1 silencing inhibit sodium-induced activation of macrophage pyroptosis and the p38 MAPK/NF-κB signaling pathway, whereas overexpression of the SGK1 gene counteracts the effect of sodium on macrophages.\nMacrophage pyroptosis, a pro-inflammatory form of cell death, plays a pivotal role in RA.\nIn our experiments, pretreatment with NaCl enhances LPS-induced pyroptosis in RAW.264.7 and THP-1 cells through the p38 MAPK/NF-κB signaling pathway.\nIn conclusion, our findings verified that high salt intake promotes the progression of RA and provided a detailed elucidation of the activation of macrophage pyroptosis induced by sodium transportation through the Slc", "dois": ["10.7150/ijbs.93242", "10.1016/j.exger.2024.112484", "10.1016/j.bbadis.2019.165634", "10.2174/0115748928376279250613051117"]}
{"pair_type": "slc_pathway", "key1": "SLC7A1", "key2": "oxidative phosphorylation", "summary": "Here, we show that SLC7A1/cationic amino acid transporter 1-dependent arginine uptake and its catabolism to the polyamine spermidine control human erythroid specification of HSPCs via the activation of the eukaryotic translation initiation factor 5A (eIF5A).\nProteomic profiling reveals mitochondrial translation to be a critical target of hypusinated eIF5A, and accordingly, progenitors with decreased hypusine activity exhibit diminished oxidative phosphorylation.\nThis affected pathway is critical for eIF5A-regulated erythropoiesis, as interventions augmenting mitochondrial function partially rescue human erythropoiesis under conditions of attenuated hypusination.\neIF5A activity is dependent on its hypusination, a posttranslational modification resulting from the conjugation of the aminobutyl moiety of spermidine to lysine.\nLevels of mitochondrial ribosomal proteins (RPs) were especially sensitive to the loss of hypusine, and we find that the ineffective erythropoiesis linked to haploinsufficiency of RPS14 in chromosome 5q deletions in myelodysplastic syndrome is associated with a diminished pool of hypusinated eIF5A.\nMoreover, patients with RPL11-haploinsufficient Diamond-Blackfan anemia as well as CD34+ progenitors with downregulated RPL11 exhibit a markedly decreased hypusination in erythroid progenitors, concomitant with a loss of mitochondrial metabolism.\nThus, eIF5A-dependent protein synthesis regulates human erythropoiesis, and our data reveal a novel role for RPs in controlling eIF5A hypusination in HSPCs, synchronizing mitochondrial metabolism with erythroid differentiation.", "dois": ["10.1182/blood.2022017584", "10.1186/s12864-021-07430-7"]}
{"pair_type": "slc_pathway", "key1": "SLC7A1", "key2": "migration", "summary": "Our previous studies have shown that upregulation of SLC7A1 in epithelial ovarian cancer (EOC) tumor cells significantly increases cancer cell proliferation, migration, and cisplatin resistance;\nTranswell assay, scratch assay, cck8 assay and cell adhesion assay showed that SLC7A1 highly expressed in CAFs promoted tumor cells invasion, migration and metastasis in vitro.\nSLC7A1 is involved in the transport of phenylalanine and arginine in EOC cells, and its knockdown reduced the proliferation and migration of EOC cells and the resistance of cells to cisplatin.\nIn general, in HGSOC, CAFs overexpressing SLC7A1 supported the migration and invasion of tumor cells;\nCell survival, migration, and invasion experiments found that hsa_circ_0032462 and SLC7A promoted OS, while miR-488-3p inhibited OS.\nTherefore, we concluded that SLC7A1 is involved in the metabolic remodelling of amino acids in EOC to promote tumor development and cisplatin resistance and is related to the tumor-infiltrating immune microenvironment of OC.\nMicroarray and PCR analyses have revealed that mRNA transcribed from CAT1 is overexpressed in more than 70% of human CRC samples, and RNA interference-mediated knockdown of CAT1 inhibited the cell growth of CRCs.\nOverexpression of SLC7A1 in OC is involved in MAPK/ ERK pathway and EMT.\nThis suggests that SLC7A1 may be a potential therapeutic target for OC metastasis.\nSLC7A1 is a biomarker for predicting EOC progression and cisplatin resistance and represents a promising target for EOC treatment.\nWe performed in vitro experiments to identify the expression and biological function of SLC7A1 in epithelial ovarian cancer (EOC) tissues and cells.\nAnti-CAT1 mAbs exhibited internalization activity, antibody-dependent cellular cytotoxicity, and migration inhibition activity against CRC cell lines.\nCell immunofluorescence indicated that SLC7A1 overexpression may affect the distribution of immune-infiltrating", "dois": ["10.3892/mmr.2025.13600", "10.1016/j.bone.2024.117333", "10.1002/cam4.7217", "10.1155/2022/5864826", "10.1111/cas.14741", "10.1016/j.reprotox.2020.07.008", "10.1016/j.wneu.2019.12.182", "10.1093/biolre/ioy085", "10.1007/s00726-016-2216-1", "10.1042/BSR20140140", "PMID:22738901"]}
{"pair_type": "slc_pathway", "key1": "SLC6A19", "key2": "apoptosis", "summary": "In conclusion, ATP1A2, MT1M, SLC6A19 and TRPV6 may be contributing to absorption of metals in PM thereby inducing apoptosis mediated by ROS.\nConversely, overexpressing TRPV6 exacerbated cell apoptosis caused by PM, while a reactive oxygen species (ROS) inhibitor N-acetyl-l-cysteine (NAC) alleviated PM-induced apoptosis.\nDownregulating these genes increased cell viability and attenuated apoptosis in cells exposed to PM.\nResults revealed that four key genes, namely ATPase Na+/K+ transporting subunit alpha 2 (ATP1A2), metallothionein 1M (MT1M), solute carrier family 6 members 19 (SLC6A19) and transient receptor potential cation channel subfamily V member 6 (TRPV6) were associated with PM toxicity, mainly in regulating the mineral absorption pathway.", "dois": ["10.3389/fbioe.2021.669434", "PMID:17127344"]}
{"pair_type": "slc_pathway", "key1": "SLC6A19", "key2": "proliferation", "summary": "Overexpression of SLC6A19 significantly inhibits RCC cell proliferation, migration and invasion both in vitro and in vivo.\nCCK-8, wound healing, and Transwell assays showed that SLC6A19 overexpression suppressed CRC cell proliferation, migration, and invasion.\nLower expression of MMRN1 and higher expression of SLC6A19 significantly promoted the proliferation and metastasis of colorectal cancer cells.\nExperimental results indicated that SLC6A19 could inhibit invasion and proliferation of ccRCC cells and GSEA pinpointed that SLC6A19 was intimately correlated with fatty acid metabolism and CPT1A.\nSLC6A19 overexpression significantly reduced CRC xenograft tumor growth.\nIn this study, we identified SLC6A19, a tryptophan transporter, as a novel suppressor gene of RCC, which is closely correlated with the metastasis and survival of RCC patients.\nMechanistically, SLC6A19 actively transports tryptophan into cells, facilitating de novo NAD biosynthesis, which in turn activates the NAD-dependent deacetylase SIRT1.\nThis activation drives the deacetylation of histone H3 at lysine 27 (H3K27), thereby restraining the transcription of NF-κB subunit p65, and effectively suppressing the epithelial-mesenchymal transition (EMT) of RCC cells.\nCell proliferation depends on the availability of amino acids.\nJAK2 (Janus kinase-2) is expressed in a wide variety of cells including tumor cells and contributes to the proliferation and survival of those cells.\nJAK2 up-regulates SLC6A19 activity which may foster amino acid uptake into JAK2 expressing cells.\nConcentrative cellular amino acid uptake is in part accomplished by Na(+) coupled amino acid transport through SLC6A19 (B(0)AT).\nIn SLC6A19-expressing oocytes but not in oocytes injected with water or JAK2 alone, the addition of leucine (2mM) to the bath generated a current (I(", "dois": ["10.1038/s41389-025-00580-3", "10.3389/fimmu.2025.1649788", "10.1038/s41598-025-10354-x", "10.1038/s41598-025-91319-y", "10.3389/fendo.2025.1521940", "10.3389/fcell.2022.1007924", "10.1039/d0fo03097j", "10.1152/ajpgi.00318.2017", "10.3945/jn.114.209817", "10.1016/j.bbrc.2011.09.074"]}
{"pair_type": "slc_pathway", "key1": "SLC6A14", "key2": "stemness", "summary": "Inhibition of SLC6A14 reduces stemness, impairs tumor growth, and sensitizes tumors to chemotherapy.\nHigh SLC6A14 expression correlates with cancer stemness signatures and earlier onset in patient cohorts.\nMechanistically, DEHP exposure promotes tumor initiation by enhancing cancer stemness through mitochondrial fusion and glutamine-driven oxidative phosphorylation.\nDEHP upregulates the glutamine transporter SLC6A14 to enhance glutamine uptake, while suppressing mitochondrial fission factor (MFF), which exacerbates mitochondrial fusion.\nCollectively, the findings uncover a novel environmental-metabolic axis linking plasticizer exposure to EOBC and establish SLC6A14 as a promising metabolic vulnerability.\nThese results provide a strong preclinical rationale for targeting SLC6A14 in young breast cancer patients and offer new insights into mitigating the oncogenic impact of environmental pollutants.", "dois": ["10.1002/advs.202510811"]}
{"pair_type": "slc_pathway", "key1": "SLC6A13", "key2": "migration", "summary": "ASCL1 upregulated SLC6A13 and inhibited proliferation, migration, and invasion of HCC cells.\nFurthermore, cell experiments showed the mRNA expressions of and were both reduced in HCC, and their overexpressions suppressed the growth, invasion, and migration of HCC cells.", "dois": ["10.17305/bb.2024.10328", "10.1155/2023/3560340"]}
{"pair_type": "slc_pathway", "key1": "SLC7A1", "key2": "glycolysis", "summary": "HS elevated the concentrations of serum amino acids and mRNA levels of ubiquitination-related genes (MuRF1 and MAFbx) in the skeletal muscle and amino acid transporter-related genes (SLC1A1 and SLC7A1) and gluconeogenesis-related genes (PCK1 and PCase) in the liver compared to the PF group.\nSerum metabolomics results revealed that heat-stressed ducks showed enhanced glycolysis and pentose phosphate pathways, as demonstrated by higher glucose 6-phosphate and 6-phogluconic acid levels in the PF vs.", "dois": ["10.1016/j.scitotenv.2023.169382", "10.1071/RD14293"]}
{"pair_type": "slc_pathway", "key1": "SLC6A12", "key2": "migration", "summary": "Overexpression of SLC6A12 led to increased migration and invasion of ovarian carcinoma cells in vitro, approximately 2.0-fold and 3.3-fold, respectively.\nSLC6A12 expression was 8.1-14.0-fold upregulated and its DNA methylation of promoter CpG sites was 41-62% decreased in tumor metastases.\nOur findings provide novel evidence for the biological and clinical significance of SLC6A12 as a metastasis-promoting gene.\nWe aimed to evaluate the expression of solute carrier family 6, member 12 (SLC6A12) and methylation of its promoter CpG sites in a xenograft mouse model of metastatic OC, and to investigate the regulatory mechanisms that promote aggressive properties during OC progression.\nMechanistically, Morusin was found to regulate the expression of SLC6A12 and inhibit NF-κB and β- catenin signaling pathways, which may represent the underlying mechanisms of its antitumor activity.\nOur results demonstrated that Morusin administration significantly impaired cell proliferation, migration and invasive activity of pancreatic cancer cells.\nOur findings suggest that Morusin holds potential as an anti-pancreatic cancer agent by targeting SLC6A12 and modulating its associated signaling pathways.\nThe meta-analysis showed that high expression of SLC6A12 was significantly associated with poor overall survival [hazard ratio (HR)=1.07, p value=0.016] and that low DNA methylation levels of SLC6A12 at specific promoter CpG site negatively affected patient survival.", "dois": ["10.2174/0115748928376279250613051117", "10.3349/ymj.2017.58.1.27"]}
{"pair_type": "slc_pathway", "key1": "SLC7A1", "key2": "ferroptosis", "summary": "Knockdown of HIF1α and YTHDF1 downregulated SLC7A1 expression and promoted Erastin-induced ferroptosis in hypoxic CaCx cells.\nHIF1α regulates the expression of YTHDF1, thereby enhancing the m6A modification level of SLC7A1, promoting its expression, and ultimately inhibiting Erastin-induced ferroptosis in CaCx cells.\nErastin repressed cell growth and induced ferroptosis in CaCx cells, while hypoxia pretreatment partly reversed the Erastin-induced cytotoxicity and ferroptosis in CaCx cells.\nAdditionally, HIF1α regulated YTHDF1 expression, leading to increased m6A methylation and activation of SLC7A1.\nRipa-56 exhibited a significant reduction in the levels of RIP-1, p-MLKL, Caspase-3, and BAX induced by glutamate, while promoting the expression of Bcl-2, Gpx-4, and SLC7A1 in the Ripa-56-treated group.\nFirst, treatment with the ferroptosis inhibitor ferrostatin-1(Fer-1) significantly alleviated ferroptosis in SAP.\nMoreover, 3-methyladenine (3-MA) inhibition of autophagy can significantly reduce iron overload and ferroptosis in SAP.\nInterestingly, autophagy occurs during the pathogenesis of SAP, and autophagy promotes the occurrence of ferroptosis in SAP.\nOur study found that ferroptosis occurs during the development of SAP, such as iron and lipid peroxidation in pancreatic tissues, decreased levels of reduced glutathione peroxidase 4 (GPX 4) and glutathione (GSH), and increased malondialdehyde(MDA) and significant mitochondrial damage.\nIn this study, we have observed that Ripa-56 possesses remarkable anti- necroptotic, anti-apoptotic and anti-ferroptosis properties.\nNotably, α-DIPA robustly suppressed LPS-induced mRNA expression of abundant genes participating in the ferroptosis pathway, including Ac", "dois": ["10.1002/jgm.70027", "10.1186/s12967-025-06296-7", "10.1186/s12876-024-03345-1", "PMID:38186000", "10.1016/j.arcmed.2022.12.003", "10.1038/s41598-024-54075-z", "10.2147/JIR.S393646"]}
{"pair_type": "slc_pathway", "key1": "SLC6A19", "key2": "migration", "summary": "Overexpression of SLC6A19 significantly inhibits RCC cell proliferation, migration and invasion both in vitro and in vivo.\nCCK-8, wound healing, and Transwell assays showed that SLC6A19 overexpression suppressed CRC cell proliferation, migration, and invasion.\nThis activation drives the deacetylation of histone H3 at lysine 27 (H3K27), thereby restraining the transcription of NF-κB subunit p65, and effectively suppressing the epithelial-mesenchymal transition (EMT) of RCC cells.\nMechanistically, SLC6A19 actively transports tryptophan into cells, facilitating de novo NAD biosynthesis, which in turn activates the NAD-dependent deacetylase SIRT1.\nIn this study, we identified SLC6A19, a tryptophan transporter, as a novel suppressor gene of RCC, which is closely correlated with the metastasis and survival of RCC patients.\nSLC6A19 was downregulated in TCGA-COAD, -READ, and -COADREAD and confirmed by immunoblotting, correlating with poor survival and CD4 T cell infiltration.\nSLC6A19 overexpression significantly reduced CRC xenograft tumor growth.\nIn conclusion, this study uncovers a novel key pathway that drives RCC invasion and metastasis, offering a promising therapeutic target for clinical intervention.\nOmega-3-related methylation-intersecting SLC6A19 potentially mediates omega-3-CD4 T cells-driven CRC risk, suggesting a candidate inhibitory target.", "dois": ["10.1038/s41389-025-00580-3", "10.3389/fimmu.2025.1649788"]}
{"pair_type": "slc_pathway", "key1": "SLC6A14", "key2": "proliferation", "summary": "Reducing SLC6A14 increased cell proliferation and suppressed apoptosis.\nA pharmacological blocker of SLC6A14, α-methyltryptophan, induced amino acid starvation in pancreatic cancer cells and reduced the growth and proliferation of these cells, both in vitro and in vivo.\nLastly, lysine can promote cell proliferation and the synthesis of β-casein through SLC6A14 in BMECs.\nUpregulated SLC6A14 expression promoted glutamine catabolism and enhanced BC cell proliferation, migration, and invasion.\nThe above results indicate that lysine promotes cell proliferation and the synthesis of β-casein through the SLC6A14-ERK-CDK1-mTOR signaling pathway in BMECs.\nFunctionally, we confirmed that SLC6A14 was highly expressed in PC and its knockdown suppressed the proliferation, migration, invasion and EMT signal via regulating Wnt/β-catenin signaling pathway.\nThe salient features of this study are that SLC6A14 is markedly up-regulated in pancreatic cancer and that pharmacological blockade of this transporter interferes with amino acid nutrition and reduces growth and proliferation of pancreatic cancer cells.\nFurther knockdown SLC6A14 with siRNA or treatment with α-MT in CRC cell lines reduced cell proliferation and migration in vitro and inhibited xenograft tumor growth in vivo.\nWhile SLC6A14 genetic deficiency does not have a major impact on cell proliferation, combined depletion of AMPK and SLC6A14 leads to an increase in apoptosis upon methionine starvation, suggesting that combined targeting of SLC6A14 and AMPK can be exploited as a therapeutic approach to starve tumor cells.\nBlockade of SLC6A14 with α-MT inhibited the activation of mTOR signaling.\nInhibition of heat shock proteins, known to be upregulated in cancer, directs SLC6A14 to degradation.\nIn PDAC cell line, knockdown inhibited cells proliferation, migration and promoted cells apoptosis.\nAdditionally, FOXA1 knockout inhibited cell proliferation and further increase", "dois": ["10.1080/15384047.2025.2546219", "10.1016/j.colsurfb.2025.114918", "10.1097/SHK.0000000000002587", "10.1097/HC9.0000000000000597", "10.21037/tlcr-24-448", "10.3748/wjg.v30.i3.252", "10.1038/s41598-024-52646-8", "10.1038/s42255-023-00936-2", "10.3389/fvets.2023.1202369", "10.1016/j.ijpharm.2023.123082", "10.1016/j.taap.2023.116402", "10.1016/j.jtherbio.2022.103375", "10.1016/j.heliyon.2022.e11321", "10.1186/s12885-022-09935-0", "10.3390/biomedicines10051113", "10.1042/BCJ20210855", "10.1093/jas/skac051", "10.1016/j.bioactmat.2021.07.009", "10.3390/ph14030216", "10.2147/OTT.S288709", "10.18632/oncotarget.27758", "10.3389/fcell.2020.594464", "10.3389/fcell.2020.583850", "10.1042/BCJ20200275", "10.1042/BCJ20200099", "10.3390/ijms21030962", "PMID:30662604", "10.1208/s12248-017-0164-7", "10.1111/bph.13616", "10.1089/cell.2015.0090", "10.1042/BJ20150437", "10.3945/jn.114.209817", "10.1158/0008-5472.CAN-14-3745"]}
{"pair_type": "slc_pathway", "key1": "SLC6A9", "key2": "oxidative stress", "summary": "genes associated with protective mechanisms, such as SLC6A9, were highly expressed in the non-inflammatory SLs.\nThese analyses disclosed specific core genes implicated in oxidative stress, especially the upregulation of nuclear factor kappa B in the inflammatory SLs, while genes associated with protective mechanisms, such as SLC6A9, were highly expressed in the non-inflammatory SLs.\nIn conclusion, the upregulation of stress response-associated genes and inflammatory pathways in response to UV-induced oxidative stress implies their involvement in the pathogenesis of inflammatory SL.", "dois": ["10.1134/S0006297924070149", "10.3390/antiox13091111", "10.3390/ijms25073973"]}
{"pair_type": "slc_pathway", "key1": "SLC6A18", "key2": "oxidative stress", "summary": "Some of these were likely beneficial for cetaceans, for example, by reducing the risk of thrombus formation during diving ( and ), erroneous DNA damage repair (), and oxidative stress-induced lung inflammation ().", "dois": ["10.1126/sciadv.aaw6671"]}
{"pair_type": "slc_pathway", "key1": "SLC6A19", "key2": "oxidative stress", "summary": "The ileum mRNA expressions of seven nutrient transporters (SLC5A8, SLC7A6, SLC6A19, SLC7A7, SLC27A2, SLC16A10, and SLC15A1) were not different between the two groups (p > 0.05).\nThe ileum of EXE had higher (p < 0.05) antioxidant protein levels of manganese superoxide dismutase and catalase compared to SED with no change (p > 0.05) in the lipid peroxidation biomarker 4-hydroxynonenal.\nThese findings suggest that 10 days of endurance exercise training up-regulates key endogenous antioxidant enzymes, decreases select inflammation markers, and alters select markers of tight junction permeability.", "dois": ["10.1186/s13104-015-1500-6"]}
{"pair_type": "slc_pathway", "key1": "SLC6A14", "key2": "migration", "summary": "Upregulated SLC6A14 expression promoted glutamine catabolism and enhanced BC cell proliferation, migration, and invasion.\nFunctionally, we confirmed that SLC6A14 was highly expressed in PC and its knockdown suppressed the proliferation, migration, invasion and EMT signal via regulating Wnt/β-catenin signaling pathway.\nFurther knockdown SLC6A14 with siRNA or treatment with α-MT in CRC cell lines reduced cell proliferation and migration in vitro and inhibited xenograft tumor growth in vivo.\nMost importantly, pharmacological blockade and gene silence of SLC6A14 both restricted epithelial-mesenchymal transition- (EMT-) driven GC metastasis, in which attenuated activation of the PI3K/AKT/mTORC1 pathway caused by amino acid starvation was involved.\nIn particular, most significant change with a dampening trend in the migration potentiality of GC cells emerged after SLC6A14 gene was silenced.\nSLC6A14 expression was positively correlated with the migrated capability of different GC cell lines, and SLC6A14 was also constitutively expressed in GC patients with venous or lymphatic invasion, lymph node, or distant metastasis and poor prognosis, thus prompting SLC6A14 as a nonnegligible presence in supporting GC migration and invasion.\nSLC6A14 may promote PC progression via modulating Wnt/β-catenin signaling.\nUpregulates SLC6A14 transcription and glutamine catabolism, thereby promoting BC growth and metastasis.\nConsistently, SLC6A14 depletion drastically depressed GC metastasis and.\nIn summary, it is conceivable that targeting SLC6A14 has a tremendous promising for the treatment of metastatic GC.\nHypoxia-induced PYCR1 enhances glycolysis, leading to increased lactate production and elevated H3K18la levels, which upregulates SLC6A14 transcription and glutamine catabolism, thereby promoting BC growth and metastasis.", "dois": ["10.1080/15384047.2025.2546219", "10.1038/s41598-024-52646-8", "10.1016/j.heliyon.2022.e11321", "10.3389/fcell.2022.945241", "10.1186/s12885-022-09935-0", "10.1155/2022/7850658", "10.2147/OTT.S288709", "10.1042/BCJ20200275", "10.1089/cmb.2019.0367", "PMID:30662604"]}
{"pair_type": "slc_pathway", "key1": "SLC7A2", "key2": "chemotherapy", "summary": "A six-gene lasso regression model (APOD, CAPN6, GPC3, PDK4, SLC7A2, SVEP1) was developed.\nWe constructed a six-gene BM-related prognostic model for predicting GC prognosis, immune cell infiltration, TMB status, and chemotherapy response.\nAccording to the findings, individuals in the low-risk scoring group have less infiltration of immune suppressive cells, fewer occurrences of immune escape and dysfunction, greater efficacy in chemotherapy and immunotherapy, and better survival outcomes.\nWe also investigated the single-cell properties of prognostic-related genes and the TME characteristic, TMB status, and chemotherapy response in high- and low-risk groups.", "dois": ["10.1186/s40246-024-00682-w", "10.3390/diagnostics13111844"]}
{"pair_type": "slc_pathway", "key1": "SLC7A1", "key2": "oxidative stress", "summary": "Vascular tone is controlled by the L-arginine/nitric oxide (NO) pathway, and NO bioavailability is strongly affected by hyperglycaemia-induced oxidative stress.\nHigh D-glucose-increased transport parallels higher reactive oxygen species (ROS) and superoxide anion (O2•-) generation, and increased U46619-contraction and reduced CGRP-dilation of vein rings.\nIn addition, compared with the control, supply of Met or Arg upregulated genes related to transcription and translation (MAPK1, MTOR, SREBF1, RPS6KB1, JAK2), insulin signaling (AKT2, IRS1), AA transport (SLC1A5, SLC7A1), and cell proliferation (MKI67).\nLittle benefit on oxidative stress induced by LPS challenge in BMEC was detected with greater supply of Met and Arg.\nCultures with incMet, incArg, or incMetArg led to attenuation of the upregulation of SOD2 and NOS2 induced by LPS.\nMethionine (Met) and arginine (Arg) are key nutrients with potential to regulate inflammation and oxidative stress.\nThe shared canonical pathways from the morula to the hatched blastocyst transition were 14-3-3-mediated signaling, xenobiotic metabolism general signaling pathway, and NRF2-mediated oxidative stress response.\nUpregulation of microRNA related to cell growth arrest and apoptosis (miR-34a, miR-92a, miR-99, and miR-184) and oxidative stress (miR-141 and miR-200a) coupled with downregulation of fat synthesis-related microRNA (miR-27ab and miR-221) were detected with HS.\nVascular dysfunction caused by high D-glucose is likely attenuated by insulin through the L-arginine/NO and O2•-/NADPH oxidase pathways.\nEnriched canonical pathways from the 4-cell to the morula transition that were shared between in vivo developed and in vitro produced embryos included oxidative phosphorylation and EIF2 signaling.", "dois": ["10.1002/jbt.22706", "10.3168/jds.2019-16631", "10.3168/jds.2022-23187", "10.1186/s12864-021-07430-7", "10.3168/jds.2018-15219", "10.1159/000484107", "10.1371/journal.pone.0122398"]}
{"pair_type": "slc_pathway", "key1": "SLC7A1", "key2": "apoptosis", "summary": "Further studies revealed that Eif5 deletion in oocytes downregulated the levels of mitochondrial fission-related proteins (p-DRP1, FIS1, MFF and MTFR) and upregulated the levels of the integrated stress response-related proteins (AARS1, SHMT2 and SLC7A1) and genes (Atf4, Ddit3 and Fgf21).\nMeanwhile, Eif5 deletion in oocytes led to a significant increase in the levels of DNA damage response proteins (γH2AX, p-CHK2 and p-p53) and proapoptotic proteins (PUMA and BAX), as well as a significant decrease in the levels of anti-apoptotic protein BCL-xL.\nRipa-56 exhibited a significant reduction in the levels of RIP-1, p-MLKL, Caspase-3, and BAX induced by glutamate, while promoting the expression of Bcl-2, Gpx-4, and SLC7A1 in the Ripa-56-treated group.\nPreclinical models confirm that combined dietary arginine deprivation, GCN2 inhibition, and senotherapy promote HCC cell apoptosis and tumor regression.\nBesides, the inhibition of the NRF3-mTORC1 axis impaired mitochondrial function, leading to cancer cell apoptosis.\nSpermine supplementation may regulate cell cycle during the G1/S phase, suppress apoptosis and modulate amino acid transport.\nInhibiting GCN2 in arginine-deprived HCC cells promotes a senescent phenotype instead, rendering these cells vulnerable to senolytic compounds.\nThese data suggest novel strategies to treat human liver cancers through targeting SLC7A1 and/or a combination of arginine restriction, inhibition of GCN2, and senolytic agents.\nSurprisingly, arginine import is uniquely dependent on the cationic amino acid transporter SLC7A1, whose inhibition slows HCC cell growth in vitro and in vivo.\nDepletion of Eif5 causes oocyte apoptosis via ROS accumulation and DNA damage response", "dois": ["10.1002/ctm2.1791", "10.1038/s41598-024-54075-z", "10.1080/2162402X.2021.1908010", "10.1016/j.micpath.2020.104303", "10.1016/j.molmet.2018.07.007", "PMID:25826076", "PMID:16703566", "10.3892/mmr.2025.13600", "10.22074/cellj.2023.2004011.1319", "10.1016/j.isci.2023.106045", "10.1016/j.cmet.2022.06.010", "10.1016/j.omto.2020.09.008", "10.1186/s12263-019-0626-x", "10.3168/jds.2018-15219", "10.1093/biolre/ioy085", "10.5713/ajas.17.0799"]}
{"pair_type": "slc_pathway", "key1": "SLC7A2", "key2": "apoptosis", "summary": "ASCT2-knockout mice exhibit homeostasis in proliferation and apoptosis through SLC7A2 (solute carrier family 7 member 2) upregulation, a process driven by ROS/NF-κB signaling.\nAdditionally, arginine uptake could effectively alleviate oxidative stress and reduce cell apoptosis via the synthesis of glutathione (GSH) and the activation of NRF2/HO-1 signaling upon ASCT2 knockdown.\nFurthermore, IFN-γ increased, but L-NMMA decreased apoptosis of M.bovis/BCG infected DCs.\nFurther, cell apoptosis was stimulated, and lymphangiogenesis was suppressed through the downregulation of CPB2 expression.\nThese findings reveal Mn activates apoptosis in TM3 cells and concurrent apoptosis/ferroptosis in TM4 cells through ROS-dependent dysregulation of apoptosis- and ferroptosis-related genes.\nIn addition, BCG induced significantly higher levels of apoptosis in DCs compared to M.bovis shown by higher levels of DNA fragmentation using flow cytometry and release of mitochondrial Cytochrome C, and up-regulation of the genes caspase-3, caspase-8, caspase-9 and dffa critical to apoptosis by qRT-PCR detection and western blot analysis.\nApoptosis inhibitor Z-VAD-FMK (20 μM) suppressed cell death in both cell lines, whereas ferroptosis inhibitor Ferrostatin-1 (10 μM) specifically attenuated TM4 cell death.\nThe pathology of acute lung injury (ALI) involves inducible nitric oxide (NO) synthase (iNOS)-derived NO-induced apoptosis of pulmonary endothelial cells.\nTaken altogether, our data show that NO synthesis was differentially increased and associated with apoptosis in M.bovis/BCG infected DCs.\nThese genes are associated with cell growth, invasion, migration, apoptosis and cancer development.\nThe percent of TUNEL-positive cells in the lung following hyperoxia exposure was significantly lower ( P < 0.001)", "dois": ["10.1002/cam4.70273", "10.1016/j.micpath.2020.104303", "10.1016/j.tcb.2019.09.001", "PMID:16703566", "10.1093/toxres/tfaf098", "10.1016/j.bcp.2025.117165", "10.1155/2022/4542487", "10.1016/j.taap.2020.115030", "10.1016/j.it.2019.11.002", "10.1080/2162402X.2019.1655964", "10.1080/2162402X.2019.1655364", "10.1152/ajplung.00223.2018"]}
{"pair_type": "slc_pathway", "key1": "SLC7A1", "key2": "proliferation", "summary": "Our previous studies have shown that upregulation of SLC7A1 in epithelial ovarian cancer (EOC) tumor cells significantly increases cancer cell proliferation, migration, and cisplatin resistance;\nIn addition, compared with the control, supply of Met or Arg upregulated genes related to transcription and translation (MAPK1, MTOR, SREBF1, RPS6KB1, JAK2), insulin signaling (AKT2, IRS1), AA transport (SLC1A5, SLC7A1), and cell proliferation (MKI67).\nMechanistically, we discovered that TRAF4 was required for the activation of AKT/mTOR and ERK1/2 signaling pathways as well as the expression of transcription factor Myc and nutrient transporters (Slc2a1, Slc7a1, and Slc7a5), signature genes involved in T cell growth and proliferation, in ST2+ mTh2 cells stimulated by IL-33.\nKnockdown of SLC7A1 significantly inhibited the proliferation, invasion, and xenograft tumor growth of meningioma cells.\nSLC7A1 is involved in the transport of phenylalanine and arginine in EOC cells, and its knockdown reduced the proliferation and migration of EOC cells and the resistance of cells to cisplatin.\nOur results revealed that SLC7A1 regulates multiple signaling pathways involved in tumor proliferation, including E2F targets, G2M checkpoint, and MYC targets.\nWe found that in vitro-polarized TRAF4-deficient (CD4-cre Traf4fl/fl) ST2+ mTh2 cells exhibited decreased IL-33-induced proliferation as compared with TRAF4-sufficient (Traf4fl/fl) cells.\nSLC7A1 enriched in cancer-associated fibroblasts (CAFs) was upregulated by TGF-β1.\nIn brief, our study demonstrated the tumor-promoting function of SLC7A1 by regulating the transcription factors FOXM1 and E2F4 in meningioma and identified SLC7A1", "dois": ["10.1038/s41420-025-02783-4", "10.3892/mmr.2025.13600", "10.1186/s12967-025-06296-7", "10.1186/s12967-025-06086-1", "10.1101/2024.09.21.614248", "10.1002/cam4.7217", "10.1172/jci.insight.169736", "10.3389/fonc.2023.1136835", "10.1101/2023.02.11.528093", "10.1155/2022/5864826", "10.3390/cancers14143525", "10.1038/s41598-022-11371-w", "10.1002/jbt.22706", "10.1016/j.omto.2020.09.008", "10.1038/s41388-020-01498-3", "10.1016/j.reprotox.2020.07.008", "10.1016/j.wneu.2019.12.182", "10.1371/journal.ppat.1007746", "10.3168/jds.2018-15219", "10.1186/s13046-018-0872-6", "10.1093/biolre/ioy085", "10.1016/j.reprotox.2018.04.004", "10.5713/ajas.17.0799", "10.1089/cell.2015.0090", "10.1007/s00726-016-2216-1", "10.1042/BSR20140140", "PMID:22738901", "PMID:16703566"]}
{"pair_type": "slc_pathway", "key1": "SLC7A2", "key2": "ferroptosis", "summary": "Through experiments, we demonstrated that knocking down CDH19 can affect the transcription levels of ACSL4 and GPX4, increase intracellular iron ion concentration and accumulation of reactive oxygen species (ROS), and inhibit the proliferation and migration of GC cells.\nThese findings reveal Mn activates apoptosis in TM3 cells and concurrent apoptosis/ferroptosis in TM4 cells through ROS-dependent dysregulation of apoptosis- and ferroptosis-related genes.\nApoptosis inhibitor Z-VAD-FMK (20 μM) suppressed cell death in both cell lines, whereas ferroptosis inhibitor Ferrostatin-1 (10 μM) specifically attenuated TM4 cell death.\nMn triggered ROS elevation in TM4 cells, accompanied by upregulated , while downregulating .\nOxidative stress and ferroptosis are essential mechanisms leading to metabolic abnormalities in cells and have been popular areas in cancer research.\nSubsequently, we successfully constructed and verified a prognostic signature comprising SLC7A2, Cadherin 19 (CDH19), and CCN1.\nFerroptosis is a unique mode of cell death that is iron-dependent and associated with oxidative stress and lipid peroxidation.\nInitially, 76 oxidative stress and ferroptosis-related genes (OFRGs) were acquired by intersecting the gene sets from oxidative stress and ferroptosis.\nTo further uncover potential biomarkers of gastric cancer (GC), we examined the expression level of CDH19, investigated the effects of knocking down CDH19 on the biological behavior of GC cells, and explored whether CDH19 is involved in ferroptosis and oxidative stress processes.\nWe developed an OFRG-related signature to predict the prognosis and treatment responsiveness of individuals with GC and identified CDH19 as a possible therapeutic target for GC.", "dois": ["10.1186/s40246-024-00682-w", "10.1093/toxres/tfaf098"]}
{"pair_type": "slc_pathway", "key1": "SLC6A20", "key2": "oxidative stress", "summary": "RPE uses proline to fuel mitochondrial metabolism, synthesize amino acids, build the extracellular matrix, fight against oxidative stress, and sustain differentiation.\nRecent studies show RPE cells prefer proline as a major metabolic substrate, and they are highly enriched for the proline transporter, SLC6A20.", "dois": ["10.1007/s00726-021-02981-1"]}
{"pair_type": "slc_pathway", "key1": "SLC7A2", "key2": "oxidative phosphorylation", "summary": "The results showed that 131 proteins in the liver were markedly altered in response to dietary lysine restriction, with 54 being downregulated and 77 being upregulated, which mainly involved in neurodegenerative diseases, oxidative phosphorylation, and metabolic pathways.\nDietary lysine restriction enhanced meat color lightness and upregulated SLC7A2 expression.", "dois": ["10.2174/0929866525666180406142451"]}
{"pair_type": "slc_pathway", "key1": "SLC7A2", "key2": "glycolysis", "summary": "Metabolomics and metabolic flux analysis showed that exposure to high glucose levels enhanced glycolysis, glucose oxidation and the synthesis of glucose-derived amino acids.\nIn addition, chronic exposure to high glucose levels increased the expression of Slc7a2 and Slc38a4, which encode amino acid transporters, as well as the levels of branched-chain amino acids and methionine cycle metabolites (~1.3-fold increase for both).\nAlpha cell exposure to hyperglycaemia enhances amino acid synthesis and transport, resulting in sustained activation of mTORC1, thereby increasing glucagon secretion.", "dois": ["10.1007/s00125-023-05967-8"]}
{"pair_type": "slc_pathway", "key1": "SLC7A2", "key2": "oxidative stress", "summary": "We found that SLC7A2 is selectively upregulated in HD cellular models and patients.\nAdditionally, arginine uptake could effectively alleviate oxidative stress and reduce cell apoptosis via the synthesis of glutathione (GSH) and the activation of NRF2/HO-1 signaling upon ASCT2 knockdown.\nOur data suggest a novel pathway that links arginine uptake to nitrosative stress via upregulation of SLC7A2 in the pathogenesis and progression of HD.\nDepleting extracellular Arg or knocking out SLC7A2 blocked iNOS induction and NO production in STHdhQ111 cells.\nHD cells exhibit an overactive response to neuroinflammatory challenges, as demonstrated by abnormally high iNOS induction and NO production, leading to increased protein nitrosylation.\nASCT2-knockout mice exhibit homeostasis in proliferation and apoptosis through SLC7A2 (solute carrier family 7 member 2) upregulation, a process driven by ROS/NF-κB signaling.\nMn triggered ROS elevation in TM4 cells, accompanied by upregulated , while downregulating .\nThese findings reveal Mn activates apoptosis in TM3 cells and concurrent apoptosis/ferroptosis in TM4 cells through ROS-dependent dysregulation of apoptosis- and ferroptosis-related genes.\nThrough experiments, we demonstrated that knocking down CDH19 can affect the transcription levels of ACSL4 and GPX4, increase intracellular iron ion concentration and accumulation of reactive oxygen species (ROS), and inhibit the proliferation and migration of GC cells.\nExcessive Mn impairs male reproduction by reducing testosterone, inducing oxidative stress, and disrupting spermatogenesis.\nFerroptosis is a unique mode of cell death that is iron-dependent and associated with oxidative stress and lipid peroxidation.\nOxidative stress and ferroptosis are essential mechanisms leading to metabolic abnormalities in cells and have been popular areas in cancer research.\nIncreased intracellular arginine serves as an effector for mTOR/S6 activation to promote cell growth in", "dois": ["10.1016/j.bcp.2025.117165", "10.1186/s40246-024-00682-w", "10.1186/s12974-024-03038-2", "10.1093/toxres/tfaf098"]}
{"pair_type": "slc_pathway", "key1": "SLC7A3", "key2": "migration", "summary": "In addition, SP1 increased solute carrier family 7 member 3 (SLC7A3) expression by binding to the SLC7A3 promoter and increased the capability of arginine uptake, thereby facilitating OS cell migration.\nIn summary, our study demonstrates that the upregulation of SIRPA promotes OS metastasis via the \"SP1 stabilization circle\" and SLC7A3-mediated arginine uptake, which might serve as a target for OS treatment.\nKnockdown of SIRPA impaired OS cell migration by decreasing specificity protein 1 (SP1) stability and arginine uptake.\nImportantly, SIRPA phosphorylated SP1 at threonine 278 (Thr278) through extracellular signal-regulated kinase (ERK) activation to protect SP1 from proteasomal degradation.\nMore interestingly, arginine promoted the stability of SP1 in an ERK-independent manner and thus formed the \"SP1 stabilization circle\".\nCombined treatment with the anti-SIRPA antibody and arginase, which blocked the circle, impaired tumor metastasis in mice bearing xenografts formed from SIRPA-overexpressing cells.\nNotably, SIRPA is upregulated in osteosarcoma tissues, particularly in metastatic tissues, and is associated with unfavorable clinical outcomes.", "dois": ["10.1080/08916934.2024.2319209", "10.1016/j.canlet.2023.216412", "PMID:22738901"]}
{"pair_type": "slc_pathway", "key1": "SLC7A2", "key2": "proliferation", "summary": "Our findings demonstrate that interruption of glucagon signaling augments islet non-alpha cell proliferation in zebrafish, rodents, and transplanted human islets in a manner requiring SLC7A2 and mTORC1 activation.\nWe found that arginine activation of mTOR signaling and induction of the glutamine transporter SLC38A5 was dependent on SLC7A2, showing that both's role in α cell proliferation is dependent on arginine transport and SLC7A2.\nLikewise, deficiency augmented beta cell proliferation via SLC7A2- and mTORC1-dependent mechanisms in zebrafish and promoted cell cycle engagement in rodent beta cells but was insufficient to drive a significant increase in beta cell mass in mice.\nLikewise, gcgr deficiency augmented beta cell proliferation via SLC7A2- and mTORC1-dependent mechanisms in zebrafish and promoted cell cycle engagement in rodent beta cells but was insufficient to drive a significant increase in beta cell mass in mice.\nEmploying cell culture, zebrafish, and knockout mouse models, we found that the cationic amino acid arginine and SLC7A2 are required for α cell proliferation in response to interrupted glucagon signaling and assessment of islet function in mice showed decreased arginine-stimulated glucagon and insulin secretion.\nSLC7A2 silencing enhanced the proliferation of NSCLC cells and their insensitivity to paclitaxel, cisplatin, and gemcitabine in vitro.\nTogether, these data indicate a central role for SLC7A2 in amino acid-stimulated α cell proliferation and islet hormone secretion.\nInhibition of glucagon signaling stimulated delta cell proliferation in mouse and transplanted human islets, and in mouse islets.\nActivation of AMPK has up-regulated SLC7A2 expression and enhanced the sensitivity of NSCLC cells to anti-tumor drugs, which could be attributed to E2F1's regulation.\nWe also used models with global deficiency of the cationic amino acid transporter, SLC7A2, and mTORC1 inhibition via rapamycin, to determine whether amino acid-dependent nutrient sensing was required for islet", "dois": ["10.1016/j.aninu.2025.03.012", "10.1016/j.bcp.2025.117165", "10.1615/CritRevEukaryotGeneExpr.2025058118", "10.1186/s40246-024-00682-w", "10.1016/j.molmet.2024.102050", "10.1101/2024.08.06.606926", "10.3390/ijms25010095", "10.1101/2023.08.10.552656", "10.1186/s12964-022-01023-x", "10.18240/ijo.2022.06.06", "PMID:30662604", "PMID:22738901", "PMID:17387163", "PMID:16703566"]}
{"pair_type": "slc_pathway", "key1": "SLC7A8", "key2": "chemotherapy", "summary": "In conclusion, curcumin synergistically enhances gemcitabine efficacy against gemcitabine-resistant CCA by induction of apoptosis, partly via inhibiting LAT2/glutamine pathway.\nNotably, SLC7A8 was identified as a potentially novel MDR gene, and functional assays demonstrated that mutant SLC7A8 promoted the resistance phenotypes of ESCC cell lines.\nKnockdown of SLC7A8 decreased the expressions of glutaminase and glutamine synthetase, resulting in inhibited cell proliferation and sensitized CCA cells to gemcitabine treatment.\nCurcumin has the potential for anti-cancer activity through various therapeutic properties and can improve the efficacy of chemotherapy.\nThis combination synergistically suppressed proliferation in gemcitabine-resistant CCA cells (KKU-213B).\nMoreover, in vivo experiments showed that a combination curcumin and gemcitabine significantly reduced tumor size, tumor growth rate and LAT2 expression in a gemcitabine-resistant CCA xenograft mouse model.\nIntriguingly, promoter hypomethylation of SLC8A3 and mutant SLC7A8 were enriched in an identical pathway, protein digestion and absorption, indicating a potentially novel MDR mechanism during treatments.\nWe aimed to investigate the synergistic effect of a combination of curcumin and gemcitabine against CCA, targeting the LAT2/glutamine pathway.\nThis approach may be an alternative strategy for the treatment of gemcitabine-resistant in CCA patients.\nThe predictive power of 5 DMET SNPs mapping in ABCC2, ABCC3, CYP2A6, PPARG, and SLC7A8 genes was greater than that of clinical factors alone (area under the curve [AUC] = 0.74 vs 0.62).\nIn conclusion, we identified a genetic signature of response to platinum-based neoadjuvant chemotherapy in EC patients.\nMultiple analyses indicated that 1 SNP in the first intron of SLC7A5, rs4240803, was significantly associated with TPN use (odds ratio = .45, 95% confidence interval", "dois": ["10.1038/s41598-024-66945-7", "10.3389/fphar.2022.1042989", "10.1172/jci.insight.150203", "10.1007/s10549-018-5060-z", "10.1016/j.trsl.2015.12.011", "10.1016/j.bbmt.2014.03.022"]}
{"pair_type": "slc_pathway", "key1": "SLC7A6", "key2": "stemness", "summary": "CD98hc serves as a chaperone for LAT1 (SLC7A5), LAT2 (SLC7A8), yLAT1 (SLC7A7), yLAT2 (SLC7A6), xCT (SLC7A11) and Asc1 (SLC7A10) providing their recruitment to the plasma membrane.\nIn this way, CD98hc connects the signaling pathways sustaining cell proliferation and migration, biosynthesis and antioxidant defense, energy production, and stem cell properties.\nThis multifaceted role makes CD98hc one of the critical regulators of tumor growth, therapy resistance, and metastases.\nIn this mini-review, we discuss the physiological functions of CD98hc, its role in regulating tumor stemness, metastases, and therapy resistance, and the clinical significance of CD98hc as a tumor marker and therapeutic target.\nCD98hc interacts with other surface molecules, such as extracellular matrix metalloproteinase inducer CD147 (EMMPRIN) and adhesion receptors integrins, and regulates glucose uptake.", "dois": ["10.3389/fonc.2023.1251100"]}
{"pair_type": "slc_pathway", "key1": "SLC7A8", "key2": "oxidative phosphorylation", "summary": "Compared with the mammary gland of AH-fed cows, the marked expression changes found in the mammary gland of CS group were for genes involved in reduced mammary growth/development (COL4A2, MAPK3, IKBKB, LGALS3), less oxidative phosphorylation (ATPsynGL, ATP6VOA1, ATP5H, ATP6VOD1, NDUFC1), enhanced lipid uptake/metabolism (SLC27A6, FABP4, SOD2, ACADM, ACAT1, IDH1, SCP2, ECHDC1), more active fatty acid beta-oxidation (HMGCS1), less amino acid/protein transport (SLC38A2, SLC7A8, RAB5a, VPS18), reduced protein translation (RPS6, RPS12, RPS16, RPS19, RPS20, RPS27), more proteasome- (PSMC2, PSMC6, PSMD14, PSMA2, PSMA3) and ubiquitin-mediated protein degradation (UBE2B, UBE2H, KLHL9, HSPH1, DNAJA1 and CACYBP), and more protein disassembly-related enzymes (SEC63, DNAJC3, DNAJB1, DNAJB11 and DNAJC12).\nMechanistically, reduced amino acid availability due to deficiency led to compromised mitochondrial oxidative phosphorylation, as well as impaired activation of mammalian target of rapamycin and c-Myc signaling pathways.\nSLC7A8 is a key amino acids supplier for the metabolic programs that sustain homeostasis and activation of type 2 innate lymphoid cells.\nThese findings identify as a key supplier of amino acids for the metabolic programs underpinning fitness and activation of ILC2s.\nILC2s depend on availability of arginine and branched-chain amino acids for sustaining cellular fitness, proliferation, and cytokine secretion in both steady state and upon activation.", "dois": ["10.1073/pnas.2215528119", "10.1186/s12864-018-4808-5"]}
{"pair_type": "slc_pathway", "key1": "SLC7A8", "key2": "stemness", "summary": "CD98hc serves as a chaperone for LAT1 (SLC7A5), LAT2 (SLC7A8), yLAT1 (SLC7A7), yLAT2 (SLC7A6), xCT (SLC7A11) and Asc1 (SLC7A10) providing their recruitment to the plasma membrane.\nIn this way, CD98hc connects the signaling pathways sustaining cell proliferation and migration, biosynthesis and antioxidant defense, energy production, and stem cell properties.\nIn this mini-review, we discuss the physiological functions of CD98hc, its role in regulating tumor stemness, metastases, and therapy resistance, and the clinical significance of CD98hc as a tumor marker and therapeutic target.\nThis multifaceted role makes CD98hc one of the critical regulators of tumor growth, therapy resistance, and metastases.\nCD98hc interacts with other surface molecules, such as extracellular matrix metalloproteinase inducer CD147 (EMMPRIN) and adhesion receptors integrins, and regulates glucose uptake.", "dois": ["10.3389/fonc.2023.1251100"]}
{"pair_type": "slc_pathway", "key1": "SLC7A9", "key2": "apoptosis", "summary": "Spermine supplementation may regulate cell cycle during the G1/S phase, suppress apoptosis and modulate amino acid transport.\nIn addition, cell apoptosis and cystine crystal adherence were promoted by the NLRP3 inflammasome.\nIn addition, extended spermine administration also markedly promoted cell proliferation, depressed apoptosis and modulated amino acid transport (p<\nRegardless of supplementation time, spermine intake significantly enhanced the expressions of amino acid transporter-related genes (SLC1A1, SLC1A5, SLC7A1, SLC7A7, and SLC15A1) in both thymus and spleen, as well as SLC7A9 in the spleen of piglets (p<0.05).\nIrrespective of the treatment period, the reduced Bax and caspase-3 gene expressions and improved Bcl-2 mRNA level were observed in the thymus and spleen of spermine-administrated piglets (p<0.05).", "dois": ["10.1007/s11255-022-03347-6", "10.5713/ajas.17.0799"]}
{"pair_type": "slc_pathway", "key1": "SLC7A8", "key2": "ferroptosis", "summary": "Inhibition of PPAR-γ led to a compensatory upregulation of SLC7A11, a subunit of the cystine-glutamine antiporter xCT, indicating a specific need for cystine uptake in Th9 cells.\nIndeed, Th9 cells were sensitive to cystine deprivation, which triggered lipid peroxidation and bioenergetic failure, resulting in a ferroptosis-like form of cell death.\nCD98hc serves as a chaperone for LAT1 (SLC7A5), LAT2 (SLC7A8), yLAT1 (SLC7A7), yLAT2 (SLC7A6), xCT (SLC7A11) and Asc1 (SLC7A10) providing their recruitment to the plasma membrane.\nIn in vitro-primed Th9 cells, PPAR-γ expression positively correlated with the expression of SLC7A8, which encodes LAT2, a transporter of large neutral amino acids, including cystine.\nDifferentially spliced SLCs were enriched in biological processes, including transmembrane transporter activity, transporter activity, ferroptosis, and choline metabolism.\nOverall, our data suggest that human Th9 cells are dependent on uptake of exogenous cystine, which opens up promising therapeutic strategies for their inhibition or depletion in allergic skin inflammation.", "dois": ["10.1016/j.jid.2024.10.616", "10.1111/cas.16351", "10.3389/fonc.2023.1251100"]}
{"pair_type": "slc_pathway", "key1": "SLC7A9", "key2": "ferroptosis", "summary": "SLC7A9 promotes gastric cancer progression by acting as a suppressor of ferroptosis, independent of SLC7A11, which is negatively regulated by p53.\nSLC7A9 suppression increases chemosensitivity by inducing ferroptosis via the inhibition of cystine transport in gastric cancer.\nErastin was more effective at inducing ferroptosis in PDO and PDX models upon SLC7A9 knockdown.\nSLC7A9 knockdown reduced cystine transport into cells, hampered intracellular cystine and GSH metabolic flow, decreased GSH synthesis, and increased lipid ROS levels in gastric cancer cells.\nDifferentially expressed genes and metabolites between the SLC7A9 overexpression and control groups were associated with ferroptosis and GSH metabolism.\nCystine/cysteine transport is related to ferroptosis.\nChemotherapy was more effective in PDX and immunocompetent mice models upon SLC7A9 knockdown.\nSLC7A9 knockdown suppressed the proliferation and increased the chemotherapy sensitivity of the cells.\nElevated SLC7A9 expression levels in gastric cancer cells were attributed to p53 loss.\nSLC7A9 is responsible for the exchange of dibasic amino acids and cystine (influx) for neutral amino acids (efflux).", "dois": ["10.1016/j.ebiom.2024.105375"]}
{"pair_type": "slc_pathway", "key1": "SLC7A8", "key2": "glycolysis", "summary": "Taken together, our data reveal that LAT2 functions as an oncogenic protein and could regulate glutamine-dependent mTOR activation to promote glycolysis and decrease GEM sensitivity in pancreatic cancer.\nMechanistically, we demonstrated that LAT2 could regulate two glutamine-dependent positive feedback loops (the LAT2/p-mTOR loop and the glutamine/p-mTOR/glutamine synthetase loop) to promote glycolysis and decrease gemcitabine (GEM) sensitivity in pancreatic cancer.\nFurthermore, we found that LAT2 could promote proliferation, inhibit apoptosis, activate glycolysis and alter glutamine metabolism to activate mTOR in vitro and in vivo.\nL-type amino acid transporter 2 (LAT2), encoded by the SLC7A8 gene, is a Na-independent neutral amino acid transporter and is responsible for transporting neutral amino acids, including glutamine, which can activate mTOR.", "dois": ["10.1186/s13046-018-0947-4", "10.1172/jci.insight.154198"]}
{"pair_type": "slc_pathway", "key1": "SLC6A13", "key2": "oxidative stress", "summary": "In the hippocampal and hypothalamic regions, the number of vacuolated neuropils increased with increasing MC-LR exposure concentration, while the expression of genes associated with neuronal development (LGALS1, CACNA2D2, and NLGN4X) and neurotransmitter transmission (SLC6A13 and AChE) was significantly down-regulated.\nFurther, based on transcriptomic and biochemical analysis, it was revealed that MC-LR exposure induces DNA damage through oxidative stress and may be an important pathway causing brain structural damage and functional disorder.\nGAT2-expressing cells pretreated with hypotaurine showed resistance to HO-induced oxidative stress.\nThese results suggest that under physiological conditions, TAUT and GAT2 would be major contributors to hypotaurine transfer across the plasma membrane, and that uptake of hypotaurine via GAT2 contributes to the cellular resistance to oxidative stress.\nThese results provide strong evidence that MC-LR exposure at realistic ambient concentrations of 0.5 and 2 µg/L can break the blood-brain barrier and raise the accumulation of MC-LR in the brain tissue, causing structural damage and functional disorder to brain neurons.\nExposure to 0.5 and 2 µg/L MC-LR resulted in a significant down-regulation of the expression of structural components of the blood-brain barrier (CLDN1), while the expression of genes associated with inflammation (NLRP3, TNF, IL-1β, and CXCL12) was significantly up-regulated with increased number of eosinophils.", "dois": ["10.1016/j.aquatox.2023.106509", "10.1248/bpb.b18-00168"]}
{"pair_type": "slc_pathway", "key1": "SLC7A8", "key2": "apoptosis", "summary": "In conclusion, curcumin synergistically enhances gemcitabine efficacy against gemcitabine-resistant CCA by induction of apoptosis, partly via inhibiting LAT2/glutamine pathway.\nFurthermore, we found that LAT2 could promote proliferation, inhibit apoptosis, activate glycolysis and alter glutamine metabolism to activate mTOR in vitro and in vivo.\nInterference with OTX2 expression inhibits proliferation, migration, invasion and promotes differentiation, apoptosis of NUGC-4 cells (from 35 year old female).\nConsequently, interferon-γ (IFN-γ) secreted by CD8 + T cells suppresses tumor growth through activation of JAK1-STAT1 signaling, thus inducing tumor cell apoptosis.\nsiRNA knockdown or pharmacological inhibition of SLC7A5/SLC7A8, TDO2, or AHR abolished MEHHP-mediated effects on leiomyoma cell survival.\nKnockdown of SLC7A8 decreased the expressions of glutaminase and glutamine synthetase, resulting in inhibited cell proliferation and sensitized CCA cells to gemcitabine treatment.\nIt also resulted in a remarkable degree of CCA cell apoptosis and cell cycle arrest, characterized by a high proportion of cells in the S and G2/M phases.\nThe treatment of primary leiomyoma and smooth muscle cells ( = 29) with various mixtures of phthalate metabolites, at concentrations equivalent to those detected in urine samples, significantly increased cell viability and decreased apoptosis.\nMEHHP had the strongest effects on both cell viability and apoptosis.\nThese findings indicate that MEHHP promotes leiomyoma cell survival by activating the tryptophan-kynurenine-AHR pathway.\nTaken together, our data reveal that LAT2 functions as an oncogenic protein and could regulate glutamine-dependent mTOR activation to promote glycolysis and decrease GEM sensitivity in pancreatic cancer.\nMechanistically, we demonstrated that LAT2 could regulate two glutamine-dependent positive feedback loops (the LAT2/p-mTOR loop an", "dois": ["10.1038/s41598-024-66945-7", "10.1186/s13046-018-0947-4", "10.1038/s41598-025-99632-2", "10.1073/pnas.2208886119", "10.1016/j.biopha.2022.113387"]}
{"pair_type": "slc_pathway", "key1": "SLC7A10", "key2": "ferroptosis", "summary": "CD98hc serves as a chaperone for LAT1 (SLC7A5), LAT2 (SLC7A8), yLAT1 (SLC7A7), yLAT2 (SLC7A6), xCT (SLC7A11) and Asc1 (SLC7A10) providing their recruitment to the plasma membrane.", "dois": ["10.3389/fonc.2023.1251100"]}
{"pair_type": "slc_pathway", "key1": "SLC7A4", "key2": "chemotherapy", "summary": "Reduced SLC27A4 by si-RNA also showed the enhanced therapeutic efficiency of everolimus, doxorubicin, and cisplatin in human lung cancer cell lines.\nAs expected, the results showed that SLC27A4 could help to maintain the protein stability and intracellular concentration of ATG4B, thereby triggering rapid autophagy through releasing ATG4B to cytoplasm under conditions of reduced nutrient availability or during stress of chemotherapy in lung cancer cells.\nFurther, we found that the high expression level of SLC7A4 increased the ATG4B stability and was conducive to rapid reaction to everolimus (RAD001)-induced autophagy in human lung cancer cells.\nCollectively, this study may help researchers better understand the mechanism of autophagy vitality in human cancers and SLC27A4/ATG4B complex might act as a new potential therapeutic target of lung tumor chemotherapy.", "dois": ["10.1007/s13277-015-4587-4"]}
{"pair_type": "slc_pathway", "key1": "SLC7A10", "key2": "proliferation", "summary": "CD98hc connects the signaling pathways sustaining cell proliferation and migration, biosynthesis and antioxidant defense, energy production, and stem cell properties.\nCD98hc serves as a chaperone for LAT1 (SLC7A5), LAT2 (SLC7A8), yLAT1 (SLC7A7), yLAT2 (SLC7A6), xCT (SLC7A11) and Asc1 (SLC7A10) providing their recruitment to the plasma membrane.\nThis multifaceted role makes CD98hc one of the critical regulators of tumor growth, therapy resistance, and metastases.", "dois": ["10.3389/fonc.2023.1251100"]}
{"pair_type": "slc_pathway", "key1": "SLC7A8", "key2": "oxidative stress", "summary": "Furthermore, NAC increased the relative abundances of fecal Prevotella, Clostridium cluster XIVa, and Roseburial/Eubacterium rectale (P < 0.05), which were negatively correlated with placental NLRP3 and positively with solute carrier family 7, member 8 (Slc7a8;\nIn conclusion, NAC supplementation during late gestation alleviated maternal-placental oxidative stress and inflammatory response, improved placental function, and altered fecal microbial communities.\nAlthough n-acetyl-cysteine (NAC) has been shown to efficiently alleviate oxidative stress, inflammatory response, and alter gut microbiota, little attention has been focused on their interactions with placental metabolic status of sows.\nCompared with the control group, although NAC did not ameliorate reproductive performance of sows (P > 0.05), it significantly improved maternal-placental health, which was accompanied by increased activities of glutathione peroxidase (GSH-Px) and superoxide dismutase (SOD), decreased level of malondialdehyde (MDA), and lowered expression of interleukin (IL)-1β and IL-18 through inhibiting NLRP3 inflammasome (P < 0.05).\nPotential biomarkers were associated with inflammatory, oxidative stress responses, and abnormal lipid metabolism.\nThe effects of NAC on the placental redox status, function, inflammasome, and fecal microbiota in sows were explored to clarify the correlation between the fecal microbiota and placenta.", "dois": ["10.1093/jas/skz058", "10.1007/s11306-025-02318-z"]}
{"pair_type": "slc_pathway", "key1": "SLC7A8", "key2": "migration", "summary": "Overexpression of solute carrier family 7 member 8 (SLC7A8) has been shown to relate to the survival time and tumor progression in cancer patients.\nDuring the progression from leukoplakia to HNSCC, we found several prognostic cell subgroups, such as AURKB + epithelial cells, SFRP1 + fibroblasts, SLC7A8 + macrophages, FCER1A + CD1C + dendritic cells, and TRGC2 + NK/T cells.\nCD98hc serves as a chaperone for LAT1 (SLC7A5), LAT2 (SLC7A8), yLAT1 (SLC7A7), yLAT2 (SLC7A6), xCT (SLC7A11) and Asc1 (SLC7A10) providing their recruitment to the plasma membrane.\nIngenuity Pathway Analysis predicts TBX1, DFNB31, TGFBR3, FBXO44, SLC7A8, DNM1, KITLG, MSH5, MLLT3, DUSP5, ADAMTSL4, ACPP and TBX1 as the transcription factors directly regulated by OTX2.\nIn this way, CD98hc connects the signaling pathways sustaining cell proliferation and migration, biosynthesis and antioxidant defense, energy production, and stem cell properties.\nAll cell subgroups had two different fates, one tending to cell proliferation, migration, and enhancement of angiogenesis capacity, and the other tending to inflammatory immune response, leukocyte chemotaxis, and T cell activation.\nInterference with OTX2 expression inhibits proliferation, migration, invasion and promotes differentiation, apoptosis of NUGC-4 cells (from 35 year old female).\nOverexpression of inhibited the proliferation, invasion, and migration of LUAD cells, likely through a mechanism involving the cell cycle.\nIncreasing the expression of inhibited the growth and migration of LUAD cells, thereby improving the prognosis of patients.", "dois": ["10.1038/s41598-025-99632-2", "10.1038/s41598-024-58978-9", "10.18632/aging.205446", "10.3389/fonc.2023.1251100", "10.1182/bloodadvances.2020003783"]}
{"pair_type": "slc_pathway", "key1": "SLC7A10", "key2": "stemness", "summary": "CD98hc serves as a chaperone for LAT1 (SLC7A5), LAT2 (SLC7A8), yLAT1 (SLC7A7), yLAT2 (SLC7A6), xCT (SLC7A11) and Asc1 (SLC7A10) providing their recruitment to the plasma membrane.\nIn this way, CD98hc connects the signaling pathways sustaining cell proliferation and migration, biosynthesis and antioxidant defense, energy production, and stem cell properties.\nIn this mini-review, we discuss the physiological functions of CD98hc, its role in regulating tumor stemness, metastases, and therapy resistance, and the clinical significance of CD98hc as a tumor marker and therapeutic target.\nThis multifaceted role makes CD98hc one of the critical regulators of tumor growth, therapy resistance, and metastases.", "dois": ["10.3389/fonc.2023.1251100"]}
{"pair_type": "slc_pathway", "key1": "SLC7A9", "key2": "chemotherapy", "summary": "SLC7A9 knockdown suppressed the proliferation and increased the chemotherapy sensitivity of the cells.\nChemotherapy was more effective in PDX and immunocompetent mice models upon SLC7A9 knockdown.\nSLC7A9 promotes gastric cancer progression by acting as a suppressor of ferroptosis, independent of SLC7A11, which is negatively regulated by p53.\nSLC7A9 knockdown reduced cystine transport into cells, hampered intracellular cystine and GSH metabolic flow, decreased GSH synthesis, and increased lipid ROS levels in gastric cancer cells.\nErastin was more effective at inducing ferroptosis in PDO and PDX models upon SLC7A9 knockdown.\nPatient-derived organoids (PDO), immunocompetent MFC mice allograft models and patient-derived xenograft (PDX) models were used to evaluate SLC7A9 impact on chemotherapeutic response and to observe therapeutic effect of SLC7A9 knockdown.\nDifferentially expressed genes and metabolites between the SLC7A9 overexpression and control groups were associated with ferroptosis and GSH metabolism.\nSLC7A9 is responsible for the exchange of dibasic amino acids and cystine (influx) for neutral amino acids (efflux).\nElevated SLC7A9 expression levels in gastric cancer cells were attributed to p53 loss.", "dois": ["10.1016/j.ebiom.2024.105375"]}
{"pair_type": "slc_pathway", "key1": "SLC7A9", "key2": "migration", "summary": "Moreover, overexpression of SLC7A9 enhanced cell proliferation and migration.\nKnockdown of SLC7A9 significantly suppressed the proliferation, invasion, and migration of the ESCC cell lines.\nSLC7A9 contributions to proliferation, invasion, and migration were evaluated in ESCC cells subjected to siRNA-mediated gene knockdown and pCMV6-entry plasmid-mediated overexpression.\nSLC7A9 influences the malignant behavior of ESCC cells.\nTumor SLC7A9 expression may serve as a novel biomarker for predicting lymph node metastasis and recurrence in ESCC patients.\nHigh SLC7A9 expression was also significantly associated with poor disease-specific and disease-free survival, and lymph node recurrence after radical surgery, but not with the other recurrence patterns.\nOn multivariate analysis, high SLC7A9 expression was an independent predictor of lymph node recurrence.\nHigh mRNA expression was significantly associated with high levels of squamous cell carcinoma-related antigen and carcinoembryonic antigen, advanced disease stage, and lymph node metastasis.", "dois": ["10.1245/s10434-021-11001-1", "PMID:22738901"]}
{"pair_type": "slc_pathway", "key1": "SLC7A9", "key2": "oxidative phosphorylation", "summary": "Duplications of the bidirectional α-ketoacid transporters SLC16A3, SLC16A7, the cystine transporters SLC7A9, SLC7A11, and N-glycan branching enzymes MGAT4B, MGAT4C in Neoaves suggests a shift to the transport of deaminated essential amino acid, and stronger mitigation of oxidative stress supported by the galectin lattice.\nMaintenance of the proteasome requires oxidative phosphorylation (ATP) and mitigation of oxidative damage, in an increasingly dysfunctional relationship with aging.", "dois": ["10.1016/j.jbc.2023.105409"]}
{"pair_type": "slc_pathway", "key1": "SLC7A10", "key2": "migration", "summary": "Meanwhile, the cell viability and the rate of division and migration of SCs in the 0.80% Lys/0.40 % Met composition group were increased (p < 0.05).\nAdditionally, it altered the amino acid transport potential in muscle by upregulating the expression of the SLC7A10 gene (p < 0.05).\nIn this way, CD98hc connects the signaling pathways sustaining cell proliferation and migration, biosynthesis and antioxidant defense, energy production, and stem cell properties.\nCD98hc serves as a chaperone for LAT1 (SLC7A5), LAT2 (SLC7A8), yLAT1 (SLC7A7), yLAT2 (SLC7A6), xCT (SLC7A11) and Asc1 (SLC7A10) providing their recruitment to the plasma membrane.", "dois": ["10.3389/fonc.2023.1251100", "10.3390/ani12233406"]}
{"pair_type": "slc_pathway", "key1": "SLC7A3", "key2": "proliferation", "summary": "Additionally, the knockdown of SLC7A3 in MCF-7 and MDA-MB-231 cells resulted in increased cell proliferation and invasion .\nHigh SLC7A3 expression could serve as a prognostic indicator for favorable outcomes in breast cancer patients due to its inhibitory effects on breast cancer cell proliferation and invasion.\nAlthough Slc7a3 is highly expressed in naïve and activated CD8 T cells, neither T cell development nor activation/proliferation is impacted by Slc7a3 depletion.\nOne-by-one depletion of 13 amino acids required for cell proliferation enabled gain-of-function genetic screens using a SLC-focused CRISPR/Cas9-based transcriptional activation approach to uncover transporters relieving cells from growth-limiting metabolic bottlenecks.\nTo infer functional relationships between SLCs and metabolites, we developed a strategy to identify SLCs able to sustain cell viability and proliferation under growth-limiting concentrations of essential nutrients.\nSurprisingly, knockout of Slc7a3 (CAT3), a major L-arginine transporter, does not affect HSCs in steady-state or under stress.\nFurthermore, the Slc7a3 deletion does not attenuate leukemia development driven by Pten loss or the oncogenic Ptpn11 mutation.\nCancer cells heavily depend on the amino acid glutamine to meet the demands associated with growth and proliferation.\nInstead, we found arginine serves as an effector for mTORC1 activation to promote cell growth in response to glutamine starvation.\nOverall, this gain-of-function approach using human cells uncovered functional transporter-nutrient relationships and revealed that transport activity up-regulation may be sufficient to overcome environmental metabolic restrictions.\nAmong the transporters identified, we characterized the cationic amino acid transporter as a gene that, when up-regulated, overcame low availability of arginine and lysine by increasing their uptake, whereas SLC7A5 was able to sustain cellular fitness upon deprivation of several neutral amino acids.\nWe show that Slc7a3, an arginine transporter, is significantly induced by p53.\nWe also show that increased intracellular arginine levels", "dois": ["10.2174/0115748928279007231130070056", "10.1038/s41598-022-24554-2", "10.26508/lsa.202201404", "10.1016/j.celrep.2019.02.037", "PMID:22738901"]}
{"pair_type": "slc_pathway", "key1": "SLC7A9", "key2": "oxidative stress", "summary": "Duplications of the bidirectional α-ketoacid transporters SLC16A3, SLC16A7, the cystine transporters SLC7A9, SLC7A11, and N-glycan branching enzymes MGAT4B, MGAT4C in Neoaves suggests a shift to the transport of deaminated essential amino acid, and stronger mitigation of oxidative stress supported by the galectin lattice.\nCystine cytotoxicity in vitro and cystine stone formation in vivo were associated with oxidative stress, and salvianolic acid B could protect against cystine stone-induced injury.\nAdditionally, reduced glutathione may predispose those with cystinuria to injury caused by oxidative stress.\nHigh doses of diquat but not acetaminophen induced Slc3a1, suggesting Slc3a1 may respond to oxidative stress but not necessarily to GSH depletion.\nWe found significantly lowered levels of both reduced and total glutathione in the knockout animals.\nActivation of the NLRP3 inflammasome and marked elevations in MDA, H2O2 and ROS levels were observed both in vivo and in vitro.\nNotably, we found that the activation of NLRP3 by cystine crystal-induced ROS production was of major importance in the pathogenesis of cystine calculi formation.\nIn kidneys, we detected a decrease in GSH levels and an impairment of maximal mitochondrial respiratory capacity in cystinuric mice that l-Ergothioneine treatment was able to restore.\nIn contrast, no renal crystals were seen in the control group, and markedly fewer crystals with significantly higher antioxidase activity and diminished oxidative stress were detected in the salvianolic acid B group.\nThe protein expression of NLRP3 and IL-1β and the concentrations of oxidative stress markers such as ROS, MDA and H2O2 in kidney tissues were estimated.\nThus, l-Ergothioneine administration prevented cystine lithiasis in the Slc7a9 mouse model by increasing urinary cystine solubility and recovered renal GSH metabolism and mitochondrial function.", "dois": ["10.1016/j.redox.2023.102801", "10.1080/10715762.2020.1812597", "10.1007/s00240-019-01114-4", "10.1016/j.jbc.2023.105409", "10.1007/s11255-022-03347-6", "10.1016/j.aninu.2020.03.009", "10.1186/s12882-019-1417-8"]}
{"pair_type": "slc_pathway", "key1": "SLC7A9", "key2": "proliferation", "summary": "SLC7A9 knockdown suppressed the proliferation and increased the chemotherapy sensitivity of the cells.\nMoreover, overexpression of SLC7A9 enhanced cell proliferation and migration.\nKnockdown of SLC7A9 significantly suppressed the proliferation, invasion, and migration of the ESCC cell lines.\nSLC7A9 promotes gastric cancer progression by acting as a suppressor of ferroptosis, independent of SLC7A11, which is negatively regulated by p53.\nIn addition, extended spermine administration also markedly promoted cell proliferation, depressed apoptosis and modulated amino acid transport (p<\nRegardless of supplementation time, spermine intake significantly enhanced the expressions of amino acid transporter-related genes (SLC1A1, SLC1A5, SLC7A1, SLC7A7, and SLC15A1) in both thymus and spleen, as well as SLC7A9 in the spleen of piglets (p<0.05).\nSpermine supplementation may regulate cell cycle during the G1/S phase, suppress apoptosis and modulate amino acid transport.\nSLC7A9 influences the malignant behavior of ESCC cells.\nCCK8, cell clonality, and EdU assays were used to observe cell proliferation.\nChemotherapy was more effective in PDX and immunocompetent mice models upon SLC7A9 knockdown.\nErastin was more effective at inducing ferroptosis in PDO and PDX models upon SLC7A9 knockdown.\nThese findings indicate that dietary SAA affects jejunal cell proliferation and functions in weaning piglets.\nTumor SLC7A9 expression may serve as a novel biomarker for predicting lymph node metastasis and recurrence in ESCC patients.\nHigh SLC7A9 expression was also significantly associated with poor disease-specific and disease-free survival, and lymph node recurrence after radical surgery, but not with the other recurrence patterns.\nThe number of proliferating cells per crypt of piglets fed the high SAA diet was lower (P < 0.05) than that for low SAA diet.\nHigh mRNA expression was significantly associated with high levels", "dois": ["10.1016/j.ebiom.2024.105375", "10.1245/s10434-021-11001-1", "10.1093/jas/sky349", "PMID:29511450", "10.5713/ajas.17.0799", "PMID:22738901"]}
{"pair_type": "slc_pathway", "key1": "SLC7A8", "key2": "proliferation", "summary": "Knockdown of SLC7A8 decreased the expressions of glutaminase and glutamine synthetase, resulting in inhibited cell proliferation and sensitized CCA cells to gemcitabine treatment.\nFurthermore, we found that LAT2 could promote proliferation, inhibit apoptosis, activate glycolysis and alter glutamine metabolism to activate mTOR in vitro and in vivo.\nTaken together, our data reveal that LAT2 functions as an oncogenic protein and could regulate glutamine-dependent mTOR activation to promote glycolysis and decrease GEM sensitivity in pancreatic cancer.\nMechanistically, we demonstrated that LAT2 could regulate two glutamine-dependent positive feedback loops (the LAT2/p-mTOR loop and the glutamine/p-mTOR/glutamine synthetase loop) to promote glycolysis and decrease gemcitabine (GEM) sensitivity in pancreatic cancer.\nILC2s depend on availability of arginine and branched-chain amino acids for sustaining cellular fitness, proliferation, and cytokine secretion in both steady state and upon activation.\nL-type amino acid transporter 2 (LAT2), encoded by the SLC7A8 gene, is a Na-independent neutral amino acid transporter and is responsible for transporting neutral amino acids, including glutamine, which can activate mTOR.\nWe demonstrated that LAT2 emerged as an oncogenic protein and could decrease the gemcitabine sensitivity of pancreatic cancer cells in vitro and in vivo.\nTransporters have been reported to be amino acid sensors involved in controlling mTOR recruitment and activation, which is crucial for the growth of both normal and tumor cells.\nIn this way, CD98hc connects the signaling pathways sustaining cell proliferation and migration, biosynthesis and antioxidant defense, energy production, and stem cell properties.\nGenetic ablation of in lymphocytes reduced the frequency of ILC2s, suppressed IL-5 and IL-13 production upon stimulation, and impaired type 2 immune responses to helminth infection.\nThese findings identify as a key supplier of amino acids for the metabolic programs underpinning fitness and activation of ILC2s.", "dois": ["10.1038/s41598-025-99632-2", "10.1111/cas.16351", "10.1038/s41598-024-66945-7", "10.1038/s41598-024-58978-9", "10.18632/aging.205446", "10.3389/fonc.2023.1251100", "10.1073/pnas.2215528119", "10.1007/s10549-018-5060-z", "10.1186/s13046-018-0947-4", "10.1038/srep21194", "10.1530/REP-15-0523"]}
{"pair_type": "slc_pathway", "key1": "SLC7A10", "key2": "oxidative stress", "summary": "These data uncover adipocyte SLC7A10 as a novel important regulator of adipocyte resilience to nutrient and oxidative stress, in part by enhancing glutathione levels and mitochondrial respiration, conducive to decreased ROS generation, lipid accumulation, adipocyte hypertrophy, insulin resistance, and type 2 diabetes.\nConversely, SLC7A10 overexpression decreases ROS generation and increases mitochondrial respiratory capacity.\nMechanistically, SLC7A10 inhibition in human and murine adipocytes decreases adipocyte serine uptake and total glutathione levels and promotes reactive oxygen species (ROS) generation.\nInterestingly, ROS scavenger reduced lipid accumulation and attenuated the lipid-storing effect of SLC7A10 inhibition.\nElucidation of mechanisms that govern lipid storage, oxidative stress, and insulin resistance may lead to improved therapeutic options for type 2 diabetes and other obesity-related diseases.", "dois": ["10.2337/db20-0096"]}
{"pair_type": "slc_pathway", "key1": "SLC7A13", "key2": "ferroptosis", "summary": "Molecularly, SLC7A13 silencing reduced cystine uptake and GSH biosynthesis, leading to increased lipid ROS levels.\nCancer cells often uptake more cystines to increase glutathione (GSH) biosynthesis and reduce reactive oxygen species (ROS), thereby preventing ROS-induced ferroptosis and leading to therapeutic resistance.\nFunctionally, SLC7A13 overexpression promoted, while its silencing attenuated, cell survival or proliferation.", "dois": ["10.1093/procel/pwaf076"]}
{"pair_type": "slc_pathway", "key1": "SLC7A13", "key2": "proliferation", "summary": "Functionally, SLC7A13 overexpression promoted, while its silencing attenuated, cell survival or proliferation.\nMolecularly, SLC7A13 silencing reduced cystine uptake and GSH biosynthesis, leading to increased lipid ROS levels.\nCancer cells often uptake more cystines to increase glutathione (GSH) biosynthesis and reduce reactive oxygen species (ROS), thereby preventing ROS-induced ferroptosis and leading to therapeutic resistance.\nSLC7A13 amplification and overexpression were associated with worse overall survival and disease-free survival in patients with luminal breast cancer.\nHere, we report that the gene for SLC7A13, a member of the SLC7A13-SLC3A1 cystine transporter, was amplified and overexpressed in 19.7% and 49.7% of breast cancers, respectively.\nThese findings suggest that the SLC7A13-SLC3A1 cystine transporter is a therapeutic target for treating luminal breast cancer.", "dois": ["10.1093/procel/pwaf076"]}
{"pair_type": "slc_pathway", "key1": "SLC7A4", "key2": "apoptosis", "summary": "Further, we found that the high expression level of SLC7A4 increased the ATG4B stability and was conducive to rapid reaction to everolimus (RAD001)-induced autophagy in human lung cancer cells.\nAs expected, the results showed that SLC27A4 could help to maintain the protein stability and intracellular concentration of ATG4B, thereby triggering rapid autophagy through releasing ATG4B to cytoplasm under conditions of reduced nutrient availability or during stress of chemotherapy in lung cancer cells.\nReduced SLC27A4 by si-RNA also showed the enhanced therapeutic efficiency of everolimus, doxorubicin, and cisplatin in human lung cancer cell lines.\nAutophagy is a highly conserved self-digestion process to promote cell survival in response to nutrient starvation and other metabolic stresses in eukaryotic cells.", "dois": ["10.1007/s13277-015-4587-4"]}
{"pair_type": "slc_pathway", "key1": "SLC7A14", "key2": "apoptosis", "summary": "The mitochondrial PARL protease has been recently known to play a role with a dynamin-related OPA1 protein in preventing apoptotic events by slowing down the release of cytochrome c out of mitochondrial cristae junctions.\nMoreover, PARL is required to activate the intramembranous proteolyses resulting in the degradation of an accumulated pro-apoptotic protein in the outer mitochondrial membrane.\nUnder these circumstances, variants of PARL are suggested to influence cell death by apoptosis which has long been believed to intrigue the neurodegeneration of LHON.", "dois": ["10.1007/s00439-010-0821-8"]}
{"pair_type": "slc_pathway", "key1": "SLC7A14", "key2": "oxidative stress", "summary": "Further, through multi-database prediction and experimental verification, a F-T2DM-specific ceRNA network was constructed, and key regulatory axes hsa_circ_0044623/hsa-mir-129-5p/MYLK3, hsa_circ_0002622/hsa-mir-200b-3p/RAB21, and hsa_circ_0078539/hsa-mir-4695-3p/SLC7A14 were screened out.\nThe GO/KEGG enrichment analysis combined with weighted gene co-expression network (WGCNA) of F-T2DM compared with Control indicated that the core pathways of F-T2DM focused on actin cytoskeleton dynamic regulation, AMPK signaling pathway, tricarboxylic acid cycle, and oxidative stress response.\nIn the enrichment analysis of F-T2DM and NF-T2DM, cytoskeleton dynamics regulation, AMPK signaling pathway, and tricarboxylic acid cycle were further enriched, and the specific activation of reactive oxygen metabolism balance and AGE-RAGE pathway was also observed.\nThese axes drive the pathological process by regulating myocardial contractility efficiency, glucose transport, mitochondrial energy metabolism, and insulin signaling pathway.", "dois": ["10.1186/s12967-025-07007-y"]}
{"pair_type": "slc_pathway", "key1": "SLC8A1", "key2": "chemotherapy", "summary": "The results of experiments revealed that SLC8A1 promotes proliferation and inhibits the apoptosis and concentration of calcium ions in HTR-8/SVneo cells.\nFour additional genes were significantly downregulated: SLC2A14, SLC6A15, SLC8A1 and SLC27A2.\nAfter 1 week of first line chemotherapy, no response was found.\nABCB1, SLC8A1, and SLC12A8 were associated with breast cancer survival in SEBCS (P < 0.05).\nIn results of MDR development during chemotherapy cancer cells become resistant to further treatment.\nABCB1 rs1202172 was differentially associated with survival depending on the chemotherapy (P = 0.035).\nThe population of SEBCS consisted of 1338 breast cancer patients who had been treated with adjuvant chemotherapy.\nSLC8A1 was identified as a hub gene within RSA and was highly expressed in uterine corpus endometrial carcinoma (UCEC).\nassays were performed to determine whether SLC8A1 influences HTR-8/SVneo cell proliferation, apoptosis and the concentration of calcium ions.\nThese findings suggest that SLC8A1 may serve as a promising prognostic biomarker and potential target for immunotherapy in the context of RSA and UCEC.\nA prognostic prediction was made to assess the impact of the hub genes on the cancer response, mutation burden, immune microenvironment, immune checkpoint, and chemotherapy.\nABC and SLC transporters are most important proteins responsible for this phenomenon.\nMembrane transporters can be major determinants of the pharmacokinetic profiles of anticancer drugs.\nIdentifying correlations between specific drug transporters and cytostatic drug resistance will require further investigation.\nThe cytostatic resistant sublines were generated by culture of A2780 cell line with an increasing concentration of the indicated drugs.\nIn this study changes of ABC and SLC genes expression pattern in drugs resistant sublines of the A2780 ovarian cancer cell line were demonstrated.\nExpression profiles of these genes give strong arguments for assumption of correlation between expression of ABC and SLC genes and drug resistance phenomenon.", "dois": ["10.1016/j.heliyon.2024.e36899", "10.3389/fonc.2022.898954", "10.1038/s41397-018-0016-6", "10.1016/j.biopha.2014.02.002"]}
{"pair_type": "slc_pathway", "key1": "SLC8A1", "key2": "ferroptosis", "summary": "Our findings demonstrate that circSLC8A1 triggers neuronal ferroptosis by stabilizing ATF3 mRNA expression through recruitment with FUS.\nIn this study, we investigated the potential involvement of circSLC8A1 in epilepsy progression and its connection to ferroptosis and oxidative stress.\nAdditionally, circRNA SLC8A1 (circSLC8A1) has been implicated in various neurological disorders and oxidative stress-related diseases but its involvement in epilepsy progression, particularly in relation to ferroptosis and oxidative stress, remains unclear.\nThe induced neuronal ferroptosis contributes to epilepsy progression.\nFerroptosis, a recently defined iron-dependent regulated cell death, has been suggested as a potential therapeutic target for epilepsy due to its association with oxidative stress.", "dois": ["10.1016/j.gene.2024.148381", "10.1016/j.yexcr.2023.113848"]}
{"pair_type": "slc_pathway", "key1": "SLC7A4", "key2": "proliferation", "summary": "As one of the important treatments for prostate cancer, androgen deprivation therapy (ADT) inhibits tumor proliferation by controlling androgen levels, either surgically or pharmacologically.\nHowever, patients treated with ADT inevitably develop biochemical recurrence and advance to castration-resistant prostate cancer which has been reported to be associated with androgen biosynthetic and catabolic pathways.\nFunctional enrichment analysis revealed some pivotal pathways that may have an impact on the prognosis of patients including the CDK-RB-E2F axis, G2M checkpoint, and KRAS signaling.", "dois": ["10.3389/fonc.2022.950094"]}
{"pair_type": "slc_pathway", "key1": "SLC8A2", "key2": "oxidative phosphorylation", "summary": "Flx treatment in CSIS rats stimulated synaptic vesicle trafficking by increasing the regulation of exo/endocytosis-associated proteins, proteins involved in synaptic plasticity including neurogenesis, Cox5a, mitochondria-associated proteins involved in oxidative phosphorylation, and ion transport proteins (Slc8a2, Atp1b2).", "dois": ["10.1016/j.jprot.2023.104925"]}
{"pair_type": "slc_pathway", "key1": "SLC8A2", "key2": "proliferation", "summary": "Overexpression of SLC8A2 had no effect on cell proliferation or cell cycle, but impaired the invasion and migration of U87MG cells, most likely through inactivating the extracellular signal-related kinases (ERK)1/2 signaling pathway, inhibiting the nuclear translocation and DNA binding activity of nuclear factor kappa B (NF-κB), reducing the level of matrix metalloproteinases (MMPs) and urokinase-type plasminogen activator (uPA)-its receptor (uPAR) system (ERK1/2-NF-κB-MMPs/uPA-uPAR), and altering the protein levels of epithelial to mesenchymal transitions (EMT)-associated proteins E-cardherin, vimentin and Snail.\nTherefore, we hypothesized that SLC8A2 might be a glioma tumor suppressor gene and detected the role of SLC8A2 in glioblastoma and explored the underlying molecular mechanism.\nIn addition, SLC8A2 inhibited the angiogenesis of U87MG cells, probably through combined inhibition of endothelium-dependent and endothelium-nondependent angiogenesis (vascular mimicry pattern).\nFinally, we confirmed that these 3 genes might promotes glioma proliferation and migration in vitro.\nIn the present study, we found that the tumorigenicity of U87MG in nude mice was totally inhibited by SLC8A2.\nTotally, SLC8A2 serves as a tumor suppressor gene and inhibits invasion, angiogenesis and growth of glioblastoma.", "dois": ["10.1007/s12672-024-01653-2", "10.14348/molcells.2017.0104"]}
{"pair_type": "slc_pathway", "key1": "SLC7A2", "key2": "migration", "summary": "Knockdown of SLC7A2 promoted viability, invasion and migration of OV cells.\nAs shown in cell culture experiments, FaDu and SCC15 cell growth, invasion, and migration were inhibited when SLC7A2 was overexpressed.\nThrough experiments, we demonstrated that knocking down CDH19 can affect the transcription levels of ACSL4 and GPX4, increase intracellular iron ion concentration and accumulation of reactive oxygen species (ROS), and inhibit the proliferation and migration of GC cells.\nAnimal studies demonstrated that the growth and LNM of HNSCC cells were inhibited by SLC7A2 overexpression.\nExpression levels of endometrial GRP, IGFBP1, and LGALS15, whose products stimulate trophectoderm cell migration and attachment, were increased by PGE2, PGI2, and IFNT.\nFurther, cell apoptosis was stimulated, and lymphangiogenesis was suppressed through the downregulation of CPB2 expression.\nIn the findings, a key gene involved in the LNM of HNSCC was identified as SLC7A2.\nIt is concluded that SLC7A2 is involved in HNSCC lymphatic metastasis by controlling CPB2 function.\nThese genes are associated with cell growth, invasion, migration, apoptosis and cancer development.\nMoreover, the effect of core gene expression on the LNM capability of HNSCC was confirmed via a footpad xenograft mice model.\nThe functions of these core genes were then validated using the TCGA biological database and their effects on the propagation, invasion, and metastasis of HNSCC cells were evaluated through cell culture experiments.", "dois": ["10.1186/s40246-024-00682-w", "10.1002/cam4.70273", "10.18632/aging.103433", "10.1016/j.taap.2020.115030", "PMID:30662604", "PMID:22738901", "10.1095/biolreprod.112.100487"]}
{"pair_type": "slc_pathway", "key1": "SLC8A3", "key2": "oxidative stress", "summary": "These results suggest that TGF-β contributes to the regulation of SLC8A3 expression in developing dopaminergic and dorsal raphe serotonergic neurons, thereby preventing oxidative stress.\nThe results show that SLC8A3 is significantly downregulated in developing dopaminergic and dorsal raphe serotonergic neurons in mutants and that low SLC8A3 abundance prevents the expression of the anti-apoptotic protein Bcl-xL.\nIn neurons lacking TGF-β signaling, the number of MDA- and 4-hydroxynonenal (4-HNE)-positive cells was significantly increased, accompanied with increased cellular 4-HNE abundance.\nExpression of the lipid peroxidation marker malondialdehyde (MDA) was increased following knockdown of expression in vitro.", "dois": ["10.3390/ijms21082735"]}
{"pair_type": "slc_pathway", "key1": "SLC8A1", "key2": "apoptosis", "summary": "Down-regulation of the SLC8A1 gene, most likely mediated by its regulator miR-223, can lead to decreased calcium in penile carcinoma and consequently to suppressed apoptosis and increased tumor cell proliferation.\nThe results of experiments revealed that SLC8A1 promotes proliferation and inhibits the apoptosis and concentration of calcium ions in HTR-8/SVneo cells.\nExogenous overexpression of ZNF503-AS1 or SLC8A1 attenuated bladder cancer cell proliferation, invasion and migration, but promoted their apoptosis, accompanied by decreased Ca-ATPase activities and increased intracellular Ca concentrations.\nOverexpression of circRNA_SLC8A1 reduced cell viability, cell invasion, wound healing, and the expression of Vimentin, N-cadherin, Col I, and Col III, while enhancing apoptosis and E-cadherin expression in HSFs.\nZNF503-AS1 can recruit transcription factor GATA6 to up-regulate SLC8A1 expression, thereby increasing the intracellular Ca concentration and repressing the proliferation, invasion and migration, and enhancing the apoptosis of bladder cancer cells.\nConsistently, apoptosis of PTC cells was enhanced by SLC8A1-AS1 overexpression.\nSilencing lncRNA 93358 inhibits the apoptosis of myocardial cells in rats with myocardial infarction by inducing the expression of SLC8A1.\nWe discovered a correlation between gene expression and the 3D chromatin architecture of SLC8A1, which encodes a sodium-calcium antiporter whose modulation is known to induce apoptosis by comparison between HCC cell lines and HMECs.\nWe investigated whether dysregulation of SLC8A1 expression is associated with apoptosis and cell proliferation in penile carcinoma via modulation of the calcium concentration.\nWe demonstrated that SLC8A1 selective pharmacological inhibition, through CB-DMB, significantly reduced cancer proliferation and induced Ca-dependent cell death in GC cells, both alone and synergically with cisplatin treatment.", "dois": ["10.1016/j.biopha.2024.117787", "10.1007/s11033-024-10018-5", "10.1007/s12013-024-01528-x", "10.1111/iep.12475", "10.1155/2022/1138709", "10.1007/s13402-020-00563-z", "10.1016/j.juro.2014.11.097", "10.1016/j.toxrep.2025.102058", "10.1016/j.heliyon.2024.e36899", "10.1038/s41598-024-55493-9", "10.1155/2023/9812061", "10.5808/gi.23015", "10.3389/fgene.2022.899034", "10.1080/21655979.2022.2073125", "10.1002/mc.22678", "10.1152/physiolgenomics.00032.2010"]}
{"pair_type": "slc_pathway", "key1": "SLC7A11", "key2": "stemness", "summary": "MiR-375 can trigger the ferroptosis through targeting SLC7A11, which is essential for miR-375-mediated inhibition on GC cell stemness.\nTogether, our results reveal that enhanced stemness increases the susceptibility to ferroptosis, and the DUBA-SLC7A11-c-Myc axis is pivotal for differentiated cancer stem cells (CSCs) resistant to ferroptosis, providing a promised targets to eradicate CSCs through ferroptosis.\nOur results demonstrate that the overexpression of SLC7A11-AS1 in gemcitabine-resistant PDAC cells can scavenge ROS by blocking SCF-mediated ubiquitination and degradation of NRF2, leading to a low level of intracellular ROS, which is required for the maintenance of cancer stemness.\nAdditionally, DUBA promotes stemness by deubiquitinating SLC7A11.\nMoreover, circRPPH1 promoted the stemness of gastric cancer cells dependent on the miR-375/SLC7A11.\nOverexpression of SLC7A11-AS1 enhanced the activin A-induced Smad2/3 phosphorylation and promoted cancer stemness properties in PDAC cells.\nAdditionally, the inhibitory effects of Tanshinone IIA on GC cell stemness were reversed by ferroptosis inhibitor (Fer-1) or overexpression of SLC7A11, which is a critical ferroptosis inhibitor.\nIn addition, bioinformatic analysis and luciferase assays were used to identify E2F1 as a critical upstream transcription factor of SLC7A11 (the gene encoding for xCT) that facilitated CRC progression and cell stemness.\nThese results suggest that the miR-375/SLC7A11 regulatory axis could serve as a potential target to provoke the ferroptosis and thus attenuate the stemness of GC cells.\nMechanistically, SLC7A11 was identified as a direct target of miR-375 and miR-375 attenuated the stemness of GC cells mainly through triggering SLC7A11-dependent ferroptosis.", "dois": ["10.32604/or.2025.070031", "10.56434/j.arch.esp.urol.20257808.140", "10.1038/s41586-025-09589-5", "10.3164/jcbn.24-240", "10.1038/s41416-025-03149-4", "10.1038/s41698-025-01004-6", "10.1093/stmcls/sxaf024", "10.1186/s40001-025-02411-y", "10.1016/j.canlet.2024.217396", "10.1007/s12672-024-01612-x", "10.7150/jca.89429", "10.14715/cmb/2024.70.8.29", "10.1021/acs.jafc.4c00118", "10.1038/s41420-024-02035-x", "10.1016/j.heliyon.2024.e28093", "10.3892/ol.2024.14320", "10.1097/MD.0000000000036830", "10.3389/fonc.2023.1251100", "10.1038/s41388-023-02744-0", "10.3389/fgene.2023.1193944", "10.1002/tox.23668", "10.1038/s41375-022-01573-6", "10.1038/s41419-022-04827-4", "10.1080/21655979.2021.2011633", "10.1002/tox.23388", "10.1186/s13287-021-02394-7", "10.3390/nano10101951", "10.1016/j.omtn.2019.11.035"]}
{"pair_type": "slc_pathway", "key1": "SLC8A3", "key2": "proliferation", "summary": "In all four cell lines we observed a concentration-dependent increase in the number of apoptotic cells, as well as reduced migration and proliferation.\nThese results indicate the role of NCX3 in cancer cell migration, proliferation and apoptosis, as inhibition of NCX1 by the specific blocker SEA0400 had no significant effect on these parameters.\nWe observed that TET2 deficiency caused impaired muscle stem cell proliferation and differentiation, resulting in the reduction in both myofiber number and muscle tissue size.\nForced expression of the sodium/calcium exchanger protein SLC8A3 could rescue the myogenic defects in TET2 knockout cells.\nIn conclusion, we have clearly shown that NCX3 plays an important anti-apoptotic, pro-migratory and proliferative role in the cancer cells by affecting mitochondrial bioenergetics, thus supporting their survival and fate.", "dois": ["10.1016/j.ejcb.2025.151493", "10.1038/s41420-022-01041-1"]}
{"pair_type": "slc_pathway", "key1": "SLC8A3", "key2": "migration", "summary": "Finally, our study identified two previously unreported model genes (SLC8A3 and SLC24A4) that contribute to the growth and migration of colorectal cancer RKO cells.\nThese results indicate the role of NCX3 in cancer cell migration, proliferation and apoptosis, as inhibition of NCX1 by the specific blocker SEA0400 had no significant effect on these parameters.\nAltogether, we developed a prognostic risk model for predicting the prognosis of COAD patients based on the expression profiles of calcium extrusion-related genes, Furthermore, we validated two previously unreported tumor suppressor genes (SLC8A3 and SLC24A4) involved in colorectal cancer progression.\nIn all four cell lines we observed a concentration-dependent increase in the number of apoptotic cells, as well as reduced migration and proliferation.\nIn conclusion, we have clearly shown that NCX3 plays an important anti-apoptotic, pro-migratory and proliferative role in the cancer cells by affecting mitochondrial bioenergetics, thus supporting their survival and fate.\nIn this study, we used the selective blocker of NCX3 - YM-244769 to investigate changes in apoptosis induction, migration, proliferation, intracellular calcium and ATP in four cancer cell lines - DLD1, HeLa, MDA-MB-231 and JIMT1.\nHowever, we verified the effect of NCX3 inhibition by using CRISPR/Cas9 to generate clones in which the SLC8A3 (NCX3) gene was deleted, and we obtained the same results.\nFinally, colorectal cancer cells migration, growth and colony formation assays were performed in RKO cells with the overexpression or knockdown SLC8A3, SLC24A2, SLC24A3, or SLC24A4.", "dois": ["10.1016/j.ejcb.2025.151493", "10.7717/peerj.17582", "10.1016/j.ympev.2014.06.019"]}
{"pair_type": "slc_pathway", "key1": "SLC8B1", "key2": "migration", "summary": "Yet, NCLX is necessary for ASM cell proliferation and migration.\nFinally, our study identified two previously unreported model genes (SLC8A3 and SLC24A4) that contribute to the growth and migration of colorectal cancer RKO cells.\nThrough cellular imaging, RNA-Seq, and biochemical assays, we demonstrate that NCLX regulates these processes by preventing mitochondrial Ca overload and supporting store-operated Ca entry, activation of Ca/calmodulin-dependent kinase II, and transcriptional and metabolic reprogramming.\nCalcium (Ca) is a ubiquitous second messenger that regulates many cellular processes, including proliferation, migration, contraction, and metabolism.\nFurthermore, mitochondria have emerged as major Ca signaling organelles that buffer Ca through uptake by the mitochondrial Ca uniporter and extrude it through the Na/Ca exchanger (NCLX/Slc8b1).\nUsing small animal respiratory mechanic measurements and immunohistochemistry, we show that smooth muscle-specific NCLX KO mice are protected against AR, fibrosis, and hyperresponsiveness in an experimental model of asthma.\nDuring AR, ASM cells dedifferentiate from a quiescent to a proliferative, migratory, and secretory phenotype.", "dois": ["10.7717/peerj.17582", "10.1016/j.jbc.2022.102259"]}
{"pair_type": "slc_pathway", "key1": "SLC8A1", "key2": "migration", "summary": "Exogenous overexpression of ZNF503-AS1 or SLC8A1 attenuated bladder cancer cell proliferation, invasion and migration, but promoted their apoptosis, accompanied by decreased Ca-ATPase activities and increased intracellular Ca concentrations.\nDown-regulation of lncRNA SLC8A1-AS1 suppressed the proliferation, colony formation, migration, and invasion of glioma cells in vitro and in vivo.\nCircRNA_SLC8A1 inhibits the proliferation, migration, EMT, and collagen deposition of HSF through competitive binding with miRNA-27a-3p, thereby activating the Nrf2-ARE pathway.\nZNF503-AS1 can recruit transcription factor GATA6 to up-regulate SLC8A1 expression, thereby increasing the intracellular Ca concentration and repressing the proliferation, invasion and migration, and enhancing the apoptosis of bladder cancer cells.\nOver-expression of circSLC8A1 inhibited cell migration, invasion and proliferation both in vitro and in vivo.\nFurthermore, the inhibitory effects of SLC8A1-AS1 on the proliferation, migration, and invasion of OSCC cells were reversed by the introduction of miR-1305 mimics.\nOverexpression of miRNA-27a-3p counteracted the effects of circRNA_SLC8A1 in HSF proliferation, apoptosis, migration, EMT, collagen deposition, and Nrf2-ARE pathway activity.\nSLC8A1-AS1 overexpression attenuated the invasion and migration of PTC cells.\nOverexpression of SLC8A1-AS1 inhbited the proliferation, migration, and invasion of OSCC cells.\nMoreover, lncRNA SLC8A1-AS1 silencing decreased the activity of the Wnt/β-catenin pathway and suppressed the epithelial to mesenchymal transition (EMT) in glioma cells.\nOverexpression of circRNA_SLC8A1 reduced cell viability, cell invasion, wound healing, and the expression of Vimentin, N-cadherin, Col", "dois": ["10.1007/s12672-025-03586-w", "10.1007/s11033-024-10018-5", "10.7717/peerj.17582", "10.3892/br.2023.1708", "10.1016/j.brainresbull.2023.110706", "10.1080/21655979.2022.2073125", "10.1016/j.brainresbull.2021.08.011", "10.1007/s13402-020-00563-z", "10.1016/j.psj.2019.10.021", "10.1186/s12943-019-1040-0"]}
{"pair_type": "slc_pathway", "key1": "SLC8B1", "key2": "oxidative phosphorylation", "summary": "Analyses of opah's unique inner-heat-producing pectoral muscle layer (PMI), an evolutionary key innovation, revealed that many proteins were co-opted from dorsal swimming muscles for thermogenesis and oxidative phosphorylation.\nTo understand the molecular basis of endothermy, we analyzed the opah genome and identified 23 genes with convergent amino acid substitutions across fish, birds, and mammals, including , which encodes the mitochondrial Na/Ca exchanger and is essential for heart function and metabolic heat production.", "dois": ["10.1016/j.xinn.2021.100185"]}
{"pair_type": "slc_pathway", "key1": "SLC8A3", "key2": "apoptosis", "summary": "BRF2 expression was upregulated in squamous carcinoma cells, which increased SLC8A3 protein expression, promoted mitochondrial autophagy, stabilized MMP, and reduced apoptosis.\nIn addition, SLC8A3 overexpression inhibited PTEN-induced putative kinase 1 (PINK1) binding to TIMM23 to promote mitochondrial autophagy and stabilize the MMP, which counteracted BRF2 knockdown-induced apoptosis.\nBRF2 mediated SLC8A3 expression to reduce apoptosis in LUSC cells by maintaining mitochondrial homeostasis.\nOn the other hand, apoptosis and Ca uptake as well as protein levels of caspase 3 were significantly increased by SLC8A3 silencing in H9c2 cells under normoxic conditions, and this symptom was remarkably reversed by echinacoside or Nimodipine (an antagonis of Ca) treatment.\nThe present results indicated that echinacoside protected against A/R-induced apoptosis in a dose manner, which was characterized by a decrease in the apoptosis and caspase 3 protein levels in H9c2 cells.\nThe results show that SLC8A3 is significantly downregulated in developing dopaminergic and dorsal raphe serotonergic neurons in mutants and that low SLC8A3 abundance prevents the expression of the anti-apoptotic protein Bcl-xL.\nThese results indicate the role of NCX3 in cancer cell migration, proliferation and apoptosis, as inhibition of NCX1 by the specific blocker SEA0400 had no significant effect on these parameters.\nIn conclusion, we have clearly shown that NCX3 plays an important anti-apoptotic, pro-migratory and proliferative role in the cancer cells by affecting mitochondrial bioenergetics, thus supporting their survival and fate.", "dois": ["10.1038/s41419-025-07813-8", "10.1016/j.ejcb.2025.151493", "10.3390/ijms21082735", "10.1016/j.biopha.2018.04.188", "10.3390/genes11020117"]}
{"pair_type": "slc_pathway", "key1": "SLC8A3", "key2": "chemotherapy", "summary": "Intriguingly, promoter hypomethylation of SLC8A3 and mutant SLC7A8 were enriched in an identical pathway, protein digestion and absorption, indicating a potentially novel MDR mechanism during treatments.\nPromoter methylation dynamics during treatments revealed 8 drug resistance protein-coding genes characterized by hypomethylation in promoter regions.\nNotably, SLC7A8 was identified as a potentially novel MDR gene, and functional assays demonstrated that mutant SLC7A8 promoted the resistance phenotypes of ESCC cell lines.\nSubclonal expansions driven by the beneficial new mutations were observed during combined therapies, which explained the emergence of MDR.\nOur integrated multiomics investigations revealed the dynamics of temporal genetic and epigenetic inter- and intratumoral heterogeneity, clonal evolutionary processes, and epigenomic changes, providing potential MDR therapeutic targets in treatment-resistant patients with ESCC during combined therapies.\nPatients with progressive disease exhibited a substantially higher genomic and epigenomic temporal heterogeneity.", "dois": ["10.1172/jci.insight.150203"]}
{"pair_type": "slc_pathway", "key1": "SLC9A1", "key2": "chemotherapy", "summary": "In summary, a higher level of hsa-miR-12462 in AML cells is associated with increased sensitivity to cytarabine chemotherapy via downregulation of SLC9A1.\nThe AML cells overexpressing hsa-miR-12462 had increased sensitivity to cytarabine chemotherapy.\nhsa-miR-12462 was further confirmed to bind exclusively to the 3'UTR of SLC9A1 in U937 cells, leading to downregulation of SLC9A1.", "dois": ["10.1186/s13045-020-00935-w", "10.1158/1541-7786.MCR-14-0011"]}
{"pair_type": "slc_pathway", "key1": "SLC8B1", "key2": "proliferation", "summary": "Yet, NCLX is necessary for ASM cell proliferation and migration.\nThrough cellular imaging, RNA-Seq, and biochemical assays, we demonstrate that NCLX regulates these processes by preventing mitochondrial Ca overload and supporting store-operated Ca entry, activation of Ca/calmodulin-dependent kinase II, and transcriptional and metabolic reprogramming.\nDuring AR, ASM cells dedifferentiate from a quiescent to a proliferative, migratory, and secretory phenotype.\nUsing small animal respiratory mechanic measurements and immunohistochemistry, we show that smooth muscle-specific NCLX KO mice are protected against AR, fibrosis, and hyperresponsiveness in an experimental model of asthma.\nCalcium (Ca) is a ubiquitous second messenger that regulates many cellular processes, including proliferation, migration, contraction, and metabolism.\nFurthermore, mitochondria have emerged as major Ca signaling organelles that buffer Ca through uptake by the mitochondrial Ca uniporter and extrude it through the Na/Ca exchanger (NCLX/Slc8b1).", "dois": ["10.1016/j.jbc.2022.102259"]}
{"pair_type": "slc_pathway", "key1": "SLC9A1", "key2": "glycolysis", "summary": "SLC9A1 plays an important role in the growth, differentiation and glycolysis of tumor cells.", "dois": ["10.7554/eLife.78425", "10.1016/j.lfs.2021.119613"]}
{"pair_type": "slc_pathway", "key1": "SLC7A5", "key2": "chemotherapy", "summary": "SLC7A5 can predict therapeutic response to immunotherapy, radiotherapy and chemotherapy in bladder cancer patients.\nPreclinical studies of At-labeled transporter ligands, particularly LAT1-targeted conjugates, demonstrate potent tumor suppression and synergy with targeted therapy, chemotherapy, radiotherapy, immunotherapy, and ferroptosis inducers.\nTargeting LAT1 with JPH203 enhances cisplatin sensitivity, suggesting that LAT1 inhibition could be a promising therapeutic strategy for overcoming chemoresistance in ESCC.\nFurthermore, we show that the OS of established glioblastoma-bearing mice can be significantly enhanced (by >300% compared to that for the untreated mouse group) when the presently described LAT1 mediated targeted chemotherapy with WP1066-loaded liposomes of Amphi-DOPA is combined with in vivo DC-targeted DNA vaccination using a survivin (a glioblastoma antigen) encoded DNA vaccine.\nAdditionally, the knockdown of SLC7A5 enhanced the sensitivity of oxaliplatin-resistant GC cells to oxaliplatin both in vitro and in vivo.\nThe low PCDRS group exhibited higher levels of anti-cancer immunity and responded better to immune checkpoint inhibitors as well as chemotherapy-related drugs.\nTreatment with JPH203 significantly suppressed cell proliferation, particularly in KYSE520 cells, indicating LAT1's role in sustaining tumor cell survival under chemotherapy stress.\nThe understanding gained from our research can be used in the development of LAT1-targeted anticancer drugs and prodrugs for site-selective and enhanced chemotherapeutic activity.\nLAT1 as an independent prognostic marker is a potential molecular targeting gene to reduce chemoresistance and tumor growth in patients with PDAC, supported by our in vitro study.\nLAT1 contributes to cisplatin resistance in ESCC by sustaining amino acid metabolism and promoting mTOR-dependent autophagy.\nTargeting SLC7A5 in combination with immunotherapy may be a potentially appropriate treatment option.\nAnti-SLC7A5 combined with cancer immunotherapy may have greater effectiveness than either therapy alone.\nBioinformatics analysis and experimental validation indicate that SLC7A5", "dois": ["10.3390/ijms262110736", "10.3390/ijms26178599", "10.1002/cam4.71234", "10.1186/s12885-025-14282-x", "10.21873/anticanres.16418", "10.1159/000517371", "10.1080/01652176.2021.1906466", "10.1038/s41598-020-80668-5", "10.1111/andr.12880", "10.3390/ijms21062132", "10.1007/s00428-019-02520-0", "10.1093/jrr/rrx080", "10.1007/s00280-017-3477-4", "10.1021/acs.molpharmaceut.7b00569", "10.1002/smll.201601249", "10.1016/j.bbmt.2014.03.022", "10.14670/HH-29.217", "10.1002/jps.23601", "PMID:22110199", "10.1111/j.1349-7006.2011.02151.x", "10.1186/bcr2604", "10.1158/1078-0432.CCR-08-0647", "10.1042/BJ20080622", "10.1007/s40291-025-00810-9", "10.1186/s10020-025-01175-9", "10.3389/fonc.2024.1505934", "10.1016/j.ejmech.2024.116841", "10.1186/s12935-024-03365-7", "10.1016/j.radonc.2024.110259", "10.3390/ijms25021063", "10.1186/s12935-023-02957-z", "10.21873/anticanres.15647", "10.1016/j.apsb.2021.09.019", "10.1074/jbc.M115.700534", "10.1200/JCO.2012.42.8896", "10.1016/j.ygyno.2010.01.041"]}
{"pair_type": "slc_pathway", "key1": "SLC9A1", "key2": "ferroptosis", "summary": "The PPI network analysis identified 12 hub genes, and we further verified that Ator elevated the mRNA expression levels of hemoglobin (, , , and ), carbonic anhydrase (, HIF-1 () and Na+/H+ exchanger ( and ) genes, while STS significantly suppressed these genes.\nKEGG analysis suggested that these 53 DEGs were most enriched in three items, namely, porphyrin and chlorophyll metabolism, ferroptosis, and the HIF-1 signaling pathway.\nWe concluded that hemoglobin, carbonic anhydrase, Na+/H+ exchanger and HIF-1 genes might be potential biomarkers of Ator-induced cerebral hemorrhage in zebrafish, as well as pharmacological targets of STS.", "dois": ["10.3389/fphar.2020.551745"]}
{"pair_type": "slc_pathway", "key1": "SLC7A5", "key2": "migration", "summary": "Knockdown of SLC7A5 obviously decreased the viability, migration, and invasion of oxaliplatin-resistant GC cells in vitro and tumor growth in vivo.\nand functional experiments confirmed that the ZNF24-SLC7A5 signaling axis promoted the proliferation, invasion and migration of KRAS mutant lung adenocarcinoma.\nSLC7A5 was associated with adverse prognosis in bladder cancer patients, activating the Wnt pathway and promoting bladder cancer cell cycle progression, proliferation, migration, and invasion.\nCirc-SLC7A5 depletion impaired cell growth, migration, invasiveness, and promoted apoptosis.\nKnocking down SLC7A5 significantly inhibited human and mouse TNBC cell proliferation, migration, and invasion.\nFinally, the proliferation and migration abilities of HNSCC cells significantly decreased after the expression of IGF2BP2 and SLC7A5 reduced.\nBy depleting CRKL in gastric cancer SGC-7901 cells, the SLC7A5 expression was impaired, and the invasion and migration of SGC-7901 cells were suppressed.\nOur results also showed that the knockdown of MIF, SOD2 and SLC7A5 by RNAi significantly decreased the proliferation and migration abilities of HEC-1A cells (p < 0.05).\nSLC7A5 deficiency abrogated proliferation, migration and mTORC1 pathway activity.\nLAT1 (SLC7A5) plays a crucial role in mediating the uptake of amino acids into breast cancer cells, influencing proliferation, invasion, migration, drug resistance, and prognosis through the mTOR signaling pathway.\nFurthermore, the depletion of LAT1 reduced PMA-induced cell migration in a wound-healing assay.\nThis correlated with increase in glutaminase 1 (GLS1) expression, whose inhibition reduced cell migration.\nProliferation assay and wound healing assay validated the effects of SLC7A5 on proliferation and migration of LUAD cells.\nCell survival, migration, and invasion experiments found that hsa_circ_0032462 and S", "dois": ["10.1186/s13046-025-03446-z", "10.1186/s12964-024-01964-5", "10.1016/j.ejmech.2024.117064", "10.1016/j.bone.2024.117333", "10.3390/ijms252011266", "10.1186/s12964-024-01826-0", "10.1111/cas.16259", "10.1002/cam4.7217", "10.1111/cas.16191", "10.1111/cas.16062", "10.1158/1078-0432.CCR-23-2025", "10.3390/cells12202504", "10.1007/s12013-023-01183-8", "10.3389/fimmu.2023.1251643", "10.1038/s41598-023-41096-3", "10.1155/2022/2373580", "10.3390/ijms22136706", "10.1002/iid3.477", "10.1016/j.exer.2021.108650", "10.1186/s13046-020-01762-0", "10.1038/s41598-019-53397-7", "10.1016/j.bbrc.2018.11.162", "10.1038/s41419-018-1119-3", "10.1016/j.tjog.2018.02.009", "10.1074/jbc.RA117.001103", "10.1038/s41598-017-12837-y", "10.1016/j.canlet.2017.02.025", "10.1371/journal.pone.0166147", "10.1016/j.juro.2015.11.071", "10.1371/journal.pone.0130496", "10.1016/j.cellsig.2014.04.002", "10.1016/j.biopha.2013.05.003", "10.1111/IGC.0b013e3181d28e13", "10.1165/rcmb.2025-0274OC", "10.1002/iid3.70222", "10.3389/fimmu.2025.1607770", "10.1186/s10020-025-01175-9", "10.1186/s12964-024-02001-1", "10.1007/s13402-024-01025-6", "10.1111/jcmm.70245", "10.1101/2024.10.12.618047", "10.1038/s41598-024-70430-6", "10.1097/CJI.0000000000000523", "10.1186/s12935-024-03365-7", "10.3389/fonc.2023.1251100", "10.1007/s12032-023-02000-1", "10.3389/fonc.2022.1043177", "10.1186/s40170-022-00295-8", "10.1016/j.heliyon.2022.e10866", "10.3892/ol.2021.12839", "10.1016/j.taap.2020.115030", "10.1097/CM9.0000000000000753", "10.3389/fonc.2019.01163", "10.1002/path.5258", "10.1371/journal.pone.0190179", "10.1016/j.yexmp.2013.12.004", "10.1016/j.canlet.2012.01.029"]}
{"pair_type": "slc_pathway", "key1": "SLC7A11", "key2": "chemotherapy", "summary": "DIFP-FA induces reduced GPX4 and SLC7A11 expression and ferroptosis through the combination of SDT/CDT and chemotherapy.\nThe KRAS mutation can enhance chemoresistance by upregulating SLC7A11, and inhibiting SLC7A11 can increase the sensitivity of KRAS-mutated NSCLC to chemotherapy.\nHQD prevent chemotherapy-induced intestinal injury by activating the p53/SLC7A11/GPX4 signaling pathway, inhibiting ferroptosis, and alleviating intestinal inflammatory injury.\nNotably, CCL20 enhances the ability of AML cells to maintain iron homeostasis by upregulating SLC7A11 protein activity, mitigating mitochondrial damage, and inhibiting ferroptosis, thereby contributing to chemotherapy resistance.\nCombined CsA and chemotherapy treatment significantly enhances tumor regression, as evidenced by increased 4-HNE and reduced SLC7A11 expression in vivo.\nA subsequent experiment demonstrated that the mutant clones are resistant to chemotherapy as well as SLC7A11-inhibitors\nPW-EA manipulated ferroptosis via the SLC7A11-GSH-GPX4 axis to directly suppress CRC tumour cells and improve the efficacy of cisplatin chemotherapy in resistant lines.\nExpression of SLC7A11 promotes tumorigenesis and chemotherapy resistance, but while SLC7A11 has been previously noted to be upregulated in hypoxic cells, its regulation has not been fully delineated.\nOur results indicate that GP90 potentiates chemotherapy sensitivity by targeting the transferrin receptor and SLC7A11/Gpx4 pathway to induce ferroptosis, which might be a useful therapeutic target in colorectal cancer patients.\nOSCC cells exhibit heightened reliance on anti-ferroptotic defenses such as GPX4, SLC7A11, FSP1, and Nrf2, and disrupting these pathways suppresses tumor growth and restores sensitivity to chemotherapy, radiotherapy, and immunotherapy.\nMoreover, sorafenib-mediated chemotherapy could block cystine/glutamate antiporter xCT (SLC7A11) to", "dois": ["10.3390/cells14211685", "10.3390/ijms262110736", "10.1002/advs.202511947", "10.1016/j.phymed.2025.157463", "10.1016/j.bcp.2025.117519", "10.1016/j.bcp.2025.117481", "10.1002/adbi.202500460", "10.1186/s40001-025-03233-8", "10.1002/1878-0261.70129", "10.1016/j.canlet.2025.218058", "10.1016/j.jtemb.2025.127755", "10.2174/0113816128383328250808123933", "10.3390/antiox14080993", "10.3390/antiox14080930", "10.1016/j.redox.2025.103798", "10.3389/fphar.2025.1586578", "10.1038/s41420-025-02652-0", "10.1186/s13048-025-01718-y", "10.1186/s41065-025-00508-2", "10.1096/fj.202500258RR", "10.1111/febs.70191", "10.1186/s13058-025-02078-7", "10.1038/s41598-025-08235-4", "10.1038/s41598-025-04415-4", "10.1016/j.lfs.2025.123820", "10.3389/fonc.2025.1558290", "10.1186/s40001-025-02787-x", "10.1016/j.jep.2025.120135", "10.1080/10715762.2025.2515202", "10.1186/s12935-025-03824-9", "10.1016/j.colsurfb.2025.114816", "10.1016/j.intimp.2025.114914", "10.1016/j.jep.2025.119945", "10.1016/j.cellsig.2025.111869", "10.1016/j.bbrc.2025.151972", "10.1159/000546096", "10.1016/j.bbadis.2025.167884", "10.1186/s12967-025-06457-8", "10.1007/s00210-025-04149-0", "10.1038/s41419-025-07621-0", "10.1186/s12935-025-03753-7", "10.1016/j.cellsig.2025.111760", "10.1016/j.mtbio.2025.101584", "10.1186/s40364-025-00748-4", "10.1038/s41598-025-87982-w", "10.1016/j.neo.2025.101136", "10.1016/j.jpha.2024.101068", "10.1016/j.lfs.2024.123297", "10.1007/s00210-024-03623-5", "10.1007/s00432-024-06036-2", "10.1186/s12935-024-03570-4", "10.1002/adbi.202400323", "10.1016/j.ebiom.2024.105375", "10.1002/cam4.70337", "10.1016/j.celrep.2024.114868", "10.1016/j.redox.2024.103362", "10.1016/j.bbrc.2024.150709", "10.1186/s12935-024-03494-z", "10.1016/j.tranon.2024.102117", "10.1101/2024.08.19.608664", "10.1186/s12951-024-02808-7", "10.1590/1414-431X2024e13679", "10.1002/advs.202402795", "10.3390/antiox13070757", "10.1007/s12094-024-03592-4", "10.1016/j.heliyon.2024.e33092", "10.1021/acs.jafc.4c00118", "10.1101/2024.06.24.600340", "10.1002/cbin.12211", "10.21037/tcr-23-2285", "10.1016/j.bcp.2024.116345", "10.1038/s41420-024-01993-6", "10.1038/s41598-024-60920-y", "10.3390/antiox13040493", "10.1007/s12032-024-02317-5", "10.1186/s13048-024-01403-6", "10.1038/s41388-024-03025-0", "10.1021/acsami.4c00558", "10.1016/j.bbrc.2024.149895", "10.1038/s42003-024-06097-6", "10.1186/s12935-024-03294-5", "10.7150/thno.92663", "10.3389/fimmu.2024.1362543", "10.3892/ol.2024.14320", "10.1038/s41419-024-06467-2", "10.1186/s12885-024-11951-1", "10.1016/j.redox.2024.103035", "10.1016/j.ijbiomac.2024.129584", "10.18632/aging.205408", "10.3390/ijms25010587", "10.1002/mco2.463", "10.1016/j.jprot.2023.105055", "10.1002/tox.24049", "10.1007/s10495-023-01900-x", "10.1007/s00432-023-05378-7", "10.1016/j.ejphar.2023.176009", "10.1021/acs.jmedchem.3c00659", "10.1002/jcp.31093", "10.1002/cbin.12072", "10.1016/j.freeradbiomed.2023.06.025", "10.1038/s41420-023-01446-6", "10.1039/d3fo00009e", "10.2147/JIR.S393646", "10.1016/j.jconrel.2023.03.030", "10.1038/s41419-023-05719-x", "10.3389/fgene.2022.1094474", "PMID:36617466", "10.1038/s41417-022-00581-z", "10.1016/j.jprot.2022.104777", "10.1155/2022/6201987", "10.1016/j.bcp.2022.115241", "10.1021/acsabm.2c00597", "10.1155/2022/1112987", "10.1016/j.biopha.2022.113280", "10.1155/2022/4930643", "10.3389/fphar.2022.816432", "10.1016/j.omtn.2022.03.020", "10.3389/fimmu.2022.869993", "10.1016/j.redox.2022.102317", "10.1038/s41375-022-01573-6", "10.3389/fonc.2022.837974", "10.1016/j.freeradbiomed.2022.03.026", "10.3390/cancers14020345", "10.1016/j.heliyon.2021.e08399", "10.3389/fonc.2021.744940", "10.1002/cam4.4395", "10.21037/atm-21-3368", "10.1158/1535-7163.MCT-21-0067", "10.1016/j.bbrc.2021.06.036", "10.1016/j.bbrc.2021.02.137", "10.1073/pnas.2021475118", "10.1016/j.phrs.2020.105305", "10.1016/j.ymthe.2020.09.024", "10.7150/thno.44705", "10.1016/j.omtn.2019.11.035", "10.1111/jcmm.14469", "10.1080/2162402X.2018.1494108", "10.1080/15548627.2018.1513758", "10.1016/j.jcmgh.2017.03.003", "10.18632/oncotarget.16449", "10.18632/oncotarget.12356", "PMID:27658422", "10.1038/onc.2014.352", "10.1158/1078-0432.CCR-13-2805", "PMID:17367118"]}
{"pair_type": "slc_pathway", "key1": "SLC7A5", "key2": "stemness", "summary": "Mechanistically, elevated extracellular acidosis impairs methionine uptake and metabolism via downregulation of SLC7A5, therefore altering H3K27me3 deposition at the promoters of key T cell stemness genes.\nIn all, CAFs-derived exosomal METTL3 promoted the proliferation, invasion, stemness and glutaminolysis in NSCLC cells by inducing SLC7A5 m6A modification.\nOur analysis revealed HCSC important hubs as candidate regulators for targeting hepatic cancer stemness such as, miR-148a, miR-214, E2F family, MYC and SLC7A5.\nThe inhibition of LAT1 by a small molecule inhibitor, JPH203, or by RNA interference led to a significant reduction in tumorsphere formation and the downregulation of several cancer stemness genes in NSCLC cells through decreased AKT serine/threonine kinase (AKT)/mammalian target of rapamycin (mTOR) activation.\nAmong them, L-type amino acid transporter 1 (LAT1) upregulation was unique in concert with increased expression of the EMT regulator SNAIL and the cancer stemness marker doublecortin-like kinase 1.\nThe treatment of the cell-permeable leucine derivative promoted AKT/mTOR phosphorylation and reversed the inhibitory effect of JPH203 in the reduction of CSC activity in pemetrexed-resistant lung cancer cells.\nNonetheless, system L inhibition did not alter expression of stemness genes in NTERA2 cells.\nWe found that CAFs promoted the proliferation, invasion, stemness and glutaminolysis in NSCLC cells.\nMoreover, SLC7A5 overexpression abolished the inhibitory effects of exosomal METTL3-decreased CAFs on NSCLC cells.\nMechanistically, exosomal METTL3-induced m6A modification in SLC7A5 mRNA and stabilized its expression in NSCLC cells.\nThe PD-L1/LAT1 subpopulation of NSCLC cells displayed great CSC activity with increase", "dois": ["10.1038/s44321-025-00250-2", "10.1007/s00795-024-00404-0", "10.1007/s13577-024-01056-z", "10.3390/ijms222010955", "10.1111/andr.12880", "10.1038/s41598-019-41978-5", "10.1038/s41598-018-20973-2", "10.1165/rcmb.2025-0274OC", "10.1002/jgm.70012", "10.3389/fonc.2023.1251100", "10.1038/s42255-022-00730-6", "10.1186/s12885-020-07709-0"]}
{"pair_type": "slc_pathway", "key1": "SLC9A1", "key2": "stemness", "summary": "Besides, mRNA expressions of NHE family were extremely associated with clinicopathological features, tumor immune microenvironment and stemness score, DNA methylation, and patient prognosis in COAD.", "dois": ["10.1155/2021/3241351"]}
{"pair_type": "slc_pathway", "key1": "SLC7A6", "key2": "chemotherapy", "summary": "Abstract: Etoposide is routinely used in combination-based chemotherapy for testicular cancer and small-cell lung cancer;\nhowever, myelosuppression, therapy-related leukemia and neurotoxicity limit its utility.\nBRAF mutations were frequently detected and were associated with particularly poor survival in this cohort, possibly related to ligand-dependent Wnt activation and altered drug transport and metabolism that could confer resistance to MMC and irinotecan.\nFurthermore, BRAF mutations were associated with gene expression changes in transport solute carrier proteins (specifically SLC7A6) and drug metabolism enzymes (CES1 and CYP3A4) that could influence the efficacy of MMC and irinotecan, respectively.\nTumor samples (230) from a Norwegian national cohort undergoing surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) with mitomycin C (MMC) for PM-CRC were subjected to targeted DNA sequencing, and associations with clinical data were analyzed.\nAbstract: Patients with peritoneal metastasis from colorectal cancer (PM-CRC) have inferior prognosis and respond particularly poorly to chemotherapy.\nBRAF-mutated tumors additionally exhibited increased expression of members of the novel butyrophilin subfamily of immune checkpoint molecules (BTN1A1 and BTNL9).", "dois": ["10.1186/s12967-024-05467-2", "10.1007/s00439-008-0607-4"]}
{"pair_type": "slc_pathway", "key1": "SLC9A1", "key2": "migration", "summary": "The increase in NBCn1 density was similar in magnitude to that observed for Na(+)/H(+)-exchanger NHE1 (SLC9A1), a transporter previously implicated in cell migration, proliferation and malignancy.\nFunctional assays demonstrated that knockdown of either gene not only suppressed proliferation, colony formation, migration, and induced apoptosis in breast cancer cells, but also led to reduced expression of the sodium-calcium exchanger NCX1.\nExtrusion of the acid load from the cancer cells raises intracellular pH, while it decreases extracellular pH creating an inverted pH gradient across the plasma membrane compared to normal cells and promoting cancer cell metabolism, proliferation, migration, and invasion.\nThe results demonstrate that in RGM1 cells, migratory velocity is increased by NHE1 activation, while NHE2 activity inhibit this process.\nThrough multi-omics analysis of GEO and TCGA cohorts, we identified two sodium homeostasis-related genes, TRPM4 and SLC9A1, as consistently upregulated oncogenes in breast cancer, with significant diagnostic and prognostic relevance.\nand disrupted NHE1 expression can reduce triple-negative breast cancer growth.\nA differential activation of NHE1 and NHE2 may therefore, play a role in the initiation and completion of the epithelial restitution process.\nCellular assays-with some discrepancies-link NHE1 activity to proliferation, migration, and invasion;\nThe role of the basolaterally expressed NHE1 (Slc9a1) and the presumably apically expressed NHE2 (Slc9a2) in epithelial restitution was investigated in the nontransformed rat gastric surface cell line RGM1.\nWhen pH 7.1 was maintained during the restitution period, migratory speed was reduced to ∼10% of the speed at pH 7,4, and the residual restitution was further inhibited by NHE1 inhibition.\nGrowth factors accelerated wound healing in a partly NHE1-dependent fashion.", "dois": ["10.3389/fimmu.2025.1623511", "10.1016/j.bbadis.2024.167450", "10.1113/JP277383", "10.1002/jcp.25758", "10.1007/s00424-014-1524-0", "10.1002/ijc.27782", "PMID:12845533"]}
{"pair_type": "slc_pathway", "key1": "SLC9A2", "key2": "chemotherapy", "summary": "There were higher abundance of macrophages M2 and neutrophils and higher sensitivity of 11 chemotherapy drugs in the high-risk group.\nA risk model was constructed by 10 differentially expressed AREs-related genes (GNS, ANKH, PTPRN2, NELL1, PLAUR, SLC9A2, SCARA3, MAPK1, HOXB2, and EN2), and it could accurately predict the prognosis of patients with GBM.\nThe chemotherapy sensitivity was predicted in different risk groups.", "dois": ["10.1016/j.wneu.2023.03.148"]}
{"pair_type": "slc_pathway", "key1": "SLC9A2", "key2": "stemness", "summary": "Besides, mRNA expressions of NHE family were extremely associated with clinicopathological features, tumor immune microenvironment and stemness score, DNA methylation, and patient prognosis in COAD.", "dois": ["10.1155/2021/3241351"]}
{"pair_type": "slc_pathway", "key1": "SLC9A1", "key2": "oxidative stress", "summary": "Loss of NHE1 activity leads to reduced oxidative stress in heart and mitigates high-fat diet-induced myocardial stress.\nGSH levels and GSH:GSSG ratios were elevated in Nhe1(-/-) hearts indicating an enhanced redox potential.\nConsistent with a reduced need for antioxidant protection, expression of heat shock proteins Hsp60 and Hsp25 was lower in Nhe1(-/-) hearts.\nSimilarly, expression of mitochondrial superoxide dismutase 2 was reduced, with no increase in expression of other ROS scavenging enzymes.\nThese changes were associated with evidence of reduced cellular stress, which persisted even upon exposure to a high-fat diet, and the better preservation of insulin signaling, as evidenced by protein kinase B/Akt phosphorylation (Ser473).\nHigh-fat diet-induced stress was attenuated in Nhe1(-/-) hearts, as indicated by smaller increases in phosphorylation of Hsp25 and α-B crystallin, and there was better preservation of insulin sensitivity, as evidenced by PKB/Akt phosphorylation.\nThese data indicate that long-term ablation of NHE1 activity increases the redox potential, mitigates high-fat diet-induced myocardial stress and fatty liver disease, leads to better preservation of insulin sensitivity, and may alter both cardiac and systemic metabolic substrate handling in mice.\nThis included upregulation of the farnesoid X receptor FXR, peroxisome proliferator-activated receptor PPARγ, its co-activator PGC1α, and sestrin 2, an antioxidant protein involved in hepatic metabolic homeostasis.\nWe propose that oxidative stress under prolonged hypoxia depletes intracellular GSH to an extent that curtails NHE1 reinsertion once the hypoxic stimulus is withdrawn.", "dois": ["10.1016/j.bbrc.2014.06.095", "10.1016/j.yjmcc.2013.09.013", "10.1002/jcp.27268"]}
{"pair_type": "slc_pathway", "key1": "SLC7A6", "key2": "apoptosis", "summary": "The rates of inhibition and apoptosis in the group treated with a combination of cisplatin and baicalein were significantly higher than those of the cisplatin and baicalein groups of A2780/CDDP shCirSLC7A6 cells.\nCirSLC7A6 knockdown notably increased the expression of miR-2682-5p and decreased SLC7A6 expression.\nBaicalein alone and in combination with cisplatin notably reduced the expression of CirSLC7A6 and SLC7A6, and increased the expression of miR-2682-5p in the A2780/CDDP shCirSLC7A6 cell xenograft.\nHigh glucose concentration also enhanced apoptosis in mice granulosa cells that were characterized by elevation of caspase-3 activity, upregulation of gene and downregulation of gene.\nIn human hepatocellular carcinoma specimens, levels of c-Myc directly correlate with those of mTORC1 activation as well as of SLC1A5 and SLC7A6.\nExposure of mice granulosa cells to high glucose concentration inhibited the steroidogenesis by decreasing estradiol and progesterone secretion and downregulation of steroidogenesis-related genes including , and .\nBetaine treatment could attenuate the apoptotic-related changes induced by high glucose concentration in granulosa cells.\nTreatment with baicalein improved the sensitivity of ovarian cancer cells to cisplatin and inhibited cell proliferation, metastasis and tumor growth.\nIntriguingly, microarray expression analysis revealed up-regulation of multiple amino acid transporters, including solute carrier family 1 member A5 (SLC1A5) and SLC7A6, leading to robust uptake of amino acids, including glutamine, into c-Myc tumor cells.\nIn A2780/CDDP shCirSLC7A6 cells, the expression levels of P-Akt, P-mTOR, P-Erk, Bcl-2 and MMP2 were lower in the combined treatment group than in the control group.\nCell proliferation and apoptosis were examined using a Cell Counting Kit", "dois": ["10.1186/s13048-023-01285-0", "10.1080/19396368.2020.1811423", "10.1002/hep.29183"]}
{"pair_type": "slc_pathway", "key1": "SLC9A1", "key2": "proliferation", "summary": "The increase in NBCn1 density was similar in magnitude to that observed for Na(+)/H(+)-exchanger NHE1 (SLC9A1), a transporter previously implicated in cell migration, proliferation and malignancy.\nProliferation was increased in Panc-1 cells and decreased in BxPC-3 cells, upon TGFβ-1 treatment, and this, as well as EMT , was unaffected by NHE1- or NBCn1 inhibition.\nWhile increased sensitivity to acidosis for cell survival in 2-dimensions was not observed, clonogenic proliferation and 3-dimensional spheroid growth in particular were greatly reduced.\nFunctional assays demonstrated that knockdown of either gene not only suppressed proliferation, colony formation, migration, and induced apoptosis in breast cancer cells, but also led to reduced expression of the sodium-calcium exchanger NCX1.\nExtrusion of the acid load from the cancer cells raises intracellular pH, while it decreases extracellular pH creating an inverted pH gradient across the plasma membrane compared to normal cells and promoting cancer cell metabolism, proliferation, migration, and invasion.\nAccordingly, knockdown of either NHE1 or NBCn1 reduced proliferation, prolonged cell cycle progression in a manner involving S phase prolongation and delayed G2/M transition, and altered the expression pattern and phosphorylation of cell cycle regulatory proteins.\nNHE1-ko significantly reduced tumor cell proliferation both in normoxia and hypoxia while CA9-ko dramatically reduced growth in hypoxic conditions.\nZoniporide reduced the maximal proliferation capacity, cell number, thymidine incorporation, and ki67 (marker of proliferation) fluorescence in haOC cells.\nNHE1 and NBCn1 are not required for EMT or EMT-associated proliferation changes, but are essential for the potentiation of invasiveness induced by Merlin knockdown.\nCombined use of a knockout mouse model, intestinal organoid technology, and specific inhibitors revealed previously unrecognized actions of NHE2 and NHE8 in enterocyte proliferation and differentiation.", "dois": ["10.3389/fimmu.2025.1623511", "10.1016/j.bbadis.2024.167450", "10.3389/fphys.2022.899286", "10.7554/eLife.68447", "10.1186/s13045-020-00935-w", "10.3389/fonc.2020.00687", "10.1080/15384101.2018.1464850", "10.18632/oncotarget.14379", "10.1016/j.bbadis.2016.10.013", "10.1007/s00424-014-1524-0", "10.1002/ijc.27782", "PMID:12845533"]}
{"pair_type": "slc_pathway", "key1": "SLC9A3", "key2": "stemness", "summary": "Besides, mRNA expressions of NHE family were extremely associated with clinicopathological features, tumor immune microenvironment and stemness score, DNA methylation, and patient prognosis in COAD.", "dois": ["10.1155/2021/3241351"]}
{"pair_type": "slc_pathway", "key1": "SLC7A11", "key2": "migration", "summary": "Moreover, Icariside II suppressed SKOV3 cell proliferation, inhibited cells migration and invasion, and promoted apoptosis by downregulating SLC7A11 expression.\nAlthough SLC7A11 can increase the migration ability of tumor cells, BAY-876 effectively suppressed the viability of prostate cancer cells, particularly those with high SLC7A11 expression.\nFunctional assays revealed that TIMP1 knockdown enhanced ferroptosis sensitivity, suppressed CRC cell proliferation and migration, and reduced expression of ferroptosis regulators GPX4 and SLC7A11.\nJPX silence suppressed viability, migration, invasion and ECM production, yet facilitated ferroptosis of keloid fibroblasts, while these effects could be reversed by Fer-1 or SLC7A11 overexpression.\nAt the same time, our results show that the combination of SAL and 5-FU not only inhibits the proliferation, migration, and invasion of CRC cell lines and , but also promotes ferroptosis of CRC cell lines by downregulating the expression of GPX4 and SLC7A11.\nThe findings indicate that Fut8 upregulation increases P53 expression and reduces SLC7A11 and GPX4 levels, leading to altered intracellular concentrations of GSH and Fe, impaired mitochondrial function, and reduced migration capacity, all of which promote atherosclerosis.\nIn vitro experiments demonstrated that overexpression of SLC7A11 inhibited migration, invasion, and Caspase-1 expression levels in TNF-α-induced RA-FLSs.\nInterference with circ-CDK8 expression reduced SLC7A11 expression by sponging miR-615-5p, suppressed OSCC cell migration and invasion, and promoted ferroptosis by increasing ROS, MDA, and iron levels and decreasing GSH and GPX4 levels in OSCC cells.\nKRT15 overexpression promoted cell proliferation, migration, invasion, colony number, epithelial-mesenchymal transition (EMT, reflected by E-Cadherin, N-Cadherin, and Vimentin expressions), and S-stage cell", "dois": ["10.1007/s12035-025-05358-7", "10.3389/fimmu.2025.1675373", "10.3390/cancers17213571", "10.2478/aite-2026-0002", "10.1186/s13018-025-06417-4", "10.1186/s41065-025-00591-5", "10.1016/j.phymed.2025.157470", "10.1016/j.phymed.2025.157413", "10.1016/j.cellsig.2025.112168", "10.1007/s11010-025-05337-5", "10.1186/s40001-025-03233-8", "10.1007/s00210-025-04698-4", "10.1016/j.gene.2025.149819", "10.1080/15384047.2025.2567815", "10.1016/j.jpha.2025.101228", "10.1016/j.tranon.2025.102553", "10.1002/btm2.70021", "10.1007/s12672-025-03626-5", "10.1038/s12276-025-01540-y", "10.3390/ph18091382", "10.1016/j.canlet.2025.218058", "10.1016/j.bbrc.2025.152599", "10.1016/j.jep.2025.120607", "10.1002/jbt.70496", "10.3389/fonc.2025.1633891", "10.2174/0113816128383328250808123933", "10.1016/j.cellsig.2025.112111", "10.1016/j.yexcr.2025.114730", "10.1007/s11010-025-05369-x", "10.1186/s41065-025-00530-4", "10.21873/invivo.14068", "10.1016/j.freeradbiomed.2025.08.051", "10.1016/j.taap.2025.117531", "10.1007/s00210-025-04359-6", "10.1016/j.jep.2025.120456", "10.1096/fj.202500937RR", "10.1038/s41598-025-13324-5", "10.21037/tp-2024-596", "10.7150/ijbs.112233", "10.1016/j.abb.2025.110553", "10.1002/advs.202408556", "10.1186/s41065-025-00508-2", "10.1007/s10735-025-10496-2", "10.1007/s00011-025-02070-z", "10.3389/fonc.2025.1593107", "10.1002/jbt.70387", "10.1016/j.ejphar.2025.177935", "10.1002/jbt.70392", "10.21037/jgo-2024-1002", "10.1016/j.cellsig.2025.111998", "10.1016/j.celrep.2025.115939", "10.3389/fonc.2025.1592862", "10.1038/s41598-025-08968-2", "10.1016/j.ijbiomac.2025.145698", "10.1007/s10616-025-00798-4", "10.1007/s10735-025-10497-1", "10.1038/s41420-025-02585-8", "10.3389/fonc.2025.1558290", "10.1016/j.jep.2025.120165", "10.1016/j.bcp.2025.117051", "10.1016/j.intimp.2025.115056", "10.1007/s12672-025-02803-w", "10.1016/j.phymed.2025.156912", "10.1021/acsbiomaterials.5c00680", "10.4251/wjgo.v17.i5.104522", "10.1016/j.mce.2025.112589", "10.1080/10715762.2025.2515202", "10.1016/j.cellsig.2025.111908", "10.3389/fonc.2025.1532555", "10.1007/s10238-025-01700-4", "10.1080/15384047.2025.2510041", "10.1016/j.phymed.2025.156840", "10.1371/journal.pone.0322746", "10.1161/ATVBAHA.124.321014", "10.21037/jgo-2024-1014", "10.1016/j.cellsig.2025.111881", "10.1142/S0192415X25500351", "10.1016/j.bj.2025.100869", "10.1038/s41420-025-02401-3", "10.1186/s12885-025-14173-1", "10.1016/j.ultsonch.2025.107368", "10.1016/j.jhazmat.2025.138359", "10.1016/j.freeradbiomed.2025.04.025", "10.1016/j.bbrc.2025.151770", "10.1007/s11033-025-10395-5", "10.3390/nu17071262", "10.1186/s13048-025-01650-1", "10.3967/bes2024.136", "10.3390/md23030123", "10.1002/2211-5463.70019", "10.1016/j.cellsig.2025.111760", "10.1186/s12967-025-06378-6", "10.3389/fmolb.2025.1523494", "10.1111/cbdd.70071", "10.1186/s40001-025-02411-y", "10.14744/AnatolJCardiol.2025.5042", "10.3390/biomedicines13020321", "10.4062/biomolther.2024.156", "10.1016/j.tice.2025.102796", "10.1016/j.peptides.2025.171366", "10.1007/s10528-025-11045-y", "10.3389/fonc.2025.1451034", "10.1002/ptr.8457", "10.1007/s12672-025-01888-7", "10.1002/cbin.12275", "10.1007/s00109-025-02515-2", "10.22038/ijbms.2024.79933.17317", "10.3389/fonc.2024.1476731", "10.32604/or.2024.050835", "10.1016/j.intimp.2025.114019", "10.1007/s12013-024-01656-4", "10.1016/j.toxicon.2025.108233", "10.3390/pharmaceutics16121605", "10.1007/s10238-024-01550-6", "10.1038/s41368-024-00326-8", "10.1016/j.canlet.2024.217396", "10.1111/cbdd.70010", "10.1016/j.phymed.2024.156224", "10.1186/s10020-024-01002-7", "10.1007/s00394-024-03519-3", "10.1016/j.intimp.2024.113436", "10.1038/s41598-024-80160-4", "10.1016/j.jep.2024.119126", "10.18502/ijph.v53i10.16705", "10.1038/s41419-024-07222-3", "10.3892/mmr.2024.13384", "10.1016/j.clbc.2024.10.001", "10.1155/2024/6594426", "10.1186/s13062-024-00544-4", "10.2174/0115680096321714240909182553", "10.1002/cam4.70337", "10.1016/j.phymed.2024.156130", "10.1016/j.surg.2024.07.075", "10.3390/ijms251910350", "10.1039/d4fo03904a", "10.1111/crj.70014", "10.1016/j.biopha.2024.117529", "10.1088/2057-1976/ad8200", "10.3892/mmr.2024.13341", "10.1007/s10863-024-10039-6", "10.1016/j.cellsig.2024.111421", "10.1016/j.prostaglandins.2024.106909", "10.1186/s13062-024-00528-4", "10.1007/s10863-024-10038-7", "10.1016/j.bioactmat.2024.08.011", "10.1016/j.jep.2024.118726", "10.3389/fphar.2024.1432520", "10.1016/j.heliyon.2024.e35457", "10.3760/cma.j.cn121090-20231218-00323", "10.1038/s41417-024-00817-0", "10.1016/j.redox.2024.103299", "10.1016/j.biochi.2024.08.001", "10.12122/j.issn.1673-4254.2024.07.12", "10.1016/j.heliyon.2024.e33674", "10.1016/j.phymed.2024.155876", "10.18632/aging.206009", "10.1186/s13071-024-06408-0", "10.1016/j.tox.2024.153886", "10.2174/0113862073324077240624094140", "10.1016/j.tice.2024.102458", "10.1186/s12903-024-04395-3", "10.3389/fimmu.2024.1344637", "10.1016/j.cellsig.2024.111278", "10.1002/mc.23778", "10.1080/17435390.2024.2369602", "10.1089/dna.2023.0434", "10.3779/j.issn.1009-3419.2024.101.12", "10.3389/fimmu.2024.1371831", "10.1002/ptr.8258", "10.1002/biof.2083", "10.19540/j.cnki.cjcmm.20231208.401", "10.1016/j.intimp.2024.112175", "10.1159/000539235", "10.1530/EC-24-0097", "10.1111/cas.16181", "10.1016/j.gene.2024.148498", "10.1016/j.yexcr.2024.114053", "10.1016/j.fct.2024.114682", "10.1007/s12032-024-02317-5", "10.1007/s11655-024-4104-y", "10.1002/tox.24272", "10.12122/j.issn.1673-4254.2024.03.04", "10.1016/j.phymed.2024.155548", "10.1016/j.heliyon.2024.e28093", "10.1007/s10815-024-03096-8"]}
{"pair_type": "slc_pathway", "key1": "SLC9A4", "key2": "proliferation", "summary": "Interestingly, 27 upregulated transcripts (e.g., Aqp1, Cacnb1, Atp1a2, Kcnab2, and Slc2a1) and 13 downregulated transcripts (e.g., Slc17a7, Slc9a4, and Slc30a3) are involved in the absorption of water, ions, and nutrients.\nGene ontology analysis suggested effects of CMA on cellular processes, such as cell adhesion, proliferation, fuel metabolism, and biotransformation.", "dois": ["10.1007/s11010-008-9931-1"]}
{"pair_type": "slc_pathway", "key1": "SLC9A3", "key2": "migration", "summary": "Loss of SLC9A3‑AS1 reduced NPC cell proliferation, colony formation, migration, and invasion but induced cell apoptosis .\nKnockdown of SLC9A3-AS1 notably further inhibited viability, migration as well as invasion in Huh7 cells.\nThe proliferation potential, migration, and invasion behaviors were weakened by si-SLC9A3-AS1 and reversed by the miR-486 inhibitor.\nInhibition of NHE3, unconfounded by chronic inflammatory or microbial pressure, may represent a permissible mechanism beneficial to the host by modulating cellular plasticity and promoting epithelial wound healing.\nNHE3-/- colonoids showed increased cell proliferation and reduced ECM adhesion.\nNHE3-/- colonoids and NHE3KD cells showed increased spontaneous motility, enhanced migration in serum gradient, and in 2 models of wound healing.\nInhibition of FAK autophosphorylation eliminated the effect of NHE3 deficiency on cell migration.\nFinally, the effects of SLC9A3‑AS1 silencing on NPC cells were reversed by inhibiting miR‑486‑5p or overexpressing E2F6.\nFurthermore, we found that knockdown of inhibited the proliferation and migration of HCT116 cells, and Hsp70 ATPase activator could rescue it.\nEctopic expression of the E620K mutant increased cell migration, invasion and colony formation in vitro, as well as OM in animals bearing GC xenograft tumors.\nAnimal experiments further revealed that the depletion of SLC9A3‑AS1 hindered NPC tumour growth .\nIn summary, SLC9A3‑AS1 exerted carcinogenic effects on NPC cells by adjusting the miR‑486‑5p/E2F6 axis.\nThus, we aimed to investigate the role of NHE3 in colonic epithelial cell proliferation and migration during wound healing.\nThis was associated with FAK and Src activation and modulation of genes associated with cell-cell interactions, cell-ECM interactions, and the formation of focal adhesions.", "dois": ["10.7150/thno.113382", "10.1007/s12672-025-02134-w", "10.1093/ibd/izaf024", "10.1021/acsomega.4c00901", "10.1080/02648725.2023.2193775", "10.2147/CMAR.S352308", "10.3892/or.2021.8116"]}
{"pair_type": "slc_pathway", "key1": "SLC9A5", "key2": "proliferation", "summary": "Furthermore, in vitro experiments showed that knockdown of SLC9A5 resulted in suppressed cell proliferation, migration, and invasion.\nSLC9A5 promotes tumor growth and cell motility via ACOX1-mediated peroxisomal fatty acid oxidation.\nMoreover, the attenuated tumor growth, migration, invasion, and increased FAO observed after SLC9A5 knockdown could be reversed by simultaneous knockdown of both SLC9A5 and ACOX1.\nInterestingly, the expression of ACOX1, as well as FAO process indicated by changes in very long chain fatty acid levels, were enhanced upon SLC9A5 knockdown in CRC cells.\nIn summary, these findings reveal the oncogenic role of SLC9A5 in CRC, particularly in relation to ACOX1-mediated peroxidation, and might serve as a promising therapeutic target for inhibiting the progression of colorectal cancer.", "dois": ["10.1016/j.yexcr.2023.113700"]}
{"pair_type": "slc_pathway", "key1": "SLC9A2", "key2": "apoptosis", "summary": "zDHHC3 suppression led to decreased expression and S-palmitoylation of SLC9A2, which further inhibited the apoptosis of Caki-2 cells.\nOur findings suggest that zDHHC3 plays an important role in KIRC, due partly to its regulation of SLC9A2 S-palmitoylation.\nAmong these hub genes, SLC9A2 was identified as a downstream gene of zDHHC3.\nThe targeting of the zDHHC3-SLC9A2 axis may provide a new option for the clinical treatment of KIRC.", "dois": ["10.1007/s00432-024-05737-y", "10.1016/j.jhazmat.2024.135038"]}
{"pair_type": "slc_pathway", "key1": "SLC7A6", "key2": "ferroptosis", "summary": "These findings suggest that SLC7A6 contributes to tumor progression by regulating ferroptosis through disruption of redox homeostasis.\nCollectively, our study highlights SLC7A6 as a promising biomarker for cancer diagnosis and prognosis and provides experimental evidence supporting its functional role in driving tumor progression via ferroptosis modulation in LIHC, CHOL, and PAAD.\nMechanistically, AlphaFold 3 predicted a potential interaction between SLC7A6 and oxidized glutathione (GSSG), which was supported by biochemical assays showing altered intracellular levels of nitric oxide (NO), GSSG, and glutathione (GSH) upon SLC7A6 knockdown.\nFunctional assays, including CCK-8, colony formation, wound healing, and Transwell migration/invasion, demonstrated that SLC7A6 promotes proliferation, migration, and invasion of tumor cells.\nDifferentially spliced SLCs were enriched in biological processes, including transmembrane transporter activity, transporter activity, ferroptosis, and choline metabolism.\nCD98hc serves as a chaperone for LAT1 (SLC7A5), LAT2 (SLC7A8), yLAT1 (SLC7A7), yLAT2 (SLC7A6), xCT (SLC7A11) and Asc1 (SLC7A10) providing their recruitment to the plasma membrane.", "dois": ["10.1016/j.ijbiomac.2025.148008", "10.1111/cas.16351", "10.1016/j.ijbiomac.2025.148832", "10.3389/fonc.2023.1251100"]}
{"pair_type": "slc_pathway", "key1": "SLC9A8", "key2": "proliferation", "summary": "Downregulation of SLC9A8 promoted CRC cell proliferation, migration, and invasion.\nSLC9A8 overexpression markedly suppressed cell proliferation, migration, and invasion.\nMoreover, whether downregulated expression of SLC9A8 promotes EMT via activation of the IL6-JAK1-STAT3 signaling pathway was investigated.\nMeanwhile, downregulation of SLC9A8 significantly promoted the in vitro migration of CRC cells via EMT by activating the IL6-JAK1/STAT3 signaling pathway.\nAlterations in NHE2 and NHE8 expression/activity affected proliferation, with C2Bbe/shNHE2 cells having lower and C2Bbe/shNHE8 having higher proliferative capacity, accompanied by amplified ERK1/2 signaling pathway and increased EGFR expression in the latter cell line.\nMoreover, knockdown of SLC9A8 also increased tumor volume, tumor weight, and metastasis in vivo.\nDownregulation of SLC9A8 plays an important role in EMT and metastasis of CRC progression and may become a new potential therapeutic target for the treatment of CRC.\nThus, both Na/H exchangers have distinct functions during cellular homeostasis by triggering different signaling pathways to regulate cellular proliferation and pH control.\nSLC9A8 has been shown to be involved in mucus layer formation, intestinal mucosal integrity, and hyperproliferation of colitis-associated tumor development.\nWe addressed the role of NHE8 [solute carrier 9A8 (SLC9A8)] and its interplay with NHE2 (SLC9A2) in luminal proton extrusion during acute and chronic enterocyte acidosis and studied the differential effects of NHE8 and NHE2 on enterocyte proliferation.\nCombined use of a knockout mouse model, intestinal organoid technology, and specific inhibitors revealed previously unrecognized actions of NHE2 and NHE8 in enterocyte proliferation and differentiation.\nSLC9A8 protein was downregulated in CRC tissues, and this down", "dois": ["10.1007/s10620-022-07805-0", "10.3389/fphys.2022.899286", "10.1152/ajpcell.00582.2020", "PMID:12845533"]}
{"pair_type": "slc_pathway", "key1": "SLC9A8", "key2": "oxidative phosphorylation", "summary": "Network analysis highlighted NDUFB2 as a key downregulated hub gene linked to mitochondrial complex I dysfunction and oxidative phosphorylation disruption.\nLASSO and SVM identified a three-mRNA panel-IL4R, EIF5A, and SLC9A8-which achieved 84% diagnostic accuracy in the discovery cohort and 99% accuracy in the real-life cohort.", "dois": ["10.3389/fimmu.2025.1570374"]}
{"pair_type": "slc_pathway", "key1": "SLC9A7", "key2": "apoptosis", "summary": "Other differentially expressed genes (SCN2B, SLC9A7 and KCNK3) emphasize the involvement of potassium-sodium pumps in tender meat.\nWe uncovered several differentially expressed genes that encode for proteins belonging to a family of tripartite motif proteins, which are involved in growth, cell differentiation and apoptosis, such as TRIM45, or play an essential role in regulating skeletal muscle differentiation and the regeneration of adult skeletal muscle, such as TRIM32.", "dois": ["PMID:37970357", "10.1111/age.12418"]}
{"pair_type": "slc_pathway", "key1": "SLC7A6", "key2": "migration", "summary": "Functional assays, including CCK-8, colony formation, wound healing, and Transwell migration/invasion, demonstrated that SLC7A6 promotes proliferation, migration, and invasion of tumor cells.\nIn A2780/CDDP shCirSLC7A6 cells, migration and invasion were significantly higher in the cisplatin and baicalein groups, compared with the combined treatment group.\nThese findings suggest that SLC7A6 contributes to tumor progression by regulating ferroptosis through disruption of redox homeostasis.\nIn this way, CD98hc connects the signaling pathways sustaining cell proliferation and migration, biosynthesis and antioxidant defense, energy production, and stem cell properties.\nCollectively, our study highlights SLC7A6 as a promising biomarker for cancer diagnosis and prognosis and provides experimental evidence supporting its functional role in driving tumor progression via ferroptosis modulation in LIHC, CHOL, and PAAD.\nTreatment with baicalein improved the sensitivity of ovarian cancer cells to cisplatin and inhibited cell proliferation, metastasis and tumor growth.\nCirSLC7A6 knockdown notably increased the expression of miR-2682-5p and decreased SLC7A6 expression.\nCell proliferation and apoptosis were examined using a Cell Counting Kit-8 assay and flow cytometry, and cell migration and invasion were analyzed using wound healing and Transwell assays.\nMechanistically, AlphaFold 3 predicted a potential interaction between SLC7A6 and oxidized glutathione (GSSG), which was supported by biochemical assays showing altered intracellular levels of nitric oxide (NO), GSSG, and glutathione (GSH) upon SLC7A6 knockdown.\nThis multifaceted role makes CD98hc one of the critical regulators of tumor growth, therapy resistance, and metastases.", "dois": ["10.1016/j.ijbiomac.2025.148008", "10.1186/s13048-023-01285-0", "10.3389/fonc.2023.1251100"]}
{"pair_type": "slc_pathway", "key1": "SLC9A3", "key2": "proliferation", "summary": "Loss of SLC9A3‑AS1 reduced NPC cell proliferation, colony formation, migration, and invasion but induced cell apoptosis .\nThe proliferation potential, migration, and invasion behaviors were weakened by si-SLC9A3-AS1 and reversed by the miR-486 inhibitor.\nNHE3-/- colonoids showed increased cell proliferation and reduced ECM adhesion.\nInhibition of NHE3, unconfounded by chronic inflammatory or microbial pressure, may represent a permissible mechanism beneficial to the host by modulating cellular plasticity and promoting epithelial wound healing.\nOverall, is a novel potential biomarker involved in CRC progression and promotes the proliferation and migration of tumor cells by positively regulating the function of Hsp70.\nColonic organoids from NHE3+/+ and NHE3-/- mice and SK-CO-15 cells with shRNA-mediated NHE3 knockdown (NHE3KD) were used to assess the intrinsic role of NHE3 in cellular proliferation, migration, wound healing, adhesion to the extracellular matrix (ECM), activation status of focal adhesion kinase (pFAKY397), and in gene transcription.\nFinally, the effects of SLC9A3‑AS1 silencing on NPC cells were reversed by inhibiting miR‑486‑5p or overexpressing E2F6.\nFurthermore, we found that knockdown of inhibited the proliferation and migration of HCT116 cells, and Hsp70 ATPase activator could rescue it.\nCombined use of a knockout mouse model, intestinal organoid technology, and specific inhibitors revealed previously unrecognized actions of NHE2 and NHE8 in enterocyte proliferation and differentiation.\nReciprocally, ovarian fibroblasts educated by ITGA6high exosomes exhibited cancer-associated fibroblasts (CAFs) phenotypes and enhanced tumor cell proliferation, thereby initiating the early stage of pre-metastatic niche formation.\nAnimal experiments further revealed that the depletion of SLC9A3‑AS1 hindered NPC tumour growth .", "dois": ["10.7150/thno.113382", "10.1007/s12672-025-02134-w", "10.1093/ibd/izaf024", "10.1021/acsomega.4c00901", "10.3389/fphys.2022.899286", "10.2147/CMAR.S352308", "10.3892/or.2021.8116", "10.1093/jas/skaa046", "10.1371/journal.pone.0168899"]}
{"pair_type": "slc_pathway", "key1": "SLC9A9", "key2": "stemness", "summary": "Besides, mRNA expressions of NHE family were extremely associated with clinicopathological features, tumor immune microenvironment and stemness score, DNA methylation, and patient prognosis in COAD.", "dois": ["10.1155/2021/3241351"]}
{"pair_type": "slc_pathway", "key1": "SLC9A9", "key2": "apoptosis", "summary": "SLC9A9 was highly associated with immune system functions, metabolism, apoptosis, endocytosis, and signaling cascades.\nEndosomal solute carrier family 9 member A9 (SLC9A9) plays important roles in the process of BCV-, OMVs-, and barrel-like proteins-triggered cytoplasmic vacuolization cell death via promoting vacuole fusion.\nA variant strain of Bergeyella cardium (BCV) induces unique cytoplasmic vacuolization cell death and minor apoptosis-like cell death in macrophages.\nOur investigation confirmed proposed functions for SLC9A9, such as endocytosis and immune regulation, while also revealing potential roles in mTOR signaling and cell survival.\nIrradiation of these cells with near-infrared light led to apoptotic tumour cell death.", "dois": ["10.1111/jcmm.14665", "10.1038/s41421-025-00840-x", "10.1002/aur.1670", "10.3389/fgene.2016.00037"]}
{"pair_type": "slc_pathway", "key1": "SLC9A9", "key2": "proliferation", "summary": "Psoriatic T cells exhibited the ability to decrease epidermal turnover time and affect keratinocyte proliferation because of the differential expression of PPIL1, HSPH1, SENP3, NUP54, FABP5, PLEKHG3, SLC9A9 and CHCHD4.\nAccording to the prevailing model, NHE9 overexpression leads to an increase in plasma membrane density of epidermal growth factor receptors (EGFRs) which consequently enhances GBM cell proliferation and migration.\nThe results showed a suppressive function of let-7f-5p on Caco2 cell proliferation and then put forward a triterpenoid (Rotundic Acid, RA) which significant antagonized the effect of cell proliferation, restitution after wounding, and colony formation caused by let-7f-5p.\nMoreover, the western blot results further indicated that the inhibitory effect of RA might be due to its suppressive role in let-7f-5p-targeted AMER3 and SLC9A9 regulation.\nOur validation study results confirmed that let-7f-5p was a potent tumor suppressor gene of Caco2 cell proliferation, and RA showed as a regulator of the effect of let-7f-5p on cell proliferation and then could be a potential chemopreventive agent for CRC treatment.\nOverexpression of Na/H Exchanger isoform 9 (NHE9) promotes tumor progression and correlates positively with insensitivity to radiochemotherapy and poor prognosis.\nNHE activities contribute to the control of the cell cycle, cell proliferation, cell migration and vesicle trafficking.\nDownregulation of NHE9 expression by miR-135a affects proliferative and migratory capacity of U87 cells.\nSelectively increasing NHE9 expression in these cells restored their ability to proliferate and migrate.\nCCK-8 and EDU assay showed that proliferation capacity of IDH1-mutant glioma cells declined.\nThere were 14 DEG which were found to participate in the regulation of cell proliferation or differentiation.", "dois": ["10.1038/s41598-023-46335-1", "10.15252/embj.2020105908", "10.2174/1871520620999200730165829", "10.1111/jcmm.14665", "10.1186/s12964-017-0209-7", "PMID:28476790", "10.1111/1346-8138.12961"]}
{"pair_type": "slc_pathway", "key1": "SLC7A6", "key2": "proliferation", "summary": "Mechanistically, si-SLC7A6-RI isoform exerted oncogenic effects by activating the PI3K-Akt-mTOR signaling pathway and promoting cell proliferation, evidenced by increased expression of key regulators Phosphorylated Mammalian Target of Rapamycin (p-mTOR) and a cell proliferation marker Proliferating Cell Nuclear Antigen (PCNA) using western blotting.\nKnockdown of the intronic region of SLC7A6-RI isoform enhanced colon cancer cell proliferation.\nExogenous expression of circ-SLC7A6 evidently inhibited the proliferation and invasion of NSCLC cells.\nFunctional assays, including CCK-8, colony formation, wound healing, and Transwell migration/invasion, demonstrated that SLC7A6 promotes proliferation, migration, and invasion of tumor cells.\nNext, we confirmed that the expression of the arginine transporter Slc7a6 was strongly induced by BmNPV infection and that Slc7a6 could promote arginine uptake to support BmNPV proliferation in host cells.\nMoreover, using Slc7a6 knockout cells which eliminate extracellular arginine uptake, we confirmed that BmNPV could induce mitochondrial autophagy, thereby supplementing intracellular arginine and providing necessary amino acids for BmNPV proliferation.\nMechanistically, CDYL2 down-regulates solute carrier family 7 member 6 (SLC7A6) by decreasing the enrichment of H3K4me3 on the promoter region of SLC7A6.\nThus, CDYL2 was regulated by STAT5A, and suppressed the amino acid transportation through down-regulation of SLC7A6, and then inhibits the mTORC1/S6K pathway, a master regulator of cell growth.\nIn vivo, knockdown of the intronic region of SLC7A6-RI isoform enhanced tumor growth in colon cancer.\nGain- and loss-of-function experiments showed that CDYL2 inhibited the proliferation and metastasis of H", "dois": ["10.1016/j.ijbiomac.2025.148008", "10.1371/journal.ppat.1013331", "10.1111/cas.16351", "10.1186/s13048-023-01285-0", "10.3389/fonc.2023.1251100", "10.3324/haematol.2022.282066", "10.1038/s41388-022-02273-2", "10.1080/15384101.2020.1806449"]}
{"pair_type": "slc_pathway", "key1": "SLC9A2", "key2": "glycolysis", "summary": "ETS1 could promote the proliferation, invasion, and aerobic glycolysis ability of OS cells, as well as tumor growth in vivo by inhibiting the expression of SLC9A2.\nIn addition, SLC9A2, suppressing by ETS1, restrains growth and invasion of OS via inhibition of aerobic glycolysis.\nThus, SLC9A2 can function as a key inhibitory factor in the aerobic glycolysis to inhibit proliferation and invasion of OS.\nCCK-8, transwell, western blotting and Seahorse XFe24 Cell Metabolic Analyzer assays demonstrated that overexpression of SLC9A2 could constrain OS cell proliferation, invasion, and aerobic glycolysis.\nDual-luciferase reporter gene assay and chromatin immunoprecipitation (ChIP) assays indicated ETS proto-oncogene 1 (ETS1) was a transcription suppressor of SLC9A2, and overexpression of ETS1 could promote methylation levels in specific regions of the SLC9A2 promoter.", "dois": ["10.1002/tox.23963"]}
{"pair_type": "slc_pathway", "key1": "SLC9A9", "key2": "oxidative stress", "summary": "These proteins were enriched in known functional pathways for NHE9: the endocytosis, protein ubiquitination and phagosome pathways, as well as some novel pathways including oxidative stress, mitochondrial dysfunction, mTOR signaling, cell death and RNA processing pathways.\nSome SNPs involved in oxidative stress and ion-channel regulation were identified to associate with the hormonal and semen alterations.\nOxidative stress and fluid-salt balance are tightly associated with thermotolerance and productivity in domestic animals.\nThe study aimed to identify single-nucleotide polymorphisms (SNPs) in genes related to oxidative stress and ion-channel regulation and their associations with semen quality and hormonal responses.\nFive SNPs within CUL3, TRPC1, and SLC9A9 in the B strain and two SNPs within MTF1 in the L2 strain were associated with sperm concentrations at Day 1 after exposure to heat stress.\nIn the B-strain TCCs, five SNPs within NDUFA8 and DAB2IP had significant effects on plasma adrenaline and corticosterone levels, and six SNPs within TRPC1, SLC9A9, and TRPC7 markedly affected plasma corticosterone and triiodothyronine levels.\nIn total, 28 SNPs within 11 candidate genes were identified to associate with hormonal changes and semen quality in both broiler- and layer-type Taiwan country chickens (TCCs) after exposure to acute heat stress at 38 °C for 4 h.\nThese SNPs in conjunction with differential hormonal responses and semen quality serve as genetic markers for thermotolerance selection in sire lines of chickens.", "dois": ["10.1016/j.jtherbio.2022.103220", "10.1074/jbc.M116.769240", "10.1007/s12402-018-0281-x"]}
{"pair_type": "slc_pathway", "key1": "SLC9A3", "key2": "chemotherapy", "summary": "With this data, we have developed multiplex methylation sensitive restriction enzyme PCR (MSRE-PCR) protocol for determining the methylation status of 10 genes (SLC9A3, C1QL2, DPYS, IRF4, ADCY8, KCNQ2, TERT, SYNDIG1, SKOR2 and GRIK1) that distinguish BC samples with different NACT response.\nWe have performed genome-wide analysis of DNA methylation by XmaI-RRBS and selected CpG dinucleotides differential methylation of which discriminates luminal B breast cancer samples with different sensitivity to NACT.\nAnalysis of these 10 markers by MSRE-PCR in biopsy samples allowed us to reveal three top informative combinations of markers, (1) IRF4 and C1QL2; (2) IRF4, C1QL2, and ADCY8; (3) IRF4, C1QL2, and DPYS, with the areas under ROC curves (AUCs) of 0.75, 0.78 and 0.74, respectively.\nThus, prediction of tumor response to treatment is imperative to avoid exposure of potential non-responders to deleterious complications.", "dois": ["10.1038/s41598-020-66197-1"]}
{"pair_type": "slc_pathway", "key1": "SLC9B2", "key2": "glycolysis", "summary": "Deletion of Brd4 increased basal bone mass and prevented bone loss induced by ovariectomy or LPS, primarily by suppressing osteoclastogenesis through inhibition of glycolysis.\nBrd4 is crucial for glycolysis-mediated OC differentiation.\nSlc9b2 is a novel target of Brd4 in mediating osteoclastogenesis.\nOverexpression of Slc9b2 partially rescued the impaired osteoclastogenesis caused by Brd4 depletion.\nUnbiased screening identified solute carrier family 9 member B2 (Slc9b2) as a downstream effector of Brd4.\nBrd4 serves as a crucial regulator of osteoclast metabolism and differentiation.", "dois": ["10.1002/ctm2.70496"]}
{"pair_type": "slc_pathway", "key1": "SLC9A6", "key2": "proliferation", "summary": "In vitro studies with osteoclasts and osteoblasts derived from NHE6 knock-out mice demonstrated normal osteoclast differentiation and osteoblast proliferation without an impairment in mineralization capacity.", "dois": ["10.1016/j.bone.2021.116178"]}
{"pair_type": "slc_pathway", "key1": "SLC9C2", "key2": "proliferation", "summary": "Acute myeloid leukemia (AML) is characterized by the uncontrolled proliferation of myeloid leukemia cells in the bone marrow and other hematopoietic tissues and is highly heterogeneous.\nThe differentially expressed 7 genes of two subgroups (HOXB-AS3, HOXB3, SLC9C2, CPNE8, MEG8, S1PR5, MIR196B) are mainly involved in glucose metabolism, glutathione biosynthesis, small G protein-mediated signal transduction, and the Rap1 signaling pathway.", "dois": ["10.1007/s13353-024-00881-0"]}
{"pair_type": "slc_pathway", "key1": "SLC10A1", "key2": "chemotherapy", "summary": "Whereas NTCP did not show any strong interactions with the cytostatics tested, we observed a very strong inhibition of OAT2 mediated [(3)H] cGMP uptake in the presence of bendamustine, irinotecan and paclitaxel.\nIn the current study, we characterized the interactions of two uptake transporter proteins, expressed mainly in the liver; the organic anion transporter 2 (OAT2, encoded by the SLC22A7 gene) and the sodium taurocholate cotransporting polypeptide (NTCP, encoded by the SLC10A1 gene), stably transfected in human embryonic kidney cells, with some antineoplastic agents that are routinely being used in cancer chemotherapy.\nThe ability of an antineoplastic drug to exert its cytostatic effect depends largely on the balance between its uptake into and extrusion from the cancer cells.\nATP driven efflux transporter proteins drive the export of antineoplastic drugs and play a pivotal role in the development of chemoresistance.\nIncubation of bendamustine with OAT2 expressing cells increased the caspase-3 activity, and this increase was inhibited by simultaneous incubation with bendamustine and probenecid, a well-known inhibitor of OATs, suggesting that bendamustine is a substrate of OAT2.\nA higher accumulation of irinotecan was observed in OAT2 expressing cells compared to control pcDNA cells by HPLC analysis of cell lysates.\nThe accumulation was diminished in the presence of cGMP, the substrate we used to functionally characterize OAT2, suggesting specificity of this uptake and the fact that OAT2 mediates uptake of irinotecan.\nAs regards uptake transporters, comparably less is known on their impact in drug action.", "dois": ["10.1016/j.phrs.2014.11.002", "PMID:15780063"]}
{"pair_type": "slc_pathway", "key1": "SLC9A2", "key2": "migration", "summary": "Importantly, SLC9A2 overexpression in SW480 cells led to a notable inhibition of cell proliferation, migration, and invasion.\nMechanistically, we found that SLC9A2 inhibits epithelial-mesenchymal transition (EMT) and metastasis by suppressing the STAT3 signaling pathway.\nThe results demonstrate that in RGM1 cells, migratory velocity is increased by NHE1 activation, while NHE2 activity inhibit this process.\nMoreover, SLC9A2 reduces VEGFA secretion, normalizing tumor vasculature and reshaping the tumor microenvironment (TME), which ultimately enhances anti-tumor immunity.\nOur study suggests that SLC9A2 acts as a tumor suppressor through the MAPK pathway and could be a potential target for CRC diagnosis and therapy.\nThese findings highlight the critical role of SLC9A2 in regulating metastasis, angiogenesis, and TME remodeling in CRC.\nBy modulating the STAT3 pathway and tumor vasculature, SLC9A2 emerges as a potential prognostic biomarker and therapeutic target.\nTargeting SLC9A2 may enhance immune responses and improve treatment outcomes in CRC, offering a promising avenue for future therapeutic strategies.\nLentiviral NHE2 expression increased the steady-state pH and reduced the restitution velocity after low pH preincubation, which was reversible by pharmacological NHE2 inhibition.\nOur analysis revealed a significant downregulation of SLC9A2 in the highly metastatic CRC cell lines.\nComparative analysis of CRC tissue samples showed reduced SLC9A2 expression in tumor tissues compared to adjacent normal tissues, with a negative correlation to TNM staging.\nImportantly, higher SLC9A2 expression was associated with better treatment responses in immunotherapy cohorts.\nBoth mRNA and protein expression levels of SLC9A2 were markedly reduced in CRC tissues and cell lines.\nWestern blotting analysis revealed that the expression levels of phosphorylated ERK (p-ERK) and phosphorylated JNK (p-JNK) proteins were significantly increased, whereas there were no significant changes", "dois": ["10.1186/s13046-025-03422-7", "10.1007/s11596-024-2871-5", "10.1002/jcp.25758"]}
{"pair_type": "slc_pathway", "key1": "SLC10A1", "key2": "glycolysis", "summary": "Gain- and loss-of-function studies showed that OPN promotes, while SPP2, LECT2, SLC10A1, CYP3A4, HSD17B13, and IYD inhibit HCC cell glycolysis as revealed by glucose utilization, lactate production, and extracellular acidification ratio.\nOur work elucidated that LINC00659 inhibited HCC progression and aerobic glycolysis via the FUS/SLC10A1 axis, revealing a novel lncRNA-RNA-binding protein-mRNA network in HCC, which might provide potential therapeutic targets for HCC.\nThe results showed that overexpressed SLC10A1 significantly suppressed the proliferation, migration, and aerobic glycolysis in HCC cells.\nThese glycolysis-related genes exhibited significant tumor-promoting or tumor suppressive effect on HCC cells and these effects were glycolysis-dependent.\nMechanical experiments further demonstrated that LINC00659 positively regulated SLC10A1 expression in HCC cells by recruiting fused protein in sarcoma (FUS).\nOur findings reveal crucial determinants for controlling the Warburg metabolism in HCC cells and provide a new insight into the oncogenic roles of OPN in HCC.", "dois": ["10.1155/2023/5852963", "10.1186/s12964-020-00539-4"]}
{"pair_type": "slc_pathway", "key1": "SLC9A8", "key2": "oxidative stress", "summary": "Elevated oxidative stress in IBD was confirmed by increased Total Oxidant Status (TOS) levels in patient plasma.\nNetwork analysis highlighted NDUFB2 as a key downregulated hub gene linked to mitochondrial complex I dysfunction and oxidative phosphorylation disruption.\nLASSO and SVM identified a three-mRNA panel-IL4R, EIF5A, and SLC9A8-which achieved 84% diagnostic accuracy in the discovery cohort and 99% accuracy in the real-life cohort.", "dois": ["10.3389/fimmu.2025.1570374"]}
{"pair_type": "slc_pathway", "key1": "SLC7A6", "key2": "oxidative stress", "summary": "Under nickel exposure conditions, we detected significantly increased intracellular ROS generation, in addition to higher amounts of DNA damage using comet assay and γ-H2AX immunofluorescence staining in Nrf2 lacking cells, as compared to Nrf2 wild-type cells.\nAbstract: Nickel (Ⅱ) is a toxic and carcinogenic metal which induces a redox imbalance following oxidative stress.\nIn this study, we investigated the protective roles of the Nrf2 gene against oxidative stress and DNA damage induced by nickel at sub-lethal doses.\nNuclear factor erythroid-2 related factor 2 (Nrf2) is a redox factor that regulates oxidation/reduction status and consequently mediates cytoprotective responses against exposure to environmental toxicants.\nIn conclusion, these findings indicate that Nrf2 is an important factor with a protective role in the suppression of mutagenicity and carcinogenicity by environmental nickel exposure in terms of gene-environment interaction.\nAdditionally, using bioinformatics tool, we found that these genes functioned principally in a variety of molecular processes, including oxidative stress response, necrosis, DNA repair and cell survival.", "dois": ["10.1186/s13104-015-1500-6", "10.3892/or.2012.2057"]}
{"pair_type": "slc_pathway", "key1": "SLC9B2", "key2": "stemness", "summary": "Besides, mRNA expressions of NHE family were extremely associated with clinicopathological features, tumor immune microenvironment and stemness score, DNA methylation, and patient prognosis in COAD.", "dois": ["10.1155/2021/3241351"]}
{"pair_type": "slc_pathway", "key1": "SLC10A1", "key2": "proliferation", "summary": "The results showed that overexpressed SLC10A1 significantly suppressed the proliferation, migration, and aerobic glycolysis in HCC cells.\nGain- and loss-of-function studies showed that OPN promotes, while SPP2, LECT2, SLC10A1, CYP3A4, HSD17B13, and IYD inhibit HCC cell glycolysis as revealed by glucose utilization, lactate production, and extracellular acidification ratio.\nThese glycolysis-related genes exhibited significant tumor-promoting or tumor suppressive effect on HCC cells and these effects were glycolysis-dependent.\nIncreased aerobic glycolysis supports cancer cell survival and rapid proliferation and predicts a poor prognosis in cancer patients.\nOur work elucidated that LINC00659 inhibited HCC progression and aerobic glycolysis via the FUS/SLC10A1 axis, revealing a novel lncRNA-RNA-binding protein-mRNA network in HCC, which might provide potential therapeutic targets for HCC.\nMechanical experiments further demonstrated that LINC00659 positively regulated SLC10A1 expression in HCC cells by recruiting fused protein in sarcoma (FUS).\nAerobic glycolysis is a hallmark of HCC and facilitates its progression.\nIncreased glycolysis predicts adverse clinical outcome in many types of human cancers, especially HCC.", "dois": ["10.1155/2023/5852963", "10.1186/s12964-020-00539-4", "10.1038/s41598-017-05656-8", "10.3892/mmr.2013.1516"]}
{"pair_type": "slc_pathway", "key1": "SLC10A1", "key2": "migration", "summary": "The results showed that overexpressed SLC10A1 significantly suppressed the proliferation, migration, and aerobic glycolysis in HCC cells.\nOur work elucidated that LINC00659 inhibited HCC progression and aerobic glycolysis via the FUS/SLC10A1 axis, revealing a novel lncRNA-RNA-binding protein-mRNA network in HCC, which might provide potential therapeutic targets for HCC.\nMechanical experiments further demonstrated that LINC00659 positively regulated SLC10A1 expression in HCC cells by recruiting fused protein in sarcoma (FUS).", "dois": ["10.1155/2023/5852963", "10.1186/s12935-021-01871-6"]}
{"pair_type": "slc_pathway", "key1": "SLC9B1", "key2": "chemotherapy", "summary": "Only two genes, NLRP3 and SLC9B1, were significantly more frequently mutated in the complete responders (23% vs. 0%).\nHowever, given the heterogeneity of IBC, no molecular feature reliably predicts the response to chemotherapy.\nNeoadjuvant chemotherapy (NACT) became a standard treatment strategy for patients with inflammatory breast cancer (IBC) because of high disease aggressiveness.\nThe pathological response to NACT, assessed on operative specimen, distinguished the patients with versus without pathological complete response (pCR versus no-pCR respectively).\nWhole-exome sequencing (WES) of clinical tumor samples provides an opportunity to identify genomic alterations associated with chemosensitivity.\nBy contrast, several biological pathways involved in protein translation, PI3K pathway, and signal transduction showed significantly higher mutation frequency in the patients with pCR.", "dois": ["10.1186/s12967-024-05790-8"]}
{"pair_type": "slc_pathway", "key1": "SLC7A7", "key2": "chemotherapy", "summary": "High-risk patients exhibited worse prognosis, higher tumor mutational burden, and better response to anti-PD-L1 therapy, while low-risk patients exhibited higher immune infiltration and increased chemotherapy sensitivity.\nAn integrative analysis identified 111 common differentially expressed genes including two bone morphogenetic proteins (BMP4 and BMP7), six solute carrier proteins (SLC10A3, SLC16A3, SLC25A1, SLC35B3, SLC7A5 and SLC7A7), transcription factor POU5F1 (POU class 5 homeobox 1), and KLK10 (kallikrein-related peptidase 10).\nWe identified 1187 tags (corresponding to 1040 genes) that are differentially expressed between the chemotherapy responsive and the persistently chemotherapy resistant ovarian cancer tissues.\nGO term GO:0050673 (epithelial cell proliferation) and GO:0050678 (regulation of epithelial cell proliferation) are enriched in the genes over expressed in the chemotherapy resistant tissue while the GO:0007229 (integrin-mediated signaling pathway) is enriched in the genes over expressed in the chemotherapy sensitive tissue.\nA network analysis revealed a subnetwork with three genes BMP7, NR2F2 and AP2B1 that were consistently over expressed in the chemoresistant tissue or cells compared to the chemosensitive tissue or cells.\nTwo next-generation sequencing technologies--MPSS (massively parallel signature sequencing) and SBS (sequencing by synthesis)--were used to sequence the transcripts of IGROV1 and IGROV1-CP cells, and to sequence the transcripts of a highly chemotherapy responsive and a highly chemotherapy resistant ovarian cancer tissue.\nGene Ontology (GO) term GO:0001837 (epithelial-to-mesenchymal transition) and GO:0034330 (cell junction assembly and maintenance) are enriched in genes that are over expressed in IGROV1-CP cells while apoptosis-related GO terms are enriched in genes over expressed in IGROV1 cells.\nHypoxia and lactate metabolism products are critical components of the tumor microenvironment in", "dois": ["10.1007/s12672-025-02873-w", "10.1016/j.ygyno.2010.01.041"]}
{"pair_type": "slc_pathway", "key1": "SLC10A1", "key2": "apoptosis", "summary": "In this study, we found that NTCP (SLC10A1) expression was downregulated in HB cells and tissues, and it was demonstrated that NTCP (SLC10A1) reduced cell viability, promoted cell cycle arrest and induced apoptosis of HB cells.\nThe top 50 genes (upregulated or downregulated) were selected and their functional involvement in various pathways associated with cancer progression was analyzed, including cell proliferation, apoptosis, metabolism and the cell cycle.\nIncubation of bendamustine with OAT2 expressing cells increased the caspase-3 activity, and this increase was inhibited by simultaneous incubation with bendamustine and probenecid, a well-known inhibitor of OATs, suggesting that bendamustine is a substrate of OAT2.", "dois": ["10.1016/j.biocel.2020.105773", "10.1016/j.phrs.2014.11.002", "10.3892/mmr.2013.1516"]}
{"pair_type": "slc_pathway", "key1": "SLC10A1", "key2": "ferroptosis", "summary": "Several significant disparities in prognosis, clinicopathological characteristics, and immune and ferroptosis-related status were found across the three subtypes, especially between C1 and C3 subgroups.\nThe risk score = (0.103) × expression value of CXCL8 + (-0.0333) × expression value of SLC10A1 + (-0.0812) × expression value of ADH4.\nThree of 21 prognostic DEGs (CXCL8, SLC10A1, and ADH4) were finally selected through machine-learning-based discovery and validation strategy.", "dois": ["10.2147/JHC.S483647", "10.3389/fgene.2022.1005271"]}
{"pair_type": "slc_pathway", "key1": "SLC9A6", "key2": "chemotherapy", "summary": "We recently identified a conceptually novel mechanism for how dysregulated pH in hypoxic cells causes chemoresistance which is based on the aberrant cellular distribution of the endosomal pH regulator, the sodium/hydrogen exchanger 6 (NHE6).\nAltered pH homeostasis in cancer cells has been linked with essentially all classical hallmarks of cancer, including chemoresistance.", "dois": ["10.2147/IJGM.S466364", "10.1080/23723556.2018.1435184"]}
{"pair_type": "slc_pathway", "key1": "SLC9B2", "key2": "oxidative phosphorylation", "summary": "MR analysis revealed significant causal associations, including SLC9B2 with rheumatoid arthritis (RA), MRM3 with ulcerative colitis (UC) and inflammatory bowel disease (IBD), and PDK1 with UC and IBD.\nReverse MR indicated bidirectional effects, with UC influencing SLC9B2 and C1QBP expression.\nMitochondria are central to immune regulation, inflammation, and cellular metabolism.\nGrowing evidence suggests that mitochondrial dysfunction contributes to autoimmune disease (AD) pathogenesis by modulating inflammatory pathways and immune cell function.\nColocalization analysis confirmed shared genetic variants, linking mitochondrial proteins to inflammatory regulation.\nThis study provides genetic evidence for the causal role of mitochondrial proteins in autoimmune inflammation, identifying potential biomarkers and therapeutic targets.", "dois": ["10.1007/s13755-025-00358-2"]}
{"pair_type": "slc_pathway", "key1": "SLC10A7", "key2": "proliferation", "summary": "Rescue experiments showed that the overexpression of SLC10A7 could impede the effects of circHECTD1 silencing on the proliferation and invasion of glioma cells.\nKnockdown of circHECTD1 inhibited proliferation and invasion in vitro, and also reduced the growth of tumor and prolonged the prognosis in vivo.\nIn this study, we identified that circHECTD1 regulates SLC10A7 by interacting with miR-296-3p in glioma cells.\nLuciferase reports and RNA immunoprecipitation data indicated that miR-296-3p was a direct target of circHECTD1 and that the miR-296-3p expression negatively regulated SLC10A7.\nIn conclusion, this study investigated a novel biomarker panel consisting of the circHECTD1/miR-296-3p/SLC10A7 axis, which is critical for glioma tumorigenesis and invasiveness and may represent a novel therapeutic target for intervening in glioma progression.", "dois": ["10.1002/jcp.30277"]}
{"pair_type": "slc_pathway", "key1": "SLC11A1", "key2": "chemotherapy", "summary": "RNA sequencing of mouse neutrophils identified Slc11a1 as a key NETs formation-related gene, which was upregulated by TCb chemotherapy in neutrophils, leading to increased intracellular ferrous ion content and ROS generation.\nOur study aims to demonstrate that Neutrophil Extracellular Traps (NETs) play a pivotal role in neoadjuvant chemotherapy-induced vascular endothelial injury in breast cancer, elucidating that chemotherapy-induced upregulation of Solute Carrier 11a1 (Slc11a1) modulates Reactive Oxygen Species (ROS) generation, which may be critical for NETs formation.\nOur research underscores the capacity of TCb neoadjuvant chemotherapy in breast cancer to augment NETs formation in neutrophils through Slc11a1-mediated ROS generation, which is linked to vascular endothelial injury.\nRNA sequencing of neutrophils from chemotherapy mouse models was performed to identify the potential NETs formation-associated gene Slc11a1, which was further validated through cellular and animal experiments by assessing Slc11a1 expression, intracellular ferrous ion content, and ROS levels.\nIn some cases, SLC11A1 could be an effective marker for identifying patients who might benefit from immunotherapy or chemotherapy.\nKnockdown of Slc11a1 in human neutrophils and mouse models demonstrated its reversal effect on TCb-induced ferrous ion upregulation, ROS generation, and NETs formation.\nChemotherapy mouse models demonstrated that TCb treatment markedly elevated NETs formation and endothelial injury, which can be mitigated by CI-amidine, a protein-arginine deiminase inhibitor.\nIn human neutrophils, we demonstrated that the TCb chemotherapeutic agents (combination of docetaxel and carboplatin) induced the formation of NETs, which subsequently facilitated damage to human umbilical vein endothelial cells in vitro.\nOur study elucidates the potential mechanisms underlying perioperative vascular endothelial injury in breast cancer patients undergoing neoadjuvant chemotherapy, offering novel insights into perioperative therapeutic management strategies for these", "dois": ["10.1186/s13058-025-02011-y", "10.1038/s41598-025-97667-z", "10.1016/j.wneu.2024.01.039", "10.3389/fimmu.2022.980378", "10.18632/oncotarget.24897"]}
{"pair_type": "slc_pathway", "key1": "SLC10A6", "key2": "proliferation", "summary": "Cell proliferation was significantly increased by 10 M estradiol as well as by ES with EC of 2.2 nM.\nThe ES-stimulated proliferation of SOAT-T47D cells was blocked by the SOAT inhibitor 4-sulfooxymethylpyrene.\nSOAT inhibition can block the ES-stimulated proliferation of T47D breast cancer cells, demonstrating that SOAT is an interesting novel drug target from the group of ES uptake carriers for anti-proliferative breast cancer therapy.\nEstrogens play a pivotal role in the development and proliferation of hormone-dependent breast cancer.\nIn the present study, expression of the sodium-dependent organic anion transporter SOAT was analyzed in breast cancer and its role for hormone-dependent proliferation of T47D breast cancer cells was elucidated.\nTo analyze the role of SOAT for breast cancer cell proliferation, T47D cells were stably transfected with SOAT and incubated under increasing concentrations of estrone-3-sulfate (ES) and estradiol at physiologically relevant concentrations.\nApart from free estrogens, which can directly activate the estrogen receptor (ER) of tumor cells, sulfo-conjugated steroids, which maintain high plasma concentrations even after menopause, first have to be imported into tumor cells by carrier-mediated uptake and then can be cleaved by the steroid sulfatase to finally activate ERs and cell proliferation.", "dois": ["10.3389/fphar.2018.00941"]}
{"pair_type": "slc_pathway", "key1": "SLC11A1", "key2": "ferroptosis", "summary": "SLC11A1, primarily expressed in macrophages, modulates immune responses and reshapes the tumor microenvironment, while SLC11A2, a ubiquitous iron transporter, regulates dietary iron absorption and ferroptosis, an iron-dependent form of programmed cell death.\nGene ontology and KEGG pathway analyses revealed that the targets of these miRNAs were enriched in functions associated with ferroptosis and fatty acid metabolism, underscoring the critical role of these miRNAs in regulating the intracellular survival of ().\nmiR-7850-5p promoted the intracellular survival of by suppressing the expression of the SLC11A1 protein.\nthe overexpression of miR-7850-5p downregulated the expression of the SLC11A1 protein in both -infected and -uninfected THP1 cells.\nThe solute carrier family 11 (SLC11) transporters, comprising SLC11A1 and SLC11A2, play pivotal roles in iron metabolism and cellular homeostasis, processes intricately linked to oncogenesis.\nDysregulation of these transporters is associated with tumor initiation, progression, metastasis, and therapy resistance.\nEmerging evidence highlights their involvement in key oncogenic pathways, including p53, JAK/STAT, Wnt and HIF signaling.\nPharmacological and genetic interventions targeting SLC11 transporters have shown the potential to disrupt tumor progression and enhance treatment efficacy.\nIron is an essential trace element in the human body, and its imbalance is closely linked to the initiation and progression of various malignancies.\nthere were a large number of abnormal ferroptosis-related alterations, which were significant for the prognosis of patients.\na substantial difference in the expression of ferroptosis-related genes between malignant and paracancerous samples, which was compatible with immunohistochemistry staining results from clinicopathological samples.", "dois": ["10.1186/s12964-025-02293-x", "10.2147/JIR.S497418", "10.3390/microorganisms12071417", "10.3389/fmolb.2022.904098"]}
{"pair_type": "slc_pathway", "key1": "SLC11A1", "key2": "oxidative phosphorylation", "summary": "Weighted gene co-expression network analysis (WGCNA) revealed methylation-associated modules enriched in metabolic and immune pathways, pinpointing key genes such as CAMK1G and SLC11A1.\nSingle-cell profiling uncovered MSO-high myeloid cells associated with inflammatory and oxidative phosphorylation pathways, while MSO-high OS cells displayed transdifferentiation toward fibroblasts via pseudotime trajectories, remodeling the extracellular matrix (ECM) to facilitate lung metastasis.\nThey were mainly involved in immune responses, cardiac muscle contraction, oxidative phosphorylation, and apoptotic signaling pathways.\nThe GSVA suggested that DNA repair, oxidative phosphorylation, peroxisome, IL-6-JAK-STAT3 signaling, and apoptosis were crucial in the development of IDD.\nEleven hub biomarkers (ITM2B, GNA15, PLAU, GNG11, HIST1H2BH, SLC11A1, RPS7, DDIT4, CD83, GNLY, and S100A12) were identified and associated with CD8 + T cells and NK cells.", "dois": ["10.1016/j.ijbiomac.2025.147473", "10.1038/s41598-025-02123-7", "10.3389/fgene.2022.864100"]}
{"pair_type": "slc_pathway", "key1": "SLC11A1", "key2": "migration", "summary": "SLC11A1 downregulation repressed KIRC cell proliferation, migration, invasion, macrophage, and lymphocyte immunity in vitro, as well as hindered tumor growth in vivo.\nSLC11A1 induced CCL2 and PD-L1 expression, thereby activating the JAK/STAT3 pathway.\nIn vitro experiments confirmed that modulation of a key LDCD regulator, SLC11A1, affected the proliferation and invasiveness of COAD cells.\nSLC11A1 deficiency constrained KIRC cell malignant phenotypes and immune response via regulating CCL2 and PD-L1-mediated JAK/STAT3 pathway, providing a promising therapeutic target for KIRC treatment.\nHerein, SLC11A1 was highly expressed in KIRC tissues and cell lines.\nIn KIRC patients, SLC11A1 is highly expressed and positively correlated with the immune-related factors CCL2 and PD-L1.\nMoreover, the impact of SLC11A1 on apoptosis and intracellular ROS level confirmed the potential association between SLC11A1 and COAD cell apoptosis.\nEpithelial Cell Transforming Sequence 2 (ECT2) has been implicated in various tumorigenic processes, including proliferation, migration, and invasion.\nECT2 is highly expressed in HNSCC samples and its downregulation inhibits proliferation, migration, invasion, induces apoptosis, and affects the cell cycle transition in HSC-3 cells.\nProliferation, migration, and invasion were measured using colony formation, EdU, and transwell assays.\nFunctional assays, including colony formation, Transwell migration, and western blotting, were performed to validate the role of key LDCD regulators in COAD cell line.\nRelative abundance of mRNA transcripts for proteins assigned to inflammatory response, movement of phagocytes, quantity of phagocytes, leukocyte migration and adhesion of immune cells and many other functions related to inflammation were different in the Escherichia coli-treated endometrium than in samples from gilts treated with saline.", "dois": ["10.1038/s41598-025-18267-5", "10.7150/jca.95515", "10.1016/j.taap.2024.116975", "10.1016/j.anireprosci.2021.106824", "10.3389/fgene.2021.668448", "10.1016/j.meegid.2016.11.011"]}
{"pair_type": "slc_pathway", "key1": "SLC7A7", "key2": "migration", "summary": "Knockdown of SLC7A7 increased the cell apoptosis rate (P = 0.006) but decreased the G1 phase ratio (P = 0.002) and cell migration (P < 0.001) and invasion (P < 0.001).\nHowever, SLC7A7 overexpression significantly decreased the percentage of apoptotic Jurkat cells (P = 0.007) but significantly increased the proportion of G1 phase cells (P = 0.029) and cell migration (P < 0.001) and invasion (P < 0.001).\nSLC7A7 was indicated to promote the migration and invasion of CRC cells in in vitro functional experiments.\nWe analyzed the role of the SLC7A7 gene in the cellular activities of Jurkat cells, specifically the cell cycle and cell proliferation, apoptosis, migration, and invasion.\nMoreover, the expression of the lysine metabolism-related genes SLC7A7 and VIM and their effect on cellular phenotypes in gastric carcinogenesis were verified in clinical samples and in vitro experiments, including cell proliferation, migration, invasion and cell cycle assays.\nOur results indicate that SLC7A7 may promote CRC metastasis through the SLC7A7/APC/Wnt/β-catenin signaling pathway.\nIn this way, CD98hc connects the signaling pathways sustaining cell proliferation and migration, biosynthesis and antioxidant defense, energy production, and stem cell properties.\nEnrichment analysis showed that SLC7A7 was significantly enriched during EMT and could be enriched in the Wnt/β-catenin signaling pathway, immune infiltration analysis of pan-cancer showed that SLC7A7 was significantly enriched in macrophages, and methylation analysis showed that SLC7A7 methylation modification affected the prognosis of specific cancers.\nAfterward, functional experiments were conducted in vitro to investigate how SLC7A7 affects tumor metastasis.\nPyroptosis represents a novel programmed cell death type which widely investigated in various disorders and can influence tumor growth, migration, and invasion.\nCD98hc serves as a chaperone for LAT1 (SLC7", "dois": ["10.1136/jitc-2024-011091", "10.1186/s12885-025-14051-w", "10.1038/s41598-024-80885-2", "10.3389/fonc.2023.1251100", "10.18632/aging.204661", "10.2147/CMAR.S328559", "10.1159/000491899", "10.1016/j.celrep.2015.04.028", "PMID:22738901"]}
{"pair_type": "slc_pathway", "key1": "SLC11A1", "key2": "oxidative stress", "summary": "These genes, including Lcn2, Mmp9, Chi3l1, Adipoq, Atp5j2, Atp5l, Atpif1, Ndufb6, Fgr, Slc11a1, and Tyrobp, are highly related to oxidative stress response, inflammatory responses, and immune system processes.\nLike MgtB, MgtU is necessary for survival in / macrophages, resistance to oxidative stress, and growth under Mg limitation conditions.\nAcquisition of these metal cations is vital for all cells, as they act as redox cofactors and regulate key cellular processes, such as DNA synthesis, electron transport, energy metabolism and oxidative stress.\nDictyostelium Nramp1 (Slc11a1), like its mammalian ortholog, mediates resistance to infection by invasive bacteria.\nThe macrophage protein Slc11a1 is proposed to protect mice from invading microbes by causing Mg starvation in host tissues.\nHowever, the Mg transporter MgtB enables the facultative intracellular pathogen serovar Typhimurium to cause disease in mice harboring a functional Slc11a1 protein.\nThe objective of this study was to monitor the nucleotide sequence variations, gene expression, serum inflammatory and oxidative stress biomarkers in diarrheic lambs.\nSignificant (P = 0.001) increases in serum IL-1α, IL-1β, IL-6, TNF-α (90.5 ± 1.7, 101.8 ± 1.7, 72.3 ± 6.6, 71.26 ± 4.89 Pg/ml, respectively), serum Fb, Cp, Hp, SAA (230.7 ± 12.4 mg/dl, 6.5 ± 0.07 mg/dl, 2.5 ± 0.09 g/dl, 7.4 ± 0.4 mg/L, respectively), free radicals (MDA, NO), cortisol (6.91 ± 0.18 μg", "dois": ["10.1016/j.gpb.2019.11.005", "10.1016/j.freeradbiomed.2017.06.014", "10.1111/j.1365-313X.2008.03775.x", "PMID:15506949", "10.1186/s12917-024-04288-1", "10.1073/pnas.2006116117", "10.1242/jcs.116210"]}
{"pair_type": "slc_pathway", "key1": "SLC11A2", "key2": "apoptosis", "summary": "Knockdown of SLC11A2 reduced ovarian cancer migration and increased cisplatin-induced apoptosis.\nProteomics analysis further discloses the key involved proteins (including Tp53, HMOX1, Ptgs2, Tfrc, Slc11a2, Mgst2, Sod1, and several GST family members) and pathways (including apoptosis, ferroptosis, and ROS synthesis).\nOverall, 6569 genes (19% of the genes investigated) were expressed in ≥1 stage of BM erythropoiesis at stable (e.g., genes involved in DNA process, cell signaling, protein organization and hemoglobin production) or variable amounts (e.g., genes related to cell differentiation, apoptosis, metabolism), the latter showing a tendency to either decrease from stage 1 to 3 (genes associated with regulation of erythroid differentiation and survival, e.g., , ) or increase from stage 2 to stage 3 (genes associated with autophagy, erythroid functions such as heme production, e.g., , ALAS2), iron metabolism (e.g., ), protection from oxidative stress (e.g., , ), and NRBC enucleation (e.g., , ).\nConclusively, this work develops a strategy based on one nanosystem to synergistically induce ferroptosis and apoptosis in vivo for tumor suppression, which holds great potential in the clinical translation for tumor therapy.\nInterestingly, genes involved in apoptosis (e.g., ) and immune response (e.g., ) were also upregulated in the last stage (stage 3) of maturation of NRBC precursors.\nHowever, at high concentrations, copper ions show increased toxicity by inducing regulated cell death, such as apoptosis, paraptosis, pyroptosis, ferroptosis, and cuproptosis.\nThe core mechanism of its effect is that ferroptosis activates the TFR1/SLC11A2/GPX4 signaling pathway, which leads to the up-regulation of oxidative stress in ApoE-/- mice, and ultimately aggravates the abnormal lipid metabolism in ApoE", "dois": ["10.1007/s12031-023-02148-5", "10.1080/15548627.2023.2200554", "10.1002/smll.202202161", "10.1158/1078-0432.CCR-19-2335", "10.1093/toxsci/kfy288", "10.1016/j.ijbiomac.2025.146695", "10.2174/0113862073271348231213071225", "10.1038/s41598-022-26789-5", "10.1038/s41420-019-0151-0", "PMID:30555088"]}
{"pair_type": "slc_pathway", "key1": "SLC11A2", "key2": "migration", "summary": "Knockdown of SLC11A2 reduced ovarian cancer migration and increased cisplatin-induced apoptosis.", "dois": ["10.1038/s41598-022-26789-5"]}
{"pair_type": "slc_pathway", "key1": "SLC7A7", "key2": "proliferation", "summary": "CDX2 increases SLC7A7 expression and proliferation of pig intestinal epithelial cells.\nKnockdown of SLC7A7 increased the cell apoptosis rate (P = 0.006) but decreased the G1 phase ratio (P = 0.002) and cell migration (P < 0.001) and invasion (P < 0.001).\nWe analyzed the role of the SLC7A7 gene in the cellular activities of Jurkat cells, specifically the cell cycle and cell proliferation, apoptosis, migration, and invasion.\nHowever, SLC7A7 overexpression significantly decreased the percentage of apoptotic Jurkat cells (P = 0.007) but significantly increased the proportion of G1 phase cells (P = 0.029) and cell migration (P < 0.001) and invasion (P < 0.001).\nMoreover, the expression of the lysine metabolism-related genes SLC7A7 and VIM and their effect on cellular phenotypes in gastric carcinogenesis were verified in clinical samples and in vitro experiments, including cell proliferation, migration, invasion and cell cycle assays.\nIn addition, luciferase reporter and chromatin immunoprecipitation assays revealed that CDX2 binds directly to the SLC7A7 promoter.\nOur findings show that nutrient transporters are activated during CDX2-induced proliferation of normal intestinal epithelial cells.\nCDX2 overexpression in IPEC-1 cells increased cell proliferation, the percentage of cells in S/G2 phase, and the abundance of transcripts of the cell cycle-related genes Cyclin A2.\nWe evaluated the role of Caudal type homeobox 2 (CDX2), an intestine-specific transcription factor, in the proliferation of pig intestinal epithelial cells (IPEC-1) and searched for novel intestinal nutrient transporter genes activated by CDX2.\nSLC7A7 plays a significant role in the pathogenesis of T-cell acute lymphoblastic leukemia.\nand cell cycle cyclin-dependent kinases 1, 2 and 4, as well as the predicted CDX2 target genes SLC1A1", "dois": ["10.1186/s12885-025-14051-w", "10.3389/fonc.2023.1251100", "10.2147/CMAR.S328559", "10.1159/000491899", "10.5713/ajas.17.0799", "10.18632/oncotarget.8894", "PMID:22738901", "10.1016/j.ygyno.2010.01.041"]}
{"pair_type": "slc_pathway", "key1": "SLC7A7", "key2": "ferroptosis", "summary": "Further exploration revealed that EMPA suppressed ferroptosis by downregulation of SLC7A7 via the AMP-activated protein kinase/Glycogen synthase kinase 3 Beta/Nuclear factor erythroid 2-related factor 2 (AMPK/GSK-3β/NRF2) signaling pathway, thereby reducing renal fibrosis.\nEMPA treatment could inhibit iron death to alleviate renal fibrosis, and the process was found to be related to the AMPK/GSK-3β/NRF2 pathway in subsequent mechanistic studies.\nThe findings indicated a link to ferroptosis, closely associated with renal fibrosis.\nTranscriptomic analysis revealed varied SLC7A7 expression in T2DM versus normal groups, and was verified by qPCR and WB.\nSignificant changes in ferroptosis-related proteins, specifically acyl-CoA synthetase long-chain family member 4 (ACSL4) and glutathione peroxidase 4 (GPX4), emerged at the protein level.\nCD98hc serves as a chaperone for LAT1 (SLC7A5), LAT2 (SLC7A8), yLAT1 (SLC7A7), yLAT2 (SLC7A6), xCT (SLC7A11) and Asc1 (SLC7A10) providing their recruitment to the plasma membrane.\nSubsequent cellular validation of T2DM and human renal proximal tubular (HK-2) cells under high-glucose conditions revealed that Collagen type I alpha 1 (COL1A1) and alpha -smooth muscle actin (α-SMA) levels increased in high-glucose group but decreased following EMPA treatment.\nThese observations imply that EMPA mitigates renal fibrosis.", "dois": ["10.1186/s13098-025-01902-6", "10.3389/fonc.2023.1251100"]}
{"pair_type": "slc_pathway", "key1": "SLC11A2", "key2": "proliferation", "summary": "Supplementation of the culture media with exogenous iron led to an increase in the proliferation of osteoclast progenitor cells and to the expression of a macrophage-like phenotype, while the development of osteoclasts was reduced.\nIn differentiating osteoclasts, levels of transcripts encoding transferrin receptor 1 and divalent metal transporter 1 (Slc11A2) were increased, while levels of transcripts encoding ferroportin (Slc40A1) and natural resistance-associated macrophage protein 1 (Slc11A1) were decreased.\nDysregulation of these transporters can increase intracellular iron, boosting reactive oxygen species production and genetic instability, thereby promoting cancer hallmark processes such as sustained proliferation, apoptosis evasion, metastasis, and resistance to therapy.\nMechanistically, si-SLC7A6-RI isoform exerted oncogenic effects by activating the PI3K-Akt-mTOR signaling pathway and promoting cell proliferation, evidenced by increased expression of key regulators Phosphorylated Mammalian Target of Rapamycin (p-mTOR) and a cell proliferation marker Proliferating Cell Nuclear Antigen (PCNA) using western blotting.\nKnockdown of the intronic region of SLC7A6-RI isoform enhanced colon cancer cell proliferation.\nThe data demonstrate transcriptional regulation of the components of cellular iron transporters during OC development and suggests that iron homeostasis may contribute to fine-tuning of the RANKL-induced OC development.\nIn vivo, knockdown of the intronic region of SLC7A6-RI isoform enhanced tumor growth in colon cancer.\nTransporters such as SLC11A2, SLC39A14, and ABCB7 notably modulate oncogenic pathways including JAK/STAT, TGF-β, Wnt, and HIF signaling.\nOur study elucidated SLC-AS in COAD, highlighting its potential as a prognostic and therapeutic target and emphasizing the suppressive influence of SLC7A6-RI in colon cancer progression.", "dois": ["10.1016/j.ijbiomac.2025.146695", "10.1111/cas.16351", "10.1007/s00223-015-0087-1", "PMID:20392994"]}
{"pair_type": "slc_pathway", "key1": "SLC11A2", "key2": "ferroptosis", "summary": "Overall, IRF7 upregulated SLC11A2 transcription by inhibiting miR-375-3p expression, thereby prompting ferroptosis of colonic ECs and UC progression in DSS-treated mice.\nThe core mechanism of its effect is that ferroptosis activates the TFR1/SLC11A2/GPX4 signaling pathway, which leads to the up-regulation of oxidative stress in ApoE-/- mice, and ultimately aggravates the abnormal lipid metabolism in ApoE-/- mice.\nGenes SLC11A2 and HMOX1 in ferroptosis pathway influenced the cecum metabolite l-glutamate and tyrosine.\nOur results suggest a potential link between ferroptosis and the dysregulation of TFR1/SLC11A2/GPX4 expression, along with the presence of oxidative stress, in the progression of AS.\nSLC11A2, a ubiquitous iron transporter, regulates dietary iron absorption and ferroptosis, an iron-dependent form of programmed cell death.\nChromatin immunoprecipitation and dual-luciferase assays showed that binding of IRF7 to the miR-375-3p promoter inhibited miR-375-3p expression, and miR-375-3p suppressed SLC11A2 transcription.\nOur findings revealed that miR-203a-3p targets zinc finger E-box binding homeobox 1 (ZEB1), subsequently enhancing the expression of the iron transporter solute carrier family 11 member 2 (SLC11A2), thereby facilitating ferroptosis-associated skeletal muscle cell death.\nAn iron overload can induce a new type of cell death, defined as ferroptosis.\nFerroptosis, a form of programmed cell death induced by excess iron-dependent lipid peroxidation product accumulation, plays a critical role in cancer.\nFinally, we found that the expression of solute carrier family 11 member 2 (SLC11A2), iron responsive element binding protein 2 (IREB2), and transferrin receptor protein 1 (TFRC) increased significantly in the low-ACTRT2 group, which trans", "dois": ["10.1093/molehr/gaaf041", "10.1016/j.ijbiomac.2025.146695", "10.3390/ijms26062506", "10.1016/j.canlet.2025.217523", "10.1111/cas.16351", "10.3389/fimmu.2024.1402669", "10.2174/0113862073271348231213071225", "10.17305/bjbms.2022.8081", "10.1002/smll.202202161", "10.18632/aging.203190", "10.1186/s12964-025-02293-x", "10.1016/j.psj.2025.105192", "10.3390/ijms25020763", "10.1016/j.freeradbiomed.2023.11.042", "10.3389/fmolb.2023.1188027", "10.1080/15548627.2023.2200554"]}
{"pair_type": "slc_pathway", "key1": "SLC11A1", "key2": "proliferation", "summary": "SLC11A1 downregulation repressed KIRC cell proliferation, migration, invasion, macrophage, and lymphocyte immunity in vitro, as well as hindered tumor growth in vivo.\nIn vitro experiments confirmed that modulation of a key LDCD regulator, SLC11A1, affected the proliferation and invasiveness of COAD cells.\nSupplementation of the culture media with exogenous iron led to an increase in the proliferation of osteoclast progenitor cells and to the expression of a macrophage-like phenotype, while the development of osteoclasts was reduced.\nSLC11A1 induced CCL2 and PD-L1 expression, thereby activating the JAK/STAT3 pathway.\nThese upregulated genes were mainly enriched in mononuclear cell proliferation and signaling biological processes.\nSLC11A1 deficiency constrained KIRC cell malignant phenotypes and immune response via regulating CCL2 and PD-L1-mediated JAK/STAT3 pathway, providing a promising therapeutic target for KIRC treatment.\nHerein, SLC11A1 was highly expressed in KIRC tissues and cell lines.\nProliferation, migration, and invasion were measured using colony formation, EdU, and transwell assays.\nIn KIRC patients, SLC11A1 is highly expressed and positively correlated with the immune-related factors CCL2 and PD-L1.\nMoreover, the impact of SLC11A1 on apoptosis and intracellular ROS level confirmed the potential association between SLC11A1 and COAD cell apoptosis.\nSolute carrier family 11 member1 (SLC11A1) is a phagosomal membrane protein located in monocytes and plays a role in innate immunity, autoimmune diseases, and infection, but its expression and biological role in KIRC is still unknown.\nIntegration of scRNA-seq data identified Monocyte clusters as high-scoring cell clusters based on genes interacting with ECT2.Mendelian randomization analysis identified three genes (LGALS2, SLC11A1, and TKT) causally related to HNS", "dois": ["10.1038/s41598-025-18267-5", "10.1007/s11250-024-04236-z", "10.7150/jca.95515", "10.1016/j.taap.2024.116975", "10.1042/BSR20231400", "10.1186/s13287-020-01846-w", "10.3389/fimmu.2018.01403", "10.1007/s00223-015-0087-1", "10.1093/infdis/jiu829", "10.1007/s10753-010-9235-y"]}
{"pair_type": "slc_pathway", "key1": "SLC12A1", "key2": "apoptosis", "summary": "Likewise, CAP, at all concentrations, exerted significant modulatory effects on the expression of genes associated with apoptosis (bax, bcl2, p53, and casp3), organogenesis (tbx2a, tbx2b, and irx3b), and ion exchange (slc12a1 and kcnj1) in Danio rerio embryos.\nCalcium homeostasis plays a key role in cell proliferation and apoptosis.\nIn IvC, differentially methylated genes (DMGs) were enriched in metabolic processes and cell death.", "dois": ["10.1016/j.scitotenv.2024.173179", "10.3389/fgene.2020.584460", "10.1002/mc.22678", "10.1681/ASN.2015111271"]}
{"pair_type": "slc_pathway", "key1": "SLC12A1", "key2": "chemotherapy", "summary": "Among these, solute carrier family 12 member 1 () and glutamate ionotropic AMPA type subunit 4 (), both implicated in ion transport, showed the strongest association with chemoresistance.\nWe further validated eight highly correlated genes associated with resistance.\nWhole RNA sequencing of 12 patient biopsies revealed 269 differentially expressed genes in chemoresistant patients.\nOur results suggest a potential link between gene expression and GLUR4 protein levels with chemoresistance in luminal breast cancer.\nIn this study, we aimed to identify genes linked to neoadjuvant chemotherapy resistance in 62 retrospectively included patients with luminal breast cancer.\nIdentifying the genes associated with chemoresistance is crucial for understanding the underlying mechanisms and discovering effective treatments.\nChemoresistance to standard neoadjuvant treatment commonly occurs in locally advanced breast cancer, particularly in the luminal subtype, which is hormone receptor-positive and represents the most common subtype of breast cancer associated with the worst outcomes.\nNotably, expression was downregulated, while protein levels of glutamate receptor 4 (GLUR4), encoded by , were elevated in patients with a worse prognosis.\nIn particular, GLUR4 protein could serve as a potential target for drug intervention to overcome chemoresistance.", "dois": ["10.3390/ijms242216104"]}
{"pair_type": "slc_pathway", "key1": "SLC7A7", "key2": "stemness", "summary": "CD98hc serves as a chaperone for LAT1 (SLC7A5), LAT2 (SLC7A8), yLAT1 (SLC7A7), yLAT2 (SLC7A6), xCT (SLC7A11) and Asc1 (SLC7A10) providing their recruitment to the plasma membrane.\nIn this way, CD98hc connects the signaling pathways sustaining cell proliferation and migration, biosynthesis and antioxidant defense, energy production, and stem cell properties.\nIn this mini-review, we discuss the physiological functions of CD98hc, its role in regulating tumor stemness, metastases, and therapy resistance, and the clinical significance of CD98hc as a tumor marker and therapeutic target.\nThis multifaceted role makes CD98hc one of the critical regulators of tumor growth, therapy resistance, and metastases.", "dois": ["10.3389/fonc.2023.1251100"]}
{"pair_type": "slc_pathway", "key1": "SLC11A2", "key2": "oxidative stress", "summary": "The core mechanism of its effect is that ferroptosis activates the TFR1/SLC11A2/GPX4 signaling pathway, which leads to the up-regulation of oxidative stress in ApoE-/- mice, and ultimately aggravates the abnormal lipid metabolism in ApoE-/- mice.\nOur results suggest a potential link between ferroptosis and the dysregulation of TFR1/SLC11A2/GPX4 expression, along with the presence of oxidative stress, in the progression of AS.\niron metabolism (e.g., ), protection from oxidative stress (e.g., , )\nThese findings suggest that reduced iron release from duodenal cells into circulation plays a role in mitigating excessive iron uptake from the diet and that finely regulated duodenal absorption is essential to protect intestinal mucosa from iron-induced oxidative damage.\nRestricted-iron diet reduced iron concentrations in skeletal muscle and oxidative damage in the majority of tissues and also increased weight loss.\nIron supplementation caused suppression of endogenous duodenal SLC11A2 expression, down-regulation of duodenal ferroportin, and overexpression of hepatic hepcidin, precluding excessive iron uptake both in the TGs and wild-type mice.\nEnriched-iron diet increased hematocrit values, serum iron, gamma-glutamyl transferase, iron concentrations and oxidative stress in the majority of tissues.\nHowever, in its free form, iron participates in redox-reactions, leading to the production of free radicals that increase oxidative stress and the risk of damaging processes.\nUsing the PD animal model of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) intoxication in mice, we showed that DMT1 expression increases in the ventral mesencephalon of intoxicated animals, concomitant with iron accumulation, oxidative stress, and dopaminergic cell loss.\nReduced iron absorption and regulated release into circulation in duodenal mucosa constitute two major mechanisms of protection against dietary iron overload;\nHowever, iron-treated TGs revealed increased mortality, resulting from oxidative mucosal damage leading to hemorrhagic erosion throughout the", "dois": ["10.1158/1078-0432.CCR-19-2335", "10.1093/toxsci/kfy288", "PMID:27681840", "10.1371/journal.pone.0061058", "10.2353/ajpath.2010.090823", "PMID:20161623", "10.1016/S1353-8020(09)70816-8", "10.1073/pnas.0804373105", "10.2174/0113862073271348231213071225", "10.1016/j.freeradbiomed.2022.09.025", "10.1038/s41420-019-0151-0", "PMID:30555088", "10.3168/jds.2017-12866", "PMID:23565323"]}
{"pair_type": "slc_pathway", "key1": "SLC7A7", "key2": "oxidative stress", "summary": "Further exploration revealed that EMPA suppressed ferroptosis by downregulation of SLC7A7 via the AMP-activated protein kinase/Glycogen synthase kinase 3 Beta/Nuclear factor erythroid 2-related factor 2 (AMPK/GSK-3β/NRF2) signaling pathway, thereby reducing renal fibrosis.\nIn addition, the CKD-associated metabolite profile along with increased nitrite plasma levels suggests that LPI may be characterized by increased oxidative stress and apoptosis, altered microbial metabolism in the intestine and uremic toxicity.\nEMPA treatment could inhibit iron death to alleviate renal fibrosis, and the process was found to be related to the AMPK/GSK-3β/NRF2 pathway in subsequent mechanistic studies.\nResults revealed that compared to BD, L-MR significantly decreased ( < 0.05) the activities of plasma total antioxidant capacity and glutathione peroxidase, plasma amino acid profiles, and significantly reduced ( < 0.05) villus height and crypt depth in the duodenum and jejunum.\nIn conclusion, L-MR may result in oxidative stress and villous atrophy but proves beneficial in improving intestinal barrier function and the activity of amino acid transporters for compensatory growth.\nLysinuric protein intolerance (LPI [MIM 222700]) is an aminoaciduria with defective transport of cationic amino acids in epithelial cells in the small intestine and proximal kidney tubules due to mutations in the SLC7A7 gene.\nThe findings indicated a link to ferroptosis, closely associated with renal fibrosis.\nSignificant changes in ferroptosis-related proteins, specifically acyl-CoA synthetase long-chain family member 4 (ACSL4) and glutathione peroxidase 4 (GPX4), emerged at the protein level.", "dois": ["10.1186/s13104-015-1500-6", "10.1186/s13098-025-01902-6", "10.1016/j.aninu.2020.03.009", "10.1016/j.metabol.2016.05.012"]}
{"pair_type": "slc_pathway", "key1": "SLC12A1", "key2": "proliferation", "summary": "Since Pax8Cre-induced Dkk1 deficiency reduced marker gene expression, Scnn1b in the collecting duct and Slc12a1 in the loop of Henle, these results together with the extended papilla phenotype are likely reasons for the decreased amount of ions and urine produced by Dkk1-deficient kidneys in the adult.\nCell viability assays showed that overexpressions of SUCLG1, PCK2, GLDC significantly decreased proliferation of RCC.\nInterestingly, Dkk1 deficiency induced by Pax8Cre in the kidneys led in newborn mice to an overgrown papilla that was generated by stimulated proliferation of the collecting duct and loop of Henle cells, implying a role for Dkk1 in the collecting duct and/or loop of Henle development.\nFlow cytometry analysis showed that overexpression of three genes(SUCLG1, PCK2, GLDC) induced G1/S/G2 phase arrest of RCC cells.\nTranswell migration, invasion, wound healing assay showed overexpression of three genes(SUCLG1, PCK2, GLDC) significantly inhibited the migration, invasion of RCC.\nCalcium homeostasis plays a key role in cell proliferation and apoptosis.\nSS-USCs were positive for VIM, weakly positive for SLC12A1 and UMOD, and negative for KRT18, NPHS1, AQP1 and AQP2, indicating a renal mesenchyme origin.\nwhile RS-USCs are positive for VIM, partially positive for KRT18, NPHS1, AQP1, SLC12A1 and UMOD, and negative for AQP2, indicating a nephron tubule origin.\nThe two subpopulations showed similar clone-forming efficiency, while SS-USCs featured faster proliferation, higher motility, and greater potential for osteogenic and adipogenic differentiation, RS-USCs showed greater potential for chondrogenic differentiation.", "dois": ["10.1681/ASN.2020101407", "10.1186/s12935-020-01405-6", "10.1007/s11427-018-9543-1", "10.1002/mc.22678", "10.1016/j.ydbio.2011.02.019"]}
{"pair_type": "slc_pathway", "key1": "SLC12A1", "key2": "oxidative phosphorylation", "summary": "The findings showed that neutrophil activation, chronic inflammation, immune regulation, impaired ribosomal function, oxidative phosphorylation, and energy metabolism disorders are important factors in the development of bronchiectasis.", "dois": ["10.1186/s40001-024-01994-2"]}
{"pair_type": "slc_pathway", "key1": "SLC12A2", "key2": "ferroptosis", "summary": "Gut microbiota dysbiosis (enrichment of nitrogen-cycle bacteria and depletion of short-chain fatty acids producers) induces chromosomal instability through the ammonium ion-solute carrier family 12 member 22 (SLC12A2)-NEK2 axis.\nTherefore, risk-based screening among high-risk populations (e.g., those who are obese, elderly, or chemically exposed), along with early interventions targeting cytogenetic abnormalities [e.g., B cell lymphoma 2 (Bcl-2) inhibitors for t(11;14), ferroptosis inducers for t(4;14)] and modifiable factors (e.g., vitamin D supplementation, gut microbiota modulation), may effectively delay disease progression and improve prognosis.", "dois": ["10.11817/j.issn.1672-7347.2025.240594"]}
{"pair_type": "slc_pathway", "key1": "SLC12A2", "key2": "chemotherapy", "summary": "Only VPA-NaDCA increased expression and decreased expression in T98G cells, whereas TMZ had no effect on gene expression in the study cells.\nVPA-NaDCA, but not TMZ, reduced expression in T98G cells.\nVPA-NaDCA increased expression only in U87 cells, and TMZ did not affect gene expression in either cell line.\nVPA-NaDCA and TMZ reduced the invasion of U87 and T98G tumors, as well as the expression of PCNA and EZH2 in the tumor.\nTMZ reduced p53 expression in tumors from both cell lines, whereas VPA-NaDCA did not affect the expression of this marker.\nHowever, VPA-NaDCA and TMZ did not affect expression in U87 cells.\nThe data suggest that VPA-NaDCA has a more effective impact than TMZ.", "dois": ["10.3390/ijms26146784", "10.1158/1535-7163.MCT-19-0910"]}
{"pair_type": "slc_pathway", "key1": "SLC12A1", "key2": "oxidative stress", "summary": "Down regulated genes included CTXN2 (Cortexin 2), CSMD1 (CUB And Sushi Multiple Domains 1), and SLC12A1 (Solute Carrier Family 12 Member 1).\nIngenuity® Pathway Analysis (IPA) revealed 3 associated networks (score>40) with genes and hubs related to inflammation (nuclear factor-kB), oxidative stress (Mitochondrial complex 1) and ubiquitination.\nSimultaneously, it elevated lipid peroxidation levels, hydroperoxides, and carbonylic proteins in the embryos, eliciting a substantial oxidative stress response.\nAlthough both kidney syndromes are multifactorial, inflammation and oxidative stress play major roles in the diversity of processes leading to these kidney malfunctions.\nThe analysis of mRNA-sequencing as well as RT-PCR data from renal tissue demonstrated that the targets modulating uric acid metabolism were SLC22A8, SLC12A1, and SLC16A7.\nLikewise, CAP, at all concentrations, exerted significant modulatory effects on the expression of genes associated with apoptosis (bax, bcl2, p53, and casp3), organogenesis (tbx2a, tbx2b, and irx3b), and ion exchange (slc12a1 and kcnj1) in Danio rerio embryos.\nregulation of renal reabsorption and secretion of uric acid to increase uric acid excretion, and alleviation of oxidative stress reaction to decrease systemic damage and, eventually, treatment of HUA.\nThe Pearson correlation analysis indicated a close association between oxidative damage biomarkers and the expression patterns of all examined genes with the elevated incidence of malformations and mortality in the embryos.\nrenal processes (SLC12A1 and LOX) and VEGF, ERBB and BDNF signalling.\nDifferentially expressed genes in this analysis are functionally associated with inflammation and immune response, mitochondrial and metabolic processes.", "dois": ["10.1016/j.scitotenv.2024.173179", "10.3390/antiox12081599", "10.1016/j.jep.2023.116814", "10.1016/j.sleep.2021.01.013", "10.1681/ASN.2015111271", "PMID:15167446"]}
{"pair_type": "slc_pathway", "key1": "SLC10A2", "key2": "chemotherapy", "summary": "Two other SNPs, rs2301159 (SLC10A2) and rs2470890 (CYP1A2), were associated with increased risk of hematological toxicity.\nThis study could not demonstrate relationship between SNPs and toxicity to induction chemotherapy in LAHNSCC patients.\nThis study evaluated the association between single-nucleotide polymorphisms (SNPs) in metabolic genes and toxicity to induction chemotherapy.\nInduction chemotherapy in locally-advanced head and neck squamous cell carcinoma (LAHNSCC) patients is potentially associated to serious adverse events.\nNevertheless, these SNPs did not remain significant after adjusting for multiple comparisons.", "dois": ["10.1016/j.oraloncology.2019.09.013"]}
{"pair_type": "slc_pathway", "key1": "SLC12A2", "key2": "glycolysis", "summary": "Laboratory tests conducted on muscle and liver biopsies of the patient showed abnormal increase in mitochondrial DNA copy number and increased glycogen levels, indicating the possibility that the transporter may play a role in energy metabolism.", "dois": ["10.1002/jcp.29623"]}
{"pair_type": "slc_pathway", "key1": "SLC12A2", "key2": "migration", "summary": "For instance, SLC12A2 was found to enhance invasion, proliferation, and migration of colorectal cancer cells while inhibiting apoptosis.\nWe found that WNK1 is a negative regulator of integrin-mediated adhesion, whereas it acts as a positive regulator of migration via the kinases OXSR1 and STK39 and the ion co-transporter SLC12A2.\nLoss of Slc12a2 in mice has been shown to lead to deafness, abnormal neuronal growth and migration, severe gastrointestinal abnormalities, and absent salivation.\nSeveral of these genes (RSRC1, ARHGAP18, ROBO1-ROBO2, GPC1, TNIK, and CTXN3-SLC12A2) have functions related to progenitor cell proliferation, migration, and differentiation, cytoskeleton reorganization, axonal connectivity, and development of forebrain structures.\nPerturbations in the timing or expression of NKCC1/KCC2 may affect essential morphogenetic events including cell proliferation, migration, synaptogenesis and plasticity, and thereby the structure and function of the cortex.\nWNK1-deficient T cells home less efficiently to lymphoid organs and migrate more slowly through them.", "dois": ["10.3389/fonc.2025.1532602", "10.3390/cells13141194", "10.7554/eLife.56934", "10.1158/1535-7163.MCT-19-0910", "10.1002/humu.23722", "10.1038/ni.3495", "10.1093/conphys/cov064", "10.1016/j.neuroimage.2010.06.036"]}
{"pair_type": "slc_pathway", "key1": "SLC10A2", "key2": "apoptosis", "summary": "In addition, overexpressed slc10a2 in NSCLC cells can further suppress the proliferation and migration, and promote apoptosis under the treatment of bexarotene.\nThe further studies revealed the increased expression of slc10a2 activated the expression of peroxisome proliferator-activated receptor γ (PPARγ), then up-regulated PTEN expression and down-regulated mTOR expression.\nWe found that the proliferation and migration were inhibited and the apoptosis of NSCLC cells was accelerated by bexarotene.\nMoreover, the expression of caspase 3, caspase 7, PTEN, P21, P53, LKB1, TSC2 were increased and the expression of Bcl-2, cyclin D1, c-FLIP were declined in NSCLC cells and slc10a2 overexpressed NSCLC cells with the treatment of bexarotene, and the opposite situations were seen after slc10a2 gene was silenced in NSCLC cells.", "dois": ["10.1186/s12885-018-4224-x"]}
{"pair_type": "slc_pathway", "key1": "SLC12A3", "key2": "glycolysis", "summary": "FAO reprogramming was triggered by IL-18 activation of SLC12A3 (NCC), leading to sodium influx, release of mitochondrial DNA, and activation of stimulator of interferon genes (STING).\nIntestinal interleukin-18 (IL-18) stimulation elicited tolerogenic macrophages by preventing their proinflammatory glycolytic polarization via metabolic reprogramming to fatty acid oxidation (FAO).", "dois": ["10.1016/j.immuni.2024.06.001"]}
{"pair_type": "slc_pathway", "key1": "SLC12A1", "key2": "migration", "summary": "AQP1 overexpression also reduced the expression of biomarkers of epithelial-mesenchymal transformation, decreased levels of vimentin and N-cadherin and increased expression of E-cadherin, resulting in decreased formation of conspicuous lamellipodial protrusions, characteristic of diminished WT cell invasion and migration.\nAQP1 overexpression inhibited invasion, migration, EMT, and cytoskeletal rearrangement of WT cells, indicating that AQP1 plays a role in the pathogenesis of WT.\nTranswell migration, invasion, wound healing assay showed overexpression of three genes(SUCLG1, PCK2, GLDC) significantly inhibited the migration, invasion of RCC.\nAQP1 overexpression significantly reduced the migratory and invasive capacity of Wit-49 cells, as evidenced by reducing the scratch healing rate and the number of perforated control cells by Wit-49 cells.\nSix hub gene (SUCLG1, PCK2, GLDC, SLC12A1, ATP1A1, PDHA1) were identified and the overall survival time of patients with RCC were significantly shorter.\nFinally, top five key genes were identified using CytoHubba, including Renin (REN), nephrosis 2 (NPHS2), Solute Carrier Family 12 Member 3 (SLC12A3), Solute Carrier Family 12 Member 1 (SLC12A1) and AQP1.", "dois": ["10.7717/peerj.16025", "10.1186/s12935-020-01405-6"]}
{"pair_type": "slc_pathway", "key1": "SLC12A2", "key2": "stemness", "summary": "A loss-of-function study showed that knockdown of SLC12A2 expression restrained proliferation and stemness of CRC cells while a gain-of-function study showed the contrary results.\nMeanwhile, the high-risk group had a higher tumor stemness score ( < 0.05).\nAt the same time, we identified that SLC12A2 could promote tumor progression in CRC, which may serve as a potential therapeutic target.", "dois": ["10.1038/s41598-024-55048-y", "10.3389/fgene.2021.763636"]}
{"pair_type": "slc_pathway", "key1": "SLC12A2", "key2": "proliferation", "summary": "For instance, SLC12A2 was found to enhance invasion, proliferation, and migration of colorectal cancer cells while inhibiting apoptosis.\nA loss-of-function study showed that knockdown of SLC12A2 expression restrained proliferation and stemness of CRC cells while a gain-of-function study showed the contrary results.\nTogether, ACVR1 expression is related to PFH and ACVR1 overexpression can promote the proliferation of sweat gland cells and inhibit apoptosis by promoting the expression of AQP5 and NKCC1.\nSeveral of these genes (RSRC1, ARHGAP18, ROBO1-ROBO2, GPC1, TNIK, and CTXN3-SLC12A2) have functions related to progenitor cell proliferation, migration, and differentiation, cytoskeleton reorganization, axonal connectivity, and development of forebrain structures.\nThese findings suggest that tumor-derived exosomal SLC12A2-DT facilitates HCC progression by modulating the interplay between HCC cells and TAMs through the Wnt/GSK3β/β-catenin signaling pathway.\nNotably, SLC12A2-DT-induced M2 macrophage polarization significantly induced lung metastasis in a murine HCC model.\nMoreover, NKCC1 depletion reduces intracellular Na concentration and cell volume (size) and mass and stimulates cell proliferation.\nAt the same time, we identified that SLC12A2 could promote tumor progression in CRC, which may serve as a potential therapeutic target.\nNKCC1, therefore, suppresses mTORC1 by inhibiting its key activating signaling pathways.\nCompared with NC group, ACVR1 overexpression significantly promoted the proliferation of sweat gland cells and inhibited the apoptosis of sweat gland cells.\nAbstract: The NKCC1 is a recognized tumorigenesis marker as it is important for tumor cell proliferation, differentiation, apoptosis, and tumor progression.\nPerturbations in the timing or expression of NKCC1/KCC2 may", "dois": ["10.1016/j.intimp.2025.114955", "10.3389/fonc.2025.1532602", "10.3390/cells13141194", "10.1016/j.pathol.2024.04.008", "10.1038/s41598-024-55048-y", "10.7554/eLife.56934", "10.1016/j.bbrc.2020.05.052", "10.1158/1535-7163.MCT-19-0910", "10.1177/1559325819852444", "10.1016/j.celrep.2019.04.034", "10.1158/1541-7786.MCR-17-0413", "10.1007/s00432-016-2274-5", "10.1016/j.neuroimage.2010.06.036"]}
{"pair_type": "slc_pathway", "key1": "SLC12A3", "key2": "ferroptosis", "summary": "Further molecular mechanism experiments showed that SLC12A3 knockdown promoted retinal degeneration by regulating RPE ferroptosis through activation of the Nrf2/HO-1 pathway.\nOur study underscores a notable causal association between thiazide diuretic use and AMD risk and reveals a potential mechanism by which inhibition or downregulation of SLC12A3 (sodium-chloride cotransporter [NCC]) contributes to AMD progression.\nGenetic analyses substantiated the causal relationship between increased SLC12A3 expression and a lowered AMD risk.\nIn vivo and in vitro experiments showed that thiazide diuretics worsened retinal damage in AMD mouse models, and SLC12A3 knockdown disrupted the balance of oxidative stress in retinal pigment epithelium (RPE) cells.", "dois": ["10.1167/iovs.66.12.24"]}
{"pair_type": "slc_pathway", "key1": "SLC12A3", "key2": "apoptosis", "summary": "Differential gene expression analysis comparing Vpr Tg and WT in the DCT cluster showed , an inhibitor of apoptosis, to be the most downregulated gene.\nDifferential gene expression analysis between Vpr Tg and WT samples in the DCT cluster showed down-regulation of the Ier3 gene, which is an inhibitor of apoptosis.\nThe in vitro knockdown of Ier3 by siRNA transfection induced apoptosis in mouse DCT cells.\nThese observations demonstrate that the salt-wasting effect of Vpr in Vpr Tg mice is mediated by loss of DCT1 segments via apoptosis dysregulation.\nThese observations suggest that the salt-wasting effect of Vpr in Vpr Tg mice is likely mediated by Ier3 down-regulation in DCT1 cells and loss of Slc12a3Pvalb DCT1 segments.\nImmunohistochemistry revealed fewer Slc12a3Pvalb DCT1 segments in Vpr Tg mice.\nImmunohistochemistry demonstrated fewer DCT1 segments in Vpr Tg mice.\nThe Pvalb DCT1 subcluster had fewer cells in Vpr Tg mice compared with those in WT mice (P < 0.01).\nThe DCT1 subcluster had fewer cells in Vpr Tg mice compared with WT (P < 0.01).\nThe percentage of distal convoluted tubule (DCT) cells was significantly lower in Vpr Tg mice compared with WT mice (P < 0.05);", "dois": ["10.1016/j.ajpath.2024.06.006", "10.1101/2023.02.02.526686", "10.3390/genes13030394", "PMID:16008036"]}
{"pair_type": "slc_pathway", "key1": "SLC9A2", "key2": "proliferation", "summary": "ETS1 could promote the proliferation, invasion, and aerobic glycolysis ability of OS cells, as well as tumor growth in vivo by inhibiting the expression of SLC9A2.\nThus, SLC9A2 can function as a key inhibitory factor in the aerobic glycolysis to inhibit proliferation and invasion of OS.\nImportantly, SLC9A2 overexpression in SW480 cells led to a notable inhibition of cell proliferation, migration, and invasion.\nCCK-8, transwell, western blotting and Seahorse XFe24 Cell Metabolic Analyzer assays demonstrated that overexpression of SLC9A2 could constrain OS cell proliferation, invasion, and aerobic glycolysis.\nWe addressed the role of NHE8 [solute carrier 9A8 (SLC9A8)] and its interplay with NHE2 (SLC9A2) in luminal proton extrusion during acute and chronic enterocyte acidosis and studied the differential effects of NHE8 and NHE2 on enterocyte proliferation.\nDual-luciferase reporter gene assay and chromatin immunoprecipitation (ChIP) assays indicated ETS proto-oncogene 1 (ETS1) was a transcription suppressor of SLC9A2, and overexpression of ETS1 could promote methylation levels in specific regions of the SLC9A2 promoter.\nIn addition, SLC9A2, suppressing by ETS1, restrains growth and invasion of OS via inhibition of aerobic glycolysis.\nAlterations in NHE2 and NHE8 expression/activity affected proliferation, with C2Bbe/shNHE2 cells having lower and C2Bbe/shNHE8 having higher proliferative capacity, accompanied by amplified ERK1/2 signaling pathway and increased EGFR expression in the latter cell line.\nCombined use of a knockout mouse model, intestinal organoid technology, and specific inhibitors revealed previously unrecognized actions of NHE2 and NHE8 in enterocyte proliferation and differentiation.", "dois": ["10.1007/s11596-024-2871-5", "10.1002/tox.23963", "10.3389/fphys.2022.899286", "10.1152/ajpcell.00582.2020", "10.1371/journal.pone.0113071", "10.3168/jds.2011-4709"]}
{"pair_type": "slc_pathway", "key1": "SLC12A3", "key2": "oxidative stress", "summary": "In vivo and in vitro experiments showed that thiazide diuretics worsened retinal damage in AMD mouse models, and SLC12A3 knockdown disrupted the balance of oxidative stress in retinal pigment epithelium (RPE) cells.\nFurther molecular mechanism experiments showed that SLC12A3 knockdown promoted retinal degeneration by regulating RPE ferroptosis through activation of the Nrf2/HO-1 pathway.\nOur study underscores a notable causal association between thiazide diuretic use and AMD risk and reveals a potential mechanism by which inhibition or downregulation of SLC12A3 (sodium-chloride cotransporter [NCC]) contributes to AMD progression.\nGenetic analyses substantiated the causal relationship between increased SLC12A3 expression and a lowered AMD risk.", "dois": ["10.1167/iovs.66.12.24"]}
{"pair_type": "slc_pathway", "key1": "SLC12A4", "key2": "proliferation", "summary": "We also observe that SLC12A4 facilitates serine uptake.\nDual targeting of SLC6A14 and either SLC25A15 or SLC12A4 diminishes serine uptake and growth of colorectal cancer cells in vitro and in vivo, particularly in cells with compromised de novo serine biosynthesis.\nTMEM88 was detectable by IHC in all histological types of ovarian tumors and its knock-down by using siRNA promoted OC cell proliferation and colony formation and re-sensitized cells to platinum.\nFurthermore, TMEM88 knock down induced upregulation of cyclin D1 and c-Myc, known Wnt target genes, supporting that TMEM88 inhibits Wnt signaling.\nWhile cells can perform de novo serine synthesis, most transformed cells rely on serine uptake to meet their increased biosynthetic requirements.\nSerine is a vital amino acid in tumorigenesis.", "dois": ["10.1038/s42255-023-00936-2", "10.1016/j.ygyno.2016.06.017"]}
{"pair_type": "slc_pathway", "key1": "SLC12A5", "key2": "ferroptosis", "summary": "High SLC12A5 levels were correlated with a poor prognosis, promoted tumorigenesis, and inhibited ferroptosis in HCC.\nFurthermore, SLC12A5 inhibited ferroptosis in HCC by upregulating the expression of xCT, a cystine transporter.\nMoreover, SLC12A5 knockdown decreased BC cell ferroptosis resistance and glucose metabolism reprogramming.\nTranscriptional activation of SLC12A5 by ETV4 modulated the migration, invasion, ferroptosis resistance and glucose metabolism reprogramming of BC cells.\nFurthermore, ETV4 overexpression counteracted the suppressive effect of SLC12A5 knockdown on the BC cell proliferative, migratory and invasive abilities, as well as on ferroptosis resistance and glucose metabolism reprogramming.\nThese findings suggested that SLC12A5 is a therapeutic target and provide insight into the link between ER stress and ferroptosis in HCC.\nMechanistically, SLC12A5 promoted ER stress to enhance calcium release and upregulated PNCK expression levels.\nHigh SLC12A5 expression was strongly associated with a poor clinical prognosis and promoted HCC growth.\nPNCK activated and induced the phosphorylation of PI3K/AKT/mTOR pathway components.\nConcomitantly, PNCK was significantly activated by calcium ions released from the ER.", "dois": ["10.3892/mmr.2024.13341", "10.1002/cam4.5605"]}
{"pair_type": "slc_pathway", "key1": "SLC12A5", "key2": "oxidative stress", "summary": "Physical trauma, psychosocial stress, and oxidative stress increase the neuronal transcription ratio of genes encoding the sodium-potassium chloride cotransporter () and the potassium chloride cotransporter (), which leads to neuronal depolarization and excitability.", "dois": ["10.1152/ajpheart.00462.2025"]}
{"pair_type": "slc_pathway", "key1": "SLC9A8", "key2": "migration", "summary": "Downregulation of SLC9A8 promoted CRC cell proliferation, migration, and invasion.\nMeanwhile, downregulation of SLC9A8 significantly promoted the in vitro migration of CRC cells via EMT by activating the IL6-JAK1/STAT3 signaling pathway.\nSLC9A8 overexpression markedly suppressed cell proliferation, migration, and invasion.\nMoreover, whether downregulated expression of SLC9A8 promotes EMT via activation of the IL6-JAK1-STAT3 signaling pathway was investigated.\nAt the cellular level, the effect of SLC9A8 on proliferation, migration, and invasion was measured using cell viability analysis, flow cytometry analysis, and Transwell assays.\nMoreover, knockdown of SLC9A8 also increased tumor volume, tumor weight, and metastasis in vivo.\nDownregulation of SLC9A8 plays an important role in EMT and metastasis of CRC progression and may become a new potential therapeutic target for the treatment of CRC.", "dois": ["10.3390/ani13111835", "10.1007/s10620-022-07805-0"]}
{"pair_type": "slc_pathway", "key1": "SLC12A5", "key2": "glycolysis", "summary": "SLC12A5 knockdown decreased BC cell ferroptosis resistance and glucose metabolism reprogramming.\nMoreover, ETV4 overexpression counteracted the suppressive effect of SLC12A5 knockdown on the BC cell proliferative, migratory and invasive abilities, as well as on ferroptosis resistance and glucose metabolism reprogramming.\nTranscriptional activation of SLC12A5 by ETV4 modulated the migration, invasion, ferroptosis resistance and glucose metabolism reprogramming of BC cells.\nThe transcription factor ETV4 was demonstrated to bind to the SLC12A5 promoter and upregulate its transcription.", "dois": ["10.3892/mmr.2024.13341"]}
{"pair_type": "slc_pathway", "key1": "SLC12A6", "key2": "apoptosis", "summary": "Combination of rGAD67 and CLP257 showed synergistic effects in alleviating hyperalgesia, altering glia activation, and inhibiting cell apoptosis and inflammatory response.\nIn conclusion, our findings suggested that melatonin restores KCC2 expression, inhibits neuronal apoptosis and attenuates secondary brain injury after TBI, partially through activation of BDNF/ERK pathway.\nIntriguingly, direct pharmacological inhibition of KCC2 in mature neurons was sufficient to rapidly induce apoptosis, an effect that was not abrogated via blockade of neuronal depolarization using tetrodotoxin (TTX).\nPrenatal TSHI induced subplate neuronal loss via apoptosis.\nCalcineurin (CaN)-mediated excitotoxicity impairs γ-aminobutyric acid (GABA) transmission and induces neuronal apoptosis.\nMoreover, SLC12A5 levels decreased following borax treatment in HepG2 cells, whereas ATF6, CHOP, GRP78, CASP3, and CYC levels exhibited a significant increase.\nImportantly, the low doses of phenobarbital and bumetanide used in the study did not increase constitutive apoptosis, alone or in combination.\nSimultaneously, melatonin administration ameliorated cortical neuronal apoptosis, reduced brain edema, and attenuated neurological deficits after TBI.\nDecreasing KCC2 expression in mature neurons resulted in the rapid activation of the extrinsic apoptotic pathway.\nEthanol-induced upregulation of KCC2 has a positive impact on neuronal survival, preserving a large part of the cortical peri-infarct zone, as well as preventing the massive post-ischemic upregulation of the pro-apoptotic protein p75.\nDownstream pro-apoptotic signaling through p75 may link GABA depolarization with post-injury neuronal apoptosis.\nConversely, these concentrations in HepG2 cells induced observable morphological and nuclear abnormalities, resulting in cell cycle arrest in the G1/G0 phase.", "dois": ["10.1111/jcmm.18380", "10.1016/j.jbc.2021.100364", "10.1007/s12035-020-02176-x", "10.1038/srep35205", "10.1111/jpi.12344", "PMID:16443823", "PMID:11755128", "PMID:11334858", "10.1016/j.ijbiomac.2024.138501", "10.1093/cercor/bhu066", "10.1371/journal.pone.0057148", "10.1007/s00702-011-0746-y", "10.1523/JNEUROSCI.3791-07.2008"]}
{"pair_type": "slc_pathway", "key1": "SLC7A7", "key2": "apoptosis", "summary": "Moreover, C1q+ macrophages suppressed CD8T cell apoptosis by upregulating Slc7a7 expression to enhance the L-arginine uptake of CD8T cells.\nKnockdown of SLC7A7 increased the cell apoptosis rate (P = 0.006) but decreased the G1 phase ratio (P = 0.002) and cell migration (P < 0.001) and invasion (P < 0.001).\nHowever, SLC7A7 overexpression significantly decreased the percentage of apoptotic Jurkat cells (P = 0.007) but significantly increased the proportion of G1 phase cells (P = 0.029) and cell migration (P < 0.001) and invasion (P < 0.001).\nWe found that in Slc7a7-deficient larvae, macrophages do enter the retina and brain to become microglia, but then die during the developmental wave of neuronal apoptosis, which triggers intense efferocytic work from them.\nSpermine supplementation may regulate cell cycle during the G1/S phase, suppress apoptosis and modulate amino acid transport.\nIn addition, extended spermine administration also markedly promoted cell proliferation, depressed apoptosis and modulated amino acid transport (p<\nIrrespective of the treatment period, the reduced Bax and caspase-3 gene expressions and improved Bcl-2 mRNA level were observed in the thymus and spleen of spermine-administrated piglets (p<0.05).\nRegardless of supplementation time, spermine intake significantly enhanced the expressions of amino acid transporter-related genes (SLC1A1, SLC1A5, SLC7A1, SLC7A7, and SLC15A1) in both thymus and spleen, as well as SLC7A9 in the spleen of piglets (p&lt;0.05).\nIn addition, the CKD-associated metabolite profile along with increased nitrite plasma levels suggests that LPI may be characterized by increased oxidative stress and apoptosis, altered microbial metabolism in the intestine and uremic toxicity.", "dois": ["10.1155/2024/1929766", "10.18632/aging.204661", "10.1159/000491899", "10.1242/jcs.249037", "10.5713/ajas.17.0799", "10.1016/j.metabol.2016.05.012", "10.1016/j.gene.2013.11.029", "10.1016/j.ymgme.2011.12.007", "10.1016/j.ygyno.2010.01.041"]}
{"pair_type": "slc_pathway", "key1": "SLC10A2", "key2": "migration", "summary": "In addition, overexpressed slc10a2 in NSCLC cells can further suppress the proliferation and migration, and promote apoptosis under the treatment of bexarotene.\nThese results suggest that bexarotene inhibits the viability of lung cancer cells via slc10a2/PPARγ/PTEN/mTOR signaling pathway.\nThe further studies revealed the increased expression of slc10a2 activated the expression of peroxisome proliferator-activated receptor γ (PPARγ), then up-regulated PTEN expression and down-regulated mTOR expression.\nWe found that the proliferation and migration were inhibited and the apoptosis of NSCLC cells was accelerated by bexarotene.\nOn the contrary, the opposite results were obtained after slc10a2 gene was silenced in NSCLC cells treated with bexarotene.", "dois": ["10.3390/nu10081057", "10.1186/s12885-018-4224-x"]}
{"pair_type": "slc_pathway", "key1": "SLC12A5", "key2": "migration", "summary": "Biofunctional investigation of SLC12A5 revealed that SLC12A5 significantly increased cell proliferation, G1-S cell cycle transition, invasion/migration abilities, but suppressed apoptosis in vitro and promoted xenograft tumour growth as well as lung metastasis in vivo.\nEctopic expression of SLC12A5 partly abolished miR-133a-3p-mediated suppression of cell migration.\nBy regulating SLC12A5 expression, EZH2 activates the WNK1-OSR1-NKCC1 pathway, enhancing its interaction with ERM to promote glioma migration.\nMoreover, we identified that SLC12A5 promoted the migration and invasion of BUC by enhancing MMP-7 expression via NF-κB-dependent transcription.\nWe constructed two SLC12A5 overexpression cell lines to verify the function of SLC12A5 that suppressed tumour cell proliferation and migration in vitro.\nTranscriptional activation of SLC12A5 by ETV4 modulated the migration, invasion, ferroptosis resistance and glucose metabolism reprogramming of BC cells.\nFurthermore, we demonstrated that SLC12A5 promoted the castration resistance development of prostate cancer in addition to the cell proliferation and migration.\nSLC12A5 and ZFHX4 facilitated proliferation, migration, and invasion in vivo and in vitro, and their effects were reversed by miR-194-3p and miR-514a-3p, respectively.\nTherefore, our findings reveal a mechanism that how the potassium-chloride cotransporter SLC12A5 promotes the tumor progression and provide a therapeutic opportunity for prostate cancer to apply the neurological disorder drug SLC12A5 inhibitors.\nIHMT-337 targets EZH2 in vitro to inhibit WNK1 activation, thereby suppressing glioma cell migration.\nMoreover, FEZF1-AS1 depletion suppressed proliferation, migration, invasion, and induced cell apoptosis.\nDownregulation of SLC12A5 inhibited the migratory and invasive abilities of BUC cells in vitro,", "dois": ["10.3892/mmr.2024.13341", "10.3390/cells13141194", "10.1186/s10020-024-00857-0", "10.1111/jcmm.18352", "10.1038/s41419-022-05544-8", "10.1016/j.arcmed.2021.05.004", "PMID:32774704", "10.1111/cas.14502", "10.1038/s41389-019-0167-6", "10.1016/j.bbagen.2017.12.004", "10.1038/cddis.2017.118", "10.1186/s12868-017-0336-5", "10.1136/gutjnl-2014-308257"]}
{"pair_type": "slc_pathway", "key1": "SLC9A5", "key2": "migration", "summary": "Furthermore, in vitro experiments showed that knockdown of SLC9A5 resulted in suppressed cell proliferation, migration, and invasion.\nMoreover, the attenuated tumor growth, migration, invasion, and increased FAO observed after SLC9A5 knockdown could be reversed by simultaneous knockdown of both SLC9A5 and ACOX1.\nSLC9A5 promotes tumor growth and cell motility via ACOX1-mediated peroxisomal fatty acid oxidation.\nIn summary, these findings reveal the oncogenic role of SLC9A5 in CRC, particularly in relation to ACOX1-mediated peroxidation, and might serve as a promising therapeutic target for inhibiting the progression of colorectal cancer.\nInterestingly, the expression of ACOX1, as well as FAO process indicated by changes in very long chain fatty acid levels, were enhanced upon SLC9A5 knockdown in CRC cells.\nThen we performed bioinformatics analysis and found that SLC9A5 was significantly enriched in peroxisomal fatty acid oxidation (FAO) pathway and negatively correlated with its first rate-limiting enzyme acyl-CoA oxidases (ACOX).", "dois": ["10.1016/j.yexcr.2023.113700"]}
{"pair_type": "slc_pathway", "key1": "SLC12A7", "key2": "proliferation", "summary": "HMG20A bound to the metastasis-specific enhancers of ADRM1 and SLC12A7, thereby promoting ADRM1 and SLC12A7 expression.\nSeventeen metastasis-specific enhancer-controlled upregulated DNA repair-related genes, with the top two upregulated genes being ADRM1 26 S proteasome ubiquitin receptor (ADRM1) and solute carrier family 12 member 7 (SLC12A7) were screened.\nKnockdown of HMG20A enhanced cisplatin sensitivity of cells, and inhibited OSCC cells from repairing DNA damage caused by cisplatin, as well as proliferation and invasion of OSCC cells.\nDNA repair was positively associated with the OSCC metastatic phenotype.", "dois": ["10.1186/s12903-022-02500-y"]}
{"pair_type": "slc_pathway", "key1": "SLC9A3", "key2": "apoptosis", "summary": "Loss of SLC9A3‑AS1 reduced NPC cell proliferation, colony formation, migration, and invasion but induced cell apoptosis .\nAnimal experiments further revealed that the depletion of SLC9A3‑AS1 hindered NPC tumour growth .\nCertain DEGs enriched in the cell cytoskeleton (LOC111217621, tubb5, and LOC111234965) and cell apoptosis (tnfrsfa, LOC111218420, LOC111223891, LOC111223286, and bcl2) were identified by kidney transcriptome analysis in response to salinity stress.\nFurthermore, DEGs associated with lipid and carbohydrate metabolism (elovl6l, acsl4, msmo1, pck1, g6pc1, pfkfb3, and ldha), ion transport (kcnk5, slc4a4, slc9a3, slc41a1, and slc22a2), and immune response (nfkbiaa, nfkbia, and LOC111231462) were identified.", "dois": ["10.1016/j.cbd.2025.101572", "10.3892/or.2021.8116"]}
{"pair_type": "slc_pathway", "key1": "SLC9A3", "key2": "glycolysis", "summary": "This work proved that SLC9A3-AS1 increased the sensitivity of liver cancer cells to TP by regulating glycolysis rate mediated via miR-449b-5p/LDHA axis.\nKnockdown of SLC9A3-AS1 notably further inhibited viability, migration as well as invasion in Huh7 cells.\nLncRNA SLC9A3-AS1 was up-regulated in liver cancer tissue samples and cells.\nMiR-449b-5p was the direct downstream miRNA of SLC9A3-AS1 and was down-regulated by SLC9A3-AS1 in Huh7 cells.\nMoreover, glycolysis rate was tested by calculating the uptake of glucose in addition to the production of lactate in Huh7 cells.\nMoreover, miR-449b-5p negatively regulated LDHA expression in Huh7 cells.", "dois": ["10.1080/02648725.2023.2193775"]}
{"pair_type": "slc_pathway", "key1": "SLC12A6", "key2": "glycolysis", "summary": "Fructose-1,6-diphosphate (FDP) shifts the metabolism of glucose from glycolysis to the pentose phosphate pathway and has anticonvulsant activity in several acute seizure animal models.", "dois": ["10.1016/j.brainres.2013.09.042"]}
{"pair_type": "slc_pathway", "key1": "SLC12A8", "key2": "chemotherapy", "summary": "Moreover, SLC12A8 knockdown enhanced the sensitivity of CRC cells to oxaliplatin chemotherapy.\nAdditionally, the SLC12A8 levels demonstrated a strong association with ICPs, chemokines, immune-activating genes, immune-suppressive genes, chemokine receptors, chemotherapy response, and immunotherapy efficacy.\nThese analyses focused on examining the relationship between SLC12A8 and prognosis, drug sensitivity, chemotherapy response, immune checkpoints (ICPs), immune cell infiltration, and immunotherapy efficacy across various tumor types.\nTitle: SLC12A8 upregulation promotes colorectal cancer progression and chemoresistance.\nExperiments in CRC cells showed that SLC12A8 upregulation promoted apoptosis resistance, EMT, and inhibited ROS production.\nTargeting SLC12A8 may improve patient responses to oxaliplatin-based treatment regimens.\nABCB1, SLC8A1, and SLC12A8 were associated with breast cancer survival in SEBCS (P < 0.05).\nABCB1 rs1202172 was differentially associated with survival depending on the chemotherapy (P = 0.035).\nThe population of SEBCS consisted of 1338 breast cancer patients who had been treated with adjuvant chemotherapy.\nThe effects of SLC12A8 on the CRC cell apoptosis, epithelial-mesenchymal transition (EMT), reactive oxygen species (ROS) production, and sensitivity to oxaliplatin were verified by experiments.\nThe associations between genetic variations of ATP-binding cassette (ABC) and solute carrier (SLC) genes and cancer survival were investigated through a meta-analysis and an association study in the Seoul Breast Cancer Study (SEBCS).\nAbstract: Membrane transporters can be major determinants of the pharmacokinetic profiles of anticancer drugs.", "dois": ["10.21037/tcr-24-87", "10.1016/j.gene.2024.148211", "10.1038/s41397-018-0016-6"]}
{"pair_type": "slc_pathway", "key1": "SLC12A6", "key2": "proliferation", "summary": "MDA-MB-231 cells cultured in the presence of DIOA exhibited an increase in cell volume, a decrease in intracellular Cl(-) concentration, and reduction in cell proliferation with the G0/G1 phase arrest, which was accompanied with down-regulation of cyclin D1 and cyclin E2, and up-regulation of p21.\nInhibition of the channels increased the expression of the cyclin-dependent kinase inhibitor p27(KIP1), along with the reduced proliferation.\nThe human potassium-chloride co-transporter 3 (KCC3, SLC12A6) is involved in cell proliferation and in electro-neutral movement of ions across the cell membrane.\nNEA enhancement in the DG and suppression in area CA1 were associated with increased NKCC1 expression in neurons and severe neuronal loss accompanied by marked glial proliferation, respectively.\nThe increased expression of p27(KIP1) after inhibition of either the GABA(A) receptors or the L-type VGCCs suggests a link between the GABA(A) receptors, membrane potential, and intracellular Ca(2+) in regulating the cell cycle.\nThese results are consistent with that when the membrane potential indirectly regulates cell proliferation with hyperpolarisation of the membrane potential resulting in decreased cell division.\nAntagonists of the GABA(A) receptors decreased the proliferation of dissociated E12 NPE cells.\nInhibition of L-type voltage-gated Ca(2+) channels (VGCCs) reduced the proliferation in the same way as inhibition of the GABA(A) receptors.\nWe constructed two SLC12A5 overexpression cell lines to verify the function of SLC12A5 that suppressed tumour cell proliferation and migration in vitro.\nTreatment with KCl, which is known to depolarise membranes, prevented some of the decreased proliferation caused by inhibition of the GABA(A) receptors.\nOverexpression of KCC2 had no significant effect on cell proliferation but dramatically suppressed cell spreading and stress fibre organization, while knockdown of KCC2 showed opposite effects.", "dois": ["10.1111/jcmm.18352", "10.1113/JP283834", "10.1152/ajpcell.00002.2017", "10.1523/JNEUROSCI.0945-16.2016", "10.1016/j.neuroscience.2015.06.057", "10.1016/j.abb.2013.06.014", "10.1159/000339040", "10.1371/journal.pone.0036874", "10.1113/jphysiol.2011.214635", "PMID:17912038", "PMID:17418819", "PMID:15262997", "PMID:9930699", "10.1038/npp.2008.77"]}
{"pair_type": "slc_pathway", "key1": "SLC12A3", "key2": "proliferation", "summary": "Functional studies of SLC12A3 and ADH6 overexpression showed reduced cell proliferation, colony formation, and migratory capacity, suggesting their involvement in inhibiting tumor progression.\nAdministration of golvatinib, a selective Met inhibitor, or transfection of small interfering RNA for Met suppressed cell proliferation and downstream signaling only in the cell lines in which hyperphosphorylation of Met was observed.\nAdministration of golvatinib inhibited these phenotypes in MDCK cells.\nIn three-dimensional culture of Madin-Darby canine kidney (MDCK) cells as a cyst formation model of ADPKD, HGF activated Met, resulting in an increased total cyst number and total cyst volume.\nThe proportion of Ki67 cells and the concentration of nitric oxide (NO) were high in SRGN high expression cells, suggesting that SRGN may be involved in the proliferation of HUVECs.\nElectron microscopy revealed swelling and vacuolar degeneration of glomerular epithelial cells, diffuse proliferation of mesangial cells and matrix, accompanied by a small amount of low-density electron-dense deposition, and segmental fusion of epithelial cell foot processes in proband B.\nFunctional assays, including cell proliferation, colony formation, and wound healing, were performed to validate the hub genes.\nThis study emphasizes the critical roles of SLC12A3, ADH6, GSTM3, and CLCNKB in WT and their potential as both diagnostic biomarkers and therapeutic targets in WT management.\nAnalysis of gene expression data from publicly available GEO datasets revealed that SLC12A3, ADH6, GSTM3, and CLCNKB hub genes were significantly dysregulated in WT.", "dois": ["10.62347/SLUH3891", "10.2174/0113892010396845250730075758", "10.1681/ASN.0000000000000297", "10.1155/2021/9973161", "10.1681/ASN.2020101407", "10.1159/000509419", "10.1007/s11010-020-03830-7"]}
{"pair_type": "slc_pathway", "key1": "SLC9A6", "key2": "apoptosis", "summary": "Notably, ectopic expression of ∆ES but not WT induced apoptosis when examined in AP-1 cells.\nSimilarly, in transfected primary cultures of mouse hippocampal neurons, membrane trafficking of the ∆ES mutant was impaired and elicited marked reductions in total dendritic length, area and arborization, and triggered apoptotic cell death.\nThese results suggest that loss-of-function mutations in NHE6 disrupt recycling endosomal function and trafficking of cargo which ultimately leads to neuronal degeneration and cell death in Christianson Syndrome.", "dois": ["10.1074/jbc.RA120.012614", "10.1186/s13024-016-0129-9"]}
{"pair_type": "slc_pathway", "key1": "SLC9A5", "key2": "stemness", "summary": "Besides, mRNA expressions of NHE family were extremely associated with clinicopathological features, tumor immune microenvironment and stemness score, DNA methylation, and patient prognosis in COAD.", "dois": ["10.1155/2021/3241351"]}
{"pair_type": "slc_pathway", "key1": "SLC12A5", "key2": "chemotherapy", "summary": "Only VPA-NaDCA increased expression and decreased expression in T98G cells, whereas TMZ had no effect on gene expression in the study cells.\nVPA-NaDCA, but not TMZ, reduced expression in T98G cells.\nVPA-NaDCA increased expression only in U87 cells, and TMZ did not affect gene expression in either cell line.\nVPA-NaDCA and TMZ reduced the invasion of U87 and T98G tumors, as well as the expression of PCNA and EZH2 in the tumor.\nTMZ reduced p53 expression in tumors from both cell lines, whereas VPA-NaDCA did not affect the expression of this marker.\nHowever, VPA-NaDCA and TMZ did not affect expression in U87 cells.", "dois": ["10.3390/ijms26146784"]}
{"pair_type": "slc_pathway", "key1": "SLC10A1", "key2": "oxidative stress", "summary": "Compared with WT mice, the exposure to APAP overdose caused liver dysfunction, oxidative stress, inflammation and cell death, which were ameliorated by NTCP deficiency.\nApparent histopathological alterations and hepatic oxidative stress showed in INH (100 mg/kg), RFP (200 mg/kg) and their combination group.\nIn conclusion, NTCP deficiency attenuates APAP-induced hepatotoxicity by enhancing the metabolism and elimination of APAP.\nAPAP detoxification, metabolism, and elimination were significantly accelerated by the upregulation of UDP-glucuronosyltransferase (Ugt1a1, Ugt1a6 and Ugt1a9), sulfotransferase (Sult1a1 and Sult2a1) and bile acid efflux transporters (Abcc2/3/4) in NTCP KO mice compared with WT mice.\nNTCP inhibitors protect against APAP-induced hepatotoxicity and thus are a potential therapeutic option.\nInterestingly, APAP-induced hepatotoxicity was ameliorated using Irbesartan and Ezetimibe (NTCP inhibitors).\nAcetaminophen (APAP) overdose can induce liver injury and is generally accompanied by disruption of bile acid homeostasis.\nPhysiologically, sodium taurocholate co-transporting polypeptide (NTCP) participates in the uptake of bile acids from portal blood into hepatocytes to maintain enterohepatic recirculation but its role in APAP-induced hepatotoxicity is unclear.\nBoth doses of INH/RFP administration significantly down-regulated the expression of Ntcp and Bsep in liver.\nIn conclusion, down-regulated expression of hepatic Ntcp and Bsep might play an important role in the development of INH and RFP induced liver injury.\nFurthermore, the combination of INH and RFP displayed stronger effect on the expression of Ntcp compared with the corresponding dose of INH or RFP alone.", "dois": ["10.1016/j.taap.2025.117266", "10.3109/15376516.2015.1033074"]}
{"pair_type": "slc_pathway", "key1": "SLC9A6", "key2": "migration", "summary": "I cannot find any excerpts in the provided source text that explicitly describe a promotion or suppression relationship between SLC9A6 and migration. The text mentions \"X-linked neuronal migration disorders\" in a general list context, but does not contain verbatim phrases or sentences that directly state how SLC9A6 promotes, activates, enhances, induces, facilitates, suppresses, inhibits, represses, reduces, or otherwise affects migration.", "dois": ["10.2147/IJGM.S466364", "10.3390/ijms25074110"]}
{"pair_type": "slc_pathway", "key1": "SLC12A3", "key2": "migration", "summary": "Regardless of salinity tolerance, all lamprey downregulated FW ion-uptake mechanisms [gill transcripts of Na(+):Cl(-) cotransporter (NCC/slc12a3) and epithelial Na(+) channel (ENaC/scnn1) and kidney Na(+)/K(+)-ATPase (NKA) protein and activity but not transcript].\nAQP1 overexpression inhibited invasion, migration, EMT, and cytoskeletal rearrangement of WT cells, indicating that AQP1 plays a role in the pathogenesis of WT.\nAQP1 overexpression significantly reduced the migratory and invasive capacity of Wit-49 cells, as evidenced by reducing the scratch healing rate and the number of perforated control cells by Wit-49 cells.\nAQP1 overexpression also reduced the expression of biomarkers of epithelial-mesenchymal transformation, decreased levels of vimentin and N-cadherin and increased expression of E-cadherin, resulting in decreased formation of conspicuous lamellipodial protrusions, characteristic of diminished WT cell invasion and migration.\nFinally, top five key genes were identified using CytoHubba, including Renin (REN), nephrosis 2 (NPHS2), Solute Carrier Family 12 Member 3 (SLC12A3), Solute Carrier Family 12 Member 1 (SLC12A1) and AQP1.", "dois": ["10.62347/SLUH3891", "10.7717/peerj.16025", "10.1093/conphys/cov064"]}
{"pair_type": "slc_pathway", "key1": "SLC12A4", "key2": "apoptosis", "summary": "Interfering with SLC12A2 expression or function resulted in a significant increase in apoptotic corpse uptake per phagocyte, whereas the loss of SLC12A4 inhibited corpse uptake.\nCollectively, the WNK1-OSR1-SPAK-SLC12A2/SLC12A4 chloride-sensing pathway and chloride flux in phagocytes are key modifiers of the manner in which phagocytes interpret the engulfed apoptotic corpse.\nEfferocytosis transcriptionally altered the genes that encode the solute carrier (SLC) proteins SLC12A2 and SLC12A4.\nThis 'switch' to pro-inflammatory sensing of apoptotic cells resulted from the disruption of the chloride-sensing pathway (and not due to corpse overload or poor degradation), including the chloride-sensing kinases WNK1, OSR1 and SPAK-which function upstream of SLC12A2-had a similar effect on efferocytosis.\nIn SLC12A2-deficient phagocytes, the canonical anti-inflammatory program was replaced by pro-inflammatory and oxidative-stress-associated gene programs.", "dois": ["10.1038/s41556-019-0431-1"]}
{"pair_type": "slc_pathway", "key1": "SLC9A8", "key2": "stemness", "summary": "Besides, mRNA expressions of NHE family were extremely associated with clinicopathological features, tumor immune microenvironment and stemness score, DNA methylation, and patient prognosis in COAD.", "dois": ["10.1155/2021/3241351"]}
{"pair_type": "slc_pathway", "key1": "SLC10A2", "key2": "proliferation", "summary": "In addition, overexpressed slc10a2 in NSCLC cells can further suppress the proliferation and migration, and promote apoptosis under the treatment of bexarotene.\nThen we explored the effects of slc10a2 on A549 cells and H1299 cells behaviors, including proliferation, invasion and apoptosis.\nMeanwhile, assays revealed that ESM1 and SLC10A2 exert opposing roles in colon cancer cell proliferation, validating the accuracy of the model.\nThe lithogenic diet induced biliary hyperplasia and reduced bile salt transporter expressions in C57L mice.\nThe lithogenic diet induced ductular proliferation in C57L mice.\nWe found that the proliferation and migration were inhibited and the apoptosis of NSCLC cells was accelerated by bexarotene.\nThe further studies revealed the increased expression of slc10a2 activated the expression of peroxisome proliferator-activated receptor γ (PPARγ), then up-regulated PTEN expression and down-regulated mTOR expression.\nSpecifically, TCDD elicited a >200-fold increase in taurolithocholic acid (TLCA), a potent G protein-coupled bile acid receptor 1 (GPBAR1) agonist associated with bile duct proliferation.\nMoreover, the expression of caspase 3, caspase 7, PTEN, P21, P53, LKB1, TSC2 were increased and the expression of Bcl-2, cyclin D1, c-FLIP were declined in NSCLC cells and slc10a2 overexpressed NSCLC cells with the treatment of bexarotene, and the opposite situations were seen after slc10a2 gene was silenced in NSCLC cells.\nA4250 improved sclerosing cholangitis in Mdr2(-/-) mice and significantly reduced serum alanine aminotransferase, alkaline phosphatase and BAs levels, hepatic expression of pro-inflammatory (Tnf-α, Vcam1, Mcp-1) and pro-fibrogenic (Col1a1, Col1a2) genes and bile duct prolif", "dois": ["10.3389/fmolb.2020.604252", "10.1186/s12885-018-4224-x", "10.1038/s41598-017-05656-8", "10.1186/s13567-015-0286-9", "10.1016/j.jhep.2015.10.024", "10.1111/j.1440-1746.2008.05500.x", "PMID:16773712"]}
{"pair_type": "slc_pathway", "key1": "SLC12A6", "key2": "migration", "summary": "In neurons, the regulation of intracellular Cl(-) concentration ([Cl(-) ](i) ) is mediated by NKCC1 and KCC2 transporters: NKCC1 increases while KCC2 decreases [Cl(-) ](i) .\nOnce in the cortex, upregulation of the potassium-chloride cotransporter KCC2 is both necessary and sufficient to reduce interneuron motility through its ability to reduce membrane potential upon GABA(A) receptor activation, which decreases the frequency of spontaneous intracellular calcium transients initiated by L-type voltage-sensitive calcium channel (VSCC) activation.\nWe found that, during migration into the cortex, ambient GABA and glutamate initially stimulate the motility of interneurons through both GABA(A) and AMPA/NMDA receptor activation.\nFurthermore, BPA evoked increase in tangential interneuron migration and increased chloride in migrating neurons.\nIn addition, insulin-like growth factor 1 (IGF-1)-induced cell migration and invasiveness were significantly increased by overexpression of KCC2.\nWe constructed two SLC12A5 overexpression cell lines to verify the function of SLC12A5 that suppressed tumour cell proliferation and migration in vitro.\nKCC2-induced cell migration and invasion were not dependent on KCC2 transport function since overexpression of an activity-deficient mutant KCC2 still increased IGF-1-induced cell migration and invasion.\nBoth pharmacological and genetic manipulations revealed that NKCC1 maintains high [Cl-]i and regulates the resting membrane potential of migratory neuroblasts whilst its functional expression is strongly reduced at the time cells reach the GCL.\nMoreover, overexpression of KCC2 significantly diminished the number of focal adhesions, while knockdown of KCC2 increased their number.\nOverexpression of KCC2 had no significant effect on cell proliferation but dramatically suppressed cell spreading and stress fibre organization, while knockdown of KCC2 showed opposite effects.\nTime-lapse video imaging of organotypic cultures treated with either drug, shows a significant increase in the average speed, step size, an", "dois": ["10.1111/jcmm.18352", "10.1093/cercor/bhz048", "10.1152/ajpcell.00002.2017", "10.1159/000485076", "10.1186/s12868-017-0336-5", "10.1016/j.expneurol.2016.10.013", "10.1007/s12035-015-9162-x", "10.1093/cercor/bht073", "10.1073/pnas.1300959110", "10.1093/cercor/bhs375", "10.1074/jbc.M111.319418", "10.1523/JNEUROSCI.3446-11.2012", "10.1113/jphysiol.2011.214635", "10.1111/j.1528-1167.2011.03111.x", "10.1113/jphysiol.2010.203703", "10.1186/1749-8104-6-4", "10.1111/j.1460-9568.2010.07258.x", "10.1016/j.neuron.2009.01.034", "PMID:17904674", "PMID:17494709", "PMID:12588844", "PMID:9930699"]}
{"pair_type": "slc_pathway", "key1": "SLC12A7", "key2": "migration", "summary": "In contrast, RNAi gene silencing of SLC12A7 stymied cell attachment strength as well as migration and invasion capacity in NCI-H295R cells.\nAltered expression of Solute Carrier Family 12 Member 7 (SLC12A7) is implicated to promote malignant behavior in multiple cancer types through an incompletely understood mechanism.\nEnforced SLC12A7 overexpression in SW-13 cells robustly promoted motility and invasive characteristics (p < 0.05) without significantly altering cell viability, growth, or colony formation potential.\nAmplification of SLC12A7 observed in ACCs is shown here, in vitro, to exacerbate the malignant behavior of ACC cells by promoting invasive capacities, possibly mediated by alterations in multiple signaling pathways, including the osmotic stress pathway.\nSLC12A7 overexpression also significantly increased rates of cellular attachment and detachment turnover (p < 0.05), potentially propelled by increased filopodia formation and/or Ezrin interaction.", "dois": ["10.1186/s12964-018-0243-0"]}
{"pair_type": "slc_pathway", "key1": "SLC12A6", "key2": "oxidative stress", "summary": "Here we show that in primary hippocampal neuronal cultures the suppression of the KCC2 function using two different shRNAs, dominant-negative KCC2 mutant C568A or DIOA inhibitor, increased the intracellular chloride concentration [Cl⁻]i and enhanced the toxicity induced by lipofectamine-dependent oxidative stress or activation of the NMDA receptors.\nMuscle transporter adaptations in 0K- versus 1K-fed mice, assessed by immunoblot, included decreased sodium pump α2-β2 subunits, decreased K-Cl cotransporter isoform 3, and increased phosphorylated (p) Na,K,2Cl cotransporter isoform 1 (NKCC1p), Ste20/SPS-1-related proline-alanine rich kinase (SPAKp), and oxidative stress-responsive kinase 1 (OSR1p) consistent with intracellular fluid (ICF) K loss and Na gain.\nThe hypochromic thalassemic red cells exhibit increased cell dehydration in association with elevated K leak and increased K-Cl cotransport activity, each of which has been linked to globin chain imbalance and related oxidative stress.\nThe effect of H(2)O(2) on cell volume was blocked by the serine-threonine phosphatase inhibitor calyculin A, indicating an important role of serine-threonine phosphorylation in the H(2)O(2)-mediated activation of KCl cotransport in Ehrlich cells.\nHence, H(2)O(2) induces KCl cotransport or K(+) and Cl(-) channels in nonadherent and adherent cells, respectively.\nIt is suggested that H(2)O(2) activates electroneutral KCl cotransport in Ehrlich ascites tumor cells and not K(+) and Cl(-) channels.\nAddition of H(2)O(2) to hypotonically exposed cells accelerates the regulatory volume decrease and the concomitant net loss of K(+), whereas no additional increase in the K(+) and Cl(-) conductance", "dois": ["10.1113/jphysiol.2010.203703", "10.1152/ajpcell.00613.2008", "PMID:12673842", "PMID:10733558", "PMID:10467272", "10.1152/ajpheart.00462.2025", "10.1152/ajprenal.00343.2023", "10.3390/ijms22031232", "10.1152/ajpcell.00362.2020", "10.1016/j.bcmd.2019.102389", "10.1016/j.jpain.2019.05.005", "10.1016/j.neuropharm.2018.03.035", "10.1152/ajpcell.00193.2015", "10.1074/jbc.M111.319418", "PMID:17301172"]}
{"pair_type": "slc_pathway", "key1": "SLC12A5", "key2": "proliferation", "summary": "Biofunctional investigation of SLC12A5 revealed that SLC12A5 significantly increased cell proliferation, G1-S cell cycle transition, invasion/migration abilities, but suppressed apoptosis in vitro and promoted xenograft tumour growth as well as lung metastasis in vivo.\nSLC12A5 overexpression would inhibit cell proliferation of U251MG.\nEZH2 facilitates glioma proliferation, migration, and invasion alongside promoting SLC12A5 DNA methylation.\nWe constructed two SLC12A5 overexpression cell lines to verify the function of SLC12A5 that suppressed tumour cell proliferation and migration in vitro.\nFurthermore, we demonstrated that SLC12A5 promoted the castration resistance development of prostate cancer in addition to the cell proliferation and migration.\nSLC12A5 and ZFHX4 facilitated proliferation, migration, and invasion in vivo and in vitro, and their effects were reversed by miR-194-3p and miR-514a-3p, respectively.\nTherefore, our findings reveal a mechanism that how the potassium-chloride cotransporter SLC12A5 promotes the tumor progression and provide a therapeutic opportunity for prostate cancer to apply the neurological disorder drug SLC12A5 inhibitors.\nMoreover, FEZF1-AS1 depletion suppressed proliferation, migration, invasion, and induced cell apoptosis.\nHigh SLC12A5 levels were correlated with a poor prognosis, promoted tumorigenesis, and inhibited ferroptosis in HCC.\nIHMT-337 targets EZH2 in vitro to inhibit WNK1 activation, thereby suppressing glioma cell migration.\nThe bM2-like TAMs were revealed to promote T cell activation and proliferation through ALCAM/CD6 interaction.\nMechanistically, SLC12A5 promoted ER stress to enhance calcium release and upregulated PNCK expression levels.\nFurthermore, SLC12A5 inhibited ferroptosis in HCC by upregulating the expression of xCT, a cystine transporter.", "dois": ["10.3389/fcell.2024.1466767", "10.3390/cells13141194", "10.1186/s10020-024-00857-0", "10.1111/jcmm.18352", "10.12182/20240360402", "10.1007/s11033-023-08371-y", "10.1002/cam4.5605", "10.1038/s41419-022-05544-8", "10.1016/j.arcmed.2021.05.004", "10.1242/jcs.247700", "PMID:32774704", "10.1038/s41389-019-0167-6", "10.1136/gutjnl-2014-308257"]}
{"pair_type": "slc_pathway", "key1": "SLC10A3", "key2": "chemotherapy", "summary": "Possible drug resistance genes like Atg14, Abcb1b, Tbx2, Slc2a9, Slc10a3 and Slc22a18 were up-regulated while Foxm1, Bcl2, Brca1, Chek1, Hiatl1 and Abcb9 were down regulated.\nGO term GO:0050673 (epithelial cell proliferation) and GO:0050678 (regulation of epithelial cell proliferation) are enriched in the genes over expressed in the chemotherapy resistant tissue while the GO:0007229 (integrin-mediated signaling pathway) is enriched in the genes over expressed in the chemotherapy sensitive tissue.\nWe identified 1187 tags (corresponding to 1040 genes) that are differentially expressed between the chemotherapy responsive and the persistently chemotherapy resistant ovarian cancer tissues.\nAn integrative analysis identified 111 common differentially expressed genes including two bone morphogenetic proteins (BMP4 and BMP7), six solute carrier proteins (SLC10A3, SLC16A3, SLC25A1, SLC35B3, SLC7A5 and SLC7A7), transcription factor POU5F1 (POU class 5 homeobox 1), and KLK10 (kallikrein-related peptidase 10).\nA network analysis revealed a subnetwork with three genes BMP7, NR2F2 and AP2B1 that were consistently over expressed in the chemoresistant tissue or cells compared to the chemosensitive tissue or cells.", "dois": ["10.1039/c7mb00334j", "10.1016/j.ygyno.2010.01.041"]}
{"pair_type": "slc_pathway", "key1": "SLC7A5", "key2": "proliferation", "summary": "Vitro experiment showed that SLC7A5 was upregulated in LUAD and knockdown of SLC7A5 obviously suppressed tumor cell proliferation.\nALYREF silencing decreased SLC7A5 expression and subsequently inactivated mTORC1 pathway, resulting in decreased tumor proliferation.\nConversely, inhibiting the expression of miR-126 markedly increased the expression of SLC7A5 and alleviated cell proliferation inhibition.\nJPH203, a specific inhibitor of SLC7A5, effectively reversed the above phenomena, inhibited mTORC1 signaling activation, and reduced the proliferation of fibroblasts.\nFurther study on the function of SLC7A5 gene in SKM-1 cell line showed that downregulation of SLC7A5 inhibited SKM-1 cells proliferation, increased apoptosis and caused cell cycle arrest in the G0/G1 stage.\nYAP/TAZ reverses KRAS inhibitor-induced proliferation retardation by activating the SLC7A5/mTORC1 axis.\nknockdown of MRPL35 suppressed NSCLC cell proliferation, invasion, and glutamine metabolism in vitro and impeded tumor growth in vivo by upregulating SLC7A5, providing a promising therapeutic target for NSCLC.\nRNA-seq analysis demonstrated increased translation and reduced proliferation in Slc7a5 KD bone marrow B cells.\nSlc7a5 deletion in chondrocytes led to general disorganization of chondrocytes in the vertebral growth plate, along with an increase in apoptosis and a decrease in cell proliferation.\nBlocking the MAPK-c-MYC-SLC7A5 signaling axis cooperates with asparagine restriction to effectively suppress melanoma cell proliferation.\nour study demonstrated that FTO promoted gastric cancer proliferation through the circFAM192A/SLC7A5 axis in the mA-dependent manner.\nDex significantly inhibited (P<0.05) cell proliferation in cytotrophoblasts and down-regulated amino acid transporter SLC7A5 in syncytiotrophoblasts.", "dois": ["10.3390/ijms262110736", "10.32604/or.2025.068292", "10.1016/j.bbrc.2025.152768", "10.3390/ijms26178599", "10.1002/cam4.71234", "10.1038/s41388-025-03543-5", "10.1186/s13046-025-03446-z", "10.1016/j.ydbio.2025.06.010", "10.1007/s00726-025-03456-3", "10.1016/j.canlet.2025.217612", "10.1038/s41467-025-56903-w", "10.1016/j.bbrc.2025.151446", "10.1186/s12964-024-01964-5", "10.1016/j.ejmech.2024.117064", "10.1038/s41598-024-79425-9", "10.3390/ijms252011266", "10.1016/j.molmet.2024.102050", "10.1016/j.humpath.2024.105670", "10.1186/s12964-024-01826-0", "10.1111/cas.16259", "10.1073/pnas.2320835121", "10.1002/cam4.7217", "10.1177/10732748241251583", "10.1111/cas.16191", "10.1007/s13577-024-01056-z", "10.7150/ijbs.94297", "10.1186/s43556-024-00172-4", "10.1016/j.jphs.2024.03.001", "10.1111/cas.16062", "10.1158/1078-0432.CCR-23-2025", "10.14715/cmb/2023.69.10.3", "10.1038/s41467-023-42458-1", "10.1371/journal.pone.0292678", "10.3389/fimmu.2023.1251643", "10.1038/s41598-023-41096-3", "10.21873/anticanres.16418", "10.1126/scisignal.abo2709", "10.1016/j.intimp.2023.109939", "10.1182/bloodadvances.2022008272", "10.1093/jrr/rrac077", "10.1016/j.jphs.2022.10.002", "10.1002/jcp.30883", "10.26508/lsa.202201404", "10.1111/jcmm.17553", "10.1186/s13046-022-02466-3", "10.1152/ajpcell.00162.2021", "10.14670/HH-18-494", "10.1016/j.bcp.2022.115103", "10.1016/j.intimp.2022.108817", "10.1038/s42003-022-03363-3", "10.1038/s41598-022-06615-8", "10.1038/s41598-022-04987-5", "10.1155/2022/2373580", "10.1111/ced.15038", "10.3892/or.2021.8228", "10.1038/s41598-021-00811-8", "10.1016/j.ejmech.2021.113806", "10.1016/j.pharmthera.2021.107964", "10.1002/iid3.477", "10.1016/j.exer.2021.108650", "10.1111/cas.15006", "10.3389/fimmu.2021.624324", "10.1038/s41598-020-80668-5", "10.1038/s41588-020-00753-3", "10.1186/s13046-020-01762-0", "10.1111/andr.12880", "10.1016/j.prp.2020.152972", "10.1161/ATVBAHA.119.313800", "10.3390/ijms21041407", "10.1038/s41416-019-0626-z", "10.15252/embr.201948469", "10.1016/j.jconrel.2019.10.037", "10.1038/s41388-019-1071-4", "10.1016/j.jaci.2019.09.025", "10.1038/s41598-019-51144-6", "10.1101/gad.327056.119", "10.1007/s00259-019-04407-3", "10.1016/j.celrep.2019.05.039", "10.3390/ijms20102428", "10.21873/anticanres.13375", "10.1016/j.celrep.2019.04.034", "10.1038/s41586-019-1126-2", "10.1111/jcmm.14176", "10.3390/ijms20010027", "10.1016/j.bbrc.2018.11.162", "10.1620/tjem.246.167", "10.1038/s41419-018-1119-3", "10.1016/j.humpath.2018.09.020", "10.1186/s13046-018-0907-z", "10.3390/ijms19082373", "10.3390/ijms19072093", "10.1038/s41598-018-26664-2", "10.3390/ijms19051278", "10.1016/j.tjog.2018.02.009", "10.1186/s13058-018-0946-6", "10.1074/jbc.RA117.001103", "10.1074/jbc.RA117.001342", "10.1242/jcs.211755", "10.1007/s00280-017-3477-4", "10.1186/s12987-017-0068-z", "10.11817/j.issn.1672-7347.2017.05.001", "10.1111/pin.12528", "10.1016/j.steroids.2016.08.004", "10.1016/j.jphs.2016.04.021", "10.1016/j.bcp.2016.02.020", "10.1016/j.juro.2015.11.071", "10.1530/JME-15-0212", "10.1371/journal.pone.0130496", "10.1097/CMR.0000000000000181", "10.1002/jcp.25076", "10.1016/j.biopha.2015.04.001", "10.1007/s12253-015-9954-3", "10.1292/jvms.14-0014", "10.1111/cas.12529", "10.1007/s11095-014-1509-x", "10.1016/j.prp.2014.05.001", "10.1002/hed.23797", "10.1038/bjc.2014.178", "10.1021/cb500120x", "10.1016/j.cellsig.2014.04.002", "PMID:24671056", "10.1038/bjc.2014.142", "10.1002/ijc.28749", "PMID:24492461", "10.1186/1471-2407-13-482", "10.3969/j.issn.1672-7347.2013.08.009", "10.1016/j.bbrc.2013.08.020", "10.1016/j.tvjl.2013.06.016", "10.1016/j.biopha.2013.05.003", "10.1007/s00259-013-2477-9", "10.1007/s12253-013-9624-2", "10.1073/pnas.1218165110", "PMID:23171689", "10.1016/j.molcel.2012.09.017", "10.1371/journal.pone.0040026", "10.3892/or.2012.1878", "10.1007/s00259-011-2017-4", "10.3892/or.2011.1522", "10.1007/s00726-011-1122-9", "10.1016/j.humpath.2011.01.013", "10.1111/j.1440-1827.2011.02650.x", "10.1016/j.febslet.2011.03.039", "10.1016/j.bbrc.2011.02.135", "10.1007/s11010-010-0665-5", "10.1177/1933719110372419", "10.1016/j.bcp.2010.05.021", "10.1111/IGC.0b013e3181d28e13", "PMID:19597571", "10.1158/0008-5472.CAN-08-2345", "10.1016/j.lungcan.2008.12.015", "10.1111/j.1349-7006.2008.01029.x", "10.1002/ijc.24034", "10.1111/j.1349-7006.2008.00969.x", "10.1016/j.cellsig.2008.09.014", "PMID:18520037", "10.1016/j.prp.2008.02.003", "10.1227/01.neu.0000316018.51292.19", "10.1038/sj.bjc.6604235", "PMID:17975149", "PMID:17889654", "PMID:17329830", "PMID:16886618", "PMID:16201532", "PMID:16175382", "PMID:15906366", "PMID:15027953", "PMID:14977877", "PMID:11745822", "10.31083/FBL45811", "10.1165/rcmb.2025-0274OC", "10.1016/j.yexcr.2025.114732", "10.3389/fendo.2025.1585859", "10.1002/iid3.70222", "10.31083/FBL26756", "10.1002/advs.202406220", "10.1186/s12964-024-02001-1", "10.1172/jci.insight.178535", "10.1007/s13402-024-01025-6", "10.3389/fgene.2024.1499915", "10.1111/jcmm.70245", "10.3892/ol.2024.14772", "10.1101/2024.10.12.618047", "10.1038/s41598-024-70430-6", "10.1111/crj.13799", "10.1186/s12935-024-03365-7", "10.1016/j.jphs.2024.02.012", "10.1038/s41420-024-01862-2", "10.1016/j.jphs.2024.01.007", "10.1016/j.jbc.2023.105602", "10.3390/ani13193092", "10.3389/fonc.2023.1251100", "10.1016/j.tranon.2023.101784", "10.1172/jci.insight.169736", "10.1186/s12935-023-02957-z", "10.3390/ijms24119171", "10.1073/pnas.2221352120", "10.1007/s12032-023-02000-1", "10.1101/2023.02.11.528093", "10.1101/2023.01.24.524966", "10.3389/fonc.2022.1025594", "10.3389/fonc.2022.1043177", "10.1186/s40170-022-00295-8", "10.1016/j.heliyon.2022.e10866", "10.1101/2022.06.30.498338", "10.3390/brainsci12060690", "10.1038/s42255-022-00584-y", "10.21873/anticanres.15647", "10.3390/diagnostics12030745", "10.3390/cancers14010229", "10.3389/fvets.2021.756375", "10.1016/j.bioactmat.2021.07.009", "10.3390/cancers13174375", "10.18632/oncotarget.27981", "10.21037/atm-21-2247", "10.3892/ol.2021.12839", "10.1002/1878-0261.12999", "10.15252/embr.202051436", "10.1186/s12885-020-07709-0", "10.1016/j.taap.2020.114995", "10.1097/CM9.0000000000000753", "10.1016/j.apsb.2019.11.001", "10.15698/cst2020.01.210", "10.3389/fonc.2019.01163", "10.1002/jcb.29409", "10.1007/s10549-018-05111-w", "10.3892/ijo.2018.4596", "10.1016/j.bbrc.2017.12.114", "10.1371/journal.pone.0190179", "10.1007/s11010-016-2862-3", "10.1016/j.placenta.2016.01.009", "10.18632/oncotarget.6512", "10.1002/hep.28223", "10.1002/jcp.25040", "10.1158/0008-5472.CAN-14-3745", "10.1038/leu.2014.338", "10.1158/0008-5472.CAN-14-0579", "10.1016/j.yexmp.2013.12.004", "10.1016/j.ygyno.2010.01.041", "10.1016/j.cell.2008.11.044", "10.1007/s11060-008-9551-3"]}
{"pair_type": "slc_pathway", "key1": "SLC10A3", "key2": "ferroptosis", "summary": "In vivo experiments also demonstrated that silencing SLC10A3 effectively induces ferroptosis in GBM and inhibits GBM progression.\nFunctional analysis showed that SLC10A3 regulates GBM growth and progression through ferroptosis and that silencing SLC10A3 enhances sensitivity to the ferroptosis inducer Erastin.\nMechanistically, SLC10A3 modulates STAT3 transcription and phosphorylation, impacting GBM ferroptosis via the STAT3-GPX4 pathway, and the STAT3 phosphorylation inhibitor Stattic effectively reverses this process.\nSLC10A3 correlated with immune infiltration in LGG and moderately correlated with the gene signature of pyroptosis, lysosome-dependent cell death, necroptosis, apoptosis, ferroptosis, alkaliptosis, and autophagy-dependent cell death.\nFerroptosis is closely related to disease progression and treatment response in human brain gliomas;\nFunctional analysis showed that SLC10A3 might participate in the transport of multiple substances, neurogenic signaling, immune response, and programmed cell death in LGG.\nIdentifying new ferroptosis regulatory factors holds promise for addressing the aberrant regulation of ferroptosis in glioblastoma (GBM) and overcoming its treatment resistance.", "dois": ["10.1038/s41598-025-05866-5", "10.1016/j.wneu.2023.07.134"]}
{"pair_type": "slc_pathway", "key1": "SLC10A3", "key2": "proliferation", "summary": "An integrative analysis identified 111 common differentially expressed genes including two bone morphogenetic proteins (BMP4 and BMP7), six solute carrier proteins (SLC10A3, SLC16A3, SLC25A1, SLC35B3, SLC7A5 and SLC7A7), transcription factor POU5F1 (POU class 5 homeobox 1), and KLK10 (kallikrein-related peptidase 10).\nGO term GO:0050673 (epithelial cell proliferation) and GO:0050678 (regulation of epithelial cell proliferation) are enriched in the genes over expressed in the chemotherapy resistant tissue while the GO:0007229 (integrin-mediated signaling pathway) is enriched in the genes over expressed in the chemotherapy sensitive tissue.", "dois": ["10.1016/j.ygyno.2010.01.041"]}
{"pair_type": "slc_pathway", "key1": "SLC12A8", "key2": "glycolysis", "summary": "LH-specific knockdown of Slc12a8 in young mice decreases activity-dependent energy and carbohydrate expenditure and skeletal muscle functions, including muscle mass, muscle force, intramuscular glycolysis, and protein synthesis.\nLH-specific overexpression of Slc12a8 in aged mice significantly ameliorates age-associated decreases in energy expenditure and skeletal muscle functions.\nOur results highlight an important role of Slc12a8 in the LH for regulation of whole-body metabolism and skeletal muscle functions and provide insights into the pathogenesis of sarcopenia and frailty during aging.", "dois": ["10.1016/j.celrep.2022.111131"]}
{"pair_type": "slc_pathway", "key1": "SLC10A4", "key2": "apoptosis", "summary": "In the peewee mutant compared to the normal C57BL/6 J mouse, only Slc10a4 expression was lower.\nHistological analysis revealed that the major organs appear normal, but abnormalities in cellular proliferation were observed in bone, liver, and testis.", "dois": ["10.1007/s00335-009-9197-2"]}
{"pair_type": "slc_pathway", "key1": "SLC10A4", "key2": "proliferation", "summary": "In the peewee mutant compared to the normal C57BL/6 J mouse, only Slc10a4 expression was lower.\nHistological analysis revealed that the major organs appear normal, but abnormalities in cellular proliferation were observed in bone, liver, and testis.", "dois": ["10.1007/s00335-009-9197-2"]}
{"pair_type": "slc_pathway", "key1": "SLC10A7", "key2": "chemotherapy", "summary": "With respect to the GSCAlite platform, PLOD2 and TGFB2 were shown to be positively related to chemotherapeutic resistance, while SLC10A7 was a favourable factor for chemotherapy efficacy.\nCorrelations between lipid homeostasis-related genes and chemotherapeutic efficacy were analysed in GSCAlite.\nWe identified a lipid homeostasis-related gene signature that correlated with survival, clinical characteristics, the TME, and chemotherapeutic efficacy in GC patients.\nThis research provides a new perspective for improving prognosis and guiding individualized chemotherapy for patients with GC.\nTreatment options for recurrent gliomas include surgery, chemotherapy, and radiation therapy, but the clinical outcome is usually limited.\nRescue experiments showed that the overexpression of SLC10A7 could impede the effects of circHECTD1 silencing on the proliferation and invasion of glioma cells.\nIn this study, we identified that circHECTD1 regulates SLC10A7 by interacting with miR-296-3p in glioma cells.\nKnockdown of circHECTD1 inhibited proliferation and invasion in vitro, and also reduced the growth of tumor and prolonged the prognosis in vivo.\nIn conclusion, this study investigated a novel biomarker panel consisting of the circHECTD1/miR-296-3p/SLC10A7 axis, which is critical for glioma tumorigenesis and invasiveness and may represent a novel therapeutic target for intervening in glioma progression.", "dois": ["10.1038/s41598-024-52647-7", "10.1002/jcp.30277"]}
{"pair_type": "slc_pathway", "key1": "SLC12A8", "key2": "migration", "summary": "Knocking down SLC12A8 led to a significant decrease in proliferation, migration, and invasion abilities, while promoting apoptosis in NSCLC cells.\nSLC12A8 promotes the migration and invasion of non-small cell lung cancer (NSCLC) cells.\nTreatment with colivelin effectively enhanced proliferation, invasion and migration capacities of the bladder cancer cells with SLC12A8 knockdown (<0.05).\nSLC12A8 promotes proliferation, invasiveness, migration and epithelial-mesenchymal transition of bladder cancer cells by activating JAK/STAT singaling.\nThe bladder cancer cell lines with SLC12A8 knockdown showed significantly attenuated proliferation, invasion and migration capacities (<0.05).\nThis study aims to investigate the impacts of SLC12A8 on the invasion, migration, and epithelial-mesenchymal transition (EMT) of non-small cell lung cancer (NSCLC) cells.\nSLC12A8 promotes bladder cancer progression by activating the JAK/STAT signaling pathway and its high expression is closely associated with a poor prognosis of the patients.\nAll these data suggested that SLC12A8 plays a promoting effect on the cells viability, invasiveness and motility in breast carcinoma by activating TLR/NLR signaling pathway.\nFunctional experiments demonstrated that SLC12A8-knockdown suppressed while SLC12A8-overexpression elevated the viability, invasiveness and motility of breast carcinoma cells.\nThe results indicate that reducing SLC12A8 expression may suppress the malignant phenotype of NSCLC cells, as well as the EMT.\nHigh SLC12A8 expression was correlated with a poor prognosis in NSCLC patients.\nSLC12A8 may serve as a target for the clinical management of NSCLC progression.\nSolute carrier family 12 member 8 impacts the biological behaviors of breast carcinoma cells by activating TLR/NLR signaling pathway.\nEndothelial cell proliferation and migration increased and apoptosis decreased with a decrease in SLC25A29 expression.", "dois": ["10.3390/ijms252111551", "10.4149/gpb_2024020", "10.12122/j.issn.1673-4254.2023.09.20", "10.1186/s12935-023-03082-7", "10.1007/s10616-020-00439-y"]}
{"pair_type": "slc_pathway", "key1": "SLC12A8", "key2": "proliferation", "summary": "Knocking down SLC12A8 led to a significant decrease in proliferation, migration, and invasion abilities, while promoting apoptosis in NSCLC cells.\nTreatment with colivelin effectively enhanced proliferation, invasion and migration capacities of the bladder cancer cells with SLC12A8 knockdown (<0.05).\nThe bladder cancer cell lines with SLC12A8 knockdown showed significantly attenuated proliferation, invasion and migration capacities (<0.05).\nSLC12A8 promotes bladder cancer progression by activating the JAK/STAT signaling pathway and its high expression is closely associated with a poor prognosis of the patients.\nAll these data suggested that SLC12A8 plays a promoting effect on the cells viability, invasiveness and motility in breast carcinoma by activating TLR/NLR signaling pathway.\nFunctional experiments demonstrated that SLC12A8-knockdown suppressed while SLC12A8-overexpression elevated the viability, invasiveness and motility of breast carcinoma cells.\nThe results indicate that reducing SLC12A8 expression may suppress the malignant phenotype of NSCLC cells, as well as the EMT.\nEndothelial cell proliferation and migration increased and apoptosis decreased with a decrease in SLC25A29 expression.\nThe bladder cancer cells with SLC12A8 knockdown showed significantly decreased expressions of p-Jak2, p-Stat3, N-cadherin and vimentin proteins with an increased expression of E-cadherin.\nAdditionally, SLC12A8 knockdown resulted in decreased levels of N-cadherin and vimentin, along with increased E-cadherin expression.\nSilencing SLC12A8 significantly reduced the protein expression of TLR/NLR-related markers, whereas overexpression of SLC12A8 caused an elevation on the protein expression of these markers.\nFurthermore, GSEA indicated that high SLC12A8 was positively correlated with TLR/NLR signaling pathway.\nGSEA identified significant gene enrichment in the JAK/STAT signaling pathway (=0.008).\nCorrelation analysis showed that SLC12A8 expression was negatively", "dois": ["10.4149/gpb_2024020", "10.12122/j.issn.1673-4254.2023.09.20", "10.1186/s12935-023-03082-7", "10.1007/s10616-020-00439-y"]}
{"pair_type": "slc_pathway", "key1": "SLC12A8", "key2": "oxidative stress", "summary": "Experiments in CRC cells showed that SLC12A8 upregulation promoted apoptosis resistance, EMT, and inhibited ROS production.\nPathway enrichment analyses revealed SLC12A8 involvement in oxidative stress and transforming growth factor-beta (TGF-β) signaling.\nSLC12A8 upregulation promotes colorectal cancer progression and chemoresistance.\nSLC12A8 expression was upregulated in CRC tissues compared with normal colorectal tissues.\nMoreover, SLC12A8 knockdown enhanced the sensitivity of CRC cells to oxaliplatin chemotherapy.\nThe aim of this study was to investigate the functions of SLC12A8 in CRC.\nOur integrative analyses identify SLC12A8 as a candidate biomarker for CRC progression.\nTargeting SLC12A8 may improve patient responses to oxaliplatin-based treatment regimens.\nFurthermore, high expression of SLC12A8 was associated with poorer prognosis in CRC patients.\nAlthough solute carrier family 12 member 8 (SLC12A8) has high expression in various tumors and affects tumor progression, its role in CRC remains unclear.\nThe effects of SLC12A8 on the CRC cell apoptosis, epithelial-mesenchymal transition (EMT), reactive oxygen species (ROS) production, and sensitivity to oxaliplatin were verified by experiments.", "dois": ["10.21037/tcr-24-87"]}
{"pair_type": "slc_pathway", "key1": "SLC10A2", "key2": "oxidative stress", "summary": "Cili alleviated overexpression of oxidative stress responsive genes (Hmox1, Gsta1, Gstm3, Nqo1, Gclc, Vldlr, and Cdkn1a), and rescued alcohol-downregulated metabolism genes (Angptl8, Slc10a2, Ces3b, Serpina12, C6, and Selenbp2).\nIngenuity pathway analysis showed that DNLA ameliorated alcohol-induced oxidative stress and xenobiotic metabolism disruption.\nOverall, Cili was effective against chronic alcohol liver injury, and the mechanisms were associated with decreased oxidative stress, improved lipid metabolism through modulating nuclear receptor CAR-, PXR-and Nrf2-mediated pathways.\nIn conclusion, DNLA was effective against alcohol-induced fatty liver disease, and the protection may be attributed to alleviated oxidative stress and restored metabolism homeostasis, probably through modulating nuclear receptor CAR-, PXR-, and Nrf2-mediated gene expression pathways.\nattenuated oxidative stress (Hmox1, Gstm3, Nupr1), reduced the expression of Nrf2 genes (Nqo1, Gclc, Vldlr);\nand rescued some metabolic genes (Insig1, Xbp1, Socs3, Slc10a2).", "dois": ["10.3390/biomedicines10112800", "10.3390/nu14091974"]}
{"pair_type": "slc_pathway", "key1": "SLC12A9", "key2": "migration", "summary": "Finally, our in vitro experiments revealed that silencing SLC12A9 dramatically inhibited glioma cell growth and migration.\nAmong the members of the SLC12 family, SLC12A9 had the highest mutation rate in glioma, with gene amplification as the major mutation type, and its expression was significantly upregulated in glioma.\nHigher SLC12A9 expression was significantly associated with older age, higher grade, wild-type isocitrate dehydrogenase (IDH), and a worse prognosis.\nGene set enrichment analysis (GSEA) revealed that SLC12A9 was mainly related to the DNA replication pathway.\nThe functional enrichment analysis indicated that SLC12A9 is mainly related to ion channel annotation.\nFurthermore, we found that SLC12A9 correlated with tumor-infiltrating immune cells and immune checkpoints.\nThus, SLC12A9 may be involved in regulating the immune response of glioma.", "dois": ["10.1016/j.gene.2024.149136"]}
{"pair_type": "slc_pathway", "key1": "SLC13A1", "key2": "glycolysis", "summary": "The excess citrate from the matrix is translocated to the cytosol for fatty acid synthesis through these transporters and thus controls the energy balance by downregulating the glycolysis, tricarboxylic acid (TCA), and fatty acid breakdown.", "dois": ["10.1007/s11010-022-04618-7"]}
{"pair_type": "slc_pathway", "key1": "SLC13A2", "key2": "chemotherapy", "summary": "Further studies are required to determine the functions of DEGs to promote the diagnosis of metastases and provide novel chemotherapy targets.", "dois": ["10.1002/cam4.1147"]}
{"pair_type": "slc_pathway", "key1": "SLC10A3", "key2": "apoptosis", "summary": "SLC10A3 correlated with immune infiltration in LGG and moderately correlated with the gene signature of pyroptosis, lysosome-dependent cell death, necroptosis, apoptosis, ferroptosis, alkaliptosis, and autophagy-dependent cell death.\nFunctional analysis showed that SLC10A3 might participate in the transport of multiple substances, neurogenic signaling, immune response, and programmed cell death in LGG.\nSLC10A3 is a potential diagnostic and prognostic biomarker for LGG and might be associated with substance transport, neurogenic signaling, immune infiltration, and programmed cell death in LGG.", "dois": ["10.1016/j.wneu.2023.07.134", "10.1039/c7mb00334j", "10.1016/j.ygyno.2010.01.041"]}
{"pair_type": "slc_pathway", "key1": "SLC13A2", "key2": "apoptosis", "summary": "Liver fibrosis was characterized by collagen deposition and activation of Jak2-Stat3 signaling, resulting in hepatocyte apoptosis.\nThe upregulation of PAOX and ATP2C2 may be associated with toxicity and apoptosis resistance in cattleyak with respect to yak.\nThese findings suggest that HFD consumption and concomitant obesity disrupts metabolite homeostasis, contributing to liver damage and cell death.\nLevels of cytochrome P450 enzymes were downregulated, as indicated by decreased Cyp2b10 and Cyb3a11 levels, alongside reduced expression of the di- and tri-carboxylic acid transporter Slc13a2, correlating with elevated Krebs cycle intermediates.\nHowever, downregulated DEFB109, DEFB121, DEFB123, DEFA1, LY6G5C, SLC13A2, CST3, CRYBA4 and ADAM28 were associated with innate immune response, sperm maturation, motility and antimicrobial functions.", "dois": ["10.1371/journal.pone.0334213", "10.1016/j.theriogenology.2022.10.039"]}
{"pair_type": "slc_pathway", "key1": "SLC12A5", "key2": "apoptosis", "summary": "Biofunctional investigation of SLC12A5 revealed that SLC12A5 significantly increased cell proliferation, G1-S cell cycle transition, invasion/migration abilities, but suppressed apoptosis in vitro and promoted xenograft tumour growth as well as lung metastasis in vivo.\nThe antiapoptosis effect by SLC12A5 was mediated through inhibiting apoptosis-inducing factor and endonuclease G-dependent apoptotic signalling pathway;\nIntriguingly, direct pharmacological inhibition of KCC2 in mature neurons was sufficient to rapidly induce apoptosis, an effect that was not abrogated via blockade of neuronal depolarization using tetrodotoxin (TTX).\nContrary to the common assumption that embryonic neocortical projection neurons express KCC2 at non-significant levels, here we show that loss of KCC2 enhances apoptosis of late-born upper-layer cortical projection neurons in the embryonic brain.\nDecreasing KCC2 expression in mature neurons resulted in the rapid activation of the extrinsic apoptotic pathway.\nCollectively, our results demonstrate that KCC2 plays a critical role in neuronal survival by limiting apoptosis, and mature neurons are highly sensitive to the loss of KCC2 function.\nIn utero electroporation of plasmids encoding truncated, transport-dead KCC2 constructs retaining the CTD was as efficient as of that encoding full-length KCC2 in preventing elimination of migrating projection neurons upon conditional deletion of KCC2.", "dois": ["10.3389/fimmu.2024.1462003", "10.1111/jcmm.18380", "10.1016/j.arcmed.2021.05.004", "10.1016/j.jbc.2021.100364", "10.15252/embr.201948880", "10.1136/gutjnl-2014-308257", "PMID:17553155", "10.12182/20240360402", "10.1016/j.xgen.2023.100362", "10.1016/j.tins.2021.01.004", "10.12688/f1000research.6358.2"]}
{"pair_type": "slc_pathway", "key1": "SLC13A2", "key2": "glycolysis", "summary": "The excess citrate from the matrix is translocated to the cytosol for fatty acid synthesis through these transporters and thus controls the energy balance by downregulating the glycolysis, tricarboxylic acid (TCA), and fatty acid breakdown.", "dois": ["10.1007/s11010-022-04618-7"]}
{"pair_type": "slc_pathway", "key1": "SLC13A2", "key2": "proliferation", "summary": "Similarly, ACLY inhibition suppressed SLC13A2-promoted cholesterol synthesis for hepatocellular proliferation and liver regeneration in vivo.\nMechanistically, SLC13A2 promotes import of citrate into hepatocytes, serving as building block for ACLY-dependent acetyl-CoA formation and de novo synthesis of cholesterol.\nIn line, the pre-administration of the HMGCR inhibitor lovastatin abolished SLC13A2-mediated liver regeneration.\nLiver-specific overexpression or depletion of SLC13A2 promoted or attenuated liver regeneration, respectively.\nSLC13A2 increased cleavage of SREBP2, and expression of cholesterol metabolism genes, including LDLR and HMGCR.\nTitle: SLC13A2 promotes hepatocyte metabolic remodeling and liver regeneration by enhancing de novo cholesterol biosynthesis.\nIn sum, this study demonstrates that citrate transported by SLC13A2 acts as an intermediate metabolite to restore the metabolic homeostasis during liver regeneration, suggesting SLC13A2 as a potential drug target after liver damage.\nHere, we screened metabolic genes differentially regulated during liver regeneration, and report that SLC13A2, a transporter for TCA cycle intermediates, is decreased in rapid response to partial hepatectomy in mice and recovered along restoration of liver mass and function.\nAbstract: Metabolic requirements of dividing hepatocytes are prerequisite for liver regeneration after injury.", "dois": ["10.1038/s44318-025-00362-y", "10.1371/journal.pone.0168899"]}
{"pair_type": "slc_pathway", "key1": "SLC12A8", "key2": "apoptosis", "summary": "Experiments in CRC cells showed that SLC12A8 upregulation promoted apoptosis resistance, EMT, and inhibited ROS production.\nKnocking down SLC12A8 led to a significant decrease in proliferation, migration, and invasion abilities, while promoting apoptosis in NSCLC cells.\nEndothelial cell proliferation and migration increased and apoptosis decreased with a decrease in SLC25A29 expression.\nThe effects of SLC12A8 on the CRC cell apoptosis, epithelial-mesenchymal transition (EMT), reactive oxygen species (ROS) production, and sensitivity to oxaliplatin were verified by experiments.\nMoreover, SLC12A8 knockdown enhanced the sensitivity of CRC cells to oxaliplatin chemotherapy.\nThe results indicate that reducing SLC12A8 expression may suppress the malignant phenotype of NSCLC cells, as well as the EMT.\nPathway enrichment analyses revealed SLC12A8 involvement in oxidative stress and transforming growth factor-beta (TGF-β) signaling.\nHigh SLC12A8 expression was correlated with a poor prognosis in NSCLC patients.\nFurthermore, high expression of SLC12A8 was associated with poorer prognosis in CRC patients.\nCell proliferation, invasion, migration, and apoptosis were evaluated using CCK-8 assay, transwell, and flow cytometry techniques, respectively.", "dois": ["10.4149/gpb_2024020", "10.21037/tcr-24-87", "10.1186/s12935-023-03082-7"]}
{"pair_type": "slc_pathway", "key1": "SLC13A3", "key2": "ferroptosis", "summary": "Furthermore, silencing of SLC13A3 depletes GSH and induces autophagic ferroptosis in β-catenin-activated liver cancer cells.\nMechanistically, tumor cells uptake itaconate via SLC13A3 from tumor-associated macrophages (TAMs), thereby activating the NRF2-SLC7A11 pathway and escaping from immune-mediated ferroptosis.\nThus, we identify the interplay between tumors and TAMs via the SLC13A3-itaconate-NRF2-SLC7A11 axis as a previously unknown immune ferroptosis resistant mechanism in the TME and SLC13A3 as a promising immunometabolic target for treating SLC13A3 cancer.\nHere, we discover SLC13A3 is an itaconate transporter in tumor cells and endows tumor ferroptosis resistance, diminishing tumor immunity and ICB efficacy.\nDeletion of ACOD1 (an essential enzyme for itaconate synthesis) in macrophages, genetic ablation of SLC13A3 in tumors, or treatment with SLC13A3i sensitize tumors to ferroptosis, curb tumor progression, and bolster ICB effectiveness.\nImmune checkpoint blockade (ICB) triggers tumor ferroptosis.\nTumors might evade ferroptosis in the tumor microenvironment (TME).", "dois": ["10.1016/j.ccell.2024.10.010", "10.1038/s41467-024-51860-2"]}
{"pair_type": "slc_pathway", "key1": "SLC13A3", "key2": "glycolysis", "summary": "In mammals, citric acid cycle intermediates play a key role in regulating various metabolic processes, such as fatty acid synthesis and glycolysis.\nThe excess citrate from the matrix is translocated to the cytosol for fatty acid synthesis through these transporters and thus controls the energy balance by downregulating the glycolysis, tricarboxylic acid (TCA), and fatty acid breakdown.", "dois": ["10.1007/s11010-022-04618-7", "10.1021/acs.biochem.5b00388"]}
{"pair_type": "slc_pathway", "key1": "SLC13A4", "key2": "proliferation", "summary": "Here, we demonstrate that adult mice have increased neurogenesis within the subgranular zone (SGZ) of the hippocampal dentate gyrus, with elevated numbers of neural progenitor cells and intermediate progenitors.\nImportantly, we did not observe any changes in proliferation when we isolated and cultured progenitors in neurosphere assays, suggestive of a cell-extrinsic requirement for sulfate in regulating hippocampal neurogenesis.\nThese include sulfonation of extracellular proteoglycans to facilitate local growth factor binding and to regulate the shape of morphogen gradients during development.\nWe have previously shown that mice lacking one allele of the sulfate transporter exhibit reduced sulfate transport into the brain, deficits in social behaviour, reduced performance in learning and memory tasks, and abnormal neurogenesis within the ventricular/subventricular zone lining the lateral ventricles.\nIn contrast, by 12 months of age there were reduced numbers of neural stem cells in the SGZ of heterozygous mice.\nCollectively, these data demonstrate a requirement for sulfate transport during postnatal brain development to ensure normal adult hippocampal neurogenesis.", "dois": ["10.1242/bio.053132"]}
{"pair_type": "slc_pathway", "key1": "SLC13A3", "key2": "oxidative stress", "summary": "The results indicate that SLC13A3 is a direct downstream target of PITX2 transcriptional regulation and that levels of PITX2 and SLC13A3 modulate responses to oxidative stress in ocular cells.\nReduction of PITX2 or SLC13A3 levels by small interfering RNA (siRNA)-mediated knockdown augmented the death of transformed human trabecular meshwork cells exposed to hydrogen peroxide.", "dois": ["10.1167/iovs.10-6967"]}
{"pair_type": "slc_pathway", "key1": "SLC13A4", "key2": "glycolysis", "summary": "The excess citrate from the matrix is translocated to the cytosol for fatty acid synthesis through these transporters and thus controls the energy balance by downregulating the glycolysis, tricarboxylic acid (TCA), and fatty acid breakdown.", "dois": ["10.1007/s11010-022-04618-7"]}
{"pair_type": "slc_pathway", "key1": "SLC13A5", "key2": "chemotherapy", "summary": "Thirteen of the genes with concordant CpG sites displayed an inverse correlation between promoter methylation and expression level in glioblastomas: B3GNT5, FABP7, ZNF217, BST2, OAS1, SLC13A5, GSTM5, ME1, UBXD3, TSPYL5, FAAH, C7orf13, and C3orf14.\nWe also screened for associations between the level of methylation of CpG sites and overall survival in a cohort of 50 patients uniformly treated by surgery, radiotherapy and chemotherapy with concomitant and adjuvant temozolomide (STUPP protocol).\nThe methylation status of the FNDC3B, TBX3, DGKI, and FSD1 promoters identified patients with MGMT-methylated tumors that did not respond to STUPP treatment (p-value < 1e-04).", "dois": ["10.1186/1471-2164-11-701"]}
{"pair_type": "slc_pathway", "key1": "SLC13A5", "key2": "oxidative phosphorylation", "summary": "The overexpression of SLC13A5 resulted in a metabolic shift toward oxidative phosphorylation, increased phosphorylation of ERK and YAP, and increased SOX2 expression, leading to increased cisplatin resistance.\nMicroarray analysis demonstrated that the expression of SLC13A5, a citrate transporter involved in TCA cycle, was significantly induced in the resulting MesoSC-like cells.\nOur findings suggest that the hydrogel-based CSC generation method is also effective for human mesothelioma cells and that SLC13A5 may contribute to MesoSC survival.", "dois": ["10.1111/pin.70001"]}
{"pair_type": "slc_pathway", "key1": "SLC13A5", "key2": "oxidative stress", "summary": "These DEGs were mainly correlated with fat metabolism, oxidative stress and some inflammatory pathways.", "dois": ["10.3390/metabo13050594"]}
{"pair_type": "slc_pathway", "key1": "SLC13A5", "key2": "apoptosis", "summary": "These mutants also exhibited fewer neurons and a concomitant increase in apoptosis across the optic tectum, a region important for sensory processing.", "dois": ["10.1371/journal.pbio.3002499"]}
{"pair_type": "slc_pathway", "key1": "SLC13A5", "key2": "glycolysis", "summary": "We show here that a genetic driver of early onset epileptic encephalopathy (EOEE), SLC13A5, a Na/citrate cotransporter (NaCT), is critical for gating the activation of local presynaptic glycolysis.\nCitrate is known to suppress glycolysis by inhibiting phosphofructokinase-1 and activate gluconeogenesis by stimulating fructose-1,6-bisphophatase;\nIn HepG2 cells with the highest NaCT expression, extracellular citrate treatment upon hypoxia induced HIF1α degradation, which led to reduced glycolysis and cellular proliferation.\ntherefore, the decrease in cellular levels of citrate would stimulate glycolysis and inhibit gluconeogenesis.\nWe show that loss of SLC13A5 or mistargeting to the plasma membrane results in suppressed glycolytic gating, activity dependent presynaptic bioenergetic deficits and synapse dysfunction.\nCytosolic citrate further regulates the energy balance of the cell by activating the fatty-acid-synthesis pathway while downregulating both the glycolysis and fatty-acid β-oxidation pathways.\nThe excess citrate from the matrix is translocated to the cytosol for fatty acid synthesis through these transporters and thus controls the energy balance by downregulating the glycolysis, tricarboxylic acid (TCA), and fatty acid breakdown.\nWe show that SLC13A5 is in part localized to a presynaptic pool of membrane-bound organelles and acts to transiently clear axonal citrate during electrical activity, in turn activating phosphofructokinase 1.\nMetformin inhibits the expression of the plasma membrane citrate transporter NaCT in HepG2 cells and decreases cellular levels of citrate.", "dois": ["10.1038/s41598-020-65621-w", "10.1101/2025.06.17.660213", "10.1007/s11010-022-04618-7", "10.3390/cancers14143355", "10.1042/BCJ20200877", "PMID:27754898", "10.1038/srep17391", "PMID:26318988", "10.1038/nature11542"]}
{"pair_type": "slc_pathway", "key1": "SLC13A5", "key2": "proliferation", "summary": "Accumulating evidence suggests that SLC13A5 is involved in hepatic lipogenesis, cell proliferation, epilepsy, and bone development in mammals.\nIn HepG2 cells with the highest NaCT expression, extracellular citrate treatment upon hypoxia induced HIF1α degradation, which led to reduced glycolysis and cellular proliferation.\nThe perturbation of SLC13A5 expression and/or activity is associated with non-alcoholic fatty liver disease, obesity, insulin resistance, cell proliferation, and early infantile epileptic encephalopathy.\nReducing expression in human hepatocarcinoma cells has recently been shown to inhibit cell proliferation.\nReduced expression in the fly intestine affects intestinal stem cell proliferation, and has recently been shown to also inhibit germ cell proliferation in males with delayed sperm maturation and decreased spermatocyte numbers.\nTogether, our findings demonstrate that knockdown of SLC13A5 promotes hepatic ketogenesis and enhances cellular stress response in HepG2 cells, suggesting a potential role of this transporter in metabolic disorders and liver cancer.\nFurther ingenuity pathway analysis predicted 40 canonical pathways and 28 upstream regulators (p < .01), of which most were associated with metabolism, cell proliferation, and stress response.\nThese results highlight a new connection between energy metabolism and cell proliferation.\nAdditional experiments showed that SLC13A5-KD sensitizes HepG2 cells to cellular stress caused by a number of chemotherapeutic agents.\nExtracellular citrate treatment induced the failure of metabolic adaptation to hypoxia and tumor growth inhibition, which can be a potential therapeutic strategy in HCCs.", "dois": ["10.3390/cancers14143355", "10.3389/fragi.2021.782162", "10.3390/metabo11100706", "10.1042/BCJ20200592", "10.1016/j.taap.2020.115117", "10.1074/jbc.M117.783860"]}
{"pair_type": "slc_pathway", "key1": "SLC15A2", "key2": "glycolysis", "summary": "Following ALA treatment, tumor cells preferentially accumulate porphyrins because of the differential activities of aerobic glycolysis, known as Warburg effect.\nAmong various human cell lines of hematological malignancies, including K562 erythroleukemia, Jurkat T-cell leukemia, Nalm6 pre-B cell leukemia, KG1a myeloid leukemia, and U937 monocytic leukemia, human myeloma cell line, KMS18, and OPM2 abundantly expressed ALA transporters, such as SLC36A1 and SLC15A2, and 1 mM ALA treatment for 24 h resulted in nearly 100% porphyrin fluorescence expression, which could be competitively inhibited by ALA transport with gamma-aminobutyric acid.", "dois": ["10.1620/tjem.249.19"]}
{"pair_type": "slc_pathway", "key1": "SLC15A1", "key2": "migration", "summary": "Our prediction model, comprising seven genes (AHNAK2, ARNTL2, CD27, LTB, SLC15A1, SLC2A1, and SYT1), has shown potential in predicting the prognosis of individuals diagnosed with LUAD.\nOverall, is a novel potential biomarker involved in CRC progression and promotes the proliferation and migration of tumor cells by positively regulating the function of Hsp70.\nFurthermore, we found that knockdown of inhibited the proliferation and migration of HCT116 cells, and Hsp70 ATPase activator could rescue it.\nWe further investigated the impact of the ferritinophagy-related gene AHNAK2 on LUAD cell proliferation, invasion, migration, and ferroptosis in vitro.\nNotably, AHNAK2 impedes ferroptosis, promoting LUAD progression in vitro.\nFor validation purposes, we used a close eukaryotic homolog of the human H-coupled oligopeptide transporter PepT1 (SLC15A1) that mediates uptake of di-tripeptides and peptide-like drugs as a test model.\nFollowing yeast overexpression of SLC15A1/PepT1 ortholog from moss Physcomitrella patens, PepT, which exhibits remarkable similarity to human PepT1, the approach was validated using dipeptide glycylsarcosine (Gly-Sar) and antiviral prodrug valacyclovir as test substrates.\nImportantly, this migration is affected by substrate binding.", "dois": ["10.3390/bioengineering11111070", "10.1021/acsomega.4c00901", "10.1016/j.vascn.2018.03.004"]}
{"pair_type": "slc_pathway", "key1": "SLC15A2", "key2": "proliferation", "summary": "Enrichment analysis indicated that SLC15A2 predominantly activates pathways related to cell proliferation, adhesion, and lipid metabolism while inhibiting pathways associated with protein synthesis, degradation, RNA metabolism, and energy metabolism.\nMechanistically, we demonstrated that exercise-generated carnosine was specifically transported to HSCs via Slc15a2 and then inhibited p53 transcriptional activity by directly interacting with its core DNA-binding domain, which led to downregulation of the p53 target genes p21 and Puma, thus promoting the proliferation and survival and inhibiting the senescence of irradiated HSCs.\nMoreover, results from in vitro experiments indicated that knockdown of SLC15A2 markedly enhanced the proliferation and migratory capacity of PCa cells.\nThe expression level of SLC15A2 in PCa tissues was significantly lower compared to benign tissues, and reduced expression of SLC15A2 was often associated with early biochemical recurrence (BCR) and decreased overall survival in PCa patients.", "dois": ["10.21873/anticanres.17402", "10.1186/s12964-024-01959-2", "10.3390/ijms21093327"]}
{"pair_type": "slc_pathway", "key1": "SLC15A1", "key2": "proliferation", "summary": "Functional analyses indicated that some DEGs were involved in the transcriptional regulation of nutrient transportation (SLC15A1, SLC5A1, and SLC3A1), cell differentiation (LGR5, HOXA5 and KLF4), cell proliferation (PLK2 and TGFB3), transcriptional regulation (JUN, FOS and ATF3), and signaling transduction (WNT10B and BMP1), suggesting that these genes were related to intestinal epithelial cell maturation and cell renewal.\nUnlike single decitabine treatment, the combined decitabine/PBA treatment caused > 95% inhibition of cell proliferation, prevented cell cycle progression especially in the S and G2-phase and induced programmed cell death.\nOverall, is a novel potential biomarker involved in CRC progression and promotes the proliferation and migration of tumor cells by positively regulating the function of Hsp70.\nThe number of Ki67 positive cells per crypt was decreased (linear, P < 0.05) with the dietary niacin on day 7 but increased (linear, P < 0.05) with dietary niacin contents on day 14.\nFurthermore, we found that knockdown of inhibited the proliferation and migration of HCT116 cells, and Hsp70 ATPase activator could rescue it.\nIn addition, extended spermine administration also markedly promoted cell proliferation, depressed apoptosis and modulated amino acid transport (p&lt;\nWe focused on the inhibition of cell proliferation, the recovery of tumor suppressors and programmed cell death, and established clinical relevance by evaluating drug responsive genes among 270 COAD patients.\nRegardless of supplementation time, spermine intake significantly enhanced the expressions of amino acid transporter-related genes (SLC1A1, SLC1A5, SLC7A1, SLC7A7, and SLC15A1) in both thymus and spleen, as well as SLC7A9 in the spleen of piglets (p&lt;0.05).\nSpermine supplementation may regulate cell cycle during the G1/S phase, suppress apoptosis and modulate amino acid transport.", "dois": ["10.3390/bioengineering11111070", "10.1021/acsomega.4c00901", "10.1186/s13148-023-01500-1", "10.3390/ani12182324", "10.1039/d0fo03097j", "10.5713/ajas.17.0799"]}
{"pair_type": "slc_pathway", "key1": "SLC15A1", "key2": "ferroptosis", "summary": "Notably, AHNAK2 impedes ferroptosis, promoting LUAD progression in vitro.\nFurthermore, we present AHNAK2 as a novel regulator of ferroptosis, which requires further investigation to understand its mechanism.\nFerritinophagy, a newly recognized autophagy process linked to ferroptosis, has been associated with LUAD development.\nWe further investigated the impact of the ferritinophagy-related gene AHNAK2 on LUAD cell proliferation, invasion, migration, and ferroptosis in vitro.\nOur prediction model, comprising seven genes (AHNAK2, ARNTL2, CD27, LTB, SLC15A1, SLC2A1, and SYT1), has shown potential in predicting the prognosis of individuals diagnosed with LUAD.\nRecent studies have shown a dysregulation of genes related to ferritinophagy in LUAD, indicating its potential as a therapeutic target.\nOur research suggests that ferritinophagy-associated genes are promising prognostic markers for LUAD and lay the groundwork for further exploration of ferritinophagy's role in LUAD.", "dois": ["10.3390/bioengineering11111070"]}
{"pair_type": "slc_pathway", "key1": "SLC15A2", "key2": "oxidative stress", "summary": "It is transported by PEPT1 and PEPT2, facilitating its protective effects against oxidative stress in neurons and intestinal epithelial cells.\nPLP mitigated pathological alterations, replenished antioxidants (SOD, CAT, and GSH), and reduced lipid peroxidation in the intestinal tissues.\nAdditionally, PLP corrected altered expressions of tight junction proteins (zo-1, zo-2, and claudin-4) and nutrient transporters (glut-1, slc15a2, slc26a6, and slc4a4) in Cd-exposed fish.\nIts antioxidant activity and regulation of intestinal tight junction proteins and nutrient transporters contribute to its effectiveness.\nFor example, Carnosine (beta-alanyl-L-histidine) has been demonstrated to act as an antioxidant, antiglycating agent, and neuroprotector.\nUpregulated expression of peptide transporters has also been positively related to inflammatory responses.\nThe proton-coupled oligopeptide transporter (POT) family consists of mainly four transporter proteins, which include two H -coupled oligopeptide transporters known as PEPT1 (SLC15A1) and PEPT2 (SLC15A2), along with two peptide/histidine transporters referred to as PHT1 (SLC15A4) and PHT2 (SLC15A3).", "dois": ["10.1007/s10695-024-01415-5", "10.1007/s00232-025-00348-1"]}
{"pair_type": "slc_pathway", "key1": "SLC15A1", "key2": "chemotherapy", "summary": "The expression of solute carrier 15A1 (SLC15A1) upregulated and an ATP-binding cassette subfamily G member 2 (ABCG2) downregulated by HT.\nOur findings suggest multiple novel predictive biomarkers of docetaxel-induced myelosuppression: SLC15A1 rs2297322, PXR rs3732359 and FMO3 rs2266782.\nOur results revealed that 11 SNPs in nine genes (SLC15A1, SLCO1A2, CYP2D6, FMO3, UGT1A1, NAT2, SULT2A1, PXR and HNF4α) were associated with docetaxel-induced myelosuppression.\nGMDR analyses suggested that a 3-locus model: SLC15A1 rs2297322-PXR rs3732359-FMO3 rs2266782 was an appropriate predictive model of docetaxel-induced myelosuppression (P = .017, Testing Bal.Acc = 0.653, CV Consistency = 10/10).\nSince SLC15A1 is an accumulating transporter for ALA, while ABCG2 is a porphyrin efflux transporter, porphyrin accumulation was enhanced.\nWe examined 61 SNPs in 36 genes that code for drug transporters, metabolism enzymes, nuclear receptors and DNA repair pathway in 110 Chinese Han patients receiving docetaxel-based chemotherapy.\nThe cytotoxicity of doxorubicin was also enhanced.\nIndeed, the amount of intracellular doxorubicin was increased by a combination of HT and ALA.\nThe combination of HT and ALA treatment can enhance the cancer-specific cytotoxicity of doxorubicin.\nMoreover, the uptake of 5-aminolevulinic acid (ALA) was enhanced by the increase in mitROS production.\nThis enhancement was observed in the human breast cancer cell line while it was not seen in normal cells.\nIn this study, we investigated whether the combination of hyperthermia and ALA can", "dois": ["10.3390/antiox10101531", "10.1111/jcpt.13084"]}
{"pair_type": "slc_pathway", "key1": "SLC15A3", "key2": "ferroptosis", "summary": "Piezo1 activation aggravated OGD-induced macrophage ferroptosis via Ca influx followed by SLC15A3 upregulation.\nConversely, Piezo1 deficiency in MoMs decreases ferroptosis and increases efferocytosis.\nIn vitro, Piezo1 activation by Yoda1 increased oxygen-glucose deprivation (OGD)-induced ferroptosis and impaired MoM efferocytosis.\nPiezo1 upregulated SLC7A11 in macrophages via a Ca/ATF4-dependent pathway.\nSLC7A11 is shown to mediate Piezo1-induced defective efferocytosis in MoMs.\nMoM-specific SLC7A11 knockdown significantly increases efferocytosis, reduces cardiomyocyte apoptosis and inflammation, and ameliorates post-MI left ventricular remodeling and function.", "dois": ["10.1002/advs.202510991"]}
{"pair_type": "slc_pathway", "key1": "SLC15A3", "key2": "glycolysis", "summary": "Associations were observed for SNP c.658A>G with carnosine content, color b* and L*, drip and cooking losses, pH24h and glycolytic potential values (P≤0.05).", "dois": ["10.1016/j.meatsci.2017.07.019"]}
{"pair_type": "slc_pathway", "key1": "SLC15A3", "key2": "apoptosis", "summary": "Piezo1 activation aggravated OGD-induced macrophage ferroptosis via Ca influx followed by SLC15A3 upregulation.\nIn this study, we examined the influence of NOD2 in human acute myeloid leukemia (AML) cells, demonstrating that IFN-γ treatment upregulated the expression of NOD2 signaling pathway members SLC15A3 and SLC15A4, downstream signaling kinase RIPK2, and the NOD2 receptor itself.\nActivation of these receptors has been shown to induce inflammatory anticancer events, including differentiation and apoptosis, across a wide variety of malignancies.\nThis priming allowed for effective induction of caspase-1-dependent cell death upon treatment with muramyl tripeptide phosphatidylethanolamine (MTP-PE), a synthetic ligand for NOD2.\nStudies have shown that more than half of the human genome expression is affected by circadian rhythms, which includes genes involved in cell cycle control, DNA repair and apoptosis that are critical in cancer biology.\nMoM-specific SLC7A11 knockdown significantly increases efferocytosis, reduces cardiomyocyte apoptosis and inflammation, and ameliorates post-MI left ventricular remodeling and function.\nMyeloid cell-specific Piezo1-deficient mice (Piezo1) exhibit significant improvements in ventricular function/remodeling after MI, accompanied by decreased apoptotic cardiomyocytes and decreased inflammation, increased numbers of macrophages, and increased border zone efferocytosis.", "dois": ["10.4049/jimmunol.1900885", "10.1002/advs.202510991", "10.3389/fonc.2025.1422122"]}
{"pair_type": "slc_pathway", "key1": "SLC15A1", "key2": "oxidative stress", "summary": "Several unique genes that are not specifically related to vascular damage increased to a much greater extent after AMPH compared to EIH in the MAV (Lbp, Reg3a, Reg3b, Slc15a1, Sct and Fst) and choroid plexus (Bmp4, Dio2 and Lbp).\nThe majority of the differentially expressed genes (DEGs) were enriched in biological pathways related to osmoregulation, metabolism and energy production, and oxidative stress.\nThe key DEGs related to the oxidative stress response were UGT, NDUFB1, QCR7, QCR8, P5CDh, COX6B, and CES1.\nIt is transported by PEPT1 and PEPT2, facilitating its protective effects against oxidative stress in neurons and intestinal epithelial cells.\nThere was a correlation between the genes related to reactive oxidative stress and damage that were significantly altered in the MAV and choroid plexus after either EIH or AMPH.\nThe metabolism-related DEGs were divided into three main categories: carbohydrate and energy metabolism (i.e., G6PC, UGT), protein and amino acid metabolism (i.e., SLC15A1, AhcY, GFAT), and lipid and fatty acid metabolism (i.e., GPAT3_4, CYP2J).\nFor example, Carnosine (beta-alanyl-L-histidine) has been demonstrated to act as an antioxidant, antiglycating agent, and neuroprotector.", "dois": ["10.1186/s13104-015-1500-6", "10.1007/s00232-025-00348-1", "10.1016/j.ygcen.2022.114120", "10.1186/1471-2164-14-147"]}
{"pair_type": "slc_pathway", "key1": "SLC13A5", "key2": "migration", "summary": "Extracellular sodium citrate significantly reduced cell viability partially due to reduction in intracellular Ca levels and decreased the migration of human PDAC cells.\nRecently, the uptake of extracellular citrate by the sodium-dependent citrate transporter (NaCT), encoded by , has been demonstrated to exert profound effects on cancer cell metabolism.\nThis approach holds promise for disrupting PDAC cell metabolism and inhibiting tumor progression.\nNotably, the combination treatment of gemcitabine and extracellular sodium citrate exhibited a synergistic anticancer effect in both two-dimensional (2D) and three-dimensional (3D) culture systems.\nFurthermore, we observed a decrease in the levels of the stem cell marker prominin I (CD133) following sodium citrate treatment.\nWe observed a positive correlation between glucose concentration and NaCT expression in PDAC cell lines.", "dois": ["10.1016/j.heliyon.2024.e37917"]}
{"pair_type": "slc_pathway", "key1": "SLC15A3", "key2": "migration", "summary": "The decrease in FES by hypermethylation was associated with OS prognosis, and might contribute to the proliferation, migration, and invasion of OS cells.\nThe proliferation, cell cycle progression, migration, and invasion of MNNG/HOS cells were significantly inhibited after transfection with FES overexpression plasmid, and the protein expression of FYN and β catenin were decreased in MNNG/HOS cells by FES overexpression.\nFollowing validation of the risk model, FES, LYL1, MAP4K1, RIPK3, SLC15A3, and STAT3 showed expression changes between the OS and control samples.", "dois": ["10.1186/s12935-020-01181-3"]}
{"pair_type": "slc_pathway", "key1": "SLC15A3", "key2": "chemotherapy", "summary": "The ten-gene signature included: CKB (Creatine kinase B), CTNNBL1 (Catenin, beta like 1), GNG11 (G protein subunit gamma 11), IGFBP7 (Insulin-like growth factor-binding protein 7), PLCG2 (Phospholipase C, gamma 2), RNF24 (Ring finger protein 24), SLC15A3 (Solute carrier family 15 member 3), TSPAN31 (Tetraspanin 31), TTI1 (TELO2 interacting protein 1) and UQCC1 (Ubiquinol-cytochrome c reductase complex assembly factor).\nRNA-seq identified a 42-gene panel discriminating sensitive and resistant BRCAwt HGSOC patients and pathway analysis pointed to the immune system as a possible driver of chemotherapy response.\nTo identify a gene signature that can predict response to first-line chemotherapy, pre-treatment tumor biopsies from a restricted cohort of BRCAwt HGSOC patients were profiled by RNA sequencing (RNA-Seq) technology.\nFrom the extended cohort analysis of the 42 DEGs (differentially expressed genes), a statistical approach combined with the random forest classifier model generated a ten-gene signature predictive of response to first-line chemotherapy.\nUsing machine-learning techniques we have identified a gene signature that could predict response to first-line chemotherapy in BRCAwt HGSOC patients, providing a useful tool towards personalized treatment modalities.\nIdentification of biomarkers helpful in predicting response to first-line chemotherapy is a challenge to improve BRCAwt HGSOC management.\nHigh-grade serous ovarian cancer (HGSOC) has poor survival rates due to a combination of diagnosis at advanced stage and disease recurrence as a result of chemotherapy resistance.\nCytotoxicity assays, combined with gene-expression analysis in primary HGSOC cell lines, allowed to define CTNNBL1, RNF24, and TTI1 as cell-autonomous contributors to tumor resistance.\nIn BRCA1 (Breast Cancer gene 1) - or BRCA2-", "dois": ["10.3390/cells12141919", "10.1186/s13046-022-02265-w"]}
{"pair_type": "slc_pathway", "key1": "SLC15A3", "key2": "oxidative stress", "summary": "Overall, our data provided a novel mechanism for targeting SLC15A3 to regulate oxidative stress in macrophages, supporting the therapeutic potential of inhibiting or silencing SLC15A3 for the precautions and treatment of pulmonary fibrosis.\nMechanistically, deficiency of SLC15A3 resisted oxidative stress in macrophages, and SLC15A3 interacted with the scaffold protein p62 to regulate its expression and phosphorylation activation, thereby regulating p62-nuclear factor erythroid 2-related factor 2 (NRF2) antioxidant stress pathway protein, which is related to the production of reactive oxygen species (ROS).\nIn this study, we demonstrated that during bleomycin (BLM)- or radiation-induced pulmonary fibrosis, the recruitment of macrophages induced an increase of SLC15A3 in the lung, and the deficiency of SLC15A3 protected mice from pulmonary fibrosis and maintained the homeostasis of the pulmonary microenvironment.\nOxidative stress in AMs plays an indispensable role in promoting fibrosis development.\nIt is transported by PEPT1 and PEPT2, facilitating its protective effects against oxidative stress in neurons and intestinal epithelial cells.", "dois": ["10.1038/s41418-024-01266-w", "10.1007/s00232-025-00348-1"]}
{"pair_type": "slc_pathway", "key1": "SLC15A4", "key2": "migration", "summary": "In our study, we discovered that TASL deficiency hinders the proliferation and migration of keratinocytes by inducing G1/S cell cycle arrest.", "dois": ["10.1038/s41598-024-61674-3"]}
{"pair_type": "slc_pathway", "key1": "SLC15A4", "key2": "apoptosis", "summary": "In this study, we examined the influence of NOD2 in human acute myeloid leukemia (AML) cells, demonstrating that IFN-γ treatment upregulated the expression of NOD2 signaling pathway members SLC15A3 and SLC15A4, downstream signaling kinase RIPK2, and the NOD2 receptor itself.\nActivation of these receptors has been shown to induce inflammatory anticancer events, including differentiation and apoptosis, across a wide variety of malignancies.\nThis priming allowed for effective induction of caspase-1-dependent cell death upon treatment with muramyl tripeptide phosphatidylethanolamine (MTP-PE), a synthetic ligand for NOD2.\nInhibition of STAT3 alleviates LPS-stimulated apoptosis and inflammatory response in HK2 cells through transcriptional regulation of TASL.\nThe expression of STAT3, TASL and inflammatory cytokines was elevated, and the change of apoptosis was up-regulated in LPS-stimulated HK2 cells.\nTranscription factor STAT3 can directly and positively regulate the expression of TASL through the promoter region binding site.\nThe expression level of TASL in LPS-stimulated HK2 cells and its effect on cell apoptosis and inflammatory factors were observed by knocking down and overexpressing STAT3, respectively.\nNOD2 is a member of the NOD-like receptor family that initiates inflammatory signaling in response to the bacterial motif muramyl dipeptide.\nToll-like receptor (TLR) adaptor interacting with SLC15A4 on the lysosome (TASL) acts as an innate immune adaptor for TLR and is implicated in the pathogenesis of SLE.", "dois": ["10.1186/s40001-023-01610-9", "10.4049/jimmunol.1900885"]}
{"pair_type": "slc_pathway", "key1": "SLC15A4", "key2": "oxidative stress", "summary": "Also, CAR exposure upregulated CAR biosynthesis ( Carns1), extracellular degradation ( Cndp1), and transport ( Slc15a4, alias Pht1) genes and elicited CAR intracellular accumulation, contributing to the outline of functional association between CAR and Cu within the cell.\nIn CNS, Cu excess and dysregulation imply oxidative stress, free-radical production, and functional impairment leading to neurodegeneration.\nSpecifically, in a murine neuron-derived cell model, i.e., the B104 neuroblastoma cells, extracellular CAR exposure up to 24 h influenced intracellular Cu entry and affected (downregulated) the key Cu-sensing system, consisting of the gene coding for the Slc31a1 transmembrane Cu importer (alias Ctr1), and the gene coding for the Cu-responsive transcription factor Sp1 ( Sp1).", "dois": ["10.1152/ajpcell.00106.2018"]}
{"pair_type": "slc_pathway", "key1": "SLC15A4", "key2": "proliferation", "summary": "SLC15A4 was associated with cell proliferation and invasion.\nIn our study, we discovered that TASL deficiency hinders the proliferation and migration of keratinocytes by inducing G1/S cell cycle arrest.\nThese findings unveil a novel role of TASL in the proliferation and differentiation of keratinocytes, providing new insights into the intricate regulatory mechanisms of keratinocyte biology.\nAbstract: Maintaining epidermal homeostasis relies on a tightly organized process of proliferation and differentiation of keratinocytes.\nTLR adaptor interacting with SLC15A4 on the lysosome (TASL) plays a role in regulating pH within the endo-lysosome.\nAlso, TASL deficiency disrupts proper differentiation process in TASL knockout human keratinocyte cell line (HaCaT) by affecting lysosomal function.\nAdditionally, our research into calcium-induced differentiation showed that TASL deficiency affects calcium modulation, which is essential for keratinocyte regulation.", "dois": ["10.1016/j.ygeno.2024.110877", "10.1038/s41598-024-61674-3"]}
{"pair_type": "slc_pathway", "key1": "SLC16A1", "key2": "ferroptosis", "summary": "Finally, through inhibiting SLC7A11 expression, silencing SLC16A1-AS1 induced ferroptosis via increasing miR-143-3p.\nThe present results suggest that silencing lncRNA SLC16A1-AS1 can induce ferroptosis through miR-143-3p/SLC7A11 signaling in renal cancer.\nIn addition, through the construction of stable SLC16A1 knockdown and overexpression models in HNSCC cells along with and experiments, the study comprehensively illuminated the pivotal role of SLC16A1 in promoting the proliferation, migration, and invasiveness of HNSCC cells, as well as enhancing their resistance to ferroptosis.\nOur research findings indicate that SLC16A1 acts as an oncogene in HNSCC, and that abnormally high expression of SLC16A1 significantly accelerates the development and progression of HNSCC by conferring resistance to ferroptosis.\nexperimental results demonstrated that when SLC16A1 was knocked down, the proliferation, migration, and invasion capabilities of HNSCC cell lines were significantly reduced and the extent of RAS-selective lethal 3-induced lipid peroxidation increased compared with control cells.\nKnockdown SLC16A1-AS1 inhibited cell viability, proliferation, and migration of renal cancer cells.\nexperiments further corroborated the pivotal role of SLC16A1 in promoting HNSCC tumor growth.\nFurthermore, it was demonstrated that SLC16A1-AS1 served as a sponge of miR-143-3p, and knockdown SLC16A1-AS1 significantly increased the enrichment of miR-143-3p.\nConversely, HNSCC cell lines overexpressing SLC16A1 exhibited enhanced proliferation, migration, and invasion capabilities, accompanied by lower levels of lipid peroxidation.\nMoreover, knockdown SLC16A1-AS1 could aggravate this effect.\nAnd then, SLC7A11 was identified as the target protein of miR-143-3p, and overexpression miR-143-3p remarkably inhibited the expression of SLC7A", "dois": ["10.1177/15330338221077803", "10.3389/fgene.2025.1595456", "10.7150/jca.110217", "10.21037/tp-24-323", "10.1186/s12935-024-03486-z"]}
{"pair_type": "slc_pathway", "key1": "SLC16A1", "key2": "stemness", "summary": "Thus, the differential expression of TMPRSS11B adds to metabolic heterogeneity in PDAC and its absence supports the reverse Warburg metabolism in PDAC cells by the enhancement of BSG-supported lactate uptake through SLC16A1 and subsequent phenotype alterations towards greater stemness.\nShRNA-mediated TMPRSS11B knock-down in Panc1 and BxPc3 cells enhanced lactate import through SLC16A1, as shown by GFP/iLACCO1 lactate uptake assay, whereas TMPRSS1B overexpression in T3M4 dampened SLC16A1-driven lactate uptake.\nMoreover, knock-down and overexpression of TMPRSS11B differentially impacted proliferation and chemoresistance under reverse Warburg conditions in Panc1 or BxPc3 and T3M4 cells, respectively, as well as their stemness properties indicated by altered colony formation rates and expression of the stem cell markers Nanog, Sox2, KLF4 and Oct4.\nThose regions exhibiting low or no TMPRSS11B expression but concomitant high expression of SLC16A1 and BSG revealed greater amounts of KLF4.\nIn contrast, other tumor areas exhibiting high expression of TMPRSS11B together with BSG and SLC16A1 were largely negative for KLF4 expression.\nSystematic bioinformatics analysis revealed that SLC16A1-AS1 was associated with histological tumor grades and overall survival status, as well as copy number variation, somatic mutation, tumor mutation burden, tumor stemness, tumor microenvironment and infiltrating immune cells.\nEmploying functional assays that are known to evaluate stemness, we demonstrate that elevated HMOX1 expression is associated with stemness in GBM and can be modulated through TGFβ.\nThese findings indicate that HMOX1 is a robust predictor of GBM CSC stemness and pathogenesis.\nFurthermore, circSIPA1L3 increased mRNA stability of the lactate export carrier SLC16A1 and the glucose intake enhancer RAB11A through either strengthening their interaction", "dois": ["10.3390/ijms26115398", "10.1186/s12943-024-02037-4", "10.1080/15384101.2020.1762048", "10.1002/stem.2411"]}
{"pair_type": "slc_pathway", "key1": "SLC16A2", "key2": "apoptosis", "summary": "DITPA treatment limits OL apoptosis mediated by SLC16A2 down-regulation primarily signaling through AKT phosphorylation, driving myelination.\nPharmacological and genetic blockade of MCT8 induces significant OL apoptosis, impairing myelination.\nCell membrane thyroid hormone (TH) transport can be facilitated by the monocarboxylate transporter 8 (MCT8), encoded by the solute carrier family 16 member 2 (SLC16A2) gene.\nHuman mutations of the gene, SLC16A2, result in the X-linked-inherited psychomotor retardation and hypomyelination disorder, Allan-Herndon-Dudley syndrome (AHDS).\nWe posited that abrogating MCT8-dependent TH transport limits oligodendrogenesis and myelination.\nWe show that human oligodendrocytes (OL), derived from the NKX2.1-GFP human embryonic stem cell (hESC) reporter line, express MCT8.\nMoreover, treatment of these cultures with DITPA (an MCT8-independent TH analog), up-regulates OL differentiation transcription factors and myelin gene expression.\nOur results highlight the potential role of MCT8 in TH transport for human OL development and may implicate DITPA as a promising treatment for developmentally-regulated myelination in AHDS.\nDITPA promotes hESC-derived OL myelination of retinal ganglion axons in co-culture.", "dois": ["10.1155/2021/1498924", "10.1016/j.ebiom.2017.10.016"]}
{"pair_type": "slc_pathway", "key1": "SLC16A1", "key2": "chemotherapy", "summary": "Our results suggest that crosstalk via direct cell-to-cell transfer of cellular components foster chemotherapy-induced tumor evolution and that targeting of CD44 and MCT1(encoded by SLC16A1) may be useful strategy to prevent recurrence of gemcitabine-exposed pancreatic cancers.\nKnocking down SLC16A1 inhibited the growth of CCA cells and enhanced their sensitivity to 5-Fluorouracil (5-FU).\nOverall, this study reveals the key role of SLC16A1 in the development of CCA and highlights its significance as a potential target for improving treatment efficacy and chemotherapy sensitivity.\nFinally, through further and experiments, we confirmed that SLC16A1, as an oncogene in CCA, promotes the growth of CCA cells and chemoresistance.\nPancreatic cancer exhibits a characteristic tumor microenvironment (TME) due to enhanced fibrosis and hypoxia and is particularly resistant to conventional chemotherapy.\nLow toxic Taxol treatments promoted cellular glucose metabolism and intracellular lactate accumulation with upregulated lactate dehydrogenase-A (LDHA) and MCT1 expressions.\nFinally, rescue experiments showed restoration of MCT1 in miR-124 overexpressing cells promoted Taxol resistance.\nImportantly, based on in vitro and in vivo results, inhibition of MCT1 significantly sensitized Taxol resistant cells.\nMoreover, co-treatment of breast cancer cells with either MCT1 inhibitor or miR-124 plus Taxol led to synergistically cytotoxic effects.\nMoreover, results from functional and pathway enrichment analyses revealed that SLC16A1 might affect clinical outcomes in CCA patients by participating in drug metabolism processes.\nTheir potential as pharmacological targets has been recognised with the discovery of potent and specific MCT1 inhibitors that act as immunosuppressant drugs by preventing proliferation of T-lymphocytes.\nIt highlights the potential for the use of ICIs and chemotherapy.\nSubgroup C2 patients showed superior outcomes and a robust response to immunotherapy and chemotherapy.\nIt is suggested that the development of other drugs specifically targeting different MCT isoforms may provide a novel approach to cancer chemotherapy.", "dois": ["10.3389/fonc.2025.1519473", "10.1186/s12935-024-03486-z", "10.7150/jca.95258", "10.1038/s41525-022-00333-w", "10.1186/s12935-019-0904-0", "10.1002/stem.2411", "10.1016/j.mam.2012.05.003"]}
{"pair_type": "slc_pathway", "key1": "SLC16A2", "key2": "chemotherapy", "summary": "It is suggested that the development of other drugs specifically targeting different MCT isoforms may provide a novel approach to cancer chemotherapy.", "dois": ["10.1016/j.mam.2012.05.003"]}
{"pair_type": "slc_pathway", "key1": "SLC16A2", "key2": "glycolysis", "summary": "HPV-positive carcinomas exhibited lower expression levels of genes involved in glycolysis and higher levels of genes involved in the tricarboxylic acid cycle, oxidative phosphorylation, and β-oxidation than the HPV-negative carcinomas.", "dois": ["10.1097/MD.0000000000035923", "10.3390/cancers12010253"]}
{"pair_type": "slc_pathway", "key1": "SLC16A2", "key2": "oxidative phosphorylation", "summary": "CLP mice presented reduced total plasma T4 concentrations, downregulated , and upregulated mRNA expression in the liver.\nThe expression of (encoding PGC1a) was downregulated, which correlated with the decrease in the number of total mitochondria, increase in the percentage of injured mitochondria, downregulation of respiratory chain complex 2 and 3 mRNA expression, and reduced maximal respiration.\nThis iTRAQ proteomics study revealed that the hepatotoxicity induced by PM is primarily related to the oxidative phosphorylation pathways.\nCLP mice also displayed downregulated , and expression in the diaphragm, suggesting that TH signaling was compromised.\nThe iTRAQ proteomics study showed that hepatotoxicity resulting from PM was mainly related to the abnormal activity of mitochondrion function-related oxidative phosphorylation pathways.\nNADH dehydrogenase family proteins and Slc16a2 could be potential biomarkers of hepatotoxicity resulting from PM.\nHPV-positive carcinomas exhibited lower expression levels of genes involved in glycolysis and higher levels of genes involved in the tricarboxylic acid cycle, oxidative phosphorylation, and β-oxidation than the HPV-negative carcinomas.\nThus, impaired diaphragm function during sepsis seems to involve altered local TH signaling, mitochondrial dysfunction, and oxidative stress defense.\nTH metabolism and responses were analyzed by measuring messenger RNA (mRNA) expression of in the liver, and , , 2, , and (encodes MCT 10 and 8), in the diaphragm.", "dois": ["10.1089/thy.2019.0124", "10.3390/cancers12010253", "10.1159/000484229"]}
{"pair_type": "slc_pathway", "key1": "SLC16A2", "key2": "oxidative stress", "summary": "CLP mice presented reduced total plasma T4 concentrations, downregulated , and upregulated mRNA expression in the liver.\nThe expression of (encoding PGC1a) was downregulated, which correlated with the decrease in the number of total mitochondria, increase in the percentage of injured mitochondria, downregulation of respiratory chain complex 2 and 3 mRNA expression, and reduced maximal respiration.\nand upregulated expression, potentially due to elevated reactive oxygen species levels.\nCLP mice also displayed downregulated , and expression in the diaphragm, suggesting that TH signaling was compromised.\nThus, impaired diaphragm function during sepsis seems to involve altered local TH signaling, mitochondrial dysfunction, and oxidative stress defense.\nSepsis induced responses consistent with NTIS, resulted in mitochondrial damage and functional impairment, and modulated the expression of key antioxidant enzymes in the diaphragm.", "dois": ["10.1089/thy.2019.0124"]}
{"pair_type": "slc_pathway", "key1": "SLC16A3", "key2": "oxidative phosphorylation", "summary": "TNFα alone reduced the expression of monocarboxylate transporters slc16a1 and slc16a3, suggesting effects of TNFα on butyrate uptake into colonocytes.\nMaintenance of the proteasome requires oxidative phosphorylation (ATP) and mitigation of oxidative damage, in an increasingly dysfunctional relationship with aging.\nDuplications of the bidirectional α-ketoacid transporters SLC16A3, SLC16A7, the cystine transporters SLC7A9, SLC7A11, and N-glycan branching enzymes MGAT4B, MGAT4C in Neoaves suggests a shift to the transport of deaminated essential amino acid, and stronger mitigation of oxidative stress supported by the galectin lattice.\nWe measured ATP levels, cell viability, mitochondrial membrane potential (MMP), reactive oxygen species (ROS), mitochondrial oxidative phosphorylation, and glycolytic activity in colonocytes following exposure to either butyrate or TNFα, or both.\nAdditional gene purging included mitochondrial BCAA aminotransferase (BCAT2), pointing to reduced oxidation of BCAA and increased hepatic conversion to triglycerides and glucose.\nEndurance in mammalian muscle depends in part on oxidation of BCAA\nWe found that both butyrate and TNFα lowered cellular ATP levels towards a quiescent cell energy phenotype, characterized by decreased oxygen consumption and extracellular acidification.\nThe relative expression levels of pyruvate dehydrogenase kinase 4 () were increased via co-treatment of butyrate and TNFα, suggesting the synergistic inhibition of glycolysis.", "dois": ["10.1016/j.jbc.2023.105409", "10.3390/biom13020258"]}
{"pair_type": "slc_pathway", "key1": "SLC16A3", "key2": "stemness", "summary": "Thus, the differential expression of TMPRSS11B adds to metabolic heterogeneity in PDAC and its absence supports the reverse Warburg metabolism in PDAC cells by the enhancement of BSG-supported lactate uptake through SLC16A1 and subsequent phenotype alterations towards greater stemness.\nMoreover, knock-down and overexpression of TMPRSS11B differentially impacted proliferation and chemoresistance under reverse Warburg conditions in Panc1 or BxPc3 and T3M4 cells, respectively, as well as their stemness properties indicated by altered colony formation rates and expression of the stem cell markers Nanog, Sox2, KLF4 and Oct4.\nThose regions exhibiting low or no TMPRSS11B expression but concomitant high expression of SLC16A1 and BSG revealed greater amounts of KLF4.", "dois": ["10.3390/ijms26115398"]}
{"pair_type": "slc_pathway", "key1": "SLC16A4", "key2": "migration", "summary": "the down-regulated genes were thought to be associated with cell migration (SLC16A4).\nEndothelial cell proliferation and migration increased and apoptosis decreased with a decrease in SLC25A29 expression.\nFurther analysis revealed that SLC25A29 was underexpressed in LUAD tissue and regulated the phenotype of endothelial cells.\nIn conclusion, this study confirmed the role of SLC family genes in LUAD prognosis and revealed the role of SLC25A29 in regulating endothelial cell phenotypes.\nNotably, SLC2A1, SLC25A29, and SLC27A4 were identified as key genes associated with survival and tumor stage.\nGiven the crucial role of the solute carrier (SLC) family in maintaining cellular energy metabolism stability, we conducted a comprehensive analysis of the association between SLC genes and LUAD prognosis.", "dois": ["10.1186/s12935-023-03082-7", "10.5051/jpis.2011.41.1.30"]}
{"pair_type": "slc_pathway", "key1": "SLC16A5", "key2": "oxidative phosphorylation", "summary": "The co-expressed DE lncRNA and mRNA were primarily enriched in GO terms such as Metabolic process, Intracellular organelle, Catalytic activity, and Oxidoreductase activity, as well as in KEGG pathways such as Ribosome and Oxidative phosphorylation.\nOverlap of co-expression and co-localization analysis, i.e., lncRNA-mRNA matches \"XR_523541.1-solute carrier family 16, member 5 ()\" and \"LNC_000285-bromodomain adjacent to zinc finger domain 2A (),\" were observed in all inter-group comparisons, indicating that they might crucially mediate the effects of dietary DHA and EPA on hepatic gene expression in tongue sole.", "dois": ["10.3389/fphys.2019.00331"]}
{"pair_type": "slc_pathway", "key1": "SLC16A4", "key2": "oxidative phosphorylation", "summary": "Both ALDOB-knockdown and SLC16A4-knockdown CRC cell lines showed increased basal motichondrial OxPhos and decreased basal glycolysis.\nMoreover, the increase of mitochondrial ATP-linked respiration and the decrease of glycolytic capacity were showed in SLC16A4-knockdown cells.\nFinally, APs/CRCs with enhanced glycolysis had increased SLC16A4 expression.\nTwo metabolic genes ALDOB and SLC16A4 were up-regulated in APs.\nFinally, the ALDOB and SLC16A4 may contribute to the glycolytic shift in APs/CRCs.\nOxygen consumption rate (OCR) was measured representing mitochondrial oxidative phosphorylation (OxPhos), and extracellular acidification rate (ECAR)was measured representing glycolysis.\nATP production shifts from OxPhos to glycolysis in the process of AP enlargement and villous transformation.", "dois": ["10.1016/j.ebiom.2019.05.031"]}
{"pair_type": "slc_pathway", "key1": "SLC16A4", "key2": "glycolysis", "summary": "Both ALDOB-knockdown and SLC16A4-knockdown CRC cell lines showed increased basal motichondrial OxPhos and decreased basal glycolysis.\nFinally, APs/CRCs with enhanced glycolysis had increased SLC16A4 expression.\nMoreover, the increase of mitochondrial ATP-linked respiration and the decrease of glycolytic capacity were showed in SLC16A4-knockdown cells.\nKnockdown or pharmacologic inhibition of CA9 in PDAC cells significantly reduced pHi in cells under hypoxic conditions, decreased gemcitabine-induced glycolysis, and increased their sensitivity to gemcitabine.\nUnder hypoxic conditions, PDAC cells had increased levels of HIF1A and HIF2A, upregulated expression of CA9, and activated glycolysis.\nIn response to hypoxia, PDAC cells that express activated KRAS increase expression of CA9, via stabilization of HIF1A and HIF2A, to regulate pH and glycolysis.\nKnockdown of KRAS in PDAC cells, or incubation with trametinib, reduced the posttranscriptional stabilization of HIF1A and HIF2A, upregulation of CA9, pHi, and glycolysis in response to hypoxia.\nIdentified genes were knocked down in WiDr and colo205 CRC cell lines, and their expression was analyzed in APs/CRCs with enhanced glycolysis.\nTwo metabolic genes ALDOB and SLC16A4 were up-regulated in APs.\nOCR/ECAR ratio was decreased in APs over 1 cm, APs with a villous component and CRCs, indicating their glycolytic tendencies.\nIn larger studies, subgroups of glioblastomas may emerge according to oncogene-related effects on glycolysis, such as control of pH via effects on carbonic anhydrases, with prognostic and treatment implications.\nFinally, the ALDOB and SLC16A4 may contribute to the glycol", "dois": ["10.1007/s00125-024-06185-6", "10.1053/j.gastro.2019.05.004", "10.1016/j.ebiom.2019.05.031", "10.1016/j.bbacli.2015.11.001"]}
{"pair_type": "slc_pathway", "key1": "SLC16A5", "key2": "chemotherapy", "summary": "Given that previous studies have shown that cimetidine, an SLC16A5-inhibitor, prevents murine cisplatin-induced ototoxic effects, the findings from this study have important implications for otoprotectant strategies in humans.\nThis study has identified a novel association between protein-coding variation in SLC16A5 and cisplatin-induced ototoxic effects.\nFunctional validation of this transporter gene revealed that in vitro SLC16A5-silencing altered cellular responses to cisplatin treatment, supporting a role for SLC16A5 in the development of cisplatin-induced ototoxic effects.\nAssociation and fine-mapping analyses identified a protein-coding variant, rs4788863 in SLC16A5, that was associated with protection against cisplatin-induced ototoxic effects in 2 independent cohorts (combined cohort: odds ratio, 0.06; 95% CI, 0.02-0.22; P = 2.17 × 10-7).\nThese results were further supported by the literature, which provided confirmatory evidence for the role that SLC16A5 plays in hearing.\nFourteen variants in eleven candidate genes (ABCC3, OTOS, TPMT, SLC22A2, NFE2L2, SLC16A5, LRP2, GSTP1, SOD2, WFS1 and ACYP2) were investigated.\nMale patients who were 17 years or older, diagnosed with germ cell testicular cancer, and previously treated with cisplatin-based chemotherapy were recruited from July 2009 to April 2013 using active surveillance methodology.\nThese findings have provided insight into the molecular mechanisms of this adverse drug reaction in adult patients with germ cell testicular cancer.\nAbstract: Cisplatin-induced ototoxic effects are an important complication that affects testicular cancer survivors as a consequence of treatment.\nThe identification of genetic variants associated with this adverse drug reaction will further our mechanistic understanding of its development and potentially lead to strategies to prevent ototoxic effects.", "dois": ["10.1016/j.ejca.2020.07.019", "10.1001/jamaoncol.2017.0502"]}
{"pair_type": "slc_pathway", "key1": "SLC16A2", "key2": "proliferation", "summary": "Both mice with a global deletion or an adult neural stem cell-specific deletion of MCT8 showed decreased expression of the cell-cycle inhibitor P27KIP1, reduced differentiation of neuroblasts, and impaired generation of new granule cell neurons, with global knockout mice also showing enhanced neuroblast proliferation.\nFunctional experiments demonstrated that knockdown of PGK1 or PCMT1 inhibited tumor cell proliferation and reduced the phosphorylation levels of mTORC, P70S6K, S6, and AKT, indicating suppression of the PI3K/AKT/mTOR pathways.\nTheir potential as pharmacological targets has been recognised with the discovery of potent and specific MCT1 inhibitors that act as immunosuppressant drugs by preventing proliferation of T-lymphocytes.\nSLC16 family members are involved in a wide range of metabolic pathways including energy metabolism of the brain, skeletal muscle, heart and tumour cells, gluconeogenesis, T-lymphocyte activation, bowel metabolism, spermatogenesis, pancreatic β-cell malfunction, thyroid hormone metabolism, and drug transport.\nTogether, our results reveal a cell-autonomous role for TH signaling in adult hippocampal neurogenesis alongside non-cell-autonomous effects on cell proliferation earlier in the lineage.\nThe MCTs comprise 14 members, and they play an important role in the growth, proliferation, and metabolism of cancer cells by transporting monocarboxylates such as lactate, pyruvate and thyroid hormones.\nMitochondrial ribosomal protein (MRPL) genes have been reported to participate in many cellular processes, such as cell proliferation, apoptosis, and cell cycle.\nTo answer this question, we used global and conditional knockouts of the TH transporter monocarboxylate transporter 8 (MCT8), having first used FACS and immunohistochemistry to demonstrate that MCT8 is the only TH transporter expressed on neuroblasts and adult slice cultures to confirm a necessary role for MCT8 in neurogenesis.\nAdult hippocampal neurogenesis is strongly dependent on thyroid hormone (TH).", "dois": ["10.1038/s41420-025-02422-y", "10.1523/JNEUROSCI.0002-22.2022", "10.1155/2021/1498924", "10.1007/s13258-021-01116-w", "10.1016/j.stemcr.2020.03.014", "PMID:27879339", "10.1016/j.mam.2012.05.003"]}
{"pair_type": "slc_pathway", "key1": "SLC16A7", "key2": "chemotherapy", "summary": "We further proved that one of the lactate metabolism related genes, SCL16A7 could promote the expression of PD-L1 in GC cells.\nIt is suggested that the development of other drugs specifically targeting different MCT isoforms may provide a novel approach to cancer chemotherapy.\nThe risk model not only provides a basis for better prognosis in GC patients, but also is a potential prognostic indicator to distinguish the molecular and immune characteristics, and the response from Immune checkpoint inhibitors (ICI) therapy and chemotherapy in GC.\nTo identify potential genetic alterations related with OS recurrence and chemotherapeutic resistance, the biopsies of a 20-year-old male osteosarcoma patient were collected at primary site (p-OS) and from its metastatic tumor (m-OS) formed after 5 months of adjuvant chemotherapy.\nNGS revealed 4 mutations (GPC3, SOX10, MDM4 and MAPK8) and 6 amplifications (MDM2, CDK4, CCND3, RUNX2, GLI1 and FRS2) in p-OS, and 3 mutations (GPC3, SOX10 and EGF) and 10 amplifications (CDK4, CCND3, MDM2, RUNX2, GLI1, FRS2, CARD11, RAC1, SLC16A7 and PMS2) in m-OS.\nIdentification of novel genetic alteration(s) related with OS recurrence and chemotherapeutic resistance would be of scientific and clinical significance.\nThis study demonstrates increased abundance and up-regulated expression of mutant GPC3 in metastatic osteosarcoma and its spheroids with multidrug resistance.\nThe group with lower risk showed increased Tumor Immune Dysfunction and Exclusion (TIDE) score and greater responsiveness to immunotherapy.\nSLC16 family members are involved in a wide range of metabolic pathways including energy metabolism of the brain, skeletal muscle, heart and tumour cells, gluconeogenesis, T-lymphocyte activation, bowel metabolism, spermatogenesis, pancreatic β-cell malfunction, thyroid hormone metabolism, and drug transport.", "dois": ["10.3389/fonc.2024.1485580", "10.1016/j.jbo.2021.100391", "10.1016/j.mam.2012.05.003"]}
{"pair_type": "slc_pathway", "key1": "SLC16A4", "key2": "apoptosis", "summary": "Endothelial cell proliferation and migration increased and apoptosis decreased with a decrease in SLC25A29 expression.\nCompound led to cancer cell cycle arrest as well as apoptosis, and it showed to sensitize these cancer cells toward an antineoplastic agent.\nAlso, the up-regulated genes on day 14 by hPDL cells cultured in osteogenic medium were thought to be associated with apoptosis, angiogenesis (ANGPTL4 and FOXO1A), and adipogenesis (ANGPTL4 and SEC14L2), and the down-regulated genes were thought to be associated with cell migration (SLC16A4).", "dois": ["10.1186/s12935-023-03082-7", "10.1021/acs.jmedchem.2c01612", "10.5051/jpis.2011.41.1.30"]}
{"pair_type": "slc_pathway", "key1": "SLC16A7", "key2": "glycolysis", "summary": "Depletion of mitochondrial DNA in parental cells induced resistance to BEZ235 and other PI3K/mTOR inhibitors, and was accompanied by increased glycolysis.\nSubsequent experiments revealed that AQR clones possess features consistent with elevated glycolysis, including increased levels of glucose, lactate, glutamine, glucose dependence, GLUT1 expression, and rates of post-glucose extracellular acidification, and decreased levels of reactive oxygen species and rates of oxygen consumption.\nTranscriptome analysis revealed the AQR clones had increased expression of the metabolite transporters SLC16A9 and SLC16A7, suggestive of altered cell metabolism.\nCombination treatment of BEZ235 with the glycolysis inhibitor 3-bromopyruvate was synergistic in AQR clones, but only additive in parental cells.\nThe results of this study provide the first evidence that a metabolic switch associated with mtDNA mutation can be an underlying mechanism for AQR.", "dois": ["10.2147/OARRR.S541568", "10.18632/oncotarget.22655"]}
{"pair_type": "slc_pathway", "key1": "SLC16A1", "key2": "migration", "summary": "SLC16A1-AS1 suppressed miR-1269 maturation and promoted cell proliferation, migration, and invasion, and inhibited cell apoptosis, while miR-1269 displayed the opposite trend.\nexperimental results demonstrated that when SLC16A1 was knocked down, the proliferation, migration, and invasion capabilities of HNSCC cell lines were significantly reduced and the extent of RAS-selective lethal 3-induced lipid peroxidation increased compared with control cells.\nKnockdown SLC16A1-AS1 inhibited cell viability, proliferation, and migration of renal cancer cells.\nUpregulation of SLC16A1-AS1 suppressed BC cell viability, colony formation, invasion, and migration and growth sponging miR-552-5p to release WIF1.\nSLC16A1-mediated lactylation was analyzed by immunofluorescence, lactate production analysis, colony formation, transwell, and wound healing assays to investigate its role in promoting the proliferation and migration of PDAC cells.\nIn addition, through the construction of stable SLC16A1 knockdown and overexpression models in HNSCC cells along with and experiments, the study comprehensively illuminated the pivotal role of SLC16A1 in promoting the proliferation, migration, and invasiveness of HNSCC cells, as well as enhancing their resistance to ferroptosis.\nAdditionally, low SLC16A1 expression inhibited the proliferation, migration, and invasion of glioma cells.\nPFN2 overexpression or circ-SLC16A1 inhibition restored proliferation and migration of NSCLC cells after silencing of circ-SLC16A1.\nConversely, HNSCC cell lines overexpressing SLC16A1 exhibited enhanced proliferation, migration, and invasion capabilities, accompanied by lower levels of lipid peroxidation.\nFurthermore, SLC16A1-AS1 modulates a range of cellular functions, including proliferation, migration, and invasion, through its interactions with diverse molecules and signaling pathways.\nIn vitro experiments showed that overexpression of SLC16A1-AS1 promoted cell proliferation and invasion but suppressed cell apoptosis", "dois": ["10.1007/s12672-025-03297-2", "10.7150/jca.110217", "10.62347/ABOI7514", "10.1016/j.heliyon.2024.e36822", "10.3748/wjg.v30.i19.2575", "10.1186/s12885-024-12327-1", "10.1002/pros.24700", "10.1186/s12935-024-03285-6", "10.1186/s11658-024-00549-x", "10.1080/19336950.2023.2273008", "10.3389/fimmu.2023.1183825", "10.1002/jbt.23247", "10.1080/21655979.2022.2070581", "10.3389/fonc.2022.871798", "10.1002/mc.23415", "10.1002/jcla.24442", "10.3389/fonc.2022.712475", "10.1002/jcla.24344", "10.1177/15330338221077803", "10.1093/carcin/bgz153", "10.1371/journal.pbio.1002202"]}
{"pair_type": "slc_pathway", "key1": "SLC16A5", "key2": "migration", "summary": "SCUBE2 is a secreted glycoprotein known for its ability to suppress tumor growth, cell migration, and epithelial-mesenchymal transition (EMT) in several cancer types, including gliomas, breast, and colorectal cancers, mainly through its regulation of signaling pathways such as Hedgehog (Shh).\nSLC16A5 is a monocarboxylate transporter involved in metabolic reprogramming, and prior studies have linked its downregulation to immune infiltration and poor prognosis in PCa.\nFunctional enrichment analysis of the ten identified genes revealed strong involvement of these genes in cancer-related processes, including gap junction assembly, tight junction formation, efflux transporter activity, and pathways such as Hedgehog signaling, leukocyte transendothelial migration, and cell-cell adhesion.\nHub gene analysis further confirmed the central roles of identified genes such as CAV1, GJA1, AMACR, and CLDN8, which are well-documented in cancer progression, metastasis, or therapeutic resistance.", "dois": ["10.1007/s11517-025-03365-3"]}
{"pair_type": "slc_pathway", "key1": "SLC16A7", "key2": "apoptosis", "summary": "Endothelial cell proliferation and migration increased and apoptosis decreased with a decrease in SLC25A29 expression.\nIn addition, the relative abundance of genes involved in the ovulatory cascade (ADAM 17, AREG, EREG, PTGS2), steroidogenesis (CYP19A1, 3BHSD, STAR), cellular stress (SOD1, CAT, GPX1, HSPA5, XBP1s, XBP1u, ATF4, ATF6), monocarboxylic acid transporters (SLC16A1, SLC16A7) and apoptosis (XIAP) was similar between groups.", "dois": ["10.3390/genes15060812", "10.1186/s12935-023-03082-7", "10.1016/j.anireprosci.2022.107033"]}
{"pair_type": "slc_pathway", "key1": "SLC16A3", "key2": "ferroptosis", "summary": "Subsequently, the effects of SLC16A3 expression on cell proliferation and invasion were analyzed using hepatocellular carcinoma (HCC) lines, and Western blot (WB) analysis was performed to explore the changes in pathway proteins and ferroptosis proteins.\nMoreover, knockdown of SLC16A3 significantly increased the level of lipid peroxidation and reactive oxygen species (ROS), while the expressions of GPX4, DHODH and SLC7A11 were inhibited.\nTCGA data and WB analysis showed that the high expression of SLC16A3 induced hypoxia, and knockdown could reverse hypoxia and inhibit ERK phosphorylation, thus limiting the malignant behavior of HCC cells.\nKnockdown of SLC16A3 decreases extracellular lactate concentration in hepatocellular carcinoma, alleviates hypoxia and induces ferroptosis.", "dois": ["10.1016/j.bbrc.2024.150709"]}
{"pair_type": "slc_pathway", "key1": "SLC16A6", "key2": "apoptosis", "summary": "mRNA-seq of liver tissue shows the temporal changes of ketone bodies-related genes, β-hydroxybutyrate dehydrogenase (BDH1) and solute carrier family 16 (monocarboxylic acid transporters), member 6 (SLC16A6).\nAmazingly, liver-derived ketogenesis evidently alleviates neuron apoptosis and inflammatory microglia activation and improves the recovery of motor function of SCI mice.\nThe results show that overexpression of HMG-CoA synthase (Hmgcs2) in mice liver dramatically alleviates SCI-mediated pathological changes and promotes ketogenesis in the liver.\nIn conclusion, a liver-spinal cord axis can be bridged via ketone bodies, and enhancing the production of the ketone body within the liver has neuroprotective effects on traumatic SCI.\nThen, a cuproptosis-related gene signature (PGK1, SLC52A2, SEC14L2, RAD23B, SLC16A6, CCL5, and MAL2) and the scoring system were constructed to quantify the cuproptosis pattern of BRCA patients in the training cohort, and the testing cohorts validated them.\nCuproptosis is a newly discovered programmed cell death dependent on overload copper-induced mitochondrial respiration dysregulation.", "dois": ["10.3389/fimmu.2022.978909", "10.1002/adbi.202300481"]}
{"pair_type": "slc_pathway", "key1": "SLC16A6", "key2": "chemotherapy", "summary": "Specifically, patients from the low-CRG_score group were characterized by higher immune cell infiltration, immune checkpoint expression, immune checkpoint inhibitor (ICI) scores, and greater sensitivity to immunotherapy.\nQuantifying cuproptosis patterns and constructing a CRG_score could help explore the potential molecular mechanisms of cuproptosis regulating BRCA advancement and provide more effective immunotherapy and chemotherapy targets.\nThen, a cuproptosis-related gene signature (PGK1, SLC52A2, SEC14L2, RAD23B, SLC16A6, CCL5, and MAL2) and the scoring system were constructed to quantify the cuproptosis pattern of BRCA patients in the training cohort, and the testing cohorts validated them.\nFinally, we screened out RAD23B as a favorable target and indicated its expression was associated with breast cancer progression, drug resistance, and poor prognosis in BRCA patients by performing real-time RT-PCR, cell viability, and IC50 assay.", "dois": ["10.3389/fimmu.2022.978909"]}
{"pair_type": "slc_pathway", "key1": "SLC16A4", "key2": "proliferation", "summary": "Functional assays revealed that overexpression of SLC16A4 significantly inhibited lung cancer cell proliferation and induced cellular senescence, suggesting its potential role in lung cancer development.\nEndothelial cell proliferation and migration increased and apoptosis decreased with a decrease in SLC25A29 expression.\nAlso, the up-regulated genes on day 14 by hPDL cells cultured in osteogenic medium were thought to be associated with apoptosis, angiogenesis (ANGPTL4 and FOXO1A), and adipogenesis (ANGPTL4 and SEC14L2), and the down-regulated genes were thought to be associated with cell migration (SLC16A4).\nThe up-regulated genes on day 7 by hPDL cells cultured in osteogenic medium were thought to be associated with calcium/iron/metal ion binding or homeostasis (PDE1A, HFE and PCDH9) and cell viability (PCDH9), and the down-regulated genes were thought to be associated with proliferation (PHGDH and PSAT1).", "dois": ["10.3390/biom15081081", "10.1186/s12935-023-03082-7", "10.5051/jpis.2011.41.1.30"]}
{"pair_type": "slc_pathway", "key1": "SLC16A3", "key2": "apoptosis", "summary": "Our findings suggest that nodakenetin inhibits the viability, promotes apoptosis, and represses glycolysis in breast cancer cells through decreasing SLC16A3 expression, proving the anti-cancer potential of nodakenetin in breast cancer.\nThe study reveals that LINC00035 promotes OC progression by regulating glycolysis and cell apoptosis through CEBPB-mediated transcriptional promotion of SLC16A3.\nSLC16A3 upregulation reversed the effects of nodakenetin on the viability, apoptosis, and glycolysis in breast cancer cells.\nLINC00035 knockdown was shown to repress SKOV3 and A2780 cell viability, migration, invasion, induce their apoptosis, and reduce glucose uptake, lactate release, and ATP production.\nRescue experiments found SLC16A3 overexpression resisting to LINC00035 knockdown on SKOV3 and A2780 cell viability, migration, invasion, apoptosis, glucose uptake, lactate release, and ATP production.\nLoss of function assays for hsa_circ_0008621 in vitro led to a significant decrease in cell proliferation, migration, invasion, and glycolysis, but an increase in cell apoptosis.\nMCT4 silencing impaired secretion of lactate generated through glycolysis and induced cell cycle arrest and apoptosis.\nMoreover, the knockdown of FARSB significantly hindered cell viability, induced G1 phase arrest, increased apoptosis, and impaired migration in HepG2 and Huh7 cells.\nThe results showed that CTPPPPD could induce the apoptosis of A549 cells, and the apoptosis rate of A549 cells treated with 0, 1.0, 2.0, and 4.0 μM of CTPPPPD for 24 h was 0%, 4.9%, 12.7%, and 31.0%, respectively.\nLINC00035 could recruit CEBPB into the SLC16A3 promoter region, thus increasing the SLC16", "dois": ["10.3390/molecules29174275", "10.1002/path.4006", "10.1007/s00210-025-04585-y", "10.1016/j.bbrc.2024.150709", "10.1016/j.heliyon.2024.e32289", "10.1002/ags3.12793", "10.1186/s12935-023-03082-7", "10.1155/2023/9783125", "10.3390/biology11060839", "10.3390/cells11091443", "10.1155/2021/5802082", "10.1038/s41419-018-0761-0", "10.1371/journal.pone.0035276", "10.1007/s12026-012-8337-z", "10.1016/j.ygyno.2010.01.041", "PMID:16465392"]}
{"pair_type": "slc_pathway", "key1": "SLC16A6", "key2": "proliferation", "summary": "Finally, we found that MCT7 (SLC16a6) knockdown suppressed ketone body excretion.\nKetone bodies serve several functions in the intestinal epithelium, such as stem cell maintenance, cell proliferation and differentiation, and cancer growth.\nThese genes were primarily related to regulation of cell proliferation, the cytoskeleton, and cell differentiation.\nAryl hydrocarbon receptor (AhR) is a transcription factor that controls the expression of genes involved in the metabolism of xenobiotics, inflammation, cell proliferation, and death.\nExpression of Emd, a nuclear membrane protein, and Prtfdc1, which is involved in cancer cell proliferation, were altered significantly in CBP30+CPTH2 samples.\nOur findings indicate that the mTORC1-autophagy axis and MCT7 are potential targets to regulate ketone body excretion from the intestinal epithelium.\nWe revealed that a fasting-mimicked culture medium, which excluded glucose, pyruvate, and glutamine, augmented ketone body production and excretion in the Caco2 and HT29 colorectal cells.", "dois": ["10.3390/biology12121467", "10.1371/journal.pone.0273868", "10.1111/j.1530-0277.2012.01787.x", "PMID:21861841"]}
{"pair_type": "slc_pathway", "key1": "SLC16A7", "key2": "migration", "summary": "Transcriptome analysis revealed the AQR clones had increased expression of the metabolite transporters SLC16A9 and SLC16A7, suggestive of altered cell metabolism.\nIn addition, we revealed common genes in NAFLD and periodontitis, including IGK, IGLJ3, IGHM, MME, SELL, ENPP2, VCAN, LCP1, IGHD, FCGR2C, ALOX5AP, IGJ, MMP9, FABP4, IL32, HBB, FMO1, ALPK2, PLA2G7, MNDA, HLA-DRA, and SLC16A7.\nGO enrichment analysis with GlueGo indicated that damaged migration of dendritic cells (DCs) might be a common pathophysiologic feature of NAFLD and periodontitis.\nOur study initially established a comorbidity model to explain the underlying mechanism of NAFLD secondary to periodontitis, found that damaged migration of DCs might be a common pathophysiological feature of NAFLD and periodontitis, and provided potential therapeutic targets.\nMCT4 was positively correlated with gene families responsible for invasion, migration, and immune modification, proving it to be one of the most important MCTs for therapeutic intervention.\nThese AQR clones showed class-specific resistance to PI3K/mTOR inhibitors, reduced G1 cell cycle arrest and impedance of migration following PI3K/mTOR inhibition, reduced PTEN expression and increased Akt and S6RP phosphorylation.\nEndothelial cell proliferation and migration increased and apoptosis decreased with a decrease in SLC25A29 expression.", "dois": ["10.1080/19336950.2023.2273008", "10.1186/s12935-023-03082-7", "10.3389/fgene.2022.939751", "10.18632/oncotarget.22655"]}
{"pair_type": "slc_pathway", "key1": "SLC16A1", "key2": "proliferation", "summary": "In addition, SLC16A1-AS1 may downregulate miR-141 through methylation to promote cancer cell proliferation.\nRemarkably, PDIA6 and SLC16A1 were observed to inhibit the proliferation of pancreatic β cells and promote apoptosis in vitro, while downregulation of PDIA6 and SLC16A1 expression led to enhanced insulin secretion.\nIn vitro experiments showed that overexpression of SLC16A1-AS1 promoted cell proliferation and invasion but suppressed cell apoptosis.\nSLC16A1-AS1 suppressed miR-1269 maturation and promoted cell proliferation, migration, and invasion, and inhibited cell apoptosis, while miR-1269 displayed the opposite trend.\nexperimental results demonstrated that when SLC16A1 was knocked down, the proliferation, migration, and invasion capabilities of HNSCC cell lines were significantly reduced and the extent of RAS-selective lethal 3-induced lipid peroxidation increased compared with control cells.\nKnockdown SLC16A1-AS1 inhibited cell viability, proliferation, and migration of renal cancer cells.\nSLC16A1-AS1 was downregulated in OSCC and it may inhibit cell proliferation by suppressing maturation of miR-5088-5p.\nSLC16A1-AS1 may inhibit cell cycle progression and restrain TNBC cell proliferation by regulating the miR-182/PDCD4 axis.\nIn turn, the reciprocal SLC16A1-AS1/IL-6 signaling between HCC cells and M2 macrophages promoted the proliferation, invasion and glycolysis of HCC cells.\nCollectively, these findings show that miR-1287-5p/PFN2 signaling was associated with downregulation of circ-SLC16A1 and reduced invasion and proliferation of NSCLC cells.\nDownregulation of circ-SLC16A1 inhibited tumor growth by reducing proliferation, lung metastasis, and lymphatic metastasis of NSCLC cells, and arrested the cell cycle in the G1 phase.", "dois": ["10.1007/s12672-025-03297-2", "10.3390/ijms26115398", "10.7150/jca.110217", "10.62347/ABOI7514", "10.1016/j.heliyon.2024.e36822", "10.7150/ijbs.94440", "10.3748/wjg.v30.i19.2575", "10.1111/jcmm.18141", "10.1186/s12885-024-12327-1", "10.1186/s12935-024-03285-6", "10.1186/s11658-024-00549-x", "10.1007/s11427-023-2400-3", "10.1186/s12885-023-10636-5", "10.1002/jbt.23247", "10.3390/cancers14143355", "10.1186/s40001-022-00745-5", "10.1007/s10266-022-00712-w", "10.1016/j.isci.2022.104435", "10.1080/21655979.2022.2070581", "10.3389/fonc.2022.871798", "10.1002/jcla.24442", "10.1080/08923973.2022.2056482", "10.1186/s12885-022-09282-0", "10.1177/15330338221077803", "10.1016/j.clinre.2020.07.001"]}
{"pair_type": "slc_pathway", "key1": "SLC16A7", "key2": "oxidative phosphorylation", "summary": "Duplications of the bidirectional α-ketoacid transporters SLC16A3, SLC16A7, the cystine transporters SLC7A9, SLC7A11, and N-glycan branching enzymes MGAT4B, MGAT4C in Neoaves suggests a shift to the transport of deaminated essential amino acid, and stronger mitigation of oxidative stress supported by the galectin lattice.\nMaintenance of the proteasome requires oxidative phosphorylation (ATP) and mitigation of oxidative damage, in an increasingly dysfunctional relationship with aging.\nAdditional gene purging included mitochondrial BCAA aminotransferase (BCAT2), pointing to reduced oxidation of BCAA and increased hepatic conversion to triglycerides and glucose.\nEndurance in mammalian muscle depends in part on oxidation of BCAA\nFat deposits are anhydrous and highly reduced, maximizing the fuel/weight ratio for prolonged flight, but fat accumulation in muscle cells of aging humans contributes to inflammation and senescence.", "dois": ["10.2147/IJGM.S447035", "10.1016/j.jbc.2023.105409"]}
{"pair_type": "slc_pathway", "key1": "SLC16A6", "key2": "migration", "summary": "The analysis identified 15 InDels and 202 non-synonymous SNVs exclusively present in tumors of non-responders, mainly in genes regulating the cell cycle, adhesion, and migration.\nThe results suggest that SLC16A6 rs7222013 and SLC25A2 rs3749780 may serve as potential predictors of poor nCRT response in LARC patients.", "dois": ["10.1111/ahg.70019"]}
{"pair_type": "slc_pathway", "key1": "SLC16A3", "key2": "migration", "summary": "Mechanistically, SLC16A3 emerged as a critical regulator promoting STAD cell proliferation, invasion, and migration while modulating the metabolic landscape.\nRescue experiments found SLC16A3 overexpression resisting to LINC00035 knockdown on SKOV3 and A2780 cell viability, migration, invasion, apoptosis, glucose uptake, lactate release, and ATP production.\nOverexpression of MCT4 and/or CD147 increased, and their knockdown decreased, migration, invasion and the degradation of fluorescently labeled gelatin.\nMoreover, MCT4 overexpression enhances cell migration and invasiveness via reorganization of the actin cytoskeleton.\nThe study reveals that LINC00035 promotes OC progression by regulating glycolysis and cell apoptosis through CEBPB-mediated transcriptional promotion of SLC16A3.\nIn fibroblasts, lactate promotes cell migration, IL-6 production and increases glycolysis.\nMore importantly, we confirmed that silencing of LCIIAR expression significantly inhibits the proliferation, and migration abilities of these tumour cells.\nTo further characterize the biological role of hsa_circ_0008621 expression in CRC, in vitro hsa_circ_0008621 inhibition was performed and the effects on cellular growth, migration, invasion, apoptosis, and glycolysis were explored.\nMCT4 was positively correlated with gene families responsible for invasion, migration, and immune modification, proving it to be one of the most important MCTs for therapeutic intervention.\nThe findings highlight SLC16A3 as a promising candidate for therapeutic intervention aimed at modulating lactic acid metabolism in the TME, thereby advancing personalized treatment strategies in gastric cancer management.\nWe investigated how lactate regulates fibroblast and macrophage movement, IL-6 secretion and metabolism via specific lactate transporters.\nMechanistically, this involves MCT4-CD147-dependent stimulation of ECM degradation and specifically of MMP-mediated collagen-I degradation.\nWhile silencing miR-491-5p promoted viability and migration, and significantly suppressed the expression of α-SMA, calponin, SM22", "dois": ["10.1007/s10565-025-10102-x", "10.1186/s12935-024-03555-3", "10.4103/NRR.NRR-D-24-00068", "10.1016/j.heliyon.2024.e32289", "10.1002/ags3.12793", "10.1242/jcs.261608", "10.62347/ZTTG4319", "10.1080/19336950.2023.2273008", "10.1186/s12935-023-03082-7", "10.3389/fimmu.2023.1183825", "10.3390/ijms24031992", "10.3389/fcell.2022.945241", "10.3389/fonc.2022.933071", "10.4196/kjpp.2022.26.3.183", "10.1155/2021/5802082", "10.1155/2021/6655529", "10.1007/s12026-012-8337-z"]}
{"pair_type": "slc_pathway", "key1": "SLC16A7", "key2": "oxidative stress", "summary": "Duplications of the bidirectional α-ketoacid transporters SLC16A3, SLC16A7, the cystine transporters SLC7A9, SLC7A11, and N-glycan branching enzymes MGAT4B, MGAT4C in Neoaves suggests a shift to the transport of deaminated essential amino acid, and stronger mitigation of oxidative stress supported by the galectin lattice.\nregulation of renal reabsorption and secretion of uric acid to increase uric acid excretion, and alleviation of oxidative stress reaction to decrease systemic damage and, eventually, treatment of HUA.\nThe analysis of mRNA-sequencing as well as RT-PCR data from renal tissue demonstrated that the targets modulating uric acid metabolism were SLC22A8, SLC12A1, and SLC16A7.\nThese targets primarily focus on pathways related to uric acid metabolism modulation, such as XOD, SLC22A12, ABCG2, SLC22A8, and others, reducing HUA.\nMonocarboxylate transporter 2 (MCT2) is a major high-affinity pyruvate transporter encoded by the SLC16A7 gene, and is associated with glucose metabolism and cancer.\nserine deficiency exacerbated inflammation and oxidative stress in D-galactose-induced aging mice.\nHowever, serine deficiency significantly exacerbated oxidative stress and inflammation in D-galactose-treated mice.\nInflammation and oxidative stress play key roles in the process of aging and age-related diseases.\nserine deficiency exacerbated the decrease of expression of phosphorylated AMPK and the increase of expression of phosphorylated NFB p65, which were caused by D-galactose injection.\nSince serine availability plays important roles in the support of antioxidant and anti-inflammatory defense system, we explored whether serine deficiency affects inflammatory and oxidative status in D-galactose-induced aging mice.\nIn conclusion, our results suggested that serine deficiency exacerbated inflammation and oxidative stress in D-galactose-induced aging mice.\nMaintenance of the proteasome requires oxidative phosphorylation", "dois": ["10.1155/2020/5821428", "10.1530/REP-09-0038", "10.3389/fmolb.2025.1621413", "10.1016/j.jbc.2023.105409", "10.1016/j.jep.2023.116814", "10.3390/ijms221910616"]}
{"pair_type": "slc_pathway", "key1": "SLC16A7", "key2": "proliferation", "summary": "SLC16A7 exhibits tumor-suppressive properties, with downregulation in most cancers, and is associated with favorable prognosis and enhanced immune responses.\nFunctional assays revealed that SLC16A7 inhibited BCa cell progression and promoted the chemotaxis and tumor-killing ability of CD8 + T cells in the BCa tumor microenvironment (TME).\nSLC16A7 functions as a tumor suppressor in BCa and is associated with improved survival outcomes.\nTheir potential as pharmacological targets has been recognised with the discovery of potent and specific MCT1 inhibitors that act as immunosuppressant drugs by preventing proliferation of T-lymphocytes.\nKaplan-Meier survival analysis indicated that higher SLC16A7 expression was correlated with better overall survival in patients with BCa.\nPathway enrichment analyses (Hallmark-GSEA and KEGG-GSEA) indicated strong associations between SLC16A7, immune responses, and tumor progression.\nSLC16A7, a member of the solute carrier family 16 (SLC16), encodes monocarboxylate transporters that are involved in the proton-coupled transport of metabolites, including lactate, pyruvate, and ketone bodies, across cell membranes.\nSLC16A7 expression was downregulated in 16 cancer types, including BCa, and upregulated in three cancer types.\nExperimental validation showed reduced SLC16A7 expression in BCa tissues and cell lines compared to that in their normal counterparts.\nSLC16A7 expression was also significantly associated with the expression of immune-regulatory molecules.\nEvidence suggests that SLC16A7 exhibits variable expression in cancers and may influence tumor development, progression, and immune regulation.\nIts expression was significantly associated with tumor stage in four cancers and showed both positive and negative correlations with prognosis, depending on the cancer type.\nEndothelial cell proliferation and migration increased and apoptosis decreased with a decrease in SLC25A29 expression.\nOur data indicated that DEGs in Brown module and Magenta module were correlated with the biological regulation, metabolic process, reproduction, and cellular proliferation.", "dois": ["10.1186/s12885-025-14345-z", "10.1186/s12935-023-03082-7", "10.1016/j.anl.2022.05.013", "10.1016/j.jbo.2021.100391", "10.1016/j.mam.2012.05.003", "10.1530/REP-09-0038"]}
{"pair_type": "slc_pathway", "key1": "SLC16A9", "key2": "glycolysis", "summary": "Depletion of mitochondrial DNA in parental cells induced resistance to BEZ235 and other PI3K/mTOR inhibitors, and was accompanied by increased glycolysis.\nInhibition of PKM2 leads to impaired EZH2 recruitment to SLC16A9, and in turn de-represses SLC16A9 expression to increase intracellular carnitine influx, programming TNBC cells to an FAO-dependent and luminal-like cell state.\nSubsequent experiments revealed that AQR clones possess features consistent with elevated glycolysis, including increased levels of glucose, lactate, glutamine, glucose dependence, GLUT1 expression, and rates of post-glucose extracellular acidification, and decreased levels of reactive oxygen species and rates of oxygen consumption.\nCombination treatment of BEZ235 with the glycolysis inhibitor 3-bromopyruvate was synergistic in AQR clones, but only additive in parental cells.\nHere, we find that deficiency in tumor glycolysis activates a metabolic switch from glycolysis to fatty acid β-oxidation (FAO) to fuel TNBC growth.\nTranscriptome analysis revealed the AQR clones had increased expression of the metabolite transporters SLC16A9 and SLC16A7, suggestive of altered cell metabolism.\nWe show that, in TNBC cells, PKM2 directly interacts with histone methyltransferase EZH2 to coordinately mediate epigenetic silencing of a carnitine transporter, SLC16A9.\nTogether, these findings reveal a new metabolic switch that drives TNBC from a metabolically heterogeneous-lineage plastic cell state to an FAO-dependent-lineage committed cell state, where dual targeting of EZH2 and FAO induces potent synthetic lethality in TNBC.", "dois": ["10.1016/j.cmet.2023.12.003", "10.1158/0008-5472.CAN-24-0460", "10.18632/oncotarget.22655", "PMID:26026093"]}
{"pair_type": "slc_pathway", "key1": "SLC16A10", "key2": "oxidative stress", "summary": "In addition, septic animals presented a three-fold increase in and expression; and upregulated expression, potentially due to elevated reactive oxygen species levels.\nThus, impaired diaphragm function during sepsis seems to involve altered local TH signaling, mitochondrial dysfunction, and oxidative stress defense.\nSepsis induced responses consistent with NTIS, resulted in mitochondrial damage and functional impairment, and modulated the expression of key antioxidant enzymes in the diaphragm.\nThe ileum mRNA expressions of seven nutrient transporters (SLC5A8, SLC7A6, SLC6A19, SLC7A7, SLC27A2, SLC16A10, and SLC15A1) were not different between the two groups (p > 0.05).\nThis study aimed at evaluating the relationship between TH signaling, mitochondrial function, and the antioxidant defense system in the diaphragms of septic mice.\nThe expression of (encoding PGC1a) was downregulated, which correlated with the decrease in the number of total mitochondria, increase in the percentage of injured mitochondria, downregulation of respiratory chain complex 2 and 3 mRNA expression, and reduced maximal respiration.\nThe ileum of EXE had higher (p < 0.05) antioxidant protein levels of manganese superoxide dismutase and catalase compared to SED with no change (p > 0.05) in the lipid peroxidation biomarker 4-hydroxynonenal.\nThese findings suggest that 10 days of endurance exercise training up-regulates key endogenous antioxidant enzymes, decreases select inflammation markers, and alters select markers of tight junction permeability.", "dois": ["10.1089/thy.2019.0124", "10.1186/s13104-015-1500-6"]}
{"pair_type": "slc_pathway", "key1": "SLC16A12", "key2": "apoptosis", "summary": "CircSLC16A12 absence protected HRECs from HG-induced apoptosis, blood-retinal barrier (BRB) injury, tube formation, inflammatory response, and oxidative stress.\nCircSLC16A12 silencing suppressed HG-induced dysfunction in HRECs partly by targeting miR-140-3p/FGF2 axis.\nCircSLC16A12 acted as a sponge for microRNA-140-3p (miR-140-3p), and circSLC16A12 knockdown-mediated effects were largely reversed by the absence of miR-140-3p in HRECs under HG condition.\nCircSLC16A12 interference reduced the expression of FGF2 by up-regulating miR-140-3p in HRECs.\nCircSLC16A12 level was enhanced in the serum samples of DR patients and high glucose (HG)-treated HRECs.\nmiR-140-3p interacted with the 3' untranslated region (3'UTR) of fibroblast growth factor 2 (FGF2), and the overexpression of FGF2 largely overturned miR-140-3p overexpression-mediated effects in HRECs.\nBudesonide-induced genes showed GO term enrichment for positive and negative regulation of transcription, signaling, proliferation, apoptosis, and movement, as well as FOXO and PI3K-Akt signaling pathways.\nReduced growth factor expression and effects on proliferation and apoptosis were highlighted.\nFurthermore, positive and negative effects on signaling, proliferation, migration and apoptosis were revealed.\nThe knockdown of ALDH18A1 in ccRCC significantly promoted apoptosis and inhibited proliferation, invasion, and epithelial-mesenchymal transition (EMT) in two human ccRCC cell lines (786-O and 769-P).", "dois": ["10.1007/s10238-024-01390-4", "10.1080/02713683.2022.2025845", "10.1186/s12920-018-0467-2"]}
{"pair_type": "slc_pathway", "key1": "SLC16A12", "key2": "oxidative stress", "summary": "CircSLC16A12 absence protected HRECs from HG-induced apoptosis, blood-retinal barrier (BRB) injury, tube formation, inflammatory response, and oxidative stress.", "dois": ["10.1080/02713683.2022.2025845"]}
{"pair_type": "slc_pathway", "key1": "SLC16A3", "key2": "proliferation", "summary": "While transcriptional repression of SLC16A3 by FBI-1 inhibited lactate efflux, repression of ZBTB7A and activation of lactate efflux by NF-κB, increased colon cancer cell growth and proliferation.\nMechanistically, SLC16A3 emerged as a critical regulator promoting STAD cell proliferation, invasion, and migration while modulating the metabolic landscape.\nAnd the key gene SLC16A3 and STRBP can significantly promote the proliferation and invasion ability of HCC cells.\nAnd SLC16A3 inhibitors significantly suppressed the proliferation of HCC, while simultaneously enhancing T-cell cytotoxicity and reducing exhaustion.\nSubsequent in vitro experiments indicated that the inhibition of β-cell proliferation and the decreased expression of Pdx-1, Creb and Slc16a3 were rescued by DNA methyltransferase 3A (DNMT3A) knockdown in β cells.\nSubsequently, the effects of SLC16A3 expression on cell proliferation and invasion were analyzed using hepatocellular carcinoma (HCC) lines, and Western blot (WB) analysis was performed to explore the changes in pathway proteins and ferroptosis proteins.\nSLC16A3 can directly mediate the proliferation of HBV-positive liver cancer cell lines in vitro.\nMoreover, knockdown of SLC16A3 significantly increased the level of lipid peroxidation and reactive oxygen species (ROS), while the expressions of GPX4, DHODH and SLC7A11 were inhibited.\nTCGA data and WB analysis showed that the high expression of SLC16A3 induced hypoxia, and knockdown could reverse hypoxia and inhibit ERK phosphorylation, thus limiting the malignant behavior of HCC cells.\nOverexpressed Solute Carrier Family 16 Member 3 (SLC16A3, also called MCT4) plays a critical role in hypoxic cancer cell growth and proliferation, by expelling glycolysis-derived lactate across the plasma membrane.\nOur results further indicate that MCT4 promotes proliferation and survival by altered cell cycle regulation and cell death mechanisms.", "dois": ["10.1007/s10565-025-10102-x", "10.1186/s12967-025-06861-0", "10.3389/fimmu.2025.1600863", "10.1038/s41598-025-09010-1", "10.3390/ijms26115398", "10.3389/fphar.2025.1579126", "10.1111/jcmm.70272", "10.1186/s12935-024-03555-3", "10.1016/j.bbrc.2024.150709", "10.3390/molecules29174275", "10.1002/ags3.12793", "10.1111/dom.15621", "10.62347/ZTTG4319", "10.1007/s00432-024-05644-2", "10.1186/s12935-023-03082-7", "10.1038/s41598-022-20874-5", "10.3389/fonc.2022.933071", "10.3390/biology11060839", "10.3390/cells11091443", "10.1016/j.ccell.2021.12.006", "10.1155/2021/6655529", "10.3390/cancers12102842", "10.3390/cells8091093", "10.1016/j.bbagrm.2019.06.004", "10.1093/neuonc/not243", "10.1016/j.mam.2012.05.003", "10.1210/en.2012-1457", "10.1007/s12026-012-8337-z", "10.1016/j.ygyno.2010.01.041", "PMID:16465392"]}
{"pair_type": "slc_pathway", "key1": "SLC16A8", "key2": "glycolysis", "summary": "siRNA-mediated SLC16A8 knockdown effectively reversed hypoxia-induced changes, including reduced glucose consumption and lactate production.\nFurthermore, SLC16A8 silencing led to decreased expression of key metabolic enzymes PKM2 and LDHA, indicating its role in glycolytic regulation.\nUnder hypoxic conditions, HIF-1α induced SLC16A8 expression, leading to enhanced metabolic reprogramming and increased lactate production.\nOur findings reveal that SLC16A8 functions as a critical mediator of hypoxia-induced metabolic reprogramming in CRC progression.\nHypoxic conditions prompted examination of SLC16A8 expression, glycolysis, lactate efflux, and Warburg effect correlations in CRC cell lines.\nSLC16A8, a lactate efflux transporter, is upregulated in various cancers, but its effects on tumor microenvironments remain understudied.\nLactic acid was previously considered a waste product of glycolysis, and has now become a key metabolite for cancer development, maintenance and metastasis.", "dois": ["10.4251/wjgo.v17.i4.99188", "10.3390/genes13040620"]}
{"pair_type": "slc_pathway", "key1": "SLC16A8", "key2": "proliferation", "summary": "Their potential as pharmacological targets has been recognised with the discovery of potent and specific MCT1 inhibitors that act as immunosuppressant drugs by preventing proliferation of T-lymphocytes.\nThe MCTs comprise 14 members, and they play an important role in the growth, proliferation, and metabolism of cancer cells by transporting monocarboxylates such as lactate, pyruvate and thyroid hormones.\nSLC16 family members are involved in a wide range of metabolic pathways including energy metabolism of the brain, skeletal muscle, heart and tumour cells, gluconeogenesis, T-lymphocyte activation, bowel metabolism, spermatogenesis, pancreatic β-cell malfunction, thyroid hormone metabolism, and drug transport.\nFour (SLC16A1, SLC16A3, SLC16A7, and SLC16A8) encode monocarboxylate transporters (MCT1, MCT4, MCT2, and MCT3, respectively) catalysing the proton-linked transport of monocarboxylates such as l-lactate, pyruvate and ketone bodies across the plasma membrane.\nThere was a significantly lower expression of the MCT3 gene in tumor samples compared to adjacent normal tissue and healthy samples (p value < 0.05).\nAltered MCT8 and MCT9 gene expression was associated with a reduced survival CONCLUSION: MCT3 expression is significantly downregulated in breast cancer tissue.\nMCT3 may represent a novel therapeutic target in breast cancer patients, or in some hormone receptor subgroups.\nIt is suggested that the development of other drugs specifically targeting different MCT isoforms may provide a novel approach to cancer chemotherapy.\nMalignant cell transformation is associated with metabolic changes.\nOne group of proteins that are affected is the monocarboxylate transporters (MCTs-SLC16A).", "dois": ["10.1007/s13258-021-01116-w", "10.1016/j.mam.2012.05.003"]}
{"pair_type": "slc_pathway", "key1": "SLC16A13", "key2": "glycolysis", "summary": "It was found for the first time that EMB promoted lactic acid accumulation and further induced redox dyshomeostasis and glycolysis disorder by simultaneously inhibiting SLC16A1/3.\nSLC16A1/3 is the critical hub for regulating the internal and external environment, glycolysis, and redox homeostasis in cervical cancer cells.\nGA-Fe@EMB can target cervical cancer marker SLC16A1/3 to regulate glycolysis and redox pathways, synergistically with photothermal therapy, which provides a new avenue for the synergistic treatment of malignant cervical cancer.", "dois": ["10.1021/acs.molpharmaceut.3c00294"]}
{"pair_type": "slc_pathway", "key1": "SLC16A12", "key2": "migration", "summary": "Using the above criteria, 17 (BCL6, BIRC3, CEBPD, ERRFI1, FBXL16, FKBP5, GADD45B, IRS2, KLF9, PDK4, PER1, RGCC, RGS2, SEC14L2, SLC16A12, TFCP2L1, TSC22D3) induced and 8 (ARL4C, FLRT2, IER3, IL11, PLAUR, SEMA3A, SLC4A7, SOX9) repressed mRNAs were common between A549, BEAS-2B and HBE cells at 6 h.\nBudesonide-induced genes showed GO term enrichment for positive and negative regulation of transcription, signaling, proliferation, apoptosis, and movement, as well as FOXO and PI3K-Akt signaling pathways.\nFurthermore, positive and negative effects on signaling, proliferation, migration and apoptosis were revealed.", "dois": ["10.1186/s12920-018-0467-2"]}
{"pair_type": "slc_pathway", "key1": "SLC16A8", "key2": "migration", "summary": "MCT4 was positively correlated with gene families responsible for invasion, migration, and immune modification, proving it to be one of the most important MCTs for therapeutic intervention.\nWe compared the effects of MCT1/2 blocker SR13800 and a broad-spectrum MCT blocker α-Cyano Hydroxy Cinnamic Acid (α-CHCA) and discovered that α-CHCA has a greater effect on diminishing the invasive behavior of the cancer cells than MCT1/2 blocker SR13800.", "dois": ["10.1080/19336950.2023.2273008"]}
{"pair_type": "slc_pathway", "key1": "SLC16A3", "key2": "chemotherapy", "summary": "The expression of SLC16A3 affected the sensitivity of HCC cells to chemotherapy and targeted drugs, and RNA sequencing data suggested that the expression level influenced tumor microenvironment and response to immunotherapy.\nMCT4 inhibition suppressed the in vitro malignant characteristics of pancreatic cancer cells and showed a synergistic effect with gemcitabine treatment.\nThe prognostic performance of model was validated through survival analysis, and its association with chemotherapy and immunotherapy sensitivity.\nMoreover, we assessed the LMS predictive efficacy in chemotherapy and immunotherapy.\nHigh LMS patients are suitable for traditional chemotherapy, while patients with low LMS are more likely to benefit from immunotherapy.\nIt is suggested that the development of other drugs specifically targeting different MCT isoforms may provide a novel approach to cancer chemotherapy.\nThe model also predicted drug sensitivity, with high-risk patients showing greater sensitivity to chemotherapy agents like 5-Fluorouracil and Paclitaxel.\nWe identified 1187 tags (corresponding to 1040 genes) that are differentially expressed between the chemotherapy responsive and the persistently chemotherapy resistant ovarian cancer tissues.\nOur riskScore model, integrating genetic and immune factors, provides a robust prognostic tool with potential clinical application in patient stratification and chemotherapy decision-making for HCC patients.\nGO term GO:0050673 (epithelial cell proliferation) and GO:0050678 (regulation of epithelial cell proliferation) are enriched in the genes over expressed in the chemotherapy resistant tissue while the GO:0007229 (integrin-mediated signaling pathway) is enriched in the genes over expressed in the chemotherapy sensitive tissue.\nAn integrative analysis identified 111 common differentially expressed genes including two bone morphogenetic proteins (BMP4 and BMP7), six solute carrier proteins (SLC10A3, SLC16A3, SLC25A1, SLC35B3, SLC7A5 and SLC7A7), transcription factor POU5F1 (POU class 5 homeobox 1), and KLK10 (kallikrein-related peptidase 10).\nTwo next-generation sequencing technologies--MPSS (massively parallel signature sequ", "dois": ["10.1038/s41598-025-09010-1", "10.1016/j.bbrc.2024.150709", "10.1016/j.heliyon.2024.e30781", "10.1007/s13402-021-00643-8", "10.1016/j.biopha.2014.02.002", "10.1016/j.mam.2012.05.003", "10.1016/j.ygyno.2010.01.041"]}
{"pair_type": "slc_pathway", "key1": "SLC16A13", "key2": "oxidative stress", "summary": "It was found for the first time that EMB promoted lactic acid accumulation and further induced redox dyshomeostasis and glycolysis disorder by simultaneously inhibiting SLC16A1/3.\nSubsequently, EMB was released and mediated the lactic acid accumulation and the GA-Fe nanoparticle synergistic Fenton reaction to promote ROS accumulation, thereby increasing the lethality of the nanoparticles on cervical cancer cells.\nSLC16A1/3 is the critical hub for regulating the internal and external environment, glycolysis, and redox homeostasis in cervical cancer cells.\nGA-Fe@EMB can target cervical cancer marker SLC16A1/3 to regulate glycolysis and redox pathways, synergistically with photothermal therapy, which provides a new avenue for the synergistic treatment of malignant cervical cancer.", "dois": ["10.1021/acs.molpharmaceut.3c00294"]}
{"pair_type": "slc_pathway", "key1": "SLC16A14", "key2": "chemotherapy", "summary": "Five genes were significantly upregulated: SLC2A9, SLC16A3, SLC16A14, SLC38A4 and SLC39A8.\nIn results of MDR development during chemotherapy cancer cells become resistant to further treatment.\nABC and SLC transporters are most important proteins responsible for this phenomenon.\nIn this study changes of ABC and SLC genes expression pattern in drugs resistant sublines of the A2780 ovarian cancer cell line were demonstrated.\nExpression profiles of these genes give strong arguments for assumption of correlation between expression of ABC and SLC genes and drug resistance phenomenon.\nThe cytostatic resistant sublines were generated by culture of A2780 cell line with an increasing concentration of the indicated drugs.", "dois": ["10.1016/j.biopha.2014.02.002"]}
{"pair_type": "slc_pathway", "key1": "SLC16A14", "key2": "migration", "summary": "Several upregulated genes in the inflammatory process (MPO, DEFA4, ELANE, AUZ1, CTSG, OLFM4, SLC16A14, and CRISP3) that were associated with the dengue disease progression are known to facilitate leukocyte-mediated migration, and neutrophil activation and degranulation process.", "dois": ["10.1016/j.trsl.2017.06.007"]}
{"pair_type": "slc_pathway", "key1": "SLC16A14", "key2": "oxidative stress", "summary": "Enrichment analyses suggested that these dysregulated lncRNAs were involved in a variety of biological processes, including those related to oxidative stress, inflammation response, and cell proliferation, development, and differentiation.", "dois": ["10.1016/j.envres.2024.120101"]}
{"pair_type": "slc_pathway", "key1": "SLC16A13", "key2": "proliferation", "summary": "Among the 5 aforementioned mRNAs, the expression of and was significantly higher in OSCC than in LP tissues.\nThe expression of FYN-binding protein (), solute carrier family 16 member 13 (), keratin 7, transmembrane portion 173 and mRNAs was significantly elevated in L cells compared with that in Sq1979 and 233 cells.\nCompared with parental Sq-1979 and 233 cells, the majority of L cells exhibited a higher proliferation rate and transplantability, and conferred a lower survival rate on the implanted mice.\nFurthermore, the expression of mRNA was significantly elevated in highly invasive OSCCs, which were classified as grades 3 and 4 by the Yamamoto-Kohama (YK) classification of invasion, compared with those in lower grades (YK-1 and -2).", "dois": ["10.31557/APJCP.2025.26.2.525", "10.31557/APJCP.2024.25.6.1953", "10.3892/ol.2017.7648"]}
{"pair_type": "slc_pathway", "key1": "SLC16A13", "key2": "ferroptosis", "summary": "These results indicate that propofol inhibits the expression of SLC16A13, alleviates myocardial cell ferroptosis via the AMPK/GPX4 pathway, and reverses damage caused by myocardial ischemia-reperfusion.\nThis study investigates the protective effects of propofol on the myocardium by inhibiting the expression of SLC16A13 through in vivo animal experiments, while also exploring its mechanism in ferroptosis to provide new strategies for preventing perioperative myocardial ischemia-reperfusion injury.\nAfterwards, we validated the in vivo results using H9C2 and further explored the mechanism by which propofol inhibits ferroptosis.\nIn addition, upregulation of SLC16A13 significantly inhibited the phosphorylation of AMPK, weakened the protective mechanism of AMPK, and exacerbated cardiac damage.\nHowever, propofol pretreatment can effectively inhibit the expression of SLC16A13, maintain normal myocardial cell morphology, and protect cardiac function.\nThe study found that L-lactic acid in myocardial tissue of the GW7647 group was further increased compared to the I/R group, and the degree of ferroptosis was aggravated.", "dois": ["10.1016/j.biopha.2024.117345"]}
{"pair_type": "slc_pathway", "key1": "SLC16A9", "key2": "chemotherapy", "summary": "Targeting the YTHDF2-m6A-SLC16A9 axis may offer a novel therapeutic strategy to overcome chemotherapy resistance in NKTCL.\nIn vivo experiments using a nude mouse model further confirmed that SLC16A9 knockdown reduces tumor growth and enhances sensitivity to ADM.\nWe also found that overexpression of YTHDF2 reduced SLC16A9 expression and increased ADM sensitivity, whereas knockdown of YTHDF2 had the opposite effect.\nFurther investigation revealed that ADM treatment reduces m6A modification levels on SLC16A9 mRNA, which is associated with decreased binding of YTHDF2 to SLC16A9 mRNA, leading to increased SLC16A9 expression.\nOur results showed that overexpression of SLC16A9 enhanced ADM resistance, while knockdown of SLC16A9 increased sensitivity to ADM.\nour study provides direct evidence that YTHDF2 modulates ADM resistance in NKTCL by regulating the m6A modification of SLC16A9.\nBy analyzing the levels of m6A modification, it was revealed that YTHDF2 regulates SLC16A9 expression via the m6A pathway, thereby influencing ADM resistance.\nNatural killer/T-cell lymphoma (NKTCL) is an aggressive malignancy with a high propensity for drug resistance, particularly to anthracyclines like adriamycin (ADM).", "dois": ["10.1016/j.tranon.2025.102448"]}
{"pair_type": "slc_pathway", "key1": "SLC17A4", "key2": "migration", "summary": "Together, our findings demonstrated that Cd exposure repressed the expression of miR-3614-5p, thus activating TXNRD1 expression, which promoted the abnormal proliferation and metastasis of BC cells.\nMoreover, miR-3614-5p mimic transfection significantly decreased the proliferative ability, migration and invasive ability of BC cell lines (T-47D and MCF-7).\nmiR-3614-5p suppressed the expression of TXNRD1 by directly binding to the 3'-untranslated region (UTR), and TXNRD1 inhibition significantly repressed the proliferation and metastasis capacity of BC cells upon Cd exposure.", "dois": ["10.1016/j.ecoenv.2022.114270"]}
{"pair_type": "slc_pathway", "key1": "SLC16A14", "key2": "proliferation", "summary": "Enrichment analyses suggested that these dysregulated lncRNAs were involved in a variety of biological processes, including those related to oxidative stress, inflammation response, and cell proliferation, development, and differentiation.\nTransporters from the ABCA family, ABCG2, and ESR2 are involved mainly in lipid metabolism, membrane transport, and cell proliferation.", "dois": ["10.1016/j.envres.2024.120101", "10.7150/jca.20766"]}
{"pair_type": "slc_pathway", "key1": "SLC17A4", "key2": "chemotherapy", "summary": "Additionally, our cellular experiments suggested knock-down of SLC17A4 contributes to inhibiting invasion, colony formation, and proliferation in PCa cells .\nGDSC database was employed to determine the sensitivity of chemotherapy drugs.\nSeveral medications that might improve patients` prognosis in the MetaScore group were identified.\nOur study supports the metabolism-based four-gene signature as a novel and robust model for predicting prognosis, and chemo-/immuno-therapy response in PCa patients.\nThen the correlation between MetaScore and tumor was deeply explored from prognostic, genomic variant, functional and immunological perspectives, and chemo-/immuno-therapy response.\nThus, the study aimed to explore the metabolic (Meta) characteristics and develop a metabolism-based signature to predict the prognosis and immuno-/chemo-therapy response for PCa patients.\nA metabolic model was developed weighted by the estimated regression coefficients in the multivariate Cox regression analysis (0.5154*GAS2 + 0.395*SLC17A4 - 0.1211*NTM + 0.2939*GC).\nFurther functional experiments were performed using PCa cells to validate the association between the expression of hub gene SLC17A4 which is one of the model component genes and tumor progression.", "dois": ["10.3389/fimmu.2022.982628"]}
{"pair_type": "slc_pathway", "key1": "SLC17A4", "key2": "proliferation", "summary": "Additionally, our cellular experiments suggested knock-down of SLC17A4 contributes to inhibiting invasion, colony formation, and proliferation in PCa cells .\nTogether, our findings demonstrated that Cd exposure repressed the expression of miR-3614-5p, thus activating TXNRD1 expression, which promoted the abnormal proliferation and metastasis of BC cells.\nImportantly, luciferase reporter assays further verified that miR-3614-5p suppressed the expression of TXNRD1 by directly binding to the 3'-untranslated region (UTR), and TXNRD1 inhibition significantly repressed the proliferation and metastasis capacity of BC cells upon Cd exposure.\nMoreover, miR-3614-5p mimic transfection significantly decreased the proliferative ability, migration and invasive ability of BC cell lines (T-47D and MCF-7).\nFurther functional experiments were performed using PCa cells to validate the association between the expression of hub gene SLC17A4 which is one of the model component genes and tumor progression.", "dois": ["10.1016/j.ecoenv.2022.114270", "10.3389/fimmu.2022.982628"]}
{"pair_type": "slc_pathway", "key1": "SLC16A8", "key2": "chemotherapy", "summary": "It is suggested that the development of other drugs specifically targeting different MCT isoforms may provide a novel approach to cancer chemotherapy.", "dois": ["10.1016/j.mam.2012.05.003"]}
{"pair_type": "slc_pathway", "key1": "SLC17A5", "key2": "apoptosis", "summary": "DMU-212 was found to regulate a diverse range of genes, including cytokines (IL8, selectin E, MPZL2, EGR1, CCL20, ITGB8, CXCL1, VCAM1, KITLG, and AREG), transport proteins (TRPC4, SLC41A2, SLC17A5, and CREB5), metabolism (CYP1B1, CYP1A1, PDK4, CSNK1G1, MVK, TCEB3C, and CDKN3), enzymes (RAB23, SPHK1, CHSY3, PLAU, PLA2G4C, and MMP10), and genes involved in signal transduction (TMEM217, DUSP8, and SPRY4), chromosome organization (HIST1H2BH and GEM), cell migration and angiogenesis (ERRFI1, HBEGF, and NEDD9), and apoptosis (TNFSF15, TNFRSF9, CD274, BCL2L11, BIRC3, TNFAIP3, and TIFA), as well as other genes with unknown function (PGM5P2, SNORD1142, LOC151760, KRTAP5-2, C1orf110, SNORA14A, MIR31, C2CD4B, SCARNA4, C2orf66, SC4MOL, LOC644714, and LOC283392).\nBlocking sialin enhances NO bioavailability, autophagy, cell survival, and eNOS expression while decreasing monocyte adhesion.\nWhile nitrate did not significantly reduce structural damage, it did decrease neuronal loss and apoptosis in the early stages of TBI.\nHowever, the knockdown of Slc17a5 reduced the effectiveness of nitrate on short-term neurobehavior in TBI mice and nullified its anti-inflammatory effects.\nPPI shows LGALS8 to directly interact with sialin and regulate autophagy, cell-cell adhesion, and apoptosis.", "dois": ["10.3109/13880209.2015.1071414", "10.1016/j.tice.2025.102955", "10.1016/j.niox.2024.04.002"]}
{"pair_type": "slc_pathway", "key1": "SLC16A12", "key2": "proliferation", "summary": "Conducting western blotting, CCK-8, transwell, and flow cytometry assays, we found the knockdown of ALDH18A1 in ccRCC significantly promoted apoptosis and inhibited proliferation, invasion, and epithelial-mesenchymal transition (EMT) in two human ccRCC cell lines (786-O and 769-P).\nBudesonide-induced genes showed GO term enrichment for positive and negative regulation of transcription, signaling, proliferation, apoptosis, and movement, as well as FOXO and PI3K-Akt signaling pathways.\nReduced growth factor expression and effects on proliferation and apoptosis were highlighted.\nExperimental results indicated that SLC6A19 could inhibit invasion and proliferation of ccRCC cells and GSEA pinpointed that SLC6A19 was intimately correlated with fatty acid metabolism and CPT1A.\nAdditionally, this study revealed the key role of ALDH18A1 in promoting ccRCC progression for the first time.\nFurthermore, positive and negative effects on signaling, proliferation, migration and apoptosis were revealed.", "dois": ["10.3389/fendo.2025.1521940", "10.1007/s10238-024-01390-4", "10.1186/s12920-018-0467-2"]}
{"pair_type": "slc_pathway", "key1": "SLC16A9", "key2": "migration", "summary": "Transcriptome analysis revealed the AQR clones had increased expression of the metabolite transporters SLC16A9 and SLC16A7, suggestive of altered cell metabolism.\nThese AQR clones showed class-specific resistance to PI3K/mTOR inhibitors, reduced G1 cell cycle arrest and impedance of migration following PI3K/mTOR inhibition, reduced PTEN expression and increased Akt and S6RP phosphorylation.", "dois": ["10.18632/oncotarget.22655", "PMID:26026093"]}
{"pair_type": "slc_pathway", "key1": "SLC17A5", "key2": "migration", "summary": "DMU-212 was found to regulate a diverse range of genes, including cytokines (IL8, selectin E, MPZL2, EGR1, CCL20, ITGB8, CXCL1, VCAM1, KITLG, and AREG), transport proteins (TRPC4, SLC41A2, SLC17A5, and CREB5), metabolism (CYP1B1, CYP1A1, PDK4, CSNK1G1, MVK, TCEB3C, and CDKN3), enzymes (RAB23, SPHK1, CHSY3, PLAU, PLA2G4C, and MMP10), and genes involved in signal transduction (TMEM217, DUSP8, and SPRY4), chromosome organization (HIST1H2BH and GEM), cell migration and angiogenesis (ERRFI1, HBEGF, and NEDD9), and apoptosis (TNFSF15, TNFRSF9, CD274, BCL2L11, BIRC3, TNFAIP3, and TIFA), as well as other genes with unknown function (PGM5P2, SNORD1142, LOC151760, KRTAP5-2, C1orf110, SNORA14A, MIR31, C2CD4B, SCARNA4, C2orf66, SC4MOL, LOC644714, and LOC283392).", "dois": ["10.3109/13880209.2015.1071414"]}
{"pair_type": "slc_pathway", "key1": "SLC16A9", "key2": "proliferation", "summary": "We also discovered a novel OCT4 putative downstream target gene SLC16A9 which demonstrated significantly increased expression following elevation of OCT4 levels.\nWe found that human skin cells cultured in the presence of BAY11 resulted in reproducible increased expression of OCT4 that did not inhibit normal cell proliferation.\nFurthermore, we demonstrated that carnitine suppressed HBV-specific CD8 T cell proliferation.\nOur results further suggest that a lower baseline plasma carnitine level increases the proliferative capacity of CD8 T cells, making patients more susceptible to the immunological effect of this treatment.\nThe MCTs comprise 14 members, and they play an important role in the growth, proliferation, and metabolism of cancer cells by transporting monocarboxylates such as lactate, pyruvate and thyroid hormones.\nA growing number of observations reveal that tumors can utilize a wide range of substrates to sustain cell survival and proliferation.", "dois": ["10.1007/s13258-021-01116-w", "10.3389/fcell.2020.583850", "PMID:26026093", "10.1016/j.jhep.2014.05.004", "10.1186/scrt163"]}
{"pair_type": "slc_pathway", "key1": "SLC16A10", "key2": "chemotherapy", "summary": "It is suggested that the development of other drugs specifically targeting different MCT isoforms may provide a novel approach to cancer chemotherapy.\nSLC16 family members are involved in a wide range of metabolic pathways including energy metabolism of the brain, skeletal muscle, heart and tumour cells, gluconeogenesis, T-lymphocyte activation, bowel metabolism, spermatogenesis, pancreatic β-cell malfunction, thyroid hormone metabolism, and drug transport.\nSLC16A2 encodes a high affinity thyroid hormone transporter (MCT8) and SLC16A10 an aromatic amino acid transporter (TAT1).\nTheir potential as pharmacological targets has been recognised with the discovery of potent and specific MCT1 inhibitors that act as immunosuppressant drugs by preventing proliferation of T-lymphocytes.", "dois": ["10.1016/j.mam.2012.05.003"]}
{"pair_type": "slc_pathway", "key1": "SLC16A10", "key2": "apoptosis", "summary": "AGEs significantly inhibited the viability of RAW 264.7 cells and enhanced their apoptosis;\nAdditionally, inhibition of miR-361-3p decreased the cell apoptosis caused by AGEs and increased the levels of p-AKT/AKT and p-PI3K/PI3K, whereas CSF1R knockdown reversed the effects of miR-361-3p.\nAGEs may regulate macrophage apoptosis via the miR-361-3p/CSF1R axis and PI3K/AKT pathway, thereby influencing DFU wound healing.\nRAW 264.7 cells were treated with advanced glycation end products (AGEs) to determine their viability and apoptosis.\nBioinformatics analysis revealed that the differentially expressed genes of mRNA and lncRNAs were considerably enriched in \"cell adhesion and apoptosis\", \"steroid biosynthesis\", and \"immune system\".", "dois": ["10.1016/j.heliyon.2024.e24598", "10.1186/s13048-022-01053-6"]}
{"pair_type": "slc_pathway", "key1": "SLC16A10", "key2": "oxidative phosphorylation", "summary": "The expression of (encoding PGC1a) was downregulated, which correlated with the decrease in the number of total mitochondria, increase in the percentage of injured mitochondria, downregulation of respiratory chain complex 2 and 3 mRNA expression, and reduced maximal respiration.\nSepsis induced responses consistent with NTIS, resulted in mitochondrial damage and functional impairment, and modulated the expression of key antioxidant enzymes in the diaphragm.\nTH is a major regulator of muscle function, via its influence on mitochondria.\nThus, impaired diaphragm function during sepsis seems to involve altered local TH signaling, mitochondrial dysfunction, and oxidative stress defense.", "dois": ["10.1089/thy.2019.0124"]}
{"pair_type": "slc_pathway", "key1": "SLC16A10", "key2": "proliferation", "summary": "Their potential as pharmacological targets has been recognised with the discovery of potent and specific MCT1 inhibitors that act as immunosuppressant drugs by preventing proliferation of T-lymphocytes.\nSLC16 family members are involved in a wide range of metabolic pathways including energy metabolism of the brain, skeletal muscle, heart and tumour cells, gluconeogenesis, T-lymphocyte activation, bowel metabolism, spermatogenesis, pancreatic β-cell malfunction, thyroid hormone metabolism, and drug transport.\nThe former were enriched in the biological processes of transcription regulation, RNA metabolism and regulation of cell proliferation.\nThe later were highly involved in cell cycle regulation.\nIt is suggested that the development of other drugs specifically targeting different MCT isoforms may provide a novel approach to cancer chemotherapy.", "dois": ["10.7717/peerj.9273", "10.1016/j.mam.2012.05.003"]}
{"pair_type": "slc_pathway", "key1": "SLC16A11", "key2": "chemotherapy", "summary": "M2 macrophages play a crucial role in promoting tumor angiogenesis and proliferation, as well as contributing to chemotherapy resistance and metastasis.\nThe risk score was identified as a promising prognostic marker for TACE response, and the high-risk subgroup showed higher sensitivity to chemotherapeutic drugs (e.g., sorafenib, doxorubicin, cisplatin, and mitomycin) and immune checkpoint inhibitor (ICI) treatments.", "dois": ["10.3389/fonc.2023.1170775"]}
{"pair_type": "slc_pathway", "key1": "SLC16A11", "key2": "glycolysis", "summary": "Consistent with this, a type 2 diabetes risk haplotype in SLC16A11 that reduces pyruvate transport (thus limiting lactate production) increases D5D/D6D activity in vitro and in humans, demonstrating a chronic effect of desaturase-mediated NAD recycling.\nHere, we show that D5D/D6D provide a mechanism for glycolytic NAD recycling that permits ongoing glycolysis and cell viability when the cytosolic NAD/NADH ratio is reduced, analogous to lactate fermentation.\nAlthough lesser in magnitude than lactate production, this desaturase-mediated NAD recycling is acutely adaptive when aerobic respiration is impaired in vivo.\nThese findings highlight key biologic roles for D5D/D6D activity independent of their HUFA end products and expand the current paradigm of glycolytic NAD regeneration.\nThe reactions catalyzed by the delta-5 and delta-6 desaturases (D5D/D6D), key enzymes responsible for highly unsaturated fatty acid (HUFA) synthesis, regenerate NAD from NADH.\nNotably, inhibition of either HUFA synthesis or lactate fermentation increases the other, underscoring their interdependence.", "dois": ["10.1016/j.cmet.2018.12.023"]}
{"pair_type": "slc_pathway", "key1": "SLC16A11", "key2": "migration", "summary": "experiments showed that may enhance the migration ability of HepG2 cells by activating the Wnt signaling pathway.\nM2 macrophages play a crucial role in promoting tumor angiogenesis and proliferation, as well as contributing to chemotherapy resistance and metastasis.\nThe high-risk group exhibited higher proliferation and invasion capacity, MSI, and degree of stemness.", "dois": ["10.3389/fonc.2023.1170775"]}
{"pair_type": "slc_pathway", "key1": "SLC17A5", "key2": "oxidative stress", "summary": "We found that the lysosome pathway was activated when after NPs exposure, with up-regulated DEGs, including glucocerebrosidase (GBA), hexosaminidase A (HEXA), sphingomyelin phosphodiesterase-1 (SMPD1), and solute carrier family 17 member 5 (SLC17A5).\nBSM exposure induced oxidative stress responses in crayfish, resulting in changes in superoxide dismutase (SOD), catalase (CAT), glutathione reductase (GSH) activity, and malondialdehyde (MDA) levels.\nTranscriptomic data indicated that BSM affects the growth of crayfish through genes related to immune response (SLC17A5, CTSD, CTSB, NFKBIA, Mincle).", "dois": ["10.1016/j.scitotenv.2024.177091", "10.1016/j.fsi.2023.109207"]}
{"pair_type": "slc_pathway", "key1": "SLC16A11", "key2": "proliferation", "summary": "M2 macrophages play a crucial role in promoting tumor angiogenesis and proliferation, as well as contributing to chemotherapy resistance and metastasis.\noverexpression of the potassium (K(+)) channel Eag family members promotes increased proliferation and results in poor prognosis.\nThe high-risk group exhibited higher proliferation and invasion capacity, MSI, and degree of stemness.", "dois": ["10.3389/fonc.2023.1170775", "10.1093/hmg/ddt160"]}
{"pair_type": "slc_pathway", "key1": "SLC17A5", "key2": "proliferation", "summary": "The functional proteins expression of the colon epithelial barrier and the proliferation of PCNA-positive intestinal epithelial cells in the colon crypts was significantly decreased compared with those of the K14-cre;\nSalivary nitrate depletion (via bilateral submandibular duct ligation or dietary restriction) impaired wound healing, characterized by reduced epithelial proliferation, aberrant collagen organization, and suppressed vascular endothelial growth factor (VEGF) and transforming growth factor-β (TGF-β) expression-phenotypes rescued by nitrate supplementation.\nMoreover, the expression of Sialin (encoded by Slc17a5), which is a nitrate transporter, increased in the colon epithelial cells by nitrate supplementation.\nIn vitro, sialin knockdown abolished nitrate-induced cell proliferation and neuropeptide release in H4 cells while disrupting O-glycosylation, a key posttranslational modification for mucosal barrier function.\nCrucially, salivary nitrate promoted the reinnervation of myelinated sensory nerve fibers, upregulated the nitrate transporter sialin (), and stimulated the secretion of regenerative neuropeptides including calcitonin gene-related peptide, vasoactive intestinal peptide, and neuropeptide Y.\nTranscriptomic profiling revealed that both nitrate-dependent upregulation of and the enhancement of the mucin type O-glycan biosynthesis pathway were mechanistically linked to myelinated sensory nerve modulation.\nLong-term nitrate supplement in drinking water restored the serum and salivary nitrate levels and increased the functional proteins expression of the colon epithelial barrier.\nTaken together, our findings suggested that nitrate supplementations were associated with the increased expression of colonic epithelial barriers-related proteins and the increased Sialin expression.\nThese findings establish a sialin-dependent sensory neuropeptide axis wherein nitrate activates sensory neurons to drive mucosal regeneration, providing both mechanistic understanding of neuroepithelial crosstalk and a druggable target for tissue repair strategies.\nSensory neuron-specific sialin knockout mice (, cKO) exhibited impaired n", "dois": ["10.1177/00220345251362203", "10.1007/s10522-024-10127-5"]}
{"pair_type": "slc_pathway", "key1": "SLC17A6", "key2": "chemotherapy", "summary": "Chemotherapy with pemetrexed and carboplatin was administrated for two cycles after the surgery.\nThen, he received chemotherapy with etoposide and carboplatin but had severe side effect, leading to the discontinuation of the regime.", "dois": ["10.3389/fonc.2021.794744"]}
{"pair_type": "slc_pathway", "key1": "SLC16A11", "key2": "stemness", "summary": "The high-risk group exhibited higher proliferation and invasion capacity, MSI, and degree of stemness.\nM2 macrophages play a crucial role in promoting tumor angiogenesis and proliferation, as well as contributing to chemotherapy resistance and metastasis.", "dois": ["10.3389/fonc.2023.1170775"]}
{"pair_type": "slc_pathway", "key1": "SLC17A6", "key2": "apoptosis", "summary": "In the hippocampal dentate gyrus of male PND 21 offspring, GFAP(+) and BLBP(+) type-1 stem cells and PAX6(+) and TBR2(+) type-2 progenitor cells decreased in the subgranular zone (SGZ) at 9 and ≥3 ppm, respectively, in parallel with increased apoptosis at ≥3 ppm.\nInverse pattern in gene expression changes in vesicular glutamate transporter isoforms, Slc17a7 and Slc17a6, from weaning might also be responsible for the synaptic plasticity suppression.\nT-2 toxin decreased transcript levels of cholinergic and glutamate receptor subunits (Chrna4, Chrnb2 and Gria2) and glutamate transporter (Slc17a6) in the dentate gyrus, suggesting decreased cholinergic signals on hilar GABAergic interneurons innervating type-2 cells and decreased glutamatergic signals on type-1 and type-2 cells.\nNeurogenesis-related changes disappeared on PND 77, suggesting that T-2 toxin reversibly affects neurogenesis by inducing apoptosis of type-1 and type-2 cells with different threshold levels.", "dois": ["10.3389/fimmu.2024.1462003", "10.1016/j.toxlet.2021.06.006", "10.1007/s00204-015-1588-4"]}
{"pair_type": "slc_pathway", "key1": "SLC17A6", "key2": "migration", "summary": "Expression levels of mRNA of Slc17a6 and Gabrg3, involved in excitation and inhibition respectively, were significantly increased at 28days post-exposure, suggesting a possible role in the CN spontaneous hyperactivity associated with tinnitus and hyperacusis.\nPain/inflammatory gene expression changes via Ntrk1 signaling may induce sterile inflammation, neuropathic pain, microglial activation and migration of nerve fibers from the trigeminal, cuneate and vestibular nuclei into the CN.", "dois": ["10.1016/j.mcn.2016.07.005"]}
{"pair_type": "slc_pathway", "key1": "SLC17A6", "key2": "proliferation", "summary": "Furthermore, real-time PCR results demonstrated a decrease in COX2 expression and an increase in GPX1, MBP, and Slc17a6/7 expression due to the platform.\nOn PND 77, ARC granule cells decreased, and Nos2 was upregulated following 15.0 ppm STC exposure, suggesting oxidative stress-mediated synaptic plasticity suppression.\nIncreased p21 SGZ cell numbers and suppressed cholinergic signaling through CHRNB2-containing receptors in GABAergic interneurons suggested potential neurogenesis suppression mechanisms.\nhowever, this dose upregulated oxidative stress and neuroinflammation-related genes in the hippocampal dentate gyrus, and increased neural stem cells and proliferation activity of the subgranular zone in the dentate gyrus.\nOn PND 21, 15.0-ppm STC decreased type-3 neural progenitor cell numbers in the subgranular zone (SGZ) due to suppressed proliferation.\nInverse pattern in gene expression changes in vesicular glutamate transporter isoforms, Slc17a7 and Slc17a6, from weaning might also be responsible for the synaptic plasticity suppression.\nIncreased γ-H2AX-immunoreactive () cell numbers in the SGZ and Ercc1 upregulation and Brip1 downregulation in the dentate gyrus suggested induction of DNA double-strand breaks in SGZ cells.\nThe constitutive gene expression levels of Gria1, Gria2, Grin2d, Slc17a6, and Slc17a7 were altered in the hippocampal dentate gyrus and amygdala on PND 77.\nThe MTT assay, DAPI staining, and FE-SEM images confirmed the successful implantation, proliferation, adhesion, and survival of ADMSCs on the liposome-coated scaffold.", "dois": ["10.1038/s41598-025-15789-w", "10.1016/j.toxlet.2021.06.006", "10.1016/j.nutres.2020.10.007"]}
{"pair_type": "slc_pathway", "key1": "SLC17A6", "key2": "oxidative stress", "summary": "On PND 77, ARC granule cells decreased, and Nos2 was upregulated following 15.0 ppm STC exposure, suggesting oxidative stress-mediated synaptic plasticity suppression.\nAdditionally, decreased SCF/c-Kit interactions and increased oxidative stress may decrease type-1 and type-2 cells at 9 ppm.\nFurthermore, real-time PCR results demonstrated a decrease in COX2 expression and an increase in GPX1, MBP, and Slc17a6/7 expression due to the platform.\nInverse pattern in gene expression changes in vesicular glutamate transporter isoforms, Slc17a7 and Slc17a6, from weaning might also be responsible for the synaptic plasticity suppression.\nT-2 toxin decreased transcript levels of cholinergic and glutamate receptor subunits (Chrna4, Chrnb2 and Gria2) and glutamate transporter (Slc17a6) in the dentate gyrus, suggesting decreased cholinergic signals on hilar GABAergic interneurons innervating type-2 cells and decreased glutamatergic signals on type-1 and type-2 cells.\nHistological assessments revealed that the hybrid platform facilitated the regeneration of myelin and neurons, correlating with improved blood levels of oxidative markers.\nAdditionally, in vitro oxidative stress tests indicated that this platform exhibited superior antioxidant and anti-inflammatory effects for ADMSCs.\nThe constitutive gene expression levels of Gria1, Gria2, Grin2d, Slc17a6, and Slc17a7 were altered in the hippocampal dentate gyrus and amygdala on PND 77.\nAfter six weeks, the rats were subjected to real-time PCR and histological analysis, utilizing Cresyl Violet/Luxol Fast Blue staining and evaluating the expression of the genes COX2, GPX1, MBP, and Slc17a6/7.\nUpregulation of Apex1 and Ogg1 and downregulation of antioxidant genes downstream of NRF", "dois": ["10.1038/s41598-025-15789-w", "10.1016/j.toxlet.2021.06.006", "10.1007/s00204-015-1588-4", "10.1016/j.nutres.2020.10.007"]}
{"pair_type": "slc_pathway", "key1": "SLC17A7", "key2": "chemotherapy", "summary": "Herein, we show that bortezomib exposure leads to microglia activation and cognitive impairment, this occurs along with decreased nuclear translocation of TFEB (transcription factor EB), which is linked to macroautophagy/autophagy disorder, STAT3 (signal transducer and activator of transcription 3) phosphorylation and IL23A (interleukin 23 subunit alpha) expression.\nThus, the endothelial TFEB-STAT3-IL23A axis in the brain represents a critical cellular event for initiating bortezomib-mediated aberrant microglial activation and synapse engulfment.\nAs a consequence, we found that brain endothelial-specific ablation of ameliorated both microglia activation and cognitive dysfunction.\nHowever, OC patients still have an adverse prognosis due to emergency of chemotherapy resistance.\nPlatinum-based chemotherapy, especially carboplatin, is the primary measure to treat patients with ovarian cancer (OC).\nTherefore, identifying the key factors that affect chemotherapy resistance and searching novel treatments had become a top priority.\nCognitive impairment caused by systemic chemotherapy is a critical question that perplexes the effective implementation of clinical treatment, but related molecular events are poorly understood.\nOur results suggest the reversal of TFEB nuclear translocation may provide a novel therapeutic approach to prevent symptoms of cognitive dysfunction during clinical use of bortezomib.", "dois": ["10.1080/15548627.2022.2162244", "10.1177/15353702221083254"]}
{"pair_type": "slc_pathway", "key1": "SLC17A7", "key2": "glycolysis", "summary": "Comparison of CSIS-resilient and control rats identified downregulated mitochondrial proteins ATP synthase subunit beta (Atp5f1b) and citrate synthase (Cs), and upregulated protein kinase C gamma type (Prkcg), vesicular glutamate transporter 1 (Slc17a7), and synaptic vesicle glycoprotein 2 A (Sv2a) involved in signal transduction and synaptic trafficking.\nCSIS-resilient compared to CSIS-susceptible rat proteome analysis revealed, among other proteins, downregulated glycolysis intermediate fructose-bisphosphate aldolase C (Aldoc), and upregulated clathrin heavy chain 1 (Cltc), calcium/calmodulin-dependent protein kinase type II (Cam2a), synaptophysin (Syp) and fatty acid synthase (Fasn) that are involved in neuronal transmission, synaptic vesicular trafficking, and fatty acid synthesis.", "dois": ["10.1016/j.jpsychires.2024.02.042"]}
{"pair_type": "slc_pathway", "key1": "SLC17A7", "key2": "migration", "summary": "Gene silencing of SETDB1 reduces cell viability and migration.\nSETDB1 silencing further reduced cell migration of pHGG cells and the expression of the mesenchymal markers N-cadherin and vimentin.\nIn addition, SETDB1 silencing significantly increased the bivalent tumor suppressor gene SLC17A7 mRNA levels in both cell lines, indicating its implication in the oncogenic process.\nThere is evidence that targeting SETDB1 may effectively inhibit pHGG progression, providing a novel insight into the therapeutic strategies for pediatric gliomas.\nmRNA analysis of epithelial-mesenchymal transition (EMT) markers upon SETDB1 silencing showed a reduction in SNAI1 levels and downregulation of CDH2 along with the EMT regulator gene MARCKS.\nGene silencing of SETDB1 in two patient-derived pHGG cell lines showed a significant reduction in cell viability followed by reduced cell proliferation and increased apoptosis.\nSETDB1 silencing affects mesenchymal markers expression.\nAltogether, our findings demonstrate a predominant oncogenic role of SETDB1 in pHGG which along with elevated H3K9me3 levels correlate significantly to tumor progression and inferior patients' survival.", "dois": ["10.1007/s00109-023-02294-8", "PMID:25749033"]}
{"pair_type": "slc_pathway", "key1": "SLC17A7", "key2": "oxidative stress", "summary": "Inverse pattern in gene expression changes in vesicular glutamate transporter isoforms, Slc17a7 and Slc17a6, from weaning might also be responsible for the synaptic plasticity suppression.\nNos2 was upregulated following 15.0 ppm STC exposure, suggesting oxidative stress-mediated synaptic plasticity suppression.\nhowever, this dose upregulated oxidative stress and neuroinflammation-related genes in the hippocampal dentate gyrus, and increased neural stem cells and proliferation activity of the subgranular zone in the dentate gyrus.\nUpregulation of Apex1 and Ogg1 and downregulation of antioxidant genes downstream of NRF2-Keap1 signaling suggested induction of oxidative DNA damage.\nThe constitutive gene expression levels of Gria1, Gria2, Grin2d, Slc17a6, and Slc17a7 were altered in the hippocampal dentate gyrus and amygdala on PND 77.", "dois": ["10.1016/j.toxlet.2021.06.006", "10.1016/j.nutres.2020.10.007"]}
{"pair_type": "slc_pathway", "key1": "SLC17A8", "key2": "oxidative stress", "summary": "Overall, this study demonstrates that both daytime and nighttime noise can induce oxidative stress and impair embryonic development of zebrafish, with nighttime noise causing more severe damage.\nIn this study, zebrafish () embryos were exposed to control group (no additional noise), daytime noise (100-1000 Hz, 130 dB, from 08:00 to 20:00) or nighttime noise (100-1000 Hz, 130 dB, from 20:00 to 08:00) for 5 days, and their embryonic development and oxidative stress levels were analyzed.\nNoise exposure, particularly at night, elevated the activities of catalase (CAT) and glutathione peroxidase (GPX), as well as the concentration of malondialdehyde (MDA), accompanied by upregulation of antioxidant-related gene expression levels.\nMoreover, an involvement of processes related to oxidative stress response and sound-sensing in the pathology of Tourette syndrome seems likely.\nThree such variants, in the , and genes, could influence oxidoreductase activity in the brain.\nTwo variants, in and genes, were involved in sensory processing of sound by inner hair cells of the cochlea.", "dois": ["10.3390/ani15152310", "10.1503/jpn.220206"]}
{"pair_type": "slc_pathway", "key1": "SLC17A8", "key2": "apoptosis", "summary": "We identified how miR-626 causes apoptosis and macula degeneration in RPE cells by targeting SLC7A5 through the mTOR signaling pathway.", "dois": ["10.14715/cmb/2023.69.10.3"]}
{"pair_type": "slc_pathway", "key1": "SLC17A8", "key2": "proliferation", "summary": "The findings demonstrate that mir-626 inhibits SLC7A5 gene expression and proliferation of ARPE-19 cells.\nShort interfering RNA (siRNA) mediated suppression of SLC7A5, a predicted target of mir-626, has the same effect on ARPE-19 cells.\nWe investigated how miR-626 inhibits mTOR activity pathways and pathway-related genes in retinal pigment epithelial cells by targeting the solute carrier family seven-member 5 (SLC7A5) in ARPE19 cells.\nWe knocked down mir-626 levels and overexpression by mir-626-siRNA transfection of human RPE cell lines, and using an MTT assay, we assessed the role of SLC7A5 on RPE cell proliferation.\nmiR-626 was an essential regulator of the expression of the Slc7a5 gene.\nWe identified how miR-626 causes apoptosis and macula degeneration in RPE cells by targeting SLC7A5 through the mTOR signaling pathway.", "dois": ["10.14715/cmb/2023.69.10.3"]}
{"pair_type": "slc_pathway", "key1": "SLC17A7", "key2": "proliferation", "summary": "In addition, SETDB1 silencing significantly increased the bivalent tumor suppressor gene SLC17A7 mRNA levels in both cell lines, indicating its implication in the oncogenic process.\nGene silencing of SETDB1 in two patient-derived pHGG cell lines showed a significant reduction in cell viability followed by reduced cell proliferation and increased apoptosis.\nThe findings demonstrate that mir-626 inhibits SLC7A5 gene expression and proliferation of ARPE-19 cells.\nShort interfering RNA (siRNA) mediated suppression of SLC7A5, a predicted target of mir-626, has the same effect on ARPE-19 cells.\nWe knocked down mir-626 levels and overexpression by mir-626-siRNA transfection of human RPE cell lines, and using an MTT assay, we assessed the role of SLC7A5 on RPE cell proliferation.\nGene ontology analysis suggested effects of CMA on cellular processes, such as cell adhesion, proliferation, fuel metabolism, and biotransformation.\nhowever, this dose upregulated oxidative stress and neuroinflammation-related genes in the hippocampal dentate gyrus, and increased neural stem cells and proliferation activity of the subgranular zone in the dentate gyrus.\nOn PND 21, 15.0-ppm STC decreased type-3 neural progenitor cell numbers in the subgranular zone (SGZ) due to suppressed proliferation.\nIncreased p21 SGZ cell numbers and suppressed cholinergic signaling through CHRNB2-containing receptors in GABAergic interneurons suggested potential neurogenesis suppression mechanisms.\nGene silencing of SETDB1 reduces cell viability and migration.\nSETDB1 silencing further reduced cell migration of pHGG cells and the expression of the mesenchymal markers N-cadherin and vimentin.\nInterestingly, 27 upregulated transcripts (e.g., Aqp1, Cacnb1, Atp1a2, Kcnab2, and Slc", "dois": ["10.14715/cmb/2023.69.10.3", "10.1007/s00109-023-02294-8", "10.1016/j.toxlet.2021.06.006", "10.1016/j.nutres.2020.10.007", "PMID:25749033", "10.1007/s11010-008-9931-1"]}
{"pair_type": "slc_pathway", "key1": "SLC17A9", "key2": "chemotherapy", "summary": "There were significant differences in clinicopathological features, immune checkpoints and infiltration, responsiveness to immunotherapy and chemotherapy, cancer stem cell, and biological pathways among the molecular subtypes.\nDifferences in clinicopathological features, immune infiltration, immune checkpoints, responsiveness to immunotherapy and chemotherapy, and biological pathways were assessed according to molecular subtypes and the risk signature.", "dois": ["10.1155/2023/6245160"]}
{"pair_type": "slc_pathway", "key1": "SLC18A1", "key2": "ferroptosis", "summary": "AIF1L may regulate MSI CRC progression by promoting ferroptosis, serving as a prospective biomarker for prognosis and a therapeutic target for personalized therapy.\nIn vitro experiments showed that AIF1L boosted cell proliferation and migration via modulating ferroptosis, showing correspondence with in vivo experiments.\nAIF1L exhibited elevated expression in MSI-H groups and demonstrated a significant correlation with ferroptosis and immune cell infiltration.\nDifferential expression analysis, weighted gene coexpression network analysis, and Cox regression models were employed to identify five cell death-related prognostic genes (POU4F1, AIF1L, SLC18A1, INSL4, and HOXC6).", "dois": ["10.1155/humu/6663166"]}
{"pair_type": "slc_pathway", "key1": "SLC17A9", "key2": "apoptosis", "summary": "AZD5153 treatment inhibited HCC cell proliferation, clonogenic survival and induced apoptosis in HCC cells.\nImportantly, miR-3150a-3p overexpression was related to the increased proliferation and decreased apoptosis of PCa cells.\nAccording to our results, LINC01679 depletion promoted cell proliferation, metastasis, tumor growth, and inhibited cell apoptosis and , which was also associated with poor survival.\nImportantly, SLC17A9 downregulation rescued the repression on PCa progression mediated by LINC01679 upregulation.\nIn addition, LINC01679 is the ceRNA that suppresses PCa development through modulating the miR-3150a-3p/SLC17A9 axis.\nRescue assays suggested that miR-3150a-3p mimics rescued the repression on PCa progression mediated by LINC01679 upregulation, but SLC17A9 downregulation reversed the miR-3150a-3p inhibitor-mediated repression on PC progression.", "dois": ["10.3389/fcell.2022.853652", "10.3389/fcell.2021.737812"]}
{"pair_type": "slc_pathway", "key1": "SLC17A9", "key2": "ferroptosis", "summary": "SLC17A9 expression correlates with tumor immune infiltration, m6A modification, and ferroptosis in LIHC and may have diagnostic and prognostic value in LIHC.\nand ferroptosis: HSPA5 (r = 0.240, p < 0.001), SLC7A11 (r = 0.180, p < 0.001), and FANCD2 (r = 0.280, p < 0.001).\nTIMER, GEPIA, and TCGA analyzed the relationship between SLC17A9 expression and immune cells, m6A modification, and ferroptosis.\nSLC17A9 silencing inhibited HepG2 cells proliferation, migration, colony formation, and reduced their ATP level.\nSLC17A9 expression in LIHC tissues was higher than in normal liver tissues (p < 0.001), and SLC17A9 was related to sex, DSS (disease-specific survival), and PFI (progression-free interval) (p = 0.015, 0.006, and 0.023).\nOur data show that SLC17A9 may influence LIHC progression.\nGene Ontology/Kyoto Encyclopedia of Genes and Genomes (GO/KEGG) functional enrichment analysis showed that SLC17A9 was closely related to neuronal cell body, presynapse, axonogenesis, PI3K/Akt signaling pathway.\nSLC17A9 expression level was related to immune cells: B cells (r = 0.094, P = 8.06E-02), CD4 T cells (r = 0.184, P = 5.95E-04), and macrophages (r = 0.137, P = 1.15E-02);\nm6A modification: HNRNPC (r = 0.220, p < 0.001), METTL3 (r = 0.180, p < 0.001), and WTAP (r = 0.130, p = 0.009);", "dois": ["10.3389/fonc.2022.809847"]}
{"pair_type": "slc_pathway", "key1": "SLC17A9", "key2": "stemness", "summary": "Mechanistically, ABI2 serving as a co-activator of transcriptional factor HHEX upregulated SLC17A9 to promote HCC cancer stem cell-like properties and tumorigenesis.\nMoreover, bioinformatics analysis and experiments verified that HHEX promoted stem cell-like properties in HCC.\nCollectively, the HHEX-mediated ABI2/SLC17A9 axis contributes to HCC growth and metastasis by maintaining the CSC population, suggesting that HHEX serves as a promising therapeutic target for HCC treatment.\nCancer stem cells (CSCs) are responsible for cancer progression owing to their stemness characteristics.\nThe results of the present study revealed correlations between stemness indices, tumor immunity and expression levels.\nNext, the involvement of in the prognosis of patients, stemness indices and the immune microenvironment was examined in 34 types of cancer.\nWe reported that HHEX was a novel CSCs target for HCC.", "dois": ["10.1186/s12967-024-05324-2", "10.3892/ol.2023.13969"]}
{"pair_type": "slc_pathway", "key1": "SLC17A7", "key2": "apoptosis", "summary": "Gene silencing of SETDB1 in two patient-derived pHGG cell lines showed a significant reduction in cell viability followed by reduced cell proliferation and increased apoptosis.\nThe neurotoxicity induced by the mitochondrial inhibitor 3-nitropropionic acid (3-NPA) is associated with a decrease of ATP synthesis and an increase of free radical production which can lead to apoptosis or necrosis.\nThe improved cognitive functions could be attributed to increased synaptic connections and plasticity, which was confirmed by the modulation of the γ-aminobutyric acid receptor system and the elevated expression of microtubule-associated protein 2, synaptophysin and Slc17a7 (vesicle glutamate transporter, Vglut1), as well as by the inhibition of Cdh2 cleavage.\nIn addition, SETDB1 silencing significantly increased the bivalent tumor suppressor gene SLC17A7 mRNA levels in both cell lines, indicating its implication in the oncogenic process.\nOn PND 77, ARC granule cells decreased, and Nos2 was upregulated following 15.0 ppm STC exposure, suggesting oxidative stress-mediated synaptic plasticity suppression.\nIncreased p21 SGZ cell numbers and suppressed cholinergic signaling through CHRNB2-containing receptors in GABAergic interneurons suggested potential neurogenesis suppression mechanisms.\nInverse pattern in gene expression changes in vesicular glutamate transporter isoforms, Slc17a7 and Slc17a6, from weaning might also be responsible for the synaptic plasticity suppression.\nInterestingly, the glutamate transporter slc17a7, carnitine-acylcarnitine translocase Slc25a20 and heat shock proteins genes, Hsp27, Hmox1 (Hsp32, HO1) as well as Hspa 1a (Hsp 70) increased only when both ALC and small dose of 3-NPA were present.", "dois": ["10.3389/fimmu.2024.1462003", "10.1016/j.toxlet.2021.06.006", "PMID:25749033", "10.1111/j.1582-4934.2010.01248.x", "10.14715/cmb/2023.69.10.3", "10.1007/s00109-023-02294-8", "10.2174/157015911795017182"]}
{"pair_type": "slc_pathway", "key1": "SLC18A2", "key2": "apoptosis", "summary": "After Pls treatment, the striking expression changes of , , , and mRNA strongly suggest that Pls exerts a beneficial role in alleviating AD pathology partly by modulating the neurotransmitter release and synaptic transmission at the transcriptional level.", "dois": ["10.3389/fnagi.2021.773713"]}
{"pair_type": "slc_pathway", "key1": "SLC18A1", "key2": "migration", "summary": "In vitro experiments showed that AIF1L boosted cell proliferation and migration via modulating ferroptosis, showing correspondence with in vivo experiments.\nDifferential expression analysis, weighted gene coexpression network analysis, and Cox regression models were employed to identify five cell death-related prognostic genes (POU4F1, AIF1L, SLC18A1, INSL4, and HOXC6).", "dois": ["10.1155/humu/6663166", "10.1002/evl3.81"]}
{"pair_type": "slc_pathway", "key1": "SLC18A2", "key2": "proliferation", "summary": "The downregulation of miR-421 and miR-550a-3p with inhibitor markedly suppressed the proliferation, invasion, and migration in OE33 cells compared with the negative control.\nThe proliferation, invasion, and migration of EAC cells were assessed using CCK8 and transwell assays.\nNECs in the hypoxia group showed high expression of genes involved in cell cycle control and proliferation.\nThe identity of NECs was confirmed by expression of slc18a2, encoding the vesicular monoamine transporter, Vmat2.\nInflammation, marked by the infiltration of inflammatory mediators and the proliferation of inflammatory cells, is closely linked to PD.\nA total of 20 target mRNAs of three miRNAs were predicted, among which seven target mRNAs-ASAP3, BCL2L2, LMF1, PPM1L, PTPN21, SLC18A2, and NR3C2-had prognostic value.", "dois": ["10.1155/padi/2323585", "10.1186/s13062-022-00352-8", "10.1038/s41598-022-13693-1"]}
{"pair_type": "slc_pathway", "key1": "SLC19A1", "key2": "stemness", "summary": "High SLC19A1 levels were associated with increased genomic instability and immune suppression.\nWe analyzed multi-omics data from a pan-cancer cohort to evaluate SLC19A1 expression and its association with multiple features, including prognosis, tumor stemness, genome instability, and immune infiltration.\nOur findings position SLC19A1 as a novel unfavorable prognostic marker in cancer, closely linked to immune suppression and genomic instability.\nSLC19A1 was found to be overexpressed in multiple cancer types compared to normal tissues, correlating with poor prognosis.\nIn addition, SLC19A1 was negatively correlated with CD8+ T-cell infiltration and positively correlated with M2 macrophage infiltration.\nThe association of SLC19A1 with M2 macrophages was confirmed in multiple immunofluorescence staining.\nFinally, SLC19A1 was associated with the response to chemotherapy and immunotherapy in a variety of tumors.", "dois": ["10.3390/biomedicines13030571"]}
{"pair_type": "slc_pathway", "key1": "SLC18A1", "key2": "proliferation", "summary": "SH-SY5Y cells can be induced to mature neurons with decreased proliferation induced by bexarotene via PI3K-Akt axis.\nAdditionally, we observed that SH-SY5Y cells show reduced proliferation rates accompanied by decreased expression of cyclin-dependent kinase 6 (CDK6) and increased expression of cyclin-dependent kinase 1 (CDK1) following 7-day exposure to bexarotene, suggesting bexarotene induces a quiescent state in SH-SY5Y cells.\nSH-SY5Y cells induced by bexarotene increased the expression of GABAergic marker glutamate decarboxylase (GAD1) and dopaminergic marker TH, but not glutamatergic marker glutamate-ammonia ligase (GLUL) and cholinergic marker solute carrier family 18 member 1 (SLC18A1).\nAIF1L may regulate MSI CRC progression by promoting ferroptosis, serving as a prospective biomarker for prognosis and a therapeutic target for personalized therapy.\nIn vitro experiments showed that AIF1L boosted cell proliferation and migration via modulating ferroptosis, showing correspondence with in vivo experiments.\nDifferential expression analysis, weighted gene coexpression network analysis, and Cox regression models were employed to identify five cell death-related prognostic genes (POU4F1, AIF1L, SLC18A1, INSL4, and HOXC6).", "dois": ["10.1155/humu/6663166", "10.1007/s12035-025-04888-4", "PMID:17242179"]}
{"pair_type": "slc_pathway", "key1": "SLC17A9", "key2": "migration", "summary": "TGF-β1-induced cell migration and actin remodeling were also decreased in SLC17A9-knockdown cells.\nFunctionally, SLC17A9 knockdown inhibited the proliferation, migration, and invasion activity of renal cancer cells, whereas its overexpression led to stronger cell viability and more malignant phenotype.\nSLC17A9 silencing inhibited HepG2 cells proliferation, migration, colony formation, and reduced their ATP level.\nKnockdown of P2X7 receptor suppressed TGF-β1-induced migration and actin remodeling.\nTGF-β1-induced actin remodeling, which contributes to cell migration, was also suppressed by pretreatment with ecto-nucleotidase and P2 receptor antagonists.\nTreatment with TGF-β1 facilitated migration of human lung cancer A549 cells, which was blocked by pretreatment with ecto-nucleotidase and P2 receptor antagonists.\nMechanistically, SLC17A9 could upregulate the expression of PTHLH, thus promoting epithelial-mesenchymal transition (EMT) in ccRCC.\nThese results indicate the involvement of TGF-β1-induced ATP release in cell migration, at least in part, through activation of P2X7 receptors.\nFurthermore, down-regulation of LINC01836 or increased expression of miR-1226-3p markedly reversed the effects of SLC17A9 overexpression on colorectal cancer cells.\nMechanistically, ABI2 serving as a co-activator of transcriptional factor HHEX upregulated SLC17A9 to promote HCC cancer stem cell-like properties and tumorigenesis.\nWe conclude that autocrine signaling through exocytosis of ATP and activation of P2 receptors is required for the amplification of TGF-β1-induced migration of lung cancer cells.\nThis study showed that LINC01836 regulated the expression of SLC17A9 through sponge miR-1226-3p by acting as a competitive endogenous RNA (ceRNA), promoted the progression of colorectal cancer, and suggested a new", "dois": ["10.31083/FBL38061", "10.1186/s12967-024-05324-2", "10.2174/0109298665248028231122064831", "10.1016/j.isci.2022.105764", "10.3389/fonc.2022.809847", "10.1242/jcs.104976"]}
{"pair_type": "slc_pathway", "key1": "SLC18A2", "key2": "oxidative stress", "summary": "VMAT2 function and related vesicle dynamics have been linked to susceptibility to oxidative stress, exogenous toxicants, and Parkinson's disease.\nAccumulation of dopamine in the neuronal cytosol can trigger oxidative stress and neurotoxicity, suggesting that the proper compartmentalization of dopamine is critical for neuron function and risk of disease.\nHowever, no evidences of oxidative stress were found in the brain of the treated fish.", "dois": ["10.3389/fphar.2021.770319", "10.1016/j.jchemneu.2016.11.003", "10.1111/ejn.13357"]}
{"pair_type": "slc_pathway", "key1": "SLC19A3", "key2": "oxidative phosphorylation", "summary": "The cerebral cortex and thalamus of affected dogs were severely deficient in TPP-dependent enzymes accompanied by decreases in mitochondrial mass and oxidative phosphorylation (OXPHOS) capacity, and increases in oxidative stress.\nThese results along with the behavioral and pathological findings indicate that the phenotype associated with AHE is consistent with a brain-specific thiamine deficiency, leading to brain mitochondrial dysfunction and increased oxidative stress.\nConsidering that brain is particularly vulnerable to thiamine deficiency because of its reliance on thiamine pyrophosphate (TPP)-dependent metabolic pathways involved in energy metabolism and neurotransmitter synthesis, we characterized the impact of this mutation on thiamine status, brain bioenergetics and the contribution of oxidative stress to this phenotype.", "dois": ["10.1042/BSR20220194", "10.1111/bpa.12188"]}
{"pair_type": "slc_pathway", "key1": "SLC19A1", "key2": "migration", "summary": "LND fibroblasts maintained with Plasmax-PV show metabolic adaptations such a higher glycolytic capacity, increased expression of the folate carrier SCL19A1, and functional alterations such a decreased mitochondrial potential and reduced cell migration compared to controls.\nThese alterations can be reverted with high levels of folic acid, suggesting that folic acid supplements might be a potential treatment for LND.", "dois": ["10.1186/s10020-023-00774-8"]}
{"pair_type": "slc_pathway", "key1": "SLC19A3", "key2": "oxidative stress", "summary": "Altogether, our results disclose that the c.1264 A > G (p.T422A) variant in SLC19A3 affects vitB1 transport, induces a mtDNA depletion and reduces the expression level of oxidative stress enzymes, altogether contributing to the LS phenotype of the patient.\nWe further disclosed decreased plasma antioxidant activities of CAT, SOD and GSH enzymes, and a 42% decrease of the mtDNA copy number in patient blood.\nThe cerebral cortex and thalamus of affected dogs were severely deficient in TPP-dependent enzymes accompanied by decreases in mitochondrial mass and oxidative phosphorylation (OXPHOS) capacity, and increases in oxidative stress.\nThese results along with the behavioral and pathological findings indicate that the phenotype associated with AHE is consistent with a brain-specific thiamine deficiency, leading to brain mitochondrial dysfunction and increased oxidative stress.\nConsidering that brain is particularly vulnerable to thiamine deficiency because of its reliance on thiamine pyrophosphate (TPP)-dependent metabolic pathways involved in energy metabolism and neurotransmitter synthesis, we characterized the impact of this mutation on thiamine status, brain bioenergetics and the contribution of oxidative stress to this phenotype.\nits deficiency results in oxidative stress and mitochondrial dysfunction.\nOxidative stress accompanies neurodegeneration and also causes abnormalities in thiaminedependent processes.\nMolecular docking revealed that the p.T422A aa change is located at a key position interacting with vitB1 and causes conformational changes compromising vitB1 import.\nIn silico modeling of the mutated transporter indicated a significant loss of alpha-helices resulting in a more open protein structure suggesting an impaired thiamine transport ability.", "dois": ["10.1007/s11011-023-01280-w", "10.17219/acem/63091", "10.1371/journal.pone.0143575", "10.1111/bpa.12188"]}
{"pair_type": "slc_pathway", "key1": "SLC18A2", "key2": "migration", "summary": "A total of 20 target mRNAs of three miRNAs were predicted, among which seven target mRNAs-ASAP3, BCL2L2, LMF1, PPM1L, PTPN21, SLC18A2, and NR3C2-had prognostic value;\nMoreover, the downregulation of miR-421 and miR-550a-3p with inhibitor markedly suppressed the proliferation, invasion, and migration in OE33 cells compared with the negative control.", "dois": ["10.1186/s13062-022-00352-8"]}
{"pair_type": "slc_pathway", "key1": "SLC20A2", "key2": "proliferation", "summary": "A mutation in SLC20A2 (c.C1849T) led to a change in an amino acid (p.R617C), which may be involved in the development of HME by inducing metabolic disorders of phosphate and abnormal proliferation and differentiation in chondrocytes.\nThe results showed that hBMECs silenced for SLC20A1 or SLC20A2 had decreased proliferative and angiogenic ability, as well as VE-cadherin expression.\nPDGFRB encodes for the platelet-derived growth factor receptor-β (PDGFRβ), a cell-surface tyrosine-kinase (RTK) receptor that regulates cell proliferation, migration, survival and differentiation.\nThe intracellular Pi concentration ([Pi]) remained constant in SLC20A1-silenced hBMECs whereas it increased in SLC20A2-silenced cells.\nThus, increased [Pi] in SLC20A2-silenced hBMECs may have a small impact on phenotypic changes.\nIn conclusion, abnormalities in Pi homeostasis caused by SLC20A2 depletion were suggested to play a minor role in PBC endothelial pathology.\nWe assessed the primary phenotypes of vascular endothelial cells, such as proliferation, tube formation, and VE-cadherin expression.\nTube formation ability was no change even at 3 mM, a concentration higher than [Pi] which was increased in SLC20A2-silenced hBMECs.\nIt was hypothesized that SLC20A2 mutations cause brain calcification most likely through haploinsufficiency.\nSLC20A2 gene codes for the 'sodium-dependent phosphate transporter 2' (PiT-2), a cell membrane transporters of inorganic phosphate, involved in Pi uptake by cells and maintenance of Pi body levels.\nA previous study founded that the SLC20 family, which includes SLC20A1 and SLC20A2, contributes to Pi homeostasis in the central nervous system.\nIn the brains of patients with PBC, calcification occurs in the cerebral small vessels, and it is primarily caused by mutated SLC", "dois": ["10.1016/j.yexcr.2025.114556", "10.1097/MNH.0000000000000984", "10.1302/2046-3758.911.BJR-2020-0112.R1", "10.3892/mmr.2020.11298", "10.1007/s10072-015-2110-8"]}
{"pair_type": "slc_pathway", "key1": "SLC20A1", "key2": "oxidative phosphorylation", "summary": "We also found numerous additional candidate regulators of mammalian phosphate homeostasis, including genes modifying protein ubiquitination and the Krebs cycle and oxidative phosphorylation pathways.", "dois": ["10.1016/j.jbc.2022.101945"]}
{"pair_type": "slc_pathway", "key1": "SLC19A3", "key2": "migration", "summary": "Thiamine depletion reduced cell viability and proliferation, while thiamine over-supplementation compensated for thiamine transporter 2 reduction by restoring thiamine uptake and transketolase activity.\nThe effects of thiamine depletion on cell function (viability, apoptosis and migration) were also addressed.\nThiamine transporter 2 modulation in our cell models suggests its major role in thiamine transport in retinal cells and its involvement in high glucose-induced damage and impaired thiamine availability.", "dois": ["PMID:38330587", "10.1177/1479164119878427"]}
{"pair_type": "slc_pathway", "key1": "SLC20A2", "key2": "glycolysis", "summary": "The genes involved in both glycolysis pathway (LDHA) and tricarboxylic acid cycle (IDH2 and OGDH) were up-regulated in gills and heart of hypoxic large yellow croakers, possibly because gill and heart tissues need enough energy to accelerate gas exchange and blood circulation.\nHypoxia also affected the ion transport in gills of large yellow croaker, through down-regulating the expression levels of numerous classical ion transporters, including HVCN1, SLC20A2, SLC4A4, RHBG, RHCG, and SCN4A, suggesting an energy conservation strategy to hypoxia stress.\nAll these results indicate that the immune processes, glycolytic pathways, and ion transport were significantly altered in gills and/or heart of large yellow croaker under hypoxia, possibly contributing to maintain cellular energy balance during hypoxia.", "dois": ["10.1097/MNH.0000000000000984", "10.1016/j.fsi.2020.06.028"]}
{"pair_type": "slc_pathway", "key1": "SLC20A1", "key2": "apoptosis", "summary": "Overexpression of SLC20A1-1 inhibited NPC growth, promoted NPC apoptosis, and enhanced macrophage recruitment and migration.\nOverall, SLC20A1-1, an IDD regulator, is involved in TNF-α-induced NPC apoptosis by sponging miR-146a-5p.\nPiT1/SLC20A1 is an inorganic phosphate transporter with additional functions including the regulation of TNFα-induced apoptosis, erythropoiesis, cell proliferation and insulin signaling.\nThese results strongly suggest that overexpression of SLC20A1 promotes apoptosis and mineralization by altering the level of Akt-1.\nMoreover, we found that SLC20A1-1 could suppress miR-146a-5p to induce TRAF6 and caspase 3 expression.\nThe PIT1/SLC20A1 protein, a well-described sodium/phosphate cotransporter and retrovirus receptor, has been identified recently as a modular of proliferation and apoptosis in vitro.\nWe have discovered that mice lacking PiT1 develop a profound underproduction anemia characterized by mild macrocytosis, dyserythropoiesis, increased apoptosis, and a near complete block in terminal erythroid differentiation.\nInhibition of Pi transporters with phosphonoformic acid (PFA) prevented Pi-mediated apoptosis of VICs.\nThe expression of SLC20A1-1 was significantly upregulated in herniated lumbar discs, and TNF-α induced SLC20A1-1 expression in NPCs.\nWe then showed that lysophosphatidylcholine-induced mineralization involved ectonucleotidase enzyme as well as apoptosis through a protein-kinase-A-dependent pathway.\nThese results suggested that was involved in cell survival via the suppression of caspase-3-dependent apoptosis, and contributed to cancer progression and poor clinical outcomes in PDAC.\nMechanistically, the acute Pi metabolic inhibition in HSCs results from extrinsic Pi loss in the bone marrow niche and the", "dois": ["10.1016/j.lfs.2023.121726", "10.1089/gtmb.2021.0222", "10.1002/pmic.202000311", "10.1038/s41598-018-37551-1", "10.1016/j.exphem.2013.01.004", "10.1371/journal.pone.0053393", "10.1074/jbc.M110.130989", "10.1371/journal.pone.0009148", "10.3892/ol.2024.14558", "10.3390/nu14163395", "10.3389/fcell.2020.00567", "10.1681/ASN.2014070642", "10.1016/j.jacc.2013.05.105", "10.1182/blood-2012-05-427302", "10.1007/s00439-010-0915-3"]}
{"pair_type": "slc_pathway", "key1": "SLCO2A1", "key2": "chemotherapy", "summary": "Rs1045642 in ABCB1, rs1047303 in HSD3B1, rs1856888 in HSD3B1, rs523349 in SRD5A2, and rs34550074 in SLCO2A1 were differentially associated with TTP between docetaxel chemotherapy and ARPI treatment.\nThe low-risk group was more sensitive to chemotherapy, such as cisplatin, gemcitabine, and vinorelbine.\nThe internal and external validation demonstrated that the 5-gene risk score (LOXL4, SLCO2A1, CST2, PDK4, and MMP11) was an effective instrument for the prognostic risk classification of GC patients.\nThe prognostic and predictive values of the SNPs for time to progression (TTP) were examined using the Cox hazard proportional model and interaction test, respectively.\nThis study identified SNPs that could predict progression as well as genetic models that could predict progression when patients were treated with docetaxel versus ARPI and abiraterone versus enzalutamide.\nGenetic predictive models using these SNPs showed a differential prognosis for treatments.", "dois": ["10.1111/cas.15718", "10.1016/j.compbiomed.2022.106037", "10.1200/JCO.2014.59.0273"]}
{"pair_type": "slc_pathway", "key1": "SLCO4A1", "key2": "ferroptosis", "summary": "The lncRNA SLCO4A1-AS1 was identified as a novel molecule mediating ferroptosis resistance in vitro.\nBIRC5, SLCO4A1, POPDC3, and HK2 were found to be downregulated in stage MS NB and related to apoptosis.\nFerroptosis is a form of regulated cell death initiated by oxidative perturbations that can be blocked by iron chelators and lipophilic antioxidants, and ferroptosis may be the silver bullet treatment for multiple cancers, including immunotherapy- and chemotherapy-insensitive cancers such as pancreatic ductal adenocarcinoma (PDAC).\nFerroptosis is an iron-dependent form of non-apoptotic regulated cell death, which could affect cancer development.", "dois": ["10.1093/bib/bbab388", "10.3389/fonc.2022.1083570", "10.3389/fgene.2021.785839"]}
{"pair_type": "slc_pathway", "key1": "SLC19A1", "key2": "proliferation", "summary": "Although SLC19A1 mRNA and protein expression were unaltered, remarkably, mitogen induced-T cell proliferation was significantly reduced at suboptimal folic acid and supraoptimal folinic acid concentrations.\nEVs with high expression of circ_SLC19A1 could be taken up by PCa cells, which promoted cell proliferation and invasion.\nIn these experiments, we performed RNA immunoprecipitation (RIP) and identified SLC19A1-AS as a ceRNA in goat granulosa cells that promoted proliferation.\nIn MCF10A and Hs578T cells, FA treatment decreased pathways associated with apoptosis, cell death and senescence, but increased those associated with cell proliferation.\nIn an in vitro study using synovial cells from arthritic mice, IL-6 + soluble IL-6 receptor (sIL-6R) weakened the anti-proliferative effect of MTX and reduced SLC19A1 expression.\nTransfection of circ_SLC19A1 small interfering RNA (siRNA) or miR-497 mimics could significantly inhibit the expression of SEPT2 and the phosphorylation of extracellular signal-regulated kinase 1 and 2 (ERK1/2).\nTherefore, cancer cells can regulate the expression of SEPT2 through miR-497 by secreting EVs with high expression of circ_SLC19A1, thus affecting the activation of the downstream ERK1/2 pathway and ultimately regulating PCa cell growth and invasion.\nThese findings suggest that physiological concentrations of FA can induce cell type-specific changes in gene regulation in a manner that is consistent with proliferative phenotype.\nMYBL2 and gene enrichment analyses in osteosarcoma and pan-cancer revealed that MYBL2 was positively correlated with cell proliferation and tumor immune pathways.\nFD caused cell cycle arrest at G0/G1 phase and increased the rate of apoptosis, which was associated with disrupted expression of folate transport and methyl transfer genes.\nHere we use HT-22 hippocampal neuron cells as model to investigate the effect of folate deprivation (FD) on", "dois": ["10.3389/fphar.2024.1450418", "10.1016/j.ijbiomac.2024.130658", "10.1158/1535-7163.MCT-23-0550", "10.1016/j.gendis.2023.04.035", "10.1038/s41421-022-00508-w", "10.1038/s41435-022-00191-7", "10.1038/s41598-022-13835-5", "10.3389/fgene.2021.670582", "10.1002/cbin.11303", "10.3727/096504017X14841698396900", "10.1016/j.biocel.2016.08.040", "10.1017/jns.2016.8", "10.5507/bp.2015.014", "PMID:23956837", "10.1186/ar3821"]}
{"pair_type": "slc_pathway", "key1": "SLCO2A1", "key2": "apoptosis", "summary": "Activation of PPARγ promoted cell proliferation and mobility, but inhibited apoptosis.\nMiR-1306-5p overexpression led to a decrease in colorectal cancer cell proliferation, migration, and invasion, while promoting apoptosis.\nBy targeting SLCO2A1, overexpression of miR-1306-5p could inhibit the PI3K/AKT/mTOR signaling pathway.\nOverexpression of miR-1306-5p inhibited the colorectal cancer cell malignant phenotypes via regulating PI3K/AKT/mTOR signaling pathway regulation by targeting SLCO2A1.\nAs an efficient pathway for chloride, Maxi-Cl is implicated in a number of physiologically and pathophysiologically important processes, such as cell volume regulation, fluid secretion, apoptosis, and charge transfer.\nIts identification as a complex with SLCO2A1 as a core pore-forming component and two auxiliary regulatory proteins, annexin A2 and S100A10 (p11), explains the activation mechanism as Tyr23 dephosphorylation at ANXA2 in parallel with calcium binding at S100A10.\nIn the resting state, SLCO2A1 functions as a prostaglandin transporter whereas upon activation it turns to an anion channel.\nMoreover, it was discovered that SLCO2A1 was a target of miR-1306-5p.\nThe internal and external validation demonstrated that the 5-gene risk score (LOXL4, SLCO2A1, CST2, PDK4, and MMP11) was an effective instrument for the prognostic risk classification of GC patients.\nA universally applicable prognostic signature of GC is proposed in this research based on pyroptosis, apoptosis, and necroptosis (PAN) molecular subtypes.", "dois": ["10.1016/j.compbiomed.2022.106037", "PMID:26464663", "10.1097/CAD.0000000000000232", "10.1158/0008-5472.CAN-07-6458", "10.1111/rda.14471", "10.1080/15384101.2022.2054245", "10.3390/life11060509"]}
{"pair_type": "slc_pathway", "key1": "SLC20A1", "key2": "glycolysis", "summary": "Among them, six RBPs (PGK1, SLC20A1, LEPR, CYP19A1, ZC3H12D, and PFKM) were shown to be the prognosis-related hub RBPs (prhRBPs).\nAs suggested in functional annotation analysis, we found an intensive enrichment of these prhRBPs in metabolic pathways, including AMPK, HIF-1 signaling pathway, Glycolysis, and steroid hormone biosynthesis.", "dois": ["10.1097/MNH.0000000000000984", "10.7150/jca.52156"]}
{"pair_type": "slc_pathway", "key1": "SLC19A2", "key2": "glycolysis", "summary": "By incorporating cofactor dependency and subcellular localization, PM identified a coordinated suppression of multivitamin transporters (e.g., -4.5% in SLC5A6, -3.5% in SLC19A2), potentially limiting cofactor availability and compounding energy deficits in ASD brains.\nWe propose that chronic microbial lipopolysaccharide (LPS) exposure in ASD suppresses vitamin transporter function, initiating mitochondrial dysfunction and transcriptomic reprogramming.\nUsing unsupervised machine learning (Isolation Forest) to detect outlier expression patterns, Euclidean distance, and percent expression difference metrics, PM revealed a consistent downregulation of glycolysis (e.g., -5.4% in PFKM) and mitochondrial enzymes (e.g., -12% in SUCLA2).\nwherein the subtle suppression of cofactor-dependent pathways may impair energy metabolism and neurodevelopment.\nThese findings suggest a convergent metabolic dysregulation signature in ASD;", "dois": ["10.3390/metabo15060399"]}
{"pair_type": "slc_pathway", "key1": "SLCO2A1", "key2": "glycolysis", "summary": "The uptake of IR-780 in fibroblasts mediated by HIF-1α/SLCO2A1 and the metabolic properties of IR-780 fibroblasts were investigated using RNA interference or signaling inhibitors.\nFurther results identified that SLCO2A1 is involved in the preferential uptake of IR-780 in fibrogenic fibroblasts, which is regulated by HIF-1α.\nVery recently, elevated glycolysis is demonstrated to play a pivotal role in the determination of fibrogenic phenotype of fibroblasts.\nIR-780 is demonstrated to recognize a unique glycolytic fibroblast lineage, which is responsible for the bulk of connective tissue deposition during cutaneous wound healing and cancer stroma formation.\nThe proteins involved in glycolysis and glycogenolysis were suppressed in shINSR cells.\nThe expressions of BBB transporters, including the ABCB1/MDR1, ABCG2/BCRP, and SLCO2A1/OATP2A1 were significantly decreased by more than 50% in shINSR cells.", "dois": ["10.7150/thno.36375", "10.1007/s11095-021-03131-8"]}
{"pair_type": "slc_pathway", "key1": "SLC19A1", "key2": "chemotherapy", "summary": "Slc19a1) mediated transport of reduced folates and antifolate drugs such as methotrexate (MTX) play an essential role in physiological folate homeostasis and MTX cancer chemotherapy.\nFinally, SLC19A1 was associated with the response to chemotherapy and immunotherapy in a variety of tumors.\nERCC1, ERCC2, XRCC1, MDM2, MTHFR, MTR, and SLC19A1 gene polymorphisms may contribute to individual variation in response and survival to platinum-based chemotherapy.\nIn conclusion, our results suggest that ERCC1 rs3212986, XRCC1 rs25487, MDM2 rs1690924, MTR rs1805087, and SLC19A1 rs1051266 gene polymorphisms may significantly act as predictive factors in NSCLC patients treated with platinum-based chemotherapy.\nRfc1 mediated transport of reduced folates and antifolate drugs such as methotrexate (MTX) plays an essential role in physiological folate homeostasis and MTX cancer chemotherapy.\nResistance to chemotherapy may arise due to promoter methylation/downregulation of expression of transporters required for drug uptake, and decitabine can reverse resistance in vitro.\nThe reduced folate carrier (RFC/SLC19A1) is the major transport system for folates in mammalian cells and tissues.\nIn conclusion, after decitabine administration, there was increased expression of some (but not other) transporters that may play a role in chemotherapy uptake.\nOur results indicate that the balance between folic acid uptake, activation and metabolism plays a crucial role in response to pemetrexed-based chemotherapy and the prognosis of MPM patients.\nCox regression analysis showed that high tumoral expression of the genes SLC46A1/PCFT (proton-coupled folate transporter) and SLC19A1/RFC-1 (reduced folate carrier 1) correlated significantly (p < 0.001 and p < 0.01, respectively) with a decreased risk of recurrent disease, measured as disease-free survival (DFS).", "dois": ["10.3390/biomedicines13030571", "10.3390/pharmaceutics16121585", "10.3791/66058", "10.1016/j.gendis.2023.04.035", "10.1186/s12885-023-11257-8", "10.2217/pgs-2022-0169", "10.3390/cancers15051424", "10.1111/jcpt.13748", "10.1159/000520596", "10.1136/thoraxjnl-2020-216504", "10.1016/j.cmet.2020.12.002", "10.18632/oncotarget.27697", "10.1038/s41598-020-65055-4", "10.1177/1010428319846231", "10.1111/bcp.13943", "10.1038/s41397-018-0014-8", "10.1016/j.gene.2017.07.025", "10.18632/oncotarget.16398", "10.1016/j.gpb.2016.11.003", "10.1097/MPH.0000000000000802", "10.1016/j.phrs.2016.08.002", "PMID:27380948", "10.2119/molmed.2014.00192", "10.1016/j.biopha.2014.03.015", "10.1038/tpj.2014.13", "10.1097/JTO.0000000000000062", "10.1186/1868-7083-6-2", "10.1371/journal.pone.0077223", "10.1007/s13277-013-0960-3", "PMID:23599757", "10.1371/journal.pone.0021820", "10.4081/ejh.2011.e3", "10.1016/j.taap.2010.04.020", "PMID:17323126", "PMID:17066090", "PMID:16875718"]}
{"pair_type": "slc_pathway", "key1": "SLC20A1", "key2": "proliferation", "summary": "PiT1/SLC20A1 is an inorganic phosphate transporter with additional functions including the regulation of TNFα-induced apoptosis, erythropoiesis, cell proliferation and insulin signaling.\nSLC20A1 overexpression in HNSCC, characterized by increased cellular invasion, migration and proliferation, is a potential prognostic biomarker and therapeutic response indicator.\nWe, however, also observed that MC3T3-E1 and NIH3T3 cells themselves regulate their endogenous PiT1 mRNA levels with lower levels in general correlating with decreased proliferation/increased cell density.\nCell proliferation experiments revealed that the cell viability of the Sh‑B‑SLC20A1 group was 76.3±4.5, 65.7±3.7 and 53.1±3.2% of that of control GH3 cells after 24, 48 and 72 h of transfection, respectively, while the cell viability of the Sh‑C‑SLC20A1 group was 86.4±5.7, 75.6±4.4 and 67.5±3.8%, respectively (P<0.05).\nSLC20A1 overexpression, which is associated with poor prognosis, may influence cell proliferation, migration, invasion, chemotherapy response, and the immune milieu.\nThe PIT1/SLC20A1 protein, a well-described sodium/phosphate cotransporter and retrovirus receptor, has been identified recently as a modular of proliferation and apoptosis in vitro.\nMoreover, over-expression of human PiT1 led to increased proliferation of both MC3T3-E1 and NIH3T3 cultures and resulted in higher cell densities in cultures of these two strictly density-inhibited cell lines.\nWe recently showed that overexpression of human PiT1 was sufficient to increase proliferation of two strict density-inhibited cell lines, murine fibroblastic NIH3T3 and pre-osteoblastic MC3T3-E1 cells, and allowed the cultures to grow to higher cell densities.", "dois": ["10.1016/j.yexcr.2025.114556", "10.1097/MNH.0000000000000984", "10.18632/aging.205597", "10.1097/SLA.0000000000006013", "10.1016/j.lfs.2023.121726", "10.3892/mmr.2019.10555", "10.1038/s41598-018-37551-1", "10.1016/j.bbcan.2018.05.001", "10.1016/j.yexcr.2014.05.014", "10.1016/j.exphem.2013.01.004", "10.1182/blood-2012-05-427302", "10.1186/1747-1028-7-7", "10.1007/s00439-010-0915-3", "10.1371/journal.pone.0009148"]}
{"pair_type": "slc_pathway", "key1": "SLC19A3", "key2": "proliferation", "summary": "Thiamine depletion reduced cell viability and proliferation, while thiamine over-supplementation compensated for thiamine transporter 2 reduction by restoring thiamine uptake and transketolase activity.\nThiamine transporter 2 modulation in our cell models suggests its major role in thiamine transport in retinal cells and its involvement in high glucose-induced damage and impaired thiamine availability.\nThiamine transporter 2 and transcription factor specificity protein 1 expression were modulated by hyperglycaemic-like conditions.\nTransketolase activity, intracellular thiamine and permeability to thiamine were decreased in cells cultured in thiamine deficiency, and in pericytes in hyperglycaemic-like conditions.\nThe effects of thiamine depletion on cell function (viability, apoptosis and migration) were also addressed.\nHigh glucose and reduced thiamine determine impairment in thiamine transport inside retinal cells and through the inner blood-retinal barrier.", "dois": ["PMID:38330587", "10.1177/1479164119878427", "PMID:26807319", "PMID:23956837"]}
{"pair_type": "slc_pathway", "key1": "SLC18B1", "key2": "proliferation", "summary": "Upregulation of CCAR1, and C1QTNF1 was associated with augmented OS risk, whereas, increases in the expression SCL18B1, RBMXL1, DOK3, HS3ST2, and ATP6VOD1 was correlated with a diminished risk of OS.\nEnergy metabolism is a prerequisite for cancer cell growth, proliferation, invasion, and metastasis.\nWe constructed a seven-gene signature consisting of SLC18B1, RBMXL1, DOK3, HS3ST2, ATP6V0D1, CCAR1, and C1QTNF1 to be used for OS progression and prognosis.\nGene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) suggested that the genes in the significant modules were enriched in kinase, immune metabolism processes, and metabolism-related pathways.\nTwo subtypes associated with energy metabolism was determined using the \"NFM\" algorithm, and significant modules related to energy metabolism were identified by WGCNA.\nThe seven-gene signature related to OS energy metabolism developed here could be used in the early diagnosis, treatment, and prognosis of OS.", "dois": ["10.1186/s12935-020-01352-2"]}
{"pair_type": "slc_pathway", "key1": "SLC19A3", "key2": "ferroptosis", "summary": "Two molecular subtypes (C1 and C2) of MIBC were identified according to the expression of ferroptosis-related genes.\nNonnegative matrix factorization (NMF) analysis was performed to identify two molecular subtypes based on 41 ferroptosis-related prognostic genes.\nA novel MIBC classification approach based on ferroptosis-related gene expression profiles was established to provide guidance for patients who are more sensitive to immunotherapy.\nThe purpose of this study was to identify the ferroptosis-related molecular subtypes in muscle invasive bladder cancer (MIBC) associated with the tumor microenvironment (TME) and immunotherapy.\nThe C2 subtype manifested poor prognosis, high enrichment in the cytokine-cytokine receptor interaction pathway, high abundance of immune cell infiltration, immune/stromal scores and low tumor purity.\nThe risk prediction model based on five pivotal genes (, , , and ) effectively predicted the prognosis of MIBC patients.", "dois": ["10.21037/tcr-22-1653"]}
{"pair_type": "slc_pathway", "key1": "SLC20A2", "key2": "apoptosis", "summary": "Inhibition of Pi transporters with phosphonoformic acid (PFA) prevented Pi-mediated apoptosis of VICs.\nOverexpression of Akt-1 (pCMVAkt-1) prevented both Pi-induced apoptosis and mineralization of VIC culture.\nWe also found damaged mitochondria and increased apoptosis in the PFBC dopaminergic neurons and astrocytes.\nThese results strongly suggest that overexpression of SLC20A1 promotes apoptosis and mineralization by altering the level of Akt-1.\nTreatment of VIC culture with Pi promoted the loss of mitochondrial membrane potential (ΔΨm) and cytochrome c release within the cytosol, leading to apoptosis.\nIn this study, we prove that dysfunctional PiT-2 leads to an imbalance of cellular Pi, which may disrupt the Golgi apparatus with impaired autophagy, mitochondria and apoptosis in PFBC.\ntreatment with PFA or siRNA against SLC20A1 restored the level of Akt-1.", "dois": ["10.1371/journal.pone.0053393", "10.1016/j.bbrc.2022.12.050"]}
{"pair_type": "slc_pathway", "key1": "SLC20A2", "key2": "migration", "summary": "PDGFRB encodes for the platelet-derived growth factor receptor-β (PDGFRβ), a cell-surface tyrosine-kinase (RTK) receptor that regulates cell proliferation, migration, survival and differentiation.\nThe expression of endothelial cell (EC) adhesion molecules increased, while that of tight and adherents junction proteins decreased, providing the molecular precondition for T-cell recruitment to ECs and paracellular migration into the brain.\nThe fusion of lymphocytes and EC membranes and transcellular migration of CD3-related gold particles were captured, suggesting enhancement of transcytosis in the brain ECs.\nImpairment of blood-brain barrier (BBB) permeability, which was closely related to T-cell invasion into the CNS, could be explained by the BBB alterations of an increase in the paracellular and transcellular pathways of brain ECs.\nExogenous fluorescent tracers and endogenous IgG and albumin leakage also revealed an impairment of transcellular pathway in the ECs.\nFTY720 significantly alleviated brain calcification, probably by reducing T-cell infiltration, modulating neuroinflammation and ossification process, and enhancing the autophagy and phagocytosis of CNS-resident immune cells.\nThe loss of function of PDGFRβ and PDGFβ could lead to the impairment of the pericytes function and blood brain barrier integrity, causing vascular and perivascular calcium accumulation.\nIt was hypothesized that SLC20A2 mutations cause brain calcification most likely through haploinsufficiency.\nOver 40 pathogenic variants of SLC20A2 have been reported, affecting the regulation of Pi homeostasis.\nSLC20A2 gene codes for the 'sodium-dependent phosphate transporter 2' (PiT-2), a cell membrane transporters of inorganic phosphate, involved in Pi uptake by cells and maintenance of Pi body levels.", "dois": ["10.3389/fnmol.2023.1073723", "10.1007/s10072-015-2110-8"]}
{"pair_type": "slc_pathway", "key1": "SLC20A2", "key2": "oxidative stress", "summary": "We show that calcifications cause oxidative stress in astrocytes and evoke expression of neurotoxic astrocyte markers.\nMethylation at four (26.7%) CpG sites was associated with placental transcript levels of 15 genes (FDR < 0.05), including genes known to be associated with adult lipid traits, inflammation and oxidative stress.\nWe demonstrated trans-tissue portability of methylation at four genes (MLLT1, PDE9A, ASAP2, and SLC20A2) implicated in birthweight by a previous study in cord blood.", "dois": ["10.1093/brain/awz032", "10.1186/s13148-020-00873-x"]}
{"pair_type": "slc_pathway", "key1": "SLC20A1", "key2": "chemotherapy", "summary": "However, patients with SLC20A1high showed good clinical outcomes following chemotherapy.\nSLC20A1 overexpression, which is associated with poor prognosis, may influence cell proliferation, migration, invasion, chemotherapy response, and the immune milieu.\nIn the present study, we examined the possible association of SLC20A1 expression with tumor staging, endocrine therapy and chemotherapy in the luminal A and luminal B subtypes of breast cancer.\nAbstract: Myelosuppression is a common and intractable side effect of cancer therapies including radiotherapy and chemotherapy, while the underlying mechanism remains incompletely understood.\nMechanistically, the acute Pi metabolic inhibition in HSCs results from extrinsic Pi loss in the bone marrow niche and the intrinsic transcriptional suppression of soluble carrier family 20 member 1 (SLC20A1)-mediated Pi uptake by p53.\nHere, using a mouse model of radiotherapy-induced myelosuppression, we show that inorganic phosphate (Pi) metabolism is acutely inhibited in hematopoietic stem cells (HSCs) during irradiation-induced myelosuppression, and closely correlated with the severity and prognosis of myelosuppression.\nmrDEGPS can predict patient survival and responses to immunotherapy and chemotherapy and facilitate clinical decision-making in patients with OSCC.\nThese findings reveal that Pi metabolism and HSC survival are causally linked by the Akt/p53-SLC20A1 axis during myelosuppression and provide valuable insights into the pathogenesis and management of myelosuppression.\nMeanwhile, Pi metabolic inhibition blunts irradiation-induced Akt hyperactivation in HSCs, thereby weakening its ability to counteract p53-mediated Pi metabolic inhibition and the apoptosis of HSCs and consequently contributing to myelosuppression progression.\nConversely, the modulation of the Pi metabolism in HSCs via a high Pi diet or renal Klotho deficiency protects against irradiation-induced myelosuppression.\nIn addition, this SLC20A1high subgroup of patients exhibited less responses to endocrine therapy, specifically in those with the luminal", "dois": ["10.18632/aging.205597", "10.3390/nu14163395", "10.1038/s41598-022-15534-7", "10.1371/journal.pone.0268799"]}
{"pair_type": "slc_pathway", "key1": "SLC20A1", "key2": "migration", "summary": "Overexpression of SLC20A1-1 inhibited NPC growth, promoted NPC apoptosis, and enhanced macrophage recruitment and migration.\nSLC20A1 overexpression in HNSCC, characterized by increased cellular invasion, migration and proliferation, is a potential prognostic biomarker and therapeutic response indicator.\nMoreover, we found that SLC20A1-1 could suppress miR-146a-5p to induce TRAF6 and caspase 3 expression.\nSLC20A1 overexpression, which is associated with poor prognosis, may influence cell proliferation, migration, invasion, chemotherapy response, and the immune milieu.\nsiRNA mediated knockdown of FKBP11 in cultured endothelial cells suppressed angiotensin II induced monocyte transmigration through the endothelial monolayer.\npro-inflammatory cytokines elicited by FKBP11 overexpression in the endothelium under AAD condition could facilitate transendothelial migration of the circulating monocytes into the aorta, where they differentiate into active macrophages and secrete MMPs and other extracellular matrix (ECM) degrading proteins, contributing to sustained inflammation and AAD.", "dois": ["10.18632/aging.205597", "10.1089/gtmb.2021.0222", "10.3389/fphys.2017.01010"]}
{"pair_type": "slc_pathway", "key1": "SLC19A3", "key2": "apoptosis", "summary": "Thiamine depletion reduced cell viability and proliferation, while thiamine over-supplementation compensated for thiamine transporter 2 reduction by restoring thiamine uptake and transketolase activity.\nThe effects of thiamine depletion on cell function (viability, apoptosis and migration) were also addressed.\nThiamine transporter 2 modulation in our cell models suggests its major role in thiamine transport in retinal cells and its involvement in high glucose-induced damage and impaired thiamine availability.", "dois": ["PMID:38330587", "10.1177/1479164119878427", "PMID:12861052", "10.1017/S0007114522000174", "PMID:14567973"]}
{"pair_type": "slc_pathway", "key1": "SLC19A2", "key2": "oxidative stress", "summary": "its deficiency results in oxidative stress and mitochondrial dysfunction.\nWe further demonstrate that deficit causes impaired insulin secretion in conjunction with mitochondrial dysfunction, loss of protection against oxidative stress, and cell cycle arrest.\nthese were concentrated in oxidative stress (SRXN1, MAFF), immune and inflammatory responses (ITPKC, AREG, MMP25, FOSL1), the nervous system (RETREG1, GADD45A, RCAN1), lipid metabolism (LRP11, LIPG, ITGA5, AMPD2), solute transport (SLC19A2, SLC28A1, SLCO4A1), and fertility (HBEGF).\nAbstract: Age-related mitochondrial dysfunction and associated oxidative stress may contribute to the development of osteoarthritis.\nWe show that -deficient β-cells are characterized by impaired thiamine uptake, which is not rescued by overexpression of the p.Lys355Gln mutant protein.\nAfter LASSO analysis of the data, four hub genes (ACADL, CYBA, SLC19A2, and UCP2) were identified as potential biomarkers for OA.", "dois": ["10.2337/db17-0821", "10.1155/2024/6822664", "10.1371/journal.pone.0274184", "10.1371/journal.pone.0143575"]}
{"pair_type": "slc_pathway", "key1": "SLC19A2", "key2": "proliferation", "summary": "Mutations in the SLC19A2 (c.1409insT) promote apoptosis and inhibit cell proliferation, thereby upregulating the mRNA and protein levels of ERS-associated factors glucose-regulated protein 78, protein kinase R-like endoplasmic reticulum kinase, C/EBP homologous protein, and activating transcription factor 4.\nFlow cytometry and cell counting kit-8 were used to analyse the effects of SLC19A2 (c.1409insT) mutation on cell apoptosis and proliferation, respectively.\nWhile thiamine is generally not limiting for cell proliferation, a DNA-barcode competition assay identifies leukemia cell lines that grow suboptimally under low thiamine and are characterized by low expression of solute carrier family 19 member 2 (SLC19A2), a thiamine transporter.\nSLC19A2 is necessary for optimal growth and ASNase resistance, when standard medium thiamine is lowered ~100-fold to human plasma concentrations.", "dois": ["10.5603/ep.101404", "10.1126/sciadv.abc7120", "PMID:23956837"]}
{"pair_type": "slc_pathway", "key1": "SLCO2A1", "key2": "migration", "summary": "In cultured primary human bone marrow CD34+ cells and human epidermal keratinocytes (HEKs) either inhibiting or silencing PGT increased migration in both cell lines.\nOverexpression of miR-1306-5p inhibited the colorectal cancer cell malignant phenotypes via regulating PI3K/AKT/mTOR signaling pathway regulation by targeting SLCO2A1.\nMiR-1306-5p overexpression led to a decrease in colorectal cancer cell proliferation, migration, and invasion, while promoting apoptosis.\nBy targeting SLCO2A1, overexpression of miR-1306-5p could inhibit the PI3K/AKT/mTOR signaling pathway.\nThus PGT directly regulates mobilization of endothelial progenitor cells (EPCs) and HEKs, which could contribute to PGT-mediated vascularization and re-epithelialization.\nImmunohistochemical examination revealed that inhibition of PGT enhanced vascularization (marked by larger numbers of vessels formed by CD34+ cells), and accelerated re-epithelialization of cutaneous wounds.\nTaken together, our data demonstrate that PGT modulates arterial blood flow, mobilization of EPCs and HEKs, and vascularization and epithelialization in wound healing by regulating vasodilatory and pro-angiogenic PGs.\nWe hypothesized that inhibition of the prostaglandin transporter (PGT) (SLCO2A1), which mediates the degradation of PGs, would increase blood flow and stimulate vascularization, thereby mitigating peripheral ischemia and accelerating wound healing in diabetes.\nIn addition, in myeloid cell DM and DFU upstream regulator analysis, we observed inhibition of interleukin-13 and IFN-γ and dysregulation of biological processes that included cell movement of monocytes, migration of dendritic cells, and chemotaxis of antigen-presenting cells pointing to an impaired migratory profile of immune cells in DM skin.", "dois": ["10.12122/j.issn.1673-4254.2025.07.14", "10.1080/15384101.2022.2054245", "10.2337/db20-0188", "10.1371/journal.pone.0133615", "10.1158/0008-5472.CAN-07-6458"]}
{"pair_type": "slc_pathway", "key1": "SLCO2A1", "key2": "proliferation", "summary": "SLCO2A1 overexpression suppressed Fadu cells proliferation and metastasis and significantly correlated with favorable survival overcome in HSCC.\nActivation of PPARγ promoted cell proliferation and mobility, but inhibited apoptosis.\nMiR-1306-5p overexpression led to a decrease in colorectal cancer cell proliferation, migration, and invasion, while promoting apoptosis.\nInterestingly, as a tumor suppressor, 15-PGDH inhibits proliferation and induces the differentiation of cancer cells (including those associated with colorectal, lung, and breast cancers).\nBy targeting SLCO2A1, overexpression of miR-1306-5p could inhibit the PI3K/AKT/mTOR signaling pathway.\nOverexpression of miR-1306-5p inhibited the colorectal cancer cell malignant phenotypes via regulating PI3K/AKT/mTOR signaling pathway regulation by targeting SLCO2A1.\nThese studies indicate that OATP2A1 is likely to promote tumorogenesis by PGE uptake into the endothelial cells, suggesting that blockade of OATP2A1 is an additional pharmacologic strategy to improve colon cancer outcomes.\nSLCO2A1 may be a tumor suppressor gene and correlates with immune infiltration for HSCC and could serve as a potential target for its diagnosis and treatment.\nIn cultured B16F10 cells, MMRN2 knockdown significantly suppressed cell proliferation, migration and invasion and caused remo-deling of the immunosuppressive microenvironment.\nProliferation and gene expression studies were conducted on the cell lines following exposure to β-estradiol, which stimulated cell proliferation in MCF-7 cells, as well as causing a significant increase in SLCO4C1 gene expression.\nIn conclusion, PPARγ is critical for the regulation of lipid metabolism and prostaglandin synthesis and secretion in sheep trophoblast cells and also has a potent effect on cell proliferation and viability.\nChemical suppression of OATP2A1 function significantly reduced tube formation and wound-healing activity of P", "dois": ["10.1111/jcmm.70838", "10.12122/j.issn.1673-4254.2025.07.14", "10.3389/fimmu.2025.1550694", "10.1016/j.intimp.2024.113243", "10.1111/rda.14471", "10.1080/15384101.2022.2054245", "10.1016/j.intimp.2021.108176", "10.1053/j.gastro.2018.11.066", "10.1038/s41598-017-16738-y", "10.1097/CAD.0000000000000232"]}
{"pair_type": "slc_pathway", "key1": "SLCO4A1", "key2": "proliferation", "summary": "SLCO4A1-AS1 promotes proliferation and inhibits apoptosis of LSCC cells by upregulation of SETD7 in a miR-7855-5p dependent way to activate the Wnt/β-catenin pathway.\nRescue experiments demonstrated that SLCO4A1-AS1 promoted LSCC proliferation and inhibited LSCC apoptosis by upregulation of SETD7 and activation of the Wnt/β-catenin pathway.\nFurthermore, silenced SLCO4A1-AS1 repressed the proliferation and facilitated apoptosis of LSCC cells.\nWe found that suppression of SLCO4A1-AS1 suppressed ALL cell proliferation and facilitated cell apoptosis.\nKnockdown of SLCO4A1-AS1 decreased glioma cell proliferation, invasive ability, self-renewal ability, and increased apoptosis.\nEctopic SLCO4A1-AS1 expression promoted CRC cell growth, whereas SLCO4A1-AS1 knockdown repressed CRC proliferation both in vitro and in vivo.\nBy knocking down SLCO4A1-AS1, we found that SLCO4A1-AS1 promoted the proliferation, migration, invasion and epithelial-mesenchymal transition (EMT) of CRC cells in vitro, as well as inhibited cell apoptosis.\nMechanistically, SLCO4A1 may affect the MAPK signaling pathway to promote NSCLC cell proliferation, migration and invasion.\nAdditionally, proliferation, migration and invasion of melanoma cells were weakened but apoptosis was facilitated due to SLCO4A1-AS1 down-regulation.\nNext, we found that SLCO4A1-AS1 promoted CRC cell proliferation, migration, and invasion.\nSLCO4A1 was found to be expressed at high levels in NSCLC tissues and cells, and promotes cell proliferation, migration and invasion.\nFunction assays manifested that silence of SLCO4A1-AS1 attenuated NSCLC cell proliferation, migration and invasion but promote", "dois": ["10.3390/ijms26115347", "10.1186/s12935-025-03783-1", "10.1038/s41598-024-82109-z", "10.1186/s40001-024-02033-w", "10.3892/ijo.2024.5618", "10.1038/s41420-022-01216-w", "10.1111/exd.14577", "10.4149/neo_2022_211230N1854", "10.1515/med-2022-0418", "10.1186/s12929-022-00789-z", "10.3389/fonc.2021.683256", "10.1111/odi.13893", "10.1111/ijlh.13501", "10.1002/cam4.3270", "10.1080/15384047.2020.1787757", "10.7150/ijbs.38041", "10.18632/aging.102081", "10.2147/OTT.S191740", "10.1186/s13046-018-0896-y", "10.1007/s00432-017-2393-7"]}
{"pair_type": "slc_pathway", "key1": "SLCO3A1", "key2": "chemotherapy", "summary": "There were no significant variations before, during, and after chemotherapy in the expression of four MTPs: ABCB1, ABCC1, ABCC2, and SLCO3A1 (OATP3A1).\nOne of the principal mechanisms of chemotherapy resistance in highly frequent solid tumors, such as colorectal cancer (CRC), is the decreased activity of drug transport into tumor cells due to low expression of important membrane proteins, such as solute carrier (SLC) transporters.\nIn conclusion, concomitant administration of cytotoxic chemotherapy and cART does not induce expression of MTP.\nFurthermore, no significant changes in viral resistance were observed pre- and post-chemotherapy, suggesting mutagenic cytotoxic chemotherapy seems not to induce mutations in HIV pro-viral DNA.\nRe-expression of HOXA4 in cell lines and primary CLL cells significantly increased apoptosis in response to treatment with fludarabine, ibrutinib and idelalisib.\nMorning fatigue severity was associated with one differentially methylated distal region containing five eCpGs mapping to three genes (i.e., CILP, ONECUT1, SLCO3A1).\nMethylation of the HOXA4, MAFB and SLCO3A1 DMRs was associated with post-treatment patient survival, with HOXA4 displaying the strongest association.\nApplying the filter to sequences from 28 drug resistant clones identified a set of 21 genes which was strongly enriched for known resistance genes or known drug targets (TOP1, TOP2A, DCK, WDR33, SLCO3A1).\nSNPs in SLCO3A1, SLC22A2 and SLC22A3 genes were defined as prognostic factors in the classification and regression tree analysis.\nOur study demonstrates enrichment for multiple CLL-specific epigenetic traits in response to chemotherapy that predict patient outcomes, and particularly implicate epigenetic silencing of HOXA4 in reducing the sensitivity of CLL cells to therapy.\nThis study examined two possible mechanisms: altered expression of membrane drug transporter protein (MTP) and acquisition of mutations in pro-viral DNA.", "dois": ["10.1002/cam4.71067", "10.1038/s41598-024-63943-7", "10.1093/carcin/bgaa136", "10.1038/s41416-020-01117-8", "10.1080/15284336.2016.1210719"]}
{"pair_type": "slc_pathway", "key1": "SLCO5A1", "key2": "proliferation", "summary": "Inducible expression of SLCO5A1 in HeLa cells led to an inhibitory effect of ∼20% after 96 h on cell proliferation.\nIncreasing endometrial calcium levels by treatment with A23187, a calcium ionophore, decreased the expression of the estrogen-responsive endometrial genes AKR1B1, ESR1, FGF7, IL1RAP, LPAR3, S100G, SPP1, and STC1 and increased the expression of genes related to prostaglandin synthesis and transport, namely PTGES, PTGS2, and SLCO5A1.\nProliferation and gene expression studies were conducted on the cell lines following exposure to β-estradiol, which stimulated cell proliferation in MCF-7 cells, as well as causing a significant increase in SLCO4C1 gene expression.\nThe cellular uptake of nutrients essential for cell growth and survival is facilitated by solute carrier (SLC) transporters.\nCalcium plays an essential role in regulating many cellular functions, including proliferation, differentiation, and apoptosis.\nAccumulating evidence suggests that altered expression of these transporters may affect BC pathogenesis by influencing cell proliferation and anticancer drug resistance.\nSLCO5A1 is highly expressed in mature dendritic cells compared to immature dendritic cells (∼6.5-fold) and SLCO5A1 expression correlates with the differentiation status of primary blood cells.\nThese data suggest that calcium ions at the maternal-conceptus interface play a critical role in the establishment and maintenance of pregnancy in pigs by regulating the expression of endometrial genes involved in conceptus implantation, as well as the attachment of endometrial epithelial and conceptus trophectoderm/chorionic epithelial cells during pregnancy.\nIn conclusion, we provide evidence that OATP5A1 might be a non-classical OATP family member which is involved in biological processes that require the reorganization of the cell shape, such as differentiation and migration.", "dois": ["10.1111/jcmm.70838", "10.1002/mrd.23166", "10.1371/journal.pone.0083257"]}
{"pair_type": "slc_pathway", "key1": "SLCO2A1", "key2": "oxidative stress", "summary": "Therefore, in the present study, we aimed to investigate the role of prostaglandin transporter OATP2A1/SLCO2A1 in the changes of PGE2 disposition in CRC cells in response to oxidative stress.\nThese results suggest that cytoplasmic OATP2A1 likely facilitates PGE2 loading into suitable intracellular compartment(s) for efficient exocytotic PGE2 release from CRC cells exposed to oxidative stress.\nH2O2 induced translocation of cytoplasmic OATP2A1 to plasma membranes in LoVo and COLO 320DM cells, but not in Caco-2 cells.\nThe shift of subcellular OATP2A1 was abolished in the presence of anti-oxidant N-acetyl-L-cysteine or an inhibitor of protein kinase C, which evokes exocytosis.\nChronic inflammation induced by reactive oxygen species is associated with increased risk of developing colorectal cancer (CRC), and prostaglandin E2 (PGE2), which serves as a key mediator of inflammatory responses, plays an important role in CRC initiation and progression.\nExposure of LoVo cells to H2O2 caused an increase in the amount of extracellular PGE2 without changing the sum of intra- and extracellular PGE2.\nIn addition, extracellular PGE2 was significantly reduced by exocytosis inhibitor cytochalasin D, suggesting that H2O2-induced PGE2 release occurs in an exocytotic manner.\nOATP2A1 knockdown decreased extracellular PGE2 in LoVo cells.\nFurthermore, mRNA expression of vascular endothelial growth factor (VEGF) was significantly reduced in LoVo cells by knockdown of OATP2A1.", "dois": ["10.1016/j.yexcr.2016.02.002", "10.1200/JCO.2014.59.0273"]}
{"pair_type": "slc_pathway", "key1": "SLCO4A1", "key2": "oxidative phosphorylation", "summary": "Protein-protein interaction analyses of DEGs revealed three key subnetworks and fifteen core genes, including UBA52 and RPS28, that have roles in protein synthesis, oxidative phosphorylation, and inflammatory responses.", "dois": ["10.3389/fgene.2023.1075950"]}
{"pair_type": "slc_pathway", "key1": "SLCO3A1", "key2": "apoptosis", "summary": "Moreover, upregulated the mRNA and protein levels of , and to promote the proliferation of GCs and facilitated cell cycle progression by increasing the mRNA and protein levels of , and , but it decreased apoptosis by downregulating the mRNA and protein levels of and .\nRe-expression of HOXA4 in cell lines and primary CLL cells significantly increased apoptosis in response to treatment with fludarabine, ibrutinib and idelalisib.\nIn conclusion, the knockdown of upregulated the mRNA and protein levels of , thereby promoting the proliferation of GCs to facilitate the growth and development of ovarian follicles, and these results provide new insights into investigations of female reproductive diseases.\nIn female mammals, the proliferation and apoptosis of granulosa cells (GCs) have been shown to determine the fate of follicles.\nMethylation of the HOXA4, MAFB and SLCO3A1 DMRs was associated with post-treatment patient survival, with HOXA4 displaying the strongest association.", "dois": ["10.3390/ijms25052468", "10.1038/s41416-020-01117-8"]}
{"pair_type": "slc_pathway", "key1": "SLC19A1", "key2": "apoptosis", "summary": "In addition, patients' PBMCs were resistant to methotrexate-induced apoptosis supporting a functionally defective SLC19A1.\nIn MCF10A and Hs578T cells, FA treatment decreased pathways associated with apoptosis, cell death and senescence, but increased those associated with cell proliferation.\nPARP1-ACSL1 pair significantly correlated with poor overall survival in breast cancer owing to the suppression of the MAPK, mTOR and NF-kB signaling pathways, which induces apoptosis, autophagy and prevents inflammatory processes.\nA ceRNA network of the SLC19A1-AS-miR-1343-WNT11 axis was constructed via comprehensive transcriptome sequencing of ovaries from goats with various fertility levels to further elucidate the function and regulatory mechanism of SLC19A1-AS in modulating miR-1343 and WNT11 during granulosa cell proliferation and apoptosis.\nTreatment of CEM/C1 cells with miR-595 mimics substantially reduced RFC1 protein expression, intracellular MTX levels, MTX-induced cytotoxicity and apoptosis rates compared to those of negative control.\nPublished knock down studies confirmed these proteins to induce apoptosis by disrupting neoplastic lipogenesis, by endorsing uracil accumulation and by suppressing arginine metabolism and glucose-derived ribonucleotide biosynthesis.\nQuantitative RT-PCR analysis revealed that, besides an increased gene expression of thymidylate synthase in PEM-resistant PC-9 cells, the ( gene expression was markedly decreased in PEM-resistant A549 cells.\nTaken together, down-regulation of IGF-1 expression and signaling is involved in FD-induced cell cycle arrest and apoptosis in HT-22 hippocampal neuron cells, which is associated with an abnormal activation of methyl transfer pathway and hypermethylation of IGF-1 gene promoter.\nPralatrexate-induced apoptosis was confirmed by caspase-3 activation and PARP cleavage.\nPEM increased the apoptosis cells in parental PC-9 and the", "dois": ["10.1158/1535-7163.MCT-23-0550", "10.1111/bcpt.12966", "10.3727/096504017X14841698396900", "10.1016/j.biocel.2016.08.040", "10.1007/s13277-013-0960-3", "10.1016/j.tox.2008.12.004", "10.1016/j.ijbiomac.2024.130658", "10.1038/s41435-022-00191-7", "10.1038/s41598-022-13835-5", "10.18632/oncotarget.27697", "10.18632/oncotarget.24704", "10.18632/oncotarget.11804", "10.1017/jns.2016.8"]}
{"pair_type": "slc_pathway", "key1": "SLCO4A1", "key2": "chemotherapy", "summary": "SLCO4A1-AS1 facilitated cell growth and enhanced the resistance of LUAD cells to chemotherapy via activating WNT pathway through miR-4701-5p/NFE2L1 axis.\nMoreover, functional assays indicated that SLCO4A-AS1 facilitated LUAD cell proliferation, motility, and cisplatin-resistance.\nThe lncRNA SLCO4A1-AS1 was identified as a novel molecule mediating ferroptosis resistance in vitro.\nIn addition, it was confirmed that NFE2L1 was involved in SLCO4A1-AS1-mediated activation of WNT pathway.\nAccording to rescue assays, NFE2L1 could involve in SLCO4A1-AS1-mediated LUAD cell growth.\nBesides, mechanism investigation revealed that miR-4701-5p could interact with SLCO4A1-AS1 and directly target to NFE2L1.", "dois": ["10.1093/bib/bbab388", "10.1002/cam4.3270"]}
{"pair_type": "slc_pathway", "key1": "SLC19A2", "key2": "apoptosis", "summary": "Mutations in the SLC19A2 (c.1409insT) promote apoptosis and inhibit cell proliferation, thereby upregulating the mRNA and protein levels of ERS-associated factors glucose-regulated protein 78, protein kinase R-like endoplasmic reticulum kinase, C/EBP homologous protein, and activating transcription factor 4.\nFlow cytometry and cell counting kit-8 were used to analyse the effects of SLC19A2 (c.1409insT) mutation on cell apoptosis and proliferation, respectively.\n4-PBA could inhibit ERS caused by SLC19A2 (c.1409insT) mutations, downregulate mRNA and protein expression levels of GRP78, CHOP, and phosphorylated eukaryotic initiation factor 2α, and protect pancreatic islet β-cells.\nTHTR-1 deficiency triggers diabetes in TRMA patients through ERS, and 4-PBA protects pancreatic islet β-cells by inhibiting ERS, which provides new ideas and intervention targets for the prevention and treatment of TRMA and diabetes.", "dois": ["10.5603/ep.101404", "PMID:14738878", "PMID:12861052", "10.1080/0886022X.2024.2438859", "10.7754/Clin.Lab.2023.230324", "10.1017/S0007114522000174", "PMID:14567973"]}
{"pair_type": "slc_pathway", "key1": "SLCO5A1", "key2": "apoptosis", "summary": "Calcium plays an essential role in regulating many cellular functions, including proliferation, differentiation, and apoptosis.\nIncreasing endometrial calcium levels by treatment with A23187, a calcium ionophore, decreased the expression of the estrogen-responsive endometrial genes AKR1B1, ESR1, FGF7, IL1RAP, LPAR3, S100G, SPP1, and STC1 and increased the expression of genes related to prostaglandin synthesis and transport, namely PTGES, PTGS2, and SLCO5A1.\nMoreover, the exposure of human islets to 19 mM glucose resulted in significantly altered expression of eight genes (FDR<5%), with five of these (GLRA1, RASD1, VAC14, SLCO5A1, CHRNA5) also exhibiting changes in DNA methylation (p < 0.05).\nThese data suggest that calcium ions at the maternal-conceptus interface play a critical role in the establishment and maintenance of pregnancy in pigs by regulating the expression of endometrial genes involved in conceptus implantation, as well as the attachment of endometrial epithelial and conceptus trophectoderm/chorionic epithelial cells during pregnancy.", "dois": ["10.1016/j.mce.2017.11.019", "10.1002/mrd.23166"]}
{"pair_type": "slc_pathway", "key1": "SLCO4A1", "key2": "migration", "summary": "SLCO4A1-AS1 knockdown suppressed PC cell growth, migration, invasion, and induced cell apoptosis.\nOverexpression of SLCO4A1-AS1 promoted cell viability, migration, invasion, and STAT3 expression but suppressed apoptosis, while knockdown of SLCO4A1-AS1 had the opposite effect.\nSLCO4A1-AS1 directly interacted with the DNA-binding protein, TOX High Mobility Group Box Family Member 4 (TOX4), to inhibit TOX4-induced migration and invasion.\nBy knocking down SLCO4A1-AS1, we found that SLCO4A1-AS1 promoted the proliferation, migration, invasion and epithelial-mesenchymal transition (EMT) of CRC cells in vitro, as well as inhibited cell apoptosis.\nMechanistically, SLCO4A1 may affect the MAPK signaling pathway to promote NSCLC cell proliferation, migration and invasion.\nIn cell lines, SLCO4A1 knockdown resulted in a significant decrease of viability, invasion, and migration when compared to control cells.\nAdditionally, proliferation, migration and invasion of melanoma cells were weakened but apoptosis was facilitated due to SLCO4A1-AS1 down-regulation.\nNext, we found that SLCO4A1-AS1 promoted CRC cell proliferation, migration, and invasion.\nSLCO4A1 was found to be expressed at high levels in NSCLC tissues and cells, and promotes cell proliferation, migration and invasion.\nFunction assays manifested that silence of SLCO4A1-AS1 attenuated NSCLC cell proliferation, migration and invasion but promoted NSCLC cell apoptosis.\nSLCO4A1-AS1 reduced cancer cell migration and invasion by disrupting cytoskeleton filaments, and was associated with longer overall survival in patients with lung adenocarcinoma.\nMoreover, knockdown of SLCO4A1-AS1 decreased SLCO4A1 expression, thus inhibiting cell migration, invasion, sphere formation, and tumorigenesis abilities and enhancing the apoptosis", "dois": ["10.3390/ijms26115347", "10.3892/ijo.2024.5618", "10.1186/s12929-023-00973-9", "10.1038/s41420-022-01216-w", "10.1111/exd.14577", "10.4149/neo_2022_211230N1854", "10.1515/med-2022-0418", "10.1155/2021/1698771", "10.3389/fonc.2021.683256", "10.1038/s41374-021-00577-7", "10.1080/15384047.2020.1787757", "10.7150/ijbs.38041", "10.2147/OTT.S191740", "10.1186/s13046-018-0896-y", "10.1007/s00432-017-2393-7"]}
{"pair_type": "slc_pathway", "key1": "SLCO4A1", "key2": "oxidative stress", "summary": "SLCO4A1 was validated as critical for Lysionotin-mediated AMPK activation.\nMechanistic studies, including kinase screening and molecular docking, show Lysionotin activates Nrf2 via AMPK binding, facilitated by the Slco4a1 channel.\nPretreatment with Lysionotin significantly enhances antioxidant capacity, reduces oxidative damage and inflammation, and maintains endothelial integrity in ALI mice.\nLysionotin preserves endothelial function and reduces oxidative stress in ALI mice by boosting antioxidant activity and attenuating inflammation.\nIt enhances the antioxidant capacity of LPS-induced PMVECs via the AMPK/Nrf2 pathway.\nIn vitro experiments confirm Lysionotin enhances antioxidant defenses and protects endothelial cells from LPS-induced injury.\nTitle: The SLCO4A1-Mediated Transmembrane Transport of Lysionotin Attenuates Acute Lung Injury Through Activating the AMPK/Nrf2 Signaling Pathway.\nthese were concentrated in oxidative stress (SRXN1, MAFF), immune and inflammatory responses (ITPKC, AREG, MMP25, FOSL1), the nervous system (RETREG1, GADD45A, RCAN1), lipid metabolism (LRP11, LIPG, ITGA5, AMPD2), solute transport (SLC19A2, SLC28A1, SLCO4A1), and fertility (HBEGF).\nOxidative stress (OS) is believed to contribute to neuronal death and dysfunction in AD.\nFive DEOSGs (NFKBIA, PLCE1, CLIC1, SLCO4A1, TRAF3IP2) were identified based on the GLM model.\nThis study explores the protective effects of Lysionotin, a flavonoid from Lysionia odorata, known for its anti-inflammatory and antioxidant properties.", "dois": ["10.1002/ptr.70024", "10.18632/aging.205084", "10.1371/journal.pone.0274184", "10.1371/journal.pone.0028791"]}
{"pair_type": "slc_pathway", "key1": "SLC17A9", "key2": "proliferation", "summary": "Functionally, SLC17A9 knockdown inhibited the proliferation, migration, and invasion activity of renal cancer cells, whereas its overexpression led to stronger cell viability and more malignant phenotype.\nSLC17A9 silencing inhibited HepG2 cells proliferation, migration, colony formation, and reduced their ATP level.\nImportantly, SLC17A9 downregulation rescued the repression on PCa progression mediated by LINC01679 upregulation.\nMechanistically, SLC17A9 could upregulate the expression of PTHLH, thus promoting epithelial-mesenchymal transition (EMT) in ccRCC.\nFurthermore, down-regulation of LINC01836 or increased expression of miR-1226-3p markedly reversed the effects of SLC17A9 overexpression on colorectal cancer cells.\nMechanistically, ABI2 serving as a co-activator of transcriptional factor HHEX upregulated SLC17A9 to promote HCC cancer stem cell-like properties and tumorigenesis.\nRescue assays suggested that miR-3150a-3p mimics rescued the repression on PCa progression mediated by LINC01679 upregulation, but SLC17A9 downregulation reversed the miR-3150a-3p inhibitor-mediated repression on PC progression.\nThis study showed that LINC01836 regulated the expression of SLC17A9 through sponge miR-1226-3p by acting as a competitive endogenous RNA (ceRNA), promoted the progression of colorectal cancer, and suggested a new prognostic biomarker and potential cancer treatment target for colorectal cancer.\nCumulatively, this study demonstrated that the SLC17A9-PTHLH-EMT axis could promote the progression of ccRCC.\nFurther analysis revealed that LINC01836 could regulate the expression of SLC17A9 by competing with miR---1226-3p.\nCollectively, the HHEX-mediated ABI2/SLC17A9 axis contributes to HCC growth and metastasis by maintaining the CSC population, suggesting that", "dois": ["10.31083/FBL38061", "10.1186/s12967-024-05324-2", "10.2174/0109298665248028231122064831", "PMID:37818081", "10.3892/ol.2023.13969", "10.1016/j.isci.2022.105764", "10.1161/CIRCULATIONAHA.122.060860", "10.3389/fonc.2022.809847", "10.3389/fcell.2022.853652", "10.3389/fcell.2021.737812"]}
{"pair_type": "slc_pathway", "key1": "SLCO5A1", "key2": "migration", "summary": "Inducible expression of SLCO5A1 in HeLa cells led to an inhibitory effect of ∼20% after 96 h on cell proliferation.\nIn conclusion, we provide evidence that OATP5A1 might be a non-classical OATP family member which is involved in biological processes that require the reorganization of the cell shape, such as differentiation and migration.", "dois": ["10.1371/journal.pone.0083257"]}
{"pair_type": "slc_pathway", "key1": "SLCO4A1", "key2": "apoptosis", "summary": "The results depicted that SLCO4A1-AS1 was upregulated in PC, and SLCO4A1-AS1 knockdown suppressed PC cell growth, migration, invasion, and induced cell apoptosis.\nSLCO4A1-AS1 promotes proliferation and inhibits apoptosis of LSCC cells by upregulation of SETD7 in a miR-7855-5p dependent way to activate the Wnt/β-catenin pathway.\nRescue experiments demonstrated that SLCO4A1-AS1 promoted LSCC proliferation and inhibited LSCC apoptosis by upregulation of SETD7 and activation of the Wnt/β-catenin pathway.\nOverexpression of SLCO4A1-AS1 promoted cell viability, migration, invasion, and STAT3 expression but suppressed apoptosis, while knockdown of SLCO4A1-AS1 had the opposite effect.\nFurthermore, silenced SLCO4A1-AS1 repressed the proliferation and facilitated apoptosis of LSCC cells.\nWe found that suppression of SLCO4A1-AS1 suppressed ALL cell proliferation and facilitated cell apoptosis.\nKnockdown of SLCO4A1-AS1 decreased glioma cell proliferation, invasive ability, self-renewal ability, and increased apoptosis.\nBy knocking down SLCO4A1-AS1, we found that SLCO4A1-AS1 promoted the proliferation, migration, invasion and epithelial-mesenchymal transition (EMT) of CRC cells in vitro, as well as inhibited cell apoptosis.\nBIRC5, SLCO4A1, POPDC3, and HK2 were found to be downregulated in stage MS NB and related to apoptosis.\nAdditionally, proliferation, migration and invasion of melanoma cells were weakened but apoptosis was facilitated due to SLCO4A1-AS1 down-regulation.\nLncRNA Slco4a1 overexpression could promote the expression of inflammatory factors and apoptosis in HUVECs.", "dois": ["10.1038/s41598-024-82109-z", "10.1111/ijlh.13501", "10.1186/s13046-018-0896-y", "10.3390/ijms26115347", "10.3389/fonc.2022.1083570", "10.1038/s41420-022-01216-w", "10.1111/exd.14577", "10.21037/tp-22-7", "10.1515/med-2022-0418", "10.1155/2021/1698771", "10.3389/fonc.2021.683256", "10.1038/s41374-021-00577-7", "10.1111/odi.13893", "10.1080/15384047.2020.1787757"]}
{"pair_type": "slc_pathway", "key1": "SLC19A1", "key2": "oxidative stress", "summary": "There was association between folate pathway gene polymorphism of Solute Carrier Family 19 Member 1 (SLC19A1) and Methylenetetrahydrofolate Reductase (MTHFR) with erythrocyte SOD and GSH-PX activities, and folate levels in male but not in female aging subjects.\nThe plasma folate levels, erythrocyte SOD and GSH-PX activities were negatively correlated with genetic risk scores in the male subjects.\nGenetic variant of genes involved in folate metabolism has strong impact on plasma folate levels in the male aging subjects.\nResults showed that five genes (GPX1, NEIL1, NFE2L2, OGG1, and SOD2) were associated with MDS, two (DNMT3B and SLC19A1) with AML, and two (CYBA and DNMT1) with both diseases.\nQuantitative real-time PCR (RT-PCR) analysis validated the significant up-regulation of CASP9, TNFRSF1B, GPX3, HYOU1, SLC3A2, SLC19A1, SLC35A4 and ITGAL, and down-regulation of BCL2A1 and COX7B.\nAfter adjustment for differences in the background characteristics of the two groups, we finally identified seven Cd-responsive genes (CASP9, TNFRSF1B, GPX3, SLC3A2, ITGAL, BCL2A1, and COX7B), all of which constituted a network that controls oxidative stress response by IPA.\nThe Ingenuity Pathway Analysis Application (IPA) revealed that differentially expressed genes were likely to modify oxidative stress and mitochondria-dependent apoptosis pathways.\nWe observed a correlation of CYBA TT, GPX1 TT, and SOD2 CC genotypes with increased oxidative stress levels, as well as NEIL1 TT and OGG1 GG genotypes with higher DNA damage.", "dois": ["10.1016/j.exger.2023.112208", "10.1002/mc.22478", "10.1016/j.tox.2008.12.004"]}
{"pair_type": "slc_pathway", "key1": "SLCO2B1", "key2": "chemotherapy", "summary": "An in vitro-part study showed that statins, by binding to SLCO2B1, can block the uptake of DHEAS competitively, decreasing the available intratumoral androgen and improving and extending the effect of primary ADT.\nThe solute carrier transporter (SLCO2B1) enables various anticancer compounds or hormones to enter cells, including the adrenal androgen dehydroepiandrosterone (DHEAS), a precursor to the most potent androgen dihydroxytestosterone (DHT), which is the substrate binding and activating the androgen receptor in normal and prostate cancer (PCa) cells.\nRs1045642 in ABCB1, rs1047303 in HSD3B1, rs1856888 in HSD3B1, rs523349 in SRD5A2, and rs34550074 in SLCO2A1 were differentially associated with TTP between docetaxel chemotherapy and ARPI treatment.\nIn addition to rs4775936 in CYP19A1, rs1128503 in ABCB1 and rs1077858 in SLCO2B1 might be differentially associated with TTP between abiraterone and enzalutamide treatments.\nThis may be related to the enhancement of the antitumor activity of the ADT drugs, but also to the cardioprotective effects associated with statin use.\nOther substrates of SLCO2B1 are statins.", "dois": ["10.4081/aiua.2025.14179", "10.1111/cas.15718"]}
{"pair_type": "slc_pathway", "key1": "SLCO2B1", "key2": "migration", "summary": "According to our data, tumor cells stimulate the migration of immature DCs to the tumor site by inducing inflammatory chemokines.\nThese molecular pairs are involved in the migration of immature DCs to the TME and disrupt the antigen-presenting function of DCs.\nBy PPI network analysis, we selected the top 10 genes, including SLCO2B1, STAB1, SERPING1, HLA-DOA, AIF1, GIMAP4, C1orf162, HLA-DMB, ADAP2, and HAVCR2.\nBy GO enrichment analysis, 143 DEGs were enriched in the following GO terms: extracellular structure organization, extracellular matrix organization, leukocyte migration class II protein complex, collagen tridermic protein complex, extracellular matrix structural constituent, growth factor binding, and platelet-derived growth factor binding.", "dois": ["10.1016/j.heliyon.2023.e15694", "10.3389/fendo.2022.1018639"]}
{"pair_type": "slc_pathway", "key1": "SLCO2B1", "key2": "apoptosis", "summary": "Twelve genes characteristic of M2 activated macrophages (SLCO2B1, GATM, MRC1, ALDH1A1, PTGS1, RNASE6, CLEC7A, DPEP2, CD163, CCL22, CCL24, and CDH1) were upregulated in endometrial CD14(+) cells.\nResults indicate that at least a subpopulation of endometrial macrophages cells differentiates along an M2 activation pathway during pregnancy and that the cells are likely to play roles in immune regulation, tissue remodeling, angiogenesis, and apoptosis.\nM2 macrophages play roles in immune regulation, tissue remodeling, angiogenesis and apoptosis.\nA role in apoptosis is suggested by the observation that the most overrepresented gene in endometrial CD14(+) cells was GZMA.\nThe most prominent pathways altered by statins included cellular stress, apoptosis, cell senescence and DNA repair (TP53, BARD1, Mre11 and RAD51);", "dois": ["10.1371/journal.pone.0181308", "10.1371/journal.pone.0013213"]}
{"pair_type": "slc_pathway", "key1": "SLCO1A2", "key2": "chemotherapy", "summary": "Our results revealed that 11 SNPs in nine genes (SLC15A1, SLCO1A2, CYP2D6, FMO3, UGT1A1, NAT2, SULT2A1, PXR and HNF4α) were associated with docetaxel-induced myelosuppression.\nWe examined 61 SNPs in 36 genes that code for drug transporters, metabolism enzymes, nuclear receptors and DNA repair pathway in 110 Chinese Han patients receiving docetaxel-based chemotherapy.\nGenes involved in angiogenesis (VEGFD, THY-1, GPNMB) and cellular adhesion (VWF, CDH13, THBS2), and extracellular matrix components (COL1A1, COL4A1, SLCO1A2) were over-represented in patients with sinusoidal dilatation.\nGene-expression profiles were first analyzed by microarray on a selected population of 19 patients: 9 patients with severe sinusoidal dilatation after a short period of chemotherapy and 10 patients without any sinusoidal dilatation after a long period of chemotherapy.\nOxaliplatin-based chemotherapy for colorectal liver metastases (CRLM) can result in vascular liver lesions such as sinusoidal dilatations.\nBetween 1998 and 2009, 83 non-tumor frozen liver samples were obtained from patients operated on for CRLM after an exclusive oxaliplatin-based chemotherapy.\nThese discoveries should help in advancing future personalized therapy of docetaxel-based chemotherapy specific to Chinese Han patients.", "dois": ["10.1111/jcpt.13084", "10.1016/j.jhep.2011.10.023"]}
{"pair_type": "slc_pathway", "key1": "SLCO1A2", "key2": "proliferation", "summary": "In addition, a survival prediction model for GC was developed based on five survival-related lipid metabolism genes, PIAS4, PLA2R1, PRKACA, SLCO1A2 and STARD4.\nLipid metabolism reprogramming plays an important role in cell growth, proliferation, angiogenesis and invasion of cancer.\nLipid metabolism gene expression is correlated with the immune microenvironment in GC patients and can accurately predict their prognosis.\nThe subgroup with a better prognosis presented higher immune scores and immune infiltrating cell abundance.\nCombined with the TIDE score results, it was found that the population with high expression of the above genes might be more sensitive to immunotherapy.", "dois": ["10.1007/s12094-022-03038-9"]}
{"pair_type": "slc_pathway", "key1": "SLCO3A1", "key2": "proliferation", "summary": "Moreover, upregulated the mRNA and protein levels of , and to promote the proliferation of GCs and facilitated cell cycle progression by increasing the mRNA and protein levels of , and , but it decreased apoptosis by downregulating the mRNA and protein levels of and .\nIn conclusion, the knockdown of upregulated the mRNA and protein levels of , thereby promoting the proliferation of GCs to facilitate the growth and development of ovarian follicles, and these results provide new insights into investigations of female reproductive diseases.\nIn this study, we found that the knockdown of enhanced the mRNA and protein levels of by regulating the chromatin accessibility probably.\nMoreover, promoted the growth of porcine follicles and development of mice follicles.\nIn female mammals, the proliferation and apoptosis of granulosa cells (GCs) have been shown to determine the fate of follicles.", "dois": ["10.3390/ijms25052468", "PMID:19234366"]}
{"pair_type": "slc_pathway", "key1": "SLCO2B1", "key2": "proliferation", "summary": "SLCO2B1 expression is sufficient to increase intracellular iron, bypass the essentiality of the transferrin receptor, and enable proliferation under iron restriction.\nHeme uptake by SLCO2B1 provides sufficient iron for proliferation through heme oxygenases.\nConsidering that elevated hormone uptake by OATP2B1 results in increased cell proliferation of hormone dependent tumors (e.g. breast or prostate), inhibition of OATP2B1 can be a good strategy to inhibit the growth of these tumors.\nCell proliferation, ER-mediated transcriptional activities and estradiol secretion were stimulated by addition of E1S to the culture medium of MCF-7 cells.\nIn this study, we investigated the relationship between expression of OATP2B1 and cell proliferation in ER-positive breast cancer.\nThe present study suggests that OATP2B1 is involved in cell proliferation by increasing the amount of estrogen in ER-positive breast cancer cells.\nThe expression level of SLCO2B1 mRNA was significantly correlated with histological grade, Ki-67 labelling index and mRNA expression of steroid sulfatase.\nUptake of E1S resulted in down-regulation of ERα protein and induction of Ki-67 in MCF-7 cells.\nThese stimulatory effects were significantly greater in MCF-7 cells overexpressing OATP2B1 than in control cells.\nSpecifically, TCDD elicited a >200-fold increase in taurolithocholic acid (TLCA), a potent G protein-coupled bile acid receptor 1 (GPBAR1) agonist associated with bile duct proliferation.\nMale C57BL/6 mice orally gavaged with TCDD (0.01-30 µg/kg) every 4 days for 28 days exhibited bile duct proliferation and pericholangitis.", "dois": ["10.1016/j.molcel.2022.05.024", "10.1016/j.jsbmb.2020.105652", "10.1038/s41598-017-05656-8", "10.1016/j.dmpk.2014.10.005", "10.1159/000322332", "PMID:19234366"]}
{"pair_type": "slc_pathway", "key1": "SLCO1B1", "key2": "glycolysis", "summary": "Furthermore, IHC and qRT-PCR analyses showed decreased expression of SLCO1B1 in HCC tissues.\nFunctional experiments revealed that SLCO1B1 overexpression inhibited the proliferation, migration, and invasion of HCC cells.\nHowever, a comprehensive analysis of a prognostic signature for HCC based on molecular subtypes related to disulfidptosis and glycolysis, as well as associated metabolomics and the immune microenvironment, is yet to be fully explored.", "dois": ["10.3389/fimmu.2023.1204338"]}
{"pair_type": "slc_pathway", "key1": "SLCO1B1", "key2": "migration", "summary": "Functional experiments revealed that SLCO1B1 overexpression inhibited the proliferation, migration, and invasion of HCC cells.", "dois": ["10.3389/fimmu.2023.1204338", "10.2174/1381612825666190110150705", "PMID:18154446"]}
{"pair_type": "slc_pathway", "key1": "SLCO1B1", "key2": "ferroptosis", "summary": "up-regulation of SLCO1B1 and retention of SN38 in the cells.\nThe anticancer effect of the combined treatment of SN38 and EP is related to changes in the redox-homeostasis of cancer cells, leading to cell death via apoptosis and/or ferroptosis.\nincreased DNA damage and apoptotic/ferroptotic cell death;\nhigh production of intracellular superoxide and hydroperoxides and depletion of glutathione;", "dois": ["10.21873/anticanres.14519"]}
{"pair_type": "slc_pathway", "key1": "SLCO1B3", "key2": "oxidative phosphorylation", "summary": "Ct-OATP1B3 directly interacts with insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2), an RNA-binding protein, which results in enhancement of the mRNA stability and expression of carnitine palmitoyltransferase 1A (CPT1A) and NADH:Ubiquinone Oxidoreductase Subunit A2 (NDUFA2), leading to increased mitochondrial fatty acid beta-oxidation (FAO) and oxidative phosphorylation (OXPHOS) activities.\nCt-OATP1B3 promotes high-grade serous ovarian cancer metastasis by regulation of fatty acid beta-oxidation and oxidative phosphorylation.\nThe increased FAO and OXPHOS activities further facilitate adenosine triphosphate (ATP) production and cellular lamellipodia formation, which is the initial step in the processes of tumor cell migration and invasion.\nCt-OATP1B3 is overexpressed in HGSOC and promotes the metastasis of HGSOC in vivo and in vitro.\nCancer-type organic anion transporting polypeptide 1B3 (Ct-OATP1B3), a newly discovered splice variant of solute carrier organic anion transporter family member 1B3 (SLCO1B3), has been reported to be overexpressed in several types of cancer.\nOur study provides an insight into the function and underlying mechanism of Ct-OATP1B3 in HGSOC metastasis, and highlights Ct-OATP1B3 as a novel prognostic marker as well as therapeutic target in HGSOC.\nThe key biochemical feature of malignant tumor is the conversion of energy metabolism from oxidative phosphorylation to glycolysis, which provides sufficient capacity and raw materials for tumor cell rapid growth.", "dois": ["10.1038/s41419-022-05014-1", "10.3389/fonc.2022.967342"]}
{"pair_type": "slc_pathway", "key1": "SLCO1B1", "key2": "proliferation", "summary": "Functional experiments revealed that SLCO1B1 overexpression inhibited the proliferation, migration, and invasion of HCC cells.\nQuercetin may lower the death rate from READ by targeting SLCO1B1 and producing enhanced effects from use of this compound, inhibiting cell growth, and inducing apoptosis in tumor cells.\nAbstract: Methotrexate (MTX) is a folic acid antagonist, the mechanism of action is to inhibit DNA synthesis, repair and cell proliferation by decreasing the activities of several folate-dependent enzymes.\nThere is growing evidence demonstrating that miRNAs target various components of the TGF-β signaling pathway, including TGF-β1, TGF-β2, regulatory SMADs (SMAD1, 2, 3, 5 and 9), co-mediator SMAD4, inhibitory SMADs (SMAD6 and 7) and the TGF-β receptors, and thereby alter the proliferation and migration of CRC cells.\nGlutathione metabolism was mainly involved in the effect of quercetin on COAD, including the enhancement of the oxidation of fatty acids, the metabolism of anticancer medications, and the stiffness of cells, and the reduction of chemical carcinogenesis, the level of anti-Müllerian hormone, the proliferation of cancer cells and transcriptional misregulation, and mediation of the activity of glutathione transferases.\nAbstract: Estrone (E1), the major circulating estrogen in postmenopausal women, promotes estrogen-receptor positive (ER+) breast tumor growth and proliferation.\nProliferation and gene expression studies were conducted on the cell lines following exposure to β-estradiol, which stimulated cell proliferation in MCF-7 cells, as well as causing a significant increase in SLCO4C1 gene expression.\nAbstract: The cellular uptake of nutrients essential for cell growth and survival is facilitated by solute carrier (SLC) transporters.\nAccumulating evidence suggests that altered expression of these transporters may affect BC pathogenesis by influencing cell proliferation and anticancer drug resistance.\nThe transforming growth factor beta (TGF-β) signaling pathway plays an important role in", "dois": ["10.1111/jcmm.70838", "10.3389/fimmu.2023.1204338", "10.3389/fphar.2022.1003812", "10.1039/c9fo01168d", "10.2174/1381612825666190110150705", "10.1007/s10549-017-4243-3", "10.1097/WCO.0b013e32833045a0"]}
{"pair_type": "slc_pathway", "key1": "SLCO1B3", "key2": "glycolysis", "summary": "The key biochemical feature of malignant tumor is the conversion of energy metabolism from oxidative phosphorylation to glycolysis, which provides sufficient capacity and raw materials for tumor cell rapid growth.", "dois": ["10.1097/FPC.0000000000000196", "10.3389/fonc.2022.967342"]}
{"pair_type": "slc_pathway", "key1": "SLCO1B3", "key2": "apoptosis", "summary": "Cell viability and apoptosis assays confirmed that the RTMs induced suicide gene-mediated apoptosis in SLCO1B3-MG expressing cells.\nThe lead RTM also showed its potential to facilitate a trans-splicing reaction into the endogenous SLCO1B3 pre-mRNA in EB-SCC cells resulting in tk-mediated apoptosis.\nOur results indicated that SLCO1B3 could suppress lipogenesis, hepatocyte apoptosis, and inflammation.\nAlthough Akt signaling was activated, the accumulation of p53 led cells to apoptosis after treatment with 50 nM microcystin-LR for 24 hr.\nFurthermore, we found that inhibiting the apoptosis-related gene CTTN suppresses the anti-apoptotic capacity of HNSCC.\nAdditionally, ANGPTL4 was significantly highly expressed in tumor cells, and the knockdown of ANGPTL4 expression on tumor cells could inhibit tumor cell migration and apoptosis.\nMicrocystin-LR induced the phosphorylation and accumulation of p53 in HEK293-OATP1B3 cells, which resulted in up-regulation of the expression of p53 transcript targets, including p21 and seven in absentia homolog 1 (siah-1).\nBoth pharmacological inhibition of transcription factor activity of p53 by pifithrin-alpha and knockdown of p53 with small hairpin RNA attenuated the susceptibility of HEK293-OATP1B3 cells to microcystin-LR.\nSpecific trans-splicing, results in the fusion of the endogenous target mRNA of SLCO1B3 and the coding sequence of the suicide gene, provided by the RTM.\nSLCO1B3-specific RTMs containing HSV-tk were analyzed regarding their trans-splicing potential in a heterologous context using a SLCO1B3 expressing minigene (SLCO1B3-MG).\nUsing a screening system we designed RNA trans-splicing molecules (RTM) specifically binding the pre-mRNA of SLCO1B3, a marker gene in epidermolysis bullosa", "dois": ["10.1371/journal.pone.0335788", "10.1038/s41598-025-21891-w", "10.1007/s12033-023-01031-3", "10.1002/jgm.3610", "10.1016/j.molonc.2013.08.005", "10.1289/ehp.1001899", "10.1158/0008-5472.CAN-08-1984", "10.1016/j.psj.2023.103023", "10.2147/CEG.S264812"]}
{"pair_type": "slc_pathway", "key1": "SLCO1B3", "key2": "migration", "summary": "Overexpression of Ct‑SLCO1B3 but not Lt‑SLCO1B3 upregulated anchorage‑independent cell growth and cell migration of NCI‑H23 cells.\nRNAi‑mediated knockdown of Ct‑SLCO1B3 inhibited in vitro anchorage‑independent cell growth, cell migration, and in vivo tumour growth of A549 cells.\nHigh level of SLCO1B3 expression can inhibit the proliferation, invasion and migration of breast cancer cells, leading to better prognosis of patients.\nIn contrast, the ability of cell proliferation, migration and invasion was significantly reduced after overexpress the SLCO1B3 in breast cancer cell lines (P < 0.05).\nFunctional experiments revealed that overexpression of DUSP2 or knockdown of SLCO1B3 significantly inhibited cell proliferation, migration, and invasion in BLCA cells.\nThe cellular function assay showed that the ability of cell proliferation, migration and invasion was significantly enhanced after knockdown of SLCO1B3 expression in breast cancer cell lines.\nThese ﬁndings suggest that Ct‑SLCO1B3 functions as a tumour‑promoting factor via regulating EMT‑related factors in NSCLC.\nMechanistically, Ct‑SLCO1B3 was found to regulate the expression of epithelial‑mesenchymal transition (EMT)‑related genes.\nHere, we reveal that Ct-OATP1B3 is overexpressed in HGSOC and promotes the metastasis of HGSOC in vivo and in vitro.\nMechanically, Ct-OATP1B3 directly interacts with insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2), an RNA-binding protein, which results in enhancement of the mRNA stability and expression of carnitine palmitoyltransferase 1A (CPT1A) and NADH:Ubiquinone Oxidoreductase Subunit A2 (NDUFA2), leading to increased mitochondrial fatty", "dois": ["10.1038/s41598-025-21891-w", "10.18632/aging.205686", "10.1007/s12033-023-01031-3", "10.1038/s41419-022-05014-1", "10.18632/aging.203502", "10.1038/s41598-020-80152-0", "10.3892/or.2020.7839", "10.1371/journal.pone.0239462"]}
{"pair_type": "slc_pathway", "key1": "SLCO1B3", "key2": "oxidative stress", "summary": "These DEGs were mainly correlated with fat metabolism, oxidative stress and some inflammatory pathways.\nIn Experiment 2, CHC increased growth performance and improved meat quality, but decreased indices of oxidative stress and inflammation as compared with similar doses of activated charcoal or herb extracts.\nBilirubin is an endogenous antioxidant that protects cells against oxidative stress.", "dois": ["10.3390/metabo13050594", "10.3390/antiox11112200", "10.4178/epih.e2019034"]}
{"pair_type": "slc_pathway", "key1": "SLCO1B1", "key2": "apoptosis", "summary": "Quercetin may lower the death rate from READ by targeting SLCO1B1 and producing enhanced effects from use of this compound, inhibiting cell growth, and inducing apoptosis in tumor cells.\nOther factors examined, i.e., topoisomerase, SLCO1B1, and apoptosis-regulating factors, were comparable among the cells.\n(ii) increased DNA damage and apoptotic/ferroptotic cell death;\n(iii) changes in the expression of membrane ABC transporters - up-regulation of SLCO1B1 and retention of SN38 in the cells.\nThe most prominent pathways altered by statins included cellular stress, apoptosis, cell senescence and DNA repair (TP53, BARD1, Mre11 and RAD51);\nThe anticancer effect of the combined treatment of SN38 and EP is related to changes in the redox-homeostasis of cancer cells, leading to cell death via apoptosis and/or ferroptosis.\nEpigenetic mechanisms, including DNA methylation, histone modifications, and non-coding RNAs such as microRNAs (miRNAs), long non-coding RNAs (lncRNAs), and circular RNAs (circRNAs) regulate pathways related to apoptosis, inflammation, angiogenesis, and blood-brain barrier dysfunction.\nPharmacogenomic profiling, involving genes such as CYP2C19, VKORC1, and SLCO1B1, can guide individualized therapy with antiplatelets, anticoagulants, and statins.", "dois": ["10.21873/anticanres.14519", "10.1039/c9fo01168d", "10.1016/j.neuint.2025.106059", "10.1371/journal.pone.0181308", "10.1016/j.canlet.2008.12.033"]}
{"pair_type": "slc_pathway", "key1": "SLCO1B1", "key2": "chemotherapy", "summary": "To explore severe toxicities induced by irinotecan-based chemotherapy and UGT1A1*6/*28 and SLCO1B1*15/*15 genotypes.\nSLCO1B1 521C was significantly associated with increased SN-38 exposure (P<0.001), which was additive with UGT1A1*28.\nPolymorphism of SLCO1B1 c.521 T > C could be a strong predictor of 6-MP dose reduction in maintenance chemotherapy in childhood ALL.\nWe have identified 3 SNPs mapping in ABCG1, ABCC5 and OATP1B1/SLCO1B1 transporter genes associated with GI toxicity induced by irinotecan in mCRC patients expanding the available knowledge of irinogenomics.\nGenetic polymorphisms of uridine diphosphate glucuronosyl transferase 1A1 (UGT1A1), and SLCO1B1 coding organic anion-transporter polypeptide 1B1, are independent risk factors known to increase irinotecan toxicity in adults.\nThe patient's genotyping revealed polymorphisms in both UGT1A1 and SLCO1B1.\nAmong these, variations in SLCO1B1 have the most significant and consistent impact on methotrexate clearance.\nGenotyping of UGT1A1 and OATP1B1 proteins showed UGT1A1*6/*28 and SLCO1B1*15/*15, respectively, which are known to lead to extremely low glucuronidation and transport activities of substrate drugs.\nThe severe toxicities in this patient are attributable to the extensive accumulation of SN-38, which may result from a synergistic or additive effect of low metabolic (UGT1A1*6/*28) and transport (SLCO1B1*15/*15) capabilities.\nMoreover, this PACSIN2 SNP was significantly associated with the incidence of severe gastrointestinal (GI) toxicity during consolidation therapy containing mercaptopurine, and remained significant in a multivariate analysis", "dois": ["10.1007/s00280-024-04694-0", "10.3389/fphar.2023.1130548", "10.1007/s00280-022-04499-z", "10.3389/fphar.2022.1003812", "10.1111/jcpt.13748", "10.1111/cts.13370", "10.2147/PGPM.S363058", "10.1007/s10549-022-06596-2", "10.3390/pharmaceutics14040878", "10.1177/10781552221076456", "10.2217/pme-2020-0089", "10.1016/j.sjbs.2020.10.052", "10.1080/10428194.2020.1839650", "10.1080/08880018.2019.1705949", "10.1111/bcp.13943", "10.1038/s41392-018-0034-5", "PMID:30360603", "10.1177/1534735418801532", "10.3892/ol.2018.9147", "10.2174/1389200218666171101124931", "10.1016/j.gpb.2016.11.003", "PMID:27380948", "10.1186/s12885-016-2373-3", "10.1097/FPC.0000000000000168", "PMID:26131212", "10.1038/tpj.2015.35", "10.1111/ped.12682", "10.1038/bjc.2015.5", "10.1097/FPC.0000000000000083", "10.1371/journal.pone.0077223", "10.1093/hmg/dds302", "10.4161/cbt.12.9.17781", "10.1136/adc.2009.163089", "10.1016/j.canlet.2008.12.033", "10.1007/s00280-008-0864-x", "PMID:17898662", "PMID:17323126"]}
{"pair_type": "slc_pathway", "key1": "SLCO4C1", "key2": "chemotherapy", "summary": "Interestingly, these 2 SNPs are associated strongly with the baseline expression of >20 genes (all P ≤10(-4)), and that 2 genes (SLC22A5 and SLCO4C1) are important organic cation/anion transporters known to affect platinum uptake and clearance.\nFDR <0.05), were associated significantly with overall response to carboplatin-based induction chemotherapy when incorporated into a model along with total carboplatin exposure.\nWe developed a genome-wide, cell-based approach to identify single nucleotide polymorphisms (SNPs) associated with platinum susceptibility and then evaluated these SNPs as predictors for response and toxicity in head and neck cancer patients treated with platinum-based therapy as part of a phase II clinical trial.\nThese findings demonstrate importantly that a genome-wide, cell-based model can identify novel germline genetic biomarkers of platinum susceptibility, which are replicable in a clinical setting with treated cancer patients and seem clinically meaningful for potentially enabling future personalization of care in such patients.\nWhen applied particularly to the treatment of head and neck cancers, such information could offer significant benefit to patients as a means of potentially reducing morbidity associated with platinum-based chemotherapy.", "dois": ["10.1016/j.trsl.2011.01.005"]}
{"pair_type": "slc_pathway", "key1": "SLCO1B3", "key2": "proliferation", "summary": "Mechanically, circSLCO1B3 not only promoted ICC proliferation and metastasis via miR-502-5p/HOXC8/SMAD3 axis, but also eradicated anti-tumor immunity via suppressing ubiquitin-proteasome-dependent degradation of PD-L1 by E3 ubiquitin ligase SPOP.\nMoreover, in vitro and in vivo experiments have showed that metformin not only obviously inhibited A549-PTX tumor xenograft and A549-PTX proliferation alone, but also enhanced PTX efficacy to A549-PTX and this may be relevant to SLCO1B3.\nTaken together, m6A-modified circSLCO1B3 was correlated with poor prognosis in ICC and promoted ICC progression not only by enhancing proliferation and metastasis via potentiating HOXC8 expression, but also by inducing immune evasion via antagonizing PD-L1 degradation.\nHigh level of SLCO1B3 expression can inhibit the proliferation, invasion and migration of breast cancer cells, leading to better prognosis of patients.\nIn contrast, the ability of cell proliferation, migration and invasion was significantly reduced after overexpress the SLCO1B3 in breast cancer cell lines (P < 0.05).\nFunctional experiments revealed that overexpression of DUSP2 or knockdown of SLCO1B3 significantly inhibited cell proliferation, migration, and invasion in BLCA cells.\nThe cellular function assay showed that the ability of cell proliferation, migration and invasion was significantly enhanced after knockdown of SLCO1B3 expression in breast cancer cell lines.\nHerein, we reported a new circRNA, which originates from exon 9 to exon 15 of the SLCO1B3 gene (named circSLCO1B3), orchestrated ICC progression by promoting tumor proliferation, metastasis and immune evasion.\nTo sum up, activation of AMPK can up-regulate SLCO1B3 expression, enhance the sensitivity of A549 cells to PTX, providing a new way to re-sensitize PTX resistance.", "dois": ["10.1111/jcmm.70838", "10.1186/s13148-025-01925-w", "10.1186/s13046-024-03006-x", "10.18632/aging.205686", "10.1016/j.cellsig.2021.110215", "10.18632/aging.203502", "10.1038/s41598-020-80152-0", "10.1371/journal.pone.0239462", "10.1007/s10549-017-4243-3", "10.1007/s00204-014-1247-1", "10.1289/ehp.1001899"]}
{"pair_type": "slc_pathway", "key1": "SLCO4C1", "key2": "apoptosis", "summary": "The results demonstrated that the downregulation of SLCO4C1 could significantly suppress the viability, sphere formation, migration and invasion abilities of cells, but enhance apoptosis in EC cell lines.\nSLCO4C1 downregulation promoted the proliferation, invasion, migration, and apoptosis of HCC cells.\nMechanistically, the present study revealed that SLCO4C1 regulated the biological functions of EC cells by inactivating the PI3K/Akt signaling pathway.\nPEPCK is associated with development of apoptotic cell death;", "dois": ["10.18632/aging.205438", "10.3892/or.2020.7478", "10.1016/j.toxlet.2016.10.002"]}
{"pair_type": "slc_pathway", "key1": "SLCO4C1", "key2": "migration", "summary": "The results demonstrated that the downregulation of SLCO4C1 could significantly suppress the viability, sphere formation, migration and invasion abilities of cells, but enhance apoptosis in EC cell lines.\nSLCO4C1 downregulation promoted the proliferation, invasion, migration, and apoptosis of HCC cells.\nThe biological functions of SLCO4C1 in HCC cells were assessed through various experiments, including CCK8 assay, colony formation assay, invasion migration assay, wound healing assay, and flow cytometry analysis.\nMechanistically, the present study revealed that SLCO4C1 regulated the biological functions of EC cells by inactivating the PI3K/Akt signaling pathway.\nFurthermore, the present results demonstrated that SLCO4C1 had effects on the epithelial‑mesenchymal transition (EMT) phenotype in EC cells and regulated the expression of EMT‑related proteins.\nCollectively, it was demonstrated that the SLCO4C1/PI3K/Akt pathway may play an important role in EC progression and metastasis and serve as a potential biomarker and target for EC diagnosis and treatment.", "dois": ["10.1177/10732748241257142", "10.1186/s12929-024-01024-7", "10.18632/aging.205438", "10.3892/or.2020.7478"]}
{"pair_type": "slc_pathway", "key1": "SLCO4C1", "key2": "proliferation", "summary": "SLCO4C1 downregulation promoted the proliferation, invasion, migration, and apoptosis of HCC cells.\nProliferation and gene expression studies were conducted on the cell lines following exposure to β-estradiol, which stimulated cell proliferation in MCF-7 cells, as well as causing a significant increase in SLCO4C1 gene expression.\nThe results demonstrated that the downregulation of SLCO4C1 could significantly suppress the viability, sphere formation, migration and invasion abilities of cells, but enhance apoptosis in EC cell lines.\nThe tumor-suppressive role of SLCO4C1 in HCC has been confirmed.\nIn this study, we provided the first evidence of SLCO4C1 functioning as a tumor suppressor in HCC.\nMBNL1 or QKI knockout markedly enhanced cancer cell migration, invasion, proliferation, and tumor growth.\nMechanistically, the present study revealed that SLCO4C1 regulated the biological functions of EC cells by inactivating the PI3K/Akt signaling pathway.\nFurthermore, the present results demonstrated that SLCO4C1 had effects on the epithelial‑mesenchymal transition (EMT) phenotype in EC cells and regulated the expression of EMT‑related proteins.\nCollectively, it was demonstrated that the SLCO4C1/PI3K/Akt pathway may play an important role in EC progression and metastasis and serve as a potential biomarker and target for EC diagnosis and treatment.\nAccumulating evidence suggests that altered expression of these transporters may affect BC pathogenesis by influencing cell proliferation and anticancer drug resistance.\nWhile the functions of circRNA and lncRNA among the top 20 differentially expressed genes remain unclear, mRNAs like SLCO4C1, TMPRSS15, and MAGEB2 have reported associations with tumor progression.\nMultiple lines of evidence indicate a strong correlation between anoikis resistance and tumor progression, invasion, and metastasis.", "dois": ["10.1111/jcmm.70838", "10.1177/10732748241257142", "10.18632/aging.205438", "10.3892/or.2020.7478"]}
{"pair_type": "slc_pathway", "key1": "SLCO1B3", "key2": "chemotherapy", "summary": "This prediction system correctly classified 69.2% of severe leukopenia/neutropenia and 75.7% of non-leukopenia/neutropenia into the respective categories, indicating that SNPs in ABCC2 and SLCO1B3 may predict the risk of leukopenia/neutropenia induced by docetaxel chemotherapy.\nIn this review, we focus on the emerging roles of SLCO1B3 protein in the development of cancer chemotherapy resistance and briefly discuss the mechanisms of resistance.\nThe variations of rs11045689 and rs73241801 in SLCO1B3 gene were significantly associated with prognosis of BC patients treated with neoadjuvant chemotherapy of TA regimen, which might serve as biomarkers for predicting prognosis of BC patients treated with neoadjuvant chemotherapy.\nOrganic anion-transporting polypeptide (SLCO1B3), an influx transporter of docetaxel, was significantly downregulated in PC346C-DOC tumours.\nIn addition, silencing of SLCO1B3 in chemo-naive PC346C resulted in a two-fold decrease in intracellular concentrations of both taxanes.\npCR rate is significantly increased for patients carrying at least one variant allele for BRCA1, ERCC1 or SLCO1B3, and for patients homozygous for CYP1B1.\nThe combined analysis indicated a significant association of rs12762549 in ABCC2 (P = 0.00022) and rs11045585 in SLCO1B3 (P = 0.00017) with docetaxel-induced leukopenia/neutropenia.\nIn accordance with this finding, intratumoural concentrations of docetaxel and cabazitaxel were significantly decreased in PC346C-DOC as compared with levels in chemotherapy-naive PC346C tumours.\nOur data suggest that ABCB1 (2677G/T) and SLCO1B3 (rs11055585) might be major genetic predictors of docetaxel-related toxicities in patients receiving docetaxel chemotherapy.", "dois": ["10.1158/1541-7786.MCR-23-1047", "10.1186/s13046-024-03006-x", "10.1111/bcpt.13866", "10.1007/s00280-022-04499-z", "10.3389/fgene.2022.942166", "10.1111/jcpt.13748", "10.2174/0929866526666190926154248", "10.3760/cma.j.issn.0253-3766.2019.08.006", "10.12688/f1000research.9417.3", "10.1038/bjc.2016.251", "10.1097/FPC.0000000000000196", "10.1186/s12885-015-1776-x", "10.1016/j.molonc.2015.07.006", "10.1186/s40064-015-1053-0", "10.4143/crt.2014.012", "10.1111/j.1349-7006.2008.00765.x"]}
{"pair_type": "slc_pathway", "key1": "SLC22A1", "key2": "glycolysis", "summary": "ACE2 overexpression significantly inhibits the glycolytic flux as evidenced by reduced glucose uptake, lactate release, extracellular acidification rate, and the expression of glycolytic genes.\nMoreover, growth advantages afforded by ACE2 knockdown are largely glycolysis-dependent.\nSHP2 activation further blocks reactive oxygen species (ROS)-HIF1α signaling.\nAddition of Ang-(1-7) or the antioxidant N-acetylcysteine compromises additive tumor growth and aerobic glycolysis induced by ACE2 knockdown.\nMechanistically, ACE2 metabolizes Ang II to Ang-(1-7), which activates Mas receptor and leads to the phosphorylation of Src homology 2-containing inositol phosphatase 2 (SHP-2).\nCollectively, our findings suggest that ACE2 is a negative glycolytic regulator, and targeting the ACE2/Ang-(1-7)/Mas receptor/ROS/HIF1α axis may be a promising therapeutic strategy for HCC treatment.\nIn this study, an integrative analysis identifies a repertoire of differentially expressed genes (, , , , , , , and ) that are inversely associated with the glycolytic phenotype in HCC.\nEmerging studies revealed key promoters of aerobic glycolysis, however, little is known about its negative regulators in HCC.\nAerobic glycolysis has pleiotropic roles in the pathogenesis of hepatocellular carcinoma (HCC).", "dois": ["10.7150/ijbs.81498"]}
{"pair_type": "slc_pathway", "key1": "SLCO1C1", "key2": "proliferation", "summary": "Metformin, a first-line antidiabetic with established safety profiles, demonstrates pleiotropic effects, including the inhibition of cellular proliferation, inflammation, and angiogenesis, all of which are implicated in the pathogenesis of CCM.\nIn conclusion, these findings indicate that metformin suppresses the development of CCM in Pdcd10 mice by targeting KLF4-mediated mitochondrial damage, thereby providing promising prospects as a novel therapeutic approach for CCM.\nThe results showed that metformin administration significantly attenuated CCM lesion burden, reduced iron deposition, and decreased collagen accumulation in Pdcd10 mice.\nMoreover, metformin significantly improved mitochondrial structural anomalies and dysfunction associated with PDCD10 deficiency, characterized by the presence of mitochondrial puncta and the loss of cristae, followed by impaired mitochondrial membrane potential and increased mitoROS in endothelial cells with the mutation.\nMetformin also normalized the defects from PDCD10 deficiency, including disruption of tight junctions and excessive proliferation of endothelial cells.\nMetformin provided these beneficial effects by downregulating KLF4.", "dois": ["10.1016/j.bbrc.2025.152241", "10.1523/JNEUROSCI.0002-22.2022"]}
{"pair_type": "slc_pathway", "key1": "SLC22A1", "key2": "migration", "summary": "increased SLC22A1/OCT1, SLC22A2/OCT2, and SLC31A1/CTR1 platinum influx transporter expression.\nMoreover, using Boyden chambers and western blot techniques, we also showed that miR-21 overexpression increased migratory, invasive, proliferative, and anti-apoptotic signaling pathways whereas opposite results were observed using an anti-miR-21-based silencing strategy.", "dois": ["10.1177/1010428317707372"]}
{"pair_type": "slc_pathway", "key1": "SLC22A1", "key2": "chemotherapy", "summary": "The downregulation of SLC22A1 was significantly associated with advanced CCA stages, since tumors with a low SLC22A1 mRNA expression presented with larger tumor diameters (p=0.02).\nA low SLC22A1 expression was associated with a worse patient survival (p<0.05).\nIn conclusion, the downregulation of OCT1 is associated with tumor progression and worse overall patient survival rates.\nReal-time PCR demonstrated a downregulation of the expression of SLC22A1 and SLC22A3 in CCA, compared to that in TST (p<0.001).\nWestern blot analysis and immunohistochemistry confirmed the downregulation of OCT1 and OCT3 protein levels in cancerous tissue compared to those in TST.\nMoreover, OCTs are considered responsible for the responsiveness towards platinum‑based chemotherapies.\nThe prognosis for CCA patients is very poor and conventional chemotherapy has been proven ineffective in improving long‑term patient survival rates.\nFor example, the transport of platinum-based anticancer drugs has been reported to be influenced by the expression and activities of OCT1-3 (SLC22A1-3), OCTN1/2 (SLC22A4/5), CTR1/2 (SLC31A1/2) and MATE1/2 (SLC47A1/2) solute carriers.\nFurthermore, the -1795G>A SNP was not associated with the pharmacokinetics of metformin, fenoterol, sumatriptan and proguanil in healthy individuals or tropisetron efficacy in patients undergoing chemotherapy.\nWe have previously reported that aberrant splicing plays an essential role in the impaired response of hepatocellular carcinoma (HCC) to sorafenib by reducing the expression of functional organic cation transporter type 1 (OCT1, gene SLC22A1) that constitutes the primary way for HCC cells to take up this and other drugs.\nFinally, we assessed the role of miR-21 in mediating renal cell carcinoma chemoresistance and further showed that miR-21 silencing significantly (1) increased chemosensitivity of pacl", "dois": ["10.3390/genes13040610", "10.1016/j.bbadis.2020.165687", "10.3390/jpm8040042", "10.1177/1010428317707372", "10.1002/bdd.1903", "10.3892/ijo.2013.1840", "PMID:16914559"]}
{"pair_type": "slc_pathway", "key1": "SLC22A1", "key2": "proliferation", "summary": "SLC22A1 expression was significantly inverse correlated with expression of the proliferation marker MIB1/Ki-67 (rs = -0.464, P < 0.0001).\nLoss of Oct3 leads to enhanced proliferation and hepatocarcinogenesis.\nFurthermore, tumor size and quantity were markedly enhanced in Oct3 mice (p<0.0001).\nOct3 tumors showed significant higher proliferation (p<0.0001).\nDownregulation of OCT is frequently observed in human hepatocellular carcinoma (HCC) and is associated with a poor outcome.\nK562S cells overexpressing the drug transporters ABCB1, ABCG2, and SLC22A1 were generated, characterized and used in proliferation assay and intracellular uptake and retention assay (IUR).\nAs another example, solute carriers mediate control over the availability of endogenous metal ions, such as copper, iron and zinc, may have key roles in regulating tumour angiogenesis, cell proliferation, epithelial-to-mesenchymal transition and aberrant MAPK and STAT-3 signal transduction in cancer.\nFunctional inhibition of OCT by quinine resulted in an activation of c-Jun N-terminal kinase (Jnk), especially in Oct3 hepatocytes.\nLoss of Oct3 in primary hepatocytes resulted in significantly reduced OCT activity determined by [H]MPP uptake.\nDNA methylation of SLC22A1 is associated with downregulation of SLC22A1 in HCC and might be a new biomarker for HCC diagnosis and prognosis.\nMoreover, targeting SLC22A1 methylation by demethylating agents may offer a novel strategy for anticancer therapy of HCC.", "dois": ["10.18632/oncotarget.23372", "10.1007/s00726-017-2515-1", "10.1186/s13045-015-0179-4", "10.1002/bdd.1903", "10.1186/gm298", "PMID:12538837"]}
{"pair_type": "slc_pathway", "key1": "SLC22A2", "key2": "apoptosis", "summary": "Incubation of hOCT2 overexpressing human embryonic kidney 293 cells (HEK-hOCT2-C) or rat renal proximal tubule cells expressing rOct2 (NRK-52E-C) with Cd(2+) resulted in an increased level of apoptosis that was reduced by OCT2 inhibitory ligand cimetidine(+).\nmiR-21 overexpression increased migratory, invasive, proliferative, and anti-apoptotic signaling pathways whereas opposite results were observed using an anti-miR-21-based silencing strategy.\nmiR-21 silencing significantly (1) increased chemosensitivity of paclitaxel, 5-fluorouracil, oxaliplatin, and dovitinib; (2) decreased expression of multi-drug resistance genes; and (4) increased SLC22A1/OCT1, SLC22A2/OCT2, and SLC31A1/CTR1 platinum influx transporter expression.\nCertain DEGs enriched in the cell cytoskeleton (LOC111217621, tubb5, and LOC111234965) and cell apoptosis (tnfrsfa, LOC111218420, LOC111223891, LOC111223286, and bcl2) were identified by kidney transcriptome analysis in response to salinity stress.\nDEGs associated with lipid and carbohydrate metabolism (elovl6l, acsl4, msmo1, pck1, g6pc1, pfkfb3, and ldha), ion transport (kcnk5, slc4a4, slc9a3, slc41a1, and slc22a2), and immune response (nfkbiaa, nfkbia, and LOC111231462) were identified.", "dois": ["10.1177/1010428317707372", "10.1021/mp400113d", "10.1016/j.cbd.2025.101572"]}
{"pair_type": "slc_pathway", "key1": "SLC22A1", "key2": "apoptosis", "summary": "Nicotine administration activated apoptosis and downregulated SLCOB1, which transport atorvastatin.\nAtorvastatin administration suppressed apoptotic pathway and downregulated SLC22A1, transporter of nicotine.\nThe combined administration of atorvastatin and nicotine reduced the influx of both atorvastatin and nicotine and enhanced the efflux of these drugs thereby altering the microenvironment of testis and improving testicular function.\nand (4) increased SLC22A1/OCT1, SLC22A2/OCT2, and SLC31A1/CTR1 platinum influx transporter expression.\nThese results indicate that calcium release from the ER, here induced by amantadine or prazosin, may prime BCR-ABL-positive cells to TKI-induced apoptosis.\nCoadministration of atorvastatin with nicotine downregulated expressions of apoptotic genes.\nWe conclude that atorvastatin-mediated alterations of BTB and drug transporters might have played a significant role in ameliorating nicotine-induced testicular toxicity.\nThis effect is due to release of intracellular calcium from the endoplasmic reticulum (ER), with changes in mitochondrial calcium and alterations in mitochondrial membrane permeability, resulting in caspase-mediated apoptosis.\nFinally, we assessed the role of miR-21 in mediating renal cell carcinoma chemoresistance and further showed that miR-21 silencing significantly (1) increased chemosensitivity of paclitaxel, 5-fluorouracil, oxaliplatin, and dovitinib;\nImmunoblotting, cell cycle analyses, and apoptosis assays were performed to evaluate functional consequences of imatinib sequestration.\nWe conclude that intracellular imatinib levels are primarily determined by lysosomal sequestration and do not depend on SLC22A1 expression.\nChanges in 36 genes involved in drug uptake/efflux and metabolism, expression/function of molecular targets, and survival/apoptosis balance were found.", "dois": ["10.1177/1010428317707372", "10.1124/mol.114.097451", "10.1021/mp300028a", "10.1038/leu.2011.231", "10.1016/j.tiv.2022.105550", "10.1111/and.13029"]}
{"pair_type": "slc_pathway", "key1": "SLC22A2", "key2": "glycolysis", "summary": "[F]FPIA uptake correlated positively with Ki-67 ( < 0.01), SLC22A5 ( < 0.001) and SLC25A20 ( = 0.001), and negatively with CPT1 ( < 0.01) and SLC22A2 ( < 0.01).", "dois": ["10.3390/biomedicines9070811"]}
{"pair_type": "slc_pathway", "key1": "SLC22A2", "key2": "migration", "summary": "and (4) increased SLC22A1/OCT1, SLC22A2/OCT2, and SLC31A1/CTR1 platinum influx transporter expression.\nIn vitro experiments further substantiated that perfluorooctanoic acid exposure promoted the malignant phenotypes of OC cells and the changes of SLC22A2, SPOCK3, and APOD expressions.\nMoreover, using Boyden chambers and western blot techniques, we also showed that miR-21 overexpression increased migratory, invasive, proliferative, and anti-apoptotic signaling pathways whereas opposite results were observed using an anti-miR-21-based silencing strategy.\nThe effects of PFAS on the phenotype of OC cells were analyzed by quantitative real-time PCR, CCK8, migration, and invasion detection.", "dois": ["10.1016/j.ecoenv.2025.119039", "10.1177/1010428317707372"]}
{"pair_type": "slc_pathway", "key1": "SLC22A2", "key2": "proliferation", "summary": "Moreover, inhibition of translational of both ODC1 and AGMAT mRNAs increased expression of ADC, SLC22A1, SLC22A2, and SLC22A3 mRNAs, as well as abundances of agmatine, putrescine, spermindine, and spermine in conceptus tissue.\nWe assessed proliferation (Ki-67) and the expression of lipid metabolism and transport proteins (CPT1, SLC22A2, SLC22A5, SLC25A20) by immunohistochemistry, along with etomoxir treatment to provide insights into [F]FPIA uptake.\nUsing five human HNSCC cell lines, we determined the concentrations of cisplatin, carboplatin, and oxaliplatin leading to 50% inhibition of cell proliferation (IC(50)).\nMean IC(50) among the five cell lines was 6.2 ± 1.9 μM for cisplatin and 11.6 ± 4.2 μM for oxaliplatin, whereas carboplatin showed significantly lower proliferation inhibition (IC(50) 107.5 ± 21.2 μM).\nEtomoxir reduced [F]FPIA uptake, which correlated with decreased Ki-67 ( < 0.05).\nSLC22A1 expression was significantly inverse correlated with expression of the proliferation marker MIB1/Ki-67 (rs = -0.464, P < 0.0001).\n[F]FPIA uptake correlated positively with Ki-67 ( < 0.01), SLC22A5 ( < 0.001) and SLC25A20 ( = 0.001), and negatively with CPT1 ( < 0.01) and SLC22A2 ( < 0.01).\nLongitudinal PET imaging showed gradual increase in [F]FPIA uptake in orthotopic glioma models with disease progression ( < 0.0001), and high tumor-to-brain contrast compared to [F]FDG ( < 0.0001).\nOur findings support the use of [F]FPIA P", "dois": ["10.3390/biomedicines9070811", "10.1007/s00726-017-2515-1", "PMID:23956837", "10.1124/jpet.111.189621", "10.1186/gm298"]}
{"pair_type": "slc_pathway", "key1": "SLC22A2", "key2": "chemotherapy", "summary": "In FP chemotherapy for oesophageal cancers, cisplatin-induced nephrotoxicity seems to be unaffected by the SLC22A2 808G>T polymorphism.\nExpression of hSLC22A2 in HEK293 cells resulted in enhanced sensitivity to oxaliplatin (12-fold) and cisplatin (1.8-fold).\nPanCareLIFE is the largest study of cisplatin-induced ototoxicity to date and confirmed a role for the polyspecific organic cation transporter SLC22A2.\nFive variants within the candidate genes were genotyped in 214 patients, of which SLC22A2 rs316019 and NFE2L2 rs6721961 associated with reduced rates of ototoxicity.\nAnthracycline-induced cardiotoxicity was associated with CBR2, CELF4, GSTM1, HAS3, RARG, and SLC28A3, and further with HNMT and SLC22A2 in younger children, with ABCB4 in females, and with SULT2B1 in males.\nHEK293/hSLC22A2 cells, compared with HEK293/Neo control cells, displayed significant increases in oxaliplatin (28.6-fold), Pt[DACH]Cl(2) (20.6-fold), ormaplatin (8.1-fold), tetraplatin (4.5-fold), transplatin (3.7-fold) and cisplatin (1.3-fold), but not carboplatin.\nAs decreased drug accumulation is a key mechanism of platinum resistance, SLCs may also contribute to the development of resistance.\nThree genes consistently associated with cisplatin-induced nephrotoxicity.\n29 SNPs in 14 genes were significantly associated with cisplatin-induced nephrotoxicity.\nThe genes ABCC3, COMT, ERCC2, GSTP1, GSTT1, LRP2, SLC22A2, and TPMT showed associations with ototoxicity due to platinum-based drugs.\nFourteen variants in eleven candidate genes (ABCC3,", "dois": ["10.1016/j.ecoenv.2025.119039", "10.1016/j.critrevonc.2025.104720", "10.2174/0115680096326784241009113454", "10.5414/CP204156", "10.2147/PGPM.S375284", "10.3390/pharmaceutics13122004", "10.1093/carcin/bgaa136", "10.1016/j.ejca.2020.07.019", "10.1093/jncics/pkaa032", "10.3389/fphar.2018.01111", "10.1177/1010428317707372", "10.1038/tpj.2016.52", "10.1111/jcpt.12097", "PMID:23420099", "10.1111/j.1476-5381.2009.00569.x"]}
{"pair_type": "slc_pathway", "key1": "SLC22A3", "key2": "migration", "summary": "Enhancement of SLC22A3 mRNA m6A methylation via the dCas13b-M3 plasmid in breast cancer cells led to increased SLC22A3 expression, accompanied by reduced cell proliferation and migration and induced apoptosis.\nMeanwhile, the phenotypes of proliferation, migration, invasion, cell cycle and apoptosis of colorectal cancer cell were significantly affected by SLC22A3 in vitro.\nMoreover, by the luciferase assays, we found that compared to the G allele of rs420038, the A allele could suppress the activity of the promoter in SLC22A3.\nOf which, SNP rs420038 G > A in SLC22A3 was related to decreased risk of colorectal cancer (adjusted odds ratio (OR) = 0.79, 95% confidence interval (CI) = 0.67-0.94, p = 0.007), and also associated with lower expression of SLC22A3 (p = 0.040) using expression quantitative trait loci (eQTL) analysis.\nThe induction of SLC22A3 mRNA methylation through the m6A CRISPR approach effectively mitigates the malignancy of breast cancer cells.\nSLC22A3 acts as protective factor in breast cancer.\nEnhanced m6A methylation of SLC22A3 mRNA and overexpression of the m6A reader IGF2BP2 upregulate its expression.\nAnalysis of breast cancer tissues from mice revealed a decrease in both SLC22A3 expression and its m6A methylation as the breast cancer progressed.\nBioinformatics analysis demonstrated a significant reduction in SLC22A3 expression in cancer tissues compared to adjacent non-cancerous tissues.\nFurthermore, the expression of SLC22A3 was significantly higher in colorectal cancer tissues than that in paired normal tissues (p < 0.001).\nMonoamines (serotonin, dopamine, norepinephrine) are crucial neuromodulators for proper placenta functions and fetal development, including cell proliferation, differentiation, and neuronal migration.", "dois": ["10.1016/j.bbadis.2025.167962", "10.1038/s41598-022-15790-7", "10.1002/ijc.32079"]}
{"pair_type": "slc_pathway", "key1": "SLC22A3", "key2": "apoptosis", "summary": "Enhancement of SLC22A3 mRNA m6A methylation via the dCas13b-M3 plasmid in breast cancer cells led to increased SLC22A3 expression, accompanied by reduced cell proliferation and migration and induced apoptosis.\nKnockdown of SLC22A3 in leukemia cells enhanced cell proliferation and suppressed cell apoptosis.\nMeanwhile, the phenotypes of proliferation, migration, invasion, cell cycle and apoptosis of colorectal cancer cell were significantly affected by SLC22A3 in vitro.\nEnhanced m6A methylation of SLC22A3 mRNA and overexpression of the m6A reader IGF2BP2 upregulate its expression.\nSLC22A3 is significantly downregulated and associated with tumor progression and worse prognosis in a variety of solid tumors.\nOverexpression of IGF2BP2 similarly increased SLC22A3 expression.\nDemethylation drug 5-aza-2'-deoxycytidine (DAC) activated transcription and increased mRNA expression of SLC22A3 in leukemia cell lines and AML fresh BMMNCs.\nThe induction of SLC22A3 mRNA methylation through the m6A CRISPR approach effectively mitigates the malignancy of breast cancer cells.\nSLC22A3 acts as protective factor in breast cancer.\nMethylation-silenced SLC22A3 expression may have potential guiding significance on antileukemia effect of DAC.\nBioinformatics analysis demonstrated a significant reduction in SLC22A3 expression in cancer tissues compared to adjacent non-cancerous tissues.\nSLC22A3 hypermethylation presented an obvious association with some specific clinical characteristics and affected the survival time of AML patients as an independent risk indicator.\nThus, SMC calcification observed in response to vitamin D sterol + DM may be partially mediated through targeting mineralization, apoptotic, osteo/chondrocytic, and cardiovascular pathway genes, although some gene changes may protect against calcification.", "dois": ["10.1158/1940-6207.CAPR-14-0348", "10.1016/j.bbadis.2025.167962", "10.1186/s13148-022-01373-w", "10.1002/ijc.32079", "10.1002/jcb.22779", "PMID:16269432"]}
{"pair_type": "slc_pathway", "key1": "SLC22A3", "key2": "chemotherapy", "summary": "An study demonstrated that SCC-25 cells with upregulated SLC22A3 expression were more sensitive to cisplatin than were SCC-4 cells with downregulated SLC22A3 expression.\nAn increased uptake of cisplatin and an enhanced cytotoxic effect were observed in SLC22A3-overexpressing SCC-4 cells, and decreased uptake was found in SLC22A3-knocked down SCC-25 cells.\nThe present study shows for the first time that the protein presence and to some extent also localization of SLC22A3 significantly associate with prognosis of pancreatic cancer in both unstratified and chemotherapy-treated patients.\nOur results demonstrated that upregulated SLC22A3 expression can increase the cisplatin uptake and subsequently improve the survival of patients with HNSCC.\nOne of the principal mechanisms of chemotherapy resistance in highly frequent solid tumors, such as colorectal cancer (CRC), is the decreased activity of drug transport into tumor cells due to low expression of important membrane proteins, such as solute carrier (SLC) transporters.\nThe release of lactate dehydrogenase (LDH) and accumulation of platinum with oxaliplatin treatment were increased in SW480 cells transfected with hOCT3 cDNA compared with empty vector-transfected cells.\nIn conclusion, the hOCT3-mediated uptake of oxaliplatin into the cancers was suggested to be important for its cytotoxicity, and hOCT3 expression may be a marker for cancer chemotherapy including oxaliplatin.\nWe found that patients with higher SLC22A3 expression had longer survival times than those with lower SLC22A3 expression ( = 0.051).\nMoreover, among advanced T-stage patients receiving adjuvant cisplatin therapy, those with higher SLC22A3 expression had longer survival times than those with lower SLC22A3 expression ( = 0.006).\nA subgroup analysis of patients treated with regimens based on nucleoside analogs suggested that patients with negative brush border staining or apical localization of SLC22A3 in tumor cells have worse overall survival.\nThrough Cox regression analysis, we found that among patients receiving the (", "dois": ["10.1093/carcin/bgaa136", "10.1038/s41598-019-56059-w", "10.1007/s00384-019-03407-x", "10.18632/oncotarget.20637", "PMID:27127130", "10.3892/ijo.2013.1840", "10.1124/dmd.108.023168"]}
{"pair_type": "slc_pathway", "key1": "SLC22A3", "key2": "oxidative stress", "summary": "however, when converted to the monovalent cation PQ(+) by either a reducing agent or NADPH oxidase on microglia, it becomes a substrate for DAT and is accumulated in DA neurons, where it induces oxidative stress and cytotoxicity.\nIn addition to DAT, PQ(+) is also a substrate for the organic cation transporter 3 (Oct3, Slc22a3), which is abundantly expressed in non-DA cells in the nigrostriatal regions.\nThis study provides a mechanism by which DAT and Oct3 modulate nigrostriatal damage induced by PQ(2+)/PQ(+) redox cycling.\nIn mice with Oct3 deficiency, enhanced striatal damage was detected after PQ treatment.\nConsistent with the Remote Sensing and Signaling Theory, this indicates an important in vivo role in the oxidative stress response for multiple SLC22 transporters within the fly renal system, perhaps through interaction with SLC22 counterparts in non-renal tissues.\nExpression in the Malpighian tubule and likely other tissues as well (e.g., gut, fat body, nervous system) appear critical for managing oxidative stress.\nOur work not only indicates the importance of SLC22 transporters in the fly renal system but also sets the stage for in vivo studies by examining their role in mammalian oxidative stress and organ crosstalk.\nUsing two tissue-selective knockdown strategies, we were able to demonstrate much greater and longer protection from oxidative stress compared to previous whole fly knockdowns as well as both parent and WT strains (CG6126: < 0.001, CG4630: < 0.01, CG16727: < 0.0001 and CG6006: < 0.01).\nUbiquitous knockdowns of related SLC22s-including transporters homologous to those previously identified by us in mammals such as the \"Fly-Like Putative Transporters\" FLIPT1 (SLC22A15) and FLIPT2 (SLC22A16)-have shown modest protection against oxidative stress.\nSeveral SLC22 transporters in the human kidney and other tissues are thought to regulate endogenous small antioxidant", "dois": ["10.1038/s41598-023-40560-4", "10.3390/ijms222413407", "10.1073/pnas.1115141108"]}
{"pair_type": "slc_pathway", "key1": "SLC22A4", "key2": "chemotherapy", "summary": "For example, the transport of platinum-based anticancer drugs has been reported to be influenced by the expression and activities of OCT1-3 (SLC22A1-3), OCTN1/2 (SLC22A4/5), CTR1/2 (SLC31A1/2) and MATE1/2 (SLC47A1/2) solute carriers.\nThe expression of prognostic signature genes was significantly correlated with the pTMN stage, immune infiltration, tumor mutational burdens, microsattelite instability, and drug sensitivity of ccRCC patients.\nThree clusters of ccRCC cases with significant difference in prognosis, immune infiltration, and chemotherapy and targeted therapy were identified.\nA range of different solute carrier families, including members from the SLC2A, SLC11A, SLC22A, SLC25A, SLC30A, SLC31A, SLC39A, SLC40A, SLC47A and SLCO1B families, and various metal substrates, including arsenic, copper, gadolinium, iron, platinum and zinc, have been implicated in these cancer-related transport processes.\nAs another example, solute carriers mediate control over the availability of endogenous metal ions, such as copper, iron and zinc, may have key roles in regulating tumour angiogenesis, cell proliferation, epithelial-to-mesenchymal transition and aberrant MAPK and STAT-3 signal transduction in cancer.", "dois": ["10.3389/fcell.2022.1021690", "10.1002/bdd.1903"]}
{"pair_type": "slc_pathway", "key1": "SLC22A4", "key2": "apoptosis", "summary": "I cannot find any excerpts in the provided text that explicitly mention SLC22A4 or describe a relationship between SLC22A4 and apoptosis.\nThe text discusses NETs (neutrophil extracellular traps), sepsis, genes like CYBB and FCAR, and mentions apoptosis only once in passing, but does not contain any verbatim phrases or sentences that establish a promotion or suppression relationship between SLC22A4 and apoptosis.", "dois": ["10.1017/S0967199418000047", "10.3389/fimmu.2023.1253833", "PMID:18670092", "PMID:18560602"]}
{"pair_type": "slc_pathway", "key1": "SLC22A4", "key2": "glycolysis", "summary": "Rats of the O+N group had a higher percentage of oxidative type I fibers and higher mRNA levels of genes encoding regulators of muscle fiber composition (Ppard, Ppargc1a, Ppargc1b), angiogenic factors (Vegfa, Vegfb), and genes involved in fatty acid utilization (Cpt1b, Slc25a20, Slc22a4, Slc22a5, Slc27a1) and oxidative phosphorylation (Cox4i1, Cox6a2) and a higher activity of the mitochondrial oxidative enzyme succinate dehydrogenase in muscle than rats of the O and L groups (P < 0.05).\nThese niacin-induced changes in muscle metabolic phenotype are indicative of an increased capacity of muscle for oxidative utilization of fatty acids and are likely mediated by the upregulation of Ppard, Ppargc1a, and Ppargc1b, which are key regulators of muscle fiber composition, mitochondrial biogenesis, angiogenesis, and genes involved in fatty acid catabolism and oxidative phosphorylation.", "dois": ["10.3945/jn.112.164038"]}
{"pair_type": "slc_pathway", "key1": "SLC22A4", "key2": "oxidative phosphorylation", "summary": "Rats of the O+N group had a higher percentage of oxidative type I fibers and higher mRNA levels of genes encoding regulators of muscle fiber composition (Ppard, Ppargc1a, Ppargc1b), angiogenic factors (Vegfa, Vegfb), and genes involved in fatty acid utilization (Cpt1b, Slc25a20, Slc22a4, Slc22a5, Slc27a1) and oxidative phosphorylation (Cox4i1, Cox6a2) and a higher activity of the mitochondrial oxidative enzyme succinate dehydrogenase in muscle than rats of the O and L groups (P < 0.05).\nThese niacin-induced changes in muscle metabolic phenotype are indicative of an increased capacity of muscle for oxidative utilization of fatty acids and are likely mediated by the upregulation of Ppard, Ppargc1a, and Ppargc1b, which are key regulators of muscle fiber composition, mitochondrial biogenesis, angiogenesis, and genes involved in fatty acid catabolism and oxidative phosphorylation.", "dois": ["10.3945/jn.112.164038"]}
{"pair_type": "slc_pathway", "key1": "SLC22A3", "key2": "proliferation", "summary": "Enhancement of SLC22A3 mRNA m6A methylation via the dCas13b-M3 plasmid in breast cancer cells led to increased SLC22A3 expression, accompanied by reduced cell proliferation and migration and induced apoptosis.\nKnockdown of SLC22A3 in leukemia cells enhanced cell proliferation and suppressed cell apoptosis.\nSolute carrier family 22 member 3 (SLC22A3) inhibited HA-induced CCA proliferation by importing bile HA into cells for degradation, and deletion resulted in HA accumulation.\nHeterologous PITX2 expression induced ABCB1, repressed hOCT3/SLC22A3, enhanced vincristine resistance and diminished proliferation inhibition wherein PITX2A and PITX2C were most effective.\nsiRNA-mediated knockdown of these genes reduced cell growth and proliferation in LNCaP cells.\nKnockdown of the 5-HT transporter SLC22A3 or inhibition of TGM2 reduces H3Q5ser levels and reverses the tumor-promoting phenotypes of CAFs in CRC.\ncompared to the G allele of rs420038, the A allele could suppress the activity of the promoter in SLC22A3.\nMeanwhile, the phenotypes of proliferation, migration, invasion, cell cycle and apoptosis of colorectal cancer cell were significantly affected by SLC22A3 in vitro.\nLoss of Oct3 leads to enhanced proliferation and hepatocarcinogenesis.\nHA promoted CCA cell proliferation by activating HRH1-Gαq signalling and hastened CAFs to secrete hepatocyte growth factor by stimulating HRH2-Gαs signalling.\nH3Q5ser triggers a phenotypic switch of CAFs towards an inflammatory-like CAF (iCAF) subtype, which further enhances CRC cell proliferation, invasive characteristics, and macrophage polarization.\nThis study revealed that depleting 5-HT, either through genetic silencing of Tph1 or using a selective TPH1 inhibitor, effectively reduced the growth of CRC tumors.", "dois": ["10.1038/s41598-025-20494-9", "10.1016/j.bbadis.2025.167962", "10.1016/j.canlet.2024.217150", "10.1136/gutjnl-2023-331715", "10.1186/s13148-022-01373-w", "10.1038/s41598-022-15790-7", "PMID:33841642", "10.1016/j.canlet.2019.01.044", "10.1002/ijc.32079", "10.1038/s41598-018-29789-6", "10.18632/oncotarget.23372", "10.1007/s00726-017-2515-1", "10.1186/gm298"]}
{"pair_type": "slc_pathway", "key1": "SLC22A5", "key2": "chemotherapy", "summary": "Critically, preclinical models revealed that Slc22a5 overexpression drove resistance to immunotherapy but not chemotherapy, by fostering an immunosuppressive microenvironment characterized by M2 macrophage accumulation and CD8 + T cell exclusion.\nThe predictive effect of SLC22A5-centric carnitine metabolism for resistance to immunotherapy rather than chemotherapy was independently validated in an external randomized trial.\nAdditionally, lung tumor-bearing murine models were established using Slc22a5-overexpressing (OE) and control Lewis Lung Carcinoma (LLC) cells, and treated with immunotherapy or chemotherapy.\nFurthermore, pharmacological inhibition of SLC22A5 by meldonium reshaped the tumor microenvironment toward a more inflamed state and re-sensitized resistant tumors to immunotherapy.\nTumor-intrinsic carnitine metabolism may predict and drive immunotherapy resistance, and targeting SLC22A5-mediated carnitine metabolism could be used to overcome resistance in advanced NSCLC.\nMetabolic transcriptional programs were divided into four categories based on different predictive effects specific to immunotherapy or chemotherapy, among which carnitine metabolism stood out as the most prominent metabolic process contributing to the resistance to immunotherapy.\nClinical and transcriptomic data were collected from two randomized controlled trials, OAK (n = 699, discovery cohort) and POPLAR (n = 192, validation cohort) comparing immunotherapy with chemotherapy.\nHerein, we aimed to uncover the predictive metabolic signatures specific to immunotherapy resistance by distinguishing the predictive versus prognostic effect of transcriptional programs in advanced non-small cell lung cancer (NSCLC) treated with immunotherapy.\nInterestingly, these 2 SNPs are associated strongly with the baseline expression of >20 genes (all P ≤10(-4)), and that 2 genes (SLC22A5 and SLCO4C1) are important organic cation/anion transporters known to affect platinum uptake and clearance.", "dois": ["10.1016/j.drup.2025.101313", "10.1038/s41392-018-0034-5", "10.1016/j.trsl.2011.01.005"]}
{"pair_type": "slc_pathway", "key1": "SLC22A4", "key2": "proliferation", "summary": "The depletion of SOS1 markedly inhibits cell growth either or and significantly increases the sensitivity of chronic myeloid leukemia cells to imatinib.\nAltogether these findings indicate that targeting SOS1 inhibition promotes imatinib sensitivity and overcomes resistance with BCR-ABL independence by SLC22A4-mediated uptake transport.\nThus, OCTN1-mediated uptake of ERGO in NPCs inhibits cellular proliferation via regulation of oxidative stress, and also promotes cellular differentiation by modulating the expression of basic helix-loop-helix transcription factors via an unidentified mechanism different from antioxidant action.\nThus, OCTN1 is involved in cellular differentiation, but inhibits their proliferation, possibly via the regulation of cellular oxidative stress.\nBAY-293, an inhibitor of SOS1/Ras, was found to depress proliferation and colony formation in chronic myeloid leukemia cells with resistance and BCR-ABL independence.\nInterestingly, the siRNA knockdown decreased the number of differentiated Neuro2a cells showing long neurites, but increased the total number of cells.\nTransfection of P19-NPCs with small interfering RNA for OCTN1 markedly promoted formation of neurospheres with a concomitant decrease of [(3)H]ERGO uptake.\nLCAR treatment significantly inhibited both APC and CD4+ T cell function, as assessed by the expression of classical activation markers, proliferation and cytokine production.\nCarnitine deficiency resulted in the hyperactivation of CD4+ T cells and enhanced cytokine production.\nIn vivo, protection from trinitrobenzene sulphonic acid colitis was observed in LCAR-treated mice and was attributed to the abrogation of both innate [interleukin (IL)-1beta and IL-6 production] and adaptive (T cell proliferation in draining lymph nodes) immune responses.\nExposure of cultured NPCs to ERGO or other antioxidants (edaravone and ascorbic acid) led to a significant decrease in the area of neurospheres with concomitant elimination of intracellular reactive oxygen species.", "dois": ["10.1667/RADE-23-00099.1", "10.1016/j.omto.2021.11.010", "10.1002/bdd.1903", "10.1371/journal.pone.0089434", "10.1016/j.neuint.2012.08.004", "10.1111/j.1365-2249.2009.03879.x", "PMID:18670092", "PMID:17447122"]}
{"pair_type": "slc_pathway", "key1": "SLC22A5", "key2": "ferroptosis", "summary": "Importantly, genome-wide analysis and pharmacological inhibitor experiments identified ferroptosis, an iron- and lipid-dependent cell death pathway associated with fibroblast activation as a novel PCD cardiomyopathy disease mechanism.\nPrimary carnitine deficiency (PCD) is an autosomal recessive monogenic disorder caused by mutations in SLC22A5.\nThis gene encodes for OCTN2, which transports the essential metabolite carnitine into the cell.", "dois": ["10.1016/j.stemcr.2023.09.002"]}
{"pair_type": "slc_pathway", "key1": "SLC22A5", "key2": "apoptosis", "summary": "This led to reduced viability and increased apoptosis in glioma cells.\nThere was increased apoptosis in gut samples from OCTN2(-/-) mice.\nOCTN2(-/-) mice developed a severe immune phenotype, where the thymus, spleen and lymph nodes became atrophied secondary to increased apoptosis.\nWe conclude that carnitine plays a major role in neonatal OCTN2(-/-) mouse gut development and differentiation, and that severe carnitine deficiency leads to increased apoptosis of enterocytes, villous atrophy, inflammation and gut injury.\nModulation of SLC22A5 level by either silencing or up-regulation of SLC22A5 also affected glioma cell survival in a FAO-dependent way.\nThese observations suggest that the survival of glioma cells is heavily reliant on both FAO and SLC22A5 activity, as well as that CPT1 and SLC22A5 might be possible drug targets.\nCarnitine can be delivered to the cell by an organic cation/carnitine transporter-SLC22A5/OCTN2.\nResearch on glioma cells (lines U87MG, LN229, T98G) with various expression levels of SLC22A5 demonstrated a correlation between the FAO rate, the level of the transporter, and the carnitine transport.\nInhibition of carnitine transport by chemotherapeutics, such as vinorelbine and vincristine, led to inhibition of FAO, which was further intensified by etomoxir-a CPT1 inhibitor.", "dois": ["10.1158/1078-0432.CCR-18-2380", "10.1371/journal.pone.0047729", "10.1097/CM9.0000000000003864", "10.1111/jnc.15124", "PMID:18560602"]}
{"pair_type": "slc_pathway", "key1": "SLC22A5", "key2": "migration", "summary": "We identify driver mutations in ADPGK, NUP93, PCGF6, PKP2 and SLC22A5, which are verified to enhance cancer cell migration and prompt metastasis with in vitro experiments.", "dois": ["10.1158/1078-0432.CCR-18-2380", "10.1038/celldisc.2016.25"]}
{"pair_type": "slc_pathway", "key1": "SLC22A5", "key2": "glycolysis", "summary": "Rats of the O+N group had a higher percentage of oxidative type I fibers and higher mRNA levels of genes encoding regulators of muscle fiber composition (Ppard, Ppargc1a, Ppargc1b), angiogenic factors (Vegfa, Vegfb), and genes involved in fatty acid utilization (Cpt1b, Slc25a20, Slc22a4, Slc22a5, Slc27a1) and oxidative phosphorylation (Cox4i1, Cox6a2) and a higher activity of the mitochondrial oxidative enzyme succinate dehydrogenase in muscle than rats of the O and L groups (P < 0.05).\n[F]FPIA uptake correlated positively with Ki-67 ( < 0.01), SLC22A5 ( < 0.001) and SLC25A20 ( = 0.001), and negatively with CPT1 ( < 0.01) and SLC22A2 ( < 0.01).\nWe assessed proliferation (Ki-67) and the expression of lipid metabolism and transport proteins (CPT1, SLC22A2, SLC22A5, SLC25A20) by immunohistochemistry, along with etomoxir treatment to provide insights into [F]FPIA uptake.\nWe found that, ) fasting downregulated numerous metabolic pathways in human adipose tissue, including triglyceride and fatty acid synthesis, glycolysis and glycogen synthesis, TCA cycle, oxidative phosphorylation, mitochondrial translation, and insulin signaling;\nIn addition to increased glycolysis, the oxidation of acetate in the citric acid cycle is another common metabolic phenotype.\n) although major overlap in fasting-induced gene regulation was observed between human and mouse adipose tissue, many genes were differentially regulated in the two species, including genes involved in insulin signaling (, ), PPAR signaling (, , , , ), glycogen metabolism (, ), and lipid droplets (, , , ).", "dois": ["10.3945/jn.112.164038", "10.3390/biomedicines9070811", "10.1152/physiolgenomics.00083.2020"]}
{"pair_type": "slc_pathway", "key1": "SLC22A6", "key2": "chemotherapy", "summary": "Our results indicate that variations in ABCC2, CYP3A5, NQO1, SLC22A6 and SLC28A3 genes might influence the left ventricular parameters.\nSLC22A6 gene rs6591722 AA genotype was associated with lower mean FS (p = 1.71E-03), 5-10 years after the diagnosis.\nGenetic variants in transporters and metabolic enzymes might modulate the individual risk to cardiac toxicity after chemotherapy.\nOne of the most common adverse effects of chemotherapy in B-ALL is the hematologic toxicity, which may be related to genetic variants in membrane transporters that are critical for drug absorption, distribution, and elimination.\nThere are genetic variants in the and transporter families present in Mexican children with B-ALL that can be considered as potential risk markers for hematologic toxicity secondary to chemotherapeutic treatment, as well as other protective variants that may be useful in addition to conventional risk stratification for therapeutic decision making in these highly vulnerable patients.\nIn this study we detected genetic variants present in a selected group genes of the and families that are associated with the risk of high-grade hematologic adverse events due to chemotherapy treatment in a group of Mexican children with B-ALL.\nWe found two types of associations among the genetic variants identified as possible predictor factors of hematologic toxicity.\nTo determine whether there is an association between the genetic variants and high-grade hematologic adverse events, logistic regression analyses were performed using co-dominant, dominant, recessive, overdominant and log-additive inheritance models.\nCardiotoxicity is contributed mainly to the use of anthracyclines and might have genetic risk factors.\nOne of these is cardiotoxicity which may lead to progressive heart failure in the long term.", "dois": ["10.3389/fonc.2023.1276352", "10.1186/s12885-018-4629-6"]}
{"pair_type": "slc_pathway", "key1": "SLC22A4", "key2": "oxidative stress", "summary": "The ET transporter (ETT), SLC22A4, is upregulated in tissues that experience high levels of oxidative stress.\nThus, OCTN1-mediated uptake of ERGO in NPCs inhibits cellular proliferation via regulation of oxidative stress, and also promotes cellular differentiation by modulating the expression of basic helix-loop-helix transcription factors via an unidentified mechanism different from antioxidant action.\nThus, octn1/slc22a4 gene deletion results in more severe hepatic fibrosis, oxidative stress, and inflammation.\nAfter injection of hepatotoxins such as dimethylnitrosamine (DMN) or concanavalin A, hepatic fibrosis, and oxidative stress, evaluated in terms of Sirius red and 4-hydroxy-2-nonenal staining, respectively, were more severe in liver of octn1/slc22a4 gene knockout (octn1(-/-)) mice than that in wild-type mice.\nThus, OCTN1 is involved in cellular differentiation, but inhibits their proliferation, possibly via the regulation of cellular oxidative stress.\nIn neuronal model Neuro2a cells, knockdown of OCTN1 by siRNA reduced the uptake of [(3)H]ERGO with concomitant up-regulation of oxidative stress marker HO-1 and Sox2, and down-regulation of neurite outgrowth marker GAP43.\nProvision of ERGO-rich feed ameliorated DMN-induced liver fibrosis and oxidative stress.\nPre-eclampsia, a condition accompanied by increased oxidative stress, is one of the leading causes of maternal morbidity and mortality.\nOverall, Octn1 is upregulated in activated stellate cells, resulting in increased delivery of its substrate antioxidant ERGO and a protective effect against liver fibrosis.\nExposure of cultured NPCs to ERGO or other antioxidants (edaravone and ascorbic acid) led to a significant decrease in the area of neurospheres with concomitant elimination of intracellular reactive oxygen species.\nBecause ERGO is highly distributed into the brain after oral ingestion, OCTN1 may contribute to the al", "dois": ["10.1016/j.redox.2023.102801", "10.1017/S0954422419000301", "10.1016/j.freeradbiomed.2017.12.030", "10.1016/j.freeradbiomed.2015.02.026", "10.1007/s11095-010-0076-z", "10.1016/j.bbrc.2025.152210", "10.3390/antiox13060717", "10.1016/j.toxlet.2024.05.014", "10.1017/S0007114522003592", "10.1248/bpb.b17-00099", "10.1016/j.xphs.2016.02.023", "10.1371/journal.pone.0089434", "10.1016/j.neuint.2012.08.004", "PMID:18670092"]}
{"pair_type": "slc_pathway", "key1": "SLC22A5", "key2": "proliferation", "summary": "In functional assays, knockdown of SLC22A5 inhibited L: -carnitine intake, resulted in lipid droplet accumulation, and suppressed the proliferation of breast cancer cells.\nSince SLC22A5 is a critical regulator of carnitine homeostasis, lipid metabolism, and cell proliferation, SLC22A5 may serve as a potential therapeutic target for breast cancer in the future.\nOCTN2 silencing reduced the proliferation rate of the colon cells, whereas OCTN2 overexpression increased the proliferation rate.\nexpression is altered in many types of cancer, giving an advantage to some of them by supplying carnitine for β-oxidation, thus providing an alternative to glucose source of energy for growth and proliferation.\nThis up-regulation was correlated positively with tumor size and Ki-67 and negatively with the progesterone receptor (PR) status, providing evidence of the opposite effects of OCTN2 and PR on tumor development.\nFatty acid oxidation (FAO) is a major energy-generating process in the mitochondria and supports proliferation, growth, and survival of cancer cells.\n[F]FPIA uptake correlated positively with Ki-67 ( < 0.01), SLC22A5 ( < 0.001) and SLC25A20 ( = 0.001), and negatively with CPT1 ( < 0.01) and SLC22A2 ( < 0.01).\nEtomoxir reduced [F]FPIA uptake, which correlated with decreased Ki-67 ( < 0.05).\nA growing number of observations reveal that tumors can utilize a wide range of substrates to sustain cell survival and proliferation.\nProper regulation of carnitine levels is important in the context of development and increased risk of cancer cells proliferation.\nThe majority of carnitine comes from the diet and is transported to the cell by ubiquitously expressed organic cation transporter novel family member 2 (OCTN2)/solute carrier family 22 member 5 (SLC22A5).\nLongitudinal PET imaging showed gradual increase in [F]FPIA uptake in orthotopic glioma models with disease progression (", "dois": ["10.21037/tlcr-24-448", "10.1007/s11033-022-08152-z", "10.3390/biomedicines9070811", "10.3389/fcell.2020.583850", "10.1016/j.bcp.2020.114115", "10.3390/molecules25010014", "10.1007/s10549-011-1925-0", "10.1111/j.1365-2249.2009.03879.x"]}
{"pair_type": "slc_pathway", "key1": "SLC22A6", "key2": "glycolysis", "summary": "Our study reveals a marked elevation of histone H3 Lysine 9 Lactylation (H3K9la) relative to acetylation in atherosclerotic aortic tissue, potentially via SLC22A6-mediated glycolytic enhancement and lactate uptake.\nWhile metabolic reprogramming toward glycolysis in endothelial cells exacerbates disease progression, the role of lactate-derived lactylation in atherogenesis remains poorly understood.\nAdditionally, endothelial-specific knockout of Slc22a6 attenuates H3K9la-driven endothelial dysfunction and atherosclerosis.\nOur findings unveil a metabolism-epigenetics-transcription regulatory axis in endothelial pathophysiology, thus providing novel therapeutic strategies for atherosclerosis by targeting the SLC22A6-dependent ACSS1-H3K9la-SCD1 pathway.", "dois": ["10.1016/j.metabol.2025.156426"]}
{"pair_type": "slc_pathway", "key1": "SLC22A6", "key2": "apoptosis", "summary": "Moreover, APM was found to be difficult to rescue cell proliferation and apoptosis caused by cisplatin in the Slc22a6 knockdown cell line.\nIntegrated evidence suggested that APM enhanced renal ion transport and metabolism, and reduced apoptosis and inflammation in the kidney tissues.\nStrikingly, Mapk15, Slc22a6, Cxcl5, and Cd44 were the potential targets of APM that conferred protection against cisplatin-induced AKI.\nThere was a significantly increased rate of cellular apoptosis in rOAT1-transfected HEK293 cells than control cells after AAI treatment.\nAmong these genes, early endosome antigen 1 (EEA1) involved in endocytosis, and BCL2 Like 1 (BCL2L1) known for its role in regulating apoptosis, were identified.\nFurthermore, we identified apoptosis, particularly the extrinsic apoptotic pathway involving FADD and CASP8, as a critical mechanism associated with glioma recurrence.\nSubsequent analysis indicated that extrinsic apoptosis-related molecules (FADD and CASP8), rather than intrinsic apoptotic molecules (BCL2 and CASP9), were strongly correlated with glioma recurrence.\nFunctional annotation revealed a significant association between the signature and apoptotic pathways.\nFurthermore, correlation analysis was performed to elucidate the relationship between six classic apoptotic genes and the recurrence score.\nThese findings indicate that AAI is taken up by OAT1, which then exert its intracellular toxic effects on renal proximal tubule cells, which in turn damage functional OAT1 and may further disturb the transport of its substrates.", "dois": ["10.1186/s12865-025-00746-z", "10.1016/j.bbrc.2023.149463", "10.18632/oncotarget.27152", "10.1177/0960327111424302"]}
{"pair_type": "slc_pathway", "key1": "SLC22A6", "key2": "proliferation", "summary": "Moreover, APM was found to be difficult to rescue cell proliferation and apoptosis caused by cisplatin in the Slc22a6 knockdown cell line.", "dois": ["10.1016/j.bbrc.2023.149463"]}
{"pair_type": "slc_pathway", "key1": "SLC22A11", "key2": "apoptosis", "summary": "Amino-bisphosphonates in nM concentrations inhibit farnesyl pyrophosphate synthase leading to accumulation of isopentenyl pyrophosphate (IPP) and the ATP/pyrophosphate adduct ApppI, which induces apoptosis in osteoclasts.\nIn MCF-7 and T47D either BP markedly suppressed cell viability with only minor effects on apoptosis.\nBlocking probenecid and novobiocin-sensitive channels and transporters enhances BP anti-tumor effects and renders SLC22A family members as good candidates as BP modulators.\nCo-treatment with probenecid enhanced BP effects on cell viability, IPP/ApppI accumulation as measurable in MCF-7 and T47D cells, caspase 3/7 activity and target gene expression.\nWe hypothesized that enhancing intracellular pyrophosphate accumulation via inhibition of probenecid-sensitive channels and transporters would sensitize tumor cells for bisphosphonates anti-tumor efficacy.\nTreatment of MDA-MB-231 with BP induced caspase 3/7 activity, with zoledronic acid being the most effective.\nNovobiocin co-treatment of MDA-MB-231 yielded identical results on viability and apoptosis compared to probenecid, rendering SLC22A family members as candidate modulators of BP effects, whereas no such evidence was found for ANKH, ABCC1 and PANX1.", "dois": ["10.1186/1476-4598-13-265"]}
{"pair_type": "slc_pathway", "key1": "SLC22A11", "key2": "glycolysis", "summary": "Two important pathways determining hyperuricemia have been confirmed (renal and gut excretion of uric acid with glycolysis now firmly implicated).\nAt the other 26 loci, probable causal genes can be identified at three (PDZK1, SLC22A11, and INHBB) with strong candidates at a further 10 loci.", "dois": ["10.1186/s13075-015-0609-2"]}
{"pair_type": "slc_pathway", "key1": "SLC22A7", "key2": "chemotherapy", "summary": "Overexpression of miR-1229-3p in GC cells induced significant chemoresistance to 5-fluorouracil (5-FU), up-regulation of thymidylate synthase (TS) and dihydroprimidine dehydrogenase (DPD) and down-regulation of SLC22A7 both in vitro and in vivo.\nIntraperitoneal injection of miR-1229-3p in mice induced significant chemoresistance to 5-FU, accompanied by high levels of miR-1229-3p in plasma and tumor tissue.\nthe organic anion transporter 2 (OAT2, encoded by the SLC22A7 gene) and the sodium taurocholate cotransporting polypeptide (NTCP, encoded by the SLC10A1 gene), stably transfected in human embryonic kidney cells, with some antineoplastic agents that are routinely being used in cancer chemotherapy.\nWhereas NTCP did not show any strong interactions with the cytostatics tested, we observed a very strong inhibition of OAT2 mediated [(3)H] cGMP uptake in the presence of bendamustine, irinotecan and paclitaxel.\nThe Ki values of OAT2 for bendamustine, irinotecan and paclitaxel were determined to be 43.3±4.33μM, 26.4±2.34μM and 10.4±0.45μM, respectively.\nIncubation of bendamustine with OAT2 expressing cells increased the caspase-3 activity, and this increase was inhibited by simultaneous incubation with bendamustine and probenecid, a well-known inhibitor of OATs, suggesting that bendamustine is a substrate of OAT2.\nA higher accumulation of irinotecan was observed in OAT2 expressing cells compared to control pcDNA cells by HPLC analysis of cell lysates.\nThe accumulation was diminished in the presence of cGMP, the substrate we used to functionally characterize OAT2, suggesting specificity of this uptake and the fact that", "dois": ["10.23736/S2724-5683.24.06748-6", "10.1186/s12885-022-10434-5", "10.2147/IJGM.S351168", "10.1038/s41598-020-59939-8", "10.1016/j.phrs.2017.03.021", "10.1111/bcp.13008", "10.1016/j.phrs.2014.11.002"]}
{"pair_type": "slc_pathway", "key1": "SLC22A8", "key2": "glycolysis", "summary": "cytochrome P450 2c11 (Cyp2c11), Cyp4a2, glutathione S-transferases mu 2 (Gstm2), and Slc22a8 (organic anion transporter 3, Oat3).\nglycerol-3-phosphate acyltransferase 1, Gpam) or glycolysis (e.g.\nMost female-specific genes were associated to lipid metabolism (e.g.\nMale-specific genes were involved in hepatic metabolism, detoxification, and secretion, e.g.", "dois": ["PMID:27056296", "10.1016/j.ygeno.2015.07.006"]}
{"pair_type": "slc_pathway", "key1": "SLC22A7", "key2": "oxidative stress", "summary": "When combined with both mycotoxins, RSV decreased the protein expression of all of the studied rOats.\nConsistent with the Remote Sensing and Signaling Theory, this indicates an important in vivo role in the oxidative stress response for multiple SLC22 transporters within the fly renal system, perhaps through interaction with SLC22 counterparts in non-renal tissues.\nAdditional evidence was found for SULT2B1 and several genes related to oxidative stress.\nIn vitro/vivo studies on OTA and CIT effects showed they elevate oxidative stress parameters.\nIn mammals, it has been difficult to show a clear in vivo role for these transporters during oxidative stress.\nExpression in the Malpighian tubule and likely other tissues as well (e.g., gut, fat body, nervous system) appear critical for managing oxidative stress.\nOur work not only indicates the importance of SLC22 transporters in the fly renal system but also sets the stage for in vivo studies by examining their role in mammalian oxidative stress and organ crosstalk.\nUbiquitous knockdowns of related SLC22s-including transporters homologous to those previously identified by us in mammals such as the \"Fly-Like Putative Transporters\" FLIPT1 (SLC22A15) and FLIPT2 (SLC22A16)-have shown modest protection against oxidative stress.\nUsing two tissue-selective knockdown strategies, we were able to demonstrate much greater and longer protection from oxidative stress compared to previous whole fly knockdowns as well as both parent and WT strains (CG6126: < 0.001, CG4630: < 0.01, CG16727: < 0.0001 and CG6006: < 0.01).\nSeveral SLC22 transporters in the human kidney and other tissues are thought to regulate endogenous small antioxidant molecules such as uric acid, ergothioneine, carnitine, and carnitine derivatives.", "dois": ["10.3390/ijms222413407", "10.1007/s12550-020-00399-4", "10.2217/pgs.15.61"]}
{"pair_type": "slc_pathway", "key1": "SLC22A8", "key2": "proliferation", "summary": "Additionally, 192IgG-saporin treatment also induced a decrease in the expression of genes that are associated with transport functions of brain vascular cells (Slc22a8, Ptprb, Sdpr), again in the dorsal hippocampus but not in the ventral hippocampus.\nMassive proliferation and activation of microglia in the white matter was associated with strong activation of astrocytes.\nIn this study, we demonstrate that RSV induced osteoblast differentiation, as measured by increased BMP-2 gene expression and secretion, and ALP activity in MC3T3-E1 osteoblast cells, without significantly affecting cell proliferation within the concentration range of 0.001-10 μM.\nMicroglial proliferation was observed in the dentate gyrus of the dorsal hippocampus and white matter.\nTo mediate its action, an active transport mechanism via solute carrier (SLC) transporters from the SLC16, SLC21/SLCO and SLC22 gene family - specifically Slc16a1, Slco1a1, Slco2b1 and Slc22a8 - may be present to allow effective entry in osteoblastic cells.\nMoreover, MC3T3-E1 osteoblasts expressed high levels of Slco1a1 and Slc16a1 mRNA and low levels of Slco2b1 and Slc22a8 mRNA, when compared with kidney and liver tissues from mice.", "dois": ["10.3389/fnins.2019.00146", "10.1159/000322332"]}
{"pair_type": "slc_pathway", "key1": "SLC22A7", "key2": "apoptosis", "summary": "We speculate that the toxic mechanism of DS to chicken might be that it induces kidney cell apoptosis, interferes with purine metabolism and inhibits the expression of OAT2.\nIncubation of bendamustine with OAT2 expressing cells increased the caspase-3 activity, and this increase was inhibited by simultaneous incubation with bendamustine and probenecid, a well-known inhibitor of OATs, suggesting that bendamustine is a substrate of OAT2.\nThe functional annotation and classification results indicated that DEPs were significantly enriched in apoptosis and metabolism-related pathways via GO and KEGG analysis.\nThe mRNA transcript levels of these DEPs were characterized by qRT-PCR, and the results showed that Slc22a7, Gatm, Glud1, Agxt2 and Gldc were significantly down-regulated, while Gsl, Gpt2 and Asns were significantly up-regulated.\nPDCD6, a new HL gene, plays an important role in apoptosis and has widespread inner ear expression, particularly in the inner hair cells.", "dois": ["10.1016/j.cbpc.2021.109129", "10.1016/j.phrs.2014.11.002", "10.1038/s41431-023-01302-2"]}
{"pair_type": "slc_pathway", "key1": "SLC22A6", "key2": "oxidative stress", "summary": "We evaluated the CREB/ATF1 transcriptional activity by analyzing the expression of their target genes, including ICAM1, PTGS2, NOX1, and SLC22A6, which are related to endothelial dysfunction through their roles in vascular inflammation, oxidative stress, and cellular uptake of PCS and IS.\nCI and CIR progressively attenuated renal function and induced oxidative stress by increasing plasma BUN, creatinine and malondialdehyde levels.\nMitochondrial dysfunction as indicated by increasing ROS, membrane depolarisation, swelling and caspase3 activation were shown.\nPaeonol recovered ALS model cell lines by reducing mitochondrial oxidative stress induced by glutamate.\nConsistent with the Remote Sensing and Signaling Theory, this indicates an important in vivo role in the oxidative stress response for multiple SLC22 transporters within the fly renal system, perhaps through interaction with SLC22 counterparts in non-renal tissues.\nIn mammals, it has been difficult to show a clear in vivo role for these transporters during oxidative stress.\nExpression in the Malpighian tubule and likely other tissues as well (e.g., gut, fat body, nervous system) appear critical for managing oxidative stress.\nOur work not only indicates the importance of SLC22 transporters in the fly renal system but also sets the stage for in vivo studies by examining their role in mammalian oxidative stress and organ crosstalk.\nUbiquitous knockdowns of related SLC22s-including transporters homologous to those previously identified by us in mammals such as the \"Fly-Like Putative Transporters\" FLIPT1 (SLC22A15) and FLIPT2 (SLC22A16)-have shown modest protection against oxidative stress.\nUsing two tissue-selective knockdown strategies, we were able to demonstrate much greater and longer protection from oxidative stress compared to previous whole fly knockdowns as well as both parent and WT strains (CG6126: < 0.001, CG4630: < 0.01, CG16727: < 0.0001 and CG6006: < 0.01).", "dois": ["10.3390/ijms222413407", "10.1016/j.jbc.2021.100575", "10.1007/s12550-020-00399-4", "10.1016/j.bbadis.2019.05.013", "10.3390/ijms25169082", "10.3390/antiox11071392", "10.1016/j.bcp.2022.114984"]}
{"pair_type": "slc_pathway", "key1": "SLC22A12", "key2": "migration", "summary": "Furthermore, SLC22A12 over-expression inhibited the proliferation, migration, and invasion of renal cancer cells by regulating PI3K/Akt pathways.\nSuch effects were reversed when knocking out SLC22A12.", "dois": ["10.3389/fonc.2021.659208"]}
{"pair_type": "slc_pathway", "key1": "SLC22A11", "key2": "oxidative stress", "summary": "P-glycoprotein (P-gp/ABCB1) and organic anion transporter 4 (OAT4/SLC22A11) mRNA expression were significantly decreased and expression of T helper 17- associated cytokines were increased in preterm and term AD placenta relative to controls.\nConsistent with the Remote Sensing and Signaling Theory, this indicates an important in vivo role in the oxidative stress response for multiple SLC22 transporters within the fly renal system, perhaps through interaction with SLC22 counterparts in non-renal tissues.\nIn mammals, it has been difficult to show a clear in vivo role for these transporters during oxidative stress.\nExpression in the Malpighian tubule and likely other tissues as well (e.g., gut, fat body, nervous system) appear critical for managing oxidative stress.\nOur work not only indicates the importance of SLC22 transporters in the fly renal system but also sets the stage for in vivo studies by examining their role in mammalian oxidative stress and organ crosstalk.\nUbiquitous knockdowns of related SLC22s-including transporters homologous to those previously identified by us in mammals such as the \"Fly-Like Putative Transporters\" FLIPT1 (SLC22A15) and FLIPT2 (SLC22A16)-have shown modest protection against oxidative stress.\nplatypus by increasing the levels of reactive oxygen species (ROS) while decreasing the catalase (CAT) content and the levels of solute carrier family 22 member 11 (slc22a11), Caspase-8 (casp-8), inducible nitric oxide synthase (NOS2), cytosolic phospholipase A2 gamma (PLA2G4).\nThese four SLC22 genes are similar to human SLC22 transporters (CG6126: SLC22A16, CG16727: SLC22A7, CG4630: SLC22A3, and CG6006: SLC22A1, SLC22A2, SLC22A3, SLC22A6, SLC22A7, SLC22A8, SLC22A11", "dois": ["10.3390/ijms222413407", "10.1016/j.dmd.2024.100031", "10.1016/j.chemosphere.2023.137989"]}
{"pair_type": "slc_pathway", "key1": "SLC22A12", "key2": "chemotherapy", "summary": "In addition, genetic variability in the transporters of anthracyclines could affect the intake in cells, including influx (SLC28A3, SLC22A12, SLCO1B1) and efflux transporters (ABCB1, ABCC1, ABCC3, ABCG2).\nThese genetic variants are proposed biomarkers in clinical practice in order to individualize chemotherapy schemes, potentially increasing the effectiveness and reducing the toxicities.\nPolymorphisms in the main enzymes of anthracyclines metabolism (CBR, AKR, NQO1, NOS3) have been related to lower enzymatic activity and higher cardiotoxicity.\nGenetic variability in genes involved in anthracyclines metabolic pathway could be one of the causes of the interindividual differences in clinical outcomes.\nThe knowledge of the role of pharmacogenetics in anthracyclines metabolism could explain the differences observed in their disposition in leukemic cells.\nMoreover, variant alleles in the genes of carcinogens and chemotherapy neutralizing enzymes (GST, SULT, NADP(H) oxidase) have been associated with ROS generation and drug efficacy, influencing the survival rates and cardiac toxicities.\nAnthracyclines in combination with cytarabine have been the standard therapy for acute myeloid leukemia (AML) for decades with high efficacy.", "dois": ["10.2174/1389200218666171101124931"]}
{"pair_type": "slc_pathway", "key1": "SLC22A12", "key2": "apoptosis", "summary": "Their coexistence is not merely additive but synergistic, exacerbating metabolic dysregulation through mechanisms such as insulin resistance and β-cell apoptosis, ultimately establishing a vicious cycle.\nHyperuricemia aggravates diabetic complications, notably diabetic cardiomyopathy, nephropathy and retinopathy via oxidative stress, inflammation, and metabolic dysregulation.\nCurrent urate-lowering therapies (ULTs), such as xanthine oxidase inhibitors and urate transporter 1 (URAT1, also known as SLC22A12) antagonists, demonstrate potential benefits in ameliorating diabetic complications but face challenges including safety concerns and dose adjustments.\nBoth disorders induce acute and chronic damage to vital organs, particularly the cardiovascular, renal systems.", "dois": ["10.1016/j.diabres.2025.112204"]}
{"pair_type": "slc_pathway", "key1": "SLC22A12", "key2": "oxidative stress", "summary": "Hyperuricemia aggravates diabetic complications, notably diabetic cardiomyopathy, nephropathy and retinopathy via oxidative stress, inflammation, and metabolic dysregulation.\nCurrent urate-lowering therapies (ULTs), such as xanthine oxidase inhibitors and urate transporter 1 (URAT1, also known as SLC22A12) antagonists, demonstrate potential benefits in ameliorating diabetic complications but face challenges including safety concerns and dose adjustments.\nalleviation of oxidative stress reaction to decrease systemic damage and, eventually, treatment of HUA.\nConsistent with the Remote Sensing and Signaling Theory, this indicates an important in vivo role in the oxidative stress response for multiple SLC22 transporters within the fly renal system, perhaps through interaction with SLC22 counterparts in non-renal tissues.\nIn mammals, it has been difficult to show a clear in vivo role for these transporters during oxidative stress.\nExpression in the Malpighian tubule and likely other tissues as well (e.g., gut, fat body, nervous system) appear critical for managing oxidative stress.\nHypouricemia was susceptible to oxidative stress, but IgA nephropathy in the patient with hypouricemia could be treated with steroid pulse therapy without adverse events.\nOur work not only indicates the importance of SLC22 transporters in the fly renal system but also sets the stage for in vivo studies by examining their role in mammalian oxidative stress and organ crosstalk.\nUbiquitous knockdowns of related SLC22s-including transporters homologous to those previously identified by us in mammals such as the \"Fly-Like Putative Transporters\" FLIPT1 (SLC22A15) and FLIPT2 (SLC22A16)-have shown modest protection against oxidative stress.\nThese four SLC22 genes are similar to human SLC22 transporters (CG6126: SLC22A16, CG16727: SLC22A7, CG4630: SLC22A3, and CG6006: SLC22A1, SLC22A2, SLC22A3, SLC22A6, SLC22", "dois": ["10.3390/ijms222413407", "10.1016/j.diabres.2025.112204", "10.1002/ccr3.9368", "10.1016/j.jep.2023.116814"]}
{"pair_type": "slc_pathway", "key1": "SLC22A13", "key2": "chemotherapy", "summary": "The transport of platinum-based anticancer drugs has been reported to be influenced by the expression and activities of OCT1-3 (SLC22A1-3), OCTN1/2 (SLC22A4/5), CTR1/2 (SLC31A1/2) and MATE1/2 (SLC47A1/2) solute carriers.\nEmerging mechanisms involving metal transporting solute carriers are being defined and seem likely to make major contributions to cancer development and progression, and to the delivery of anticancer and tumour imaging agents.\nSolute carriers mediate control over the availability of endogenous metal ions, such as copper, iron and zinc, may have key roles in regulating tumour angiogenesis, cell proliferation, epithelial-to-mesenchymal transition and aberrant MAPK and STAT-3 signal transduction in cancer.\nA range of different solute carrier families, including members from the SLC2A, SLC11A, SLC22A, SLC25A, SLC30A, SLC31A, SLC39A, SLC40A, SLC47A and SLCO1B families, and various metal substrates, including arsenic, copper, gadolinium, iron, platinum and zinc, have been implicated in these cancer-related transport processes.", "dois": ["10.1002/bdd.1903", "PMID:16914559"]}
{"pair_type": "slc_pathway", "key1": "SLC22A13", "key2": "proliferation", "summary": "As another example, solute carriers mediate control over the availability of endogenous metal ions, such as copper, iron and zinc, may have key roles in regulating tumour angiogenesis, cell proliferation, epithelial-to-mesenchymal transition and aberrant MAPK and STAT-3 signal transduction in cancer.", "dois": ["10.1002/bdd.1903"]}
{"pair_type": "slc_pathway", "key1": "SLC22A12", "key2": "proliferation", "summary": "Furthermore, SLC22A12 over-expression inhibited the proliferation, migration, and invasion of renal cancer cells by regulating PI3K/Akt pathways.\nIn summary, as a transporter for many vital metabolites, SLC22A12 may affect tumor cell survival through its impacts on the mentioned metabolites.\nGene set enrichment analysis (GSEA) showed that SLC22A12 expression levels are related to metabolism, cell cycle, and tumor-related signaling pathways.\nSuch effects were reversed when knocking out SLC22A12.\nMoreover, patients in the SLC22A12 low expression group had a higher pathological stage and worse survival than the high expression group.\nSolute Carrier Family 22 Member 12 (SLC22A12) resulted in an independent prognostic predictor for both overall survival (OS) and disease-free survival (DFS).\nGO and KEGG analyses revealed that SLC22A12 transports multiple organic compounds, ions, and hormones and participates in the extracellular structure organization.\nAdditionally, qRT-PCR assay, immunoblotting test (IBT), and immunohistochemical (IHC) analyses of cancer tissues/cells and the corresponding normal controls verified that SLC22A12 is downregulated in ccRCC.\nSLC22A12 expression was lower in tumoral tissue compared to normal tissue.\nReceiver operator characteristic (ROC) curves showed that the low expression level of SLC22A12 could be a good diagnostic marker for ccRCC (AUC=0.7258; p <0.0001).\nIn conclusion, this study uncovered that SLC22A12 is a promising prognostic and diagnostic biomarker for ccRCC.\nAccumulation of minor changes in the cellular homeostasis may be one cause of ccRCC.", "dois": ["10.3389/fonc.2021.659208"]}
{"pair_type": "slc_pathway", "key1": "SLC22A13", "key2": "oxidative stress", "summary": "Consistent with the Remote Sensing and Signaling Theory, this indicates an important in vivo role in the oxidative stress response for multiple SLC22 transporters within the fly renal system, perhaps through interaction with SLC22 counterparts in non-renal tissues.\nExpression in the Malpighian tubule and likely other tissues as well (e.g., gut, fat body, nervous system) appear critical for managing oxidative stress.\nOur work not only indicates the importance of SLC22 transporters in the fly renal system but also sets the stage for in vivo studies by examining their role in mammalian oxidative stress and organ crosstalk.\nUbiquitous knockdowns of related SLC22s-including transporters homologous to those previously identified by us in mammals such as the \"Fly-Like Putative Transporters\" FLIPT1 (SLC22A15) and FLIPT2 (SLC22A16)-have shown modest protection against oxidative stress.\nThese four SLC22 genes are similar to human SLC22 transporters (CG6126: SLC22A16, CG16727: SLC22A7, CG4630: SLC22A3, and CG6006: SLC22A1, SLC22A2, SLC22A3, SLC22A6, SLC22A7, SLC22A8, SLC22A11, SLC22A12 (URAT1), SLC22A13, SLC22A14)-many of which are highly expressed in the kidney.\nUsing two tissue-selective knockdown strategies, we were able to demonstrate much greater and longer protection from oxidative stress compared to previous whole fly knockdowns as well as both parent and WT strains (CG6126: < 0.001, CG4630: < 0.01, CG16727: < 0.0001 and CG6006: < 0.01).\nSeveral SLC22 transporters in the human kidney and other tissues are thought to regulate endogenous small antioxidant molecules such as uric acid, ergothioneine, carnitine, and carnitine derivatives.", "dois": ["10.3390/ijms222413407"]}
{"pair_type": "slc_pathway", "key1": "SLC22A14", "key2": "oxidative stress", "summary": "Consistent with the Remote Sensing and Signaling Theory, this indicates an important in vivo role in the oxidative stress response for multiple SLC22 transporters within the fly renal system, perhaps through interaction with SLC22 counterparts in non-renal tissues.\nExpression in the Malpighian tubule and likely other tissues as well (e.g., gut, fat body, nervous system) appear critical for managing oxidative stress.\nOur work not only indicates the importance of SLC22 transporters in the fly renal system but also sets the stage for in vivo studies by examining their role in mammalian oxidative stress and organ crosstalk.\nUbiquitous knockdowns of related SLC22s-including transporters homologous to those previously identified by us in mammals such as the \"Fly-Like Putative Transporters\" FLIPT1 (SLC22A15) and FLIPT2 (SLC22A16)-have shown modest protection against oxidative stress.\nThese four SLC22 genes are similar to human SLC22 transporters (CG6126: SLC22A16, CG16727: SLC22A7, CG4630: SLC22A3, and CG6006: SLC22A1, SLC22A2, SLC22A3, SLC22A6, SLC22A7, SLC22A8, SLC22A11, SLC22A12 (URAT1), SLC22A13, SLC22A14)-many of which are highly expressed in the kidney.\nUsing two tissue-selective knockdown strategies, we were able to demonstrate much greater and longer protection from oxidative stress compared to previous whole fly knockdowns as well as both parent and WT strains (CG6126: < 0.001, CG4630: < 0.01, CG16727: < 0.0001 and CG6006: < 0.01).\nSeveral SLC22 transporters in the human kidney and other tissues are thought to regulate endogenous small antioxidant molecules such as uric acid, ergothioneine, carnitine, and carnitine derivatives.", "dois": ["10.3390/ijms222413407"]}
{"pair_type": "slc_pathway", "key1": "SLC22A15", "key2": "proliferation", "summary": "Subsequent knockdown experiments performed in HCC cell lines showed that all three prognostic SLCs positively regulated the proliferation of HCC cells, among which SLC22A15 and SLC2A1 were required for migration and invasion of the cells, demonstrating remarkable consistency with the roles identified by bioinformatics methods in HCC.\nFurther functional analyses suggested the potential regulation of the three prognostic SLCs on cell proliferation and metastasis.\nFurthermore, the low level of true disease-specific changes simplifies identification of functionally relevant methylation changes, illustrated here by identification and functional confirmation of SLC22A15 as a tumour suppressor in acute lymphoblastic leukaemia.\nBy performing bioinformatics analyses of HCC dataset from The Cancer Genome Atlas database, we identified three novel signature SLCs (SLC51B, SLC22A15, and SLC2A1) that are indicative of poor prognosis.\nTherefore, our study provides a novel prognostic biomarker for HCC and reveals the significant roles of SLCs in HCC progression, which might have been undervalued in the past.", "dois": ["10.1038/s41416-025-03239-3", "10.1093/abbs/gmab076"]}
{"pair_type": "slc_pathway", "key1": "SLC22A15", "key2": "migration", "summary": "Subsequent knockdown experiments performed in HCC cell lines showed that all three prognostic SLCs positively regulated the proliferation of HCC cells, among which SLC22A15 and SLC2A1 were required for migration and invasion of the cells, demonstrating remarkable consistency with the roles identified by bioinformatics methods in HCC.", "dois": ["10.1093/abbs/gmab076", "10.3390/cells8121535"]}
{"pair_type": "slc_pathway", "key1": "SLC22A14", "key2": "oxidative phosphorylation", "summary": "Here, we show that SLC22A14 is a riboflavin transporter localized at the inner mitochondrial membrane of the spermatozoa mid-piece and show by genetic, biochemical, multi-omic, and nutritional evidence that riboflavin transport deficiency suppresses the oxidative phosphorylation and reprograms spermatozoa energy metabolism by disrupting flavoenzyme functions.\nSpecifically, we find that fatty acid β-oxidation (FAO) is defective with significantly reduced levels of acyl-carnitines and metabolites from the TCA cycle (the citric acid cycle) but accumulated triglycerides and free fatty acids in Slc22a14 knockout spermatozoa.\nWe demonstrate that Slc22a14-mediated FAO is essential for spermatozoa energy generation and motility.\nFurthermore, sperm from wild-type mice treated with a riboflavin-deficient diet mimics those in Slc22a14 knockout mice, confirming that an altered riboflavin level causes spermatozoa morphological and bioenergetic defects.", "dois": ["10.1016/j.celrep.2021.109025"]}
{"pair_type": "slc_pathway", "key1": "SLC22A15", "key2": "chemotherapy", "summary": "A four-gene signature (S100A9, SLC22A15, TRIM54, and PPARGC1A) was identified as the TAM-related prognostic genes for liver cancer, independent of multiple clinicopathological parameters.\nIn addition, TIMSig could predict the response to chemotherapy.", "dois": ["10.3389/fmolb.2022.983840", "PMID:16914559"]}
{"pair_type": "slc_pathway", "key1": "SLC22A16", "key2": "proliferation", "summary": "Proper regulation of carnitine levels is important in the context of development and increased risk of cancer cells proliferation.\nThe overexpression of upregulated the expression of adipogenic marker genes and proliferation-related genes, and promoted the proliferation of adipocytes and the accumulation of triglycerides.\nThe knockdown of downregulated the expression of adipogenic marker genes and proliferation-related genes, inhibited the proliferation of adipocytes, and impaired the accumulation of triglycerides in adipocytes.\nInterference with inhibits the expression of adipogenic marker genes and proliferation-related genes.\nIron-depletion additionally reduced H-spermidine uptake in direct agreement with the lowered levels of the polyamine importer, SLC22A16.\nThe ability of iron chelators to inhibit proliferation was rescuable by putrescine and spermidine, and under some conditions by spermine.\nA growing number of observations reveal that tumors can utilize a wide range of substrates to sustain cell survival and proliferation.\nThis study identified the role of in the differentiation and proliferation of chicken adipocytes, providing a potential target for improving abdominal adipogenesis in chickens.\nThe cellular senescence was evaluated by the assays of cell proliferation, cell cycle, senescence-associated β-galactosidase activity, and senescence-associated secretory phenotype factors.\nCollectively, iron and polyamine metabolism are intimately coupled, which has significant ramifications for understanding the integrated role of iron and polyamine metabolism in proliferation.\nConsidering this, proliferation depends on adequate iron and polyamines, and although iron-depletion impairs proliferation, the metabolic link between iron and polyamine metabolism has never been thoroughly investigated.\nAmong the SLCs, the plasma membrane transporters OCTN2 (Organic cation transport novel 2 or SLC22A5), CT2 (Carnitine transporter 2 or SLC22A16), MCT9 (Monocarboxylate transporter 9 or SLC16A9) and ATB [Sodium- and chloride-dependent neutral and basic amino acid transporter B(0+) or SLC6A14] together with the mitochondrial membrane transporter CAC (", "dois": ["10.1186/s13046-025-03420-9", "10.21037/tlcr-24-448", "10.3390/genes15060758", "10.3389/fcell.2020.583850", "10.1097/MD.0000000000017997", "10.1016/j.bbadis.2018.05.007"]}
{"pair_type": "slc_pathway", "key1": "SLC22A15", "key2": "oxidative stress", "summary": "Ubiquitous knockdowns of related SLC22s-including transporters homologous to those previously identified by us in mammals such as the \"Fly-Like Putative Transporters\" FLIPT1 (SLC22A15) and FLIPT2 (SLC22A16)-have shown modest protection against oxidative stress.\nAdditionally, knocking down four SLC22 members increased resistance to oxidative stress via paraquat testing ( < 0.05, < 0.05, < 0.01 and < 0.05).\nConsistent with the Remote Sensing and Signaling Theory, this indicates an important in vivo role in the oxidative stress response for multiple SLC22 transporters within the fly renal system, perhaps through interaction with SLC22 counterparts in non-renal tissues.\nExpression in the Malpighian tubule and likely other tissues as well (e.g., gut, fat body, nervous system) appear critical for managing oxidative stress.\nUsing two tissue-selective knockdown strategies, we were able to demonstrate much greater and longer protection from oxidative stress compared to previous whole fly knockdowns as well as both parent and WT strains (CG6126: < 0.001, CG4630: < 0.01, CG16727: < 0.0001 and CG6006: < 0.01).\nSeveral SLC22 transporters in the human kidney and other tissues are thought to regulate endogenous small antioxidant molecules such as uric acid, ergothioneine, carnitine, and carnitine derivatives.\nConsistent with recent evidence that SLC22 is central to a Remote Sensing and Signaling Network (RSSN) involved in signaling and metabolism, these phenotypes support a key role for SLC22 in handling reactive oxygen species.\nThe SLC22 family of transporters is widely expressed, evolutionarily conserved, and plays a major role in regulating homeostasis by transporting small organic molecules such as metabolites, signaling molecules, and antioxidants.", "dois": ["10.3390/ijms222413407", "10.3390/ijms21062002"]}
{"pair_type": "slc_pathway", "key1": "SLC22A16", "key2": "oxidative stress", "summary": "Ubiquitous knockdowns of related SLC22s-including transporters homologous to those previously identified by us in mammals such as the \"Fly-Like Putative Transporters\" FLIPT1 (SLC22A15) and FLIPT2 (SLC22A16)-have shown modest protection against oxidative stress.\nAdditionally, knocking down four SLC22 members increased resistance to oxidative stress via paraquat testing ( < 0.05, < 0.05, < 0.01 and < 0.05).\nConsistent with the Remote Sensing and Signaling Theory, this indicates an important in vivo role in the oxidative stress response for multiple SLC22 transporters within the fly renal system, perhaps through interaction with SLC22 counterparts in non-renal tissues.\nExpression in the Malpighian tubule and likely other tissues as well (e.g., gut, fat body, nervous system) appear critical for managing oxidative stress.\nThese four SLC22 genes are similar to human SLC22 transporters (CG6126: SLC22A16, CG16727: SLC22A7, CG4630: SLC22A3, and CG6006: SLC22A1, SLC22A2, SLC22A3, SLC22A6, SLC22A7, SLC22A8, SLC22A11, SLC22A12 (URAT1), SLC22A13, SLC22A14)-many of which are highly expressed in the kidney.\nUsing two tissue-selective knockdown strategies, we were able to demonstrate much greater and longer protection from oxidative stress compared to previous whole fly knockdowns as well as both parent and WT strains (CG6126: < 0.001, CG4630: < 0.01, CG16727: < 0.0001 and CG6006: < 0.01).\nEvolutionary analysis of putative SLC22 orthologs reveals that, while many of the 25 SLC22 fruit fly orthologs do not fall within previously established SLC22 subclades, at least four members appear orthologous to mammalian SLC22 members (S", "dois": ["10.3390/ijms222413407", "10.3390/ijms21062002"]}
{"pair_type": "slc_pathway", "key1": "SLC22A16", "key2": "glycolysis", "summary": "CT2 knockdown reduced basal oxygen consumption without a concomitant increase in glycolysis.", "dois": ["10.1007/s10495-015-1137-x"]}
{"pair_type": "slc_pathway", "key1": "SLC22A17", "key2": "oxidative stress", "summary": "Two novel variants in SLC22A17 and SLC22A7 were significantly associated with anthracycline-induced cardiotoxicity and improved a genotype-guided risk prediction model, which could improve patient risk stratification.\nSignificant associations were identified in SLC22A17 (rs4982753; p = 0.0078) and SLC22A7 (rs4149178; p = 0.0034), with replication in the second cohort (p = 0.0071 and 0.047, respectively).\nAdditional evidence was found for SULT2B1 and several genes related to oxidative stress.", "dois": ["10.2217/pgs.15.61"]}
{"pair_type": "slc_pathway", "key1": "SLC22A16", "key2": "apoptosis", "summary": "Mechanistically, the downregulation of PSMB10 boosted SLC22A16-mediated drug endocytosis and further induced chemotherapy drug-mediated senescence through the RPL6/RPS6-MDM2-P21 pathway in AML cells.", "dois": ["10.1186/s13046-025-03420-9"]}
{"pair_type": "slc_pathway", "key1": "SLC22A16", "key2": "stemness", "summary": "The genetic inactivation of PSMB10 resulted in increased senescence and cytotoxic T lymphocyte (CTL) killing, as well as increased intracellular drug concentrations and drug-induced cellular senescence in different types of human AML cells, which also impeded human and murine leukemia initiation and stemness maintenance in vivo with a 19-fold decrease in the frequency of human LSCs and a 7.6-fold decrease of drug-resistant mouse LSCs, while normal hematopoietic cells remained unaffected.\nMechanistically, the downregulation of PSMB10 boosted SLC22A16-mediated drug endocytosis and further induced chemotherapy drug-mediated senescence through the RPL6/RPS6-MDM2-P21 pathway in AML cells.\nHowever, whether and how drug-resistant LSCs retain stemness via senescence and immune regulation remains unknown.", "dois": ["10.1186/s13046-025-03420-9"]}
{"pair_type": "slc_pathway", "key1": "SLC22A18", "key2": "apoptosis", "summary": "Stable overexpression of SLC22A18 inhibited growth and adherence, induced apoptosis in vitro and reduced in vivo tumor growth of U251 cells.\nSATB1 shRNA expression vectors could efficiently induce the expression of SLC22A18 protein, increase the caspase-3 protein, inhibit the expression of SATB1, c-Met and bcl-2 protein, the growth, invasion, metastasis and angiogenesis of U251 cells, and induce apoptosis in vitro.\nUpregulated expression of SLC22A18 enhanced the radiosensitivity of glioma U251 cells and also enhanced irradiation-induced apoptosis of U251 cells, but irradiation-induced apoptosis did not correlate with radiosensitizing effect of upregulated expression of SLC22A18.\n5-Aza-cdR may induce glioma U251 cell division and apoptosis and enhance demethylation and protein and mRNA expression of SLC22A18.\nCompared to single knockdown of SDHD, knockdown of SDHD together with SLC22A18 or with CDKN1C led to small but significant increases in cell proliferation and resistance to apoptosis, and to a gene expression profile closely related to the known transcriptional profile of SDH-deficient tumours.\nThese results show that upregulated expression of SLC22A18 radiosensitizes human glioma U251 cells by suppressing DNA repair capacity.\nSLC22A18 downregulation via promoter methylation is associated with the development and progression of glioma, suggesting that SLC22A18 is an important tumor suppressor in glioma.\nThe SLC22A18 promoter is methylated in U251 cells and treatment with the demethylating agent 5-aza-2-deoxycytidine increased SLC22A18 expression and reduced cell proliferation.\nDownregulation of the putative tumor suppressor gene SLC22A18 has been reported in a number of human cancers.\nIn the orthotopic mice model, the upregulated expression of SLC22A18 in U251", "dois": ["10.1039/c7mb00334j", "10.1038/cgt.2014.4", "10.2147/IJN.S33584", "10.3892/mmr.2011.620", "10.1093/hmg/ddw218", "10.1186/1479-5876-10-149", "10.1186/1479-5876-9-156"]}
{"pair_type": "slc_pathway", "key1": "SLC22A16", "key2": "chemotherapy", "summary": "Mechanistically, the downregulation of PSMB10 boosted SLC22A16-mediated drug endocytosis and further induced chemotherapy drug-mediated senescence through the RPL6/RPS6-MDM2-P21 pathway in AML cells.\nSelected genes were involved in FAC chemotherapy drugs transport (ABCB1, ABCC2, ABCG2, SLC22A16), metabolism (CYP1B1, CYP2C19, GSTT1, GSTM1, GSTP1, TYMS, MTHFR, DPYD), drug-induced damage repair (ERCC1, ERCC2, XRCC1) and involved in regulation of DNA damage response and cell cycle control (ATM, TP53).\nThe observed synergistic effects in tumor cells was due to enhanced intracellular doxorubicin accumulation via upregulation of the organic cationic transporter SLC22A16 by plasma treatment.\nEndoribonuclease-prepared siRNAs (esiRNA)-mediated knockdown of SLC22A16 inhibited the additive cytotoxic effect in tumor cells.\nThe expression of cbr1 and slc22a16 was markedly decreased, while p-gp was significantly upregulated in HCC rats.These findings suggest that HCC could significantly alter the pharmacokinetic profile of DOX, which may be associated with the decreased expression of cbr1 and slc22a16 rather than the upregulation of p-gp expression.\nThese results suggested CBR1 rs20572, ABCG2 rs2231142, SLC22A16 rs6907567 and AKR1A1 rs2088102 might be potential protective factors for the reduction of hematologic toxicity incidence during anthracycline-based chemotherapy in breast cancer patients.\nA genetic variant of SLC22A16 is a potential predictive biomarker for response to platinum-based chemotherapy for non-small cell lung cancer.\nOrganic cation transporter 6 (OCT6) encoded by solute carrier family 22 member 16 (SLC22", "dois": ["10.1186/s13046-025-03420-9", "10.3390/jpm12040618", "10.1016/j.lfs.2021.119392", "10.1080/10428194.2020.1839650", "10.21873/anticanres.14426", "10.1080/00498254.2020.1765049", "10.1038/s41598-020-62662-z", "10.1007/s13318-019-00592-6", "10.1038/s41419-018-1221-6", "10.18632/oncotarget.24148", "10.1371/journal.pone.0168519", "10.18632/oncotarget.11053", "10.1007/s00268-015-3263-6", "10.1111/bcp.12021", "PMID:20302569", "PMID:17559346"]}
{"pair_type": "slc_pathway", "key1": "SLC22A18", "key2": "chemotherapy", "summary": "Inactivation of special AT-rich sequence-binding protein 1 (SATB1) using short hairpin RNA (shRNA) downregulated MGMT expression and upregulated solute carrier family 22 member 18 (SLC22A18) expression in GBM cells.\nConsequently, SATB1 inhibition might be a promising strategy combined with TMZ chemotherapy to treat TMZ-resistant GBM.\nFinally, in TMZ-resistant GBM, SATB1 knockdown enhanced TMZ efficacy.\nIn this study, upregulation of SATB1 and MGMT, and downregulation of SLC22A18 resulted in acquisition of TMZ resistance in GBM U87 cells.\nSilencing SATB1 overcomes temozolomide resistance by downregulating MGMT expression and upregulating SLC22A18 expression in human glioblastoma cells.\nProteins encoded by the SLC22A18 gene, which is similar to the transmembrane transporter, may influence the sensitivity of chemotherapeutics as well as the metabolism and growth of cells.\nImportantly, in recurrent, compared with the primary, lesions in 15 paired identical tumors, the SATB1 and MGMT protein levels were increased and the SLC22A18 levels were decreased.\nOverexpression of in U87S cells inhibited cell viability and enhanced the cytotoxicity of TMZ.\nAnd activation of BMP boosted the effect of on cell viability and TMZ-mediated cytotoxicity.\nBMPs are known to increase temozolomide (TMZ) response in GSCs, however, the intracellular molecular mechanism remains largely unknown.\nThis suggested SATB1-mediated posttranscriptional regulation of the MGMT and SLC22A18 protein levels.\nGlioblastoma stem-like cells (GSCs) are responsible for tumorigenesis and chemotherapy resistance.\nOvercoming chemoresistance will prevent cancer relapse and contribute to clinical chemotherapy.\nIt has been proven that multidrug resistance (MDR) is the main cause of chemotherapy failure in lung cancer.\nCurrently, patients were treated by resection followed by radiotherapy", "dois": ["PMID:35411243", "10.1016/j.gendis.2019.09.002", "10.1038/s41417-018-0040-3", "10.1039/c7mb00334j", "10.3779/j.issn.1009-3419.2012.01.04"]}
{"pair_type": "slc_pathway", "key1": "SLC22A18", "key2": "migration", "summary": "Previous study revealed that SLC22A18 is downregulated in colorectal cancer tissues and that it acts as a suppressor in colorectal cancer, although the effects of SLC22A18 variants on colon cancer cell proliferation, migration, and invasion are unknown.\nSLC22A18 knockdown (1) increased MCF7 cell growth concomitantly with a >7-fold increase of annexin A8 (involved in cell growth and migration;\nThen, functional studies indicated that the ectopic expression of miR-137 significantly inhibited NSCLC cell proliferation, invasion and migration by targeting SLC22A18.\nExogenous IGFBP-1 blocked the increase of invasion activity induced by SLC22A18 knockdown.\nIn addition, SLC22A18 knockdown decreased the expression of insulin-like growth factor-binding protein 1 (IGFBP-1) and increased the invasion ability of HepG2 cells.\nOur results suggest that SLC22A18 may act as a tumor suppressor by regulating the expression levels of cell growth-related proteins, and vinca alkaloids might show therapeutic efficacy against low-SLC22A18-expressing breast cancer.\nOur results suggest that suppression of SLC22A18 decreased the supply of intracellular free fatty acids from triglyceride-rich lipid droplets by impairing the lysosomal/autophagy degradation pathway and reduced the invasive activity of HepG2 cells by decreasing IGFBP-1 expression.\nHowever, the role of SLC22A18 in tumor suppression remains unclear.\nGrowth of HepG2 cells was decreased by SLC22A18 knockdown, but was restored by free fatty acid supplementation.\nThe SLC22A18 gene, which encodes an orphan transporter, is located at the 11p15.5 imprinted region, an important tumor suppressor gene region.\nFurthermore, these three variants caused significantly higher proliferation, migration, and invasion of colon cancer cells than the wild type.\nOur findings suggest that missense variants of SLC22A18 can potentially serve as biomarkers or prognostic tools that enable clinicians to predict colorectal cancer progression", "dois": ["10.1038/s41598-024-54658-w", "10.1007/s11095-018-2565-4", "10.1016/j.xphs.2018.08.011", "10.1016/j.ijbiomac.2014.12.002"]}
{"pair_type": "slc_pathway", "key1": "SLC22A18", "key2": "oxidative stress", "summary": "Additionally, knocking down four SLC22 members increased resistance to oxidative stress via paraquat testing ( < 0.05, < 0.05, < 0.01 and < 0.05).\nAnother probable pathway to tumorigenesis is based on the possibility of an oncogenic nature of SARS-CoV-2 through hijacking the p53 protein, leading to cell oxidative stress and interfering with the DNA repair mechanisms.\nConsistent with recent evidence that SLC22 is central to a Remote Sensing and Signaling Network (RSSN) involved in signaling and metabolism, these phenotypes support a key role for SLC22 in handling reactive oxygen species.", "dois": ["10.3390/ijms21062002", "10.3390/pathogens13121070"]}
{"pair_type": "slc_pathway", "key1": "SLC22A23", "key2": "migration", "summary": "Knockdown of circSLC22A23 inhibited GC cell proliferation, migration and invasion.\nThen circSLC22A23 was knocked-down with short hairpin RNA to analyze its oncogenic effects on the proliferation, migration, and invasion of GC cells.\nCircSLC22A23 regulated the transcription of EGFR through activation of HNRNPU in GC cells, suggesting that circSLC22A23 may serve as a potential therapeutic target for the treatment of GC.\nCircular RNA CircSLC22A23 Promotes Gastric Cancer Progression by Activating HNRNPU Expression.\nMoreover, rescue assays showed that the tumor suppressive effect of circSLC22A23 knockdown was reversed by HNRNPU overexpression.\nFinally, epidermal growth factor receptor (EGFR) was found to be one of the downstream target genes of HNRNPU that was up regulated by circSLC22A23.\nCircSLC22A23 was found to be highly expressed in GC cells, GC tissues, and plasma from GC patients.\nRNA pulldown and RNA immunoprecipitation assays verified the interaction between circSLC22A23 and heterogeneous nuclear ribonucleoprotein U (HNRNPU).", "dois": ["10.1007/s10620-024-08291-2"]}
{"pair_type": "slc_pathway", "key1": "SLC22A18", "key2": "proliferation", "summary": "The SLC22A18 promoter is methylated in U251 cells and treatment with the demethylating agent 5-aza-2-deoxycytidine increased SLC22A18 expression and reduced cell proliferation.\nPrevious study revealed that SLC22A18 is downregulated in colorectal cancer tissues and that it acts as a suppressor in colorectal cancer, although the effects of SLC22A18 variants on colon cancer cell proliferation, migration, and invasion are unknown.\nWe found that SLC22A18 and SLC22A18AS knockdown inhibits cell proliferation in vitro.\nThen, functional studies indicated that the ectopic expression of miR-137 significantly inhibited NSCLC cell proliferation, invasion and migration by targeting SLC22A18.\nKnockdown of SDHD in SNB19 and SHSY5Y cells resulted in the accumulation of succinate, the stabilization of HIF1 protein and a reduction in cell proliferation.\nCompared to single knockdown of SDHD, knockdown of SDHD together with SLC22A18 or with CDKN1C led to small but significant increases in cell proliferation and resistance to apoptosis, and to a gene expression profile closely related to the known transcriptional profile of SDH-deficient tumours.\nSLC22A18 downregulation via promoter methylation is associated with the development and progression of glioma, suggesting that SLC22A18 is an important tumor suppressor in glioma.\nStable overexpression of SLC22A18 inhibited growth and adherence, induced apoptosis in vitro and reduced in vivo tumor growth of U251 cells.\nFurthermore, these three variants caused significantly higher proliferation, migration, and invasion of colon cancer cells than the wild type.\nThis pathway is involved in cellular proliferation, differentiation, and immune homeostasis.", "dois": ["10.3390/pathogens13121070", "10.1038/s41598-024-54658-w", "10.3390/cancers12082075", "10.1093/hmg/ddw218", "10.1016/j.ijbiomac.2014.12.002", "10.1186/1479-5876-9-156"]}
{"pair_type": "slc_pathway", "key1": "SLC22A16", "key2": "migration", "summary": "SK-MEL 28 and THP-1 monocytes co-culture led to greater THP-1 cell migration and SK-MEL-28 cytotoxicity when compared with controls.\nEndoribonuclease-prepared siRNAs (esiRNA)-mediated knockdown of SLC22A16 inhibited the additive cytotoxic effect in tumor cells.\nThe observed synergistic effects in tumor cells was due to enhanced intracellular doxorubicin accumulation via upregulation of the organic cationic transporter SLC22A16 by plasma treatment.", "dois": ["10.1038/s41419-018-1221-6"]}
{"pair_type": "slc_pathway", "key1": "SLC22A17", "key2": "migration", "summary": "LCN2-silencing using shRNA method significantly reduced the migration ability of cells (p<0.05).\nWe previously identified LCN2 as an up-regulated gene in endometrial carcinoma, and found that the overexpression of LCN2 and its receptor, SLC22A17, was associated with a poor prognosis.\nThese results indicated that LCN2 was involved in the migration and survival of endometrial carcinoma cells under various stresses in an iron-dependent manner.\nNumerous reports have further shown that LCN2 is involved in the control of cell differentiation, energy expenditure, cell death, chemotaxis, cell migration, and many other biological processes.\nThe survival function of LCN2 may be exerted through the PI3K pathway and suppression of the p53-p21 pathway.\nThese functions of LCN2 may increase the malignant potential of endometrial carcinoma cells.\nIn contrast, LCN2 overexpression was significantly increased cisplatin resistance.\nCytotoxic stresses significantly decreased the viability of LCN2-silenced cells more than that of control cells.\nAfter UV irradiation, the expression of phosphorylated Akt (pAkt) was decreased in LCN2-silenced cells, and the PI3K inhibitor canceled the difference induced in UV sensitivity by LCN2.", "dois": ["10.3389/fimmu.2023.1229885", "10.1371/journal.pone.0155220", "10.1074/jbc.M114.606459"]}
{"pair_type": "slc_pathway", "key1": "SLC22A17", "key2": "chemotherapy", "summary": "For seven genetic variants in CELF4, GPR35, HAS3, RARG, SLC22A17, SLC22A7 and SLC28A3, replication studies were performed, however without consistent results.\nDespite multiagent chemotherapy, only 71% of patients survives and these survivors often experience long-term toxicities.\nThe main objective of this systematic review is to provide an overview of the discovery of novel associations of germline polymorphisms with treatment response and/or chemotherapy-induced toxicities in osteosarcoma.\nEleven articles reported on doxorubicin-induced cardiomyopathy.\nSix studies included analysis for treatment efficacy.\nGenetic variants in ABCC3, ABCC5, FasL, GLDC, GSTP1 were replicated in studies using heterogeneous efficacy outcomes.", "dois": ["10.1186/s12885-022-10434-5"]}
{"pair_type": "slc_pathway", "key1": "SLC22A17", "key2": "ferroptosis", "summary": "Our findings reveal that LCN2 promotes iron accumulation, mitochondrial dysfunction, and ferroptosis in osteocytes in a process dependent on LCN2 receptor SLC22A17.\nUsing in vitro and in vivo approaches, we establish the LCN2-SLC22A17 axis as a key pathway linking iron homeostasis, osteocyte dysfunction, and skeletal remodeling.\nGenetic ablation of (-Cre;) in osteocytes mitigates their ferroptotic vulnerability by preserving mitochondrial integrity and limiting iron overload.\nHere, we identify Lipocalin-2 (LCN2), a cytokine secreted by bone cells with endocrine effects on other tissues, as a local regulator of osteocyte iron metabolism and a mediator of skeletal deterioration.\nThese findings provide insight into a previously unrecognized mechanism underlying iron-driven bone loss and suggest that targeting LCN2 could offer therapeutic potential for osteoporosis.\nRemarkably, LCN2 deletion enhances osteocyte dendricity and lacunocanalicular network, supporting their function in bone remodeling.", "dois": ["10.3389/fmolb.2025.1609307", "10.21203/rs.3.rs-6430607/v1", "10.1161/STROKEAHA.124.046736", "10.3389/fcell.2022.945586"]}
{"pair_type": "slc_pathway", "key1": "SLC22A17", "key2": "proliferation", "summary": "In conclusion, the hyperosmotic/-tonic upregulation of SLC22A17 in mCCD(cl.1) cells, via NFAT5, and by AVP, via CREB, suggests that SLC22A17 contributes to adaptive osmotolerance, whereas LCN2 downregulation could counteract increased proliferation and permanent damage of osmotically stressed cells.\nComparing transcriptional changes in mouse, zebrafish, and human AD brains for cell intrinsic differential gene expression and weighted gene co-expression networks revealed common altered downstream effectors of NGFR signaling, such as PFKP, which can enhance proliferation and neurogenesis in vitro when blocked.\nHistological analyses of the changes in proliferation and neurogenesis, single-cell transcriptomics, spatial proteomics, and functional knockdown studies showed that the induced expression of Ngfr reduced the reactive astrocyte marker Lipocalin-2 (Lcn2), which we found was sufficient to reduce neurogenesis in astroglia.\nAnti-neurogenic effects of Lcn2 was mediated by Slc22a17, blockage of which recapitulated the pro-neurogenicity by Ngfr.\nLcn2-R upregulation and Lcn2 downregulation via Wnt/β-catenin may promote adaptive osmotolerant survival of IMCD cells in response to hyperosmolarity/-tonicity whereas Lcn2 upregulation and Lcn2-R downregulation via TLR-4 and/or normosmolarity/-tonicity may protect IMCD cells against bacterial infections and prevent autocrine death induction by Lcn2.\nNgfr, which promotes neurogenic fate of astroglia during the amyloid pathology-induced neuroregeneration in zebrafish brain, stimulated proliferative and neurogenic outcomes.\nThese molecules play a key role in tumor growth, invasion, and iron-dependent metabolism of cancer cells.\nSeveral features of cancer cells such as proliferation, invasion, metastatic spreading, and drug resistance are affected by their interaction with several tumor microenvironment (TME) components, including neutrophil gelatinase-associated lipocal", "dois": ["10.1038/s41536-023-00311-5", "10.3389/fcell.2022.945586", "10.3390/ijms20215398", "10.1186/s12964-018-0285-3", "10.1074/jbc.M114.606459"]}
{"pair_type": "slc_pathway", "key1": "SLC22A31", "key2": "glycolysis", "summary": "The overexpression of GGH in colon cancer-derived cell lines (SW48 and SW480) inhibited PKM, GLUT1, and LDHA expression and decreased the extracellular lactate content and intracellular ATP level.", "dois": ["10.3389/fimmu.2022.979521"]}
{"pair_type": "slc_pathway", "key1": "SLC22A23", "key2": "proliferation", "summary": "Knockdown of circSLC22A23 inhibited GC cell proliferation, migration and invasion.\nThen circSLC22A23 was knocked-down with short hairpin RNA to analyze its oncogenic effects on the proliferation, migration, and invasion of GC cells.\nCircSLC22A23 regulated the transcription of EGFR through activation of HNRNPU in GC cells, suggesting that circSLC22A23 may serve as a potential therapeutic target for the treatment of GC.\nCircular RNA CircSLC22A23 Promotes Gastric Cancer Progression by Activating HNRNPU Expression.\nMoreover, rescue assays showed that the tumor suppressive effect of circSLC22A23 knockdown was reversed by HNRNPU overexpression.\nFinally, epidermal growth factor receptor (EGFR) was found to be one of the downstream target genes of HNRNPU that was up regulated by circSLC22A23.", "dois": ["10.1007/s10620-024-08291-2"]}
{"pair_type": "slc_pathway", "key1": "SLC23A1", "key2": "proliferation", "summary": "Vitamin C effectively inhibited ALL cell line proliferation, induced apoptosis, and disrupted cell cycle progression.\nOur previous work showed that maternal selenium deficiency suppressed proliferation, induced autophagy dysfunction, and apoptosis in the placenta of mice.\nIn SLC23A1 knockout cells, treatment with 200 μM Vitamin C significantly restored cell viability and reduced apoptosis compared to controls.\nOncogenic codon V600E mutations of the BRAF gene affect 10-15% of colorectal cancers, resulting in activation of the MAPK/ERK signaling pathway and increased cell proliferation and survival.\nWe further identified that the increased expression of Solute Carrier Family 23 Member 1 (SLC23A1) in ALL cells enhanced their sensitivity to Vitamin C.\nMechanistically, high-dose Vitamin C induced apoptosis in ALL cells by activating the ER stress response through the PERK/CHOP pathway.\nOur results demonstrated that high-dose Vitamin C exhibited potent cytotoxicity toward ALL cells at relatively low concentrations (200 μM) while sparing normal human bone marrow mononuclear cells even at concentrations as high as 1 mM.\nHigh-dose Vitamin C has shown significant anti-tumor effects in various cancers, including hematological malignancies.\nSLC23A1 may serve as a potential biomarker for predicting the therapeutic response to Vitamin C treatment in ALL patients.\nVitamin C transporter gene SLC23A1 expression, as well as vitamin C metabolite levels, were inversely correlated with DNA methylation levels.\nAs vitamin C is an important cofactor for the activity of TET DNA demethylase enzymes, low vitamin C levels could directly contribute to the high methylation levels in these tumors by decreasing enzymatic TET activity.", "dois": ["10.1177/09603271251345656", "10.1038/s41388-025-03326-y", "10.1093/mtomcs/mfac062"]}
{"pair_type": "slc_pathway", "key1": "SLC23A1", "key2": "apoptosis", "summary": "In SLC23A1 knockout cells, treatment with 200 μM Vitamin C significantly restored cell viability and reduced apoptosis compared to controls.\nVitamin C effectively inhibited ALL cell line proliferation, induced apoptosis, and disrupted cell cycle progression.\nMechanistically, high-dose Vitamin C induced apoptosis in ALL cells by activating the ER stress response through the PERK/CHOP pathway.\nWe further identified that the increased expression of Solute Carrier Family 23 Member 1 (SLC23A1) in ALL cells enhanced their sensitivity to Vitamin C.\nOur results demonstrated that high-dose Vitamin C exhibited potent cytotoxicity toward ALL cells at relatively low concentrations (200 μM) while sparing normal human bone marrow mononuclear cells even at concentrations as high as 1 mM.\nFurthermore, SLC23A1 may serve as a potential biomarker for predicting the therapeutic response to Vitamin C treatment in ALL patients.\nHigh-dose Vitamin C has shown significant anti-tumor effects in various cancers, including hematological malignancies.", "dois": ["10.1177/09603271251345656", "10.1093/mtomcs/mfac062"]}
{"pair_type": "slc_pathway", "key1": "SLC22A17", "key2": "apoptosis", "summary": "Furthermore, we identified neuronal populations undergoing apoptosis, mediated by the Lcn2-SLC22A17 pathway in response to IL-1β and IL-6 signaling.\nOur study provides evidence that endothelial pyroptosis, characterized by the release of IL-1β and IL-6, triggers microglial polarization through NF-κB pathway activation, ultimately leading to microglia-mediated neuronal apoptosis in the choroid plexus post-ICH.\nAdditionally, Card9 KO suppressed cardiomyocyte apoptosis in the border region and attenuated matrix metalloproteinase (MMP) expression.\nUnder neuroinflammatory stress conditions, LCN2 is produced and secreted by activated microglia and reactive astrocytes, resulting in neuronal apoptosis.\nEndothelial pyroptosis post-ICH induced the production of IL-1β and IL-6, which activated microglial polarization characterized by elevated expression of Msr1, Lcn2, and Spp1 via the NF-κB pathway in the choroid plexus.\nThe effects of LCN2 on cell migration, cell viability, and apoptosis under various stresses, including ultraviolet (UV) irradiation and cisplatin treatment, were examined using the scratch wound healing assay, WST-1 assay, and Apostrand assay, respectively.\nFunctional enrichment analysis of hub genes mainly involved biological processes such as inflammation, osteoblastic differentiation, apoptosis, and ferroptosis.\nReduced secretion of LCN2 (lipocalin 2) from reactive astrocytes through autophagic and proteasomal regulation alleviates inflammatory stress and neuronal damage.\nFinally, we observed that LPS-induced and secreted LCN2 levels were reduced in the astrocyte-cultured medium under the above-mentioned conditions, resulting in increased neuronal viability, even under inflammatory stress.\nNotably, we found two effective conditions that led to the reduction of induced LCN2 levels in reactive astrocytes: proteasome inhibition and macroautophagic/autophagic flux activation.", "dois": ["10.1016/j.nbd.2024.106695", "10.3389/fmolb.2025.1609307", "10.1161/STROKEAHA.124.046736", "10.1038/s41392-023-01635-w", "10.1080/15548627.2023.2180202", "10.1371/journal.pone.0155220", "10.1074/jbc.M115.685644"]}
{"pair_type": "slc_pathway", "key1": "SLC23A2", "key2": "migration", "summary": "Curcumin treatment inhibited proliferation and migration of cancer cells in a dose dependent manner.\nSVCT2 downregulation also reduced the MMP2 activity.\nTaken together, our results indicate that curcumin inhibited human cancer cell growth and migration by regulating SVCT2 through a downregulating p53.\nWe found that curcumin reduced the expression of SVCT2 in cancer cells with a wild type p53, but not in those with a mutant type of p53.\nSVCT2 plays an important role in tumor progression and metastasis, however, the molecular mechanisms of curcumin on SVCT2 have not been studied to date.", "dois": ["10.1002/cbf.3824"]}
{"pair_type": "slc_pathway", "key1": "SLC23A2", "key2": "apoptosis", "summary": "In conclusion, we identified a novel susceptibility gene SLC23A2 for NSCPO, it may function by decreasing AA level, increasing the ROS levels, inducing apoptosis, and inhibiting autophagy through the activation of the PI3K-AKT-mTOR pathway in etiology of cleft palate.\nKnock down SLC23A2 in human embryonic palatal mesenchymal cell line (HEPM) induced decreased intracellular ascorbic acid (AA), increased reactive oxygen species (ROS), inhibited cell proliferation and triggered apoptosis, activated the PI3K-AKT-mTOR signaling pathway and inhibited autophagy;\nexperiments have shown that knockdown of in GMSM-K inhibits the expression of in the PI3K-Akt signaling pathway, promoting an increase in ROS and triggering increased apoptosis.\nThe interaction results showed that the ROS and apoptosis levels increased in GMSM-K cells with normal gene function when stimulated by Sin-1 (exogenous ROS mimics) and ROS and apoptosis levels can be reduced by AA supplementation.\nIn addition, increased ROS and apoptosis levels were also observed in zebrafish, and could not be rescued by AA supplementation.\nKnocked down SLC23A2 in HEPM cells or zebrafish, they became more sensitive to Sin-1, and AA supplementation was ineffective.\nThe /exogenous ROS/AA interaction is involved in lip and craniofacial development by influencing the levels of ROS and apoptosis.\nGMSM-K cells became more sensitive to Sin-1, and AA supplementation was ineffective after knockdown.", "dois": ["10.1038/s10038-025-01352-y", "10.3389/fped.2025.1632778", "10.3389/fmed.2023.1157773", "PMID:30285010", "10.1016/j.oftal.2017.12.016"]}
{"pair_type": "slc_pathway", "key1": "SLC23A2", "key2": "proliferation", "summary": "Knock down SLC23A2 in human embryonic palatal mesenchymal cell line (HEPM) induced decreased intracellular ascorbic acid (AA), increased reactive oxygen species (ROS), inhibited cell proliferation and triggered apoptosis, activated the PI3K-AKT-mTOR signaling pathway and inhibited autophagy;\nIn conclusion, we identified a novel susceptibility gene SLC23A2 for NSCPO, it may function by decreasing AA level, increasing the ROS levels, inducing apoptosis, and inhibiting autophagy through the activation of the PI3K-AKT-mTOR pathway in etiology of cleft palate.\nCurcumin treatment inhibited proliferation and migration of cancer cells in a dose dependent manner.\nSVCT2 downregulation also reduced the MMP2 activity.\nTaken together, our results indicate that curcumin inhibited human cancer cell growth and migration by regulating SVCT2 through a downregulating p53.\nWe found that curcumin reduced the expression of SVCT2 in cancer cells with a wild type p53, but not in those with a mutant type of p53.\nSVCT2 plays an important role in tumor progression and metastasis, however, the molecular mechanisms of curcumin on SVCT2 have not been studied to date.\nWe found that a novel gene SLC23A2, the vitamin C transporter gene is significantly associated with non-syndromic cleft palate only (NSCPO) (p = 3.25E-07, OR = 8.45, 95%CI:3.73-19.17).\nSLC23A2 is expressed in the craniofacial region of zebrafish (24hpf to 120hpf), obvious craniofacial abnormalities appeared in zebrafish (48hpf) when knock down the slc23a2 (slc23a2-MO).", "dois": ["10.1038/s10038-025-01352-y", "10.3389/fonc.2024.1407538", "10.1002/cbf.3824", "10.3389/fmed.2023.1157773"]}
{"pair_type": "slc_pathway", "key1": "SLC23A1", "key2": "oxidative stress", "summary": "These results suggested that maternal selenium deficiency may impair progesterone biosynthesis, reduce nutrient transporters expression, and promote immune response by increasing the oxidative stress of the placentae.\nIn the present study, dietary selenium deficiency in dams significantly suppressed glutathione peroxidase (GSH-Px) activity, total antioxidant capacity (T-AOC), and increased malondialdehyde (MDA) content in the placentae, confirming the oxidative stress in the placenta.\nRecently, we obtained evidence of differential regulation of SVCT expression in response to acute oxidative stress in cells from species that differ in their capacity to synthesize vitamin C, with a marked decrease in SVCT1 mRNA and protein levels in rat hepatoma cells that was not observed in human hepatoma cells.\nVitamin C (ascorbate, ascorbic acid) supplementation has reduced oxidative stress in persons with IBD.\nVitamin C is known to protect mucosal tissues from oxidative stress and inhibit nitrosamine formation in the stomach.\nIon transporters and transmembrane transporters, such as Heph, Trf, Slc39a8, Slc23a1, Atp7b, and Kcnc1, were reduced in the selenium-deficient placentae.\nExpression of oxidative stress response genes (glutathione peroxidase 1 (GPX1) and superoxide dismutase 1 (SOD1)) were significantly increased in AD mice jejunum, and this increase was mitigated by AA supplementation.\nOxidative stress is suggested to play a major role in the initiation and progression of IBD.\nThe functional annotation analysis revealed that some of these genes are potentially linked to heat tolerance (, , and ), immune response (, , and ), and oxidative stress response ().\nThe expression of SVCT2 is relatively widespread, where it serves to either deliver ascorbic acid to tissues with high demand of the vitamin for enzymatic reactions or to protect metabolically highly active cells or specialized tissues from oxidative stress.\nDietary antioxidants are essential nutrients that inhibit the oxidation of biologically important molecules and suppress the toxicity of reactive oxygen or nitrogen species.\nThe SVCT1 and SVCT2 transporters are rather", "dois": ["10.1093/mtomcs/mfac062", "10.3390/nu13020617", "10.3945/ajcn.113.068015", "10.3945/jn.112.168690", "PMID:11214969", "10.1101/2025.05.21.655101", "10.3390/ani13203269", "10.1016/j.freeradbiomed.2015.04.024", "10.1007/s12263-013-0346-6", "10.1016/j.mam.2012.12.002", "10.1016/B978-0-12-394316-3.00011-9", "10.1017/S0007114511002273", "10.1371/journal.pone.0002816"]}
{"pair_type": "slc_pathway", "key1": "SLC23A2", "key2": "glycolysis", "summary": "KEGG pathway network analysis of 858 DPPs revealed 33 statistically significant signaling pathways, including spliceosome, glycolysis/gluconeogenesis, B-cell receptor signaling pathway, HIF-1 signaling pathway, and fatty acid degradation.\nOverlapping Venn plots showed 14 common molecules among datasets of DPPs, DEGs, and OS-related DDPs, including FTCD, NDRG2, CCT2, PECR, SLC23A2, PNPLA7, ANLN, HNRNPM, HJURP, MCM2, STMN1, TCOF1, TOP2A, and SSRP1.\nThe drug sensitivities of OS-related DPPs were identified, including LMOD1, CAV2, UBE2E2, RAPH1, ANXA5, HDLBP, CUEDC1, APBB1IP, VCL, SRSF10, SLC23A2, EPB41L2, ESR1, PLEKHA4, SAFB2, SMARCAD1, VCAN, PSD4, RDH16, NOP56, MEF2C, BAIAP2L2, NAGS, SRSF2, FHOD3, and STMN1.\nIncreasing evidence demonstrates that phosphoproteins and phosphorylation-mediated molecular pathways influence the occurrence and development of hepatic carcinoma.", "dois": ["10.1007/s13167-023-00335-3"]}
{"pair_type": "slc_pathway", "key1": "SLC24A2", "key2": "apoptosis", "summary": "Similarly, increased frequency of tryptic phosphopeptides were observed from MOK, SMIM19, NXNL1, SLC24A2, Nbla10317, AHRR, C10orf90, MAEA, SRSF8, TBATA, TNIK, UBE2G1, PDE4C, PCGF2, KIR3DP1, TJP2, CPNE8, and NGF amongst others.\nSTRING analysis showed an increase in cytoplasmic proteins and proteins associated with alternate splicing, exocytosis of luminal proteins, and proteins involved in the regulation of the cell cycle, mitochondrial functions or metabolism and apoptosis.", "dois": ["10.1186/s12014-021-09320-2"]}
{"pair_type": "slc_pathway", "key1": "SLC24A2", "key2": "migration", "summary": "Finally, colorectal cancer cells migration, growth and colony formation assays were performed in RKO cells with the overexpression or knockdown SLC8A3, SLC24A2, SLC24A3, or SLC24A4.\nFinally, our study identified two previously unreported model genes (SLC8A3 and SLC24A4) that contribute to the growth and migration of colorectal cancer RKO cells.\nAltogether, we developed a prognostic risk model for predicting the prognosis of COAD patients based on the expression profiles of calcium extrusion-related genes, Furthermore, we validated two previously unreported tumor suppressor genes (SLC8A3 and SLC24A4) involved in colorectal cancer progression.", "dois": ["10.7717/peerj.17582"]}
{"pair_type": "slc_pathway", "key1": "SLC23A3", "key2": "oxidative stress", "summary": "The expression of SVCT2 is relatively widespread, where it serves to either deliver ascorbic acid to tissues with high demand of the vitamin for enzymatic reactions or to protect metabolically highly active cells or specialized tissues from oxidative stress.\nThe SVCT1 and SVCT2 transporters are rather specific for ascorbic acid, which is an important antioxidant and plays a crucial role in a many metal-containing enzymes.\nTransporters for vitamin C and its oxidized form dehydroascorbic acid (DHA) are crucial to maintain physiological concentrations of this important vitamin that is used in a variety of biochemical processes.", "dois": ["10.1016/j.mam.2012.12.002", "10.1016/B978-0-12-394316-3.00011-9"]}
{"pair_type": "slc_pathway", "key1": "SLC24A2", "key2": "proliferation", "summary": "PH could alleviate CI by suppressing the secretion of pro-inflammatory cytokines and mitigating astrocyte activity by restraining microglia's activation in hippocampus, further facilitating neurogenesis and proliferation, thereby enhancing pre-synaptic protein.\nMoreover, a miR-130a-3p mimic could ameliorate the cell proliferation defect induced by dexamethasone through normalization of expression.\nNotably, we found that treatment with dexamethasone, a glucocorticoid known to induce CP in mice, suppressed miR-130a-3p expression in both MEPM and O9-1 cells.\nOn the other hand, inhibitors of miR-130a-3p and miR-301a-3p significantly reduced cell proliferation in MEPM and O9-1 cells.\nAmong them, overexpression of the miR-449 family (miR-449a-3p, miR-449a-5p, miR-449b, miR-449c-3p, and miR-449c-5p) and miR-486b-5p resulted in reduced cell proliferation in primary mouse embryonic palatal mesenchymal (MEPM) cells and mouse cranial neural crest cell line O9-1.\nMoreover, PH or piracetam treatment significantly increased the expression of Ki67 and DCX co-labeled positive cells in hippocampal DG.\nFurthermore, LPS was capable of reducing the expression of BrdU and DCX co-labeled positive cells in hippocampal dentate gyrus (DG), which was reversed only by PH.", "dois": ["10.1016/j.jep.2023.117214", "10.3390/ijms222212453"]}
{"pair_type": "slc_pathway", "key1": "SLC23A2", "key2": "oxidative stress", "summary": "Maternal BPB exposure caused offspring hepatomegaly, transaminase elevation, drove oxidative stress and lipid metabolism imbalance through the Ppard-Slc23a2 dysregulation.\nOn the other hand, the levels of Glutathione, Reduced (GSH), myeloperoxidase (MDA), 8-isoprostane, tumor necrosis factor-α (TNF-α) and interleukin-6(IL-6) were significantly increased, but the levels of VC in brain tissue of the model group were decreased in Cre;svct2 f/f mice brain tissues, indicating the protective effect of VC against oxidative stress and inflammation during pregnancy.\nVitamin C is known to protect mucosal tissues from oxidative stress and inhibit nitrosamine formation in the stomach.\nExpression of oxidative stress response genes (glutathione peroxidase 1 (GPX1) and superoxide dismutase 1 (SOD1)) were significantly increased in AD mice jejunum, and this increase was mitigated by AA supplementation.\nThe study confirmed that BPB induces hepatotoxicity through circadian disruption and oxidative stress pathways, establishing these genes as dual biomarkers for early detection and therapeutic response prediction.\nReactive oxygen species (ROS) overproduction and ROS-signaling pathways activation attack the eyes.\nThe expression of SVCT2 is relatively widespread, where it serves to either deliver ascorbic acid to tissues with high demand of the vitamin for enzymatic reactions or to protect metabolically highly active cells or specialized tissues from oxidative stress.\nDietary antioxidants are essential nutrients that inhibit the oxidation of biologically important molecules and suppress the toxicity of reactive oxygen or nitrogen species.\nVitamin C (VC) is a key antioxidant of the Central Nervous System (CNS) and SLC23A2 (SVCT2) is the only transporter that actively transports VC into the brain.\nThe SVCT1 and SVCT2 transporters are rather specific for ascorbic acid, which is an important antioxidant and plays a crucial role in a many metal-containing enzymes.", "dois": ["10.1016/j.ecoenv.2025.118702", "10.3390/nu13020617", "10.3945/jn.112.168690", "10.3389/fped.2025.1632778", "10.1101/2025.05.21.655101", "10.1016/j.neuroscience.2023.05.023", "10.3389/fmed.2023.1157773", "10.3390/antiox9111101", "10.1016/j.oftal.2017.12.016", "10.1007/s12263-013-0346-6", "10.1016/j.mam.2012.12.002", "10.1016/B978-0-12-394316-3.00011-9", "10.1017/S0007114511002273", "10.1371/journal.pone.0002816", "PMID:16177205"]}
{"pair_type": "slc_pathway", "key1": "SLC24A3", "key2": "chemotherapy", "summary": "We observed significant decrease in total colonic ACF formation, malonaldehyde (MDA) and lactate dehydrogenase (LDH), increase in superoxide dismutase (SOD), up-regulation of APC, Bax and Slc24a3, and down-regulation of Defa24 and Bcl-2 in rats treated with Strobilanthes crispus.\nPlants that have been used for decades in folk and traditional medicine have been accepted as one of the commonest sources of discovered natural agents of cancer chemotherapy and chemoprevention.\nEach oral cancer cell line expressed miR-365 downstream targets molybdenum cofactor synthesis-2 (MOCS2), erythropoietin receptor (EPOR), IQ motif containing-K (IQCK), carboxypeptidase A3 (CPA3), solute carrier family 24 member-3 (SLC24A3), and coiled-coil domain containing 47 (CCDC47)-although the expression levels varied somewhat.\nThese results suggest this differential expression may signal potential targets for patient treatment with tumors exhibiting miR-365 and chemotherapeutic resistance.\nThese data suggest that many of the miR-365 targets are expressed in the oral cancers screened, with the differential expression of UBR3, ZCCHC14, HOMEZ, and NUDT12, which may be correlated with chemoresistance among two specific oral cancer cell lines (SCC25, SCC9).", "dois": ["10.3390/life14060741", "10.1097/MD.0000000000035005", "10.1186/s12906-015-0926-7"]}
{"pair_type": "slc_pathway", "key1": "SLC24A3", "key2": "apoptosis", "summary": "We observed significant decrease in total colonic ACF formation, malonaldehyde (MDA) and lactate dehydrogenase (LDH), increase in superoxide dismutase (SOD), up-regulation of APC, Bax and Slc24a3, and down-regulation of Defa24 and Bcl-2 in rats treated with Strobilanthes crispus.\nSeveral are connected with oxidative stress-induced cell apoptosis and others are related to imbalanced homeostasis or intake of drugs/toxins.", "dois": ["10.1186/s12906-015-0926-7"]}
{"pair_type": "slc_pathway", "key1": "SLC24A3", "key2": "ferroptosis", "summary": "Accumulating evidence showed that ferroptosis, an iron-dependent form of programmed cell death, is closely correlated with cancer initiation and clinical outcome through reshaping the tumor microenvironment.\nC2 subtypes, a 5-gene prognostic signature (LSP1, IL1R2, MPO, CRIP1, and SLC24A3) was developed using LASSO Cox stepwise regression analysis and further validated in independent AML cohorts.\nThus, we concluded that molecular subtyping using ferroptosis signatures could characterize the TIME and provide implications for monitoring clinical outcomes and predicting novel therapies.", "dois": ["10.3389/fcell.2023.1207642"]}
{"pair_type": "slc_pathway", "key1": "SLC24A3", "key2": "migration", "summary": "Finally, colorectal cancer cells migration, growth and colony formation assays were performed in RKO cells with the overexpression or knockdown SLC8A3, SLC24A2, SLC24A3, or SLC24A4.\nFinally, our study identified two previously unreported model genes (SLC8A3 and SLC24A4) that contribute to the growth and migration of colorectal cancer RKO cells.\nFunctional enrichment analysis of differentially expressed genes (DEGs) implied that cell activation involved in immune response, leukocyte cell-cell adhesion and migration, and cytokine production were the main biological processes.\nWe constructed a prognostic model based on the expression of calcium extrusion-related genes (SLC8A1, SLC8A2, SLC8A3, SLC8B1, SLC24A2, SLC24A3 and SLC24A4) in COAD.\nAltogether, we developed a prognostic risk model for predicting the prognosis of COAD patients based on the expression profiles of calcium extrusion-related genes, Furthermore, we validated two previously unreported tumor suppressor genes (SLC8A3 and SLC24A4) involved in colorectal cancer progression.\nC2 subtypes, a 5-gene prognostic signature (LSP1, IL1R2, MPO, CRIP1, and SLC24A3) was developed using LASSO Cox stepwise regression analysis and further validated in independent AML cohorts.", "dois": ["10.7717/peerj.17582", "10.3389/fcell.2023.1207642"]}
{"pair_type": "slc_pathway", "key1": "SLC24A3", "key2": "oxidative stress", "summary": "We observed significant decrease in total colonic ACF formation, malonaldehyde (MDA) and lactate dehydrogenase (LDH), increase in superoxide dismutase (SOD), up-regulation of APC, Bax and Slc24a3, and down-regulation of Defa24 and Bcl-2 in rats treated with Strobilanthes crispus.\nSeveral are connected with oxidative stress-induced cell apoptosis and others are related to imbalanced homeostasis or intake of drugs/toxins.\nOur results support the in vivo protection of S. crispus against CRC formation (azoxymethane-induced aberrant crypt foci) and suggest that the mechanism is highly specific to protect from oxidative insults and the following apoptotic cascade.", "dois": ["10.1186/s12906-015-0926-7"]}
{"pair_type": "slc_pathway", "key1": "SLC24A4", "key2": "apoptosis", "summary": "We found some significant associations with candidate loci associated with AD (SLC24A4, MS4A6A, HS3ST1) and progressive supranuclear palsy (MAPT and EIF2AK3).\nFinally, knockdown of the Drosophila JADE1 homolog rhinoceros (rno) enhanced tau-induced toxicity and apoptosis in vivo in a humanized 0N4R mutant tau knock-in model, as quantified by rough eye phenotype and terminal deoxynucleotidyl transferase dUTP nick end-labeling (TUNEL) in the fly brain.\nRecent studies highlight the role of immune dysregulation, vascular smooth muscle cell (VSMC) apoptosis, and metabolic-epigenetic interactions in AD pathogenesis, underscoring the need for novel biomarkers and therapeutic targets.", "dois": ["10.3389/fgene.2025.1586880", "10.1007/s00401-021-02379-z"]}
{"pair_type": "slc_pathway", "key1": "SLC24A4", "key2": "migration", "summary": "Finally, our study identified two previously unreported model genes (SLC8A3 and SLC24A4) that contribute to the growth and migration of colorectal cancer RKO cells.\nFinally, colorectal cancer cells migration, growth and colony formation assays were performed in RKO cells with the overexpression or knockdown SLC8A3, SLC24A2, SLC24A3, or SLC24A4.\nAltogether, we developed a prognostic risk model for predicting the prognosis of COAD patients based on the expression profiles of calcium extrusion-related genes, Furthermore, we validated two previously unreported tumor suppressor genes (SLC8A3 and SLC24A4) involved in colorectal cancer progression.", "dois": ["10.3389/fgene.2025.1586880", "10.1007/s13258-024-01562-2", "10.7717/peerj.17582", "10.1016/j.ajhg.2011.07.011", "10.1016/S0151-9638(08)75485-1"]}
{"pair_type": "slc_pathway", "key1": "SLC24A4", "key2": "stemness", "summary": "Additionally, the modulation in myeloid-derived suppressor cell (MDSC) infiltration and miRNA hsa-mir-1247-3p mediated targeting of tumor suppressor SLC24A4 and oncogenes RAB3B and HJURP appears to primarily regulate LUAD patient survival.\nIt has been suggested that the high mortality rate of LUAD is linked to the acquisition of progenitor-like cells with stem-like characteristics that assist the whole tumor in regulating immune cell infiltration.\nWe found 3 stem cell-related genes, ORC1L, KIF20A, and DLGAP5, present in LUAD that also correlate with changes in immune infiltration rates and reduced patient survival rates.", "dois": ["10.1371/journal.pone.0294171"]}
{"pair_type": "slc_pathway", "key1": "SLC24A4", "key2": "proliferation", "summary": "Tgfb3 is involved in epithelial cell proliferation, cellular component disassembly process, ECM cellular component, and decomposition of cell components.", "dois": ["10.1002/alz.13796", "10.1155/2023/4038278", "10.1016/S0151-9638(08)75485-1"]}
{"pair_type": "slc_pathway", "key1": "SLC24A4", "key2": "oxidative phosphorylation", "summary": "Through KEGG analysis, the DBGs were associated with oxidative phosphorylation, complement and coagulation cascades, arginine and proline metabolism, metabolic pathways, arachidonic acid metabolism, and ECM-receptor interaction.\nThese candidate genes (CSF1, C1S, CST6, SLC24A4, HOXA10, HOXA11, MMP9, and ITGA11) and enriched signaling pathways could be valuable references for exploring the molecular mechanisms underlying goat embryo implantation.", "dois": ["10.1093/jas/skac401"]}
{"pair_type": "slc_pathway", "key1": "SLC24A4", "key2": "oxidative stress", "summary": "Additionally, gene ontology analysis identified a trend among significantly altered transcripts in roles for oxidative stress response.", "dois": ["10.1016/j.ibror.2018.06.001"]}
{"pair_type": "slc_pathway", "key1": "SLC24A5", "key2": "oxidative stress", "summary": "This study highlights the genes upregulated by cumulative VL exposure involved in pigmentation, immune response, oxidation/reduction, and matrix remodeling across skin types providing relevant information on daily solar exposure.\nTop ten upregulated genes by repeated VL exposure in microarray included melanogenic genes such as tyrosinase (TYR), tyrosinase-related protein-1 (TYRP1), dopachrome tautomerase (DCT), premelanosome protein (PMEL), melan-A (MLANA), and solute carrier family 24, member 5 (SLC24A5) and genes involved in inflammation/matrix remodeling/cell signaling including chemokine (C-C motif) ligand 18 (CCL18), BCL2-related protein A1 (BCL2A1), and cartilage oligomeric matrix protein (COMP).", "dois": ["10.1111/phpp.12819"]}
{"pair_type": "slc_pathway", "key1": "SLC24A5", "key2": "proliferation", "summary": "These genes are associated with melanin production and melanocyte proliferation.", "dois": ["10.1371/journal.pone.0198011", "10.1016/j.cbpc.2015.07.011"]}
{"pair_type": "slc_pathway", "key1": "SLC25A1", "key2": "chemotherapy", "summary": "Since upregulation of SLC25A1 is induced by adverse conditions in the tumor environment, exposure to IR, or both pharmacologic inhibition of SLC25A1 might be an effective strategy for radiosensitization of cancer cells particularly in chronically hypoxic tumor fractions.\nOverexpression of SLC25A1 attenuated both the decreased proliferation and enhanced apoptosis caused by DMC-GF (p < 0.01).\nExposure to acute or chronic cycling severe hypoxia/reoxygenation stress triggered upregulated expression of SLC25A1 in lung cancer, prostate cancer, and glioblastoma cells.\nInterestingly, exposure to ionizing radiation (IR) further promoted SLC25A1 expression.\nWe show that SLC25A1 can contribute to the increased antioxidant defense of cancer cells allowing them to escape the cytotoxic effects of IR.\nInhibition of SLC25A1 by 1,2,3-benzene-tricarboxylic acid (BTA) disturbed cellular and mitochondrial redox homeostasis, lowered mitochondrial metabolism, and reduced metabolic flexibility of cancer cells.\nMoreover, analysis of publically available databases applying the Kaplan-Meier plotter tool (kmplot.com) revealed that overexpression of SLC25A1 was associated with reduced survival of lung cancer patients suggesting a potential link to aggressive cancers.\nEven more important, combining IR with BTA was able to overcome increased radioresistance induced by adaptation to chronic cycling severe hypoxia/reoxygenation stress.\nAdditionally, exposure to 8 µM DMC-GF led to a marked (> 70%) reduction in SLC25A1, a mitochondrial citrate transporter, protein levels (p < 0.01).\nGlioma stem cells (GSCs) exhibit significant resistance to conventional radiotherapy and chemotherapy, contributing to high recurrence rates in gliomas.\nPronounced resistance of lung cancer cells to radiotherapy and chemotherapy is a major barrier to successful treatment.\nAn integrative analysis identified 111 common differentially expressed genes including two bone morphogenetic proteins (BMP4 and BMP7), six solute carrier proteins (SLC10A", "dois": ["10.1186/s12967-025-06355-z", "10.3389/fonc.2018.00170", "10.1016/j.ygyno.2010.01.041"]}
{"pair_type": "slc_pathway", "key1": "SLC24A5", "key2": "migration", "summary": "This study further supports the role of human SLC24A5 gene in skin pigmentation suggesting that variations in SLC24A5 haplotypes can correlate with human migration and ancestry.\nUsing compound haplotype systems consisting of rapidly evolving microsatellites linked to one single-nucleotide polymorphism in each gene, we estimate that the onset of the sweep shared by Europeans and East Asians at KITLG occurred approximately 30,000 years ago, after the out-of-Africa migration, whereas the selective sweeps for the European-specific alleles at TYRP1, SLC24A5, and SLC45A2 started much later, within the last 11,000-19,000 years, well after the first migrations of modern humans into Europe.\nFunctions and pathways associated with hair color were enriched, including melanosomes, melanocyte migration, melanin biosynthesis processes and functions, and melanogenesis pathways.\nHere, we demonstrate that a canonical Eurasian skin pigmentation gene, , was introduced to southern Africa via recent migration and experienced strong adaptive evolution in the KhoeSan.\nOur extended bulk RNA sequencing analyses show that additional pigmentation-related genes, affecting melanin production, melanosome motility and melanophore migration, are dysregulated in the embryonic skin of the mutated animals.\nUsing four-population demographic simulations with selection, we show that the allele was introduced into the KhoeSan only 2,000 y ago via a back-to-Africa migration and then experienced a selective sweep (s = 0.04 to 0.05 in ≠Khomani and Nama).\nTo address this, we investigated anterior-posterior expression levels of a primary set of candidate target genes with known functions in melanophore migration and stripe patterning in the adult zebrafish, and their related gene regulatory network.\nMoreover, changes in subsistence and migration associated with the Neolithic transition have been hypothesized to involve genetic adaptation.\nIt has been recently shown that the variation of a G in an A allele of the coding single-nucleotide polymorphism (SNP) rs1426654 within SLC24A5 gene varies in frequency among several population samples according to skin pigmentation.\nFocusing on the intersection of results from these selection", "dois": ["10.1093/genetics/iyaf236", "10.1007/s13258-024-01562-2", "10.7554/eLife.77514", "10.1093/molbev/msac108", "10.1073/pnas.1801948115", "10.1002/ajhb.23170", "10.7717/peerj.4080", "10.1093/molbev/mss207", "10.2174/138920208784139528"]}
{"pair_type": "slc_pathway", "key1": "SLC25A1", "key2": "ferroptosis", "summary": "Pharmacological inhibition of SLC25A1 and ACLY significantly enhances cancer cell susceptibility to ferroptosis both in vitro and in vivo.\nHere, we use a targeted CRISPR-Cas9 screen of the SLC superfamily to identify SLC25A1 as a critical ferroptosis regulator in human cancer cells.\nTargeting the SLC25A1-ACLY axis is therefore a potential therapeutic strategy for ferroptosis-targeted cancer intervention.\nSLC25A1 drives citrate export from the mitochondria to the cytosol, where it fuels acetyl-CoA synthesis by ATP citrate lyase (ACLY).\nThis acetyl-CoA supply sustains FSP1 acetylation and prevents its degradation by the proteasome via K29-linked ubiquitin chains.", "dois": ["10.1038/s44318-025-00369-5", "10.1007/s11033-022-07583-y"]}
{"pair_type": "slc_pathway", "key1": "SLC25A1", "key2": "apoptosis", "summary": "Overexpression of SLC25A1 attenuated both the decreased proliferation and enhanced apoptosis caused by DMC-GF (p < 0.01).\nThe targeted silencing of SLC25A1 or inhibition of its protein led to a significant decrease in proliferative, invasive and migratory capabilities of ESCC cells, accompanied by increased apoptosis.\nDuring metabolic stress, SLC25A1 increased oxidative phosphorylation (OXPHOS) to protect protects CRC cells from energy stress-induced cell apoptosis.\nKnockdown or pharmacological inhibition of SLC25A1 significantly suppressed AML cell proliferation by inducing apoptosis, without affecting cell cycle progression or differentiation.\nKnockdown of SLC25A1 significantly inhibited the growth of CRC cells by suppressing the progression of the G1/S cell cycle and inducing cell apoptosis both in vitro and in vivo, whereas SLC25A1 overexpression suppressed the malignant phenotype.\nWe further demonstrated that the inhibition of could inhibit the proliferation and increase the apoptosis of AML cells.\nWithin LUAD cells, SLC25A1 was observed to not only boost proliferation but also hinder apoptosis and further augment fatty acid synthesis.\nThis shift promotes NADPH generation through increased cytosolic conversion of malate to pyruvate, protecting cells from glucose deprivation-induced apoptosis.\nMechanistically, we demonstrated that SLC25A1 inhibition disrupted citrate homeostasis, leading to mitochondrial dysfunction and reduced fatty acid metabolism.\nThe present results indicate that knockdown or blockade of SLC25A1 can significantly impede the malignant biological behavior of ESCC.\nCollectively, SLC25A1 plays a pivotal role in the promotion of CRC growth and survival by reprogramming energy metabolism.", "dois": ["10.1038/s41467-025-64734-y", "10.1186/s12967-025-06355-z", "10.3892/ijo.2025.5721", "10.3892/ijo.2024.5716", "10.4149/gpb_2025036", "10.3324/haematol.2024.287269", "10.1038/s41420-023-01640-6", "10.3389/fgene.2022.1081262", "10.1038/s41419-021-04411-2", "10.1016/j.ygyno.2010.01.041", "10.1016/j.mcn.2008.07.027"]}
{"pair_type": "slc_pathway", "key1": "SLC25A1", "key2": "migration", "summary": "Overexpression of miR-331-3p or inhibition of SLC25A1 resulted in significantly suppressed proliferation, migration and invasion of PTC cells.\nThe Slc25a1 regulates mitochondrial citrate transport and has been shown to affect cell proliferation and migration in cancer.\nThe targeted silencing of SLC25A1 or inhibition of its protein led to a significant decrease in proliferative, invasive and migratory capabilities of ESCC cells, accompanied by increased apoptosis.\nSUCLG1 enhanced mitochondrial quality and promoted mitochondrial fusion, thereby driving proliferation and migration of tumor cells, inhibiting apoptosis and altering the cell cycle.\nIn conclusion, the present study suggests that lncBRM promotes PTC by regulating miR-331-3p and targeting SLC25A1.\nSLC25A1 promotes lymph node metastasis of esophageal squamous cell carcinoma by regulating lipid metabolism.\nLong non-coding RNA BRM promotes proliferation and invasion of papillary thyroid carcinoma by regulating the microRNA-331-3p/SLC25A1 axis.\nlncBRM knockout significantly suppressed cell proliferation, migration and invasion.\nAdditionally, silencing of the SLC25A1 gene significantly inhibited xenograft tumor growth.\nThe present results indicate that knockdown or blockade of SLC25A1 can significantly impede the malignant biological behavior of ESCC.\nRescue assays demonstrated that inhibition of miR-331-3p significantly abrogated the effects of lncBRM knockout on PTC cell proliferation, migration and invasion.\nIn activated BMDMs and PBMC-derived macrophages, astragaloside IV interacted with Slc25a1, attenuated citrate transport, maintained mitochondrial function, therefore enhancing the shift from the M1- to M2-like macrophages.\nSUCLG1 altered the mechanism of mitochondrial quality control to enhance cell aerobic respiration, thereby driving the pathogenesis of PNF.\nSolute carrier family 25 member 1 (SLC25A1) affects lipid metabolism and energy regulation in multiple types of tumor cell, affecting", "dois": ["10.1016/j.phymed.2025.156449", "10.3892/ijo.2025.5721", "10.3892/ijo.2024.5716", "10.3892/ol.2020.11418"]}
{"pair_type": "slc_pathway", "key1": "SLC25A1", "key2": "stemness", "summary": "Our research shows that PTL inhibits the growth and stemness of LCSCs through SLC25A1-mediated mitochondrial function.\nMoreover, in different patient-derived tumors, resistance to cisplatin or to epidermal growth factor receptor (EGFR) inhibitor treatment is acquired through SLC25A1-mediated implementation of mitochondrial activity and induction of a stemness phenotype.\nHere we show that administration of PTL stimulated cell cycle arrest at the G1 phase, induced apoptosis, and decreased the stemness of LCSCs.\nIn addition, the inhibitory effect of PTL on mitochondrial function and self-renewal capacity of LCSCs was abolished by the knockdown of SLC25A1 or treatment with SLC25A1 inhibitor CTPI-2.\nWe demonstrate that SLC25A1 plays a key role in maintaining the mitochondrial pool of citrate and redox balance in CSCs, whereas its inhibition leads to reactive oxygen species build-up thereby inhibiting the self-renewal capability of CSCs.\nRNA sequencing (RNA-Seq) further shows that PTL decreased SLC25A1 expression at the mRNA level and that inhibition of SLC25A1 synergistically decreased the expression of IDH2 and several pivotal genes involved in mitochondrial respiratory chain complex, resulting in the production of ROS and mitochondrial dysfunction.\nWe show here that lung CSCs rely upon oxidative phosphorylation for energy production and survival through the activity of the mitochondrial citrate transporter, SLC25A1.\nFurther research indicates that PTL caused the production of ROS and the reduction of oxidative phosphorylation (OXPHOS) and mitochondrial membrane potential (MMP) levels of LCSCs.", "dois": ["10.1038/s41420-023-01640-6", "10.1038/s41418-018-0101-z"]}
{"pair_type": "slc_pathway", "key1": "SLC25A1", "key2": "glycolysis", "summary": "CIC inhibition or Slc25a1 knockdown reduces the occupancy of H3K9ac to hypoxia-inducible factor-1α (HIF-1α) binding sites in promoters of glycolytic genes to restrain glycolysis.\nBy restraining glycolysis, CIC inhibition increases NAD content to ensure mitochondrial biogenesis for oxidative phosphorylation.\nMechanistically, serine starvation impairs acetyl-CoA-dependent gene expression by inhibiting the entry of glycolytic carbon into the TCA cycle and down-regulating the mitochondrial citrate exporter SLC25A1, a critical enzyme in the production of nucleocytosolic acetyl-CoA from glucose.\nIn lipopolysaccharide-activated macrophages, the citrate carrier (CIC) exports citrate from mitochondria to enhance glycolytic genes through histone acetylation.\nIsotopic tracing of [U-C] glucose shows that CIC blockage prevents citrate accumulation and itaconate production by reducing glycolytic flux and facilitating metabolic flux in the TCA cycle.\nMechanistically, METTL3 directly interacts with ATP citrate lyase (ACLY) and a mitochondrial citrate transporter (SLC25A1) and then further affects the glycolytic pathway.\nThis shuttle supports glycolysis, lipid biosynthesis, and protein acetylation.\nAbstract: The developing mammalian heart undergoes an important metabolic shift from glycolysis towards mitochondrial oxidation that is critical to support the increasing energetic demands of the maturing heart.\nAbstract: The developing mammalian heart undergoes an important metabolic shift from glycolysis toward mitochondrial oxidation, such that oxidative phosphorylation defects may present with cardiac abnormalities.\nSituated at a critical metabolic intersection, citrate, derived via glycolysis, serves as either a combustible fuel for aerobic mitochondrial bioenergetics or as a continuously replenished cytosolic carbon source for lipid biosynthesis, an essentially anaerobic process.\nUsing isotope tracing and time-resolved metabolomic analyses, we demonstrate that serine is required to maintain glucose flux through glycolysis and the TCA cycle to", "dois": ["10.1177/00220345211051594", "10.1161/CIRCULATIONAHA.118.035741", "10.1242/dmm.035337", "10.1074/jbc.M115.672360", "10.1038/s42003-024-07110-8", "10.1152/ajpcell.00194.2024", "10.2147/JIR.S446013", "10.1073/pnas.2302489120", "10.1158/0008-5472.CAN-22-2679", "10.1101/2023.05.22.541833", "10.1016/j.celrep.2022.110391", "10.3389/fcell.2021.626316", "10.1021/acs.jproteome.0c00394", "10.1016/j.gene.2019.144321", "10.1158/0008-5472.CAN-11-1011"]}
{"pair_type": "slc_pathway", "key1": "SLC25A1", "key2": "oxidative phosphorylation", "summary": "Furthermore, Slc25a1 inhibition under HFD conditions activated the SIRT1/PGC1α pathway, promoting mitochondrial proliferation and enhancing oxidative phosphorylation for energy production.\nDuring metabolic stress, SLC25A1 increased oxidative phosphorylation (OXPHOS) to protect protects CRC cells from energy stress-induced cell apoptosis.\nWe show here that lung CSCs rely upon oxidative phosphorylation for energy production and survival through the activity of the mitochondrial citrate transporter, SLC25A1.\nBy restraining glycolysis, CIC inhibition increases NAD content to ensure mitochondrial biogenesis for oxidative phosphorylation.\nFunctional pathway analysis revealed TIC-specific activation of oxidative phosphorylation, PI3K-Akt signaling, and ribosome-related processes.\nMoreover, in different patient-derived tumors, resistance to cisplatin or to epidermal growth factor receptor (EGFR) inhibitor treatment is acquired through SLC25A1-mediated implementation of mitochondrial activity and induction of a stemness phenotype.\nAmong the 640 vulnerability genes identified, many were involved in mitochondrial metabolism, and metabolic flux analysis confirmed enhanced oxidative phosphorylation use in Dnmt3a versus Dnmt3a (WT) HSPCs.\nWe demonstrate that SLC25A1 plays a key role in maintaining the mitochondrial pool of citrate and redox balance in CSCs, whereas its inhibition leads to reactive oxygen species build-up thereby inhibiting the self-renewal capability of CSCs.\nMechanistic analysis via the Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway indicated that DMC-GF's anti-GSC activity is associated with disruption of mitochondrial oxidative phosphorylation.\nCollectively, SLC25A1 plays a pivotal role in the promotion of CRC growth and survival by reprogramming energy metabolism.\nFurther research indicates that PTL caused the production of ROS and the reduction of oxidative phosphorylation (OXPHOS) and mitochondrial membrane potential (MMP) levels of LCSCs.\nAbstract: The developing mammalian heart undergoes an important metabol", "dois": ["10.1038/s41586-025-08980-6", "10.1186/s12967-025-06355-z", "10.1074/jbc.M115.672360", "10.1158/0008-5472.CAN-11-1011", "10.3390/cells14161255", "10.1152/ajpcell.00194.2024", "10.2147/JIR.S446013", "10.1038/s41420-023-01640-6", "10.1101/2023.05.22.541833", "10.1016/j.celrep.2022.110391", "10.1038/s41419-021-04411-2", "10.1038/s41418-018-0101-z"]}
{"pair_type": "slc_pathway", "key1": "SLC25A2", "key2": "migration", "summary": "The analysis identified 15 InDels and 202 non-synonymous SNVs exclusively present in tumors of non-responders, mainly in genes regulating the cell cycle, adhesion, and migration.\nThe results suggest that SLC16A6 rs7222013 and SLC25A2 rs3749780 may serve as potential predictors of poor nCRT response in LARC patients.", "dois": ["10.1111/ahg.70019"]}
{"pair_type": "slc_pathway", "key1": "SLC25A1", "key2": "oxidative stress", "summary": "This enables cells to alleviate oxidative stress, sustain mitochondrial function, and promote RCC malignancy in vitro and in vivo.\nPreviously, a similar pathway has been shown to mitigate detachment-induced oxidative stress in anchorage-independent tumor spheroids.\nMechanistically, SMIM4 interacts with and facilitates the assembly of SLC25A1-containing complexes, enabling SLC25A1-mediated malate/citrate exchange.\nHere, we show that pancreatic ductal adenocarcinoma (PDAC) patients with low integral membrane protein SMIM4 expression exhibits a poor prognosis and reduces oxidative stress in tumors, which can be confirmed in cultured human PDAC cells and mice Pdx1-Cre/Kras/Trp53R (KPC) cells.\nMoreover, PDAC cells with low level of SMIM4 are resistant to RSL3-induced toxicity, indicating that PDAC tumors with high SMIM4 expression are promising candidates for treatment with oxidative stress inducers.\nThis shift promotes NADPH generation through increased cytosolic conversion of malate to pyruvate, protecting cells from glucose deprivation-induced apoptosis.\nCollectively, we unveil a lactylation-dependent mechanism that reprograms mitochondrial metabolism to confer oxidative stress resistance and drive RCC progression.\nUnder low-glucose, high-lactate conditions mimicking the tumor microenvironment, MDH2 elevated the NADH/NAD ratio to drive ATP production and boosted NADPH generation to reduce ROS.\nDysregulation of these transporters, such as the mitochondrial pyruvate carrier (MPC), citrate carrier (SLC25A1), and voltage-dependent anion channel (VDAC), disrupts energy metabolism, redox balance, and cellular signaling, contributing to the pathogenesis of neurodegenerative diseases (NDDs), cardiovascular diseases (CVDs), type 2 diabetes (T2D), and cancer.\nIn NDDs, impaired transporters exacerbate oxidative stress and neuronal death, while in CVDs, they lead to energy deficits and heart failure.", "dois": ["10.1038/s41467-025-64734-y", "10.1016/j.ijbiomac.2025.146571", "10.1016/j.celrep.2023.112971", "10.1186/s12967-025-06976-4", "10.3390/antiox14070857", "10.1016/j.jiph.2023.10.035", "10.1093/schbul/sbad066", "10.1007/s11033-022-07583-y"]}
{"pair_type": "slc_pathway", "key1": "SLC25A3", "key2": "apoptosis", "summary": "By investigating the underlying mechanisms, we found that Rv0928 interacted with the macrophage mitochondrial phosphate carrier protein SLC25A3, reduced mitochondrial membrane potential and caused mitochondrial cytochrome c release, which ultimately activated caspase-9-mediated intrinsic apoptosis.\nA 10-gene model was obtained, including 7 negative impact factors (SLC39A14, AACS, ERP29, LAMP3, TMEM106C, TMED2, and SLC25A3) and 3 positive ones (CNPY2, GRB10, and PBK), which related with several important oncogenic pathways (KRAS signaling, TNF- signaling pathway, and WNT signaling pathway) and several cancer-related cellular processes (epithelial mesenchymal transition and cellular apoptosis).\nFurthermore, PiC has also been described to affect cell survival mechanisms via interactions with cyclophilin D and the viral mitochondrial-localized inhibitor of apoptosis (vMIA).\nBy using Rv0928-overexpressing (Ms::Rv0928), we unexpectedly found that Rv0928 not only increased apoptosis, but also augmented the inflammatory response of infected macrophages.\nDeletion of Mir1p and depletion of its human orthologue (SLC25A3/PHC) abolish stress-induced mitochondrial targeting of Ybh3p in yeast and that of BAX in human cells, respectively.\nYbh3p induces cell death and disruption of the mitochondrial transmembrane potential via the mitochondrial phosphate carrier Mir1p.\nMitochondrial outer membrane permeabilization is a watershed event in the process of apoptosis, which is tightly regulated by a series of pro- and anti-apoptotic proteins belonging to the BCL-2 family, each characteristically possessing a BCL-2 homology domain 3 (BH3).\nUpon lethal insult, Ybh3p translocates to mitochondria and triggers BH3 domain-dependent apoptosis.\nYeast cells lacking YBH3 display prolonged chronological and replicative lif", "dois": ["10.1038/emboj.2011.197", "10.3389/fmicb.2023.1291358", "10.1155/2022/9774219", "10.1016/j.bbrc.2015.06.031"]}
{"pair_type": "slc_pathway", "key1": "SLC25A3", "key2": "glycolysis", "summary": "Unexpectedly, meclizine suppressed glycolytic enzyme expression and reduced lactate accumulation, suggesting that meclizine does not induce a glycolytic shift in SLC25A3-deleted hearts.\nThis was accompanied by increased glycolytic activity and reduced mitochondrial flux, leading us to hypothesize that pharmacologically enhancing glycolysis might be protective when the mitochondrial energy machinery is intrinsically impaired.\nTogether, these findings identify meclizine as a clinically approved compound that promotes cardioprotection in mitochondrial disease not by driving glycolysis, but by preserving mitochondrial membrane organization and redox balance, highlighting mitochondrial quality and NAD redox homeostasis as therapeutic targets for primary mitochondrial cardiomyopathies.\nTo test this, we turned to meclizine, an FDA-approved antihistamine previously shown to shift metabolism toward glycolysis.\nFurther studies suggested the potential link between the accumulation of glycolytic byproducts and Ca homeostasis imbalance in SLC25A3-KO hiPSC-CMs.\nWe previously reported that the cardiomyocyte-specific deletion of the mitochondrial phosphate carrier (SLC25A3), which imports phosphate required for ATP synthesis, produces a model of mitochondrial cardiomyopathy in which total cardiac ATP levels are preserved despite defective mitochondrial ATP production.", "dois": ["10.1101/2025.09.03.674000", "10.1016/j.celrep.2024.115065"]}
{"pair_type": "slc_pathway", "key1": "SLC25A3", "key2": "migration", "summary": "in the control of cell adherence and migration (POP3), or endoplasmic reticulum and mitochondrial functions (SYVN1, NACA and SLC25A3).", "dois": ["10.1371/journal.pone.0022564"]}
{"pair_type": "slc_pathway", "key1": "SLC25A1", "key2": "proliferation", "summary": "Furthermore, Slc25a1 inhibition under HFD conditions activated the SIRT1/PGC1α pathway, promoting mitochondrial proliferation and enhancing oxidative phosphorylation for energy production.\nMechanistically, SLC25A1 loss results in a proliferation defect and activates two distinct senescence pathways, oncogene-induced senescence (OIS) and mitochondrial dysfunction-induced senescence (MiDAS), both involving the p53 tumor suppressor and driven by two discernible signals: the accumulation of 2HG, inducing OIS, and mitochondrial dysfunction, triggering MiDAS.\nOverexpression of SLC25A1 attenuated both the decreased proliferation and enhanced apoptosis caused by DMC-GF (p < 0.01).\nSurprisingly, inactivation of both Slc25a1 alleles results in alterations in the development of multiple organs, and in a severe proliferation defect by activating two senescence programs, oncogene-induced senescence (OIS) and mitochondrial dysfunction-induced senescence (MiDAS), which converge upon the induction of the p53 tumor suppressor.\nCellular experiments showed that SLC25A1 knockdown significantly reduced the proliferation of lung adenocarcinoma cells.\nOverexpression of miR-331-3p or inhibition of SLC25A1 resulted in significantly suppressed proliferation, migration and invasion of PTC cells.\nInhibiting these senescence programs or blocking p53 activity reverses the growth defect caused by SLC25A1 dysfunction and restores proliferation.\nReplenishing the pool of NAD or promoting the clearance of 2HG rescues the proliferation defect of cells with dysfunctional SLC25A1 in a cooperative fashion.\nKnockdown or pharmacological inhibition of SLC25A1 significantly suppressed AML cell proliferation by inducing apoptosis, without affecting cell cycle progression or differentiation.\nThe Slc25a1 regulates mitochondrial citrate transport and has been shown to affect cell proliferation and migration in cancer.\nSolute carrier family 25 member 1 (SLC25A", "dois": ["10.4149/gpb_2025036", "10.3324/haematol.2024.287269", "10.1186/s12967-025-06355-z", "10.1016/j.phymed.2025.156449", "10.3892/ijo.2025.5721", "10.3892/ijo.2024.5716", "10.1038/s41418-024-01428-w", "10.1152/ajpcell.00194.2024", "10.1002/ctm2.1766", "10.1101/2024.04.25.590465", "10.1038/s41420-024-01805-x", "10.1007/s12672-023-00830-z", "10.1101/2023.07.18.549409", "10.3389/fgene.2022.1081262", "10.1177/00220345211051594", "10.3389/fcell.2021.626316", "10.1021/acs.jproteome.0c00394", "10.3892/ol.2020.11418", "PMID:23100451", "10.1158/0008-5472.CAN-11-1011", "10.1016/j.ygyno.2010.01.041"]}
{"pair_type": "slc_pathway", "key1": "SLC25A3", "key2": "oxidative phosphorylation", "summary": "Variants in the SLC25A3 gene, which codes for the mitochondrial phosphate transporter (PiC), lead to a failure of inorganic phosphate (Pi) transport across the mitochondrial membrane, which is required in the final step of oxidative phosphorylation.\nPiC delivers phosphate, a key substrate of oxidative phosphorylation, across the inner mitochondrial membrane.\nwe show that CYTB-187AA is mainly localized in the mitochondrial matrix and promotes the pluripotent state in primed-to-naive transition by interacting with solute carrier family 25 member 3 (SLC25A3) to modulate ATP production.\nThe mitochondrial phosphate carrier (PiC) is a mitochondrial solute carrier protein, which is encoded by SLC25A3 in humans.\nWe demonstrate that this CuCOX peak is enhanced under metabolic conditions favoring oxidative phosphorylation, such as high Cu supplementation or galactose-containing media, and correlates with increased mitochondrial respiration.\nFunctional RNA interference (RNAi) experiments targeting key Cu transporters revealed that CuCOX formation is independent of the high-affinity Cu importer CTR1, but instead relies on alternative transporters including DMT1, LAT1, and the mitochondrial carrier SLC25A3.\nThis transport activity is also relevant for allowing effective mitochondrial calcium handling.\nThe significance of PiC has been supported by the recent discovery of a fatal human condition associated with PiC mutations.\nFurthermore, PiC has also been described to affect cell survival mechanisms via interactions with cyclophilin D and the viral mitochondrial-localized inhibitor of apoptosis (vMIA).\nCopper (Cu) is an essential trace element required for mitochondrial respiration via its incorporation into cytochrome c oxidase (CuCOX), the terminal enzyme of the electron transport chain.\nThe mitochondrial genome transcribes 13 mRNAs coding for well-known proteins essential for oxidative phosphorylation.", "dois": ["PMID:27780865", "PMID:17273968", "10.1101/2025.06.11.659066", "10.1016/j.cmet.2024.04.012", "10.1016/j.bbrc.2015.06.031", "10.1007/8904_2014_364"]}
{"pair_type": "slc_pathway", "key1": "SLC25A3", "key2": "proliferation", "summary": "Furthermore, circCNST was colocalized with miR-421 in the cytoplasm and acted as a sponge of miR-421, which attenuated circCNST-induced proliferation-promoting effects in OS cells by targeting SLC25A3.\nKnockdown of circCNST repressed cell viability, colony formation, and xenograft tumor growth, while restored expression of circCNST reversed these effects.\nIn conclusion, our findings demonstrate that circCNST promotes the tumorigenesis of OS cells by sponging miR-421, and provides a potential biomarker for patients with OS.\nPiC2 deletion using CRISPR/Cas9 showed that the transporter is required for proliferation and differentiation of primary myoblasts, as both processes are delayed upon PiC2 knock-out.\nSpermidine also upregulated expression of the epithelial stem cell-associated keratins K15 and K19, and dose-dependently modulated K15 promoter activity in situ and the colony forming efficiency, proliferation and K15 expression of isolated human K15-GFP+ cells in vitro.\nUnder these conditions, spermidine promoted hair shaft elongation and prolonged hair growth (anagen).\nIn primary human epidermal keratinocytes, spermidine slightly promoted entry into the S/G2-M phases of the cell cycle.\nThe mitochondrial phosphate transporter SLC25A3, also known as PiC2, binds Cu and transports the ion through these membranes in eukaryotic cells, ultimately aiding in the metallation of COX.\nWe used the well-established differentiation model of primary myoblasts derived from mouse satellite cells, wherein Cu availability is necessary for growth and maturation, and showed that PiC2 is a target of MTF1, and its expression is both induced during myogenesis and favored by Cu supplementation.\nThese data indicate an important role for PiC2 in both the delivery of Cu to the mitochondria and COX, favoring the differentiation of primary myoblasts.\nThe effects of PiC2 deletion were rescued by the addition of Cu to the growth medium, implying the deleterious", "dois": ["10.3389/fmolb.2022.1037941", "10.1177/0963689720926147", "PMID:27780865", "10.1371/journal.pone.0022564"]}
{"pair_type": "slc_pathway", "key1": "SLC25A3", "key2": "oxidative stress", "summary": "These results indicate that reduced expression of SLC25A3 in fatty liver contributes to electron leak from mitochondria by limiting Cu availability, rendering hepatocytes more susceptible to oxidative stress.\nC1 and C3 cells were prone to produce reactive oxygen species (ROS), and increased ROS was associated with reduced mRNA expression of glutathione peroxidase (GPX) 1 and glutathione disulfide reductase (GSX) in these cell lines.\nInterestingly, cytoplasmic and mitochondrial Cu accumulation significantly reduced in C1 cells, demonstrating a predominant contribution of SLC25A3 to Cu transport into mitochondrial matrix.\nSLC25A3 deficiency had insignificant effect on mitochondrial membrane potential (MtMP) and oxygen consumption rate (OCR) in untreated cells but suppressed them when cells were exposed to oleic acid.\nMitochondrial dysfunction causes oxidative stress, triggering hepatocyte death and inflammation.\nFirstly, we established a high fat diet (HFD)-fed ICR mouse NAFLD model characterized by obesity with insulin resistance and found transcriptional upregulation of Slc25a17 and downregulation of Slc25a3 (isoform B) and Slc25a13 in their fatty liver.\nThis study provides evidence that SLC25A3 is a novel risk factor for developing NASH.\nA mitochondrial phosphate and Cu carrier, SLC25A3, was further studied in wild-type (wt) and SLC25A3-defective HepG2 cells (C1 and C3).\nThis desensitization of MPTP opening due to loss or reduction in PiC protein attenuated cardiac ischemic-reperfusion injury, as well as partially protected cells in culture from Ca(2+) overload induced death.", "dois": ["10.1016/j.yexcr.2023.113740", "10.1038/cdd.2014.36"]}
{"pair_type": "slc_pathway", "key1": "SLC25A4", "key2": "apoptosis", "summary": "Furthermore, our findings indicated that the expression of Slc25a4 was increased in failing hearts, and the downregulation of Slc25a4 improved mitochondrial function and reduced cell apoptosis.\nResults showed that PBD-2 could interact with pro-apoptotic solute carrier family 25 member 4 (SLC25A4), also known as adenine nucleotide translocase 1, and thereby inhibited SIV-induced cell apoptosis.\nAltogether, these indicate that PBD-2 protects pigs against SIV infection, which may result from its role as a SLC25A4 blocker to alleviate cell apoptosis, providing a novel therapeutic and prophylactic strategy of using PBD-2 to combat SIV.\nWe identified a cell subcluster named C5 that exhibited a close association with mitochondrial malfunction and cellular apoptosis characteristics, and identified Slc25a4 as a significant biomarker of C5.\nAs a downstream effector of BCL2L13 in its pro-apoptotic pathway, SLC25A4 is found as one of the hub genes that involved in the physiological function of BCL2L13 in kidney cancer tissues.\nSlc25a4 served as the hub gene for C5, highlighting its significant potential as a novel therapeutic target for MI.\nReal-time polymerase chain reaction (RT-PCR), bulk RNA-sequencing dataset analysis, western blotting, immunohistochemical and immunofluorescence staining, Mito-Tracker staining, TUNEL staining, and flow cytometry analysis were conducted to validate the impact of the marker gene on mitochondrial function and cell apoptosis of CMs under hypoxic conditions.\nThe molecular docking analysis suggested that PBD-2 interacted with porcine SLC25A4 mainly through strong hydrogen binding, with the predicted binding affinity being -13.23 kcal/mol.\nThe death of cardiomyocytes (CMs) and the dysfunction of the remaining viable CMs are the main pathological factors contributing to heart failure (HF) following MI.\nTogether, these data demonstrate an essential role for autophagy in protecting my", "dois": ["10.1038/s41598-024-59975-8", "10.1016/j.antiviral.2022.105292", "10.1080/15548627.2019.1591672", "10.1016/j.mam.2012.05.006", "10.3389/fgene.2024.1410145", "10.1096/fj.202201724RR", "10.1186/s12935-021-02039-y", "10.3390/genes11020117", "10.3390/ijms17050664", "10.1111/age.12184", "PMID:18158317", "PMID:17316384"]}
{"pair_type": "slc_pathway", "key1": "SLC25A4", "key2": "migration", "summary": "overexpressing OS cells exhibited suppressed proliferation, migration, invasion and enhanced apoptosis.\nFurthermore, combining bioinformatics analysis with literature review, TCONS_00032546 and TCONS_00026102 may induce effects by increasing the CCND1-FGF19-FGF3-FGF4 gene cluster and SLC25A4 via complex mechanisms during neural remodeling.\nSilencing of TCONS_00032546 or TCONS_00026102 with lentiviruses in vivo could significantly shorten or prolong the atrial effective refractory period thereby increasing or preventing AF inducibility by promoting or inhibiting the neurogenesis.\nFurther, the detection of REST-downstream genes involved in cytostasis and migration inhibition demonstrated that CCND1 and CCNE1 were reduced;\nThen CCK-8 assay showed significantly decreased cell proliferation, and the inhibition of migration was verified by scratch wound healing assay and transwell assay.\nCDK5R1, BBC3, EGR1, SLC25A4, PDCD7, MAPK11, MAPK12, FADD and DAXX were enhanced, among which BBC3 and DAXX were direct targets of REST, as verified by ChIP (chromatin immunoprecipitation) and Western blotting.\nUsing cell cycle analysis and Annexin V/PI straining assay, G1 phase cell cycle arrest was found to be a reason for the suppression of cell proliferation and migration upon REST silencing, while apoptosis was not affected by REST silencing.\nThese data suggested that REST is a master regulator that maintains GBM cells proliferation and migration, partly through regulating cell cycle by repressing downstream genes, which might represent a potential target for GBM therapy.\nBesides, the expression of CCND1-FGF19-FGF4-FGF3 gene cluster and SLC25A4, the nearby genes of TCONS_00032546 and TCONS_00026102, were negatively correlated with that of lncRNAs.\nBioinformatics analysis showed that the aberrantly expressed genes were associated with neural development, migration and neurodegenerative disorders", "dois": ["10.1590/1414-431X2024e13639", "10.3389/fgene.2024.1410145", "10.1096/fj.202201724RR", "10.3390/ijms17050664", "10.1002/jcb.25037", "10.1111/age.12184"]}
{"pair_type": "slc_pathway", "key1": "SLC25A5", "key2": "ferroptosis", "summary": "The six pivotal CDRDDEGs in AS patients, healthy controls, were identified as CLIC4, BIRC2, MATK, PKN2, SLC25A5, and EDEM1.\nOur focus extended specifically to ferroptosis-related DEGs (FRDEGs), cuproptosis-related DEGs (CRDEGs), anoikis-related DEGs (ARDEGs), autophagy-related DEGs (AURDEGs), and pyroptosis-related DEGs (PRDEGs).\nAmong AS patients, 82 FRDEGs, 29 CRDEGs, 54 AURDEGs, 21 ARDEGs, and 74 PRDEGs were identified.\nRelative to healthy controls, a myriad of differentially expressed genes (DEGs) linked to cell death surfaced in AS patients.\nEmploying machine learning techniques, LASSO, RF, and SVM-RFE were employed to discern key DEGs related to cell death (CDRDDEGs).\nLeveraging machine learning (ML) methodologies, we formulated disease prediction models employing cell death-related DEGs (CDRDEGs) and identified biomarkers intertwined with cell death in AS.", "dois": ["10.1038/s41598-024-65745-3"]}
{"pair_type": "slc_pathway", "key1": "SLC25A5", "key2": "glycolysis", "summary": "SLC25A5 attenuated cell proliferation, upregulated the expression of programmed cell death-related signatures, and exerted its biological function by inhibiting the MAPK signaling pathway.\nNine of these are directly involved in mitochondrial energy metabolism and glycolysis; CKB, DBT, HSPD1, HSPA9, LRPPRC, NDUFS2, PRDX6, SLC25A5, TPI1, UCHL1, UQCRC1, VCL, YWHAZ, YWHAE.\nValidated by GSE395282 and GSE175356, DEMs with high-risk scores were associated with the phenotypes of increasing tumor immune infiltration and decreasing glycolysis and apoptosis contents.\nThis study provides further evidence for a role for Parkin in regulating mitochondrial activity within cells.", "dois": ["10.1038/s41419-022-04692-1", "10.1002/pmic.200900126"]}
{"pair_type": "slc_pathway", "key1": "SLC25A6", "key2": "chemotherapy", "summary": "This group demonstrated increased sensitivity to vincristine, etoposide, and oxaliplatin.\nDrug sensitivity assays in DLBCL cell lines were performed to validate the model's predictive capacity for chemotherapy response.\nWe identified eleven hub genes (CHERP, SYNE2, INTS1, FAP, MMP9, LRP5, RBM8A, PRMT5, SLC25A6, PABPC4, PSTPIP2) using RNA sequencing, RNA immunoprecipitation sequencing, and protein interaction profiling.\nThe ERG scoring system offers a robust and precise tool for predicting survival and guiding personalized treatment in DLBCL patients.", "dois": ["10.3389/fimmu.2025.1644020"]}
{"pair_type": "slc_pathway", "key1": "SLC25A4", "key2": "glycolysis", "summary": "Due to this enzymic inhibition, OA was reported to induce numerous alterations in relevant cellular physiological processes, including several metabolic pathways such as glucose uptake, lipolysis and glycolysis, heme metabolism, and glycogen and protein synthesis.\nUpregulation of these HIF-1α target proteins was accompanied by a rise in glycolysis as measured by extracellular acidification rate (ECAR) in lung homogenates.\nThe GO and KEEG enrichment analysis showed that these 18 genes were mainly involved in the production of metabolites and energy, glycolysis, amino acid biosynthesis and so on.\nProminent examples include members of the TCA cycle (IDH2), electron transport chain (NDUFA6), the ATP synthase complex (ATP5F1B) and ADP/ATP intracellular transport (SLC25A4).\nSpecifically, the expression patterns of GAPDH, TOMM5, SLC25A4, COII, QARS, and RGS5 genes were determined in SHSY5Y human neuroblastoma cells exposed to OA for 3, 24, or 48 h.\nProteomic analysis further revealed specific deficits in the mitochondrial ATP synthase (Atp5a1) within complex V and in the ATP/ADP translocase (Slc25a4).\nqRT-PCR validation confirmed that NDUFB3, NGLY1, and SLC25A4 are highly expressed in RA.\nThe early AD prediction model including ENO2, TPI1, AEBP1, HERC1, PCSK1, PREPL, SLC25A4, UQCRC2, CHST6, DDIT4, ACSS1 and SUCLA2 was constructed by LASSO analysis.\nA concomitant reduction in mitochondrial respiration was also observed as indicated by a partial loss of oxygen consumption rates (OCR) in isolated mitochondrial fractions of SARS-CoV-2-infected hamster lungs.\nProminent nuclear localization of HIF-1α and increased expression of HIF-1α target proteins, including glucose transporter 1 (", "dois": ["10.1016/j.brainres.2023.148545", "10.3390/ijms24010558", "10.3389/fimmu.2024.1453587", "10.1016/j.cbpb.2024.110952", "10.1080/15287394.2012.690703"]}
{"pair_type": "slc_pathway", "key1": "SLC25A5", "key2": "proliferation", "summary": "SLC25A5 attenuated cell proliferation, upregulated the expression of programmed cell death-related signatures, and exerted its biological function by inhibiting the MAPK signaling pathway.\nMoreover, SLC25A5-AS1 could inhibit GC cell proliferation, induce G1/G1 cell cycle arrest and cell apoptosis in vitro, as well as GC growth in vivo.\nAts-1 targeted translocation to the mitochondria where it up-regulated the expression of NDUFB5, NDUFB3, NDUFS7, COX6C, and SLC25A5, thereby enhancing energy production and inhibiting HEK293T cells apoptosis while enhancing HEK293T cells proliferation, and ultimately facilitating Anaplasma phagocytophilum replication in HEK293T cells.\nDual-luciferase reporter assay confirmed the direct interaction between SLC25A5-AS1 and miR-19a-3p, rescue experiment showed that co-transfection miR-19a-3p mimics and pcDNA-SLC25A5-AS1 could partially restore the ability of GC cell proliferation and the inhibition of cell apoptosis.\nTaken together, this study indicated that SLC25A5-AS1 was down-regulated in GC and functioned as a suppressor in the progression of GC.\nSLC25A5 was downregulated in cancer, and its upregulation was related to better overall survival in patients from public datasets and in clinical cases.\nAfter intracellular expression of Ats-1, adenosine triphosphate levels and the proliferation of HEK293T cells were both up-regulated, while HEK293T cells apoptosis was inhibited.\nThe mechanism analyses further found that SLC25A5-AS1 might act as a competing endogenous RNAs (ceRNA), which was involved in the derepression of PTEN expression, a target gene of miR-19a-3p, and regulate malignant phenotype via PI3K/AKT signalling pathway in GC.\nGenomics of Drug Sensitivity in Cancer (GD", "dois": ["10.1186/s12866-022-02668-x", "10.1155/2022/4703524", "10.1038/s41419-022-04692-1", "10.1016/j.biopha.2021.111279", "10.1111/jcmm.14200"]}
{"pair_type": "slc_pathway", "key1": "SLC25A5", "key2": "migration", "summary": "In-vitro experiments of JEG-3 cells, PFOS exposure impaired trophoblast motility including the compromised abilities of migration, invasion and vascularization.\nMechanistically, these pathological effects on cells resulted from SLC25A5-mediated mitochondrial damages, characterized by excessive ROS generation, decreased ATP production and mitochondrial membrane potential loss, and accompanied by the activation of p38 MAPK and JNK signaling pathways.", "dois": ["10.1016/j.ecoenv.2022.114256"]}
{"pair_type": "slc_pathway", "key1": "SLC25A5", "key2": "chemotherapy", "summary": "Neuroblastoma is a common solid cancer in young children with poor clinical outcomes following conventional chemotherapy.\nThe mitochondrion is a gatekeeper of apoptotic processes, and mediates drug resistance to several chemotherapy agents used to treat cancer.\nAmong mitochondria-associated gene targets, we found that high expression of the mitochondrial adenine nucleotide translocase 2 (SLC25A5/ANT2), was a strong predictor of poor neuroblastoma patient prognosis and contributed to a more malignant phenotype in pre-clinical models.\nInhibiting this transporter with PENAO reduced cell viability in a panel of neuroblastoma cell lines in a TP53-status-dependant manner.\nSAHA and PENAO synergistically reduced cell viability, and induced apoptosis, in neuroblastoma cells independent of TP53-status.\nThe SAHA and PENAO drug combination significantly delayed tumour progression in pre-clinical neuroblastoma mouse models, suggesting that these clinically advanced inhibitors may be effective in treating the disease.", "dois": ["10.1002/ijc.34349"]}
{"pair_type": "slc_pathway", "key1": "SLC25A5", "key2": "oxidative stress", "summary": "Lower VT (LHe, -269 °C) positively affected the mRNA expression levels of apoptotic genes (BAD, BID, BTK, TP53, and TP53I3) and mitochondrial genes (COX6B1, DERA, FIS1, NDUFA1, NDUFA4, PRDX2, SLC25A5, TFB1M, and UQCRB), and reduced oxidative stress from freezing.\nEventually, the presence of multiple rare sequence variants in the Solute Carrier Family 25 Member 5 (SLC25A5) gene is suggestive of the role of this gene as a key factor linking mitochondria metabolism, ADP/ATP ratio and oxidative stress thus affecting extracellular matrix homeostasis and activation of pro-osteogenic factors.\nErythroid and B-cell development may be particularly vulnerable to Ant2 depletion-mediated mitochondrial dysfunction and oxidative stress.\nAnt2 depletion caused anemia in a cell-autonomous manner by maturation arrest of erythroid precursors with increased reactive oxygen species and premature deaths.\nMoreover, data reveal that changes in mitochondrial metabolic pathways are sustained by a genetic background and emphasize that a persistent chronic oxidative stress can further influence extracellular matrix homeostasis and cell signalling through the TGFβ-BMP axis.\nFurthermore, several signalling pathways essential for normal cellular function (actin cytoskeleton signalling, HGF signalling, NRF2-mediated oxidative stress, integrin signalling, calcium signalling) were also significantly regulated.", "dois": ["10.1371/journal.pone.0244098", "10.1016/j.cryobiol.2020.09.009", "10.1016/j.cellsig.2019.03.020", "10.1038/cdd.2014.230"]}
{"pair_type": "slc_pathway", "key1": "SLC25A5", "key2": "stemness", "summary": "Metabolic transporters, in particular SLC1A5 and SLC25A5, are upregulated in EVs derived from TKI-resistant cells and plasma from patients harbouring TKI-resistant tumors and in TKI-resistant cell lines.\nFurthermore, we also provide evidence for the increased abundance of pSTAT3 and the stemness marker ALDH1A1 upon EV-induced resistance.\nOur findings support the role of metabolic transporters within tumor-derived EVs in reshaping the tumor microenvironment to promote therapy resistance, which could have potential diagnostic, prognostic, and therapeutic implications.\nWe report here that TKI-sensitive cells are rendered resistant upon incubation with EVs derived from TKI-resistant cell lines.\nNotably, resistant EVs trigger phenotypic and functional switching of lung-derived fibroblasts into tumor-associated fibroblasts, significantly increasing their migratory and invasive capacities.", "dois": ["10.7150/thno.100374"]}
{"pair_type": "slc_pathway", "key1": "SLC25A4", "key2": "proliferation", "summary": "SLC25A4 attenuated cell proliferation, cell invasion, and exerted its biological function by inhibiting the STAT3 signaling pathway.\n-overexpressing OS cells exhibited suppressed proliferation, migration, invasion and enhanced apoptosis.\nResults showed that PBD-2 could interact with pro-apoptotic solute carrier family 25 member 4 (SLC25A4), also known as adenine nucleotide translocase 1, and thereby inhibited SIV-induced cell apoptosis.\nThis remodeling impairs mitochondrial lipid transport and results in neutral lipid accumulation, thereby suppressing HCC proliferation.\nThen CCK-8 assay showed significantly decreased cell proliferation, and the inhibition of migration was verified by scratch wound healing assay and transwell assay.\nPorcine β-defensin 2 (PBD-2) is a host defense peptide and our previous study has shown that PBD-2 inhibits proliferation of enveloped pseudorabies virus both in vitro and in transgenic (TG) mice.\nUsing cell cycle analysis and Annexin V/PI straining assay, G1 phase cell cycle arrest was found to be a reason for the suppression of cell proliferation and migration upon REST silencing, while apoptosis was not affected by REST silencing.\nELF-MF exposure altered the expression levels of several PBMC proteins without affecting cell proliferation, cell viability, or cell cycle progression.\nElevated NAD activates sirtuin 1 (SIRT1) and AMP-activated protein kinase (AMPK), leading to remodeling of lipid metabolism.\nThe proportion of Ki67 cells and the concentration of nitric oxide (NO) were high in SRGN high expression cells, suggesting that SRGN may be involved in the proliferation of HUVECs.\nThis study proposes a stratified therapeutic approach: targeting the SLC25A4-NAD-SIRT1-AMPK axis may benefit HCC patients with preserved SLC25A4 expression.\nIn conclusion, ELF-MF exposure induces metabolic reprogramming in human PBMCs, characterized by the upregulation of mitochon", "dois": ["10.1016/j.bcp.2025.117530", "10.3390/ijms26136035", "10.1038/s41598-025-03102-8", "10.3389/fgene.2024.1410145", "10.1016/j.antiviral.2022.105292", "10.3390/ijms21176437", "10.1007/s11010-020-03830-7", "10.3892/mmr.2019.10478", "10.3390/ijms17050664"]}
{"pair_type": "slc_pathway", "key1": "SLC25A10", "key2": "chemotherapy", "summary": "In conclusion, our findings suggest that SLC25A10 may serve as a novel therapeutic target to overcome cisplatin resistance and enhance the efficacy of chemotherapy in CC.\nSLC25A10 promotes cisplatin resistance by inhibiting ferroptosis in cervical cancer.\nGenetic or pharmacological inhibition of the mitochondrial dicarboxylate carrier (SLC25A10) or the oxoglutarate-carrier (SLC25A11) increased the cytotoxic effects of ionizing radiation (IR).\nAdditionally, SLC25A10 and MAP3K9 were identified as genes associated with gemcitabine + paclitaxel resistance.\nOur results demonstrated that SLC25A10 promotes cervical cancer cell growth, migration, and resistance to DDP.\nBut only targeting of SLC25A10 was effective in overcoming chronic-cycling hypoxia-induced enhanced death resistance in vitro and in vivo by disturbing increased antioxidant capacity.\nOthers and we have shown that adaptation of cancer cells to cycling severe hypoxia and intermittent reoxygenation stress (chronic-cycling hypoxia) increases cellular antioxidant capacity thereby supporting resistance to chemotherapy and radiotherapy.\nOur study reveals a role of SLC25A10 in supporting both, redox- and energy-homeostasis, ensuring radioresistance of cancer cells with tolerance to chronic-cycling hypoxia thereby proposing a novel strategy to overcome a mechanism of hypoxia-induced therapy resistance with potential clinical relevance regarding decreased patient survival.\nTherefore, identifying new therapeutic targets and combination therapies to overcome DDP resistance is a critical need.", "dois": ["10.1038/s41420-025-02712-5", "10.1038/s41598-025-09395-z", "10.1016/j.canlet.2018.09.002"]}
{"pair_type": "slc_pathway", "key1": "SLC25A6", "key2": "proliferation", "summary": "The results show that carvacrol significantly reduced LPS-induced expression of IL-1β, IL-6, IL-18, and TNF-α and alleviated the effects of LPS on cell proliferation and apoptosis of HMEC-1.\nFurthermore, carvacrol has been shown to reduce VDAC1 protein expression, improve mitochondrial function and energy metabolism by regulating MMP, mPTP opening, ROS levels, and ATP production, and increase SLC25A6 protein expression.\nKnockdown of PABPC4 significantly inhibited cell proliferation, reduced colony formation, and delayed tumor growth.\nThe results of this study demonstrate that carvacrol exerts a protective effect on human microvascular endothelial cells by improving mitochondrial function and alleviating oxidative stress through the inhibition of VDAC1.\nIn the mechanism of inflammatory injury, SLC25A6 may act as a downstream effector of VDAC1.\nAssessment of apoptosis, necrosis, and proliferation was conducted using the YO-PRO-1/PI apoptosis and necrosis detection kit and EdU assay.", "dois": ["10.3389/fimmu.2025.1644020", "10.1021/acsomega.4c10795"]}
{"pair_type": "slc_pathway", "key1": "SLC25A6", "key2": "apoptosis", "summary": "apoptosis was reduced, enzymatic activity of cytochrome C oxidase (COX) and superoxide dismutase and expression of uncoupling protein 2, voltage-dependent anion channel 1, and Bcl 2 were upregulated and SLC25A6, MDA levels were downregulated.\nThe results show that carvacrol significantly reduced LPS-induced expression of IL-1β, IL-6, IL-18, and TNF-α and alleviated the effects of LPS on cell proliferation and apoptosis of HMEC-1.\nFurthermore, carvacrol has been shown to reduce VDAC1 protein expression, improve mitochondrial function and energy metabolism by regulating MMP, mPTP opening, ROS levels, and ATP production, and increase SLC25A6 protein expression.\nUsing ANT3-specific small interfering RNA (siRNA) and an inhibitor for hcmv-miR-UL36-5p, it was shown that inhibition of apoptosis by hcmv-miR-UL36-5p in these cells specifically occurred via inhibition of ANT3 expression.\nThe expression level of ANT3 protein was confirmed, by western blotting, to be directly downregulated by overexpression of hcmv-miR-UL36-5p in HEK293 cells, U373 cells and HELF cells.\nIn the mechanism of inflammatory injury, SLC25A6 may act as a downstream effector of VDAC1.\nIt has been reported that a cellular gene, solute carrier family 25, member 6 (SLC25A6), which is also designated adenine nucleotide translocator 3 (ANT3), was identified as a candidate target of hcmv-miR-UL36-5p by hybrid PCR.\nIn this study, ANT3 was further demonstrated to be a direct target of hcmv-miR-UL36-5p by luciferase reporter assays.\nDescribed as a decisive player in the programmed cell death, it was recently shown to play a role in cancer.\nAny deficiency or dysfunction of this membrane protein leads to serious consequences on cell metabolism an", "dois": ["10.1186/s40001-020-00431-4", "10.1007/s00705-015-2498-8", "10.1016/j.mam.2012.05.006", "10.1021/acsomega.4c10795"]}
{"pair_type": "slc_pathway", "key1": "SLC25A10", "key2": "ferroptosis", "summary": "SLC25A10 promotes cisplatin resistance by inhibiting ferroptosis in cervical cancer.\nAmong the intersecting candidates, SLC25A10, a mitochondrial carrier protein, emerged as a potential key regulator of ferroptosis.\nIn summary, this study demonstrates the critical role of MPV17 in protecting cardiomyocytes from ferroptosis and elucidates the Nrf2-MPV17-SLC25A10/mitochondrial glutathione signaling pathway in the regulation of myocardial ferroptosis.\nInhibition of DIC and OGC aggravated ferroptosis and increased mitochondrial ROS, membrane depolarization, and GSH depletion.\nPYCR1 overexpression inhibited lipid reactive oxygen species production and promoted SLC25A10 expression in colorectal cancer cells.\nFerroptosis inhibitor deferoxamine suppressed the antitumor effects of PYCR1 silencing, whereas ferroptosis inducer erastin inhibited the protumor effects of PYCR1 overexpression.\nOverexpression of MPV17 delivered via adenovirus significantly reduced ferroptosis in both cardiomyocytes with high levels of iron and cardiac I/R tissues.\nThis led to increased intracellular lipid peroxidation and accumulation of reactive oxygen species (ROS), ultimately promoting iron-mediated cell death (ferroptosis) in cervical cancer cells.\nThis mechanistic study shows that MPV17 can increase mitochondrial glutathione levels through maintaining the protein homeostasis of SLC25A10, which is a mitochondrial inner-membrane glutathione transporter.\nSLC25A10 overexpression reversed the antitumor effects of PYCR1 silencing in vitro and inhibited the antitumor effects of erastin in vivo.\nMechanistically, we found that inhibiting SLC25A10 expression restricted the transport of glutathione (GSH) and reduced the expression of glutathione peroxidase 4 (GPX4).\nTherefore, PYCR1 is an oncogenic gene that promotes colorectal tumor growth and desensitizes colorectal cancer cells to 5-F", "dois": ["10.3390/ijms251910832", "10.1007/s13577-022-00775-5", "10.1016/j.redox.2021.102021", "10.1038/s41420-025-02712-5", "10.1038/s41420-025-02528-3"]}
{"pair_type": "slc_pathway", "key1": "SLC25A10", "key2": "apoptosis", "summary": "In addition, SLC25A10 knockdown caused an increase in apoptosis and a decrease in mitosis in osteosarcoma cells.\nIn H/R cardiomyocytes, MTH treatment significantly improved cell injury, mitochondrial dysfunction, and inhibited the mitochondrial apoptosis pathway, which were partially reversed by SLC25A10 deletion.\nThese findings suggested that MTH treatment could protect against MI/RI by modulating SLC25A10 expression to suppress mitochondrial apoptosis pathway, providing new theoretical basis for clinical application of MTH treatment for MI/RI.\nFunctional assays demonstrated that silencing SLC25A10 via shRNA or CRISPR/Cas9 significantly suppressed OS cell proliferation, migration, and mitochondrial function, resulting in mitochondrial membrane depolarization, oxidative damage, and apoptosis.\nOur previous studies showed that overexpression of two mitochondrial anion transporters, the dicarboxylate (DIC, Slc25a10) and oxoglutarate (OGC, Slc25a11) carriers, in NRK-52E cells resulted in increased mitochondrial uptake of glutathione (GSH) and protection from chemically induced apoptosis.\nInhibition of OGC and DIC resulted in a significant decrease in mGSH and increased apoptosis.\nPYCR1 overexpression inhibited lipid reactive oxygen species production and promoted SLC25A10 expression in colorectal cancer cells.\nIn ischemia/reperfusion (I/R) rats, MTH treatment significantly improved myocardial injury, attenuated myocardial infarction, and inhibited the mitochondrial apoptosis pathway.\nSTUB1-mediated downregulation of SLC25A10 suppressed OS cell proliferation and migration, indicating a tumor-suppressive role for STUB1 in OS through modulation of SLC25A10.\nSLC25A10 overexpression reversed the antitumor effects of PYCR1 silencing in vitro and inhibited the antitumor effects of erastin in vivo.\nTherefore, PYCR1 is an oncogenic gene that promotes colorectal", "dois": ["10.1016/j.cellsig.2025.111855", "10.1007/s12265-024-10503-z", "10.1007/s13577-022-00775-5", "PMID:16600197", "PMID:16291728", "10.3892/ol.2020.11863", "10.3390/antiox9050411", "10.1016/j.bcp.2013.02.013"]}
{"pair_type": "slc_pathway", "key1": "SLC25A11", "key2": "chemotherapy", "summary": "Genetic or pharmacological inhibition of the mitochondrial dicarboxylate carrier (SLC25A10) or the oxoglutarate-carrier (SLC25A11) increased the cytotoxic effects of ionizing radiation (IR).\nOthers and we have shown that adaptation of cancer cells to cycling severe hypoxia and intermittent reoxygenation stress (chronic-cycling hypoxia) increases cellular antioxidant capacity thereby supporting resistance to chemotherapy and radiotherapy.\nOur study reveals a role of SLC25A10 in supporting both, redox- and energy-homeostasis, ensuring radioresistance of cancer cells with tolerance to chronic-cycling hypoxia thereby proposing a novel strategy to overcome a mechanism of hypoxia-induced therapy resistance with potential clinical relevance regarding decreased patient survival.\nBut only targeting of SLC25A10 was effective in overcoming chronic-cycling hypoxia-induced enhanced death resistance in vitro and in vivo by disturbing increased antioxidant capacity.", "dois": ["10.1016/j.canlet.2018.09.002"]}
{"pair_type": "slc_pathway", "key1": "SLC25A10", "key2": "glycolysis", "summary": "We also show that OGC regulates mitochondrial respiration and glycolysis.", "dois": ["10.7554/eLife.94187", "PMID:25797253", "10.1016/j.redox.2017.08.022"]}
{"pair_type": "slc_pathway", "key1": "SLC25A10", "key2": "oxidative phosphorylation", "summary": "We propose that SLC25A10 loss-of-function causes pathological disarrangements in respiratory-demanding conditions and oxidative stress vulnerability.\nThe yeast SLC25A10 ortholog knockout strain showed defects in mitochondrial respiration and mitochondrial DNA content, similarly to what observed in the patient skeletal muscle, and growth susceptibility to oxidative stress.\nInhibition of electron transport chain complexes and oxidative phosphorylation worsened RSL3-induced ferroptosis.\nInhibition of DIC and OGC aggravated ferroptosis and increased mitochondrial ROS, membrane depolarization, and GSH depletion.\nIn conclusion, we suggest that ferroptotic stimuli diminishes mitochondrial bioenergetics and stimulates GSH depletion and glutathione peroxidase 4 inactivation leading to ferroptosis.\nGenetic and functional analyses conducted on patient fibroblasts showed that SLC25A10 mutations are associated with reduction in RNA quantity and aberrant RNA splicing, and to absence of SLC25A10 protein and its transporting function.\nMitochondria do not produce GSH, and although the transport of GSH to mitochondria is not fully understood, two carrier proteins, the dicarboxylate carrier (DIC, SLC25A10) and the oxoglutarate carrier (OGC, SLC25A11) have been suggested to participate in GSH transport.\nAlbeit patient fibroblasts were depleted in the main antioxidant molecules NADPH and glutathione, transport assays demonstrated that SLC25A10 is unable to transport glutathione.\nResults showed that mitochondria are highly sensitive to ferroptotic stimuli displaying fragmentation, and lipid peroxidation shortly after the onset of ferroptotic stimulus.", "dois": ["10.1093/hmg/ddx419", "PMID:25797253", "10.7554/eLife.94187", "10.1016/j.redox.2021.102021", "PMID:25945240"]}
{"pair_type": "slc_pathway", "key1": "SLC25A10", "key2": "migration", "summary": "Functional assays demonstrated that silencing SLC25A10 via shRNA or CRISPR/Cas9 significantly suppressed OS cell proliferation, migration, and mitochondrial function, resulting in mitochondrial membrane depolarization, oxidative damage, and apoptosis.\nSTUB1-mediated downregulation of SLC25A10 suppressed OS cell proliferation and migration, indicating a tumor-suppressive role for STUB1 in OS through modulation of SLC25A10.\nIn contrast, SLC25A10 overexpression promoted OS cell proliferation and migration.\nOur results demonstrated that SLC25A10 promotes cervical cancer cell growth, migration, and resistance to DDP.\nFunctional gain- and loss-of-function experiments demonstrated that SLC25A10 promotes tumor cell proliferation, migration, and invasion, while exacerbating mitochondrial dysfunction and impairing autophagic flux.\nMoreover, disruption of the SLC25A10/p62/KEAP1/Nrf2 signaling axis reactivated autophagy and inhibited PCa cell growth.\nShort hairpin RNA knockdown of SLC25A10 significantly suppressed cell proliferation as determined by cell counting, MTT assay and cell colony formation assays.\nIn vivo, knockout of SLC25A10 markedly inhibited the growth of subcutaneous OS xenografts in nude mice.", "dois": ["10.1038/s41420-025-02712-5", "10.1038/s41420-025-02528-3", "10.1016/j.cellsig.2025.111855", "10.3892/ol.2020.11863"]}
{"pair_type": "slc_pathway", "key1": "SLC25A11", "key2": "apoptosis", "summary": "Mechanistically, OTUD1 enhances NPC radiosensitivity by deubiquitinating and stabilizing SLC25A11, leading to increased Reactive oxygen species (ROS) and apoptosis.\nOur previous studies showed that overexpression of two mitochondrial anion transporters, the dicarboxylate (DIC, Slc25a10) and oxoglutarate (OGC, Slc25a11) carriers, in NRK-52E cells resulted in increased mitochondrial uptake of glutathione (GSH) and protection from chemically induced apoptosis.\nInhibition of OGC and DIC resulted in a significant decrease in mGSH and increased apoptosis.\nAdditionally, the expression of genes associated with mitochondria (NNT, TOMM40, and SLC25A11), energy metabolism (PCK1 and pdhC), inducing mitochondria-dependent apoptosis (NFKB1, RAC1, and TRAF2), and oxidative stress (GSTT1) was affected by BPA exposure.\nActivation of the caspase-3/9 pathway indicated a concentration-dependent, mitochondria-dependent apoptotic process.\nTUNEL staining demonstrated enhanced apoptotic signals with increasing BPA concentrations.\nTranscriptome analysis identified differentially expressed genes (DEGs) primarily enriched in energy metabolism and apoptosis pathways.\nPT cells from NPX rats that were first preincubated with GSH were protected from cytotoxicity due to the mitochondrial inhibitor antimycin A by overexpression of either of the two mitochondrial GSH transporters.\nClinically, low OTUD1 and SLC25A11 expression is associated with poor radiotherapy response and survival outcomes.\nThese findings provide insights into NPC radioresistance and suggest that using DAC in combination with radiotherapy to target the TFAP2C-OTUD1-SLC25A11 axis could be a promising strategy to overcome radioresistance.\nTransmission electron microscopy (TEM) analysis revealed mitochondrial injury and dysfunction as potential mechanisms of gill damage.\nIntegrated biomarker response version 2 (IBRv2) values further", "dois": ["10.1038/s41419-025-07858-9", "10.1016/j.aquatox.2025.107259", "PMID:16600197", "PMID:16291728", "10.3390/antiox9050411", "10.1016/j.bcp.2013.02.013"]}
{"pair_type": "slc_pathway", "key1": "SLC25A10", "key2": "proliferation", "summary": "Knockdown of SLC25A10 suppressed cell proliferation, induced senescence-associated β-galactosidase activity, and triggered G1 phase arrest by downregulating cyclin-dependent kinase 4 ()/ and upregulating cyclin-dependent kinase inhibitor 2A ().\nFunctional assays demonstrated that silencing SLC25A10 via shRNA or CRISPR/Cas9 significantly suppressed OS cell proliferation, migration, and mitochondrial function, resulting in mitochondrial membrane depolarization, oxidative damage, and apoptosis.\nSTUB1-mediated downregulation of SLC25A10 suppressed OS cell proliferation and migration, indicating a tumor-suppressive role for STUB1 in OS through modulation of SLC25A10.\nIn contrast, SLC25A10 overexpression promoted OS cell proliferation and migration.\nShort hairpin RNA knockdown of SLC25A10 significantly suppressed cell proliferation as determined by cell counting, MTT assay and cell colony formation assays.\nFunctional gain- and loss-of-function experiments demonstrated that SLC25A10 promotes tumor cell proliferation, migration, and invasion, while exacerbating mitochondrial dysfunction and impairing autophagic flux.\nMoreover, disruption of the SLC25A10/p62/KEAP1/Nrf2 signaling axis reactivated autophagy and inhibited PCa cell growth.\nSLC25A10 promotes HCC progression by suppressing cellular senescence.\nIn addition, SLC25A10 knockdown caused an increase in apoptosis and a decrease in mitosis in osteosarcoma cells.\nPharmacological or genetic inhibition of SLC25A10 triggers tumor suppression through HMGB1-mediated SASP signaling, positioning SLC25A10 as a promising therapeutic target for HCC intervention.\nIn vivo, knockout of SLC25A10 markedly inhibited the growth of subcutaneous OS xenografts in nude mice.\nMechanically, pharmacological inhibition of HMGB1 with NecroX-7 partially reversed the anti-proliferative and pro-senescent effects of SLC25A10 knockdown", "dois": ["10.21037/tcr-2024-2319", "10.1038/s41420-025-02528-3", "10.1016/j.cellsig.2025.111855", "10.2174/0113862073288546240528085144", "10.1007/s13577-022-00775-5", "10.3892/ol.2020.11863", "10.1155/2019/2951427", "10.1016/j.bcp.2013.02.013", "10.1371/journal.pone.0017715"]}
{"pair_type": "slc_pathway", "key1": "SLC25A11", "key2": "glycolysis", "summary": "Blocking malate transport by knockdown of SLC25A11 significantly impaired ATP production and inhibited the growth of cancer cells, which was not observed in normal cells.\nTherefore blocking SLC25A11 may have an advantage in stopping cancer growth by reducing ATP production.\nIn in vivo experiments, heterozygote of SLC25A11 knock out mice suppressed KRAS lung tumor formation by cross breeding.\nWe also show that OGC regulates mitochondrial respiration and glycolysis.\nCancer cells critically depended on the oxoglutarate carrier SLC25A11 for transporting NADH from cytosol to mitochondria as a malate form for the purpose of ATP production.\nWe have proposed that the oxoglutarate carrier SLC25A11 is important for ATP production in cancer by NADH transportation from the cytosol to mitochondria as a malate.\nThe concomitant down-regulation of all participating proteins (SLC25A11, SLC25A12, GOT2 and MDH2) of malate-aspartate shuttle might be responsible for the metabolic in-coordination between the cytosol and mitochondria resulting in the failure of energy metabolism.\nBioinformatics data mining and immunochemical validation of pivotal perturbed proteins revealed a global failure of the cellular energy metabolism in the infarcted tissues as seen by the parallel down-regulation of proteins related to glycolysis, pyruvate dehydrogenase complex, TCA cycle and oxidative phosphorylation.", "dois": ["10.7554/eLife.94187", "10.1016/j.ebiom.2019.01.036", "10.1016/j.redox.2017.08.022", "10.1016/j.jprot.2013.08.017"]}
{"pair_type": "slc_pathway", "key1": "SLC25A10", "key2": "oxidative stress", "summary": "Slc25a10-Hepa1-6 cells showed disordered glucose homeostasis, increased oxidative stress levels, and damaged electron transport chains.\nWe propose that SLC25A10 loss-of-function causes pathological disarrangements in respiratory-demanding conditions and oxidative stress vulnerability.\nThe yeast SLC25A10 ortholog knockout strain showed defects in mitochondrial respiration and mitochondrial DNA content, similarly to what observed in the patient skeletal muscle, and growth susceptibility to oxidative stress.\nthe decreased glucose metabolism, severe oxidative stress and damaged electron transport chain were recovered.\nCompensatory renal hypertrophy following reduction in renal mass leads to a hypermetabolic state and increases in basal mitochondrial oxidative stress and susceptibility to several nephrotoxicants.\nAnalysis of the hippocampus performed 6 months after the exposure revealed increased expression of many genes related to oxidative stress response and/or antioxidant activity (, and ), reactive oxygen species metabolism (, and ) and oxygen transport ( and ).\nOur previous studies showed that overexpression of two mitochondrial anion transporters, the dicarboxylate (DIC, Slc25a10) and oxoglutarate (OGC, Slc25a11) carriers, in NRK-52E cells resulted in increased mitochondrial uptake of glutathione (GSH) and protection from chemically induced apoptosis.\nOGC but not DIC downregulation by siRNA depleted mGSH levels and sensitized HCC cells to hypoxia-induced ROS generation and cell death as well as impaired cell growth in three-dimensional multicellular HCC spheroids, effects that were reversible upon mGSH replenishment by GSH ethyl ester, a membrane permeable GSH precursor.\nPT cells from NPX rats that were first preincubated with GSH were protected from cytotoxicity due to the mitochondrial inhibitor antimycin A by overexpression of either of the two mitochondrial GSH transporters.\nAdditionally, 101 DMPs were suggestively significant (p-values <1 × 10) and annotated to genes involved in glucocorticoid-related pathways, inflammatory response, oxidative", "dois": ["10.1093/hmg/ddx419", "10.1016/j.redox.2017.08.022", "PMID:25797253", "10.1016/j.abb.2008.03.008", "PMID:16600197", "10.1186/s12967-025-06976-4", "10.1007/s11306-025-02318-z", "10.1016/j.envres.2025.121286", "10.1016/j.bbamcr.2019.03.016", "10.3389/fnmol.2017.00182", "10.3390/jcm4071428", "10.1016/j.bcp.2013.02.013"]}
{"pair_type": "slc_pathway", "key1": "SLC25A11", "key2": "migration", "summary": "Loss of OGC promoted cell proliferation and migration through Slug-mediated EMT.\nOGC silencing aggravated EMT, while overexpression attenuated TGF-β2-induced EMT, cell proliferation, and migration.\nOGC knockdown significantly enhanced RPE EMT, as evidenced by upregulated expression of α-SMA, fibronectin, collagen type I, and Slug, while E-cadherin was downregulated.\nOGC depletion stimulated EMT via pSmad2/3 upregulation, dependent on the PI3K/AKT signaling pathway activation.\nIn vivo studies further demonstrate that subretinal fibrosis was significantly augmented in OGC mice via TGF-β2-dependent PI3K signaling.\nmodulating OGC expression in RPE affects EMT and mitochondrial function, making OGC a potential therapeutic target for subretinal fibrosis in nAMD.\nEpithelial-to-mesenchymal transition (EMT) in RPE cells is a key early step in subretinal fibrosis.", "dois": ["10.1111/acel.70271"]}
{"pair_type": "slc_pathway", "key1": "SLC25A12", "key2": "oxidative stress", "summary": "Therefore, excessive Ca(2+) levels are responsible for boosting AGC activity, mitochondrial metabolism and, to a more variable degree, oxidative stress in autistic brains.\nFurthermore, oxidized mitochondrial proteins were markedly increased in four of the six patients.\nExpression of AGC1, the predominant AGC isoform in brain, and cytochrome c oxidase activity were both increased in autistic patients, indicating an activation of mitochondrial metabolism.\nAGC and altered Ca(2+) homeostasis play a key interactive role in the cascade of signaling events leading to autism: their modulation could provide new preventive and therapeutic strategies.\nAGC transport rates were significantly higher in tissue homogenates from all six patients, including those with no history of seizures and with normal electroencephalograms prior to death.\nneocortical Ca(2+) levels were significantly higher in all six patients;", "dois": ["10.1038/mp.2008.63", "10.3233/JND-190421"]}
{"pair_type": "slc_pathway", "key1": "SLC25A12", "key2": "ferroptosis", "summary": "SLC25A12 was identified as a key mediator of arsenic-induced islet β-cell dysfunction and ferroptosis.\nThus, SLC25A12-mediated glutamate translocation and MtROS generation contributed to NaAsO-triggered islet β-cell dysfunction and ferroptosis.\nMechanistically, SLC25A12 suppression inhibited glutamate transport from the cytoplasm to mitochondria and decreased MtROS levels by alleviating mitochondrial dysfunction.", "dois": ["10.1016/j.ecoenv.2025.119351"]}
{"pair_type": "slc_pathway", "key1": "SLC25A11", "key2": "oxidative phosphorylation", "summary": "The concomitant down-regulation of all participating proteins (SLC25A11, SLC25A12, GOT2 and MDH2) of malate-aspartate shuttle might be responsible for the metabolic in-coordination between the cytosol and mitochondria resulting in the failure of energy metabolism.\nBioinformatics data mining and immunochemical validation of pivotal perturbed proteins revealed a global failure of the cellular energy metabolism in the infarcted tissues as seen by the parallel down-regulation of proteins related to glycolysis, pyruvate dehydrogenase complex, TCA cycle and oxidative phosphorylation.\nAccording to co-expression network studies, SLC25A11, SLC25A29, and SLC25A44 were involved in the energy metabolism of PC and prevented tumor growth, invasion, and metastasis.\nThe high-risk group had a lower activation of oxidative phosphorylation and a more abundant immune infiltration phenotype than the low-risk group.\nMitochondria do not produce GSH, and although the transport of GSH to mitochondria is not fully understood, two carrier proteins, the dicarboxylate carrier (DIC, SLC25A10) and the oxoglutarate carrier (OGC, SLC25A11) have been suggested to participate in GSH transport.\nInhibition of electron transport chain complexes and oxidative phosphorylation worsened RSL3-induced ferroptosis.", "dois": ["10.7554/eLife.94187", "10.1186/s12967-022-03756-2", "10.1016/j.redox.2021.102021", "10.1016/j.jprot.2013.08.017"]}
{"pair_type": "slc_pathway", "key1": "SLC25A15", "key2": "apoptosis", "summary": "Furthermore, SLC25A15 siRNA was able to promote apoptosis of A375 cells, which exhibited decreased expression levels of the anti-apoptotic protein Bcl-2 while showing increased pro-apoptotic protein Bax and cleaved caspase-3.\nIn conclusion, circFOXO3 acts as a miR-29a-3p sponge to exhibit oncogenic activity that affects the cell cycle and cell apoptosis in PCa through transcriptional up-regulation of SLC25A15.\nKnock-down circFOXO3 could remarkably inhibit PCa cell cycle, proliferation and promote cell apoptosis in vitro.\nSLC25A15 could reverse the tumour suppressing roles of knock-down circFOXO3 in PCa.\nKnockdown the expression of SLC25A15 by siRNA could effectively inhibit the proliferation of A375 melanoma cells, as detected by CCK8 and colony formation.", "dois": ["10.1111/jcmm.14791", "10.1186/s12935-023-03082-7", "10.1051/medsci/201834f113"]}
{"pair_type": "slc_pathway", "key1": "SLC25A11", "key2": "oxidative stress", "summary": "Additionally, the expression of genes associated with mitochondria (NNT, TOMM40, and SLC25A11), energy metabolism (PCK1 and pdhC), inducing mitochondria-dependent apoptosis (NFKB1, RAC1, and TRAF2), and oxidative stress (GSTT1) was affected by BPA exposure.\nDuring AAA formation, NETs regulate the stability of the mitochondrial carrier protein SLC25A11, leading to the depletion of mitoGSH and subsequent activation of NET-induced ferroptosis of SMCs.\nFurthermore, NETs decreased the stability and dimerization of SLC25A11, leading to the depletion of mitoGSH.\nNeutrophil extracellular traps (NETs) induce oxidative stress, which may initiate ferroptosis, an iron-dependent programmed cell death, during abdominal aortic aneurysm (AAA) formation.\nCompensatory renal hypertrophy following reduction in renal mass leads to a hypermetabolic state and increases in basal mitochondrial oxidative stress and susceptibility to several nephrotoxicants.\nOur previous studies showed that overexpression of two mitochondrial anion transporters, the dicarboxylate (DIC, Slc25a10) and oxoglutarate (OGC, Slc25a11) carriers, in NRK-52E cells resulted in increased mitochondrial uptake of glutathione (GSH) and protection from chemically induced apoptosis.\nOGC but not DIC downregulation by siRNA depleted mGSH levels and sensitized HCC cells to hypoxia-induced ROS generation and cell death as well as impaired cell growth in three-dimensional multicellular HCC spheroids, effects that were reversible upon mGSH replenishment by GSH ethyl ester, a membrane permeable GSH precursor.\nThis depletion induced the ferroptosis of SMCs and promoted AAA formation.\nPT cells from NPX rats that were first preincubated with GSH were protected from cytotoxicity due to the mitochondrial inhibitor antimycin A by overexpression of either of the two mitochon", "dois": ["10.1016/j.freeradbiomed.2024.05.036", "10.1016/j.redox.2017.08.022", "10.1016/j.abb.2008.03.008", "PMID:16600197", "10.1016/j.aquatox.2025.107259", "10.3390/jcm4071428", "10.1016/j.bcp.2013.02.013"]}
{"pair_type": "slc_pathway", "key1": "SLC25A13", "key2": "proliferation", "summary": "Furthermore, in vitro and in vivo experiments demonstrated that SLC25A13 is significantly overexpressed in glioblastoma tissues compared to paraneoplastic tissues, promoting glioblastoma cell proliferation and migration while inhibiting apoptosis.\nMechanistically, NAT8L downregulation triggers aspartate outflow from mitochondria via the exporter SLC25A13 to promote glucose flux into the pentose phosphate pathway, boosting purine biosynthesis.\nOverall, this work demonstrates that NAT8L expression in liver cells limits the cytosolic availability of aspartate necessary for enhancing the pentose phosphate pathway and purine biosynthesis, counteracting cell proliferation.\nThese results suggest that the increased cytoplasmic supply of either carbamylphosphate, produced by CPS1, or aspartate may be sufficient to promote tumorigenesis, as well as the need for an alternative explanation of CPS1 activity in the absence of expression and NAG.\nAberrant overexpression of carbamylphosphate synthetase 1 () and (citrin) genes has been associated with faster proliferation of tumor cells due to metabolic reprogramming that increases the activity of the CAD complex and pyrimidine biosynthesis.\nWe demonstrated that NAT8L downregulation is associated with increased proliferation of hepatocellular carcinoma cells and immortalized hepatocytes.\nThe overexpression of NAT8L instead decreased cell growth.\nSpecifically, aspartate represents a limiting amino acid for nucleotide synthesis in cancer.\nThe pro-tumoral effect of NAT8L silencing depended on glutamine oxidation and the rewiring of glucose metabolism.\nA20 overexpression impacted 1595 genes that were enriched for biological processes related to inflammatory and immune responses, cellular proliferation, energy production, oxidoreductase activity, and lipid and fatty acid metabolism.\nThese pathways were modulated by A20 in a manner that favored decreased inflammation, heightened proliferation, and optimized metabolic control and energy production.\nFunctional experiments confirmed that knockdown inhibited cell proliferation and migration, induced apoptosis, and enhanced the efficacy of immunotherapy in LUAD.\nOur findings showed that upregulated NDUFB7", "dois": ["10.21037/tlcr-2025-204", "10.1186/s12935-025-03696-z", "10.1016/j.heliyon.2024.e35663", "10.3390/ijms24076754", "10.1016/j.redox.2022.102585", "10.3390/diseases8010002", "10.1111/asj.13212", "10.1097/SHK.0000000000000214", "10.1371/journal.pone.0017715"]}
{"pair_type": "slc_pathway", "key1": "SLC25A16", "key2": "ferroptosis", "summary": "Differentially spliced SLCs were enriched in biological processes, including transmembrane transporter activity, transporter activity, ferroptosis, and choline metabolism.\nIn patients with COAD, tumor tissues exhibited higher expression of longer mitochondrial carrier SLC25A16 isoforms than adjacent normal tissues, consistent with bioinformatics analysis.", "dois": ["10.1111/cas.16351"]}
{"pair_type": "slc_pathway", "key1": "SLC25A16", "key2": "oxidative phosphorylation", "summary": "The ADP/ATP carrier (AAC) is crucial for mitochondrial functions by importing ADP and exporting ATP across the inner mitochondrial membrane.", "dois": ["10.1016/j.csbj.2022.03.032"]}
{"pair_type": "slc_pathway", "key1": "SLC25A13", "key2": "oxidative phosphorylation", "summary": "Indeed, we find that citrin is upregulated in multiple cancer types and is essential for supplementing NAD+ for glycolysis and NADH for oxidative phosphorylation.\nCitrin, encoded by SLC25A13 gene, is an inner mitochondrial transporter that is part of the malate-aspartate shuttle, which regulates the NAD+/NADH ratio between the cytosol and mitochondria.\nConsequently, citrin deficiency associates with autophagy, whereas its overexpression in cancer cells increases energy production and cancer invasion.\nThe association of citrin with glycolysis and NAD+/NADH ratio led us to hypothesize that it may play a role in carcinogenesis.\nClinical symptoms can be traced back to disruption of the malate-aspartate shuttle due to the lack of citrin.", "dois": ["10.1038/s41388-019-0976-2", "10.1016/j.ymgmr.2023.100967"]}
{"pair_type": "slc_pathway", "key1": "SLC25A11", "key2": "stemness", "summary": "Additionally, siRNA-mediated SLC25A11 knockdown and KN612-mediated MAS inhibition decreased the oxygen consumption rate, ATP levels, mitochondrial activity, and cell viability in GBM TSs and decreased the stemness and invasion ability of GBM cells.", "dois": ["10.1186/s12935-025-03813-y"]}
{"pair_type": "slc_pathway", "key1": "SLC25A14", "key2": "oxidative stress", "summary": "Knocking out DJ-1 (also known as PARK7 in humans and Park7 in mice), which is a gene associated with an early-onset form of Parkinson's disease, downregulated the expression of two uncoupling proteins (UCP4 (SLC25A27) and UCP5 (SLC25A14)), compromised calcium-induced uncoupling and increased oxidation of matrix proteins specifically in SNc dopaminergic neurons.\nThe engagement of plasma membrane L-type calcium channels during normal autonomous pacemaking created an oxidant stress that was specific to vulnerable SNc dopaminergic neurons.\nThe oxidant stress engaged defences that induced transient, mild mitochondrial depolarization or uncoupling.", "dois": ["10.1038/nature09536"]}
{"pair_type": "slc_pathway", "key1": "SLC25A14", "key2": "apoptosis", "summary": "Different clusters of genes associated with apoptosis, signal transduction, energy metabolism, lipid metabolism, etc., such as FXR1, PHLDA1, MAEA, PIK3R1, ICAM2, PITPN, CALM2, CAMK2D, PKIA, DRD2, SLC25A14, CKB, AADAC, LIPA, ACOX3, FADS1, were concerned.\nThe expression of DNAJC19, DNM1L, LRPPRC, SLC25A12, SLC25A14, SLC25A24 and TOMM20 were reduced in at least two of the brain regions of autism patients.\nQuantitative real-time PCR arrays were used to quantify the expression of 84 genes related to diverse functions of mitochondria, including biogenesis, transport, translocation and apoptosis.", "dois": ["10.1186/2040-2392-3-12", "10.1016/j.peptides.2008.06.024", "PMID:16111824"]}
{"pair_type": "slc_pathway", "key1": "SLC25A13", "key2": "oxidative stress", "summary": "In vitro, miR-509-3p significantly decreased SLC25A13 expression, resulting in enhanced HRVEC viability, reduced apoptosis, and lower ROS levels under HG conditions.\nOverexpression of SLC25A13 reversed these protective effects, while miR-509-3p knockdown exacerbated oxidative stress and apoptosis.\nmiR-509-3p exerts a protective effect in DR by targeting SLC25A13, reducing oxidative stress, apoptosis, and ferroptosis in retinal endothelial cells.\nFerroptosis marker analysis revealed that miR-509-3p upregulated GPX4 expression and downregulated TlR4 and ASCL4, whereas SLC25A13 overexpression reversed these effects, further linking miR-509-3p to the regulation of ferroptosis.\nThe aim of this study was to investigate the regulatory role of miR-509-3p in DR, focusing on its interaction with SLC25A13 and its impact on retinal endothelial cell function, oxidative stress, apoptosis, and ferroptosis.\nThese results indicate that reduced expression of SLC25A3 in fatty liver contributes to electron leak from mitochondria by limiting Cu availability, rendering hepatocytes more susceptible to oxidative stress.\nC1 and C3 cells were prone to produce reactive oxygen species (ROS), and increased ROS was associated with reduced mRNA expression of glutathione peroxidase (GPX) 1 and glutathione disulfide reductase (GSX) in these cell lines.\nSLC25A3 deficiency had insignificant effect on mitochondrial membrane potential (MtMP) and oxygen consumption rate (OCR) in untreated cells but suppressed them when cells were exposed to oleic acid.\nMitochondrial dysfunction causes oxidative stress, triggering hepatocyte death and inflammation.\nFirstly, we established a high fat diet (HFD)-fed ICR mouse NAFLD model characterized by obesity with insulin resistance and found transcriptional upregulation of Slc25a17 and downregulation of Slc25a3 (isoform B) and Slc25a13 in their", "dois": ["10.1007/s00592-024-02400-3", "10.1016/j.yexcr.2023.113740"]}
{"pair_type": "slc_pathway", "key1": "SLC25A17", "key2": "apoptosis", "summary": "Furthermore, the pro-apoptotic effect of SLC25A17 knockdown was reversed when treated with autophagy inhibitor 3-MA in TNBC cells, suggesting that SLC25A17 knockdown-induced autophagic cell death.\nOn the other hand, SLC25A17 knockdown promoted autophagy through triggering ROS accumulation, which was counteracted by N-acetyl-l-cysteine (NAC).\nMoreover, it prompted apoptosis and autophagy.\nFunctional assays demonstrated that SLC25A17 knockdown suppressed proliferation, epithelial-mesenchymal transition (EMT), migration, and invasion.\nIn a nude mice xenograft study, SLC25A17 knockdown markedly decreased breast tumor growth and metastasis.\nMechanistically, SLC25A17 performed its function through regulation JAK2/STAT3 signaling in TNBC.\nSLC25A17 up-regulation may be a critical factor driving TNBC progression by modulating ROS production and autophagy.\nConsequently, targeting SLC25A17 could be an effective therapeutic strategy against TNBC.\nSLC25A17 was highly expressed in breast cancer tissues, which was found to be associated with unfavorable prognosis.\nAdditionally, SLC25A17 overexpression exacerbates lipid accumulation in A549 cells by activating the janus kinase 2/signal transducer and activator of transcription 3 (JAK2/STAT3) pathway, while AG490, a JAK2 inhibitor, eliminates this effect.\nUpregulated PEX3 promotes abnormal lipid metabolism in LUAD cells by interacting with solute carrier family 25 member 17 (SLC25A17) to upregulate its protein levels.", "dois": ["10.1016/j.taap.2025.117534", "10.1186/s12935-024-03270-z"]}
{"pair_type": "slc_pathway", "key1": "SLC25A15", "key2": "migration", "summary": "", "dois": ["10.1186/s12935-023-03082-7"]}
{"pair_type": "slc_pathway", "key1": "SLC25A16", "key2": "proliferation", "summary": "In patients with COAD, tumor tissues exhibited higher expression of longer mitochondrial carrier SLC25A16 isoforms than adjacent normal tissues, consistent with bioinformatics analysis.\nKnockdown of the intronic region of SLC7A6-RI isoform enhanced colon cancer cell proliferation.\nsi-SLC7A6-RI isoform exerted oncogenic effects by activating the PI3K-Akt-mTOR signaling pathway and promoting cell proliferation, evidenced by increased expression of key regulators Phosphorylated Mammalian Target of Rapamycin (p-mTOR) and a cell proliferation marker Proliferating Cell Nuclear Antigen (PCNA) using western blotting.\nIn vivo, knockdown of the intronic region of SLC7A6-RI isoform enhanced tumor growth in colon cancer.", "dois": ["10.1111/cas.16351"]}
{"pair_type": "slc_pathway", "key1": "SLC25A13", "key2": "migration", "summary": "Furthermore, in vitro and in vivo experiments demonstrated that SLC25A13 is significantly overexpressed in glioblastoma tissues compared to paraneoplastic tissues, promoting glioblastoma cell proliferation and migration while inhibiting apoptosis.\nFunctional experiments confirmed that knockdown inhibited cell proliferation and migration, induced apoptosis, and enhanced the efficacy of immunotherapy in LUAD.", "dois": ["10.21037/tlcr-2025-204", "10.1186/s12935-025-03696-z"]}
{"pair_type": "slc_pathway", "key1": "SLC25A17", "key2": "migration", "summary": "sgRNA-mediated knockdown of SLC25A17 and SLC27A6 suppressed cell proliferation and migration in enzalutamide-resistant cells.\nFunctional assays demonstrated that SLC25A17 knockdown suppressed proliferation, epithelial-mesenchymal transition (EMT), migration, and invasion.\nIn a nude mice xenograft study, SLC25A17 knockdown markedly decreased breast tumor growth and metastasis.\nSLC25A17 up-regulation may be a critical factor driving TNBC progression by modulating ROS production and autophagy.\nSLC25A17 was highly expressed in breast cancer tissues, which was found to be associated with unfavorable prognosis.\nAnalysis of The Cancer Genome Atlas database exhibiting high SLC25A17 and SLC27A6 gene expression in prostate cancer patients were associated with poor survival than those with low expression of these proteins.\nOn the other hand, SLC25A17 knockdown promoted autophagy through triggering ROS accumulation, which was counteracted by N-acetyl-l-cysteine (NAC).\nFurthermore, the pro-apoptotic effect of SLC25A17 knockdown was reversed when treated with autophagy inhibitor 3-MA in TNBC cells, suggesting that SLC25A17 knockdown-induced autophagic cell death.\nMechanistically, SLC25A17 performed its function through regulation JAK2/STAT3 signaling in TNBC.\nConsequently, targeting SLC25A17 could be an effective therapeutic strategy against TNBC.\nIn conclusion, SLC25A17 and SLC27A6 and its interactive network play an essential role in the development of enzalutamide resistance through metabolic reprogramming and may be identified as therapeutic target(s) to circumvent drug resistance.\nInhibition of SLC25A17 and SLC27A6 resulted in downregulation of fatty acid synthase and acetyl-CoA carboxylase with parallel decrease in the levels of lactic acid in enzalutamide resistant cells.\nAn induction of G1/S cell cycle arrest and abundance of hypo-diploid cells along with the reduction in the", "dois": ["10.1186/s12935-024-03270-z", "10.1002/mc.23383"]}
{"pair_type": "slc_pathway", "key1": "SLC25A15", "key2": "oxidative stress", "summary": "Oxidative stress can promote cancer by increasing mutagenicity, genomic instability, cell survival, proliferation, and stress resistance pathways.\nBoth transcriptional and translational levels of ANXA5, APOD, and SLC25A15 exhibited significantly higher in STAD samples.\nSubsequently, 743 STAD samples were categorized into three clusters with the enrichment scores being C2 (upregulated) > C3 (normal) > C1 (downregulated).\nOxidative metabolic score significantly correlates with immune cells and immune checkpoints.\nAs a direct and indirect result of oncogenic mutations, cancer depends on cellular metabolic reprogramming.\nPan-cancer analysis concluded and highlighted the crucial part of OMRGs in the appearance and development of STAD.", "dois": ["10.3389/fendo.2023.1090906"]}
{"pair_type": "slc_pathway", "key1": "SLC25A15", "key2": "stemness", "summary": "A stemness-based signature based on 9 genes (ERCC6L, IQCC, NKAPD1, BLMH, SLC25A15, MRPL4, VPS35, SUMO3, and CINP) was constructed with good performance in prognosis prediction, and its robustness was validated in GSE26942 cohort.\nTumor stemness is related to intratumoral heterogeneity, immunosuppression, and anti-tumor resistance.\nThe stemness score showed a negative relationship to tumor immune dysfunction and exclusion (TIDE) score and immune infiltration, especially T cells and B cells.\nWe downloaded single-cell RNA sequencing (scRNA-seq) data of GC patients from the Gene-Expression Omnibus (GEO) database and screened GC stemness- related genes using CytoTRACE.\nWe developed a prognostic model with stemness-correlated genes to evaluate prognosis and immunotherapy responsiveness in GC.\nEarly GC patients had significantly higher levels of stemness.\nHigh-risk patients exhibited a tendency to develop immune escape and low response to PD-L1 immunotherapy.", "dois": ["10.2174/0109298673278775231101064235"]}
{"pair_type": "slc_pathway", "key1": "SLC25A17", "key2": "chemotherapy", "summary": "Moreover, patients in the high-expression group were more sensitive to chemotherapy.\nFor patients with high SLC25A17 expression, the OS and PFS were shorter than those with low SLC25A17 expression, indicating a worse prognosis.\nPatients in the low-expression group exhibited more immune cell infiltration, higher TME scores, higher IPS scores and lower TIDE scores than those in the high-expression groups, suggesting better immunotherapeutic response with lower SLC25A17 expression.\nSLC25A17 can effectively predict the prognosis of HNSCC patients and could be a precise individual-targeted indicator for the treatment of HNSCC patients.\nUnivariate Cox and multivariate COX analyses showed that SLC25A17, age, and lymph node metastasis are independent prognostic risk factors for HNSCC, and the survival prediction model based on these factors had reliable predictive value.", "dois": ["10.1186/s12859-023-05399-6"]}
{"pair_type": "slc_pathway", "key1": "SLC25A15", "key2": "proliferation", "summary": "Knockdown the expression of SLC25A15 by siRNA could effectively inhibit the proliferation of A375 melanoma cells, as detected by CCK8 and colony formation.\nSLC25A15 could reverse the tumour suppressing roles of knock-down circFOXO3 in PCa.\nIn conclusion, circFOXO3 acts as a miR-29a-3p sponge to exhibit oncogenic activity that affects the cell cycle and cell apoptosis in PCa through transcriptional up-regulation of SLC25A15.\nAll these results suggest that the overexpression of SLC25A15 is involved in the progression of melanoma and may predict the prognosis of melanoma.\nFurthermore, SLC25A15 siRNA was able to promote apoptosis of A375 cells, which exhibited decreased expression levels of the anti-apoptotic protein Bcl-2 while showing increased pro-apoptotic protein Bax and cleaved caspase-3.\nDual targeting of SLC6A14 and either SLC25A15 or SLC12A4 diminishes serine uptake and growth of colorectal cancer cells in vitro and in vivo, particularly in cells with compromised de novo serine biosynthesis.\nWe identify SLC6A14 and SLC25A15 as major cytoplasmic and mitochondrial serine transporters, respectively.\nUsing bioinformatics methods to screen the data from TCGA and GEO, we found that SLC25A15 is overexpressed in patients with melanoma and negatively related with the overall and disease-free survival rates.\nhowever, SLC25A15 was overexpressed in PCa samples compared with normal tissues.\nFurthermore, we demonstrated circFOXO3 could act as miR-29a-3p sponge to up-regulate SLC25A15 expression by bioinformatics analysis, dual-luciferase reporter assays and biotinylated RNA pull-down assays.\nIn this study, we have investigated the effect of SLC25A15, which encodes the mitochondrial ornithine carrier 1, on melanoma progression.\nTargeting glutamine pathway selectively suppressed the proliferation of", "dois": ["10.1038/s42255-023-00936-2", "10.1186/s12935-023-03082-7", "10.3389/fendo.2023.1090906", "10.1111/jcmm.14791", "10.1051/medsci/201834f113", "10.1186/s13046-018-0872-6"]}
{"pair_type": "slc_pathway", "key1": "SLC25A15", "key2": "oxidative phosphorylation", "summary": "Comparative analyses of these DEPs revealed downregulated expression of specific proteins with well-established links to tumor metastasis, such as SLC25A15, DIRAS2, PLA2R1, and MTARC1.\nThe metastasis-related DEPs were primarily enriched in categories associated with mitochondrial dysfunction and may promote tumor progression by activating oxidative phosphorylation and PI3K/AKT signaling pathways.", "dois": ["10.3389/fonc.2022.887977"]}
{"pair_type": "slc_pathway", "key1": "SLC25A17", "key2": "oxidative stress", "summary": "These include genes with a potential role in protection against oxidative stress (Dhcr24, Cdo1, Akr1b7, Prdx6), inflammation (Ltb4dh, Wdr1), ion transport (Pdzk1ip1, Slc12a2, Slc25a17) and transcription (Zfp36l3, Pdzk1ip1).\nThese results indicate that reduced expression of SLC25A3 in fatty liver contributes to electron leak from mitochondria by limiting Cu availability, rendering hepatocytes more susceptible to oxidative stress.\nMitochondrial dysfunction causes oxidative stress, triggering hepatocyte death and inflammation;\nTitle: An implication of the mitochondrial carrier SLC25A3 as an oxidative stress modulator in NAFLD.\nThis study provides evidence that SLC25A3 is a novel risk factor for developing NASH.\nFirstly, we established a high fat diet (HFD)-fed ICR mouse NAFLD model characterized by obesity with insulin resistance and found transcriptional upregulation of Slc25a17 and downregulation of Slc25a3 (isoform B) and Slc25a13 in their fatty liver.\nSLC25A3 deficiency had insignificant effect on mitochondrial membrane potential (MtMP) and oxygen consumption rate (OCR) in untreated cells but suppressed them when cells were exposed to oleic acid.\nInterestingly, cytoplasmic and mitochondrial Cu accumulation significantly reduced in C1 cells, demonstrating a predominant contribution of SLC25A3 to Cu transport into mitochondrial matrix.\nA mitochondrial phosphate and Cu carrier, SLC25A3, was further studied in wild-type (wt) and SLC25A3-defective HepG2 cells (C1 and C3).\nC1 and C3 cells were prone to produce reactive oxygen species (ROS), and increased ROS was associated with reduced mRNA expression of glutathione peroxidase (GPX) 1 and glutathione disulfide re", "dois": ["10.1016/j.yexcr.2023.113740", "10.1016/j.exer.2008.06.001"]}
{"pair_type": "slc_pathway", "key1": "SLC25A12", "key2": "apoptosis", "summary": "The expression of DNAJC19, DNM1L, LRPPRC, SLC25A12, SLC25A14, SLC25A24 and TOMM20 were reduced in at least two of the brain regions of autism patients.\nQuantitative real-time PCR arrays were used to quantify the expression of 84 genes related to diverse functions of mitochondria, including biogenesis, transport, translocation and apoptosis.\nSeveral genes showed brain region-specific expression alterations in autism patients compared to controls.", "dois": ["10.1186/2040-2392-3-12"]}
{"pair_type": "slc_pathway", "key1": "SLC25A18", "key2": "apoptosis", "summary": "Reducing SLC25A18 expression attenuated mitochondrial dysfunction and neuronal apoptosis caused by Aβ42.\nOverexpression of SLC25A18 increased ATP and intracellular superoxide anions but decreased mitochondrial membrane potential.\nThe results indicate that SLC25A18 affects mitochondrial function and neuronal apoptosis, and is related to AD, which makes it a potential target for treating brain dysfunction.\nFunctional enrichment analysis demonstrated that the pathogenesis of HF is closely related to the inflammatory response, immune response, vascular regulation, the Wnt signaling pathway, glutathione metabolism, sphingolipid metabolism, and apoptosis.\nNext, We found that Aβ42 treatment elevated SLC25A18 expression in Neuro 2A cells.\nIn this study, we further analysed Gene Expression Omnibus (GEO) data and discovered that the expression of the Mitochondria glutamate carrier SLC25A18 is associated with AD by screening the differentially expressed genes in different regions of the brains of Alzheimer's disease patients.\nTo verify the expression of SLC25A18 during Alzheimer's disease development, we analysed animal models (5×FAD transgenic AD animal model, chemically induced AD animal model, natural ageing animal model), and the results showed that the expression of SLC25A18 was increased in animal models of AD.\nFurther investigation of the different regions found that SLC25A18 expression was elevated in the EC, TeA, and CA3, and expressed in neurons.", "dois": ["10.1016/j.mito.2024.101918", "10.3389/fgene.2025.1618390"]}
{"pair_type": "slc_pathway", "key1": "SLC25A17", "key2": "proliferation", "summary": "sgRNA-mediated knockdown of SLC25A17 and SLC27A6 suppressed cell proliferation and migration in enzalutamide-resistant cells.\nFunctional assays demonstrated that SLC25A17 knockdown suppressed proliferation, epithelial-mesenchymal transition (EMT), migration, and invasion.\nSLC25A17 inhibits autophagy to promote triple-negative breast cancer tumorigenesis by ROS-mediated JAK2/STAT3 signaling pathway.\nFurthermore, the pro-apoptotic effect of SLC25A17 knockdown was reversed when treated with autophagy inhibitor 3-MA in TNBC cells, suggesting that SLC25A17 knockdown-induced autophagic cell death.\nOn the other hand, SLC25A17 knockdown promoted autophagy through triggering ROS accumulation, which was counteracted by N-acetyl-l-cysteine (NAC).\nUpregulated PEX3 promotes abnormal lipid metabolism in LUAD cells by interacting with solute carrier family 25 member 17 (SLC25A17) to upregulate its protein levels.\nInhibition of SLC25A17 and SLC27A6 resulted in downregulation of fatty acid synthase and acetyl-CoA carboxylase with parallel decrease in the levels of lactic acid in enzalutamide resistant cells.\nAdditionally, SLC25A17 overexpression exacerbates lipid accumulation in A549 cells by activating the janus kinase 2/signal transducer and activator of transcription 3 (JAK2/STAT3) pathway, while AG490, a JAK2 inhibitor, eliminates this effect.\nIn conclusion, our study demonstrates that USF2 overexpression enhances SLC25A17-mediated JAK2/STAT3 signaling by promoting PEX3 transcriptional activation, thereby exacerbating abnormal lipid metabolism in A549 cells and accelerating LUAD progression.\nIn a nude mice xenograft study, SLC25A17 knockdown markedly decreased breast tumor growth and metastasis.", "dois": ["10.1016/j.taap.2025.117534", "10.1186/s12935-024-03270-z", "10.1002/mc.23383"]}
{"pair_type": "slc_pathway", "key1": "SLC25A19", "key2": "chemotherapy", "summary": "angiogenesis promoting factors, cell growth and proliferation-associated genes signal transducers and kinases) are also implicated in clinical responsiveness of tumors towards chemotherapy.\nAmong the genes identified by this approach were genes from diverse functional groups such as structural constituents of ribosomes (RPL6, RPL7, RPS12, RPS15A), kinases (CABC1, CCT2, RPL41), transcriptional and translational regulators (SFRS2, TUFM, ZBTB4), signal transducers (FLNA), control of cell growth and proliferation (RPS6), angiogenesis promoting factors (ITGB1), and others (SLC25A19, NCKAP1, BST1, DBH, FZD7, NACA, MTHFD2).\nIn conclusion, our pharmacogenomic approach revealed that response of tumor cells towards ART is multi-factorial and is determined by gene expression associated with either ART sensitivity or resistance.", "dois": ["10.1016/j.cbi.2010.02.002"]}
{"pair_type": "slc_pathway", "key1": "SLC25A19", "key2": "glycolysis", "summary": "SLC25A19 deficiency leads to reduced cell viability, increased integrated stress response (ISR), enhanced glycolysis and elevated cell sensitivity to 2-deoxyglucose (2-DG) treatment.", "dois": ["10.1016/j.freeradbiomed.2024.06.019"]}
{"pair_type": "slc_pathway", "key1": "SLC25A19", "key2": "ferroptosis", "summary": "In vitro experiments have confirmed that silencing SLC25A19 can significantly inhibit the proliferation and migration ability of cancer cells and induce ferroptosis in HCC.\nThe results of gene enrichment analyses showed that SLC25A19 is significantly correlated with immune infiltration, fatty acid metabolism, and ferroptosis marker genes.\nIn conclusion, these findings indicate that SLC25A19 is novel prognostic biomarker related to immune invasion and ferroptosis in HCC, and it is an excellent candidate for therapeutic target against HCC.", "dois": ["10.1016/j.intimp.2024.112367"]}
{"pair_type": "slc_pathway", "key1": "SLC25A19", "key2": "migration", "summary": "In vitro experiments have confirmed that silencing SLC25A19 can significantly inhibit the proliferation and migration ability of cancer cells and induce ferroptosis in HCC.\nSuppression of SLC25A19 resulted in significant inhibition of cell proliferation, colony formation, and cell migration, alongside a boost in cell apoptosis.\nSingle-cell analysis further demonstrated h eightened expression of SLC25A19 in the immune microenvironment of HCC, and in vitro experiments indicated that SLC25A19 may regulate the proliferation, migration, invasion, cycle, and apoptosis of liver cancer cells through the Wnt pathway.\nIn the HepG2 animal model, overexpression of SLC25A19 significantly promotes tumor growth, while knockdown inhibits tumor growth.\nAll things considered, our findings show that increased UCHL5 expression stimulates AKT/mTOR signaling, subsequently triggering the expression of c-Myc, SLC25A19, and ICAM5, which in turn promotes carcinogenesis in bladder cancer.\nIn vivo experiments revealed that silenced SLC25A19 displayed reduced growth rates and formed smaller xenografts.\nSubsequently, a series of cell function experiments, including CCK8, EdU, clone formation, trans-well and scratch assays, were conducted to illustrate the effect of SLC25A19 on the growth and metastasis of cancer cells.\nThe functional influences of SLC25A19 on CRC cell phenotypes were evaluated through a series of assays including celigo cell count, colony formation, CCK-8, flow cytometry, wound healing, and transwell assays following knocking down SLC25A19.", "dois": ["10.1016/j.gene.2025.149299", "10.1002/cam4.70253", "10.1016/j.intimp.2024.112367", "10.3390/cancers14225538"]}
{"pair_type": "slc_pathway", "key1": "SLC25A18", "key2": "oxidative stress", "summary": "Overexpression of SLC25A18 increased ATP and intracellular superoxide anions but decreased mitochondrial membrane potential.\nNext, We found that Aβ42 treatment elevated SLC25A18 expression in Neuro 2A cells.\nReducing SLC25A18 expression attenuated mitochondrial dysfunction and neuronal apoptosis caused by Aβ42.\nThe results indicate that SLC25A18 affects mitochondrial function and neuronal apoptosis, and is related to AD, which makes it a potential target for treating brain dysfunction.", "dois": ["10.1080/02770903.2024.2311241", "10.1016/j.mito.2024.101918"]}
{"pair_type": "slc_pathway", "key1": "SLC25A12", "key2": "glycolysis", "summary": "The mitochondrial malate aspartate shuttle system (MAS) maintains the cytosolic NAD+/NADH redox balance, thereby sustaining cytosolic redox-dependent pathways, such as glycolysis and serine biosynthesis.\nAralar/slc25a12/AGC1 is the neuronal isoform of the aspartate-glutamate mitochondrial carrier, a component of the malate-aspartate shuttle (MAS) which plays an important role in redox balance, which is essential to maintain glycolytic pyruvate supply to neuronal mitochondria.\nThe concomitant down-regulation of all participating proteins (SLC25A11, SLC25A12, GOT2 and MDH2) of malate-aspartate shuttle might be responsible for the metabolic in-coordination between the cytosol and mitochondria resulting in the failure of energy metabolism.\nBioinformatics data mining and immunochemical validation of pivotal perturbed proteins revealed a global failure of the cellular energy metabolism in the infarcted tissues as seen by the parallel down-regulation of proteins related to glycolysis, pyruvate dehydrogenase complex, TCA cycle and oxidative phosphorylation.\nKetogenic diets (KD) are high-fat/low-carbohydrate diets, which decrease glycolysis thus bypassing the mentioned defects.\nTherefore, we evaluated the possible fuels used in each case by studying the relative contribution of oxidative phosphorylation and glycolysis to mitochondrial movement using specific inhibitors.\nWe found that the ATP synthase inhibitor oligomycin caused a smaller inhibition of mitochondrial movement in Aralar-KO than control neurons, whereas the glycolysis inhibitor iodoacetate had similar effects in neurons from both genotypes.\nIn line with these findings, the decrease in cytosolic ATP/ADP ratio caused by oligomycin was more pronounced in control than in Aralar-KO neurons, but no differences were observed with iodoacetate.", "dois": ["10.1523/JNEUROSCI.1463-21.2022", "10.1016/j.neuint.2019.104541", "10.3390/nu14173605", "10.1016/j.jprot.2013.08.017"]}
{"pair_type": "slc_pathway", "key1": "SLC25A19", "key2": "proliferation", "summary": "In vitro experiments have confirmed that silencing SLC25A19 can significantly inhibit the proliferation and migration ability of cancer cells and induce ferroptosis in HCC.\nSuppression of SLC25A19 resulted in significant inhibition of cell proliferation, colony formation, and cell migration, alongside a boost in cell apoptosis.\nSingle-cell analysis further demonstrated h eightened expression of SLC25A19 in the immune microenvironment of HCC, and in vitro experiments indicated that SLC25A19 may regulate the proliferation, migration, invasion, cycle, and apoptosis of liver cancer cells through the Wnt pathway.\nIn the HepG2 animal model, overexpression of SLC25A19 significantly promotes tumor growth, while knockdown inhibits tumor growth.\nAll things considered, our findings show that increased UCHL5 expression stimulates AKT/mTOR signaling, subsequently triggering the expression of c-Myc, SLC25A19, and ICAM5, which in turn promotes carcinogenesis in bladder cancer.\nIn vivo experiments revealed that silenced SLC25A19 displayed reduced growth rates and formed smaller xenografts.\nAmong the genes identified by this approach were genes from diverse functional groups such as structural constituents of ribosomes (RPL6, RPL7, RPS12, RPS15A), kinases (CABC1, CCT2, RPL41), transcriptional and translational regulators (SFRS2, TUFM, ZBTB4), signal transducers (FLNA), control of cell growth and proliferation (RPS6), angiogenesis promoting factors (ITGB1), and others (SLC25A19, NCKAP1, BST1, DBH, FZD7, NACA, MTHFD2).\nWe also found that UCHL5 downregulation significantly suppressed both tumor growth in vivo and cell proliferation and migration in vitro.\nSubsequently, a series of cell function experiments, including CCK8, EdU, clone formation, trans-well and scratch assays, were conducted to illustrate the effect of SLC25A19 on the growth and metastasis of cancer cells.", "dois": ["10.1016/j.gene.2025.149299", "10.1002/cam4.70253", "10.1016/j.intimp.2024.112367", "10.3390/cancers14225538", "10.1016/j.cbi.2010.02.002"]}
{"pair_type": "slc_pathway", "key1": "SLC25A19", "key2": "oxidative stress", "summary": "The essentiality of thiamin stems from its roles as a cofactor [mainly in the form of thiamin pyrophosphate (TPP)] in critical metabolic reactions including oxidative energy metabolism and reduction of cellular oxidative stress.", "dois": ["10.1152/ajpgi.00192.2017"]}
{"pair_type": "slc_pathway", "key1": "SLC25A20", "key2": "apoptosis", "summary": "SLC25A20 suppressed HCC growth and metastasis, both in vitro and in vivo, by suppression of G1-S cell transition, epithelial-to-mesenchymal transition (EMT), and induction of cell apoptosis.\nMechanistically, SLC25A20 down-regulation promoted HCC growth and metastasis through suppression of fatty-acid oxidation.\nAltogether, SLC25A20 plays a critical tumor-suppressive role in carcinogenesis of HCC;\nDown-regulation of SLC25A20 is associated with a poor prognosis in patients with HCC.\nSLC25A20 may serve as a novel prognostic factor and therapeutic target for patients with HCC.\nTranscriptome analysis revealed differential expression of 176 genes, with downregulation of steroidogenesis and fatty acid synthesis pathways, and upregulation of apoptosis, fatty acid oxidation, and innate immune responses in NEFA treated cells.\nFurthermore, 234 different expression genes were identified in the gastric tissue transcriptome, which were mainly involved in biological processes such as cell adhesion, angiogenesis, apoptosis, cell migration and lipids metabolism by regulating the MAPK signaling pathway.\nNetwork pharmacology showed that the treatment of CAG by BBR mainly involved in inflammatory response, apoptosis, angiogenesis and metabolic processes.\nThe neurotoxicity induced by the mitochondrial inhibitor 3-nitropropionic acid (3-NPA) is associated with a decrease of ATP synthesis and an increase of free radical production which can lead to apoptosis or necrosis.\nOther genes associated with stress and apoptosis, Parp-1, Bcl-2, and Bax were not affected by 3-NPA or ALC.", "dois": ["10.1093/biolre/ioaf238", "10.3389/fphar.2024.1499753", "10.1038/s41419-021-03648-1", "10.2174/157015911795017182"]}
{"pair_type": "slc_pathway", "key1": "SLC25A20", "key2": "glycolysis", "summary": "PPARα upregulates genes driving increased mitochondrial and peroxisomal mass and β-oxidation capacity, including mitochondrial lipid import proteins CPT1A, CPT2 and SLC25A20, electron transport chain components, peroxisomal proteins PEX11A and ACOX1, and thioredoxin-interacting protein (TXNIP), a negative regulator of glycolysis.\nThis endows acid-adapted cancer cells with increased capacity for utilizing fatty acids for metabolic needs, while limiting glycolysis.\nSilencing PDK4 expression induced glucose utilization by upregulating glucose transporters (SLC2A1, SLC2A10) and glycolytic enzymes (GAPDH, ENO1, LDHA).\nSpecifically, genes involved in fatty acid oxidation (e.g., CPT1A, CPT1B, HADHA, SLC25A20) were upregulated, whereas those related to glucose metabolism remained largely unchanged except for the marked upregulation of PDK4.\nUsing metabolic profiling, shotgun lipidomics, imaging and biochemical analyses, we show that the acid adaptation-induced phenotype is characterized by a shift toward oxidative metabolism, increased lipid droplet-, triacylglycerol-, peroxisome content and mitochondrial hyperfusion.\nRats of the O+N group had a higher percentage of oxidative type I fibers and higher mRNA levels of genes encoding regulators of muscle fiber composition (Ppard, Ppargc1a, Ppargc1b), angiogenic factors (Vegfa, Vegfb), and genes involved in fatty acid utilization (Cpt1b, Slc25a20, Slc22a4, Slc22a5, Slc27a1) and oxidative phosphorylation (Cox4i1, Cox6a2) and a higher activity of the mitochondrial oxidative enzyme succinate dehydrogenase in muscle than rats of the O and L groups (P < 0.05).\nIn contrast, genes associated with fatty acid oxidation (SLC27A1, CPT1B) showed downregulation upon PDK4 silencing compared with controls, suggesting a metabol", "dois": ["10.3945/jn.112.164038", "10.1093/biolre/ioaf238", "10.1002/ijc.34404", "10.3390/biomedicines9070811"]}
{"pair_type": "slc_pathway", "key1": "SLC25A20", "key2": "migration", "summary": "Knockdown of HADHA inhibited glioma cell proliferation and diminished their migration and invasion capacities and influenced the tumor growth in vivo.\nFurthermore, 234 different expression genes were identified in the gastric tissue transcriptome, which were mainly involved in biological processes such as cell adhesion, angiogenesis, apoptosis, cell migration and lipids metabolism by regulating the MAPK signaling pathway.\nIntegrating transcriptomics and metabolomics analyses indicated that BBR directly regulated Carnitine C3:0, LPC (0:0/20:3), L-Glutamic Acid and FFA (15:0) by acting on SLC25A20, PNLIPRP1, PLA2G4C, GSR, GFPT2, GCLM, CTPS1, ACSL1, ACOT4 and ACOT2.\nHADHA significantly influences the development of gliomas, both in vivo and in vitro.", "dois": ["10.3389/fphar.2024.1499753", "10.1186/s12935-024-03316-2"]}
{"pair_type": "slc_pathway", "key1": "SLC25A19", "key2": "apoptosis", "summary": "Suppression of SLC25A19 resulted in significant inhibition of cell proliferation, colony formation, and cell migration, alongside a boost in cell apoptosis.\nSingle-cell analysis further demonstrated heightened expression of SLC25A19 in the immune microenvironment of HCC, and in vitro experiments indicated that SLC25A19 may regulate the proliferation, migration, invasion, cycle, and apoptosis of liver cancer cells through the Wnt pathway.\nIn the HepG2 animal model, overexpression of SLC25A19 significantly promotes tumor growth, while knockdown inhibits tumor growth.\nMechanistically, the p53 pathway was found to be upregulated by SLC25A19 knockdown and mediated the function of SLC25A19.", "dois": ["10.1002/cam4.70253", "10.1016/j.gene.2025.149299", "10.1017/S0007114522000174"]}
{"pair_type": "slc_pathway", "key1": "SLC25A20", "key2": "oxidative phosphorylation", "summary": "Rats of the O+N group had a higher percentage of oxidative type I fibers and higher mRNA levels of genes encoding regulators of muscle fiber composition (Ppard, Ppargc1a, Ppargc1b), angiogenic factors (Vegfa, Vegfb), and genes involved in fatty acid utilization (Cpt1b, Slc25a20, Slc22a4, Slc22a5, Slc27a1) and oxidative phosphorylation (Cox4i1, Cox6a2) and a higher activity of the mitochondrial oxidative enzyme succinate dehydrogenase in muscle than rats of the O and L groups (P < 0.05).\nThese niacin-induced changes in muscle metabolic phenotype are indicative of an increased capacity of muscle for oxidative utilization of fatty acids and are likely mediated by the upregulation of Ppard, Ppargc1a, and Ppargc1b, which are key regulators of muscle fiber composition, mitochondrial biogenesis, angiogenesis, and genes involved in fatty acid catabolism and oxidative phosphorylation.\nThe carnitine/acylcarnitine carrier (CAC) is a crucial protein for cellular energy metabolism, facilitating the exchange of acylcarnitines and free carnitine across the mitochondrial membrane, thereby enabling fatty acid β-oxidation and oxidative phosphorylation (OXPHOS).\nBy intersecting WGCNA-derived module genes with identified mitochondrial genes, we compiled a list of 60 mitochondrial dysfunction- related genes (MRGs) significantly enriched in pathways pertinent to mitochondrial function, such as the citrate cycle and oxidative phosphorylation.\nIn particular, one of these pathways was enriched to be associated with fat metabolism, namely the thermogenesis pathway, to which fat-metabolism-related genes such as ACSL1, ACSL4, ACSL5, CPT1A, CPT1C, SLC25A20, and FGF21 were enriched.\nThrough Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analysis, 16 pathways were significantly enriched (Q-value", "dois": ["10.3945/jn.112.164038", "10.1016/j.ijbiomac.2025.148609", "10.2174/0115672050353736241218054012", "10.3390/biom14091158", "10.3390/ani12131650"]}
{"pair_type": "slc_pathway", "key1": "SLC25A20", "key2": "oxidative stress", "summary": "Integrated transcriptomic and metabolomic analyses revealed that PFBS significantly disrupted lipid metabolism, notably downregulating PPARG, a key regulator of placental lipid homeostasis, and carnitine shuttle genes CPT1A and SLC25A20, which are essential for mitochondrial fatty acid import.\nHowever, PFBS exposure did not induce oxidative stress nor alter mitochondrial morphology.\nFurther functional assessments found increased mitochondrial DNA copy number, yet decreased ATP production, indicating mitochondrial dysfunction.\nThe cell proliferation, invasion, angiogenesis, and treatment of gliomas are significantly influenced by oxidative stress.\nThese findings demonstrate that PFBS induces metabolic toxicity in human STBs, primarily by disrupting lipid metabolism and mitochondrial energy production.\nDisruptions in mitochondrial function may therefore mediate the adverse effects of environmental exposure on pregnancy outcomes.\n9 ORGs (H6PD, BMP2, SPP1, HADHA, SLC25A20, TXNIP, ACTA1, CCND1, EEF1A1) were selected via differential expression analysis, LASSO and Cox analysis, and incorporated into the risk model with high predictive accuracy.\nIn particular, placental mitochondria function refines during pregnancy to optimize the dynamic growth of the fetus and placenta.\nThis mechanism may underlie the observed associations between PFBS exposure, placental dysfunction, and adverse pregnancy outcomes.\nThe placenta plays a critical role in the pathogenesis of pregnancy complications, and disrupted placentation is implicated in the mechanistic pathways linking PFBS exposure to these disorders.\nThis study investigated the effects of PFBS on the metabolism and mitochondrial function of human syncytiotrophoblast (STB), the primary nutrient-transporting cells of the placenta.", "dois": ["10.1016/j.tox.2025.154269", "10.1186/s12935-024-03316-2"]}
{"pair_type": "slc_pathway", "key1": "SLC25A12", "key2": "migration", "summary": "In addition, SLC25A12-silenced HCC cells show a strong reduction of cell migration.\nAGC1-knockdown in mouse lung carcinoma and melanoma cell lines leads to increased pulmonary metastasis following subcutaneous or intravenous injections, respectively.\nOn the other hand, conventional in vitro metastasis assays show no indication of increased metastasis capacity of AGC1-knockdown cells.\nLow AGC1 expression correlates with worse patient prognosis in many cancers.\nFurthermore, SLC25A12 knockdown by small interfering RNA, impairs HepG2 cell proliferation by inducing cell cycle arrest.\nAGC1 sustains HCC cell growth by supplying cytosolic aspartate for nucleotide biosynthesis.\nWe previously described that loss-of-aspartate glutamate carrier 1 (SLC25A12 or AGC1), an important component of the malate-aspartate shuttle, impairs cytosolic aspartate levels, NAD/NADH ratio, mitochondrial respiration, and tumor growth.\nThis study highlights that certain branches of metabolism impact tumor growth and tumor metastasis differently.\nIn addition, it also argues that commonly known metastasis indicators, including EMT genes, cell migration, or colony formation, do not always reflect metastatic capacity in vivo.", "dois": ["10.1186/s40170-020-00232-7", "10.1016/j.bbadis.2018.10.018"]}
{"pair_type": "slc_pathway", "key1": "SLC25A20", "key2": "proliferation", "summary": "[F]FPIA uptake correlated positively with Ki-67 ( < 0.01), SLC22A5 ( < 0.001) and SLC25A20 ( = 0.001), and negatively with CPT1 ( < 0.01) and SLC22A2 ( < 0.01).\nWe assessed proliferation (Ki-67) and the expression of lipid metabolism and transport proteins (CPT1, SLC22A2, SLC22A5, SLC25A20) by immunohistochemistry, along with etomoxir treatment to provide insights into [F]FPIA uptake.\nKnockdown of HADHA inhibited glioma cell proliferation and diminished their migration and invasion capacities and influenced the tumor growth in vivo.\nOur findings support the use of [F]FPIA PET for the detection and longitudinal monitoring of glioma, showing a positive correlation with tumor proliferation, and suggest transcellular flux-mediated radiotracer uptake.\nLongitudinal PET imaging showed gradual increase in [F]FPIA uptake in orthotopic glioma models with disease progression ( < 0.0001), and high tumor-to-brain contrast compared to [F]FDG ( < 0.0001).\nEtomoxir reduced [F]FPIA uptake, which correlated with decreased Ki-67 ( < 0.05).\nThe cell proliferation, invasion, angiogenesis, and treatment of gliomas are significantly influenced by oxidative stress.\nA growing number of observations reveal that tumors can utilize a wide range of substrates to sustain cell survival and proliferation.\nHADHA significantly influences the development of gliomas, both in vivo and in vitro.\nAmong the SLCs, the plasma membrane transporters OCTN2 (Organic cation transport novel 2 or SLC22A5), CT2 (Carnitine transporter 2 or SLC22A16), MCT9 (Monocarboxylate transporter 9 or SLC16A9) and ATB [Sodium- and chloride-dependent neutral and basic amino acid transporter B(0+) or SLC6", "dois": ["10.1186/s12935-024-03316-2", "10.3390/biomedicines9070811", "10.3389/fcell.2020.583850"]}
{"pair_type": "slc_pathway", "key1": "SLC25A21", "key2": "ferroptosis", "summary": "We identified 24 prognostic ferroptosis-related lncRNAs, 15 of which (SNAI3-AS1, GDNF-AS1, WDFY3-AS2, CPB2-AS1, WAC-AS1, SLC25A21-AS1, ARHGEF26-AS1, LINC00641, LINC00844, MIR155HG, MIR22HG, PVT1, SNHG18, PAXIP1-AS2, and SBF2-AS1) were used to construct a ferroptosis-related lncRNAs signature (FRLS) according to the least absolute shrinkage and selection operator (LASSO) regression.\nRecent studies have demonstrated that long non-coding RNAs (lncRNAs) are implicated in the regulation of tumor cell ferroptosis.", "dois": ["10.3389/fcell.2021.675555"]}
{"pair_type": "slc_pathway", "key1": "SLC25A21", "key2": "apoptosis", "summary": "Overexpression of SLC25A21 significantly inhibited cell proliferation, migration and invasion and induced apoptosis .\nFurthermore, overexpression of SLC25A21 inhibited cell proliferation and cell cycle progression, and was correlated with apoptosis through mitochondrial apoptosis signaling pathway.\nFurthermore, we revealed that SLC25A21 suppressed BCa growth by inducing the efflux of mitochondrial α-KG to the cytosol, decreasing to against oxidative stress, and activating the ROS-mediated mitochondrion-dependent apoptosis pathway.\nFinally, we demonstrated that high expression of SLC25A21-AS1 promoted resistance to cisplatin-induced apoptosis and was correlated with poor tumour grade and overall survival.\nSustaining renal expression of Slc25a21 slowed down AKI progression by reducing cellular apoptosis, necroptosis, and the inflammatory response, likely through its regulation of 2-oxoadipate conversion.\nExposure to 2-oxoadipate and quinolinic acid decreased the level of mitochondrial complexes in neuronal cells (SH-SY5Y) and induced apoptosis.\nThe SLC25 family of mitochondrial carriers plays a critical role in maintaining mitochondrial function and regulating apoptosis.\nIn recent years, targeting mitochondrial apoptosis has emerged as a promising therapeutic strategy for Acute Myeloid Leukemia (AML).", "dois": ["10.1038/s41419-024-07308-y", "10.1038/s41419-024-07231-2", "10.1038/gim.2017.251", "PMID:16600197", "10.1002/ctm2.944", "10.1620/tjem.2022.J029", "10.3389/fonc.2021.682710"]}
{"pair_type": "slc_pathway", "key1": "SLC25A21", "key2": "oxidative phosphorylation", "summary": "Slc25a21 is highly expressed in proximal tubular epithelial cells, and its down-regulation contributes to compromised mitochondrial biogenesis and integrity, as well as impaired oxidative phosphorylation.\nMechanistically, reduced Slc25a21 in AKI disrupts mitochondrial 2-oxoadipate transport, affecting related metabolites influx and the tricarboxylic acid cycle.\nThe results of gene set enrichment analysis (GSEA) indicated that the epithelial-mesenchymal transition, KRAS signalling, oxidative phosphorylation, and reactive oxygen species pathways were enriched.\nSustaining renal expression of Slc25a21 slowed down AKI progression by reducing cellular apoptosis, necroptosis, and the inflammatory response, likely through its regulation of 2-oxoadipate conversion.\nThese findings demonstrate a previously unappreciated metabolic function of Slc25a21 in tubular cells, and suggest that targeting mitochondrial metabolic homeostasis by sustaining Slc25a21 expression could be a potential novel therapeutic strategy for AKI.", "dois": ["10.1038/s41419-024-07231-2", "10.3389/fgene.2022.970316"]}
{"pair_type": "slc_pathway", "key1": "SLC25A11", "key2": "proliferation", "summary": "Loss of OGC promoted cell proliferation and migration through Slug-mediated EMT.\nOGC silencing aggravated EMT, while overexpression attenuated TGF-β2-induced EMT, cell proliferation, and migration.\nOGC knockdown significantly enhanced RPE EMT, as evidenced by upregulated expression of α-SMA, fibronectin, collagen type I, and Slug, while E-cadherin was downregulated.\nOGC depletion stimulated EMT via pSmad2/3 upregulation, dependent on the PI3K/AKT signaling pathway activation.\nIn vivo studies further demonstrate that subretinal fibrosis was significantly augmented in OGC mice via TGF-β2-dependent PI3K signaling.\nOGC overexpression improved mitochondrial bioenergetics, whereas its inhibition reduced mitochondrial respiration, which was further aggravated by co-treatment with TGF-β2.\nPT cells from NPX rats that were first preincubated with GSH were protected from cytotoxicity due to the mitochondrial inhibitor antimycin A by overexpression of either of the two mitochondrial GSH transporters.\nOur previous studies showed that overexpression of two mitochondrial anion transporters, the dicarboxylate (DIC, Slc25a10) and oxoglutarate (OGC, Slc25a11) carriers, in NRK-52E cells resulted in increased mitochondrial uptake of glutathione (GSH) and protection from chemically induced apoptosis.\nCompensatory renal hypertrophy following reduction in renal mass leads to a hypermetabolic state and increases in basal mitochondrial oxidative stress and susceptibility to several nephrotoxicants.\nEpithelial-to-mesenchymal transition (EMT) in RPE cells is a key early step in subretinal fibrosis.\nThis study explores the role of oxoglutarate carrier (OGC; Slc25a11) on EMT and investigates the molecular mechanisms, focusing on its role in mitochondrial metabolism and GSH transport.", "dois": ["10.1111/acel.70271", "10.1016/j.bcp.2013.02.013"]}
{"pair_type": "slc_pathway", "key1": "SLC25A21", "key2": "oxidative stress", "summary": "Furthermore, we revealed that SLC25A21 suppressed BCa growth by inducing the efflux of mitochondrial α-KG to the cytosol, decreasing to against oxidative stress, and activating the ROS-mediated mitochondrion-dependent apoptosis pathway.", "dois": ["PMID:16600197", "10.3389/fonc.2021.682710"]}
{"pair_type": "slc_pathway", "key1": "SLC25A22", "key2": "migration", "summary": "SLC25A22 promotes proliferation and migration of CRC cells with mutations KRAS, and formation and metastasis of CRC xenograft tumors in mice.\nKnockdown of SLC25A22 in KRAS mutant CRC cells reduced their proliferation, migration, and invasion in vitro, and tumor formation and metastasis in mice, compared with cells without SLC25A22 knockdown.\nSLC25A22, a member of mitochondrial carrier system (MCS) family encoding a mitochondrial glutamate transporter, has been reported to have vital roles in promoting proliferation and migration in cancer.\nOur study identified that SLC25A22 promoted development of GBC activating MAPK/ERK pathway.\nAsparagine synthetase mediated synthesis of asparagine from aspartate to promote cell migration.\nDownregulation of SLC25A22 inhibited GBC cell growth and proliferation in vitro and in vivo and also had an effect on metastasis of GBC cells through the EMT processes.\nCirc_0007534 knockdown repressed CRC cell proliferation, colony formation, migration, invasion, and glycolysis.\nSLC25A22 induces intracellular synthesis of aspartate, activation of mitogen-activated protein kinase kinase and extracellular signal-regulated kinase signaling and reduces oxidative stress.\nIncubation of KRAS mutant CRC cells with knockdown of SLC25A22 with aspartate increased proliferation and reduced apoptosis, which required GOT1, indicating that oxaloacetate is required for cell survival.\nKnockdown of SLC25A22 reduced aspartate biosynthesis, leading to apoptosis, decreased cell proliferation in KRAS mutant CRC cells.\nIn addition, inhibition of SLC25A22 promoted mitochondrial apoptosis via downregulating BCL-2 and upregulating cleaved PARP, Cytochrome-c, and BAX mediated by MAPK/ERK pathway.\nCirc_0007534 exerted its function by repressing miR-613 expression, and miR-613 exerted its function via inhibiting SLC25A", "dois": ["10.26355/eurrev_202003_20665", "10.1186/s12935-019-0746-9", "10.1053/j.gastro.2016.07.011"]}
{"pair_type": "slc_pathway", "key1": "SLC25A13", "key2": "chemotherapy", "summary": "Deficiency of citrin, the liver-type aspartate-glutamate carrier, arises from biallelic mutations of the gene SLC25A13.\nAfterwards, the patient underwent 5 additional cycles of chemotherapy and her condition remained stable for 7 months after surgery.\nThe patient in this paper had been diagnosed to have CD by SLC25A13 analysis at the age 10 months, and then in response to dietary therapy, her prolonged jaundice and marked hepatosplenomegaly resolved gradually.\nAfter 4 rounds of adjuvant chemotherapy, right hepatic lobectomy and portal venous embolectomy were performed at her age 5 years and 3 months, and metastatic hepatoblastoma was confirmed by histopathological analysis.\nAlthough citrin deficiency (CD) is associated with higher risk of hepatocellular carcinoma (HCC) in adult patients, this association remains inconclusive in pediatric cases.", "dois": ["10.1007/s12672-024-01059-0"]}
{"pair_type": "slc_pathway", "key1": "SLC25A22", "key2": "glycolysis", "summary": "Circ_0007534 knockdown repressed CRC cell proliferation, colony formation, migration, invasion, and glycolysis.\nReduced oxidized nicotinamide adenine dinucleotide inhibited glycolysis and decreased levels of adenosine triphosphate, which inactivated mitogen-activated protein kinase kinase and extracellular signal-regulated kinase signaling via activation of AMP-activated protein kinase.\nKnockdown of SLC25A22 reduced aspartate biosynthesis, leading to apoptosis, decreased cell proliferation in KRAS mutant CRC cells.\nDecreased levels of oxaloacetate in cells with knockdown of SLC25A22 reduced regeneration of oxidized nicotinamide adenine dinucleotide and reduced nicotinamide adenine dinucleotide phosphate.\nCirc_0007534 repressed miR-613 expression to upregulate SLC25A22 level.\nAlso, Circ_0007534 repressed miR-613 expression to upregulate SLC25A22 level.\nCirc_0007534 and SLC25A22 levels were upregulated, and miR-613 level was downregulated in CRC tissues/cells.\nSLC25A22 induces intracellular synthesis of aspartate, activation of mitogen-activated protein kinase kinase and extracellular signal-regulated kinase signaling and reduces oxidative stress.\nCirc_0007534 exerted its function by repressing miR-613 expression, and miR-613 exerted its function via inhibiting SLC25A22 expression.\nWe demonstrated that circ_0007534 knockdown suppressed the growth of CRC cells by regulating miR-613/SLC25A22 axis, providing potential target for the treatment of CRC.\nSLC25A22 promotes proliferation and migration of CRC cells with mutations KRAS, and formation and metastasis of CRC xenograft tumors in mice.\nKnockdown of SLC25A22 in KRAS mutant CRC cells reduced their proliferation, migration, and invasion in vitro, and tumor formation and metastasis in", "dois": ["10.26355/eurrev_202003_20665", "10.1053/j.gastro.2016.07.011"]}
{"pair_type": "slc_pathway", "key1": "SLC25A22", "key2": "ferroptosis", "summary": "The animal study further confirms that SLC25A22 inhibits ferroptosis-mediated tumor suppression.\nThe downregulation of SLC25A22 expression was associated with increased sensitivity to ferroptosis, but not to apoptosis.\nThe RSL3-induced ferroptosis of LUAD led to upregulation of SLC25A22 and SIRT3, and SIRT3 protected RSL3-induced LUAD from ferroptosis in vitro and in vivo.\nTherefore, our results demonstrated that SIRT3 protected LUAD cells from RSL3-induced ferroptosis, and this effect is at least partially due to its deacetylation of SLC25A22, revealing that the SIRT3-SLC25A22 axis has an important role in regulating the ferroptosis of LUAD cells.\nSLC25A22 is a novel metabolic repressor of ferroptosis by producing GSH and MUFAs.\nSolute carrier family 25 member A22 (SLC25A22) is a glutamate transporter in the inner mitochondrial membrane that is known to suppress ferroptosis in pancreatic ductal adenocarcinoma (PDAC).\nHere, we identify solute carrier family 25 member 22 (SLC25A22), a mitochondrial glutamate transporter, as a driver of ferroptosis resistance in pancreatic ductal adenocarcinoma (PDAC) cells.\nMechanistically, on the one hand, SLC25A22-dependent NAPDH synthesis blocks ferroptotic cell death in PDAC cells through mediating the production of glutathione (GSH), the most important hydrophilic antioxidant.\nOn the other hand, SLC25A22 promotes the expression of stearoyl-CoA desaturase in PDAC cells in an AMP-activated protein kinase-dependent manner, resulting in the production of antiferroptotic monounsaturated fatty acids (MUFAs).\nThese findings establish a previously unrecognized metabolic defense pathway to limit ferroptotic cell death.", "dois": ["10.1089/ars.2022.0203", "10.3390/antiox14040403"]}
{"pair_type": "slc_pathway", "key1": "SLC25A22", "key2": "apoptosis", "summary": "In addition, inhibition of SLC25A22 promoted mitochondrial apoptosis via downregulating BCL-2 and upregulating cleaved PARP, Cytochrome-c, and BAX mediated by MAPK/ERK pathway.\nAt the same time, the expression of SLC25A22 promoted the progression of the cellcycle of osteosarcoma cell lines and inhibited the apoptosis of osteosarcoma cells.\nIncubation of KRAS mutant CRC cells with knockdown of SLC25A22 with aspartate increased proliferation and reduced apoptosis, which required GOT1, indicating that oxaloacetate is required for cell survival.\nThe downregulation of SLC25A22 expression was associated with increased sensitivity to ferroptosis, but not to apoptosis.\nKnockdown of SLC25A22 reduced aspartate biosynthesis, leading to apoptosis, decreased cell proliferation in KRAS mutant CRC cells.\nSLC25A22 induces intracellular synthesis of aspartate, activation of mitogen-activated protein kinase kinase and extracellular signal-regulated kinase signaling and reduces oxidative stress.\nThe animal study further confirms that SLC25A22 inhibits ferroptosis-mediated tumor suppression.\nMechanistically, on the one hand, SLC25A22-dependent NAPDH synthesis blocks ferroptotic cell death in PDAC cells through mediating the production of glutathione (GSH), the most important hydrophilic antioxidant.\nSLC25A22 is a novel metabolic repressor of ferroptosis by producing GSH and MUFAs.\nOn the other hand, SLC25A22 promotes the expression of stearoyl-CoA desaturase in PDAC cells in an AMP-activated protein kinase-dependent manner, resulting in the production of antiferroptotic monounsaturated fatty acids (MUFAs).\nHere, we identify solute carrier family 25 member 22 (SLC25A22), a mitochondrial glutamate transporter, as a driver of ferroptosis resistance in pancreatic ductal adenocarcinoma (PDAC", "dois": ["10.1089/ars.2022.0203", "10.1177/1533033818811143", "10.1053/j.gastro.2020.08.016", "10.1186/s12935-019-0746-9", "10.1053/j.gastro.2016.07.011"]}
{"pair_type": "slc_pathway", "key1": "SLC25A12", "key2": "proliferation", "summary": "Furthermore, SLC25A12 knockdown by small interfering RNA, impairs HepG2 cell proliferation by inducing cell cycle arrest.\nIn the cell model, we showed that a reduced expression of AGC1 induces a deficit of OPC proliferation leading to their spontaneous and precocious differentiation into oligodendrocytes.\nIn both neuronal precursor cells and oligodendrocytes precursor cells (NPCs and OPCs), the AGC1 determines reduced proliferation with an accelerated differentiation of OPCs, both associated with gene expression dysregulation.\nThe inhibition of HATs by curcumin arrests the proliferation of OPCs leading to their differentiation, while the inhibition of HDACs by suberanilohydroxamic acid (SAHA) has only a limited effect on proliferation, but it significantly stimulates the differentiation of OPCs.\nMoreover, loss of AGC1 reduces allograft tumor growth that is further compromised by treatment with the glutaminase inhibitor CB-839.\nHere, we show that mitochondrial aspartate export via the aspartate-glutamate carrier 1 (AGC1) supports cell proliferation and cellular redox homeostasis.\nThe AGC1 silencing in an in vitro model of OPCs was documented to cause defects of proliferation and differentiation, mediated by alterations of histone acetylation/deacetylation.\nEpigenetic regulation of gene expression through histone acetylation plays a crucial role in the proliferation/differentiation of both NPCs and OPCs and is modulated by mitochondrial metabolism.\nInterestingly, this effect seems to be related to a dysregulation in the expression of trophic factors and receptors involved in OPC proliferation/differentiation, such as Platelet-Derived Growth Factor α (PDGFα) and Transforming Growth Factor βs (TGFβs).\nThese data clearly show that AGC1 impairment alters myelination not only by acting on N-acetyl-aspartate production in neurons but also on OPC proliferation and suggest new potential therapeutic targets for the treatment of AGC1 deficiency.\nWe also confirmed the OPC reduction in vivo in AG", "dois": ["10.1186/s11658-024-00563-z", "10.3389/fncel.2021.773709", "10.1016/j.yjmcc.2021.01.010", "10.3390/ijms20184486", "10.1016/j.bbadis.2018.10.018", "10.1016/j.cmet.2018.07.021", "10.1002/ajmg.b.30739"]}
{"pair_type": "slc_pathway", "key1": "SLC25A22", "key2": "oxidative phosphorylation", "summary": "Cu induces oxidative phosphorylation via alterations in the mitochondrial proteome and lipidome necessary for the formation of the respiratory supercomplexes.\nBiosynthesis of glucose-derived glutathione requires activity of glutamyl pyruvate transaminase 2, entry of glucose-derived pyruvate to mitochondria via alanine, and the glutamate exporter, SLC25A22.\nSpecifically, Cu induces TCA cycle-dependent oxidation of glucose and its utilization for glutathione biosynthesis to protect against H O generated during mitochondrial respiration, therefore coordinating bioenergy production with redox protection.\nThe mitochondrion is a key cellular structure involved in many metabolic functions such as ATP synthesis by oxidative phosphorylation, tricarboxylic acid cycle or fatty acid oxidation.\nAccumulation of copper is associated with progression and relapse of ccRCC and drives tumor growth.Cu accumulation and allocation to cytochrome c oxidase (CuCOX) remodels metabolism coupling energy production and nucleotide biosynthesis with maintenance of redox homeostasis.\nProgression of human ccRCC is associated with gene expression signature characterized by induction of ETC/OxPhos/GSH/Cu-related genes and decrease in HIF/glycolytic genes in subpopulations of cancer cells.\nEnhanced, concordant expression of genes related to ETC/OxPhos, GSH, and Cu characterizes metabolically active subpopulations of ccRCC cells in regions adjacent to proliferative subpopulations of ccRCC cells, implicating oxidative metabolism in supporting tumor growth.\nGlutathione derived from glucose maintains redox homeostasis in Cu-treated cells, reducing Cu-H O Fenton-like reaction mediated cell death.\nCu stimulates glutathione biosynthesis and glutathione derived specifically from glucose is necessary for survival of Cu cells.\nSpatial transcriptomics identified that proliferating cancer cells are embedded in clusters of cells with oxidative metabolism supporting effects of metabolic states on ccRCC progression.", "dois": ["10.1101/2024.01.16.575895", "10.1007/s10863-010-9323-6"]}
{"pair_type": "slc_pathway", "key1": "SLC25A13", "key2": "apoptosis", "summary": "In vitro, miR-509-3p significantly decreased SLC25A13 expression, resulting in enhanced HRVEC viability, reduced apoptosis, and lower ROS levels under HG conditions.\nFurthermore, in vitro and in vivo experiments demonstrated that SLC25A13 is significantly overexpressed in glioblastoma tissues compared to paraneoplastic tissues, promoting glioblastoma cell proliferation and migration while inhibiting apoptosis.\nKnockdown of citrin by a vector-based short-hairpin RNA technique reduced cell viability and induced apoptosis of a hepatocellular carcinoma cell line, Hep3B cells.\nOverexpression of SLC25A13 reversed these protective effects, while miR-509-3p knockdown exacerbated oxidative stress and apoptosis.\nmiR-509-3p exerts a protective effect in DR by targeting SLC25A13, reducing oxidative stress, apoptosis, and ferroptosis in retinal endothelial cells.\nIn vivo, agomiR-509-3p increased retinal thickness, reduced pathological damage, and decreased apoptosis in DR mice.\nCitrin knockdown also increased the expression of Bax and Bak, and reduced expression of Bcl-xL and Bcl-2.\nOur results indicated that citrin downregulation induces apoptosis of hepatocytes through the mitochondrial death pathway, highlighting the importance of citrin in survival of hepatocytes and maintenance of liver function.\nCaspase-3/7 and caspase-9 were activated, and PARP was cleaved.\nThese alterations resulted in the release of cytochrome c from the mitochondria.\nWe found apoptotic hepatocytes in one such patient.\nFerroptosis marker analysis revealed that miR-509-3p upregulated GPX4 expression and downregulated TlR4 and ASCL4, whereas SLC25A13 overexpression reversed these effects, further linking miR-509-3p to the regulation of ferroptosis.", "dois": ["10.1007/s00592-024-02400-3", "10.1016/j.bbrc.2007.10.105", "10.21037/tlcr-2025-204", "10.1186/s12935-025-03696-z", "10.1016/j.heliyon.2024.e35663"]}
{"pair_type": "slc_pathway", "key1": "SLC25A21", "key2": "migration", "summary": "SLC25A21-AS1 enhanced the chemosensitivity and inhibited the proliferation, migration, and invasion ability of ovarian cancer cells at least partially by blocking EZH2-mediated silencing of KCNK4.\nOverexpression of SLC25A21 significantly inhibited cell proliferation, migration and invasion and induced apoptosis.\nOverexpression of SLC25A21-AS1 enhanced the sensitivity of ovarian cancer cells to paclitaxel and cisplatin, and inhibited cell proliferation, invasion, and migration, while SLC25A21-AS1-silencing showed the opposite effect.\nSLC25A21 depletion selectively accelerated the growth, invasion, migration, and metastasis of KRAS-mutant CRC cells in vitro and in vivo, and inhibited Gln-derived α-ketoglutarate (α-KG) efflux from mitochondria, thereby potentiating Gln replenishment, accompanied by increased GTP availability for persistent KRAS activation in KRAS-mutant CRC.\nSLC25A21-AS1 promotes the proliferation and migration of ESCC cells by regulating the NPM1/c-Myc axis and SLC25A21 expression.\nLncRNA SLC25A21-AS1 expression was downregulated by PA and associated with the proliferation and migration of ESCC cells in vitro and in vivo.\nOverexpression of SLC25A21-AS1 inhibited glioma cell growth, invasion, and migration while miR-221-3p/miR-222-3p-overexpressed groups could offset this effect.\nMoreover, the enhanced SLC25A21 expression significantly suppressed tumor growth in a xenograft mouse model.\nMeanwhile, KNCK4-overexpression rescued the promotive effect of SLC25A21-AS1-silencing on cell proliferation, invasion and migration.\nOverexpression of KCNK4 inhibited cell proliferation, invasion, migration ability, and enhanced the sensitivity of ovarian cancer cells to paclitaxel and cisplatin.\nOur studies demonstrate that SLC25A21 plays a significant role as a", "dois": ["10.1172/jci.insight.167874", "10.1111/iep.12488", "10.1007/s10142-023-01035-x", "10.1002/ctm2.944", "10.1007/s12033-022-00472-6", "10.3389/fonc.2021.682710"]}
{"pair_type": "slc_pathway", "key1": "SLC25A24", "key2": "oxidative phosphorylation", "summary": "Several carrier proteins evolutionarily related to ANT, including SLC25A24 and SLC25A25, are believed to promote the exchange of cytosolic ATP-Mg with phosphate in the mitochondrial matrix.\nAlthough loss-of-function recessive mutations cause a defect in oxidative phosphorylation and an increase in oxidative stress which drives the pathology, it is unclear how the dominant missense mutations in these proteins cause human diseases.\nThey allow a net accumulation of adenine nucleotides inside mitochondria, which is essential for mitochondrial biogenesis and cell growth.", "dois": ["10.1002/iub.2767"]}
{"pair_type": "slc_pathway", "key1": "SLC25A23", "key2": "oxidative stress", "summary": "It consists of six MCU subunits, an essential MCU regulator (EMRE), and solute carrier 25A23 (SLC25A23).\nThey regulate processes, such as mitochondrial Ca (mCa) uptake, mitochondrial adenosine triphosphate (ATP) production, calcium dynamics, oxidative stress (OS), and cell death.", "dois": ["10.1091/mbc.E13-08-0502", "10.1016/j.jare.2024.02.013"]}
{"pair_type": "slc_pathway", "key1": "SLC25A24", "key2": "apoptosis", "summary": "miR-361-5p and SLC25A24 expression levels were manipulated using miRNA mimics and inhibitors, and their effects on cell viability, apoptosis, and mitochondrial function were assessed.\nmiR-361-5p inhibition markedly decreased KGN cells viability and increased apoptosis (P < 0.01), while miR-361-5p overexpression had the opposite effects (P < 0.01).\nMechanistic studies revealed that SLC25A24 positively regulates the cGMP/PKG1 signaling pathway in CRC, influencing mitochondrial potential, apoptosis, and proliferation-related markers.\nFunctional experiments indicated that SLC25A24 overexpression suppresses CRC cell proliferation, migration, and invasion.\nSLC25A24 expression was inversely correlated with miR-361-5p levels, and its knockdown reversed the effects of miR-361-5p inhibition.\nmiR-361-5p plays a pivotal role in maintaining mitochondrial function and reducing KGN cells dysfunction by targeting SLC25A24.\nQuantitative real-time PCR arrays were used to quantify the expression of 84 genes related to diverse functions of mitochondria, including biogenesis, transport, translocation and apoptosis.", "dois": ["10.1016/j.intimp.2025.114664", "10.1007/s10815-024-03349-6", "10.1186/2040-2392-3-12"]}
{"pair_type": "slc_pathway", "key1": "SLC25A21", "key2": "proliferation", "summary": "SLC25A21-AS1 enhanced the chemosensitivity and inhibited the proliferation, migration, and invasion ability of ovarian cancer cells at least partially by blocking EZH2-mediated silencing of KCNK4.\nOverexpression of SLC25A21 significantly inhibited cell proliferation, migration and invasion and induced apoptosis .\nOverexpression of SLC25A21-AS1 enhanced the sensitivity of ovarian cancer cells to paclitaxel and cisplatin, and inhibited cell proliferation, invasion, and migration, while SLC25A21-AS1-silencing showed the opposite effect.\nThe overexpression of SLC25A21 inhibited the AML cell survival and proliferation by dysregulating the expression of CXCL8.\nSLC25A21-AS1 promotes the proliferation and migration of ESCC cells by regulating the NPM1/c-Myc axis and SLC25A21 expression.\nLncRNA SLC25A21-AS1 expression was downregulated by PA and associated with the proliferation and migration of ESCC cells in vitro and in vivo.\nFurthermore, overexpression of SLC25A21 inhibited cell proliferation and cell cycle progression, and was correlated with apoptosis through mitochondrial apoptosis signaling pathway.\nA series of functional experiments revealed that the upregulation of SLC25A21-AS1 markedly blocked the proliferation and metastasis of EOC cells in vitro, while its downregulation had the opposite effect.\nA series of subsequent experiments found that SLC25A21-AS1 inhibits EOC cell proliferation and metastasis by modulating PTBP3 through the ubiquitin-proteasome pathway and that the combination of SLC25A21-AS1 and PTBP3 provides the necessary conditions for the for the function to be realized.\nMoreover, the enhanced SLC25A21 expression significantly suppressed tumor growth in a xenograft mouse model.\nMeanwhile, KNCK4-overexpression rescued the promotive effect of SLC25A21-AS1-silencing on cell proliferation, invasion and migration.", "dois": ["10.1016/j.thromres.2025.109498", "10.1038/s41419-024-07308-y", "10.1007/s10142-023-01035-x", "10.1186/s40364-022-00432-x", "10.1002/ctm2.944", "10.1620/tjem.2022.J029", "10.1007/s12033-022-00472-6", "10.3389/fonc.2021.682710"]}
{"pair_type": "slc_pathway", "key1": "SLC25A23", "key2": "proliferation", "summary": "We identified subsets of putative biomarkers for proliferation and involution as well as a small set of putative biomarkers for propranolol's mechanism of action for IHs, namely EPAS1, LASP1, SLC25A23, MYO1B, and ALDH1A1.\nGene Ontology (GO)-based functional annotation analysis of validated genes revealed a cluster of hypermethylated and downregulated genes enriched under the GO term \"mitochondrion,\" such as those associated with metabolic reprogramming in carcinogenic process (Clpx, Mrpl54, Mrps34, and Slc25a23).\nThey show a distinctive mechanism of tumor growth in which a rapid proliferative phase is followed by a regression phase (involution).", "dois": ["10.1002/jat.4495", "10.1038/s41598-020-60025-2"]}
{"pair_type": "slc_pathway", "key1": "SLC25A22", "key2": "proliferation", "summary": "In summary, SLC25A22 is highly expressed in osteosarcoma, promoting osteosarcoma cell proliferation and invasion by inhibiting the phosphatase and tensin homolog signaling pathway.\nIncubation of KRAS mutant CRC cells with knockdown of SLC25A22 with aspartate increased proliferation and reduced apoptosis, which required GOT1, indicating that oxaloacetate is required for cell survival.\nSLC25A22 Promotes Proliferation and Metastasis of Osteosarcoma Cells via the PTEN Signaling Pathway.\nSLC25A22 promotes proliferation and metastasis by activating MAPK/ERK pathway in gallbladder cancer.\nDownregulation of SLC25A22 inhibited GBC cell growth and proliferation in vitro and in vivo and also had an effect on metastasis of GBC cells through the EMT processes.\nSLC25A22 Promotes Proliferation and Survival of Colorectal Cancer Cells With KRAS Mutations and Xenograft Tumor Progression in Mice via Intracellular Synthesis of Aspartate.\nExogenous addition of polyamines could significantly promote cell proliferation in DLD1 cells, highlighting their potential role as oncogenic metabolites that function downstream of SLC25A22-mediated glutamine metabolism.\nIn CRC cells that express activated KRAS, SLC25A22 promotes accumulation of succinate, resulting in increased DNA methylation, activation of WNT signaling to β-catenin, increased expression of LGR5, proliferation, stem cell features, and resistance to 5-fluorouacil.\nKnockdown of SLC25A22 reduced aspartate biosynthesis, leading to apoptosis, decreased cell proliferation in KRAS mutant CRC cells.\nSLC25A22 promotes proliferation and migration of CRC cells with mutations KRAS, and formation and metastasis of CRC xenograft tumors in mice.\nKnockdown of SLC25A22 in KRAS mutant CRC cells reduced their proliferation, migration, and invasion in vitro, and tumor formation and metastasis in mice", "dois": ["10.1053/j.gastro.2020.08.016", "10.26355/eurrev_202003_20665", "10.1186/s12935-019-0746-9", "10.1177/1533033818811143", "10.18632/oncotarget.21093", "10.1053/j.gastro.2016.07.011", "10.1007/s10863-010-9323-6"]}
{"pair_type": "slc_pathway", "key1": "SLC25A13", "key2": "ferroptosis", "summary": "Ferroptosis marker analysis revealed that miR-509-3p upregulated GPX4 expression and downregulated TlR4 and ASCL4, whereas SLC25A13 overexpression reversed these effects, further linking miR-509-3p to the regulation of ferroptosis.\nmiR-509-3p exerts a protective effect in DR by targeting SLC25A13, reducing oxidative stress, apoptosis, and ferroptosis in retinal endothelial cells.\nOverexpression of SLC25A13 reversed these protective effects, while miR-509-3p knockdown exacerbated oxidative stress and apoptosis.\nIn vitro, miR-509-3p significantly decreased SLC25A13 expression, resulting in enhanced HRVEC viability, reduced apoptosis, and lower ROS levels under HG conditions.", "dois": ["10.1007/s00592-024-02400-3"]}
{"pair_type": "slc_pathway", "key1": "SLC25A26", "key2": "chemotherapy", "summary": "The text discusses chemotherapy in a general context related to NSCLC treatment selection and mentions genes associated with chemoresponse, but SLC25A26 is not explicitly mentioned in the provided excerpt, and no direct mechanistic relationship between SLC25A26 and chemotherapy is stated in the available text.", "dois": ["10.3390/cancers13174296"]}
{"pair_type": "slc_pathway", "key1": "SLC25A25", "key2": "migration", "summary": "SLC25A25-AS1 silencing impeded NSCLC cell proliferation and triggered apoptosis, while restricting cell migration and invasion.\nIn summary, by controlling the miR-195-5p/ITGA2 axis, SLC25A25-AS1 served tumour-promoting roles in NSCLC cells.\nFurthermore, the antitumour effects of SLC25A25-AS1 silencing on malignant behaviours were counteracted when ITGA2 was restored or when miR-195-5p was silenced.\nTumour growth was also impaired by SLC25A25-AS1 silencing.\nHigh SLC25A25-AS1 expression was markedly associated with shorter overall survival time of patients with NSCLC.\nSLC25A25-AS1 was overexpressed in both NSCLC tissues and cell lines.\nAs compared with normal lung tissues, increased expression of SLC25A25-AS1 was demonstrated in NSCLC tissues using The Cancer Genome Atlas database.", "dois": ["10.3892/ol.2021.12790"]}
{"pair_type": "slc_pathway", "key1": "SLC25A23", "key2": "oxidative phosphorylation", "summary": "Suppressing SLC25A23 disrupts cellular calcium homeostasis, impairs oxidative phosphorylation, and interferes with redox signaling, leading to death of senescent cells.\nOnly L929 cells exhibited up-regulation of two important genes responsible for oxidative phosphorylation and subsequent ATP production: Slc25a23 and Slc25a31.\nIn response to physiological glutamate signals, cytosolic Ca(2+) activates respiration by stimulation of the NADH malate-aspartate shuttle through Ca(2+)-binding to the mitochondrial aspartate/glutamate carrier (Aralar/AGC1/Slc25a12), and by stimulation of adenine nucleotide uptake through Ca(2+) binding to the mitochondrial ATP-Mg/Pi carrier (SCaMC-3/Slc25a23).\nGlutamate-induced Ca(2+)-activation of SCaMC-3 imports adenine nucleotides into mitochondria, counteracting the depletion of matrix ATP and the impaired respiration, while Aralar-dependent lactate metabolism prevents substrate exhaustion.\nBy increasing matrix content of adenine nucleotides, SCaMC-3 activity protects against glutamate-induced PTP opening and lowers matrix free Ca(2+), resulting in protracted appearance of DCD and protection against excitotoxicity in vitro and in vivo, while the lack of lactate protection during in vivo excitotoxicity explains increased vulnerability to kainite-induced toxicity in Aralar +/- mice.\nOxidative phosphorylation is required in order to respond to the metabolic challenge caused by glutamate.", "dois": ["10.1016/j.bbabio.2016.04.003", "10.1074/jbc.M112.409144", "10.1073/pnas.2417724121", "10.4149/av_2020_305"]}
{"pair_type": "slc_pathway", "key1": "SLC25A25", "key2": "apoptosis", "summary": "SLC25A25-AS1 silencing impeded NSCLC cell proliferation and triggered apoptosis, while restricting cell migration and invasion.\nZn is required for the activity of many mitochondrial proteins, which regulate mitochondrial dynamics, apoptosis and mitophagy.\nLoss of SLC-25A25 suppresses the abnormal mitochondrial Zn accumulation and defective mitochondrial structure and functions caused by loss of SLC-30A9.\nTumour growth was also impaired by SLC25A25-AS1 silencing.\nFurthermore, the antitumour effects of SLC25A25-AS1 silencing on malignant behaviours were counteracted when ITGA2 was restored or when miR-195-5p was silenced.\nLoss of SLC-30A9 leads to mitochondrial Zn accumulation, which damages mitochondria, impairs animal development and shortens the life span.\nIn summary, by controlling the miR-195-5p/ITGA2 axis, SLC25A25-AS1 served tumour-promoting roles in NSCLC cells.", "dois": ["10.1249/MSS.0000000000003722", "PMID:27553025", "10.1007/s13238-021-00881-4", "10.3892/ol.2021.12790"]}
{"pair_type": "slc_pathway", "key1": "SLC25A22", "key2": "stemness", "summary": "Organoids from ApcKrasSLC25A22 mice had reduced expression of LGR5 and other markers of stemness compared with organoids derived from ApcKras mice.\nIn CRC cells that express activated KRAS, SLC25A22 promotes accumulation of succinate, resulting in increased DNA methylation, activation of WNT signaling to β-catenin, increased expression of LGR5, proliferation, stem cell features, and resistance to 5-fluorouacil.\nLevel of SLC25A22 correlated with levels of LGR5, nuclear β-catenin, and a stem cell-associated gene expression pattern in human colorectal tumors with mutations in KRAS and reduced survival times of patients.\nKnockdown of SLC25A22 in human colorectal tumor organoids reduced clonogenicity.\nApcKrasSLC25A22 mice developed fewer colon tumors than ApcKras mice (P < .01).\nKnockdown of lysine demethylases, or succinate supplementation, restored expression of LGR5 to SLC25A22-knockout CRC cells.\nExpression of the protocadherin genes reduced WNT signaling to β-catenin and expression of the stem cell marker LGR5.\nThis results in inhibition of demethylases and epigenetic alterations in cells that increase proliferation and stem cell features.\nMutant KRAS promotes glutaminolysis, a process that uses steps from the tricarboxylic cycle to convert glutamine to α-ketoglutarate and other molecules via glutaminase and SLC25A22.\nKnockout of SLC25A22 in CRC cells that express mutant KRAS increased their sensitivity to 5-fluorouacil.", "dois": ["10.1053/j.gastro.2020.08.016"]}
{"pair_type": "slc_pathway", "key1": "SLC25A24", "key2": "migration", "summary": "Functional experiments indicated that SLC25A24 overexpression suppresses CRC cell proliferation, migration, and invasion.", "dois": ["10.1016/j.intimp.2025.114664"]}
{"pair_type": "slc_pathway", "key1": "SLC25A25", "key2": "oxidative phosphorylation", "summary": "Several carrier proteins evolutionarily related to ANT, including SLC25A24 and SLC25A25, are believed to promote the exchange of cytosolic ATP-Mg with phosphate in the mitochondrial matrix.\nAlthough loss-of-function recessive mutations cause a defect in oxidative phosphorylation and an increase in oxidative stress which drives the pathology, it is unclear how the dominant missense mutations in these proteins cause human diseases.\nInterestingly, some pathways are related to glycolipid metabolism, including oxidative phosphorylation, pyruvate metabolism, citrate cycle, etc.\nThe overexpression of significantly affected the expression of 1381 genes, and the pathways enriched with the DEGs mainly include oxidative phosphorylation, focal adhesion, ECM-receptor interaction, glutathione metabolism and MAPK signaling pathway.\nThey allow a net accumulation of adenine nucleotides inside mitochondria, which is essential for mitochondrial biogenesis and cell growth.", "dois": ["10.1002/iub.2767", "10.3390/ijms24108648"]}
{"pair_type": "slc_pathway", "key1": "SLC25A24", "key2": "proliferation", "summary": "SLC25A24-mutant fibroblasts and cells expressing p.Arg217Cys or p.Arg217His variants showed altered mitochondrial morphology, a decreased proliferation rate, increased mitochondrial membrane potential, and decreased ATP-linked mitochondrial oxygen consumption.\nFunctional experiments indicated that SLC25A24 overexpression suppresses CRC cell proliferation, migration, and invasion.\nMechanistic studies revealed that SLC25A24 positively regulates the cGMP/PKG1 signaling pathway in CRC, influencing mitochondrial potential, apoptosis, and proliferation-related markers.\nOur findings demonstrated that SLC25A24 expression is markedly reduced in CRC cell lines and tissues.\nKaplan-Meier survival analysis revealed that lower SLC25A24 expression is associated with worse overall survival and progression-free survival in CRC patients.\nIngenuity Pathway Analysis revealed enrichment for a host of biological pathways including lipid metabolism, molecular transport, immune response, cell morphology and development, and cell growth and proliferation.\nThis research highlights the SLC25A24-PKG1 axis as a potential therapeutic target to bolster anti-tumor immunity and curb CRC progression.\nWe previously reported differential expression of genes with identified roles in cellular growth and proliferation, lipid metabolism, endometrial remodeling, inflammation, angiogenesis, and metabolic exchange in endometrial tissue on day 7 of the estrous cycle (D7), between heifers ranked as either high (HF) or low (LF) for fertility.", "dois": ["10.1016/j.intimp.2025.114664", "10.1016/j.ajhg.2017.09.017", "10.1152/physiolgenomics.00042.2015"]}
{"pair_type": "slc_pathway", "key1": "SLC25A25", "key2": "oxidative stress", "summary": "Several carrier proteins evolutionarily related to ANT, including SLC25A24 and SLC25A25, are believed to promote the exchange of cytosolic ATP-Mg with phosphate in the mitochondrial matrix.\nAlthough loss-of-function recessive mutations cause a defect in oxidative phosphorylation and an increase in oxidative stress which drives the pathology, it is unclear how the dominant missense mutations in these proteins cause human diseases.\nExercise induced canonical early response genes (, , and ) and activated pathways related to angiogenesis, oxidative stress, stress kinase signaling, vascular remodeling, and metabolic stress signaling.\nAcute exercise causes a short-term stress, activating immediate gene expression responses.\nEndothelial cells, positioned throughout the vasculature, play a central role in sensing and responding to these stress signals.", "dois": ["10.1091/mbc.E13-08-0502", "10.1152/ajpendo.00250.2025", "10.1002/iub.2767"]}
{"pair_type": "slc_pathway", "key1": "SLC25A24", "key2": "oxidative stress", "summary": "These findings demonstrate that mitochondrial dysfunction with increased sensitivity to oxidative stress is due to the SLC25A24 mutations.\nKnockdown of the transporter led to vast reduction of mitochondrial Ca(2+) buffering capacity and sensitized cells to mPT-mediated necrotic death triggered by oxidative stress and Ca(2+) overload.\nHowever, upon HO exposure, the membrane potential was significantly elevated in cells harboring the mutated SLC25A24.\nIn contrast to control cells, the probands' cells showed mitochondrial swelling, which was exacerbated upon treatment with hydrogen peroxide (HO).\nAlthough loss-of-function recessive mutations cause a defect in oxidative phosphorylation and an increase in oxidative stress which drives the pathology, it is unclear how the dominant missense mutations in these proteins cause human diseases.\nUnder normal culture conditions, the mitochondrial membrane potential of the probands' fibroblasts was intact, whereas ATP content in the mitochondrial matrix was lower than that in control cells.\nThese findings revealed that SCaMC-1 exerts a negative feedback control between cellular Ca(2+) overload and mPT-dependent cell death, suggesting that the carrier might represent a novel target for cancer therapy.\nATP and ADP contribute to Ca(2+) buffering in the mitochondrial matrix, resulting in desensitization of the mPT.\nSCaMC-1 promotes cancer cell survival by desensitizing mitochondrial permeability transition via ATP/ADP-mediated matrix Ca(2+) buffering.", "dois": ["10.1016/j.ajhg.2017.09.016", "10.1091/mbc.E13-08-0502", "10.1038/cdd.2011.139", "10.1002/iub.2767"]}
{"pair_type": "slc_pathway", "key1": "SLC25A26", "key2": "apoptosis", "summary": "Furthermore, overexpression of SLC25A26 in CaSki cells increases mitochondrial SAM availability and promotes hypermethylation of mitochondrial DNA, leading to decreased expression of key respiratory complex subunits, reduction of mitochondrial ATP and release of cytochrome c.\nIn this study we show that SLC25A26 is down-regulated due to gene promoter hypermethylation, as a mechanism to promote cell survival and proliferation.\nGene ontology analysis showed enrichment of biological processes such as apoptosis, proliferation, and stress response in the network and suggested a relationship between down-regulation of the eight genes and activation of tumourigenic pathways.\nAll these events concur to arrest the cell cycle in the S phase, induce apoptosis and enhance chemosensitivity of SAM carrier-overexpressing CaSki cells to cisplatin.\nIn addition, increased SAM transport into mitochondria leads to impairment of the methionine cycle with accumulation of homocysteine at the expense of glutathione, which is strongly reduced.\nThe SLC25A26 gene encodes the mitochondrial carrier that catalyzes the import of S-adenosylmethionine (SAM) into the mitochondrial matrix, required for mitochondrial methylation processes, and is down-regulated in cervical cancer cells.", "dois": ["10.1111/febs.14028", "10.1002/path.4168"]}
{"pair_type": "slc_pathway", "key1": "SLC25A23", "key2": "apoptosis", "summary": "Notably, we observed that salinomycin treatment or SLC25A23 suppression elevates reactive oxygen species, upregulating death receptor 5 via Jun N-terminal protein kinase (JNK) pathway activation.\nSuppressing SLC25A23 disrupts cellular calcium homeostasis, impairs oxidative phosphorylation, and interferes with redox signaling, leading to death of senescent cells.\nUsing a CRISPR/Cas9-based genetic screen, we identify here SLC25A23 as a vulnerability of senescent cancer cells.\nMitochondrial Ca uptake is an important determinant of cell fate and governs respiration, mitophagy/autophagy, and the mitochondrial pathway of apoptosis.\nMCU dysfunction has been shown to alter mitochondrial Ca dynamics, in turn eliciting cell apoptosis.\nTaken together, down-regulation of mitochondria-related genes observed especially in macrophages indicates dysfunctional mitochondria, possibly contributing to energy collapse and induction of intrinsic pathway of apoptosis.\nSalinomycin prompts a pyroptosis-apoptosis-necroptosis (PAN)optosis-like cell death in senescent cells, including apoptosis and two forms of immunogenic cell death: necroptosis and pyroptosis.\nWe show that a combination of a death receptor 5 (DR5) agonistic antibody and salinomycin is a robust senolytic cocktail.\nRegulatory proteins that interact with them include mitochondrial Ca uptake 1/2 (MICU1/2), MCU dominant-negative β-subunit (MCUb), MCU regulator 1 (MCUR1), and solute carrier 25A23 (SLC25A23).\nChanges in mitochondrial Ca uptake have been implicated in pathological conditions affecting multiple organs, including the heart, skeletal muscle,", "dois": ["10.1073/pnas.2417724121", "10.1152/ajpcell.00502.2020", "10.1038/s41598-020-60025-2", "10.4149/av_2020_305"]}
{"pair_type": "slc_pathway", "key1": "SLC25A22", "key2": "oxidative stress", "summary": "SLC25A22 induces intracellular synthesis of aspartate, activation of mitogen-activated protein kinase kinase and extracellular signal-regulated kinase signaling and reduces oxidative stress.\nAn increased ratio of oxidized nicotinamide adenine dinucleotide phosphate to reduced nicotinamide adenine dinucleotide phosphate induced oxidative stress and glutathione oxidation, which suppressed cell proliferation.\nKnockdown of SLC25A22 reduced aspartate biosynthesis, leading to apoptosis, decreased cell proliferation in KRAS mutant CRC cells.\nDecreased levels of oxaloacetate in cells with knockdown of SLC25A22 reduced regeneration of oxidized nicotinamide adenine dinucleotide and reduced nicotinamide adenine dinucleotide phosphate.\nKnockdown of SLC25A22 in KRAS mutant CRC cells reduced their proliferation, migration, and invasion in vitro, and tumor formation and metastasis in mice, compared with cells without SLC25A22 knockdown.\nIncubation of KRAS mutant CRC cells with knockdown of SLC25A22 with aspartate increased proliferation and reduced apoptosis, which required GOT1, indicating that oxaloacetate is required for cell survival.\nReduced oxidized nicotinamide adenine dinucleotide inhibited glycolysis and decreased levels of adenosine triphosphate, which inactivated mitogen-activated protein kinase kinase and extracellular signal-regulated kinase signaling via activation of AMP-activated protein kinase.", "dois": ["10.1053/j.gastro.2016.07.011"]}
{"pair_type": "slc_pathway", "key1": "SLC25A25", "key2": "proliferation", "summary": "SLC25A25-AS1 silencing impeded NSCLC cell proliferation and triggered apoptosis, while restricting cell migration and invasion.\nIn contrast, PPARGC1A, SLC25A25 and SOCS2 were downregulated with TSPY expression, and possess favorable prognoses for HCC patients.\nIn summary, by controlling the miR-195-5p/ITGA2 axis, SLC25A25-AS1 served tumour-promoting roles in NSCLC cells.\nAlthough various studies showed that TSPY expression is associated with poor prognosis in the patients and its overexpression promotes cell proliferation of various cancer cell lines, it remains unclear how TSPY contributes to the clinical outcomes of the HCC patients.\nTumour growth was also impaired by SLC25A25-AS1 silencing.\nHigh SLC25A25-AS1 expression was markedly associated with shorter overall survival time of patients with NSCLC.\nFurthermore, the antitumour effects of SLC25A25-AS1 silencing on malignant behaviours were counteracted when ITGA2 was restored or when miR-195-5p was silenced.\nWe demonstrate that TSPY could exacerbate the oncogenesis of HCC by differentially upregulate the expression of pro-oncogenic genes and downregulate those of anti-oncogenic genes in male HCC patients, thereby contributing to the male predominance in this deadly cancer.\nThe results showed that TSPY upregulates various genes associated with cell-cycle and cell-viability, and suppresses cell-death related genes.", "dois": ["10.3892/ol.2021.12790", "10.1186/s13578-019-0287-x", "PMID:27553025"]}
{"pair_type": "slc_pathway", "key1": "SLC25A26", "key2": "proliferation", "summary": "In this study we show that SLC25A26 is down-regulated due to gene promoter hypermethylation, as a mechanism to promote cell survival and proliferation.\nFurthermore, overexpression of SLC25A26 in CaSki cells increases mitochondrial SAM availability and promotes hypermethylation of mitochondrial DNA, leading to decreased expression of key respiratory complex subunits, reduction of mitochondrial ATP and release of cytochrome c.\nAll these events concur to arrest the cell cycle in the S phase, induce apoptosis and enhance chemosensitivity of SAM carrier-overexpressing CaSki cells to cisplatin.\nGene ontology analysis showed enrichment of biological processes such as apoptosis, proliferation, and stress response in the network and suggested a relationship between down-regulation of the eight genes and activation of tumourigenic pathways.\nA total of 13 genes (, , , , , , , , , , , , and ) had a significant impact on proliferation in 100% of the NSCLC cell lines in both CRISPR-Cas9 ( = 78) and RNA interference (RNAi) assays ( = 92).\nThe SLC25A26 gene encodes the mitochondrial carrier that catalyzes the import of S-adenosylmethionine (SAM) into the mitochondrial matrix, required for mitochondrial methylation processes, and is down-regulated in cervical cancer cells.\nWe selected eight genes, THOC7, PSMD6, SLC25A26, TMF1, RYBP, SHQ1, EBLN2, and GBE1, which were highly down-regulated in cases with loss, as confirmed at the protein level for RYBP and TMF1 by immunohistochemistry.", "dois": ["10.3390/cancers13174296", "10.1111/febs.14028", "10.1002/path.4168"]}
{"pair_type": "slc_pathway", "key1": "SLC25A28", "key2": "migration", "summary": "In cellular experiments, butyrate significantly suppressed the cell viability, migration and invasion of T47D in a dose-dependent manner.\nIn addition, butyrate promoted the expression of cuproptosis-related genes including PDXK (pyridoxal kinase) and SLC25A28 (solute carrier family 25 member 28), which was lowly expressed in BC tumors.\nIn summary, butyrate inhibits the development of BC by facilitating the expression of PDXK and SLC25A28 through inhibition of TLR4.\nImportantly, overexpression of TLR4 can reverses the promotion of butyrate to PDXK and SLC25A28 expression and the prevention of butyrate to the malignant biological behaviors of T47D cells.\nThe knockdown of PDXK reduced the proliferation, migration and invasion of HCC cells.\nBesides, the upregulated PDXK could promote the proliferation and metastasis of HCC.", "dois": ["10.1007/s00432-024-05807-1", "10.1186/s13062-023-00358-w"]}
{"pair_type": "slc_pathway", "key1": "SLC25A26", "key2": "glycolysis", "summary": "Elevated SLC25A26 induced mitochondrial fragmentation, suppressed glycolysis and oxidative phosphorylation, and decreased ATP production.", "dois": ["10.1242/dev.204761"]}
{"pair_type": "slc_pathway", "key1": "SLC25A27", "key2": "oxidative phosphorylation", "summary": "The levels of CC genes involved in inflammation (CXCL1, CXCL3, TNF, PTGES), oxidative phosphorylation (NDUFB7, NDUFA4L2, SLC25A27), apoptosis (DAPK3, BCL6B) and metabolism (PCK1, LDHC) were analyzed using real-time quantitative PCR and compared between the two groups.\nOur data revealed different CC genes expression involving in inflammation, oxidative phosphorylation, apoptosis and metabolism between LPOS and FPOS in PORs.\nThe LPOS group had significantly lower mRNA expression of NDUFB7 (0.12 vs 1.00, < 0.001) and NDUFA4L2 (0.33 vs 1.00, < 0.01) than the FPOS group.", "dois": ["10.7150/ijms.55955"]}
{"pair_type": "slc_pathway", "key1": "SLC25A29", "key2": "apoptosis", "summary": "Endothelial cell proliferation and migration increased and apoptosis decreased with a decrease in SLC25A29 expression.\nInvestigation of the upstream regulatory mechanisms of SLC25A29 revealed that SLC25A29 expression gradually decreased as the lactate concentration increased.\nChIP-qPCR experiments confirmed the critical regulatory role played by H3K14la and H3K18la modifications in the promoter region of SLC25A29.\nFurther analysis revealed that SLC25A29 was underexpressed in LUAD tissue and regulated the phenotype of endothelial cells.\nIn conclusion, this study confirmed the role of SLC family genes in LUAD prognosis and revealed the role of SLC25A29 in regulating endothelial cell phenotypes.\nThis phenomenon suggested that the expression of SLC25A29 may be related to lactylation modification.", "dois": ["10.1186/s12935-023-03082-7"]}
{"pair_type": "slc_pathway", "key1": "SLC25A29", "key2": "ferroptosis", "summary": "Molecular simulations indicate that SLC25A29-mediated pathways contribute to mitochondrial metabolism and redox homeostasis, implicating POLD1 regulation and suggesting a link to ferroptosis.", "dois": ["10.1007/s11357-025-01538-4"]}
{"pair_type": "slc_pathway", "key1": "SLC25A28", "key2": "oxidative stress", "summary": "Mechanistically, SLC25A28 knockout suppressed mitochondrial iron accumulation, inhibited heme synthesis, and reduced NOX2-mediated oxidative stress.\nHowever, SLC25A28 overexpression enhanced mitochondrial iron overload and NOX2-driven inflammation, which could be reversed by pharmacological blockade of NOX2 or heme synthesis.\nThese findings demonstrate that microglial SLC25A28 regulates neuroinflammation and functional recovery after SCI by promoting mitochondrial iron-dependent heme synthesis and NOX2 activation.\nWe found that SLC25A28 deficiency reduced spinal cord edema, blood-spinal cord barrier disruption, and motor deficits.\nRestoration of heme synthesis in A28-MGKO microglia attenuated the anti-inflammatory effects of SLC25A28 knockout.", "dois": ["10.1111/cns.70638"]}
{"pair_type": "slc_pathway", "key1": "SLC25A29", "key2": "glycolysis", "summary": "SLC25A29-knockout cells also showed an altered metabolic status with enhanced mitochondrial respiration and reduced glycolysis.\nIn conclusion, aberrant elevated SLC25A29 in cancer functioned to transport more arginine into mitochondria, improved mitochondria-derived NO levels, thus modulated metabolic status to facilitate increased cancer progression.\nSLC25A29-knockout cells dramatically altered the variation of metabolic processes, whereas addition of arginine failed to reverse the effect, highlighting the necessity of transporting arginine into mitochondria by SLC25A29.", "dois": ["10.1038/s41388-018-0139-x"]}
{"pair_type": "slc_pathway", "key1": "SLC25A27", "key2": "apoptosis", "summary": "The levels of CC genes involved in inflammation (CXCL1, CXCL3, TNF, PTGES), oxidative phosphorylation (NDUFB7, NDUFA4L2, SLC25A27), apoptosis (DAPK3, BCL6B) and metabolism (PCK1, LDHC) were analyzed using real-time quantitative PCR and compared between the two groups.\nOur data revealed different CC genes expression involving in inflammation, oxidative phosphorylation, apoptosis and metabolism between LPOS and FPOS in PORs.\nQuantitative real-time PCR arrays were used to quantify the expression of 84 genes related to diverse functions of mitochondria, including biogenesis, transport, translocation and apoptosis.\nDAPK3 (3.81 vs 1.00, < 0.05) and BCL6B (2.59 vs 1.00, < 0.01) mRNA expression was significantly higher in the LPOS group than in the FPOS group.\nMtD could impair highly energy-dependent processes such as neurodevelopment, thereby contributing to autism.\nsolute carrier family 25, member 27 (SLC25A27) showed consistently reduced expression in the ACG, MC and THL of autism patients.", "dois": ["10.7150/ijms.55955", "10.1186/2040-2392-3-12", "PMID:16111824"]}
{"pair_type": "slc_pathway", "key1": "SLC25A13", "key2": "glycolysis", "summary": "Simultaneously, MAS dysfunction promotes glycolysis coupled to lactate production and reduces lactate-mediated gluconeogenesis, culminating in severe hyperlactatemia that triggers VEGF-induced vascular leakage.\nCitrin deficiency (CD) is a pan-ethnic autosomal recessive inborn error of metabolism due to-pathogenic variants in the SLC25A13 gene which results in disruptions of multiple metabolic pathways including glycolysis, gluconeogenesis, lipogenesis, the urea cycle, and tricarboxylic cycle.\nIndeed, we find that citrin is upregulated in multiple cancer types and is essential for supplementing NAD+ for glycolysis and NADH for oxidative phosphorylation.\nCitrin-deficient hepatocytes have primary defects in glycolysis and de novo lipogenesis and exhibit secondarily downregulated PPARα, leading to impaired β-oxidation.\nKetogenic diets (KD) are high-fat/low-carbohydrate diets, which decrease glycolysis thus bypassing the mentioned defects.\nCitrin deficiency may cause an impairment of glycolysis due to an increase in the cytosolic NADH/NAD ratio leading to an energy shortage in the liver.\nHepatic glycolysis is coupled with hepatic lipogenesis via the NADH shuttles composed of the malate-aspartate shuttle and malate-citrate shuttle.\nThe mitochondrial malate aspartate shuttle system (MAS) maintains the cytosolic NAD+/NADH redox balance, thereby sustaining cytosolic redox-dependent pathways, such as glycolysis and serine biosynthesis.\nCD manifests as different age-dependent phenotypes and affects crucial hepatic metabolic pathways including malate-aspartate-shuttle, glycolysis, gluconeogenesis, de novo lipogenesis and the tricarboxylic acid and urea cycles.\nWith an improved understanding of its molecular basis, it became apparent that a defect of citrin is primarily affecting the malate-aspartate shuttle with however multiple secondary effects on many central metabolic pathways including glycolysis, gluconeogenesis, de novo lipogenesis and ureagenesis.", "dois": ["10.3389/fimmu.2025.1652516", "10.2169/internalmedicine.2595-23", "10.1038/s41388-019-0976-2", "10.1016/j.ymgme.2025.109215", "10.1002/jimd.12768", "10.1002/jimd.12772", "10.3390/nu14173605", "10.1002/jimd.12294", "10.1111/asj.13212", "10.2147/TACG.S162084", "10.1007/s10545-018-0176-1", "10.11477/mf.1416200211", "PMID:27896073", "10.1007/8904_2011_42", "PMID:16613706", "PMID:16199199"]}
{"pair_type": "slc_pathway", "key1": "SLC25A29", "key2": "proliferation", "summary": "Endothelial cell proliferation and migration increased and apoptosis decreased with a decrease in SLC25A29 expression.\nKnockout of SLC25A29 by CRISPR/Cas9 inhibited proliferation and migration of cancer cells both in vitro and in vivo.\nSLC25A29-knockout cells also showed an altered metabolic status with enhanced mitochondrial respiration and reduced glycolysis.\nIn conclusion, aberrant elevated SLC25A29 in cancer functioned to transport more arginine into mitochondria, improved mitochondria-derived NO levels, thus modulated metabolic status to facilitate increased cancer progression.\nAll of above impacts could be reversed after rescuing SLC25A29 expression in SLC25A29-knockout cells.\nOur current study found a member of solute carrier family 25 (SLC25A29), the main arginine transporter on mitochondria, significantly elevated in various cancer cells.\nSLC25A29-knockout cells dramatically altered the variation of metabolic processes, whereas addition of arginine failed to reverse the effect, highlighting the necessity of transporting arginine into mitochondria by SLC25A29.", "dois": ["10.1186/s12935-023-03082-7", "10.1038/s41388-018-0139-x"]}
{"pair_type": "slc_pathway", "key1": "SLC25A30", "key2": "apoptosis", "summary": "Real-time PCR analyses on the adult normal livers showed that two genes (Creld2, Slc25a30), whose expression are induced by endoplasmic reticulum stress and cellular oxidative stress, respectively, were significantly upregulated and two genes (Fabp4, Ell3), whose products are involved in lipid efflux and apoptosis, respectively, were significantly downregulated more than twofold by gestational arsenic exposure compared with control mice.", "dois": ["10.1093/toxsci/kfs203"]}
{"pair_type": "slc_pathway", "key1": "SLC25A30", "key2": "oxidative stress", "summary": "Real-time PCR analyses on the adult normal livers showed that two genes (Creld2, Slc25a30), whose expression are induced by endoplasmic reticulum stress and cellular oxidative stress, respectively, were significantly upregulated and two genes (Fabp4, Ell3), whose products are involved in lipid efflux and apoptosis, respectively, were significantly downregulated more than twofold by gestational arsenic exposure compared with control mice.\nThese results suggested that gestational arsenic exposure induces tumor-augmenting changes, including oxidative stress and L1 activation, in a late-onset manner, which would particularly promote tumorigenic expansion of cells with a C61A Ha-ras mutation.\nConsistently, expression of an oxidative-stress-inducible gene heme oxygenase-1 (HO-1) was upregulated in the livers of the arsenic group.\nThe gene expression changes suggested alterations in lipid metabolism and associated oxidative stress augmentation.", "dois": ["10.1093/toxsci/kfs203"]}
{"pair_type": "slc_pathway", "key1": "SLC25A28", "key2": "proliferation", "summary": "Data from the current study indicate that SLC25A28 overexpression promotes diet-induced obesity and accelerates lipid accumulation by regulating hormone secretion and inhibiting lipolysis in adipose tissue.\nBesides, the upregulated PDXK could promote the proliferation and metastasis of HCC.\nThe knockdown of PDXK reduced the proliferation, migration and invasion of HCC cells.\nIron promoted proliferation, carcinogenesis and Warburg effect of osteosarcoma cells.\nOur recent research indicates that PINK1 functions as a tumor suppressor in colorectal cancer by regulating cellular metabolism.\nHowever, inhibiting the NLRP3-IL1B signaling pathway with an IL1R (interleukin 1 receptor) antagonist or NLRP3 inhibitor did not hinder colon tumor growth after PINK1 loss.\nThis study suggests that therapies aimed at reducing mitochondrial iron levels may effectively inhibit colon tumor growth, particularly in patients with low PINK1 expression.\nCell proliferation ability of osteosarcoma cell lines was measured by CCK-8, EdU incorporation and colony formation assays.\nManipulating the mitochondrial iron uptake protein MCU (mitochondrial calcium uniporter) also affected cell and xenograft tumor growth.\nClinically used drugs deferiprone and minocycline reduced mitochondrial iron and superoxide levels, resulting in decreased colon tumor cell growth.\nSLC25A28 overexpression accelerated lipid accumulation in white and brown adipose tissue (BAT), enhanced body weight, reduced serum triglyceride (TG), and impaired serum glucose tolerance.\nMoreover, SLC25A28 overexpression inhibited the BAT formation by downregulating UCP-1 and the mitochondrial biosynthesis marker PGC-1.\nThe results showed that adipose TG lipase (ATGL) protein expression was reduced significantly in white and BAT after overexpression SLC25A28 compared to the control group.\nAdipocyte proliferation and hypertrophy are the root causes of adipose tissue expansion.\nRemarkably, serum fibroblast growth factor (FGF21) protein expression was negatively relate", "dois": ["10.1080/15548627.2024.2425594", "10.1155/2024/5511454", "10.1186/s13062-023-00358-w", "10.1186/s12935-020-01494-3", "10.1074/jbc.RA120.013229"]}
{"pair_type": "slc_pathway", "key1": "SLC25A27", "key2": "proliferation", "summary": "This supports the high ROS production and MMP required for the rapid growth of LGG, thereby promoting its proliferation and invasion.\nAdditionally, SDHB expression was significantly higher in LGG cells, and knockdown of SDHB inhibited cell proliferation and invasion, supporting its role in tumor progression.\nThe prognostic model, constructed using the StepCox[forward] + plsRcox approach, included five genes: SDHB, SDHC, SLC25A27, UQCRB, and NDUFA13.\nOur findings suggest that he high expression of SDHB in LGG contributes to maintaining elevated SDH and Complex II activity, ensuring the structural and functional integrity of mitochondrial ETC complexes.", "dois": ["10.1186/s12935-025-03958-w"]}
{"pair_type": "slc_pathway", "key1": "SLC25A31", "key2": "oxidative phosphorylation", "summary": "Only L929 cells exhibited up-regulation of two important genes responsible for oxidative phosphorylation and subsequent ATP production: Slc25a23 and Slc25a31.\nUpregulated proteins were related to oxidative phosphorylation (SLC25A-31), mitochondria (ATP5PD), ion transport (VDAC2-3), endoplasmic reticulum transport (PHB, TMED10, CANX), and cytoskeleton remodeling (TUB1A-C, ANXA1).\nIn aerobic eukaryotic cells, the high energy metabolite ATP is generated mainly within the mitochondria following the process of oxidative phosphorylation.\nThe mitochondrial ATP is exported to the cytoplasm using a specialized transport protein, the ADP/ATP carrier, to provide energy to the cell.\nThe objective of this review is to summarize the current knowledge of the involvement of the ADP/ATP carrier, encoded by the SLC25A4, SLC25A5, SLC25A6 and SLC25A31 genes, in human diseases and of the efforts made at designing different model systems to study this carrier and the associated pathologies through biochemical, genetic, and structural approaches.", "dois": ["10.3390/biomedicines12091934", "10.4149/av_2020_305", "10.1016/j.mam.2012.05.006"]}
{"pair_type": "slc_pathway", "key1": "SLC25A27", "key2": "oxidative stress", "summary": "Knocking out DJ-1 (also known as PARK7 in humans and Park7 in mice), which is a gene associated with an early-onset form of Parkinson's disease, downregulated the expression of two uncoupling proteins (UCP4 (SLC25A27) and UCP5 (SLC25A14)), compromised calcium-induced uncoupling and increased oxidation of matrix proteins specifically in SNc dopaminergic neurons.\nThe oxidant stress engaged defences that induced transient, mild mitochondrial depolarization or uncoupling.\nHere we show, using transgenic mice that expressed a redox-sensitive variant of green fluorescent protein targeted to the mitochondrial matrix, that the engagement of plasma membrane L-type calcium channels during normal autonomous pacemaking created an oxidant stress that was specific to vulnerable SNc dopaminergic neurons.\nMitochondrial oxidant stress is widely viewed as being responsible for this loss, but why these particular neurons should be stressed is a mystery.", "dois": ["10.1155/2021/9939331", "10.1038/nature09536"]}
{"pair_type": "slc_pathway", "key1": "SLC25A32", "key2": "glycolysis", "summary": "Akt1 primarily affects the expression of genes in chondrocytes under HT-2 exposure that involved in autophagy, cell proliferation and glycolysis and other cell functions, potentially contributing to the pathogenesis of KBD.\nin the module most associated with HT-2-siAkt1, the hub genes were GNAL, SLC25A32, ACADSB, CABLES1 and GINS4.\nFructose and mannose metabolism, amino acid biosynthesis, and glucose/energy metabolic pathways were significantly downregulated.", "dois": ["10.1016/j.toxicon.2025.108432"]}
{"pair_type": "slc_pathway", "key1": "SLC25A32", "key2": "oxidative phosphorylation", "summary": "Flavin adenine dinucleotide (FAD) is an essential co-factor for many mitochondrial enzymes and impaired mitochondrial FAD-transport was supported by a reduced oxidative phosphorylation complex II activity in the patient's muscle, decreased ATP production in fibroblasts, and a deficiency of mitochondrial FAD-dependent enzymes.", "dois": ["10.1038/ejhg.2017.62"]}
{"pair_type": "slc_pathway", "key1": "SLC25A28", "key2": "chemotherapy", "summary": "Through machine learning algorithms, three hub genes (ECH1, SLC25A28 and ULK1) were identified to be closely associated with sorafenib resistance.\nFurthermore, experimental validation confirmed the upregulation of ECH1, SLC25A28 and ULK1 expressions in sorafenib-resistant HCC cells, with sorafenib treatment altering their expression profiles.\nNotably, these genes stratified sorafenib-resistant HCC patients into distinct subgroups with different drug sensitivities, immune cell infiltrations, and responses to chemotherapy and immunotherapy.\nA novel ferroptosis-related signature comprising these genes emerged as a robust diagnostic model, validated by ROC curve analysis, for predicting sorafenib resistance in HCC patients.\nKnockdown of ULK1 in sorafenib-resistant HCC cells potently enhanced sorafenib-induced ferroptosis, thereby alleviating sorafenib resistance.\nFerroptosis, an iron-dependent form of regulated cell death, has emerged as a crucial target in cancer therapy, showing potential to enhance treatment efficacy and overcome drug resistance.\nPrevious studies have demonstrated that sorafenib triggers ferroptosis in HCC cells and that ferroptosis plays a significant role in the development of sorafenib resistance.\nUsing the GSE109211 dataset, we identified differentially expressed ferroptosis-related genes associated with sorafenib resistance.\nOur findings not only identify pivotal ferroptosis-related genes as diagnostic biomarkers for sorafenib resistance but also provide insights into the role of ferroptosis in modulating sorafenib responsiveness.\nThis study offers a promising strategy to overcome sorafenib resistance and improve patient outcomes in HCC treatment, highlighting the potential of ferroptosis-targeted therapies in cancer management.", "dois": ["10.1016/j.intimp.2025.115557"]}
{"pair_type": "slc_pathway", "key1": "SLC25A32", "key2": "proliferation", "summary": "Knockdown of SLC25A32 inhibited the proliferation and invasion of GBM cells, but overexpression of SLC25A32 significantly promoted cell growth and invasion.\nMoreover, buthionine sulfoximine (BSO) treatment further sensitizes cells to ROS-mediated inhibition of cell proliferation upon SLC25A32 knock-down.\nSLC25A32 knockdown decreased breast tumour cell proliferation, invasion, and metastasis.\nInstead, SLC25A32 inhibition results in a respiratory chain dysfunction at the FAD-dependent complex II enzyme, induction of Reactive Oxygen Species (ROS) and depletion of reduced glutathione (GSH), which impairs cancer cell proliferation.\nTreatment of cells with the FAD precursor riboflavin and with GSH rescues cancer cell proliferation upon SLC25A32 down-regulation.\nWhile it is known that cancer cells require one-carbon and FAD-dependent mitochondrial metabolism to sustain cell proliferation, the role of SLC25A32 in cancer cell growth remains unexplored.\nOur results indicate that the reduction of mitochondrial FAD concentrations by targeting SLC25A32 has potential clinical applications as a single agent or in combination with approved cancer drugs that lead to increased oxidative stress and reduced tumor growth.\nOur study demonstrated that SLC25A32 plays a significant role in promoting the malignant phenotype of GBM.\nThe involvement of SLC25A32 in tumorigenesis may be due to its regulation of mitochondrial folate and FAD metabolism, which have been linked to cancer progression.\nThe probable contribution of toward facilitating the proliferation of cancerous cells remains inadequately explored.\nChanges in SLC25A32 expression or function may contribute to cancer development, making it a potential therapeutic target for cancer treatment.\nsiRNA-mediated knock-down and CRISPR-mediated knock-out of SLC25A32 in cancer cells of different origins, resulted in the identification of cell lines sensitive and resistant to SLC25A32 inhibition.\nMechanistically, tracing of deuterated serine revealed that SLC25A32 knock-down does not affect the mitochondrial/cytosolic folate flux as measured by Liqui", "dois": ["10.1007/s12291-024-01217-9", "10.1016/j.toxicon.2025.108432", "10.1155/2024/1373659", "10.1158/1535-7163.MCT-23-0550", "10.1186/s12885-023-11097-6", "10.18632/oncotarget.27486"]}
{"pair_type": "slc_pathway", "key1": "SLC25A29", "key2": "oxidative phosphorylation", "summary": "Functional groups displaying highly significant (P < 0.0001) increased expression included mitochondrion, oxidative phosphorylation and fatty acid metabolism while functional groups with decreased expression were mainly associated with structural genes and included the sarcoplasm, laminin complex and cytoskeleton.\nSixteen genes showed increased expression, including the mitochondrial genes ACADVL, MRPS21 and SLC25A29 encoded by the nuclear genome.\nThe high-risk group had a lower activation of oxidative phosphorylation and a more abundant immune infiltration phenotype than the low-risk group.\nAccording to co-expression network studies, SLC25A11, SLC25A29, and SLC25A44 were involved in the energy metabolism of PC and prevented tumor growth, invasion, and metastasis.\nExercise training in Thoroughbred racehorses results in coordinate changes in the gene expression of functional groups of genes related to metabolism, oxidative phosphorylation and muscle structure.\nThe most abundant mRNA transcripts in the muscle transcriptome were those involved in muscle contraction, aerobic respiration and mitochondrial function.", "dois": ["10.1186/s12967-022-03756-2", "10.1186/1471-2164-11-398"]}
{"pair_type": "slc_pathway", "key1": "SLC25A31", "key2": "oxidative stress", "summary": "Ant2 depletion caused anemia in a cell-autonomous manner by maturation arrest of erythroid precursors with increased reactive oxygen species and premature deaths.\nErythroid and B-cell development may be particularly vulnerable to Ant2 depletion-mediated mitochondrial dysfunction and oxidative stress.\nB-lymphocyte development was similarly affected by Ant2 depletion, and splenocytes showed a reduction in maximal respiration capacity and cellular ATP levels as well as an increase in cell death accompanying mitochondrial permeability transition pore opening.", "dois": ["10.1038/cdd.2014.230"]}
{"pair_type": "slc_pathway", "key1": "SLC25A32", "key2": "oxidative stress", "summary": "Folate supplementation elevated the expression of MTHFD2 and SLC25A32, alleviated oxidative stress and effectively suppressed myofibroblast differentiation and silica-induced pulmonary fibrosis in mice.\nOur results indicate that the reduction of mitochondrial FAD concentrations by targeting SLC25A32 has potential clinical applications as a single agent or in combination with approved cancer drugs that lead to increased oxidative stress and reduced tumor growth.\nMoreover, buthionine sulfoximine (BSO) treatment further sensitizes cells to ROS-mediated inhibition of cell proliferation upon SLC25A32 knock-down.\nInstead, SLC25A32 inhibition results in a respiratory chain dysfunction at the FAD-dependent complex II enzyme, induction of Reactive Oxygen Species (ROS) and depletion of reduced glutathione (GSH), which impairs cancer cell proliferation.\nIn an in vitro psoriatic keratinocyte model, riboflavin reduction induced upregulation of inflammatory cytokines, ROS response and delayed keratinisation.\nTreatment of cells with the FAD precursor riboflavin and with GSH rescues cancer cell proliferation upon SLC25A32 down-regulation.\nSLC25A32 transports tetrahydrofolate (THF) as well as FAD into mitochondria and regulates mitochondrial one-carbon metabolism and redox balance.\nPsoriasis is a chronic inflammatory skin disease characterised by oxidative stress in the epidermis.\nRiboflavin (vitamin B2), an essential vitamin with antioxidant properties, may play a role in modulating this condition.", "dois": ["10.1111/exd.70106", "10.1186/s12967-023-04241-0", "10.18632/oncotarget.27486"]}
{"pair_type": "slc_pathway", "key1": "SLC25A33", "key2": "chemotherapy", "summary": "Among these proteins, we have identified many differentially abundant proteins identified as having a role in cancer (IFIT1, FASTKD2, PIP4K2B, ARID1B, SLC25A33: overexpressed in TR;\nThe standard treatment for patients with locally advanced non-metastatic rectal cancer is neoadjuvant radio-chemotherapy (NRCT) with 5-fluorouracil (5-FU) followed by surgery, but the resistance rate to this treatment remains high with approximately 30% of non-responders.\nWe have highlighted 384 differentially abundant proteins between NR and PR, 248 between NR and TR and 417 between PR and TR.\nWe have also identified that DPYD, the main degradation enzyme of 5-FU, was overexpressed in NR, as well as several ribosomal and mitochondrial proteins also overexpressed in NR.\nThe lack of evidence available in clinical practice to predict NRCT resistance to 5-FU and to guide clinical practice therefore encourages the search for biomarkers of this resistance.\nFrom these retrospective study, we implemented a protein extraction protocol from FFPE biopsy to highlight protein differences between different response groups to RCTN with 5-FU in patients with locally advanced non-metastatic rectal cancer.\nFrom clinical data, we were able to classify the twenty-three patients in our cohort into three treatment response groups: non-responders (NR), partial responders (PR) and total responders (TR), and to compare the proteomes of these different groups.", "dois": ["10.1186/s12014-018-9192-2"]}
{"pair_type": "slc_pathway", "key1": "SLC25A31", "key2": "apoptosis", "summary": "Pretreatment with BD1047, a sigma-1 receptor antagonist, before cocaine exposure reduces HIV-1, CATB secretion, and neuronal apoptosis.\nTaken together, down-regulation of mitochondria-related genes observed especially in macrophages indicates dysfunctional mitochondria, possibly contributing to energy collapse and induction of intrinsic pathway of apoptosis.\nDescribed as a decisive player in the programmed cell death, it was recently shown to play a role in cancer.\nOur results show that during later stages of infection, ECTV significantly decreases the expression of mitochondria-related genes regulating many aspects of mitochondrial physiology and functions, including mitochondrial transport, small molecule transport, membrane polarization and potential, targeting proteins to mitochondria, inner membrane translocation, and apoptosis.\nUpregulated proteins were related to oxidative phosphorylation (SLC25A-31), mitochondria (ATP5PD), ion transport (VDAC2-3), endoplasmic reticulum transport (PHB, TMED10, CANX), and cytoskeleton remodeling (TUB1A-C, ANXA1).\nBD1047 treatment protects HIV-1-infected MDM exposed to cocaine by upregulating proteins that reduce mitochondrial damage, ER transport, and exocytosis associated with CATB-induced neurotoxicity.\nWe found fifteen (15) proteins related to HIV-1 infection, CATB, and mitochondrial function.\nMeanwhile, alteration of the expression of several mitochondria-related genes in fibroblasts without apoptosis induction may represent poxviral strategy to control cellular energy metabolism for efficient replication.", "dois": ["10.1016/j.mam.2012.05.006", "10.3390/biomedicines12091934", "10.4149/av_2020_305"]}
{"pair_type": "slc_pathway", "key1": "SLC25A32", "key2": "stemness", "summary": "SLC25A32 is significantly associated with the survival prognosis of some cancers, immune infiltrating cells, tumour stemness, and immune-related markers.", "dois": ["10.1155/2024/1373659"]}
{"pair_type": "slc_pathway", "key1": "SLC25A28", "key2": "apoptosis", "summary": "And PDXK deficiency facilities cuproptosis in HCC.\nAnd PDXK deficiency increased the sensitivity of HCC cells to cuproptosis inducer.\nBesides, the upregulated PDXK could promote the proliferation and metastasis of HCC.\nThe knockdown of PDXK reduced the proliferation, migration and invasion of HCC cells.", "dois": ["10.1186/s13062-023-00358-w", "10.3390/genes16050581"]}
{"pair_type": "slc_pathway", "key1": "SLC25A33", "key2": "migration", "summary": "Silencing of SLC25A33 suppressed the PDGF-stimulated proliferation and migration of VSMCs and cell cycle progression.\nThe effects of small interfering RNAinduced silencing of SLC25A33 mRNA on platelet-derived growth factor (PDGF)-induced proliferation and migration of VSMCs were analyzed.\nFurthermore, the downregulation of SLC25A33 reduced carotid artery ligation-induced neointima in mice.\nKnockdown of SLC25A33 inhibited PDGF-induced production of mtDNA and ROS, consequently inactivating the cyclic GMP-AMP synthesis (cGAS)-stimulator of interferon genes (STING)-TANK-binding kinase 1 (TBK1)-nuclear factor kappa B (NF-κB) pathway.\nThis study suggests that targeting SLC25A33 in VSMCs could be a novel therapeutic strategy to prevent occlusive vascular diseases.\nVascular smooth muscle cells (VSMCs) play a crucial role in the development of occlusive vascular diseases through abnormal proliferation and migration.\nThis study aimed to investigate the effects of SLC25A33 inhibition on the proliferation and migration of VSMCs, as well as its impact on neointima formation.", "dois": ["10.4093/dmj.2024.0632"]}
{"pair_type": "slc_pathway", "key1": "SLC25A33", "key2": "proliferation", "summary": "Silencing of SLC25A33 suppressed the PDGF-stimulated proliferation and migration of VSMCs and cell cycle progression.\nThis study aimed to investigate the effects of SLC25A33 inhibition on the proliferation and migration of VSMCs, as well as its impact on neointima formation.\nThe effects of small interfering RNAinduced silencing of SLC25A33 mRNA on platelet-derived growth factor (PDGF)-induced proliferation and migration of VSMCs were analyzed.\nFurthermore, the downregulation of SLC25A33 reduced carotid artery ligation-induced neointima in mice.\nKnockdown of SLC25A33 inhibited PDGF-induced production of mtDNA and ROS, consequently inactivating the cyclic GMP-AMP synthesis (cGAS)-stimulator of interferon genes (STING)-TANK-binding kinase 1 (TBK1)-nuclear factor kappa B (NF-κB) pathway.\nThis study suggests that targeting SLC25A33 in VSMCs could be a novel therapeutic strategy to prevent occlusive vascular diseases.\nVascular smooth muscle cells (VSMCs) play a crucial role in the development of occlusive vascular diseases through abnormal proliferation and migration.", "dois": ["10.4093/dmj.2024.0632"]}
{"pair_type": "slc_pathway", "key1": "SLC25A29", "key2": "migration", "summary": "Endothelial cell proliferation and migration increased and apoptosis decreased with a decrease in SLC25A29 expression.\nKnockout of SLC25A29 by CRISPR/Cas9 inhibited proliferation and migration of cancer cells both in vitro and in vivo.\nIn conclusion, aberrant elevated SLC25A29 in cancer functioned to transport more arginine into mitochondria, improved mitochondria-derived NO levels, thus modulated metabolic status to facilitate increased cancer progression.\nAll of above impacts could be reversed after rescuing SLC25A29 expression in SLC25A29-knockout cells.\nOur current study found a member of solute carrier family 25 (SLC25A29), the main arginine transporter on mitochondria, significantly elevated in various cancer cells.\nSLC25A29-knockout cells dramatically altered the variation of metabolic processes, whereas addition of arginine failed to reverse the effect, highlighting the necessity of transporting arginine into mitochondria by SLC25A29.\nSLC25A29-knockout cells also showed an altered metabolic status with enhanced mitochondrial respiration and reduced glycolysis.\nFurther analysis revealed that SLC25A29 was underexpressed in LUAD tissue and regulated the phenotype of endothelial cells.\nIn conclusion, this study confirmed the role of SLC family genes in LUAD prognosis and revealed the role of SLC25A29 in regulating endothelial cell phenotypes.\nInvestigation of the upstream regulatory mechanisms of SLC25A29 revealed that SLC25A29 expression gradually decreased as the lactate concentration increased.\nChIP-qPCR experiments confirmed the critical regulatory role played by H3K14la and H3K18la modifications in the promoter region of SLC25A29.\nDeletion of SLC25A29 resulted in severe decrease of NO production, indicating that the mitochondria is a significant source of NO.", "dois": ["10.1186/s12935-023-03082-7", "10.1038/s41388-018-0139-x"]}
{"pair_type": "slc_pathway", "key1": "SLC25A33", "key2": "oxidative stress", "summary": "The PCR results showed that SLC25A33 and NDUFS1 expression were increased in DR rats modeling group.\nSignificant key genes were predominantly associated with mitochondrial function, fatty acid oxidation and oxidative stress.\nGene co-expression network analysis highlights the importance of mitochondria and oxidative stress in the pathophysiology of DR.\nAmong all key genes analyzed, six up-regulated genes (, SLC25A33, NDUFS1, MRPS23, CYB5R1, MECR, and MRPL15) were highly and significantly relevant in the context of DR formation.", "dois": ["10.7717/peerj.12126"]}
{"pair_type": "slc_pathway", "key1": "SLC25A34", "key2": "proliferation", "summary": "NKRF inhibited SLC25A34 transcription in CRC cells, and silencing SLC25A34 overturned the suppressive effects of NKRF knockdown on cell proliferation, growth, and mobility.\nSLC25A34 was reduced in CRC tissues and cells, and overexpression of SLC25A34 repressed the malignant phenotype of CRC cells.\nOverexpression of MYLIP in CRC cells inhibited NKRF expression by degrading NKRF to activate SLC25A34 transcription and inhibit xenograft formation and lung metastases.", "dois": ["10.1007/s10620-024-08735-9"]}
{"pair_type": "slc_pathway", "key1": "SLC25A34", "key2": "apoptosis", "summary": "Overexpression of SLC25A34 repressed the malignant phenotype of CRC cells.\nCCK-8, colony formation, TUNEL, and Transwell assays were used to detect CRC cell proliferation, growth, mobility, and apoptosis.\nOverexpression of MYLIP in CRC cells inhibited NKRF expression by degrading NKRF to activate SLC25A34 transcription and inhibit xenograft formation and lung metastases.\nNKRF inhibited SLC25A34 transcription in CRC cells, and silencing SLC25A34 overturned the suppressive effects of NKRF knockdown on cell proliferation, growth, and mobility.", "dois": ["10.1007/s10620-024-08735-9"]}
{"pair_type": "slc_pathway", "key1": "SLC25A28", "key2": "ferroptosis", "summary": "HSC-specific blockade of BRD7-P53-SLC25A28 axis could abrogate erastin-induced HSC ferroptosis.\nIn the current study, we reported that the BRD7-P53-SLC25A28 axis played a crucial role in regulating ferroptosis in hepatic stellate cells (HSCs).\nAttractively, BRD7 upregulation, p53 mitochondrial translocation, combination of SLC25A28 and p53, and ferroptosis induction occurred in primary human HSCs.\nAltogether, this study demonstrates that ZFAS1 is a crucial element of ferroptosis in ccRCC, as it is responsible for the regulation of miR-185-5p and SLC25A28.\nOverall, these findings reveal novel signal transduction and regulatory mechanism of ferroptosis, and also suggest BRD7-P53-SLC25A28 axis as potential targets for liver fibrosis.\nOverexpressed SLC25A28 increased the production of ROS and caused a decrease in NADPH and GSH in cells treated with FINS.\nZFAS1 increased mRNA and protein levels of solute carrier family 25 member 28 (SLC25A28) via functioning as a miR-185-5p sponge.\nCRISPR/Cas9-mediated BRD7 knockout conferred resistance to HSC ferroptosis, whereas specific BRD7 plasmid-mediated BRD7 overexpression facilitated HSC ferroptosis.\nImportantly, mitochondrial p53 interacted with solute carrier family 25 member 28 (SLC25A28) to form complex and enhanced the activity of SLC25A28, which could lead to the abnormal accumulation of redox-active iron and hyperfunction of electron transfer chain (ETC).\nSLC25A28 knockdown impaired BRD7-or p53-mediated ferroptotic events.\nIn addition, overexpression of ZFAS1 enhanced ferroptosis both in vitro and in vivo.\nSite-directed mutations of serine 392 completely blocked the binding of BRD7 to p53,", "dois": ["10.1016/j.intimp.2025.115557", "10.1016/j.ijbiomac.2025.140602", "10.1016/j.brainres.2024.149274", "10.7554/eLife.86354", "10.1016/j.redox.2020.101619"]}
{"pair_type": "slc_pathway", "key1": "SLC25A35", "key2": "proliferation", "summary": "Functionally, SLC25A35 promoted the proliferation and metastasis of HCC cells both in vitro and in vivo, as well as the carcinogenesis in a DEN-induced HCC mice model.\nHere, we found that SLC25A35 markedly reprogramed mitochondrial metabolism, characterized by increased oxygen consumption rate and ATP production and decreased ROS level, via enhancing fatty acid oxidation (FAO).\nMechanistic studies revealed that SLC25A35 facilitated FAO and mitochondrial biogenesis through upregulating peroxisome proliferator-activated receptor γ coactivator 1α (PGC-1α) via increasing acetyl-CoA-mediated acetylation of PGC-1α.\nMeanwhile, SLC25A35 also enhanced mitochondrial biogenesis characterized by increased mitochondrial mass and DNA content.\nClinically, SLC25A35 was highly expressed in HCC and correlated with adverse patients' survival.\nTogether, our results suggest a crucial oncogenic role of SLC25A35 in HCC by reprogramming mitochondrial metabolism and suggest SLC25A35 as a potential therapeutic target for the treatment of HCC.", "dois": ["10.1186/s12964-025-02109-y"]}
{"pair_type": "slc_pathway", "key1": "SLC25A37", "key2": "apoptosis", "summary": "Further, we identified that mitochondrial impairment mainly contributed to these phenomena and mitochondrial proteins SLC25A37 and TIMM50 were crucial targets for miR-7 to induce cell death in RMS.\nChemical inhibitors of apoptosis and necroptosis were able to prevent miR-7-induced cell death.\nMorphologic features and molecular characteristics with apoptosis and necroptosis were found in miR-7-transfected RMS cells.\nImmunohistochemistry and RT-qPCR showed that among the MacPCD model genes, BID, SLC25A37 and BNIP3L were highly expressed in tumour tissues, whereas ACSL1, SDHB and ALDH2 were highly expressed in normal tissues.\nTranscripts were selected for validation based on mechanistic plausibility and three were significantly over-expressed by qPCR in high cytotoxicity patients: multi-specific organic anion transporter C (), mitoferrin-1 (), and Porimin ().\nThese include , encoding a mitochondrial iron transporter, , encoding an arylamine drug transporter, and , encoding a transmembrane protein that mediates cell death.\nMiR-7 executed anti-tumor effect in RMS beyond proliferation inhibition.\nOur results extended the mechanism of miR-7 antitumor role in rhabdomyosarcoma cancer, and provided potential implications for its therapy.", "dois": ["10.1007/s10565-025-10023-9", "10.1016/j.bbamcr.2020.118826", "10.1002/prp2.388"]}
{"pair_type": "slc_pathway", "key1": "SLC25A37", "key2": "oxidative phosphorylation", "summary": "Differential expression of two genes inside the mitochondria involved in critical mitochondrial complexes: BCS1L (β = 1.30), SLC25A37 (β = -2.44), and two genes on the outer mitochondrial membrane vital for mitochondrial integrity: BCL2L1 (β = -1.68) and FIS1 (β = -2.35) were significantly associated with changes in fatigue scores of study subjects during EBRT.\nGenes related to oxidative phosphorylation, energy production, and mitochondrial membrane integrity are associated with worsening fatigue during EBRT.", "dois": ["10.1074/jbc.RA120.013229", "10.1016/j.jpainsymman.2014.03.010"]}
{"pair_type": "slc_pathway", "key1": "SLC25A28", "key2": "glycolysis", "summary": "SLC25A28 deficiency inhibited microglial activation by restricting the aerobic glycolysis.\nmicroglial SLC25A28 deficiency ameliorated neuroinflammation, brain edema, blood-brain barrier injury and ethological alterations in mice after ICH.", "dois": ["10.1007/s10753-023-01931-1"]}
{"pair_type": "slc_pathway", "key1": "SLC25A37", "key2": "proliferation", "summary": "Furthermore, over-expression of miR-22 down-regulates the expression of its target genes (MXI1 and SLC25A37) in this ovarian cancer cell line, highlighting an miRNA-mediated regulatory network potentially important for cellular proliferation.\nTo gain further insight into the effect of miRNAs on cellular proliferation in cancer, we showed that over-expression of miR-22, one of the top iGrowth-associated miRNAs, leads to growth inhibition in an ovarian cancer cell line (SKOV3).\nIn addition, we found reduced expression of the hematopoietic stem cells (HSC) marker cmyb and HSC transcription factors tal1 and hoxb4a in Rpl11-deficient zebrafish embryos, indicating that the hematopoietic defects may be related to impaired HSC formation, differentiation, and proliferation.\nIron promoted proliferation, carcinogenesis and Warburg effect of osteosarcoma cells.\nMitochondrion-mediated iron accumulation promotes carcinogenesis and Warburg effect of osteosarcoma cells.\nIron-induced reactive oxygen species (ROS) played an important role in these processes.\nMoreover, iron upregulated the expression of mitoferrin 1 (SLC25A37) and mitoferrin 2 (SLC25A28).\nKnock-down of mitoferrin 1 (SLC25A37) and mitoferrin 2 (SLC25A28) decreased the production of ROS.\nClinically used drugs deferiprone and minocycline reduced mitochondrial iron and superoxide levels, resulting in decreased colon tumor cell growth.\nThis study suggests that therapies aimed at reducing mitochondrial iron levels may effectively inhibit colon tumor growth, particularly in patients with low PINK1 expression.\nManipulating the mitochondrial iron uptake protein MCU (mitochondrial calcium uniporter) also affected cell and xenograft tumor growth.\nMeanwhile, iron deprivation might be a novel effective strategy in the treatment of osteosarcoma.\nWe found a substantial enrichment for miRNAs (53 miRNAs, FDR < 0.05)", "dois": ["10.1080/15548627.2024.2425594", "10.1186/s12935-020-01494-3", "10.1016/j.bbamcr.2020.118826", "10.1074/jbc.RA120.013229", "10.1007/s00439-014-1434-4", "10.1186/1471-2164-14-896"]}
{"pair_type": "slc_pathway", "key1": "SLC25A37", "key2": "oxidative stress", "summary": "Nevertheless, further investigations are needed to shed light on the molecular mechanisms of HBD in the oxidative stress of MS patients.\nThis supports a model for RRMS in children with an apparent iron-deficient biochemical subtype of MS, with oligodendrocyte cell death and impaired myelination possibly caused by deficits of energy- and antioxidant capacity in mitochondria.\ninvolved in iron transport into mitochondria.\nIron is an essential cofactor in myelin synthesis.\nAlthough the exact pathophysiology of MS has not been identified, mitochondrial stress can be one of the culprits in MS development.\nHerein, we have applied microarray analysis, single-cell sequencing analysis, and study to elucidate the role of mitochondrial stress in PBMCs of MS patients.", "dois": ["10.2147/IJGM.S548720", "10.3389/fimmu.2021.709173", "10.1016/j.ymgmr.2019.100465"]}
{"pair_type": "slc_pathway", "key1": "SLC25A38", "key2": "migration", "summary": "Knock-out of SLC25A38 could enhance the migration ability of UM cells, and promote distant metastasis in mice models.\nSLC25A38, located on chromosome 3, was the dominant downregulated gene in metastatic UM patients.\nThrough the inhibition of CBP/HIF-mediated pathway followed by the suppression of pro-angiogenic factors, SLC25A38 was situated upstream of metastasis-related pathways, especially angiogenesis.\nLow expression of SLC25A38 promotes angiogenesis and metastasis, and identifies increased metastatic risk and worse survival in UM patients.\nLow expression of SLC25A38 was an independent predictive and prognostic factor in UM.\nKaplan-Meier survival analysis showed that the high-risk group was associated with poorer overall survival (OS) and metastasis-free survival (MFS) in UM patients.", "dois": ["10.1186/s12935-024-03539-3", "10.1038/s41419-022-04718-8"]}
{"pair_type": "slc_pathway", "key1": "SLC25A38", "key2": "apoptosis", "summary": "Overexpression of appoptosin in SH-SY5Y cells markedly increased cell apoptosis accompanied by reduced HO-1 expression, increased intracellular heme level, ROS overproduction and ΔΨm impairment.\nAppoptosin (SLC25A38) is a pro-apoptotic protein, which is upregulated in Alzheimer's disease (AD) brains and plays an important role in promoting the pathological progress of AD.\nAppoptosin overexpression causes overproduction of reactive oxygen species (ROS) and caspase-dependent apoptosis, whereas appoptosin downregulation abolishes β-amyloid-induced mitochondrial fragmentation and neuronal death during Alzheimer's disease.\nBy contrast, co-expression of MFN1, MITOL and a dominant-negative form of DRP1, DRP1(K38A), partially rescued appoptosin-induced mitochondrial fragmentation and apoptosis, whereas co-expression of FIS1 aggravated appoptosin-induced apoptosis.\nHerein, we found that overexpression of appoptosin resulted in mitochondrial fragmentation in a manner independent of its carrier function, ROS production or caspase activation.\nCurcumin inhibits appoptosin-induced apoptosis in SH-SY5Y cells by upregulating the expression of HO-1, reducing the production of intracellular heme and ROS, and preventing the ΔΨm loss.\nHowever, pretreatment with curcumin (2.5-20 μmol/L) dose-dependently attenuated all above-mentioned pathological changes in appoptosin-transfected SH-SY5Y cells.", "dois": ["10.1242/jcs.176792", "10.1038/aps.2014.166", "PMID:24765149"]}
{"pair_type": "slc_pathway", "key1": "SLC25A27", "key2": "chemotherapy", "summary": "The first priority genes to be selected were genes that are known to be amplified in cancer, which included NKX2.1, CHST9, CTNND2, SLC25A27, FGFR2, EGFR, and PTGER1.", "dois": ["10.1002/cam4.311"]}
{"pair_type": "slc_pathway", "key1": "SLC25A38", "key2": "proliferation", "summary": "Loss of SLC25A38 causes depletion of mitochondrial, but not cellular, pyridoxal 5'-phosphate, and impairs cellular proliferation under both physiological and low vitamin B6 conditions.\nThe proliferation defect of SLC25A38-null K562 cells in physiological and low vitamin B6 media can be explained by the loss of serine hydroxymethyltransferase-2-dependent production of one-carbon units and downstream de novo nucleotide synthesis.", "dois": ["10.1038/s41467-025-56130-3"]}
{"pair_type": "slc_pathway", "key1": "SLC25A39", "key2": "apoptosis", "summary": "Functional assays revealed that overexpression of SLC25A39 promoted CRC cell proliferation and migration while inhibiting apoptosis.\nConversely, SLC25A39 knockdown suppressed cell growth and migration while enhancing apoptosis in vitro.\nMechanistically, SLC25A39 loss impaired mitochondrial oxidative phosphorylation, increased reactive oxygen species (ROS), and triggered apoptosis.\nFunctionally, SLC25A39 overexpression promoted LUAD cell proliferation and migration, while its knockdown or deletion suppressed these malignant traits in vitro and in vivo.\nFGF21 knockout exacerbates neural apoptosis and brain edema, increases lesion volume, and worsens neurological deficits following TBI.", "dois": ["10.1186/s12967-025-06969-3", "10.1002/iid3.1231", "10.1038/s41698-025-01081-7", "10.7150/jca.98844"]}
{"pair_type": "slc_pathway", "key1": "SLC25A38", "key2": "oxidative stress", "summary": "A significant oxidative stress was evidenced by decreased reduced glutathione and aconitase activity, and increased MnSOD protein expression.\nThis model successfully recapitulated the main features of CSA, including reduced heme content and mitochondrial respiration, increase in mitochondrial iron, ROS levels and sensitivity to oxidative stress.\nThis oxidative stress depleted and damaged mtDNA, decreased complex I and IV activities and depleted ATP content.\nWe developed and characterized a K562 erythroleukemia cell line with markedly reduced expression of the SLC25A38 protein (A38-low cells).\nNon-syndromic microcytic congenital sideroblastic anemia (cSA) is predominantly caused by defective genes encoding for either ALAS2, the first enzyme of heme biosynthesis pathway or SLC25A38, the mitochondrial importer of glycine, an ALAS2 substrate.\nMutations in the SLC25A38 gene are responsible for the second most common form of congenital sideroblastic anemia (CSA), a severe condition for which no effective treatment exists.\nNotably, our study uncovered a new role for extracellular pyridoxal 5'-phosphate (PLP) and other P2 receptor antagonists in rescuing the altered parameters of A38-low cells (for example, the heme content of the A38-low cells was increased from about 50% to about 80% by the P2 receptor antagonists treatment compared with the value of the controls).\nThe protein-level of ferrochelatase, the terminal-enzyme of heme process, was increased both in patient-derived lymphoblastoid and CD34+ cells, however, its activity was drastically decreased.", "dois": ["10.3390/ijms252413314", "10.1016/j.ymgme.2018.12.012"]}
{"pair_type": "slc_pathway", "key1": "SLC25A39", "key2": "ferroptosis", "summary": "Consequently, genetic inhibition of the NFE2L2-GSH-SLC25A39 pathway enhances cuproptosis-mediated tumor suppression in cell culture and in mouse tumor models.\nExogenous addition of glycine significantly increased the levels of the anti-oxidant GSH and the expression of anti-oxidant-related genes (glutathione peroxidase 4 [GPX4], catalase [CAT], superoxide dismutase 1 [SOD1], superoxide dismutase 2 [SOD2], and mitochondrial solute carrier family 25, member 39 [SLC25A39]), decreased the lipid peroxidation caused by reactive oxygen species (ROS) and reduced the level of malondialdehyde (MDA) by enhancing the functions of mitochondria, peroxisomes and lipid droplets (LDs) and the levels of lipid metabolism-related factors (peroxisome proliferator activated receptor coactivator 1 alpha [PGC-1α], peroxisome proliferator-activated receptor γ [PPARγ], sterol regulatory element binding factor 1 [SREBF1], autocrine motility factor receptor [AMFR], and ATP).\nIt is found that mitochondrial inhibition either increases or decreases ferroptosis susceptibility in cellular models, depending on contextual factors that dictate whether mitochondria act as a net GSH producer or consumer, respectively.\nGCLM and GCLC are rate-limiting enzymes in GSH synthesis, and increased GSH is transported into mitochondria via the solute carrier family 25 member 39 (SLC25A39) transporter.\nThese findings not only reveal distinct mechanisms of GSH in inhibiting cuproptosis and ferroptosis, but also suggest a potential combination strategy to suppress PDAC tumor growth.\nThese effects further reduced ferroptosis and maintained the normal structure and function of the cell membrane.\nMechanistically, GSH inhibits cuproptosis by chelating copper, contrasting its role in blocking ferroptosis by inhibiting lipid peroxidation.\nBut mitochondria also consume GSH via the SLC25A39 transporter.\nIt is demonstrated that mitochondrial function an", "dois": ["10.1002/advs.202504175", "10.1038/s41598-024-81317-x", "10.1093/jas/skac425"]}
{"pair_type": "slc_pathway", "key1": "SLC25A39", "key2": "migration", "summary": "Functional assays revealed that overexpression of SLC25A39 promoted CRC cell proliferation and migration while inhibiting apoptosis.\nFunctionally, SLC25A39 overexpression promoted LUAD cell proliferation and migration, while its knockdown or deletion suppressed these malignant traits in vitro and in vivo.\nConversely, SLC25A39 knockdown suppressed cell growth and migration while enhancing apoptosis in vitro.\nMechanistically, elevated SLC25A39 levels correlated with reduced reactive oxygen species (ROS) accumulation in CRC.\nMechanistically, SLC25A39 loss impaired mitochondrial oxidative phosphorylation, increased reactive oxygen species (ROS), and triggered apoptosis.\nNotably, we found that reduced expression of the m-AAA protease AFG3L2 in LUAD post-translationally stabilizes SLC25A39, leading to its accumulation.\nFurthermore, bioinformatic analyses unveiled the high SLC25A39 levels was associated with decreased expression of immune checkpoints and reduced responsiveness to immunotherapy.\nOur findings underscore the pivotal role of SLC25A39 in CRC progression and suggest its candidacy as a therapeutic target in CRC management.\nBioinformatics and tissue analyses revealed significantly elevated SLC25A39 protein levels despite stable mRNA expression, correlating with poorer patient survival.\nThese findings demonstrate that AFG3L2 downregulation drives SLC25A39's oncogenic activity, positioning SLC25A39 as a promising therapeutic target for LUAD.", "dois": ["10.1038/s41698-025-01081-7", "10.7150/jca.98844"]}
{"pair_type": "slc_pathway", "key1": "SLC25A39", "key2": "oxidative phosphorylation", "summary": "Mechanistically, SLC25A39 loss impaired mitochondrial oxidative phosphorylation, increased reactive oxygen species (ROS), and triggered apoptosis.", "dois": ["10.1038/s41698-025-01081-7"]}
{"pair_type": "slc_pathway", "key1": "SLC25A26", "key2": "oxidative phosphorylation", "summary": "Elevated SLC25A26 induced mitochondrial fragmentation, suppressed glycolysis and oxidative phosphorylation, and decreased ATP production.\nThe pathogenic mutation gene of this patient with COXPD28 is SLC25A26 gene mutation (p.A66E, p.A12P), which causes the decrease of SLC25A26 expression level, mitochondrial oxidative phosphorylation dysfunction, and induces COXPD28.\nCombined oxidative phosphorylation deficiency 28 (COXPD28) is associated with mitochondrial dysfunction caused by mutations in SLC25A26, the gene which encodes the mitochondrial S-adenosylmethionine carrier (SAMC) that responsible for the transport of S-adenosylmethionine (SAM) into the mitochondria.\nA gradual decline in mitochondrial SAM (mitoSAM) causes hierarchical defects in fly and mouse, comprising loss of mitoSAM-dependent metabolites and impaired assembly of the oxidative phosphorylation system.\nComplex I stability and iron-sulfur cluster biosynthesis are directly controlled by mitoSAM levels, while other protein targets are predominantly methylated outside of the organelle before import.\nThe mitoSAM pool follows its cytosolic production, establishing mitochondria as responsive receivers of one-carbon units.\nThe one-carbon metabolite and methyl group donor S-adenosylmethionine (SAM) is pivotal for energy metabolism.\ncellular methylation potential is required for energy metabolism, with direct relevance for pathophysiology, aging, and cancer.\nThe variants in this region probably resulted in a variable loss of mitochondrial SAMC transport function and cause the COXPD28.\nthe change of the SAMC structure may lead to insufficient methylation and cause disease by affecting the SAM transport.\nAll these results suggest that FBXO24 safeguards mitochondrial integrity by controlling SLC25A26 stability, ensuring ATP production for sperm motility.\nFBXO24 mediates K6-linked polyubiquitylation of SLC25A26 at lysine residue 31, targeting it for degradation.", "dois": ["10.1242/dev.204761", "10.1016/j.gene.2021.145891", "10.3760/cma.j.cn112138-20211208-00875", "10.1126/sciadv.abf0717"]}
{"pair_type": "slc_pathway", "key1": "SLC25A39", "key2": "proliferation", "summary": "Functional assays revealed that overexpression of SLC25A39 promoted CRC cell proliferation and migration while inhibiting apoptosis.\nFunctionally, SLC25A39 overexpression promoted LUAD cell proliferation and migration, while its knockdown or deletion suppressed these malignant traits in vitro and in vivo.\nIn addition, the AFG3L2-SLC25A39 axis is identified as a distinct mechanism by which cytoplasmic CRABP2 increases mitochondrial glutathione stability to promote cell proliferation independent of the nuclear RB1 pathway.\nConversely, SLC25A39 knockdown suppressed cell growth and migration while enhancing apoptosis in vitro.\nAdditionally, reduced SLC25A39 expression attenuated tumor growth in xenograft models.\nWe find that mitochondrial GSH import is necessary for cell proliferation in vitro and red blood cell development in mice.\nHeterologous expression of an engineered bifunctional bacterial GSH biosynthetic enzyme (GshF) in mitochondria enables mitochondrial GSH production and ameliorates the metabolic and proliferative defects caused by its depletion.\nOur findings underscore the pivotal role of SLC25A39 in CRC progression and suggest its candidacy as a therapeutic target in CRC management.\nThese findings demonstrate that AFG3L2 downregulation drives SLC25A39's oncogenic activity, positioning SLC25A39 as a promising therapeutic target for LUAD.\nOur study identifies SLC25A39, a mitochondrial glutathione transporter, as a key oncogenic factor in LUAD.\nMechanistically, SLC25A39 loss impaired mitochondrial oxidative phosphorylation, increased reactive oxygen species (ROS), and triggered apoptosis.\nLoss of SLC25A39 reduces mitochondrial GSH import and abundance without affecting cellular GSH levels.", "dois": ["10.1038/s41698-025-01081-7", "10.1002/advs.202500552", "10.7150/jca.98844", "10.1038/s41586-021-04025-w"]}
{"pair_type": "slc_pathway", "key1": "SLC25A39", "key2": "oxidative stress", "summary": "SLC25A39/40, involved in mitochondrial GSH (mGSH) import from the cytoplasm, is essential for protection against oxidative stress and mitochondrial dysfunction.\nThe mitochondrial transporter SLC25A39 has been implicated in the import of mitochondrial glutathione (mGSH) from the cytoplasm, crucial for mitigating oxidative stress and preserving mitochondrial function.\nExogenous addition of glycine significantly increased the levels of the anti-oxidant GSH and the expression of anti-oxidant-related genes (glutathione peroxidase 4 [GPX4], catalase [CAT], superoxide dismutase 1 [SOD1], superoxide dismutase 2 [SOD2], and mitochondrial solute carrier family 25, member 39 [SLC25A39]), decreased the lipid peroxidation caused by reactive oxygen species (ROS) and reduced the level of malondialdehyde (MDA) by enhancing the functions of mitochondria, peroxisomes and lipid droplets (LDs) and the levels of lipid metabolism-related factors (peroxisome proliferator activated receptor coactivator 1 alpha [PGC-1α], peroxisome proliferator-activated receptor γ [PPARγ], sterol regulatory element binding factor 1 [SREBF1], autocrine motility factor receptor [AMFR], and ATP).\nMechanistically, elevated SLC25A39 levels correlated with reduced reactive oxygen species (ROS) accumulation in CRC.\nMechanistically, we observed that FGF21 enhances the mitochondrial uptake of glutathione (GSH), an essential redox metabolite, by targeting SLC25A39, a recently identified mitochondrial GSH transporter.\nImportantly, FGF21 was found to prevent mitochondrial damage and sustain redox homeostasis post-TBI.\nOur findings provide preliminary evidence that FGF21 confers protective effects against mitochondrial oxidative stress-related damage following TBI.\nAdditionally, we elucidated a novel role for SLC25A39-dependent mitochondrial GSH transport in both the pathological", "dois": ["10.1002/advs.202504175", "10.1016/j.prp.2025.155935", "10.1186/s12967-025-06969-3", "10.7150/jca.98844", "10.1093/jas/skac425", "10.3390/ijms23158573"]}
{"pair_type": "slc_pathway", "key1": "SLC25A40", "key2": "ferroptosis", "summary": "Mechanistically, SLC25A40 promotes cell proliferation by increasing NADPH-mediated lipid synthesis and suppresses ferroptosis by decreasing mitochondrial ROS accumulation.\nSilencing SLC25A40 suppressed NSCLC growth by inhibiting cell proliferation and inducing ferroptosis, whereas its overexpression promoted NSCLC growth.\nThis research highlights the pivotal role of SLC25A40 in NSCLC progression by modulating both cell proliferation and ferroptosis, suggesting it as a promising therapeutic target in the management of NSCLC.", "dois": ["10.1016/j.yexcr.2025.114727"]}
{"pair_type": "slc_pathway", "key1": "SLC25A40", "key2": "chemotherapy", "summary": "Two PDX models, both with prior chemotherapy and/or PARPi exposure, were refractory to all AMA, one of which harboured the fusion, known to upregulate drug efflux MDR1.\nDespite initial response to platinum-based chemotherapy and PARP inhibitor therapy (PARPi), nearly all recurrent high-grade serous ovarian cancer (HGSC) will acquire lethal drug resistance\nEribulin is therefore worthy of further consideration in clinical trials, particularly in ovarian carcinoma with early failure of carboplatin/paclitaxel chemotherapy.\nDespite high response rates to initial chemotherapy, the majority of women diagnosed with High-Grade Serous Ovarian Cancer (HGSOC) ultimately develop drug resistance within 1-2 years of treatment.\nOf 13 PRR HGSC PDX, six were primary PRR, derived from chemotherapy-naïve samples (one was mutant) and seven were from samples obtained following chemotherapy treatment in the clinic\nWe previously identified the most common mechanism of acquired resistance in HGSOC to date, transcriptional fusions involving the ATP-binding cassette (ABC) transporter , which has well established roles in multidrug resistance.\nDespite harbouring secondary mutations, two -mutant PDX models derived from heavily pre-treated individuals were sensitive to AMA.\nThe co-culture of fusion-negative and positive populations had no effect on cellular proliferation but markedly altered drug sensitivity to doxorubicin, paclitaxel and cisplatin.\nUsing a panel of fusion-negative and positive HGSOC single-cell clones, we demonstrate that in addition to mediating drug resistance, fusion-positive cells display impaired proliferative capacity, elevated oxidative metabolism, altered actin cellular morphology and an extracellular matrix/inflammatory enriched transcriptional profile.", "dois": ["10.1177/17588359231208674", "10.3390/cancers13225644"]}
{"pair_type": "slc_pathway", "key1": "SLC25A40", "key2": "oxidative stress", "summary": "SLC25A39/40, involved in mitochondrial GSH (mGSH) import from the cytoplasm, is essential for protection against oxidative stress and mitochondrial dysfunction.\nThe expression of genes supporting mitochondrial energy production (CREB5 and SLC25A40) and angiogenic genes (p < 0.05) was significantly downregulated in diabetic patients after CPB.\nDecreased PGC-1α in diabetic patients may lead to impaired mitochondrial function and attenuated antiapoptotic and angiogenic responses after CPB.\nOur findings contribute to understanding the role of mGSH in the maintenance of the mitochondrial redox state.\nConsequently, there was a significant decrease in mGSH levels in the kidneys of BDL mice compared with those in sham mice.\nBDL resulted in a decrease in mRNA in the liver and a decrease in mRNA and protein in the kidneys.\nAntioxidant markers (NOX4 and GPX4), angiogenic factors (TGF-β, NT3, and Ang1), and the antiapoptotic factor BCL-xL were significantly lower in diabetic patients after CPB (p < 0.05).", "dois": ["10.1016/j.athoracsur.2018.08.009", "10.3390/ijms23158573"]}
{"pair_type": "slc_pathway", "key1": "SLC25A42", "key2": "chemotherapy", "summary": "Low expression of was associated with chemotherapy sensitive in HCC patients.\nThe molecular mechanisms driving hepatocellular carcinoma (HCC) predicting chemotherapy sensitivity remain unclear;\nWe further correlated these results with clinical variables to screen for driver genes and evaluate the predict ability of chemotherapy sensitive of key genes in liver cancer (LC) patients.\nIn conclusion, machine learning modeling combined with genomic profiling provides a promising approach to identify the driver gene in LC, which may help improve diagnostic accuracy and chemotherapy sensitivity for this disease.", "dois": ["10.1089/cbr.2025.0094"]}
{"pair_type": "slc_pathway", "key1": "SLC25A40", "key2": "proliferation", "summary": "Mechanistically, SLC25A40 promotes cell proliferation by increasing NADPH-mediated lipid synthesis and suppresses ferroptosis by decreasing mitochondrial ROS accumulation.\nSilencing SLC25A40 suppressed NSCLC growth by inhibiting cell proliferation and inducing ferroptosis, whereas its overexpression promoted NSCLC growth.\nThe down-regulation of SLC25A40 significantly decreased the mitochondrial concentration of glutathione and cell proliferation.\nCollectively, the present results demonstrated that the expression of SLC25A40 was up-regulated in K562/ADM cells, which enhanced to cell proliferation, and that the expression of SLC25A40 affected drug resistance to ADM.\nThis research highlights the pivotal role of SLC25A40 in NSCLC progression by modulating both cell proliferation and ferroptosis, suggesting it as a promising therapeutic target in the management of NSCLC.\nWe find that mitochondrial GSH import is necessary for cell proliferation in vitro and red blood cell development in mice.\nCells lacking both SLC25A39 and its paralogue SLC25A40 exhibit defects in the activity and stability of proteins containing iron-sulfur clusters.\nHeterologous expression of an engineered bifunctional bacterial GSH biosynthetic enzyme (GshF) in mitochondria enables mitochondrial GSH production and ameliorates the metabolic and proliferative defects caused by its depletion.", "dois": ["10.1016/j.yexcr.2025.114727", "10.1248/bpb.b23-00293", "10.3390/cancers13225644", "10.1038/s41586-021-04025-w"]}
{"pair_type": "slc_pathway", "key1": "SLC25A42", "key2": "apoptosis", "summary": "SLC25A42 promotes the proliferation of gastric cancer (GC) cells while suppresses apoptosis in vitro and in vivo.\nMechanistically, SLC25A42 promotes the growth and inhibits apoptosis of GC cells by reprograming lipid metabolism.\nOn the one hand, SLC25A42 enhances fatty acid oxidation-mediated mitochondrial respiration to provide energy for cell survival.\nOn the other hand, SLC25A42 decreases the levels of free fatty acids and ROS to inhibit ferroptosis.", "dois": ["10.1038/s41419-025-07644-7"]}
{"pair_type": "slc_pathway", "key1": "SLC25A42", "key2": "ferroptosis", "summary": "SLC25A42 decreases the levels of free fatty acids and ROS to inhibit ferroptosis.\nSLC25A42 promotes the proliferation of gastric cancer (GC) cells while suppresses apoptosis in vitro and in vivo.\nMechanistically, SLC25A42 promotes the growth and inhibits apoptosis of GC cells by reprograming lipid metabolism.\nSLC25A42 enhances fatty acid oxidation-mediated mitochondrial respiration to provide energy for cell survival.\nSLC25A42 reprograms lipid metabolism in GC cells by upregulating the acetylation and thus the expression of CPT2.", "dois": ["10.1038/s41419-025-07644-7"]}
{"pair_type": "slc_pathway", "key1": "SLC25A42", "key2": "glycolysis", "summary": "Moreover, extracellular acidification rate revealed significantly reduced glycolysis, glycolytic capacity, and glycolytic reserve as compared to control individuals.\nFunctional analyses on fibroblasts obtained from this patient revealed that the deletion causes significant decrease in mitochondrial oxygen consumption and ATP production compared to healthy individuals.\nSLC25A42 is the main transporter of coenzyme A (CoA) into mitochondria.", "dois": ["10.1002/jmd2.12218"]}
{"pair_type": "slc_pathway", "key1": "SLC25A42", "key2": "proliferation", "summary": "SLC25A42 promotes the proliferation of gastric cancer (GC) cells while suppresses apoptosis in vitro and in vivo.\nMechanistically, SLC25A42 promotes the growth and inhibits apoptosis of GC cells by reprograming lipid metabolism.\nOn the one hand, SLC25A42 enhances fatty acid oxidation-mediated mitochondrial respiration to provide energy for cell survival.\nOn the other hand, SLC25A42 decreases the levels of free fatty acids and ROS to inhibit ferroptosis.\nMoreover, we found that SLC25A42 reprograms lipid metabolism in GC cells by upregulating the acetylation and thus the expression of CPT2.", "dois": ["10.1038/s41419-025-07644-7"]}
{"pair_type": "slc_pathway", "key1": "SLC25A43", "key2": "proliferation", "summary": "In contrast, suppressed SLC25A43 expression in BT-474 cells resulted in a significantly increased proliferation rate together with an enhanced G1-to-S transition.\nKD of SLC25A43 also reduced the inhibitory effect of trastuzumab on cell proliferation in the HER2-positive cancer cell line BT-474 (P<0.05), and the drug-induced G0/G1 block (P<0.05).\nWe found that SLC25A43 knockdown in MCF10A cells significantly inhibited cell cycle progression during G1-to-S transition, thus significantly reducing the proliferation rate and fraction of Ki-67 positive MCF10A cells.\nIn line with our previous results, we show a role for SLC25A43 as a regulator of cell cycle progression and proliferation through a putative mitochondrial checkpoint.\nSLC25A43 has previously been identified to be genetically altered and associated with cell proliferation in human epidermal growth factor receptor 2-positive breast cancer.\nHER2-positive tumors with negative or low SLC25A43 protein expression had significantly lower S-phase fraction compared to tumors with medium or high expression (P = 0.024).\nIn addition, SLC25A43 protein expression was shown to be related to S-phase fraction in HER2-positive breast cancer.\nWe have also found that low protein expression of SLC25A43 significantly correlates with a lower S phase fraction in HER2-positive breast cancer.\nMoreover, SLC25A43 influenced the percentage of Ki-67-positive cells.\nIn a previous study of HER2-positive tumours we could demonstrate a common loss in the gene encoding for the mitochondrial transporter SLC25A43 and also a significant relation between SLC25A43 protein expression and S-phase fraction.", "dois": ["10.3390/cancers12040892", "10.3892/ol.2017.6452", "10.1016/j.bbrc.2015.12.088", "10.3892/or.2013.2247", "10.1186/1471-2407-12-350"]}
{"pair_type": "slc_pathway", "key1": "SLC25A44", "key2": "oxidative phosphorylation", "summary": "Blocking BCAA entry into mitochondria by knockdown of SLC25A44 inhibited M2 macrophage polarization.\nBCAA supplementation promoted M2 macrophage polarization both in vitro and in vivo and increased oxidative phosphorylation in M2 macrophages.\nThe high-risk group had a lower activation of oxidative phosphorylation and a more abundant immune infiltration phenotype than the low-risk group.\nAccording to co-expression network studies, SLC25A11, SLC25A29, and SLC25A44 were involved in the energy metabolism of PC and prevented tumor growth, invasion, and metastasis.\nMoreover, the recruitment of numerous immune cells was positively correlated with SLC25A11 and SLC25A44 but negatively correlated with SLC25A29.\nFurthermore, M2 macrophages polarization was suppressed by knockdown of Branched-chain amino-acid transaminase 2 (BCAT2) and branched chain keto acid dehydrogenase E1 subunit alpha (BCKDHA), both of which are key enzymes involved in BCAA oxidation.\nMetabolomic analysis identified increased BCAA metabolism as one of the most significantly rewired pathways upon alternative activation.\nOverall, our findings suggest that BCAA catabolism plays an important role in polarization toward M2 macrophages.", "dois": ["10.3389/fimmu.2024.1469163", "10.1186/s12967-022-03756-2"]}
{"pair_type": "slc_pathway", "key1": "SLC25A43", "key2": "apoptosis", "summary": "In contrast, suppressed SLC25A43 expression in BT-474 cells resulted in a significantly increased proliferation rate together with an enhanced G1-to-S transition.\nKD of SLC25A43 also reduced the inhibitory effect of trastuzumab on cell proliferation in the HER2-positive cancer cell line BT-474 (P<0.05), and the drug-induced G0/G1 block (P<0.05).\nFurther analysis of cell cycle phase distribution showed that KD increased the paclitaxel-induced G2/M block in these two cell lines (P<0.05).\nWe found that KD of SLC25A43 resulted in a decreased cytotoxic effect of paclitaxel in the two cancer cell lines (P<0.05).\nWe found that SLC25A43 knockdown in MCF10A cells significantly inhibited cell cycle progression during G1-to-S transition, thus significantly reducing the proliferation rate and fraction of Ki-67 positive MCF10A cells.\nThe mitochondria have been identified as key players of apoptosis, cell proliferation and cell cycle regulation.\nOur findings demonstrate that the mitochondrial protein SLC25A43 affects drug efficacy and cell cycle regulation following drug exposure in breast cancer cell lines.\nIn line with our previous results, we show a role for SLC25A43 as a regulator of cell cycle progression and proliferation through a putative mitochondrial checkpoint.\nWe have also found that low protein expression of SLC25A43 significantly correlates with a lower S phase fraction in HER2-positive breast cancer.\nAn increasing body of evidence is pointing towards mitochondrial regulation of the cell cycle.\nThese novel data further strengthen the connection between mitochondrial function and the cell cycle, both in non-malignant and in cancer cells.", "dois": ["10.1016/j.bbrc.2015.12.088", "10.3892/or.2013.2247"]}
{"pair_type": "slc_pathway", "key1": "SLC25A45", "key2": "proliferation", "summary": "Defective cellular transport processes can lead to aberrant accumulation of trace elements, iron, small molecules and hormones in the cell, which in turn may promote the formation of reactive oxygen species, promoting DNA damage and aberrant expression of key regulatory cancer genes.\nAs DNA damage and uncontrolled proliferation are hallmarks of cancer, including epithelial ovarian cancer (EOC), we hypothesized that inherited variation in the cellular transport genes contributes to EOC risk.", "dois": ["10.1371/journal.pone.0128106"]}
{"pair_type": "slc_pathway", "key1": "SLC25A46", "key2": "apoptosis", "summary": "Therefore, in addition to its role in mitochondrial dynamics, SLC25A46 plays a role in preventing mitochondria-induced apoptosis in INS-E cells exposed to nutrient stress.\nImportantly, insulin-secreting cells lacking SLC25A46 had an exacerbated sensitivity to lipotoxic conditions, undergoing massive apoptosis when exposed to palmitate.\nBy protecting mitochondria, SLC25A46 might help to maintain β-cell mass essential for blood glucose control.", "dois": ["10.1091/mbc.E16-07-0545", "10.1242/jcs.260049", "10.1186/1471-2164-10-261"]}
{"pair_type": "slc_pathway", "key1": "SLC25A46", "key2": "migration", "summary": "These observations suggest that in addition to the role in mitochondrial function, plasma membrane-localized dSLC25A46 plays a role in cell proliferation and/or migration to control optic stalk formation.\nMorphology and development of optic stalk of photoreceptor neurons in Drosophila are precisely regulated via cell proliferation and migration.\nPhysiologic functions of PCH1-associated genes include regulation of RNA metabolism, mitochondrial fission and neuronal migration.", "dois": ["10.3390/genes16050585", "10.1016/j.brainres.2018.03.028"]}
{"pair_type": "slc_pathway", "key1": "SLC25A43", "key2": "oxidative phosphorylation", "summary": "Their characteristic feature is the presence of highly reduced mitochondria that have lost the ability to produce ATP by oxidative phosphorylation and in some cases even by substrate phosphorylation, with all ATP being imported from the cytosol.\nTogether, our findings suggest that AIC facilitate the ATP import into highly reduced anaerobic mitochondria, compensating for their diminished or absent energy metabolism.\nInstead, nearly all species retained carriers orthologous to human SLC25A43 protein, a little-characterized MCP.\nHeterologous expression of metamonad SLC25A43 carriers confirmed their mitochondrial localization, and functional analysis revealed that SLC25A43 orthologues represent a distinct group of ATP transporters, which we designate as ATP-importing carriers (AIC).\nOur bioinformatic analyses revealed remarkable reduction of MCP repertoire in Metamonada with striking loss of the major ADP/ATP carrier (AAC).", "dois": ["10.1098/rsob.240202"]}
{"pair_type": "slc_pathway", "key1": "SLC25A46", "key2": "oxidative phosphorylation", "summary": "This study suggests that severely damaged mitochondrial cristae might be the predominant cause of reduced OXPHOS in SLC25A46 mutant fibroblasts.\nSLC25A46 mutations have been found to lead to mitochondrial hyper-fusion and reduced mitochondrial respiratory function, which results in optic atrophy, cerebellar atrophy, and other clinical symptoms of mitochondrial disease.\nOverexpression of SLC25A46 in INS-1E cells caused complete mitochondrial fragmentation, resulting in a mild mitochondrial defect associated with lowered glucose-induced insulin secretion.\nIn contrast, inactivation of the Slc25a46 gene resulted in dramatic mitochondrial hyperfusion, without affecting respiratory activity or insulin secretion.\nBy using mutation fibroblasts derived from patients containing highly fused mitochondria with low oxidative phosphorylation, we concluded that unhealthy mitochondria redistributed the subcellular localization of lysosomes, which implies a strong connection between mitochondria and lysosomes.\nOur proteomic approach confirmed known mitochondrial interactors of SLC25A46 including MICOS complex subunits and also OPA1 and VDACs, while we identified novel interactors including the ADP/ATP translocases SLC25A4 and SLC25A5, subunits of the OXPHOS complexes and FF-ATP synthase, and components of the mitochondria-ER contact sites.\nOur results show that SLC25A46 interacts with a large number of proteins and protein complexes involved in the mitochondria architecture, energy production, and flux and also in inter-organellar contacts.\nA total of 79 co-immunoprecipitated proteins were common in two or more tissues, mainly participating in mitochondrial activities such as oxidative phosphorylation (OXPHOS) and ATP production, active transport of ions or molecules, and the metabolism.", "dois": ["10.1242/jcs.260049", "10.1002/exp.20210215", "10.1021/acs.jproteome.1c00728", "10.1186/s12951-021-00882-9"]}
{"pair_type": "slc_pathway", "key1": "SLC25A46", "key2": "proliferation", "summary": "These observations suggest that in addition to the role in mitochondrial function, plasma membrane-localized dSLC25A46 plays a role in cell proliferation and/or migration to control optic stalk formation.\nMorphology and development of optic stalk of photoreceptor neurons in Drosophila are precisely regulated via cell proliferation and migration.\nGenes linked to transcription, cell cycle, cell growth, proliferation and differentiation, cell adhesion, and immune functions were found to be overrepresented within the set of the differentially expressed genes.", "dois": ["10.1016/j.brainres.2018.03.028", "10.1186/1471-2164-10-261"]}
{"pair_type": "slc_pathway", "key1": "SLC25A43", "key2": "oxidative stress", "summary": "Slc25a43 (one of the candidates) knockout (KO) ESCs presented reduced damage caused by ROS and higher cell viability when exposed to HO.\nIn addition, we identified that KO of Slc25a43 activated mitochondria-related genes including Nlrx1 to protect ESCs from oxidative damage.\nSubsequently, ROS production and mitochondrial function analysis also confirmed that Slc25a43 was a main target gene of oxidative toxicity.", "dois": ["10.1038/s41419-022-04738-4"]}
{"pair_type": "slc_pathway", "key1": "SLC25A46", "key2": "oxidative stress", "summary": "Slc25a46-/- mice present segmental premature aging phenotypes characterized by shortened life span of no more than 2 months, obviously defective motor ability, gastrocnemius muscle atrophy, and imbalance of redox level in brain and liver.\nThe underlying mechanism for multiple organ disorder may attribute to mitochondrial dysfunction, which is mainly manifested in the damaged mitochondrial structure (eg, vacuolar structure, irregular swelling, and disorganized cristae) and an age-associated decrease in respiratory chain enzyme (mainly complex I and IV) activity.\nThe mitochondrial theory of aging postulates that accumulation of mtDNA mutations and mitochondrial dysfunction are responsible for producing aging phenotypes.\nTo more comprehensively explore the complex relationship between aging and mitochondria dysfunction, we have developed a mouse model with Slc25a46 knockout, a nuclear gene described as encoding mitochondrial carriers, by CRISPR/Cas9 gene editing to mimic some typical aging phenotypes in human.", "dois": ["10.1093/gerona/glaa306"]}
{"pair_type": "slc_pathway", "key1": "SLC25A47", "key2": "apoptosis", "summary": "Conversely, hUC-MSCs increased the Slc25a47 expression and NAD level within mitochondria, thereby enhanced Sirt3 protein activity and alleviated mitochondrial dysfunction in the liver.\nSlc25a47, a newly identified liver-specific mitochondrial NAD transporter, was notably reduced in CCl-treated mice and HO-stimulated hepatocytes.\nFurthermore, Slc25a47 knockdown could partially abrogate the protective effects of hUC-MSCs on HO-induced mitochondrial fission and oxidative stress in hepatocytes.\nOxidative stress and mitochondrial functionality alteration directly contributes to the hepatocyte apoptosis and development of liver fibrosis.\nOur study illustrates that Slc25a47 is a key molecular for hUC-MSCs to improve liver fibrosis and regulates mitochondrial function through Sirt3 for the first time, and providing a theoretical basis for the clinical translation of hUC-MSCs transplantation in the treatment of patients with liver fibrosis/cirrhosis.", "dois": ["10.1016/j.biopha.2024.116133"]}
{"pair_type": "slc_pathway", "key1": "SLC25A47", "key2": "oxidative stress", "summary": "Furthermore, Slc25a47 knockdown could partially abrogate the protective effects of hUC-MSCs on HO-induced mitochondrial fission and oxidative stress in hepatocytes.\nConversely, hUC-MSCs increased the Slc25a47 expression and NAD level within mitochondria, thereby enhanced Sirt3 protein activity and alleviated mitochondrial dysfunction in the liver.\nSlc25a47, a newly identified liver-specific mitochondrial NAD transporter, was notably reduced in CCl-treated mice and HO-stimulated hepatocytes.\nOxidative stress and mitochondrial functionality alteration directly contributes to the hepatocyte apoptosis and development of liver fibrosis.", "dois": ["10.1016/j.biopha.2024.116133"]}
{"pair_type": "slc_pathway", "key1": "SLC25A48", "key2": "apoptosis", "summary": "A 9-gene recurrence-associated signature (AC062021.1, CCT7P2, CTB-1I21.1, DGCR6, RP11- 158M2.5, SLC22A6, SLC25A48, ADAM12, and FAM225B) was established, demonstrating robust predictive performance.\nFunctional annotation revealed a significant association between the signature and apoptotic pathways.\nFurthermore, we identified apoptosis, particularly the extrinsic apoptotic pathway involving FADD and CASP8, as a critical mechanism associated with glioma recurrence.\nSubsequent analysis indicated that extrinsic apoptosis-related molecules (FADD and CASP8), rather than intrinsic apoptotic molecules (BCL2 and CASP9), were strongly correlated with glioma recurrence.\nBy utilizing the STRING protein-interaction network, we systematically investigated the correlations between these six classic apoptotic genes and the 9-gene signature.\nFurthermore, correlation analysis was performed to elucidate the relationship between six classic apoptotic genes and the recurrence score.\nAdditionally, we characterized the expression patterns of key extrinsic apoptotic mediators, FADD and CASP8, in both normal and tumor tissues.", "dois": ["10.1186/s12865-025-00746-z"]}
{"pair_type": "slc_pathway", "key1": "SLC25A48", "key2": "oxidative stress", "summary": "Notably, human cells carrying a single nucleotide polymorphism on the SLC25A48 gene and cancer cells lacking SLC25A48 exhibited decreased mitochondrial choline import, increased oxidative stress, and impaired cell proliferation.\nCholine uptake into the mitochondrial matrix via SLC25A48 facilitated the synthesis of betaine and purine nucleotides, whereas loss of SLC25A48 resulted in increased production of mitochondrial reactive oxygen species and imbalanced mitochondrial lipids.", "dois": ["10.1016/j.cmet.2024.07.010"]}
{"pair_type": "slc_pathway", "key1": "SLC25A48", "key2": "proliferation", "summary": "Notably, human cells carrying a single nucleotide polymorphism on the SLC25A48 gene and cancer cells lacking SLC25A48 exhibited decreased mitochondrial choline import, increased oxidative stress, and impaired cell proliferation.\nCholine uptake into the mitochondrial matrix via SLC25A48 facilitated the synthesis of betaine and purine nucleotides, whereas loss of SLC25A48 resulted in increased production of mitochondrial reactive oxygen species and imbalanced mitochondrial lipids.\nTogether, this study demonstrates that SLC25A48 regulates mitochondrial choline catabolism, bioenergetics, and cell survival.\nWe found that SLC25A48 was required for brown fat thermogenesis, mitochondrial respiration, and mitochondrial membrane integrity.\nHere, we report that SLC25A48, a previously uncharacterized mitochondrial inner-membrane carrier protein, controls mitochondrial choline transport and the synthesis of choline-derived methyl donors.", "dois": ["10.1016/j.cmet.2024.07.010"]}
{"pair_type": "slc_pathway", "key1": "SLC25A48", "key2": "oxidative phosphorylation", "summary": "SLC25A48 was upregulated in glioblastoma when compared to the milder form.\nThese genes are associated with essential pathways for the tumor, such as glucose metabolization, gluconeogenesis, calcium and vitamin D metabolism, tumor progression and activation of the invasion cascade.\nThe deregulation of mitochondrial metabolism has not yet been fully elucidated.\nGenes involved in mitochondrial metabolism can influence the proliferative cascade and be associated with tumor invasion.", "dois": ["10.1016/j.heliyon.2024.e40414"]}
{"pair_type": "slc_pathway", "key1": "SLC25A49", "key2": "apoptosis", "summary": "Single-cell analysis further demonstrated h eightened expression of SLC25A19 in the immune microenvironment of HCC, and in vitro experiments indicated that SLC25A19 may regulate the proliferation, migration, invasion, cycle, and apoptosis of liver cancer cells through the Wnt pathway.\nSubsequently, we developed a prognostic model using a Lasso regression approach with SLC25A19, SLC25A49, and SLC25A51 as features, and generated a risk score for each HCC patient.\nThe risk scores derived from the features SLC25A19, SLC25A49, and SLC25A51 effectively predicted the prognosis of HCC patients, with area under the curve (AUC) values exceeding 0.7 in the test group.", "dois": ["10.1016/j.gene.2025.149299"]}
{"pair_type": "slc_pathway", "key1": "SLC25A48", "key2": "glycolysis", "summary": "Among these genes, we highlight that none of them had been reported in glioblastoma until this research, and we suggest these genes as possible biomarkers to be further explored, since they are associated with essential pathways for the tumor, such as glucose metabolization, gluconeogenesis, calcium and vitamin D metabolism, tumor progression and activation of the invasion cascade.", "dois": ["10.1016/j.heliyon.2024.e40414"]}
{"pair_type": "slc_pathway", "key1": "SLC25A49", "key2": "glycolysis", "summary": "Specific ablation of Slc25a49 in cardiomyocytes leads to exacerbated Dox-induced cardiomyopathy, characterized by compromised mitochondrial respiration enhanced glycolysis and increased glycolytic metabolite glucose-6-phosphate (G6P) levels, subsequently activating the activator protein-1 (AP-1) complex.", "dois": ["10.1002/advs.202502163"]}
{"pair_type": "slc_pathway", "key1": "SLC25A49", "key2": "migration", "summary": "in vitro experiments indicated that SLC25A19 may regulate the proliferation, migration, invasion, cycle, and apoptosis of liver cancer cells through the Wnt pathway.\nSubsequently, we developed a prognostic model using a Lasso regression approach with SLC25A19, SLC25A49, and SLC25A51 as features, and generated a risk score for each HCC patient.\nThe risk scores derived from the features SLC25A19, SLC25A49, and SLC25A51 effectively predicted the prognosis of HCC patients, with area under the curve (AUC) values exceeding 0.7 in the test group.", "dois": ["10.1016/j.gene.2025.149299"]}
{"pair_type": "slc_pathway", "key1": "SLC25A49", "key2": "proliferation", "summary": "Single-cell analysis further demonstrated h eightened expression of SLC25A19 in the immune microenvironment of HCC, and in vitro experiments indicated that SLC25A19 may regulate the proliferation, migration, invasion, cycle, and apoptosis of liver cancer cells through the Wnt pathway.\nIn the HepG2 animal model, overexpression of SLC25A19 significantly promotes tumor growth, while knockdown inhibits tumor growth.\nSubsequently, we developed a prognostic model using a Lasso regression approach with SLC25A19, SLC25A49, and SLC25A51 as features, and generated a risk score for each HCC patient.\nThe risk scores derived from the features SLC25A19, SLC25A49, and SLC25A51 effectively predicted the prognosis of HCC patients, with area under the curve (AUC) values exceeding 0.7 in the test group.", "dois": ["10.1016/j.gene.2025.149299"]}
{"pair_type": "slc_pathway", "key1": "SLC25A51", "key2": "apoptosis", "summary": "We found that lowering SLC25A51 levels led to increased apoptosis and prolonged survival in orthotopic xenograft models.\nSingle-cell analysis further demonstrated h eightened expression of SLC25A19 in the immune microenvironment of HCC, and in vitro experiments indicated that SLC25A19 may regulate the proliferation, migration, invasion, cycle, and apoptosis of liver cancer cells through the Wnt pathway.", "dois": ["10.1016/j.gene.2025.149299", "10.1016/j.cmet.2024.01.013"]}
{"pair_type": "slc_pathway", "key1": "SLC25A51", "key2": "glycolysis", "summary": "Overexpression of SLC25A51 promotes hepatocellular carcinoma progression by driving aerobic glycolysis through activation of SIRT5.\nMechanistically, glucose metabolism reprogramming from oxidative phosphorylation to glycolysis by activation of mitochondrial sirtuin 5 (SIRT5) was found to contribute to the promotion of growth and metastasis by SLC25A51 in HCC cells.\nKnockdown of SLC25A51 attenuated, while overexpression of SLC25A51 enhanced the growth and metastasis of HCC cells both in vitro and in vivo.", "dois": ["10.1016/j.freeradbiomed.2022.02.014"]}
{"pair_type": "slc_pathway", "key1": "SLC25A51", "key2": "migration", "summary": "Our findings reveal a novel lncRNA-microRNA-metabolic axis wherein LINC02802 facilitates NSCLC progression by reprogramming mitochondrial metabolism via miR-1976-mediated upregulation of SLC25A51.\nElevated SLC25A51 enhances mitochondrial NAD import, leading to an increased NAD/NADH ratio and promoting oxidative TCA cycle flux.\nMechanistically, LINC02802 acts as a competing endogenous RNA (ceRNA) for miR-1976, thereby relieving the suppression of solute carrier family 25 member 51(SLC25A51).\nFunctionally, this shift supports tumor cell proliferation and migration.\nRescue experiments confirmed that the oncogenic effect of LINC02802 is dependent on the miR-1976/SLC25A51 axis.\nInterestingly, either silencing LINC02802 with antisense oligonucleotides (ASOs) or treating cells with fludarabine phosphate, an SLC25A51 inhibitor, successfully reversed cisplatin resistance in lung cancer cells.\nTargeting this axis may offer therapeutic potential for metabolic intervention in NSCLC.", "dois": ["10.7150/ijbs.116639", "10.1016/j.gene.2025.149299"]}
{"pair_type": "slc_pathway", "key1": "SLC25A51", "key2": "oxidative phosphorylation", "summary": "Mechanistically, glucose metabolism reprogramming from oxidative phosphorylation to glycolysis by activation of mitochondrial sirtuin 5 (SIRT5) was found to contribute to the promotion of growth and metastasis by SLC25A51 in HCC cells.\nThe nicotinamide adenine dinucleotide (NAD/NADH) pair is a cofactor in redox reactions and is particularly critical in mitochondria as it connects substrate oxidation by the tricarboxylic acid (TCA) cycle to adenosine triphosphate generation by the electron transport chain (ETC) and oxidative phosphorylation.\n-null cells have large decreases in TCA cycle flux, mitochondrial respiration, ETC complex I activity, and mitochondrial levels of NAD and NADH.\nSolute carrier family 25 member 20 (SLC25A51) is a newly identified mammalian mitochondrial NAD transporter.\nMCART1 is the long sought mitochondrial transporter for NAD in human cells.\nIsolated mitochondria from cells lacking or overexpressing have greatly decreased or increased NAD uptake in vitro, respectively.", "dois": ["10.1016/j.freeradbiomed.2022.02.014", "10.1126/sciadv.abe5310"]}
{"pair_type": "slc_pathway", "key1": "SLC25A51", "key2": "oxidative stress", "summary": "We find that depletion of mitochondrial NAD owing to deficiency of the mitochondrial NAD transporter SLC25A51 impairs BNIP3-mediated mitophagy.\nNotably, mitochondrial NAD depletion promotes mitochondrial DNA (mtDNA) release from mitochondria to the cytosol upon oxidative stress, thereby exacerbating the type I interferon response to free cytosolic mtDNA via activation of the CGAS-STING1 signaling pathway.", "dois": ["10.1080/15548627.2025.2589909"]}
{"pair_type": "slc_pathway", "key1": "SLC25A51", "key2": "proliferation", "summary": "Here, we report that SLC25A51 is upregulated in multiple cancers, which promotes cancer cells proliferation.\nNotably, BACH1 deficiency promoted taurocholic acid (TCA)-induced proliferation of human umbilical vein endothelial cells (HUVECs), whereas this phenotype could be reversed by shRNA-mediated knockdown of SLC25A51.\nFurther studies confirmed that administration of the specific BACH1 inhibitor HPPE effectively alleviated TCA-induced suppression of HUVECs proliferation.\nIn the HepG2 animal model, overexpression of SLC25A19 significantly promotes tumor growth, while knockdown inhibits tumor growth.\nTogether, the data indicate that AML cells upregulate SLC25A51 to decouple mitochondrial NAD/NADH for a proliferative advantage by supporting oxidative reactions from a variety of fuels.\nOur findings reveal a novel lncRNA-microRNA-metabolic axis wherein LINC02802 facilitates NSCLC progression by reprogramming mitochondrial metabolism via miR-1976-mediated upregulation of SLC25A51.\nWe found that lowering SLC25A51 levels led to increased apoptosis and prolonged survival in orthotopic xenograft models.\nElevated SLC25A51 enhances mitochondrial NAD import, leading to an increased NAD/NADH ratio and promoting oxidative TCA cycle flux.\nMechanistically, LINC02802 acts as a competing endogenous RNA (ceRNA) for miR-1976, thereby relieving the suppression of solute carrier family 25 member 51(SLC25A51).\nInterestingly, either silencing LINC02802 with antisense oligonucleotides (ASOs) or treating cells with fludarabine phosphate, an SLC25A51 inhibitor, successfully reversed cisplatin resistance in lung cancer cells.\nNotably, we find fludarabine phosphate, an FDA-approved drug, is able to bind with and inhibit SLC25A51 functions, causing mitochondrial NAD decrease and proteins hyperacetylation, which could further synergize with aspirin", "dois": ["10.7150/ijbs.116639", "10.1186/s10020-025-01215-4", "10.1016/j.gene.2025.149299", "10.1016/j.cmet.2024.01.013", "10.1038/s41418-023-01185-2"]}
{"pair_type": "slc_pathway", "key1": "SLC25A53", "key2": "proliferation", "summary": "In vitro experiments confirmed that itaconate secreted by TREM2 macrophages inhibited cardiomyocyte apoptosis and promoted fibroblast proliferation.\nUsing RNA-seq, protein and molecular docking, and Targeted Metabolomics (LC-MS), our data demonstrated that macrophages expressing TREM2 exhibited decreased SLC25A53 transcription through the SYK-SMAD4 signaling pathway after efferocytosis, which impaired NAD transport into mitochondria, downregulated SLC25A53 thereby causing the breakpoint in the TCA cycle and subsequently increased itaconate production.", "dois": ["10.1038/s41418-023-01252-8"]}
{"pair_type": "slc_pathway", "key1": "SLC25A53", "key2": "apoptosis", "summary": "In vitro experiments confirmed that itaconate secreted by TREM2 macrophages inhibited cardiomyocyte apoptosis and promoted fibroblast proliferation.\nUsing RNA-seq, protein and molecular docking, and Targeted Metabolomics (LC-MS), our data demonstrated that macrophages expressing TREM2 exhibited decreased SLC25A53 transcription through the SYK-SMAD4 signaling pathway after efferocytosis, which impaired NAD transport into mitochondria, downregulated SLC25A53 thereby causing the breakpoint in the TCA cycle and subsequently increased itaconate production.", "dois": ["10.1038/s41418-023-01252-8"]}
{"pair_type": "slc_pathway", "key1": "SLC26A1", "key2": "chemotherapy", "summary": "Through drug sensitive analysis, we screened chemotherapy drugs suitable for different groups.\nVitro experiments illustrated the high expression of C4orf48 and SLC26A1 in PCa compared with normal controls.\nFurthermore, functional enrichment analysis revealed different metabolic and signaling pathways in the high- and low-risk groups.\nNotably, the high-risk group had a higher TMB, a lower level of immune infiltration, and a lower expression of immune checkpoints.\nWe validated the expression of the two genes with the largest regression coefficients using qRT-PCR.\nThe discovery was in concordance with bioinformatic analysis results.\nA gene signature with 9 CARMRs was developed in our study, which served as biomarkers for PCa.\nThis brings benefits in determining the prognosis of patients with PCa and guiding personalized treatment.", "dois": ["10.7150/jca.112843"]}
{"pair_type": "slc_pathway", "key1": "SLC26A2", "key2": "apoptosis", "summary": "Consistently, suppressing FGFR3 signaling by blocking either FGFR3 or phosphorylation of the downstream effector favors the recovery of slc26a2 cartilage cultures from impaired growth and unbalanced cell proliferation and apoptosis.\nOverall, our data demonstrate that the variants p.Val341del and p.Ile421Thr in SLC26A2 cause MED-4 and that these two variants promote chondrocyte proliferation while inhibiting chondrocyte differentiation.\nContinuous endoplasmic reticulum stress and cytosolic Ca overload in turn triggered apoptosis of growth plate chondrocytes.\nLoss-of-function defects are caused primarily by apoptosis, and morphants are insensitive to sound stimulation and imbalanced swimming behaviours.\nAs a consequence, the ATF6 arm of the unfolded protein response (UPR) is preferentially triggered to overactivate FGFR3 signaling by inducing excessive FGFR3 in slc26a2 chondrocytes.\nOur study unveils a previously unrecognized pathogenic mechanism underlying ACG1B and AO2, and supports suppression of FGFR3 signaling as a promising therapeutic approach for SLC26A2-related chondrodysplasias.\nMelatonin, known for its anti-oxidant and anti-inflammatory properties, emerged as a promising therapeutic approach in our study, which enhanced survival, proliferation, and maturation of chondrocytes by attenuating endoplasmic reticulum stress and Ca overload.\nIn chondrocyte assays, NVP-BGJ398 suppressed the defective phenotype of -deficient chondrocytes and restored the phosphorylation downstream of FGFR3 in a concentration-dependent manner.\nThe effect of NVP-BGJ398 on chondrocytes was assessed by Alcian blue staining, proliferation, apoptosis, and chondrocyte-specific markers and then verified by western blotting for variations in the downstream markers of FGFR3.\nIt has been reported that Slc26a2 deficiency triggers the ATF", "dois": ["10.1371/journal.pone.0136832", "10.1016/j.gendis.2024.101350", "10.1186/s13023-024-03228-4", "10.1016/j.jot.2023.09.003", "10.1016/j.ebiom.2019.01.010", "10.1158/1541-7786.MCR-16-0234", "PMID:15703192"]}
{"pair_type": "slc_pathway", "key1": "SLC26A2", "key2": "chemotherapy", "summary": "Three machine learning methods, support vector machine (SVM), decision tree (DT), and Extreme Gradient Boosting (XGBoost), identified three TMEscore-related genes (ADH1C, SLC26A2, and NANS) associated with the response to chemotherapy.\nThe TMEscore-related gene signature had a better predictive value for response to chemotherapy than for survival.\nA TMEscore-related gene signature was constructed, and three external cohorts validated that the gene signature could predict the response to chemotherapy.\nThe TIIC-based TMEscore was associated with the survival of CRC patients who underwent fluoropyrimidine-based chemotherapy, and predicted the response to chemotherapy.\nThe TMEscore was higher in patients who responded to chemotherapy than in those who did not, and was associated with the survival rate of patients who underwent chemotherapy.\nThis study aimed to explore the prognostic value of a TIIC-related tumor microenvironment score (TMEscore) in patients with colorectal cancer (CRC) who underwent chemotherapy and construct a TMEscore-related gene signature to determine its predictive value.\nThe association between the TMEscore, chemotherapy response, and survival rate was analyzed.\nNoticeably, EC patients with ATP5F1D-high expression had better immune treatment responses and were more sensitive to chemotherapy drugs.\nGene profiles of patients who underwent fluoropyrimidine-based chemotherapy were collected, and their TIIC fractions were calculated and clustered.\nTumor-infiltrating immune cells (TIICs) are associated with chemotherapy response.\nFive datasets and clinical samples showed that the expression of the three TMEscore-related genes was increased in tumor tissues compared to those in control tissues.", "dois": ["10.1007/s10528-023-10646-9", "10.3389/fonc.2022.953321"]}
{"pair_type": "slc_pathway", "key1": "SLC26A2", "key2": "migration", "summary": "PDGF treatment up-regulated SLC26A2 expression in HASMCs, whereas the knockdown of SLC26A2 inhibited PDGF-stimulated proliferation, migration, and production of inflammatory factors, and enhanced the expression of cell contractile phenotype marker proteins in HASMCs.\nFurthermore, we validated that LINc02086/miR-770-5p/SLC26A2 axis promoted migration in LSCC.\nThese findings indicate that NEAT1-mediated miR-9-5p targeting of SLC26A2 inhibits the PDGF-induced proliferation and production of inflammatory factors in HASMCs.\nAnd we found that LINC02086 and LINC02575 promoted the proliferation, migration, and invasion of LSCC cells while AC011933.2 and FAM30A inhibited these biological functions in vitro.\nLuciferase reporter and RIP experiments validated that NEAT1 targeted miR-9-5p to regulate SLC26A2, thereby influencing the biological function of PDGF-induced HASMCs.\nThis study aimed to investigate the expression of SLC26A2 in human ASMCs (HASMCs) and the regulatory mechanism of SLC26A2 in the proliferation and inflammatory factor production of HASMCs.\nTo investigate its role in airway inflammation and airway remodeling, we treated HASMCs with platelet-derived growth factor (PDGF) in an in vitro model and determined SLC26A2 expression in cells using western blotting.\nThey played a significant role in the progress of LSCC via affecting the proliferation and metastasis of tumor cells.", "dois": ["10.3349/ymj.2021.62.9.858", "10.1186/s12885-021-08422-2"]}
{"pair_type": "slc_pathway", "key1": "SLC26A3", "key2": "chemotherapy", "summary": "eggerthii S13-F8 upregulated protective markers, such as Aqp8, Slc26a3, and mucin-related genes (TFF3, FCGBP, and Muc2), while downregulating pro-inflammatory mediators, including IL-1α, IL-22, and Cxcl2.\neggerthii S13-F8 demonstrates significant potential in mitigating severe diarrhea caused by 5-FU chemotherapy, providing a strong foundation for its development as a live biotherapeutic for CID treatment.\neggerthii S13-F8 significantly alleviated weight loss and diarrhea.\nFive resistance markers, SERPINA6, BEX1, AGTR1, SLC26A3, and LAPTM4B, were identified in three of the four datasets (p value overlap < 1 × 10(-6)).\nSince these external sets included patients who received differing treatment regimens, the validated markers represent markers of general chemotherapy resistance.\nWe found a number of markers of resistance to anthracycline-based chemotherapy.\nATP12A, SLC26A3 and AQP8, involved in the transport of ions and water;\nThese five genes identified resistant tumors that could not have been identified by merely taking ER status or proliferation into account.\nThe identification of these genes might lead to a better understanding of the mechanisms involved in (clinically) observed chemotherapy resistance and could possibly assist in the recognition of breast cancers in which chemotherapy does not contribute to response or survival.\nWe set out to identify genes associated with chemotherapy resistance.\neggerthii S13-F8 preserved the villus height-to-crypt depth (V/C) ratio and protected goblet cells in colonic tissues.\neggerthii S13-F8 modulated gut microbiota composition by suppressing pathogenic bacteria (Pseudomonas aeruginosa, Salmonella, γ-Proteobacteria, and Shigella) and enriching beneficial taxa, such as Lactobacillus and Akkermansia muciniphila.\nGene expression analysis showed that B. eggerthii S13-F8 upregulated protective markers, such", "dois": ["10.1007/s12602-025-10595-2", "10.1016/j.toxlet.2022.09.013", "10.1007/s10549-012-2340-x"]}
{"pair_type": "slc_pathway", "key1": "SLC26A2", "key2": "oxidative stress", "summary": "Ulcerative colitis (UC) is a recurrent inflammatory condition of the bowel with a multifaceted pathogenesis, including programmed cell death, oxidative stress, and immune-mediated inflammation.\n3'-Methoxydaidzein (MHD), a key constituent of Puerariae Radix, inhibited LPS-induced inflammatory responses in Caco2 cells and alleviated DSS-induced colonic injury in UC mice via upregulation of SLC26A2.\nCluster with high expression of SLC26A2 showed a UC phenotype with a milder degree of damage.\nHub genes associated with disulfidptosis, CXCL1, HMGCS2, AQP8, and SLC26A2, were further screened and validated.\nAdditionally, we identified the hub gene SLC26A2 as playing a significant role in UC, and MHD demonstrates potential as a targeted therapeutic strategy for UC.", "dois": ["10.1371/journal.pone.0324586"]}
{"pair_type": "slc_pathway", "key1": "SLC26A3", "key2": "apoptosis", "summary": "Further investigation revealed that 15 preserved the integrity of the gastric mucus layer and enhanced the expression of gastric mucin proteins MUC6, as well as gastric mucosal proteins CFTR and SLC26A3, thereby strengthening the protective function of the gastric mucosal barrier in rats.\nPHI treatment improved the intestinal mucosal barrier by protecting goblet cells, promoting gene expressions of , , and , increasing tight junction proteins (TJs), and reducing epithelial cell apoptosis.\nAdditionally, 15 inhibited apoptosis in gastric mucosal cells, further mitigating ethanol-induced gastric ulcer damage.", "dois": ["10.1016/j.bioorg.2025.108699", "10.3390/ijms24032238", "10.1016/j.ejmech.2017.10.016", "10.3892/or.2010.1126"]}
{"pair_type": "slc_pathway", "key1": "SLC26A2", "key2": "proliferation", "summary": "These findings indicate that NEAT1-mediated miR-9-5p targeting of SLC26A2 inhibits the PDGF-induced proliferation and production of inflammatory factors in HASMCs.\nPDGF treatment up-regulated SLC26A2 expression in HASMCs, whereas the knockdown of SLC26A2 inhibited PDGF-stimulated proliferation, migration, and production of inflammatory factors, and enhanced the expression of cell contractile phenotype marker proteins in HASMCs.\nOverall, our data demonstrate that the variants p.Val341del and p.Ile421Thr in SLC26A2 cause MED-4 and that these two variants promote chondrocyte proliferation while inhibiting chondrocyte differentiation.\nConsistently, suppressing FGFR3 signaling by blocking either FGFR3 or phosphorylation of the downstream effector favors the recovery of slc26a2 cartilage cultures from impaired growth and unbalanced cell proliferation and apoptosis.\nCompared with SLC26A2WT, the expressions of SLC26A2Val162Leu and SLC26A2Val162Glyfs*12 were decreased, along with reduced proliferation of human primary chondrocytes.\nThe beneficial effect of increased macromolecular sulfation was confirmed by chondrocyte proliferation studies in cryosections of the tibial epiphysis by proliferating cell nuclear antigen immunohistochemistry: the percentage of proliferating cells, significantly reduced in the placebo group, reached normal values in dtd newborns from NAC-treated females.\nFurthermore, we validated that LINc02086/miR-770-5p/SLC26A2 axis promoted migration in LSCC.\nMelatonin, known for its anti-oxidant and anti-inflammatory properties, emerged as a promising therapeutic approach in our study, which enhanced survival, proliferation, and maturation of chondrocytes by attenuating endoplasmic reticulum stress and Ca overload.\nIn chondrocyte assays, NVP-BGJ398 suppressed the defective phenotype of -deficient chondrocytes and restored the phosph", "dois": ["10.1016/j.gendis.2024.101350", "10.1186/s13023-024-03228-4", "10.3760/cma.j.cn511374-20230515-00286", "10.1016/j.jot.2023.09.003", "10.3349/ymj.2021.62.9.858", "10.1186/s12885-021-08422-2", "10.1096/fj.201901040RR", "10.1016/j.ebiom.2019.01.010", "10.1093/hmg/ddv289", "10.1074/jbc.M113.503466", "PMID:15703192"]}
{"pair_type": "slc_pathway", "key1": "SLC26A3", "key2": "oxidative stress", "summary": "Gene expression signature showed dysregulation in mediators associated with autophagy, ubiquitination, ER stress, oxidative stress, carbohydrate metabolism, solute transport, and T cell regulation in the colonic mucosa from patients with UC, suggesting that these genes could be involved in the pathogenesis of UC.\nAdditionally, the high expression of ALDOB and SLC26A genes is linked to increased inflammation and energy demand.\nLastly, the elevated expression of the SOD2 gene can be considered a response to oxidative stress-related inflammatory processes in the disease.\nOne of the key pathological contributors to the development and progression of inflammatory bowel disease (IBD) is oxidative stress, which results in reactive oxygen species (ROS)-induced mucosal damage.\nThis stress leads to dysfunction of the intestinal barrier.\nIn addition, the levels of oxidative stress (MPO, SOD, and MDA) and inflammatory cytokines (TNF-α, IL-1β, IL-6, and IL-10) were reversed by PHI in colitis mice.\nThe gene expressions of FOXO4, ALDOB, SOD2, TOD2, SLC26A3, and SLC39A4 were associated with the clinical course and histological activity and are of relevance since these provide the utility of new prognostic markers in IBD.\nGene expressions of IRGM, CTLA4, FOXO4, SLC26A3, SLC39A4, SOD2, TDO2, and ALDOB were associated with clinical outcomes, such as medical treatment in response to aminosalicylates, histological remission, clinical course, and evolution.", "dois": ["10.1007/s13258-025-01625-y", "10.1155/2020/9238970", "10.3390/ijms24032238"]}
{"pair_type": "slc_pathway", "key1": "SLC26A3", "key2": "proliferation", "summary": "Our in vivo and in vitro experiments demonstrated that up-regulation of SLC26A3 inhibited CRC proliferation and metastasis, while down-regulation of SLC26A3 promoted CRC progression by modulating the expression level of IκB.\nCollectively, these results suggest that a SLC26A3/NHERF2-IκB/NF-κB/p65 signaling loop suppresses proliferation and metastasis in CRC cells.\nThese findings propose a novel SLC26A3-driven signaling loop that regulates proliferation and metastasis in CRC, providing promising therapeutic interventions and prognostic targets for the management of CRC.\nIn this study, we reported a novel role of SLC26A3 in suppressing CRC progression.\nThus, SLC26A3 impeded the nuclear translocation of NF-κB/p65, enhancing the transcription of SLC26A3 and establishing a positive regulatory feedback loop in CRC cells.\nMechanistically, SLC26A3 augmented the interaction between NHERF2 and IκB, subsequently reducing its degradation.\nThis process inhibited the dissociation of p65 from the IκB/p65/p50 complex and reduced the translocation of p65 from the cytoplasm to the nucleus.\nMoreover, our investigation revealed that NF-κB/p65 directly bound to the promoter of SLC26A3, leading to a decline in its mRNA expression.\nFurthermore, we identified NHERF2 as a novel interacting protein of SLC26A3 responsible for stabilizing the IκB protein and removing ubiquitination modification.\nWe found that SLC26A3 expression was downregulated in CRC, which was proportionally correlated with survival.\nCdx2 expression in the EPC-hTERT.D1 cells decreased cell proliferation but did not induce intestinalization.\nTreatment of newly confluent Caco-2/15 cells with SAHA resulted in growth arrest, increased histone acetylation and up-regulation of the expression of intestine-specific genes such as those encoding sucrase-isomaltase, villin and the ion exchanger SLC26A", "dois": ["10.1007/s11596-024-2871-5", "10.1038/s41389-023-00488-w", "10.1111/apha.13774", "10.1093/ibd/izy350", "10.1152/ajpgi.00108.2017", "10.1002/jcb.25274", "10.1038/ismej.2014.111", "10.1007/s10549-012-2340-x", "10.1371/journal.pone.0018280", "10.3892/or.2010.1126", "10.1093/carcin/bgn227", "PMID:17001077"]}
{"pair_type": "slc_pathway", "key1": "SLC26A4", "key2": "apoptosis", "summary": "After SLC26A4 mutation, pendrin was transferred from the membrane, the chloride intracellular channel function was reduced, and the excessive accumulation of chloride in the cytoplasm induced cell apoptosis by inhibited PI3K/Akt/mTOR pathway phosphorylation.\nFurthermore, inhibiting SLC26A4 promoted apoptosis of cardiac hypertrophy cells.\nMoreover, SLC26A4 silencing inhibits autophagy of cardiomyocytes and induces apoptosis of cardiomyocytes.\nIn addition to all these effects, the overexpression of SLC26A4-AS1 promoted apoptosis of TPC-1 cells.\nFlow cytometry assay was used to test the apoptosis of PE-induced cardiomyocytes transfected by small interfere RNA (siRNA)-SLC26A4.\nQuantitative reverse transcription polymerase chain reaction and Western blotting were performed to measure the expression of ANP, BNP, β-MHC, SLC26A4, NLRP3, apoptosis associated speck-like protein containing a C-terminal caspase recruitment domain (ASC), and caspase-1.\nSLC26A4 was involved in cardiac hypertrophy by promoting autophagy and activating the NLRP3 inflammasome pathway.\nSLC26A4 promoted autophagy and activation of the NLRP3 inflammasome pathway, regulating the gene and protein expression of LC3, beclin-1, p62, ACS, NLRP3, and caspase-1.\nCompared with the vector group, the chloride concentration, cell apoptotic rate, and the expression levels of caspase-3, caspase-9, and Bax were downregulated.\nTop KEGG pathways related to these targets included cancer, TNF signalling, apoptosis, NF-kappa B, and cAMP signalling pathways.\nMolecular analysis identified 2747 genes potentially shared between AD and HL, involved in apoptosis, oxidative stress, inflammation, and metabolic dysregulation.", "dois": ["10.1155/2022/6496799", "10.1002/jcp.29145", "10.1074/jbc.M116.746909", "10.1093/jpp/rgaf068", "10.1016/j.arr.2025.102799", "10.1038/s41598-025-97874-8", "10.7717/peerj.8253", "10.18632/oncotarget.10166"]}
{"pair_type": "slc_pathway", "key1": "SLC26A3", "key2": "migration", "summary": "In conclusion, Ado signaling during PMN TEM induces an adaptive tissue response to inflammatory acidification through the induction of SLC26A3 expression, thereby promoting pH homeostasis.\nUtilizing loss- and gain-of-function approaches, as well as murine and human colonoids, we demonstrate that Ado-induced SLC26A3 promotes an adaptive IECs phenotype that buffers local pH during active inflammation.\nGiven the significant amount of adenosine (Ado) generated during PMN TEM, we profiled the influence of Ado on IECs gene expression by microarray and identified the induction of SLC26A3, the major apical Cl/HCO exchanger in IECs.\nExtending these studies, chronic murine colitis models were used to demonstrate that SLC26A3 expression rebounds during chronic DSS-induced inflammation.\nImportantly, SLC9A2 overexpression in SW480 cells led to a notable inhibition of cell proliferation, migration, and invasion.\nOur study suggests that SLC9A2 acts as a tumor suppressor through the MAPK pathway and could be a potential target for CRC diagnosis and therapy.\nUsing unbiased approaches, we sought to define acid-adaptive pathways elicited by PMN TEM.\nUsing newly developed tools, we revealed that active PMN transepithelial migration (TEM) significantly acidifies the local microenvironment, a decrease of nearly 2 pH units.\nCorrelation analysis indicated a potential link between SLC9A2 expression and the MAPK signaling pathway.\nWestern blotting analysis revealed that the expression levels of phosphorylated ERK (p-ERK) and phosphorylated JNK (p-JNK) proteins were significantly increased, whereas there were no significant changes in the expression levels of ERK and JNK following SLC9A2 overexpression.\nGene expression analysis revealed that CX", "dois": ["10.1007/s11596-024-2871-5", "10.1038/s41385-019-0237-2"]}
{"pair_type": "slc_pathway", "key1": "SLC26A5", "key2": "oxidative stress", "summary": "Other relevant functional pathways were significant at unadjusted enrichment p-values of 0.001-0.11 and included calcium signaling, neurotransmission/neurological processes and oxidative stress.\nThe neurological process clusters included 7 genes (EML2, OTOR, SLC26A5, TBL1X, TECTA, USH1C and USH1G) known to modulate cochlear outer hair cell motility.", "dois": ["10.1016/j.ntt.2013.04.008"]}
{"pair_type": "slc_pathway", "key1": "SLC26A4", "key2": "migration", "summary": "In addition, the overexpression of SLC26A4-AS1 inactivated the MAPK pathway by promoting TP53 and decreased cell migration, proliferation, and invasion.\nLncRNA SLC26A4-AS1 markedly inhibited migration, invasion, and metastasis capability of cancer cells in vitro and in vivo.\nEnhanced interaction between DDX5 and transcriptional factor E2F1 due to silencing of SLC26A4-AS1 promoted binding of the DDX5-E2F1 complex at promoters of the MRN genes and, thus, stimulate the MRN/ATM dependent DSB signaling and thyroid cancer metastasis.\nIntriguingly, SLC26A4-AS1 could simultaneously interact with DDX5 and the E3 ligase TRIM25, which promoting DDX5 degradation through the ubiquitin-proteasome pathway.\nTaken together, the overexpression of lncRNA SLC26A4-AS1 coffered anti-oncogenic effects on PTC through the inactivation of the MAPK pathway.\nNotably, SLC26A4-AS1 elevated E-cadherin expression while it reduced that of ERK and Vimentin.\nIn addition to all these effects, the overexpression of SLC26A4-AS1 promoted apoptosis of TPC-1 cells.\nIn particular, SLC26A4-AS1 inhibited expression of multiple DNA double-strand breaks (DSBs) repair genes, especially genes coding proteins in the MRE11/RAS50/NBS1 (MRN) complex.\nAdditionally, the overexpression of lncRNA SLC26A4-AS1 reduced xenograft tumor volume in nude mice.\nLncRNA SLC26A4-AS1 regulating TP53 had the potential to participate in PTC by regulating the MAPK pathway.\nWe found that lncRNA SLC26A4-AS1 was continuously, significantly down-regulated in normal tissues, thyroid cancer, and lymph node metastasis specimens.\nLow SLC26A4-AS1 levels in tissues were significantly associated with poor prognosis of thy", "dois": ["10.1183/23120541.00011-2025", "10.1093/jpp/rgaf068", "10.34172/aim.28745", "10.1016/j.omtn.2020.12.024", "10.1038/s41388-020-01460-3", "10.1155/2020/3651051", "10.1002/jcp.29145", "10.1177/0003489415575060", "10.3892/mmr.2014.2148", "10.1038/jhg.2010.96"]}
{"pair_type": "slc_pathway", "key1": "SLC26A4", "key2": "oxidative stress", "summary": "We found that albino Slc26a4 mice exhibited significantly less severe hearing loss along with reduced macrophage activation than their pigmented counterpart did.\nExcessive mucus production, as implicated by significant overexpression of the pendrin coding gene, SLC26A4, was identified as a potential novel mechanism for silica-induced pulmonary toxicity.\nIn this study, an ARHL animal model was established by inducing continuous oxidative stress to promote short-term aging of cells, determined on the basis of expression of hearing-loss-induced phenotypes and aging-related factors.\nAge-related hearing loss (ARHL) is the most common sensory disorder among the elderly, associated with aging and auditory hair cell death due to oxidative-stress-induced mitochondrial dysfunction.\nContinuous oxidative stress and HFD accelerated cellular aging.\nExpression of , , , , and , which are ARHL-related factors, were modified by oxidative stress in the cells of the hearing organ.\nMolecular analysis identified 2747 genes potentially shared between AD and HL, involved in apoptosis, oxidative stress, inflammation, and metabolic dysregulation.\nGenes involved in oxidative stress, inflammation, respiratory diseases, cancer, and tissue remodeling and fibrosis were significantly differentially expressed in the rat lungs;\nBrain injuries are associated with oxidative stress and a need to restore neuronal homeostasis.\nFunctional enrichment analysis highlighted dysregulation in proteolysis and phosphate metabolism, implicating metabolic stress and chronic inflammation in disease progression.\nThree-dimensional morphometric analyses revealed that macrophages in pigmented Slc26a4 mice were significantly larger, more rounded, and structurally distinct from those in albino mice, suggesting divergent activation states.\nTranscriptomic profiling showed no upregulation of melanogenesis-related genes, implying that melanin accumulation arises from impaired degradation rather than increased synthesis.\nWe found that intermittent hypoxia, HFD, and galactose injection accelerated cellular aging in", "dois": ["10.3390/ijms21197068", "PMID:17959752", "10.2147/IJGM.S548720", "10.1016/j.arr.2025.102799", "10.1016/j.nbd.2025.106962", "10.2147/JIR.S458580", "10.1089/neu.2019.6962", "10.1530/EC-17-0106", "PMID:27599561", "10.1002/jat.2733", "PMID:23662038"]}
{"pair_type": "slc_pathway", "key1": "SLC26A4", "key2": "proliferation", "summary": "In addition, the overexpression of SLC26A4-AS1 inactivated the MAPK pathway by promoting TP53 and decreased cell migration, proliferation, and invasion.\nTherefore, circSLC26A4 may suppress the maturation of miR-15a in NSCLC to inhibit cancer cell proliferation.\nFunctionally, cellular experiments indicated that circSLC26A4 knockdown repressed the proliferation, invasion, and tumor growth in vitro and in vivo.\nA cell proliferation assay revealed that overexpression of circSLC26A4 reduced the inhibitory effects of overexpression of miR-15a on cell proliferation.\nThe application of 10 mM salicylate showed an increase in cell toxicity and decrease in cell viability, leading to a significant decrease in cell proliferation.\nIn conclusion, these findings demonstrate that circSLC26A4 facilitates cervical cancer progression through the QKI/circSLC26A4/miR-1287-5p/HOXA7 axis, which might bring novel therapeutic strategies for cervical cancer.\nATP12A inhibition by ouabain decreased bacterial proliferation.\nAdditionally, the overexpression of lncRNA SLC26A4-AS1 reduced xenograft tumor volume in nude mice.\nIn addition to all these effects, the overexpression of SLC26A4-AS1 promoted apoptosis of TPC-1 cells.\nConditional inactivation of Efnb2 in early-stage embryonic ear tissues disrupted cell proliferation, cell survival, and epithelial folding at the origin of the endolymphatic epithelium.\nMechanistically, RNA binding protein (RBP) quaking (QKI) was identified to interact with the QKI response elements (QREs) in SLC26A4 gene introns, thereby promoting circSLC26A4 biogenesis.\nTaken together, the overexpression of lncRNA SLC26A4-AS1 coffered anti-oncogenic effects on PTC through the inactivation of the MAPK pathway.\nRecent studies have unraveled novel roles for guanylin peptides in several organ systems including involvement in appetite regulation, olfactory function", "dois": ["10.1016/j.biopha.2023.115445", "10.1016/j.anl.2022.03.009", "10.3892/ol.2021.12983", "10.1016/j.omtn.2019.11.032", "10.1002/jcp.29145", "10.1038/s41598-019-42751-4", "10.1016/j.ydbio.2014.02.019", "10.1159/000356641", "10.1002/ajmg.a.33456"]}
{"pair_type": "slc_pathway", "key1": "SLC26A6", "key2": "apoptosis", "summary": "In the vitro study, compared to the control group, downregulated Slc26a6 NRK cells showed alleviation of the cell viability decrease, cell apoptosis rate, ROS generation, and SOD activity decrease after oxalate treatment.\nMechanistically, UCB can promote apoptosis in renal tubular epithelial cells, enhance oxalate secretion by upregulating Slc26a6 expression, and facilitate CaOx crystal nucleation and aggregation, all of which contribute to renal CaOx crystalline pathogenesis.\nRats infected with lentivirus-siRNA exhibited attenuated SOD generation, cell apoptosis, and crystal formation in the kidneys.", "dois": ["10.1016/j.cbpa.2024.111593", "10.1155/2018/1724648", "10.1080/19490976.2025.2546158"]}
{"pair_type": "slc_pathway", "key1": "SLC26A6", "key2": "oxidative stress", "summary": "Downregulated Expression of Solute Carrier Family 26 Member 6 in NRK-52E Cells Attenuates Oxalate-Induced Intracellular Oxidative Stress.\nIn the vitro study, compared to the control group, downregulated Slc26a6 NRK cells showed alleviation of the cell viability decrease, cell apoptosis rate, ROS generation, and SOD activity decrease after oxalate treatment.\nThis study is aimed at investigating the effect of Slc26a6 expression on oxalate-induced cell oxidation and crystal formation.\nIn conclusion, the results of the present study indicate that reducing the expression of Slc26a6 in the kidney may be a potential strategy for preventing stone formation.\nRats infected with lentivirus-siRNA exhibited attenuated SOD generation, cell apoptosis, and crystal formation in the kidneys.\nCrystal adhesion and vesicles were significantly less after oxalate exposure than in the untreated controls.\nPLP corrected altered expressions of tight junction proteins (zo-1, zo-2, and claudin-4) and nutrient transporters (glut-1, slc15a2, slc26a6, and slc4a4) in Cd-exposed fish.\nPLP mitigated pathological alterations, replenished antioxidants (SOD, CAT, and GSH), and reduced lipid peroxidation in the intestinal tissues.\nIts antioxidant activity and regulation of intestinal tight junction proteins and nutrient transporters contribute to its effectiveness.\nSolute carrier family 26 member 6 (Slc26a6), which is mainly expressed in the intestines and kidneys, is a multifunctional anion transporter that is crucial in the transport of oxalate anions.", "dois": ["10.1007/s10695-024-01415-5", "10.1155/2018/1724648", "10.1016/j.cbpa.2024.111593"]}
{"pair_type": "slc_pathway", "key1": "SLC26A6", "key2": "migration", "summary": "Knockdown of SLC26A6 reduced transporter activity whereas enhanced cellular migration.\nβ-estradiol-mediated cellular migration was independent of SLC26A6 transporter activity, whereas enhanced SLC26A6 expression attenuated cellular migration even in the presence of β-estradiol treatment.\nThese results indicate β-estradiol treatment enhances cancer cell migration and dysregulates oxalate transport by inhibiting SLC26A6 activity, suggesting reduced oxalate transporting activity may involve in the oxalate homeostasis.\nThe β-estradiol stimulation attenuated oxalate or bicarbonate transporting activities through SLC26A6.", "dois": ["10.1016/j.tiv.2022.105373"]}
{"pair_type": "slc_pathway", "key1": "SLC26A7", "key2": "apoptosis", "summary": "SLC26A7 encodes a chloride/bicarbonate exchanger expressed in the renal outer medullary collecting duct.\nCASP9 plays a central role in cardiomyocyte apoptosis.", "dois": ["10.1093/hmg/ddz070", "10.1097/FPC.0b013e32834b68f9"]}
{"pair_type": "slc_pathway", "key1": "SLC26A7", "key2": "oxidative stress", "summary": "Here, we discuss the recent developments in this field, focusing on genetic predisposition, epigenetic modifications, lymphocytes, cytokines, oxidative stress, infectious agents, proteins, microRNAs, autoantibodies, serum pepsinogen, gastrin, esophagogastroduodenoscopy and microscopic findings, and the risk of gastric neoplasm.", "dois": ["10.3390/cimb45070334"]}
{"pair_type": "slc_pathway", "key1": "SLC26A6", "key2": "chemotherapy", "summary": "Solute carrier (SLC) transporters play important roles in various physiological and pathological processes, such as cellular uptake of nutrients, cellular metabolism, tumor initiation and chemotherapy resistance.\nKnockdown of SLC26A6 suppressed HCC tumorigenesis both in vitro and in vivo, indicating it as a promising therapeutic target.\nFinally, multifaceted bioinformatic analyses indicated that SLC26A6 might associate with multiple cancer-related pathways.\nThis study highlights the potential roles of SLC genes in HCC tumorigenesis, and suggested SLC26A6 as a promising therapeutic target in HCC patients.\nClinical-relevant DESLCs identified a poor prognostic HCC subtype exhibiting unique clinicopathological and genomic proﬁles.\nSLC26A6 was overexpressed in HCC tissues both in mRNA and protein levels.\nWe identified 118 differentially expressed SLC genes (DESLCs) and found that there was a preferential enrichment for activated DESLCs in HCC.", "dois": ["10.21037/tcr-20-1751"]}
{"pair_type": "slc_pathway", "key1": "SLC26A8", "key2": "apoptosis", "summary": "These are involved in energy balance and metabolism (SUGCT, HECW1, MMADHC), cells apoptosis (APP, SRBD1, NTN1, PUF60, SLC26A8, DAP, SUGCT), angiogenesis (RYR2, LDB2, SOX5), skin protection to solar radiation (FZD10, BCO2, WNT5B, COL6A2, SIRT1) as well as growth (NELL1).", "dois": ["10.1111/age.70014"]}
{"pair_type": "slc_pathway", "key1": "SLC26A9", "key2": "apoptosis", "summary": "In addition, downregulation of SLC26A9 in CRC cells induced cell cycle arrest and apoptosis but inhibited cell proliferation and xenograft tumor growth both in vitro and in vivo.\nExogenous expression of SLC26A9 in GC cells induced upregulation of the Cl/HCO exchanger AE2, G2/M cell cycle arrest and apoptosis and suppressed their proliferation, migration and invasion.\nWe also found that and had a regulatory relationship at the cellular level, for example, high expression of was noted to inhibit cancer cell proliferation and migration yet promote apoptosis.\nHigh expression of inhibits cancer cell proliferation and migration, yet promotes cancer cell apoptosis.\nIn addition, we found that SLC26A9 expression decreases during human gastric carcinogenesis, and that exogenous SLC26A9 expression in GC cells reduces their malignant behavior.\nAnalysis of human gastric precancerous and cancerous tissues revealed that SLC26A9 expression progressively decreased from atrophic gastritis to GC, and that downregulation of SLC26A9 was correlated with patient survival.", "dois": ["10.1016/j.aninu.2025.03.008", "10.21037/tcr-2024-2443", "10.1038/s41420-024-01888-6", "10.1007/s13402-022-00672-x"]}
{"pair_type": "slc_pathway", "key1": "SLC26A9", "key2": "oxidative stress", "summary": "Here, we discuss the recent developments in this field, focusing on genetic predisposition, epigenetic modifications, lymphocytes, cytokines, oxidative stress, infectious agents, proteins, microRNAs, autoantibodies, serum pepsinogen, gastrin, esophagogastroduodenoscopy and microscopic findings, and the risk of gastric neoplasm.", "dois": ["10.3390/cimb45070334"]}
{"pair_type": "slc_pathway", "key1": "SLC26A11", "key2": "chemotherapy", "summary": "The BCOR-CCNB3 sarcoma with RNF213-SLC26A11 fusion may indicate a subset of tumors that undergo histopathological changes in response to chemotherapy.\nNotably, RNA sequencing revealed a RNF213-SLC26A11 fusion in the tumor sample.\nThe patient received 5 courses of preoperational chemotherapy, and the tumor was resected and analyzed.\nIn addition, the immunohistochemical results showed the altered staining patterns of BCOR, bcl2, CyclinD1, TLE1, AR, SMA, CD117, STAB2, CD56, and CD99 in tumor tissues after chemotherapy.\nPrimitive small round cells and larger myoid cells in the resected tumor tissue but not in biopsy were observed, and arterioles stenosis and occlusion were also detected, indicating a dramatic change of histopathological features of this tumor.", "dois": ["10.1186/s12957-022-02611-4"]}
{"pair_type": "slc_pathway", "key1": "SLC26A9", "key2": "proliferation", "summary": "downregulation of SLC26A9 in CRC cells induced cell cycle arrest and apoptosis but inhibited cell proliferation and xenograft tumor growth both in vitro and in vivo.\nExogenous expression of SLC26A9 in GC cells induced upregulation of the Cl/HCO exchanger AE2, G2/M cell cycle arrest and apoptosis and suppressed their proliferation, migration and invasion.\nIn the proximal duodenum of young Slc26a9 KO mice, the glands and villi/crypts were elongated and proliferation was enhanced.\nSLC26A9 alters the proliferation, migration, and invasion potential of breast cancer cells by regulating the PI3K/AKT signaling pathway.\nWe also found that and had a regulatory relationship at the cellular level, for example, high expression of was noted to inhibit cancer cell proliferation and migration yet promote apoptosis.\nHigh expression of inhibits cancer cell proliferation and migration, yet promotes cancer cell apoptosis.\nHEP promoted cell proliferation, as evidenced by the increased ( < 0.05) expression of proliferating cell nuclear antigen () and Proliferation Ki-67 (), and reduced necrotic apoptosis by downregulating ( < 0.05) the mRNA expression of cysteinyl aspartate specific proteinase 3 () and cysteinyl aspartate specific proteinase 9 ().\nSLC26A9 promotes colorectal tumorigenesis by modulating Wnt/β-catenin signaling.\nSLC26A9 promotes the initiation and progression of breast cancer by activating the PI3K/AKT signaling pathway.\nAnalysis of human gastric precancerous and cancerous tissues revealed that SLC26A9 expression progressively decreased from atrophic gastritis to GC, and that downregulation of SLC26A9 was correlated with patient survival.\nMoreover, increased levels of SLC26A9 were associated with a high risk of disease and poor prognosis.\nWe observed that SLC26A9 was expressed at low levels in the cytoplasm of adjacent tissues, polyps and adenomas but was significantly increased in colorectal adenocar", "dois": ["10.1016/j.aninu.2025.03.008", "10.21037/tcr-2024-2443", "10.1016/j.bbamcr.2025.119912", "10.1038/s41420-024-01888-6", "10.1038/s41598-023-50471-z", "10.1007/s13402-022-00672-x", "10.1007/s00424-014-1543-x"]}
{"pair_type": "slc_pathway", "key1": "SLC26A11", "key2": "migration", "summary": "Exogenous expression of the ZM fusion in the U87MG glioblastoma line enhanced cell migration and invasion.\nSixty-seven in-frame fusion transcripts were identified, including three recurrent fusion transcripts: FGFR3-TACC3, RNF213-SLC26A11, and PTPRZ1-MET (ZM).", "dois": ["10.1101/gr.165126.113"]}
{"pair_type": "slc_pathway", "key1": "SLC26A11", "key2": "ferroptosis", "summary": "β-ELE can bind to TFEB, notably activate TFEB, lysosome and transcriptional increase on downstream gene GLA, MCOLN1, SLC26A11 involved in lysosome activity in EGFR wild-type NSCLC cells.\nFurthermore, β-ELE induced ferroptosis, which could be promoted by TFEB overexpression or compromised by TFEB knockout.\nThis study firstly demonstrated that TFEB promoted GPX4 lysosome degradation contributes to β-ELE induced ferroptosis in EGFR wild-type NSCLC, which gives a clue that TFEB mediated GPX4 degradation would be a novel strategy for ferroptosis induction and NSCLC therapy.\nFerroptosis, a promising strategy for cancer therapy could be triggered via suppression on glutathione peroxidase 4 (GPX4).\nβ-ELE increased GPX4 ubiquitination and lysosomal localization, with the increase on lysosome degradation of GPX4.\nGenetic knockout or inactivation of TFEB compromised β-ELE induced lysosome degradation of GPX4, which was further demonstrated in orthotopic NSCLC NOD/SCID mice model.", "dois": ["10.1016/j.jare.2023.08.018"]}
{"pair_type": "slc_pathway", "key1": "SLC27A1", "key2": "migration", "summary": "Laboratory experiments confirmed that downregulation of SLC27A1 expression in colorectal cancer cell lines (Caco-2 and T84) significantly inhibited cell migration and invasion abilities, directly validating the functional role of this gene in promoting tumor metastasis.\nSLC27A1 is responsible for transporting extracellular long-chain fatty acids (LCFAs) into cells, and the model constructed based on the expression level of this gene achieved an accuracy of over 95% in assisting the assessment of patients' metastatic risk across different datasets.\nFurther studies revealed that the process of intracellular LCFAs being catalyzed to synthesize diacylglycerol-3-phosphate (DAG-3P) is closely related to CRC metastasis.\nUsing machine learning techniques, we identified Solute Carrier Family 27 Member 1 (SLC27A1) as the biomarker most closely associated with CRC metastasis.", "dois": ["10.1038/s41598-025-17143-6"]}
{"pair_type": "slc_pathway", "key1": "SLC27A1", "key2": "glycolysis", "summary": "Besides, protein levels of FASN, ACACA, and SLC27A1 were all decreased, whereas PPARγ and CPT1A were increased.\nGlycolysis/gluconeogenesis, steroid hormone biosynthesis, and fatty acid biosynthesis were all significantly downregulated, according to gene set variation analysis and gene set enrichment analysis.\nSilencing PDK4 expression induced glucose utilization by upregulating glucose transporters (SLC2A1, SLC2A10) and glycolytic enzymes (GAPDH, ENO1, LDHA).\nFunctional enrichment revealed key pathways including fatty acid metabolism, PPAR signaling, and glycolysis/gluconeogenesis.\nRelapsed FL patients were characterised by 38 differentially expressed ICT genes, among which ATP9A, SLC2A1 and KCNN4 were under-expressed, indicating a down-regulation of both excitability and glycolysis.\nA completely different profile of K channel encoding genes emerged in DLBCL accompanied by the over-expression of the fatty acid transporter-encoding gene SLC27A1 as well as of the metabolism regulator NCoR1.\nIn contrast, genes associated with fatty acid oxidation (SLC27A1, CPT1B) showed downregulation upon PDK4 silencing compared with controls, suggesting a metabolic shift favoring glucose oxidation even in the presence of NEFA.\nMost DEGs were significantly enriched in ECM-receptor interaction, starch and sucrose metabolism, glycolysis/gluconeogenesis, pyruvate metabolism, amino acids biosynthesis and metabolism, peroxisome, and PPAR signaling pathway.\nSome genes related to glycogen degradation, glucose transport, and glycolysis (e.g., , , , , , , , , , , , , and ) were up-regulated, while some genes related to fatty acid degradation and transport (e.g., , , , , and ) and amino acid metabolism (e.g., , , , and ) were down-regulated in the fast-growth group.\nRats of the O+N group had a higher percentage of oxidative type I fibers and higher mRNA levels of genes encoding regulators of muscle fiber composition (", "dois": ["10.3945/jn.112.164038", "10.1093/biolre/ioaf238", "10.3390/ani15172602", "10.3389/fgene.2023.1217952", "10.1002/ptr.7679", "10.1038/s41598-019-44661-x"]}
{"pair_type": "slc_pathway", "key1": "SLC27A1", "key2": "oxidative phosphorylation", "summary": "Rats of the O+N group had a higher percentage of oxidative type I fibers and higher mRNA levels of genes encoding regulators of muscle fiber composition (Ppard, Ppargc1a, Ppargc1b), angiogenic factors (Vegfa, Vegfb), and genes involved in fatty acid utilization (Cpt1b, Slc25a20, Slc22a4, Slc22a5, Slc27a1) and oxidative phosphorylation (Cox4i1, Cox6a2) and a higher activity of the mitochondrial oxidative enzyme succinate dehydrogenase in muscle than rats of the O and L groups (P < 0.05).\nThese niacin-induced changes in muscle metabolic phenotype are indicative of an increased capacity of muscle for oxidative utilization of fatty acids and are likely mediated by the upregulation of Ppard, Ppargc1a, and Ppargc1b, which are key regulators of muscle fiber composition, mitochondrial biogenesis, angiogenesis, and genes involved in fatty acid catabolism and oxidative phosphorylation.\nTen oxidative phosphorylation pathway genes were downregulated, suggesting that a decrease in cardiomyocyte ATP synthesis might explain the decreased contractile function in obese hearts.\nExpression of myocardial PGC-1α and multiple downstream target genes in the oxidative phosphorylation pathway, including several in the electron transport and ATP synthase complexes of the inner mitochondrial membrane, were down-regulated.\nV(max) also correlated with expression of genes for the cardiac fatty acid transporters Cd36 and Slc27a1.", "dois": ["10.3945/jn.112.164038", "10.1016/j.yjmcc.2013.02.005", "10.1155/2012/205648"]}
{"pair_type": "slc_pathway", "key1": "SLC27A1", "key2": "apoptosis", "summary": "These are AATK, SLC27A1, and CDKAL and are important in apoptosis and fatty acid transport.\nAt 24 h after intrafollicular injection, the relative mRNA transcript abundance for proteins involved in steroidogenesis (CYP19A1, 3BHSD, STAR, FSHR), metabolism (GLUT1, GLUT3, INSR, IRS1, IRS2, SLC27A1, PPARG), and cell proliferation and apoptosis (CCND2;\nNonivamide also induced browning of porcine subcutaneous adipocytes by up-regulating the expression of brown and beige adipocyte gene markers, such as Prdm16, Cidea, and Slc27a1.\nMechanistically, SiNP dysregulated the expression of Scd1, Slc27a1, and Cpt1a, and induced over synthesis and efflux obstruction of fatty acid through the PPARγ signaling pathway.\nOverall, SiNPs were visualized by coupling with FITC, and the uterine accumulation of SiNP induced fatty acid metabolic disorder, biological dysfunction, and trophoblast apoptosis, which were mediated in part by the PPARγ signaling pathway.\nMany obesity-associated diseases, such as insulin resistance in skeletal muscle, cardiac lipotoxicity, and hepatic steatosis, are thought to be driven by the overflow of fatty acids from adipose stores and the subsequent ectopic accumulation of lipids resulting in apoptosis, ER stress, and inactivation of the insulin receptor signaling cascade.\nFirst, we found 25 μM nonivamide promoted apoptosis of porcine subcutaneous pre-adipocytes.\nIt was found that SiNP penetrated the trophoblast membrane, leading to apoptosis and suppression of cell proliferation, tube formation, and invasion in a dose-dependent manner.\nIncreasing oleic acid concentrations induced intracellular lipid droplet accumulation, thus resulting in a foam cell-like morphology, but had no effects on apoptosis, necrosis or proliferation.", "dois": ["10.1016/j.jep.2025.119741", "10.1155/2015/492395", "10.1093/biolre/ioaf238", "10.7717/peerj.14084", "10.1016/j.bbrc.2022.06.047", "10.1016/j.envint.2021.106497", "10.1016/j.anireprosci.2020.106536", "10.1016/j.ygcen.2016.04.020", "10.1016/j.bbalip.2011.09.010"]}
{"pair_type": "slc_pathway", "key1": "SLC26A9", "key2": "migration", "summary": "Exogenous expression of SLC26A9 in GC cells induced upregulation of the Cl/HCO exchanger AE2, G2/M cell cycle arrest and apoptosis and suppressed their proliferation, migration and invasion.\nTranswell and scratch assays demonstrated that Slc26a9 overexpression promotes Panc02 cell migration in vitro.\nSLC26A9 alters the proliferation, migration, and invasion potential of breast cancer cells by regulating the PI3K/AKT signaling pathway.\nWe also found that and had a regulatory relationship at the cellular level, for example, high expression of was noted to inhibit cancer cell proliferation and migration yet promote apoptosis.\nHigh expression of inhibits cancer cell proliferation and migration, yet promotes cancer cell apoptosis.\nSLC26A9 promotes the initiation and progression of breast cancer by activating the PI3K/AKT signaling pathway.\nSlc26a9 promotes the perineural invasion of pancreatic cancer in mice.\nThese results suggest that Slc26a9 facilitates PNI in pancreatic cancer and may serve as a promising therapeutic target.\nIn addition, we found that SLC26A9 expression decreases during human gastric carcinogenesis, and that exogenous SLC26A9 expression in GC cells reduces their malignant behavior.\nSLC26A9 acts as an oncogene in the development of breast cancer.\nIn vivo, mice implanted with Slc26a9-overexpressing cells exhibited pronounced abdominal mechanical hyperalgesia, elevated hunch scores, and anxiety-like behaviors as early as day 7, along with confirmed PNI in the pancreas.", "dois": ["10.1016/j.bbrc.2025.152952", "10.21037/tcr-2024-2443", "10.1016/j.bbamcr.2025.119912", "10.1007/s13402-022-00672-x"]}
{"pair_type": "slc_pathway", "key1": "SLC27A1", "key2": "proliferation", "summary": "In addition, treatment increased the transcript levels of the fatty acid transporters CD36 and SLC27A1, and decreased the production of 17-beta-estradiol and progesterone.\nAt 24 h after intrafollicular injection, the relative mRNA transcript abundance for proteins involved in steroidogenesis (CYP19A1, 3BHSD, STAR, FSHR), metabolism (GLUT1, GLUT3, INSR, IRS1, IRS2, SLC27A1, PPARG), and cell proliferation and apoptosis (CCND2;\nThe downregulated genes were strongly enriched in the cell proliferation and apoptosis pathways according to the GO analysis, including FOS, FOSB, PAK6 and RAB26.\nMechanistically, SiNP dysregulated the expression of Scd1, Slc27a1, and Cpt1a, and induced over synthesis and efflux obstruction of fatty acid through the PPARγ signaling pathway.\nIt was found that SiNP penetrated the trophoblast membrane, leading to apoptosis and suppression of cell proliferation, tube formation, and invasion in a dose-dependent manner.\nIncreasing oleic acid concentrations induced intracellular lipid droplet accumulation, thus resulting in a foam cell-like morphology, but had no effects on apoptosis, necrosis or proliferation.\nFurthermore, the inhibition of FATP1 with arylpiperazine 5k (DS22420314) interfered with the uptake of FA and cell viability.\nSERBP1-OE induced the apoptosis of HeLa cells.\nThe SERBP1-regulated alternative splicing of ME3, LPIN3, CROT, PDP1, SLC27A1 and ALKBH7 was validated by RT-qPCR analysis.\nAdditionally, knocking down the expression of could significantly enhance the malignant biological behavior of ovarian cancer cells.\nCell Counting Kit-8 (CCK8) assay and colony-forming experiments were conducted to evaluate the role of in the proliferation of ovarian cancer cells, so as to verify the clinical application value", "dois": ["10.7717/peerj.14084", "10.21037/atm-21-3026", "10.1016/j.envint.2021.106497", "10.1016/j.anireprosci.2020.106536", "10.1038/s41598-019-50531-3", "10.1158/2159-8290.CD-17-1371", "10.1016/j.ygcen.2016.04.020"]}
{"pair_type": "slc_pathway", "key1": "SLC27A1", "key2": "oxidative stress", "summary": "We previously demonstrated that MΦ fatty acid transport protein 1 (FATP1, Slc27a1) was necessary to maintain the oxidative and anti-inflammatory AAM phenotype in vivo in a model of diet-induced obesity.\nThe role of TNC in fibrosis and DCM was found to involve pathways related to p53 signaling and Serpin1k, Ccn1, Cpt1a, and Slc27a1, as identified by RNA sequencing analysis.\nCompared to Fatp1Ldlr mice, Fatp1Ldlr mice exhibited significantly larger lesion area and elevated oxidative stress and inflammation in the atherosclerotic plaque.\nOur findings indicate that in diabetes, TNC contributes to cardiac contractile dysfunction, myocardial fibrosis, oxidative stress, inflammation, and metabolic disturbances in diabetic mouse heart.\nConversely, recombinant human TNC promoted pro-inflammatory and oxidative stress markers in cardiomyocytes.\nThese results suggest the potential of dietary grapes to modulate hepatic gene expression, prevent oxidative damage, induce fatty acid metabolism, ameliorate NAFLD, and increase longevity when co-administered with a high-fat diet.\nUsing pathway analysis tools (GO, KEGG and Reactome), relative to the STD group, differentially expressed genes of the STD5GP group were significantly enriched in RNA, mitochondria, and protein translation related pathways, as well as drug metabolism, glutathione, detoxification, and oxidative stress associated pathways.\nThe expression of was confirmed to be upregulated by about five-fold (RT-qPCR), and, based on RNA-Seq data, the expression of additional genes associated with the reduction of oxidative stress and detoxification ( and , , , ) were enhanced by dietary grape supplementation.\nAtherosclerotic plaque composition, oxidative stress, and inflammation were analyzed histologically.\nPlacentas were collected on Gestational Day 21 for mRNA and oxidative stress analysis, and frozen placental sections were analyzed for fat accumulation as well as beta-catenin and Dickkopf homolog 1 (Xenopus laevis) (DKK", "dois": ["10.1186/s12933-025-02780-y", "10.1016/j.atherosclerosis.2017.10.009", "10.3390/foods11131984", "10.1074/jbc.M117.817692", "10.1095/biolreprod.111.094482"]}
{"pair_type": "slc_pathway", "key1": "SLC27A2", "key2": "glycolysis", "summary": "In the diet induced obese rats, 23 genes and 9 metabolites showed significant changes, in which the increased levels of alanine, lactate and lactate dehydrogenase B (Ldhb) and the decreased levels of citrate and pyruvate indicated an enhanced glycolysis and a disordered Krebs cycle.\nMost DEGs were significantly enriched in ECM-receptor interaction, starch and sucrose metabolism, glycolysis/gluconeogenesis, pyruvate metabolism, amino acids biosynthesis and metabolism, peroxisome, and PPAR signaling pathway.\nSome genes related to glycogen degradation, glucose transport, and glycolysis (e.g., , , , , , , , , , , , , and ) were up-regulated, while some genes related to fatty acid degradation and transport (e.g., , , , , and ) and amino acid metabolism (e.g., , , , and ) were down-regulated in the fast-growth group.\nGenes related to glycolysis and gluconeogenesis, phosphorylation and cell cycle were significantly correlated with SUVmax (r ≥ 0.5).\nRRM2, which is related to the toxicity of Gemcitabine was positively correlated with SUVmax, and SLC27A2 which is associated with Cisplastin response was negatively correlated with SUVmax.\nFurthermore, the closeness centrality of Slc27a2, Apobr, alanine and histidine in the correlations network of pathways, genes and metabolites was 0.5036, 0.5111, 0.5702, and 0.5352, respectively.\nThe pathway enrichment analysis of genes and metabolites proved that a disturbed glucose metabolism and biosynthesis of amino acids are typical metabolic features of cafeteria-induced obesity.\nThese results suggest that fast-growth fish may uptake adequate energy (e.g., glucose, fatty acid, and amino acids) from fodder, with excess energy substances used to synthesize collagen to accelerate bone and muscle growth after normal life activities are maintained.", "dois": ["10.3389/fgene.2023.1217952", "10.1039/d1ay00821h", "10.4174/astr.2019.96.4.153"]}
{"pair_type": "slc_pathway", "key1": "SLC27A2", "key2": "proliferation", "summary": "Cutaneous squamous cell carcinoma (CSCC) is a malignant skin tumor characterized by the abnormal proliferation of keratinocytes.\nThen, we identified six biomarkers (SLC27A2, ACOX2, PECR, CRAT, FADS1 and ELOVL5) were screened.\nOverall, we obtained six immune cell-related biomarkers (SLC27A2, ACOX2, PECR, CRAT, FADS1 and ELOVL5) associated with CSCC, which laid a theoretical foundation for the treatment of CSCC.\nEventually, the lower expression of biomarkers in tumor group was observed, which was consistent with the result from public databases.", "dois": ["10.1007/s00403-024-03587-9"]}
{"pair_type": "slc_pathway", "key1": "SLC27A2", "key2": "apoptosis", "summary": "At the genomic level, we found that during the overwintering phase, genes associated with cell proliferation (ccnb1, spag5, hdac7) were downregulated while genes linked to testicular fat metabolism (slc27a2, scd, pltp) were upregulated.\nThis is associated with a number of adverse effects, including lipid deposition in cardiomyocytes, elevated levels of inflammation and oxidative stress, impaired cardiac function, decreased cardiomyocyte viability, and increased apoptosis.\nIn hepatocellular carcinoma, silencing of PGAM5 reduces growth, which has been attributed to decreased mitophagy and enhanced apoptosis.\nA total of nine apoptosis-related genes (SLC27A2, TNFAIP2, IFI44, CSF2, IL4, MDK, DOCK8, WNT5A, APP) were ultimately screened as associated hub genes and utilized to construct a prognosis model.\nThe administration of semaglutide was observed to partially reverse the cardiac dysfunction induced by an excessive high-fat diet, to protect cardiomyocytes, and to significantly reduce the expression of Slc27a2.\nAn excessively high-fat diet has been demonstrated to result in an increased expression of solute carrier family 27 member 2 (Slc27a2/FATP2) on cardiomyocyte membranes.\nThe reduction of Slc27a2 expression downstream of this receptor has been demonstrated to enhance lipid metabolism and mitigate lipid overdeposition in cardiomyocytes, thereby conferring cardioprotection.\nOverall, the small molecule inhibitors of lipid handling proteins BMS309403, HTS01037, NAV2729, SB-FI-26, and sulfosuccinimidyl oleate (SSO) caused a drug-specific, dose-/time-dependent inhibition of FA/LDL uptake, associated with reduced proliferation, cell cycle arrest, and apoptosis.\nFurthermore, in January, we observed the regulation of autophagy and apoptosis (becn1, casp13), which may have the function of protecting reproductive organs and ensuring their maturity for the breeding", "dois": ["10.1016/j.cbi.2025.111583", "10.1681/ASN.2017030314", "10.1186/s12920-024-01853-3", "10.1007/s10695-024-01335-4", "10.3390/cancers15194796", "10.3390/cancers14236004", "10.3389/fmolb.2021.567730", "10.4149/neo_2018_180122N48"]}
{"pair_type": "slc_pathway", "key1": "SLC27A2", "key2": "migration", "summary": "The expression of SLC27A2 was upregulated in both DTC tissues and cell lines and was correlated with clinical progression.\nUpregulated SLC27A2/FATP2 in differentiated thyroid carcinoma promotes tumor proliferation and migration.\nOur results show that SLC27A2 plays an important role in tumor proliferation and migration, providing a new putative target for the diagnosis and treatment of TC.\nIn vitro studies further confirmed that SLC27A2 knockdown attenuated the proliferation and invasion of DTC cells.\nWe found that specific upregulation of SLC27A2 could significantly inhibited the proliferation, migration, and invasion of renal cancer cell lines.\nSLC27A2 was significantly downregulated in clinical specimens and renal cancer cell lines and predicted poor prognosis.\nIn terms of mechanism, SLC27A2 may further inhibit the epithelial-to-mesenchymal transition by negatively regulating CDK3.\nSLC27A2 could also influence the Epithelial-mesenchymal transition (EMT) signaling pathway, linked to the progression and metastasis of renal cancer.\nOur work suggests that functional inhibition of SLC27A2-CDK3-EMT axis may be an attractive therapeutic target for metastasis of ccRCC.\nUpregulation of PXDNL and LINC02038 and downregulation of SLC27A2, KLRB1, IGHV1-12 and IGKV1OR2-108 in high-risk score group synergistically contribute to immunosuppressive microenvironment which characterized by immunosuppressive neutrophils, impaired cytotoxic T lymphocytes migration and natural killer cell cytotoxicity.\nThrough RNA sequence analysis and gene set enrichment analysis, we found that the MAPK pathway is the main downstream signaling pathway for the regulation by SLC27A2.\nSLC27A2 affects cell proliferation and differentiation by inducing changes in the proto-oncogene C-FOS.", "dois": ["10.1038/s41597-023-02032-2", "10.1038/s41420-022-01145-8", "10.1002/jcla.24148", "PMID:31949772"]}
{"pair_type": "slc_pathway", "key1": "SLC27A3", "key2": "oxidative stress", "summary": "The background working of the AMPK pathway through upregulation of AKT1, AMPK, SIRT1, PYGM, SLC2A4 and SERBP1 genes, and downregulation of PPARGCIA, IGF2, PPARA, SLC27A3, SLC16A3, TSC1/2, KCNJ2, KCNJ16, etc., evidence the repression of cellular transcriptional activity and energetic homeostasis modifications in response to heat stress.\nHigh inflammatory response was found to be responsible for oxidative-stress-mediated apoptosis of GCs and nodes towards the involvement of the NF-κB pathway and repression of the Nrf2 pathway.\nIncreased accumulation of reactive oxygen species and apoptosis was observed in the heat-stress group.\nIn spite of the upregulation of inflammatory (CYCS, TLR2, TLR4, IL6, etc.), pro-apoptotic (BAD, BAX, TNFSF9, MAP3K7, TNFRSF6B, FADD, TRADD, RIPK3, etc.) and caspase executioner genes (CASP3, CASP8, CASP9), antioxidants and anti-apoptotic genes (HMOX1, NOS2, CAT, SOD, BCL2L1, GPX4, etc.) were also upregulated in heat-stressed GCs.", "dois": ["10.1016/j.jad.2025.119734", "10.3390/cells11091443"]}
{"pair_type": "slc_pathway", "key1": "SLC27A3", "key2": "proliferation", "summary": "The background working of the AMPK pathway through upregulation of AKT1, AMPK, SIRT1, PYGM, SLC2A4 and SERBP1 genes, and downregulation of PPARGCIA, IGF2, PPARA, SLC27A3, SLC16A3, TSC1/2, KCNJ2, KCNJ16, etc., evidence the repression of cellular transcriptional activity and energetic homeostasis modifications in response to heat stress.\nHeat-stressed GCs exhibited transient proliferation senescence and resumed proliferation at 48 h post-stress, while post-stress immediate culture-media change had a relatively positive effect on proliferation resumption.\nNotably, apigenin (5-20 μg/ml) remarkably inhibited Huh7 cell proliferation and colony formation as compared to the vehicle control, which was in a dose-dependent manner.\nIn the present study, we investigated the effects of apigenin on human hepatoma Huh7 cell proliferation, cell cycle distribution, apoptosis, and colony formation in vitro, as well as on the tumorigenicity of Huh7 cells in vivo.\nIn conclusion, apigenin exhibits inhibitory effects on hepatoma cell growth, which is likely mediated through alteration of gene expression profiles.\nAccompanying with the decreased growth, apigenin-treated cells showed a cell cycle arrest at G2/M phase and an increased rate of apoptosis.\nDownregulation of MDM4, TP53, PIDD1, PARP3, MAPK14 and MYC, and upregulation of STK26, STK33, TGFB2, CDKN1A and CDKN2A, at the interface of the MAPK and p53 signaling pathway, can be attributed to transient cellular senescence and apoptosis in GCs.", "dois": ["10.3390/cells11091443", "10.1016/j.phymed.2010.08.006"]}
{"pair_type": "slc_pathway", "key1": "SLC27A4", "key2": "chemotherapy", "summary": "As expected, the results showed that SLC27A4 could help to maintain the protein stability and intracellular concentration of ATG4B, thereby triggering rapid autophagy through releasing ATG4B to cytoplasm under conditions of reduced nutrient availability or during stress of chemotherapy in lung cancer cells.\nCollectively, this study may help researchers better understand the mechanism of autophagy vitality in human cancers and SLC27A4/ATG4B complex might act as a new potential therapeutic target of lung tumor chemotherapy.\nReduced SLC27A4 by si-RNA also showed the enhanced therapeutic efficiency of everolimus, doxorubicin, and cisplatin in human lung cancer cell lines.\nFurther, we found that the high expression level of SLC7A4 increased the ATG4B stability and was conducive to rapid reaction to everolimus (RAD001)-induced autophagy in human lung cancer cells.\nThen, co-immunoprecipitation (Co-IP) and GST-pull down assays indicated that the candidate protein-SLC27A4 directly interacts with ATG4B in lung cancer cell lines.", "dois": ["10.1007/s10528-023-10497-4", "10.3390/ijms21051846", "10.1007/s13277-015-4587-4"]}
{"pair_type": "slc_pathway", "key1": "SLC27A4", "key2": "ferroptosis", "summary": "SLC27A4-mediated selective uptake of mono-unsaturated fatty acids promotes ferroptosis defense in hepatocellular carcinoma.\nOur findings revealed a plausible role for SLC27A4 in ferroptosis defense via lipid remodeling, which might represent an attractive therapeutic target to increase the effectiveness of sorafenib treatment in HCC.\nLipidomic analysis revealed that overexpression of SLC27A4 significantly promoted the selective uptake of mono-unsaturated fatty acids (MUFAs), which induced a high level of MUFA-containing phosphatidylcholine and phosphatidylethanolamine in HCC cells, consequently resulting in resistance to lipid peroxidation and ferroptosis.\nImportantly, silencing SLC27A4 significantly promoted the sensitivity of HCC to sorafenib treatment, both in vitro and in vivo.", "dois": ["10.1016/j.freeradbiomed.2023.03.013"]}
{"pair_type": "slc_pathway", "key1": "SLC27A4", "key2": "apoptosis", "summary": "Endothelial cell proliferation and migration increased and apoptosis decreased with a decrease in SLC25A29 expression.\nReduced SLC27A4 by si-RNA also showed the enhanced therapeutic efficiency of everolimus, doxorubicin, and cisplatin in human lung cancer cell lines.\nAs expected, the results showed that SLC27A4 could help to maintain the protein stability and intracellular concentration of ATG4B, thereby triggering rapid autophagy through releasing ATG4B to cytoplasm under conditions of reduced nutrient availability or during stress of chemotherapy in lung cancer cells.\nActivated M1-like TAMs and inefficient glucose and lipid metabolism delayed tumor cell growth and promoted apoptosis.\nHowever, the cell apoptosis marker cleaved caspase 3 increased significantly in mice treated with 50 mg/kg DEX compared with controls.\nTumor volume, blood vessel invasion, and levels of the cell proliferation markers Ki67 and c-Myc and the anti-apoptotic marker Bcl2 decreased in response to high-dose DEX.\nFurther, we found that the high expression level of SLC7A4 increased the ATG4B stability and was conducive to rapid reaction to everolimus (RAD001)-induced autophagy in human lung cancer cells.\nCollectively, this study may help researchers better understand the mechanism of autophagy vitality in human cancers and SLC27A4/ATG4B complex might act as a new potential therapeutic target of lung tumor chemotherapy.\nThen, co-immunoprecipitation (Co-IP) and GST-pull down assays indicated that the candidate protein-SLC27A4 directly interacts with ATG4B in lung cancer cell lines.\nMoreover, 23 genes (including SLC2A10, TNFRSF1A, PRKAA1, SLC27A4, ITGB2, THY1, RHOA, MYL10, ACTB, PRKCB, PIK3R2, RAC2, DMD, LATS2, YAP1, WWTR1, SMAD7, CTGF, FGF1, AXIN2, GLI2", "dois": ["10.3390/ijms21051846", "10.1007/s13277-015-4587-4", "10.1016/j.psj.2024.104498", "10.1186/s12935-023-03082-7", "10.3389/fendo.2017.00233"]}
{"pair_type": "slc_pathway", "key1": "SLC27A4", "key2": "glycolysis", "summary": "Specifically, sEV-NAMPT activates the NF-κB transcription factor through toll-like receptor 4 (TLR4), leading to elevated SLC27A4 expression.\nLipidomic and metabolomic analyses revealed a positive correlation between SLC27A4 and intracellular levels of triacylglycerol (TG) and dihydroxyacetone phosphate (DHAP).\nIncreased TG levels enhance lipolysis via hepatic lipase and facilitate the conversion of glycerol-3-P to DHAP, an intermediate that bridges lipid metabolism and glycolysis.\nOur study demonstrates that sEV-NAMPT enhances glycolysis, tumorigenesis, and metastasis in HCC.\nThis study uncovers a novel regulatory axis involving sEV-NAMPT and SLC27A4 in glycolysis, independent of traditional fatty acid metabolism pathways.\nSLC27A4 functions primarily as a long-chain fatty acid transporter and acyl-CoA synthetase.\nHowever, high-dose DEX treatment decreased the expression of glucose and lipid metabolic pathway-related genes such as glycolysis-associated genes.", "dois": ["10.1002/jev2.70071", "10.3390/ijms21051846", "10.21037/atm-21-2027"]}
{"pair_type": "slc_pathway", "key1": "SLC27A4", "key2": "migration", "summary": "In addition, the capacity of migration and invasion decreased in both cell lines after knockdown of SLC27A4.\nSilencing SLC27A4 expression significantly reduced uptake of free fatty acids in two breast cancer cell lines, Hs578T and MDA-MB-231.\nSome of the proteins involved in fatty acid transport have been demonstrated to promote the proliferation, migration, and invasion in breast cancer cells.\nFunctionally, downregulation of HOXD-AS1 repressed the proliferation, invasion abilities of HCC cell in vitro and the distant metastasis of HCC cell in vivo.\nFurther investigations demonstrated that HOXD-AS1 directly bound with miR-326 and thereby regulated its endogenous target gene, solute carrier family 27 member 4 (SLC27A4).\nAll these findings indicated that HOXD-AS1-miR-326-SLC27A4 axis participated into the progression of HCC.\nTaken together, our results confirm that high SLC27A4 is associated with tumor progression in breast cancer cells.\nCell growth inhibition was observed in SLC27A4-silenced Hs578T and cell cycle was arrested at G2/M.\nThe epithelial⁻mesenchymal transition signaling pathway was inhibited because protein expression of Slug, vimentin, α-smooth muscle actin, and other regulators was lower than that in control cells.\nEndothelial cell proliferation and migration increased and apoptosis decreased with a decrease in SLC25A29 expression.", "dois": ["10.1016/j.psj.2024.104498", "10.1186/s12935-023-03082-7", "10.1186/s12935-020-01217-8", "10.3390/ijms19113434"]}
{"pair_type": "slc_pathway", "key1": "SLC27A2", "key2": "chemotherapy", "summary": "Furthermore, we demonstrated that reduced SLC27A2 induced chemo-resistance in CD166 LCSCs by negatively regulating Bmi1-ABCG2 signaling, and ABCG2 was a direct transcriptional target of Bmi1.\nSignificantly, SLC27A2 expression was reduced in CD166 LCSCs.\nReduced SLC27A2 correlated chemo-response and poor patient survival.\nOur results indicated that enhanced SLC27A2 expression sensitized CD166 LCSCs to cisplatin by in vitro and in vivo experiments.\nWe aim to investigate the biological function of SLC27A2 and its underlying mechanisms in regulating chemo-resistance to cisplatin in LCSCs.\nHere, our findings testified that CD166 cells which were derived from fresh primary NSCLC samples displayed stem cell-like features and were resistant to chemotherapy drug cisplatin.\nLung cancer stem cells (LCSCs) represent a subpopulation that is responsible for chemo-resistance.\nHowever, cisplatin resistance is a major problem that restricts the use of cisplatin.\nIn addition, patients in the low-PTMRS group showed improved responses to chemotherapy and immune checkpoint inhibitors.\nHowever, ccRCC is found poorly responsitive to radiotherapy and chemotherapy.", "dois": ["10.1038/s41598-025-23772-8", "10.1038/s41420-022-01145-8", "10.1002/mc.22430", "10.1016/j.biopha.2014.02.002"]}
{"pair_type": "slc_pathway", "key1": "SLC27A4", "key2": "oxidative phosphorylation", "summary": "In mice, deficiency in one or both RabGAPs leads to reduced insulin- and contraction-stimulated glucose uptake and to elevated fatty acid (FA) uptake and oxidation in both glycolytic and oxidative muscle fibers without altering mitochondrial copy number and the abundance of proteins for oxidative phosphorylation.", "dois": ["10.2337/db20-0180"]}
{"pair_type": "slc_pathway", "key1": "SLC27A2", "key2": "oxidative phosphorylation", "summary": "Downregulation of key fatty acid synthase (FAS) pathway genes (ACSL, SLC27A2, FabI) reduced substrate competition for DHA precursors.\nFurthermore, suppressed oxidative phosphorylation (evidenced by COX downregulation) and redirected carbon/nitrogen flux-achieved through diminished tricarboxylic acid (TCA) cycle activity (via downregulation of HAL and proC)-collectively favored DHA accumulation.\nCanonical metabolic pathway analysis showed downregulation of the oxidative phosphorylation (Z-score: -4.707, control vs. sham) in HFpEF and LLTS improved the oxidative phosphorylation (Z-score = -2.309, active vs. sham).\nWe characterized RAB5C (RAB5C, member RAS oncogene family) as an endosomal modulator of mitochondrial homeostasis, and SLC27A2 (solute carrier family 27 (fatty acid transporter), member 2) as a novel partner of MFN2 relevant in autophagy.\nLLTS, by modulating the functioning of crucial upstream regulators, improves cardiac metabolism and mitochondrial oxidative phosphorylation.\nHFpEF was associated with the abnormalities of metabolic upstream regulators, including PPARGC1α, insulin receptor signaling, PPARα, PPARδ, PPARGC1β, the fatty acid transporter, and lysine-specific demethylase 5A (KDM5A).", "dois": ["10.3390/ijms25084312", "10.1002/biot.70107", "10.1080/15548627.2024.2440843"]}
{"pair_type": "slc_pathway", "key1": "SLC27A5", "key2": "chemotherapy", "summary": "Additionally, drug sensitivity and enrichment analyses were conducted to assess the impact of key genes on chemotherapy responses and signaling pathways.\nThese genes can predict the sensitivity of ESCC patients to neoadjuvant chemoradiotherapy and hold significant clinical relevance in prognostication.\nPrognostic genes were then screened, and key genes associated with chemoradiotherapy sensitivity were determined using random survival forest analysis.\nThese findings provide predictive biomarkers for chemoradiotherapy response and support the development of individualized treatment strategies for ESCC patients.\nA nomogram was established to predict the prognosis of ESCC by integrating key genes with clinical stages, demonstrating favorable predictability and reliability.\nThis study identified three key genes that predict chemoradiotherapy sensitivity and prognosis and are involved in multiple tumor-related biological processes in ESCC.\nThis study aimed to identify chemoradiotherapy sensitivity-related genes and analyze their prognostic value and potential associations with the tumor microenvironment in ESCC.\nUtilizing the Gene Expression Omnibus database, we identified differentially expressed genes between ESCC patients who achieved complete and incomplete pathological responses following chemoradiotherapy.\nThree key genes including , , and were identified.\nThese genes were also found to be significantly correlated with certain immune cells and immunoregulatory genes within the tumor microenvironment and were involved in critical tumor-related signaling pathways, including the epithelial-mesenchymal transition and P53 pathways.\nWe examined the relationships between key genes, infiltrating immune cells, and immunoregulatory genes.", "dois": ["10.3389/fmolb.2024.1512715"]}
{"pair_type": "slc_pathway", "key1": "SLC27A4", "key2": "proliferation", "summary": "Endothelial cell proliferation and migration increased and apoptosis decreased with a decrease in SLC25A29 expression.\nFunctionally, downregulation of HOXD-AS1 repressed the proliferation, invasion abilities of HCC cell in vitro and the distant metastasis of HCC cell in vivo.\nThese findings indicate that high-dose DEX-inhibited tumor progression is a complicated process, not only activated by M1-like TAMs, but also decreased by the uptake and consumption of glucose and lipids that block the raw material and energy supply of cancer cells.\nThese results suggested that the hypertrophy of goose pectoral muscles might be achieved through more lipid deposition and less leukocyte infiltration to promote the proliferation of cells within the muscles, and the low expression of MYL10 and high expressions of GLI2/CTGF/SMAD7 might the keys to induce the pectoral muscle hypertrophy of LD geese from 6 to 30 weeks of age over that of SW geese.\nCell growth inhibition was observed in SLC27A4-silenced Hs578T and cell cycle was arrested at G2/M.\nIn addition, the capacity of migration and invasion decreased in both cell lines after knockdown of SLC27A4.\nSome of the proteins involved in fatty acid transport have been demonstrated to promote the proliferation, migration, and invasion in breast cancer cells.\nTumor volume, blood vessel invasion, and levels of the cell proliferation markers Ki67 and c-Myc and the anti-apoptotic marker Bcl2 decreased in response to high-dose DEX.\nActivated M1-like TAMs and inefficient glucose and lipid metabolism delayed tumor cell growth and promoted apoptosis.\nAdditionally, knocking down the expression of could significantly enhance the malignant biological behavior of ovarian cancer cells.\nIngenuity Pathway Analysis revealed enrichment for a host of biological pathways including lipid metabolism, molecular transport, immune response, cell morphology and development, and cell growth and proliferation.\nIn transcriptional regulation, intra-breed bioinformatics analysis identified 3331 genes whose expression levels were opposite to the trend of pectoral muscle hypertrophy both in LD", "dois": ["10.1016/j.psj.2024.104498", "10.1186/s12935-023-03082-7", "10.21037/atm-21-3026", "10.1186/s12935-020-01217-8", "10.3390/ijms21051846", "10.3390/ijms19113434", "10.1152/physiolgenomics.00042.2015"]}
{"pair_type": "slc_pathway", "key1": "SLC27A5", "key2": "glycolysis", "summary": "Bacillus infection has cell-type specificity, and affects the accumulation of key products such as Succinate and lactic acid through the interaction between different epithelial cell metabolic activities and microorganisms and the communication between different cell types (key receptors SLC27A5, PPARA), thereby affecting glycolysis and TCA cycle and other processes to strengthen the adaptability of yak GIT in extreme environments.", "dois": ["10.1002/advs.202514862"]}
{"pair_type": "slc_pathway", "key1": "SLC27A5", "key2": "migration", "summary": "experiments revealed that SLC27A5 inhibited cell proliferation and migration of HCC cells and could upregulate FDX1, the key regulator of cuproptosis.\nGSEA analysis and in vitro assays suggested that SLC27A5 downregulation promoted tumor cell migration via enhancing epithelial-mesenchymal transition.\nSLC27A5 is a potential biomarker of HCC and SLC27A5 downregulation promoted HCC progression by enhancing EMT.\nFinally, downregulation of SLC27A5 altered tumor metabolism and cellular homeostasis, induced oxidative stress, and disrupted intracellular environmental stability, thereby suppressing the growth of gastric adenocarcinoma.\nFurthermore, by downregulating SERPINE1, nano-curcumin liposomes modulated cell adhesion and migration, inhibiting the invasive and metastatic potential of tumor cells.", "dois": ["10.1016/j.ijpharm.2025.126368", "10.18632/aging.205334", "10.1186/s12935-021-01871-6"]}
{"pair_type": "slc_pathway", "key1": "SLC27A5", "key2": "apoptosis", "summary": "SLC27A5 inhibited cell proliferation and migration of HCC cells and could upregulate FDX1, the key regulator of cuproptosis.\ndownregulation of SLC27A5 altered tumor metabolism and cellular homeostasis, induced oxidative stress, and disrupted intracellular environmental stability, thereby suppressing the growth of gastric adenocarcinoma.\nsilencing of PGAM5 reduces growth, which has been attributed to decreased mitophagy and enhanced apoptosis.\nnano-curcumin liposomes inhibited growth and survival of gastric adenocarcinoma cells by interfering with the expression of FDX1, GPX4, SERPINE1 and SLC27A5, which were closely linked to copper-induced oxidative stress.\nNano-curcumin liposomes downregulated the expression of FDX1 and GPX4, disrupted mitochondrial energy metabolism, and induced oxidative stress, thereby promoting tumor-associated programmed cell death linked to cuproptosis.\nwe demonstrated that SLC27A5 acts as a novel tumor suppressor by suppressing TXNRD1 expression via the KEAP1/NRF2 pathway in HCC.\nnano-curcumin liposomes significantly inhibited proliferation and invasive capacity of gastric adenocarcinoma cells while promoting cellular oxidative stress.\nreduced SCL27A5 expression contributes to tumor progression and poor prognosis.\nKnockout of SLC27A5 increases polyunsaturated lipids, leading to increased NADP/NADPH ratio, ROS production as well as lipid peroxidation and the subsequent accumulation of 4-hydroxy-2-nonenal (4-HNE) in hepatoma cells.\nblockade of NRF2/TXNRD1 using genetic approaches or inhibitors sensitizes SLC27A5-deficient hepatoma cells to sorafenib treatment.\nby downregulating SERPINE1, nano-curcumin liposomes modulated cell adhesion and migration, inhibiting the invasive and metastatic potential of tumor cells.\nNano-curcumin liposomes hold great potential in inhibiting tumor growth and survival, as well", "dois": ["10.18632/aging.205334", "10.1038/s41418-019-0399-1", "10.1016/j.ijpharm.2025.126368", "10.3390/cancers15194796"]}
{"pair_type": "slc_pathway", "key1": "SLC27A5", "key2": "proliferation", "summary": "experiments revealed that SLC27A5 inhibited cell proliferation and migration of HCC cells and could upregulate FDX1, the key regulator of cuproptosis.\nHere, we investigated the hypoxia-induced downregulation of SLC27A5 and its impact on HCC proliferation via the repression of hepatocyte nuclear factor 4 alpha (HNF4A).\nHypoxia reduces SLC27A5 to promote hepatocellular carcinoma proliferation by repressing HNF4A.\nFinally, downregulation of SLC27A5 altered tumor metabolism and cellular homeostasis, induced oxidative stress, and disrupted intracellular environmental stability, thereby suppressing the growth of gastric adenocarcinoma.\nCellular experiments demonstrated that nano-curcumin liposomes significantly inhibited proliferation and invasive capacity of gastric adenocarcinoma cells while promoting cellular oxidative stress.\nThis study revealed that nano-curcumin liposomes inhibited growth and survival of gastric adenocarcinoma cells by interfering with the expression of FDX1, GPX4, SERPINE1 and SLC27A5, which were closely linked to copper-induced oxidative stress.\nThis study investigated how nano-curcumin liposomes mediated the inhibition of gastric adenocarcinoma cell proliferation and survival via cuproptosis.\nThe findings recapitulated that UBAP2 promoted HCC progression and radioresistance via SLC27A5 stability mediated by the ubiquitin-proteasome pathway.\nUtilizing in vitro and in vivo hepatocellular carcinoma models, we have demonstrated that hypoxic conditions significantly reduce SLC27A5 transcription, which is mediated by the suppression of HNF4A.\nSolute carrier family 27 member 5 (SLC27A5/FATP5), a pivotal enzyme in hepatic fatty acid transport and bile acid metabolism, is frequently downregulated in hepatocellular carcinoma, resulting in poor prognosis.\nThis reduction leads to the activation of the AKT pathway and an increase in cyclin-dependent kinase 2 (CDK2) and Cyclin", "dois": ["10.1016/j.ijpharm.2025.126368", "10.1016/j.bbamcr.2025.119916", "10.1016/j.bbadis.2024.167481", "10.18632/aging.205334", "10.3390/biomedicines10020234", "10.21037/atm-21-3026"]}
{"pair_type": "slc_pathway", "key1": "SLC27A5", "key2": "stemness", "summary": "-US upregulation by SLC27A5 suppressed the stemness of HCC.\nIn conclusion, SLC27A5/PABPC1 inhibits HCC stemness via APA-regulated expression of METTL14, providing potential avenues for the development of novel therapeutic strategies.\nMechanistically, SLC27A5 facilitates the usage of the proximal polyadenylation site of by downregulating the expression of the APA-associated factor PABPC1, resulting in the shortening of the -3'UTR and the conversion of -UL to -US.\nDeficiency of SLC27A5 promotes the progression of hepatocellular carcinoma (HCC) and is strongly associated with a poor prognosis.", "dois": ["10.1016/j.gendis.2024.101488"]}
{"pair_type": "slc_pathway", "key1": "SLC27A5", "key2": "oxidative stress", "summary": "Finally, downregulation of SLC27A5 altered tumor metabolism and cellular homeostasis, induced oxidative stress, and disrupted intracellular environmental stability, thereby suppressing the growth of gastric adenocarcinoma.\nThis study revealed that nano-curcumin liposomes inhibited growth and survival of gastric adenocarcinoma cells by interfering with the expression of FDX1, GPX4, SERPINE1 and SLC27A5, which were closely linked to copper-induced oxidative stress.\nAlcohol abstinence modulates protein half-lives through Srebf1-Slc27a5 axis, reducing inflammation, steatosis, and oxidative stress, potentially aiding in alcohol-induced liver damage treatment.\nKnockout of SLC27A5 increases polyunsaturated lipids, leading to increased NADP/NADPH ratio, ROS production as well as lipid peroxidation and the subsequent accumulation of 4-hydroxy-2-nonenal (4-HNE) in hepatoma cells.\nMass spectrometry analysis found that 4-HNE directly modifies cysteine residues (Cys513, 518) on KEAP1, thus leading KEAP1/NRF2 pathway activation and increases the expression levels of NRF2 target genes, such as TXNRD1.\nCollectively, we demonstrated that SLC27A5 acts as a novel tumor suppressor by suppressing TXNRD1 expression via the KEAP1/NRF2 pathway in HCC.\nSLC27A5 deficiency activates NRF2/TXNRD1 pathway by increased lipid peroxidation in HCC.\nFurther, SLC27A5 expression negatively correlates with TXNRD1 expression in hepatoma cells and clinical HCC samples, and blockade of NRF2/TXNRD1 using genetic approaches or inhibitors sensitizes SLC27A5-deficient hepatoma cells to sorafenib treatment.\nNano-curcumin liposomes hold great potential in inhibiting tumor growth and survival, as well as inducing cuproptosis and oxidative stress.", "dois": ["10.1038/s41418-019-0399-1", "10.1016/j.ijpharm.2025.126368", "10.1016/j.redox.2025.103674"]}
{"pair_type": "slc_pathway", "key1": "SLC27A6", "key2": "migration", "summary": "Down-regulation of SLC27A6 inhibited cell proliferation, migration, and invasion and induced apoptosis.\nsgRNA-mediated knockdown of SLC25A17 and SLC27A6 suppressed cell proliferation and migration in enzalutamide-resistant cells.\nHigher SLC27A6 expression, on the other hand, promoted NPC cell migration and invasion.\nDNA promoter hypermethylation downregulated the expression of SLC27A6.\nFurthermore, re-expression of SLC27A6 inhibited the growth capacity of NPC cells but strengthened the CSC markers.\nFurthermore, SLC27A6 overexpression level in NPC cell lines led to significant suppression of cell proliferation, clonogenicity, and tumorigenesis.\nFurthermore, we observed that SLC27A6 enhanced the intracellular amount of triglyceride (TG) and total cholesterol (T-CHO) in NPC cells, contributing to lipid biosynthesis and increasing metastatic potential.\nIn particular, re-expression of SLC27A6 faciliated epithelial-mesenchymal transition (EMT) signals in xenograft tumors.\nHere, we found a significant reduction of SLC27A6 mRNA in NPC tissues compared with normal nasopharyngeal epithelia (NNE).\nOur findings revealed the dual role of SLC27A6 in NPC and shed novel light on the link between lipid metabolism and CSC maintenance.\nInhibition of SLC25A17 and SLC27A6 resulted in downregulation of fatty acid synthase and acetyl-CoA carboxylase with parallel decrease in the levels of lactic acid in enzalutamide resistant cells.\nKnockdown of SLC27A6 inhibited c-MYC expression.\nAn induction of G1/S cell cycle arrest and abundance of hypo-diploid cells along with the reduction in the protein expression CyclinD1 and CDK6, the checkpoint factors, was observed including increased cell death as evident by BAX upregulation in knockdown cells.", "dois": ["10.1007/s10528-022-10218-3", "10.3389/fonc.2021.780410", "10.1002/mc.23383"]}
{"pair_type": "slc_pathway", "key1": "SLC27A6", "key2": "oxidative stress", "summary": "These DEGs were associated mainly with lipid metabolism, oxidative stress, and some inflammatory pathways.\nThe expressions of , , , and in LO2 cells were significantly higher ( < 0.05) while the expressions of , , and were significantly lower ( < 0.05) on the NA treatment compared to the NAM treatment, indicating that NA played a role in liver metabolism by directly regulating fatty acid anabolism and transport, inflammatory factor expression, and oxidative stress;\nThe differences in the expression of these DEGs between RPN and RPM were predominantly related to the processes of steroid catabolism, steroid hydroxylase, monooxygenase activity, oxidoreductase activity, hemoglobin binding, and ferric iron binding, which are involved mainly in lipid anabolism and redox processes.", "dois": ["10.3390/metabo14030150"]}
{"pair_type": "slc_pathway", "key1": "SLC27A6", "key2": "apoptosis", "summary": "Down-regulation of SLC27A6 inhibited cell proliferation, migration, and invasion and induced apoptosis.\nThe effects of SLC27A6 on the proliferation, migration, and apoptosis of PTC cells were detected by cell counting kit-8 (CCK8), colony formation assay, transwell assay, and flow cytometry.\nKyoto encyclopedia of genes and genomes (KEGG) pathways associated with herpes simplex virus 1 infection, calcium signaling pathway, cell adhesion molecules, apoptosis, and mitogen-activated protein kinase (MAPK)/peroxisome proliferators-activated receptors (PPAR) signaling pathways were enriched.\nKnockdown of SLC27A6 inhibited c-MYC expression.\nOur results suggest that SLC27A6 is overexpressed in PTC tissues and affects the progression of PTC by regulating c-MYC.\nSpearman correlation analysis showed that SLC27A6 was positively correlated with c-MYC.", "dois": ["10.62347/EGUX7327", "10.1016/j.fsi.2022.108510", "10.1007/s10528-022-10218-3"]}
{"pair_type": "slc_pathway", "key1": "SLC27A6", "key2": "proliferation", "summary": "Down-regulation of SLC27A6 inhibited cell proliferation, migration, and invasion and induced apoptosis.\nsgRNA-mediated knockdown of SLC25A17 and SLC27A6 suppressed cell proliferation and migration in enzalutamide-resistant cells.\nFurthermore, SLC27A6 overexpression level in NPC cell lines led to significant suppression of cell proliferation, clonogenicity , and tumorigenesis .\nWhen SLC27A6 expression in non-tumorigenic cell H184B5F5/M10 was repressed, the fatty acids uptake capacity and cell proliferation was inhibited, and cell cycle was delayed.\nThe protein expression of cell cycle regulators including cell division protein kinase 4 (CDK4), CDK6, and cyclin D1 was significantly decreased in SLC27A6-silenced H184B5F5/M10.\nHigher SLC27A6 expression, on the other hand, promoted NPC cell migration and invasion.\nFurthermore, re-expression of SLC27A6 inhibited the growth capacity of NPC cells but strengthened the CSC markers.\nAdditionally, knocking down the expression of could significantly enhance the malignant biological behavior of ovarian cancer cells.\nIn conclusion, this study reveals inverse correlation between SLC27A6 expression and tumoral tissues and provides a new insight into SLC27A6-mediated cell growth and cell cycle regulation in non-tumorigenic breast cells.\nAn induction of G1/S cell cycle arrest and abundance of hypo-diploid cells along with the reduction in the protein expression CyclinD1 and CDK6, the checkpoint factors, was observed including increased cell death as evident by BAX upregulation in knockdown cells.\nDownregulation of SLC27A6 by DNA Hypermethylation Promotes Proliferation but Suppresses Metastasis of Nasopharyngeal Carcinoma Through Modulating Lipid Metabolism.\nSolute Carrier Family 27 Member 6 (SLC27A6) Possibly Promotes the Proliferation of Papillary Thyroid Cancer by Regulating c-MYC.", "dois": ["10.62347/EGUX7327", "10.1007/s10528-022-10218-3", "10.3389/fonc.2021.780410", "10.1002/mc.23383", "10.21037/atm-21-3026", "10.7150/ijms.29946"]}
{"pair_type": "slc_pathway", "key1": "SLC27A6", "key2": "oxidative phosphorylation", "summary": "Compared with the mammary gland of AH-fed cows, the marked expression changes found in the mammary gland of CS group were for genes involved in reduced mammary growth/development (COL4A2, MAPK3, IKBKB, LGALS3), less oxidative phosphorylation (ATPsynGL, ATP6VOA1, ATP5H, ATP6VOD1, NDUFC1), enhanced lipid uptake/metabolism (SLC27A6, FABP4, SOD2, ACADM, ACAT1, IDH1, SCP2, ECHDC1), more active fatty acid beta-oxidation (HMGCS1), less amino acid/protein transport (SLC38A2, SLC7A8, RAB5a, VPS18), reduced protein translation (RPS6, RPS12, RPS16, RPS19, RPS20, RPS27), more proteasome- (PSMC2, PSMC6, PSMD14, PSMA2, PSMA3) and ubiquitin-mediated protein degradation (UBE2B, UBE2H, KLHL9, HSPH1, DNAJA1 and CACYBP), and more protein disassembly-related enzymes (SEC63, DNAJC3, DNAJB1, DNAJB11 and DNAJC12).", "dois": ["10.62347/EGUX7327", "10.1186/s12864-018-4808-5"]}
{"pair_type": "slc_pathway", "key1": "SLC28A1", "key2": "chemotherapy", "summary": "In NSCLC patients, CDA+435 C>T variants were associated with response (p=0.026) and time to progression (p=0.016) and SLC28A1+1561 G>A variants were associated with neutropenia (p=0.030) and thrombocytopenia nadir (p=0.037).\nCDA+435, and SLC28A1+1561 are worthy of further investigation as potential indicators of patient outcome after gemcitabine treatment.\nGenetic polymorphisms in genes related to metabolism and action sites of gemcitabine showed associations with the therapeutic efficacy, in terms of OS, TTP and disease progression in pancreatic cancer patients treated with gemcitabine-based chemotherapy.\nThe polymorphisms and haplotypes were analyzed in relation to overall survival (OS), time-to-progression (TTP) and disease progression.\nThe frequencies of the haplotypes for the CMPK1, SLC28A1, DCTD and TLE4 genes differed according to disease progression.\n102 genetic polymorphisms were selected from 23 genes involved in the metabolism and action sites of gemcitabine and screened for polymorphisms using the MassARRAY(®) system.\nBy pyrosequencing, the frequency of qualifying variants was characterized from germline DNA of 94 healthy Asian donors and 53 NSCLC patients receiving gemcitabine-based chemotherapy.\nThe study population consisted of 102 pancreatic cancer patients who had been treated with a gemcitabine-based chemotherapeutic regimen.\nAll genes involved in gemcitabine transport, metabolism and activity were screened for suitable variants for analysis using publications and public databases.", "dois": ["10.1097/FPC.0000000000000375", "10.2217/pgs.12.82", "10.1158/0008-5472.CAN-10-2736", "10.1016/j.lungcan.2008.04.010"]}
{"pair_type": "slc_pathway", "key1": "SLC28A1", "key2": "apoptosis", "summary": "IFN-β upregulated expression of the drug transporters SLC28A1 in BxPC-3 (252%) and SLC28A3 in BxPC-3 (127%) and CFPAC-1 (223%) (all p < 0.001).\nBoth ex vivo and in vivo data demonstrate a significant reduction in the number of proliferating cells, whereas apoptosis was increased.\nThis was driven by cell cycle modulation and associated with an upregulation of genes involving intracellular uptake of gemcitabine.", "dois": ["10.1186/s12885-020-07420-0"]}
{"pair_type": "slc_pathway", "key1": "SLC28A1", "key2": "oxidative stress", "summary": "Sixteen common upregulated DEGs were screened; these were concentrated in oxidative stress (SRXN1, MAFF), immune and inflammatory responses (ITPKC, AREG, MMP25, FOSL1), the nervous system (RETREG1, GADD45A, RCAN1), lipid metabolism (LRP11, LIPG, ITGA5, AMPD2), solute transport (SLC19A2, SLC28A1, SLCO4A1), and fertility (HBEGF).", "dois": ["10.1371/journal.pone.0274184"]}
{"pair_type": "slc_pathway", "key1": "SLC28A3", "key2": "proliferation", "summary": "Two out of three drug-transporter genes were strongly upregulated following epi-drug treatment (a range fold increase of 17−124 and 9−60 for Slc28a1 and Slc28a3, respectively;\nVPA combined with gemcitabine significantly reduced tumor size with 74% compared to vehicle-treated mice and upregulated expression of immune-related pathways (range pathway score 0.86−1.3).\nTreatment effects were determined by cell proliferation and colony forming assays.\nAll epi-drugs, except hydralazine, potentiated the gemcitabine response in KPC3 cells (range decrease IC50 value 1.7−2-fold;\nOn colony formation, the cytotoxic effect of 0.5 ng/mL gemcitabine was 1.4 to 6.3 times stronger (p < 0.01).", "dois": ["10.3390/biomedicines10030517", "PMID:15667311"]}
{"pair_type": "slc_pathway", "key1": "SLC28A1", "key2": "glycolysis", "summary": "The key biochemical feature of malignant tumor is the conversion of energy metabolism from oxidative phosphorylation to glycolysis, which provides sufficient capacity and raw materials for tumor cell rapid growth.", "dois": ["10.3389/fonc.2022.967342"]}
{"pair_type": "slc_pathway", "key1": "SLC29A2", "key2": "migration", "summary": "These genes are associated with endothelial dysfunction, smooth muscle proliferation and migration, angiogenesis, and abnormal extracellular matrix (ECM) dynamics.", "dois": ["10.3389/fnut.2025.1564741"]}
{"pair_type": "slc_pathway", "key1": "SLC29A4", "key2": "oxidative stress", "summary": "Three autistic children having low CSF 5HIAA and elevated oxidative stress received antioxidative supplements followed by CSF 5HIAA normalisation.\nOxidative stress was found to be present in autistic children where these reactive oxygen derivatives can cause damage to DNA, which changes DNA function and regulation of gene expression.\nCompared to controls, the autism group showed a significant increase in oxidative DNA damage in lymphocytes, plasma ceruloplasmin and copper levels with a high copper/zinc ratio, thiol proteins, and superoxide dismutase (SOD) activity.\nIn autism, we found diverse combinations for FR autoimmunity and/or oxidative stress, both amenable to treatment.\nTwo or more aberrant pro-oxidant and/or antioxidant factors predisposed to low CSF serotonin metabolites.\nIn addition, excessive amounts of these toxic oxygen derivatives are likely to damage the enzyme producing the neuromessenger serotonin in the brain, diminished in about 1/3 of the autistic children.\nParental and postnatal FR autoantibodies tend to block folate passage to the brain affecting folate-dependent pathways restored by folinic acid treatment, while an abnormal redox status tends to induce reduced serotonin turnover, corrected by antioxidant therapy.\nA known SLC6A4 mutation was identified only in 1 autistic child with low CSF 5HIAA and a novel SLC29A4 mutation was identified in identical twins.\nGenetic analysis included the SLC6A4 and SLC29A4 genes encoding synaptic serotonin reuptake proteins.", "dois": ["10.1155/2020/9095284"]}
{"pair_type": "slc_pathway", "key1": "SLC28A1", "key2": "migration", "summary": "SNPs in the genes ADAMTS9 (rs7631391), DOCK2 (rs77594147), SLC28A1 (rs28649017), ARHGAP5 (rs7151991), and CIITA (rs45601437) were most highly differentiated in the Asian comparison.\nWe found SNPs within or proximal to the genes CIITA (rs6498115), SMC6 (rs1834619), and KLHL29 (rs2288697) were most differentiated in the Amerindian-specific branch, while SNPs in the genes ADAMTS9 (rs7631391), DOCK2 (rs77594147), SLC28A1 (rs28649017), ARHGAP5 (rs7151991), and CIITA (rs45601437) were most highly differentiated in the Asian comparison.\nThese analyses have identified candidate genes for selection within Amerindian ancestry, and by comparison of the two analyses, those for which the differentiation may have arisen during the migration from Asia to the Americas.", "dois": ["10.1093/molbev/msw249"]}
{"pair_type": "slc_pathway", "key1": "SLC29A1", "key2": "migration", "summary": "Epigenetic reprogramming of classical and basal‑like tumor cells did not have a major impact on gemcitabine response, although the gemcitabine transporter gene (solute carrier family 29 member 1) was epigenetically regulated.\nFollowing HAT inhibitor treatment, classical cell lines exhibited a loss of epithelial marker gene expression, decreased chemotherapy response gene score and increased cell migration , indicating a tumor‑promoting phenotype.", "dois": ["10.3892/ijo.2024.5614"]}
{"pair_type": "slc_pathway", "key1": "SLC28A2", "key2": "chemotherapy", "summary": "In tumors from patients pretreated with protein kinase inhibitors (PKIs), genes encoding for specific copper (SLC31A1 and SLC31A2, χ-test adjusted p-values: 6.9e-09 and 2.5e-09) and nucleoside transporters (SLC28A2 and SLC28A3, χ-test adjusted p-values: 3.5e-06 and 6.8e-07) were deleted significantly more frequently than in patients pretreated with chemotherapy.\nThese findings contradict mechanisms of selective pressure, as they would be expected to originate during treatment with chemotherapy rather than with PKIs.\nWe analyzed 13 germline single nucleotide polymorphisms and one deletion-glutathione S-transferase (GST) M1-within six drug pathway-associated genes (GSTM1, GSTP1, cytidine deaminase (CDA), solute carrier (SLC) 28A1, SLC28A2, and deoxycytidine kinase).\nFurther studies should look into the relationship between CDA genotypes, plasmatic CDA activity, and clinical outcome in patients receiving gemcitabine-based chemotherapy.\nPatients carrying the nonsynonymous CDA SNP 79A >C (CDA*2) had a 21% lower gemcitabine clearance as compared to wild-type patients (outcomes and complications.0.0009), but the risk for chemotherapy-associated neutropenia (61% vs.\nAlterations in drug transport over the cancer cell membrane can severely alter intratumoral drug exposure, contributing to resistance.\nThis study quantified the impact of drug pathway-associated genetic variants on the pharmacokinetics (PK) of gemcitabine and cisplatin in patients with advanced non-small-cell lung cancer (NSCLC).\nPK models were fitted to the data using nonlinear mixed-effects modeling, and genetic data were tested on drug PK and hematological toxicity.\nOther gene polymorphisms were not associated with drug PK parameters or hematological toxicity.", "dois": ["10.2147/PGPM.S502355", "10.1016/j.biopha.2022.114210", "10.1007/s00280-011-1670-4"]}
{"pair_type": "slc_pathway", "key1": "SLC28A2", "key2": "migration", "summary": "Surprisingly, addition of TGF-β induced a set of genes, including Slc28a2, Tubb2a, and Cpe, that were expressed preferentially in fetal IECs.\nMoreover, TGF-β significantly increased the peak velocity of migrating IECs and, conversely, reduced the time required to reach the peak velocity, as confirmed by the motion vector prediction (MVP) method.\nThe wound repair response was enhanced significantly by the addition of TGF-β.", "dois": ["10.1016/j.bbrc.2020.01.108"]}
{"pair_type": "slc_pathway", "key1": "SLC28A1", "key2": "oxidative phosphorylation", "summary": "The key biochemical feature of malignant tumor is the conversion of energy metabolism from oxidative phosphorylation to glycolysis, which provides sufficient capacity and raw materials for tumor cell rapid growth.", "dois": ["10.3389/fonc.2022.967342"]}
{"pair_type": "slc_pathway", "key1": "SLC29A1", "key2": "proliferation", "summary": "Importantly, knocking down Slc29a1 in PC12 cells inhibited proliferation and induced differentiation into neuron-like cells.\nIn conclusion, this study showed that miR-33-3p regulated Slc29a1, which in turn controlled the proliferation and differentiation of PC12 cells.\nMechanistically, miR-33-3p repressed the expression of Slc29a1 in PC12 cells.\nWe found that miR-33-3p significantly suppressed PC12 cell proliferation, but had no effect on apoptosis.\nFurthermore, miR-33-3p promoted the differentiation of PC12 cells into Tuj1-positive and choline acetyltransferase-positive neuron-like cells.\nThus, we hypothesize that the miR-33-3p/Slc29a1 axis could be a promising therapeutic target for recovering neurons and the cholinergic nervous system.\nInducible re-expression of KDM6A in KDM6A-null cell lines suppressed proliferation and sensitized cells again to AraC treatment.\nRNA expression analysis and functional studies revealed that resistance to AraC was conferred by downregulation of the nucleoside membrane transporter ENT1 (SLC29A1) by reduced H3K27 acetylation at the ENT1 locus.\nFollowing HAT inhibitor treatment, classical cell lines exhibited a loss of epithelial marker gene expression, decreased chemotherapy response gene score and increased cell migration, indicating a tumor‑promoting phenotype.\nEpigenetic reprogramming of classical and basal‑like tumor cells did not have a major impact on gemcitabine response, although the gemcitabine transporter gene (solute carrier family 29 member 1) was epigenetically regulated.", "dois": ["10.3892/ijo.2024.5614", "10.22038/IJBMS.2022.61118.13528", "10.1007/s11064-021-03377-z", "10.1038/s41375-019-0497-6", "10.3892/mmr.2017.8319", "PMID:29312800", "PMID:16353156"]}
{"pair_type": "slc_pathway", "key1": "SLC28A3", "key2": "migration", "summary": "Experiments such as cell invasion, migration, scratch, and in vivo tumorigenicity were performed to determine the function of SLC28A3.\nHigh expression of SLC38A3 contributes to cellular malignant traits, and periodate-oxidized adenosine bound stably to SLC38A3.", "dois": ["10.1038/s41598-024-81040-7"]}
{"pair_type": "slc_pathway", "key1": "SLC28A3", "key2": "apoptosis", "summary": "IFN-β upregulated expression of the drug transporters SLC28A1 in BxPC-3 (252%) and SLC28A3 in BxPC-3 (127%) and CFPAC-1 (223%) (all p < 0.001).\nBoth ex vivo and in vivo data demonstrate a significant reduction in the number of proliferating cells, whereas apoptosis was increased.", "dois": ["10.1186/s12885-020-07420-0"]}
{"pair_type": "slc_pathway", "key1": "SLC29A1", "key2": "oxidative stress", "summary": "The dual exosomes on the coating acted through upregulating the expression of eNOS and downregulating NOX1 and NOX4 to reduce oxidative stress and effectively repair endothelial function.\nThe correlation analysis provided evidence of a link between purinergic signaling genes and biomarkers of inflammation and oxidative stress.\nModification of purine transport by oxidant stress may contribute to ischemia/reperfusion induced vascular damage and should be considered in the development of therapeutic strategies.\nThis decrease in transport function was mimicked by the intracellular superoxide generator menadione and could be reversed by the superoxide dismutase mimetic MnTMPyP.\nAdditionally, these data suggest that the generation of intracellular superoxide in ischemia/reperfusion leads to the down-regulation of ENBT1 function.\nCRC molecular pathogenesis is heterogeneous and may be followed by mutations in oncogenes and tumor suppressor genes, chromosomal and microsatellite instability, alternative splicing alterations, hypermethylation of CpG islands, oxidative stress, impairment of different signaling pathways and energy metabolism.\nThe dual exosomes also upregulated the expression of SLC29a1 and SLC2a1 and downregulated CD300a, CD36, and Lp-PLA to promote efferocytosis and inhibit inflammation.\nIn contrast, the expression of type 2 purinergic receptors (P2RX4 and PR2Y11), an ATP release channel (gap junction hemichannel GJB1), and an adenosine uptake protein (SLC29A1) followed the opposite response, increasing after calving and remaining elevated through 21 d.", "dois": ["10.1016/j.mvr.2014.06.008", "10.3168/jds.2013-7379", "10.1021/acsami.5c02721", "10.1186/s12864-016-3351-5"]}
{"pair_type": "slc_pathway", "key1": "SLC30A1", "key2": "oxidative phosphorylation", "summary": "Integrating the network pharmacology and proteomics results revealed that JTD may regulate expressions of cytochrome c oxidase subunit 7C, metabotropic glutamate receptor 2, Slc30a1 zinc transporter 1, and apolipoprotein A-IV in VD mice and that their mechanisms involve biological processes like oxidative phosphorylation, regulation of neuron death, glutamate secretion, cellular ion homeostasis, and lipoprotein metabolism.", "dois": ["10.1155/2023/9021546"]}
{"pair_type": "slc_pathway", "key1": "SLC28A1", "key2": "proliferation", "summary": "Two out of three drug-transporter genes were strongly upregulated following epi-drug treatment (a range fold increase of 17−124 and 9−60 for Slc28a1 and Slc28a3, respectively;\nVPA combined with gemcitabine significantly reduced tumor size with 74% compared to vehicle-treated mice and upregulated expression of immune-related pathways (range pathway score 0.86−1.3).\nTreatment effects were determined by cell proliferation and colony forming assays.\nAll epi-drugs, except hydralazine, potentiated the gemcitabine response in KPC3 cells (range decrease IC50 value 1.7−2-fold;\nOn colony formation, the cytotoxic effect of 0.5 ng/mL gemcitabine was 1.4 to 6.3 times stronger (p < 0.01).", "dois": ["10.3390/biomedicines10030517", "10.1158/0008-5472.CAN-10-2736", "PMID:15667311"]}
{"pair_type": "slc_pathway", "key1": "SLC29A4", "key2": "migration", "summary": "RAB26, MR1, CCL2, SLC29A4, IBTK, VEGFB, and GOLGA8B play critical roles.\nResearch has shown that interference with endoglin can promote the proliferation and migration and significantly inhibit the apoptosis of vascular endothelial cells.\nEndoglin interacts closely with 11 proteins such as CCL2 and SEPRINE1, which participate in the vital pathway of plaque formation.\nThe endoglin gene in vascular endothelial cells regulates the PI3K-Akt, Wnt, TNF, and cellular metabolism pathways by activating the SMAD pathway.\nInterference with endoglin particularly encourages the expression of VEGFB in vascular endothelial cells.\nTransforming growth factor-ß (TGF-ß) and its receptor (TGF-ßR) can inhibit the release of inflammatory factors through the SMAD pathway-mediated immune response, thereby suppressing the progression of CAD.", "dois": ["10.1186/s12944-021-01545-2"]}
{"pair_type": "slc_pathway", "key1": "SLC29A2", "key2": "chemotherapy", "summary": "Human equilibrative nucleoside transporters (hENT) 1 and 2, encoded by SLC29A1 and SLC29A2, permit the bidirectional passage of nucleoside analogues into cells and may correlate with clinical responses to chemotherapy in patients with colorectal cancer (CRC).\nFurther assessment of the association between hENTs and drug-based treatment of mCRC is required to elucidate the mechanisms of chemotherapy resistance.\nResults In the in vitro model, the expression of twelve drug-transporters genes was found to be significantly down-regulated after exposure to paclitaxel, including ABCC10, SLC28A3, SLC29A2, and ATP7B (involved in the transport of taxanes, antimetabolites, and cisplatin, respectively).\nThese findings indicate that most patients with metastatic CRC (mCRC) may have low hENT1 expression, and treatment with nucleoside analogues may be inefficient.\nHowever, some patients still show high hENT1 expression and have a high probability of benefiting from these drugs.\nThe function and activity of these transporters could be of pharmacological significance considering the roles that they play not only in nucleotide synthesis and metabolism but also in the pharmacokinetics and delivery of a variety of nucleobase analogues used in anticancer and antiviral drug therapy.\nThe present review provides an overview of the recent advances in our understanding of the molecular basis of nucleobase transport systems, focusing on the transporters that mediate purine nucleobases, and discusses the involvement of intracellular metabolism in purine nucleobase transport and chemotherapy using ganciclovir.", "dois": ["10.1097/FPC.0000000000000375", "10.1007/s10637-018-0677-7", "10.1248/bpb.b17-00374", "10.4238/gmr16019549"]}
{"pair_type": "slc_pathway", "key1": "SLC29A1", "key2": "chemotherapy", "summary": "Genetic polymorphisms in SLC28A3, SLC29A1 and RRM1 can influence the clinical outcome of MBC patients treated with PG chemotherapy.\nMoreover, SLC29A1 rs3734703 was shown to associate with both chemotherapy response and survival (adjusted OR 2.561 in the overdominant model;\nHuman equilibrative nucleoside transporters (hENT) 1 and 2, encoded by SLC29A1 and SLC29A2, permit the bidirectional passage of nucleoside analogues into cells and may correlate with clinical responses to chemotherapy in patients with colorectal cancer (CRC).\nAmong these 17 poly-miRTS, five Ara-C metabolic gene single nucleotide polymorphisms (SNPs, NT5C2 rs10786736 and rs8139, SLC29A1 rs3734703, DCTD rs7278, and RRM1 rs1042919) were identified to significantly associate with complete AML remission and/or overall and relapse-free survival (OS and RFS, respectively), and four anthracycline-metabolic gene SNPs (ABCC1 rs3743527, rs212091, and rs212090 and CBR1 rs9024) were significantly associated with chemotherapy-related toxicities.\nRNA expression analysis and functional studies revealed that resistance to AraC was conferred by downregulation of the nucleoside membrane transporter ENT1 (SLC29A1) by reduced H3K27 acetylation at the ENT1 locus.\nThe development of a drug resistance, either de novo or induced resistance, significantly limits the effectiveness of chemotherapy.\nIndividualized chemotherapy based on genetic profiling may help to optimize ara-C dosing, leading to improvements in clinical outcome and reduced toxicity.\nOur findings revealed that TGFBR1 inhibitors unintentionally target the nucleoside transporter SLC29A1 (ENT1), leading to reduced intracellular cytarabine levels.\nIncreased expression of SLC29A1 in vitro has been described as a potential critical factor determining the sensitivity of pancreatic cancer cells to gemcitabine and 5-", "dois": ["10.1016/j.drup.2025.101242", "10.3390/cancers17050896", "10.2147/PGPM.S502355", "10.7759/cureus.71896", "10.5937/jomb0-47459", "10.3892/ijo.2024.5614", "10.3390/pharmaceutics14040878", "10.1159/000520596", "10.1016/j.esmoop.2021.100236", "10.1101/mcs.a004713", "10.1038/s41375-019-0497-6", "10.1111/bcp.13943", "10.1097/FPC.0000000000000375", "10.1158/1078-0432.CCR-17-1523", "10.3892/mmr.2017.8319", "10.1186/s12967-017-1339-9", "10.4238/gmr16019549", "PMID:27733154", "10.1111/his.12805", "10.1002/pbc.25379", "10.1016/j.ejca.2013.11.028", "10.1016/j.pan.2013.09.005", "10.1016/j.ejca.2012.07.022", "10.1097/FPC.0b013e32834dd7e2"]}
{"pair_type": "slc_pathway", "key1": "SLC29A3", "key2": "chemotherapy", "summary": "Genes involved in the drug metabolism or elimination (SLC29A3) may be new prognostic biomarkers for patients with advanced NSCLC who receive gemcitabine as the first-line chemotherapy and may unveil an unexplored molecular pathway correlated with the drug response and further may be predictive biomarkers for these patients.\nMore evidently significant association was found between the SLC29A3 polymorphism and overall survival in patients treated with gemcitabine-based chemotherapy (C/T+T/T versus C/C: median OS 12.0 months, 95 % CI 10.5-13.5 months versus median OS 10.0 months, 95 % CI 9.0-11.0 months, P = 0.027 for log-rank test).\nAdditionally, we compile studies on the inhibition of ENT3, which may serve as an effective strategy to potentiate the anticancer activity of chemotherapy.\nPatients with SLC29A3 C/T+T/T genotype had longer overall survival (median OS 12.3 months, 95 % CI 11.0-13.6 months) than those with C/C genotype (median OS 11.0 months, 95 % CI 9.9-12.1 months, P = 0.030 for log-rank test).\nENT3 plays an essential regulatory role in transporting intracellular hydrophilic nucleosides, nucleotides, hydrophilic anticancer and antiviral nucleoside drugs, energy metabolism, subcellular localization, protein stability, and signal transduction.\nThe association between gene polymorphisms and the efficacy of gemcitabine therapy may be better known by understanding the intricacies of genetics that target a few or more genes in drug-targeting metabolic pathways.\nSeveral polymorphisms in the genes involved in drug metabolism or elimination are known to be associated with pharmacokinetic or pharmacodynamic variability, but their correlations with overall survival (OS) and response rate (RR) in lung cancer have been unknown.", "dois": ["10.7759/cureus.71896", "10.1016/j.yexcr.2023.113892", "10.1186/s12885-018-4471-x", "10.1007/s12032-014-0865-z"]}
{"pair_type": "slc_pathway", "key1": "SLC29A2", "key2": "oxidative stress", "summary": "The network-identified susceptibility genes represented biological processes mainly associated with purine nucleotide biosynthetic processes, lymphocyte proliferation, NF-KB activation, JAK-STAT signaling, and apoptotic signaling at oxidative stress.\nIn both cell lines the expression of the transporter SLC29A2 was reduced by the combined treatment.", "dois": ["10.1371/journal.pone.0173825"]}
{"pair_type": "slc_pathway", "key1": "SLC29A2", "key2": "proliferation", "summary": "Overexpression of FNDC3B or SLC29A2 in unamplified HCC cells promoted cell proliferation through activation of the signal transducer and activator of transcription 3 signaling pathway.\nKnockdown of these genes in amplified cells decreased cell proliferation, anchorage-independent growth, and tumor formation in xenograft models.\nImportantly, up-regulation of SLC29A2 in HCC tissues was significantly associated with advanced stages (P = 0.0031), vascular invasion (P = 0.0353), and poor patient survival (P = 0.0325).\nAberrant up-regulation of FNDC3B and SLC29A2 occurred in multiple HCC data sets.\nnutrient recovery and DNA methyltransferases inhibitor supplements partly rescued cell proliferation with decrease of DNA methylation and reactivation of several depressed genes, implying the possible intrinsic relationships among cell physiological state, mRNA expression, and DNA methylation.\nThe network-identified susceptibility genes represented biological processes mainly associated with purine nucleotide biosynthetic processes, lymphocyte proliferation, NF-KB activation, JAK-STAT signaling, and apoptotic signaling at oxidative stress.\nThese genes are associated with endothelial dysfunction, smooth muscle proliferation and migration, angiogenesis, and abnormal extracellular matrix (ECM) dynamics.\nIn an integrated transcriptome and DNA methylation analyses, 135 negatively correlated genes were determined, wherein the hub genes of gins2, cdca5, fbxo5, slc29a2, suv39h1b, and zgc:174160 were predominant responsive to the nutrient condition changes.\nThe down-regulated genes mainly annotated to the pathways of DNA replication and cell cycle that were consistent with cell physiological changes.", "dois": ["10.3389/fnut.2025.1564741", "10.1016/j.scitotenv.2020.137980", "10.1371/journal.pone.0173825", "PMID:27271752", "10.1002/hep.23847"]}
{"pair_type": "slc_pathway", "key1": "SLC29A4", "key2": "proliferation", "summary": "Research has shown that interference with endoglin can promote the proliferation and migration and significantly inhibit the apoptosis of vascular endothelial cells.\nConsistent with previous study, SK4 overexpression (SK4-OE) promoted proliferation and invasion ability of BHT10 cells compared with negative control (NC).\nCellular proliferation and invasion experiments were performed to assess the influences of SK4 on cell behaviors.\nInterference with endoglin particularly encourages the expression of VEGFB in vascular endothelial cells.", "dois": ["10.7717/peerj.19391", "10.1186/s12944-021-01545-2"]}
{"pair_type": "slc_pathway", "key1": "SLC29A3", "key2": "migration", "summary": "Finally, cellular functional experiments evidenced that miR-1224-5p mimic can reduce the cell viability, invasion, and migration, while overexpression of SLC29A3 presented an opposite effect.\nImportantly, co-transfection experiments indicated that SLC29A3 can reverse miR-1224-5p-mediated inhibition in the malignant progression of RC cells.\nOur work raised the possibility that miR-1224-5p functioned as a tumor suppressor in RC, which achieved its function via targeting SLC29A3.\nWhat is more, we affirmed that miR-1224-5p could direct target SLC29A3, which was expressed at high levels in RC tissues.\nIn addition, SLC29A3 could be used as an independent predictive factor of prognosis in patients with RC, and the higher SLC29A3 expression, the lower survival rate.", "dois": ["10.1002/iub.2352"]}
{"pair_type": "slc_pathway", "key1": "SLC29A3", "key2": "proliferation", "summary": "Patient-derived monocytes harboring the G208R SLC29A3 mutation showed enhanced survival and proliferation in a TLR8-antagonist-sensitive manner.\nTLR7 increased phagocyte numbers by driving the proliferation of Ly6Chi immature monocytes and their maturation into Ly6Clow phagocytes in Slc29a3-/- mice.\nH syndrome results from loss-of-function mutations in SLC29A3 which leads to abnormal proliferation and function of histiocytes.\nThis deficiency leads to abnormal function and proliferation of histiocytes.\nDownstream of TLR7, FcRγ and DAP10 were required for monocyte proliferation.\nMoreover, we uncovered that T cell lysosomes are an important source of salvaged metabolites for survival and proliferation.\nIt results from mutations in the gene encoding the human equilibrative nucleoside transporter 3, leading to impaired histiocyte apoptosis and unchecked proliferation.\nLoss-of-function mutations in the lysosomal nucleoside transporter SLC29A3 cause lysosomal nucleoside storage and histiocytosis: phagocyte accumulation in multiple organs.\nHere, we show that equilibrative nucleoside transporter 3 (ENT3) is highly expressed in peripheral T cells and has a key role in maintaining T cell homeostasis by supporting the proliferation and survival of T cells.\nOur results identify ENT3 as a vital metabolite transporter that supports T cell homeostasis and activation by regulating lysosomal integrity and the availability of nucleosides.\nThese results demonstrated that TLR7/8 responses to lysosomal nucleoside stress drive SLC29A3 disorders.\nHistiocytosis is accompanied by inflammation in SLC29A3 disorders.\nHerein, histiocytosis in Slc29a3-/- mice was shown to depend on Toll-like receptor 7 (TLR7), which senses a combination of nucleosides and oligoribonucleotides (ORNs).\nENT3 deficiency leads to an enlarged and disturbed lysosomal compart", "dois": ["10.5114/reum/191751", "10.12659/AJCR.944198", "10.3389/fimmu.2023.1061182", "10.1084/jem.20230054", "10.3390/cancers14215271", "10.7759/cureus.23281", "10.1111/dth.15082", "10.1016/j.celrep.2018.04.077"]}
{"pair_type": "slc_pathway", "key1": "SLC29A2", "key2": "apoptosis", "summary": "These alterations were associated with dysregulated vascular tone and smooth muscle contractility, apoptosis, and abnormal ECM dynamics.", "dois": ["10.3389/fnut.2025.1564741"]}
{"pair_type": "slc_pathway", "key1": "SLC29A3", "key2": "apoptosis", "summary": "Slc29a3 HSPCs accumulate less TBA despite elevated levels of TBA in Slc29a3 mouse plasma and have elevated basal ER stress, reactive oxygen species (ROS), and radiation-induced apoptosis.\nReintroduction of ENT3 allows for increased accumulation of TBA into HSPCs, which results in TBA-mediated alleviation of ER stress and erythroid apoptosis.\nFinally, inhibition of ENT3 activity by dypridamole and depletion of ENT3 by siRNA-induced knockdown resulted in increased caspase 3/7 activities in β-cells.\nDepletion of ENT3 causes mitochondrial dysfunction which is associated with enhanced β-cell apoptosis.\nThus, apoptotic loss of islet β-cells may contribute to the occurrence of autoantibody-negative insulin-dependent diabetes in individuals with non-functional ENT3 mutations.\nHere, we demonstrate that lysosomal ENT3 transport of taurine-conjugated bile acids (TBA) facilitates TBA chemical chaperone function and alleviates endoplasmic reticulum (ER) stress in expanding mouse hematopoietic stem and progenitor cells (HSPCs).\nFurthermore, ENT3 depletion in β-cells increased mitochondrial DNA content and promoted an energy crisis characterised by enhanced ATP-linked respiration and proton leak.\nIt results from mutations in the gene encoding the human equilibrative nucleoside transporter 3, leading to impaired histiocyte apoptosis and unchecked proliferation.", "dois": ["10.1038/s41467-021-21451-6", "10.5114/reum/191751", "10.1016/j.bbadis.2015.07.002"]}
{"pair_type": "slc_pathway", "key1": "SLC28A3", "key2": "chemotherapy", "summary": "In tumors from patients pretreated with protein kinase inhibitors (PKIs), genes encoding for specific copper (SLC31A1 and SLC31A2, χ-test adjusted p-values: 6.9e-09 and 2.5e-09) and nucleoside transporters (SLC28A2 and SLC28A3, χ-test adjusted p-values: 3.5e-06 and 6.8e-07) were deleted significantly more frequently than in patients pretreated with chemotherapy.\nGenetic polymorphisms in SLC28A3, SLC29A1 and RRM1 can influence the clinical outcome of MBC patients treated with PG chemotherapy.\nAnthracycline-induced cardiotoxicity was associated with CBR2, CELF4, GSTM1, HAS3, RARG, and SLC28A3, and further with HNMT and SLC22A2 in younger children, with ABCB4 in females, and with SULT2B1 in males.\nAs part of a precision medicine initiative, we used pharmacogenetic testing, focused on RARG, UGT1A6 and SLC28A3 variants, to help predict an individual's risk of experiencing anthracycline-induced cardiotoxicity.\nThe primary purpose of our study was to investigate the association between genetic polymorphisms in the genes involved in PG pathways and clinical outcomes in MBC patients treated with PG chemotherapy.\nResults In the in vitro model, the expression of twelve drug-transporters genes was found to be significantly down-regulated after exposure to paclitaxel, including ABCC10, SLC28A3, SLC29A2, and ATP7B (involved in the transport of taxanes, antimetabolites, and cisplatin, respectively).\nOur results indicate that variations in ABCC2, CYP3A5, NQO1, SLC22A6 and SLC28A3 genes might influence the left ventricular parameters.\nSLC28A3 single nucleotide polymorphism (rs7853758) was also incorporated as a constant covariate of the delay compartment of amrubicinol", "dois": ["10.1016/j.critrevonc.2025.104720", "10.2147/PGPM.S502355", "10.1200/PO.22.00580", "10.1016/j.biopha.2022.114210", "10.1186/s12885-022-10434-5", "10.2217/fon-2021-1021", "10.1158/1078-0432.CCR-21-1762", "10.1111/bcpt.13593", "10.1111/cas.14194", "10.1111/bcp.13943", "10.1007/s12253-019-00613-4", "10.1007/s10637-018-0677-7", "10.1186/s12885-018-4629-6", "10.1007/s11912-018-0696-8", "10.1161/CIRCGEN.117.001753", "10.2174/1389200218666171101124931", "10.1111/bcp.13008", "10.1002/pbc.25379", "10.1016/j.ejca.2013.11.028", "10.1097/FPC.0b013e32834dd7e2"]}
{"pair_type": "slc_pathway", "key1": "SLC30A1", "key2": "apoptosis", "summary": "Furthermore, overexpression of ZnT5 and ZnT7 is accompanied by activation of PI3K/Akt pathway and inhibiting HG-induced apoptosis.\nThis may account for the inhibition of HG-induced RPMC apoptosis and peritoneum injury, likely through targeting PI3K/Akt pathway-mediated cell survival.\nMeanwhile, two different zincs inhibited the ZEA-induced loss of mitochondrial membrane potential and elevation of late-stage apoptosis via activating the mitochondrial apoptotic pathway by recovering the mRNA and protein expression of pro-apoptotic genes (Bax, Casp3, Casp9).\nHowever, in the Znhigh group, we found a prevention of villus atrophy and decreased caspase-3-mediated apoptosis of jejunal epithelium.\nIncreased levels of apoptosis were observed after knockdown of ZnT5 and ZnT7.\nKnockdown of zip10 reduced free Zn in HGC, ceased their normal developmental apoptosis, and resulted in displacement and later disappearance of hatching glands and hatching enzymes he1a and catL1b, and inability to hatch.\nIn cells, Zn is involved in the regulation of intermediary metabolism, gene expression, cell growth, differentiation, apoptosis, and antioxidant defense mechanisms.\nOverexpression of ZnT5 and ZnT7 respectively resulted in a decrease in the expression of caspace 3, caspace 8, BAX, and AIF and coincided with cell survival in the presence of HG.\nAbstract: Zinc is an essential micronutrient and cytoprotectant involved in many types of apoptosis.\nFree Zn in embryos and apoptosis were investigated using fluorescent dyes whereas gene expression was investigated by whole-mount in situ hybridization (WISH).\nThe results showed high levels of free Zn in the hatching gland cells (HGC) along with abundant expression of zip10 and znt1a in normal embryo.\nMost Zn-dependent genes that were expressed differently between early and late passages were correlated with changes in the expression of anti-apoptotic", "dois": ["10.1093/mtomcs/mfab026", "10.1016/j.exger.2017.09.006", "10.1038/srep14277", "10.1016/j.cellsig.2012.12.013", "10.3390/biom14060650", "10.1016/j.bbrc.2020.05.131", "10.1186/1746-6148-10-75"]}
{"pair_type": "slc_pathway", "key1": "SLC30A1", "key2": "proliferation", "summary": "Mechanistically, we demonstrated that elevated zinc levels resulting from Slc30a1 deficiency promoted melanocyte proliferation and that mt2 played a protective role in the process of Slc30a1/zinc-mediated melanocyte hyperplasia.\nThis study uncovered the critical function of Slc30a1-mediated zinc homeostasis in melanocyte development and suggests that accumulated zinc in melanocytes would be a risk for inducing melanoma and that mt2 is a potential target for controlling diseases related to abnormal melanocyte development.\nThe essential trace element, zinc, regulates virtually all aspects of cellular physiology, particularly cell proliferation and survival.\nZinc is a transition metal and catalytic cofactor involved in many biological processes including proliferation, development, differentiation, and metabolism.\nHere, we found that melanocytes were increased in slc30a1a and slc30a1b double mutant zebrafish.\nSMART-seq data revealed that genes involved in the melanoma pathway and the gene mt2, which encodes zinc-binding protein, were significantly upregulated in the mutants.\nIn addition, the expression of mt2 was specifically increased in mutant melanocytes, as detected by in situ hybridization, suggesting an essential role of this gene in the tissue.\nSlc30a1a and Slc30a1b are zinc exporters in zebrafish.\nFinally, an integrative analysis of the cryo-EM structure and site-specific mutagenesis of human SLC30A1 are performed and a zinc transport mechanism of SLC30A1 unique within the SLC30A family, with His43 serving as a critical residue for zinc selectivity, is identified.\nIt is also found that Slc30a1 safeguards both intestinal barrier integrity and systemic zinc homeostasis.", "dois": ["10.1002/advs.202406421", "10.1016/j.ejcb.2022.151272", "10.1002/jcb.27285", "10.1186/s12974-016-0603-x"]}
{"pair_type": "slc_pathway", "key1": "SLC30A1", "key2": "oxidative stress", "summary": "Furthermore, CBD enhanced the transcription of oxidative stress modulators with potent anti-inflammatory activity that are controlled by Nfe2l2/Nrf2 (Mt1, Mt2a, Slc30a1, Hmox1).\nCo-incubation of zinc with ZEA significantly reduced the ZEA-induced reactive oxygen species and malondialdehyde elevation by promoting the transcription of Mtf1 and Mt2.\nMoreover, CBD treatment of BV-2 cells, was found to induce a robust change in the expression of genes related to oxidative stress, glutathione deprivation and inflammation.\nThe results shown that both zinc sulfate and zinc gluconate addition increased the intracellular zinc concentration and influenced the expression of zinc transporters (Slc30a1 and Slc39a1) in a time-dependent manner.\nThese results show that CBD, but much less so THC, affects the expression of genes involved in zinc homeostasis and suggest that the regulation of zinc levels could have an important role through which CBD may exert its antioxidant and anti-inflammatory effects.\nA subset of genes was found to be regulated by the metal responsive element (MRE)-binding transcription factor-1 (MTF-1) and is shown to be related to zinc homeostasis.\nAmong these genes, ZnT1, Mt2 and the zinc transporters ZIPs are known to function together to control the intracellular zinc concentration.\nWe found that CBD upregulates the expression of the mRNAs for metallothionein 2 (Mt2), N-myc-downstream regulated gene 1 and matrix metalloproteinase 23 as well as of the zinc transporters ZnT1/Slc30a1 and Zip4/Slc39a4 but downregulates the expression of the mRNA for the zinc transporter Zip10/Slc39a10 as well as for the zinc finger protein 472.\nMicroarray-based gene expression profiling demonstrated that CBD exerts its immunoregulatory effects in activated memory TMOG cells via (a) suppressing proinflammatory Th17-related transcription, (b) by promoting T cell exhaustion/tolerance, (c", "dois": ["10.1038/srep14277", "10.1186/s12974-016-0603-x", "10.1016/j.neuint.2011.12.002"]}
{"pair_type": "slc_pathway", "key1": "SLC30A2", "key2": "glycolysis", "summary": "The overexpression of GGH in colon cancer-derived cell lines (SW48 and SW480) inhibited PKM, GLUT1, and LDHA expression and decreased the extracellular lactate content and intracellular ATP level.", "dois": ["10.3389/fimmu.2022.979521"]}
{"pair_type": "slc_pathway", "key1": "SLC30A2", "key2": "apoptosis", "summary": "Among the DEGs, a lot of redox metabolism- (e.g., ACOX3, SMOX, GPX3, GLO1, and P4HA1), ion transport- (e.g., MICU3, MCTP, PYX, STEAP3, and SLC30A2), drug metabolism- (e.g., HSP70, HSP90A, CYP2L1, and CYP9E2), immune response- (e.g., SMAD4, HDAC1, and DUOX), and apoptosis-related genes (e.g., CTSL, CASP7, and BIRC2) were identified, which suggests that Hg exposure may perturb the redox equilibrium, disrupt the ion homeostasis, weaken immune response and ability, and cause apoptosis.\nCP addition upregulated the expression of the Zn absorptive transporter Slc39a4 and of methallothionein Mt1 in a Zn-sensitive manner, while downregulating the expression of the Zn exporter Slc30a2 and of methallothionein 2 (Mt2).\nIn addition, CP induced apoptosis modestly and modulated antimicrobial gene expression.\nThe results presented in this study validate the considerable potential of CBD to induce broad transcriptional and signalling alterations, related to immune modulation, apoptosis, and metabolic processes in K-562S cells.\nMoreover, ZnSO4 had been shown to bolster apoptosis and trigger the Wnt/β-catenin signaling pathway, effects which were mitigated by the overexpression of .\nAdditionally, ZnSO treatment induced cytotoxicity and oxidative stress in GC cells, while overexpression rescued ZnSO-induced, migration, invasion, and proliferation.\nThe impact of zinc sulfate (ZnSO) on GC cells was evaluated by detecting apoptosis markers, Wnt/β-catenin signaling pathway activity, and oxidative stress biomarkers, focusing on the regulatory effect of overexpression.\nThe subsequent transcriptomic profiling revealed 3518 DEGs at 12 h an", "dois": ["10.31083/j.fbl2910351", "10.1016/j.gmg.2025.100076", "10.1016/j.biopha.2024.116555", "10.3390/antiox11101944"]}
{"pair_type": "slc_pathway", "key1": "SLC30A1", "key2": "stemness", "summary": "Slc30a1-deficient zebrafish develop zinc accumulation in NC cells, with increased expression of stemness markers and PA dorsal genes, and SMART-seq analyses revealed that the genes and may serve as downstream targets.\nOur findings indicate that the Slc30a1/zinc-- axis is an essential regulatory network controlling PA differentiation, shedding new light on the function of zinc homeostasis in maintaining NC cell stemness and multipotency in vertebrates.", "dois": ["10.1002/mco2.91"]}
{"pair_type": "slc_pathway", "key1": "SLC28A2", "key2": "proliferation", "summary": "Mechanistic studies revealed that ALDH2 deficiency facilitated VSMC proliferation by upregulating the expression of the glutamine transporter SLC38A2, which is a novel ALDH2 target gene.\nImportantly, downregulation of SLC38A2 by adeno-associated virus serotype 2 (AAV2) shRNA or by the inhibitor MeAIB has promising therapeutic potential in limiting VSMC proliferation and neointima formation.\nFurther bioinformatics analysis, luciferase assays, and ChIP-qPCR revealed that ALDH2 deficiency increased SLC38A2 expression via activating transcription factor 4 (ATF4) and that ATF4 knockdown largely reversed the ability of ALDH2 deficiency to promote VSMC proliferation.\nOur study elucidates a novel mechanism through which ALDH2 deficiency aggravates neointimal formation by enhancing VSMC proliferation through an increase in glutamine uptake, suggesting a promising translational strategy for the prevention of vascular injury-induced restenosis.\nMoreover, ALDH2 deficiency promoted the accumulation of 4-HNE adducted proteins, thereby activating ATF4, which subsequently increased SLC28A2 transcriptional activity in VSMCs.\nGlobal ALDH2 knockout and VSMC-specific ALDH2 knockout exacerbated injury-induced neointima formation, whereas VSMC-specific ALDH2 overexpression reduced neointima formation.\nALDH2 deficiency facilitated VSMC proliferation by upregulating the expression of the glutamine transporter SLC38A2.\nATF4 knockdown largely reversed the ability of ALDH2 deficiency to promote VSMC proliferation.\nFinally, we demonstrated that VSMC proliferation was aggravated and that neointima formation occurred in ALDH2 mutant mice.", "dois": ["10.1016/j.metabol.2025.156411", "PMID:17634277", "PMID:15667311"]}
{"pair_type": "slc_pathway", "key1": "SLC30A2", "key2": "migration", "summary": "knockdown repressed proliferation, invasion, and migration of GC cells, induced apoptosis, as well as arrested the cell cycle.\nAdditionally, ZnSO treatment induced cytotoxicity and oxidative stress in GC cells, while overexpression rescued ZnSO-induced, migration, invasion, and proliferation.\nSome ion transport genes such as CAMK1, ATP1α3, KCNJ1 and SLC30A2 were identified that may contribute to freshwater adaptation.\nOur analysis revealed significant upregulation of in GC samples compared to normal samples, and high expression was linked to poor prognosis.\nMoreover, ZnSO4 had been shown to bolster apoptosis and trigger the Wnt/β-catenin signaling pathway, effects which were mitigated by the overexpression of .\nOur results implied that was essential for GC progression by modulating zinc homeostasis and cellular processes.\nFunctional assays, including Cell counting kit-8 (CCK-8) and transwell assays, were carried out on GC cell lines to determine the impact of knockdown on cell behavior.", "dois": ["10.1111/mec.70104", "10.31083/j.fbl2910351"]}
{"pair_type": "slc_pathway", "key1": "SLC27A5", "key2": "ferroptosis", "summary": "SLC27A5 deficiency facilitates the resistance towards sorafenib in HCC cells, which is mediated by suppressing ferroptosis.\nIn conclusion, we describe that SLC27A5 serves as a suppressor in sorafenib resistance and promotes sorafenib-triggered ferroptosis via restraining the NRF2/GSR pathway in HCC, providing a potential therapeutic strategy for overcoming sorafenib resistance.\nSLC27A5 promotes sorafenib-induced ferroptosis in hepatocellular carcinoma by downregulating glutathione reductase.\nFurther mechanism studies reveal that the loss of SLC27A5 enhances the glutathione reductase (GSR) expression in a nuclear factor erythroid 2-related factor 2 (NRF2)-dependent manner, which maintains glutathione (GSH) homeostasis and renders insensitive to sorafenib-induced ferroptosis.\nNotably, SLC27A5 negatively correlates with GSR, and genetic or pharmacological inhibition of GSR strengthens the efficacy of sorafenib through GSH depletion and the accumulation of lipid peroxide products in SLC27A5-knockout and sorafenib-resistant HCC cells.", "dois": ["10.1038/s41419-023-05558-w"]}
{"pair_type": "slc_pathway", "key1": "SLC29A4", "key2": "apoptosis", "summary": "Research has shown that interference with endoglin can promote the proliferation and migration and significantly inhibit the apoptosis of vascular endothelial cells.", "dois": ["10.1186/s12944-021-01545-2"]}
{"pair_type": "slc_pathway", "key1": "SLC28A2", "key2": "oxidative stress", "summary": "Key genes most highly and significantly upregulated include ALDH2, MT1, TMEM6, CDK20, and COX62b, while CALU, ST3GAL4, CRTC2, SLC28A2, and COMMA1 are downregulated.\nExcess dietary Zn causes oxidative stress, increases goblet cell number and mucus production, and are associated with increased intestinal permeability and systemic inflammation.", "dois": ["10.1002/mnfr.201800947"]}
{"pair_type": "slc_pathway", "key1": "SLC30A2", "key2": "stemness", "summary": "CP addition upregulated the expression of the Zn absorptive transporter Slc39a4 and of methallothionein Mt1 in a Zn-sensitive manner, while downregulating the expression of the Zn exporter Slc30a2 and of methallothionein 2 (Mt2).\nCP had antiproliferative effects and reduced the expression of proliferative and stemness genes in jejunal organoids, effects that were largely independent of Zn chelation.", "dois": ["10.1016/j.biopha.2024.116555"]}
{"pair_type": "slc_pathway", "key1": "SLC30A2", "key2": "proliferation", "summary": "knockdown repressed proliferation, invasion, and migration of GC cells, induced apoptosis, as well as arrested the cell cycle.\nCP addition upregulated the expression of the Zn absorptive transporter Slc39a4 and of methallothionein Mt1 in a Zn-sensitive manner, while downregulating the expression of the Zn exporter Slc30a2 and of methallothionein 2 (Mt2).\nAdditionally, ZnSO treatment induced cytotoxicity and oxidative stress in GC cells, while overexpression rescued ZnSO-induced, migration, invasion, and proliferation.\nCP had antiproliferative effects and reduced the expression of proliferative and stemness genes in jejunal organoids, effects that were largely independent of Zn chelation.\nIn this study we aimed to characterize the effect of calprotectin on mouse jejunal organoids as a model epithelium, focusing on Zn metabolism and cell proliferation.\nTargeting or zinc signaling may represent a potential therapeutic approach for GC treatment.\nOur analysis revealed significant upregulation of in GC samples compared to normal samples, and high expression was linked to poor prognosis.\nMoreover, ZnSO4 had been shown to bolster apoptosis and trigger the Wnt/β-catenin signaling pathway, effects which were mitigated by the overexpression of .\nOur results implied that was essential for GC progression by modulating zinc homeostasis and cellular processes.\nThe purpose of this study was to investigate the role of , a zinc transporter, in GC development and its capacity as a target for therapy.\nFunctional assays, including Cell counting kit-8 (CCK-8) and transwell assays, were carried out on GC cell lines to determine the impact of knockdown on cell behavior.\nOverall, CP exerts modulatory effects in murine jejunal organoids that are in part related to Zn sequestration and partially reproduced in vivo, supporting the validity of mouse jejunal organoids as a model for mouse epithelium.", "dois": ["10.31083/j.fbl2910351", "10.1016/j.biopha.2024.116555"]}
{"pair_type": "slc_pathway", "key1": "SLC30A2", "key2": "oxidative stress", "summary": "Functional studies in vitro suggest that substitution of threonine for serine at amino acid 288 leads to hyperphosphorylation retaining ZnT2 in the ER and lysosomes, increasing ER and lysosomal Zn accumulation, ER stress, the generation of reactive oxygen species, and STAT3 activation.\nHere we report that women who harbor a common ZnT2 variant (TS) present with elevated levels of several oxidative and endoplasmic reticulum (ER) stress markers in their breast milk.\nIn contrast, ectopic expression of SNP2 was associated with the expansion of cytoplasmic Zn pools, elevated reactive oxygen species, and increased Zn efflux.\nAdditionally, ZnSO treatment induced cytotoxicity and oxidative stress in GC cells, while overexpression rescued ZnSO-induced, migration, invasion, and proliferation.\nThe subsequent transcriptomic profiling revealed 3518 DEGs at 12 h and 3433 DEGs at 4 h of treatment, including significant modulation of metallothionein-regulated oxidative stress responses (, , and ) and p53-mediated apoptosis (, , , , , and ).", "dois": ["10.31083/j.fbl2910351", "10.1038/s41598-018-21505-8", "10.1152/physiolgenomics.00137.2010", "10.1016/j.gmg.2025.100076"]}
{"pair_type": "slc_pathway", "key1": "SLC30A3", "key2": "apoptosis", "summary": "Our functional validation revealed that SLC30A3 can inhibit the growth and metastatic spread of GBM cells in vitro and in vivo, and can activate the MAPK signaling pathway to promote apoptosis of GBM cells.\nFurthermore, histone deacetylase 1 (HDAC1), overexpressed in GBM tissues, could inhibit SLC30A3 expression by promoting histone H3K27ac deacetylation modification of the SE region of SLC30A3.\nZinc depletion and high glucose induced apoptosis and necrosis in INS-1E cells.\nMoreover, overexpression of HDAC1 resulted in a significant increase in DNA replication activity, a significant decline in apoptosis and cell cycle arrest in GBM cells.", "dois": ["10.1002/iub.2463", "PMID:17680010", "10.1371/journal.pone.0005684"]}
{"pair_type": "slc_pathway", "key1": "SLC30A3", "key2": "oxidative stress", "summary": "The previous study has shown that SLC30A3 protect cells from oxidative stress in ERK1/2 signal dependent manner, thus we determined the activity of ERK1/2 in SLC30A3 knockdown cells under ER stress condition.\nZnT3 tyrosine dimerization was detected under normal conditions and it was enhanced by oxidative stress.\nThe ERK1/2 pathway is thought to have an association with defensive effects of SLC30A3 on cellular stress such as ER stress.\nThese results showed that SLC30A3 has a protective role to ER stress-induced toxicities.\nIn conclusion, this study suggested that SLC30A3 is supposed to play a protective role against ER stress, which is related to ERK1/2 activation.\nCell viability under tunicamycin treatment was significantly decreased in SLC30A3 knockdown cells by siRNA in comparison with negative control (NC) cells.\nThe level of ERK1/2 phosphorylation was significantly increased by tunicamycin treatment in NC cells, not in SLC30A3 knockdown cells.\nCleaved caspase-3 level was significantly increased in SLC30A3 knockdown cells, not in NC cells.\nTherefore we investigated that the role of SLC30A3 against ER stress.\nIt was thought that both SLC30A3 and ER stress could be related to the cause of AD and ALS, however the relationship between ER stress and SLC30A3 has not been elucidated.", "dois": ["10.1016/j.jtemb.2024.127540", "10.1016/j.bbrc.2016.09.119", "10.1371/journal.pone.0005896"]}
{"pair_type": "slc_pathway", "key1": "SLC30A4", "key2": "proliferation", "summary": "lnc-SLC30A4-1 (15-fold), and lnc-SPAM1-6 (10-fold) were highly overexpressed in ccRCC, whereas lnc-ACACA-1 (135-fold), lnc-FOXG1-2 (19-fold), lnc-LCP2-2 (2-fold), lnc-RP3-368B9 (19-fold), and lnc-TTC34-3 (314-fold) were downregulated.\nSmall interfering RNA (siRNA)-mediated knockdown of lnc-BMP2-2 and lnc-CPN2-1 did not influence cell proliferation.", "dois": ["10.1186/s13148-015-0047-7"]}
{"pair_type": "slc_pathway", "key1": "SLC30A4", "key2": "apoptosis", "summary": "I cannot find any excerpts in the provided source text that explicitly describe promotion, suppression, activation, inhibition, enhancement, or reduction relationships between SLC30A4 and apoptosis. The text discusses genetic loci, colitis severity, and identifies Slc30a4 as a candidate gene, but does not contain verbatim phrases or sentences describing a mechanistic relationship between SLC30A4 and apoptosis.", "dois": ["10.1002/ibd.21479"]}
{"pair_type": "slc_pathway", "key1": "SLC30A5", "key2": "apoptosis", "summary": "SLC30A5 knockdown in Huh7 cells reduced proliferation, migration, and invasion while promoting apoptosis.\nHowever, in the Znhigh group, we found a prevention of villus atrophy and decreased caspase-3-mediated apoptosis of jejunal epithelium.\nChronic exposure to Zn accelerated senescence and untreated cells at later passages, where doubling time had increased, displayed relocation of labile Zn and altered expression of genes involved in the response to Zn toxicity, including SLC30A1, SLC39A6, SLC30A5, SLC30A10 and metallothioneins, indicating that senescent cells have altered zinc homeostasis.\nFurthermore, pigs receiving high Zn diet showed a down-regulation of interferon (IFN)-α, oligoadenylate synthetase (OAS), Zn transporter SLC39A4 (ZIP4), but up-regulation of metallothionein-1 (MT1), as well as the Zn transporters SLC30A1 (ZnT1) and SLC30A5 (ZnT5).\nMost Zn-dependent genes that were expressed differently between early and late passages were correlated with changes in the expression of anti-apoptotic genes.\nShort-term treatment with a high dose of Zn leads to cell death, but only in the population of cells at both earlier and later passages that had already entered senescence.", "dois": ["10.1016/j.exger.2017.09.006", "10.7150/jca.97214", "10.1186/1746-6148-10-75"]}
{"pair_type": "slc_pathway", "key1": "SLC30A6", "key2": "proliferation", "summary": "Zinc is a transition metal and catalytic cofactor involved in many biological processes including proliferation, development, differentiation, and metabolism.\nUpregulation of SLC30A5, SLC30A6, SLC30A7 transcripts, encoding zinc efflux transporters ZnT5, ZnT6, ZnT7, localized on endoplasmic reticulum membranes, might be part of a coordinated transcriptional program associated to the increased activity of the early secretory pathway, while transcriptional upregulation of several specific ZIP transporters (SLC39A6, SLC39A7, SLC39A9, SLC39A10, and SLC39A11) could contribute in meeting the increased demand of zinc in cancer cells.", "dois": ["10.1002/jcb.27285"]}
{"pair_type": "slc_pathway", "key1": "SLC30A5", "key2": "migration", "summary": "SLC30A5 knockdown in Huh7 cells reduced proliferation, migration, and invasion while promoting apoptosis.\nThis study highlights the clinical relevance of SLC30A5 in HCC, emphasizing its role in cell proliferation and migration.\nSLC30A5, a member of the solute transporter protein family, is implicated in tumorigenesis and cancer progression.\nIn HCC, upregulation of SLC30A5 expression correlated with adverse prognosis.\nSLC30A5 overexpression was associated with advanced disease stages, higher histological grades, and vascular invasion.\nSignificant associations were observed between SLC30A5 expression and immune cell infiltration, immune checkpoints, molecules involved in angiogenesis, and EMT.\nCo-expression analysis explored the relationship between SLC30A5 and immune cell infiltration, immune checkpoints, pathway molecules related to tumor angiogenesis and epithelial-mesenchymal transition (EMT).", "dois": ["10.7150/jca.97214", "PMID:37168332"]}
{"pair_type": "slc_pathway", "key1": "SLC30A5", "key2": "proliferation", "summary": "and assays demonstrated that SLC30A5 knockdown in Huh7 cells reduced proliferation, migration, and invasion while promoting apoptosis.\nThis study highlights the clinical relevance of SLC30A5 in HCC, emphasizing its role in cell proliferation and migration.\nUpregulation of SLC30A5, SLC30A6, SLC30A7 transcripts, encoding zinc efflux transporters ZnT5, ZnT6, ZnT7, localized on endoplasmic reticulum membranes, might be part of a coordinated transcriptional program associated to the increased activity of the early secretory pathway, while transcriptional upregulation of several specific ZIP transporters (SLC39A6, SLC39A7, SLC39A9, SLC39A10, and SLC39A11) could contribute in meeting the increased demand of zinc in cancer cells.\nSLC30A5, a member of the solute transporter protein family, is implicated in tumorigenesis and cancer progression.\nZinc is a transition metal and catalytic cofactor involved in many biological processes including proliferation, development, differentiation, and metabolism.", "dois": ["10.7150/jca.97214", "PMID:37168332", "10.1002/jcb.27285", "PMID:17555576"]}
{"pair_type": "slc_pathway", "key1": "SLC30A7", "key2": "chemotherapy", "summary": "The low CupScore subtype was characterised by immune activation, isocitrate dehydrogenase mutations, sensitivity to chemotherapy, and clinical benefits.\nNovel cuproptosis regulator SLC30A7 knockdown inhibited the cuproptosi via JAK2/STAT3/ATP7A pathway in GBM.\nThe novel cuproptosis-related genes SLC30A7 was involved in regulation the tumorigenicity of GBM cell via JAK2/STAT3/ATP7A pathway and .\nThe high CupScore subtype was characterised by activation of the stroma and metabolism and poor survival.\nWe identified three distinct cuproptosis regulation patterns, including immune activation, metabolic activation, and immunometabolic double deletion patterns.\nThe CupScore was shown to predict the abundance of tumour inflammation, molecular subtype, stromal activity, gene variation, signalling pathways, and patient prognosis.\nCuproptosis regulators have been shown to play a vital role in TME complexity.\nConstructing CupScores were trained to evaluate the regulation patterns of cuproptosis in individual tumours.\nMachine learning strategies were used to construct a CupScore to quantify the cuproptosis regulation patterns of individual tumours.", "dois": ["10.18632/aging.205545"]}
{"pair_type": "slc_pathway", "key1": "SLC30A3", "key2": "proliferation", "summary": "Interestingly, 27 upregulated transcripts (e.g., Aqp1, Cacnb1, Atp1a2, Kcnab2, and Slc2a1) and 13 downregulated transcripts (e.g., Slc17a7, Slc9a4, and Slc30a3) are involved in the absorption of water, ions, and nutrients.\nGene ontology analysis suggested effects of CMA on cellular processes, such as cell adhesion, proliferation, fuel metabolism, and biotransformation.", "dois": ["10.1007/s11010-008-9931-1", "PMID:17555576"]}
{"pair_type": "slc_pathway", "key1": "SLC30A7", "key2": "apoptosis", "summary": "Furthermore, knock-down of NFE2L2 down-regulated its target HMOX1 gene expression, decreased SLC30A7 activity but increased HG-induced apoptosis.\nSLC30A7 was found to be up-regulated, while NFE2L2 was activated in kidneys of STZ-induced diabetic mice and HG-induced apoptosis of NRK-52E cells.\nThe current study provides new evidence that SLC30A7 has anti-oxidant stress effects in HG-induced apoptosis via the NFE2L2/HMOX1 signal transduction pathway.\nWe have previously reported that zinc transporter 7 in SLC30 family (SLC30A7) inhibits apoptosis in rat peritoneal mesothelial cells under high glucose (HG) conditions.\nExcessive expression of TP53 induces cell cycle arrest and apoptosis of hematopoietic cells in individuals with IBMF.\nThere were significantly increased production of ROS and depolarization in MMP and increases in marker proteins of mitochondria-associated apoptosis and autophagy in ZnT7-OE cells, similar to the PA-cells, parallel to increases in K-acetylation.\nExcessive expression of TP53 and down-regulation of AKT activation induced by ZNT7 deficiency might impair cell survival, which may contribute to the pathophysiology of bone marrow failure in affected individuals with BMF8.\nThe results showed that HG caused damage to HRMECs through the pyroptosis pathway rather than the apoptosis pathway.\nApoptosis and oxidant stress are known to be involved in the pathogenesis of diabetic kidney disease (DKD).\nIn the current study, we aimed to investigate whether SLC30A7 had effect for anti-oxidant stress in renal tubular epithelial cells under HG.", "dois": ["10.18632/aging.205545", "10.1177/09603271221099589", "10.1016/j.diabres.2020.108445", "10.1002/jcp.28692", "10.1016/j.jtemb.2025.127658", "10.1016/j.jtemb.2023.127198"]}
{"pair_type": "slc_pathway", "key1": "SLC30A7", "key2": "migration", "summary": "Following the knockdown of the CHAF1B gene, protein and mRNA levels of the PSMB6, SLC30A7 and SMC3 genes were significantly upregulated, while those of the BLM and TWF2 genes were significantly downregulated.\nOur experiments revealed that the knockdown of the CHAF1 gene reduced the invasion and migration ability of HUH-7 cells.\nThe knockdown of the CHAF1B gene inhibited tumor growth.", "dois": ["10.3892/or.2018.6437"]}
{"pair_type": "slc_pathway", "key1": "SLC30A7", "key2": "glycolysis", "summary": "In summary, circRNA_100290 serves as a ceRNA to counteract miR-378a-mediated GLUT1 suppression, thus promoting glycolysis and cell proliferation in OSCC.\ncircRNA_100290 could remarkably relieve miR-378a-induced inhibition on GLUT1 via acting as a competing endogenous RNA (ceRNA).\nReportedly, hsa_circular RNA (circRNA)_100290 (circ_SLC30A7) is significantly upregulated (fold change = 6.91, p < 0.0000001) in OSCC.\nGlucose transporter 1 (GLUT1), a major glucose transporter regulating the glucose uptake, is upregulated in OSCC and participated in the cell glycolysis of OSCC.\nIn OSCC cell lines, cell proliferation and glycolysis could be remarkably downregulated by circRNA_100290 silence, which could be rescued by GLUT1 overexpression.\nmiR-378a inhibition remarkably attenuated the effect of circRNA_100290 silence on cell proliferation and glycolysis in OSCC cell lines.", "dois": ["10.1002/jcp.28692"]}
{"pair_type": "slc_pathway", "key1": "SLC30A7", "key2": "proliferation", "summary": "Reportedly, hsa_circular RNA (circRNA)_100290 (circ_SLC30A7) is significantly upregulated (fold change = 6.91, p < 0.0000001) in OSCC.\nIn OSCC cell lines, cell proliferation and glycolysis could be remarkably downregulated by circRNA_100290 silence, which could be rescued by GLUT1 overexpression.\nIn summary, circRNA_100290 serves as a ceRNA to counteract miR-378a-mediated GLUT1 suppression, thus promoting glycolysis and cell proliferation in OSCC.\nmiR-378a inhibition remarkably attenuated the effect of circRNA_100290 silence on cell proliferation and glycolysis in OSCC cell lines.\nThe effect of miR-378a overexpression on OSCC cells was similar to those of circRNA_100290 silence.\nHerein, the expression of circRNA_100290 and GLUT1 remarkably increased in oral tumor tissue specimens and cells.\ncircRNA_100290 could remarkably relieve miR-378a-induced inhibition on GLUT1 via acting as a competing endogenous RNA (ceRNA).\nZinc is a transition metal and catalytic cofactor involved in many biological processes including proliferation, development, differentiation, and metabolism.\nUpregulation of SLC30A5, SLC30A6, SLC30A7 transcripts, encoding zinc efflux transporters ZnT5, ZnT6, ZnT7, localized on endoplasmic reticulum membranes, might be part of a coordinated transcriptional program associated to the increased activity of the early secretory pathway, while transcriptional upregulation of several specific ZIP transporters (SLC39A6, SLC39A7, SLC39A9, SLC39A10, and SLC39A11) could contribute in meeting the increased demand of zinc in cancer cells.", "dois": ["10.1002/jcp.28692", "10.1002/jcb.27285"]}
{"pair_type": "slc_pathway", "key1": "SLC30A7", "key2": "oxidative stress", "summary": "We observed Bonferroni-corrected statistically significant interactions between urine cadmium levels and polymorphisms in gene SLC30A7 and RAC1.\nGenetic variation in oxidative stress and cadmium metabolism and transport genes may confer differential susceptibility to potential cadmium effects.\nThe interaction of cadmium with genes involved in oxidative stress, cadmium metabolism and transport pathways on albuminuria can provide biological insight on the relationship between cadmium and albuminuria at low exposure levels.", "dois": ["10.1016/j.envint.2017.05.008", "10.1074/jbc.M117.817692"]}
{"pair_type": "slc_pathway", "key1": "SLC30A8", "key2": "proliferation", "summary": "ZnT8 haploinsufficiency disrupts expression of a distinct array of important β-cell markers, decreases cellular proliferation via mitogen-activated protein (MAP) kinase cascades and downregulates insulin gene expression.\nOverall, harmine, 2-2c and 5-IT are unique among DYRK1A inhibitors in their ability to enhance both beta cell proliferation and differentiation.\nTransient transfection of GBM cells with a miR-143 oligonucleotide inhibitor (miR-143-inh) resulted in reduced cell proliferation, increased apoptosis, and cell cycle arrest.\nRemarkably, the pro-differentiation effect is independent of DYRK1A inhibition: although silencing DYRK1A induces human beta cell proliferation, it has no effect on differentiation;\nThe small molecule DYRK1A inhibitor, harmine, induces human beta cell proliferation, expands beta cell mass, enhances expression of beta cell phenotypic genes, and improves human beta cell function i and .\nThis effect was not associated with enhanced β-cell proliferation or mass.\nHarmine, 2-2c and 5-IT increase expression of PDX1, MAFA, NKX6.1, SLC2A2, PCSK1, MAFB, SIX2, SLC2A2, SLC30A8, ENTPD3 in normal and T2D human islets.\nThe reduced in vitro cell growth and in vivo tumor growth following miRNA-143 inhibition suggests that miR-143 is a potential therapeutic target for GBM therapy.\nIn contrast to the hypothesis, lowered ZnT8 expression reduces MIN6 cell survival by affecting zinc-dependent transcription factors that control the β-cell phenotype.\nSLC30A8, a glucose metabolism-related protein, was identified as a direct target of miR-143 in GBM cells.\nWe used CRISPR/Cas9 technology to generate ZnT8 haploinsufficient mouse MIN6 β-cells and showed that ZnT8 haploinsufficiency is associated with downregulation of mRNAs for and , which encode", "dois": ["10.1101/2024.05.17.594179", "10.3390/ijms20215485", "10.3390/cancers10100382", "10.1073/pnas.1721418115", "PMID:20873210"]}
{"pair_type": "slc_pathway", "key1": "SLC30A9", "key2": "apoptosis", "summary": "Loss of SLC-25A25 suppresses the abnormal mitochondrial Zn accumulation and defective mitochondrial structure and functions caused by loss of SLC-30A9.\nLoss of SLC-30A9 leads to mitochondrial Zn accumulation, which damages mitochondria, impairs animal development and shortens the life span.\nZn is required for the activity of many mitochondrial proteins, which regulate mitochondrial dynamics, apoptosis and mitophagy.", "dois": ["10.1007/s13238-021-00881-4"]}
{"pair_type": "slc_pathway", "key1": "SLC30A9", "key2": "proliferation", "summary": "Genetic silencing of SLC30A9 suppressed DLBCL cell growth via regulating the activation of AMP-activated protein kinase (AMPK) pathway.\nDeletion of NAT10 expression inhibited cell proliferation and induced G0/G1 phase arrest.\nNAT10 regulated the mRNA stability of SLC30A9 in an ac4C-dependent manner.\nUpregulation of SLC30A5, SLC30A6, SLC30A7 transcripts, encoding zinc efflux transporters ZnT5, ZnT6, ZnT7, localized on endoplasmic reticulum membranes, might be part of a coordinated transcriptional program associated to the increased activity of the early secretory pathway, while transcriptional upregulation of several specific ZIP transporters (SLC39A6, SLC39A7, SLC39A9, SLC39A10, and SLC39A11) could contribute in meeting the increased demand of zinc in cancer cells.\nZinc is a transition metal and catalytic cofactor involved in many biological processes including proliferation, development, differentiation, and metabolism.\nAcRIP-seq identified solute carrier family 30 member 9 (SLC30A9) as a downstream target of NAT10 in DLBCL.\nSLC30A9, a nuclear receptor coactivator involved in the transcriptional regulation of Wnt-responsive genes, revealed the differential expression of alternative transcripts in CRC and normal colonic mucosa.\nNAT10-mediated ac4C modification regulated the occurrence and progression of DLBCL.\nHigh expression of NAT10 was associated with poor prognosis of DLBCL patients.\nFurthermore, knockout of NAT10 increased the sensitivity of DLBCL cells to ibrutinib.", "dois": ["10.1002/ctm2.1747", "10.1002/jcb.27285"]}
{"pair_type": "slc_pathway", "key1": "SLC30A8", "key2": "glycolysis", "summary": "Placental zinc transporters regulate insulin and glucagon secretion, as well as gluconeogenesis and glycolysis.\nOur findings implicate additive effects across pathophysiological pathways involved in type 2 diabetes, including glycolysis, gluconeogenesis, and insulin secretion.\nHK1 encodes the enzyme hexokinase, the first step in glycolysis and a likely candidate for the control of glucose metabolism.\nAdditionally, genes in glycolysis/gluconeogenesis, pyruvate metabolism, fatty acid metabolism, glutathione metabolism and one carbon pool by folate were differentially expressed in palmitate-treated human islets.", "dois": ["10.3390/jcm13123500", "10.1371/journal.pone.0269378", "10.1186/1741-7015-12-103", "10.1371/journal.pgen.1000312"]}
{"pair_type": "slc_pathway", "key1": "SLC30A9", "key2": "oxidative stress", "summary": "A mutation in SLC30A9, a zinc transporter, causes an increased sensitivity to oxidative stress in the nematode Caenorhabditis elegans.\noxy-7 showed increased production of ROS and decreased longevity due to its increased oxidative stress.\nWe further showed that knockdown of human SLC30A9 caused increased ROS production in human cells as well.\noxy-7(qa5004) which showed an increased sensitivity to ROS in C. elegans.\nThe lncRNA Xist expression is reduced under H/R conditions, followed by the increased level of miRNA-133c, thus downregulating the expression of Slc30a9.\nThe functional enrichment analyses revealed that the lncRNAs involved in the ceRNA network might functions in oxidative stress and calcium signaling pathway.\nGenetic analysis revealed that oxy-7 has a causative mutation in Y71H2AM.9, a homologue of SLC30A9 which encodes a zinc transporter in mitochondria.\nThese results suggested an important role of mitochondrial zinc homeostasis in the regulation of ROS.\nthe identified ceRNA network which included the lncRNA Xist/miR-133c/Slc30a9 axis might contribute a better understanding to the pathogenesis and development of MI/R injury and offer a novel targeted therapy way.\nMany genes are involved in the regulation of ROS.\nOxygen is essential for aerobic organisms, but generates reactive oxygen species (ROS), which can cause cellular dysfunction by damaging cellular molecules.\nTo identify these genes, we screened for mutants with an altered sensitivity to oxidative stress in the nematode Caenorhabditis elegans.", "dois": ["10.1016/j.bbrc.2022.09.107", "10.1155/2022/7260801"]}
{"pair_type": "slc_pathway", "key1": "SLC30A8", "key2": "oxidative stress", "summary": "Possession of common risk alleles at the SLC30A8 locus, encoding the beta-cell granule zinc transporter ZnT8, may affect cytosolic Zn concentrations and thus susceptibility to hypoxia and oxidative stress.\nAccumulating evidence points to a role for oxidative stress in both processes.\nAlthough the production of reactive oxygen species (ROS) results from enhanced mitochondrial respiration during stimulation with glucose and other fuels, the expression of antioxidant defense genes is unusually low (or disallowed) in beta cells.\nBetter understanding of the role of oxidative changes, its modulation by genes involved in disease risk, and effects on beta-cell identity may facilitate the development of new therapeutic strategies to this disease.\nEvidence of oxidative stress was provided by upregulation of several metallothionein genes.\nSeveral studies demonstrated that neuroendocrine axis dysfunction, insulin resistance, oxidative stress, chronic inflammatory response, and gut microbiota dysbiosis are core pathological links associated with it.\nRecent Advances: Oversupply of nutrients, including glucose and fatty acids, and the subsequent overstimulation of beta cells, are believed to be an important contributor to insulin secretory failure in T2D.\nHypoxia has also recently been implicated in beta-cell damage.\nIGF2BP2, TSPAN8, and HNF1B (TCF2) were upregulated while JAZF1 and SLC30A8 were downregulated.\nThere were changes in expression of genes linked to glucotoxicity.", "dois": ["10.1089/ars.2016.6755", "10.1074/jbc.M111.246082", "10.1017/S0967199425000061", "10.1016/j.csbj.2022.10.030", "PMID:24476591", "10.1371/journal.pone.0011499"]}
{"pair_type": "slc_pathway", "key1": "SLC31A1", "key2": "ferroptosis", "summary": "EDB treatment significantly alleviated ferroptosis and cuproptosis in MCAO mice and OGD/R models of neuronal, in vitro and in vivo, the protective pathway of ferroptosis SLC7A11/GPX4 was detected to be activated and the cuproptosis-promoting protein SLC31A1 and FDX1 were down-regulated.\nOur findings establish a fundamental pathogenic SLC31A1/KDM5B/FTH1 molecular axis linking dysregulated copper metabolism and cuproptosis to ferroptosis execution in psoriasis and AD, providing significant mechanistic insights and pinpointing promising therapeutic targets for these refractory skin disorders.\nFunctional validation using disease models showed that pharmacologically inhibiting cuproptosis with the copper chelator tetrathiomolybdate (TTM), or genetically knocking down the copper importer SLC31A1, effectively alleviated chronic skin inflammation and hallmark pathological changes induced by imiquimod (IMQ) or calcipotriol (MC903).\nMechanistically, we uncovered that SLC31A1-mediated cuproptosis promotes intracellular α-ketoglutarate (α-KG) accumulation, driving activation of the lysine demethylase KDM5B.\nActivated KDM5B specifically demethylates H3K4me3 marks at the promoter of the ferroptosis regulator ferritin heavy chain 1 (FTH1), suppressing its transcription and consequently sensitizing keratinocytes to ferroptotic cell death, thereby amplifying inflammatory tissue damage.\niron-dependent ferroptosis correlating with Th22/Th17 responses, copper-dependent cuproptosis with elevated MTF1/ATP7B/SLC31A1 expression, and NETosis amplifying immune responses through interaction with the Th17 axis.\nHowever, at high concentrations, copper ions show increased toxicity by inducing regulated cell death, such as apoptosis, paraptosis, pyroptosis, ferroptosis, and cuproptosis.", "dois": ["10.3390/ijms26083747", "10.1007/s11011-025-01559-0", "10.1016/j.mito.2023.05.003", "10.1002/mco2.70425", "10.62347/LOYI1808", "10.1080/15548627.2023.2200554"]}
{"pair_type": "slc_pathway", "key1": "SLC31A1", "key2": "stemness", "summary": "ID1 depletion freed TCF12 to transactivate the cisplatin influx transporter SLC31A1, increasing intracellular cisplatin levels and cytotoxicity.\nFurther autophagy stimulation by serum-starvation and chemical modes triggered proteolysis of the stemness regulator ID1, driving the differentiation of chemo-resistant CSCs into chemo-sensitive non-CSCs.\nIn addition, CRGs were significantly correlated with RNA stemness score, DNA stemness score, microsatellite instability, and tumor mutational burden.\nThis study reveals a novel autophagy-ID1-TCF12-SLC31A1 axis where targeted autophagic degradation of ID1 enables rapid remodeling of CSCs to reverse chemo-resistance.\nPatient-derived tumor spheroids exhibited a functional association between autophagy, ID1, SLC31A1, and platinum sensitivity.\nOvarian CSCs exhibited increased basal autophagy compared to non-CSCs.\nThis study investigated the role of targeted autophagic protein degradation in regulating ovarian cancer stem cell (CSC) fate decisions and chemo-resistance.", "dois": ["10.1113/EP092310", "10.1186/s13046-024-03147-z", "10.3389/fonc.2022.934076"]}
{"pair_type": "slc_pathway", "key1": "SLC31A2", "key2": "chemotherapy", "summary": "In tumors from patients pretreated with protein kinase inhibitors (PKIs), genes encoding for specific copper (SLC31A1 and SLC31A2, χ-test adjusted p-values: 6.9e-09 and 2.5e-09) and nucleoside transporters (SLC28A2 and SLC28A3, χ-test adjusted p-values: 3.5e-06 and 6.8e-07) were deleted significantly more frequently than in patients pretreated with chemotherapy.\nThese findings contradict mechanisms of selective pressure, as they would be expected to originate during treatment with chemotherapy rather than with PKIs.\nThe protective effect of chemotherapy on CBC risk was statistically significant only among patients with an elevated PRS (P = 0.04).\nWe observed two loci (rs59657211, 9q32, SLC31A2/FAM225A and rs3815096, 6p22.1, TRIM31) with suggestive genome-wide significant associations (P < 1 × 10).\nDrug resistance is a perpetual problem in cancer therapy with many underlying mechanisms.\nAlterations in drug transport over the cancer cell membrane can severely alter intratumoral drug exposure, contributing to resistance.\nThe selection of effective genes that accurately predict chemotherapy responses might improve cancer outcomes.\nMoreover, we detected 16 transporters that were differentially expressed at RNA level between these treatment groups.", "dois": ["10.1186/s13058-024-01765-1", "10.1016/j.biopha.2022.114210", "10.1038/s41392-018-0034-5"]}
{"pair_type": "slc_pathway", "key1": "SLC31A1", "key2": "chemotherapy", "summary": "ELF3 transcriptionally activated SLC31A1 to trigger cuproptosis that drove cisplatin-induced AKI through mitochondrial dysfunction, indicating that SLC31A1 might be a promising therapeutic target to mitigate AKI during cisplatin chemotherapy.\nZNF711 down-regulation promoted, while ZNF711 overexpression drastically inhibited CDDP resistance, both in vivo and in vitro.\nMechanistically, the histone demethylase JHDM2A was recruited to the SLC31A1 promoter by ZNF711 and decreased the H3K9me2 level, resulting in the activation of SLC31A1 transcription and enhancement of CDDP uptake.\nZNF711 down-regulation exerts a great impact on CDDP resistance for EOC patients by suppressing SLC31A1 and inhibiting CDDP influx.\nSLC31A1 silencing restored renal function, alleviated mitochondrial dysfunction, and apoptosis in cisplatin-induced AKI mice.\nE74 like ETS transcription factor 3 (ELF3) could directly bind to SLC31A1 promoter and promote its transcription.\nELF3 was up-regulated and positively correlated with SLC31A1 expression upon cisplatin-induced AKI.\nSLC31A1 level was predominantly increased by cisplatin exposure in AKI models.\nMoreover, Cu supplementation intensified cisplatin-induced cell death, mitochondrial dysfunction, and oxidative stress in HK-2 cells, indicating the involvement of cuproptosis in cisplatin-induced AKI, whereas these changes were partially counteracted by SLC31A1 knockdown.\nKnock-down of PTBP1 can enhance the anti-proliferation and apoptosis-induced effects of cisplatin in MG-63 and U-2OS cells.\nMoreover, PTBP1 knock-down significantly up-regulated the expression of the copper transporter SLC31A1, as indicated by transcriptome sequencing.", "dois": ["10.1016/j.cbi.2024.110943", "10.1002/tox.24067", "10.1111/cns.14380", "10.1186/s12885-023-10966-4", "10.1016/j.biopha.2022.114210", "10.3389/fphar.2022.934722", "10.1016/j.ebiom.2021.103558", "10.1007/s10388-021-00865-7", "10.7150/jca.51621", "10.1007/s12032-020-01450-1", "10.1111/jcmm.15183", "10.18632/oncotarget.24962", "10.18632/oncotarget.24794", "10.1177/1010428317707372", "10.1371/journal.pone.0108908", "10.1002/bdd.1903"]}
{"pair_type": "slc_pathway", "key1": "SLC30A8", "key2": "apoptosis", "summary": "Being the more sensitive transporter, we further explored ZnT8 (Slc30A8): the effect of ZnT8 over expression on cytokine induced apoptosis was investigated as well as expression of the insulin gene and two apoptosis associated genes, BAX and BCL2.\nOur study provides evidence that ZnT8 has protective effects against apoptosis of renal tubular epithelial cells through induction of TNFAIP3 and subsequent suppression of the NF-κB pathway.\nAlso, ZnT8 over-expression after hZnT8-EGFP transfection significantly ameliorates HG-induced NF-κB-dependent transcriptional activity and apoptotic protein expressions in NRK-52E cells, but the inhibitory effect of ZnT8 was significantly abolished with TNFAIP3 siRNA.\nFurthermore, treatment with ZnSO blunted HG-induced apoptosis and NF-κB activation.\nHigh glucose (HG)-induced apoptosis in a normal rat kidney tubular epithelial cell line (NRK-52E cells) was performed in vitro.\nZnT8 overexpression after hZnT8-EGFP transfection decreased HG-stimulated inflammatory activity and apoptosis in NRK-52E cells.\nUrine albumin to creatinine ratio, proinflammatory cytokines, and apoptosis were enhanced in kidneys of STZ and ZnT8-KO-STZ mice compared to control or ZnT8-KO mice.\nZnT8 over expressing cells were more sensitive to IL-1beta induced apoptosis whereas no differences were observed with IFN-gamma, TNF-alpha, or a mixture of cytokines.\nInterestingly, sc-beta cells with the KO mutation showed increased cytoplasmic zinc, and cells with either KO or R138X mutation were resistant to apoptosis when extracellular zinc was limiting.\nKO cells were not viable and displayed elevated markers for ER stress and apoptosis.\nApoptosis of kidney tubular epithelial cells contributes to diabetic kidney disease (DKD) pathophys", "dois": ["10.3390/cells12060903", "10.1530/JOE-21-0271", "10.1007/s00125-019-05046-x", "10.1186/1741-7015-12-103", "10.1371/journal.pone.0011499", "10.1007/s12011-022-03361-w", "10.12688/wellcomeopenres.15447.2", "10.1074/jbc.RA119.010937", "10.3390/cancers10100382", "10.1186/1472-6823-9-7", "10.1097/MED.0b013e328308192b"]}
{"pair_type": "slc_pathway", "key1": "SLC32A1", "key2": "chemotherapy", "summary": "Cognitive impairment caused by systemic chemotherapy is a critical question that perplexes the effective implementation of clinical treatment, but related molecular events are poorly understood.\nHerein, we show that bortezomib exposure leads to microglia activation and cognitive impairment, this occurs along with decreased nuclear translocation of TFEB (transcription factor EB), which is linked to macroautophagy/autophagy disorder, STAT3 (signal transducer and activator of transcription 3) phosphorylation and IL23A (interleukin 23 subunit alpha) expression.\nOur results suggest the reversal of TFEB nuclear translocation may provide a novel therapeutic approach to prevent symptoms of cognitive dysfunction during clinical use of bortezomib.", "dois": ["10.1080/15548627.2022.2162244"]}
{"pair_type": "slc_pathway", "key1": "SLC31A1", "key2": "migration", "summary": "Treatment with si-METTL3 or oe-SLC31A1 suggested increased cell viability, proliferation, migration and invasion, and reduced cell damage and apoptosis rate, while cells treated with oe-METTL3 or si-SLC31A1 had reversed results.\nAdditionally, restored miR-375 expression resulted in suppressed cell proliferation, migration and invasion, and increased apoptosis by targeting SLC31A1.\nUp-regulating SLC31A1 partially reversed the inhibitory effect of METTL3 on HTR-8SV/neo cell migration and invasion.\nMETTL3 reduces SLC31A1 mRNA stability and down-regulates its expression in an mA-YTHDF2-dependent manner, thereby inhibiting trophoblast migration and invasion.\nIn vitro study shows that SLC31A1 can promote cell proliferation, and migration, and depress the cell apoptosis of glioma cells.\nThe in vitro KD experiment shows the SLC31A1 knockdown depressed the glioma cell proliferation and migration and promoted the apoptosis rate.\nFurther functional analysis of SLC31A1 showed that its elevation was associated with increased glioma cell malignancy, promoting proliferation and migration.\nAdditionally, treatment with the mitotic inhibitor MP-HJ-1b markedly suppressed SLC31A1 expression, consequently inhibiting glioma cell proliferation and migration.\nThe proliferation, migration, and invasiveness of Her2 + enriched BC cells were decreased by SLC31A1 knockdown, also resulting in a decrease in tumor volume in mouse model.\nNext, in vitro experiments demonstrated that hMSC-derived exosomes overexpressing miR-375 promoted apoptosis while suppressing proliferation, migration and invasion.\nMETTL3 reduced SLC31A1 mRNA stability and inhibited SLC31A1 expression through mA modification in a YTHDF2-dependent manner.\nWe conclude that exosomal miR-375 from hMSCs inhibits glioma cell progression through SLC31A1 suppression, and ultimately serves as a potential target in the treatment of gliomas", "dois": ["10.1016/j.abb.2025.110651", "10.1007/s00432-025-06191-0", "10.1186/s12885-025-14151-7", "10.1016/j.placenta.2025.03.004", "10.1007/s00210-024-03731-2", "10.1038/s41598-024-76162-x", "10.1016/j.heliyon.2024.e36445", "10.1007/s10142-023-01210-0", "10.1021/acs.molpharmaceut.3c00276", "10.1038/s41417-019-0079-9", "10.1111/cpr.12568", "10.1177/1010428317707372", "PMID:11391004"]}
{"pair_type": "slc_pathway", "key1": "SLC31A2", "key2": "apoptosis", "summary": "CTR2S29L leads to increased intracellular Cu concentration and Cu-induced apoptosis in cultured cell lines.\nThe polytons identified were mostly endoplasmic reticulum-located, integral proteins involved in protein maturation, N-glycosylation, protein folding, anterograde transport of proteins, protein secretion, and the regulation of apoptosis.\nPyroptosis was also related to a better response of melanoma to interferon-α, paclitaxel, cisplatin and imatinib.\nA higher pyroptosis score was associated with a more favorable overall survival.\nOur results demonstrated that pyroptosis is a protective factor associated with melanoma prognosis.\nPyroptosis, as a special programmed cell death process that releases inflammatory factors and has been widely studied in tumors, but its role in melanoma has not been fully elucidated.\nInterestingly, we found that the elevated infiltration of multiple immune cells, such as CD4 T cells, CD8 T cells, dendritic cells, and M1 macrophages, may be associated with the occurrence of pyroptosis.", "dois": ["10.31083/j.fbl2903123", "10.7150/ijms.83009", "10.1038/s41598-022-24879-y", "10.1093/mtomcs/mfac024", "10.1684/mrh.2013.0339", "10.1097/FPC.0b013e328352f436"]}
{"pair_type": "slc_pathway", "key1": "SLC31A1", "key2": "glycolysis", "summary": "In summary, ARNTL2 facilitates the progression of BLCA via activating ENO1-mediated glycolysis in a SLC31A1-independent and -dependent manner.\nUp-regulation of SLC31A1, ENO1, and enhancement of SLC31A1-mediated ENO1 activity were critical for ARNTL2-triggered glycolysis and malignant growth in BLCA cells.\nDepletion of SLC31A1 and inhibition of glycolysis completely blunted the growth ability of BLCA cells.\nInhibiting SLC31A1 and glycolysis may be an aspirational approach for the treatment of BLCA patients with overexpression of ARNTL2.\nFibroblast-specific SLC31A1 deficiency enhances mitochondrial copper depletion, augments glycolysis, promotes fibroblast proliferation and triggers CF.\nOverexpression of ARNTL2 facilitates the proliferation and tumorigenesis of BLCA cells through suppression of apoptosis and enhancement of glycolysis.\nFurthermore, FX decreases whole‑cell ATP levels, which indicates that promotion of glycolysis does not compensate for FX‑induced ATP depletion in mitochondria.\nThese changes were associated with mitochondrial copper depletion, enhanced glycolysis, and CF.\nFX switches mitochondrial respiration to aerobic glycolysis in PC cells.\nTargeted deletion of CTR1 in neuroblastoma cells produced copper deficiency that was associated with a metabolic shift favoring glycolysis over oxidative phosphorylation.\nARNTL2 was positively correlated with SLC31A1 and ENO1 in BLCA patients.\nLower copper concentrations are accompanied by SLC31A1 down-regulation and mitochondrial copper depletion in CF.", "dois": ["10.3892/ijo.2025.5737", "10.1016/j.lfs.2024.122974", "10.1093/eurheartj/ehaf130", "10.1091/mbc.E24-11-0512", "10.1101/2024.09.09.612106", "10.1007/s00277-024-05841-6"]}
{"pair_type": "slc_pathway", "key1": "SLC32A1", "key2": "apoptosis", "summary": "Simultaneously, Hcy promotes neuronal apoptosis and LDH leakage in mouse neuroblastoma (N2a) cells.\nFurthermore, it was observed that four genes (snap25, cplx1, slc32a1 and atp6v1e2) related to the synaptic vesicle cycle exhibited decreased expression in Hcy-treated N2a cells compared to the Control group.\nPathological damage and apoptosis were detected in the DG, CA3, and CA1 regions of the hippocampus, along with the cortical area.\nPANoptosis represents an emerging paradigm in programmed cell death, integrating three critical processes: pyroptosis, apoptosis, and necroptosis.\nAdditionally, ten hub genes, SLC17A7, SNAP25, GAD1, SLC17A6, SLC32A1, PVALB, SYP, GRIN2A, SLC12A5, and SYN2, were identified as marker genes for the early subtype.\nStudies have shown that apoptosis, necroptosis, and pyroptosis play important roles in AD development.\nThe results highlighted significant alterations in 457 mRNAs in the Hcy-treated group compared to the Control group.\nThe expression levels of these four genes, as well as their corresponding proteins, were subsequently confirmed using RT-qPCR and western blot analysis, respectively.\nMoreover, synaptic structural impairment was observed within the hippocampal.\nOur research findings demonstrate that Hcy induces depressive - like symptoms in normal Sprague-Dawley rats.\nIn conclusion, this study shed light on the detrimental impact of hyperhomocysteinemia on the nervous system, particularly with regard to the synaptic vesicle cycle.\nSingle-cell RNA sequencing analysis revealed that key genes associated with the early subtype are predominantly expressed in neuronal cells, while the differential genes for the metabolic subtype are primarily found in endothelial cells and astrocytes.", "dois": ["10.1038/s41598-025-98306-3", "10.3389/fimmu.2024.1462003"]}
{"pair_type": "slc_pathway", "key1": "SLC32A1", "key2": "proliferation", "summary": "ATRA or UDP-4 treatment inhibited the cell growth and promoted limited cell death, but to a different extent.", "dois": ["10.3390/biom12020218"]}
{"pair_type": "slc_pathway", "key1": "SLC33A1", "key2": "apoptosis", "summary": "Moreover, the potential mechanism of annonacin () was predicted by transcriptomic analysis, which suggested that SLC33A1 is a potential target in HCC.\nAnnonacin () and muricin P (), which reduced intracellular ATP levels and promoted apoptosis, exhibited synergistic cytotoxicity with sorafenib.\nannonacin () displayed synergistic antitumor activity by promoting tumor cell apoptosis.", "dois": ["10.1021/acs.jnatprod.3c00667", "10.3390/ijerph17165866"]}
{"pair_type": "slc_pathway", "key1": "SLC31A1", "key2": "oxidative phosphorylation", "summary": "Targeted deletion of CTR1 in neuroblastoma cells produced copper deficiency that was associated with a metabolic shift favoring glycolysis over oxidative phosphorylation.", "dois": ["10.1091/mbc.E24-11-0512", "10.1101/2024.09.09.612106"]}
{"pair_type": "slc_pathway", "key1": "SLC34A1", "key2": "chemotherapy", "summary": "Our results also suggested that MXD3 expression is associated with immune or chemotherapeutic outcomes in various cancers.\nhigher MXD3 expression levels were associated with decreased sensitivity of cancer cell lines to several mitogen-activated protein kinase kinase (MEK) inhibitors but led to increased activities of other kinase inhibitors, including Akt inhibitors.\nMXD3 exhibited higher predictive power for response outcomes and overall survival of immune checkpoint blockade sub-cohorts than three of seven standardized biomarkers.\nMethylation of MXD3 was inversely associated with messenger (m)RNA expression levels and mediated dysfunctional T-cell phenotypes and worse prognoses of cohorts from different cancer types.\nOur results also suggested that MXD3 is associated with tumor immune evasion via different mechanisms involving T-cell exclusion in different cancer types and by tumor infiltration of immune cells in thymoma (THYM), liver hepatocellular carcinoma (LIHC), and head and neck squamous cell carcinoma (HNSC).\nMXD3 was aberrantly expressed in almost all The Cancer Genome Atlas (TCGA) cancer types and subtypes and was associated with the tumor stage, metastasis, and worse prognoses of various cohorts.\nour study strongly suggests that MXD3 is an immune-oncogenic molecule and could serve as a biomarker for cancer detection, prognosis, therapeutic design, and follow-up.", "dois": ["10.1016/j.csbj.2021.08.047"]}
{"pair_type": "slc_pathway", "key1": "SLC31A1", "key2": "proliferation", "summary": "MiR-522-3p inhibited proliferation and activation by regulating SLC31A1 expression in T cells.\nTreatment with si-METTL3 or oe-SLC31A1 suggested increased cell viability, proliferation, migration and invasion, and reduced cell damage and apoptosis rate, while cells treated with oe-METTL3 or si-SLC31A1 had reversed results.\nLentivirus knockdown of SLC31A1 blocked the lactate-induced proliferation and invasion of trophoblasts by inhibiting cell cuproptosis.\nElevated SLC31A1 expression increases intracellular copper, inducing cuproptosis and inhibiting ESCC cell proliferation and tumor growth.\nAdditionally, restored miR-375 expression resulted in suppressed cell proliferation, migration and invasion, and increased apoptosis by targeting SLC31A1.\nMechanically, we identified that Grhl2 mediated SLC31A1 expression through transcription and participated in SLC31A1-inhibited proliferation, invasion, and cuproptosis of trophoblasts.\nConversely, promoting SLC31A1 significantly facilitated the proliferation and invasion of wild-type breast cancer cells.\nIn vitro study shows that SLC31A1 can promote cell proliferation, and migration, and depress the cell apoptosis of glioma cells.\nSLC31A1 knockdown significantly reduces cell proliferation and mobility.\nThe in vitro KD experiment shows the SLC31A1 knockdown depressed the glioma cell proliferation and migration and promoted the apoptosis rate.\nFibroblast-specific SLC31A1 deficiency enhances mitochondrial copper depletion, augments glycolysis, promotes fibroblast proliferation and triggers CF.\nFurther functional analysis of SLC31A1 showed that its elevation was associated with increased glioma cell malignancy, promoting proliferation and migration.\nAdditionally, treatment with the mitotic inhibitor MP-HJ-1b markedly suppressed SLC31A1 expression, consequently inhibiting glioma cell proliferation and migration.\nThe proliferation, migration, and invasiveness of Her2 + enriche", "dois": ["10.1016/j.bbagen.2025.130876", "10.1016/j.abb.2025.110651", "10.1002/advs.202502501", "10.1186/s12885-025-14151-7", "10.1016/j.placenta.2025.03.004", "10.3892/ijo.2025.5737", "10.1093/eurheartj/ehaf130", "10.1016/j.sleep.2025.01.025", "10.1016/j.neo.2025.101125", "10.1007/s00210-024-03731-2", "10.1007/s12011-024-04440-w", "10.1038/s41598-024-76162-x", "10.1007/s10616-024-00658-7", "10.1016/j.heliyon.2024.e36445", "10.1007/s10815-024-03256-w", "10.1016/j.lfs.2024.122974", "10.1016/j.jep.2024.118444", "10.1016/j.heliyon.2024.e29212", "10.1038/s41598-023-44681-8", "10.1007/s10142-023-01210-0", "10.1021/acs.molpharmaceut.3c00276", "10.3390/biology12010100", "10.1007/s10616-021-00472-5", "10.1111/jcmm.15183", "10.1038/s41417-019-0079-9", "10.1111/cpr.12568", "10.1002/bdd.1903"]}
{"pair_type": "slc_pathway", "key1": "SLC34A1", "key2": "apoptosis", "summary": "We previously reported that the sodium-phosphate cotransporter NaPi-IIa (SLC34A1) mediated the reabsorption of lithium in the rat kidney.\nGSK3β plays a role in apoptosis and some kinds of acute kidney injuries, and the formation of p-GSK3β is considered to contribute to protection against acute kidney injury.\nR26tdTomato proximal tubular-specific reporter mice revealed that KU55933 upregulated p53 and subsequent pro-apoptotic signaling in tubular epithelia of cisplatin-treated mice, leading to marked mitochondrial injury and apoptosis.", "dois": ["10.1038/s41598-020-61456-7", "10.1016/j.dmpk.2016.02.003"]}
{"pair_type": "slc_pathway", "key1": "SLC34A1", "key2": "oxidative stress", "summary": "Their functional roles were mainly categorized as stone matrix, calcium and phosphate regulation, urinary concentration and constitution, and inflammation/oxidative stress.\nIPA network analysis revealed that these genes connected via signaling pathways and a proinflammatory/oxidative environment.", "dois": ["10.1016/j.euf.2017.04.010"]}
{"pair_type": "slc_pathway", "key1": "SLC33A1", "key2": "oxidative phosphorylation", "summary": "I have carefully reviewed the provided source text, which appears to be from a single paper about transcriptional profiling in type 2 diabetes mellitus.\nUnfortunately, I cannot find any verbatim phrases or sentences in this text that explicitly describe a relationship between SLC33A1 and oxidative phosphorylation. The text does not mention SLC33A1 at all, and while it references disease pathways generally, it does not provide specific details about oxidative phosphorylation or its relationship to any SLC transporter.\nThe excerpts provided are too general and do not contain the specific entities requested (SLC33A1 and oxidative phosphorylation) in any meaningful relationship context.", "dois": ["10.3390/ijerph17165866"]}
{"pair_type": "slc_pathway", "key1": "SLC34A2", "key2": "chemotherapy", "summary": "Furthermore, we demonstrated that SLC34A2 induced chemoresistance in BCSCs via SLC34A2-Bmi1-ABCC5 signaling.\nNotably, patients with SLC34A2-EPHB1, CCT6P3-GSTP1, and BARHL2-APC fusions showed sensitivity to the combination of chemotherapy and immunotherapy.\nIn conclusion, our work indicated that decreased SLC34A2 expression sensitized BCSCs to doxorubicin via SLC34A2-Bmi1-ABCC5 signaling and shed new light on understanding the mechanism of chemoresistance in BCSCs.\nSignificantly, enhanced SLC34A2 expression correlated with chemoresponse and survival of breast cancer patients.\nWe subsequently indicated that increased SLC34A2 expression in BCSCs directly contributed to their chemoresistance by a series of in vitro and in vivo experiments.\nFurther function study demonstrated that overexpression of miR-939 suppressed GC cell growth, and enhanced 5-fluorouracil-induced chemosensitivity by compromising cellular growth and inducing apoptosis in vitro and in vivo.\nMechanistically, we elucidated that miR-939 exerted its function mainly through inhibiting SLC34A2/Raf/MEK/ERK pathway, which is activated in GC.\nWe detected that reduced expression of miR-939 was associated with chemoresistance and increased risk of tumor recurrence in GC patients.\nMultivariate analysis identified miR-939, SLC34A2, and their combination as independent indicators for poor prognosis and tumor recurrence in GC patients.\nFollowing sorting of CD44(+)CD24(-) cells from spheres, we showed that CD44(+)CD24(-) cells displayed stem cell-like features and were resistant to chemotherapy drug doxorubicin.\nOur data indicate that miR-939 acts as a tumor suppressor miRNA in GC, and miR-939/SLC34A2 axis represents a novel therapeutic strategy for future GC treatment.\nWe further identified solute carrier family 34 member 2 (SLC34A2)", "dois": ["10.1177/03000605251394187", "10.1002/gcc.23258", "10.1016/j.bbrep.2021.101104", "10.1002/ijc.30674", "10.1186/s12943-017-0586-y", "10.1007/s13277-015-4226-0", "10.1002/cncr.27967"]}
{"pair_type": "slc_pathway", "key1": "SLC31A1", "key2": "apoptosis", "summary": "Treatment with si-METTL3 or oe-SLC31A1 suggested increased cell viability, proliferation, migration and invasion, and reduced cell damage and apoptosis rate, while cells treated with oe-METTL3 or si-SLC31A1 had reversed results.\nAdditionally, restored miR-375 expression resulted in suppressed cell proliferation, migration and invasion, and increased apoptosis by targeting SLC31A1.\nSLC31A1 silencing restored renal function, alleviated mitochondrial dysfunction, and apoptosis in cisplatin-induced AKI mice.\nIn vitro study shows that SLC31A1 can promote cell proliferation, and migration, and depress the cell apoptosis of glioma cells.\nThe in vitro KD experiment shows the SLC31A1 knockdown depressed the glioma cell proliferation and migration and promoted the apoptosis rate.\nIntriguingly, copper exposure dose-dependently increased CPT1A expression in chemoresistant breast cancer cells, but this could be abolished upon SLC31A1 knockdown, along with enhanced apoptosis, which elucidated that copper uptake contributed to CPT1A expression.\nPX478 (an HIF‑1 inhibitor) acted with DSF to enhance the inhibitory effects on the viability and on the induction of apoptosis of A549 cells.\nKnocking down SIRT7 caused cuproptosis of HeLa and SiHa cells, characterized by increased Cu content, disrupted mitochondrial structure, decreased membrane potential, elevated ROS production, and upregulation of cuproptosis-related proteins SLC31A1 and HSP70, and downregulation of FDX1, LIAS and DLAT.\nThe LNP-miR-155 cy5 inhibitor reduced cell proliferation, migration, and colony formation and promoted cell apoptosis.\nThe conditioned medium from these macrophages markedly inhibited TNBC cell migration and invasion, while promoting apoptosis.\nLentivirus knockdown of SLC31A1 blocked the lactate-induced proliferation and invasion of trophoblasts by inhibiting cell cupr", "dois": ["10.1007/s00432-025-06191-0", "10.1021/acsnano.5c02892", "10.3390/ijms26083747", "10.3892/ijo.2025.5737", "10.1016/j.intimp.2025.114165", "10.1186/s40001-024-02093-y", "10.1007/s10815-024-03256-w", "10.1016/j.lfs.2024.122974", "10.1016/j.intimp.2024.112574", "10.1016/j.cbi.2024.110943", "10.1016/j.gene.2024.148191", "10.1016/j.intimp.2023.111326", "10.1002/tox.24067", "10.1038/s41598-023-45761-5", "10.1038/s41598-023-44681-8", "10.3390/medicina59091639", "10.1186/s41065-023-00297-6", "10.1007/s10142-023-01210-0", "10.1007/s10528-023-10473-y", "10.1111/cns.14380", "10.7150/ijms.83009", "10.1111/crj.13633", "10.3389/fimmu.2023.1164667", "10.1016/j.mito.2023.05.003", "10.1080/15548627.2023.2200554", "10.3390/ijms24021667", "10.1007/s00432-022-04471-7", "10.1186/s12859-022-04894-6", "10.1007/s11356-021-14853-y", "10.1111/jcmm.15183", "10.1111/cpr.12568", "10.1177/1010428317707372", "PMID:15361835", "10.1016/j.abb.2025.110651", "10.1016/j.placenta.2025.03.004", "10.1016/j.neo.2025.101125", "10.1016/j.heliyon.2024.e37007", "10.1186/s13046-024-03147-z", "10.1007/s00277-024-05841-6", "10.3892/ijmm.2023.5343", "10.1021/acs.molpharmaceut.3c00276", "10.3390/biology12010100", "10.1038/s41417-019-0079-9", "10.4161/cc.23275"]}
{"pair_type": "slc_pathway", "key1": "SLC34A2", "key2": "oxidative stress", "summary": "SPAK (SPS1-related proline/alanine-rich kinase) and OSR1 (oxidative stress-responsive kinase 1), kinases controlled by WNK (with-no-K[Lys] kinase), are powerful regulators of cellular ion transport and blood pressure.\nSPAK and OSR1 both increased the maximal transport rate of the carrier.\nI(Pi) was observed in NaPi-IIb expressing oocytes but not in water injected oocytes, and was significantly increased by co-expression of SPAK, (T233E)SPAK, OSR1, (T185E)OSR1 or SPAK+OSR1, but not by co-expression of (T233A)SPAK, (D212A)SPAK, (T185A)OSR1, or (D164A)OSR1.\nSPAK and OSR1 are powerful stimulators of the intestinal Na+-coupled phosphate co-transporter NaPi-IIb.", "dois": ["10.1159/000368531"]}
{"pair_type": "slc_pathway", "key1": "SLC34A2", "key2": "apoptosis", "summary": "In cellular assays in vitro, knockdown of SLC34A2 dramatically inhibited the proliferation and colony formation, induced the apoptosis and arrests the cell cycle progression of HCT-116 CRC cells.\nIn cellular assays in vivo, knockdown of SLC34A2 significantly inhibited the growth of xenografts, decreasing Ki-67 and proliferating cell nuclear antigen (PCNA) expression and increasing apoptosis rate.\nConversely, inhibiting miR-124-3p in NSCLC cells led to increased cell viability and reduced apoptosis.\nOverexpression of miR-124-3p reduced NSCLC cell resistance to gefitinib by suppressing cell viability, inducing apoptosis, and decreasing N-cadherin expression.\nOur results suggest that additional Met supplementation with 20 μg/mL may promote the synthesis of milk proteins in bovine mammary epithelial cells under hyperthermia by inhibiting apoptosis, activating the AKT-mTOR-RPS6KB1 signalling pathway, and regulating the entry of amino acids into these cells.\nIt suppresses cell proliferation, induces cell cycle arrest, and apoptosis, and inhibits clonogenicity.\nFunctional assays revealed that MOGAT2 knockdown in H1299 cells promoted proliferation and migration, induced G2 cell cycle arrest, and decreased apoptosis.\nFurther function study demonstrated that overexpression of miR-939 suppressed GC cell growth, and enhanced 5-fluorouracil-induced chemosensitivity by compromising cellular growth and inducing apoptosis in vitro and in vivo.\nOur results show that additional Met supplementation increases the mRNA and protein levels of BCL2 (B-cell lymphoma-2, an anti-apoptosis agent), and decreases the mRNA and protein levels of BAX (Bcl-2-associated X protein, a pro-apoptosis agent), especially at an additional supplementary concentration of 20 μg/mL (group Met80).\nHowever, we observed a dose-response increase of phosphorylated-Erk1/2, suggesting the involvement of the MAPK pathway in the me", "dois": ["10.1016/j.mrfmmm.2024.111894", "10.1016/j.bioorg.2024.107590", "10.1158/1078-0432.CCR-19-3321", "10.18632/oncotarget.7538", "PMID:25691052", "10.1152/physiolgenomics.00059.2013", "10.1097/JTO.0b013e3182570919", "10.3389/fimmu.2024.1456719", "10.1186/s12967-024-04988-0", "10.5187/jast.2021.e93", "10.3390/cancers12102769", "10.1042/BSR20180268", "10.1016/j.biopha.2018.01.124", "10.1186/s12943-017-0586-y"]}
{"pair_type": "slc_pathway", "key1": "SLC35A2", "key2": "apoptosis", "summary": "Knockdown of SLC35A2 could reduce BRCA cell proliferation, motility, and cause G2/M arrest and cell apoptosis via ERK signaling.\nOur research substantiates that SLC35A2 exerts a notable influence on mitochondrial autophagy in osteosarcoma, thereby exerting cascading effects on the proliferation, migration, invasion, and apoptosis of osteosarcoma cells.\nHere, we report that SLC35A2 promotes BRCA progression by activating extracellular signal regulated kinase (ERK).\nIn conclusion, AC074117.1/hsa-let-7b-5p axis-mediated high expression of SLC35A2 acts as a tumor promoter in BRCA via ERK signaling, which provides a potential target for BRCA treatment.\nMechanistically, SLC35A2 orchestrates mitochondrial autophagy via the PI3K/AKT/mTOR signaling pathway.\nIn summation, our study elucidates that SLC35A2's modulation of mitochondrial autophagy through the PI3K/AKT/mTOR signaling pathway constitutes a pivotal factor in the malignant progression of osteosarcoma, unveiling promising therapeutic targets for patients grappling with this condition.\nMoreover, ERK activation can rescue the inhibitory effects of knockdown SLC35A2 in BRCA.\nThe results indicated that SLC35A2 expression was upregulated and linked to an unfavorable prognosis in BRCA.\nLeveraging data from the (The Cancer Genome Atlas) TCGA and (Genotype-Tissue Expression) GTEx databases, we have discerned that SLC35A2 is notably upregulated in osteosarcoma and correlates with the prognosis of osteosarcoma patients.\nCell Counting Kit-8, 5-ethynyl-2'-deoxyuridine, transwell, flow cytometer and western blotting were used to assess the proliferation, motility, cell cycle and apoptosis of BRCA cells in vitro.", "dois": ["10.1016/j.gene.2023.148110", "10.1111/febs.17044"]}
{"pair_type": "slc_pathway", "key1": "SLC35A1", "key2": "proliferation", "summary": "Notably, proliferation and glycosylation of the SLC35A1-deficient patient fibroblasts were enhanced by supplementation of the cell culture medium with 10 mM GlcNAc.\nKnockout of either CMAS or SLC35A1 enabled cytokine-independent proliferation and survival of AML cells.\nAberrant activation of cytokine and growth factor signal transduction pathways confers enhanced survival and proliferation properties to acute myeloid leukemia (AML) cells.\nMore than 182 genes (p < 0.01) were found to suppress the cytokine-independent growth of TF-1 cells.\nFurthermore, NSG (NOD/SCID/IL2Rγ) mice injected with CMAS or SLC35A1-knockout TF-1 cells exhibited a shorter survival than mice injected with wild-type cells.\nThe conjugation of carbohydrate residues to specific molecules and receptors is critical for normal hematopoiesis, as it favors the proliferation and clearance of hematopoietic precursors.\nTogether, these results demonstrate a novel role of sialylation in regulating oncogenic transformation and drug resistance development in leukemia.\nWe also found that sialylation modulated the expression and stability of the CSF2 receptor.\nMechanistically, abrogation of sialylation biosynthesis in TF-1 cells induced a strong activation of ERK signaling, which sensitized cells to MEK inhibitors but conferred resistance to JAK inhibitors.", "dois": ["10.1155/humu/6290620", "10.3390/ijms24065109", "10.1016/j.canlet.2021.04.006"]}
{"pair_type": "slc_pathway", "key1": "SLC34A2", "key2": "migration", "summary": "In contrast, the repression of SLC34A2 mitigated the miR-650 silencing-induced inhibition of migration and invasion in LCCs and LCSCs.\nGW2974 (EGFR inhibitor) increased SLC34A2 knockdown-inhibited cell proliferation, migration/invasion, as well as enhanced SLC34A2 knockdown-increased the TMZ sensitivity of glioma cells.\nOverexpression of SLC34A2 inhibited the proliferation, migration, and invasion of OS cells.\nThe following studies proved that SLC34A2 knockdown exhibited suppressive effects on cell proliferation and migration/invasion.\nOur result also revealed a dramatic inhibitory effects of SLC34A2 on cell growth, migration and invasion of several NSCLC cell lines.\nOur previous researches have reported that overexpression of SLC34A2 significantly inhibited proliferation, migration and invasion of LUAD cells.\nOur data suggested MEG3 was involved in stem cell-like state of LCCs and curbed migration and invasion through miR-650/SLC34A2 axis in NSCLC.\nMoreover, restoring SLC34A2 expression effectively reversed the miR-410-mediated promotion of cell growth, invasion and migration in NSCLC cells.\nFunctional assays revealed that MOGAT2 knockdown in H1299 cells promoted proliferation and migration, induced G2 cell cycle arrest, and decreased apoptosis.\nSLC34A2 knockdown also inhibited epithelial-mesenchymal transition (EMT) phenotype, as evidenced by the increased E-cadherin expression, and the decreased N-cadherin and fibronectin expressions.\nFurthermore, a series of in vivo and in vitro gain- or loss-of-functional assays elucidated the role of SLC34A2 in boosting cell proliferation, cell cycle progression, migration, invasion, and adhesion of PTC cells.\nUpregulation of MEG3 suppressed migration and invasion in LCCs and LCSCs.\nFurthermore, miR-650 mimic attenuated the MEG3 upregulation-mediated inhibition of migration and invasion.", "dois": ["10.1038/s41417-025-00928-2", "10.1038/s41598-025-95551-4", "10.3389/fimmu.2024.1456719", "10.1002/2211-5463.13623", "10.1038/s41388-020-1181-z", "10.1016/j.biopha.2019.109457", "10.1186/s12943-019-1028-9", "10.1002/jcb.28305", "10.1371/journal.pone.0191270", "10.1089/dna.2017.3750", "10.1016/j.phrs.2017.04.022", "10.3727/096504016X14719078133483", "10.1186/s12943-017-0586-y", "10.18632/oncotarget.7538", "10.1186/s12929-015-0158-7"]}
{"pair_type": "slc_pathway", "key1": "SLC35A2", "key2": "chemotherapy", "summary": "Seven PLGs (MX1, MLLT6, PEDS1, STK4, TOMM34, SLC35A2, and LZTS3) were used to establish the PLriskScore.\nA prognostic model based on primary location-related genes was developed to predict prognosis and chemotherapy response in RCC.\nTumor microenvironment scores and chemotherapy responses across PLriskScore subgroups were assessed in bulk RNA sequencing datasets.\nMachine learning algorithms identified MX1 as a novel key target, closely related to chemoresistance and tumor microenvironment dysregulation.\nMX1 was identified as a pivotal target that promotes angiogenesis and chemoresistance, thereby providing a potential therapeutic strategy for patients with RCC.\nA higher PLriskScore was significantly associated with poorer prognosis, advanced TNM stages, and increased stromal scores.", "dois": ["10.1186/s40246-025-00840-8", "PMID:15543237"]}
{"pair_type": "slc_pathway", "key1": "SLC34A3", "key2": "proliferation", "summary": "Moreover, stimulating cell growth upregulated oNaPi-IIc protein levels, whereas suppressing cell proliferation downregulated oNaPi-IIc protein levels.\nImmunoreactive oNaPi-IIc protein levels increased during the proliferative phase and decreased during differentiation.", "dois": ["10.2152/jmi.62.209"]}
{"pair_type": "slc_pathway", "key1": "SLC35A3", "key2": "glycolysis", "summary": "Further expression analysis revealed that CDK1, DSC2, ERO1A, MET, PYGL, and SLC35A3 were highly expressed in PDAC and CHST12 was highly expressed in normal pancreatic tissues.\nA prognostic risk score model, formulated upon the expression levels of six key GRGs - ME1, PLOD2, NUP50, CXCR4, SLC35A3, and SRD35A3 - emerged as a viable tool for predicting patient outcomes.\nGSEA results of the training set revealed that genes in the training set were significantly related to glycolysis pathway and iconic glycolysis pathway.\nGSEA analysis of glycolysis-related pathways was then performed on PDAC data to identify significantly enriched GRGs.\nThe downregulation of CXCR4 notably diminished the glycolytic capacity of gastric cancer (GC) cells, alongside their migratory, invasive, and proliferative capabilities.\nGlycolysis plays a pivotal role in tumor microenvironment (TME) reprogramming.\nRisk regression analysis further revealed that there were seven significantly expressed glycolysis related genes.\nThe constructed glycolysis-related gene model effectively predicts the occurrence and development of PDAC.\nIn the same line, the expression levels of glycolysis related model genes in PDAC were analyzed and verified using immunohistochemical images.\nThe genes were combined with other patient's clinical information and used to construct a glycolysis-related gene model using cox regression analysis.\nIn this research, the functions of glycolysis-associated genes (GRGs) were evaluated to predict the outcome and reveal the characteristics of the immune microenvironment in individuals with stomach cancer.\nTo identify the key glycolysis-related genes (GRGs) in the occurrence and development of pancreatic ductal carcinoma (PDAC), and to construct a glycolysis-related gene model for predicting the prognosis of PDAC patients.\nThe various subtypes of GC were outlined through consensus clustering, derived from the expression patterns of these GRGs.\nThere were 108 differentially expressed GRGs.\nAmong them, 29 GRGs were closely related to prognosis based on", "dois": ["10.1186/s12885-024-12747-z", "10.3389/fcell.2021.647106"]}
{"pair_type": "slc_pathway", "key1": "SLC35A3", "key2": "apoptosis", "summary": "In vitro experiments showed that overexpression of SLC35A3 inhibited the proliferation and invasion capability of colorectal cancer cells and promoted apoptosis.\nProliferation, apoptosis and differentiation were not affected in the chondrocytes of Slc35a3-/-mice, suggesting that the chondrodysplasia phenotypes were mainly caused by the abnormal extracellular matrix quality.", "dois": ["10.1038/s41598-023-51028-w", "10.1371/journal.pone.0284292"]}
{"pair_type": "slc_pathway", "key1": "SLC35A2", "key2": "proliferation", "summary": "Knockdown of SLC35A2 could reduce BRCA cell proliferation, motility, and cause G2/M arrest and cell apoptosis via ERK signaling.\nFunctional experiments demonstrated that SLC35A2 silencing inhibited the proliferation, migration, and invasion of BC cells, affecting their metastatic potential through modulation of the Wnt/β-catenin/EMT signaling pathway.\nDifferent BC cell lines were used in experiments, and the roles of SLC35A2 in cell proliferation, invasion, and migration was assessed through gene silencing and functional assays.\nOur research substantiates that SLC35A2 exerts a notable influence on mitochondrial autophagy in osteosarcoma, thereby exerting cascading effects on the proliferation, migration, invasion, and apoptosis of osteosarcoma cells.\nHere, we report that SLC35A2 promotes BRCA progression by activating extracellular signal regulated kinase (ERK).\nFurthermore, our CRC cell models revealed the tumor-promoting role of SLC35A2 and discovered that the upregulation of SLC35A2 is associated with chemoresistance against irinotecan.\nIn conclusion, AC074117.1/hsa-let-7b-5p axis-mediated high expression of SLC35A2 acts as a tumor promoter in BRCA via ERK signaling, which provides a potential target for BRCA treatment.\nHere we showed that glucose has the ability to induce lactose synthesis in dairy cow mammary epithelial cells, as well as increase cell viability and proliferation.\nIn vitro, 12 mM glucose enhanced lactose content, along with the expression of genes involved in glucose transportation and the lactose biosynthesis pathway, including GLUT1, SLC35A2, SLC35B1, HK2, β4GalT-I, and AKT1.\nIn addition, we found that AKT1 knockdown inhibited cell growth and lactose synthesis as well as expression of GLUT1, SLC35A2, SLC35B1, HK2, and β4GalT-I.", "dois": ["10.1186/s40246-025-00840-8", "10.7150/ijms.109767", "10.3390/ph17121695", "10.1038/s41598-024-84584-w", "10.1016/j.gene.2023.148110", "10.1111/febs.17044", "10.2147/JIR.S419994", "10.1186/s12917-016-0704-x"]}
{"pair_type": "slc_pathway", "key1": "SLC35A4", "key2": "apoptosis", "summary": "Quantitative real-time PCR (RT-PCR) analysis validated the significant up-regulation of CASP9, TNFRSF1B, GPX3, HYOU1, SLC3A2, SLC19A1, SLC35A4 and ITGAL, and down-regulation of BCL2A1 and COX7B.\nThe Ingenuity Pathway Analysis Application (IPA) revealed that differentially expressed genes were likely to modify oxidative stress and mitochondria-dependent apoptosis pathways.\nAfter adjustment for differences in the background characteristics of the two groups, we finally identified seven Cd-responsive genes (CASP9, TNFRSF1B, GPX3, SLC3A2, ITGAL, BCL2A1, and COX7B), all of which constituted a network that controls oxidative stress response by IPA.", "dois": ["10.1016/j.tox.2008.12.004"]}
{"pair_type": "slc_pathway", "key1": "SLC34A1", "key2": "proliferation", "summary": "MXD3 is a member of the MXD family of basic-helix-loop-helix-leucine-zipper (bHLHZ) transcription factors that plays pivotal roles in cell cycle progression and cell proliferation.\nClonal analysis after injury and repair showed that the bulk of labeled cells proliferate after injury with increased clone size after severe compared with mild injury.\nSimilar results were observed in cultured proximal tubules, in which labeled clones proliferated and expressed dedifferentiation and injury markers.\nWhen mice with completely labeled kidneys were subject to injury and repair there was no dilution of fate marker despite substantial proliferation, indicating that unlabeled progenitors do not contribute to kidney repair.\nDuring nephrogenesis and early kidney growth, single proximal tubule clones expanded, suggesting that differentiated cells also contribute to tubule elongation.", "dois": ["10.1016/j.csbj.2021.08.047", "10.1073/pnas.1310653110"]}
{"pair_type": "slc_pathway", "key1": "SLC35A3", "key2": "proliferation", "summary": "In vitro experiments showed that overexpression of SLC35A3 inhibited the proliferation and invasion capability of colorectal cancer cells and promoted apoptosis.\nProliferation, apoptosis and differentiation were not affected in the chondrocytes of Slc35a3-/-mice, suggesting that the chondrodysplasia phenotypes were mainly caused by the abnormal extracellular matrix quality.\nIn the growth plate cartilage of Slc35a3-/-embryos, extracellular space was drastically reduced, and many flat proliferative chondrocytes were reshaped.\nCompared with adjacent normal tissues and colonic epithelial cells, the expression of SLC35A3 was decreased in CRC tissues and CRC cell lines.\nThe results of this study indicate that decreased expression of SLC35A3 is closely associated with poor prognosis and immune cell infiltration in colorectal cancer, and it can serve as a promising independent prognostic biomarker and potential therapeutic target.\nLow expression of SLC35A3 was associated with N stage, pathological stage, and lymphatic infiltration, and it was unfavorable for OS, disease-specific survival (DSS), recurrence-free survival (RFS), and post-progression survival (PPS).\nGSEA revealed that SLC35A3 may be involved in energy metabolism, DNA repair, and cancer pathways.\nGO and KEGG analysis indicated that SLC35A3 may be involved in transmembrane transport protein activity, cell communication, and interaction with neurotransmitter receptors.\nThese findings suggest that SLC35A3 regulates GAG biosynthesis and the chondrodysplasia phenotypes were partially caused by the decreased GAG synthesis.\nSLC35A3 is considered an uridine diphosphate N-acetylglucosamine (UDP-GlcNAc) transporter in mammals and regulates the branching of N-glycans.\nDuring embryogenesis, Slc35a3 mRNA was expressed in the presomitic mesoderm of wild-type mice, suggesting that SLC35A3 transports UDP-GlcNAc used for the sugar modification that is essential for somite formation.", "dois": ["10.1038/s41598-023-51028-w", "10.1371/journal.pone.0284292", "10.1096/fj.202101520R"]}
{"pair_type": "slc_pathway", "key1": "SLC34A2", "key2": "proliferation", "summary": "Moreover, SLC34A2 induced autophagy to promote ESCC cell proliferation, whereas inhibition of autophagy suppressed the proliferation of ESCC cells.\nGW2974 (EGFR inhibitor) increased SLC34A2 knockdown-inhibited cell proliferation, migration/invasion, as well as enhanced SLC34A2 knockdown-increased the TMZ sensitivity of glioma cells.\nIn cellular assays in vitro, knockdown of SLC34A2 dramatically inhibited the proliferation and colony formation, induced the apoptosis and arrests the cell cycle progression of HCT-116 CRC cells.\nFurther studies showed that SLC34A2 interacted with an autophagy-related protein STX17 to promote autophagy and proliferation of ESCC cells by inhibiting the ubiquitination and degradation of STX17.\nSimultaneously, downregulation of SLC34A2 decreased the transcriptional activity and protein expression level of c-Myc in BC cells, whereas restoration of c-Myc expression could compromise the anti-proliferation effect of SLC34A2 depletion.\nOverexpression of SLC34A2 inhibited the proliferation, migration, and invasion of OS cells.\nOverexpression of SLC34A2 promoted ESCC cell proliferation, while silencing SLC34A2 had the opposite effect.\nThe following studies proved that SLC34A2 knockdown exhibited suppressive effects on cell proliferation and migration/invasion.\nOur previous researches have reported that overexpression of SLC34A2 significantly inhibited proliferation, migration and invasion of LUAD cells.\nOur present study illustrated that SLC34A2 has an important role in promoting proliferation and tumorigenicity of BC, and may represent a novel therapeutic target for this disease.\nSolute carrier family 34 member 2 (SLC34A2), a family member of sodium-driven phosphate cotransporters, has been reported to facilitate cell proliferation and tumor growth.", "dois": ["10.1038/s41417-025-00928-2", "10.3389/fimmu.2024.1456719", "10.1016/j.bioorg.2024.107590", "10.1590/1984-3143-AR2023-0131", "10.1111/1759-7714.15314", "10.1016/j.prp.2021.153706", "10.1165/rcmb.2020-0259OC", "10.3390/cancers12102769", "10.1038/s41388-020-1181-z", "10.1186/s12943-019-1028-9", "10.1002/jcb.28305", "10.1042/BSR20180268", "10.1016/j.bbcan.2018.05.001", "10.1016/j.biopha.2018.01.124", "10.1089/dna.2017.3750", "10.1016/j.phrs.2017.04.022", "10.3727/096504016X14719078133483", "10.1038/cddis.2017.13", "10.1158/1078-0432.CCR-14-1350", "10.1152/physiolgenomics.00059.2013", "10.1158/1078-0432.CCR-12-0550", "10.1097/JTO.0b013e3182570919"]}
{"pair_type": "slc_pathway", "key1": "SLC34A2", "key2": "stemness", "summary": "SLC34A2 promotes neuroblastoma cell stemness via enhancement of miR-25/Gsk3β-mediated activation of Wnt/β-catenin signaling.\nOur results demonstrate that miR-25/Gsk3β-mediated activation of Wnt signaling is responsible for SLC34A2-induced enhancement of neuroblastoma cell stemness.\nTransfection of miR-25 inhibitor or a Gsk3β overexpression plasmid attenuated the effects of SLC34A2 overexpression on the stemness of neuroblastoma cells.\nHere, we examined the roles of the transcription factor SLC34A2 in regulating the stemness of neuroblastoma cells.\nKnockdown of SLC34A2 attenuated the expression of stemness markers and spheroid formation capacity of neuroblastoma cell-derived spheroids, and overexpression of SLC34A2 exerted the opposite effects in neuroblastoma cells.\nBy using lentiviral-based approach, si-SLC34A2-transduced CD147 BCSCs showed decreased ability of sphere formation, cell viability in vitro, and tumorigenicity in vivo, which suggested the essential role of SLC34A2 in CD147 BCSCs.\nSignificantly, SLC34A2 expression in CD147 BCSCs was enhanced compared with that in differentiated adherent progeny of CD147 BCSCs and adherently cultured cell line cells.\nFinally, we indicated that SLC34A2 could regulate SOX2 to maintain the stem cell-like features in CD147 BCSCs through PI3K/AKT pathway.\nFurthermore, PI3K/AKT pathway and SOX2 were found necessary to maintain the stemness of CD147 BCSCs by using LY294002 or lentiviral-si-SOX2.\nIn this study, we aim to investigate the biological function of SLC34A2 in affecting the stem cell-like phenotypes in BCSCs and its underlying mechanisms.\nTherefore, our report identifies a novel role of SLC34A2 in BCSCs' state regulation and establishes a rationale for targeting the SLC34", "dois": ["10.3389/fimmu.2024.1456719", "10.1002/2211-5463.13623", "10.1002/2211-5463.12594", "10.1177/1010428317695927"]}
{"pair_type": "slc_pathway", "key1": "SLC35A4", "key2": "oxidative stress", "summary": "Knock out of SLC35A4 or AltSLC35A4 enhanced sensitivity to oxidative stress in a rescuable manner, indicating a direct implication for these proteins in stress resistance.\nPrevious studies employing ribosome profiling have revealed that during oxidative stress induced by sodium arsenite, the reference coding sequence of SLC35A4 exhibits the largest increase in translational efficiency among all cellular mRNAs.\nOur results confirmed this translational upregulation, with the emergence of SLC35A4 protein isoforms during oxidative stress in an upstream ORF-dependent manner.\nIn conclusion, our research provides compelling evidence for the functional significance of the dual-coding nature of SLC35A4 for resistance to oxidative stress and highlights the importance of considering AltProts in the functional study of eukaryotic genes.\nThe Ingenuity Pathway Analysis Application (IPA) revealed that differentially expressed genes were likely to modify oxidative stress and mitochondria-dependent apoptosis pathways.\nAfter adjustment for differences in the background characteristics of the two groups, we finally identified seven Cd-responsive genes (CASP9, TNFRSF1B, GPX3, SLC3A2, ITGAL, BCL2A1, and COX7B), all of which constituted a network that controls oxidative stress response by IPA.", "dois": ["10.1002/pro.70197", "10.7554/eLife.03971", "10.1016/j.tox.2008.12.004"]}
{"pair_type": "slc_pathway", "key1": "SLC35B1", "key2": "apoptosis", "summary": "The polytons identified were mostly endoplasmic reticulum-located, integral proteins involved in protein maturation, N-glycosylation, protein folding, anterograde transport of proteins, protein secretion, and the regulation of apoptosis.\nAmong the singletons, we identified SLC31A2, SLC35B1, SLC39A13, CRACM1, and MTCH2 as putative binding partners of SLC41A1.", "dois": ["10.1684/mrh.2013.0339"]}
{"pair_type": "slc_pathway", "key1": "SLC35B1", "key2": "ferroptosis", "summary": "Differentially spliced SLCs were enriched in biological processes, including transmembrane transporter activity, transporter activity, ferroptosis, and choline metabolism.\nWe developed a prognostic risk model based on the screened 6-SLC-AS (SLC7A6_RI_37208 (SLC7A6-RI), SLC11A2_AP_21724, SLC2A8_ES_87631, SLC35B1_AA_42317, SLC39A11_AD_43204, and SLC7A8_AP_26712).", "dois": ["10.1111/cas.16351"]}
{"pair_type": "slc_pathway", "key1": "SLC35B1", "key2": "stemness", "summary": "A loss-of-function study showed that knockdown of SLC12A2 expression restrained proliferation and stemness of CRC cells while a gain-of-function study showed the contrary results.\nAs a result, we developed a prognostic risk model based on the screened 6-SLC genes (SLC39A8, SLC2A3, SLC39A13, SLC35B1, SLC4A3, SLC12A2).", "dois": ["10.1038/s41598-024-55048-y"]}
{"pair_type": "slc_pathway", "key1": "SLC35B1", "key2": "proliferation", "summary": "One H-2Kd restricted peptide SLC35B1 which was shared by MIP derived from both NOD mice pancreatic tissues and islet β-cell line, but absent in MIP from NOD thymus tissues, showed ability to stimulate IFN-γ secretion and proliferation of NOD mice splenic CD8 T cells.\nHere we showed that glucose has the ability to induce lactose synthesis in dairy cow mammary epithelial cells, as well as increase cell viability and proliferation.\nIn vitro, 12 mM glucose enhanced lactose content, along with the expression of genes involved in glucose transportation and the lactose biosynthesis pathway, including GLUT1, SLC35A2, SLC35B1, HK2, β4GalT-I, and AKT1.\nMechanistically, si-SLC7A6-RI isoform exerted oncogenic effects by activating the PI3K-Akt-mTOR signaling pathway and promoting cell proliferation, evidenced by increased expression of key regulators Phosphorylated Mammalian Target of Rapamycin (p-mTOR) and a cell proliferation marker Proliferating Cell Nuclear Antigen (PCNA) using western blotting.\nKnockdown of the intronic region of SLC7A6-RI isoform enhanced colon cancer cell proliferation.\nIn addition, we found that AKT1 knockdown inhibited cell growth and lactose synthesis as well as expression of GLUT1, SLC35A2, SLC35B1, HK2, and β4GalT-I.\nA concentration of 12 mM glucose was the optimum concentration to induce cell growth and lactose synthesis in cultured dairy cow mammary epithelial cells.\nA loss-of-function study showed that knockdown of SLC12A2 expression restrained proliferation and stemness of CRC cells while a gain-of-function study showed the contrary results.\nAt the same time, we identified that SLC12A2 could promote tumor progression in CRC, which may serve as a potential therapeutic target.\nIn vivo, knockdown of the intronic region of SLC7A6-RI i", "dois": ["10.1111/cas.16351", "10.1038/s41598-024-55048-y", "10.1016/j.jprot.2022.104746", "10.1186/s12917-016-0704-x"]}
{"pair_type": "slc_pathway", "key1": "SLC35B2", "key2": "apoptosis", "summary": "The increase in apoptosis-related proteins (BAD and BCL2) in the morphant influenced the cellular component of pectoral fins and resulted in chondrocyte reduction throughout the different CC phases.", "dois": ["10.3390/jdb7030015"]}
{"pair_type": "slc_pathway", "key1": "SLC35A4", "key2": "oxidative phosphorylation", "summary": "Pathway analyses revealed the involvement of oxidative phosphorylation and mitochondrial dysfunction in the hippocampal processes of aging and EE-induced reversal.\nAmong these, solute carrier family 35, member A4 (Slc35a4) and potassium inwardly rectifying channel, subfamily J, member 2 (Kcnj2) were confirmed to show hippocampal expression changes parallel to that of memory in the WMI.\nThese genes have critical roles in the integrated stress response, cellular metabolism, and the effects of stress on neurovascular coupling, respectively.\nMitochondrial dysfunction may underly mid-life cognitive and molecular changes.", "dois": ["10.1111/gbb.70027", "10.1101/2025.02.20.639157"]}
{"pair_type": "slc_pathway", "key1": "SLC35B2", "key2": "migration", "summary": "Knocking down SLC35B2 or TPST2, or pharmacologicically inhibiting sulfation, resulted in the inhibition of PDAC cell proliferation and migration in vitro.\nTPST2-deficient MIA PaCa-2 cells showed inhibited xenograft tumor growth.\nInhibition of sulfation destabilizes integrin β4 protein, which may have accounted for the suppression of metastasis.\nOrthotopic inoculation of Tpst2 knockout KPC cells in mice showed inhibition of primary tumor growth, local invasion, and metastasis.\nOur results provide evidence that the pectoral fin phenotypic anomaly induced by knockdown is related to disruption of the mesoderm and ECM, consequently interfering with mesoderm migration, CC, and subsequent endoskeleton formation.\nTargeting the SLC35B2-TPST2 axis of tyrosine sulfation may represent a novel approach for therapeutic intervention of PDAC.\nMechanistically, the integrin β4 was found to be a novel substrate of TPST2.\nSolute carrier family 35 member B (SLC35B2) is a key transporter that transports the universal sulfate donor 3'-phosphoadenosine 5'-phosphosulfate into the Golgi apparatus where the protein sulfation occurs.\nTyrosine sulfation, catalyzed by the tyrosylprotein sulfotransferase 2 (TPST2), is a post-translational modification essential for protein-protein interactions and cellular functions.\nHigh expressions of SLC35B2 and TPST2 were correlated with poor PDAC patient survival.", "dois": ["10.1016/j.jcmgh.2023.05.003", "10.3390/jdb7030015"]}
{"pair_type": "slc_pathway", "key1": "SLC35B2", "key2": "proliferation", "summary": "Knocking down SLC35B2 or TPST2, or pharmacologicically inhibiting sulfation, resulted in the inhibition of PDAC cell proliferation and migration in vitro.\nFurthermore, genes involved in osteoblast proliferation and differentiation, including Gli1, Slc35b2, Lrrc17, and Junb were differentially expressed.\nHeterozygous mutation of TNFSF11 was also associated with a slightly increased expression of genes involved in osteoclast proliferation and differentiation, including Tcirg1, Junb, Anxa2, and Atp6ap1.\nTPST2-deficient MIA PaCa-2 cells showed inhibited xenograft tumor growth.\nOrthotopic inoculation of Tpst2 knockout KPC cells in mice showed inhibition of primary tumor growth, local invasion, and metastasis.\nWe identify five factors, including the HIV co-receptors CD4 and CCR5, that are required for HIV infection yet are dispensable for cellular proliferation and viability.\nTyrosylprotein sulfotransferase 2 (TPST2) and solute carrier family 35 member B2 (SLC35B2) function in a common pathway to sulfate CCR5 on extracellular tyrosine residues, facilitating CCR5 recognition by the HIV envelope.\nSolute carrier family 35 member B (SLC35B2) is a key transporter that transports the universal sulfate donor 3'-phosphoadenosine 5'-phosphosulfate into the Golgi apparatus where the protein sulfation occurs.\nTyrosine sulfation, catalyzed by the tyrosylprotein sulfotransferase 2 (TPST2), is a post-translational modification essential for protein-protein interactions and cellular functions.", "dois": ["10.1016/j.tice.2024.102412", "10.1016/j.jcmgh.2023.05.003", "10.1038/ng.3741"]}
{"pair_type": "slc_pathway", "key1": "SLC35B3", "key2": "chemotherapy", "summary": "An integrative analysis identified 111 common differentially expressed genes including two bone morphogenetic proteins (BMP4 and BMP7), six solute carrier proteins (SLC10A3, SLC16A3, SLC25A1, SLC35B3, SLC7A5 and SLC7A7), transcription factor POU5F1 (POU class 5 homeobox 1), and KLK10 (kallikrein-related peptidase 10).\nWe identified 1187 tags (corresponding to 1040 genes) that are differentially expressed between the chemotherapy responsive and the persistently chemotherapy resistant ovarian cancer tissues.\nA network analysis revealed a subnetwork with three genes BMP7, NR2F2 and AP2B1 that were consistently over expressed in the chemoresistant tissue or cells compared to the chemosensitive tissue or cells.\nGO term GO:0050673 (epithelial cell proliferation) and GO:0050678 (regulation of epithelial cell proliferation) are enriched in the genes over expressed in the chemotherapy resistant tissue while the GO:0007229 (integrin-mediated signaling pathway) is enriched in the genes over expressed in the chemotherapy sensitive tissue.\nGene Ontology (GO) term GO:0001837 (epithelial-to-mesenchymal transition) and GO:0034330 (cell junction assembly and maintenance) are enriched in genes that are over expressed in IGROV1-CP cells while apoptosis-related GO terms are enriched in genes over expressed in IGROV1 cells.", "dois": ["10.3390/cancers13153903", "10.1016/j.ygyno.2010.01.041"]}
{"pair_type": "slc_pathway", "key1": "SLC35B3", "key2": "glycolysis", "summary": "We investigated the DEGs associated with the starch and sucrose metabolism pathways, citrate cycle pathway, glycolysis pathway, and a handful of sugar transporter proteins, which were considered to be important regulators of sugar and acid accumulation.", "dois": ["10.3390/ijms242316992"]}
{"pair_type": "slc_pathway", "key1": "SLC35B3", "key2": "migration", "summary": "Novel loci include those mapping to LHX8 and TSBP1 (combined clefts), ARHGEF18 and ARHGEF19 (cleft lip with/without palate), FBN2 (cleft lip only), SLC35B3 (cleft palate only), CASC20 (Pierre Robin Sequence) and CHRM2 (non-syndromic cleft palate only).\nSeveral novel hits were in regions previously associated with facial morphology in GWAS or were in regions involved in key developmental processes, including neural crest cell migration and craniofacial development.", "dois": ["10.1093/hmg/ddaf131"]}
{"pair_type": "slc_pathway", "key1": "SLC35B4", "key2": "migration", "summary": "down-regulation of SLC35B4 by transfecting short hairpin RNA in DU145 human prostate cancer cell suppressed proliferation, migration and invasion.", "dois": ["10.1111/jcmm.13649"]}
{"pair_type": "slc_pathway", "key1": "SLC35B4", "key2": "proliferation", "summary": "down-regulation of SLC35B4 by transfecting short hairpin RNA in DU145 human prostate cancer cell suppressed proliferation, migration and invasion.\nSLC35B4 is important for the proliferation and tumorigenesis of HCC cells.\nCCK-8, plate colony formation and soft agar assays revealed that SLC35B4 is essential for survival and proliferation in GC cells and nude mice models.\nCollectively, our findings defined SLC35B4 as an important downstream oncogenic target of YAP1, suggesting that dysregulated signaling of a novel YAP1/SLC35B4 axis promotes GC development and progression, and this axis could be a potential candidate for prognosis and therapeutics in GC.\nSLC35B4 is directly transactivated by YAP1-TEADs complex in gastric cancer (GC) cells.\nMechanistically, SLC35B4 is important for the O-GlcNAc modification of c-Myc and thus the stabilization of c-Myc, which is required for HCC tumorigenesis.", "dois": ["10.3389/fphar.2022.851089", "10.1038/s41419-019-1674-2", "10.1111/jcmm.13649"]}
{"pair_type": "slc_pathway", "key1": "SLC35B3", "key2": "proliferation", "summary": "An integrative analysis identified 111 common differentially expressed genes including two bone morphogenetic proteins (BMP4 and BMP7), six solute carrier proteins (SLC10A3, SLC16A3, SLC25A1, SLC35B3, SLC7A5 and SLC7A7), transcription factor POU5F1 (POU class 5 homeobox 1), and KLK10 (kallikrein-related peptidase 10).\nGO term GO:0050673 (epithelial cell proliferation) and GO:0050678 (regulation of epithelial cell proliferation) are enriched in the genes over expressed in the chemotherapy resistant tissue while the GO:0007229 (integrin-mediated signaling pathway) is enriched in the genes over expressed in the chemotherapy sensitive tissue.", "dois": ["10.1016/j.ygyno.2010.01.041"]}
{"pair_type": "slc_pathway", "key1": "SLC35A2", "key2": "migration", "summary": "MDA-MB-468 and MCF-7 cells transfected with SLC35A2 shRNA had unchanged cell viability but significantly reduced cell migration and invasion.\nFocal Slc35a2 KO or KD in vivo disrupts corticogenesis through altered neuronal migration and that KO leads to reduced seizure threshold.\nFunctional experiments demonstrated that SLC35A2 silencing inhibited the proliferation, migration, and invasion of BC cells, affecting their metastatic potential through modulation of the Wnt/β-catenin/EMT signaling pathway.\nIn contrast, MDA-MB-231 and HCC1806 cells transfected with the SLC35A2 expression vector showed increased migration.\nSlc35a2 KO or KD caused disrupted radial migration of electroporated neurons evidenced by heterotopic cells located in lower cortical layers and in the sub-cortical white matter.\nBy tracing neuronal development with 5-Ethynyl-2'-deoxyuridine (EdU) birthdating experiments, we found that Slc35a2 deficiency disrupts corticogenesis by delaying radial migration of neurons from the subventricular zone.\nOur research substantiates that SLC35A2 exerts a notable influence on mitochondrial autophagy in osteosarcoma, thereby exerting cascading effects on the proliferation, migration, invasion, and apoptosis of osteosarcoma cells.\nTogether, these results demonstrate a direct causal role for SLC35A2 in MOGHE-like phenotypes, including a critical role in neuronal migration during brain development, and identify neurons as key contributors to SLC35A2-related epileptogenesis.\nEffects of SLC35A2 expression alteration on metastatic behaviors and membrane glycan profile of HCC cells were observed by using respectively invasion, migration, cell adhesion assay, in vivo lung metastatic nude mouse model and lectins microarray.\nSLC35A2 plays important roles in promoting HCC metastasis by regulating cellular glycosylation modification and inducing the cell adhesive ability of HCC cells.\nSLC35A2 expression alteration significantly affected the invasion,", "dois": ["10.1186/s40246-025-00840-8", "10.1093/hmg/ddaf156", "10.1111/epi.18413", "10.1038/s41598-024-84584-w", "10.1111/epi.18166", "10.1016/j.nbd.2024.106657", "10.1016/j.neulet.2024.137881", "10.3390/ijms25074110", "10.1016/j.gene.2023.148110", "10.1101/2023.11.29.569243", "10.2147/JIR.S419994", "10.21873/invivo.13076", "10.1007/s13402-022-00749-7", "10.3390/cells11152273"]}
{"pair_type": "slc_pathway", "key1": "SLC35B3", "key2": "apoptosis", "summary": "An integrative analysis identified 111 common differentially expressed genes including two bone morphogenetic proteins (BMP4 and BMP7), six solute carrier proteins (SLC10A3, SLC16A3, SLC25A1, SLC35B3, SLC7A5 and SLC7A7), transcription factor POU5F1 (POU class 5 homeobox 1), and KLK10 (kallikrein-related peptidase 10).\nGene Ontology (GO) term GO:0001837 (epithelial-to-mesenchymal transition) and GO:0034330 (cell junction assembly and maintenance) are enriched in genes that are over expressed in IGROV1-CP cells while apoptosis-related GO terms are enriched in genes over expressed in IGROV1 cells.", "dois": ["10.1016/j.ygyno.2010.01.041"]}
{"pair_type": "slc_pathway", "key1": "SLC35C1", "key2": "apoptosis", "summary": "Histological analysis revealed decreased mucins and increased apoptosis in both jejunum and ileum for IUGR piglets.", "dois": ["10.3389/fphys.2020.00561"]}
{"pair_type": "slc_pathway", "key1": "SLC35C1", "key2": "migration", "summary": "In addition, in vitro experiments showed that SLC35C1 knockdown significantly inhibited the proliferation, migration and invasive ability of glioma cells, while SLC35C1 overexpression promoted proliferation, migration, invasion and colony formation of glioma cells.\nRescue assays validated the role of TCS/miR-218-1-3p/SLC35C1 axis in regulating the viability, migration, invasion and inflammatory response of trophoblast cells.\nTCS regulated miR-218-1-3p/SLC35C1 axis to modulate the proliferation, migration, invasion and inflammatory response of trophoblast cells in vitro, which might provide novel insights for spontaneous abortion prevention.\nLeukocyte adhesion deficiency type II is a hereditary disorder of neutrophil migration caused by mutations in the guanosine diphosphate-fucose transporter gene (SLC35C1).\nInterfering expression inhibited tumor cell proliferation and migration.\nMoreover, neutrophil migration to the inflamed peritoneum was strongly reduced by 89%.\nThe down-regulated expression of PD-L1 leads to a decline in lung cancer cell proliferation and migration.\nSupported by western blot analysis, functional experiments demonstrated that miR-218-1-3p overexpression impeded the proliferation, migration and invasion while exacerbating the inflammatory response of trophoblast cells.\nWe found that E-, L-, and P-selectin-dependent leukocyte rolling in cremaster muscle venules was virtually absent.", "dois": ["10.7150/jca.84652", "10.1038/s41598-023-32375-0", "10.1097/HEP.0000000000000322", "10.1186/s12884-022-04791-z", "10.3389/fonc.2021.779153", "10.1093/hmg/ddu001", "10.1182/blood-2008-01-132035"]}
{"pair_type": "slc_pathway", "key1": "SLC35C1", "key2": "stemness", "summary": "The specificity of our method is confirmed using sister stem cells carrying repairable mutations in enzymes required for fucosylation, Fut9 and Slc35c1.\nThis analysis nearly doubles the number of experimentally confirmed glycoproteins, identifies previously unknown glycosylation sites and multiple glycosylated stemness factors, and uncovers evolutionarily conserved as well as species-specific glycoproteins in embryonic stem cells.\nWe apply this method to human and mouse embryonic stem cells to illuminate the stem cell glycoproteome.", "dois": ["10.1038/nature24015"]}
{"pair_type": "slc_pathway", "key1": "SLC35C2", "key2": "migration", "summary": "Both in vitro and in vivo studies demonstrated that SLC35C2 promoted the proliferation, migration, invasion and metastasis in HCC cells.\nThe knockdown and overexpression of SLC35C2 inhibited or promoted stemness in HCC cell.\nInhibition of ACSL4 with PRGL493 can reverse the lipogenesis, stemness and proliferation induced by SLC35C2 overexpression.\nIn conclusion, our study demonstrates the pivotal role of SLC35C2 in stemness and malignant progression in HCC by promoting lipogenesis.\nThrough RNA-seq and lipidomics analysis, it was found that SLC35C2 regulated lipid reprogramming, particularly triglyceride synthesis.\nThe present study identified SLC35C2 as a crucial factor in maintaining the stem-cell characteristics of HCC cells through CRISPR-dCas9 screening.\nMechanistically, SLC35C2 stimulated lipogenesis through the up-regulation of SREBP1, ACC, FAS, and SCD-1, thereby increasing lipid accumulation in HCC cells.\nSLC35C2 interacted with ACSL4, which plays a critical role in lipogenesis, and to protect it from degradation.\nThese findings suggest that SLC35C2 is a prognostic marker and promising therapeutic target for HCC treatment.\nFurther investigation demonstrated that SLC35C2 was significantly elevated in HCC tissues and correlated with a poor prognosis in HCC patients.\nIt is an independent prognostic factor for HCC patients.", "dois": ["10.1016/j.cellsig.2025.111589", "10.1007/s10549-019-05307-8"]}
{"pair_type": "slc_pathway", "key1": "SLC35C2", "key2": "proliferation", "summary": "Both in vitro and in vivo studies demonstrated that SLC35C2 promoted the proliferation, migration, invasion and metastasis in HCC cells.\nThe knockdown and overexpression of SLC35C2 inhibited or promoted stemness in HCC cell.\nInhibition of ACSL4 with PRGL493 can reverse the lipogenesis, stemness and proliferation induced by SLC35C2 overexpression.\nIn conclusion, our study demonstrates the pivotal role of SLC35C2 in stemness and malignant progression in HCC by promoting lipogenesis.\nThe present study identified SLC35C2 as a crucial factor in maintaining the stem-cell characteristics of HCC cells through CRISPR-dCas9 screening.\nMechanistically, SLC35C2 stimulated lipogenesis through the up-regulation of SREBP1, ACC, FAS, and SCD-1, thereby increasing lipid accumulation in HCC cells.\nSLC35C2 interacted with ACSL4, which plays a critical role in lipogenesis, and to protect it from degradation.\nThrough RNA-seq and lipidomics analysis, it was found that SLC35C2 regulated lipid reprogramming, particularly triglyceride synthesis.\nFurther investigation demonstrated that SLC35C2 was significantly elevated in HCC tissues and correlated with a poor prognosis in HCC patients.\nThese findings suggest that SLC35C2 is a prognostic marker and promising therapeutic target for HCC treatment.\nIt is an independent prognostic factor for HCC patients.", "dois": ["10.1016/j.cellsig.2025.111589", "10.1007/s10549-019-05307-8"]}
{"pair_type": "slc_pathway", "key1": "SLC35D2", "key2": "chemotherapy", "summary": "Survival differences according to the genotype of these SNPs were independent of sex, smoking, histology and chemotherapy regimens.\nThese results suggested the variants at multiple genetic loci might contribute to the risk of death in advanced NSCLC patients receiving chemotherapy.\nIn this study, we genotyped 271 817 single-nucleotide polymorphisms in 348 advanced NSCLC patients who received chemotherapy and analyzed their association with prognosis by using Cox proportional hazard regression model adjusted for known prognostic factors.\nThese SNPs were located in the genomic regions of the FAM154A, ANKS1A, DLST, THSD7B, NCOA2, CDH8, SLC35D2, NALCN and EGF genes.", "dois": ["10.1093/carcin/bgs356"]}
{"pair_type": "slc_pathway", "key1": "SLC35C2", "key2": "stemness", "summary": "The knockdown and overexpression of SLC35C2 inhibited or promoted stemness in HCC cell.\nInhibition of ACSL4 with PRGL493 can reverse the lipogenesis, stemness and proliferation induced by SLC35C2 overexpression.\nIn conclusion, our study demonstrates the pivotal role of SLC35C2 in stemness and malignant progression in HCC by promoting lipogenesis.\nThe present study identified SLC35C2 as a crucial factor in maintaining the stem-cell characteristics of HCC cells through CRISPR-dCas9 screening.\nBoth in vitro and in vivo studies demonstrated that SLC35C2 promoted the proliferation, migration, invasion and metastasis in HCC cells.\nMechanistically, SLC35C2 stimulated lipogenesis through the up-regulation of SREBP1, ACC, FAS, and SCD-1, thereby increasing lipid accumulation in HCC cells.\nSLC35C2 interacted with ACSL4, which plays a critical role in lipogenesis, and to protect it from degradation.\nThrough RNA-seq and lipidomics analysis, it was found that SLC35C2 regulated lipid reprogramming, particularly triglyceride synthesis.\nFurther investigation demonstrated that SLC35C2 was significantly elevated in HCC tissues and correlated with a poor prognosis in HCC patients.\nThese findings suggest that SLC35C2 is a prognostic marker and promising therapeutic target for HCC treatment.\nIt is an independent prognostic factor for HCC patients.\nCancer stem cells (CSC) are a contributing factor to the recurrence and metastasis of HCC.", "dois": ["10.1016/j.cellsig.2025.111589"]}
{"pair_type": "slc_pathway", "key1": "SLC35D2", "key2": "proliferation", "summary": "Proteoglycans and glycosaminoglycans modulate numerous cellular processes relevant to tumour progression, including cell proliferation, cell-matrix interactions, cell motility and invasive growth.\nKnockdown of β4GalT7 expression resulted in a decrease in cell viability, motility and adhesion to fibronectin, while these parameters were unchanged in EXT1-silenced cells.\nInterestingly, EXT1-depleted cells showed a downregulation of the UDP-sugar transporter SLC35D1, whereas SLC35D2 was downregulated in β4GalT7-depleted cells, indicating an intricate regulatory network that connects all glycosaminoglycans synthesis.\nImportantly, these changes were associated with a decreased expression of syndecan-1, decreased signalling response to HGF and an increase in the synthesis of hyaluronan, due to an upregulation of the hyaluronan synthases HAS2 and HAS3.\nThe results of our in vitro study suggest that a modulation of breast cancer cell behaviour via interference with heparan sulphate biosynthesis may result in a compensatory upregulation of hyaluronan biosynthesis.\nThese findings have important implications for the development of glycosaminoglycan-targeted therapeutic approaches for malignant diseases.", "dois": ["10.1007/s10719-016-9735-6"]}
{"pair_type": "slc_pathway", "key1": "SLC35E1", "key2": "proliferation", "summary": "SLC35E1 promotes keratinocyte proliferation in psoriasis by regulating zinc homeostasis.\nOur results indicated that SLC35E1 can promote keratinocyte proliferation by regulating zinc ion homeostasis and zinc ion supplementation has potential as a therapy for psoriasis.\nIn addition, SLC35E1 deficiency inhibited keratinocyte proliferation in both mice and cultured cells.\nOn a molecular level, SLC35E1 was found to regulate zinc ion concentrations and subcellular localization, while zinc ion chelation reversed the IMQ-induced psoriatic phenotype in Slc35e1 mice.\nHere, we found that SLC35E1 was highly expressed in keratinocytes of patients with psoriasis and that Slc35e1 mice displayed a less severe imiquimod (IMQ)-induced psoriasis-like phenotype than their wild-type siblings.\nKeratinocyte hyperproliferation is a key pathogenic factor in psoriasis.", "dois": ["10.1038/s41419-023-05874-1"]}
{"pair_type": "slc_pathway", "key1": "SLC35D1", "key2": "proliferation", "summary": "Proteoglycans and glycosaminoglycans modulate numerous cellular processes relevant to tumour progression, including cell proliferation, cell-matrix interactions, cell motility and invasive growth.\nKnockdown of β4GalT7 expression resulted in a decrease in cell viability, motility and adhesion to fibronectin, while these parameters were unchanged in EXT1-silenced cells.\nInterestingly, EXT1-depleted cells showed a downregulation of the UDP-sugar transporter SLC35D1, whereas SLC35D2 was downregulated in β4GalT7-depleted cells, indicating an intricate regulatory network that connects all glycosaminoglycans synthesis.\nImportantly, these changes were associated with a decreased expression of syndecan-1, decreased signalling response to HGF and an increase in the synthesis of hyaluronan, due to an upregulation of the hyaluronan synthases HAS2 and HAS3.\nThe results of our in vitro study suggest that a modulation of breast cancer cell behaviour via interference with heparan sulphate biosynthesis may result in a compensatory upregulation of hyaluronan biosynthesis.\nThese findings have important implications for the development of glycosaminoglycan-targeted therapeutic approaches for malignant diseases.", "dois": ["10.1007/s10719-016-9735-6"]}
{"pair_type": "slc_pathway", "key1": "SLC35E1", "key2": "apoptosis", "summary": "We identified a gene expression signature of 42 genes, mostly encoding proteins that either play a role in the nucleus, such as the transcription factor ETS2, or are associated with transport function, such as the solute carrier SLC35E1, or the regulation of apoptosis, such as caspase-1.", "dois": ["10.1016/j.cgh.2007.10.022"]}
{"pair_type": "slc_pathway", "key1": "SLC35D3", "key2": "apoptosis", "summary": "In Nestin-Cre;Isl1(f/f) KO mouse brain, differentiation of striatonigral neurons was defective, as evidenced by decreased expression of striatonigral-enriched genes, including substance P, prodynorphin, solute carrier family 35, member D3 (Slc35d3), and PlexinD1.\nRNA-seq analysis revealed eight hub genes, including Map2k3, Nfs1, Chchd4, Hdac6, Siglec5, Slc35d3, Entpd1, and LOC103690108, and nine hub pathways among the control, PTZ, and Q808 groups.\nThe morphological change and neuronal apoptosis in the hippocampus were detected by hematoxylin and eosin (HE) and terminal deoxynucleotidyl transferase-mediated dUTP nick end-labeling (TUNEL) staining, respectively.\nBrain apoptosis is one of the main causes of epileptogenesis.\nStriatonigral axonal projections were also impaired, and abnormal apoptosis was observed in Isl1 KO striatum.\nThe antiapoptotic effect and potential mechanism of Q808, an innovative anticonvulsant chemical, have never been reported.\nThe morphological changes of neurons and the number of apoptotic cells in the DG area were diminished by Q808 treatment.", "dois": ["10.1016/j.biopha.2024.116746", "10.1073/pnas.1319138111"]}
{"pair_type": "slc_pathway", "key1": "SLC35F2", "key2": "ferroptosis", "summary": "SLC35F2 inhibits ferroptosis by facilitating TRIM59-mediated p53 degradation.\nThrough multi-omics analyses, we discerned that SLC35F2 influences the transcriptome and inhibits ferroptosis in pancreatic cancer cells.\nIn summary, our work establishes a novel mechanism wherein the SLC35F2-SYVN1-TRIM59 axis critically regulates ferroptosis of pancreatic cancer cells by inhibiting endogenous p53.\nMoreover, our findings reveal the pivotal involvement of p53 in mediating SLC35F2-mediated ferroptosis, both in vitro and in vivo.\nHowever, the precise role and mechanisms underlying wild-type p53 activation in promoting ferroptosis in pancreatic cancer cells remain obscure.\nFurther mechanistic investigations demonstrated that SLC35F2 competitively interacts with the E3 ubiquitin ligase SYVN1 of TRIM59, thereby stabilizing TRIM59 expression and consequentially promoting p53 degradation.\nUtilizing protein 3D structure analysis and drug screening, we identified irinotecan hydrochloride and lapatinib ditosylate as compounds targeting SLC35F2, augmenting the antitumor effect of imidazole ketone erastin (IKE) in a wild-type p53 patient-derived xenograft (PDX) model.", "dois": ["10.1038/s41388-023-02843-y"]}
{"pair_type": "slc_pathway", "key1": "SLC35C1", "key2": "proliferation", "summary": "Reduced SLC35C1 significantly promotes cell proliferation and colony formation of HEK293 cells.\nIn addition, in vitro experiments showed that SLC35C1 knockdown significantly inhibited the proliferation, migration and invasive ability of glioma cells, while SLC35C1 overexpression promoted proliferation, migration, invasion and colony formation of glioma cells.\nTCS regulated miR-218-1-3p/SLC35C1 axis to modulate the proliferation, migration, invasion and inflammatory response of trophoblast cells in vitro, which might provide novel insights for spontaneous abortion prevention.\nDecreased SLC35C1 may cause over-activation of Wnt signalling in colorectal cancer.\nInterfering expression inhibited tumor cell proliferation and migration.\nThe down-regulated expression of PD-L1 leads to a decline in lung cancer cell proliferation and migration.\nWe found that SLC35C1, a GDP-fucose transporter, negatively regulates the Wnt signalling pathway.\nIn conclusion, we identified SLC35C1 as a negative regulator of the Wnt signalling pathway in colon cancer.\nAbstract: The canonical Wnt signalling pathway is a critical pathway involved in the proliferation of cells.\nRescue assays validated the role of TCS/miR-218-1-3p/SLC35C1 axis in regulating the viability, migration, invasion and inflammatory response of trophoblast cells.\nSupported by western blot analysis, functional experiments demonstrated that miR-218-1-3p overexpression impeded the proliferation, migration and invasion while exacerbating the inflammatory response of trophoblast cells.\nMoreover, solute carrier family 35 member C1 (SLC35C1) was validated as a target gene of miR-218-1-3p, and miR-218-1-3p was sustained to negatively modulate SLC35C1 expression in trophoblast cells.\nMeanwhile, in HEK293 cells silencing SLC35C1 activates canonical Wnt pathway, whereas overexpressing SLC35C1 inhibits it.\nConsistently, the reduction of SLC35C1 in H", "dois": ["10.1097/HEP.0000000000001003", "10.1158/2326-6066.CIR-22-0606", "10.7150/jca.84652", "10.1038/s41598-023-32375-0", "10.1097/HEP.0000000000000322", "10.1186/s12884-022-04791-z", "10.3389/fonc.2021.779153", "10.1111/jcmm.14969"]}
{"pair_type": "slc_pathway", "key1": "SLC35F3", "key2": "apoptosis", "summary": "Identified in GWAS studies, gene candidates may be grouped into blood group and immune system-related genes (, , , , , ), extracellular matrix and connective tissue genes (, , , , , ), signaling and cell communication (, , , , ), nervous system and neurodevelopment (, , , , , ), metabolism and transporters (, , , , ), lipids and cholesterol (, , ), transcription and gene regulation (, , ), apoptosis (, ), and poorly characterized genes (, , , , , , , , , , ).", "dois": ["10.3390/genes16050581"]}
{"pair_type": "slc_pathway", "key1": "SLC35F3", "key2": "glycolysis", "summary": "Solute carrier family 35 member F3 () mediates intracellular thiamine transport, which is crucial for carbohydrate metabolism as thiamine is required for key pathways such as glycolysis and the tricarboxylic acid cycle.", "dois": ["10.3390/nu15020469"]}
{"pair_type": "slc_pathway", "key1": "SLC35F2", "key2": "proliferation", "summary": "Knockdown of SLC35F2 inhibited cell proliferation, migration, and invasion while promoting apoptosis (P < 0.05), as demonstrated by CCK-8, EdU, colony formation, flow cytometry, TUNEL, scratch, and Transwell assays.\nAdditionally, we demonstrated that depletion in APC/C promotes SLC35F2-mediated cell proliferation, colony formation, migration, and invasion in HeLa cells.\nCRISPR/Cas9-mediated knockout of SLC35F2 attenuated the tumorigenic properties of PTC, including cell proliferation, migration and invasion and induced G1 phase arrest.\nMoreover, SLC35F2 expedited the proliferation and migration of PTC cells by targeting transforming growth factor-β type I receptor (TGFBR1) and phosphorylation of apoptosis signal-regulating kinase 1 (p-ASK-1), thereby activating the mitogen-activated protein kinase signaling pathway.\nRNA interference-mediated downregulation of SLC35F2 expression by lentiviral vector can attenuate the proliferation, migration and invasion of H1299 cells.\nOur study highlights that APC/C is a critical regulator of SLC35F2 protein turnover and depletion of APC/C promotes SLC35F2-mediated tumorigenesis.\nProliferation decreased significantly compared with that of non-transfected H1299 cells.\nIn contrast, ectopic expression of SLC35F2 brought about aggressive malignant phenotypes of PTC cells.\nThese findings suggest that SLC35F2 drives NSCLC progression by modulating the cAMP/CREB1 axis, highlighting its potential as a therapeutic target.\nThe cell cycle of H1299 cells was changed, the percentage of H1299 cells in S and G2/M phases being significantly decreased compared with untransfected H1299 cells (S phase: 15.3% ± 3.0% vs. 10.5% ± 1.7%, P < 0.05), whereas the percentage of H1299 cells in G0/G1 phase increased markedly (81", "dois": ["10.1007/s10616-025-00814-7", "10.1038/s41388-023-02843-y", "10.1016/j.bbagen.2023.130454", "10.2147/OTT.S229332", "10.1111/cas.13478", "10.1186/1475-2867-13-73"]}
{"pair_type": "slc_pathway", "key1": "SLC35F2", "key2": "chemotherapy", "summary": "YM155 generated DNA damage through intercalation, which was contingent on the expression of SLC35F2 and its drug-importing activity.\nSLC35F2 expression and YM155 sensitivity correlated across a panel of cancer cell lines, and targeted genome editing verified SLC35F2 as the main determinant of YM155-mediated DNA damage toxicity in vitro and in vivo.\nA subset of these solute carriers play a significant role in the cellular uptake of many cancer therapeutics, ranging from chemotherapeutics such as antimetabolites, topoisomerase inhibitors, platinum-based drugs and taxanes to targeted therapies such as tyrosine kinase inhibitors.\nThis frequently serves to feed the increased metabolic demands of the tumor cell for amino acids, nucleotides and other metabolites, but also presents a therapeutic opportunity, as increased transporter expression may serve to increase intracellular concentrations of substrate drugs.\nThese findings suggest a new route to targeted DNA damage by exploiting tumor and patient-specific import of YM155.\nWe propose that among the oncogenic changes in SLC transporter expression there exist emergent vulnerabilities that can be exploited therapeutically, extending the application of precision medicine from tumor-specific drug targets to tumor-specific determinants of drug uptake.", "dois": ["10.3390/molecules22040539", "10.1038/nchembio.1590"]}
{"pair_type": "slc_pathway", "key1": "SLC35F2", "key2": "migration", "summary": "Knockdown of SLC35F2 inhibited cell proliferation, migration, and invasion while promoting apoptosis (P < 0.05), as demonstrated by CCK-8, EdU, colony formation, flow cytometry, TUNEL, scratch, and Transwell assays.\nAdditionally, we demonstrated that depletion in APC/C promotes SLC35F2-mediated cell proliferation, colony formation, migration, and invasion in HeLa cells.\nCRISPR/Cas9-mediated knockout of SLC35F2 attenuated the tumorigenic properties of PTC, including cell proliferation, migration and invasion and induced G1 phase arrest.\nAdditionally, the depletion of βTrCP1 accumulated SLC35F2 protein and promoted SLC35F2-mediated cell growth, migration, invasion, and colony formation ability in HeLa cells.\nMoreover, SLC35F2 expedited the proliferation and migration of PTC cells by targeting transforming growth factor-β type I receptor (TGFBR1) and phosphorylation of apoptosis signal-regulating kinase 1 (p-ASK-1), thereby activating the mitogen-activated protein kinase signaling pathway.\nMoreover, knockdown of SLC35F2 repressed the growth of bladder cancer cells in the monolayer and spheroid model and suppressed migration and invasion of bladder cancer cells.\nRNA interference-mediated downregulation of SLC35F2 expression by lentiviral vector can attenuate the proliferation, migration and invasion of H1299 cells.\nThe malignant behaviors induced by overexpression of SLC35F2 could be abrogated by silencing of TGFBR1 using a specific inhibitor.\nThe depletion of βTrCP1 promotes SLC35F2-mediated carcinogenesis.\nOur study highlights that APC/C is a critical regulator of SLC35F2 protein turnover and depletion of APC/C promotes SLC35F2-mediated tumorigenesis.\nThe role of APC/C regulating SLC35F2-mediated tumorigenesis was confirmed by in vitro oncogenic experiments in H", "dois": ["10.1007/s10616-025-00814-7", "10.1016/j.bbrc.2023.09.095", "10.1016/j.bbagen.2023.130454", "10.3390/cells10010080", "10.2147/OTT.S229332", "10.1111/cas.13478", "10.1186/1475-2867-13-73"]}
{"pair_type": "slc_pathway", "key1": "SLC35F4", "key2": "apoptosis", "summary": "Here, we studied the role of the CNC protein, Nfe2, in the developmental response to pro-oxidant exposure in the zebrafish (Danio rerio).\nIn response to pro-oxidant exposure, members of the Cap'n'Collar (CNC) basic leucine zipper (b-ZIP) transcription factor family (including Nfe2 and Nfe2-related factors, Nrfs) activate the expression of genes whose protein products contribute to reduced toxicity.\nAcross time and treatment, there were six genes (dhx40, cfap70, dnajb9b, slc35f4, spi-c, and gpr19) that were significantly up-regulated in KO compared to WT and four genes (fhad1, cyp4v7, nlrp12, and slc16a6a) that were significantly down-regulated.\nMore specifically, in animals exposed to pro-oxidants a total of 968 genes were differentially expressed between WT and KO across developmental time, representing pathways involved in coagulation, embryonic organ development, body fluid level regulation, erythrocyte differentiation, and oxidation-reduction, amongst others.\nThese results demonstrate that the zebrafish Nfe2 may be a regulator of both primitive erythropoiesis and the OSR during development.\nDevelopment is a complex and well-defined process characterized by rapid cell proliferation and apoptosis.", "dois": ["10.1016/j.aquatox.2016.09.019"]}
{"pair_type": "slc_pathway", "key1": "SLC35F2", "key2": "apoptosis", "summary": "Knockdown of SLC35F2 inhibited cell proliferation, migration, and invasion while promoting apoptosis (P < 0.05), as demonstrated by CCK-8, EdU, colony formation, flow cytometry, TUNEL, scratch, and Transwell assays.\nOur findings suggest that SLC35F2 exerts its oncogenic effect on PTC progression through the mitogen-activated protein kinase pathway, with dependence on activation of TGFBR-1 and apoptosis signal-regulating kinase 1.\nMoreover, SLC35F2 expedited the proliferation and migration of PTC cells by targeting transforming growth factor-β type I receptor (TGFBR1) and phosphorylation of apoptosis signal-regulating kinase 1 (p-ASK-1), thereby activating the mitogen-activated protein kinase signaling pathway.\nAdditionally, the GSEA highlighted the enrichment of apoptosis, adhesion, small cell lung cancer (SCLC), and p53 signaling pathways in the subgroup of LUAD patients with elevated SLC35F2 expression.\nONC212 induces apoptosis, MCL1 downregulation, and mitochondrial depolarization in AML U937 cells.\nYM155 induced apoptosis in AML cells, which was characterized by p38 MAPK phosphorylation and downregulation of survivin and MCL1 expression.\nWe investigated the mechanism underlying the combined cytotoxicity of DAC and YM155 in acute myeloid leukemia (AML) cells because of increasing evidence that YM155 induces apoptosis in cancer cells.\nIn U937/HQ cells, ONC212 triggered apoptosis through NOXA-mediated MCL1 downregulation, enhancing YM155 cytotoxicity.\nEctopic MCL1 expression alleviates mitochondria-mediated apoptosis in ONC212-treated U937 cells.\nCRISPR/Cas9-mediated knockout of SLC35F2 attenuated the tumorigenic properties of PTC, including cell proliferation, migration and invasion and induced G1 phase arrest.", "dois": ["10.1016/j.bcp.2024.116242", "10.1007/s10495-023-01918-1", "10.7150/thno.63806", "10.1038/nchembio.1590", "10.1007/s10616-025-00814-7", "10.1016/j.heliyon.2023.e23828", "10.1016/j.bcp.2021.114544", "10.2147/OTT.S229332", "10.1111/cas.13478"]}
{"pair_type": "slc_pathway", "key1": "SLC35F4", "key2": "oxidative stress", "summary": "Across time and treatment, there were six genes (dhx40, cfap70, dnajb9b, slc35f4, spi-c, and gpr19) that were significantly up-regulated in KO compared to WT and four genes (fhad1, cyp4v7, nlrp12, and slc16a6a) that were significantly down-regulated.\nIn response to pro-oxidant exposure, members of the Cap'n'Collar (CNC) basic leucine zipper (b-ZIP) transcription factor family (including Nfe2 and Nfe2-related factors, Nrfs) activate the expression of genes whose protein products contribute to reduced toxicity.\nComparing diquat and tBOOH exposed embryos relative to the WT untreated control, a greater number of genes were up-regulated in the tBOOH condition as compared to diquat (tBOOH: 304 vs diquat: 148), including those commonly found to be differentially regulated in the vertebrate oxidative stress response (OSR).\nMore specifically, in animals exposed to pro-oxidants a total of 968 genes were differentially expressed between WT and KO across developmental time, representing pathways involved in coagulation, embryonic organ development, body fluid level regulation, erythrocyte differentiation, and oxidation-reduction, amongst others.\nEarly in development, KO animals suffered from hypochromia that was made more severe through exposure to pro-oxidants.\nFollowing acute waterborne exposures to diquat or tert-buytlhydroperoxide (tBOOH) at one of three developmental stages, wildtype (WT) and nfe2 knockout (KO) embryos and larvae were morphologically scored and their transcriptomes sequenced.\nWT and KO eleutheroembryos and larvae were phenotypically equally affected by exposure to pro-oxidants, where tBOOH caused more pronounced phenotypes as compared to diquat.", "dois": ["10.1016/j.aquatox.2016.09.019"]}
{"pair_type": "slc_pathway", "key1": "SLC35F4", "key2": "proliferation", "summary": "Across time and treatment, there were six genes (dhx40, cfap70, dnajb9b, slc35f4, spi-c, and gpr19) that were significantly up-regulated in KO compared to WT and four genes (fhad1, cyp4v7, nlrp12, and slc16a6a) that were significantly down-regulated.\nDevelopment is a complex and well-defined process characterized by rapid cell proliferation and apoptosis.", "dois": ["10.1016/j.aquatox.2016.09.019"]}
{"pair_type": "slc_pathway", "key1": "SLC35F6", "key2": "apoptosis", "summary": "SLC35F6 is involved in cell apoptosis through the Bcl2/BAX/caspase3 pathway and can also affect mitochondrial membrane potential.", "dois": ["10.5713/ab.24.0547"]}
{"pair_type": "slc_pathway", "key1": "SLC35F6", "key2": "migration", "summary": "SLC35F6 is involved in cell apoptosis through the Bcl2/BAX/caspase3 pathway and can also affect mitochondrial membrane potential.\nSKAP1 could affect the expression of CD3 and CD4, and influence the migration and proliferation ability of cells.\nChanges in the expression levels of KSR1 could alter the expression of IL1-β, IL6, and TNF-α, as well as cell migration and proliferation.", "dois": ["10.5713/ab.24.0547"]}
{"pair_type": "slc_pathway", "key1": "SLC35G5", "key2": "chemotherapy", "summary": "We identified several genes that were commonly mutated in pre-NACT samples specific to platinum-resistant (CSPG4, SLC35G5, TUBA3D) or sensitive (CYP2D6, NUTM1, DNAH5) cases.\nThe mutated genes detected in chemo-naive pre-NACT tumor samples from either resistant or sensitive cases could potentially have a role in the prediction of chemotherapy response in patients scheduled to receive NACT;\nNACT significantly impacts the somatic mutation status irrespective of the time to recurrence.", "dois": ["10.1186/s13048-022-00983-5"]}
{"pair_type": "slc_pathway", "key1": "SLC35G1", "key2": "apoptosis", "summary": "Network modelling pinpointed as signature of competent CCs three down-regulated outliers (EFHD1, HS6ST2, SLC35G1) and two hubs (CDC6, KIF11), while the unsuccessful ones revealed six outliers (HBA1, SLC39A8, ERO1A, TKDP5, CALCRL, ELOVL6) and the hub CASP3.\nThe profile of EAfs enclosing competent oocyte converged towards cumulus expansion and controlled cell-cycle quiescence pathways whereas lipid dysregulation, oxidative stress and apoptosis characterized CC surrounding incompetent oocytes.", "dois": ["10.3389/fendo.2025.1629815"]}
{"pair_type": "slc_pathway", "key1": "SLC35F6", "key2": "proliferation", "summary": "SLC35F6 negatively regulates outer mitochondrial membrane permeability and positively regulates apoptotic signaling pathways and cell population proliferation.\nUlva lactuca polysaccharide (ULP), a natural extract with known antitumor properties, exerts its effects by upregulating miR-542-3p, which in turn inhibits SLC35F6 expression and significantly increases TP53 protein levels.\nKnockdown of SLC35F6 in H22 and HepG2 cells markedly reduced cell growth while elevating TP53 expression, supporting SLC35F6 as a key regulatory factor in the miR-542-3p/TP53 axis.\nWhile this study did not confirm direct mutual regulation between SLC35F6 and TP53, our findings provide evidence that targeting SLC35F6 can suppress HCC progression.\nSLC35F6 is involved in cell apoptosis through the Bcl2/BAX/caspase3 pathway and can also affect mitochondrial membrane potential.\nCollectively, these results identify SLC35F6 as a potential therapeutic target for HCC and provide mechanistic insights into its regulation through the miR-542-3p/SLC35F6/TP53 axis.\nHere, we demonstrate that SLC35F6 is overexpressed in HCC and is associated with poor prognosis.\nSLC35F6 is upregulated in BC patients compared to normal individuals and is linked to a worse prognosis.\nKaplan-Meier analysis indicated that patients exhibiting elevated SLC35F6 protein expression had a worse prognosis.\nThe expression levels of both SLC35F6 mRNA and protein were elevated in BC tissue relative to benign tissue.\nMultivariate Cox regression analysis confirmed that SLC35F6, TNM stage and grade are independent risk factors for bladder cancer.\nSKAP1 could affect the expression of CD3 and CD4, and influence the migration and proliferation ability of cells.\nChanges in the expression levels of KSR1 could alter the expression of IL1-β, IL6, and TNF-α, as well as cell migration and proliferation.", "dois": ["10.1016/j.ijbiomac.2025.142252", "10.1186/s13000-024-01582-2", "10.5713/ab.24.0547", "10.1002/jcla.23312"]}
{"pair_type": "slc_pathway", "key1": "SLC35G1", "key2": "oxidative stress", "summary": "Network modelling pinpointed as signature of competent CCs three down-regulated outliers (EFHD1, HS6ST2, SLC35G1) and two hubs (CDC6, KIF11), while the unsuccessful ones revealed six outliers (HBA1, SLC39A8, ERO1A, TKDP5, CALCRL, ELOVL6) and the hub CASP3.\nThe profile of EAfs enclosing competent oocyte converged towards cumulus expansion and controlled cell-cycle quiescence pathways whereas lipid dysregulation, oxidative stress and apoptosis characterized CC surrounding incompetent oocytes.", "dois": ["10.3389/fendo.2025.1629815"]}
{"pair_type": "slc_pathway", "key1": "SLC35G5", "key2": "proliferation", "summary": "In patients with poor outcomes within 24 months post-RT, CLTCL1, RGL3 and H3C12 showed significant prognostic value in multivariate Cox analyses, while SLC35G5, GARS1 and JPH3 were identified as prognostic markers for CCRT.", "dois": ["10.1038/s41598-025-05025-w"]}
{"pair_type": "slc_pathway", "key1": "SLC36A1", "key2": "glycolysis", "summary": "Following ALA treatment, tumor cells preferentially accumulate porphyrins because of the differential activities of aerobic glycolysis, known as Warburg effect.\nAmong various human cell lines of hematological malignancies, including K562 erythroleukemia, Jurkat T-cell leukemia, Nalm6 pre-B cell leukemia, KG1a myeloid leukemia, and U937 monocytic leukemia, human myeloma cell line, KMS18, and OPM2 abundantly expressed ALA transporters, such as SLC36A1 and SLC15A2, and 1 mM ALA treatment for 24 h resulted in nearly 100% porphyrin fluorescence expression, which could be competitively inhibited by ALA transport with gamma-aminobutyric acid.\nCompared with IPAA, metabolomics via gas chromatography-mass spectrometry revealed that increases in availability of Thr, Ile, Val, and Leu led to greater concentrations of essential AA (Leu, Ile, Thr), nonessential AA (Gly, Glu, Gln, Ser, Pro, Asp), and various metabolites including uric acid, phosphoric acid, N-acetylglutamic acid, and intermediates of glycolysis and the tricarboxylic acid cycle.\nAlthough LI1.29 led to the second highest response in mTORC1 phosphorylation status, it resulted in the lowest phosphorylation of Akt and eEF2 and mRNA abundance of CSN2 and various AA transporters (SLC7A5, SLC36A1, SLC38A2, SLC38A9, SLC43A1).", "dois": ["10.1620/tjem.249.19", "10.3168/jds.2017-13707"]}
{"pair_type": "slc_pathway", "key1": "SLC35G6", "key2": "migration", "summary": "We found that genes involved in identified pathways or with high accumulation scores in the effusion-based DLBCL cases were associated with migration/invasion.", "dois": ["10.1186/s40364-021-00330-8"]}
{"pair_type": "slc_pathway", "key1": "SLC36A1", "key2": "proliferation", "summary": "We find SLC36A1 is overexpressed in kidney cancer, which promotes mTOR activity and kidney cancer cell proliferation.\nThe growth rates of the cells were evaluated, and knockdown of PAT1 led to induced cellular growth, suggesting a role for PAT1 in regulating cellular proliferation of SMCs.\nMammalian Target of Rapamycin Complex 1 (mTORC1) is activated by growth factor-regulated phosphoinositide 3-kinase (PI3K)/Akt/Rheb signalling and extracellular amino acids (AAs) to promote growth and proliferation.\nCollectively, we uncover a functional TFE3-SLC36A1 axis that responds to glucose starvation and enhances starvation tolerance in kidney cancer.\nWe have recently shown that intracellular Proton-assisted Amino acid Transporter 1 (PAT1)/SLC36A1 is an essential mediator of AA-dependent mTORC1 activation.\nWe recently reported TFE3 constitutively localizes to the cell nucleus and promotes cell proliferation in kidney cancer even under nutrient replete condition.\nThe results showed that 0.5 and 1.0 mmol/L proline enhanced cell viability.\nThese data indicated that proline activates themTORC1 signaling and modulates the intracellular redox environment via enhancing proline transport.\nElevated PI3K/Akt/Rheb signalling increases intracellular levels of PATs and synergistically enhances PAT-induced growth via a mechanism requiring endocytosis.\nFurthermore, through an unbiased functional genomic study, we identify SLC36A1, a lysosomal amino acid transporter, as a TFE3 target gene sensitive to TFE3 protein level.\nAdditionally, proline dose-dependently enhanced the mRNA expression of proline transporters [solute carrier family () , , , , and ], elevated proline concentration, and protein abundance of proline dehydrogenase (PRODH).\nIn light of the recent identification of the vacuolar H(+)-ATPase as another Rag-interacting component, we propose a model in which", "dois": ["10.1016/j.jbc.2024.107270", "10.3390/biom11050742", "10.1152/ajpendo.00322.2013", "10.1371/journal.pone.0036616"]}
{"pair_type": "slc_pathway", "key1": "SLC36A1", "key2": "oxidative stress", "summary": "The downregulation of SLC36A1 and SLC7A1 mRNA abundance induced by LPS was attenuated in the incArg cultures.\nLittle benefit on oxidative stress induced by LPS challenge in BMEC was detected with greater supply of Met and Arg.\nMethionine (Met) and arginine (Arg) are key nutrients with potential to regulate inflammation and oxidative stress.\nAlthough challenge with LPS led to lower abundance of proteins related to the antioxidant response (NFE2L2, NQO1, GPX1), lower levels of ATG7, and lower mRNA abundance of GPX3, we found little effect in cultures with incMet or incArg.", "dois": ["10.3168/jds.2019-16631"]}
{"pair_type": "slc_pathway", "key1": "SLC36A2", "key2": "proliferation", "summary": "The results showed that 0.5 and 1.0 mmol/L proline enhanced cell viability.\nThese data indicated that proline activates themTORC1 signaling and modulates the intracellular redox environment via enhancing proline transport.\nThese effects of proline (0.5 mmol/L) were accompanied by the enhanced protein abundance of p-mTORC1, p-p70S6K, p-S6, and p-4E-BP1.\nThis study used porcine trophectoderm cell line 2 (pTr2) to investigate the underlying mechanisms of proline in cell proliferation and redox homeostasis.\nAdditionally, proline dose-dependently enhanced the mRNA expression of proline transporters [solute carrier family () , , , , and ], elevated proline concentration, and protein abundance of proline dehydrogenase (PRODH).\nL-proline (proline) is a key regulator of embryogenesis, placental development, and fetal growth.", "dois": ["10.3390/biom11050742"]}
{"pair_type": "slc_pathway", "key1": "SLC36A4", "key2": "proliferation", "summary": "Consistent with this, PAT4 promotes HCT116 human colorectal cancer cell proliferation in culture and tumour growth in xenograft models.\nOverexpressed PAT4 is also able to promote rapamycin resistance in human embryonic kidney-293 cells.\nWe show that independent of other major pathological factors, high PAT4 expression is associated with reduced relapse-free survival after colorectal cancer surgery.\nFurthermore, in HCT116 cells two non-essential amino acids, glutamine and serine, which are often rapidly metabolised by tumour cells, regulate rapamycin-resistant mTORC1 in a PAT4-dependent manner.\nInducible knockdown in HCT116 cells reveals that PAT4 regulates a form of mTORC1 with two distinct properties: first, it preferentially targets eukaryotic translation initiation factor 4E-binding protein 1 (4E-BP1), and second, it is resistant to rapamycin treatment.\nFurthermore, our data predict that colorectal cancer cells with high PAT4 expression will be more resistant to depletion of serine and glutamine, allowing them to survive and outgrow neighbouring normal and tumorigenic cells, and potentially providing a new route for pharmacological intervention.", "dois": ["10.1038/onc.2015.363"]}
{"pair_type": "slc_pathway", "key1": "SLC37A1", "key2": "proliferation", "summary": "In the present study, we demonstrate for the first time that epidermal growth factor (EGF) transactivates SLC37A1 promoter sequence and induces SLC37A1 mRNA, and protein expression through the EGFR/MAPK/Fos transduction pathway in ER-negative SkBr3 breast cancer cells.\nOn the basis of our data, the up-regulation of SLC37A1 gene expression should be included among the well-known stimulatory action exerted by EGF in breast cancer cells.\nPhospholipid biosynthesis exerts an important role in the proliferation of tumor cells;\nInterestingly, we also show that SLC37A1 protein localizes in the endoplasmic reticulum, hence supporting its possible involvement in phospholipid biosynthesis.\nThe sequence homology with the bacterial glycerol-3-phosphate transporter (30%) suggests that SLC37A1 might be able to catalyze an exchange of glycerol-3-phosphate against phosphate.\nGlycerol-3-phosphate, found in different cellular compartments, is a fundamental substrate in phospholipid biosynthesis.\nIn addition, further studies are required to provide evidence concerning the potential role of EGF-mediated SLC37A1 induction in breast tumor cells.\nThese findings were corroborated by comparable results obtained in ER-positive endometrial Ishikawa tumor cells.", "dois": ["10.1007/s10549-009-0620-x"]}
{"pair_type": "slc_pathway", "key1": "SLC37A2", "key2": "apoptosis", "summary": "Loss of the transporter Slc37a2 blocks phagosomal shrinkage, resulting in the expansion of the gastrosome and the dramatic bloating of the cell.\nSERPINE2/STMN1 overexpression increased viability and decreased apoptosis of dexamethasone-treated MC3T3-E1 cells.\nLRG1, SERPINE2, STMN1, COL14A1, SLC37A2, and MMP2 were determined as the key genes/proteins in FHN.\nThe protein expression of Bax and Bcl-2 were used to evaluate cell apoptosis.\nDEGs were mainly involved in PI3K-Akt pathway and DEPs were mainly focused in glycolysis/gluconeogenesis pathway.\nNotably, 14 down-regulated and 22 up-regulated genes/proteins were detected at both the transcript and protein level.\nUsing both living fish embryos and mammalian macrophages, we show that processing depends on the shrinkage and packaging of phagosomes into a unique cellular compartment, the gastrosome, with distinct molecular and ultra-structural characteristics.\nThis, in turn, affects the ability of microglia to phagocytose and migrate toward brain injuries.\nEffective intracellular processing of ingested cells is likely to be crucial for microglial function, but the underlying cellular mechanisms are poorly understood.\nThus, this work identifies a conserved crucial step in the phagocytic pathway of immune cells and provides a potential entry point for manipulating their behavior in development and disease.", "dois": ["10.1016/j.devcel.2019.02.014", "10.1016/j.yexcr.2021.112513"]}
{"pair_type": "slc_pathway", "key1": "SLC37A2", "key2": "glycolysis", "summary": "Conversely, overexpression of SLC37A2 lowers macrophage glycolysis and significantly reduces LPS-induced pro-inflammatory cytokine expression.\nImportantly, SLC37A2 deficiency impaired apoptotic cell-induced glycolysis, subsequently attenuating IL-10 production.\nBlockade of glycolysis normalizes the differential expression of pro-inflammatory cytokines between control and SLC37A2 deficient macrophages.\nOur study demonstrated that SLC37A2 deficiency impaired IL-4-induced macrophage activation, independently of glycolysis or mitochondrial respiration.\nSolute Carrier Family 37 Member 2 (SLC37A2) Negatively Regulates Murine Macrophage Inflammation by Controlling Glycolysis.\nIncreased flux of glucose through glycolysis is a hallmark of inflammatory macrophages and is essential for optimal effector functions.\nIn conclusion, our study suggests that SLC37A2 dampens murine macrophage inflammation by down-regulating glycolytic reprogramming as a part of macrophage negative feedback system to curtail acute innate activation.\nOur previous study demonstrated that solute carrier family 37 member 2 (SLC37A2), an endoplasmic reticulum-anchored phosphate-linked glucose-6-phosphate transporter, negatively regulates macrophage Toll-like receptor activation by fine-tuning glycolytic reprogramming.\nWe demonstrate that SLC37A2 plays a pivotal role in murine macrophage inflammatory activation and cellular metabolic rewiring.\nSLC37A2 deletion reprograms macrophages to a hyper-glycolytic process and accelerates LPS-induced inflammatory cytokine production, which partially depends on nicotinamide adenine dinucleotide (NAD) biosynthesis.", "dois": ["10.3389/fcvm.2021.777098", "10.1016/j.yexcr.2021.112513", "10.1016/j.isci.2020.101125"]}
{"pair_type": "slc_pathway", "key1": "SLC37A2", "key2": "proliferation", "summary": "Esophageal squamous cell carcinoma (ESCC) has a dismal prognosis, and hypoxia plays a key role in metastasis and proliferation of ESCC.\nA hypoxia risk model containing six genes (PNPLA1, CARD18, IL-18, SLC37A2, ADAMTS18, and FAM83C) was constructed by screening key HRGs.", "dois": ["10.1002/cam4.5002", "10.2147/IJN.S343361"]}
{"pair_type": "slc_pathway", "key1": "SLC37A2", "key2": "ferroptosis", "summary": "Our study further confirmed that RAB10 mediates metabolic reprogramming in BC cells by regulating the Slc37a2/mTOR pathway, leading to enhanced autophagy and inhibition of ferroptosis.\nA comprehensive multi-omics analysis, including metabolomics and proteomics, following RAB10 knockdown, demonstrated the crucial role of RAB10 in regulating central carbon metabolism, which is essential for autophagy and ferroptosis in BC cells.", "dois": ["10.1007/s00018-025-05788-5", "10.2147/IJN.S343361"]}
{"pair_type": "slc_pathway", "key1": "SLC37A3", "key2": "apoptosis", "summary": "Cell functional experiments suggested that SLC37A3 knockdown inhibited HCC cell proliferation and metastasis, but promoted apoptosis.\nFurther rescue experiments demonstrated that silencing SLC37A3 or upregulating miR-211-5p reversed the effects of TUSC7 elevation on cell proliferation and apoptosis.\nMeanwhile, TUSC7 overexpression inhibited cell proliferation while promoting cell apoptosis.\nMechanistically, TUSC7 interacted with miR-211-5p, thereby regulating the downstream target gene, solute carrier family 37 member 3 (SLC37A3).", "dois": ["10.1002/kjm2.70003", "10.1016/j.bbadis.2023.166661", "10.1186/1472-6793-13-9"]}
{"pair_type": "slc_pathway", "key1": "SLC37A4", "key2": "chemotherapy", "summary": "Significantly, our research demonstrates that both SRSF9 and its regulated splicing isoforms of SLC37A4-S contribute to cisplatin chemotherapy resistance in oral cancer cells.", "dois": ["10.1016/j.jare.2025.03.013"]}
{"pair_type": "slc_pathway", "key1": "SLC37A4", "key2": "apoptosis", "summary": "However, persistent metabolic stress overrides an adaptation and induces apoptosis through increased expression of pro-apoptotic markers (decreased ratio of BCL2/BAX genes).\nThe aim of this study was to investigate the expression of molecular markers of the UPR response and apoptosis related to a deficiency of SLC37A4 in kidney cells.\nWe demonstrated that under chronic metabolic stress conditions caused by SLC37A4 deficiency, the ER stress-induced UPR was triggered, resulting in suppression of the UPR molecular markers and cell survival promotion (decreased expression levels of ATF4, DDIT3, HSPA5, with the exception of XBP1s).\nExpression analysis in a novel model system supports the hypothesis that renal dysfunction in the GSD Ib is partly due to the ER stress and increased apoptosis.\nThe leukocytes from the proband showed increased mRNA levels of sXBP-1, BIP, and CHOP genes in the unfolded protein response pathway, and enhanced Bax mRNA and caspase-3 activity, which might contribute to leukocytopenia.\nIn this model system we used RT-qPCR analysis to investigate the expression of molecular markers of the UPR response (ATF4, DDIT3, HSPA5, and XBP1s) and apoptosis (BCL2, BAX).\nWe hypothesize that restoration of neutrophil function and normalisation of neutrophil apoptosis leads to improvement of wound healing and ameliorates symptoms of inflammatory bowel disease.\nMolecular markers of the adaptive responses to the metabolic stress caused by a deficiency of SLC37A4, such as markers related to the endoplasmic reticulum (ER) stress and unfolded protein response (UPR), have not been extensively studied.\nWe established a cellular model system characterized by a deficiency of SLC37A4, which presents pathological manifestations of GSD Ib in the kidney.\nDeficiency of SLC37A4 leads to abnormal storage of glycogen in the liver and kidneys, resulting in long-term complications of renal disease and hepatocellular adenomas, whose mechanisms are poorly understood.", "dois": ["10.1002/mgg3.1568", "10.1016/j.gene.2019.04.002", "10.3390/ph16010117", "10.1186/s13023-020-01503-8"]}
{"pair_type": "slc_pathway", "key1": "SLC37A3", "key2": "proliferation", "summary": "Cell functional experiments suggested that SLC37A3 knockdown inhibited HCC cell proliferation and metastasis, but promoted apoptosis.\nIn conclusion, our findings suggest that TUSC7 regulates cell proliferation in CLL through the miR-211-5p/SLC37A3 axis.\nFurther rescue experiments demonstrated that silencing SLC37A3 or upregulating miR-211-5p reversed the effects of TUSC7 elevation on cell proliferation and apoptosis.\nMeanwhile, TUSC7 overexpression inhibited cell proliferation while promoting cell apoptosis.\nXenograft tumour experiments also suggested that SLC37A3 knockdown significantly inhibited HCC tumourigenesis in vivo.", "dois": ["10.1002/kjm2.70003", "10.1016/j.bbadis.2023.166661"]}
{"pair_type": "slc_pathway", "key1": "SLC37A3", "key2": "glycolysis", "summary": "The expression levels of insulin secretion-related and glycolysis/gluconeogenesis-related genes were also altered, suggesting that SLC37A3 might be involved in the regulation of glucose homeostasis.\nSLC37A3 represents a prospective diagnostic and prognostic biomarker for HCC that functions in glucose metabolism regulation.", "dois": ["10.1016/j.bbadis.2023.166661"]}
{"pair_type": "slc_pathway", "key1": "SLC37A4", "key2": "oxidative stress", "summary": "Increasing evidences highlight the role of empagliflozin in regulating the cellular energy sensors SIRT1/AMPK and Akt/mTOR, which leads to improvement of mitochondrial structure and function, stimulation of autophagy, decrease of oxidative stress and suppression of inflammation.\nThe biological processes associated with these genes are oxidative stress, apoptosis regulation, and glucose and fatty-acid homeostasis.\nModulation of these pathways shift the oxidative metabolism from carbohydrates to lipids oxidation and results crucial in reducing insulin levels, insulin resistance, glucotoxicity and lipotoxicity.\nG6PT defect results in excessive accumulation of glycogen and fat in the liver, kidney, and intestinal mucosa and into both glycogenolysis and gluconeogenesis impairment.", "dois": ["10.3389/fendo.2023.1145111", "10.3390/ph16010117"]}
{"pair_type": "slc_pathway", "key1": "SLC38A1", "key2": "chemotherapy", "summary": "Patients with a high level of SLC38A1 expression presented significantly shorter overall survival in whole-cohort, chemotherapy-only, and non-inv(16) AML (p = 0.0049, 0.0247, and 0.0005 respectively).\nWe demonstrated that functional inhibition of SNAT1 with α-(methylamino) isobutyric acid (MeAIB), as well as siRNA-mediated downregulation reduces cancer cell growth, cellular migration, invasion, and leads to induction of senescence in melanoma cells.\nConsequently, these results demonstrate that the amino acid transporter SNAT1 is essential for cancer growth, and indicates a potential target for cancer chemotherapy.\nMoreover, both univariate and multivariate analyses showed that high SLC38A1 expression was an independent unfavorable prognostic biomarker for AML (p = 0.0057 and 0.0483, respectively).\nIn summary, our study revealed SLC38A1 as a valuable prognostic and predictive marker for AML.\nFurther, glutamine transporter SLC38A1 might serve as a potential target for the development of novel therapeutic drugs in the treatment of AML.\nEspecially SNAT1/SLC38A1, a member of the sodium neutral amino acid transporter (SNAT) family, plays an essential role during major net import of glutamine.\nThe results showed that patients with high SLC38A1 expression had a lower mutation rate of NPM1 gene and higher incidence of adverse-risk karyotype (p = 0.0010 and 0.0051, respectively).", "dois": ["10.3390/cancers14092151", "10.1002/jcp.28632", "10.1074/jbc.M115.700534"]}
{"pair_type": "slc_pathway", "key1": "SLC37A4", "key2": "glycolysis", "summary": "Mechanistically, deficiency of G6PT promotes glycolysis and lactate production in macrophages.\nUsing a combination of enzymological, cell-culture, and in vivo approaches, we demonstrate that G6PT and G6PC3 collaborate to destroy 1,5-anhydroglucitol-6-phosphate (1,5AG6P), a close structural analog of glucose-6-phosphate and an inhibitor of low- hexokinases, which catalyze the first step in glycolysis in most tissues.\nGranulocytes from patients deficient in G6PC3 or G6PT accumulate 1,5AG6P to concentrations (∼3 mM) that strongly inhibit hexokinase activity.\nIn a model of G6PC3-deficient mouse neutrophils, physiological concentrations of 1,5-anhydroglucitol caused massive accumulation of 1,5AG6P, a decrease in glucose utilization, and cell death.\n1,5-Anhydroglucitol (1,5AG), a natural monosaccharide, is erroneously phosphorylated by glucose-phosphorylating enzymes to produce 1,5-anhydroglucitol-6-phosphate (1,5AG6P), a powerful inhibitor of hexokinases.\nThe endoplasmic reticulum transporter (SLC37A4/G6PT) and the phosphatase G6PC3 cooperate to dephosphorylate 1,5AG6P.\nFailure to eliminate 1,5AG6P is the mechanism of neutrophil dysfunction and death in G6PC3-deficient mice.\nWe show that 1,5AG6P is made by phosphorylation of 1,5-anhydroglucitol, a compound normally present in human plasma, by side activities of ADP-glucokinase and low- hexokinases.\nIn conclusion, we show that the neutropenia in patients with G6PC3 or G6PT mutations is a metabolite-repair deficiency, caused by a failure to eliminate the nonclassical metabolite 1,5AG6P.", "dois": ["10.3177/jnsv.71.46", "10.1016/j.jaci.2025.01.028", "10.1007/s10875-022-01323-4", "10.1073/pnas.1816143116"]}
{"pair_type": "slc_pathway", "key1": "SLC37A4", "key2": "proliferation", "summary": "This splicing anomaly leads to the production of a truncated isoform, SLC37A4-S, which is associated with a poor prognosis and significantly augments the proliferation and metastatic potential of oral cancer cells relative to the wild-type isoform, SLC37A4-L.\nNutrient or energy deficiency stresses the survival, proliferation, and differentiation of neutrophils and their precursors.\nMore than 10 neutrophils are produced every minute in an adult bone marrow-a process that is tightly regulated by a small group of cytokines and chemical mediators and dependent on nutrients and energy.\nNeutrophils are the shortest-lived blood cells, which requires a prodigious degree of proliferation and differentiation to sustain physiologically sufficient numbers and be poised to respond quickly to infectious emergencies.\nIn vivo and in vitro experiments with subcutaneous graft tumors, CCK8, EdU, transwell, and others were used to detect the effects of SRSF9 and its induced SLC37A4-S isoforms on the malignant phenotype of oral cancer cells.\nSignificantly, our research demonstrates that both SRSF9 and its regulated splicing isoforms of SLC37A4-S contribute to cisplatin chemotherapy resistance in oral cancer cells.\nThis study elucidates the mechanism by which SRSF9 phase separation mediates splicing in oral cancer, thereby establishing a basis for considering SRSF9 and its associated SLC37A4-S isoforms as potential therapeutic targets for oral cancer treatment.\nOur investigation revealed a multitude of aberrant alternative splicing events within head and neck tumor tissues, most notably the pronounced skipping of exon 7 in the SLC37A4 gene.\nMechanically, SRSF9 may play a regulatory role in the aberrant splicing of SLC37A4.\nDisruption of SRSF9 LLPS through the use of inhibitors or mutants effectively prevents its regulatory influence on the splicing of SLC37A4.", "dois": ["10.1016/j.jare.2025.03.013", "10.1111/bjh.19192"]}
{"pair_type": "slc_pathway", "key1": "SLC38A1", "key2": "glycolysis", "summary": "upregulated the ferroptosis-associated genes, including Ptgs2 (prostaglandin-endoperoxide synthase 2), GLS2 (glutaminase 2), solute carrier family 1 member 5 (SLC1A5), and solute carrier family 38 member 1 (SLC38A1) in HT22 cells, indicating the inductive role of FA in the ferroptosis of HT22 cells.\nDiapause furthermore activates expression of glutamine transporters SLC38A1/2.\nInvestigating the underlying mechanisms revealed elevated expression and activity of amino acid transporters SLC1A5, SLC38A1 upon starvation, whereas archazolid had no additional effect.\nAnalysis of the cellular metabolic phenotype revealed that glutamine deprivation led to a significant increase in glycolytic activity, indicated by an elevated glycolytic capacity and reserve, when V-ATPase function was inhibited concomitantly.\nHowever, this does not lead to a therapeutic benefit, as cells are able to circumvent cell death and growth inhibition by a metabolic shift toward glycolysis.\nCollectively, these data indicated that FA induces ferroptosis in hippocampal neuronal cells by upregulation of the Warburg effect.\nWe showed that FA (0.1, 0.5 and 1.0 mM, 6 h) upregulated the Warburg effect in HT22 cells, as evidenced by up-regulations of pyruvate kinase M2 (PKM2), pyruvate dehydrogenase kinase 1(PDK-1), and lactate dehydrogenase (LDHA) proteins;\nFurthermore, the inhibition of the Warburg effect by dichloroacetate (DCA) protected HT22 cells against FA-induced ferroptosis and cell death.\nHere, we characterize the transcriptional and metabolite profiles of mouse diapause embryos and identify unique gene expression and metabolic signatures with activated lipolysis, glycolysis, and metabolic pathways regulated by AMPK.\nThese results suggest that the controlled environment population may have enhanced glucose metabolic ability via activation of glycolysis/gluconeogenesis, the TCA cycle,", "dois": ["10.1016/j.tox.2020.152650", "10.3390/ani14020199", "10.3389/fnut.2023.1124678", "10.1016/j.devcel.2019.12.018", "PMID:27613819"]}
{"pair_type": "slc_pathway", "key1": "SLC38A2", "key2": "chemotherapy", "summary": "At a clinically relevant dose, alanine supplementation synergizes with OXPHOS inhibition or conventional chemotherapy eliciting marked antitumor activity in patient-derived xenografts.\nProteomic profiling of the combination N: UB: Vinc at 2450.94 µM uncovered distinct molecular responses, including upregulation of MAP1LC3B2 (LogFC = 1.4), GMNN (LogFC = 1.3), and SLC38A2 (LogFC = 1.5), promoting apoptosis, cell cycle regulation, and mTOR signaling inhibition.\nadapting to this, these SMARCA4/2-deficient cells rely on elevated SLC38A2, an amino acid transporter, to increase glutamine import for fueling OXPHOS.\nFurthermore, supplementation of alanine, also imported by SLC38A2, restricts glutamine uptake through competition and selectively induces death in SMARCA4/2-deficient cancer cells.\nOur findings reveal multiple druggable vulnerabilities of SMARCA4/2-loss exploiting a GLUT1/SLC38A2-mediated metabolic shift.\nConsequently, SMARCA4/2-deficient cells and tumors are highly sensitive to inhibitors targeting OXPHOS or glutamine metabolism.\nParticularly, unlike dietary deprivation approaches, alanine supplementation can be readily applied to current regimens for better treatment of these aggressive cancers.\nThese results established a mechanistic rationale for combining postbiotics such as N and UB with standard chemotherapy, highlighting a promising avenue for safer and more effective lymphoma management in the future.", "dois": ["10.3389/fimmu.2025.1664468", "10.1038/s41467-023-38594-3", "10.1074/jbc.M115.700534"]}
{"pair_type": "slc_pathway", "key1": "SLC38A2", "key2": "ferroptosis", "summary": "Proteomic profiling of the combination N: UB: Vinc at 2450.94 µM uncovered distinct molecular responses, including upregulation of MAP1LC3B2 (LogFC = 1.4), GMNN (LogFC = 1.3), and SLC38A2 (LogFC = 1.5), promoting apoptosis, cell cycle regulation, and mTOR signaling inhibition.\nConcurrently, key oncogenic and metabolic proteins were downregulated, including NNMT (LogFC = -2.9), PLTP (LogFC = -2.5), and CYP4X1 (LogFC = -2.0), which implicated the suppression of MAPK-Akt signaling, ferroptosis activation, and lipid metabolism disruption.\nPathway enrichment analyses highlighted cell cycle regulation, TNF signaling, and ferroptosis.", "dois": ["10.7554/eLife.80647", "10.3389/fimmu.2025.1664468", "10.3390/cells14161234"]}
{"pair_type": "slc_pathway", "key1": "SLC38A1", "key2": "oxidative phosphorylation", "summary": "These results suggest that the controlled environment population may have enhanced glucose metabolic ability via activation of glycolysis/gluconeogenesis, the TCA cycle, and inositol phosphate metabolism, while the ex situ population may meet higher energy requirements via enhancement of the amino acid metabolism of the liver and muscle and oxidative phosphorylation.", "dois": ["10.3390/ani14020199"]}
{"pair_type": "slc_pathway", "key1": "SLC38A1", "key2": "migration", "summary": "C5a increased SLC38A1, and SLC38A1 knockdown or overexpression inhibited or promoted RPE cell viability and migration.\nBy contrast, HIF-1 overexpression induced miR-373-3p downregulation and SLC38A1 upregulation, reducing cell growth and migration, which could be reversed by a miR-373-3p inhibitor.\nImportantly, the miR-373-3p inhibitor and mimic reproduced phenomena similar to those induced by HIF-1 downregulation and overexpression, respectively (including altered SLC38A1 expression, mTOR activation, cell growth, and migration).\nHypoxia enhanced the levels of miR-373-3p and hypoxia-inducible factor (HIF)-1, while knockdown not only boosted the migration and proliferation of HTR8 cells but also suppressed the hypoxia-induced upregulation of miR-373-3p and SLC38A1.\nC5a promotes RPE cell viability and migration, and SLC38A1-mediated improved glutamine metabolism is the downstream signal pathway of the C5a complement pathway.\nThe C5a complement system may target the SLC38A1 to promote RPE cell migration.\nWe found that the knockdown of SLC38A1 notably suppressed the growth and migration of HCC cells.\nInhibition of SLC38A1 reduced tumour growth and suppressed proliferation and migration of SW480 cells.\nSLC38A1 knockdown suppressed HCC cell proliferation, migration, invasion, and EMT and inhibited ferroptosis in vitro.\nInhibiting Slc38a1 using shRNA technology could decrease the growth and migration of representative pancreatic cancer cells.\nTCF12 targeted SLC38A1 to promote HCC cell proliferation, migration and invasion and restrained ferroptosis, providing a novel sight for HCC pathogenesis.\nCircRUNX1 promoted CRC cell growth, metastasis and glutamine metabolism and repressed apoptosis by elevating SLC38A1 through sponging miR-485-5p, which might provide a novel target for CRC treatment.", "dois": ["10.1007/s12010-025-05263-8", "10.1007/s00430-025-00832-4", "10.1371/journal.pone.0301356", "10.1007/s00432-023-05360-3", "10.5009/gnl210542", "10.1155/2022/6582357", "10.3390/cancers14092151", "10.1111/eci.13540", "10.1016/j.clinre.2021.101648", "10.1074/jbc.RA118.006378", "10.1016/j.tjog.2018.02.009", "10.18632/oncotarget.20693", "10.1007/s11596-017-1690-3", "10.1186/1471-230X-14-70", "10.3978/j.issn.1000-9604.2013.09.03"]}
{"pair_type": "slc_pathway", "key1": "SLC38A2", "key2": "oxidative phosphorylation", "summary": "less oxidative phosphorylation (ATPsynGL, ATP6VOA1, ATP5H, ATP6VOD1, NDUFC1), enhanced lipid uptake/metabolism (SLC27A6, FABP4, SOD2, ACADM, ACAT1, IDH1, SCP2, ECHDC1), more active fatty acid beta-oxidation (HMGCS1), less amino acid/protein transport (SLC38A2, SLC7A8, RAB5a, VPS18), reduced protein translation (RPS6, RPS12, RPS16, RPS19, RPS20, RPS27)\nwe overexpressed the glutamine transporter SLC38A2 to enhance glutamine uptake and metabolic fitness in nutrient-deprived environments.\nadapting to this, these SMARCA4/2-deficient cells rely on elevated SLC38A2, an amino acid transporter, to increase glutamine import for fueling OXPHOS.\nMechanistically, quantitative PCR demonstrated upregulation of glutamine metabolic and glycolytic pathways, while Seahorse assays confirmed enhanced oxidative phosphorylation and glycolysis.\nOur findings establish SLC38A2 as a critical metabolic regulator that enhances CAR-T antitumor efficacy, providing a promising strategy to improve the durability and efficacy of CAR-T cell therapies in TME.\nSLC38A2 knockout reversed these enhancements, highlighting its role in sustaining CAR-T metabolic fitness.\nSMARCA4/2-loss represses expression of the glucose transporter GLUT1, causing reduced glucose uptake and glycolysis accompanied with increased dependency on oxidative phosphorylation (OXPHOS)\nConsequently, SMARCA4/2-deficient cells and tumors are highly sensitive to inhibitors targeting OXPHOS or glutamine metabolism.\nOur findings reveal multiple druggable vulnerabilities of SMARCA4/2-loss exploiting a GLUT1/SLC38A2-mediated metabolic shift.\nAt a clinically relevant dose, alanine supplementation synergizes with OXPHOS inhibition or conventional chemotherapy eliciting marked antitum", "dois": ["10.1136/jitc-2025-012321", "10.1101/2024.11.12.24317218", "10.1038/s41467-023-38594-3", "10.1186/s12864-018-4808-5"]}
{"pair_type": "slc_pathway", "key1": "SLC38A2", "key2": "stemness", "summary": "SNAT2/SLC38A2 Confers the Stemness of Gastric Cancer Cells via Regulating Glutamine Level.\nPWAR6 promotes immune evasion by inhibiting NRF2 degradation through competitive binding with Keap1, thereby upregulating SLC38A2 expression, which enhances glutamine uptake in CRC cells and depletes glutamine availability for NK cells.\nNotably, SNAT2-mediated promoting effects on GC cell stemness were rescued by Gln deprivation.\nSNAT2 can promote the stemness of GC cells in a Gln-dependent manner.\nSNAT2 overexpression significantly increased the Gln consumption in GC cells and increased the expression of stemness markers, sphere-formation ability and ALDH activity.\nThe Gln transporter SNAT2 was highly expressed in GC spheres compared to that in the parental GC cells.\nIn vivo and in vitro assays confirmed PWAR6's roles in CRC cell stemness, migration, and glutamine uptake.\nWhat's more, high expression of SNAT2 was associated with a poor GC patient survival through different online datasets.", "dois": ["10.1186/s13045-024-01643-5", "10.1007/s10620-021-07110-2"]}
{"pair_type": "slc_pathway", "key1": "SLC38A2", "key2": "glycolysis", "summary": "Direct binding and repression of transcripts encoding glutamine transporter SLC38A2 correlated with increased cellular glutamine content in ZFP36/ZFP36L1-deficient T cells.\nWe also identify SLC38A2 as a key transporter of both alanine and glutamine that is upregulated by TGF-β and alanine deprivation.\nFurthermore, supplementation of alanine, also imported by SLC38A2, restricts glutamine uptake through competition and selectively induces death in SMARCA4/2-deficient cancer cells.\nMechanistically, quantitative PCR demonstrated upregulation of glutamine metabolic and glycolytic pathways, while Seahorse assays confirmed enhanced oxidative phosphorylation and glycolysis.\nOur findings establish SLC38A2 as a critical metabolic regulator that enhances CAR-T antitumor efficacy, providing a promising strategy to improve the durability and efficacy of CAR-T cell therapies in TME.\nSLC38A2 knockout reversed these enhancements, highlighting its role in sustaining CAR-T metabolic fitness.\nConcurrently, we overexpressed the glutamine transporter SLC38A2 to enhance glutamine uptake and metabolic fitness in nutrient-deprived environments.\nadapting to this, these SMARCA4/2-deficient cells rely on elevated SLC38A2, an amino acid transporter, to increase glutamine import for fueling OXPHOS.\nCombined inhibition of GPT2 and SLC38A2 suppresses fibrogenic responses in fibroblasts and in human precision-cut lung slices, highlighting a potential therapeutic strategy for fibrotic lung disease.\nMechanistically, alanine deficiency suppresses glycolysis and depletes tricarboxylic acid cycle intermediates, while supplementation provides carbon and nitrogen for intracellular glutamate and proline biosynthesis, particularly in the absence of glutamine.\nThese enzymes span numerous metabolic pathways including glycolysis, one-carbon metabolism and glutaminolysis.\nOur findings reveal multiple druggable vulnerabilities of SMARCA4/2-loss exploiting a GLUT1/SLC38A2-mediate", "dois": ["10.1136/jitc-2025-012321", "10.1101/2025.07.23.666333", "10.1096/fj.202401788RR", "10.1016/j.ygeno.2024.110949", "10.1038/s41467-023-38594-3", "10.1038/s41598-022-24132-6", "10.3389/fphar.2022.963066", "10.3168/jds.2017-13707"]}
{"pair_type": "slc_pathway", "key1": "SLC38A2", "key2": "oxidative stress", "summary": "Increased expression of glutamine transporter SNAT2/SLC38A2 promotes glutamine dependence and oxidative stress resistance, and is associated with worse prognosis in triple-negative breast cancer.\nSLC38A2 knockdown decreased Gln consumption, inhibited cell growth, induced autophagy and led to ROS production in a subgroup of Gln-sensitive cell lines.\nExogenous IL-6 (0.1 ng/mL) downregulated HO-1 expression, initiating an identical regulatory cascade, while HO-1 overexpression reversed the IL-6-mediated reduction in the expression of the autophagy markers LC3 and ATG5, suppressing myogenic enhancement.\nThis alleviated oxidative stress and promoted myogenic differentiation.\nThis establishes the co-culture-induced IL-6/HO-1 axis as a core regulator of iron-dependent oxidative stress and autophagy during myogenic differentiation.\nHO-1 knockdown reduced intracellular iron accumulation in MuSCs, suppressing iron-dependent autophagy.\nComparative transcriptomics of mono-cultured versus co-cultured MuSCs revealed differential expression of oxidative stress-related genes.\nProteomic profiling of co-culture supernatants identified significant DCX, IMP2A, NUDT16L1, SLC38A2, and IL-6 upregulation.\nProteomic profiling of the combination N: UB: Vinc at 2450.94 µM uncovered distinct molecular responses, including upregulation of MAP1LC3B2 (LogFC = 1.4), GMNN (LogFC = 1.3), and SLC38A2 (LogFC = 1.5), promoting apoptosis, cell cycle regulation, and mTOR signaling inhibition.\nROS analysis revealed significant oxidative stress, while flow cytometry confirmed enhanced apoptosis (p < 0.0001) in the combination groups.\nLncRNA nuclear paraspeckle assembly transcript 1 (NEAT1) was related to HO-induced oxidative injury and up-regulated by melatonin in HT22 cells.", "dois": ["10.3390/cells14161234", "10.3390/ijms232112891", "10.1038/s41416-020-01113-y", "10.3389/fimmu.2025.1664468", "10.3724/SP.J.1123.2024.04003"]}
{"pair_type": "slc_pathway", "key1": "SLC38A2", "key2": "migration", "summary": "SLC38A2 downregulation significantly inhibited the proliferation, invasion and migration of GC cells.\nmiR-10b-5p facilitates the metabolic reprogramming of PLC by targeting SLC38A2, which ultimately boosts the proliferation, migration, and invasion of PLC cells.\nMechanistically, PWAR6 promotes immune evasion by inhibiting NRF2 degradation through competitive binding with Keap1, thereby upregulating SLC38A2 expression, which enhances glutamine uptake in CRC cells and depletes glutamine availability for NK cells.\nMeanwhile, the cell viability and the rate of division and migration of SCs in the 0.80% Lys/0.40 % Met composition group were increased (p < 0.05).\nFurthermore, accumulated β-catenin in nucleus enhances the transcription of CEMIP to reciprocally regulate β-catenin and contributes to over-expression of glutaminase 1 and glutamine transporters (SLC1A5 and SLC38A2).\nHere, we find that a novel metastasis-related protein, cell migration-inducing and hyaluronan-binding protein (CEMIP), can act as a novel adaptor protein of O-GlcNAc transferase (OGT) to promote CRC metastasis through glutamine metabolic reprogramming.\nMechanistically, miR-10b-5p targeted SLC38A2 to promote PLC tumor growth.\nmiR-10b-5p facilitated proliferation, migration, and invasion of PLC cells.\nIn addition, this work also finds that SLC38A2 plays an essential role in the process of CD169+ macrophages promoting alanine uptake by DCs.\nSLC38A2 acted as an amino acid sensor upstream of mTOR and was involved in the 0.80% Lys/0.40% Met regulation of muscle growth and development, thus implicating the mTOR signaling pathway in these processes.\nCollectively, this study reveals the importance of glutamine metabolic reprogramming in CEMIP-induced CRC metastasis, indicating the great potential of CEMIP and glutamine metabolism for CRC metast", "dois": ["10.1096/fj.202401788RR", "10.1186/s13045-024-01643-5", "10.1002/advs.202309331", "10.1080/15384047.2024.2315651", "10.3233/CBM-220229", "10.1186/s12876-023-02689-4", "10.3390/ani12233406", "10.1038/s41388-021-02023-w", "10.1074/jbc.RA118.006378"]}
{"pair_type": "slc_pathway", "key1": "SLC38A3", "key2": "glycolysis", "summary": "The expression levels of SLC38A3, SLC2A1, and ASRGL1 are higher in tumor samples by RT-qPCR, with IHC confirming increased SLC38A3 expression.\nFinally, SLC38A3 may function as oncogenes in EC, as revealed by the results of in vitro experiments.\nSubsequently, six prognostic genes were derived, including ASRGL1, SLC38A3, SLC2A1, ALDH1B1, GAD1, and GLYATL1.\nIn this study, we developed six novel prognostic genes in EC based on glycolysis, and corresponding prognostic models were developed.\nMetabolic syndrome associated with glucose metabolism plays a pivotal role in tumorigenesis, potentially elevating the risk of endometrial cancer (EC).\nNotably, we identified SLC38A3 as the key gene, which offers valuable insights for further research into EC.", "dois": ["10.1186/s12885-024-13418-9"]}
{"pair_type": "slc_pathway", "key1": "SLC38A2", "key2": "apoptosis", "summary": "Proteomic profiling of the combination N: UB: Vinc at 2450.94 µM uncovered distinct molecular responses, including upregulation of MAP1LC3B2 (LogFC = 1.4), GMNN (LogFC = 1.3), and SLC38A2 (LogFC = 1.5), promoting apoptosis, cell cycle regulation, and mTOR signaling inhibition.\nNaCl induced p53-dependent apoptosis and upregulated Na+-transporter SLC38A2, which promoted caspase-3 activation.\nWe describe how Slc38a2 senses amino acid availability and passes this onto intracellular signaling pathways and how it regulates protein synthesis, cellular proliferation and apoptosis through the mechanistic (mammalian) target of rapamycin (mTOR) and general control nonderepressible 2 (GCN2) pathways.\nOur results suggest that additional Met supplementation with 20 μg/mL may promote the synthesis of milk proteins in bovine mammary epithelial cells under hyperthermia by inhibiting apoptosis, activating the AKT-mTOR-RPS6KB1 signalling pathway, and regulating the entry of amino acids into these cells.\nThese findings illustrated that hyperthermia promoted cell apoptosis and reduced the transport of amino acids into cells, which inhibited the milk proteins synthesis in MAC-T cells.\nWe show that genetic depletion and pharmacological inhibition of WNK1 or its downstream phosphorylation targets OXSR1 and STK39 strongly reduce cell proliferation and induce apoptosis in leukaemia cells in vitro and in vivo.\nOnly fetal hsFLT1 expression led to impaired placental morphology characterized by reduced placental efficiency, enlarged maternal sinusoids, reduced fetal capillaries, and impaired labyrinthine differentiation, associated with increased apoptosis.\nOur results show that additional Met supplementation increases the mRNA and protein levels of BCL2 (B-cell lymphoma-2, an anti-apoptosis agent), and decreases the mRNA and protein levels of BAX (Bcl-2-associated X protein", "dois": ["10.1016/j.ecoenv.2025.119259", "10.3389/fimmu.2025.1664468", "10.1172/jci.insight.194570", "10.1038/s41467-025-59969-8", "10.1080/15384047.2024.2315651", "10.3390/ijms232112891", "10.1016/j.ccell.2015.02.006", "10.5187/jast.2021.e128", "10.5187/jast.2021.e93", "10.1016/j.neuropharm.2019.107789", "10.3389/fendo.2019.00165", "10.3892/or.2015.3868", "PMID:16918137"]}
{"pair_type": "slc_pathway", "key1": "SLC38A3", "key2": "apoptosis", "summary": "Our data demonstrate that SLC38A3 enhances cell viability, cell migration and invasion in vitro, and promotes tumor growth and metastasis in vivo, while reducing apoptosis and oxidative stress.\nMechanistically, we show that SLC38A3 suppresses the activity of glycogen synthase kinase 3-β (Gsk3β), a negative regulator of β-catenin, and increases protein levels of β-catenin, leading to the upregulation of epithelial-to-mesenchymal-transition (EMT)-inducing transcription factors and EMT markers in breast cancer.\nGlutamine transporter SLC38A3 promotes breast cancer metastasis via Gsk3β/β-catenin/EMT pathway.\nIn summary, we show that SLC38A3 is overexpressed in breast cancer and promotes breast cancer metastasis via the GSK3β/β-catenin/EMT pathway, presenting a novel therapeutic target to explore for breast cancer.\nHere we show that solute carrier family 38-member 3 (SLC38A3) is overexpressed in breast cancer, particularly in triple-negative breast cancer (TNBC) cells and tissues.\nOur study reveals that SLC38A3 regulates cellular glutamine, glutamate, asparagine, aspartate, alanine, and glutathione (GSH) levels in breast cancer cells.\nOur results suggest that additional Met supplementation with 20 μg/mL may promote the synthesis of milk proteins in bovine mammary epithelial cells under hyperthermia by inhibiting apoptosis, activating the AKT-mTOR-RPS6KB1 signalling pathway, and regulating the entry of amino acids into these cells.\nThese findings illustrated that hyperthermia promoted cell apoptosis and reduced the transport of amino acids into cells, which inhibited the milk proteins synthesis in MAC-T cells.\nCompared with the CON group, hyperthermia significantly decreased the cell viability ( < 0.05) and elevated the apoptotic rate ( < 0.05) of MAC-T cells.", "dois": ["10.1016/j.canlet.2024.216653", "10.5187/jast.2021.e128", "10.5187/jast.2021.e93", "10.1631/jzus.B2000043"]}
{"pair_type": "slc_pathway", "key1": "SLC38A3", "key2": "proliferation", "summary": "Overall, is a novel potential biomarker involved in CRC progression and promotes the proliferation and migration of tumor cells by positively regulating the function of Hsp70.\nFurthermore, we found that knockdown of inhibited the proliferation and migration of HCT116 cells, and Hsp70 ATPase activator could rescue it.\nCATLE cells showed enhanced proliferation in serum-free media indicative of autonomous growth.\nCompared to control cells, CATLE cells showed reduced protein expression of the tumor suppressor gene PTEN (decreased to 26% of control) and the putative tumor suppressor gene SLC38A3 (14% of control).\nThe invasive capacity of these chronic arsenic-treated lung epithelial (CATLE) cells increased to 320% of control and colony formation increased to 280% of control.\nAfter 38 weeks of continuous arsenic exposure, secreted matrix metalloproteinase-2 (MMP2) activity increased to over 200% of control, levels linked to arsenic-induced cancer phenotypes in other cell lines.\nMorphological evidence of epithelial-to-mesenchymal transition (EMT) occurred in CATLE cells together with appropriate changes in expression of the EMT markers vimentin (VIM; increased to 300% of control) and e-cadherin (CDH1; decreased to 16% of control).\nCATLE cells showed increased KRAS (291%), ERK1/2 (274%), phosphorylated ERK (p-ERK; 152%), and phosphorylated AKT1 (p-AKT1; 170%) protein expression.\nIncreased transcript expression of metallothioneins, MT1A and MT2A and the stress response genes HMOX1 (690%) and HIF1A (247%) occurred in CATLE cells possibly in adaptation to chronic arsenic exposure.", "dois": ["10.1021/acsomega.4c00901", "10.1016/j.taap.2015.03.014"]}
{"pair_type": "slc_pathway", "key1": "SLC38A3", "key2": "migration", "summary": "Our data demonstrate that SLC38A3 enhances cell viability, cell migration and invasion in vitro, and promotes tumor growth and metastasis in vivo, while reducing apoptosis and oxidative stress.\nSLC38A3 overexpression promoted epithelial - mesenchymal transition (EMT) and migration of HCC827 and A549 human lung adenocarcinoma cells, and accelerated tumor metastasis in mice.\nWe found that SLC38A3 decreased the cellular concentrations of glutamine and histidine, and the deficiency of glutamine or histidine activated PDK1/AKT signaling that in turn, triggered NSCLC metastasis.\nMechanistically, we show that SLC38A3 suppresses the activity of glycogen synthase kinase 3-β (Gsk3β), a negative regulator of β-catenin, and increases protein levels of β-catenin, leading to the upregulation of epithelial-to-mesenchymal-transition (EMT)-inducing transcription factors and EMT markers in breast cancer.\nSLC38A3 activated PDK1/AKT signaling and promoted metastasis of NSCLC through regulating glutamine and histidine transport, suggesting SLC38A3 as a potential therapeutic target for treatment of NSCLC.\nIn summary, we show that SLC38A3 is overexpressed in breast cancer and promotes breast cancer metastasis via the GSK3β/β-catenin/EMT pathway, presenting a novel therapeutic target to explore for breast cancer.\nOverall, is a novel potential biomarker involved in CRC progression and promotes the proliferation and migration of tumor cells by positively regulating the function of Hsp70.\nFurthermore, we found that knockdown of inhibited the proliferation and migration of HCT116 cells, and Hsp70 ATPase activator could rescue it.", "dois": ["10.1038/s41598-024-81040-7", "10.1021/acsomega.4c00901", "10.1016/j.canlet.2024.216653", "10.1002/glia.23137", "10.1016/j.canlet.2017.01.036"]}
{"pair_type": "slc_pathway", "key1": "SLC38A1", "key2": "proliferation", "summary": "Subsequently, increased uptake of amino acids by the transporters (SLC38A1 and SLC7A5) activates mammalian target of rapamycin complex 1 (mTORC1), a master regulator of cell growth, and stimulates cell proliferation.\nSLC38A1 silencing prominently attenuated the OTUD5-induced increase in HCC cell proliferation.\nInhibition of SLC38A1 reduced tumour growth and suppressed proliferation and migration of SW480 cells.\nSLC38A1 knockdown suppressed HCC cell proliferation, migration, invasion, and EMT and inhibited ferroptosis in vitro.\nMoreover, the knockdown of SLC38A1 and HIF1A by RNAi resulted in a significant decrease in the proliferation of HEC1A cells (p < 0.05).\nTCF12 targeted SLC38A1 to promote HCC cell proliferation, migration and invasion and restrained ferroptosis, providing a novel sight for HCC pathogenesis.\nThese results suggest that theanine accelerates cellular proliferation and subsequent neuronal specification through a mechanism relevant to upregulation of Slc38a1 gene in undifferentiated neural progenitor cells.\nThe twofold aim of this study was to provide insight into whether a variance in the expression of SLC38A1 exists between human colorectal cancer and healthy human tissues and to determine how silencing or overexpressing the SLC38A1 gene could affect the proliferation, viability and migration of colorectal cancer cells.\nUpregulation of transcript expression is found for one of the GLN transporter isoforms, Slc38a1, besides the promotion of both proliferation and neuronal commitment along with acceleration of the phosphorylation of mechanistic target of rapamycin (mTOR) and relevant downstream proteins, in murine NPCs cultured with theanine.\nIn neural progenitor cells with sustained exposure to L-theanine, upregulation of the L-GLN transporter isoform Slc38a1 expression and promotion of both proliferation and neuronal commitment are seen along with marked acceleration of the phosphorylation of mammalian target of rapamycin (", "dois": ["10.1007/s12010-025-05263-8", "10.3390/cancers17050739", "10.1186/s12885-024-13326-y", "10.1186/s13062-024-00475-0", "10.1371/journal.pone.0301356", "10.3390/cancers16020405", "10.3389/fnut.2023.1124678", "10.21037/tcr-22-2203", "10.1097/CAD.0000000000001328", "10.3892/etm.2022.11483", "10.1155/2022/6582357", "10.3390/biom11050742", "10.1016/j.clinre.2021.101648", "10.1089/cbr.2020.3608", "10.1016/j.neuropharm.2019.107789", "10.1016/j.neuint.2019.104505", "10.1016/j.theriogenology.2019.01.002", "10.3892/ijo.2018.4596", "10.1016/j.tjog.2018.02.009", "10.18632/oncotarget.20693", "10.1007/s11064-017-2317-6", "10.1007/s11596-017-1690-3", "10.1371/journal.pone.0157453", "10.1016/j.bbrep.2015.09.021", "10.1002/hep.28223", "10.1007/s11064-015-1591-4", "10.3892/or.2015.3868", "10.1523/JNEUROSCI.2778-14.2015", "10.1186/1471-230X-14-70", "10.3978/j.issn.1000-9604.2013.09.03", "10.1371/journal.pone.0048270"]}
{"pair_type": "slc_pathway", "key1": "SLC38A4", "key2": "chemotherapy", "summary": "Five genes were significantly upregulated: SLC2A9, SLC16A3, SLC16A14, SLC38A4 and SLC39A8.\nResistance to platinum-based chemotherapy is a prevalent factor in OV patients, leading to increased mortality.\nIn results of MDR development during chemotherapy cancer cells become resistant to further treatment.\nStudies have indicated that ovarian cancer stem cells (OCSCs), which are chemoresistant and help in disease recurrence, are enriched by platinum-based chemotherapy.\nA six-gene diagnostic and prognostic model (C19orf33, CBX2, CSMD1, INSRR, PRLR, and SLC38A4) was developed based on the differentially expressed stem cell-related gene model, which can act as a potent diagnostic biomarker and can characterize the clinicopathological properties of OV.\nABC and SLC transporters are most important proteins responsible for this phenomenon.\nThe platinum resistance in OV is driven by transcriptome heterogeneity and tumor heterogeneity.\nExpression profiles of these genes give strong arguments for assumption of correlation between expression of ABC and SLC genes and drug resistance phenomenon.", "dois": ["10.1155/2023/4500561", "10.1074/jbc.M115.700534", "10.1016/j.biopha.2014.02.002"]}
{"pair_type": "slc_pathway", "key1": "SLC38A4", "key2": "apoptosis", "summary": "Functional assays demonstrated that SLC38A4 depletion promoted HCC cellular proliferation, stemness and migration, and inhibited HCC cellular apoptosis in vitro, and further repressed HCC tumorigenesis in vivo.\nSLC38A4 increased HMGCS2 expression via upregulating AXIN1 and repressing Wnt/β-catenin/MYC axis.\nSLC38A4 downregulation was identified as a novel oncofetal event, and SLC38A4 was identified as a novel tumour suppressor in HCC.\nDNA hypermethylation contributed to the downregulations of Slc38a4/SLC38A4 in the foetal liver and HCC.\nHMGCS2 was identified as a critical downstream target of SLC38A4.\nLow expression of SLC38A4 was associated with poor prognosis of HCC patients.\nFunctional rescue assays showed that HMGCS2 overexpression reversed the oncogenic roles of SLC38A4 depletion in HCC.\nSLC38A4 silencing was identified as an oncofetal molecular event.", "dois": ["10.1038/s41416-021-01490-y", "10.3892/or.2015.3868"]}
{"pair_type": "slc_pathway", "key1": "SLC38A1", "key2": "ferroptosis", "summary": "Overall, GluOC coordinately regulated SLC7A11 and SLC38A1 to inhibit ferroptosis in TNBC.\nAdditionally, GluOC increased ATP production and tricarboxylic acid flux resistance to ferroptosis through SLC38A1.\nMechanistically, silencing of lncRNA ZFAS1 attenuated ferroptosis and PF progression by lncRNA ZFAS1 acting as a competing endogenous RNA (ceRNA) and sponging miR-150-5p to downregulate SLC38A1 expression.\nupregulated the ferroptosis-associated genes, including Ptgs2 (prostaglandin-endoperoxide synthase 2), GLS2 (glutaminase 2), solute carrier family 1 member 5 (SLC1A5), and solute carrier family 38 member 1 (SLC38A1) in HT22 cells, indicating the inductive role of FA in the ferroptosis of HT22 cells.\nSLC38A1 knockdown suppressed HCC cell proliferation, migration, invasion, and EMT and inhibited ferroptosis in vitro.\nTCF12 targeted SLC38A1 to promote HCC cell proliferation, migration and invasion and restrained ferroptosis, providing a novel sight for HCC pathogenesis.\nthrough screening analyses and validation experiments, we identified SLC38A1 as a ferroptosis-related regulator for skeletal muscle aging.\nHere, we found that lncRNA ZFAS1 was upregulated in bleomycin (BLM)-induced PF rats lung tissues and transforming growth factor-β1 (TGF-β1)-treated HFL1 cells, and positively correlated with the expression of solute carrier family 38 member 1 (SLC38A1), which is an important regulator of lipid peroxidation.\nIn contrast, SLC38A1 overexpression markedly reduced the accumulation of ROS, mtROS, iron concentration, and lipid peroxidation associated with D-gal treatment in these cells.\nThis study elucidated the mechanism of GluOC in inhib", "dois": ["10.1016/j.exger.2025.112880", "10.1016/j.bcp.2025.117100", "10.1016/j.intimp.2025.114042", "10.3389/fimmu.2024.1402669", "10.1016/j.phrs.2023.107056", "10.1002/jcla.24930", "10.1097/CAD.0000000000001328", "10.1016/j.tox.2020.152650", "10.18632/aging.103176", "10.1007/s12010-025-05263-8", "10.2147/JHC.S500394", "10.3390/cancers17050739", "10.1007/s43032-023-01259-z", "10.3389/fgene.2023.1118391", "10.21037/tcr-22-2203", "10.3389/fgene.2022.1090467", "10.3389/fnut.2022.1010918", "10.3389/fgene.2022.886860", "10.3389/fgene.2022.919188", "10.3389/fonc.2021.730716", "10.3389/fmolb.2021.675193", "10.1038/s41420-021-00473-5"]}
{"pair_type": "slc_pathway", "key1": "SLC38A2", "key2": "proliferation", "summary": "Furthermore, the increased proliferation and invasion rates and Gln level induced by SLC38A2 overexpression in EU cells were alleviated by CB-839, a glutaminase inhibitor.\nSLC38A2 downregulation significantly inhibited the proliferation, invasion and migration of GC cells.\nMechanistic studies revealed that ALDH2 deficiency facilitated VSMC proliferation by upregulating the expression of the glutamine transporter SLC38A2, which is a novel ALDH2 target gene.\nImportantly, downregulation of SLC38A2 by adeno-associated virus serotype 2 (AAV2) shRNA or by the inhibitor MeAIB has promising therapeutic potential in limiting VSMC proliferation and neointima formation.\nFurther bioinformatics analysis, luciferase assays, and ChIP-qPCR revealed that ALDH2 deficiency increased SLC38A2 expression via activating transcription factor 4 (ATF4) and that ATF4 knockdown largely reversed the ability of ALDH2 deficiency to promote VSMC proliferation.\nWe describe how Slc38a2 senses amino acid availability and passes this onto intracellular signaling pathways and how it regulates protein synthesis, cellular proliferation and apoptosis through the mechanistic (mammalian) target of rapamycin (mTOR) and general control nonderrepressible 2 (GCN2) pathways.\nSLC38A2 knockdown repressed EC cell proliferation and invasion.\nmiR-10b-5p facilitates the metabolic reprogramming of PLC by targeting SLC38A2, which ultimately boosts the proliferation, migration, and invasion of PLC cells.\nSLC38A2 overexpression promoted Gln metabolism and oxygen consumption rate, resulting in an increase in cell proliferation and invasion in the adenomyosis context.\nThis study identified that circTSN, which is highly expressed in GC, was able to contribute to the proliferation and metastasis of GC cell through miR-1825/SLC38A2 axis and this might provide a new candidate target for the precision treatment of GC.", "dois": ["10.1136/jitc-2025-012321", "10.1016/j.metabol.2025.156411", "10.1172/jci.insight.194570", "10.1016/j.jbc.2025.110525", "10.1038/s41467-025-59969-8", "10.1136/jitc-2024-011044", "10.1096/fj.202401788RR", "10.1038/s44318-024-00359-z", "10.1007/s12672-024-01407-0", "10.3892/etm.2024.12506", "10.1080/15384047.2024.2315651", "10.3233/CBM-220229", "10.1186/s12876-023-02689-4", "10.3389/fphys.2022.992679", "10.3390/biom11050742", "10.1002/1878-0261.12999", "10.1016/j.cell.2021.02.021", "10.1038/s41416-020-01113-y", "10.1158/2159-8290.CD-19-0959", "10.1016/j.neuropharm.2019.107789", "10.3892/ijo.2018.4596", "10.1002/jcp.25040", "10.3892/or.2015.3868", "10.1016/j.ccell.2015.02.006", "10.1095/biolreprod.112.100222"]}
{"pair_type": "slc_pathway", "key1": "SLC38A4", "key2": "glycolysis", "summary": "In addition, chronic exposure to high glucose levels increased the expression of Slc7a2 and Slc38a4, which encode amino acid transporters, as well as the levels of branched-chain amino acids and methionine cycle metabolites (~1.3-fold increase for both).\nMetabolomics and metabolic flux analysis showed that exposure to high glucose levels enhanced glycolysis, glucose oxidation and the synthesis of glucose-derived amino acids.\nTranscriptomic analysis also identified 18 DEGs associated with HIF-1 signaling pathway (hif1α, tf, epo, hmox, gult1, mknk2, ldha, pfkfb3, hkdc, aldoa) and biological process (hif2α, apoeb, bcl6, mr1, errfi1, slc38a4, igfbp1a, ap4m1) as further validated by quantitative real-time PCR.\nThese results indicated that black rockfish may mainly utilize glycolysis to maintain homeostasis, and hif1α facilities hypoxia tolerance by modulating ldha expression.\nMeanwhile, hif1α recognized the hypoxia response element located in the promoter of ldha and directly bound to the promoter to transactivate ldha expression.\nMoreover, hif1α was positively or negatively correlated with glucose (ldha, pfkfb3, hkdc, aldoa) and lipid (apoeb) metabolism-related genes.\nGO annotation and Kyoto Encyclopedia of Genes and Genomes analysis demonstrated that the DEGs are mainly enriched in the biochemical metabolic pathways and HIF-1 signaling pathways.\nAlpha cell exposure to hyperglycaemia enhances amino acid synthesis and transport, resulting in sustained activation of mTORC1, thereby increasing glucagon secretion.", "dois": ["10.1007/s00125-023-05967-8", "10.1016/j.cbd.2023.101098"]}
{"pair_type": "slc_pathway", "key1": "SLC38A4", "key2": "migration", "summary": "Functional assays demonstrated that SLC38A4 depletion promoted HCC cellular proliferation, stemness and migration, and inhibited HCC cellular apoptosis in vitro, and further repressed HCC tumorigenesis in vivo.\nSLC38A4 increased HMGCS2 expression via upregulating AXIN1 and repressing Wnt/β-catenin/MYC axis.\nStarvation promoted migration compared to normal culture conditions whereas all trophoblast functional activities were decreased in rapamycin treatment.\nSLC38A4 downregulation was identified as a novel oncofetal event, and SLC38A4 was identified as a novel tumour suppressor in HCC.\nDNA hypermethylation contributed to the downregulations of Slc38a4/SLC38A4 in the foetal liver and HCC.\nSLC38A4 silencing was identified as an oncofetal molecular event.\nHMGCS2 was identified as a critical downstream target of SLC38A4.\nLow expression of SLC38A4 was associated with poor prognosis of HCC patients.\nFunctional rescue assays showed that HMGCS2 overexpression reversed the oncogenic roles of SLC38A4 depletion in HCC.", "dois": ["10.1016/j.placenta.2024.09.011", "10.1038/s41416-021-01490-y"]}
{"pair_type": "slc_pathway", "key1": "SLC38A4", "key2": "stemness", "summary": "Functional assays demonstrated that SLC38A4 depletion promoted HCC cellular proliferation, stemness and migration, and inhibited HCC cellular apoptosis in vitro, and further repressed HCC tumorigenesis in vivo.\nSLC38A4 increased HMGCS2 expression via upregulating AXIN1 and repressing Wnt/β-catenin/MYC axis.\nSLC38A4 downregulation was identified as a novel oncofetal event, and SLC38A4 was identified as a novel tumour suppressor in HCC.\nFunctional rescue assays showed that HMGCS2 overexpression reversed the oncogenic roles of SLC38A4 depletion in HCC.\nLow expression of SLC38A4 was associated with poor prognosis of HCC patients.", "dois": ["10.1038/s41416-021-01490-y"]}
{"pair_type": "slc_pathway", "key1": "SLC38A4", "key2": "proliferation", "summary": "Functional assays demonstrated that SLC38A4 depletion promoted HCC cellular proliferation, stemness and migration, and inhibited HCC cellular apoptosis in vitro, and further repressed HCC tumorigenesis in vivo.\nThe increase in SLC38A4 expression and associated α-cell proliferation was dependent on mechanistic target of rapamycin pathway.\nWe confirmed increased α-cell proliferation and expression of SLC38A4 in pancreas sections from patients with glucagon cell hyperplasia and neoplasia (GCHN) with loss-of-function mutations in the glucagon receptor.\nSLC38A4 increased HMGCS2 expression via upregulating AXIN1 and repressing Wnt/β-catenin/MYC axis.\nSLC38A4 downregulation was identified as a novel oncofetal event, and SLC38A4 was identified as a novel tumour suppressor in HCC.\nThus, we present a model where TFAP2C in trophoblasts controls proliferation by repressing Cdkn1a and activating the MAPK pathway, further supporting differentiation of glycogen cells by activating the AKT pathway.\nLoss of TFAP2C led to upregulation of imprinted gene H19 and downregulation of Slc38a4 and Ascl2.\nDNA hypermethylation contributed to the downregulations of Slc38a4/SLC38A4 in the foetal liver and HCC.\nSLC38A4 silencing was identified as an oncofetal molecular event.\nHMGCS2 was identified as a critical downstream target of SLC38A4.\nLow expression of SLC38A4 was associated with poor prognosis of HCC patients.\nAll 11 genes have been implicated in the control of cell proliferation or somatic growth.\nFunctional rescue assays showed that HMGCS2 overexpression reversed the oncogenic roles of SLC38A4 depletion in HCC.\nDeletion of TFAP2C in TPBPA(+) progenitors at E8.5 results in growth arrest of the junctional zone.", "dois": ["10.1038/s41416-021-01490-y", "10.1210/en.2019-00022", "10.1242/dev.128553", "10.3892/or.2015.3868", "10.1152/ajpregu.00182.2008"]}
{"pair_type": "slc_pathway", "key1": "SLC38A5", "key2": "glycolysis", "summary": "Since many SLC38A5 substrates are activators of mTORC1 as well as TCA cycle intermediates/precursors, we speculate amino acid insufficiency as a possible link between SLC38A5 deletion and inactivation of mTORC1, glycolysis and mitochondrial respiration, and the underlying mechanism for PDAC attenuation.\nExperimental validation demonstrates inhibition of mTORC1, glycolysis and mitochondrial respiration in KO cells, suggesting a serious metabolic crisis associated with SLC38A5 deletion.\nSLC38A5 transcriptionally mediated by ETV4 expedites CRC cell growth, metastasis, glycolysis, L-OHP resistance, which provides a promising therapeutic target for CRC treatment.\nMoreover, SLC38A5 deficiency could hinder CRC cell proliferation, migration, invasion, glycolysis, and improved L-OHP sensitivity in vitro.\nUpon HSC activation, metabolism is reprogrammed with Myc as a key regulator, transcriptionally controlling LDHA, GLS1, and glutamine transporters SLC1A5 and SLC38A5.\nUsing CRISPR/Cas9-mediated knockout of SLC38A5, we show its tumor promoting role in an in vitro cell line model as well as in a subcutaneous xenograft mouse model.\nOverall, we show that SLC38A5 promotes PDAC, thereby identifying a novel, hitherto unknown, therapeutic target for PDAC.\nHere we show that SLC38A5 (SN2/SNAT5), a neutral amino acid transporter is highly upregulated and functional in PDAC cells.\nUsing metabolomics and RNA sequencing, we show significant reduction in many amino acid substrates of SLC38A5 as well as OXPHOS inactivation in response to SLC38A5 deletion.\nParticularly, amino acids are critical for cancer growth and, as intermediates, connect glucose, lipid and nucleotide metabolism.\nPancreatic ductal adenocarcinoma (PDAC) cells have a great demand for nutrients in the form of sugars, amino acids, and lipids.", "dois": ["10.1016/j.prp.2025.156033", "10.1016/j.phymed.2024.156223", "10.1038/s41598-023-43983-1"]}
{"pair_type": "slc_pathway", "key1": "SLC38A5", "key2": "stemness", "summary": "In conclusion, CDH17 plays a crucial role in maintaining colorectal cancer cell stemness and chemoresistance via LGR5/Wnt/MYC signaling and SLC38A5 expression.\nLoss of CDH17 resulted in a marked down-regulation of the intestinal cancer stem cell (CSC) marker LGR5, leading to the inhibition of Wnt/β-catenin signaling, suppression of pluripotency genes such as MYC, and a subsequent reduction in stemness properties.\nCDH17 silencing also down-regulated various transporters associated with drug-resistance, including the glutamine-transporter SLC38A5.\nNotably, SLC38A5 silencing was necessary for CDH17-driven effects on drug resistance and survival.\nPharmacological inhibition of SLC38A5 with amiloride, significantly increased cell sensitivity to 5-FU and irinotecan, and improved mouse survival in metastasis models.", "dois": ["10.1038/s41419-025-07811-w"]}
{"pair_type": "slc_pathway", "key1": "SLC38A5", "key2": "migration", "summary": "Upregulation of SLC38A5 promotes proliferation, migration, and invasion of osteosarcoma cells, while the PI3K inhibitor BKM120 can counteract these effects.\nSLC38A5 promotes osteosarcoma cell proliferation, migration, and invasion via the glutamine-mediated PI3K/AKT/mTOR signaling pathway and inhibits ferroptosis.\nFurthermore, the deletion of SLC38A5 decreased the proliferation and migration of gemcitabine-resistant PDAC cells.\nSLC38A5 inhibition could attenuate the pro-tumoral abilities of CAFs in terms of proliferation, migration, and invasion.\nMoreover, SLC38A5 deficiency could hinder CRC cell proliferation, migration, invasion, glycolysis, and improved L-OHP sensitivity in vitro.\nA series of in vitro functional experiments, including CCK-8, colony formation, wound healing, and transwell invasion assays, were conducted to evaluate the effects of SLC38A5 on the proliferation, migration, and invasion of osteosarcoma cells.\nImportantly, some cell migration-related genes, including AOC3, CCR6, SSTR5, and SCL7A11, were significantly downregulated.\nBET inhibitor treatment in HCC cell lines reduces cell migration through the downregulation of SMARCA4.\nAdditionally, silencing of SLC38A5 inhibits tumor growth in vivo.\nThe absence of subretinal neovascularization in DKO mice is associated with inhibited migration of ECs into the photoreceptor cell layer.\nFurthermore, knockdown of SMARCA4 gene expression by siRNA treatment significantly reduced cell migration and the expression of migration-related genes.\nSLC38A5 transcriptionally mediated by ETV4 expedites CRC cell growth, metastasis, glycolysis, L-OHP resistance, which provides a promising therapeutic target for CRC treatment.\nSimilarly, we observed that knockdown of SLC38A5 restored gemcitabine sensitivity by hindering tumor growth and metastasis in the orthotopic mouse model.\nMice with a loss of LRP5 display underdeveloped intraretinal", "dois": ["10.1016/j.prp.2025.156033", "10.1186/s12967-024-05803-6", "10.3389/ebm.2024.10070", "10.3390/cells12202509", "10.1016/j.tranon.2023.101790", "10.1016/j.heliyon.2023.e19208", "10.1038/s41598-021-91284-2", "10.1371/journal.pone.0075186"]}
{"pair_type": "slc_pathway", "key1": "SLC38A7", "key2": "chemotherapy", "summary": "Reduced levels of SLC38A7 and SLC46A1 diminish the proliferative potential of cancer cells, and elevated expression of these SLCs in breast tumors from patients correlates with reduced survival.\nTherapy-resistant cells throughout the concentration gradient display higher expression of the solute carriers SLC38A7 and SLC46A1 and elevated intracellular concentrations of their associated metabolites.\nHere, we modeled the spatiotemporal changes promoting chemotherapy resistance in breast cancer.\nUsing pairwise cell competition assays at each step during the acquisition of chemoresistance, we reveal an important priming phase that renders cancer cells previously exposed to sublethal drug concentrations refractory to dose escalation.\nOur work provides mechanistic evidence to support dose-intensive treatment modalities for patients with solid tumors and reveals two members of the SLC family as potential actionable targets.", "dois": ["10.1016/j.celrep.2023.113191"]}
{"pair_type": "slc_pathway", "key1": "SLC38A5", "key2": "proliferation", "summary": "Upregulation of SLC38A5 promotes proliferation, migration, and invasion of osteosarcoma cells, while the PI3K inhibitor BKM120 can counteract these effects.\nSLC38A5 promotes osteosarcoma cell proliferation, migration, and invasion via the glutamine-mediated PI3K/AKT/mTOR signaling pathway and inhibits ferroptosis.\nα cell expression of the AA transporter Slc38a5 was markedly increased in mice with interrupted glucagon signaling and played a role in α cell proliferation.\nWe found that arginine activation of mTOR signaling and induction of the glutamine transporter SLC38A5 was dependent on SLC7A2, showing that both's role in α cell proliferation is dependent on arginine transport and SLC7A2.\nFurthermore, the deletion of SLC38A5 decreased the proliferation and migration of gemcitabine-resistant PDAC cells.\nSLC38A5 inhibition could attenuate the pro-tumoral abilities of CAFs in terms of proliferation, migration, and invasion.\nmost notably, mice deficient in Slc38a5 exhibit markedly decreased α cell hyperplasia to glucagon pathway blockade-induced hyperaminoacidemia.\nMechanistically, SLC38A5 mediates the activation of the PI3K/AKT/mTOR signaling pathway by transporting glutamine, which subsequently enhances the SREBP1/SCD-1 signaling pathway, thereby suppressing ferroptosis in osteosarcoma cells.\nOur findings suggest that SLC38A5 enhances BC cell viability by glutamine metabolism, inhibits the chemical sensitivity of cisplatin in BC cells, and promotes tumor growth, emphasizing the clinical relevance of SLC38A5 in BC management as a novel potential therapeutic target.\nWe confirm and extend these findings by demonstrating that glucagon pathway blockade selectively increases expression of the sodium-coupled neutral amino acid transporter Slc38a5 in a subset of highly proliferative α cells and that Slc38a5 controls the pancreatic response to glucagon pathway blockade;\nMoreover, SLC38A5 deficiency could hinder CRC", "dois": ["10.1016/j.prp.2025.156033", "10.1016/j.isci.2024.111447", "10.1186/s12967-024-05803-6", "10.3389/ebm.2024.10070", "10.1111/bjh.19516", "10.3390/antiox13030291", "10.1007/s12282-023-01516-8", "10.3390/cells12202509", "10.1016/j.tranon.2023.101790", "10.1101/2023.08.10.552656", "10.3324/haematol.2022.282066", "10.7554/eLife.73105", "10.1042/BCJ20210585", "10.3390/ph14030216", "10.1016/j.cmet.2017.05.011", "10.1016/j.cmet.2017.05.006", "10.1007/s11010-008-9931-1"]}
{"pair_type": "slc_pathway", "key1": "SLC38A5", "key2": "oxidative stress", "summary": "SLC38A5 transports glutamine, methionine, glycine and serine, and therefore activates mTOR signaling and induces epigenetic modifications.\nSLC7A11 transports cystine and increases the cellular levels of glutathione, which protects against oxidative stress and lipid peroxidation via glutathione peroxidase, a seleno (Se)-enzyme.\nNiclosamide decreased the glutathione levels, inhibited proliferation, suppressed GPX4 expression, increased lipid peroxidation, and induced ferroptosis in TNBC cells.\nOur previous work discovered niclosamide, an antiparasitic drug, as a potent inhibitor of SLC38A5.\nIn addition to the direct inhibition of SLC38A5 and SLC7A11, the pretreatment of TNBC cells with niclosamide reduced the expression of both transporters.\nHere, we found SLC7A11 to be inhibited by niclosamide with an value in the range of 0.1-0.2 μM.\nPharmacological inhibition of SLC38A5 with amiloride, significantly increased cell sensitivity to 5-FU and irinotecan, and improved mouse survival in metastasis models.\nConsequently, the loss of CDH17 increased sensitivity to 5-FU, irinotecan, oxidative stress and anoikis in CRC cells.\nCDH17 silencing also down-regulated various transporters associated with drug-resistance, including the glutamine-transporter SLC38A5.\nNotably, SLC38A5 silencing was necessary for CDH17-driven effects on drug resistance and survival.\nBoth conditions also lower reproductive hormone levels, increase oxidative stress, and promote germ cell apoptosis.\nSe-Met activated Nrf2 and induced the expression of Nrf2-target genes, including SLC7A11.\nWe found that SLC38A5 interacts with methionine and Se-Met with comparable affinity.\nSince SLC38A5 transports methionine, we examined its role in Se-Met uptake in TNBC cells.", "dois": ["10.1111/andr.70130", "10.1038/s41419-025-07811-w", "10.3390/antiox13030291", "10.1074/jbc.M113.457242"]}
{"pair_type": "slc_pathway", "key1": "SLC38A7", "key2": "glycolysis", "summary": "Analysis of the cellular metabolic phenotype revealed that glutamine deprivation led to a significant increase in glycolytic activity, indicated by an elevated glycolytic capacity and reserve, when V-ATPase function was inhibited concomitantly.\nHowever, this does not lead to a therapeutic benefit, as cells are able to circumvent cell death and growth inhibition by a metabolic shift toward glycolysis.\nFurthermore, we found that the export of lysosomal glutamine derived from exogenous sources plays no role in the phenotype as knock-down of SLC38A7, the lysosomal glutamine exporter, could not increase V-ATPase inhibition-induced cell death or reduce proliferation.", "dois": ["10.3389/fnut.2023.1124678"]}
{"pair_type": "slc_pathway", "key1": "SLC38A7", "key2": "migration", "summary": "SLC38A7 silencing suppressed cell viability, migration, invasion, oxidative phosphorylation, and mitochondrial function in cancer cells.\nOur results suggest that SLC38A7, stabilized by METTL3 and IGF2BP2-mediated mA methylation, enhances cell viability, migration, invasion, oxidative phosphorylation, and mitochondrial function in GC, highlighting its role as a potential therapeutic target for GC.\nSLC38A7 overexpression had the opposite biological effects.\nSolute carrier (SLC) 38 family, responsible for trans-membrane transport of neutral amino acids, plays a role in the proliferation, invasion, and metastasis of cancer cells, but its role in gastric cancer (GC) progression remains unclear.", "dois": ["10.1016/j.jbc.2024.107843"]}
{"pair_type": "slc_pathway", "key1": "SLC38A3", "key2": "oxidative stress", "summary": "Our data demonstrate that SLC38A3 enhances cell viability, cell migration and invasion in vitro, and promotes tumor growth and metastasis in vivo, while reducing apoptosis and oxidative stress.\nOncogenic TF DEAF1 binds to the SLC38A3 promoter, elevates glutamine transporter SLC38A3 expression, enhances influx of glutamine and GSH production, leads to reduced ROS levels in cells and, thereby, promotes HCC progression.\nMechanistically, we show that SLC38A3 suppresses the activity of glycogen synthase kinase 3-β (Gsk3β), a negative regulator of β-catenin, and increases protein levels of β-catenin, leading to the upregulation of epithelial-to-mesenchymal-transition (EMT)-inducing transcription factors and EMT markers in breast cancer.\nIn summary, we show that SLC38A3 is overexpressed in breast cancer and promotes breast cancer metastasis via the GSK3β/β-catenin/EMT pathway, presenting a novel therapeutic target to explore for breast cancer.\nOur study reveals that SLC38A3 regulates cellular glutamine, glutamate, asparagine, aspartate, alanine, and glutathione (GSH) levels in breast cancer cells.\nMoreover, Nrf2 KO mice during acidosis showed increased expression of renal markers of oxidative stress and injury and NRF2 activity was increased during metabolic acidosis in WT kidney.\nAmmonia toxicity in the brain primarily affects astrocytes via a mechanism in which oxidative stress (OS), is coupled to the imbalance between glutamatergic and GABAergic transmission.\nTreatment of cultured cortical mouse astrocytes with ammonia (5 mM NHCl for 24 h) evoked Nrf2 nuclear translocation, increased its activity in a p38 MAPK pathway-dependent manner, and enhanced Nrf2 binding to promoter.\nHere, we tested the hypothesis that activation of Nrf2 is the process that links ammonia-induced OS formation in astrocytes to downregulation and inactivation of SN1 and that", "dois": ["10.1093/carcin/bgaf032", "10.1016/j.taap.2013.06.013", "10.1016/j.canlet.2024.216653", "10.3390/ijms222011233", "10.1038/s41598-018-24000-2"]}
{"pair_type": "slc_pathway", "key1": "SLC38A9", "key2": "apoptosis", "summary": "Subsequent utilisation of arginine as a specific SLC38A9 activator during ammonia stress demonstrated that augmented SLC38A9 expression hindered autophagy, exacerbated ammonia toxicity, and caused a physiological decline (total cholesterol, total triglyceride, acid phosphatase, alkaline phosphatase, aspartate aminotransferase, and alanine aminotransferase levels were significantly increased), oxidative stress, and apoptosis.\narginine pretreatment mitigated the α toxin-induced decrease in cell viability and the increase in cytotoxicity and apoptosis.\nThese findings illustrated that hyperthermia promoted cell apoptosis and reduced the transport of amino acids into cells, which inhibited the milk proteins synthesis in MAC-T cells.\nThe expression of HSP70 and BAX (pro-apoptotic) proteins was upregulated ( < 0.05) while that of B-cell lymphoma (BCL)2 (antiapoptotic) protein was downregulated ( < 0.05) by hyperthermia.\nIn conclusion, arginine administration attenuated α toxin-induced intestinal injury and , which could be associated with the downregulation of inflammation via regulating SLC38A9/mTORC1 pathway.\nRBM25 was found to upregulate the expression of genes pertinent to the inflammatory response and viral processes, as well as to mediate the AS of genes associated with cellular apoptosis and inflammation.\nBy profiling the transcriptome of the abnormally developed embryos using RNA-seq, we identified increased apoptosis, dysregulated amino acid metabolism, and glycolysis/gluconeogenesis disorders that occurred in mutant fish.\nMulti-omics integration revealed the solute carrier family 38 member 9 (SLC38A9)-mammalian target of rapamycin axis as a signalling nexus for amino acid-mediated modulation of autophagy flux, and q-PCR was used to assess the expression of autophagy-related genes (LC3a and sqstm1), revealing an initial inhibition followed by the restoration of autophagic flux during ammonia stress.\nArginine pretreatment also alleviated the α toxin", "dois": ["10.3390/ijms23084200", "10.3389/fimmu.2024.1357072", "10.1016/j.envpol.2023.123211", "10.7717/peerj.16312", "10.1016/j.isci.2023.106045", "10.5187/jast.2021.e128"]}
{"pair_type": "slc_pathway", "key1": "SLC38A7", "key2": "proliferation", "summary": "In addition, SLC38A7 knockdown induced a decrease in proliferation with G1 arrest in lung adenocarcinoma cell lines.\nSLC38A7 silencing suppressed cell viability, migration, invasion, oxidative phosphorylation, and mitochondrial function in cancer cells.\nOur results suggest that SLC38A7, stabilized by METTL3 and IGF2BP2-mediated mA methylation, enhances cell viability, migration, invasion, oxidative phosphorylation, and mitochondrial function in GC, highlighting its role as a potential therapeutic target for GC.\nIt is widely known that most cancer cells display an increased reliance on glutaminolysis to sustain proliferation and survival.\nOur findings demonstrate that SNAT7 plays a pivotal role in promoting tumour malignancy and is significantly associated with poor prognosis in lung adenocarcinoma.\nSLC38A7 overexpression had the opposite biological effects.\nGlutamine metabolism plays a crucial role in cancer cell proliferation and modulates the tumour microenvironment.\nSurprisingly, a combination of glutamine deprivation with archazolid did not lead to synergistic induction of cell death or reduction in proliferation.\nSolute carrier (SLC) 38 family, responsible for trans-membrane transport of neutral amino acids, plays a role in the proliferation, invasion, and metastasis of cancer cells, but its role in gastric cancer (GC) progression remains unclear.\nFurthermore, we found that the export of lysosomal glutamine derived from exogenous sources plays no role in the phenotype as knock-down of SLC38A7, the lysosomal glutamine exporter, could not increase V-ATPase inhibition-induced cell death or reduce proliferation.", "dois": ["10.1007/s10147-025-02851-w", "10.1016/j.jbc.2024.107843", "10.3389/fnut.2023.1124678"]}
{"pair_type": "slc_pathway", "key1": "SLC38A9", "key2": "glycolysis", "summary": "By profiling the transcriptome of the abnormally developed embryos using RNA-seq, we identified increased apoptosis, dysregulated amino acid metabolism, and glycolysis/gluconeogenesis disorders that occurred in mutant fish.\ndeficiency increased whole-body free amino acid and lactate levels but reduced glucose and pyruvate levels.\nThe change of glycolysis-related metabolites in viable mutant fish was ameliorated.\nCompared with IPAA, metabolomics via gas chromatography-mass spectrometry revealed that increases in availability of Thr, Ile, Val, and Leu led to greater concentrations of essential AA (Leu, Ile, Thr), nonessential AA (Gly, Glu, Gln, Ser, Pro, Asp), and various metabolites including uric acid, phosphoric acid, N-acetylglutamic acid, and intermediates of glycolysis and the tricarboxylic acid cycle.\nLysosomal localized amino acid transporter member 9 of the solute carrier family 38 (SLC38A9) regulates essential amino acids' efflux from lysosomes in an arginine-regulated fashion.\nThese results improved our understanding of the physiological functions of SLC38A9 and revealed its indispensable role in embryonic development, metabolic regulation, and stress adaption.", "dois": ["10.3390/ijms23084200", "10.3168/jds.2017-13707"]}
{"pair_type": "slc_pathway", "key1": "SLC38A5", "key2": "ferroptosis", "summary": "SLC38A5 suppresses ferroptosis through glutamine-mediated activation of the PI3K/AKT/mTOR signaling in osteosarcoma.\nSLC38A5 promotes osteosarcoma cell proliferation, migration, and invasion via the glutamine-mediated PI3K/AKT/mTOR signaling pathway and inhibits ferroptosis.\nMechanistically, SLC38A5 mediates the activation of the PI3K/AKT/mTOR signaling pathway by transporting glutamine, which subsequently enhances the SREBP1/SCD-1 signaling pathway, thereby suppressing ferroptosis in osteosarcoma cells.\nNiclosamide, an FDA-approved anti-helminthic, blocks the functions of SLC7A11 and SLC38A5, thus inducing ferroptosis and suppressing macropinocytosis, with the resultant effective reversal of tumor-promoting actions of oncogenic changes in p53 and KRAS.\nTherefore, suppression of SLC38A5 triggers ferroptosis via two pathways that regulate lipid ROS levels.\nWe also found that the inhibition of SLC38A5 triggered the ferroptosis signaling pathway via RNA sequencing.\nOur studies show that the predominant effect of p53 deletion is to induce SLC7A11 with the resultant potentiation of antioxidant machinery and protection of cancer cells from ferroptosis, whereas KRAS activation induces not only SLC7A11 but also SLC38A5, thus offering protection from ferroptosis as well as improving amino acid nutrition in cancer cells via accelerated macropinocytosis.\nAlso, silencing SLC38A5 induced mitochondrial dysfunction and reduced glutamine uptake and glutathione (GSH) levels, and downregulated the expressions of GSH-related genes NRF2 and GPX4.\nThe blockade of glutamine uptake negatively modulated the mTOR-SREBP1-SCD1 signaling pathway.", "dois": ["10.1186/s12967-024-05803-6", "10.3390/cells13110951", "10.3390/cells12202509", "10.3390/antiox13030291"]}
{"pair_type": "slc_pathway", "key1": "SLC38A9", "key2": "migration", "summary": "This redistribution was mediated by promoting outward transport through SLC38A9-BORC-kinesin 1/3 axis and simultaneously reducing inward transport via inhibiting the recruitment of Rab7 and JIP4 onto lysosomes.\nInhibition of LAT1, the amino acid transporter responsible for phenylalanine uptake, reduced peripheral lysosomes and impaired cancer cell migration and proliferation, highlighting the importance of lysosome positioning in these coordinated cellular activities.\nPeripheral lysosomes are involved in processes such as lysosomal exocytosis, cell migration, and metabolic signaling-functions that are particularly important for cancer cell motility and growth.\nAmino acids, as essential nutrients, have been shown to promote lysosome movement toward the cell periphery.\nWe examined the 15 amino acids present in cell culture media and found that 10 promoted lysosome redistribution toward the cell periphery to varying extents, with aromatic amino acids showing the strongest effect.\nLysosome positioning, or lysosome cellular distribution, is critical for lysosomal functions in response to both extracellular and intracellular cues.", "dois": ["10.1101/2024.10.12.618047"]}
{"pair_type": "slc_pathway", "key1": "SLC38A9", "key2": "ferroptosis", "summary": "Molecularly, we identify that SLC38A9-mTOR axis mediates cholesterol sensing and signal transduction to instruct lineage differentiation of LT-HSCs as well as to dictate ferroptosis sensitivity of LT-HSCs through orchestrating SLC7A11/GPX4 expression and ferritinophagy.\nMechanistically, we unravel that cholesterol directly and distinctively enhances ferroptosis resistance and boosts myeloid but dampens lymphoid lineage differentiation of LT-HSCs.\nImportantly, a mTOR inhibitor rapamycin and a ferroptosis inducer imidazole ketone erastin prevent excess cholesterol-induced HSC expansion and myeloid bias.", "dois": ["10.1016/j.redox.2023.102661"]}
{"pair_type": "slc_pathway", "key1": "SLC38A9", "key2": "proliferation", "summary": "This redistribution was mediated by promoting outward transport through SLC38A9-BORC-kinesin 1/3 axis and simultaneously reducing inward transport via inhibiting the recruitment of Rab7 and JIP4 onto lysosomes.\nUsing [2Fe-2S]CO as a universal paradigm, nanomedicines are developed (e.g., ZnPc-SFeCO) that degrade Arg in the lysosome, inhibiting SLC38A9 activation and blocking mTORC1 recruitment.\nMammalian target of rapamycin complex 1 (mTORC1), a key regulator of cell proliferation and metabolism, is linked to abnormal activation in various diseases like cancers.\nThus SLC38A9 is a physical and functional component of the amino acid sensing machinery that controls the activation of mTOR.\nGain of SLC38A9 function rendered cells resistant to amino acid withdrawal, whereas loss of SLC38A9 expression impaired amino-acid-induced mTORC1 activation.\nInhibition of LAT1, the amino acid transporter responsible for phenylalanine uptake, reduced peripheral lysosomes and impaired cancer cell migration and proliferation, highlighting the importance of lysosome positioning in these coordinated cellular activities.\nThe mechanistic target of rapamycin (serine/threonine kinase) complex 1 (MTORC1) acts as a crucial regulator of cellular metabolism by integrating growth factor presence, energy and nutrient availability to coordinate anabolic and catabolic processes, and controls cell growth and proliferation.\nCell growth and proliferation are tightly linked to nutrient availability.\nSLC38A9 is a component of the lysosomal amino acid sensing machinery that controls mTORC1.\nSLC38A9 is the first component of this complex shown to physically engage amino acids, suggesting a role at the core of the amino acid-sensing mechanism.\nCombining lysosome-dispersing amino acids with mTOR-activating amino acids synergistically enhances mTOR activation, which may be particularly relevant in cancer cells.\nPeripheral lysosomes are involved in processes such as lysosomal exocytosis, cell migration, and metabol", "dois": ["10.1002/adma.202504798", "10.1101/2024.10.12.618047", "PMID:27690010", "10.1080/15548627.2015.1091143", "10.1038/nature14107"]}
{"pair_type": "slc_pathway", "key1": "SLC38A10", "key2": "apoptosis", "summary": "These results demonstrate an indirect relationship between the expression of SLC38A10 and p53 and a role in the cell defense mechanism against neurotoxicity.\nInterestingly, KO cells showed significantly lower cell viability and higher cell death compared to WT cells under both glutamate and hydrogen peroxide exposure.\nWe found decreased intracellular p53 protein levels under glutamate and hydrogen peroxide treatment in KO cortical cells.\nFurther, we evaluated the possible role of p53 in neuronal cell apoptosis in KO cells.\nIn contrast, caspase 3/7 activity remains unaltered under all conditions.", "dois": ["10.3389/fmolb.2021.671865"]}
{"pair_type": "slc_pathway", "key1": "SLC38A9", "key2": "oxidative stress", "summary": "Subsequent utilisation of arginine as a specific SLC38A9 activator during ammonia stress demonstrated that augmented SLC38A9 expression hindered autophagy, exacerbated ammonia toxicity, and caused a physiological decline (total cholesterol, total triglyceride, acid phosphatase, alkaline phosphatase, aspartate aminotransferase, and alanine aminotransferase levels were significantly increased), oxidative stress, and apoptosis.\nThis lysosomal NO production is attenuated by treatment with a NO scavenger, while co-overexpression of mTOR and a lysosomal arginine transporter (SLC38A9) enhances lysosomal NO production and suppresses autophagy.\nExtracellular stimuli, such as nutrient deprivation or oxidative stress, induce nuclear translocation and activation of TFEB and TFE3, which then associate with the FACT complex to regulate stress-induced gene transcription.\nMulti-omics integration revealed the solute carrier family 38 member 9 (SLC38A9)-mammalian target of rapamycin axis as a signalling nexus for amino acid-mediated modulation of autophagy flux, and q-PCR was used to assess the expression of autophagy-related genes (LC3a and sqstm1), revealing an initial inhibition followed by the restoration of autophagic flux during ammonia stress.\nTFEB (transcription factor EB) and TFE3 (transcription factor binding to IGHM enhancer 3) orchestrate the cellular response to a variety of stressors, including nutrient deprivation, oxidative stress and pathogens.\nThe present study showed that ammonia stress led to liver metabolic disruption, functional incapacitation, and oxidative damage.\nIn contrast, reduction of FACT levels by siRNA or treatment with the FACT inhibitor curaxin, severely impairs induction of numerous antioxidant and lysosomal genes, revealing a crucial role of FACT as a regulator of cellular homeostasis.\nFurthermore, upregulation of antioxidant genes induced by TFEB over-expression is significantly reduced by curaxin, consistent with a role of FACT", "dois": ["10.1016/j.jcmgh.2019.03.005", "10.1016/j.envpol.2023.123211", "10.1080/15548627.2022.2029671"]}
{"pair_type": "slc_pathway", "key1": "SLC38A10", "key2": "oxidative stress", "summary": "Interestingly, KO cells showed significantly lower cell viability and higher cell death compared to WT cells under both glutamate and hydrogen peroxide exposure.\nIn this study, we have investigated the role of SLC38A10 under acute oxidative and glutamate stress in mouse primary cortical cells from SLC38A10 knockout (KO) mice.\nThe ER/golgi localized transporter, SLC38A10, transports glutamate, glutamine, and alanine in brain cells, and the aim of this study was to determine the possible effects of removal of SLC38A10 in primary cortical cells under glutamate and oxidative challenges.\nPrimary cortical neuronal cultures of wild-type (WT) cell and SLC38A10 KO mice were subjected to different concentrations of glutamate and hydrogen peroxide.\nThese results demonstrate an indirect relationship between the expression of SLC38A10 and p53 and a role in the cell defense mechanism against neurotoxicity.\nWe found decreased intracellular p53 protein levels under glutamate and hydrogen peroxide treatment in KO cortical cells.\nFurther, we evaluated the possible role of p53 in neuronal cell apoptosis in KO cells.\nIn contrast, caspase 3/7 activity remains unaltered under all conditions.", "dois": ["10.1021/acs.jproteome.5c00231", "10.3389/fmolb.2021.671865"]}
{"pair_type": "slc_pathway", "key1": "SLC38A11", "key2": "apoptosis", "summary": "Higher mRNA levels of BCL2, IL13RA1 and SLC38A11 were seen in patients with relapse despite IRT, though these differences did not pass the false discovery rate correction.\nThe top DEGs were found to regulate apoptosis, cell adhesion and RNA processing, and the most highly connected nodes in the network of encoded proteins were ESR2, PHB and RC3H1.", "dois": ["10.1186/s12974-023-02859-x"]}
{"pair_type": "slc_pathway", "key1": "SLC39A1", "key2": "chemotherapy", "summary": "A three-gene signature (SLC39A1, CTSA and CLIC1) based on EMT expression pattern were established through WGCNA analysis.\nThe TCGA-LGG dataset revealed the creation of two molecular subtypes that presented different prognoses, clinical implications, TME, mutation landscapes, chemotherapy, and immunotherapy.\nThe chemo drug sensitivity and immunotherapy of subtypes were estimated through GDSC database and NTP algorithm.\nLow-risk patients showed a positive outlook, increased immune cell presence, and higher expression of immune checkpoint proteins.\nIn addition, several promising drugs, including birinapant, fluvastatin, clofarabine, dasatinib, tanespimycin, TAK-733, GDC-0152, AZD8330, trametinib and ingenol-mebutate had great potential to the treatment of high risk patients.", "dois": ["10.3389/fphar.2023.1276466"]}
{"pair_type": "slc_pathway", "key1": "SLC39A1", "key2": "glycolysis", "summary": "According to GSEA, RAB13 is involved in a number of processes in LIHC, including MTORC1 signaling, MYC targets v1, G2M checkpoint, MITOTIC spindle, DNA repair, P53 pathway, glycolysis, PI3K-AKT-MTOR signaling, etc.\nThe expression of SLC39A1, JTB, SSR2, SNAPIN, and RHOC was strongly positively linked with RAB13, according to a correlation study.", "dois": ["10.1038/s41598-023-43699-2"]}
{"pair_type": "slc_pathway", "key1": "SLC39A1", "key2": "ferroptosis", "summary": "Additionally, SLC39A1 could promote ferroptosis, and triggered significant crosstalk in PI3K-AKT signal pathway, cAMP signal pathway, and peroxisome proliferators-activated receptor (PPAR) signal pathway.\nImmunoblotting revealed down-regulated sarco(endo)plasmic reticulum Ca-ATPase 2a, glutathione peroxidase 4, ferroptosis-suppressing CDGSH iron-sulfur domain 1 (CISD1), and mitochondrial regulating glycogen synthase kinase-3β phosphorylation with elevated p53, myosin heavy chain-β isozyme, IκB phosphorylation, and solute carrier family 7 member 11 (SLC7A11) as well as unchanged SLC39A1, SLC1A5, and ferroptosis-suppressing protein 1 following BSO challenge, all of which, except glutamine transporter SLC7A11 and p53, were abrogated by metallothionein.\nTaken together, these findings support a regulatory modality for CISD1 in the impedance of ferroptosis in metallothionein-offered protection against GSH depletion-evoked cardiac aberration.\nMetallothionein itself did not affect myocardial morphology and function, although it mitigated BSO-provoked myocardial anomalies, loss of mitochondrial integrity and energy, and ferroptosis.", "dois": ["10.1016/j.ajpath.2024.02.009", "10.3389/fcell.2022.977960"]}
{"pair_type": "slc_pathway", "key1": "SLC39A1", "key2": "apoptosis", "summary": "Knockdown of SLC39A1 inhibited cell proliferation by arresting the cell cycle and promoted cell apoptosis, accompanied by suppressing autophagic flux.\nIn vitro experimental results show that SLC39A1 promotes proliferation of glioma cells, inhibits their apoptosis, and promotes expression of MMP2\\MMP9.\nMeanwhile, two different zincs inhibited the ZEA-induced loss of mitochondrial membrane potential and elevation of late-stage apoptosis via activating the mitochondrial apoptotic pathway by recovering the mRNA and protein expression of pro-apoptotic genes (Bax, Casp3, Casp9).\nA CCK-8 and flow cytometer were used to measure the effects of SLC39A1 on U87 cell proliferation or apoptosis\nInhibition of DRP1 abolished SLC39A1-induced mitochondrial division and MMP depolarization, while overexpression of DRP1 reversed mitochondrial fusion and MMP hyperpolarization in SLC39A1 silenced cells, accompanied by recuperative cell proliferative ability.\nMechanistically, SLC39A1 interacts with a member of the dynamin superfamily of GTPases dynamin-related protein 1 (DRP1), followed by facilitating mitochondrial fission and MMP reduction.\nBSO evoked cardiac remodeling and contractile anomalies, including cardiac hypertrophy, interstitial fibrosis, enlarged left ventricular chambers, deranged ejection fraction, fraction shortening, cardiomyocyte contractile capacity, intracellular Ca handling, sarcoplasmic reticulum Ca reuptake, loss of mitochondrial integrity (mitochondrial swelling, loss of aconitase activity), mitochondrial energy deficit, carbonyl damage, lipid peroxidation, ferroptosis, and apoptosis.\nLiver samples were examined for inflammation, fibrosis, proliferation, and apoptosis.\nOur findings reveal a key role of SLC39A1-DRP1 interaction in HCC progression by disturbing mitochondrial quality control and providing a competitive peptide as a potential anti-tumour therapy.", "dois": ["10.1038/srep14277", "10.1002/ctm2.70362", "10.1016/j.ajpath.2024.02.009", "10.1186/s12935-020-01675-0", "10.1080/15476286.2014.996462"]}
{"pair_type": "slc_pathway", "key1": "SLC39A4", "key2": "chemotherapy", "summary": "The subsequent increase in integrin α3β1 signaling, via JNK, inhibits expression of the gemcitabine transporter ENT1, so that cells take up smaller amounts of the drug.\nIncreased ITGA3 and ITGB1 expression and subsequent integrin α3β1 signaling, via c-Jun-N-terminal kinase (JNK), inhibited expression of the gemcitabine transporter ENT1, which reduced gemcitabine uptake by pancreatic cancer cells.\nZIP4 overexpression significantly reduced accumulation of gemcitabine in pancreatic cancer cells, increased growth of xenograft tumors in mice, and increased expression of the integrin subunits ITGA3 and ITGB1.\nActivation of this pathway might help mediate resistance of pancreatic tumors to chemotherapeutic agents.\nZEB1-knockdown cells had increased sensitivity to gemcitabine.\nexpression levels of ITGA3 and ITGB1 were reduced in cells with ZIP4 knockdown.\nspheroids established from these cells had increased sensitivity to gemcitabine.\nWe found ZIP4 to activate STAT3 to induce expression of ZEB1, which induced expression of ITGA3 and ITGB1 in KPC cells.\nPancreatic cancer cells with ITGA3 or ITGB1 knockdown had reduced proliferation and formed smaller tumors in mice, despite overexpression of ZIP4.\nIn studies of pancreatic cancer cell lines and mice, we found that ZIP4 increases expression of the transcription factor ZEB1, which activates expression of ITGA3 and ITGB1.\nMIA PaCa-2 cells that overexpressed ZIP4 had increased resistance to gemcitabine, 5-fluorouracil, and cisplatin, whereas AsPC-1 cells with ZIP4 knockdown had increased sensitivity to these drugs.\nPancreatic tumors undergo rapid growth and progression, become resistant to chemotherapy, and recur after surgery.\nIn mice, xenograft tumors grown from AsPC-1 cells with ZIP4 knockdown were smaller and more sensitive to gemcit", "dois": ["10.1053/j.gastro.2019.10.038"]}
{"pair_type": "slc_pathway", "key1": "SLC39A1", "key2": "oxidative stress", "summary": "Co-incubation of zinc with ZEA significantly reduced the ZEA-induced reactive oxygen species and malondialdehyde elevation by promoting the transcription of Mtf1 and Mt2.\nImmunoblotting revealed down-regulated sarco(endo)plasmic reticulum Ca-ATPase 2a, glutathione peroxidase 4, ferroptosis-suppressing CDGSH iron-sulfur domain 1 (CISD1), and mitochondrial regulating glycogen synthase kinase-3β phosphorylation with elevated p53, myosin heavy chain-β isozyme, IκB phosphorylation, and solute carrier family 7 member 11 (SLC7A11) as well as unchanged SLC39A1, SLC1A5, and ferroptosis-suppressing protein 1 following BSO challenge, all of which, except glutamine transporter SLC7A11 and p53, were abrogated by metallothionein.\nThe results shown that both zinc sulfate and zinc gluconate addition increased the intracellular zinc concentration and influenced the expression of zinc transporters (Slc30a1 and Slc39a1) in a time-dependent manner.\nMetallothionein itself did not affect myocardial morphology and function, although it mitigated BSO-provoked myocardial anomalies, loss of mitochondrial integrity and energy, and ferroptosis.\nBSO evoked cardiac remodeling and contractile anomalies, including cardiac hypertrophy, interstitial fibrosis, enlarged left ventricular chambers, deranged ejection fraction, fraction shortening, cardiomyocyte contractile capacity, intracellular Ca handling, sarcoplasmic reticulum Ca reuptake, loss of mitochondrial integrity (mitochondrial swelling, loss of aconitase activity), mitochondrial energy deficit, carbonyl damage, lipid peroxidation, ferroptosis, and apoptosis.\nInhibition of CISD1 using pioglitazone nullified GSH-offered benefit against BSO-induced cardiomyocyte ferroptosis and contractile and intracellular Ca derangement.", "dois": ["10.1016/j.ajpath.2024.02.009", "10.1038/srep14277"]}
{"pair_type": "slc_pathway", "key1": "SLC39A1", "key2": "proliferation", "summary": "Knockdown of SLC39A1 inhibited cell proliferation by arresting the cell cycle and promoted cell apoptosis, accompanied by suppressing autophagic flux.\nIn vitro experimental results show that SLC39A1 promotes proliferation of glioma cells, inhibits their apoptosis, and promotes expression of MMP2\\MMP9.\nHigh SLC39A1 is critical for a more aggressive tumor phenotype by promoting cell proliferation and invasion.\nHNRNPA2B1 might be regulating SMCs proliferation and phenotypic transition rno-miR-330-3p/TGFβR3 and rno-miR-125a-3p/slc39a1.\nWe found SLC39A1 transfection impaired tumor metabolism and perturbed tumor metabolism-related pathways, which was a likely cause of the alteration in cell proliferation, migration, and cell cycle progression in RCC cells.\nA CCK-8 and flow cytometer were used to measure the effects of SLC39A1 on U87 cell proliferation or apoptosis;\nAfter SLC39A1 overexpression or knockdown, proliferation and invasion assays were conducted for proliferation and invasion estimation, respectively.\nInhibition of DRP1 abolished SLC39A1-induced mitochondrial division and MMP depolarization, while overexpression of DRP1 reversed mitochondrial fusion and MMP hyperpolarization in SLC39A1 silenced cells, accompanied by recuperative cell proliferative ability.\nMoreover, the inhibition effect of SLC39A8 overexpression could be enhanced by low concentration zinc supplement.\nand assays demonstrated that overexpressing SLC39A1 could promote gastric cancer growth and invasion, while silencing SLC39A1 led to opposite effects.\nFurthermore, we found that overexpression of SLC39A8 or treatment with low concentration of zinc chloride could effectively inhibit the proliferation, migration and invasion of ccRCC cells.\nLiver samples were examined for inflammation, fibrosis, proliferation, and apoptosis.\nThe HNRNPA2B1 expression levels determined were consistent with the proliferation-related and collagen synthesis-related gene CO", "dois": ["10.1002/ctm2.70362", "10.3389/fcell.2022.977960", "10.1155/2022/1256021", "10.3389/fgene.2022.974740", "10.2147/JHC.S349966", "10.3389/fonc.2021.651921", "10.1186/s12935-020-01675-0", "10.1002/jcb.27285"]}
{"pair_type": "slc_pathway", "key1": "SLC39A1", "key2": "migration", "summary": "We found SLC39A1 transfection impaired tumor metabolism and perturbed tumor metabolism-related pathways, which was a likely cause of the alteration in cell proliferation, migration, and cell cycle progression in RCC cells.\nAdditionally, SLC39A1 could promote ferroptosis, and triggered significant crosstalk in PI3K-AKT signal pathway, cAMP signal pathway, and peroxisome proliferators-activated receptor (PPAR) signal pathway.\nFurthermore, we found that overexpression of SLC39A8 or treatment with low concentration of zinc chloride could effectively inhibit the proliferation, migration and invasion of ccRCC cells.\nMoreover, the inhibition effect of SLC39A8 overexpression could be enhanced by low concentration zinc supplement.\nThe knockdown of NR2F1-AS1 impaired PDAC cell proliferation, migration, invasion and tumorigenesis.\nSLC39A1 significantly altered several metabolisms at transcriptional, protein and metabolic levels, including purine and pyrimidine metabolism, amino acids and derivatives metabolism, lactose metabolism, and free fatty acid metabolism.", "dois": ["10.3389/fcell.2022.977960", "10.2147/JHC.S349966", "10.3389/fcell.2021.736980", "10.3389/fonc.2021.651921"]}
{"pair_type": "slc_pathway", "key1": "SLC39A4", "key2": "migration", "summary": "The in vitro experiments revealed that suppressing the expression of SLC39A4 in ICC cell lines resulted in reduced cell proliferation, colony formation, and cell migration.\nThe zinc transporter SLC39A4 influences epithelial cell morphology and migration in various cancers\nSLC39A4 silencing by lentivirus-mediated shRNA blocked human lung cancer cell epithelial-mesenchymal transition and metastasis in vitro and in vivo, respectively.\nRNAi knockdown of Zip4 in mouse Hepa cells significantly increased apoptosis and modestly slowed progression from G(0)/G(1) to S phase when cells were released from hydroxyurea block into zinc-deficient medium.\nZIP4 may play a role in the acquisition of zinc by hepatocellular carcinomas, and potentially many different cancerous cell-types, leading to repressed apoptosis, enhanced growth rate and enhanced invasive behavior.\nCell migration assays revealed that RNAi knockdown of Zip4 in Hepa cells depressed in vitro migration whereas forced over-expression in Hepa cells and MCF-7 cells enhanced in vitro migration.\nIntegrated analysis of gene expression in non-small cell lung cancer revealed that SLC39A4 expression is significantly correlated with increased tumour size and regional lymph node spread, as well as shorter overall survival (OS) and disease-free survival (DFS).\nSLC39A4 has been identified to be a regulator of tumor cell metastasis and proliferation in vivo and in vitro, with an area under the curve of 0.874 for diagnosing CESC.\nSolute carrier family 39 member 4 (SLC39A4) produces a zinc ion transporter involved in metastasis and invasion of tumors.\nCollectively, these data suggest that SLC39A4 may be a novel therapeutic target and predictive marker of tumour metastasis in non-small cell lung cancer.", "dois": ["10.1016/j.bbamcr.2024.119755", "10.1186/s12935-024-03251-2", "10.1016/j.tranon.2023.101839", "10.2147/CMAR.S282269", "10.1038/s41598-017-07830-4", "10.1371/journal.pone.0013158"]}
{"pair_type": "slc_pathway", "key1": "SLC39A5", "key2": "apoptosis", "summary": "SLC39A5 promoted LUAD cell proliferation by accelerating the G1-to-S phase transition and inhibiting apoptosis.\nSLC39A5 promoted LUAD cell proliferation by activating the phosphatidylinositol 3-kinase (PI3K)/protein kinase B (AKT) signaling.\nSLC39A5 played an oncogenic role in LUAD by activating the PI3K/AKT signaling.\nActivation of NF-κB contributed to the upregulation of pyroptosis in GCs, while pyroptosis factors were downregulated after the inhibition of NF-κB with JSH-23.\nDEHP treatment and overexpression of SLC39A5 activated NF-κB-related factors, followed by an increase in the transcript expression level of NLRP3.\nThus, DEHP contributes to ovarian dysfunction by inducing pyroptosis via the SLC39A5/NF-κB/NLRP3 axis in GCs.\nZIP5 knockdown inhibited the proliferation, migration and invasion of ESCC and suppressed COX2, cyclin D1 and E-cadherin expression, which led to the inhibition of cell progression in ESCC.\nZIP5 knockdown decreased proliferation by 28 and 38%, respectively, according to the MTT and CCK-8 assays.\nDEHP treatment also disrupted the normal expression of ovarian function-related genes and inhibited the proliferation of GCs.\nWe conducted MTT and CCK-8 assays to determine the role of ZIP5 in cell proliferation, Transwell assays to detect migration and invasion, and flow cytometry (FCM) to detect apoptosis and cell cycle percentage using KYSE170K cells.", "dois": ["10.1016/j.ecoenv.2023.114625", "10.1016/j.prp.2021.153541", "10.3892/or.2015.4097"]}
{"pair_type": "slc_pathway", "key1": "SLC39A5", "key2": "migration", "summary": "Knockdown of SLC39A5 inhibited GC cell proliferation, migration, and invasion.\nTaken together, these results indicate that Slc39a5 plays a critical role in endothelial sprouting and migration in venous angiogenesis by regulating zinc homeostasis.\nWe observed the morphogenesis and migration abnormalities of the SLC39A5 knockout (KO) human embryonic kidney cells (HEK293) and found a significant injury of ECM constituents.\nOverall, the SLC39A5 depletion-induced zinc deficiency destabilized Smad proteins, which inhibited the TGF-β signalling and downstream ECM synthesis, thus contributing to the pathogenesis of high myopia.\nIn conclusion, SLC39A5 promotes the progression of GC via the BATF-HIP1R axis, which suggests that SLC39A5 acts as a therapeutic or diagnostic target for GC.\nMigration and invasion decreased by 54 and 68%, respectively, according to the Transwell assays.\nBATF overexpression reversed the inhibitory effect of SLC39A5 depletion on the behavior of GC cells and tumor growth.\nFurther analysis revealed significantly reduced proliferation and delayed cell migration in the caudal vein of morphants.\nZIP5 knockdown inhibited the proliferation, migration and invasion of ESCC and suppressed COX2, cyclin D1 and E-cadherin expression, which led to the inhibition of cell progression in ESCC.\nFurthermore, SLC39A5 increased Moloney murine leukemia virus 1 (proto-oncogene serine/threonine-protein kinase 1 [PIM1]) kinase activity by enhancing zinc influx, which in turn triggered basic leucine zipper ATF-like transcription factor (BATF) phosphorylation and stabilized BATF protein.\nSLC39A5 re-expression reversed the phenotype of TGF-β signalling and ECM synthesis in the KO cells.\nMoreover, knocking down expression using either a morpholino or CRISPR/Cas9-mediated gene editing led to cardiac ischaemia and an accumulation of red bloo", "dois": ["10.1016/j.jbc.2025.110754", "10.1111/jcmm.16803", "10.1098/rsob.200281", "10.3727/096504016X14648701447896", "10.3892/or.2015.4097"]}
{"pair_type": "slc_pathway", "key1": "SLC39A6", "key2": "chemotherapy", "summary": "LIMMA and SAM identified genes potentially affected by the presence of AML, including homeodomain-interacting protein kinase 1 (HIPK1), mex-3 homolog D (MEX3D), and genes potentially affected by chemotherapy, including argininosuccinate synthase 1 (ASS1), notch homolog 1 (NOTCH1), zinc transporter ZIP6 (SLC39A6), and TP53-regulated inhibitor of apoptosis 1 (TRIAP1).\nThe expression of 2 genes with potential biological significance in oral mucositis, ASS1 and SLC39A6 (alias LIV-1), was confirmed by quantitative real-time reverse transcriptase-polymerase chain reaction (qRT-PCR).\nWe investigated molecular events in CIOM from buccal mucosa tissue collected before and 2 days after chemotherapy from patients with acute myeloid leukemia (AML) and healthy controls by microarray analysis.\nMicroarray analysis was performed using Human Genome U133 Plus 2.0 Array on buccal mucosa punch biopsies from patients with AML before (n = 4) or after chemotherapy (n = 4), and from healthy controls (n = 3).\nOur results suggest that AML-specific deregulated immune responses and inflammatory tissue damage to the oral mucosa caused by chemotherapy may not be overcome by the natural cellular repair processes and therefore contribute to CIOM.\nHowever, patients with high expression displayed a lower pCR rate than patients with low expression after anthracycline-based neoadjuvant chemotherapy, including in multivariate analysis adjusted on grade and molecular subtypes.\nWe searched for correlations between expression and clinicopathological data, including disease-free survival (DFS), overall survival (OS), pathological complete response to chemotherapy (pCR), and potential vulnerability and actionability to anti-cancer drugs used or under development in BC.", "dois": ["10.3390/pharmaceutics15030938", "10.1155/2022/8168517", "10.1016/j.tripleo.2011.05.009"]}
{"pair_type": "slc_pathway", "key1": "SLC39A2", "key2": "proliferation", "summary": "Furthermore, by suppressing NET formation, Cc-ELNs mitigated pyroptosis in intestinal epithelial cells (IECs) and promoted the proliferation of both IECs and intestinal stem cells (ISCs).\nMechanistically, Cc-ELNs delivered miR-5106, which downregulated Slc39a2 expression, thereby restoring zinc homeostasis in neutrophils and reducing NET formation.", "dois": ["10.1186/s12951-025-03466-z", "10.3390/ijms232415746", "10.1042/BSR20200764"]}
{"pair_type": "slc_pathway", "key1": "SLC39A6", "key2": "stemness", "summary": "BRY812 has an inhibitory effect on the growth, migration and stemness of CRC cells, and may exert its killing effect by downregulating the AKT pathway.", "dois": ["10.1038/s41598-025-03713-1"]}
{"pair_type": "slc_pathway", "key1": "SLC39A4", "key2": "glycolysis", "summary": "Using LASSO and multivariate Cox regression analyses, a six-gene signature including , , , , , and was constructed.\nThe results showed that glycolysis and immune response were the main risk factors for overall survival (OS) in UM patients.\nTaken together, this study identified a new prognostic six-gene signature related to glycolysis and immune response.\nTwo-factor survival analysis showed that UM patients with high hypoxia or immune response scores and high risk scores had the worst prognosis.\nIn addition, risk scores were related to the immune infiltration profiles.\nUnivariate and multivariate Cox regression analyses showed that risk score was an independent risk factor for OS in UM patients.", "dois": ["10.3389/fimmu.2021.738068"]}
{"pair_type": "slc_pathway", "key1": "SLC39A4", "key2": "stemness", "summary": "Moreover, SLC39A4 knockdown enhanced cancer cell sensitivity to cisplatin-induced death by inhibiting stemness in lung cancer cells.\nSLC39A4 silencing by lentivirus-mediated shRNA blocked human lung cancer cell epithelial-mesenchymal transition and metastasis in vitro and in vivo, respectively.\nCP had antiproliferative effects and reduced the expression of proliferative and stemness genes in jejunal organoids, effects that were largely independent of Zn chelation.\nThe zinc transporter SLC39A4 influences epithelial cell morphology and migration in various cancers.\nSLC39A4 expression is significantly correlated with increased tumour size and regional lymph node spread, as well as shorter overall survival (OS) and disease-free survival (DFS).\nCollectively, these data suggest that SLC39A4 may be a novel therapeutic target and predictive marker of tumour metastasis in non-small cell lung cancer.", "dois": ["10.1016/j.biopha.2024.116555", "10.1038/s41598-017-07830-4"]}
{"pair_type": "slc_pathway", "key1": "SLC39A6", "key2": "glycolysis", "summary": "Low-salinity stress obviously increased SLC39A6, SLC5A9, NKAα1, CYP1A1, CYP1B1, and GSTA expression.\nAfter q-value correction, 7 pathways (Glycolysis/Gluconeogenesis; Pentose phosphate pathway; Biosynthesis of amino acids; Fructose and mannose metabolism; Metabolism of xenobiotics by cytochrome P450; and Glycine, serine and threonine metabolism) remained significant.\nIn contrast, the genes encoding Aldoaa, GPI, FBP2 and GAPDH exhibited downregulation.", "dois": ["10.1016/j.cbpb.2020.110437"]}
{"pair_type": "slc_pathway", "key1": "SLC39A7", "key2": "ferroptosis", "summary": "Mechanistically, METTL9 mediated methylation of SLC39A7 at the His45 and His49 residues suppressed ferroptosis through the endoplasmic reticulum (ER) stress regulatory protein kinase R-like endoplasmic reticulum kinase (PERK)/ATF4 signaling pathway and the downstream protein SLC7A11.\nBy interrogating zinc-related genes in a genome-wide RNAi screen of ferroptosis, we identified SLC39A7, encoding ZIP7 that controls zinc transport from endoplasmic reticulum (ER) to cytosol, as a novel genetic determinant of ferroptosis.\nGenetic and chemical inhibition of the ZIP7 protected cells against ferroptosis, and the ferroptosis protection upon ZIP7 knockdown can be abolished by zinc supplementation.\nImportantly, the knockdown of HERPUD1 abolished the ferroptosis protection phenotypes of ZIP7 inhibition.\nTogether, we have uncovered an unexpected role of ZIP7 in ferroptosis by maintaining ER homeostasis.\nHere, we reported that zinc is also essential for ferroptosis in breast and renal cancer cells.\nZinc chelator suppressed ferroptosis, and zinc addition promoted ferroptosis, even during iron chelation.\nThe name of ferroptosis indicates that the ferroptotic death process depends on iron, but not other metals, as one of its canonical features.\nInhibition of solute carrier family 39 member 7 (SLC39A7/ZIP7), a potential ER iron efflux channel supposed by us, alleviated PFOS-induced mitochondrial iron overload and further elevated ER iron level.\nUpon inhibition of ACSL4, the ZIP7-VDAC3 interaction was reduced, mitigating mitochondrial iron overload and exacerbating iron accumulation in ER.\nWe found that the genetic and chemical inhibition of ZIP7 triggered ER stresses, including the induction of the expression of HERPUD1 and ATF3.\nMoreover, SLC7A11 transported cystine for intracellular glutathione synthesis, eliminating intracellular reactive oxygen species (ROS) and inhibiting", "dois": ["10.1186/s10020-025-01271-w", "10.1002/tox.24142", "10.1038/s41419-021-03482-5", "10.1016/j.scitotenv.2024.177679", "10.1093/toxres/tfae010"]}
{"pair_type": "slc_pathway", "key1": "SLC39A7", "key2": "migration", "summary": "Our study revealed that SLC39A7 promotes the proliferation, invasion and migration of glioma cells via the TNF-α-mediated NF-κB signaling pathway, which provides potential targets for glioma therapy.\nOur results indicated that SLC39A7 significantly promoted the proliferation, invasion and migration of glioma cells.\nThe experiments indicated that silencing of SLC39A7 expression resulted in decreased cell proliferation, increased cell apoptosis, and attenuated migratory and invasive ability using CCK-8, colony formation, flow cytometry, transwell assays, respectively in cervical cancer cell lines, HeLa and ME-180 cells.\nWe determined that SLC39A7 promotes the malignant behaviors of glioma by activating the TNF-α-mediated NF-κB signaling pathway.\nFurthermore, SLC39A7 promoted tumorigenesis in orthotopic models.\nThese findings provide evidence that SLC39A7 plays a positive role in the progression of cervical cancer and its knockdown might be as a potential therapeutic target for cervical cancer treatment.", "dois": ["10.1186/s12967-022-03535-z", "10.7150/jca.54158", "10.1042/BSR20200041", "10.17179/excli2017-690"]}
{"pair_type": "slc_pathway", "key1": "SLC39A8", "key2": "stemness", "summary": "The drastic changes of these genes, including Slc39a8 which was a potential indicator of cell differentiation, in contrast the slight changes of self-renewal genes, imply that differentiation may be the default fate of stem cells and self-renewal may rely on a maintenance mechanism.\nA loss-of-function study showed that knockdown of SLC12A2 expression restrained proliferation and stemness of CRC cells while a gain-of-function study showed the contrary results.\nThis indicates that the Ras/Raf/ERK pathway, in addition to JAK/STAT, may also be a key player to carry on external LIF signal into mouse embryonic stem cells to promote self-renewal.\nCompared with the slight decay of Oct4/Nanog/Sox2 during the 14 days, the expression of cell differentiation genes such as Gata4/6 underwent a drastic increase, which indicates that the upregulated expression of cell differentiation genes may better reflect the loss of self renewal than the down regulated expression of the stemness indicators Oct4, Sox2 and Nanog.", "dois": ["10.1038/s41598-024-55048-y", "10.1007/s11693-008-9015-2"]}
{"pair_type": "slc_pathway", "key1": "SLC39A9", "key2": "glycolysis", "summary": "The transcriptomic analysis performed by BRB-seq approach revealed an upregulation of several androgen-sensitive genes, such as Akap5, Slc39a9, an androgen receptor or lactate dehydrogenase A (Ldha), which produces lactate, and downregulation of several genes associated with the insulin pathway such as Tsc2 or the hexokinase Hkdc1.\nMetabolomics analysis showed a reduction in most glycolysis metabolites, except for pyruvate and lactate.\nThe consequences of inhibition of GLUT5 led to an increase in fatty acids cell content, a perturbation in glycolysis and amino-acid metabolism but an enhanced androgen production.", "dois": ["10.1016/j.mce.2025.112658"]}
{"pair_type": "slc_pathway", "key1": "SLC39A7", "key2": "oxidative stress", "summary": "In the nucleus pulposus (NP), impaired mitochondria lead to apoptosis, oxidative stress, senescence, extracellular matrix degradation and synthesis, excessive autophagy, inflammation, mitochondrial instability, and pyroptosis, with key regulatory targets including AMPK, PGC-1α, SIRT1, SIRT3, Progerin, p65, Mfn2, FOXO3, NDUFA4L2, SLC39A7, ITGα5/β1, Nrf2, and NLRP3 inflammasome.\nIn the annulus fibrosus (AF), mitochondrial damage induces apoptosis and oxidative stress mediated by PGC-1α, while in the cartilage endplate (CEP), mitochondrial dysfunction similarly triggers apoptosis and oxidative stress.", "dois": ["10.1074/jbc.M111.246082", "10.3389/fphar.2025.1579507"]}
{"pair_type": "slc_pathway", "key1": "SLC39A8", "key2": "chemotherapy", "summary": "Five genes were significantly upregulated: SLC2A9, SLC16A3, SLC16A14, SLC38A4 and SLC39A8.\nIn summary, CLEC3B promotes chemosensitivity via interacting with SLC39A8 and SLC39A14 to induce ferroptosis.\nIn vitro experimental results indicated that the overexpression of SLC39A8 inhibited the proliferation and invasion of colorectal cancer cells.\nMechanistic assays found that CLEC3B promoted CDDP chemosensitivity via inducing ferroptosis.\nFunctional assays showed that CLEC3B promoted CDDP chemosensitivity.\nTNBC patients with high CLEC3B levels had better prognosis than those with low CLEC3B levels after chemotherapy.\nMoreover, CLEC3B interacted with SLC39A8 and SLC39A14 and knockdown of them reversed the effect of CLEC3B overexpression on chemosensitivity.\nLasso-penalized Cox regression analysis was utilized to construct a prognostic risk model, including spermidine/spermine N1-acetyltransferase 1 (SAT1), SAT2, TFRC, SLC39A8, MAP1LC3A, ALOX15, and PROM2.\nLASSO and multivariate Cox methods were employed to establish a prognostic gene signature (ALOX12, HSPA1A, IL13, MID2, RFFL, and SLC39A8) and the corresponding scoring system, termed PCDscore, which exhibited robust predictive ability.\nNotably, SAT1 showed significant influence in cisplatin and gemcitabine resistance.\nFinally, in vitro experiments demonstrated that the combination of gemcitabine and cisplatin could induce ferroptosis in AsPC1 cells, probably through elevated SAT1 expression.\nHowever, cisplatin chemoresistance often generate in a notable proportion of TNBC patients, leading therapeutic failure.\nIn results of MDR development during chemotherapy cancer cells become resistant to further treatment.", "dois": ["10.1186/s40001-025-02855-2", "10.1038/s41419-025-07733-7", "10.1016/j.compbiomed.2024.107933", "10.1089/dna.2021.0594", "10.1016/j.biopha.2014.02.002"]}
{"pair_type": "slc_pathway", "key1": "SLC39A9", "key2": "oxidative stress", "summary": "Several genes with pleiotropic roles include transporters (SLC39A9), wound healing, ion channel regulators, oxidative stress mediators, cytochromes, cytokines, telomere regulators, circadian rhythm, ultradian rhythms, hormonal regulation, and the serotonin system.", "dois": ["10.3390/ijms26031039"]}
{"pair_type": "slc_pathway", "key1": "SLC39A8", "key2": "proliferation", "summary": "As an miR-205_R-1 sponge, circAMN1 regulated the expression of SLC39A8 to control erastin-induced ferroptosis and regulated the proliferation, invasion, and migration of trophoblast cells.\nIn vitro experimental results indicated that the overexpression of SLC39A8 inhibited the proliferation and invasion of colorectal cancer cells.\nFurthermore, we found that overexpression of SLC39A8 or treatment with low concentration of zinc chloride could effectively inhibit the proliferation, migration and invasion of ccRCC cells.\nZnT8 haploinsufficiency disrupts expression of a distinct array of important β-cell markers, decreases cellular proliferation via mitogen-activated protein (MAP) kinase cascades and downregulates insulin gene expression.\nMoreover, the inhibition effect of SLC39A8 overexpression could be enhanced by low concentration zinc supplement.\nP4HA1 facilitates the advancement of colorectal cancer, while its suppression diminishes the proliferation and migration of colorectal cancer cells.\nOur previous work showed that maternal selenium deficiency suppressed proliferation, induced autophagy dysfunction, and apoptosis in the placenta of mice.\nWe identify 30 independent genome-wide significant variants after Bonferroni correction for the number of measures studied (126 variants at nominal genome-wide significance) implicating genes involved in myelination (SEMA3A), neurite elongation and guidance (NUAK1, STRN, DPYSL2, EPHA3, SEMA3A, HGF, SHTN1), neural cell proliferation and differentiation (GMNC, CELF4, HGF), neuronal migration (CCDC88C), cytoskeletal organization (CTTNBP2, MAPT, DAAM1, MYO16, PLEC), and brain metal transport (SLC39A8).\nThese results suggested that maternal selenium deficiency may impair progesterone biosynthesis, reduce nutrient transporters expression, and promote immune response by increasing the oxidative stress of the placentae.\nWith the progression of tumor, the expression of SLC39A8 decreased progressively.", "dois": ["10.3389/fmed.2025.1614012", "10.3389/fmicb.2025.1590400", "10.3390/cells14070483", "10.3390/antiox13040451", "10.1038/s41467-024-46023-2", "10.1038/s41598-024-55048-y", "10.1016/j.compbiomed.2024.107933", "10.1038/s41398-022-02137-z", "10.1093/mtomcs/mfac062", "10.3389/fcell.2021.786684", "10.3389/fonc.2021.651921", "10.1042/BSR20200764", "10.3390/ijms20215485", "10.1152/ajpgi.00165.2018", "10.1007/s11693-008-9015-2"]}
{"pair_type": "slc_pathway", "key1": "SLC39A10", "key2": "apoptosis", "summary": "We then generated transgenic mice with T cell-specific deletion of Slc39a10 (cKO) and found that its loss not only protects against disease progression in IBD and experimental autoimmune encephalomyelitis (EAE), but also induces massive apoptosis via a p53/p21- and Bcl2-independent process.\nMoreover, reduced intracellular Zn concentration in macrophages led to the stabilization of p53, which increased apoptosis upon LPS stimulation.\nFurthermore, it is shown that loss of Slc39a10 causes zinc deficiency in fetal HSCs, which in turn leads to DNA damage, apoptosis, and G cell cycle arrest.\nTaken together, these results suggest that Slc39a10 plays a role in promoting the survival of macrophages through a Zn/p53-dependent axis in response to inflammatory stimuli.\nGenetic ablation of Zip10 in early B-cell stages resulted in significant reductions in B-cell populations, and the inducible deletion of Zip10 in pro-B cells increased the caspase activity in parallel with a decrease in intracellular Zn levels.\nKnockdown of zip10 reduced free Zn in HGC, ceased their normal developmental apoptosis, and resulted in displacement and later disappearance of hatching glands and hatching enzymes he1a and catL1b, and inability to hatch.\nTogether, these findings indicate that SLC39A10 safeguards hematopoiesis by protecting against zinc deficiency-induced necroptosis, thus providing compelling evidence that SLC39A10 and zinc homeostasis promote the development of fetal HSCs.\nSimilarly, the depletion of intracellular Zn by a chemical chelator resulted in spontaneous caspase activation leading to cell death.\nIn addition, inhibiting necroptosis partially restores hematopoiesis in mouse HSCs, providing mechanistic insights into the requirement for zinc in mediating hematopoiesis.\nFree Zn in embryos and apoptosis were investigated using fluorescent dyes whereas gene expression was investigated by whole-mount in situ hybridization (WISH).", "dois": ["10.1007/s11427-024-2817-y", "10.1016/j.phrs.2023.106703", "10.1073/pnas.1708018114", "10.1073/pnas.1323549111", "10.1002/advs.202205345", "10.2147/JHC.S320326", "10.2147/OTT.S245537", "10.1016/j.bbrc.2020.05.131"]}
{"pair_type": "slc_pathway", "key1": "SLC39A10", "key2": "proliferation", "summary": "Conversely, SLC39A10 knockdown inhibited gastric cancer cell proliferation and colony formation.\nFunctional studies showed that ectopic expression of SLC39A10 in gastric cancer cells dramatically enhanced the proliferation, colony formation, invasiveness abilities of these gastric cancer cells and tumorigenic potential in nude mice.\nPartial hepatectomy transiently upregulated miR-141-3p levels just after the initiation of hepatocyte proliferation, whereas mRNA was downregulated.\nMitotic inhibition translated to impaired proliferation in both models, with TAMR cells displaying increased sensitivity.\nConsistent with our proposed model, activated ZIP6 levels correlated with mitotic cells, which could be efficiently inhibited through use of our anti-ZIP6 monoclonal antibody.\nWe demonstrate that ZIP10 drives OS proliferation and chemoresistance through ITGA10-mediated activation of the PI3K/AKT pathway, which might serve as a target for OS treatment.\nAs a result, the MAPK/ERK and PI3K/AKT pathways, two major downstream effectors of CK2, were activated, while c-Myc, a downstream target of these two pathways, formed a vicious feedback loop with SLC39A10 to drive the malignant progression of gastric cancer.\nKnockdown of ZIP10 suppressed OS cell proliferation and chemoresistance.\nNotably, the overexpression of miR-141-3p inhibited the proliferation of Huh7 cells.\nIn this study, we identified microRNA 141-3p as an osmosensitive miRNA, which inhibits proliferation during liver cell swelling.\nIn this study, we investigate that overexpression of hsa_circ_0057552 inhibited the proliferation and motility of ESCC cells in vitro and in vivo, whereas its silencing exerts the opposite effect.\nPrevious studies have reported that its upregulation promotes breast cancer metastasis by enhancing the influx of zinc ions (Zn);\nUpregulation of microRNA 141-3p, controlled by Src-, Erk-, and p38-MAPK signalling, results in decreased mRNA levels of various genes involved in", "dois": ["10.1016/j.micinf.2025.105548", "10.1038/s12276-023-01062-5", "10.2147/OTT.S430212", "10.2147/OTT.S384688", "10.37349/etat.2022.00080", "10.1016/j.jhepr.2022.100440", "10.1186/s13046-021-02146-8", "10.2147/JHC.S320326", "10.2147/OTT.S245537", "10.1042/BSR20200764", "10.1002/jcb.27285", "10.1042/BCJ20160388"]}
{"pair_type": "slc_pathway", "key1": "SLC39A10", "key2": "oxidative stress", "summary": "CBD downregulates the expression of the mRNA for the zinc transporter Zip10/Slc39a10 as well as for the zinc finger protein 472.\nMoreover, CBD treatment of BV-2 cells, was found to induce a robust change in the expression of genes related to oxidative stress, glutathione deprivation and inflammation.\nThese results show that CBD, but much less so THC, affects the expression of genes involved in zinc homeostasis and suggest that the regulation of zinc levels could have an important role through which CBD may exert its antioxidant and anti-inflammatory effects.\nA subset of genes was found to be regulated by the metal responsive element (MRE)-binding transcription factor-1 (MTF-1) and is shown to be related to zinc homeostasis.\nAmong these genes, ZnT1, Mt2 and the zinc transporters ZIPs are known to function together to control the intracellular zinc concentration.\nMany of these genes were shown to be controlled by Nrf2 and ATF4 transcription factors.\nCannabidiol (CBD) has been shown to exhibit anti-inflammatory, antioxidant and neuroprotective properties.", "dois": ["10.1016/j.neuint.2011.12.002", "PMID:16221973"]}
{"pair_type": "slc_pathway", "key1": "SLC39A10", "key2": "stemness", "summary": "And revealed the underlying molecular features involving tumor stemness, immune regulation, and genomic alterations associated with the risk score.\nHowever, this does not establish an explicit relationship between SLC39A10 and stemness as requested.", "dois": ["10.3389/fgene.2022.857215"]}
{"pair_type": "slc_pathway", "key1": "SLC39A5", "key2": "proliferation", "summary": "SLC39A5 promoted LUAD cell proliferation by accelerating the G1-to-S phase transition and inhibiting apoptosis.\nSLC39A5 promoted LUAD cell proliferation by activating the phosphatidylinositol 3-kinase (PI3K)/protein kinase B (AKT) signaling.\nKnockdown of SLC39A5 inhibited GC cell proliferation, migration, and invasion.\nZIP5 knockdown decreased proliferation by 28 and 38%, respectively, according to the MTT and CCK-8 assays.\nBATF overexpression reversed the inhibitory effect of SLC39A5 depletion on the behavior of GC cells and tumor growth.\nFurther analysis revealed significantly reduced proliferation and delayed cell migration in the caudal vein of morphants.\nDEHP treatment also disrupted the normal expression of ovarian function-related genes and inhibited the proliferation of GCs.\nOral zinc supplementation is shown to improve survival and weight gain of SBS mice and increase the proliferation of intestinal crypt cells in vitro.\nZIP5 knockdown inhibited the proliferation, migration and invasion of ESCC and suppressed COX2, cyclin D1 and E-cadherin expression, which led to the inhibition of cell progression in ESCC.\nFurthermore, SLC39A5 increased Moloney murine leukemia virus 1 (proto-oncogene serine/threonine-protein kinase 1 [PIM1]) kinase activity by enhancing zinc influx, which in turn triggered basic leucine zipper ATF-like transcription factor (BATF) phosphorylation and stabilized BATF protein.\nSLC39A5 played an oncogenic role in LUAD by activating the PI3K/AKT signaling.\nSLC39A5 knockdown inhibited the tumorigenesis of LUAD cells in a nude mouse model of xenograft tumors.\nCOX2 expression was decreased by 68 and 75% at the mRNA and protein level, respectively, and cyclin D1 mRNA and protein expression was decreased following 62 and 60%, respectively, by knockdown of ZIP", "dois": ["10.1016/j.jbc.2025.110754", "10.1038/s41467-024-52216-6", "10.1016/j.ecoenv.2023.114625", "10.1016/j.prp.2021.153541", "10.1098/rsob.200281", "10.1042/BSR20200764", "10.3727/096504016X14648701447896", "10.3892/or.2015.4097"]}
{"pair_type": "slc_pathway", "key1": "SLC39A11", "key2": "migration", "summary": "Knockdown of promoted the migration of LUAD cells in both the A549 cell line and H1975 cell line.\nSome SNPs-encoding ZIP11 variants rescued Zn levels, proliferation, migration, and invasiveness of knockdown (KD) cells.\nConversely, single MBS mutations mimicked the traits of KD cells, confirming the transporter's role in establishing and maintaining proliferative, migratory, and invasive traits.\nWe also proposed that a metal-binding site (MBS) in ZIP11 is crucial for transmembrane Zn2+ transport and required for maintenance of various pathogenic phenotypes observed in HeLa cells.", "dois": ["10.1093/mtomcs/mfae006", "10.21037/atm-22-3576"]}
{"pair_type": "slc_pathway", "key1": "SLC39A7", "key2": "proliferation", "summary": "genetic ablation of SLC39A7 (ZIP7) results in decreased cytosolic zinc levels, increased ER zinc levels, impaired cell proliferation, and induction of ER stress.\nsilencing of SLC39A7 expression resulted in decreased cell proliferation, increased cell apoptosis, and attenuated migratory and invasive ability using CCK-8, colony formation, flow cytometry, transwell assays, respectively in cervical cancer cell lines, HeLa and ME-180 cells.\nKnockdown of SLC39A7 exhibited a significant decrease in cell viability and proliferation of colorectal cancer cells.\nSLC39A7 promotes the proliferation, invasion and migration of glioma cells via the TNF-α-mediated NF-κB signaling pathway, which provides potential targets for glioma therapy.\nmiR-15a-3p inhibited the proliferation, invasion, and EMT process of PCa cells via targeting SLC39A7 and suppressing Wnt/β-catenin signaling pathway, which may represent a new therapeutic objective for PCa treatment.\nSLC39A7 significantly promoted the proliferation, invasion and migration of glioma cells.\nOverexpression of SYNJ2BP could facilitate MAM contact organization and NLRX1-SLC39A7 complex formation, thus promoted mitochondrial Zn homeostasis, NP cell proliferation and intervertebral disc rejuvenation.\ntargeted depletion of the eight genes reduced the proliferation potential of TNBC cell models, while most remarkable effects were for combined SLC39A7, TIMM13, BANF1, and MVD knockdown in conjunction with doxorubicin.\nSLC39A7 overexpression attenuated the effects of miR-15a-3p on cell proliferation, invasion, Wnt/β-catenin pathway and EMT molecules.\ndownregulation of SLC39A7 promoted the cleavage of PARP and enhanced the expression of Bad, Caspase-9, and cleaved-Caspase-3, as well as suppressed Bcl-2 expression.\nMitotic inhibition translated to impaired proliferation in", "dois": ["10.1016/j.freeradbiomed.2023.12.028", "10.1080/15548627.2023.2274205", "10.3390/ijms231810901", "10.1186/s12967-022-03535-z", "10.37349/etat.2022.00080", "10.7150/jca.54158", "10.1042/BSR20200764", "10.1042/BSR20200041", "10.1089/cbr.2018.2722", "10.1002/jcb.27285", "10.1124/mol.118.112557", "10.1371/journal.pone.0191212", "10.17179/excli2017-690", "10.1093/abbs/gmx094", "10.1016/j.jid.2017.03.031", "10.1371/journal.pgen.1006349", "PMID:17673939"]}
{"pair_type": "slc_pathway", "key1": "SLC39A11", "key2": "apoptosis", "summary": "SLC39A11-SRD5A3 and GALNT2-SRD5A3) that all served as prognostic biomarkers of breast cancer.\nPARP1-ACSL1 pair significantly correlated with poor overall survival in breast cancer owing to the suppression of the MAPK, mTOR and NF-kB signaling pathways, which induces apoptosis, autophagy and prevents inflammatory processes.\nIn both A549 and H1975 cell lines, knockout of inhibited the apoptosis of LUAD cells, whereas knockout of promoted the apoptosis of LUAD cells.", "dois": ["10.21037/atm-22-3576", "10.1038/s41598-022-13835-5"]}
{"pair_type": "slc_pathway", "key1": "SLC39A7", "key2": "apoptosis", "summary": "The experiments indicated that silencing of SLC39A7 expression resulted in decreased cell proliferation, increased cell apoptosis, and attenuated migratory and invasive ability using CCK-8, colony formation, flow cytometry, transwell assays, respectively in cervical cancer cell lines, HeLa and ME-180 cells.\nIt was also shown that knockdown of SLC39A7 interfered with cell cycle progression and induced G2/M cell cycle arrest, as well as boosted early and late apoptosis in colorectal cancer cells.\nFurthermore, downregulation of SLC39A7 promoted the cleavage of PARP and enhanced the expression of Bad, Caspase-9, and cleaved-Caspase-3, as well as suppressed Bcl-2 expression.\nIn molecular levels, Western blot further demonstrated that silencing of SLC39A7 significantly upregulated the expression of Bax and E-cadherin, downregulated the expression of Bcl-2 and MMP-2 in both HeLa and ME-180 cells.\nIn conclusion, we developed a prognostic model based on ferroptosis and infiltrated immune cells that effectively stratified breast cancer patients and demonstrated the role of SLC39A7 in breast cancer pathogenesis through the regulation of apoptosis.\nIn the nucleus pulposus (NP), impaired mitochondria lead to apoptosis, oxidative stress, senescence, extracellular matrix degradation and synthesis, excessive autophagy, inflammation, mitochondrial instability, and pyroptosis, with key regulatory targets including AMPK, PGC-1α, SIRT1, SIRT3, Progerin, p65, Mfn2, FOXO3, NDUFA4L2, SLC39A7, ITGα5/β1, Nrf2, and NLRP3 inflammasome.\nOur findings revealed that knocking down the expression of the hub gene SLC39A7 significantly impacted cancer cell apoptosis and combining ferroptosis and TME scores yielded high prognostic power.\nA phenotypic screen identified compounds that interfere with trafficking of Notch and induce apoptosis via an", "dois": ["10.1002/tox.24142", "10.1016/j.freeradbiomed.2023.12.028", "10.1042/BSR20200041", "10.1038/s41589-018-0200-7", "10.1093/abbs/gmx094", "10.1371/journal.pgen.1006349", "10.1074/jbc.M115.640524", "10.3389/fphar.2025.1579507", "10.17179/excli2017-690", "10.1016/j.ijrobp.2017.03.023"]}
{"pair_type": "slc_pathway", "key1": "SLC39A8", "key2": "ferroptosis", "summary": "inhibition of Slc39a14 and Slc39a8 significantly relieves VC by intercepting iron overload-induced ferroptosis in VSMCs, providing new insights into the VC treatment.\nCLEC3B promotes chemosensitivity via interacting with SLC39A8 and SLC39A14 to induce ferroptosis.\ncoumestrol was unable to upregulate the expression of ferroptosis pathway-related genes in CRC cell lines after SLC39A8 interference.\nCoumestrol was found to induce apoptosis in CRC cell lines by upregulating the expression of ferroptosis pathway-related genes SLC39A8, NCOA4, VDAC2, and NOX2.\ncircAMN1 regulated the expression of SLC39A8 to control erastin-induced ferroptosis and regulated the proliferation, invasion, and migration of trophoblast cells.\nwhether metalloproteins SLC39a14 and SLC39a8 are involved in ferroptosis induced by iron overload.\ncombined lead and cadmium exposure may exacerbate neurotoxicity by mediating microglia ferroptosis via STEAP3, SLC39A8.\na reduced ac4C level shortens the half-life of and mRNA, resulting in low levels of intracellular cystine and reduced GSH, failing to detoxify ROS, and leading to increased cellular oxPLs, which facilitate ferroptosis induction.\nzrt-/irt-like protein 8 (ZIP8), encoded by SLC39A8, was closely associated with ferroptosis of monocytes during sepsis.\nCLEC3B promoted CDDP chemosensitivity via inducing ferroptosis.\nthe heightened expression of ZIP8 may facilitate this progression.\ndownregulation of ZIP8 alleviated the lipopolysaccharide-induced lipid peroxidation, as well as restoring the reduction of GPX4, FTH1 and xCT.\nKEGG enrichment analysis suggested that ZIP8 plays", "dois": ["10.1186/s40001-025-02855-2", "10.1016/j.burns.2025.107513", "10.1186/s12890-025-03555-7", "10.1016/j.intimp.2024.113854", "10.1186/s12933-024-02224-z", "10.1016/j.redox.2023.102985", "10.1089/dna.2021.0594", "10.1097/HP.0000000000001385", "10.3389/fmed.2025.1614012", "10.7150/jca.94628", "10.3390/antiox13040451", "10.3390/ijms25020763", "10.3390/antiox12051116", "10.7150/jca.68568", "10.3389/fonc.2021.711776"]}
{"pair_type": "slc_pathway", "key1": "SLC39A11", "key2": "proliferation", "summary": "transcriptional upregulation of several specific ZIP transporters (SLC39A6, SLC39A7, SLC39A9, SLC39A10, and SLC39A11) could contribute in meeting the increased demand of zinc in cancer cells.\nSome SNPs-encoding ZIP11 variants rescued Zn levels, proliferation, migration, and invasiveness of knockdown (KD) cells.\nZinc is a transition metal and catalytic cofactor involved in many biological processes including proliferation, development, differentiation, and metabolism.\nOur laboratory reported a function of ZIP11 in maintaining nuclear Zn levels in HeLa cervical cancer cells.\nConversely, single MBS mutations mimicked the traits of KD cells, confirming the transporter's role in establishing and maintaining proliferative, migratory, and invasive traits.\nAs DNA damage and uncontrolled proliferation are hallmarks of cancer, including epithelial ovarian cancer (EOC), we hypothesized that inherited variation in the cellular transport genes contributes to EOC risk.\nDefective cellular transport processes can lead to aberrant accumulation of trace elements, iron, small molecules and hormones in the cell, which in turn may promote the formation of reactive oxygen species, promoting DNA damage and aberrant expression of key regulatory cancer genes.\nOverall, the intricate role of Zn in cellular dynamics and cancer progression underscores the significance of Zn transporters like ZIP11 in potential therapeutic interventions.\nDisruptions in the cellular regulation of Zn2+ ions often lead to pathological states.\nMammalian Zn transporters, such as ZIP11, play a key role in homeostasis of this ion.\nZinc (Zn) is a vital micronutrient with essential roles in biological processes like enzyme function, gene expression, and cell signaling.\nWe also proposed that a metal-binding site (MBS) in ZIP11 is crucial for transmembrane Zn2+ transport and required for maintenance of various pathogenic phenotypes observed in HeLa cells.", "dois": ["10.1111/cas.16351", "10.1093/mtomcs/mfae006", "10.21037/atm-22-3576", "10.1038/s41598-022-13835-5", "10.1042/BSR20200764", "10.1002/jcb.27285", "10.1371/journal.pone.0128106"]}
{"pair_type": "slc_pathway", "key1": "SLC39A4", "key2": "proliferation", "summary": "The in vitro experiments revealed that suppressing the expression of SLC39A4 in ICC cell lines resulted in reduced cell proliferation, colony formation, and cell migration.\nSLC39A4 has been identified to be a regulator of tumor cell metastasis and proliferation in vivo and in vitro, with an area under the curve of 0.874 for diagnosing CESC.\nThe effects of silencing solute carrier family 39 member 4 gene (SLC39A4) expression using siRNA were investigated using assays measuring cell proliferation, colony formation, and cell migration.\nZIP4 overexpression significantly reduced accumulation of gemcitabine in pancreatic cancer cells, increased growth of xenograft tumors in mice, and increased expression of the integrin subunits ITGA3 and ITGB1;\nPancreatic cancer cells with ITGA3 or ITGB1 knockdown had reduced proliferation and formed smaller tumors in mice, despite overexpression of ZIP4;\nOral zinc supplementation is shown to improve survival and weight gain of SBS mice and increase the proliferation of intestinal crypt cells in vitro.\nWe found ZIP4 to activate STAT3 to induce expression of ZEB1, which induced expression of ITGA3 and ITGB1 in KPC cells.\nCP had antiproliferative effects and reduced the expression of proliferative and stemness genes in jejunal organoids, effects that were largely independent of Zn chelation.\nIn studies of pancreatic cancer cell lines and mice, we found that ZIP4 increases expression of the transcription factor ZEB1, which activates expression of ITGA3 and ITGB1.\nThe assessment of the effect of SLC39A4 on cell growth and migration in CESC was conducted using MTT, colony formation, and Transwell assays.\nThe histopathological examination showed epidermal parakeratosis with mild hyperkeratosis, severe spongiform edema of the stratum cornicum, significant proliferation of acanthocytes, and vacuolation of keratinocytes.\nThese studies suggest that oral CQ (or other 8-hydroxyquinolines) coupled with zinc", "dois": ["10.1038/s41467-024-52216-6", "10.1016/j.bbamcr.2024.119755", "10.1016/j.biopha.2024.116555", "10.1186/s12935-024-03251-2", "10.1016/j.tranon.2023.101839", "10.7499/j.issn.1008-8830.2204123", "10.2147/CMAR.S282269", "10.1042/BSR20200764", "10.2147/OTT.S245094", "10.1053/j.gastro.2019.10.038", "10.1371/journal.pone.0072543", "PMID:18003899", "PMID:12699353"]}
{"pair_type": "slc_pathway", "key1": "SLC39A12", "key2": "proliferation", "summary": "We used a congenic breeding program and comparative genomics to exploit this variation in the rat and identified the gene Slc39a12 as a major regulator of hypoxia-induced pulmonary vascular remodelling.\nWe show that ZIP12 expression in pulmonary vascular smooth muscle cells is hypoxia dependent and that targeted inhibition of ZIP12 inhibits the rise in intracellular labile zinc in hypoxia-exposed pulmonary vascular smooth muscle cells and their proliferation in culture.\nHere we report that ZIP12 expression is increased in many cell types, including endothelial, smooth muscle and interstitial cells, in the remodelled pulmonary arterioles of rats, cows and humans susceptible to hypoxia-induced pulmonary hypertension.\nWe demonstrate that genetic disruption of ZIP12 expression attenuates the development of pulmonary hypertension in rats housed in a hypoxic atmosphere.\nSlc39a12 encodes the zinc transporter ZIP12.", "dois": ["10.3389/fgene.2022.1092678", "10.1042/BSR20200764", "10.1038/nature14620"]}
{"pair_type": "slc_pathway", "key1": "SLC39A13", "key2": "ferroptosis", "summary": "Downregulation of the Zinc Transporter ZIP13 (Slc39a13) Leads to Ferroptosis by Inhibiting Mitochondrial Iron-Sulfur Cluster Biosynthesis and Induces Ischemia/Reperfusion Injury in Mouse Hearts.\nFinally, ferrostatin-1, a ferroptosis inhibitor, alleviated I/R-induced ferroptosis as well as cardiac injury in cKO mice.\nIn contrast, ZIP13 overexpression prevented I/R-induced ferroptosis, mitochondrial Fe accumulation, and suppression of ISC biosynthesis.\nZIP13 cKO (cardiac-specific conditional knockout) induced ferroptosis and suppressed mitochondrial iron-sulfur cluster (ISC) biosynthesis.\nSimilar to the action of cKO, I/R led to ZIP13 downregulation, ferroptosis, mitochondrial Fe accumulation, and suppression of ISC biosynthesis.\nThese findings highlight that ZIP13 downregulation at reperfusion triggers ferroptosis by suppressing the mitochondrial ISC biosynthesis followed by mitochondrial Fe accumulation.\nIn support, cKO of ZIP13 aggravated I/R-induced ferroptosis and mitochondrial Fe accumulation.\nZIP13 cKO also reduced glutathione levels as well as solute carrier family 7 member 11 (SLC7A11) expression.\nThis study proposes a previously unknown mechanism by which ZIP13 downregulation contributes to ferroptosis in the setting of myocardial I/R.\nWhile ferroptosis is involved in the pathogenesis of myocardial ischemia/reperfusion (I/R) injury, the exact mechanism underlying the induction of ferroptosis by I/R remains elusive.\nSince downregulation of Zrt, Irt-like protein 13 (ZIP13) plays a role in I/R injury by targeting mitochondria, we hypothesized that ZIP13 downregulation during I/R leads to ferroptosis through a mitochondria-dependent mechanism.\nDownregulation of SLC7A11 may also contribute to the action of ZIP13 downregulation.", "dois": ["10.1089/ars.2024.0815"]}
{"pair_type": "slc_pathway", "key1": "SLC39A11", "key2": "ferroptosis", "summary": "Differentially spliced SLCs were enriched in biological processes, including transmembrane transporter activity, transporter activity, ferroptosis, and choline metabolism.\nWe developed a prognostic risk model based on the screened 6-SLC-AS (SLC7A6_RI_37208 (SLC7A6-RI), SLC11A2_AP_21724, SLC2A8_ES_87631, SLC35B1_AA_42317, SLC39A11_AD_43204, and SLC7A8_AP_26712).", "dois": ["10.1111/cas.16351"]}
{"pair_type": "slc_pathway", "key1": "SLC39A13", "key2": "apoptosis", "summary": "The polytons identified were mostly endoplasmic reticulum-located, integral proteins involved in protein maturation, N-glycosylation, protein folding, anterograde transport of proteins, protein secretion, and the regulation of apoptosis.\nAmong the singletons, we identified SLC31A2, SLC35B1, SLC39A13, CRACM1, and MTCH2 as putative binding partners of SLC41A1.", "dois": ["10.1684/mrh.2013.0339"]}
{"pair_type": "slc_pathway", "key1": "SLC39A7", "key2": "chemotherapy", "summary": "Mechanistically, targeted depletion of the eight genes reduced the proliferation potential of TNBC cell models, while most remarkable effects were for combined SLC39A7, TIMM13, BANF1, and MVD knockdown in conjunction with doxorubicin.\nThe immune cell infiltration levels were higher, and the response to immunotherapy and chemotherapy was better in the low-risk groups.\nA total of 6 NRGs (FASLG, IPMK, FLT3, SLC39A7, HSP90AA1, and LEF1), which were associated with the prognosis of BC patients, were selected to establish our signature.\nEight RD-derived genes were identified as TNBC-essential genes, which were highly predicative of overall survival (OS) and relapse-free survival (RFS) in an additional cohort of basal breast cancer ( = 442).\nOur data have identified gene signatures predicative of RD and pCR in TNBC with potential clinical implications.\nHerein, we identified a gene panel predictive of RD and pCR in TNBC from the discovery ( = 90) treatment-naive tumor transcriptomic data.\nOrthogonal partial least squares-discriminant analysis (OPLS-DA) and receiver operating characteristic curve (ROC) analyses revealed significant predictive power for the identified gene panels with an area under the curve (AUC) of 0.75 for the validation cohort ( = 50) to discriminate RD from pCR.\nProtein-Protein Interaction (PPI) network analysis of the pCR-derived gene signature identified an 87-immune gene signature highly predictive of pCR, which correlated with better OS, RFS, and distant-metastasis-free survival (DMFS) in an independent cohort of basal and, to a lesser extent, HER2+ breast cancer.", "dois": ["10.3390/ijms231810901", "10.1186/s12967-022-03535-z"]}
{"pair_type": "slc_pathway", "key1": "SLC39A13", "key2": "stemness", "summary": "A loss-of-function study showed that knockdown of SLC12A2 expression restrained proliferation and stemness of CRC cells while a gain-of-function study showed the contrary results.\nAs a result, we developed a prognostic risk model based on the screened 6-SLC genes (SLC39A8, SLC2A3, SLC39A13, SLC35B1, SLC4A3, SLC12A2).", "dois": ["10.1038/s41598-024-55048-y"]}
{"pair_type": "slc_pathway", "key1": "SLC39A14", "key2": "chemotherapy", "summary": "In summary, CLEC3B promotes chemosensitivity via interacting with SLC39A8 and SLC39A14 to induce ferroptosis.\nMechanistic assays found that CLEC3B promoted CDDP chemosensitivity via inducing ferroptosis.\nFunctional assays showed that CLEC3B promoted CDDP chemosensitivity.\nTNBC patients with high CLEC3B levels had better prognosis than those with low CLEC3B levels after chemotherapy.\nMoreover, CLEC3B interacted with SLC39A8 and SLC39A14 and knockdown of them reversed the effect of CLEC3B overexpression on chemosensitivity.\nHowever, cisplatin chemoresistance often generate in a notable proportion of TNBC patients, leading therapeutic failure.\nCisplatin is one of effect chemotherapeutic drugs for triple-negative breast cancer (TNBC).\nHere, we aimed to study the functions and regulatory mechanisms of CLEC3B in cisplatin chemoresistance in TNBC.\nThus, identification of key regulatory mechanisms for chemoresistance is important.\nIt is known that intestinal flora affects the number and function of NK cells through metabolites, thereby regulating the response of tumors to chemotherapy or immunotherapy.", "dois": ["10.1186/s40001-025-02855-2", "10.1038/s41419-025-07733-7"]}
{"pair_type": "slc_pathway", "key1": "SLC39A12", "key2": "oxidative stress", "summary": "Loss of Slc39a12 in hippocampal neurons results in cellular oxidative stress, further leading to neuronal damage.\nSlc39a12 knockdown in HT22 cells induced increased Nox4 expression, decreased SOD2 expression, increased MDA level, and reduced GSH and intracellular Zn.\nIncreased Nox4 expression, decreased SOD2 expression, elevated MDA level, and reduced GSH level were detected in serum and hippocampal neurons in the MIA group, with nuclear pyknosis and reduced Nissl bodies observed in neurons.\nThe expression of Slc39a12 in hippocampal neurons of rats in the MIA group decreased.\nOxidative stress in HT22 cells after transfection and HO stimulation was reversed when ZnCl was added.", "dois": ["10.1016/j.gene.2021.145824", "10.1016/j.heliyon.2024.e26271"]}
{"pair_type": "slc_pathway", "key1": "SLC39A13", "key2": "proliferation", "summary": "ZIP13 knockout suppressed the malignant phenotypes of ovarian cancer cells both in vitro and in vivo.\nThe expression of ZIP13 in ovarian cancer cell lines was depleted to explore its effect on proliferation, adhesion, migration, and invasion both in vitro and in vivo assays.\nA loss-of-function study showed that knockdown of SLC12A2 expression restrained proliferation and stemness of CRC cells while a gain-of-function study showed the contrary results.\nFurther investigation revealed that ZIP13 regulated intracellular zinc distribution and then affected the expressions of genes involved in extracellular matrix organization and cytokine-mediated signaling pathway.\nZIP13 is shown to be a novel driver of metastatic progression by modulating the Src/FAK signaling pathway, which may serve as a promising biomarker for prognostic evaluation and targeted therapy in ovarian cancer.\nThis led to the activation of Src/FAK pathway with increased expressions of pro-metastatic genes but decreased expressions of tumor suppressor genes.", "dois": ["10.1038/s41598-024-55048-y", "10.1186/s13046-021-01999-3", "10.1042/BSR20200764"]}
{"pair_type": "slc_pathway", "key1": "SLC39A14", "key2": "apoptosis", "summary": "METTL14 overexpression or SLC39A14 knockdown enhanced viability, promoted proliferation and cell cycle progression, restrained apoptosis, reduced LC3II/LC3I and Beclin-1 levels, and increased p62 expression in ESCs.\nKnockdown of SLC39A14 inhibited glioma cell proliferation, migration, and invasion, while promoting apoptosis.\nIn conclusion, METTL14 promotes proliferation and inhibits apoptosis and autophagy activation in ESCs by inhibiting SLC39A14.\nThe inhibition of solute carrier family 39 member 14 (SLC39A14) expression enhanced apoptosis and inhibited cell cycle progression in AML cells.\nImmunostaining for cleaved caspase-3 (cCASP3), a marker of apoptosis, showed increased number of PCs with positive immunolabeling for cCASP3 in Slc39a14-KO mice relative to WT.\nOverexpression of ZIP14 in HeLa and Caski cells increased p38 phosphorylation, inhibited cell growth and migration, and enhanced apoptosis.\nThe overexpression of significantly inhibited the proliferation, migration, and invasion of Huh7 HCC cells while promoting their apoptosis.\nA contributory role of decreases in [Zn](i) in LPS-induced apoptosis (as determined by caspase-3/7 activation, annexin-V binding, and cytochrome c release) in SPAECs was revealed by mimicking the effect of LPS with the zinc chelator, TPEN, and inhibiting LPS- (or TPEN)-induced apoptosis with exogenous zinc.\nPretreatment of wild-type SPAEC with 250 μM of the NO donor S-nitroso-N-acetylpenicillamine (SNAP) increased labile zinc in a relatively similar fashion to addition of extracellular zinc and reduced sensitivity of SPAEC to LPS-induced apoptosis (e.g., caspase-3/7 activation) in a N,N,N',N'-tetrakis(2-pyridyl", "dois": ["10.3390/genes16080887", "10.1016/j.burns.2025.107513", "10.1016/j.jri.2025.104447", "10.2174/0115680096250711231024063841", "10.1186/s12885-023-11637-0", "10.1038/s41598-019-44954-1", "10.1152/ajplung.00385.2011", "10.1152/ajplung.00376.2010", "10.4240/wjgs.v17.i10.111454", "10.1016/j.nbd.2025.107115", "10.1016/j.ijbiomac.2025.146695", "10.1111/febs.70103", "10.1007/s11427-022-2347-0", "10.1155/2022/9774219", "10.3390/ijms22094646", "10.1002/mgg3.1160", "10.4103/2045-8932.105032"]}
{"pair_type": "slc_pathway", "key1": "SLC39A8", "key2": "migration", "summary": "As an miR-205_R-1 sponge, circAMN1 regulated the expression of SLC39A8 to control erastin-induced ferroptosis and regulated the proliferation, invasion, and migration of trophoblast cells.\nFurthermore, we found that overexpression of SLC39A8 or treatment with low concentration of zinc chloride could effectively inhibit the proliferation, migration and invasion of ccRCC cells.\nMoreover, the inhibition effect of SLC39A8 overexpression could be enhanced by low concentration zinc supplement.\nP4HA1 facilitates the advancement of colorectal cancer, while its suppression diminishes the proliferation and migration of colorectal cancer cells.\nWe assessed multiple phenotypes and traits (associated with rs13107325) of the knock-in mice, including body and brain weight, concentrations of metal ions (including cadmium, zinc, manganese, and iron) transported by SLC39A8, blood lipids, proliferation and migration of neural stem cells (NSCs), cortical development, behaviors and cognition, transcriptome, dendritic spine density, and synaptic transmission.\nHIP1R knockdown significantly reduced RA FLS invasiveness and migration ( < 0.05).\nWith the progression of tumor, the expression of SLC39A8 decreased progressively.\nSilencing P4HA1 markedly reduces the proliferative and migratory abilities of colorectal cancer cells.\nHIP1R is a new gene implicated in RA FLS invasiveness and migration, and regulates unique pathways and cell processes relevant to both RA as well as cancer biology.\nThrough bioinformatics analysis of tumor databases, SLC39A8 was identified as a key gene of ZIP family in ccRCC, which could be used as an effective indicator for diagnosing ccRCC and judging its prognosis.\nDimensionality reduction reveals three major gene ontologies constraining CT (neural signaling, ion transport, cell migration) and four constraining GWC (neural cell development, cellular homeostasis, tissue repair, ion transport).\nThe prognosis of patients with low expression of SLC39A8 is significantly worse.", "dois": ["10.3389/fmed.2025.1614012", "10.3390/cells14070483", "10.1007/s12021-025-09722-9", "10.3390/antiox13040451", "10.1038/s41467-024-46023-2", "10.1038/s41398-022-02137-z", "10.3389/fonc.2021.651921"]}
{"pair_type": "slc_pathway", "key1": "SLC39A8", "key2": "oxidative stress", "summary": "Interestingly, expression of hSLC39A8 mutants of both CDG type II and Leigh syndrome reduced mitochondrial Mn levels and activity of Mn-dependent mitochondrial superoxide dismutase MnSOD, and in turn increased oxidative stress.\nConsistent with this Se deficit, liver expression of selenoproteins glutathione peroxidases 1 and 2 was downregulated, along with decreases in antioxidant superoxide dismutases 1 and 2, consistent with increased oxidative stress.\nAn imbalance in the levels of these metals weakens the structural, regulatory, and catalytic roles of different enzymes, proteins, receptors, and transporters and is known to provoke the development of various neurological conditions through different mechanisms, such as via induction of oxidative stress, increased α-synuclein aggregation and fibril formation, and stimulation of microglial cells, thus resulting in inflammation and reduced production of metalloproteins.\nThese results suggested that maternal selenium deficiency may impair progesterone biosynthesis, reduce nutrient transporters expression, and promote immune response by increasing the oxidative stress of the placentae.\nIn the present study, dietary selenium deficiency in dams significantly suppressed glutathione peroxidase (GSH-Px) activity, total antioxidant capacity (T-AOC), and increased malondialdehyde (MDA) content in the placentae, confirming the oxidative stress in the placenta.\nConsistently, overproduction of oxPLs, as well as increased mitochondrial depolarization and decreased activities of antioxidant enzymes, support the notion of ferroptosis induction in NAT10-depleted cancer cells.\nMechanistically, a reduced ac4C level shortens the half-life of and mRNA, resulting in low levels of intracellular cystine and reduced GSH, failing to detoxify ROS, and leading to increased cellular oxPLs, which facilitate ferroptosis induction.\nWe found that plasma NTBI damaged intestinal morphology, caused intestinal oxidative stress injury and reactive oxygen species (ROS) accumulation, and induced intestinal epithelial cell apoptosis.\nCollectively, our findings suggest that NAT10 restra", "dois": ["10.1093/mtomcs/mfac062", "10.3390/ijms22157820", "10.1152/ajpgi.00165.2018", "10.1074/jbc.M111.246082", "10.3389/fendo.2025.1629815", "10.3390/ijms26031039", "10.1186/s12933-024-02224-z", "10.1007/s11427-022-2347-0", "10.3390/antiox12051116", "10.3390/ijms22094646", "10.1038/s41598-018-21464-0"]}
{"pair_type": "slc_pathway", "key1": "SLC39A6", "key2": "proliferation", "summary": "Experimentally, the suppression of SLC39A6 expression promoted ESCC cell apoptosis but abrogated proliferation and invasion, and induced an EMT phenotype that included enhanced expression of E-cadherin, loss of vimentin, and morphological changes in ESCC cells in vitro.\nResults of this investigation demonstrate that inhibition of IRE1 signaling enzyme function affects the expression of NRIP1, EBBP, ESRRA, E2IG5, PGRMC2, and SLC39A6 genes in U87 glioma cells in gene specific manner and these changes possibly contribute to the suppression of the cell proliferation.\nKnockdown of SLC39A6 expression suppressed proliferation and invasion in ESCC cells.\nKnockdown of SLC39A6 reduced proliferation of ESCC cells in culture and metastasis of xenograft tumors in mice.\nFurthermore, knockdown of SLC39A6 inhibited the proliferation, migration and invasion of liver cancer cells and .\nSLC39A6 was overexpressed in tissues from GA patients and in GA cell lines, and SLC39A6 knockdown in GA cell lines inhibited their proliferation, migration and invasion.\nRNA analyses show significant correlations between CelTIL responses, high proliferation genes (e.g., CCNE1, MKI67), and low expression of luminal genes (e.g., NAT1, SLC39A6).\nCollectively, the results of the present study suggested that SLC39A6 may be a promising prognostic biomarker for liver cancer and is associated with the proliferation, migration and invasion of liver cancer.\nConsistent with our proposed model, activated ZIP6 levels correlated with mitotic cells, which could be efficiently inhibited through use of our anti-ZIP6 monoclonal antibody.\nPTCH1, a receptor of Hedgehog (Hh) pathway, is reported to suppress cell proliferation.\nCells that overexpressed SLC39A6 had significant increases in intracellular levels of zinc and were more invasive in assays, activating phosphatidylinositol 3-kinase signaling to AKT serine/thr", "dois": ["10.1038/s41467-024-50056-y", "10.37349/etat.2022.00080", "10.22038/IJBMS.2021.58542.13003", "10.3892/ol.2022.13197", "10.1038/s41598-021-85408-x", "10.1042/BSR20200764", "10.1186/s12885-019-6222-z", "10.1002/jcb.27285", "10.18632/oncotarget.23219", "10.1002/jcb.26547", "10.1515/enr-2017-0002", "10.1053/j.gastro.2017.02.006", "10.1042/BCJ20160388", "10.1186/s12967-015-0681-z", "10.1038/ng.2638", "10.1002/dvdy.22341", "PMID:17673939"]}
{"pair_type": "slc_pathway", "key1": "SLC39A14", "key2": "oxidative phosphorylation", "summary": "Large-scale proteomics showed that Zip14 silencing down-regulated ribosomal mitochondrial proteins, many metal-binding proteins, and others involved in oxidative phosphorylation and insulin secretion.", "dois": ["10.1038/s41598-019-44954-1"]}
{"pair_type": "slc_pathway", "key1": "SLC39A13", "key2": "migration", "summary": "The expression of ZIP13 in ovarian cancer cell lines was depleted to explore its effect on proliferation, adhesion, migration, and invasion both in vitro and in vivo assays.\nZIP13 knockout suppressed the malignant phenotypes of ovarian cancer cells both in vitro and in vivo.\nThis led to the activation of Src/FAK pathway with increased expressions of pro-metastatic genes but decreased expressions of tumor suppressor genes.\nFurther investigation revealed that ZIP13 regulated intracellular zinc distribution and then affected the expressions of genes involved in extracellular matrix organization and cytokine-mediated signaling pathway.\nZIP13 is shown to be a novel driver of metastatic progression by modulating the Src/FAK signaling pathway, which may serve as a promising biomarker for prognostic evaluation and targeted therapy in ovarian cancer.", "dois": ["10.1186/s13046-021-01999-3"]}
{"pair_type": "slc_pathway", "key1": "SLC39A14", "key2": "migration", "summary": "Knockdown of SLC39A14 inhibited glioma cell proliferation, migration, and invasion, while promoting apoptosis.\nIn vitro experiments demonstrated that knocking down SLC39A14 significantly inhibited cell proliferation, migration and invasion.\nMechanistically, SLC39A14 knockdown inhibited the cGMP-PKG signaling pathway activation.\nOverexpression of ZIP14 in HeLa and Caski cells increased p38 phosphorylation, inhibited cell growth and migration, and enhanced apoptosis.\nThe overexpression of significantly inhibited the proliferation, migration, and invasion of Huh7 HCC cells while promoting their apoptosis.\nMoreover, SLC39A14 knockdown also facilitated erastin-induced ferroptosis, leading to the suppression of mouse transplantation tumor growth.\ncirc_001842 was found to elevate SLC39A14 expression by binding to miR-502-5p, consequently resulting in augmented RCC cell proliferation, migration and invasion, as well as EMT in vitro and tumour growth in vivo.\nSilencing SLC39A14 inhibits ferroptosis and tumor progression, potentially involving the regulation of the cGMP-PKG signaling pathway.\nMechanistic analyses suggested that pro-carcinogenic effects exerted by SLC39A14 are mediated through activation of the PI3K/Akt/mTOR signaling pathway.\nIn vivo study showed that SLC39A14 facilitated progression within murine models bearing ESCC tumors.\nexperiments further confirmed the influence of ZIP14 on CC cell migration.\nOur findings suggest that SLC39A14 may serve as a potential biomarker for ESCC due to its pro-oncogenic role during ESCC progression.\nThe knockdown of exerted the opposite effect.\nConversely, ZIP14 knockdown produced the opposite effects.", "dois": ["10.4240/wjgs.v17.i10.111454", "10.1016/j.intimp.2024.113831", "10.2174/0115680096250711231024063841", "10.1186/s12885-023-11637-0", "10.1111/jcmm.15529", "10.2147/OTT.S103640"]}
{"pair_type": "slc_pathway", "key1": "SLC40A1", "key2": "glycolysis", "summary": "Suppressing glycolysis reduced both H3K14la and EC activation, suggesting a link between glycolysis and lactylation.\nIn sepsis, increased glycolysis leads to lactate buildup, which induces lysine lactylation (Kla) on histones and other proteins.\nMoreover, H3K14la was enriched at promoter regions of ferroptosis-related genes such as transferrin receptor (TFRC) and solute carrier family 40 member 1 (SLC40A1), which contributed to EC activation and lung injury under septic conditions.\nFor the first time, we reported the role of lactate-dependent H3K14 lactylation in regulating EC ferroptosis to promote vascular dysfunction during sepsis-induced lung injury.\nAs a co-activator of N-methyl-D-aspartate receptor (NMDAR), sarcosine also exerted its pro-ferroptosis effect via regulating ferrous export through the NMDAR/MXD3/SLC40A1 axis.\nOur findings suggest that manipulation of the glycolysis/H3K14la/ferroptosis axis may provide novel therapeutic approaches for sepsis-associated ARDS.\nMetabolic flux analysis showed limited conversion of sarcosine to other metabolites in LUAD cells, while untargeted metabolomic profiling and seahorse assays indicated a metabolic shift from glycolysis to oxidative phosphorylation.\nSeptic mice presented elevated levels of lactate and H3K14la in lung tissues, particularly in pulmonary ECs.", "dois": ["10.1186/s40164-025-00657-0", "10.1002/mco2.70049"]}
{"pair_type": "slc_pathway", "key1": "SLC40A1", "key2": "apoptosis", "summary": "Conversely, the cardiomyocyte-specific knockdown of SLC40A1 improved cardiac dysfunction after MI by enhancing mitochondrial function, suppressing oxidative stress, and reducing cardiomyocytes apoptosis.\nAdditionally, it can inhibit DOX-induced apoptosis by activating PI3K-Akt signaling pathway.\nβ-eudesmol inhibited cell proliferation and promoted cell apoptosis and ferroptosis via regulating MAPK pathway in BC.\nFurthermore, CAP inhibited DOX-induced apoptosis by modulating the phosphoinositide 3-kinase (PI3K)- protein kinase B (Akt) signaling pathway.\nAdditionally, we employed RNA-seq to identify the inhibitory effect of CAP on DOX-induced myocardial apoptosis, which was further confirmed through western blotting.\nThe overexpression of SLC40A1 in the cardiomyocytes of adult mice resulted in significant iron deficiency, leading to mitochondrial dysfunction, oxidative stress, and apoptosis, subsequently resulting in the development of fatal HF.\nSpecifically, CAP activated the PI3K-Akt pathway and regulated downstream BCL2 and BAX to mitigate DOX-induced apoptosis.\nβ-eudesmol promoted cell apoptosis, as evidenced by the decline level of Bcl-2 and the raised level of Bax and cleaved caspase-3.\nThe eventual cell death was significantly inhibited by deferoxamine, ferrostatin-1 and Z-VAD-FMK, suggesting a mixed cell death of ferroptosis and apoptosis.\nCopper chelators reduce ferroptosis sensitivity but do not inhibit other types of cell death, such as apoptosis, necroptosis, and alkaliptosis.\nUnlike apoptosis, necrosis and autophagy, ferroptosis is a novel type of regulated cell death, and the mechanism by which selenium nanoparticles induce ferroptosis in cancer cells has rarely been investigated.\nIn vitro silencing of PDGFRA impeded cell proliferation and migration while promoting apoptosis and inhibiting MMP2 and MMP9 expression in HDF.", "dois": ["10.1155/cdr/9106621", "10.7150/ijbs.89368", "10.18632/aging.205138", "10.4103/0304-4920.365459", "10.1016/j.redox.2019.101297", "10.1016/j.bbrc.2016.10.068", "10.1016/j.taap.2025.117533", "10.3389/fnagi.2025.1506276", "10.1038/s41598-025-93834-4", "10.1186/s40001-024-02179-7", "10.1016/j.ijbiomac.2024.138841", "10.1016/j.envpol.2024.123626", "10.1016/j.compbiomed.2024.108080", "10.1016/j.ecoenv.2024.115960", "10.1016/j.toxicon.2023.107529", "10.1093/jb/mvad036", "10.1080/15548627.2023.2165323", "10.1016/j.freeradbiomed.2021.02.010"]}
{"pair_type": "slc_pathway", "key1": "SLC40A1", "key2": "chemotherapy", "summary": "Mechanistically, CAP downregulated transferrin (Trf) and upregulated solute carrier family 40 member 1 (SLC40A1), which helped maintain iron levels in the cells and prevent ferroptosis.\nIn particular, core binding factor (CBF) AMLs, which are associated with good outcomes with chemotherapy, consistently have low level of SLC40A1 expression.\nAML cell lines that expressed relatively low levels of FPN endogenously, or were engineered via gene knockdown, had an increased sensitivity to chemotherapy relative to controls expressing high levels of FPN.\nMechanistically, we determined that miR-147a directly bound to the 3'-untranslated region of SLC40A1 and inhibited SLC40A1-mediated iron export, thereby facilitating iron overload, lipid peroxidation, and ferroptosis.\nβ-elemene in combination with cetuximab was shown to induce iron-dependent reactive oxygen species (ROS) accumulation, glutathione (GSH) depletion, lipid peroxidation, upregulation of HO-1 and transferrin, and downregulation of negative regulatory proteins for ferroptosis (GPX4, SLC7A11, FTH1, glutaminase, and SLC40A1) in KRAS mutant CRC cells.\nGiven the significance of ferroptosis in chemotherapy, we validated that sarcosine enhanced the sensitization of cisplatin by promoting ferroptosis in LUAD cells, PDOs, and xenograft models.\nFPN leukemic stem cells (LSCs) had decreased viability following addition of iron alone and in combination with Ara-C treatment relative to FPN LSCs.\nPrimary FPN AML bulk cells also had increased sensitivity to Ara-C treatment, iron treatment and the combination of Ara-C and iron relative to FPN cells.\nAs a co-activator of N-methyl-D-aspartate receptor (NMDAR), sarcosine also exerted its pro-ferroptosis effect via regulating ferrous export through the NMDAR/MXD3/SLC40A1 axis.\nFurthermore, miR-147a mimic-treated human glioblastoma cells exhibite", "dois": ["10.1186/s40164-025-00657-0", "10.18632/aging.205138", "10.1155/2022/2843990", "10.3389/fmolb.2021.650264", "10.7150/thno.44705", "10.1016/j.leukres.2019.02.011", "10.1016/j.bbrc.2016.10.068"]}
{"pair_type": "slc_pathway", "key1": "SLC43A2", "key2": "chemotherapy", "summary": "BCH, the inhibitor of SLC43A2, sensitizes tumors to anticancer drugs.\nYes-associated protein (YAP) activation confers resistance to chemotherapy and targeted therapy.\nYAP activates the transcription of SLC43A2, the methionine transporter, to increase methionine uptake in cancer cells.\nMimicking of YAP methylation abolishes the reduction effect of methionine-restricted diet on YAP-induced drug resistance.\nIn this study, we report that methionine deprivation remarkably suppresses the transcriptional activity of YAP-TEAD in cancer cells.\nThus, our results unravel the positive feedback between YAP R124 methylation and SLC43A2 that contributes to anticancer drug resistance.\nDisrupting this positive feedback could be a potential strategy for cancer therapy.\nHowever, it remains unclear whether methionine affects drug resistance by influencing YAP activity.\nKnockdown of SLC43A2 decreases the level of YAP R124me2a.\nMethionine promotes PRMT1-catalyzed asymmetric dimethylation at R124 of YAP (YAP R124me2a).\nMethionine participates in cellular processes by converting to methyl donor for the methylation of DNA, RNA and protein.", "dois": ["10.1038/s41467-024-55769-8"]}
{"pair_type": "slc_pathway", "key1": "SLC43A2", "key2": "glycolysis", "summary": "circPETH, a circular RNA (circRNA) transported via extracellular vesicles (EVs) from tumor-associated macrophages (TAMs) to hepatocellular carcinoma (HCC) cells, facilitates glycolysis and metastasis in recipient HCC cells.\ncircPETH-147aa, encoded by circPETH in an m6A-driven manner, promotes PKM2-catalyzed ALDOA-S36 phosphorylation via the MEG pocket.\nNorathyriol reverses circPETH-147aa-facilitated acquisition of metabolic and metastatic phenotypes by HCC cells, increases anti-PD1 efficacy, and enhances cytotoxic CD8 T-cell function.\ncircPETH-147aa impairs anti-HCC immunity by increasing HuR-dependent SLC43A2 mRNA stability and driving methionine and leucine deficiency in cytotoxic CD8 T cells.", "dois": ["10.1038/s41467-024-55577-0"]}
{"pair_type": "slc_pathway", "key1": "SLC43A1", "key2": "apoptosis", "summary": "In vitro experiments demonstrated that silencing XRCC3 significantly inhibited 22Rv1 and DU145 cell proliferation, migration and invasion, while promoted apoptosis.\nFurther, silencing XRCC3 promoted DNA damage-induced p53/Bax signaling pathway activation, which was absent with overexpression.\nSilencing XRCC3 exerts anti-PCa effects by promoting DNA damage-induced p53/Bax signaling pathway activation in an AR expression-independent manner.\nTwo AR expression-independent genes (SLC43A1 and XRCC3) were available for the optimal prognostic model.", "dois": ["10.1007/s00432-024-05989-8", "10.1097/FPC.0b013e328352f436"]}
{"pair_type": "slc_pathway", "key1": "SLC41A3", "key2": "proliferation", "summary": "Moreover, silencing SLC41A3 impeded LIHC cell proliferation, migration, and invasion .\nCellular experiments showed that knockdown of SLC41A1 inhibited proliferation, migration and invasion of HCC, whereas SLC41A1 overexpression exerted the tumor-promoting effects.\nAdditionally, we carried out cell functional experiments to determine the expression of SLC41A3 in the cell lines of LIHC, as well as the effects of its silence on cell proliferation, migration, and invasion.\nOur data showed that SLC41A3 was greatly increased in the cell lines of LIHC.\nUsing bioinformatics techniques, we found SLC41A1 was upregulated in HCC, which was verified by immunostaining of HCC patients.\nUsing Gene Ontology (GO) , Kyoto Encyclopedia of Genes and Genomes (KEGG), gene set enrichment analysis (GSEA), protein-protein interaction (PPI) network, we found SLC41A1 overexpression was related to several tumor-promoting pathways and molecules, such as degradation of extracellular matrix, cell adhesion and O-linked glycosylation, and expression of CXCL1, CXCL5 and MUC1.\nHigher expression of SLC41A3 displayed an intimate association with higher pathological stages and poorer prognosis.\nRecent studies revealed SLC41A3 acted as an oncogene and predicted poor survival for hepatocellular carcinoma (HCC) patients.\nCollectively, our study demonstrated that highly expressed SLC41A3 was a probable indication of LIHC occurrence, and SLC41A3 could be regarded as a prospective target in the treatment of LIHC.\nSLC41A1 was correlated with clinicopathological characteristics, and could be utilized as independently diagnostic and prognostic markers for HCC.", "dois": ["10.7150/ijms.100155", "10.1155/2021/8556888", "10.1161/HYPERTENSIONAHA.120.14909"]}
{"pair_type": "slc_pathway", "key1": "SLC43A2", "key2": "migration", "summary": "The top upregulated DEGs were CXCL10, CXCL9, FCGR3A, GBP5, GBP4, LILRB2, ADIPOQ, PLIN1, SLC43A2, and MYO1G.\nmRNA expression of amino acid transporters remains largely undisturbed except for SLC43A2 and SLC38A4 which are downregulated in starved and rapamycin-treated cells, respectively.\nStarvation promoted migration compared to normal culture conditions whereas all trophoblast functional activities were decreased in rapamycin treatment.\nThese DEGs were mainly enriched in the following biological processes: the activation and migration of immune cells, the release of proinflammatory factors, and the IFN-γ signaling pathway.\nDEGs were related to migration and various immune response-relevant pathways such as \"chemokine (C-C motif) ligand 4 production\", \"cell migration\", \"interleukin-13 production\", \"regulation of receptor signaling pathway via JAK-STAT\", or \"lymphocyte apoptotic process\", underlining the pro-inflammatory effects of PGD2 metabolite-induced immune responses in ILC2s as well as the anti-inflammatory effects of DP2 inhibition via fevipiprant.\nAfter viral CNS infection with red-spotted grouper nervous necrosis virus (RGNNV), the number of slc43a2 T cells synchronously increased in the spleen and brain.\nSingle-cell transcriptomic analysis indicated that slc43a2 T cells mature and functionally differentiate within the spleen and then migrate into the brain to trigger an immune response.\nThis study suggests a novel route for T cell migration from the spleen to the brain during viral infection in fish.\nPGD2 is rapidly degraded to its metabolites, which initiate type 2 innate lymphoid cells (ILC2) migration and IL-5/IL-13 cytokine secretion in a PGD2 receptor 2 (DP2)-dependent manner.", "dois": ["10.1016/j.placenta.2024.09.011", "10.1371/journal.pone.0307750", "10.1007/s11427-023-2473-x", "10.3389/fphar.2023.1110741"]}
{"pair_type": "slc_pathway", "key1": "SLC43A2", "key2": "proliferation", "summary": "ESCC progression was inhibited by enhanced ferroptosis and apoptosis and impaired cell proliferation.\nMCR blocked cancer progression via stimulating ferroptosis through the positive feedback loop between SLC43A2 and NFκB signaling pathways.\nBlocked NFκB signaling pathway further decreased the expression of SLC43A2 and GPX4 in both mRNA and protein level, which in turn downregulated the methionine intake and stimulated ferroptosis, respectively.\nMechanistically, MCR and silent of SLC43A2, a methionine transporter, diminished phosphorylation of IKKα/β and p65.\nRNA-seq and enrichment analysis suggested the blocked tumor progression was affected by ferroptosis, together with the NFκB signaling pathway activation in ESCC.\nTop CpG sites were linked to immune regulation, cell growth and proliferation, and molecular mechanisms of cancer, including lung cancer.\nStudies have indicated dietary restriction of methionine/cystine provided a therapeutic benefit in diseases such as cancer.\nIn this study, we proposed a novel feedback regulation mechanism underlie the correlation between dietary restriction of methionine/cystine and ESCC progression.\nHere, we discovered the dietary restriction of methionine/cystine has a large effect on cellular methionine metabolism as assayed in a ECA109 derived xenograft model.\nConsistently, GSH content and GPX4 expression were downregulated by MCR both in vivo and in vitro.\nOur results provided the theoretical basis and new targets for ferroptosis-based clinical antitumor treatments for ESCC patients.", "dois": ["10.1101/2025.04.03.25325041", "10.1038/s41419-023-05860-7", "10.4149/209_150531N303"]}
{"pair_type": "slc_pathway", "key1": "SLC43A2", "key2": "stemness", "summary": "SLC43A2 is expected to be a potential stemness-related biomarker in AML.\nFurthermore, we identified eight stemness-related genes that have potential to be biomarkers, including SLC43A2, CYBB, CFP, GRN, CST3, TIMP1, CFD and IGLL1.\nEight stemness-related genes were identified as stemness biomarkers through gene selection by three machine learning methods.\nOverall, we established a novel stemness classification using the mRNAsi score and eight stemness-related genes that may be biomarkers.\nThese genes, except IGLL1, had a negative correlation with mRNAsi.\nWe found that patients in stemness subgroup I had a poor prognosis and benefited from nilotinib, MK-2206 and axitinib treatment.\nAccording to the mRNAsi score, we performed consensus clustering and identified two stemness subgroups.\nIn addition, the mutation profiles of these two stemness subgroups were different, which suggested that patients in different subgroups had different biological processes.\nThere was a strong significant negative correlation between mRNAsi and the immune score (r= -0.43, p<0.001).\nStem cells play an important role in acute myeloid leukemia (AML).", "dois": ["10.3389/fimmu.2023.1202825"]}
{"pair_type": "slc_pathway", "key1": "SLC43A1", "key2": "migration", "summary": "Knockdown of LAT3 inhibited cell proliferation, migration, and invasion, and the phosphorylation of p70S6K and 4EBP-1.\nsilencing XRCC3 significantly inhibited 22Rv1 and DU145 cell proliferation, migration and invasion, while promoted apoptosis.\nLAT3 was highly expressed in PC cells expressing androgen receptor (AR), and its expression was increased by dihydrotestosterone treatment and decreased by bicalutamide treatment.\nIn chromatin immunoprecipitation sequencing of AR, binding of AR to the SLC43A1 region was increased by dihydrotestosterone stimulation.\nL-type amino acid transporter 3 (LAT3, SLC43A1) is abundantly expressed in prostate cancer (PC) and is thought to play an essential role in PC progression through the cellular uptake of essential amino acids.\nour results suggest that LAT3 plays an important role in the progression of PC.\nHigh LAT3 expression was correlated with the pathological T stage and a high International Society of Urological Pathology grade.\nhigh expression of LAT3 was an independent prognostic factor for recurrence-free survival (hazard ratio: 3.24; P = .0018).\nSeparase (ESPL1) was identified as a downstream target of LAT3 by RNA sequencing analysis.\nFunctional enrichment of 55 common DEGs among 3 sub-datasets revealed several immune-related terms, such as neutrophil extravasation, leucocyte migration, antimicrobial humoral immune response mediated by an antimicrobial peptide, toll-like receptor 4 bindings, IL-17 signalling pathway, and TGF-beta signalling pathway.\nSLC43A1 and SOX6 were significantly decreased in EAE mice spleen.", "dois": ["10.1007/s00432-024-05989-8", "10.1111/iep.12488", "10.1111/cas.14991"]}
{"pair_type": "slc_pathway", "key1": "SLC43A2", "key2": "oxidative stress", "summary": "The resulting decrease in SLC43A2 reduced phenylalanine absorption and oxidative stress, further driving PDAC progression.\nVIRMA facilitated SLC43A2 mRNA degradation through an m6A-YTHDF2 pathway.", "dois": ["10.1038/s41388-025-03283-6"]}
{"pair_type": "slc_pathway", "key1": "SLC39A14", "key2": "proliferation", "summary": "METTL14 overexpression or SLC39A14 knockdown enhanced viability, promoted proliferation and cell cycle progression, restrained apoptosis, reduced LC3II/LC3I and Beclin-1 levels, and increased p62 expression in ESCs.\nKnockdown of SLC39A14 inhibited glioma cell proliferation, migration, and invasion, while promoting apoptosis.\nIn conclusion, METTL14 promotes proliferation and inhibits apoptosis and autophagy activation in ESCs by inhibiting SLC39A14.\nMeanwhile, overexpression of SRSF1 and SLC39A14B promoted the proliferation and cell cycle entry of RCC cells.\nIn vitro experiments demonstrated that knocking down SLC39A14 significantly inhibited cell proliferation, migration and invasion.\nRestoration of circ_000829 reduced the levels of SRSF1 and SLC39A14B, thereby repressing the RCC cell proliferation and tumor growth.\nSLC39A14B upregulation negated the effect of SLC39A14 knockdown on RCC cell proliferation.\ncirc_001842 was found to elevate SLC39A14 expression by binding to miR-502-5p, consequently resulting in augmented RCC cell proliferation, migration and invasion, as well as EMT in vitro and tumour growth in vivo.\nOverexpression of ZIP14 in HeLa and Caski cells increased p38 phosphorylation, inhibited cell growth and migration, and enhanced apoptosis.\nMechanistic analyses suggested that pro-carcinogenic effects exerted by SLC39A14 are mediated through activation of the PI3K/Akt/mTOR signaling pathway.\nDysregulation of these transporters can increase intracellular iron, boosting reactive oxygen species production and genetic instability, thereby promoting cancer hallmark processes such as sustained proliferation, apoptosis evasion, metastasis, and resistance to therapy.\nIn vivo study showed that SLC39A14 facilitated progression within murine models bearing ESCC tumors.\nZip14 mRNA was upregulated during high glucose stimulation and Zip14 silencing", "dois": ["10.4240/wjgs.v17.i10.111454", "10.1016/j.ijbiomac.2025.146695", "10.1016/j.jri.2025.104447", "10.1016/j.intimp.2024.113831", "10.2174/0115680096250711231024063841", "10.1186/s12885-023-11637-0", "10.1155/2022/8645830", "10.1002/jcsm.12700", "10.1042/BSR20200764", "10.1111/jcmm.15529", "10.1039/c9mt00301k", "10.3390/ijms20215485", "10.1038/s41598-019-44954-1", "10.2147/OTT.S103640", "10.1186/s40608-015-0076-y"]}
{"pair_type": "slc_pathway", "key1": "SLC43A2", "key2": "ferroptosis", "summary": "MCR blocked cancer progression via stimulating ferroptosis through the positive feedback loop between SLC43A2 and NFκB signaling pathways.\nBlocked NFκB signaling pathway further decreased the expression of SLC43A2 and GPX4 in both mRNA and protein level, which in turn downregulated the methionine intake and stimulated ferroptosis, respectively.\nMechanistically, MCR and silent of SLC43A2, a methionine transporter, diminished phosphorylation of IKKα/β and p65.\nRNA-seq and enrichment analysis suggested the blocked tumor progression was affected by ferroptosis, together with the NFκB signaling pathway activation in ESCC.\nESCC progression was inhibited by enhanced ferroptosis and apoptosis and impaired cell proliferation.\nConsistently, GSH content and GPX4 expression were downregulated by MCR both in vivo and in vitro.", "dois": ["10.1038/s41419-023-05860-7"]}
{"pair_type": "slc_pathway", "key1": "SLC43A3", "key2": "chemotherapy", "summary": "The loss of slc43a3 in mice dramatically reduces the absorption and the biodistribution of the chemotherapeutic drug 6-mercaptopurine.\nThe results of this study show that loss of slc43a3 dramatically reduces the absorption of 6-MP from the gastrointestinal tract and attenuates the levels achieved in peripheral tissues.\nFurthermore, the loss of slc43a3 decreases the tissue:blood concentration ratios of 6-MP and its metabolites, particularly in those tissues that show high levels of expression of slc43a3, such as the heart and lungs.\nWe established a classification system comprising 7-SLCs to predict the prognosis of glioma patients and their potential responses to immunotherapy and chemotherapy.\nThese data suggest that variations in SLC43A3 expression in humans may contribute to the variability in plasma levels that have been reported when using this drug therapeutically.\nWe have previously determined that changes in the expression levels of SLC43A3-encoded equilibrative nucleobase transporter 1 (ENBT1) can significantly alter 6-mercaptopurine (6-MP) toxicity in ALL cells.\nWe have established that SLC43A3-encoded equilibrative nucleobase transporter 1 mediates the transport of 6-MP into cells in both mice and humans.\nTherefore, it is possible that differences in SLC43A3 expression in humans may contribute to the variability seen in 6-MP plasma levels and therapeutic response.\nThis study shows that activation of PKC decreases ENBT1-mediated uptake, suggesting that aberrant activation of PKC in ALL could decrease ENBT1-mediated 6-MP uptake potentially leading to decreased therapeutic efficacy.\nFurthermore, the orphan protein SLC43A3, a core member of the 7-SLC classification system, was identified as a key facilitator of tumour cell proliferation and migration, suggesting its potential as a novel target for cancer therapy.\nThe function and activity of these transporters could be of pharmacological significance considering the roles that they play not only in nucleotide synthesis and metabolism but also in the pharmacokinetics and delivery of a variety of nucleobase analogues used in anticancer and antiviral drug therapy.", "dois": ["10.1016/j.dmd.2025.100054", "10.1016/j.bbagen.2025.130765", "10.1111/jcmm.18339", "10.1248/bpb.b17-00374"]}
{"pair_type": "slc_pathway", "key1": "SLC43A2", "key2": "apoptosis", "summary": "ESCC progression was inhibited by enhanced ferroptosis and apoptosis and impaired cell proliferation.\nMCR blocked cancer progression via stimulating ferroptosis through the positive feedback loop between SLC43A2 and NFκB signaling pathways.\nBlocked NFκB signaling pathway further decreased the expression of SLC43A2 and GPX4 in both mRNA and protein level, which in turn downregulated the methionine intake and stimulated ferroptosis, respectively.\nMechanistically, MCR and silent of SLC43A2, a methionine transporter, diminished phosphorylation of IKKα/β and p65.", "dois": ["10.4149/209_150531N303", "10.1038/s41419-023-05860-7"]}
{"pair_type": "slc_pathway", "key1": "SLC43A1", "key2": "proliferation", "summary": "LAT3 was highly expressed in PC cells expressing androgen receptor (AR), and its expression was increased by dihydrotestosterone treatment and decreased by bicalutamide treatment.\nJPH203, a selective LAT1 inhibitor, demonstrated inhibitory effects on cell proliferation in EDR cells.\nKnockdown of LAT3 inhibited cell proliferation, migration, and invasion, and the phosphorylation of p70S6K and 4EBP-1.\nLAT1 expression then mediated leucine uptake, enhanced mTORC1 signaling, and eventually resulted in AI resistance.\nIn vitro experiments demonstrated that silencing XRCC3 significantly inhibited 22Rv1 and DU145 cell proliferation, migration and invasion, while promoted apoptosis.\nLAT1 expression could mediate leucine uptake, mTORC1 signaling, and cell proliferation.\nL-type amino acid transporter 3 (LAT3, SLC43A1) is abundantly expressed in prostate cancer (PC) and is thought to play an essential role in PC progression through the cellular uptake of essential amino acids.\nIn summary, our results suggest that LAT3 plays an important role in the progression of PC.\nHigh LAT3 expression was correlated with the pathological T stage and a high International Society of Urological Pathology grade.\nIn the multivariate analysis, high expression of LAT3 was an independent prognostic factor for recurrence-free survival (hazard ratio: 3.24; P = .0018).", "dois": ["10.1007/s00432-024-05989-8", "10.3390/cancers13174375", "10.1111/cas.14991", "10.1042/BSR20140140"]}
{"pair_type": "slc_pathway", "key1": "SLC43A1", "key2": "oxidative phosphorylation", "summary": "A network of ncRNA positively related to IS and interacted with RNA coding for viral response proteins (P < 1 × 10-48), while reduced amino acid catabolic gene expression occurred without a change in expression of oxidative-phosphorylation genes.\n16 quantitatively tracking changes in IS across four independent studies (P = 0.0000053: negatively: AGL, G0S2, KPNA2, PGM2, RND3 and TSPAN9 and positively: ALDH6A1, DHTKD1, ECHDC3, MCCC1, OARD1, PCYT2, PRRX1, SGCG, SLC43A1 and SMIM8).", "dois": ["10.1093/nar/gky570"]}
{"pair_type": "slc_pathway", "key1": "SLC43A3", "key2": "migration", "summary": "Furthermore, the orphan protein SLC43A3, a core member of the 7-SLC classification system, was identified as a key facilitator of tumour cell proliferation and migration, suggesting its potential as a novel target for cancer therapy.", "dois": ["10.1111/jcmm.18339"]}
{"pair_type": "slc_pathway", "key1": "SLC43A3", "key2": "proliferation", "summary": "Furthermore, the orphan protein SLC43A3, a core member of the 7-SLC classification system, was identified as a key facilitator of tumour cell proliferation and migration, suggesting its potential as a novel target for cancer therapy.\nThey play a crucial role in regulating the metabolism and functions of malignant cells and immune cells within the tumour microenvironment, making them a promising target in cancer therapy.\nOur findings unveiled specific SLC expression patterns and their correlation with the immune-suppressive microenvironment and metabolic status.\nThe 7-SLC classification system was validated in distinguishing subgroups within the microenvironment, specifically identifying subsets involving malignant cells and tumour-associated macrophages.\nCurrently, reshaping its tumour microenvironment has emerged as an appealing strategy to enhance therapeutic efficacy.\nWe established a classification system comprising 7-SLCs to predict the prognosis of glioma patients and their potential responses to immunotherapy and chemotherapy.\nAs the largest group of transmembrane transport proteins, solute carrier proteins (SLCs) are responsible for the transmembrane transport of various metabolites and ions.", "dois": ["10.1111/jcmm.18339", "10.1158/0008-5472.CAN-15-0418"]}
{"pair_type": "slc_pathway", "key1": "SLC44A1", "key2": "apoptosis", "summary": "Flow cytometry analysis demonstrated that LINC00704 silencing induced EOC cell cycle arrest and apoptosis.\nMoreover, rescue experiments showed that SLC44A1 overexpression could reverse LINC00704 silencing-mediated effects on the malignant behaviors of EOC cells.\nMechanistically, bioinformatics analysis, RNA pull-down, luciferase reporter and RNA immunoprecipitation assays revealed that LINC00704 upregulated SLC44A1 expression by competitively binding to miR-323a-3p.\nIn conclusion, LINC00704 promotes EOC cell aggressiveness in vitro by regulating the miR-323a-3p/SLC44A1 axis.\nCCK-8 and EdU assays showed that LINC00704 knockdown inhibited EOC cell proliferation.\nTranswell assays indicated the inhibitory effects of LINC00704 silencing on EOC cell migration and invasion.", "dois": ["10.1007/s12672-025-01866-z"]}
{"pair_type": "slc_pathway", "key1": "SLC44A1", "key2": "migration", "summary": "LINC00704 promotes EOC cell aggressiveness in vitro by regulating the miR-323a-3p/SLC44A1 axis.\nTranswell assays indicated the inhibitory effects of LINC00704 silencing on EOC cell migration and invasion.\nMoreover, rescue experiments showed that SLC44A1 overexpression could reverse LINC00704 silencing-mediated effects on the malignant behaviors of EOC cells.\nLINC00704 upregulated SLC44A1 expression by competitively binding to miR-323a-3p.", "dois": ["10.1007/s12672-025-01866-z"]}
{"pair_type": "slc_pathway", "key1": "SLC44A1", "key2": "proliferation", "summary": "LINC00704 promotes EOC cell aggressiveness in vitro by regulating the miR-323a-3p/SLC44A1 axis.\nCCK-8 and EdU assays showed that LINC00704 knockdown inhibited EOC cell proliferation.\nenforced expression of the MCPIP1 gene in BE(2)-C cells caused a significant decrease in neuroblastoma proliferation and viability.\nLINC00704 upregulated SLC44A1 expression by competitively binding to miR-323a-3p.\nSLC44A1 overexpression could reverse LINC00704 silencing-mediated effects on the malignant behaviors of EOC cells.\nFlow cytometry analysis demonstrated that LINC00704 silencing induced EOC cell cycle arrest and apoptosis.\nTranswell assays indicated the inhibitory effects of LINC00704 silencing on EOC cell migration and invasion.\nThe choline transporter, CTL1, encoded by the SLC44A1 gene, was significantly repressed at the specific mRNA and protein levels and most importantly this translated into a decreased choline transport in MCPIP1-overexpressing cells.", "dois": ["10.1007/s12672-025-01866-z", "10.1002/jcb.25354"]}
{"pair_type": "slc_pathway", "key1": "SLC44A1", "key2": "stemness", "summary": "It directly regulates Pou5f1 and Nanog and is essential to maintaining stemness by inhibiting neural differentiation.", "dois": ["10.1111/bpa.12619"]}
{"pair_type": "slc_pathway", "key1": "SLC44A2", "key2": "apoptosis", "summary": "Temporal dynamics revealed stage-specific host modulation: early-phase DEPs orchestrated metabolic reprogramming and transmembrane transport via the solute carrier superfamily (e.g., SLC25A, SLC30A, and SLC44A2), whereas the late infection phase featured concurrent upregulation of innate immune effectors (e.g., Mx1, OAS1, ISG15, and TRIM21) and suppression of apoptosis inhibitors (e.g., TMEM192, PDCD4, and DPP9), suggesting synchronized antiviral activation and apoptotic regulation.\nThis study established the role of a novel VWF-SLC44A2-NET axis in regulating mitochondrial homeostasis and function, leading to cardiac apoptosis and contributing to HF pathogenesis.\nMechanistically, NETs induced mitochondrial dysfunction in cardiomyocytes, inhibiting mitochondrial biogenesis via the NE-TLR4-mediated suppression of PGC-1α.\nFurthermore, VWF/ADAMTS13 regulated NET formation via SLC44A2.\nTargeting this axis may offer a potential therapeutic approach for HF treatment.\nAdditionally, sacubitril/valsartan amplifies the cardioprotective effects of the VWF-SLC44A2-NET axis blockade.", "dois": ["10.1186/s13567-025-01629-2", "10.1093/eurheartj/ehae517"]}
{"pair_type": "slc_pathway", "key1": "SLC44A3", "key2": "migration", "summary": "CHML knockout significantly inhibited the migration and invasion of HCC cells in vitro, whereas CHML overexpression promoted these phenotypes (<0.05).\nCHML promoted the migration and invasion of HCC cells through multiple pathways.\nThis metabolic shift activated MAPK and PI3K-AKT signaling cascades, ultimately driving HCC cell migration and invasion.\nThe subsequent mechanistic analysis demonstrated that CHML upregulated the Solute carrier family 44 member 3 (SLC44A3) to enhance choline uptake, thereby increasing phosphatidic acid (PA) production.\nThis study aimed to elucidate the mechanism through which CHML regulates the migration and invasion of HCC cells.\nNotably, the integration of transcriptomics and untargeted metabolomics identified choline metabolism as a pivotal pathway in CHML-regulated migration and invasion.\nTranscriptomic sequencing revealed CHML-mediated regulation of migration-associated pathways, whereas untargeted metabolomics identified choline metabolism as a key significantly altered pathway.\naortic expression of SLC44A3 was increased in carriers of the MI risk allele at chromosome 1p21.3, increased in ischaemic (vs. non-diseased) coronary arteries, up-regulated in human aortic endothelial cells treated with interleukin-1β (vs. vehicle), and associated with smooth muscle cell migration in vitro.", "dois": ["10.3389/fonc.2025.1575809", "10.1093/eurheartj/ehaa1040"]}
{"pair_type": "slc_pathway", "key1": "SLC44A2", "key2": "proliferation", "summary": "Recently, it was reported that deletion of SLC44A2 impairs adhesion and increases proliferation in cultured lung mesenchymal cells.\nSlc44a2 KO cells and HET cells demonstrated lower adherence and faster proliferation than the WT cells.\nMechanistically, SLC44A2 inhibits mitochondrial fatty acid oxidation, thereby reducing energy supply and increase ROS stress.\nThis effect is achieved by promoting mitochondrial E3 ubiquitin ligase 1 (MUL1)-regulated degradation of carnitine palmitoyltransferase 2 (CPT2) via enhancing the interaction between MUL1 and CPT2, without increasing MUL1 expression, which ultimately contributes to the proliferation and metastasis of CRC.\nFunctional assays demonstrated that SLC44A2 suppressed CRC growth and metastasis both in vitro and in vivo.\nTogether, SLC44A2 functions as a critical tumor suppressor in CRC and potential therapeutic target in the treatment of this malignancy.\nThese results suggest that Slc44a2 is necessary for proper cellular localization of adhesion proteins and growth regulation that may be related to altered adhesion signals.\nIn the present investigation, we observed a significant reduction in SLC44A2 expression in colorectal cancer (CRC), and low SLC44A2 expression was closely associated with poorer survival of CRC patients.", "dois": ["10.1038/s41419-025-07781-z", "10.1016/j.tice.2021.101599"]}
{"pair_type": "slc_pathway", "key1": "SLC44A3", "key2": "proliferation", "summary": "The majority of L cells exhibited a higher proliferation rate and transplantability, and conferred a lower survival rate on the implanted mice.", "dois": ["10.3892/ol.2017.7648"]}
{"pair_type": "slc_pathway", "key1": "SLC44A4", "key2": "chemotherapy", "summary": "In addition, ASG-5ME, an antibody specific for SLC44A4 that is universally expressed in pancreatic cancer and also carries a conjugate chemotherapy particle was safe at the appropriate dosing in a phase I trial (Abstract #176).\nThe high-risk group exhibited poor survival outcomes, lower immune cell infiltration, and decreased sensitivity to conventional chemotherapies and immunotherapies.\nOverall, we identified an ITH-related prognostic signature for COAD that was closely related to the tumor microenvironment and chemotherapy response.\nThe relationship between the NK cell-related risk score and overall survival, clinical features, tumor immune characteristics, as well as response to commonly used immunotherapies and chemotherapy, was explored.\nThe patients classified by the risk score had distinguishable sensitivity to chemotherapeutic drugs.\nThis signature may help clinicians make more personalized and precise treatment decisions for COAD patients.\nSignificant differences were observed among the clusters in terms of prognosis, clinical characteristics, immune infiltration, and therapeutic response.\nFurthermore, six NK cell-related genes (DPYSL3, SLPI, SLC44A4, ZNF521, LIMCH1, and AHR) were identified to construct a prognostic model for ccRCC prediction.\nHowever, the relationship between ITH and prognosis, the immune microenvironment, and the chemotherapy response in COAD patients remains unknown, and this knowledge is urgently needed.", "dois": ["10.1186/s40001-024-01659-0", "10.3389/fmed.2022.925661", "10.6092/1590-8577/1474"]}
{"pair_type": "slc_pathway", "key1": "SLC44A1", "key2": "chemotherapy", "summary": "A 75-year-old female patient with no smoking history and mild renal dysfunction developed recurrent lung adenocarcinoma and was initially treated with pembrolizumab immunotherapy followed by chemotherapy using docetaxel showing a certain efficacy but the disease finally progressed.\nComprehensive genome profiling showed a novel SLC44A1-BRAF fusion and the tumor progression was controlled with the MEK inhibitor trametinib.", "dois": ["10.7759/cureus.54739"]}
{"pair_type": "slc_pathway", "key1": "SLC44A4", "key2": "ferroptosis", "summary": "The suppression of TSPAN1 was found to enhance ferroptosis and to reduce glycolytic activity.\nFurther studies were conducted to investigate the effects of TSPAN1 on mitochondrial function, energy metabolism, and the cytoskeleton, and elucidated the interaction between TSPAN1 and SLC44A4.\nThe downregulation of TSPAN1 markedly suppressed cell proliferation and the incidence of malignant biological behaviors.", "dois": ["10.1016/j.gene.2025.149553"]}
{"pair_type": "slc_pathway", "key1": "SLC44A4", "key2": "glycolysis", "summary": "Moreover, the suppression of TSPAN1 was found to enhance ferroptosis and to reduce glycolytic activity.\nFurther studies were conducted to investigate the effects of TSPAN1 on mitochondrial function, energy metabolism, and the cytoskeleton, and elucidated the interaction between TSPAN1 and SLC44A4.\nThis study provides a comprehensive analysis of TSPAN1's role in endometrial cancer, shedding light on its potential as a key regulator of ferroptosis and glycolysis.", "dois": ["10.1016/j.gene.2025.149553"]}
{"pair_type": "slc_pathway", "key1": "SLC44A4", "key2": "proliferation", "summary": "Our findings indicated that the downregulation of TSPAN1 markedly suppressed cell proliferation and the incidence of malignant biological behaviors.\nMoreover, the suppression of TSPAN1 was found to enhance ferroptosis and to reduce glycolytic activity.\nFurther studies were conducted to investigate the effects of TSPAN1 on mitochondrial function, energy metabolism, and the cytoskeleton, and elucidated the interaction between TSPAN1 and SLC44A4.", "dois": ["10.1016/j.gene.2025.149553"]}
{"pair_type": "slc_pathway", "key1": "SLC44A5", "key2": "apoptosis", "summary": "Furthermore, SLC44A5 knockdown cells also exhibited cell apoptosis by reducing the expression levels of apoptosis markers, caspase‑3 and caspase‑9 in MHCC‑97H and SMMC‑7721 cells, and suppressed invasion.\nTherefore, the present study investigated the expression of SLC44A5 in HCC tissues and cell lines, and assessed the effect of SLC44A5 on the viability, cell cycle, apoptosis and invasion of HCC cell lines.\nNetwork analysis revealed interactions among host biomarkers-THG1L, SLC44A5, KCNN3-and viral components such as nsp4 (CHIKV RNA polymerase) and BCL2-like 11 (an apoptosis facilitator), highlighting a multifactorial virus-host interplay.\nKnockdown of SLC44A5 using short hairpin RNA inhibited cell viability and arrested the cells in G1 of the cell cycle by reducing the expression of cell cycle markers, proliferating cell nuclear antigen and cyclin‑dependent kinase 2 in MHCC‑97H and SMMC‑7721 cells.", "dois": ["10.3892/mmr.2016.5136", "10.1007/s00284-025-04489-3"]}
{"pair_type": "slc_pathway", "key1": "SLC44A5", "key2": "migration", "summary": "Functional assays revealed that ectopic expression of miR-144-5p and miR-144-3p significantly blocked the malignant abilities of LUSQ cells, eg, cancer cell proliferation, migration, and invasion.\nAmong these targets, we identified 3 genes (SLC44A5, MARCKS, and NCS1) that might be regulated by both strands of miR-144.", "dois": ["10.1111/cas.13853"]}
{"pair_type": "slc_pathway", "key1": "SLC44A5", "key2": "proliferation", "summary": "Furthermore, cell viability assays indicated that SLC44A5 knockdown increased cell proliferation, whereas SLC44A5 overexpression repressed proliferation.\nTaken together, our results suggest that calves with reduced SLC44A5 expression are larger due to enhanced cell proliferation.\nUptake studies in HeLa cells demonstrated that SLC44A5 knockdown reduces choline efflux, whereas SLC44A5 overexpression resulted in the opposite effect.\nLuciferase assays and quantitative polymerase chain reaction (QPCR) assays revealed that SLC44A5 transcripts with the A polymorphism are expressed at lower levels than those carrying the G polymorphism.\nCows with higher birth weights carried the A polymorphism in the SLC44A5 5' UTR, and the presence of the A polymorphism correlated with a high rate of dystocia.\nTo identify genes that regulate birth weight, we conducted a genome-wide association study using 1151 microsatellite markers and identified a single nucleotide polymorphism (SNP) associated with birth weight: A-326G in the 5' untranslated region (UTR) of solute carrier family 44, member 5 (SLC44A5).\nSLC44A5 encodes a choline transporter-like protein, and choline is a component of the major phospholipids of cell membranes.\nFunctional assays revealed that ectopic expression of miR-144-5p and miR-144-3p significantly blocked the malignant abilities of LUSQ cells, eg, cancer cell proliferation, migration, and invasion.\nAmong these targets, we identified 3 genes (SLC44A5, MARCKS, and NCS1) that might be regulated by both strands of miR-144.\nOverexpression of NCS1 was detected in LUSQ clinical specimens, and its aberrant expression enhanced malignant transformation of LUSQ cells.\nThis study provides novel insights into the molecular mechanisms that control birth weight in Holsteins and suggests that SLC44A5 may serve as a potential target for preventing dystocia.", "dois": ["10.1111/cas.13853", "10.1371/journal.pone.0041267"]}
{"pair_type": "slc_pathway", "key1": "SLC45A1", "key2": "glycolysis", "summary": "Deletion of the glucose-proton symporter was the truncal alteration most significantly associated with mitochondrial GBM, and the reintroduction of SLC45A1 in mitochondrial glioma cells induced acidification and loss of fitness.\nIt relied exclusively on oxidative phosphorylation for energy production, whereas the glycolytic/plurimetabolic subtype was sustained by aerobic glycolysis and amino acid and lipid metabolism.\nMitochondrial, but not glycolytic/plurimetabolic, GBM exhibited marked vulnerability to inhibitors of oxidative phosphorylation.", "dois": ["10.1038/s43018-020-00159-4"]}
{"pair_type": "slc_pathway", "key1": "SLC45A1", "key2": "chemotherapy", "summary": "Meanwhile, CGREF1, CUX2, GP1BA, SLC45A1 and TRA2A were mutated with the trendy oppose as therapeutic effects.", "dois": ["10.1186/s12935-018-0521-3"]}
{"pair_type": "slc_pathway", "key1": "SLC45A1", "key2": "oxidative phosphorylation", "summary": "Deletion of the glucose-proton symporter was the truncal alteration most significantly associated with mitochondrial GBM, and the reintroduction of SLC45A1 in mitochondrial glioma cells induced acidification and loss of fitness.\nIt relied exclusively on oxidative phosphorylation for energy production, whereas the glycolytic/plurimetabolic subtype was sustained by aerobic glycolysis and amino acid and lipid metabolism.\nMitochondrial, but not glycolytic/plurimetabolic, GBM exhibited marked vulnerability to inhibitors of oxidative phosphorylation.", "dois": ["10.1038/s43018-020-00159-4"]}
{"pair_type": "slc_pathway", "key1": "SLC39A10", "key2": "chemotherapy", "summary": "The expression of ZIP10 was significantly induced by chemotherapy and highly associated with the clinical outcomes of OS.\nKnockdown of ZIP10 suppressed OS cell proliferation and chemoresistance.\nMoreover, overexpression of ZIP10 promoted ITGA10 expression and conferred chemoresistance.\nTreatment with the CREB inhibitor 666-15 or the PI3K/AKT inhibitor GSK690693 impaired tumor chemoresistance in ZIP10-overexpressing cells.\nFinally, a xenograft mouse model established by subcutaneous injection of 143B cells confirmed that ZIP10 mediates chemotherapy resistance in OS cells via the ZIP10-ITGA10-PI3K/AKT axis.\nWe demonstrate that ZIP10 drives OS proliferation and chemoresistance through ITGA10-mediated activation of the PI3K/AKT pathway, which might serve as a target for OS treatment.\nIn addition, ZIP10 promoted Zn content-induced cAMP-response element binding protein (CREB) phosphorylation and activation, which are required for integrin α10 (ITGA10) transcription and ITGA10-mediated PI3K/AKT pathway activation.", "dois": ["10.3389/fgene.2022.857215", "10.1186/s13046-021-02146-8", "10.20892/j.issn.2095-3941.2018.0277"]}
{"pair_type": "slc_pathway", "key1": "SLC45A2", "key2": "apoptosis", "summary": "Transcriptomic validation in zebrafish further demonstrated dose-dependent dysregulation of key genes (tdo2b, ctsba, gdf2, slc45a2, ungb).\nProtein-protein interaction networks and functional enrichment analyses indicated critical involvement of apoptosis, oxidative stress response, TP53 signaling, and neuroactive ligand-receptor pathways.\nOur patient's G6PC3 mRNA expression level was also reduced, leading to increased apoptosis of her fibroblasts under endoplasmic reticulum stress.\nCollectively, these findings establish oxidative stress, apoptotic cascades, and endocrine disruption as central mechanisms underlying ZPT-induced sperm toxicity, thereby providing critical insights for environmental risk assessment and regulatory policy development.", "dois": ["10.1016/j.taap.2025.117547", "10.1038/jid.2011.157"]}
{"pair_type": "slc_pathway", "key1": "SLC45A2", "key2": "glycolysis", "summary": "SLC45A2 is identified as a proton/glucose exporter in melanosomes, and its ablation increases the acidification of melanosomal pH through enhanced glycolysis.\nMoreover, Slc45a2 deficiency significantly upregulates the activities of glycolytic enzymes and phosphatidylinositol 3-kinase/protein kinase B signaling to promote glycolysis-dependent survival and metastasis of melanoma cells.\nIntriguingly, C-glucose-labeled metabolic flux and biochemical assays show that melanosomes are active glucose-metabolizing organelles, indicating that elevated glycolysis mainly occurs in melanosomes owing to Slc45a2 deficiency.\nCollectively, our study reveals that the proton/glucose exporter SLC45A2 mediates melanin synthesis and melanoma metastasis primarily by modulating melanosomal glucose metabolism.", "dois": ["10.1016/j.jid.2022.04.008"]}
{"pair_type": "slc_pathway", "key1": "SLC45A2", "key2": "migration", "summary": "The fusion protein promotes cell growth, accelerates migration, resists serum starvation-induced cell death, and is essential for cancer growth in mouse xenograft cancer models.\nIntroduction of SLC45A2-AMACR into the mouse liver using a sleeping beauty transposon system and somatic knockout of phosphatase and TENsin homolog (Pten) generated spontaneous liver cancers within a short period.\nThe chimeric protein is translocated to the lysosomal membrane and activates the extracellular signal-regulated kinase signaling cascade.\nIn this report, we show that gene fusion between solute carrier family 45 member 2 (SLC45A2) and alpha-methylacyl-coenzyme A racemase (AMACR) occurs in eight different types of human malignancies, with frequencies ranging from 45% to 97%.\nConclusion: The gene fusion between SLC45A2 and AMACR may be a driving event for human liver cancer development.", "dois": ["10.7554/eLife.77514", "10.1002/hep4.1724", "10.1093/molbev/mss207"]}
{"pair_type": "slc_pathway", "key1": "SLC45A2", "key2": "oxidative phosphorylation", "summary": "GSEA analysis found the mTORC1 signaling pathway and oxidative phosphorylation pathway is correlated to the cholesterol metabolism scores in melanoma cells in the UM dataset.\nOverall, this study provides the first single-cell level investigation of cholesterol metabolism in UM and identifies SLC45A2 as a potential key gene affecting UM progression by regulating cholesterol metabolism.\nexperiments showed that SLC45A2 depletion attenuated the metastatic and proliferative capacities of uveal melanoma cells.", "dois": ["10.3389/fimmu.2025.1660268"]}
{"pair_type": "slc_pathway", "key1": "SLC45A2", "key2": "proliferation", "summary": "These genes are associated with melanin production and melanocyte proliferation.\nThe main gene pathways affected were, cellular growth and proliferation, angiogenesis, lipid metabolism, cellular and tissue morphology and development, inflammation and metabolic exchange.\nFurazolidone was screened as a potential small molecule drug for the treatment of CM, and its mechanism may be related to the inhibition of CM cell proliferation by acting on GMPR.\nand 9q34.3 SEC16A, a putative oncogene with roles in secretion and cellular proliferation.\n7p21.1 AHR, the dioxin receptor involved in anti-apoptotic pathways and melanoma progression;\n11q23.3 CADM1, a metastasis suppressor gene involved in modifying tumour interaction with cell-mediated immunity;", "dois": ["10.3389/fcell.2022.858633", "10.1038/ncomms12048", "10.1016/j.cbpc.2015.07.011", "10.1186/1471-2164-15-234"]}
{"pair_type": "slc_pathway", "key1": "SLC45A3", "key2": "chemotherapy", "summary": "Additionally, higher expression of increases the probability of non-response, death, and the risk of death.\nis a potential predictive biomarker of treatment response and death in children with B-cell ALL.\nFinally, overexpression, together with MRD+, are associated with poorer survival, and together with overexpression of and , it could improve the risk classification of patients with normal karyotype.\nGene expression and differential methylation were compared between patients with MRD-/- and MRD at the end of induction chemotherapy.\n, , , and can predict refractoriness, but is the best predictor.\n, , , , , , , , and were overexpressed and hypomethylated in MRD patients.\nOur goal was to identify predictive biomarkers of treatment response, which could also serve as prognostic biomarkers of death, by identifying methylated and differentially expressed genes between patients with positive minimal residual disease (MRD+) and negative minimal residual disease (MRD-).", "dois": ["10.3389/fmolb.2024.1385140"]}
{"pair_type": "slc_pathway", "key1": "SLC45A4", "key2": "apoptosis", "summary": "PVT1-214 knockdown suppressed cell growth, invasion and migration in vitro, whereas PVT1-214 overexpression promoted tumor proliferation in vivo.\nWhen miR-671-5p is inhibited, SLC45A4 is released from the complementary binding complex, thereby increasing SLC45A4 protein levels in GC cells.\nIn addition, PVT1-214 positively regulates SLC45A4 expression through its competitive endogenous RNA (ceRNA) activity against miR-671-5p.\nThe present work revealed the candidate ceRNA regulatory pathway by which PVT1-214 regulates SLC45A4 expression in GC cells, which is achieved through competitive binding to endogenous miR-671-5p.\nSLC45A4 expression was positively related to PVT1-214 expression.\nPVT1-214 competes with endogenous RNA (ceRNA) by binding to miR-671-5p.\nPVT1-214 overexpression in GC cells and tissues was positively related to tumor size, malignancy grade, lymphatic metastasis and clinical stage.", "dois": ["10.1186/s12957-025-03805-2"]}
{"pair_type": "slc_pathway", "key1": "SLC39A9", "key2": "proliferation", "summary": "Testosterone, BSA-T, and androstenedione each increased proliferation in vascular endothelial cells, indicating the potential involvement of SLC39A9 in ovulatory angiogenesis.\nDutasteride inhibited testosterone-induced BCa progression dependent on SLC39A9 in AR-negative BCa and repressed oncogenic signaling pathways, including those of metalloproteases, p21, BCL-2, NF-KB, and WNT.\nDutasteride treatment led to significant inhibition of the testosterone-induced increase dependent on AR and SLC39A9 in cell viability and migration of T24 and J82 BCa cells and induced alterations in the expression level of cancer progression proteins, such as metalloproteases, p21, BCL-2, NF-KB, and WNT in AR-negative BCa.\nExposing mLTC-1 cells to MSNBA reduced the intracellular fructose content, limited cell proliferation, and enhanced progesterone and androgens production (Δ4-androstenedione and testosterone).\nAlso, Dutasteride treatment reduced cell proliferation and migration via blocking the SRD5A1 in BCa.\nTaken together, these data support the conclusion that SLC39A9 activation via androgen induces zinc influx in key ovarian cells.\nStudies in fish ovary demonstrated that androgens bind to SLC39A9 and increase intracellular zinc to regulate ovarian cell function.\nUpregulation of SLC30A5, SLC30A6, SLC30A7 transcripts, encoding zinc efflux transporters ZnT5, ZnT6, ZnT7, localized on endoplasmic reticulum membranes, might be part of a coordinated transcriptional program associated to the increased activity of the early secretory pathway, while transcriptional upregulation of several specific ZIP transporters (SLC39A6, SLC39A7, SLC39A9, SLC39A10, and SLC39A11) could contribute in meeting the increased demand of zinc in cancer cells.\nIn conclusion, GLUT5 supported fructose intake in the murine Leydig cell", "dois": ["10.1016/j.mce.2025.112658", "10.1210/endocr/bqae071", "10.1186/s12967-023-03972-4", "10.1158/0008-5472.CAN-21-0982", "10.3389/fgene.2020.00819", "10.1042/BSR20200764", "10.1002/jcb.27285"]}
{"pair_type": "slc_pathway", "key1": "SLC45A2", "key2": "oxidative stress", "summary": "We found in lesser kestrel Falco naumanni nestlings that the GSH:GSSG ratio, which decreases with systemic oxidative stress, increased with the size of the colony where they were reared, but the expression in feather melanocytes of five genes involved in pheomelanin synthesis (Slc7a11, Slc45a2, CTNS, MC1R and AGRP) did not vary with colony size.\nFurthermore, albino (slc45a2) mutants, which completely lack melanosomes, developed abnormal lens reflections similar to the congenital cataract caused by mutation of the myosin chaperon Unc45b, and an in situ spin trapping assay revealed increased oxidative stress in the lens of albino mutants.\nExposure to the competitive environment did not affect systemic oxidative stress and damage, indicating that a protective epigenetic mechanism that changes the expression of Slc7a11 may have been activated.\nWe found that zebra finches Taeniopygia guttata developing pheomelanin-pigmented feathers during a 12-day exposure to the pro-oxidant diquat dibromide downregulated the expression of Slc7a11 in feather melanocytes, but not the expression of other genes that affect pheomelanogenesis by mechanisms different from cysteine transport such as MC1R and Slc45a2.\nAccordingly, diquat-treated birds did not suffer increased oxidative stress.\nPheomelanogenesis may thus increase the susceptibility to suffer chronic oxidative stress.\nCompetitive environments promote high testosterone levels, produce oxidative stress and, consequently, impair cellular homeostasis.\nAltered levels of trace elements are associated with increased oxidative stress that is eventually responsible for pathologic conditions.\nThis was independent of phenotypic factors and antioxidant capacity, thus supporting an effect of pheomelanin-induced oxidative stress on melanomagenesis.\nTherefore, a genetic control favouring the production of large amounts of pheomelanin for pigmentation may lead to physiological costs under environmental conditions that promote oxidative stress.\nOur results suggest that exogenous oxidative stress induced a hormetic response that enhanced the oxidative status of birds and, consequently", "dois": ["10.1016/j.cbpc.2019.108667", "10.1111/mec.15171", "10.1111/mec.14322", "10.1111/mec.13952", "10.1038/srep25046", "10.7196/samj.7046", "10.1016/j.taap.2025.117547", "10.1016/j.canep.2019.101582", "10.1111/jeb.13379"]}
{"pair_type": "slc_pathway", "key1": "SLC45A4", "key2": "migration", "summary": "PVT1-214 knockdown suppressed cell growth, invasion and migration in vitro, whereas PVT1-214 overexpression promoted tumor proliferation in vivo.\nWhen miR-671-5p is inhibited, SLC45A4 is released from the complementary binding complex, thereby increasing SLC45A4 protein levels in GC cells.\nIn addition, PVT1-214 positively regulates SLC45A4 expression through its competitive endogenous RNA (ceRNA) activity against miR-671-5p.\nThe present work revealed the candidate ceRNA regulatory pathway by which PVT1-214 regulates SLC45A4 expression in GC cells, which is achieved through competitive binding to endogenous miR-671-5p.\nSLC45A4 expression was positively related to PVT1-214 expression.\nPVT1-214 competes with endogenous RNA (ceRNA) by binding to miR-671-5p.\nPVT1-214 overexpression in GC cells and tissues was positively related to tumor size, malignancy grade, lymphatic metastasis and clinical stage.", "dois": ["10.1186/s12957-025-03805-2"]}
{"pair_type": "slc_pathway", "key1": "SLC45A4", "key2": "glycolysis", "summary": "Silencing of SLC45A4 significantly inhibited the proliferation, invasion, and metastasis of OCC by suppressing glucose uptake and glycolysis, and it also reduced the expression of HIF-α glycolysis signaling pathway in OC tissues.\nSLC45A4 promotes glycolysis and prevents AMPK/ULK1-induced autophagy in TP53 mutant pancreatic ductal adenocarcinoma.\nKnockdown of SLC45A4 reduced glucose uptake and ATP production, which led to activation of autophagy via AMPK/ULK1 pathway.\nThese findings suggest that SLC45A4 silencing can restrain the malignant progression of OC by inhibiting glucose uptake in OCC and affecting the reprogramming of glycolytic energy metabolism, indicating that SLC45A4 may serve as a potential therapeutic target for OC intervention.\nSLC45A4 is involved in malignant progression of ovarian cancer through glycolytic metabolic reprogramming.\nThe present study found that SLC45A4 prevents autophagy via AMPK/ULK1 axis in TP53 mutant PDA, which may be a promising biomarker and therapeutic target in TP53 mutant PDA.\nSilencing SLC45A4 inhibited proliferation in TP53 mutant PDA cells.\nDeleting SLC45A4 in TP53 mutant HPAF-II cells inhibited the growth of xenografts in nude mice.", "dois": ["10.1038/s41598-024-74249-z", "10.1002/jgm.3364"]}
{"pair_type": "slc_pathway", "key1": "SLC45A3", "key2": "proliferation", "summary": "Altogether, these results indicate that SLC45A3-ELK4 regulates cancer cell proliferation by its transcript, not translated protein.\nNonetheless, when the fusion RNA, but not ELK4 is silenced, cell proliferation is inhibited in both androgen-dependent and castration-resistant prostate cancer cells.\nThese haemodynamic improvements were related to decrease pulmonary vascular remodelling, lung inflammation and pulmonary vascular cell proliferation in situ.\nThis growth arrest can be rescued by exogenous expression of the fusion and a mutant designed to prevent translation of the ELK4 protein.\nIn vivo inhibition of miR-138-5p restored KCNK3 mRNA expression and SLC45A3 protein expression in the lungs.\nThe possible curative mechanisms involve at least the normalization of lung KCNK3 as well as SLC45A3 expression.\nThis fusion RNA, SLC45A3-ELK4, generated by cis-splicing between neighboring genes, was found in prostate cancer.\nHere we report a new phenomenon whereby a fusion transcript functions as a long non-coding chimeric RNA (lnccRNA).\nIn addition, similar to many long non-coding RNAs, the fusion RNA is enriched in the nuclear fraction.\nIntriguingly, we found that the fusion RNA level is less than 1% of wild type ELK4, unlikely to perturb the general pool of ELK4 protein.\nIn the same setting, the mutant could also suppress CDKN1A and several other targets of SLC45A3-ELK4.\nThe fusion RNA encodes the same protein as ELK4.", "dois": ["10.1158/2767-9764.crc-21-0156", "10.1002/mc.23413", "10.1186/s12931-020-01444-7", "10.1016/j.canlet.2017.07.007", "10.18632/oncotarget.11790", "10.1158/2159-8290.CD-12-0212", "10.1158/2159-8290.CD-12-0042"]}
{"pair_type": "slc_pathway", "key1": "SLC45A4", "key2": "oxidative phosphorylation", "summary": "Knockdown of SLC45A4 reduced glucose uptake and ATP production, which led to activation of autophagy via AMPK/ULK1 pathway.\nSilencing SLC45A4 inhibited proliferation in TP53 mutant PDA cells.\nDeleting SLC45A4 in TP53 mutant HPAF-II cells inhibited the growth of xenografts in nude mice.\nSLC45A4 promotes glycolysis and prevents AMPK/ULK1-induced autophagy in TP53 mutant pancreatic ductal adenocarcinoma.\nThe present study found that SLC45A4 prevents autophagy via AMPK/ULK1 axis in TP53 mutant PDA, which may be a promising biomarker and therapeutic target in TP53 mutant PDA.\nExtracellular acidification rate and oxygen consumption rate assays were used to evaluate glycolysis and oxidative phosphorylation.", "dois": ["10.1002/jgm.3364"]}
{"pair_type": "slc_pathway", "key1": "SLC45A4", "key2": "proliferation", "summary": "Silencing of SLC45A4 significantly inhibited the proliferation, invasion, and metastasis of OCC by suppressing glucose uptake and glycolysis, and it also reduced the expression of HIF-α glycolysis signaling pathway in OC tissues.\nTumor cells promote malignant behaviors such as proliferation, invasion, and metastasis of cancer cells through glucose metabolic reprogramming, but the role of the H-dependent sugar cotransporter SLC45A4 in regulating metabolic reprogramming in ovarian cancer (OC) remains largely unknown.\nSilencing SLC45A4 inhibited proliferation in TP53 mutant PDA cells.\nKnockdown of SLC45A4 reduced glucose uptake and ATP production, which led to activation of autophagy via AMPK/ULK1 pathway.\nPVT1-214 knockdown suppressed cell growth, invasion and migration in vitro, whereas PVT1-214 overexpression promoted tumor proliferation in vivo.\nDeleting SLC45A4 in TP53 mutant HPAF-II cells inhibited the growth of xenografts in nude mice.\nIn vivo experiments using shRNA to knock down SLC45A4 in xenograft models in nude mice demonstrated a significant inhibition of tumor growth.\nThese findings suggest that SLC45A4 silencing can restrain the malignant progression of OC by inhibiting glucose uptake in OCC and affecting the reprogramming of glycolytic energy metabolism, indicating that SLC45A4 may serve as a potential therapeutic target for OC intervention.\nThe present study found that SLC45A4 prevents autophagy via AMPK/ULK1 axis in TP53 mutant PDA, which may be a promising biomarker and therapeutic target in TP53 mutant PDA.\nIn addition, PVT1-214 positively regulates SLC45A4 expression through its competitive endogenous RNA (ceRNA) activity against miR-671-5p.\nMoreover, high level of SLC45A4 expression was tightly associated with poor clinical outcomes in PDA patients.\nSLC45A4 was overexpressed in PDA for which", "dois": ["10.1186/s12957-025-03805-2", "10.1038/s41598-024-74249-z", "10.1002/jgm.3364"]}
{"pair_type": "slc_pathway", "key1": "SLC39A6", "key2": "migration", "summary": "Furthermore, knockdown of SLC39A6 inhibited the proliferation, migration and invasion of liver cancer cells and .\nIn addition, SLC39A6 negatively correlated with miR-192 in HCC samples and promoted HCC cell migration and invasion.\nSLC39A6 was overexpressed in tissues from GA patients and in GA cell lines, and SLC39A6 knockdown in GA cell lines inhibited their proliferation, migration and invasion.\nInterestingly, our previous study showed PTCH1 silencing promoted cell proliferation but inhibited cell migration and invasion of NSCLC cells.\nCollectively, the results of the present study suggested that SLC39A6 may be a promising prognostic biomarker for liver cancer and is associated with the proliferation, migration and invasion of liver cancer.\nCells that overexpressed SLC39A6 had increased expression of mRNAs and proteins associated with metastasis, such as matrix metalloproteinase (MMP) 1, MMP3, MYC, and snail family transcriptional repressor 2 (SNAI2 or SLUG).\nSuppression of migration and invasion caused by miR-192 overexpression was alleviated by exogenous Snail expression.\nMoreover, miR-192 decreased SLC39A6 expression, subsequently downregulating SNAIL and upregulating E-cadherin expression.\nIn conclusion, we newly determined that miR-192 targeted the SLC39A6/SNAIL pathway to reduce tumor metastasis in HCC cells.\nCells that overexpressed SLC39A6 had significant increases in intracellular levels of zinc and were more invasive in assays, activating phosphatidylinositol 3-kinase signaling to AKT serine/threonine kinase 1 and mitogen-activated protein kinase 1.\nIn addition, we also observed that the proliferation and migration of A549 cells was obviously prevented by miR-3935 overexpression.\nKnockdown of SLC39A6 reduced proliferation of ESCC cells in culture and metastasis of xenograft tumors in mice.", "dois": ["10.1038/s41598-025-03713-1", "10.3892/ol.2022.13197", "10.1186/s12885-019-6222-z", "10.18632/oncotarget.23219", "10.1002/jcb.26547", "10.1053/j.gastro.2017.02.006", "10.1042/BCJ20160388", "10.18632/oncotarget.6603", "10.1042/BJ20130483"]}
{"pair_type": "slc_pathway", "key1": "SLC46A1", "key2": "glycolysis", "summary": "Analyses of SOX2 gene targets with central functions metabolism (CERK, ECHS1, HS6SDT1, LPCAT4, PFKP, SLC16A3, SLC46A1, and TST) document significant expression correlation with SOX2 among RNA-Seq datasets derived from patient tumors and metastases.\nSOX2 expression in prostate cancer cell lines confers increased glycolysis and glycolytic capacity, as well as increased basal and maximal oxidative respiration and increased spare respiratory capacity.\nInterestingly, phenotypic and gene expression analyses after CRISPR-mediated deletion of SOX2 in castration-resistant prostate cancer cells, as well as ectopic SOX2 expression in androgen-sensitive prostate cancer cells, demonstrated that SOX2 promotes changes in multiple metabolic pathways and metabolites.\nThese data support a key role for SOX2 in metabolic reprogramming of prostate cancer cells and reveal new mechanisms to understand how SOX2 enables metastatic progression, lineage plasticity, and therapy resistance.\nFurther, SOX2 expression was associated with increased quantities of mitochondria, and metabolomic analyses revealed SOX2-associated changes in the metabolism of purines, pyrimidines, amino acids and sugars, and the pentose phosphate pathway.", "dois": ["10.1038/s41388-021-02157-x"]}
{"pair_type": "slc_pathway", "key1": "SLC46A1", "key2": "ferroptosis", "summary": "We used CIBERSORT to compare alterations in the mucosal immune microenvironment between the above two group samples, and found that M1 macrophages and neutrophil infiltration increased in IBD.\nIn this study, 27 ferroptosis-related genes (FRGs) were identified differentially expressed between IBD and non-IBD control samples.\nThe random forest model identified eight decisive genes, out of which ferroptosis-related hub genes (, , , , , and ) were confirmed by RT-qPCR in the IBD mouse model.\nFurthermore, scRNA sequencing data based on these 23 hub genes uncovered the highest ferroptosis scores in CD8 T effector memory (Tem) cells, and their expression underwent significant changes along the differentiation trajectory of CD8 Tem cells.\nSubsequently, 23 hub genes were identified, which could distinguish IBD samples into two distinct clusters with noticeable differences in immune therapy response.\nTwo clusters based on consensus clustering of 27 FRGs led to significant changes in the abundance of CD4 memory resting T cells, M2 macrophages, and resting mast cells.\nThis study reveals ferroptosis-mediated immune microenvironment in IBD and provides multiple potential targets for IBD treatment.", "dois": ["10.1089/dna.2023.0260"]}
{"pair_type": "slc_pathway", "key1": "SLC46A1", "key2": "apoptosis", "summary": "FOLR1 and SLC46A1 were (P<0.01) down-regulated, while SLC19A1 was up-regulated (P<0.01) in FD group.\nFD caused cell cycle arrest at G0/G1 phase and increased the rate of apoptosis, which was associated with disrupted expression of folate transport and methyl transfer genes.\nTaken together, down-regulation of IGF-1 expression and signaling is involved in FD-induced cell cycle arrest and apoptosis in HT-22 hippocampal neuron cells, which is associated with an abnormal activation of methyl transfer pathway and hypermethylation of IGF-1 gene promoter.\nIn addition, patients' PBMCs were resistant to methotrexate-induced apoptosis supporting a functionally defective SLC19A1.\nIn MCF10A and Hs578T cells, FA treatment decreased pathways associated with apoptosis, cell death and senescence, but increased those associated with cell proliferation.\nThe folate transporters SLC19A1, SLC46A1 and FOLR1 were differentially expressed between cell lines tested.\nFolate deficiency contributes to impaired adult hippocampal neurogenesis, yet the mechanisms remain unclear.\nHere we use HT-22 hippocampal neuron cells as model to investigate the effect of folate deprivation (FD) on cell proliferation and apoptosis, and to elucidate the underlying mechanism.\nIGF-1 supplementation in FD media significantly abolished FD-induced decrease in cell viability.\nHowever, IGF-1 had limited effect in rescuing the cell phenotype when added 24h after FD.\nThe expression of the total and all the 3 classes of IGF-1 mRNA variants was significantly (P<0.01) down-regulated and IGF-1 concentration was decreased (P<0.05) in the culture media.\nIGF-1 signaling pathway was also compromised with diminished activation (P<0.05) of STAT3, AKT and mTOR.\nFD cells exhibited significantly (P<0.05) higher protein content of BHMT,", "dois": ["10.1158/1535-7163.MCT-23-0550", "10.1016/j.biocel.2016.08.040", "10.1038/s41435-022-00191-7", "10.1017/jns.2016.8"]}
{"pair_type": "slc_pathway", "key1": "SLC46A1", "key2": "chemotherapy", "summary": "The proton-coupled folate transporter (PCFT) (also known as SLC46A1) mediates folate uptake across the intestinal brush border membrane and the choroid plexus, and is an important route for the delivery of antifolate drugs in cancer chemotherapy.\nTreatment with 5-Aza-2'-deoxycytidine which induced demethylation but not with the histone deacetylase inhibitor trichostatin A, restored 50-fold PCFT expression only in leukemia cells.\nCox regression analysis showed that high tumoral expression of the genes SLC46A1/PCFT (proton-coupled folate transporter) and SLC19A1/RFC-1 (reduced folate carrier 1) correlated significantly (p < 0.001 and p < 0.01, respectively) with a decreased risk of recurrent disease, measured as disease-free survival (DFS).\nCurrent advances including for example the deciphering of the dominant folate transporter proton-coupled folate transporter (PCFT/SLC46A1) facilitated the synthesis of experimental antifolates aimed at selectively targeting solid tumor cells, which reside in an acidic microenvironment where PCFT supposedly functions optimally.\nReduced levels of SLC38A7 and SLC46A1 diminish the proliferative potential of cancer cells, and elevated expression of these SLCs in breast tumors from patients correlates with reduced survival.\nTherapy-resistant cells throughout the concentration gradient display higher expression of the solute carriers SLC38A7 and SLC46A1 and elevated intracellular concentrations of their associated metabolites.\nThe potential translational implications of the restoration of PCFT expression in chemotherapy of leukemia are discussed.\nWe conclude that SLC46A1/PCFT and SLC19A1/RFC-1 are associated with DFS of patients with colorectal cancer and hypothesize that poor response to 5-fluorouracil plus leucovorin therapy in some patients may be linked to low expression of these genes.\nWe further investigated the particular drug-resistant subclone and established a gemcitabine sensitivity gene panel (GSGP) (SLC46A1,", "dois": ["10.1016/j.celrep.2023.113191", "10.3389/fphar.2023.1193791", "10.1038/s41586-021-03579-z", "10.1177/1010428319846231", "10.2119/molmed.2014.00192", "10.1016/j.drup.2012.07.002", "10.1074/jbc.M111.306860", "10.1016/j.bbrc.2008.09.074"]}
{"pair_type": "slc_pathway", "key1": "SLC46A2", "key2": "apoptosis", "summary": "These exogenous miRNAs, which are abundant and conserved among plants, may be absorbed by the SLC46A2 transporter in the rumen epithelium during feeding and distributed to other tissues via exosomal encapsulation.\nMoreover, exosomes derived from bovine serum were found to mediate these effects, as miR166a-3p-enriched exosomes inhibited cell proliferation and promoted apoptosis, further supporting the cross-kingdom role of plant-derived miRNAs in regulating biological processes.\nTransfection experiments confirmed that miR166a-3p reduces the expression of proliferation markers (PCNA, Cyclin D, and Cyclin E) and the anti-apoptotic gene Bcl2, while upregulating the pro-apoptotic gene Bax.", "dois": ["10.1016/j.ijbiomac.2024.138470"]}
{"pair_type": "slc_pathway", "key1": "SLC46A2", "key2": "proliferation", "summary": "These exogenous miRNAs, which are abundant and conserved among plants, may be absorbed by the SLC46A2 transporter in the rumen epithelium during feeding and distributed to other tissues via exosomal encapsulation.\nmiR166a-3p-enriched exosomes inhibited cell proliferation and promoted apoptosis, further supporting the cross-kingdom role of plant-derived miRNAs in regulating biological processes.\nTransfection experiments confirmed that miR166a-3p reduces the expression of proliferation markers (PCNA, Cyclin D, and Cyclin E) and the anti-apoptotic gene Bcl2, while upregulating the pro-apoptotic gene Bax.\nIt revealed that psoriasis pathophysiological processes encompass mA epigenetic alterations, and that mA alterations may specifically influence cell proliferation and neural regulation, and closely associated with osteoarticular involvement and metabolic syndrome in psoriasis.", "dois": ["10.1016/j.ijbiomac.2024.138470", "10.31083/j.fbl2909311"]}
{"pair_type": "slc_pathway", "key1": "SLC46A1", "key2": "proliferation", "summary": "Although SLC19A1 mRNA and protein expression were unaltered, remarkably, mitogen induced-T cell proliferation was significantly reduced at suboptimal folic acid and supraoptimal folinic acid concentrations.\nl-LV displayed an 8-fold and 3.5-fold higher substrate affinity than d-LV for the reduced folate carrier (RFC/SLC19A1) and proton coupled folate transporter (PCFT/SLC46A1), respectively.\nIn MCF10A and Hs578T cells, FA treatment decreased pathways associated with apoptosis, cell death and senescence, but increased those associated with cell proliferation.\nThese findings suggest that physiological concentrations of FA can induce cell type-specific changes in gene regulation in a manner that is consistent with proliferative phenotype.\nFD caused cell cycle arrest at G0/G1 phase and increased the rate of apoptosis, which was associated with disrupted expression of folate transport and methyl transfer genes.\nHere we use HT-22 hippocampal neuron cells as model to investigate the effect of folate deprivation (FD) on cell proliferation and apoptosis, and to elucidate the underlying mechanism.\nTitle: Folate deprivation induces cell cycle arrest at G0/G1 phase and apoptosis in hippocampal neuron cells through down-regulation of IGF-1 signaling pathway.\nFOLR1 and SLC46A1 were (P<0.01) down-regulated, while SLC19A1 was up-regulated (P<0.01) in FD group.\nThe folate transporters SLC19A1, SLC46A1 and FOLR1 were differentially expressed between cell lines tested.\nThe patient demonstrated a combined immunodeficiency with an impaired T cell proliferation response, pan-hypogammaglobulinemia, and an imbalanced pro-inflammatory cytokine profile.\nT cell proliferation, methotrexate resistance, NK cell cytotoxicity, Treg cells and cytokine production by T cells were examined by flow cytometric assays.\nUsing proliferation assays, we investigated their potential to protect cancer cells from cytot", "dois": ["10.3389/fphar.2024.1450418", "10.1158/1535-7163.MCT-23-0550", "10.1038/s41435-022-00191-7", "10.1016/j.biocel.2016.08.040", "10.1017/jns.2016.8", "10.1016/j.clim.2014.03.014"]}
{"pair_type": "slc_pathway", "key1": "SLC46A3", "key2": "apoptosis", "summary": "Moreover, miRNA-3679 promotes the proliferation of HCC cells and inhibits their apoptosis by suppressing ZADH2.\nFlow cytometry showed that the number of apoptotic cells of the miR-3679 inhibitor+si-2 group was significantly lower than that of the miR-3679 inhibitor group (<0.01).", "dois": ["10.12182/20220960505"]}
{"pair_type": "slc_pathway", "key1": "SLC46A3", "key2": "chemotherapy", "summary": "These antibiotics significantly inhibited the transport function of SLC46A3 in a concentration-dependent manner.\nWe recently demonstrated that erythromycin and clarithromycin inhibit SLC46A3 and attenuate the cytotoxicity of T-DM1;\nThese results suggest that the attenuation of T-DM1 cytotoxicity by macrolide and ketolide antibiotics involves their lysosomal accumulation and results in their greater lysosomal concentrations to inhibit the SLC46A3 function and T-DM1 degradation.\nThe immunofluorescence staining of trastuzumab revealed that azithromycin and solithromycin inhibit the degradation of T-DM1 in the lysosomes.\nTrastuzumab emtansine (T-DM1), a HER2-targeting antibody-drug conjugate (ADC), is catabolized in the lysosomes, where Lys-SMCC-DM1, a potent cytotoxic agent, is processed by proteinase degradation and subsequently released from the lysosomes to the cytoplasm through the lysosomal membrane transporter SLC46A3, resulting in an antitumor effect.\nThis suggests a potential drug-ADC interaction during cancer chemotherapy.\nMacrolides used in the clinic, such as roxithromycin, azithromycin, and josamycin, as well as solithromycin, a ketolide under clinical development, significantly attenuated T-DM1 cytotoxicity in addition to erythromycin and clarithromycin.", "dois": ["10.1021/acs.molpharmaceut.3c00490", "10.1158/1078-0432.CCR-18-1976"]}
{"pair_type": "slc_pathway", "key1": "SLC46A3", "key2": "migration", "summary": "Hepatocellular carcinoma cell lines that stably overexpressed SLC46A3 inhibited the levels of migration and invasion compared with control HCC cells, and formed smaller xenograft tumors with more metastases in mice compared with HCC cells that did not overexpress SLC46A3.\nThe proliferation, invasion, migration and sphere-forming abilities of SLC46A3 knock-down and overexpressing cell lines were evaluated and the expression of related molecules in the epithelial mesenchymal transition (EMT) were detected by RT-PCR, western blot and immunofluorescence assay.\nIn addition, overexpression of SLC46A3 obviously inhibited epithelial-to-mesenchymal transition-activating transcription factors such as N-cadherin and Vimentin.\nTumors that expressed low levels of SLC46A3 had more aggressive phenotypes, and patients with these tumors had shorter survival times after surgery compared to patients whose tumors expressed high levels of SLC46A3.", "dois": ["10.1016/j.biopha.2019.108864"]}
{"pair_type": "slc_pathway", "key1": "SLC39A9", "key2": "apoptosis", "summary": "Progesterone antagonized testosterone actions, blocking increases in zinc, Erk phosphorylation and apoptosis, further evidence that ZIP9 is specifically activated by androgens.\nPotential interactions of (-)-epicatechin and (+)-catechin with the membrane androgen receptor, ZIP9 (SLC39A9), which mediates androgen induction of apoptosis in these cancer cells, were investigated.\nCo-treatments with 100 nM prochloraz, vinclozolin and M2 blocked or attenuated the 20 nM testosterone-induced increases in apoptosis, intracellular free zinc levels, and expression of the proapoptotic gene, Bax.\n(-)-Epicatechin (200 nM) mimicked the effects of 100 nM testosterone in inducing apoptosis of PC3-ZIP9 cells, whereas (+)-catechin (concentration range 200 nM-1000 nM) did not significantly increase apoptosis and instead blocked the apoptotic response to testosterone.\nTreatment with a zinc chelator or a MAPK inhibitor blocked testosterone-induced increases in Bax, p53, and JNK mRNA expression.\nTestosterone treatment of MDA-MB-468 and PC-3-ZIP9 cells caused activation of G proteins and second messenger pathways as well as increases in intracellular free zinc concentrations that were accompanied by induction of apoptosis.\nMDA-MB-468 cells showed similar apoptotic, cAMP, and free zinc signaling responses to (-)-epicatechin to those observed in PC3-ZIP9 cells, as well as antagonism by (+)-catechin of testosterone-induced apoptosis and modulation of cAMP and caspase-3 levels.\nTestosterone promotes serum starvation-induced cell death and apoptosis in transfected cells and in croaker ovarian follicle cells that is associated with rapid increases in intracellular free zinc concentrations, suggesting an involvement of zinc in this nonclassical androgen action to promote apoptosis.\nTestosterone treatment caused up-regulation of proapoptotic genes Bax (Bcl-2-associated X protein), p53 (tumor protein p53), and JN", "dois": ["10.1158/0008-5472.CAN-21-0982", "10.1016/j.steroids.2019.05.007", "10.1210/en.2014-1201", "10.1210/en.2014-1198", "10.1016/j.jsbmb.2021.105906", "10.1016/j.mce.2017.02.025"]}
{"pair_type": "slc_pathway", "key1": "SLC46A3", "key2": "proliferation", "summary": "Moreover, miRNA-3679 promotes the proliferation of HCC cells and inhibits their apoptosis by suppressing ZADH2.\nThe proliferation, invasion, migration and sphere-forming abilities of SLC46A3 knock-down and overexpressing cell lines were evaluated and the expression of related molecules in the epithelial mesenchymal transition (EMT) were detected by RT-PCR, western blot and immunofluorescence assay.\nHepatocellular carcinoma cell lines that stably overexpressed SLC46A3 inhibited the levels of migration and invasion compared with control HCC cells, and formed smaller xenograft tumors with more metastases in mice compared with HCC cells that did not overexpress SLC46A3.\nIn addition, overexpression of SLC46A3 obviously inhibited epithelial-to-mesenchymal transition-activating transcription factors such as N-cadherin and Vimentin.\nT-DM1 and the mTOR inhibitor everolimus demonstrated synergistic activity at inhibiting cell proliferation at multiple T-DM1 concentrations across four HER2-positive breast cancer cell lines.\n5-Ethynyl-2'-deoxyuridine (EdU) staining was done to determine the effect of transfection of miRNA-3679 inhibitor and simultaneous transfection of miRNA-3679 and ZADH2 inhibitors on cell proliferation.\nEdU analysis showed that the number of positive cells in the miRNA-3679 inhibitor group was lower than that in the NC group and the Inhibitor NC group (<0.05).", "dois": ["10.1186/s13058-025-02000-1", "10.12182/20220960505", "10.1016/j.biopha.2019.108864"]}
{"pair_type": "slc_pathway", "key1": "SLC47A1", "key2": "chemotherapy", "summary": "In addition, genetic or pharmacological inhibition of MATE1 did not significantly alter plasma levels of oxaliplatin, suggesting that MATE1 inhibitors are unlikely to influence the safety or drug-drug interaction liability of oxaliplatin-based chemotherapy.\nThe urinary excretion of oxaliplatin was reduced by about 2-fold in mice with a deficiency of MATE1 or both OCT2 and MATE1 ( < 0.05), without impacting markers of acute renal injury.\nFor example, the transport of platinum-based anticancer drugs has been reported to be influenced by the expression and activities of OCT1-3 (SLC22A1-3), OCTN1/2 (SLC22A4/5), CTR1/2 (SLC31A1/2) and MATE1/2 (SLC47A1/2) solute carriers.\nIn conclusion, emerging mechanisms involving metal transporting solute carriers are being defined and seem likely to make major contributions to cancer development and progression, and to the delivery of anticancer and tumour imaging agents.\nWe hypothesized that TKIs may differentially interact with the renal transporter MATE1 () and influence the elimination and toxicity of the MATE1 substrate oxaliplatin.\nA range of different solute carrier families, including members from the SLC2A, SLC11A, SLC22A, SLC25A, SLC30A, SLC31A, SLC39A, SLC40A, SLC47A and SLCO1B families, and various metal substrates, including arsenic, copper, gadolinium, iron, platinum and zinc, have been implicated in these cancer-related transport processes.", "dois": ["10.3390/pharmaceutics13122004", "10.1038/s41392-018-0034-5", "10.1002/bdd.1903"]}
{"pair_type": "slc_pathway", "key1": "SLC39A14", "key2": "glycolysis", "summary": "The results also showed that the key enzymes of glucose-related pathways (glycolysis (ALDOC, ENO1, HK1), pyruvate metabolism (LDHA, PDHA1), and tricarboxylic acid cycle (IDH1, OGDA, SDHB, CS) were significantly downregulated in GCs of atretic follicles by proteomic analysis (P < 0.05).\nMoreover, SLC39A14 and SLC16A1 were most significantly expressed in the GCs of healthy follicles (P < 0.01), and this correlation was positively associated with amino acids content.", "dois": ["10.1016/j.repbio.2025.101008"]}
{"pair_type": "slc_pathway", "key1": "SLC47A1", "key2": "apoptosis", "summary": "Further studies revealed that SLC47A1 was a regulator of ferroptosis rather than apoptosis or necrosis.\nHere, we found that solute carrier family 47 member 1 (SLC47A1) promoted GC progression by regulating ferroptosis.\nLarge-scale lipidomics and functional analyses revealed that the silencing of SLC47A1 increased RSL3- or erastin-induced ferroptosis by favoring ACSL4-SOAT1-mediated production of polyunsaturated fatty acid cholesterol esters.\nKnockdown of SLC47A1 significantly inhibited cell proliferation, colony formation, and tumor growth.\nMechanistically, GATA6 promoted SLC47A1 transcription, leading to elevated SLC47A1 expression and promoting ferroptosis in GC cells.\nKnockdown of SLC47A1 promoted ferroptosis in GC cells, as evidenced by increased erastin-induced cytoplasmic membrane rupture, cell death, lipid peroxidation, and malondialdehyde levels.\nIn summary, our study revealed the significant role of SLC47A1 in the development and progression of GC through regulating ferroptosis.\nHere, we report a previously unrecognized role for the lipid flippase solute carrier family 47 member 1 (SLC47A1) as a regulator of lipid remodeling and survival during ferroptosis.\nClinically, SLC47A1 was elevated during the progression of gastritis to GC, and its high expression was associated with poor prognosis in patients with GC.\nThe depletion of PPARA and SLC47A1 similarly sensitized cells to ferroptosis induction, whereas transfection-enforced re-expression of SLC47A1 restored resistance to ferroptosis in PPARA-deficient cells.\nTargeting the GATA6/SLC47A1 axis may be a promising therapeutic strategy for GC.\nPharmacological or genetic blockade of the PPARA-SLC47A1 pathway increased the anticancer activity of a ferroptosis inducer in mice.\nWe identified peroxisome proliferator activated receptor alpha (PP", "dois": ["10.1080/15548627.2023.2259732", "10.3390/ijms241411358", "10.1080/15548627.2023.2200554", "10.1038/s41467-022-35707-2", "10.1089/dna.2025.0015"]}
{"pair_type": "slc_pathway", "key1": "SLC47A1", "key2": "proliferation", "summary": "Knockdown of SLC47A1 significantly inhibited cell proliferation, colony formation, and tumor growth.\nHere, we found that solute carrier family 47 member 1 (SLC47A1) promoted GC progression by regulating ferroptosis.\nMechanistically, GATA6 promoted SLC47A1 transcription, leading to elevated SLC47A1 expression and promoting ferroptosis in GC cells.\nKnockdown of SLC47A1 promoted ferroptosis in GC cells, as evidenced by increased erastin-induced cytoplasmic membrane rupture, cell death, lipid peroxidation, and malondialdehyde levels.\nFurther studies revealed that SLC47A1 was a regulator of ferroptosis rather than apoptosis or necrosis.\nIn summary, our study revealed the significant role of SLC47A1 in the development and progression of GC through regulating ferroptosis.\nAs another example, solute carriers mediate control over the availability of endogenous metal ions, such as copper, iron and zinc, may have key roles in regulating tumour angiogenesis, cell proliferation, epithelial-to-mesenchymal transition and aberrant MAPK and STAT-3 signal transduction in cancer.\nTargeting the GATA6/SLC47A1 axis may be a promising therapeutic strategy for GC.\nClinically, SLC47A1 was elevated during the progression of gastritis to GC, and its high expression was associated with poor prognosis in patients with GC.\nInduction of ferroptosis driven by iron-dependent phospholipid peroxidation ameliorates the malignant progression of GC.\nGC development is a multistep and multifactorial process, and the molecular characterization of the multistage progression of gastric lesions to GC is poorly understood.", "dois": ["10.1089/dna.2025.0015", "10.1002/bdd.1903"]}
{"pair_type": "slc_pathway", "key1": "SLC47A1", "key2": "ferroptosis", "summary": "Pharmacological or genetic blockade of the PPARA-SLC47A1 pathway increased the anticancer activity of a ferroptosis inducer in mice.\nHere, we found that solute carrier family 47 member 1 (SLC47A1) promoted GC progression by regulating ferroptosis.\nUpon ferroptosis induction, SLC47A1 upregulation inhibits DHA/DPA polyunsaturated fatty acid containing glycerophospholipids (PUFA-PLs) accumulation to block ferroptosis.\nLarge-scale lipidomics and functional analyses revealed that the silencing of SLC47A1 increased RSL3- or erastin-induced ferroptosis by favoring ACSL4-SOAT1-mediated production of polyunsaturated fatty acid cholesterol esters.\nA recent article by Lin and colleagues in Nature Communications systematically analyzed phospholipid transporters (phospholipid scramblases, flippases, and floppases), and identified that the lipid flippase solute carrier family 47 member 1 (SLC47A1) functions as a regulator of lipid remodeling and promotes ferroptosis resistance.\nMechanistically, GATA6 promoted SLC47A1 transcription, leading to elevated SLC47A1 expression and promoting ferroptosis in GC cells.\nKnockdown of SLC47A1 promoted ferroptosis in GC cells, as evidenced by increased erastin-induced cytoplasmic membrane rupture, cell death, lipid peroxidation, and malondialdehyde levels.\nFurther studies revealed that SLC47A1 was a regulator of ferroptosis rather than apoptosis or necrosis.\nIn summary, our study revealed the significant role of SLC47A1 in the development and progression of GC through regulating ferroptosis.\nDepletion of either PPARA or SLC47A1 sensitized cells to ferroptosis by favoring ACSL4-SOAT1-mediated production of polyunsaturated fatty acid containing (PUFA) cholesterol esters.\nHere, we report a previously unrecognized role for the lipid flippase solute carrier family", "dois": ["10.1089/dna.2025.0015", "10.1016/j.ceca.2023.102703", "10.1038/s41467-022-35707-2", "10.1080/15548627.2023.2200554"]}
{"pair_type": "slc_pathway", "key1": "SLC47A2", "key2": "apoptosis", "summary": "PARP1-ACSL1 pair significantly correlated with poor overall survival in breast cancer owing to the suppression of the MAPK, mTOR and NF-kB signaling pathways, which induces apoptosis, autophagy and prevents inflammatory processes.", "dois": ["10.1038/s41598-022-13835-5"]}
{"pair_type": "slc_pathway", "key1": "SLC47A1", "key2": "oxidative stress", "summary": "Multi-omics integration uncovers CKI-mediated inhibition of the HIF-1α/SREBP1 axis, suppressing de novo lipogenesis (DNL), and downregulation of the PPARα/SLC47A1 pathway, impairing fatty acid oxidation and lipid efflux.\nThis dual blockade results in intracellular PUFAs accumulation and elevated lipid peroxidation, triggering mitochondrial dysfunction and oxidative stress-induced cell death.\nAdenosine monophosphate-activated protein kinase (AMPK) is stimulated in embryos during diabetic pregnancy by maternal hyperglycaemia-induced embryo oxidative stress.\nSeveral studies demonstrated that neuroendocrine axis dysfunction, insulin resistance, oxidative stress, chronic inflammatory response, and gut microbiota dysbiosis are core pathological links associated with it.", "dois": ["10.1016/j.phymed.2025.157323", "10.1016/j.csbj.2022.10.030", "10.1002/dmrr.2451", "PMID:23774469", "PMID:21677353"]}
{"pair_type": "slc_pathway", "key1": "SLC39A10", "key2": "migration", "summary": "XYA-2 at 1 μΜ inhibited the colony formation and migration ability of MGC803 (72.6% and 67.6%, respectively) and MKN28 (78.5% and 96.6%, respectively) cells.\nThe molecular mechanism studies based on transcriptomics and proteomics analyses indicated that XYA-2 might exert its anticancer activity by synergistically inhibiting the expression of MYC and SLC39A10, two downstream genes of STAT3 in vitro and in vivo.\nTogether, these findings suggested that XYA-2 may be a potent STAT3 inhibitor for treating gastric cancer, and dual inhibition of MYC and SLC39A10 may be an effective therapeutic strategy for STAT3-activated cancer.\nFinally, GSEA analysis showed that the high-risk group was enriched in tumor migration, invasion and growth-related pathways.\nIn addition, the prognostic survival analysis showed that COL5A2-high/FEN1-low, POP1-low/GFRA1-high, EXO1-low/PLEKHS1-low,SLC39A10-high/CHI3L1-low, MMP7-high/PPP1R1 B-low, SLC5A6-low/BYSL-low had worse OS (P < 0.05).", "dois": ["10.1016/j.heliyon.2023.e18242", "10.1016/j.phrs.2023.106703", "10.2147/JHC.S320326", "10.2147/OTT.S245537", "10.1042/BCJ20160388", "10.1158/1541-7786.MCR-10-0394"]}
{"pair_type": "slc_pathway", "key1": "SLC47A2", "key2": "proliferation", "summary": "The PARP1-SRD5A3 pair significantly correlated with poor overall survival in breast cancer through regulating androgen receptors to induce cell proliferation.", "dois": ["10.1038/s41598-022-13835-5"]}
{"pair_type": "slc_pathway", "key1": "SLC48A1", "key2": "ferroptosis", "summary": "Four genes (ABCB6, FLVCR1, SLC48A1 and SLC7A11) were identified to construct prognostic and diagnostic models.\nAs an inducer of ferroptosis, erastin inhibited HCC cell proliferation and progression, and it was showed to affect Th17 cell differentiation and IL-17 signaling pathway through bioinformatics analysis, indicating it a potential agent of cancer immunotherapy.\nIn this study, we comprehensively analyzed genes related to ferroptosis and iron metabolism to construct diagnostic and prognostic models and explore the relationship with the immune microenvironment in HCC.\nIntegrated analysis, cox regression and the least absolute shrinkage and selection operator (LASSO) method of 104 ferroptosis- and iron metabolism-related genes and HCC-related RNA sequencing were performed to identify HCC-related ferroptosis and iron metabolism genes.\nThe prognostic and diagnostic models based on the four genes indicated superior diagnostic and predictive performance, indicating new possibilities for individualized treatment of HCC patients.", "dois": ["10.1186/s12964-020-00663-1"]}
{"pair_type": "slc_pathway", "key1": "SLC39A8", "key2": "apoptosis", "summary": "Knockdown of circ_SLC39A8 inhibited apoptosis and inflammation in OA chondrocytes, while these effects were reversed by downregulating miR-591.\nCoumestrol was found to induce apoptosis in CRC cell lines by upregulating the expression of ferroptosis pathway-related genes SLC39A8, NCOA4, VDAC2, and NOX2.\nZIP8 knockdown exacerbated liver damage, further decreased antioxidant enzyme activity, promoted inflammatory mediator expression, and upregulated the rate of apoptosis.\nOur previous work showed that maternal selenium deficiency suppressed proliferation, induced autophagy dysfunction, and apoptosis in the placenta of mice.\nZnCl pretreatment before TgCtwh3 infection improved liver injury, increased antioxidant enzyme activity, restrained the expression of inflammatory mediators, and decreased the rate of apoptosis.\nCoumestrol facilitates apoptosis in CRC cells by interacting with ZIP8 protein via the ferroptosis pathway.\nHowever, coumestrol was unable to upregulate the expression of ferroptosis pathway-related genes in CRC cell lines after SLC39A8 interference.\nWe found that plasma NTBI damaged intestinal morphology, caused intestinal oxidative stress injury and reactive oxygen species (ROS) accumulation, and induced intestinal epithelial cell apoptosis.\nTNF-α treatment of primary human lung epithelia and A549 cells induced ZIP8 expression, resulting in significantly higher cell death attributable to both apoptosis and necrosis following Cd exposure.\nOur findings indicated that knockdown of circ_SLC39A8 delayed the progression of OA via modulating the miR-591-IRAK3 axis, providing new insight into the molecular mechanisms of OA pathogenesis.\nThe profile of EAfs enclosing competent oocyte converged towards cumulus expansion and controlled cell-cycle quiescence pathways whereas lipid dysregulation, oxidative stress and apoptosis characterized CC surrounding incompetent oocytes.\nNetwork modelling pinpointed as signature of competent CCs three down-regulated outliers (EFHD1, HS6ST2", "dois": ["10.1016/j.burns.2025.107513", "10.1016/j.ygeno.2024.110977", "10.1016/j.compbiomed.2024.107933", "10.1186/s13018-021-02323-7", "10.1152/ajplung.00351.2011", "10.3389/fendo.2025.1629815", "10.7150/jca.94628", "10.1007/s11427-022-2347-0", "10.1093/mtomcs/mfac062", "10.1016/j.actatropica.2022.106629", "10.3390/ijms22094646", "10.1097/HP.0000000000001385"]}
{"pair_type": "slc_pathway", "key1": "SLC48A1", "key2": "proliferation", "summary": "As an essential microelement, the iron ion is involved in cell proliferation, metabolism, and differentiation.\nThe MAPK pathway is responsible for cell proliferation and plays an important role in hyperplastic growth, which has a positive effect on meat tenderness.\nAs an inducer of ferroptosis, erastin inhibited HCC cell proliferation and progression, and it was showed to affect Th17 cell differentiation and IL-17 signaling pathway through bioinformatics analysis, indicating it a potential agent of cancer immunotherapy.\nThis study verified that the iron metabolism-related gene signature (SLC39A8 and SLC48A1) could be used as a prognostic biomarker for patients with COAD.\nWe identified the prognostic value of two iron metabolism-related genes [SLC39A8 (encoding solute carrier family 39 member 8) and SLC48A1 (encoding solute carrier family 48 member 1)] in COAD.\nFour genes (ABCB6, FLVCR1, SLC48A1 and SLC7A11) were identified to construct prognostic and diagnostic models.\nThe diagnostic models successfully distinguished HCC from normal samples and proliferative nodule samples.\nPoorer overall survival (OS) was exhibited in the high-risk group than that in the low-risk group in both the training cohort (P < 0.001, HR = 0.27) and test cohort (P < 0.001, HR = 0.27).\nThe prognostic and diagnostic models based on the four genes indicated superior diagnostic and predictive performance, indicating new possibilities for individualized treatment of HCC patients.\nFunctional analysis showed that the tumor microenvironment and immune cell infiltrate were different between the low risk and high risk subgroups.\nCompared with low-risk groups, high-risk groups had higher TMB; and exhibited higher expression of CD83, B7H3, OX40 and CD134L.\nhigher fractions of macrophages, follicular helper T cells, memory B cells, and neutrophils;\nIron metabolism plays a crucial role in the occurrence and development of colon adenocarcinoma (COAD).", "dois": ["10.3389/fcell.2021.786684", "10.1158/1541-7786.MCR-21-0385", "10.1186/s12964-020-00663-1", "10.1186/s12863-016-0467-1", "10.1074/jbc.M111.220178"]}
{"pair_type": "slc_pathway", "key1": "SLC39A14", "key2": "oxidative stress", "summary": "IRG1/itaconate can alleviate the TAA-induced hepatic fibrosis in mice by regulating the expression of SLC39A14, consequently suppressing hepatic stellate cell ferroptosis.\nWe identified three immune-mediated ferroptosis genes, namely, Cp, Slc7a11 and Slc39a14, which possibly regulated by neutrophils during the development of ALI, and their pathways may be involved in anti-oxidative stress and anti-lipid metabolism.\nFunctionally, SLC39A14 was highly enriched in pathways related to angiogenesis, the epithelial-to-mesenchymal transition, cytokine signaling, and oxidative stress adaptation including vascular endothelial growth factor (VEGF) and cell metabolism-related signaling.\nAcupuncture promoted the levels of GSH, GSH-px, and SOD, decreased the level of MDA (P < 0.05), promoted the expression of GPX4 and System Xc- ( < 0.05), decreased the expression of TfR1 and SLC39A14 ( < 0.01), and increased the expression of FTH 1 and SLC40A1 ( < 0.05), inhibited the expression of TGF-β1, desmin, FSP-1, and α-SMA ( < 0.05), promoted the expression of Nephrin, Podocin, and CD2AP (P < 0.05).\n4-octyl itaconate (4-OI) significantly attenuated the histopathological damage in hepatic tissues, preserved the normal hepatic function, effectively reduced the release of inflammatory cytokines, and mitigated oxidative stress markers such as ROS and MDA in Thioacetamide (TAA)-induced fibrotic mice.\nMechanistically, we found that ALR could regulate iron homeostasis through the iNOS/NO/Solute carrier family 39 member 14 (SLC39A14) pathway to reduce ferroptosis in AKI.\nConversely, Slc39a14 overexpression exacerbates calcification and promotes intracellular iron accumulation in VSM", "dois": ["10.3390/ijms22157820", "10.1186/s12935-025-04003-6", "10.1111/febs.70103", "10.3390/antiox14010096", "10.1016/j.intimp.2024.113945", "10.1016/j.heliyon.2024.e33675", "10.1186/s12933-024-02224-z", "10.1007/s11427-022-2347-0", "10.1186/s12931-023-02429-y", "10.1016/j.freeradbiomed.2022.09.025", "10.3390/ijms22094646"]}
{"pair_type": "slc_pathway", "key1": "SLC49A1", "key2": "oxidative stress", "summary": "Heme is critical for a variety of cellular processes, but excess intracellular heme may result in oxidative stress and membrane injury.\nDisruption of FLVCR1 function blocks development of erythroid progenitors, likely due to heme toxicity.\nFeline leukemia virus subgroup C receptor (FLVCR1), a member of the SLC49 family of four paralogous genes, is a cell surface heme exporter, essential for erythropoiesis and systemic iron homeostasis.", "dois": ["10.1016/j.mam.2012.07.013"]}
{"pair_type": "slc_pathway", "key1": "SLC49A2", "key2": "oxidative stress", "summary": "Heme is critical for a variety of cellular processes, but excess intracellular heme may result in oxidative stress and membrane injury.", "dois": ["10.1016/j.mam.2012.07.013"]}
{"pair_type": "slc_pathway", "key1": "SLC49A3", "key2": "oxidative stress", "summary": "Heme is critical for a variety of cellular processes, but excess intracellular heme may result in oxidative stress and membrane injury.", "dois": ["10.1016/j.mam.2012.07.013"]}
{"pair_type": "slc_pathway", "key1": "SLC49A4", "key2": "oxidative stress", "summary": "Heme is critical for a variety of cellular processes, but excess intracellular heme may result in oxidative stress and membrane injury.", "dois": ["10.1016/j.mam.2012.07.013"]}
{"pair_type": "slc_pathway", "key1": "SLC50A1", "key2": "apoptosis", "summary": "Further in vitro and in vivo experiments confirmed that SLC50A1 can regulate cellular glycolysis and the cell cycle, thereby promoting the proliferation of HCC cells while reducing apoptosis.", "dois": ["10.1038/s41420-024-02261-3"]}
{"pair_type": "slc_pathway", "key1": "SLC50A1", "key2": "glycolysis", "summary": "Further in vitro and in vivo experiments confirmed that SLC50A1 can regulate cellular glycolysis and the cell cycle, thereby promoting the proliferation of HCC cells while reducing apoptosis.\nMoreover, our findings indicate that SLC50A1 enhances resistance of HCC cells to DOX and 2-DG.\nThe recognition and binding of the modified SLC50A1 by IGF2BP2 subsequently promote its stability and translational expression.\nFurthermore, we discovered that the m6A methyltransferase METTL3 mediates the methylation modification of SLC50A1.\nConsequently, our research identifies the METTL3/SLC50A1 axis as a novel therapeutic target in the context of HCC.\nThe relationship between SLC50A1, a member of the SLC family involved in glucose transmembrane transport, and HCC remains unclear.\nMetabolic reprogramming has been found to be closely associated with the occurrence and development of hepatocellular carcinoma (HCC).", "dois": ["10.1038/s41420-024-02261-3"]}
{"pair_type": "slc_pathway", "key1": "SLC51A", "key2": "ferroptosis", "summary": "Additionally, chromatin immunoprecipitation assays, using mice renal tissues, revealed that agonist-activated FXR could bind to its known target genes (Slc51a, Slc51b, Osgin1, and Mafg) and ferroptosis-related genes (Aifm2, Ggt6, and Gsta4).\nFXR deficiency exhibited more ferroptosis responses, such as increase in lipid peroxidation, iron content and heme oxygenase 1 protein, and a decrease in glutathione/glutathione disulfide ratio and glutathione peroxidase 4 levels in HK2 cells and mice.\nThese findings indicate that activated FXR regulates the transcription of ferroptosis-related genes and protects against cisplatin-induced acute kidney injury.\nHere, the ability of activated farnesoid X receptor (FXR) to attenuate cisplatin-induced AKI through the regulation of ferroptosis was examined.\nIncreased blood urea nitrogen, serum creatinine, and ferroptotic responses in the cisplatin-induced AKI mouse model were mitigated upon treatment with the FXR agonist GW4064 but were exacerbated in FXR knockout mice.\nRNA sequencing analysis revealed that ferroptosis-associated genes were novel targets of FXR.\nFXR agonist upregulated the expression of lipid and glutathione metabolism-related genes and downregulated cell death-related genes.\nFurthermore, activated FXR-dependent MAFG, a transcriptional repressor, could bind to Hmox1, Nqo1, and Tf in the renal tissues of FXR agonist-treated mice.\nPrevious studies have reported that cisplatin induces ferroptosis and lipid peroxide accumulation.\nFerroptosis, a type of regulated cell death, is characterized by iron-dependent lipid peroxidation.", "dois": ["10.1016/j.redox.2022.102382"]}
{"pair_type": "slc_pathway", "key1": "SLC50A1", "key2": "proliferation", "summary": "Further in vitro and in vivo experiments confirmed that SLC50A1 can regulate cellular glycolysis and the cell cycle, thereby promoting the proliferation of HCC cells while reducing apoptosis.\nMoreover, our findings indicate that SLC50A1 enhances resistance of HCC cells to DOX and 2-DG.\nThe recognition and binding of the modified SLC50A1 by IGF2BP2 subsequently promote its stability and translational expression.", "dois": ["10.1038/s41420-024-02261-3"]}
{"pair_type": "slc_pathway", "key1": "SLC40A1", "key2": "migration", "summary": "CA9 suppression by inhibitors (S4 and U104) decreased viability and migration of MM cells, accompanied by overexpression of TFRC, IREB1/2 and FPN1(SLC40A1) and by downregulation of FTH/FTL.\nThe PI3K/AKT signaling pathway mediates TBMS1-induced ferroptosis, which was accompanied by altered expression of NRF2, SLC40A1, and GPX4, ultimately suppressing cell proliferation and collagen synthesis.\nThe natural IGF1R inhibitor PPP induced ferroptosis through blockage of PI3K/AKT/NRF2 signaling pathway and subsequent inhibition of downstream gene expression of SLC7A11 and SLC40A1 in hepatocellular carcinoma.\nmiR-4735-3p facilitates ferroptosis and tumor suppression in ccRCC by targeting SLC40A1.\nFurthermore, PRPF19 regulates the expression of solute carrier family 40 member 1 (SLC40A1) and mono-ADP ribosylhydrolase 2 (MACROD2), knockdown of SLC40A1 or MACROD2 decreases the sensitivity of tongue cancer cells to radiation and cisplatin treatment.\nβ-elemene in combination with cetuximab was shown to induce iron-dependent reactive oxygen species (ROS) accumulation, glutathione (GSH) depletion, lipid peroxidation, upregulation of HO-1 and transferrin, and downregulation of negative regulatory proteins for ferroptosis (GPX4, SLC7A11, FTH1, glutaminase, and SLC40A1) in KRAS mutant CRC cells.\nstudies indicated that TBMS1 hindered HSFs proliferation, migration, and myofibroblast activation.\nFerroportin Q248H but not low iron stores was associated with lower circulating macrophage migration inhibitory factor as well.\nFerroportin Q248H and low iron stores are both associated with lower circulating tumor necrosis factor-alpha, while only ferroportin Q248H is associated with lower circulating mac", "dois": ["10.3389/fphar.2025.1654108", "10.1016/j.taap.2025.117533", "10.1016/j.phymed.2025.156840", "10.1155/cdr/9106621", "10.1080/00207454.2024.2401661", "10.4103/cjop.CJOP-D-22-00152", "10.3389/fonc.2023.1157861", "10.1155/2022/4213401", "10.1093/abbs/gmab059", "10.18632/oncotarget.27844", "10.7150/thno.44705", "10.1016/j.redox.2019.101297", "10.1016/j.cca.2010.04.031"]}
{"pair_type": "slc_pathway", "key1": "SLC51A", "key2": "proliferation", "summary": "Fecal bile acids decreased 2.8-fold, suggesting enhanced intestinal reabsorption due to induction of ileal transporters (Slc10a2, Slc51a) and increases in whole gut transit time and intestinal permeability.\nSpecifically, TCDD elicited a >200-fold increase in taurolithocholic acid (TLCA), a potent G protein-coupled bile acid receptor 1 (GPBAR1) agonist associated with bile duct proliferation.\nMale C57BL/6 mice orally gavaged with TCDD (0.01-30 µg/kg) every 4 days for 28 days exhibited bile duct proliferation and pericholangitis.", "dois": ["10.2147/CMAR.S324072", "10.1038/s41598-017-05656-8"]}
{"pair_type": "slc_pathway", "key1": "SLC51A", "key2": "oxidative stress", "summary": "FXR deficiency exhibited more ferroptosis responses, such as increase in lipid peroxidation, iron content and heme oxygenase 1 protein, and a decrease in glutathione/glutathione disulfide ratio and glutathione peroxidase 4 levels in HK2 cells and mice.\nAdditionally, chromatin immunoprecipitation assays, using mice renal tissues, revealed that agonist-activated FXR could bind to its known target genes (Slc51a, Slc51b, Osgin1, and Mafg) and ferroptosis-related genes (Aifm2, Ggt6, and Gsta4).\nThese findings indicate that activated FXR regulates the transcription of ferroptosis-related genes and protects against cisplatin-induced acute kidney injury.\nHere, the ability of activated farnesoid X receptor (FXR) to attenuate cisplatin-induced AKI through the regulation of ferroptosis was examined.\nIncreased blood urea nitrogen, serum creatinine, and ferroptotic responses in the cisplatin-induced AKI mouse model were mitigated upon treatment with the FXR agonist GW4064 but were exacerbated in FXR knockout mice.\nFurthermore, activated FXR-dependent MAFG, a transcriptional repressor, could bind to Hmox1, Nqo1, and Tf in the renal tissues of FXR agonist-treated mice.\nRNA sequencing analysis revealed that ferroptosis-associated genes were novel targets of FXR.\nFXR agonist upregulated the expression of lipid and glutathione metabolism-related genes and downregulated cell death-related genes.\nFerroptosis, a type of regulated cell death, is characterized by iron-dependent lipid peroxidation.\nPrevious studies have reported that cisplatin induces ferroptosis and lipid peroxide accumulation.\nFurthermore, oxidative stress seemed to play a major role in the early damage response by CPZ.\nIn addition, genes associated with oxidative stress were altered by weaning transition, including decreased catalase () and lactate dehydrogenase () and increased glutathione peroxidase", "dois": ["10.1186/s13287-024-03692-6", "10.1016/j.redox.2022.102382", "10.3389/fmicb.2020.00694"]}
{"pair_type": "slc_pathway", "key1": "SLC51B", "key2": "glycolysis", "summary": "Differential signals are mainly enriched in steroid hormone biosynthesis, cell adhesion, and immune synapses, with metabolic pathways including cytochrome P450 drug metabolism, amino acid metabolism, and glycolysis.\nOur analysis revealed overexpression of MISP, CHMP2B, IL-18, TMSB4X, and EFEMP1, and downregulation of IFITM3, CA4, AGR2, and SLC51B in drug-resistant cells.\nProteomics and metabolomics analysis showed co-enrichment signals in drug metabolism, amino acids, glucose metabolism, ferroptosis, and other biological processes.", "dois": ["10.3389/fphar.2024.1394241"]}
{"pair_type": "slc_pathway", "key1": "SLC51B", "key2": "ferroptosis", "summary": "Additionally, chromatin immunoprecipitation assays, using mice renal tissues, revealed that agonist-activated FXR could bind to its known target genes (Slc51a, Slc51b, Osgin1, and Mafg) and ferroptosis-related genes (Aifm2, Ggt6, and Gsta4).\nThese findings indicate that activated FXR regulates the transcription of ferroptosis-related genes and protects against cisplatin-induced acute kidney injury by regulating the transcription of ferroptosis-related genes.\nFXR deficiency exhibited more ferroptosis responses, such as increase in lipid peroxidation, iron content and heme oxygenase 1 protein, and a decrease in glutathione/glutathione disulfide ratio and glutathione peroxidase 4 levels in HK2 cells and mice.\nRNA sequencing analysis revealed that ferroptosis-associated genes were novel targets of FXR.\nIncreased blood urea nitrogen, serum creatinine, and ferroptotic responses in the cisplatin-induced AKI mouse model were mitigated upon treatment with the FXR agonist GW4064 but were exacerbated in FXR knockout mice.\nFurthermore, activated FXR-dependent MAFG, a transcriptional repressor, could bind to Hmox1, Nqo1, and Tf in the renal tissues of FXR agonist-treated mice.\nFXR agonist upregulated the expression of lipid and glutathione metabolism-related genes and downregulated cell death-related genes.", "dois": ["10.1016/j.redox.2022.102382", "10.3389/fphar.2024.1394241"]}
{"pair_type": "slc_pathway", "key1": "SLC51B", "key2": "migration", "summary": "Subsequent knockdown experiments performed in HCC cell lines showed that all three prognostic SLCs positively regulated the proliferation of HCC cells, among which SLC22A15 and SLC2A1 were required for migration and invasion of the cells, demonstrating remarkable consistency with the roles identified by bioinformatics methods in HCC.\nBy performing bioinformatics analyses of HCC dataset from The Cancer Genome Atlas database, we identified three novel signature SLCs (SLC51B, SLC22A15, and SLC2A1) that are indicative of poor prognosis.\nFurther functional analyses suggested the potential regulation of the three prognostic SLCs on cell proliferation and metastasis.", "dois": ["10.1093/abbs/gmab076"]}
{"pair_type": "slc_pathway", "key1": "SLC51B", "key2": "proliferation", "summary": "Further functional analyses suggested the potential regulation of the three prognostic SLCs on cell proliferation and metastasis.\nSubsequent knockdown experiments performed in HCC cell lines showed that all three prognostic SLCs positively regulated the proliferation of HCC cells, among which SLC22A15 and SLC2A1 were required for migration and invasion of the cells, demonstrating remarkable consistency with the roles identified by bioinformatics methods in HCC.\nBy performing bioinformatics analyses of HCC dataset from The Cancer Genome Atlas database, we identified three novel signature SLCs (SLC51B, SLC22A15, and SLC2A1) that are indicative of poor prognosis.\nAdditionally, the upregulation of ion transport, transmembrane transport, and liver cell proliferation-related genes in green-shelled ducks further supports the observed superiority in eggshell strength.\nThe liver of green shell duck has stronger cell proliferation ability to maintain its homeostasis, and the eggshell gland has stronger ability to secrete eggshell matrix protein, which may be the reason why the eggshell is stronger than that of white shell duck.\nRNA-Seq analysis suggests that genes associated with ion transport, transmembrane transport, and liver cell proliferation and differentiation in the eggshell gland could play important roles in eggshell formation.\nTherefore, our study provides a novel prognostic biomarker for HCC and reveals the significant roles of SLCs in HCC progression, which might have been undervalued in the past.", "dois": ["10.1186/s12864-025-11452-w", "10.1093/abbs/gmab076"]}
{"pair_type": "slc_pathway", "key1": "SLC51B", "key2": "stemness", "summary": "A significant reduction in the stemness-related markers, CD24, CD44, CD20, FOXM1, and EpCAM, was found after the knockdown of CAD and other genes in HepG2 and Huh7 cells.\nFive genes, CAD, SLC51B, LGALS3, B3GAT3, and MT3, identified from 572 glycosylation-related genes, were used to construct a gene signature and predict HCC patient survival in the TCGA cohort.\nThe results demonstrated a significant positive correlation between patients in the high-risk group and both elevated gene expression and HCC dedifferentiation status.\nGlycosylation-related molecular subtypes are associated with HCC stemness and disease prognosis.\nThe ICGC-LIRI-JP cohort confirmed a similar relationship between glycosylation-related subtypes and stemness.\nThe relationship between gene expression profiles and stemness was confirmed using bulk and single-cell RNA-sequencing data.\nThe role of CAD and other genes in regulating the stemness of HCC was also validated by RT-qPCR, CCK-8, and colony formation assay.\nThis study explores the relationship between glycosylation and stemness in HCC.\nThese results provide new directions for further research on the relationship between glycosylation and stemness phenotypes.\nHowever, its function in regulating the acquisition and maintenance of the cancer stemness-like phenotype in HCC remains largely unknown.\nThere is also very little known about how CAD and other potential glycosylation regulators may influence stemness.", "dois": ["10.3389/fonc.2022.913432"]}
{"pair_type": "slc_pathway", "key1": "SLC40A1", "key2": "oxidative phosphorylation", "summary": "As a co-activator of N-methyl-D-aspartate receptor (NMDAR), sarcosine also exerted its pro-ferroptosis effect via regulating ferrous export through the NMDAR/MXD3/SLC40A1 axis.\nMetabolic flux analysis showed limited conversion of sarcosine to other metabolites in LUAD cells, while untargeted metabolomic profiling and seahorse assays indicated a metabolic shift from glycolysis to oxidative phosphorylation.\nSarcosine enhanced pyruvate dehydrogenase activity to generate more ROS by interacting with PDK4, reducing PDHA1 phosphorylation.\nAccordingly, the main pathways disturbed include metabolic pathways, proteasome, oxidative phosphorylation, cancer, etc.\nBy gene ontology analyses, these differentially expressed genes were significantly enriched in several major biological processes including oxidation reduction, translation, iron ion transport, cell redox, homeostasis, etc.\nFinally, at least four of these genes, frh3 (ferrintin H3), mgst1 (microsomal glutathione S-transferase-like), cmbl (carboxymethylenebutenolidase homolog) and slc40a1 (solute carrier family 40 [iron-regulated transporter], member 1) could be confirmed in individual medaka fish similarly treated by arsenic;", "dois": ["10.1186/s40164-025-00657-0", "10.1371/journal.pone.0068737"]}
{"pair_type": "slc_pathway", "key1": "SLC51B", "key2": "oxidative stress", "summary": "FXR agonist upregulated the expression of lipid and glutathione metabolism-related genes and downregulated cell death-related genes.\nFXR deficiency exhibited more ferroptosis responses, such as increase in lipid peroxidation, iron content and heme oxygenase 1 protein, and a decrease in glutathione/glutathione disulfide ratio and glutathione peroxidase 4 levels in HK2 cells and mice.\nFenofibrate binds tightly to MOXD1 and PDZK1IP1, inhibits their hepatic expression independently of PPAR-α signalling, and ameliorates lipid deposition, oxidative stress and inflammatory responses in NIAAA model mice.\nAdditionally, chromatin immunoprecipitation assays, using mice renal tissues, revealed that agonist-activated FXR could bind to its known target genes (Slc51a, Slc51b, Osgin1, and Mafg) and ferroptosis-related genes (Aifm2, Ggt6, and Gsta4).\nThese findings indicate that activated FXR regulates the transcription of ferroptosis-related genes and protects against cisplatin-induced acute kidney injury by regulating the transcription of ferroptosis-related genes.\nPrevious studies have reported that cisplatin induces ferroptosis and lipid peroxide accumulation.\nIncreased blood urea nitrogen, serum creatinine, and ferroptotic responses in the cisplatin-induced AKI mouse model were mitigated upon treatment with the FXR agonist GW4064 but were exacerbated in FXR knockout mice.\nHepatic MOXD1 and PDZK1IP1 expression was elevated in patients with ALD and NIAAA model mice, with no significant difference in SLC51B expression between the groups.\nWe also analysed the binding affinity of fenofibrate to proteins of hub genes using molecular docking techniques, and the effects on hub gene expression, lipid deposition, oxidative stress and inflammation in the liver of National Institute on Alcohol Abuse and Alcoholism (NIAAA) model mice.", "dois": ["10.1016/j.lfs.2023.122321", "10.1016/j.redox.2022.102382"]}
{"pair_type": "slc_pathway", "key1": "SLC52A1", "key2": "proliferation", "summary": "Interestingly, increased expression of SLC52A1 suppresses cellular senescence through the uptake of riboflavin and an increase in intracellular flavin adenine dinucleotide (FAD), an enzyme cofactor synthesized from riboflavin.\nCollectively, these results suggest that the FAD increase by senescence-inducing stress leads to LSD1-mediated demethylation of histone H3 and p53, which results in the suppression of pro-senescence genes to inhibit senescence induction.\nFirst, we found that LSD1 inhibition promoted DNA damage-induced cellular senescence, whereas ectopic expression of LSD1 suppressed cellular senescence, suggesting that LSD1 suppresses senescence.\nWe have recently identified the riboflavin transporter SLC52A1, whose expression is increased in response to senescence-inducing stimuli.\nHowever, how FAD suppresses cellular senescence has not been fully elucidated.\nIn addition, the demethylation activity of LSD1 against histone H3 and p53 was increased by senescence-inducing stress in a riboflavin uptake-dependent manner.\nFurthermore, it was revealed that the LSD1 demethylation activity was required for suppression of pro-senescence genes Sirtuin-4 and p21 whose expression is modified by methylation status of histone H3 and possibly p53, respectively.\nCellular senescence is defined as a permanent proliferation arrest caused by various stresses, including DNA damage.", "dois": ["10.1038/s41598-025-91004-0"]}
{"pair_type": "slc_pathway", "key1": "SLC52A2", "key2": "apoptosis", "summary": "After FFAR2 was silenced, the promoting role of AKK in the viability and M1 to M2 macrophage polarization and the inhibitory role in oxidative stress, inflammation, apoptosis, energy metabolism disorder, necroptosis, and pyroptosis were both reverted.\nConclusively, AKK might mediate SCFAs-SLC52A2/FFAR2 pathways to exert protective activities against intestinal inflammatory response in UC, suggesting that AKK might represent a novel and promising candidate for UC therapy.\nFlow cytometry measured cell apoptosis and macrophage polarization.\nThen, a cuproptosis-related gene signature (PGK1, SLC52A2, SEC14L2, RAD23B, SLC16A6, CCL5, and MAL2) and the scoring system were constructed to quantify the cuproptosis pattern of BRCA patients in the training cohort, and the testing cohorts validated them.\nAKK reduced the pathological damage of mice colon tissues, alleviated oxidative stress and inflammatory response, upregulated the expression of Occludin-1 and SCFAs receptors, and stimulated M1 to M2 macrophage polarization in vivo.\nCuproptosis is a newly discovered programmed cell death dependent on overload copper-induced mitochondrial respiration dysregulation.\nThe expression and mutation patterns of 12 cuproptosis-related genes were systematically evaluated in the BRCA training group.\nOur results confirmed the essential function of cuproptosis in regulating the progression, prognosis, immune cell infiltration, and response to breast cancer immunotherapy.", "dois": ["10.3389/fimmu.2022.978909", "10.1007/s00210-025-03787-8"]}
{"pair_type": "slc_pathway", "key1": "SLC52A2", "key2": "proliferation", "summary": "Moreover, knockdown of 5 ERIGs of this signature contributed to the suppression the Hep3B cell proliferation.", "dois": ["10.1186/s12885-022-10463-0"]}
{"pair_type": "slc_pathway", "key1": "SLC52A2", "key2": "chemotherapy", "summary": "Quantifying cuproptosis patterns and constructing a CRG_score could help explore the potential molecular mechanisms of cuproptosis regulating BRCA advancement and provide more effective immunotherapy and chemotherapy targets.\nHe was misdiagnosed with pure red cell aplasia (PRCA) and treated with hormones and chemotherapy drugs, but there was no obvious effect.\nThen, a cuproptosis-related gene signature (PGK1, SLC52A2, SEC14L2, RAD23B, SLC16A6, CCL5, and MAL2) and the scoring system were constructed to quantify the cuproptosis pattern of BRCA patients in the training cohort, and the testing cohorts validated them.\nOur results confirmed the essential function of cuproptosis in regulating the progression, prognosis, immune cell infiltration, and response to breast cancer immunotherapy.\nFinally, we screened out RAD23B as a favorable target and indicated its expression was associated with breast cancer progression, drug resistance, and poor prognosis in BRCA patients by performing real-time RT-PCR, cell viability, and IC50 assay.\nSpecifically, patients from the low-CRG_score group were characterized by higher immune cell infiltration, immune checkpoint expression, immune checkpoint inhibitor (ICI) scores, and greater sensitivity to immunotherapy.", "dois": ["10.3389/fimmu.2022.978909", "10.1016/j.cca.2021.10.031"]}
{"pair_type": "slc_pathway", "key1": "SLC52A3", "key2": "chemotherapy", "summary": "The chemotherapy response of each GBM patient was predicted based on the public pharmacogenomic database, Genomics of Drug Sensitivity in Cancer (GDSC, http://www.cancerrxgene.org).\nThe R package \"pRRophetic\" was applied to drug sensitivity (IC50) value prediction.\nThis study established a transcription factor-based risk model to predict the prognosis of PC and potential therapeutic drugs.", "dois": ["10.1155/2021/6894278"]}
{"pair_type": "slc_pathway", "key1": "SLC52A2", "key2": "oxidative stress", "summary": "After FFAR2 was silenced, the promoting role of AKK in the viability and M1 to M2 macrophage polarization and the inhibitory role in oxidative stress, inflammation, apoptosis, energy metabolism disorder, necroptosis, and pyroptosis were both reverted.\nAKK reduced the pathological damage of mice colon tissues, alleviated oxidative stress and inflammatory response, upregulated the expression of Occludin-1 and SCFAs receptors, and stimulated M1 to M2 macrophage polarization in vivo.\nConclusively, AKK might mediate SCFAs-SLC52A2/FFAR2 pathways to exert protective activities against intestinal inflammatory response in UC, suggesting that AKK might represent a novel and promising candidate for UC therapy.\nIn an in vitro psoriatic keratinocyte model, riboflavin reduction induced upregulation of inflammatory cytokines, ROS response and delayed keratinisation.\nPsoriasis is a chronic inflammatory skin disease characterised by oxidative stress in the epidermis.\nRiboflavin (vitamin B2), an essential vitamin with antioxidant properties, may play a role in modulating this condition.\nIn this context, patient specific RTD models, based on induced pluripotent stem cell (iPSC) technology, have provided evidence of redox imbalance, involving mitochondrial and peroxisomal dysfunction.\nSuch oxidative stress condition likely causes cytoskeletal perturbation, associated with impaired differentiation of RTD motor neurons.\nAmong the antioxidants tested, EPI-743 restored the redox status, improved neurite length and ameliorated intracellular calcium influx into RTD motoneurons.\nTranscriptome analysis of data series GSE41662 and GSE121212", "dois": ["10.1007/s00210-025-03787-8", "10.1128/mBio.01704-20", "10.1111/exd.70106", "10.3390/biomedicines10061329", "10.3390/ijms21197402"]}
{"pair_type": "slc_pathway", "key1": "SLC52A3", "key2": "migration", "summary": "In vitro, it was revealed that rs13042395 C allele had higher binding affinity to inhibitory transcription factor Meis homeobox 1 (MEIS1) compared with T allele, knock-down of MEIS1 could up-regulate SLC52A3, and overexpression of SLC52A3 contributed to the increased ability of proliferation, colony formation, migration and invasion in GCa cells.\nSLC52A3 promoted the GCa cells aggressiveness by down-regulating the GJA1 expression.\nSubsequently, the bioinformatics analysis combined with experiments in vitro suggested that Gap junction protein alpha 1 (GJA1) was the downstream effector of SLC52A3, SLC52A3 may promote the GCa cells aggressiveness by down-regulating the GJA1 expression.", "dois": ["10.1111/jcmm.15798", "10.1097/WNR.0000000000000674"]}
{"pair_type": "slc_pathway", "key1": "SLC52A3", "key2": "apoptosis", "summary": "Knockdown of RFT2 also reduced anti-apoptotic proteins Bcl-2, Bcl-xl and survivin levels, caused activation of caspase-3 and apoptosis.\nLoss of mutant embryos was associated with both defects in placental formation and increased rates of apoptosis in embryonic cells.\nIn contrast, ectopic overexpression of RFT2 in ESCC cells promoted cell proliferation under restricted conditions (soft agar), conferred resistance to cisplatin, and enhanced tumorigenicity in nude mice.\nKnockdown of RFT2 in ESCC cells resulted in decreases of intracellular flavin status, mitochondrial membrane potential and cellular ATP levels, and inhibitions of cell proliferation, colony formation and anchorage-independent growth.", "dois": ["10.1097/WNR.0000000000000674", "10.1016/j.canlet.2014.07.013", "10.1093/hmg/ddw053"]}
{"pair_type": "slc_pathway", "key1": "SLC52A3", "key2": "proliferation", "summary": "In vitro, it was revealed that rs13042395 C allele had higher binding affinity to inhibitory transcription factor Meis homeobox 1 (MEIS1) compared with T allele, knock-down of MEIS1 could up-regulate SLC52A3, and overexpression of SLC52A3 contributed to the increased ability of proliferation, colony formation, migration and invasion in GCa cells.\nFunctionally, SLC52A3a, but not SLC52A3b, strongly promotes the proliferation and colony formation of ESCC cells.\nSLC52A3 promoted the GCa cells aggressiveness by down-regulating the GJA1 expression.\nAccordingly, NF-κB signaling upregulates SLC52A3 transcription upon TNFα stimulation.\nKnockdown of RFT2 also reduced anti-apoptotic proteins Bcl-2, Bcl-xl and survivin levels, caused activation of caspase-3 and apoptosis.\nKnockdown of RFT2 increased p21 and p27 protein levels, decreased their downstream targets cyclin E1 and Cdk2 protein levels and caused pRb hypophosphorylation, leading to cell cycle arrest at G1-G1/S.\nSubsequently, the bioinformatics analysis combined with experiments in vitro suggested that Gap junction protein alpha 1 (GJA1) was the downstream effector of SLC52A3, SLC52A3 may promote the GCa cells aggressiveness by down-regulating the GJA1 expression.\nIn contrast, ectopic overexpression of RFT2 in ESCC cells promoted cell proliferation under restricted conditions (soft agar), conferred resistance to cisplatin, and enhanced tumorigenicity in nude mice.\nKnockdown of RFT2 in ESCC cells resulted in decreases of intracellular flavin status, mitochondrial membrane potential and cellular ATP levels, and inhibitions of cell proliferation, colony formation and anchorage-independent growth.\nValidation experiments also found that riboflavin depletion decreased p21 and p27 protein levels by ∼20%,", "dois": ["10.1111/jcmm.15798", "10.1093/jn/nxy047", "10.1007/s00018-018-2757-4", "10.1097/WNR.0000000000000674", "10.1152/ajpgi.00340.2015", "10.1016/j.canlet.2014.07.013"]}
{"pair_type": "slc_pathway", "key1": "SLC52A3", "key2": "oxidative stress", "summary": "Transcriptome analysis of data series GSE41662 and GSE121212 demonstrated upregulation of riboflavin metabolising genes (SLC52A2, SLC52A3, RFK, FLAD1 and SLC25A32) in psoriatic lesional skin.\nPsoriasis is a chronic inflammatory skin disease characterised by oxidative stress in the epidermis.\nWe also observed a significant increase in the level of expression of oxidative stress-responsive genes in the intestine of the cKO mice compared with control littermates.\nSupplementation of the RFVT-3 cKO mice with pharmacological doses of RF led to a complete correction of the growth retardation and to normalization in the level of expression of the oxidative stress-responsive genes in the gut.\nIn an in vitro psoriatic keratinocyte model, riboflavin reduction induced upregulation of inflammatory cytokines, ROS response and delayed keratinisation.\nSuch oxidative stress condition likely causes cytoskeletal perturbation, associated with impaired differentiation of RTD motor neurons.\nIn this context, patient specific RTD models, based on induced pluripotent stem cell (iPSC) technology, have provided evidence of redox imbalance, involving mitochondrial and peroxisomal dysfunction.\nAmong the antioxidants tested, EPI-743 restored the redox status, improved neurite length and ameliorated intracellular calcium influx into RTD motoneurons.\nRiboflavin (vitamin B2), an essential vitamin with antioxidant properties, may play a role in modulating this condition.\nMitochondrial dysfunction is a key element in the pathogenesis of neurodegenerative disorders, such as riboflavin transporter deficiency (RTD).\nRecent studies have highlighted concurrent pathogenic contribution of cellular energy dysmetabol", "dois": ["10.1152/ajpgi.00340.2015", "10.1111/exd.70106", "10.3390/biomedicines10061329", "10.3390/ijms21197402"]}
{"pair_type": "slc_pathway", "key1": "SLC53A1", "key2": "chemotherapy", "summary": "Here we show that knockdown of the phosphate exporter XPR1/SLC53A1 induces the growth arrest and apoptosis of OCCC cells in vitro.\nMoreover, we show that knockdown of XPR1/SLC53A1 inhibits the proliferation of OCCC cells xenografted into immunocompromised mice.\nThese results suggest that XPR1/SLC53A1 plays a critical role in the tumorigenesis of OCCC cells.\nWe speculate that XPR1/SLC53A1 might be a promising molecular target for the therapeutic treatment of OCCC.\nOvarian clear cell carcinoma (OCCC) is a chemotherapy-resistant epithelial ovarian cancer with poor prognosis.", "dois": ["10.1111/cas.15358"]}
{"pair_type": "slc_pathway", "key1": "SLC40A1", "key2": "proliferation", "summary": "The PI3K/AKT signaling pathway mediates TBMS1-induced ferroptosis, which was accompanied by altered expression of NRF2, SLC40A1, and GPX4, ultimately suppressing cell proliferation and collagen synthesis.\nSpecific immune cell subsets, such as Naive T_RGCC, CTL_TYROBP_CL4, Mac_SLC40A1, and M1_CCL3L1, likely contribute to DFU formation through overactivation and proliferation, leading to tissue damage and ulcer exacerbation.\nThese findings support the involvement of HAMP-SLC40A1 signaling in aberrant hepatocyte proliferation in the HCC microenvironment.\nThe natural IGF1R inhibitor PPP induced ferroptosis through blockage of PI3K/AKT/NRF2 signaling pathway and subsequent inhibition of downstream gene expression of SLC7A11 and SLC40A1 in hepatocellular carcinoma.\nCell proliferation assay demonstrated that miR-18a-5p promoted prostate cancer cell proliferation.\nmiR-18a-5p expression was found upregulated in human prostate cancer tissues while SLC40A1 was down-regulated.\nSLC40A1 knockdown by siRNA abrogated the inhibitory effect of Leo on prostate cancer progression.\nstudies indicated that TBMS1 hindered HSFs proliferation, migration, and myofibroblast activation.\nRestoration of SLC40A1 reversed the effects of miR-18a-5p in prostate cancer cells.\nMoreover, we noticed that miR-18a-5p was downregulated and the solute carrier family 40 member 1 (SLC40A1) is upregulated by Leo treatment.\nWe also found SLC40A1 was downregulated by miR-18a-5p in prostate cancer cell lines.\nTaken together, our results suggest that miR-18a-5p might function as a tumor-promoting factor in PCa and might contribute to its proliferation", "dois": ["10.3390/genes16101166", "10.3389/fphar.2025.1654108", "10.1016/j.taap.2025.117533", "10.1016/j.bbrc.2025.152417", "10.3389/fphar.2025.1567942", "10.1016/j.phymed.2025.156840", "10.1186/s40001-024-02179-7", "10.1016/j.ijbiomac.2024.138841", "10.1080/00207454.2024.2401661", "10.1016/j.toxicon.2023.107529", "10.4103/cjop.CJOP-D-22-00152", "10.4103/0304-4920.365459", "10.1155/2022/4213401", "10.1016/j.prp.2021.153448", "10.1186/s12920-021-00977-0", "10.1093/abbs/gmab059", "10.3389/fphys.2020.589351", "10.18632/oncotarget.27844", "10.1016/j.redox.2019.101297", "10.1074/jbc.RA117.000834", "10.1007/s00223-015-0087-1", "PMID:20392994"]}
{"pair_type": "slc_pathway", "key1": "SLC53A1", "key2": "apoptosis", "summary": "Here we show that knockdown of the phosphate exporter XPR1/SLC53A1 induces the growth arrest and apoptosis of OCCC cells in vitro.", "dois": ["10.1111/cas.15358"]}
{"pair_type": "slc_pathway", "key1": "SLC53A1", "key2": "proliferation", "summary": "Moreover, we show that knockdown of XPR1/SLC53A1 inhibits the proliferation of OCCC cells xenografted into immunocompromised mice.\nHere we show that knockdown of the phosphate exporter XPR1/SLC53A1 induces the growth arrest and apoptosis of OCCC cells in vitro.\nThese results suggest that XPR1/SLC53A1 plays a critical role in the tumorigenesis of OCCC cells.", "dois": ["10.1111/cas.15358"]}
{"pair_type": "slc_pathway", "key1": "SLC4A10", "key2": "chemotherapy", "summary": "Patients in the long-survival group exhibited enrichment of IL7R NK cells, SLC4A10 CD8 T cells, and dendritic cells, which were significantly associated with longer PFS.\nWe retrospectively analyzed 96 treatment-naïve patients with advanced NSCLC who received first-line ICI-based regimens (anti-PD-1 ± platinum chemotherapy) at Hunan Cancer Hospital.", "dois": ["10.1186/s12967-025-07408-z"]}
{"pair_type": "slc_pathway", "key1": "SLC4A1", "key2": "glycolysis", "summary": "In humanized mice, truncation of the Band 3 N-terminus disrupted glycolytic activation, reduced 2,3-bisphosphoglycerate synthesis, and impaired exercise tolerance despite preserved cardiopulmonary function, establishing the physiological relevance of this module.\nMechanistically, BLVRB Cys109 acts as a nitric oxide (NO) relay, trans-nitrosating glycolytic enzymes such as GAPDH at active site Cys152, transiently inhibiting glycolysis.\ndefine the most comprehensive proteome of ultra-pure human red blood cells (3,775 proteins) and map the O₂-dependent interactome, revealing a Band 3-BLVRB-hemoglobin module that links oxygen sensing to metabolic remodeling via reversible inhibitory S-nitrosation of GAPDH C152.\nUsing deep proteomics of ultra-pure RBCs and cross-linking interactomics, we identify biliverdin reductase B (BLVRB) as a previously unrecognized Band 3 interactor that binds the N-terminal cytosolic domain under normoxia and dissociates under hypoxia, when band 3-deoxyhemoglobin interactions increase threefold.\nHere, we define the erythrocyte as an oxygen-responsive system organized around a Band 3 (SLC4A1)-centered metabolon.\nO2-dependent BLVRB-Band 3 binding regulates metabolism via S-nitrosation of GAPDH\nBand 3 N-terminus is required for hypoxic remodeling and exercise tolerance in vivo.\nThis reversible interaction forms an oxygen-sensitive switch coupling structural, redox, and metabolic remodeling.\nCollectively, our findings define a Band 3-BLVRB-hemoglobin axis that links oxygen sensing, NO signaling, and redox homeostasis, providing a unifying model for how an anucleate cell achieves environmental adaptability through reversible protein-protein interactions and post-translational chemistry.\nThis S-nitrosation-mediated feedback mirrors conserved mechanisms in plants, where GAPDH-SNO redirects carbon flow toward the Calvin-Benson cycle under nitros", "dois": ["10.1101/2025.11.29.691178", "10.1074/jbc.RA118.006393"]}
{"pair_type": "slc_pathway", "key1": "SLC8A2", "key2": "migration", "summary": "Overexpression of SLC8A2 had no effect on cell proliferation or cell cycle, but impaired the invasion and migration of U87MG cells, most likely through inactivating the extracellular signal-related kinases (ERK)1/2 signaling pathway, inhibiting the nuclear translocation and DNA binding activity of nuclear factor kappa B (NF-κB), reducing the level of matrix metalloproteinases (MMPs) and urokinase-type plasminogen activator (uPA)-its receptor (uPAR) system (ERK1/2-NF-κB-MMPs/uPA-uPAR), and altering the protein levels of epithelial to mesenchymal transitions (EMT)-associated proteins E-cardherin, vimentin and Snail.\nSLC8A2 serves as a tumor suppressor gene and inhibits invasion, angiogenesis and growth of glioblastoma.\nIn addition, SLC8A2 inhibited the angiogenesis of U87MG cells, probably through combined inhibition of endothelium-dependent and endothelium-nondependent angiogenesis (vascular mimicry pattern).\nIn the present study, we found that the tumorigenicity of U87MG in nude mice was totally inhibited by SLC8A2.\nTherefore, we hypothesized that SLC8A2 might be a glioma tumor suppressor gene and detected the role of SLC8A2 in glioblastoma and explored the underlying molecular mechanism.\nFinally, we identified two previously unreported model genes (SLC8A3 and SLC24A4) that contribute to the growth and migration of colorectal cancer RKO cells.\nFinally, we confirmed that these 3 genes might promotes glioma proliferation and migration in vitro.", "dois": ["10.1007/s12672-024-01653-2", "10.7717/peerj.17582", "10.14348/molcells.2017.0104"]}
{"pair_type": "slc_pathway", "key1": "SLC8A1", "key2": "oxidative stress", "summary": "SAX exposure progressively upregulated the expression of SLC8A1, and CAMK2D while markedly inhibited the expression of RYR2, ATP2A2, CASQ2, CACNA1C, and PLN in dose-response manner.\nIn this study, we investigated the potential involvement of circSLC8A1 in epilepsy progression and its connection to ferroptosis and oxidative stress.\nAdditionally, circRNA SLC8A1 (circSLC8A1) has been implicated in various neurological disorders and oxidative stress-related diseases but its involvement in epilepsy progression, particularly in relation to ferroptosis and oxidative stress, remains unclear.\nThe results showed that the mRNA expression levels of ITPR 1, ITPR 2, RyR2, RyR3, SERCA1s, SLC8A1, PMCA1, CACNA1S, CaLM and CRT were generally decreased by Se deficiency, while mRNA expression levels of TRPC1, TRPC3, stromal interacting molecule 1, ORAI1 and ITPR3 were increased by Se deficiency.\nMoreover, SAX administration provoked redox alterations via inhibiting the activities of HO-1, SOD, GPx, GSR, GST, and CAT while augmenting the levels of ROS and MDA.\nIn conclusion, the results demonstrated that Se deficiency might cause heart injury via modulating the Ca-related pathway genes, and then induce Ca overload in the heart of broilers.\nFerroptosis, a recently defined iron-dependent regulated cell death, has been suggested as a potential therapeutic target for epilepsy due to its association with oxidative stress.\nOur findings demonstrate that circSLC8A1 triggers neuronal ferroptosis by stabilizing ATF3 mRNA expression through recruitment with FUS.\nA growing body of research indicates that changes in circular RNAs (circ-RNAs) were observed in CKD with pathogenic implications, including modifying intracellular signaling, exaggerating oxidative stress, cellular apoptosis and inflammation.", "dois": ["10.1080/03079457.2016.1259528", "10.1016/j.tice.2025.103238", "10.1016/j.toxrep.2025.102058", "10.1016/j.yexcr.2023.113848"]}
{"pair_type": "slc_pathway", "key1": "SLC9B2", "key2": "apoptosis", "summary": "In contrast, risk factors included TIM14 and AIFM1 for any ischemic stroke, MRPL32 and SLC9B2 for large artery stroke, AIFM1 and HOGA1 for cardioembolic stroke, and SOD2, GRPEL1, and AIFM1 for small vessel stroke.\nMitochondrial dysfunction, particularly in energy metabolism, oxidative stress, and apoptosis, has long been implicated in stroke pathogenesis.", "dois": ["10.1016/j.jad.2025.120832"]}
{"pair_type": "slc_pathway", "key1": "SLC2A2", "key2": "ferroptosis", "summary": "It downregulates Slc2a2, counteracts ferroptosis, and is associated with improved motor and cognitive performance in mice.\nGene-set enrichment indicated activation of mitochondrial damage-related pathways in neurons, a hallmark of ferroptosis.\nFerroptosis emerged as the dominant program.\nThis study advances understanding of mTBI pathogenesis at single-cell resolution, identifying ferroptosis as a critical determinant of neuronal death and uncovering Tmsb4x as a promising therapeutic target for mitigating cognitive dysfunction.\nFunctional assays show that the c-Jun-regulated gene Tmsb4x protects hippocampal neurons after mTBI.\nNeuronal death in the hippocampus following mild traumatic brain injury (mTBI) is a hallmark of cognitive dysfunction, yet the underlying molecular mechanisms remain poorly understood.", "dois": ["10.1002/advs.202512362"]}
{"pair_type": "slc_pathway", "key1": "SLC9B2", "key2": "oxidative stress", "summary": "In contrast, risk factors included TIM14 and AIFM1 for any ischemic stroke, MRPL32 and SLC9B2 for large artery stroke, AIFM1 and HOGA1 for cardioembolic stroke, and SOD2, GRPEL1, and AIFM1 for small vessel stroke.\nMitochondrial dysfunction, particularly in energy metabolism, oxidative stress, and apoptosis, has long been implicated in stroke pathogenesis.", "dois": ["10.1016/j.jad.2025.120832"]}
{"pair_type": "slc_pathway", "key1": "SLC12A4", "key2": "oxidative stress", "summary": "Interfering with SLC12A2 expression or function resulted in a significant increase in apoptotic corpse uptake per phagocyte, whereas the loss of SLC12A4 inhibited corpse uptake.\nCollectively, the WNK1-OSR1-SPAK-SLC12A2/SLC12A4 chloride-sensing pathway and chloride flux in phagocytes are key modifiers of the manner in which phagocytes interpret the engulfed apoptotic corpse.\nIn SLC12A2-deficient phagocytes, the canonical anti-inflammatory program was replaced by pro-inflammatory and oxidative-stress-associated gene programs.\nThis 'switch' to pro-inflammatory sensing of apoptotic cells resulted from the disruption of the chloride-sensing pathway (and not due to corpse overload or poor degradation), including the chloride-sensing kinases WNK1, OSR1 and SPAK-which function upstream of SLC12A2-had a similar effect on efferocytosis.", "dois": ["10.1038/s41556-019-0431-1"]}
{"pair_type": "slc_pathway", "key1": "SLC15A4", "key2": "oxidative phosphorylation", "summary": "IRF5 and SLC15A4, which are regulated by polymorphisms associated with SLE susceptibility, are functionally associated with OXPHOS as well as blood interferon activity and metabolome.\nIn particular, activation of the OXPHOS pathway is persistent in inactive SLE, and this activation is associated with organ damage.\nRecently, analysis of a functional genome database of genetic polymorphisms and transcriptomic data from various immune cell subsets revealed the importance of the oxidative phosphorylation (OXPHOS) pathway in the pathogenesis of SLE.\nThe finding that hydroxychloroquine (HCQ), which improves the prognosis of SLE, targets toll-like receptor (TLR) signaling upstream of OXPHOS suggests the clinical importance of this pathway.\nFuture analyses of OXPHOS-associated disease-susceptibility polymorphisms, gene expression, and protein function may be useful for risk stratification of SLE.", "dois": ["10.3390/biom13040591"]}
{"pair_type": "slc_pathway", "key1": "SLC39A9", "key2": "migration", "summary": "Dutasteride treatment led to significant inhibition of the testosterone-induced increase dependent on AR and SLC39A9 in cell viability and migration of T24 and J82 BCa cells and induced alterations in the expression level of cancer progression proteins, such as metalloproteases, p21, BCL-2, NF-KB, and WNT in AR-negative BCa.\nMechanism dissection revealed that DHT/mAR-SLC39A9 might function by altering G protein-mediated MAPK/MMP9 intracellular signaling to increase nAR-negative BCa cell migration and invasion.\nVascular endothelial cell migration also increased after treatment with testosterone, but not after treatment with BSA-T or androstenedione, suggesting that androgens stimulate vascular endothelial cell migration through nuclear AR but not SLC39A9.\nTo dissect the androgens potential impacts on these nAR-negative muscle invasive BCa, we first found that the androgens, dihydrotestosterone (DHT) might function via a novel membrane AR (mAR-SLC39A9) to increase nAR-negative BCa cell migration and invasion.\nExpression of migration markers MYL9 and CYR61 was elevated in ZIP9 cells and further increased together with cell migration by forskolin treatment and blocked with H-89, indicating they are mediated through an AC/PKA pathway.\nAlso, Dutasteride treatment reduced cell proliferation and migration via blocking the SRD5A1 in BCa.\nTestosterone treatment further increased migration, biomarker expression and zinc in ZIP9 cells, suggesting it may act through similar pathways to induce tumorigenic responses.\nTogether, these results suggest that androgens may not only function via the classic nAR to increase the nAR-positive BCa cell invasion, they may also function via this newly identified mAR-SLC39A9 to increase the nAR-negative/mAR-positive BCa cell invasion.\nPreclinical studies using multiple in vitro nAR-negative BCa cell lines and an in vivo mouse model all demonstrated that targeting this newly identified DHT/mAR-SLC39A9/G/MAP", "dois": ["10.1210/endocr/bqae071", "10.1016/j.mce.2023.112060", "10.1186/s12967-023-03972-4", "10.1038/s41388-019-0964-6", "PMID:27654922"]}
{"pair_type": "slc_pathway", "key1": "SLC15A3", "key2": "proliferation", "summary": "The proliferation, cell cycle progression, migration, and invasion of MNNG/HOS cells were significantly inhibited after transfection with FES overexpression plasmid, and the protein expression of FYN and β catenin were decreased in MNNG/HOS cells by FES overexpression.\nThe decrease in FES by hypermethylation was associated with OS prognosis, and might contribute to the proliferation, migration, and invasion of OS cells.\nThese 40 genes were enriched in processes related to immune activation, such as the acute-phase response, cellular responses to external stimuli, and cell population proliferation.\nFES, and its upstream FYN and β catenin, might coordinately exert a tumor suppressor effect in OS cells.\nThe effects of FES overexpression on cell proliferation, cell cycle, migration, and invasion of MNNG/HOS were analyzed by CCK8, flow cytometry, and Transwell assays.", "dois": ["10.1016/j.jaci.2023.10.027", "10.1186/s12935-020-01181-3"]}
{"pair_type": "slc_pathway", "key1": "SLC8A1", "key2": "proliferation", "summary": "Functionally, LKB1 loss enhances proliferation and survival through SIK2 inhibition and upregulation of the sodium/calcium (Na /Ca ) exchanger SLC8A1.\nDown-regulation of the SLC8A1 gene, most likely mediated by its regulator miR-223, can lead to decreased calcium in penile carcinoma and consequently to suppressed apoptosis and increased tumor cell proliferation.\nWe demonstrated that SLC8A1 selective pharmacological inhibition, through CB-DMB, significantly reduced cancer proliferation and induced Ca-dependent cell death in GC cells, both alone and synergically with cisplatin treatment.\nThe results of experiments revealed that SLC8A1 promotes proliferation and inhibits the apoptosis and concentration of calcium ions in HTR-8/SVneo cells.\nExogenous overexpression of ZNF503-AS1 or SLC8A1 attenuated bladder cancer cell proliferation, invasion and migration, but promoted their apoptosis, accompanied by decreased Ca-ATPase activities and increased intracellular Ca concentrations.\nDown-regulation of lncRNA SLC8A1-AS1 suppressed the proliferation, colony formation, migration, and invasion of glioma cells in vitro and in vivo.\nCircRNA_SLC8A1 inhibits the proliferation, migration, EMT, and collagen deposition of HSF through competitive binding with miRNA-27a-3p, thereby activating the Nrf2-ARE pathway.\nZNF503-AS1 can recruit transcription factor GATA6 to up-regulate SLC8A1 expression, thereby increasing the intracellular Ca concentration and repressing the proliferation, invasion and migration, and enhancing the apoptosis of bladder cancer cells.\nOverexpression of circSLC8A1 significantly inhibited the proliferation and invasion of NSCLC cells.\nOver-expression of circSLC8A1 inhibited cell migration, invasion and proliferation both in vitro and in vivo.\nMiR-106b-5p mimics reversed the inhibitory effects of circSLC8A1 overexpression on cell proliferation and invasion.", "dois": ["10.3389/fphys.2025.1687578", "10.1007/s12672-025-03586-w", "10.3389/fvets.2025.1634086", "10.3389/fgene.2025.1510849", "10.1016/j.biopha.2024.117787", "10.1007/s11033-024-10018-5", "10.1016/j.heliyon.2024.e36899", "10.1038/s44321-024-00114-1", "10.15252/emmm.202317719", "10.1111/iep.12475", "10.3389/fendo.2023.1117111", "10.3390/cells11193156", "10.1080/21655979.2022.2073125", "10.1080/15384101.2021.1995968", "10.1016/j.brainresbull.2021.08.011", "10.1681/ASN.2020101407", "10.1007/s13402-020-00563-z", "10.1186/s12943-019-1040-0", "10.1002/mc.22678", "10.1016/j.juro.2014.11.097"]}
{"pair_type": "slc_pathway", "key1": "SLC13A2", "key2": "stemness", "summary": "High-risk tumors exhibited elevated tumor mutational burden (TMB) and microsatellite instability-high (MSI-H) frequency, while risk scores were inversely associated with stemness.", "dois": ["10.21037/tcr-2025-1329"]}
{"pair_type": "slc_pathway", "key1": "SLC27A2", "key2": "stemness", "summary": "FAO supports ISC renewal, and HNF4 transcription factors directly activate FAO genes, including Acsl5 and Acsf2 (encode regulators of acyl-CoA synthesis), Slc27a2 (encodes a fatty acid transporter), Fabp2 (encodes fatty acid binding protein), and Hadh (encodes hydroxyacyl-CoA dehydrogenase).\nmessenger RNA levels of Lgr5 stem cell markers (Lgr5, Olfm4, Smoc2, Msi1, and Ascl2) were down-regulated in organoids incubated with etomoxir, an inhibitor of FAO, indicating that FAO was required for renewal of ISCs.\nIn mice, the transcription factors HNF4A and HNF4G regulate the expression of genes required for FAO and are required for renewal of ISCs.\nSingle knockout of either HNF4A or HNF4G did not affect maintenance of ISCs, but double-knockout of HNF4A and HNF4G resulted in ISC loss.\nIncubation of organoids derived from double-knockout mice with acetate or dichloroacetate restored stem cells.", "dois": ["10.1053/j.gastro.2019.11.031"]}
{"pair_type": "slc_pathway", "key1": "SLC30A3", "key2": "oxidative phosphorylation", "summary": "Lower expression was strongly associated with impaired synaptic plasticity (long-term potentiation, long-term depression, calcium signaling pathway, and axon guidance), mitochondrial dysfunction (the citrate cycle and oxidative phosphorylation), and pathways common to major neurodegenerative diseases (Parkinson's disease, AD, Huntington's disease, and amyotrophic lateral sclerosis).", "dois": ["10.3390/genes16111380"]}
{"pair_type": "slc_pathway", "key1": "SLC27A3", "key2": "apoptosis", "summary": "The background working of the AMPK pathway through upregulation of AKT1, AMPK, SIRT1, PYGM, SLC2A4 and SERBP1 genes, and downregulation of PPARGCIA, IGF2, PPARA, SLC27A3, SLC16A3, TSC1/2, KCNJ2, KCNJ16, etc., evidence the repression of cellular transcriptional activity and energetic homeostasis modifications in response to heat stress.\nIncreased accumulation of reactive oxygen species and apoptosis was observed in the heat-stress group.\nHigh inflammatory response was found to be responsible for oxidative-stress-mediated apoptosis of GCs and nodes towards the involvement of the NF-κB pathway and repression of the Nrf2 pathway.\nDownregulation of MDM4, TP53, PIDD1, PARP3, MAPK14 and MYC, and upregulation of STK26, STK33, TGFB2, CDKN1A and CDKN2A, at the interface of the MAPK and p53 signaling pathway, can be attributed to transient cellular senescence and apoptosis in GCs.\nIn spite of the upregulation of inflammatory (CYCS, TLR2, TLR4, IL6, etc.), pro-apoptotic (BAD, BAX, TNFSF9, MAP3K7, TNFRSF6B, FADD, TRADD, RIPK3, etc.) and caspase executioner genes (CASP3, CASP8, CASP9), antioxidants and anti-apoptotic genes (HMOX1, NOS2, CAT, SOD, BCL2L1, GPX4, etc.) were also upregulated in heat-stressed GCs.\nAccompanying with the decreased growth, apigenin-treated cells showed a cell cycle arrest at G2/M phase and an increased rate of apoptosis.", "dois": ["10.1016/j.phymed.2010.08.006", "10.3390/cells11091443"]}
{"pair_type": "slc_pathway", "key1": "SLC26A9", "key2": "stemness", "summary": "These results suggest that S9-A13 may act on the SLC26A9-TP53 axis to enable multi-target regulation of TNBC cancer stem cells.\nHowever, the interplay between ion transport, microenvironmental regulation, and classical stemness pathways remains underexplored in existing reviews.\nIn this work, we systematically integrated multi-omics databases, network pharmacology, protein-protein interaction (PPI) analysis, functional pathway enrichment, and molecular modeling to highlight the \"bridging\" role of SLC26A9 and its interacting proteins in TNBC stem cell self-renewal, drug resistance, and microenvironmental regulation.\nCancer stem cells (CSCs) play a crucial role in TNBC recurrence, metastasis, and drug resistance.\nComprehensive molecular docking and 100-ns molecular dynamics (MD) simulations demonstrated that the small molecule S9-A13 exhibited high affinity and stable binding to both SLC26A9 and tumor protein p53 (TP53), with docking affinities of -7.737 and -8.447 kcal/mol and molecular mechanics/generalized Born surface area (MM/GBSA) binding free energies of -34.47 and -25.65 kcal/mol, respectively.\nIn summary, this review provides a structured framework and testable hypotheses for developing SLC26A9-based multi-target precision therapies for TNBC CSCs, while emphasizing that these computational findings are hypothesis-generating and require rigorous experimental and clinical validation prior to translation.", "dois": ["10.3389/fbioe.2025.1703343"]}
{"pair_type": "slc_pathway", "key1": "SLC37A2", "key2": "stemness", "summary": "Similarly, knockdown of SLC37A2, SLC37A3, and G6PC3 was linked to smaller spheroids and reduced expression of GLUT1 and VEGF, without affecting HIF-1α levels.\nHypoxia has been implicated in promoting features associated with cancer stem cell (CSC) phenotypes and chemoresistance.\nSilencing HIF-1α correlated with reduced neurosphere size and a decrease in markers commonly associated with CSC phenotypes.\nDifferential regulation of CSC markers was observed, with PROM1, ABCB5, CD44, and FGFR2 appearing to be influenced by G6PC3/HIF-1α, while ABCG2, DLL1, GATA3, PTCH1, and FLOT2 were more closely associated with SLC37A2/HIF-1α.\nOur findings suggest that GBM-derived 3D neurosphere cultures exhibit HIF-1α-regulated molecular features consistent with CSC and a potential mimicry of chemoresistance-associated traits rather than a direct demonstration of chemoresistance.\nThese correlative observations support a potential link between metabolic reprogramming and the emergence of such phenotypes in response to hypoxic stress.", "dois": ["10.1016/j.bbrc.2025.153050"]}
{"pair_type": "slc_pathway", "key1": "SLC25A39", "key2": "glycolysis", "summary": "In its absence, myoblasts undergo a reductive shift, characterized by mitochondrial elongation, membrane depolarization, and suppression of glycolysis, ultimately leading to growth arrest.\nWe find that continued glutamine oxidation is required to sustain glycolysis, maintain mitochondrial fission, and preserve a redox balance that supports progression towards myogenic commitment.\nDepleting mitochondrial glutathione or silencing Slc25a39 forces exit from PMA.\nMechanistically, PMA is driven by Nrf2-dependent increased glutathione (GSH) biosynthesis and upregulation of mitochondrial GSH carrier Slc25a39 when glutamine is limited.\nTogether, these data suggest that a reciprocal Slc25a39-Nrf2 redox axis functions as a nutrient-dependent checkpoint, coupling glutamine availability to mitochondrial remodeling and metabolic reprogramming, necessary to establish irreversible myogenic commitment.\nConsistent with this, both loss and overexpression of Slc25a39 impair myoblast differentiation in vitro and disrupt regeneration in vivo.", "dois": ["10.1101/2025.10.02.680066"]}
{"pair_type": "slc_pathway", "key1": "SLC39A14", "key2": "ferroptosis", "summary": "IRG1/itaconate can alleviate the TAA-induced hepatic fibrosis in mice by regulating the expression of SLC39A14, consequently suppressing hepatic stellate cell ferroptosis.\nSubsequently, miR-1275 downregulated the expression of SLC39A14, a crucial iron transporter that is upregulated in aged livers and plays a pivotal role in promoting ferroptosis.\nIn addition, deleting hepatic Slc39a14 expression in Trf-LKO mice significantly reduced hepatic iron accumulation, thereby reducing ferroptosis-mediated liver fibrosis induced by either a high-iron diet or CCl4 injections.\nNotably, this study is the first to reveal the pivotal role of SLC39A14 in the pathogenesis of hepatic fibrosis in murine models and elucidate how IRG1/itaconate mediates downstream ferroptosis-related signaling pathways by targeting SLC39A14, thereby inhibiting ferroptosis-induced hepatic fibrosis.\nMoreover, SLC39A14 knockdown also facilitated erastin-induced ferroptosis, leading to the suppression of mouse transplantation tumor growth.\nExosomes derived from hBMSCs delivered abundant miR-16-5p into hepatocytes, which post-transcriptionally suppressed the expression of SLC39A14 and reduced cell ferroptosis induced by hepatic IRI.\nOur research demonstrates that iron overload occurs during VC, and that inhibition of Slc39a14 and Slc39a8 significantly relieves VC by intercepting iron overload-induced ferroptosis in VSMCs, providing new insights into the VC treatment.\nIn summary, CLEC3B promotes chemosensitivity via interacting with SLC39A8 and SLC39A14 to induce ferroptosis.\nSilencing SLC39A14 inhibits ferroptosis and tumor progression, potentially involving the regulation of the cGMP-PKG signaling pathway.\nTFRC ablation led to condylar cartilage thickness and condyle length alterations and induced the ferroptosis of chondrocyte by upregulating SLC39A14.", "dois": ["10.1016/j.ijbiomac.2025.146695", "10.1186/s40001-025-02855-2", "10.1172/jci.insight.189130", "10.1016/j.freeradbiomed.2025.06.018", "10.1021/acs.jafc.4c12006", "10.1038/s41419-025-07733-7", "10.1016/j.burns.2025.107513", "10.1111/febs.70103", "10.3390/ijms26062724", "10.1016/j.redox.2025.103556", "10.1016/j.intimp.2024.113945", "10.1002/advs.202411380", "10.1016/j.cellsig.2024.111416", "10.1016/j.talanta.2024.126839", "10.1016/j.freeradbiomed.2024.08.002", "10.1186/s12933-024-02224-z", "10.1186/s13075-024-03328-3", "10.3724/abbs.2024024", "10.1186/s12885-023-11637-0", "10.1016/j.freeradbiomed.2023.10.381", "10.1186/s12931-023-02429-y", "10.1186/s12906-023-03946-5", "10.1002/jmv.28386", "10.1002/jcsm.12700", "10.1182/blood.2019002907", "10.1038/s41435-025-00364-0", "10.1186/s12935-025-04003-6", "10.34133/bmr.0258", "10.3390/antiox14010096", "10.1016/j.heliyon.2024.e33675", "10.1007/s12672-024-00969-3", "10.1007/s12031-023-02187-y", "10.3390/ijms25020763", "10.3389/fncel.2022.1016682", "10.3389/fmolb.2022.962742", "10.7150/jca.68568"]}
{"pair_type": "slc_pathway", "key1": "SLC37A3", "key2": "stemness", "summary": "Hypoxia has been implicated in promoting features associated with cancer stem cell (CSC) phenotypes and chemoresistance.\nSilencing HIF-1α correlated with reduced neurosphere size and a decrease in markers commonly associated with CSC phenotypes.\nSimilarly, knockdown of SLC37A2, SLC37A3, and G6PC3 was linked to smaller spheroids and reduced expression of GLUT1 and VEGF, without affecting HIF-1α levels.\nDifferential regulation of CSC markers was observed, with PROM1, ABCB5, CD44, and FGFR2 appearing to be influenced by G6PC3/HIF-1α, while ABCG2, DLL1, GATA3, PTCH1, and FLOT2 were more closely associated with SLC37A2/HIF-1α.\nOur findings suggest that GBM-derived 3D neurosphere cultures exhibit HIF-1α-regulated molecular features consistent with CSC and a potential mimicry of chemoresistance-associated traits rather than a direct demonstration of chemoresistance.\nThese correlative observations support a potential link between metabolic reprogramming and the emergence of such phenotypes in response to hypoxic stress.\nThis was accompanied by elevated transcript levels of genes involved in adaptive and angiogenic responses, including GLUT1, VEGF, SLC37A2, SLC37A3, and G6PC3.\nWe observed that neurospheres from human GBM-derived cell lines (U87, U118, U138, and U251) were associated with increased expression of hypoxia-inducible factor (HIF)-1α compared to 2D monolayers.", "dois": ["10.1016/j.bbrc.2025.153050"]}
{"pair_type": "slc_pathway", "key1": "SLC43A1", "key2": "glycolysis", "summary": "Although LI1.29 led to the second highest response in mTORC1 phosphorylation status, it resulted in the lowest phosphorylation of Akt and eEF2 and mRNA abundance of CSN2 and various AA transporters (SLC7A5, SLC36A1, SLC38A2, SLC38A9, SLC43A1).\nCompared with IPAA, metabolomics via gas chromatography-mass spectrometry revealed that increases in availability of Thr, Ile, Val, and Leu led to greater concentrations of essential AA (Leu, Ile, Thr), nonessential AA (Gly, Glu, Gln, Ser, Pro, Asp), and various metabolites including uric acid, phosphoric acid, N-acetylglutamic acid, and intermediates of glycolysis and the tricarboxylic acid cycle.\nOverall, data indicate that an increase in Val at an ideal ratio of Lys:Met could further enhance milk protein synthesis by altering intracellular concentrations of essential AA and metabolites that could play a regulatory role, increasing phosphorylation status of mTORC1 and key signaling proteins, and upregulation of AA transporters.", "dois": ["10.3168/jds.2017-13707"]}
{"pair_type": "slc_pathway", "key1": "SLC39A12", "key2": "ferroptosis", "summary": "Identifying genes linked to iron accumulation could reveal new pathways for neuroprotection and therapeutic targeting.\nNigrostriatal iron accumulation is a hallmark of ageing and neurodegenerative diseases, but the molecular mechanisms regulating iron deposition in the human brain remain unclear.\nOur data implicate a role of coordinated interactions among iron, zinc, and calcium homoeostasis pathways in nigrostriatal iron accumulation in the general population, with region-specific regulation differing between substantia nigra and dorsal striatum.\nReplicated genes converged on metal ion transport and inflammatory pathways, with notable associations involving calcium channel (CACNB2), zinc transporter (SLC39A12/ZIP12), and sorting nexin (SNX31) genes.\nOverlap with Parkinson's disease substantia nigra differential expression data highlighted a subset of genes (5.22%), particularly SLC39A12.\nWe identified 230 genes associated with nigrostriatal iron, of which 40 were replicable.\nThese findings nominate new mechanistic targets for experimental validation in neurodegeneration.", "dois": ["10.1016/j.ebiom.2025.106076"]}
{"pair_type": "slc_pathway", "key1": "SLC12A2", "key2": "oxidative phosphorylation", "summary": "TICs exhibited strong stemness potential, genomic instability, and early activation of epithelial-mesenchymal transition (EMT) and interferon signaling, accompanied by suppression of oxidative phosphorylation.", "dois": ["10.21203/rs.3.rs-7914753/v1"]}
{"pair_type": "slc_pathway", "key1": "SLC40A1", "key2": "oxidative stress", "summary": "SLC40A1 inhibition suppresses osteoblast formation by facilitating iron accumulation and activating the PERK/ATF4/CHOP pathway-mediated oxidative stress.\nDNMT3B induced ferroptosis and oxidative stress in NPCs by downregulating SLC40A1, promoting a degenerative cell phenotype.\nConversely, the cardiomyocyte-specific knockdown of SLC40A1 improved cardiac dysfunction after MI by enhancing mitochondrial function, suppressing oxidative stress, and reducing cardiomyocytes apoptosis.\nPulmonary iron overload is associated with oxidative stress, restrictive lung disease with decreased total lung capacity and reduced blood oxygen saturation in homozygous Slc40a1 mice compared to wild-type controls.\nBioinformatics elucidated that hypermethylated genes were enriched in oxidative stress and ferroptosis, and the ferroptosis suppressor gene SLC40A1 was identified with lower expression and higher methylation in severely degenerated human NP tissue.\nWe highlight the emerging roles of SLC40A1 and GPX4 in coordinating iron balance and mitigating lipid peroxidation to enhance endometrial decidualization.\nDNA methyltransferase DNMT3B aggravates ferroptosis and oxidative stress in NPCs via regulating SLC40A1.\nThis study aimed to investigate the effects of solute carrier family 40 member 1 (SLC40A1) on iron accumulation, oxidative stress and differentiation in osteoblasts and potential mechanisms.\nThe up-regulation of liver genes for heme degradation (Hmox1 and Prdx1), iron cellular transport (Slc40a1), and GSH synthesis and utilization (mGST1 and Gclc) were early markers of the oxidative stress response.\n1,25(OH)D inhibits ferroptosis in zebrafish larvae and ZFL caused by excessive FAC via promoting the expression of slc40a1 and hmox1a genes and increasing SLC40A1 protein levels.\nNRF2 attenuated PQ-induced ferroptosis in A549 cells,", "dois": ["10.1177/15230864251363577", "10.1016/j.cbpc.2025.110285", "10.1186/s12974-025-03373-y", "10.1080/13510002.2024.2428147", "10.1016/j.ijbiomac.2024.136962", "10.1016/j.freeradbiomed.2024.05.007", "10.1016/j.ecoenv.2024.115960", "10.7150/ijbs.89368", "10.1016/j.psj.2023.102976", "10.1016/j.tiv.2023.105655", "10.1111/febs.16272", "10.1074/jbc.RA119.009548", "10.1016/j.neurobiolaging.2013.10.078", "10.1016/j.taap.2010.01.017", "10.3390/v17101302", "10.3390/genes16101166", "10.3390/ijms26199662", "10.1097/MD.0000000000044384", "10.1093/biolre/ioaf198", "10.1111/febs.70101", "10.1038/s41420-025-02421-z", "10.20517/cdr.2024.123", "10.1016/j.heliyon.2024.e33675", "10.1016/j.envpol.2024.123626", "10.1038/s41598-024-54278-4", "10.1016/j.envpol.2024.123332", "10.1186/s40246-023-00562-9", "10.18632/aging.204945", "10.3390/metabo13091005", "10.1242/dev.201690", "10.1016/j.freeradbiomed.2023.04.022", "10.3389/fsurg.2022.1060036", "10.1155/2022/4213401", "10.1016/j.ecoenv.2022.113373", "10.1016/j.freeradbiomed.2021.02.010", "10.1007/s00795-020-00259-1", "10.1016/j.neulet.2018.05.045", "10.1016/j.amjms.2017.08.012", "10.1371/journal.pone.0179889", "10.1016/j.ebiom.2017.04.036", "10.1371/journal.pone.0068737"]}
{"pair_type": "slc_pathway", "key1": "SLC9A9", "key2": "migration", "summary": "NHE9 overexpression leads to an increase in plasma membrane density of epidermal growth factor receptors (EGFRs) which consequently enhances GBM cell proliferation and migration.\nmicroRNA 135a (miR-135a) targets NHE9 to downregulate its expression in U87 cells.\nDownregulation of NHE9 expression by miR-135a affects proliferative and migratory capacity of U87 cells.\nDownregulation of NHE9 expression by miR-135a acidifies sorting endosomes limiting EGFR trafficking to the glioblastoma cell membrane.\nmiR-135a targets NHE9 to inhibit proliferation and migration of glioblastoma cells.\nSelectively increasing NHE9 expression in these cells restored their ability to proliferate and migrate.\nOverexpression of Na/H Exchanger isoform 9 (NHE9) promotes tumor progression and correlates positively with insensitivity to radiochemotherapy and poor prognosis.\nIt is recognized that the overexpression of the endosomal Na /H exchanger NHE9 is a potent driver of GBM progression.\nmiR-135a takes a two-pronged approach affecting epidermal growth factor receptors (EGFRs) to suppress tumor cell growth and migration.\nWhile miR-135a targets EGFR transcripts to decrease the total number of receptors made, by targeting NHE9 it routes the few EGFRs made away from the plasma membrane to dampen oncogenic signaling.\nTranswell assay and monolayer cell migration scratch assay also showed that IDH1-mutant glioma cells reduced migration and invasion capabilities.\nNeuritogenesis was increased in males and showed a strong inverse correlation with Sema5a and Slc9a9 expression levels, whereas, in the females, neuritogenesis was decreased and correlated with Anxa2 and Junb levels.\nSema5a and Slc9a9, which were involved in neuritogenesis and social behaviors, were downregulated only in males, while Anxa2 and Junb, which were", "dois": ["10.1186/s13293-024-00614-2", "10.1038/s41598-023-46335-1", "10.1111/jcmm.14665", "10.1186/s12964-017-0209-7", "10.1007/s00439-009-0663-4"]}
{"pair_type": "slc_pathway", "key1": "SLC41A1", "key2": "glycolysis", "summary": "Mechanistic studies revealed that E-DEVs@Mg enhanced glycolysis and oxidative phosphorylation, restoring the metabolic fitness of exhausted CD8 T cells.\nDendritic cells were genetically modified to overexpress magnesium-specific channel protein MgtE (SLC41A1), enabling efficient Mg encapsulation into dendritic cell-derived EVs (E-DEVs).\nThe resulting Mg-loaded vesicles (E-DEVs@Mg) displayed strong tropism toward tumor-draining lymph nodes (TDLNs) and effectively modulated T-cell metabolism.", "dois": ["10.1021/acsnano.5c14528"]}
{"pair_type": "slc_pathway", "key1": "SLC39A13", "key2": "oxidative stress", "summary": "Notably, ETV4 acts as a repressor of SLC39A13, disrupting metal homeostasis and promoting calcium-dependent lipid peroxidation via cPLA2-ALOX15.\nETV4 knockdown increased SLC39A13 expression, reversing OTA-induced repression.\nWe demonstrated that OTA-induced oxidative stress in porcine intestinal epithelial cells (IPEC-J2) promotes ferroptosis, a lipid peroxidation-driven cell death, through epigenomic dysregulation.\nThese findings demonstrate that OTA triggers ferroptosis through epigenomic remodeling, linking chromatin state changes to disrupted metal homeostasis and calcium-dependent lipid peroxidation, and positioning ferroptosis as a therapeutic target against OTA-induced intestinal injury.\nThe intestinal epithelium serves as a frontline defense against dietary contaminants, such as Ochratoxin A (OTA), a mycotoxin linked to oxidative stress and cell death.\nOTA-treated cells exhibited increased levels of reactive oxygen species, lipid peroxides, and cell death (p ≤ 0.05).\nFerroptosis-related pathways, including lipid peroxidation, iron metabolism, and PUFA metabolism, were enriched.", "dois": ["10.1016/j.ecoenv.2025.119540"]}
{"pair_type": "slc_pathway", "key1": "SLC15A4", "key2": "glycolysis", "summary": "SLC15A4 could be in close proximity to AMP-activated protein kinase (AMPK) and mTOR, and SLC15A4 deficiency impaired TLR-mediated AMPK activation.\nProximity-dependent biotin identification revealed glycolysis as highly enriched gene ontology terms.\nFurthermore, SLC15A4 was required for M1-prone metabolic change and inflammatory IL-12 cytokine productions after TLR9 stimulation.\nFluxome analyses in macrophages indicated that SLC15A4 loss causes insufficient biotransformation of pyruvate to the tricarboxylic acid cycle, while increasing glutaminolysis to the cycle.\nthus, SLC15A4 was critical for macrophage's respiratory homeostasis.\nOur findings reveal a mechanism of metabolic regulation in which an amino acid transporter acts as a gatekeeper that protects immune cells' ability to acquire an M1-prone metabolic phenotype in inflammatory tissues by mitigating metabolic stress.\nAssociations were observed for SNP c.658A>G with carnosine content, color b* and L*, drip and cooking losses, pH24h and glycolytic potential values (P≤0.05).", "dois": ["10.1016/j.meatsci.2017.07.019", "10.1073/pnas.2100295118"]}
{"pair_type": "slc_pathway", "key1": "SLC41A1", "key2": "chemotherapy", "summary": "SLC41A1 expression level was positively correlated with serum magnesium whereas TRPM6 expression level was negatively correlated with serum magnesium.\nThe average serum magnesium levels dropped 6.98 and 5.20% during and after completion of chemotherapy.\nSerum magnesium level decreased during cisplatin-based chemotherapy in head and neck cancer patients.\nHead and neck cancer patients scheduled to undergo neoadjuvant cisplatin-based chemotherapy were eligible for enrollment.\nWe aimed to investigate expression of magnesium transporter genes in patients with head and neck cancer who underwent cisplatin-based neoadjuvant chemotherapy and their association with serum magnesium level.\nBlood samples were obtained at three time points: prior to, during, and after completion of chemotherapy.\nExpression levels of magnesium transporter genes were determined by quantitative real-time PCR.", "dois": ["10.1007/s00405-015-3563-3"]}
{"pair_type": "slc_pathway", "key1": "SLC41A1", "key2": "oxidative stress", "summary": "Mechanistically, LPS is observed to activate the transcription factor signal transducer and activator of transcription 5A (STAT5A), which binds to the solute carrier family 41 member 1 (SLC41A1) promoter, thereby upregulating the Mg⁺ efflux transporter and depleting intracellular Mg⁺ levels.\nMg⁺ efflux destabilizes the mitochondrial permeability transition pore (mPTP), thus facilitating its opening via the interaction of oligomycin sensitivity-conferring protein (OSCP) and cyclophilin D (CypD), which releases reactive oxygen species (ROS) and mitochondrial DNA (mtDNA) and exacerbates oxidative stress.\nExogenous supplementation with Mg⁺ restores intracellular Mg⁺ homeostasis, suppresses mPTP opening, and reduces mtDNA and ROS leakage, thereby rescuing DPSCs viability and differentiation capacity.\nThis study identifies SLC41A1-mediated Mg⁺ dysregulation as a pivotal driver of LPS-induced mitochondrial damage and demonstrates that Mg⁺ replenishment is a therapeutic strategy to counteract inflammation-driven regenerative failure.\nIndeed, variants in magnesium transport channels, such as TRPM7 and SLC41A1, have been recently detected in PD individuals.\nPathogenic mechanisms implicated in the development of Parkinson disease (PD) are multifaceted and include alpha synuclein aggregation, oxidative stress due to generation of reactive oxygen species (ROS), mitochondrial dysfunction, apoptosis, imbalance of trace elements as well as endoplasmic reticulum stress, and inflammation.\nLow levels of magnesium have been associated with accelerated dopaminergic cell loss in animal PD models, and magnesium has been shown to have a neuroprotective effect in PD models.\nNovel androgen-responsive genes identified here participate in protein synthesis and trafficking, response to oxidative stress, transcription, proliferation, apoptosis, and differentiation.", "dois": ["10.1042/CS20150355", "10.1002/advs.202505666", "10.1684/mrh.2024.0523", "10.1186/1471-2164-10-476"]}
{"pair_type": "slc_pathway", "key1": "SLC41A1", "key2": "oxidative phosphorylation", "summary": "Thus, our data delineate the effect of dietary Mg content and of SLC41A1 functionality on the energy-production in cardiac mitochondria.\nWe have investigated the effects of dietary Mg content and presence/functionality of the Na/Mg exchanger SLC41A1 on enzymatic functions of selected constituents of the Krebs cycle and complexes of the electron transport chain (ETC).\nOur data demonstrate that both, the type of Mg diet and the genotype largely impact on the activities of enzymes of the Krebs cycle and ETC.\nMoreover, a compensatory effect of genotype on the effect of low Mg diet on activities of the tested Krebs cycle enzymes has been identified.", "dois": ["10.3390/ijms21218221"]}
{"pair_type": "slc_pathway", "key1": "SLC41A1", "key2": "migration", "summary": "Cellular experiments showed that knockdown of SLC41A1 inhibited proliferation, migration and invasion of HCC, whereas SLC41A1 overexpression exerted the tumor-promoting effects.\nUsing Gene Ontology (GO) , Kyoto Encyclopedia of Genes and Genomes (KEGG), gene set enrichment analysis (GSEA), protein-protein interaction (PPI) network, we found SLC41A1 overexpression was related to several tumor-promoting pathways and molecules, such as degradation of extracellular matrix, cell adhesion and O-linked glycosylation, and expression of CXCL1, CXCL5 and MUC1.\nThe results of single-sample GSEA (ssGSEA) showed SLC41A1 might regulate infiltration of multiple immune cells, resulting in the imbalance between immune suppression and immune surveillance.\nUsing bioinformatics techniques, we found SLC41A1 was upregulated in HCC, which was verified by immunostaining of HCC patients.\nSLC41A1 was correlated with clinicopathological characteristics, and could be utilized as independently diagnostic and prognostic markers for HCC.", "dois": ["10.1096/fj.202500808RR", "10.7150/ijms.100155", "10.1161/HYPERTENSIONAHA.120.14909"]}
{"pair_type": "slc_pathway", "key1": "SLC41A1", "key2": "apoptosis", "summary": "Furthermore, overexpression of SLC41A1 promoted Mg efflux and suppressed Akt/mTOR activity, which is the upstream regulator of Bax and Bcl-2.\nOverexpression of SLC41A1 reduced the mitochondrial membrane potential, induced Bax while suppressed Bcl-2 expression.\nOverexpression of SLC41A1 suppressed orthotopic tumour growth in a mouse model and reduced the cell proliferation, colony formation, and invasiveness of KP3 and Panc-1 cells, which may have been associated with the increased population of apoptotic-prone cells.\nSuppression of Bax abrogated the tumour-suppressive effects of SLC41A1.\nAn increase in Akt activity and supplementation with Mg abolished SLC41A1-induced tumour suppression.\nMechanistically, LPS is observed to activate the transcription factor signal transducer and activator of transcription 5A (STAT5A), which binds to the solute carrier family 41 member 1 (SLC41A1) promoter, thereby upregulating the Mg⁺ efflux transporter and depleting intracellular Mg⁺ levels.\nMg⁺ efflux destabilizes the mitochondrial permeability transition pore (mPTP), thus facilitating its opening via the interaction of oligomycin sensitivity-conferring protein (OSCP) and cyclophilin D (CypD), which releases reactive oxygen species (ROS) and mitochondrial DNA (mtDNA) and exacerbates oxidative stress.\nThe released mtDNA activates the absent in melanoma 2 (AIM2) inflammasome, thereby amplifying gasdermin D (GSDMD)-mediated pyroptosis.\nThis study identifies SLC41A1-mediated Mg⁺ dysregulation as a pivotal driver of LPS-induced mitochondrial damage and demonstrates that Mg⁺ replenishment is a therapeutic strategy to counteract inflammation-driven regenerative failure.\nExogenous supplementation with Mg⁺ restores intracellular Mg", "dois": ["10.1002/advs.202505666", "10.1161/HYPERTENSIONAHA.120.14909", "10.1016/j.cbd.2025.101572", "10.1684/mrh.2024.0523", "10.18632/aging.101940", "10.1684/mrh.2013.0339", "10.1684/mrh.2010.0222", "10.1186/1471-2164-10-476", "PMID:18029156"]}
{"pair_type": "slc_pathway", "key1": "SLC41A1", "key2": "proliferation", "summary": "Cellular experiments showed that knockdown of SLC41A1 inhibited proliferation, migration and invasion of HCC, whereas SLC41A1 overexpression exerted the tumor-promoting effects.\nOverexpression of SLC41A1 suppressed orthotopic tumour growth in a mouse model and reduced the cell proliferation, colony formation, and invasiveness of KP3 and Panc-1 cells, which may have been associated with the increased population of apoptotic-prone cells.\nFurthermore, overexpression of SLC41A1 promoted Mg efflux and suppressed Akt/mTOR activity, which is the upstream regulator of Bax and Bcl-2.\nThe increased efflux capacity is accompanied by an insensitivity of mutant NME to cAMP stimulation suggesting disturbed hormonal regulation and leads to a reduced proliferation rate in p.A350V compared with wt cells.\nAn increase in Akt activity and supplementation with Mg abolished SLC41A1-induced tumour suppression.\nOverexpression of SLC41A1 reduced the mitochondrial membrane potential, induced Bax while suppressed Bcl-2 expression.\nUsing Gene Ontology (GO) , Kyoto Encyclopedia of Genes and Genomes (KEGG), gene set enrichment analysis (GSEA), protein-protein interaction (PPI) network, we found SLC41A1 overexpression was related to several tumor-promoting pathways and molecules, such as degradation of extracellular matrix, cell adhesion and O-linked glycosylation, and expression of CXCL1, CXCL5 and MUC1.\nSuppression of Bax abrogated the tumour-suppressive effects of SLC41A1.\nOverall, our findings show that consistent with its proposed function, Mg(2+) uptake mediated by MgtE is able to restore cell growth and proliferation of TRPM7-deficient cells and supports the concept of functional homology between MgtE and its vertebrate homologs.\nHere, we report that overexpression of MgtE is able to rescue the growth of TRPM7-KO DT40 B", "dois": ["10.1096/fj.202500808RR", "10.7150/ijms.100155", "10.2147/IJN.S440419", "10.1161/HYPERTENSIONAHA.120.14909", "10.18632/aging.101940", "10.3390/toxics6030034", "10.1371/journal.pone.0071096", "10.1371/journal.pone.0044452", "10.1186/1471-2164-10-476"]}
{"pair_type": "slc_pathway", "key1": "SLC41A2", "key2": "apoptosis", "summary": "Furthermore, elevated expression of SLC41A2 notably decreased the proliferation, migration and invasion of colon cancer cells, along with increased apoptosis.\nBy inhibiting the ubiquitin-proteasome degradation of GSK3β, SLC41A2 can significantly upregulate the expression of GSK3β, which ultimately suppresses the proliferation and migration of colon cancer cells.\nBy transfecting plasmids or siRNA to overexpress or knock down SLC41A2 in colon cancer cells, the effects of SLC41A2 on colon cancer cell proliferation, migration, and apoptosis were detected through EdU, MTT, wound-healing, Transwell, and JC-1 experiments.\nThe overexpression of SLC41A2 and rescue experiments confirmed that SLC41A2 enhances the protein stability of GSK3β by inhibiting its ubiquitin-proteasome degradation and causes the upregulation of GSK3β, thereby suppressing the progression of colon cancer.\nOverexpression of TMPRSS3 increased cell viability, whereas suppression of TMPRSS3 increased the percentage of apoptotic cells and decreased cell viability, compared to the control group.\nTMPRSS3 is an important molecule in the regulation of cell viability and cell apoptosis of HEI-OC1 cells.\nMagnesium may influence blood pressure by modulating vascular tone and structure through its effects on myriad biochemical reactions that control vascular contraction/dilation, growth/apoptosis, differentiation and inflammation.", "dois": ["10.1161/HYPERTENSIONAHA.120.14909", "10.1002/jgm.3118", "10.3109/13880209.2015.1071414", "10.1042/BJ20120248", "10.2174/0115665240397574250630060947", "10.1097/FPC.0b013e328352f436", "10.1684/mrh.2010.0222"]}
{"pair_type": "slc_pathway", "key1": "SLC41A2", "key2": "migration", "summary": "By inhibiting the ubiquitin-proteasome degradation of GSK3β, SLC41A2 can significantly upregulate the expression of GSK3β, which ultimately suppresses the proliferation and migration of colon cancer cells.\nFurthermore, elevated expression of SLC41A2 notably decreased the proliferation, migration and invasion of colon cancer cells, along with increased apoptosis.\nBy transfecting plasmids or siRNA to overexpress or knock down SLC41A2 in colon cancer cells, the effects of SLC41A2 on colon cancer cell proliferation, migration, and apoptosis were detected through EdU, MTT, wound-healing, Transwell, and JC-1 experiments.\nThe overexpression of SLC41A2 and rescue experiments confirmed that SLC41A2 enhances the protein stability of GSK3β by inhibiting its ubiquitin-proteasome degradation and causes the upregulation of GSK3β, thereby suppressing the progression of colon cancer.", "dois": ["10.2174/0115665240397574250630060947", "10.1161/HYPERTENSIONAHA.120.14909", "10.3109/13880209.2015.1071414"]}
{"pair_type": "slc_pathway", "key1": "SLC41A2", "key2": "proliferation", "summary": "By inhibiting the ubiquitin-proteasome degradation of GSK3β, SLC41A2 can significantly upregulate the expression of GSK3β, which ultimately suppresses the proliferation and migration of colon cancer cells.\nFurthermore, elevated expression of SLC41A2 notably decreased the proliferation, migration and invasion of colon cancer cells, along with increased apoptosis.\nBy transfecting plasmids or siRNA to overexpress or knock down SLC41A2 in colon cancer cells, the effects of SLC41A2 on colon cancer cell proliferation, migration, and apoptosis were detected through EdU, MTT, wound-healing, Transwell, and JC-1 experiments.\nThe overexpression of SLC41A2 and rescue experiments confirmed that SLC41A2 enhances the protein stability of GSK3β by inhibiting its ubiquitin-proteasome degradation and causes the upregulation of GSK3β, thereby suppressing the progression of colon cancer.\nRecent studies have shown that the vertebrate magnesium transporters Solute carrier family 41, members 1 and 2 (SLC41A1, SLC41A2) and Magnesium transporter subtype 1 (MagT1) can endow vertebrate B-cells lacking the ion-channel kinase Transient receptor potential cation channel, subfamily M, member 7 (TRPM7) with a capacity to grow and proliferate.\nOverall, our findings show that consistent with its proposed function, Mg(2+) uptake mediated by MgtE is able to restore cell growth and proliferation of TRPM7-deficient cells and supports the concept of functional homology between MgtE and its vertebrate homologs.\nHere, we report that overexpression of MgtE is able to rescue the growth of TRPM7-KO DT40 B-cells.", "dois": ["10.2174/0115665240397574250630060947", "10.1161/HYPERTENSIONAHA.120.14909", "10.3390/toxics6030034", "10.1371/journal.pone.0044452"]}
{"pair_type": "slc_pathway", "key1": "SLC41A3", "key2": "ferroptosis", "summary": "We identified 1620 sorafenib-response target genes involved in the PPAR signaling pathway, antigen processing and presentation, and ferroptosis.\nSLC41A3, SEC61A1, LRP4, PPM1G, and HSP90AA1 were independent risk factors for a poor prognosis for patients with HCC and had diagnostic value.\nA risk model based on SLC41A3, SEC61A1, LRP4, PPM1G, and HSP90AA1 expression showed that patients with HCC in the high-risk group had a worse prognosis.\nThe high risk based on the sorafenib-response targets SLC41A3, SEC61A1, LRP4, PPM1G, and HSP90AA1 represented the poor prognosis for patients with HCC and significantly correlated with the levels of immune infiltrating cells in HCC.", "dois": ["10.1155/2022/7257738"]}
{"pair_type": "slc_pathway", "key1": "SLC41A3", "key2": "migration", "summary": "Moreover, silencing SLC41A3 impeded LIHC cell proliferation, migration, and invasion .\nCellular experiments showed that knockdown of SLC41A1 inhibited proliferation, migration and invasion of HCC, whereas SLC41A1 overexpression exerted the tumor-promoting effects.\nAdditionally, we carried out cell functional experiments to determine the expression of SLC41A3 in the cell lines of LIHC, as well as the effects of its silence on cell proliferation, migration, and invasion.\nOur data showed that SLC41A3 was greatly increased in the cell lines of LIHC.\nHigher expression of SLC41A3 displayed an intimate association with higher pathological stages and poorer prognosis.\nRecent studies revealed SLC41A3 acted as an oncogene and predicted poor survival for hepatocellular carcinoma (HCC) patients.\nCollectively, our study demonstrated that highly expressed SLC41A3 was a probable indication of LIHC occurrence, and SLC41A3 could be regarded as a prospective target in the treatment of LIHC.\nUsing Gene Ontology (GO) , Kyoto Encyclopedia of Genes and Genomes (KEGG), gene set enrichment analysis (GSEA), protein-protein interaction (PPI) network, we found SLC41A1 overexpression was related to several tumor-promoting pathways and molecules, such as degradation of extracellular matrix, cell adhesion and O-linked glycosylation, and expression of CXCL1, CXCL5 and MUC1.\nThe results of single-sample GSEA (ssGSEA) showed SLC41A1 might regulate infiltration of multiple immune cells, resulting in the imbalance between immune suppression and immune surveillance.\nSLC41A1 was correlated with clinicopathological characteristics, and could be utilized as independently diagnostic and prognostic markers for HCC.", "dois": ["10.7150/ijms.100155", "10.1155/2021/8556888", "10.1161/HYPERTENSIONAHA.120.14909"]}
{"pair_type": "slc_pathway", "key1": "SLC7A11", "key2": "proliferation", "summary": "EOGT knockdown promotes ferroptosis and inhibits hepatocellular carcinoma proliferation by regulating SLC7A11 via HEY1.\nHnRNPU promotes proliferation and inhibits ferroptosis by regulating the mRNA stability of SLC7A11 and SLC3A2.\nKnockdown of EOGT inhibited HCC cell proliferation and enhanced sensitivity to ferroptosis by downregulating SLC7A11, a process mediated by HEY1.\nIGF2BP2 plays a critical role in NSCLC by stabilizing SLC7A11 mRNA via m6A modification, promoting cell proliferation and suppressing ferroptosis.\nIncreased CAPG inhibits ferroptosis to drive tumor proliferation and sorafenib resistance in hepatocellular carcinoma via the WDR74-p53-SLC7A11 pathway.\nIcariside II suppressed SKOV3 cell proliferation, inhibited cells migration and invasion, and promoted apoptosis by downregulating SLC7A11 expression.\nVB promoted the proliferation and inhibited apoptosis, inflammation and ferroptosis in OGD/R-treated SK-N-SH cells by regulating METTL14/CHAC1/NRF2/SLC7A11/GPX4 pathway.\nConsistent with its inhibitory role in ferroptosis, FERRIN promotes in vitro cancer cell proliferation and in vivo xenograft tumor growth through its modulation of SLC7A11.\nTIMP1 knockdown enhanced ferroptosis sensitivity, suppressed CRC cell proliferation and migration, and reduced expression of ferroptosis regulators GPX4 and SLC7A11.\nKnockdown of circRNA_0030042 promoted the proliferation, repressed the iron ion level, ROS level, increased SLC7A11 and GPX4 protein expressions in HO-induced AC16 cells via miR-568/PRG4 pathway.\nCD2AP silencing inhibited HCC cell proliferation and enhanced disulfidptosis susceptibility in SLC7A11-high cells, likely via NADPH depletion and actin network disruption.", "dois": ["10.1016/j.tice.2025.103181", "10.1016/j.jep.2025.120607", "10.1016/j.tranon.2025.102624", "10.2478/aite-2026-0002", "10.1016/j.freeradbiomed.2025.11.001", "10.1016/j.bcp.2025.117519", "10.1080/15384047.2025.2567815", "10.1007/s11033-025-11273-w", "10.1016/j.intimp.2025.115703", "10.1016/j.bbrc.2025.153109", "10.1016/j.bcp.2025.117628", "10.1016/j.cellsig.2025.112300", "10.1016/j.cellsig.2025.112295", "10.1080/00498254.2025.2598384", "10.1038/s41419-025-08227-2", "10.1016/j.yexcr.2025.114849", "10.1007/s00210-025-04854-w", "10.1016/j.mtbio.2025.102551", "10.1016/j.ijbiomac.2025.148831", "10.1016/j.ijbiomac.2025.148554", "10.1016/j.cellsig.2025.112168", "10.1016/j.tranon.2025.102553", "10.1016/j.canlet.2025.218058", "10.1016/j.cellsig.2025.112111", "10.1016/j.bmc.2025.118374", "10.1158/0008-5472.CAN-24-4949", "10.1016/j.freeradbiomed.2025.08.051", "10.1080/21505594.2025.2530164", "10.1007/s00210-025-04324-3", "10.1080/15384047.2025.2510041", "10.1080/16078454.2025.2451446", "10.1007/s10528-024-10959-3", "10.1016/j.phymed.2025.157640", "10.3390/ijms262311539", "10.1016/j.taap.2025.117664", "10.1186/s13048-025-01857-2", "10.2147/JIR.S563272", "10.1530/JOE-25-0095", "10.1007/s12032-025-03144-y", "10.1016/j.phymed.2025.157470", "10.1186/s12935-025-03960-2", "10.1002/kjm2.70139", "10.3389/fphar.2025.1681890", "10.1038/s41390-025-04492-1", "10.3389/fimmu.2025.1674321", "10.1007/s10238-025-01917-3", "10.1007/s10238-025-01933-3", "10.4239/wjd.v16.i11.111223", "10.1590/1414-431X2025e14679", "10.1016/j.intimp.2025.115485", "10.1038/s41420-025-02832-y", "10.1186/s43556-025-00355-7", "10.1186/s13018-025-06417-4", "10.1002/advs.202507384", "10.3390/cancers17213571", "10.3390/ijms262110736", "10.1016/j.gene.2025.149819", "10.1186/s41065-025-00591-5", "10.1038/s12276-025-01569-z", "10.1016/j.bbrc.2025.152788", "10.3892/ol.2025.15244", "10.1016/j.taap.2025.117531", "10.1016/j.cellsig.2025.111998", "10.17219/acem/200588", "10.1016/j.cmet.2025.10.003", "10.3389/fimmu.2025.1675373", "10.1016/j.jare.2025.10.069", "10.1016/j.jare.2025.10.025", "10.7150/jca.116777", "10.3389/fphar.2025.1685331", "10.2147/CMAR.S551549", "10.1016/j.brainresbull.2025.111543", "10.1007/s11010-025-05337-5", "10.1007/s00210-025-04698-4", "10.1016/j.bbrc.2025.152599", "10.1186/s10020-025-01375-3", "10.1186/s12865-025-00755-y", "10.1007/s11626-025-01115-1", "10.1002/kjm2.70110", "10.1002/ptr.70010", "10.1016/j.redox.2025.103839", "10.1016/j.reprotox.2025.109036", "10.1016/j.prp.2025.156180", "10.1007/s00109-025-02588-z", "10.1111/fcp.70044", "10.1016/j.redox.2025.103811", "10.1016/j.abb.2025.110553", "10.1016/j.cellsig.2025.111908", "10.1007/s12672-025-03626-5", "10.1016/j.clinsp.2025.100786", "10.32604/or.2025.067247", "10.1016/j.jep.2025.120456", "10.1016/j.jep.2025.120357", "10.1038/s41418-025-01580-x", "10.3390/ph18091382", "10.1101/2025.07.01.662602", "10.1016/j.bbrc.2025.152417", "10.1016/j.ejphar.2025.177870", "10.1016/j.ejphar.2025.177839", "10.1016/j.cbi.2025.111596", "10.1007/s11010-025-05369-x", "10.1007/s12033-025-01507-4", "10.1016/j.jpha.2025.101228", "10.1002/btm2.70021", "10.1038/s12276-025-01540-y", "10.3164/jcbn.24-240", "10.31557/APJCP.2025.26.9.3157", "10.21873/invivo.14068", "10.1016/j.bbrc.2025.152207", "10.1016/j.acthis.2025.152274", "10.1016/j.bcp.2025.117051", "10.1016/j.bioactmat.2025.05.009", "10.1096/fj.202500937RR", "10.1186/s41065-025-00530-4", "10.1016/j.jep.2025.120165", "10.1016/j.intimp.2025.115056", "10.1007/s00210-025-04359-6", "10.7150/ijbs.111419", "10.3389/fonc.2025.1620122", "10.3389/fonc.2025.1633891", "10.2174/0113816128383328250808123933", "10.1038/s41598-025-13324-5", "10.1016/j.yexcr.2025.114726", "10.2147/CMAR.S540437", "10.3389/fimmu.2025.1595900", "10.1038/s41419-025-07809-4", "10.1002/jbt.70387", "10.1002/jbt.70392", "10.1016/j.ijbiomac.2025.145698", "10.1007/s10616-025-00798-4", "10.1016/j.phymed.2025.156912", "10.1002/advs.202501935", "10.1016/j.cellsig.2025.111772", "10.1016/j.tice.2025.102793", "10.1002/bab.2710", "10.3390/cancers17152486", "10.1038/s41420-025-02652-0", "10.3390/ijms26157204", "10.1016/j.phymed.2025.156925", "10.1016/j.phymed.2025.156840", "10.1186/s41065-025-00508-2", "10.3760/cma.j.cn112152-20240219-00078", "10.1007/s10735-025-10525-0", "10.1007/s00011-025-02070-z", "10.1007/s10735-025-10496-2", "10.12122/j.issn.1673-4254.2025.07.02", "10.1016/j.yexcr.2025.114659", "10.3390/metabo15070476", "10.7150/ijbs.112233", "10.3760/cma.j.cn112137-20241018-02359", "10.1186/s40001-025-02842-7", "10.1007/s10735-025-10497-1", "10.3389/fonc.2025.1593107", "10.1038/s41420-025-02585-8", "10.1161/ATVBAHA.124.321014", "10.1016/j.envpol.2025.126381", "10.1016/j.cellsig.2025.111760", "10.1007/s00210-025-03849-x", "10.21037/jgo-2024-1002", "10.1016/j.intimp.2025.114914", "10.3389/fonc.2025.1592862", "10.1016/j.bbrc.2025.151887", "10.18240/ijo.2025.06.02", "10.31083/FBL39559", "10.1096/fj.202402701RR", "10.3389/fonc.2025.1558290", "10.1007/s12672-025-02803-w", "10.1093/jpp/rgae085", "10.3390/biom15060835", "10.3389/fphar.2025.1567942", "10.1007/s12672-025-02687-w", "10.1016/j.bcp.2025.116897", "10.1111/jdi.14407", "10.1038/s41388-025-03334-y", "10.1007/s12013-024-01656-4", "10.3390/ijms26115231", "10.1007/s00018-025-05742-5", "10.1007/s10238-025-01700-4", "10.3390/antiox14050614", "10.4251/wjgo.v17.i5.104522", "10.3389/fphar.2025.1540667", "10.1016/j.bbrc.2025.151770", "10.1016/j.bj.2025.100869", "10.1038/s41420-025-02401-3", "10.1002/jbt.70267", "10.1016/j.micinf.2025.105505", "10.1016/j.ijbiomac.2025.142388", "10.1016/j.brainresbull.2025.111272", "10.1007/s00210-024-03623-5", "10.1007/s12033-024-01166-x", "10.21037/jgo-2024-1014", "10.1186/s12885-025-14173-1", "10.1186/s12882-025-04123-1", "10.1038/s41420-025-02488-8", "10.3389/fmolb.2025.1557218", "10.1007/s11033-025-10395-5", "10.3389/fphar.2025.1572364", "10.1038/s41419-025-07541-z", "10.1186/s13048-025-01650-1", "10.3390/nu17071262", "10.2147/IJN.S509007", "10.1002/jbt.70246", "10.1002/advs.202415814", "10.1016/j.phymed.2025.156493", "10.1002/cbin.12275", "10.1007/s11010-024-05068-z", "10.1186/s12967-025-06378-6", "10.3390/md23030123", "10.1186/s40001-025-02411-y", "10.2147/CMAR.S497238", "10.4143/crt.2024.933", "10.1186/s12967-025-06296-7", "10.1016/j.jot.2024.10.014", "10.1111/cbdd.70071", "10.1002/ctm2.70257", "10.4062/biomolther.2024.156", "10.1016/j.peptides.2025.171366", "10.1002/ptr.8457", "10.1007/s00109-025-02515-2", "10.1002/mc.23874", "10.1016/j.jare.2024.04.009", "10.21037/tcr-24-1421", "10.2174/0113862073363731250218054917", "10.1186/s12920-025-02108-5", "10.3389/fmolb.2025.1523494", "10.3390/cancers17050739", "10.3967/bes2024.136", "10.1007/s10528-025-11045-y", "10.1016/j.jep.2024.119126", "10.1007/s10528-025-11035-0", "10.1007/s12672-025-01888-7", "10.1016/j.toxicon.2025.108228", "10.1016/j.toxicon.2025.108233", "10.1016/j.ijbiomac.2024.138841", "10.1007/s10495-024-02042-4", "10.1186/s12943-024-02224-3", "10.3389/fonc.2025.1451034", "10.1038/s41598-025-85329-z", "10.32604/or.2024.050835", "10.1016/j.heliyon.2024.e40590", "10.1016/j.gene.2024.148944", "10.3390/cells14020108", "10.1016/j.intimp.2024.113436", "10.1038/s41598-024-83276-9", "10.1007/s10238-024-01550-6", "10.1016/j.intimp.2024.113819", "10.1142/S0192415X25500363"]}
{"pair_type": "slc_pathway", "key1": "SLC5A7", "key2": "proliferation", "summary": "We found that choline inhibited the proliferation, migration, and invasion of HCC cells by downregulating autophagy.\nFunctionally, ectopic expression of circFBXW4 strikingly impairs the proliferation, migration, and invasion capacities of CRC cells in vitro and in vivo, whereas circFBXW4 knockdown has the opposite effects.\nMechanistically, circFBXW4 competitively binds to miR-338-5p and prevents it from interacting with and repressing its target SLC5A7, thus suppressing the progression of CRC.\nThis study reveals the specific critical role of circFBXW4 in inhibiting CRC progression via the miR-338-5p/SLC5A7 axis and provides an additional target for eradicating CRC.\nBy comparing the results among general knockout (KO) mice, transgenic (TG) mice and wild-type (WT) mice, we discovered that DDAH1 upregulated the proliferation and neural differentiation of NSCs in the subgranular zone (SGZ) under ischemic insult.\nUpregulated expression of the solute carrier family 5 member 7 (SLC5A7), a specific choline transporter, correlated with better HCC prognosis.\nWe further discovered that choline could promote SLC5A7 expression, upregulate cytoplasm p53 expression to impair the AMPK/mTOR pathway, and attenuate autophagy.\ncircFBXW4 downregulation is clearly correlated with malignant features and patient overall survival in CRC.", "dois": ["10.21037/hbsn-22-476", "10.1016/j.apsb.2024.02.001", "10.1002/advs.202300129", "10.1158/0008-5472.CAN-12-3190"]}
{"pair_type": "slc_pathway", "key1": "SLC48A1", "key2": "oxidative phosphorylation", "summary": "We found that the levels of the rate-limiting heme synthesis enzyme ALAS1 and uptake protein SLC48A1, along with OXPHOS complex subunits, progressively increased as lung tumorigenesis advanced.\nTo further verify the importance of heme in promoting tumorigenicity, we generated NSCLC cell lines with increased heme synthesis or uptake by overexpressing either the rate-limiting heme synthesis enzyme ALAS1 or uptake protein SLC48A1, respectively.\nThese data show that elevated heme flux and function underlie enhanced OXPHOS and tumorigenicity of NSCLC cells.\nNotably, tumors formed by cells with increased heme synthesis or uptake also displayed elevated OCRs and ATP levels.\nHeme is a central molecule for oxidative metabolism and ATP generation via mitochondrial oxidative phosphorylation (OXPHOS).\nThese findings show that elevated heme availability due to increased heme synthesis and uptake causes intensified oxygen consumption and ATP generation, promoting tumorigenic functions and tumor growth in NSCLC.\nThese results show that the advancing of lung tumorigenesis requires progressive increase in cellular heme synthesis and uptake, leading to intensified OXPHOS activity and ATP generation and promoting aggressive tumorigenic functions.\nHere, we showed that levels of heme synthesis and uptake, mitochondrial heme, oxygen-utilizing hemoproteins, oxygen consumption, ATP generation, and key mitochondrial biogenesis regulators were enhanced in NSCLC cells relative to nontumorigenic cells.\nThese cells exhibited enhanced migration and invasion and accelerated tumor growth in mice.\nFurther analyses indicated that HeSP2 effectively diminished OXPHOS in both ADC and SCC, reduced angiogenesis, alleviated tumor hypoxia, and suppressed cell proliferation.\nEngineered heme-sequestering peptides (HSP) reduced heme uptake, intracellular heme levels, and tumorigenic functions of NSCLC cells.\nImportantly, treatment of KLLuc mice with a heme-sequestering protein, HeSP2, that inhibits heme uptake in tumor cells effectively arrested lung tumor progression, and both ADC and SCC tumors were strongly suppressed.", "dois": ["10.1158/0008-5472.CAN-18-2156", "10.1158/1541-7786.MCR-21-0385"]}
{"pair_type": "slc_pathway", "key1": "SLC1A4", "key2": "chemotherapy", "summary": "Activation of MYC upregulated NDRG1 (N-myc downstream regulated 1), WNT10B (wingless-type mouse mammary tumour virus integration site family, member 10B), CASP9 (caspase 9, apoptosis-related cysteine peptidase) and CDKN2A (cyclin-dependent kinase inhibitor 2A), and downregulated ID3 (inhibitor of DNA binding 3, dominant negative helix-loop-helix protein) and SLC1A4 (solute carrier family 1 [glutamate/neutral amino acid transporter], member 4).\nThese findings might provide novel therapeutic targets for glioma chemotherapy.", "dois": ["PMID:22906261"]}
{"pair_type": "slc_pathway", "key1": "SLC2A12", "key2": "glycolysis", "summary": "I cannot find any explicit phrases or sentences in the provided source text that describe promotion or suppression relationships between SLC2A12 and glycolysis. The source text appears to contain only a single title about p53 and glycolytic enzymes, with no mention of SLC2A12 or direct mechanistic relationships between SLC2A12 and glycolysis.", "dois": ["10.1074/jbc.M111.240812"]}
{"pair_type": "slc_pathway", "key1": "SLC2A14", "key2": "glycolysis", "summary": "Our analysis showed that SLC2A14 (Glut-14; a glucose transporter) was the most significant gene upregulated in responder patients' T-cell population.\nFurther, scRNAseq analysis revealed upregulation of T-cell genes regulating glycolysis.\nResults: Pretreatment PBMC from responders had a higher reserve respiratory capacity and higher basal glycolytic activity compared with nonresponders.\nFlow cytometry analysis confirmed significantly elevated cell surface expression of the Glut-14 in CD3+, CD8+, and CD4+ circulating populations in responder patients.\nOur results suggest a glycolytic signature characterizes checkpoint inhibitor responders\nDifferential levels of specific lipid, amino acid, and glycolytic pathway metabolites were observed by response.\nMoreover, LDHC was also upregulated in the responder population.\nconsistently, both ECAR and lactate-to-pyruvate ratio were significantly associated with overall survival.\nMetabolomic analysis revealed that responder and nonresponder patient samples cluster differently, suggesting differences in metabolic signatures at baseline.", "dois": ["10.1158/1078-0432.CCR-21-3114"]}
{"pair_type": "slc_pathway", "key1": "SLC4A9", "key2": "apoptosis", "summary": "Finally, RNAi-mediated attenuation of SLC4A9 increased apoptosis in MDA-MB-231 breast cancer spheroids and dramatically reduced growth of MDA-MB-231 breast tumors or U87 gliomas in murine xenografts.\nFurthermore, treatment of spheroids with S0859, a small-molecule inhibitor of sodium-driven bicarbonate transporters, increased apoptosis in the cell lines tested.\nIn cancer cell spheroids, SLC4A4 or SLC4A9 disruption by either genetic or pharmaceutical approaches acidified intracellular pH and reduced cell growth.", "dois": ["10.1158/0008-5472.CAN-15-1862"]}
{"pair_type": "slc_pathway", "key1": "SLC6A3", "key2": "glycolysis", "summary": "The overexpression of SLC6A3 in 786-O cells increased the glycolytic activity, decreased ferroptosis levels, and promoted viability and invasion of ccRCC cells.\nConversely, knockdown of SLC6A3 in OS-RC-2 cells reduced glycolytic activity, increased ferroptosis levels, and inhibited viability and invasion of ccRCC cells.\nIt influences the promotion of tumor growth by enhancing glycolysis and suppressing ferroptosis.\nThis research aimed to investigate the function of SLC6A3 in promoting the metabolism and development of ccRCC tumor cells.", "dois": ["10.25259/Cytojournal_35_2025"]}
{"pair_type": "slc_pathway", "key1": "SLC6A3", "key2": "ferroptosis", "summary": "The overexpression of SLC6A3 in 786-O cells increased the glycolytic activity, decreased ferroptosis levels, and promoted viability and invasion of ccRCC cells.\nConversely, knockdown of SLC6A3 in OS-RC-2 cells reduced glycolytic activity, increased ferroptosis levels, and inhibited viability and invasion of ccRCC cells.\nIt influences the promotion of tumor growth by enhancing glycolysis and suppressing ferroptosis.\nThis research aimed to investigate the function of SLC6A3 in promoting the metabolism and development of ccRCC tumor cells.", "dois": ["10.25259/Cytojournal_35_2025"]}
{"pair_type": "slc_pathway", "key1": "SLC6A3", "key2": "chemotherapy", "summary": "Rs2975226 in the dopamine transporter gene (SLC6A3 ) (MAF: 0.54) was associated with acute CINV (OR 5.79;\nacute CINV occurred in 76% of patients with GA/AA genotypes and in 41% of patients with GG genotype (OR 5.59;\nPolymorphisms in HTR3B and SLC6A3 may contribute to the variability in response to antiemetic prophylaxis for CINV in children.\nFinally, three common key targets (SLC6A2, SLC6A3, and SLC6A4) and two key compounds (6-Gingerol and nuciferin) were screened according to the above three target datasets.\nRs3782025 in the 5-hydroxytryptamine type 3 (5-HT 3 ) receptor gene ( HTR3B ) [minor allele frequency (MAF): 0.48] affected response to 5-HT 3 receptor antagonists;\nChemotherapy-induced nausea and vomiting (CINV) remains a common adverse effect for children with cancer.\nIn children, chemotherapy emetogenicity and patient factors such as susceptibility to motion sickness and age group determine a patient's risk of CINV.\nThis prospective study included 100 children with cancer (median age 6.4 years, range 0.8–17.9) who received moderately to highly emetogenic chemotherapy.\nBesides known risk factors, genetic factors may play a role in interindividual variation in the occurrence of CINV.\nWe investigated the influence of candidate gene polymorphisms on the efficacy of antiemetics and on the background sensitivity to CINV in children.\nGenotypes were determined by whole-genome sequencing ( n = 79) or Sanger sequencing ( n = 21) for 71 genetic polymorphisms involved in motion sickness and antiemetic pathways.\nOdds ratios (ORs) and 95% confidence intervals (CIs) were calculated to estimate associations between acute CINV and genotypes adjusting for susceptibility to motion sickness and age group.\nThere were 1074 unique targets for chemotherapy-induced peripheral", "dois": ["10.1097/MD.0000000000031281", "10.1097/FPC.0000000000000460"]}
{"pair_type": "slc_pathway", "key1": "SLC7A1", "key2": "chemotherapy", "summary": "I cannot find any explicit phrases or sentences in the provided title that describe promotion or suppression relationships between SLC7A1 and chemotherapy.", "dois": ["10.2147/JIR.S393646"]}
{"pair_type": "slc_pathway", "key1": "SLC7A4", "key2": "oxidative stress", "summary": "Obesity, a global health issue, is associated with numerous diseases and has been shown to affect male reproductive health by inducing endocrine hormonal changes, chronic inflammation, oxidative stress and epigenetic alterations in reproductive cells.\nIt also confirmed that SLC30A8 and SLC7A4 were significantly upregulated in the testes of spontaneously obese mice.\nHigh-fat diet-induced obesity upregulates GNG5, INHA, MSH5, SLC30A8 and SLC7A4 in testes, suggesting their potential as regulatory targets in testicular damage associated with obesity.", "dois": ["10.1017/S0967199425000061"]}
{"pair_type": "slc_pathway", "key1": "SLC9A7", "key2": "proliferation", "summary": "Using 5-(N-ethyl-N-isopropyl)-Amiloride (EIPA) to inhibit NHE7 activity, we observed disrupted cell cycle progression and suppressed NSCLC cell proliferation without inducing apoptosis.\nFurthermore, EIPA demonstrated a suppressive effect on CSC activity, evidenced by decreased tumorsphere numbers and inhibition of CSC markers such as ALDH1A2, ABCG2, CD44, and CD133.\nOur findings suggest that targeting NHE7 with inhibitors like EIPA may have therapeutic potential in NSCLC treatment by disrupting cell cycle progression and suppressing CSC activity.\nThe alkaline intracellular environment of cancer cells is critical for cell proliferation and controlled by various plasma membrane transporters including Na+/H+ exchangers (NHEs).\nThe observed increase in PD-L1 expression in BMI1-overexpressing NSCLC cells upon EIPA treatment highlights the potential benefit of combining NHE7 inhibitors with anti-PD-L1 agents as a promising new therapeutic strategy for NSCLC.\nFlow cytometric analysis revealed that EIPA treatment or NHE7 knockdown in NSCLC cells led to downregulated PD-L1 expression, associated with inhibited STAT3 activity.\nInterestingly, EIPA's CSC-targeting activity was preferentially observed in NSCLC cells overexpressing BMI1, while increased PD-L1 expression was detected in BMI1-overexpressing NSCLC cells.\nBy analyzing the database from The Cancer Genome Atlas, we found a positive correlation between mRNA levels (the gene encoding NHE7) and poor overall survival in lung adenocarcinoma patients.", "dois": ["PMID:37970357"]}
{"pair_type": "slc_pathway", "key1": "SLC10A6", "key2": "chemotherapy", "summary": "Further analysis of this amplicon indicates that it encompassed genes involved in DNA repair (RAD51L, MLH3), reactive oxygen species (GPX2, CSTZ1, NGB, RDH11, ZADH1), and transportome (ABCD4, ATP6V1D, SLC10A6).\nEfficacy of camptothecins (CPTs) such as irinotecan has been recognized in chemotherapy of cancers including melanoma.\nMoreover, losses were also detected at the loci of topoisomerases (TOP1, SPO11, TOP3B) as well as at the loci of genes guarding chromosomal stability (TP53, ZW10, H2AFX, CHK1, CCDN1, MCM5, CENPB, DNMT3B), which would facilitate the development of drug resistance.\nA novel gain at 14q23.2-31.1 was revealed by alignment of whole genome profiles of parental cell line and irinotecan-resistant clones.\nTo gain global insight into acquired CPT-resistance, we established irinotecan-resistant clones derived from melanoma cells and compared their whole genomes by high resolution array-CGH.\nIn addition, genes located at 14q23.3-31.1 would be promising targets to overcome acquired CPT-resistance in melanoma.\nTaken together, our data suggest that genes involved in genome stability may greatly contribute to the development of CPTs-resistance.\nHowever, the majority of responding patients will gradually acquire drug resistance.\nLittle is known of the genes responsible for the acquired CPT-resistance in cancer.", "dois": ["PMID:18497997"]}
{"pair_type": "slc_pathway", "key1": "SLC11A1", "key2": "stemness", "summary": "Five MRGs (ACSL1, NDUFA2, CYP1B1, SLC11A1, and COX6B1) correlated with survival outcomes were identified based on metabolism-related co-expression module analysis.\nThe MC1 subtype, which is associated with the worst prognosis, shows a higher number of segments and homologous recombination defects and significantly lower mRNA expression-based stemness index (mRNAsi) and epigenetic-regulation-based mRNAsi.", "dois": ["10.1042/BSR20231400"]}
{"pair_type": "slc_pathway", "key1": "SLC9A4", "key2": "apoptosis", "summary": "Histological abnormalities were observed in the gastric mucosa of 9-week-old NHE4-/- mice, including sharply reduced numbers of parietal cells, a loss of mature chief cells, increased numbers of mucous and undifferentiated cells, and an increase in the number of necrotic and apoptotic cells.", "dois": ["PMID:15684419"]}
{"pair_type": "slc_pathway", "key1": "SLC12A3", "key2": "oxidative phosphorylation", "summary": "Dysfunction of oxidative phosphorylation complex IV and reduced maximal mitochondrial respiratory capacity were found in patient fibroblasts.\nIn vitro pharmacological inhibition of complex IV, mimicking the effect of the mtDNA variants, inhibited NCC phosphorylation and NCC-mediated sodium uptake.", "dois": ["10.1681/ASN.2021050596"]}
{"pair_type": "slc_pathway", "key1": "SLC13A2", "key2": "migration", "summary": "Knocking down DBNDD1 inhibited cell proliferation, migration, and invasion in vitro (DLD1/HCT116 cells), alongside decreased GDF15 expression and reduced p-NF-κB p65–p-I-κB signaling.\nAdditionally, DBNDD1 knockdown resulted in reduced tumor growth in vivo, highlighting that the DBNDD1–GDF15–NF-κB signaling pathway drives colorectal cancer pathogenesis.\nExperimental validation demonstrated increased levels of DBNDD1 and growth differentiation factor 15 (GDF15) in colorectal cancer, promoting constant NF-κB (RELA) activation via DBNDD1-dependent GDF15 induction.\nUsing least absolute shrinkage and selection operator (LASSO) regression, we selected 13 hub genes [ABCB5, AOC1, ARHGAP44, CACNG3, dysbindin domain–containing protein 1 (DBNDD1), GAS7, GTF2IRD1, PRSS22, SCN4A, TTC22, DLX6, PDK4, and SLC13A2] from these modules.\nThrough this approach, five modules associated with colorectal cancer were identified, which were enriched in MAPK signaling and cholesterol metabolism pathways.\nThis study highlights the crucial role of the DBNDD1–GDF15–NF-κB signaling pathway in colorectal cancer development, positioning DBNDD1 as a promising target for precision medicine strategies aimed at enhancing patient outcomes.\nSurvival analysis indicated that higher expression of DBNDD1 correlated with worse overall survival in patients with colorectal cancer.", "dois": ["10.1158/1541-7786.MCR-25-0153"]}
{"pair_type": "slc_pathway", "key1": "SLC13A3", "key2": "oxidative phosphorylation", "summary": "Using specific inhibitors, it was demonstrated that succinate is transported in cancer cells by the mechanism of plasma membrane Na(+)-dependent dycarboxylic acid transporter NaDC3 (SLC13A3 gene).\nProstate cancer cells reprogram their metabolism, so that they support their elevated oxidative phosphorylation and promote a cancer friendly microenvironment.\nAn important finding was that prostate cancer cells at acidic pH 6.8 are capable of consuming exogenous succinate, while physiological pH 7.4 was not favorable for this process.\nThe mechanism of succinate influx via NaDC3 in metastatic prostate cancer cells could yield a novel target for anti-cancer therapy and has the potential to be used for imaging-based diagnostics to detect non-glycolytic tumors.", "dois": ["PMID:26175936"]}
{"pair_type": "slc_pathway", "key1": "SLC13A4", "key2": "apoptosis", "summary": "We discovered that an SLC 13 family protein, sodium sulfate cotransporter 2 ( SLC 13A4, NaS‐2), facilitates transport of thiosulfate, but not sulfide, across the cell membrane, regulating intracellular concentrations and thus mediating cytoprotective effects of Na 2 S and STS .\nProtective effects of thiosulfate were associated with inhibition of caspase‐3 activity by persulfidation at Cys163 in caspase‐3.\nThe protective effects of H 2 S are mediated by thiosulfate that is transported across cell membrane by NaS‐2 and exerts antiapoptotic effects via persulfidation of caspase‐3.\nWe observed that thiosulfate in cell culture medium is not only required but also sufficient to mediate cytoprotective effects of Na 2 S against oxygen glucose deprivation and reoxygenation of human neuroblastoma cell line ( SH ‐ SY 5Y) and murine primary cortical neurons.", "dois": ["10.1161/JAHA.115.002125"]}
{"pair_type": "slc_pathway", "key1": "SLC16A2", "key2": "migration", "summary": "Glycometabolism pathways were further found to negatively correlate with the infiltration level of CD8 T-cells and natural killer cells but positively correlate with M2 macrophage infiltration and expressions of tissue degeneration biomarkers, which suggested the deficit immune surveillance and risk of tumor migration.\nThe concomitant accumulation of presumptive migrating granule cells in the molecular layer, suggests that inward radial migration to the internal granular layer is stalled.\nBy contrast, at day 18, the external germinal layer thickness was increased, with an increase in presence of Axonin-1-positive post-mitotic granule cells in the initial stage of radial migration.\nMCT8-deficient Purkinje cells also induced non-autonomous effects as they led to a reduced granule cell precursor proliferation, a thinner external germinal layer and a loss of PAX6 expression.", "dois": ["10.1097/MD.0000000000035923", "PMID:27879339"]}
{"pair_type": "slc_pathway", "key1": "SLC16A10", "key2": "glycolysis", "summary": "Lactic acid transport across the plasma membrane is fundamental for the metabolism of and pH regulation of all cells, removing lactic acid produced by glycolysis and allowing uptake by those cells utilizing it for gluconeogenesis (liver and kidney) or as a respiratory fuel (heart and red muscle).", "dois": ["PMID:12739169"]}
{"pair_type": "slc_pathway", "key1": "SLC16A13", "key2": "apoptosis", "summary": "Decreased SLC16A13 Expression Level Can Increase Apoptosis in KATO2 Cell Line, A Promising Biomarker\nSLC16A13 Downregulation Contributes to Apoptosis Induction in A549 Lung Cancer Cell Line", "dois": ["10.31557/APJCP.2025.26.2.525", "10.31557/APJCP.2024.25.6.1953"]}
{"pair_type": "slc_pathway", "key1": "SLC16A13", "key2": "migration", "summary": "I cannot find any explicit phrases or sentences in the provided source text that describe a promotion or suppression relationship between SLC16A13 and migration.\nThe only text provided is a title that mentions \"Decreased SLC16A13 Expression Level Can Increase Apoptosis in KATO2 Cell Line, A Promising Biomarker\" which describes a relationship between SLC16A13 and apoptosis, not migration.", "dois": ["10.31557/APJCP.2024.25.6.1953"]}
{"pair_type": "slc_pathway", "key1": "SLC17A5", "key2": "oxidative phosphorylation", "summary": "KEGG pathway enrichment analysis results showed that the DEGs were mainly concentrated in oxidative phosphorylation, Parkinson's disease, non-alcoholic fatty liver disease, Alzheimer's disease and Huntington's disease etc.\nCombined with the analysis results of the above methods, 11 key genes were screened out, including UQCRC1, GZMB, NDUFB9, NSF, SLC17A5, CTSH, NDUFB10, UQCR10, ATOX1, CST7 and CTSW, which could be used as candidate genes for the diagnosis and treatment of MDD.", "dois": ["PMID:30112561"]}
{"pair_type": "slc_pathway", "key1": "SLC18A1", "key2": "apoptosis", "summary": "I have carefully reviewed all the provided text for relationships between SLC18A1 and apoptosis. Unfortunately, the source text provided appears to contain only a fragment of a title about metastatic colorectal cancers and PDLIM2, with no content related to SLC18A1 or apoptosis.", "dois": ["10.2147/CMAR.S149002"]}
{"pair_type": "slc_pathway", "key1": "SLC19A3", "key2": "chemotherapy", "summary": "The results suggested that chemotherapy-induced hypermethylation of and may be specific to males and females, respectively, and that there were no alterations in methylation following chemotherapy.\nThe promoter methylation status of cyclin-dependent kinase inhibitor 2B (), solute carrier family 19 member 3 () and deleted in lung and esophageal cancer 1 () genes was examined prior to and following various chemotherapeutic regimens in order to identify any alterations.", "dois": ["PMID:27168825"]}
{"pair_type": "slc_pathway", "key1": "SLC20A1", "key2": "oxidative stress", "summary": "I apologize, but I cannot find any explicit phrases or sentences in the provided source text that describe promotion, suppression, activation, inhibition, or other regulatory relationships between SLC20A1 and oxidative stress.\nThe title mentions \"Hyperphosphatemia, Phosphoprotein Phosphatases, and Microparticle Release in Vascular Endothelial Cells\" but does not contain any text about SLC20A1 or oxidative stress, nor any relationship between them.\nTo provide verbatim excerpts as requested, I would need abstracts or text that actually discuss both SLC20A1 and oxidative stress together with their mechanistic relationships.", "dois": ["10.1681/ASN.2014070642"]}
{"pair_type": "slc_pathway", "key1": "SLC19A1", "key2": "oxidative phosphorylation", "summary": "I apologize, but based on the provided source text, I cannot find any explicit phrases or sentences that describe a promotion, suppression, or mechanistic relationship between SLC19A1 and oxidative phosphorylation.\nThe only text provided is a single title: \"SLC19A1 May Serve as a Potential Biomarker for Diagnosis and Prognosis in Osteosarcoma\"\nThis title does not mention oxidative phosphorylation at all, nor does it contain any information about relationships between SLC19A1 and metabolic pathways.\nTo complete this task properly, I would need access to the full abstracts or additional paper content that discusses both SLC19A1 and oxidative phosphorylation together.", "dois": ["10.7754/Clin.Lab.2020.200246"]}
{"pair_type": "slc_pathway", "key1": "SLC22A2", "key2": "oxidative phosphorylation", "summary": "Among the genes identified, there was an overrepresentation of gene ontology terms involved in energy production, fatty acid and lipid metabolism, oxidation, and transport.\nGenes having possible relevance to hypertension onset included Actn2, Ankrd1, ApoE, Cd36, Csrp3, Me1, Myl3, Nppa, Nppb, Pln, Postn, Spp1 , Slc21a4, Slc22a2, Thbs4 , and Tnni3.", "dois": ["10.1161/HYPERTENSIONAHA.110.155366"]}
{"pair_type": "slc_pathway", "key1": "SLC22A7", "key2": "proliferation", "summary": "The majority of the affected genes differed by a magnitude of four-fold or less between strains/gender, with some previously known to be sex-hormone regulated (SLC22A7 and SLC21A1).\nOne gene of particular interest was ornithine decarboxylase, a significant marker of cell proliferation and tumor promotion, which was expressed at an 18-fold greater level in SD rats.", "dois": ["PMID:16917072"]}
{"pair_type": "slc_pathway", "key1": "SLC22A8", "key2": "oxidative phosphorylation", "summary": "In-depth analysis of two selected pathways revealed a significant increase in plasma urea level correlating with increased renal Arginase II activity, hyperargininemia, and increased kidney arginine content as well as a significant increase in plasma creatinine concentration and a reduced capacity of the kidney to secrete anionic drugs (furosemide) paralleled by an approximate 80% decrease in the expression level of organic anion transporter 3 (SLC22a8).\nFurthermore, kidneys from cKO mice exhibited a significant decrease in the NAD-to-NADH ratio, which reflects the oxidative phosphorylation-to-glycolysis ratio and/or the status of mitochondrial function.", "dois": ["PMID:27056296"]}
{"pair_type": "slc_pathway", "key1": "SLC23A2", "key2": "chemotherapy", "summary": "mRNA levels of four transporters, SLC22A2, SLC23A2, ABCB1 and ABCC2, two DNA repair-related enzymes, Rad51 and MSH2, and one metabolic enzyme, dihydropyrimidine dehydrogenase (DPYD), showed a strong correlation (|r|>0.7) with IC(50) values for 5-FU.\nIn conclusion, mRNA levels of SLC22A2, SLC23A2, ABCB1, ABCC2, Rad51, MSH2 and DPYD were confirmed to be strongly correlated with IC50 values for 5-FU, and mRNA levels of ABCC2, MSH2 and DPYD were confirmed to be strongly correlated with IC(50) values for CDDP.\nEffective chemotherapy against esophageal carcinoma is considered achievable with a combination of 5-fluorouracil (5-FU) and cisplatin (CDDP).\nThe effects of factors known to influence sensitivity to 5-FU and CDDP, namely transporters, DNA repair enzymes and metabolic enzymes, were examined.\nThe aim of this study was to clarify the factors which affect sensitivity to 5-FU and CDDP.", "dois": ["PMID:23420099"]}
{"pair_type": "slc_pathway", "key1": "SLC25A4", "key2": "ferroptosis", "summary": "Forced overexpression of SLC25A4 in two LUAD cell lines inhibited their growth, viability, and migration.\nThe majority of these genes are associated with mitochondrial protein transport, ferroptosis, calcium signaling, metabolism, OXPHOS function, TCA cycle, apoptosis, and MARylation.", "dois": ["10.1096/fj.202201724RR"]}
{"pair_type": "slc_pathway", "key1": "SLC25A18", "key2": "glycolysis", "summary": "These results showed that increased SLC25A18 expression inhibits Warburg effect and cell proliferation via Wnt/β-catenin cascade, and suggest a better prognosis after treatment.\nExogenous overexpression of SLC25A18 decreased glucose consumption, lactate production, intracellular ATP concentration and cell proliferation and abrogated expression of CTNNB1, PKM2, LDHA and MYC.\nFunction experiments were implemented to estimate the variation of aerobic glycolysis and cell proliferation due to and up- or down-regulation of SLC25A18.\nInhibition of Wnt/β-catenin restored SLC25A18-repressed cellular activities.", "dois": ["PMID:32509397"]}
{"pair_type": "slc_pathway", "key1": "SLC25A18", "key2": "proliferation", "summary": "These results showed that increased SLC25A18 expression inhibits Warburg effect and cell proliferation via Wnt/β-catenin cascade, and suggest a better prognosis after treatment.\nExogenous overexpression of SLC25A18 decreased glucose consumption, lactate production, intracellular ATP concentration and cell proliferation and abrogated expression of CTNNB1, PKM2, LDHA and MYC.\nInhibition of Wnt/β-catenin restored SLC25A18-repressed cellular activities.", "dois": ["PMID:32509397"]}
{"pair_type": "slc_pathway", "key1": "SLC25A19", "key2": "oxidative phosphorylation", "summary": "Mitochondrial cytopathies, among which the Leigh syndrome (LS), are caused by variants either in the mitochondrial or the nuclear genome, affecting the oxidative phosphorylation process.\nOur findings demonstrate the usefulness of genomic investigations to improve LS diagnosis in consanguineous populations and further allow for treating the patients harboring variants in SLC19A3 and SLC25A19 that contribute to thiamine transport, by thiamine and biotin supplementation.", "dois": ["10.1042/BSR20220194"]}
{"pair_type": "slc_pathway", "key1": "SLC25A21", "key2": "chemotherapy", "summary": "Long Non-Coding RNA SLC25A21-AS1 Promotes Multidrug Resistance in Nasopharyngeal Carcinoma by Regulating miR-324-3p/IL-6 Axis", "dois": ["10.2147/CMAR.S251820"]}
{"pair_type": "slc_pathway", "key1": "SLC25A25", "key2": "ferroptosis", "summary": "The mechanism might be associated with the decrease of Slc25a25-mediated ferroptosis.\nRNA-seq analysis revealed a high correlation between ferroptosis pathway genes and Slc25a25 ion transport-related genes, which was further validated by the detection of ferroptosis-related markers.\nMolecular docking indicated that glycine has binding sites with Slc25a25, with the highest binding energy of −3.7 kcal·mol −1 .", "dois": ["10.1249/MSS.0000000000003722"]}
{"pair_type": "slc_pathway", "key1": "SLC25A32", "key2": "apoptosis", "summary": "AGF347 induced apoptosis in SKOV3 cells.", "dois": ["10.1158/1535-7163.MCT-23-0550"]}
{"pair_type": "slc_pathway", "key1": "SLC25A33", "key2": "glycolysis", "summary": "I have carefully reviewed all the provided source text for verbatim phrases or sentences that explicitly describe a promotion, suppression, activation, inhibition, or other relationship between SLC25A33 and glycolysis.\nAfter thorough analysis, I could not find any excerpts in the provided source text that mention SLC25A33 in relation to glycolysis. The title provided discusses insulin-like growth factor 1 signaling, mitochondrial biogenesis, and mitophagy in cancer cells, but does not contain information about SLC25A33 or its relationship to glycolysis.\nWithout relevant source material containing both entities (SLC25A33 and glycolysis), I cannot provide verbatim excerpts as requested.", "dois": ["10.1074/jbc.M117.792838"]}
{"pair_type": "slc_pathway", "key1": "SLC25A37", "key2": "ferroptosis", "summary": "Knockdown of SLC25A37 can impair p53-mediated mitochondrial iron overload and ferroptosis.\nHSC-specific knockdown of DACH1, p53, and SLC25A37 can abolish the induction of HSC ferroptosis and reversal of hepatic fibrogenesis by erastin treatment.\nThe binding of p53 to SLC25A37 can enhance the iron uptake capacity of SLC25A37, which may cause an overload of iron in the mitochondria and hyperactive mitochondrial electron transport chain.\nDACH1 knockout can resist ferroptosis, whereas DACH1 knockin can enhance it.\nFurthermore, treatment with erastin can induce HSC ferroptosis and relieve fibrotic lesion damage in the mouse model of hepatic fibrogenesis.\nThe mutation of serine 392 can prevent the combination of DACH1 and p53, the mitochondrial translocation of p53, and DACH1-mediated ferroptosis.\nInterestingly, the upregulation of DACH1 resulted in the mitochondrial translocation of p53 by inducing phosphorylation at serine 392.\nMoreover, SLC25A37 was identified as a candidate target for mitochondrial p53.\nConclusions: Our findings suggest that the DACH1/P53/SLC25A37 signaling pathway is a promising target for fibrotic disorders and reveals new regulatory mechanisms of ferroptosis.", "dois": ["10.1097/HC9.0000000000000396", "10.2147/JIR.S490258"]}
{"pair_type": "slc_pathway", "key1": "SLC25A38", "key2": "chemotherapy", "summary": "Two adult ALL patients that were positive for SLC25A38 were analyzed and the level of SLC25A38 significantly reduced or disappeared following combined chemotherapy, however, reappeared upon ALL recurrence.", "dois": ["PMID:24765149"]}
{"pair_type": "slc_pathway", "key1": "SLC25A28", "key2": "oxidative phosphorylation", "summary": "The title mentions mitoferrin1 and mitoferrin2 (which are alternative names for SLC25A37 and SLC25A28, respectively) and their requirement for liver regeneration and cell proliferation, but does not contain explicit statements about their relationship to oxidative phosphorylation.\nWithout access to the abstract content that would contain mechanistic details, I cannot extract any verbatim excerpts meeting the specified criteria.", "dois": ["10.1074/jbc.RA120.013229"]}
{"pair_type": "slc_pathway", "key1": "SLC28A2", "key2": "apoptosis", "summary": "Comparison of gene expression profiles of G-CSF-stimulated, Stat3alpha-overexpressing 32D cells with those of cells with normal Stat3alpha expression revealed novel Stat3 gene targets, which may contribute to neutrophil expansion and improved survival, most notably Slc28a2, a purine nucleoside transporter, which is critical for maintenance of intracellular nucleotide levels and prevention of apoptosis, and Gpr65, an acid-sensing, G protein-coupled receptor with pro-oncogenic and antiapoptotic functions.\nThis effect was a result of decreased apoptosis but not of increased proliferation.", "dois": ["PMID:17634277"]}
{"pair_type": "slc_pathway", "key1": "SLC30A1", "key2": "glycolysis", "summary": "I have carefully reviewed the provided source text for the pair SLC30A1 and glycolysis. The title and abstract information provided does not contain any verbatim phrases or sentences that explicitly describe promotion, suppression, activation, inhibition, or any other direct relationship between SLC30A1 (a zinc transporter) and glycolysis (the metabolic pathway).\nThe single paper title provided (\"Lipogenesis Is Decreased by Grape Seed Proanthocyanidins According to Liver Proteomics of Rats Fed a High Fat Diet\") discusses lipogenesis, grape seed proanthocyanidins, and liver proteomics, but does not mention either SLC30A1 or glycolysis explicitly in the title.\nWithout access to excerpts from the abstract or body text that mention both entities or describe their relationship, I cannot provide any verbatim phrases meeting the specified criteria.", "dois": ["10.1074/mcp.M000055-MCP201"]}
{"pair_type": "slc_pathway", "key1": "SLC30A3", "key2": "glycolysis", "summary": "However, several conserved and treatment specific responses were identified that are consistent with proliferation (Fos, Cdkn1a, Anapc1), and water imbibition (Slc30a3, Slc30a5) responses elicited by EE.\nFunctional annotation of differentially expressed genes was associated with cell growth and proliferation, cytoskeletal organization, extracellular matrix modification, nucleotide synthesis, DNA replication, protein synthesis and turnover, lipid metabolism, glycolysis and immunological responses as is expected from the uterotrophic response.", "dois": ["PMID:17555576"]}
{"pair_type": "slc_pathway", "key1": "SLC30A5", "key2": "glycolysis", "summary": "However, several conserved and treatment specific responses were identified that are consistent with proliferation (Fos, Cdkn1a, Anapc1), and water imbibition (Slc30a3, Slc30a5) responses elicited by EE.\nFunctional annotation of differentially expressed genes was associated with cell growth and proliferation, cytoskeletal organization, extracellular matrix modification, nucleotide synthesis, DNA replication, protein synthesis and turnover, lipid metabolism, glycolysis and immunological responses as is expected from the uterotrophic response.", "dois": ["PMID:17555576"]}
{"pair_type": "slc_pathway", "key1": "SLC30A9", "key2": "oxidative phosphorylation", "summary": "As a case study, we find that poorly characterized transporter SLC30A9 (ZnT9) coevolves with several components of the mitochondrial oxidative phosphorylation chain, suggesting mitochondrial localization.", "dois": ["10.1042/BCJ20210342"]}
{"pair_type": "slc_pathway", "key1": "SLC32A1", "key2": "oxidative stress", "summary": "The ceRNA Regulatory Network in Vitiligo: Evidence from Bioinformatics Analysis\nThis title alone does not contain any verbatim phrases or sentences that explicitly describe promotion, suppression, or other regulatory relationships between SLC32A1 and oxidative stress.\nWithout access to the abstract or full content of this paper, or additional papers in the candidate excerpts pool, I cannot extract any relevant verbatim phrases that meet the specified criteria.", "dois": ["10.2147/CCID.S528604"]}
{"pair_type": "slc_pathway", "key1": "SLC35A2", "key2": "ferroptosis", "summary": "I cannot find any explicit phrases or sentences in the provided source text that describe a promotion, suppression, or mechanistic relationship between SLC35A2 and ferroptosis. The title mentions a comprehensive analysis of SLC35A2 in pan-cancer and breast cancer, but no abstract content was provided that contains verbatim excerpts relating SLC35A2 to ferroptosis.", "dois": ["10.2147/JIR.S419994"]}
{"pair_type": "slc_pathway", "key1": "SLC35A3", "key2": "migration", "summary": "Furthermore, we found that SLC35A3‐KO enhances cell spreading and suppresses both cell migration and cell proliferation, which is similar to the phenomena observed in the OGT‐KD cells.", "dois": ["10.1096/fj.202101520R"]}
{"pair_type": "slc_pathway", "key1": "SLC35B1", "key2": "glycolysis", "summary": "We propose that under physiological conditions, increases in cytosolic Ca2+ inhibit ATP import into the ER lumen to limit ER ATP consumption.\nThese findings suggest that ATP usage in the ER may increase mitochondrial OxPhos while decreasing glycolysis, i.e. an 'anti-Warburg' effect.\nSignificantly, we show that mitochondria supply ATP to the ER and a SERCA-dependent Ca2+ gradient across the ER membrane is necessary for ATP transport into the ER, through SLC35B1/AXER.\nFurthermore, the ATP level in the ER is readily depleted by oxidative phosphorylation (OxPhos) inhibitors and that ER protein misfolding increases ATP uptake from mitochondria into the ER.\nThe endoplasmic reticulum (ER) imports ATP and uses energy from ATP hydrolysis for protein folding and trafficking.", "dois": ["10.7554/eLife.49682"]}
{"pair_type": "slc_pathway", "key1": "SLC35B1", "key2": "oxidative phosphorylation", "summary": "Significantly, we show that mitochondria supply ATP to the ER and a SERCA-dependent Ca2+ gradient across the ER membrane is necessary for ATP transport into the ER, through SLC35B1/AXER.\nFurthermore, the ATP level in the ER is readily depleted by oxidative phosphorylation (OxPhos) inhibitors and that ER protein misfolding increases ATP uptake from mitochondria into the ER.\nThese findings suggest that ATP usage in the ER may increase mitochondrial OxPhos while decreasing glycolysis, i.e.", "dois": ["10.7554/eLife.49682"]}
{"pair_type": "slc_pathway", "key1": "SLC35A5", "key2": "apoptosis", "summary": "I apologize, but I cannot find any explicit phrases or sentences in the provided source text that describe a promotion or suppression relationship between SLC35A5 and apoptosis. The only information provided is a title \"Whole-genome studies identify solute carrier transporters in cellular susceptibility to paclitaxel\" which does not contain any statements about the relationship between these two entities.\nTo properly complete this task, I would need access to the actual abstracts and their content that discuss SLC35A5 and apoptosis mechanisms.", "dois": ["10.1097/FPC.0b013e328352f436"]}
{"pair_type": "slc_pathway", "key1": "SLC35B2", "key2": "oxidative stress", "summary": "Moreover, SLC35B2 is a novel transcription target gene of the Hippo pathway, constituting a positive feedback loop that facilitates HCC progression under oxidative stress.\nOxidative stress upregulates the transcription of SLC35B2, a Golgi-resident transporter of sulfate donor 3ʹ-phosphoadenosine 5ʹ-phosphosulfate, leading to increased sulfation of SAV1.\nOur findings reveal a regulatory mechanism of the SLC35B2/SAV1 sulfation axis in response to oxidative stress, highlighting its potential as a promising therapeutic target for HCC.\nSulfation of SAV1 disrupts the formation of the SAV1-MST1 complex, resulting in a decrease of MST1 phosphorylation and subsequent inactivation of Hippo signaling.\nThese molecular events ultimately foster the growth of HCC cells both in vivo and in vitro.", "dois": ["10.1097/HEP.0000000000000783"]}
{"pair_type": "slc_pathway", "key1": "SLC35C1", "key2": "oxidative stress", "summary": "N-glycosylation of TIS and target core fucosylation of PON1 are mediated by the fucose salvage-FUT8-SLC35C1 axis with PON3 directly modulating GDP-Fuc transfer on PON1 scaffolds.\nThese genes characterize the oxidative stress, inflammatory niche, and unfolded protein response as important factors for this modulation.\nCore fucosylation in the Golgi impacts PON1 stability and folding prior to secretion, promoting a more degradation-resistant PON1.\nLabel-free proteomics of N-glycoproteomes identified fucosylation of the antioxidant PON1 as a critical component of the therapy-induced secretome (TIS).\nOur findings demonstrate that core fucosylation is a common modification indirectly induced by targeted therapies that paradoxically promotes resistance.", "dois": ["10.7554/eLife.75191"]}
{"pair_type": "slc_pathway", "key1": "SLC35F5", "key2": "chemotherapy", "summary": "Our \"Response Index\" system, consisting of TNFRSF1B, SLC35F5 and OPRT, has great potential for predicting the efficacy of 5-FU-based chemotherapy against liver metastases from colorectal cancer.\nFour genes (TNFRSF1B, SLC35F5, NAG-1 and OPRT) had significantly different expression profiles in 5-FU-nonresponding and responding tumors (p < 0.05).\nAmong the 11 cases with positive scores in our response index, 9 achieved a reduction in their liver metastases after 5-FU-based chemotherapy, whereas only 1 of the 11 cases with negative scores responded well to chemotherapy.\nthe results were well correlated with the individual chemosensitivities.\nWe identified genes related to 5-fluorouracil (5-FU) sensitivity in colorectal cancer and utilized these genes for predicting the 5-FU sensitivity of liver metastases.\nA \"Response Index\" system using three genes (TNFRSF1B, SLC35F5 and OPRT) was then developed using a discriminate analysis;", "dois": ["PMID:16477629"]}
{"pair_type": "slc_pathway", "key1": "SLC36A4", "key2": "apoptosis", "summary": "I cannot find any explicit phrases or sentences in the provided source text that describe promotion or suppression relationships between SLC36A4 and apoptosis. The single title provided does not contain any content about SLC36A4 or its relationship to apoptosis.", "dois": ["10.1631/jzus.B2000043"]}
{"pair_type": "slc_pathway", "key1": "SLC39A2", "key2": "oxidative phosphorylation", "summary": "Mitochondrial respiratory control rate (RCR) and oxidative phosphorylation were decreased in Zip2 knockout mice and worsened by I/R.\nThese results suggest that Zip2 regulates mitochondrial respiration via phosphorylation of STAT3 during myocardial I/R, which may represent the underlying mechanism of Zip2 cardioprotection against I/R injury.\nMoreover, the impairment of mitochondrial function by Zip2 knockout was reversed by STAT3 overexpression.\nIn I/R myocardial tissue, STAT3 overexpression significantly improved the mitochondrial respiratory function, while STAT3 dominant negative mutant (STAT3 S727A) inhibited mitochondrial respiratory function.\nPhosphorylation levels of STAT3 (Ser) and ERK were significantly decreased in Zip2 knockout mice after I/R.\nThe results showed that, compared with the sham group, cardiac zinc concentration in myocardium was decreased in wild-type mice and further reduced in Zip2 knockout mice after I/R.", "dois": ["PMID:32820305"]}
{"pair_type": "slc_pathway", "key1": "SLC39A6", "key2": "oxidative stress", "summary": "Looking through the provided source text, I can only find one title that mentions SLC39A6's family (Slc39/ZiP) but does not contain any abstracts or text that explicitly describes promotion or suppression relationships between SLC39A6 and oxidative stress.\nSince the source material consists only of a title without accompanying abstract text that contains explicit mechanistic relationships between SLC39A6 and oxidative stress, I cannot extract verbatim phrases or sentences demonstrating promotion/suppression relationships between these two entities.", "dois": ["10.1074/jbc.M111.246082"]}
{"pair_type": "slc_pathway", "key1": "SLC39A6", "key2": "oxidative phosphorylation", "summary": "Genes correlated to energy metabolism included AK3 and COX7B, mainly involved in mitochondria structure and oxidative phosphorylation processes.\nGenes correlated to trace element metabolism included COMMD1, SLC39A6, FTL, CHRFAM7A, SCGN, and S100A6, mainly involved in ion metabolisms of copper, zinc, ferri, and calcium.\nThe metabolic levels of energy and substance including lipid, protein, nucleic acid, carbohydrate, and trace element were obviously reduced in patients of PDS, which might be an important pathogenesis mechanism for its occurrence.", "dois": ["PMID:23185754"]}
{"pair_type": "slc_pathway", "key1": "SLC39A3", "key2": "proliferation", "summary": "Results: The analytic results suggested that SLC39A1, SLC39A3, SLC39A4, SLC39A5, SLC39A6, SLC39A7, SLC39A9, SLC39A10, SLC39A11 and SLC39A13 were significantly up-regulated in BC tissues compared with normal breast tissues.\nMoreover, SLC39A7 was associated with proliferation and cloning of BC.\nHigh expression of SLC39A2, SLC39A3, SLC39A4, SLC39A5, SLC39A7, SLC39A12 and SLC39A13 was significantly associated with worse OS in patients with BC.\nThe SLC39A7 played a key role in growth and survival of BC cells.", "dois": ["10.1042/BSR20200764"]}
{"pair_type": "slc_pathway", "key1": "SLC41A1", "key2": "ferroptosis", "summary": "We observed that the expression levels of TRPM7, SLC41A1, MRS2, MAGT1, CNNM2, and CNNM3 were significantly reduced in advanced‐stage KIRC patients compared to those in early‐stage patients.\nExogenous Mg 2+ supplementation has been shown to further sensitize KIRC cells to ferroptosis, under both basal conditions and in the presence of CNNM3 knockdown, with a significant enhancement of lipid peroxidation and ferroptosis being observed.\nIt was established that low expression of Mg 2+ transporters, including TRPM7, SLC41A1, MRS2, MAGT1, CNNM2, CNNM3, and CNNM4, is linked to a poor prognosis in KIRC.\nThe study thus identifies a potential \"Mg 2+ ‐Fe 2+ \" homeostatic mechanism in KIRC cells, with CNNM3 serving as a critical regulatory component.", "dois": ["10.1096/fj.202500808RR"]}
{"pair_type": "slc_pathway", "key1": "SLC41A3", "key2": "apoptosis", "summary": "Incubation of PASMCs with a high concentration of Mg 2+ markedly inhibited PASMC proliferation and migration, and increased apoptosis, whereas a low level of Mg 2+ produced the opposite effects.\nsiRNA targeting Slc41a1/2, Cnnm2, and Trpm7 attenuated PASMC proliferation and migration, but promoted apoptosis;\nand Slc41a3 overexpression also caused similar effects.\nThe results, for the first time, provide the supportive evidence that Mg 2+ transporters participate in the development of PH by modulating PASMC proliferation, migration, and apoptosis;", "dois": ["10.1161/HYPERTENSIONAHA.120.14909"]}
{"pair_type": "slc_pathway", "key1": "SLC44A4", "key2": "oxidative stress", "summary": "Additional inflammation-related genes (C8orf34, C2, FBN2, SLC44A4, CHD13, INMT, NRG1) within TOH-DMR regions showed subtype-specific expression patterns linked to smoking exposure, supporting their potential as prognostic biomarkers and providing insights into disease etiology.\nGenes involved in smoking-related inflammation, oxidative stress, and immune regulation were enriched within TOH regions harboring DMRs.", "dois": ["10.1158/1055-9965.EPI-25-0159"]}
{"pair_type": "slc_pathway", "key1": "SLC48A1", "key2": "apoptosis", "summary": "I have carefully reviewed the provided source text for explicit relationships between SLC48A1 and apoptosis. Unfortunately, the only text provided is a single title that does not mention either SLC48A1 or apoptosis, nor does it contain any abstract or additional content that would describe relationships between these entities.", "dois": ["10.1074/jbc.M111.220178"]}
{"pair_type": "slc_pathway", "key1": "SLC48A1", "key2": "glycolysis", "summary": "To further verify the importance of heme in promoting tumorigenicity, we generated NSCLC cell lines with increased heme synthesis or uptake by overexpressing either the rate-limiting heme synthesis enzyme ALAS1 or uptake protein SLC48A1, respectively.\nThese cells exhibited enhanced migration and invasion and accelerated tumor growth in mice.\nThese data show that elevated heme flux and function underlie enhanced OXPHOS and tumorigenicity of NSCLC cells.\nNotably, tumors formed by cells with increased heme synthesis or uptake also displayed elevated OCRs and ATP levels.\nThese findings show that elevated heme availability due to increased heme synthesis and uptake causes intensified oxygen consumption and ATP generation, promoting tumorigenic functions and tumor growth in NSCLC.\nTumors of human non–small cell lung cancer (NSCLC) are heterogeneous but exhibit elevated glycolysis and glucose oxidation relative to benign lung tissues.\nHeme is a central molecule for oxidative metabolism and ATP generation via mitochondrial oxidative phosphorylation (OXPHOS).\nHere, we showed that levels of heme synthesis and uptake, mitochondrial heme, oxygen-utilizing hemoproteins, oxygen consumption, ATP generation, and key mitochondrial biogenesis regulators were enhanced in NSCLC cells relative to nontumorigenic cells.", "dois": ["10.1158/0008-5472.CAN-18-2156"]}
{"pair_type": "slc_pathway", "key1": "SLC48A1", "key2": "migration", "summary": "These cells exhibited enhanced migration and invasion and accelerated tumor growth in mice.\nTo further verify the importance of heme in promoting tumorigenicity, we generated NSCLC cell lines with increased heme synthesis or uptake by overexpressing either the rate-limiting heme synthesis enzyme ALAS1 or uptake protein SLC48A1, respectively.\nThese data show that elevated heme flux and function underlie enhanced OXPHOS and tumorigenicity of NSCLC cells.\nSignificance: These findings show that elevated heme availability due to increased heme synthesis and uptake causes intensified oxygen consumption and ATP generation, promoting tumorigenic functions and tumor growth in NSCLC.", "dois": ["10.1158/0008-5472.CAN-18-2156"]}
{"pair_type": "slc_pathway", "key1": "SLC41A2", "key2": "oxidative stress", "summary": "In addition, expression of SLC41A2 increased the sensitivity of TRPM7-knockdown cells to apoptotic stimuli and boosted ROS generation in response to cell stress.\nRe-expression of TRPM7 or of a kinase-inactive mutant of TRPM7 in TRPM7-knockdown cells increased cellular Mg2+ and ROS levels, as did expression of the Mg2+ transporter SLC41A2 (solute carrier family 41 member 2).\nDepletion of TRPM7 lowered cellular Mg2+, decreased the concentration of ROS and lessened p38 MAPK (mitogen-activated protein kinase) and JNK (c-Jun N-terminal kinase) activation as well as decreased caspase 3 activation and PARP [poly(ADP-ribose) polymerase] cleavage in response to apoptotic stimuli.\nIn the present study, we show that depletion of TRPM7 by RNA interference in fibroblasts increases cell resistance to apoptotic stimuli by decreasing ROS levels in an Mg2+-dependent manner.\nTaken together, these data uncover an essential role for Mg2+ in TRPM7's control of cell survival and in the regulation of cellular ROS levels.", "dois": ["10.1042/BJ20120248"]}
